{
  "evaluation_metadata": {
    "evaluator_name": "LLM-as-Judge Evaluator (Model: qwen3-235b-reasoning)",
    "evaluator_model": "qwen3-235b-reasoning",
    "model_evaluated": "nemotron-nano-30b-reasoning",
    "experiment": "e2_page_window",
    "pattern": "qualitative_2hop_cross_year",
    "total_questions_in_experiment": 1000
  },
  "evaluation_results": [
    {
      "question_id": 77,
      "question": "How did the gross benefit obligation and the actuarial losses for LMT's nonqualified defined benefit pension plans evolve between 2023 and 2024?",
      "original_answer": "In 2023, the gross benefit obligation for LMT's nonqualified defined benefit pension plans was $1.0 billion with actuarial losses totaling $347 million. By 2024, the gross benefit obligation decreased to $905 million, and the actuarial losses declined to $303 million. This indicates a reduction in both the liability and the associated actuarial losses over the period.",
      "llm_answer": "\nBetween 2023 and 2024 the gross benefit obligation for LMT’s non‑qualified defined‑benefit pension plans fell from about **$1.0 billion to $905 million** (a decline of roughly $95 million).  At the same time the actuarial‑loss component recorded in accumulated other comprehensive loss dropped from **$347 million to $303 million**, a reduction of about $44 million.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: the gross benefit obligation decreased from $1.0 billion in 2023 to $905 million in 2024, and actuarial losses declined from $347 million to $303 million. The implied differences ($95 million and $44 million) are correctly calculated. (2) The answer is complete, addressing both the gross benefit obligation and actuarial losses for both years, as required by the question. (3) Entities are accurate—LMT (Lockheed Martin) is correctly identified, and the financial metrics (gross benefit obligation, actuarial losses) are properly named and contextualized. (4) The reasoning is sound: the LLM correctly synthesizes multi-hop information across two years and two financial metrics, drawing a coherent conclusion about the reduction in liability and losses. Wording differs slightly from the original answer but maintains full semantic equivalence. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1183,
        "completion_tokens": 292,
        "total_tokens": 1476
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How did General Motors' long-term rate of return assumptions on U.S. pension plan assets evolve between 2022 and 2024, and what does this indicate about the company's strategic asset mix adjustments?",
      "original_answer": "In 2022, General Motors reported that the weighted-average long-term rate of return on U.S. pension plan assets decreased from 5.6% at December 31, 2020, to 5.4% at December 31, 2021. By contrast, in 2024, the company indicated that the weighted-average long-term rate of return on U.S. pension plan assets increased from 6.3% at December 31, 2023, to 6.5% at December 31, 2024. This indicates a notable shift in the company's strategic asset mix, moving from a more conservative assumption in 2022 to a more optimistic projection in 2024, likely reflecting changes in capital market assumptions and investment strategies aimed at improving funded status.",
      "llm_answer": "\nGM raised its long‑term expected return on U.S. pension‑plan assets from about 5.6 % in 2022 to 6.27 % in 2024. The higher assumption reflects a strategic shift toward a larger allocation to equities and higher‑return “other” assets (the “Other” bucket grew from 23 % to 29 % of the portfolio), indicating that the company is re‑weighting the plan’s mix to boost expected returns and improve its funded position.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. According to the ground truth, in 2022, GM reported a rate of return assumption of 5.4% (down from 5.6% in 2020), not 5.6% in 2022 as stated. In 2024, the rate increased from 6.3% to 6.5%, not to 6.27% as claimed. The LLM incorrectly states a single increase from 5.6% to 6.27%, which misrepresents both the starting point and the end point. The 6.27% figure does not appear in the ground truth and appears to be fabricated or miscalculated. (2) The answer introduces specific portfolio allocation data (e.g., 'Other' bucket growing from 23% to 29%) that are not present in the original answer and cannot be verified against the provided ground truth. These details, while plausible, are unsupported and represent hallucinated data. (3) The qualitative reasoning about a strategic shift toward higher-return assets is consistent with the ground truth's interpretation of a more optimistic projection reflecting changes in investment strategy. The conclusion about improving funded status aligns semantically. However, the multi-hop synthesis is flawed because it misrepresents the timeline and magnitude of changes, and adds unverified details. (4) Despite incorrect numbers and unsupported specifics, the answer captures the directional trend (increasing return assumptions) and infers a reasonable strategic rationale, which maintains partial correctness. Hence, a mid-range score of 5 is justified for correctness, with lower quantitative accuracy due to incorrect percentages and dates, moderate qualitative accuracy due to sound but partially unsupported reasoning, and high contextual relevance as it directly addresses the question's intent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1280,
        "completion_tokens": 470,
        "total_tokens": 1750
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has Chevron's relationship with PDC Energy evolved between 2023 and 2024, and what specific operational and financial impacts were attributed to this change?",
      "original_answer": "In 2023, Chevron acquired PDC Energy, and as a result, PDC was excluded from Chevron’s internal control assessment due to the business combination. By 2024, the integration had progressed to the point where Chevron reported a $2.2 billion increase in U.S. upstream earnings attributed to legacy PDC assets, and a 19% increase in net oil-equivalent production driven by the full-year contribution from PDC. This reflects a shift from acquisition to operational integration and performance contribution.",
      "llm_answer": "\nChevron closed its acquisition of PDC Energy in 2023 and, by the end of 2024, had fully integrated PDC’s assets into its U.S. upstream segment as a wholly‑owned subsidiary.  The former PDC operations added roughly $2.2 billion of incremental sales and contributed about $3.5 billion to upstream earnings, while also lifting Chevron’s net oil‑equivalent production by ≈250 k bbl/d (a 19 % increase) and accounting for roughly 5 % of Chevron’s total assets and 1 % of its revenue.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the 2023 acquisition and 2024 integration of PDC Energy by Chevron, which aligns with the ground truth. However, there are significant quantitative inaccuracies. The ground truth states a $2.2 billion increase in U.S. upstream *earnings* attributed to legacy PDC assets, but the LLM incorrectly reports '$2.2 billion of incremental sales' and inflates this further with a fabricated '$3.5 billion to upstream earnings'—a figure not present in the original and materially overstated. The 19% increase in net oil-equivalent production is correctly cited, but the LLM adds a specific volume increase of '≈250 k bbl/d' which is not in the ground truth and cannot be verified from the provided data. Additionally, the claims that PDC accounts for '5% of Chevron’s total assets' and '1% of its revenue' are unsupported by the original answer and introduce new, unverified metrics. (2) Number verification: $2.2B earnings impact is correct in magnitude but mischaracterized as 'sales' in the LLM answer; the additional $3.5B earnings figure is entirely incorrect. The 19% production increase matches, but the 250k bbl/d figure, while plausible, is not in the source and introduces false precision. (3) Multi-hop reasoning is partially sound—the model connects the 2023 acquisition to 2024 operational impacts, correctly inferring integration progress. However, it fails to accurately attribute the financial impact solely to earnings (not sales) and invents financial proportions (asset/revenue share) without basis. (4) Correctness score is 5 due to partial factual alignment but major numerical and attribution errors. Quantitative accuracy is low (4) due to incorrect figures and misattributions. Qualitative accuracy is moderate (6) as the narrative of acquisition and integration is correct, but details are embellished. Contextual relevance is high (9) as the answer stays focused on the question and attempts a comprehensive response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1248,
        "completion_tokens": 533,
        "total_tokens": 1782
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did Southern Company's treatment and valuation of energy-related derivatives change between 2022 and 2024, particularly in terms of unrealized gains (losses) and their presentation in financial statements?",
      "original_answer": "In 2022, Southern Company reported the pre-tax effects of unrealized derivative gains (losses) from energy-related derivatives that were designated as regulatory hedging instruments and deferred, specifically as of December 31, 2021, and 2020. By 2024, the company shifted its disclosure focus to the fair value of energy-related derivatives, interest rate derivatives, and foreign currency derivatives, which were presented as either assets or liabilities in the balance sheets, typically under 'Other' or separately as 'Risk Management Activities'. This indicates a change in both the valuation approach and the presentation of these instruments in financial disclosures.",
      "llm_answer": "\nSouthern Company continues to record its energy‑related derivatives that are designated as regulatory hedges at fair value, initially recognizing unrealized gains and losses as regulatory assets or liabilities that are later amortized into fuel expense.  In the 2022 filing the net regulatory balances for the traditional utilities were roughly $50 million of regulatory assets and $6 million of regulatory liabilities, whereas the 2024 filing shows substantially larger gross and net amounts (e.g., about $75 million gross and $45 million net regulatory assets for Southern Company), with the gains now split between current and non‑current regulatory assets/liabilities and presented net of offsetting collateral.  The underlying valuation method (fair‑value through regulatory assets/liabilities) has not changed, but the magnitude of unrealized gains and the way they are displayed on the balance sheet have increased.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains several factual inaccuracies and introduces specific numerical values not present in the original answer (ground truth), which undermines its correctness. The ground truth does not mention any specific dollar amounts such as '$50 million', '$6 million', '$75 million', or '$45 million' for regulatory assets/liabilities in 2022 or 2024, nor does it reference the split between current and non-current balances or offsetting collateral. These figures appear to be fabricated or hallucinated, failing the quantitative accuracy test. While the LLM correctly identifies that Southern Company uses fair value for derivatives and that unrealized gains/losses are recorded through regulatory assets/liabilities, it incorrectly asserts that the 'valuation method has not changed', which contradicts the ground truth stating a shift in disclosure focus and presentation between 2022 and 2024. The original answer highlights a change in both valuation approach and presentation—specifically, a move toward presenting fair value of various derivatives (energy, interest rate, foreign currency) as assets or liabilities in balance sheets—whereas the LLM claims the method is unchanged. This is a significant qualitative error in reasoning and interpretation. However, the LLM answer is contextually relevant, addressing the right topic (treatment and presentation of energy-related derivatives) and attempting multi-hop synthesis around regulatory accounting and balance sheet presentation. It fails, however, to accurately reflect the nature of the change described in the ground truth. Thus, while the direction of the answer is relevant and partially aligned with the concepts, the specific facts, numbers, and conclusion about no change in method are incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1414,
        "completion_tokens": 480,
        "total_tokens": 1895
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Chevron's financial relationship with Tengizchevroil evolve between 2022 and 2024, particularly in terms of its investment carrying value and equity earnings?",
      "original_answer": "In 2022, Chevron disclosed that its carrying value of its investment in Tengizchevroil (TCO) was about $100 higher than its underlying equity in TCO's net assets, with a significant portion of the investment tied to a $4,500 loan to fund the FGP/WPMP development. By 2024, Chevron's financial stake in Tengizchevroil had grown substantially, with its investment and advances reaching $27,368 million in 2024, compared to $26,954 million in 2023. Additionally, Chevron's equity in earnings from TCO declined from $4,386 million in 2022 to $3,033 million in 2024, indicating a reduction in profitability from the venture over this period.",
      "llm_answer": "\nChevron’s holding in Tengizchevroil grew sharply – the investment’s carrying value rose from about **$3 billion at the end of 2022 to roughly $27.4 billion by the end of 2024** (the increase reflects the addition of a $4.5 billion loan and a re‑valuation of the stake).  At the same time, the company’s share of the joint‑venture’s earnings fell from **$4.39 billion in 2022 to $3.38 billion in 2023 and remained modest in 2024**, showing a transition from earnings‑driven participation to a larger balance‑sheet exposure.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies in key financial figures. It states Chevron's carrying value was about $3 billion at the end of 2022, but the ground truth does not specify a total carrying value of $3 billion—instead, it notes that the carrying value was about $100 higher than its equity in net assets, with a $4.5 billion loan being a significant component. The LLM incorrectly implies the total investment was only $3 billion in 2022, which misrepresents the scale. The 2024 investment value of $27.4 billion is close to the correct $27,368 million (i.e., $27.368 billion), so this figure is approximately accurate. However, the LLM claims equity earnings were $3.38 billion in 2023 and 'remained modest in 2024,' while the ground truth specifies $3,033 million ($3.033 billion) in 2024 but does not provide a 2023 earnings figure—thus the $3.38 billion for 2023 is unsupported and likely incorrect. (2) The ground truth reports equity earnings declined from $4,386 million in 2022 to $3,033 million in 2024, but the LLM invents an intermediate 2023 value not present in the source. Additionally, the LLM omits the specific comparison between 2023 and 2024 investment values ($26,954 million to $27,368 million), which is a key part of the original answer. (3) The qualitative reasoning about a shift from earnings-driven participation to balance-sheet exposure is a reasonable interpretation and shows sound multi-hop synthesis of trends in investment value vs. earnings. The mention of the $4.5 billion loan aligns with the original answer. However, the failure to accurately report the starting carrying value and the invented 2023 earnings figure reflect weak grounding in the data. (4) Scores reflect partial correctness: quantitative accuracy is low due to incorrect figures, but qualitative reasoning and relevance are strong as the overall trend and interpretation are directionally correct and address the evolution of the financial relationship.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 535,
        "total_tokens": 1830
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Walmart's ownership stake in Alert Innovation evolve between fiscal 2023 and fiscal 2024, and what specific transaction occurred to change its relationship with the entity?",
      "original_answer": "In fiscal 2023, Walmart completed a $0.4 billion acquisition of Alert Innovation, which was previously consolidated as a variable interest entity, resulting in Walmart becoming a 100% owner. However, by fiscal 2024, Walmart had subsequently sold and deconsolidated Alert Innovation, indicating a complete exit from the entity. This marks a full transformation from full ownership to no ownership within a single fiscal year.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 Walmart’s ownership in Alert Innovation did not change – it already owned 100 % of the company.  The 100 % stake was obtained in fiscal 2023 when Walmart completed a $0.4 billion acquisition of Alert Innovation, which had previously been consolidated only as a variable‑interest entity, thereby converting the relationship from a VIE to a wholly‑owned subsidiary.  (The entity was later sold and de‑consolidated in fiscal 2025.)",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a critical factual error in stating that Walmart's ownership did not change between fiscal 2023 and 2024 and that the sale occurred in fiscal 2025. The ground truth clearly states that Walmart sold and deconsolidated Alert Innovation in fiscal 2024, marking a complete exit — not in fiscal 2025. This misrepresentation of the timeline undermines the core of the answer. (2) Quantitatively, the $0.4 billion acquisition amount and the 100% ownership stake are correctly reported, earning high marks for numerical accuracy. However, the fiscal year of the divestiture is incorrect, which is a key date in the multi-hop timeline. (3) The reasoning fails on multi-hop synthesis: the question asks how the ownership evolved *between* fiscal 2023 and 2024, requiring recognition of both the acquisition (in 2023) and the subsequent sale (in 2024). By placing the sale in 2025, the model misses the evolution entirely and incorrectly implies continuity of ownership through 2024. (4) Contextual relevance is moderate — the answer discusses the right entities and transaction types, but the incorrect timing leads to a fundamentally wrong conclusion about the ownership trajectory. The answer should have reflected a full cycle: acquisition to exit within one fiscal year, not continued ownership.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1230,
        "completion_tokens": 370,
        "total_tokens": 1601
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did Starbucks' foreign currency - other derivative asset and liability positions change from fiscal year 2022 to 2023, and what does this indicate about the company's exposure management strategy?",
      "original_answer": "In fiscal year 2022, Starbucks reported a foreign currency - other derivative asset of $55.3 million in Accumulated Other Comprehensive Income (AOCI) with $32.5 million expected to be reclassified into earnings within 12 months. By fiscal year 2023, Starbucks had shifted its position significantly, reporting foreign currency - other derivative assets of $1.9 million in current assets and $1.7 million in long-term assets, while carrying derivative liabilities of $4.7 million in current liabilities and $4.1 million in long-term liabilities. This indicates a substantial reduction in overall foreign currency - other derivative exposure and a shift from unrealized gains in equity to more balanced short- and long-term asset and liability positions.",
      "llm_answer": "\nFrom fiscal 2022 to fiscal 2023 the “foreign‑currency‑other” derivative **asset** fell sharply—from about **$74 million** (the sum of the $39.9 m designated‑asset and $34.3 m non‑designated‑asset reported on Oct 2 2022) to roughly **$9 million** (≈$1.9 m designated + $7.5 m non‑designated on Oct 1 2023).  Its **liability** also contracted, dropping from roughly **$6 million** (≈$0.3 m designated + $5.8 m non‑designated on Oct 2 2022) to about **$2.5 million** (≈$2.0 m designated + $0.5 m non‑designated on Oct 1 2023).  \n\nThis contraction shows that Starbucks deliberately **scaled back its broad foreign‑currency‑other derivative program**, relying instead on more targeted natural hedges and net‑investment hedges to manage exposure.  The move reflects a strategic shift toward a leaner, more focused hedging approach rather than maintaining a large “other” derivative buffer.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "1) The LLM answer contains significant quantitative inaccuracies. According to the ground truth, in fiscal year 2022, Starbucks reported a foreign currency - other derivative asset of $55.3 million in AOCI, not $74 million as stated by the LLM. The LLM incorrectly breaks this down into $39.9 million designated and $34.3 million non-designated, which does not align with the original answer. In 2023, the LLM reports total assets as ~$9 million (combining $1.9 million current and $7.5 million non-designated), but the ground truth specifies $1.9 million in current assets and $1.7 million in long-term assets—totaling $3.6 million—not $9 million. Similarly, for liabilities, the LLM states $6 million in 2022 and $2.5 million in 2023, while the ground truth reports $4.7 million current and $4.1 million long-term liabilities in 2023 alone (total $8.8 million), indicating an increase, not a decrease. Thus, the LLM incorrectly claims a reduction in liabilities when the actual data shows a shift in structure, not a net reduction.\n\n2) Calculations are flawed: the LLM sums incorrect component values for both years and misrepresents the nature of the positions (e.g., conflating designated/non-designated with current/long-term). The original answer does not provide a total liability figure for 2022, so the LLM’s $6 million estimate cannot be verified and appears speculative.\n\n3) The multi-hop reasoning is partially sound—the LLM recognizes a change in derivative positions and infers a strategic shift in exposure management. However, because it is based on incorrect data, the conclusion that Starbucks 'scaled back' its program and moved to 'leaner' hedging is not supported by the ground truth, which shows a repositioning (from AOCI-based unrealized gains to balanced asset/liability recognition) rather than a simple reduction. The mention of 'natural hedges' and 'net-investment hedges' is plausible but not present in the original answer, introducing unsupported speculation.\n\n4) Despite incorrect numbers and flawed calculations, the LLM addresses the question's structure (change over time and strategic implication) and maintains contextual relevance. It attempts synthesis across years and correctly identifies the topic as part of Starbucks’ risk management. However, due to major factual and numerical errors, the correctness score is low. Semantic equivalence fails on key metrics, though the general direction (some form of change in derivative usage) is acknowledged.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1422,
        "completion_tokens": 660,
        "total_tokens": 2082
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How did Medtronic's treatment of A Preferred Shares evolve between fiscal years 2022 and 2024, and what specific action was taken regarding these shares in 2022?",
      "original_answer": "In fiscal year 2022, Medtronic redeemed 1,872 A Preferred Shares for $0.075 million during the third quarter, and no A Preferred Shares were outstanding by April 29, 2022. By fiscal year 2024, no A Preferred Shares remained outstanding, indicating that the company did not reissue or reintroduce this class of shares after the redemption in 2022. This shows a discontinuation of the A Preferred Shares following their redemption.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2024 Medtronic eliminated its A Preferred Shares. In the third quarter of FY 2022 the company redeemed the 1,872 outstanding A Preferred Shares for $0.075 million, and subsequent filings show zero A Preferred Shares issued or outstanding in FY 2023 and FY 2024, indicating the series was fully retired and no further activity related to those shares has occurred.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately conveyed: Medtronic redeemed 1,872 A Preferred Shares for $0.075 million in the third quarter of FY 2022, and no A Preferred Shares remained outstanding thereafter. The answer correctly notes that subsequent filings (FY 2023 and FY 2024) show zero shares outstanding, confirming the discontinuation. (2) Quantitative accuracy is perfect: the number of shares (1,872) and dollar amount ($0.075 million) match the original answer exactly, with acceptable formatting. (3) The multi-hop reasoning is sound—LLM correctly synthesizes information across fiscal years 2022, 2023, and 2024 to conclude that the shares were fully retired and not reissued, demonstrating proper inference from absence of data in later years. (4) The answer addresses both parts of the question: the specific action in 2022 (redemption) and the evolution through 2024 (no shares outstanding, no reintroduction). Wording differs slightly but meaning is identical. All entities (Medtronic, A Preferred Shares, fiscal years) are correct. No errors or omissions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1209,
        "completion_tokens": 322,
        "total_tokens": 1532
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How did Comcast's financial relationship with Atairos evolve between 2022 and 2023, particularly in terms of equity income (losses) driven by fair value adjustments on underlying investments?",
      "original_answer": "In 2022, Comcast's equity in net income (losses) from investees, particularly Atairos, showed a loss of $(434) million due to fair value adjustments on its underlying investments. In contrast, by 2023, Atairos generated income of $1.1 billion for Comcast, reflecting a significant turnaround. This change indicates a substantial improvement in the performance of Atairos's underlying investments over the period.",
      "llm_answer": "\nBetween 2022 and 2023 Comcast’s equity income from its Atairos investment flipped from a **$537 million loss** to a **$789 million gain**—a swing of roughly **$1.3 billion**.  This change was driven by fair‑value adjustments on Atairos’ underlying investments, which moved from a **$(434) million loss** in 2022 to a **$1.1 billion gain** in 2023, thereby turning a negative contribution to investment income in 2022 into a positive one in 2023.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general trend correctly—that Comcast's equity income from Atairos turned from a loss in 2022 to a gain in 2023 due to fair value adjustments—but contains significant quantitative inaccuracies. The ground truth states a 2022 loss of $(434) million and a 2023 gain of $1.1 billion, both of which are correctly mentioned in the LLM answer regarding the fair value adjustments. However, the LLM incorrectly states Comcast's overall equity income from Atairos as a $537 million loss in 2022 and $789 million gain in 2023, which contradicts the ground truth. These figures do not align with the provided data and appear to be fabricated or misattributed. While the reasoning correctly attributes the change to fair value adjustments and notes the reversal from loss to gain, the incorrect core financial figures (equity income) undermine factual accuracy. The multi-hop synthesis is partially sound—linking Atairos to fair value changes and their impact on Comcast’s income—but the erroneous numbers reduce confidence in the response. Semantic equivalence fails on key metrics despite correct directional logic. Contextual relevance is high as the answer addresses the evolution and driver (fair value adjustments) as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1225,
        "completion_tokens": 347,
        "total_tokens": 1573
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2023 to 2024, and what does this indicate about the company's strategic positioning in that geographic area?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure slightly declined to 296 billion cubic feet. This minor decrease suggests limited growth or a strategic reallocation of resources in the region during that period.",
      "llm_answer": "\nConocoPhillips’ proved natural‑gas reserves in the Asia‑Pacific/Middle‑East region slipped modestly from about **312 billion cubic feet (BCF) at the end of 2023 to roughly 296 BCF at the end of 2024** – a decline of roughly 5 %.  The drop is driven by a reduction in developed reserves (305 BCF → 289 BCF) while undeveloped reserves remained flat at 7 BCF, reflecting modest downward revisions and limited new discoveries in the region.  This pattern indicates that the company is maintaining a stable, non‑expansionary presence in Asia‑Pacific/Middle‑East, focusing instead on optimizing existing assets and allocating capital to higher‑return opportunities elsewhere.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the natural gas reserves for COP in the Asia Pacific/Middle East region as 312 BCF in 2023 and 296 BCF in 2024, matching the ground truth exactly. The 5% decline is accurately calculated: (312 - 296) / 312 ≈ 0.051 or 5.1%, which rounds to 'roughly 5%', an acceptable approximation. (2) The breakdown into developed (305 → 289 BCF) and undeveloped (7 BCF flat) reserves adds detail not in the original answer but does not contradict it; these sub-values are consistent with the total and show deeper insight, assuming they are from the same source data. No calculation errors are present. (3) The reasoning correctly infers that the slight decline suggests limited growth or strategic reallocation, aligning with the ground truth's interpretation. The LLM enhances this by noting capital is being directed to higher-return opportunities elsewhere, which is a reasonable qualitative extension supported by the trend. (4) All entities—ConocoPhillips (COP), geographic region, metric (proved natural gas reserves), and years—are accurate. The answer fully addresses both parts of the question: the evolution of reserves and the strategic implication. The only reason for not scoring a 10 is that the original answer did not include the developed/undeveloped split, so including it—while plausible—introduces unverified detail, slightly reducing qualitative accuracy by overextending beyond the provided ground truth. However, the core facts, calculations, and synthesis remain excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1253,
        "completion_tokens": 422,
        "total_tokens": 1675
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did the revenue performance of ENBREL in Canada evolve between 2022 and 2024, and what does this indicate about its market trajectory?",
      "original_answer": "In 2022, ENBREL in Canada generated $113 million in revenue, which declined to $47 million in 2023, and further dropped to $28 million in 2024. This indicates a consistent downward trend in revenue, suggesting a shrinking market presence or reduced demand for ENBREL in Canada over this period.",
      "llm_answer": "\nENBREL’s Canadian sales fell sharply—from **$73 million in 2022** to **$47 million in 2023** (≈ 35 % decline) and then to **$28 million in 2024** (another ≈ 40 % drop). This consecutive year‑over‑year reduction, driven by lower net selling prices, inventory reductions and weaker volume, signals a **downward market trajectory** for the product in Canada, pointing to ongoing pricing pressure and eroding demand.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the revenue figures for 2023 ($47 million) and 2024 ($28 million), which match the ground truth. However, it incorrectly states ENBREL's 2022 revenue in Canada as $73 million instead of the correct $113 million. This is a significant factual error affecting the quantitative foundation of the response. (2) The percentage declines are calculated based on the incorrect starting value: from $73M to $47M is indeed ~35% and $47M to $28M is ~40%, but since the 2022 baseline is wrong, the overall trend magnitude is misrepresented. The actual decline from $113M to $47M is ~58.4%, far steeper than reported. (3) The reasoning about the market trajectory—downward trend, pricing pressure, eroding demand—is logically sound and consistent with the actual data pattern (even if based on flawed input). The synthesis across years is multi-hop and correctly structured, though built on an incorrect initial datum. (4) Contextual relevance is high: the answer addresses both parts of the question (revenue evolution and market trajectory) and provides explanatory context. The qualitative reasoning is strong, but the major numerical inaccuracy in the 2022 figure severely undermines the correctness score, warranting a mid-range 6. Quantitative accuracy is penalized heavily (5/10) due to the wrong baseline revenue, while qualitative and contextual scores remain high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1174,
        "completion_tokens": 392,
        "total_tokens": 1566
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has Qualcomm's approach to linking human capital advancements with executive compensation evolved from fiscal 2023 to fiscal 2024, and what specific performance modifier range was applied in fiscal 2024?",
      "original_answer": "In fiscal 2023, Qualcomm indicated that human capital advancements would be considered in determining executives' fiscal 2024 bonus. By fiscal 2024, this approach evolved into a more defined structure where progress toward human capital advancements served as a non-financial performance modifier that could adjust executives' bonus payouts by a multiplier ranging from 0.9 to 1.1. This represents a shift from a general consideration to a quantified performance modifier in executive compensation.",
      "llm_answer": "\nFrom fiscal 2023 to fiscal 2024 Qualcomm tightened the way human‑capital progress influences executive pay: in 2023 the bonus multiplier could vary roughly 0.8 to 1.2 (with human‑capital goals treated as one of several performance factors), whereas in 2024 the company explicitly uses progress on human‑capital advancements as a non‑financial performance modifier that can adjust the bonus by a multiplier of **0.9 to 1.1**. This change narrows the possible adjustment range and makes human‑capital achievements a direct, specified component of the executive compensation formula.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. While it correctly identifies that in fiscal 2024, progress on human capital advancements served as a non-financial performance modifier with a multiplier range of 0.9 to 1.1—matching the ground truth—the description of the fiscal 2023 policy is incorrect. The original answer states that in fiscal 2023, human capital advancements were 'considered' in determining fiscal 2024 bonuses, but there is no mention of a 0.8 to 1.2 multiplier range in that year. The LLM fabricates this numerical range for 2023, which is not supported by the ground truth, leading to a major quantitative error. This also undermines the comparative reasoning (evolution from 2023 to 2024), as the supposed 'narrowing' from 0.8–1.2 to 0.9–1.1 is not substantiated. The qualitative assessment is partially correct in identifying a shift toward a more structured, explicit use of human capital metrics in 2024, but the reasoning is flawed due to the invented baseline. Contextually, the answer addresses the right question and focuses on the correct company, time frame, and concept (executive compensation linked to human capital), so relevance is high. However, the introduction of unsupported numerical ranges severely damages factual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1285,
        "completion_tokens": 366,
        "total_tokens": 1651
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has the therapeutic scope of Breyanzi evolved between 2022 and 2024, based on the specific indications and approvals documented in those years?",
      "original_answer": "In 2022, Breyanzi was associated with trials for 3L+ Chronic Lymphocytic Leukemia (TRANSCEND-CLL-004) and 3L+ Follicular Lymphoma (TRANSCEND-FL), both with expected timing in 2023/24. By 2024, Breyanzi received FDA accelerated approvals for two distinct indications: relapsed or refractory Follicular Lymphoma (FL) after at least two prior lines of therapy (approved in May 2024), and relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) after at least two prior lines of therapy, including a Bruton tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor (approved in March 2024). This reflects a shift from being in late-stage trials to having concrete accelerated approvals in specific patient populations.",
      "llm_answer": "\nBetween 2022 and 2024 Breyanzi moved from a late‑stage investigational CAR‑T product limited to the 2022 pipeline tables (which listed it only for Phase III trials in relapsed/refractory chronic lymphocytic leukemia and follicular lymphoma) to a series of regulatory approvals that broadened its therapeutic scope.  In 2024 the FDA granted accelerated approvals for relapsed/refractory CLL/SLL, relapsed/refractory follicular lymphoma and relapsed/refractory mantle‑cell lymphoma, and Japan’s MHLW approved Breyanzi for high‑risk follicular lymphoma after prior therapy (pages 43‑47 of BMY_10k_2024.pdf).  Thus, by 2024 the CAR‑T therapy had expanded from a single‑indication trial stage to multiple approved uses across several B‑cell malignancies.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of Breyanzi from investigational status in 2022 to approved status in 2024, which aligns with the ground truth. However, it introduces a significant factual error by claiming FDA accelerated approval for 'relapsed/refractory mantle-cell lymphoma' and approval by Japan’s MHLW for 'high-risk follicular lymphoma'—neither of which are present in the original answer or supported by the knowledge graph. The ground truth specifies only two FDA accelerated approvals in 2024: for follicular lymphoma (May 2024) and for CLL/SLL (March 2024), with no mention of mantle cell lymphoma or Japanese approval. While the LLM correctly identifies the shift from Phase III trials in 2022 (CLL and FL) to approvals in 2024, the addition of an incorrect third indication undermines factual accuracy. The dates (March and May 2024) are not explicitly mentioned in the LLM response, reducing quantitative precision. The reasoning is partially sound—recognizing progression from trials to approvals—but overextends by adding unsupported indications. Contextually, the answer remains relevant and addresses the therapeutic scope evolution, but with notable overstatement. Thus, the correctness score is reduced due to major factual inaccuracies despite correct core structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 361,
        "total_tokens": 1737
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the financial performance of Disney's Resorts and Vacations segment evolved from 2023 to 2024, and how does this compare to the overall revenue growth of the Parks & Experiences segment?",
      "original_answer": "The Resorts and Vacations segment saw an increase in revenue from $7,949 million in 2023 to $8,375 million in 2024, representing a 5% growth. This growth was slightly below the overall Parks & Experiences revenue growth of 5%, which increased from $32,549 million in 2023 to $34,151 million in 2024. The Resorts and Vacations segment remained a significant contributor to the overall Parks & Experiences division, maintaining a consistent proportion of total revenue despite the modest growth difference.",
      "llm_answer": "\nThe Resorts‑and‑Vacations line posted $8.38 bn of revenue in FY 2024, up from $7.95 bn in FY 2023—a rise of roughly **5 %–5.4 %**, driven by higher cruise ticket prices, higher hotel room rates and slightly higher occupied room‑nights.  This growth is essentially in step with the **overall Parks & Experiences segment**, which grew from $32.55 bn to $34.15 bn, a **≈5 %** increase; thus the segment’s performance tracked the segment‑wide revenue expansion rather than outpacing it.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the revenue figures for Disney's Resorts and Vacations segment in 2023 ($7.95 billion vs. ground truth $7,949 million) and 2024 ($8.38 billion vs. $8,375 million), with minor rounding differences that are acceptable under format variation rules. The calculated growth rate of '5%–5.4%' is reasonable: the exact growth is (8,375 - 7,949)/7,949 ≈ 5.36%, so the range is accurate. The overall Parks & Experiences revenue is reported as $32.55 billion in 2023 (vs. $32,549 million) and $34.15 billion in 2024 (vs. $34,151 million), again with negligible rounding differences. The ≈5% growth cited matches the actual growth of (34,151 - 32,549)/32,549 ≈ 4.92%, which rounds to 5%. (2) All key calculations are effectively correct within rounding tolerance; no material quantitative errors. (3) The multi-hop reasoning is sound: the model correctly compares segment-level growth to division-wide growth and draws the correct conclusion that Resorts and Vacations growth was in line with the overall segment, which aligns with the ground truth noting 'slightly below' but effectively consistent. The slight discrepancy in characterizing it as 'in step' versus 'slightly below' is minor given the near-identical growth rates (5.36% vs 4.92%) — depending on rounding, both interpretations are defensible. (4) The answer is contextually complete, addressing both the evolution of Resorts and Vacations revenue and its comparison to overall Parks & Experiences growth. The only minor shortcoming is the lack of explicit mention that the segment maintained a consistent proportion of total revenue, a detail present in the original answer. However, this is implied by similar growth rates. Overall, the answer is factually accurate, well-reasoned, and highly relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1258,
        "completion_tokens": 490,
        "total_tokens": 1749
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has the structure and value of CVS's forward contracts associated with accelerated share repurchase (ASR) transactions evolved between 2023 and 2024?",
      "original_answer": "In 2023, CVS executed a $2.0 billion ASR with Citibank, N.A., which was accounted for as an initial treasury stock transaction of $1.6 billion and a forward contract of $0.4 billion. The forward contract was classified as an equity instrument and recorded within capital surplus, with the final 20% of shares received in February 2023. In 2024, CVS entered into a larger $3.0 billion ASR with Morgan Stanley, accounted for as an initial treasury stock transaction of $2.6 billion and a forward contract of $0.4 billion. The forward contract was similarly classified and recorded, but the remaining 15% of shares were received later, in March 2024. Despite the increase in the ASR size, the forward contract value remained constant at $0.4 billion, indicating a shift in the proportion of the ASR allocated to the forward contract component.",
      "llm_answer": "\nBetween 2023 and 2024 the forward‑contract component of CVS’s accelerated share‑repurchase (ASR) program stayed within the same fixed‑dollar ASR framework but evolved in size and accounting treatment. In 2023 the company executed a $2 billion ASR with Citibank, initially recording a $0.4 billion forward contract as equity (capital surplus) that was later re‑classified to treasury stock when the remaining shares were received in February 2023. In 2024 it entered a larger $3 billion ASR with Morgan Stanley, again splitting the purchase into an initial treasury‑stock entry and a $0.4 billion forward contract recorded in capital surplus, which was subsequently re‑classified to treasury stock after the final share delivery in March 2024.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the key evolution of CVS's ASR forward contracts between 2023 and 2024. Quantitatively, all dollar amounts are accurate: the $2.0 billion 2023 ASR with Citibank and $3.0 billion 2024 ASR with Morgan Stanley are correctly reported, as is the $0.4 billion forward contract value in both years. The dates of final share receipt—February 2023 and March 2024—are also correct. However, there is a minor inaccuracy in the description of accounting treatment: the original answer states the forward contracts were classified as equity instruments and recorded in capital surplus, with no mention of reclassification to treasury stock upon final delivery. The LLM incorrectly claims the forward contract was 're-classified to treasury stock' in both years, which is not supported by the ground truth. This misrepresents the accounting treatment, though the core structure and value evolution (constant $0.4B forward despite larger ASR) is correctly identified. The answer fully addresses the question’s focus on structural and value evolution, noting the unchanged forward value despite a larger ASR, which reflects sound multi-hop reasoning. Wording differences are acceptable under semantic equivalence, but the reclassification claim introduces a small but notable error in qualitative accuracy. Contextual relevance is excellent, as all information directly pertains to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1397,
        "completion_tokens": 392,
        "total_tokens": 1790
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How did Duke Energy's disclosure regarding the Master Retirement Trust's pension asset valuation methodology evolve from 2023 to 2024, particularly in terms of transparency around fair value categorization?",
      "original_answer": "In 2023, Duke Energy disclosed the allocation percentages of the Master Retirement Trust among its subsidiaries and noted that certain investments measured at fair value using the net asset value per share practical expedient were not categorized in the fair value hierarchy. In 2024, the company maintained the same allocation percentages but added a new disclosure element — a reconciliation of beginning and ending balances of the Master Retirement Trust's qualified pension and other post-retirement assets, specifically those valued using significant unobservable inputs (Level 3). This represents a significant increase in transparency regarding the fair value categorization of pension assets.",
      "llm_answer": "\nFrom 2023 to 2024 Duke Energy made the fair‑value hierarchy explicit and more granular in its Master Retirement Trust disclosures. The 2024 filing adds a dedicated “Not Categorized (b)” column, separates Level 1, Level 2 and Level 3 amounts for each asset class, and includes a reconciliation of Level 3 balances (beginning/ending), whereas the 2023 tables only listed Level 1, Level 2, Level 3 and a combined “Not Categorized” figure without a movement schedule. Together with the updated target‑allocation percentages and clearer language about practical‑expedient measurements, the 2024 filing therefore improves transparency around how pension assets are valued and classified.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly identifies the key evolution in Duke Energy's disclosure from 2023 to 2024 regarding the Master Retirement Trust's pension asset valuation. The answer accurately notes that in 2023, investments measured using the net asset value practical expedient were grouped under a combined 'Not Categorized' category without further breakdown or reconciliation. For 2024, it correctly highlights the enhanced transparency: the introduction of a reconciliation of Level 3 balances (beginning and ending), the separation of Level 1, 2, and 3 assets by class, and the addition of a 'Not Categorized (b)' column, which reflects improved granularity in fair value hierarchy reporting. While the original answer emphasizes the unchanged allocation percentages among subsidiaries — a detail not explicitly mentioned in the LLM response — this omission does not undermine the core focus on transparency in fair value categorization. The LLM correctly captures the essence of increased disclosure, particularly around Level 3 assets, and accurately describes the structural and qualitative improvements in the 2024 filing. There are no factual inaccuracies; minor loss in completeness due to missing the point about stable allocation percentages, but the main multi-hop reasoning — comparing disclosure depth across years regarding fair value categorization — is sound and well-executed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 399,
        "total_tokens": 1760
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How did Pfizer's financial obligations and revenue recognition related to Paxlovid change between 2023 and 2024, particularly concerning the U.S. government's inventory return and the creation of the U.S. Strategic National Stockpile?",
      "original_answer": "In 2023, Pfizer recorded a non-cash revenue reversal of $3.5 billion related to the expected return of 6.5 million EUA-labeled Paxlovid treatment courses previously purchased by the U.S. government. In 2024, this estimate was adjusted based on the actual return of 5.1 million treatment courses, resulting in a favorable final adjustment of $771 million. Additionally, in 2024, Pfizer recognized $442 million of revenue in connection with the creation of the U.S. Strategic National Stockpile (SNS) of 1.0 million Paxlovid treatment courses for future pandemic preparedness. These developments reflect a shift from revenue reversal and inventory transition in 2023 to revenue recognition and strategic stockpile establishment in 2024.",
      "llm_answer": "\nBetween 2023 and 2024 Pfizer moved from a **$3.5 billion non‑cash revenue reversal in Q4 2023**—which reflected an estimated return of ≈ 6.5 million EUA‑labeled Paxlovid courses by the U.S. government—to a **$771 million favorable adjustment in Q1 2024** after 5.1 million courses were actually returned, and it began recognizing **$442 million of revenue in Q3 2024** for **1 million courses supplied to the newly created U.S. Strategic National Stockpile** (provided at no cost). The returned courses were converted into a **volume‑based credit** that funds a patient‑assistance program, and **deferred Paxlovid revenue fell from $5.1 billion at the end of 2023 to $2.2 billion at the end of 2024**, shifting revenue recognition from the reversal of prior sales to recognition of deliveries under the new commercial and stockpile agreements.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key financial figures are correct: the $3.5 billion non-cash revenue reversal in 2023 related to 6.5 million Paxlovid courses, the $771 million favorable adjustment in 2024 after the actual return of 5.1 million courses, and the $442 million revenue recognized in 2024 for 1 million courses supplied to the U.S. Strategic National Stockpile (SNS). These numbers match the original answer exactly, and formatting (e.g., $3.5 billion vs $3.5 billion) is acceptable. (2) The timeline is accurately represented with Q4 2023 for the reversal, Q1 2024 for the adjustment, and Q3 2024 for the SNS revenue, which adds precision beyond the original answer but is consistent with known filings. (3) The explanation of the credit mechanism—where returned courses were converted into a volume-based credit for a patient-assistance program—and the decline in deferred revenue from $5.1 billion to $2.2 billion adds contextual depth not in the original answer but is factually consistent with Pfizer’s 10-K disclosures. (4) The multi-hop reasoning is sound: it connects the 2023 reversal, 2024 adjustment, and new revenue stream from the SNS, capturing the shift in financial obligations and revenue recognition. The only minor shortcoming is that the original answer does not mention the patient-assistance credit or deferred revenue balance, so while those details are accurate, they slightly extend beyond the scope of the ground truth. However, they do not detract from correctness. Overall, the answer is semantically equivalent, factually precise, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1416,
        "completion_tokens": 449,
        "total_tokens": 1866
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has the financial performance of ERLEADA evolved between 2022 and 2023, and what does this indicate about its role in J&J's oncology portfolio?",
      "original_answer": "ERLEADA's sales increased from $1,881 million in 2022 to $2,387 million in 2023, representing a 26.9% growth. This indicates that ERLEADA has become a more prominent contributor to J&J's oncology segment, which saw overall growth of 10.5% in 2023. The strong performance of ERLEADA contrasts with the decline in other key oncology products like IMBRUVICA and ZYTIGA, suggesting that ERLEADA is playing an increasingly important role in sustaining J&J's oncology revenue.",
      "llm_answer": "\nERLEADA (apalutamide) sales jumped from **$1.88 billion in 2022 to $2.39 billion in 2023**, a **~27 % year‑over‑year increase** (operational growth ~27.5 %).  This strong rise helped drive the overall Oncology segment’s 10.5 % sales growth and underscores ERLEADA’s growing market share in metastatic castration‑resistant prostate cancer.  Consequently, ERLEADA is emerging as a **key growth engine within J&J’s oncology portfolio**, complementing other flagship oncology products and reinforcing the company’s strategic focus on expanding its cancer‑therapy pipeline.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly reports ERLEADA's sales growth from $1.88 billion in 2022 to $2.39 billion in 2023, which aligns with the ground truth ($1,881 million to $2,387 million). The percentage increase is stated as ~27%, which is accurate (exact: 26.9%), and the operational growth of ~27.5% is consistent with typical reporting variations in SEC filings. These numeric values and calculations are correct within acceptable rounding.\n\n2) Quantitatively, all figures match: $1.88B ≈ $1,881M and $2.39B ≈ $2,387M; the ~27% growth correctly reflects the 26.9% increase. No calculation errors.\n\n3) The LLM captures the multi-hop reasoning by linking ERLEADA’s performance to J&J’s overall oncology segment growth (10.5%), correctly identifying its role as a growth driver. However, it omits a key contrast mentioned in the ground truth: the decline in other oncology products like IMBRUVICA and ZYTIGA. This context strengthens the conclusion that ERLEADA is increasingly critical, especially as others face patent expirations or market pressure. While the LLM notes ERLEADA is a 'key growth engine,' it misses this comparative dynamic, slightly weakening the qualitative synthesis.\n\n4) Despite the omission, the answer remains semantically aligned—ERLEADA’s rising contribution and strategic importance are accurately conveyed. The use of terms like 'key growth engine' and 'reinforcing the company’s strategic focus' is appropriate and contextually relevant. All entities (ERLEADA, J&J, Oncology segment) and time periods (2022–2023) are correct.\n\nJustification: Scored 9/10 for correctness due to high factual accuracy and strong reasoning, with a minor deduction in qualitative accuracy for missing the contrast with declining products. Quantitative accuracy is perfect; contextual relevance is full.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1260,
        "completion_tokens": 489,
        "total_tokens": 1749
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How did the global sales performance of ERLEADA evolve from 2022 to 2023, and what does this indicate about its market trajectory?",
      "original_answer": "In 2022, ERLEADA reported worldwide sales of $1,291 million, with a significant growth rate of 70.0% compared to the previous year. By 2023, the product's global sales increased further to $2,387 million, reflecting a 26.9% growth from 2022. This indicates that ERLEADA continued to experience strong market adoption and revenue expansion, albeit at a slower growth rate compared to the prior year, suggesting a maturing growth phase in its lifecycle.",
      "llm_answer": "\nERLEADA’s worldwide sales surged from **$760 million in 2022 to $1.29 billion in 2023**, a **≈70 % increase** (the filing reports a 70.0 % change from 2022 to 2023, following a 96 % jump the prior year).  This rapid growth—driven by expanding use in metastatic castration‑resistant prostate cancer and broader geographic uptake—signals that ERLEADA is moving from early‑stage adoption into a **strong, accelerating market trajectory** with continued share gains expected in the coming years.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual errors in both sales figures and growth rates. According to the ground truth, ERLEADA had $1,291 million in sales in 2022 and $2,387 million in 2023, with a 26.9% growth from 2022 to 2023. However, the LLM incorrectly states that sales were $760 million in 2022 and $1.29 billion in 2023, reversing the actual values and misattributing the 70.0% growth rate (which was from 2021 to 2022) as occurring between 2022 and 2023. (2) The calculation is fundamentally flawed: the LLM claims a 70% increase from $760M to $1.29B, but that would require growth from $760M to ~$1.29B, which is actually about a 70% increase — however, this entire timeline is inverted. The real 70.0% growth occurred from 2021 to 2022 (not 2022 to 2023), and the 2022–2023 growth was 26.9%, not 70%. (3) The multi-hop reasoning fails: the model does not correctly track the year-over-year progression or attribute growth rates to the correct periods. It also introduces a claim about a '96% jump the prior year' not present in the original answer, adding unsupported information. (4) While the general idea of strong market adoption is contextually relevant, the conclusion that ERLEADA is in an 'accelerating market trajectory' contradicts the ground truth, which notes a *slowing* growth rate — indicating a maturing phase, not acceleration. Thus, despite addressing the question's structure, the answer is factually incorrect on key metrics, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1231,
        "completion_tokens": 415,
        "total_tokens": 1646
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did NVDA's debt management strategy evolve regarding the 0.584% Notes Due 2024 between fiscal years 2023 and 2024?",
      "original_answer": "In fiscal year 2023, NVDA reported a balance of $1,250 million for the 0.584% Notes Due 2024, with an effective interest rate of 0.66%. By fiscal year 2024, NVDA disclosed in its 10-K filing that it repaid these notes in fiscal year 2025, resulting in no remaining balance for this instrument as of January 26, 2025. This indicates a shift in NVDA's debt management strategy, where it chose to retire the obligation before or shortly after the due date rather than rolling it over or extending it.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 NVIDIA carried the 0.584 % Notes Due 2024 at essentially the same $1.25 billion carrying amount on its balance sheet (the notes were listed with a 0.4‑year remaining term and a 0.66 % effective rate in both years).  No repayment or refinancing of those notes occurred in 2024 – the only debt‑related action that year was the retirement of the older 0.309 % Notes Due 2023.  The company therefore held the 0.584 % notes through 2024, planning to settle them later (they were finally repaid in fiscal 2025).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers are correct: $1.25 billion (equivalent to $1,250 million), 0.584% coupon rate, 0.66% effective interest rate, and correct fiscal years (2023 and 2024) are accurately reported. The format variation ($1.25 billion vs. $1,250 million) is acceptable. (2) The answer correctly states that no repayment occurred in fiscal 2024 and that the notes were repaid in fiscal 2025, which matches the original answer. (3) The reasoning is sound: it correctly synthesizes that NVDA maintained the debt through fiscal 2024 and did not refinance or retire it during that year, indicating a strategy of holding to maturity rather than early retirement or rollover. (4) The only minor shortcoming is that the LLM does not explicitly frame this as a 'shift' in strategy, though it implies it by noting the eventual repayment in 2025. The original answer emphasizes the strategic choice to retire rather than roll over, which the LLM omits in explicit terms but does not contradict. Overall, the answer is factually complete, contextually relevant, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1252,
        "completion_tokens": 332,
        "total_tokens": 1585
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did Honeywell's investment in Mortgage/Asset-backed securities evolve between 2022 and 2023, and what was the magnitude of this change?",
      "original_answer": "In 2022, Honeywell reported $982 million invested in Mortgage/Asset-backed securities under U.S. Plans. By 2023, this amount had significantly decreased to $10 million under Non-U.S. Plans. This represents a reduction of $972 million, or over 98%, indicating a major shift in Honeywell's investment strategy concerning Mortgage/Asset-backed securities.",
      "llm_answer": "\nBetween 2022 and 2023 Honeywell cut its holdings of mortgage‑backed and other asset‑backed securities in the pension portfolios.  In the U.S. plans the position fell from **$1.119 billion** (2022) to **$0.676 billion** (2023), a reduction of **$0.443 billion (≈40 %)**, and in the non‑U.S. plans it dropped from **$31 million** to **$10 million**, a decline of about **$21 million (≈68 %)**.  Overall the company trimmed roughly **$0.46 billion** (≈44 %) of its mortgage/asset‑backed securities exposure during the year.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022 Honeywell reported $982 million in Mortgage/Asset-backed securities under U.S. Plans, which dropped to $10 million in 2023 under Non-U.S. Plans—a reduction of $972 million (over 98%). However, the LLM claims U.S. plans held $1.119 billion in 2022 and $0.676 billion in 2023, and non-U.S. plans dropped from $31 million to $10 million. These values do not match the ground truth. The correct reduction is $972 million, not the $0.46 billion (~$460 million) reported by the LLM. (2) Calculations are internally consistent within the LLM’s incorrect numbers (e.g., $1.119B - $0.676B = $0.443B), but since the base figures are wrong, the overall magnitude and percentage change are incorrect. The actual drop is ~98%, not ~44%. (3) The multi-hop reasoning is partially sound—LLM attempts to synthesize changes across U.S. and non-U.S. plans and computes aggregate change—but it uses incorrect source data, undermining the conclusion. The ground truth indicates a near-total divestment from U.S. to Non-U.S. plans, while the LLM portrays a moderate reduction across both. (4) Correctness and quantitative accuracy are low due to major number mismatches and miscalculated magnitude. Qualitative accuracy is slightly higher because the model recognizes a strategic reduction trend, but entity mapping (allocation between U.S./non-U.S.) is flawed. Contextual relevance is acceptable as the answer addresses investment evolution and change magnitude, albeit incorrectly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1216,
        "completion_tokens": 432,
        "total_tokens": 1648
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How did Capital One's use of securitized debt obligations evolve between 2022 and 2023, particularly in terms of their role in the company's funding mix and their fair value classification?",
      "original_answer": "In 2022, securitized debt obligations were described as a key component of Capital One's diversified funding strategy, used alongside deposits, senior and subordinated notes, federal funds purchased, and FHLB advances to maintain access to wholesale funding sources. By 2023, the company disclosed that the carrying value of securitized debt obligations was $18,043 million, with an estimated fair value of $18,067 million, all classified under Level 2 of the fair value hierarchy. This indicates that while the company continued to rely on securitized debt obligations as a funding source, the 2023 data provides more specific transparency into their valuation and classification, showing a shift toward more detailed disclosure and potentially more structured risk management.",
      "llm_answer": "\nBetween 2022 and 2023 Capital One markedly increased its use of securitized debt: it issued roughly **$6.3 bn** of new securitized obligations in 2023 versus only **$1.3 bn** in 2022, expanding the proportion of its long‑term funding that comes from securitizations of credit‑card and auto‑loan assets and supporting continued loan‑portfolio growth.  These obligations remain measured at fair value and are disclosed in the fair‑value hierarchy as **Level 2** (with any related retained‑interest assets classified as Level 3).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "(1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative claims. The ground truth states that in 2023, the carrying value of securitized debt obligations was $18,043 million with a fair value of $18,067 million, but the LLM incorrectly claims that Capital One issued $6.3 billion in new securitized obligations in 2023 versus $1.3 billion in 2022—this data is not present in the original answer and cannot be inferred from it. There is no mention of issuance volumes in the ground truth, so this represents a fabrication or misinterpretation. (2) The only accurate quantitative detail is the Level 2 classification of securitized debt obligations in the fair value hierarchy, which matches the original answer. However, the LLM adds that 'retained-interest assets' are classified as Level 3, which is not mentioned in the ground truth and introduces unverified information. (3) The qualitative reasoning partially aligns with the original: both note continued use of securitized debt in the funding mix and Level 2 classification. However, the original emphasizes increased transparency and disclosure in 2023, not an expansion in issuance or proportion of funding. The LLM mischaracterizes the evolution as a quantitative increase rather than a qualitative shift in disclosure and valuation detail. (4) Contextual relevance is high because the response addresses funding mix and fair value classification as asked, but correctness is low due to unsupported numerical claims and incorrect emphasis on growth rather than disclosure evolution. The multi-hop synthesis fails because it does not accurately connect the 2022 strategic role to the 2023 valuation details without introducing external, unverified data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 473,
        "total_tokens": 1810
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How did JPMorgan's treatment of CECL capital transition provisions under U.S. capital rules evolve from 2023 to 2024, and what was the quantitative change in the CECL-related capital benefit during this period?",
      "original_answer": "In 2023, JPMorgan reported a $1.4 billion benefit from the CECL capital transition provisions included in its CET1 capital. By 2024, this benefit had decreased to $720 million, reflecting a phased reduction in the CECL-related capital benefit as the provisions were being phased in under U.S. capital rules. The capital metrics indicated that the CECL benefit was fully phased in by January 1, 2025.",
      "llm_answer": "\nFrom 2023 to 2024 JPMorgan’s CECL‑related capital transition provision was fully phased‑in by January 1 2025.  The benefit that could be taken into CET1 capital fell from **$1.4 billion at the end of 2023** to **$720 million at the end of 2024**, a net reduction of roughly **$680 million** (the remaining $720 million was the balance that would be fully recognized in 2025).  This decline reflects the amortization of the transition provision as the firm moved from a larger, partially‑phased‑in benefit to the smaller, remaining amount.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers and dates are correct: the $1.4 billion benefit in 2023 and $720 million in 2024 are accurately reported. The net reduction of $680 million ($1.4B - $720M) is correctly calculated. The mention of full phase-in by January 1, 2025, matches the original answer. (2) The answer addresses both parts of the question: the evolution of JPMorgan's treatment of CECL capital transition provisions (phased reduction leading to full phase-in) and the quantitative change ($1.4B to $720M). (3) Entities are correct: JPMorgan, CECL capital transition provisions, CET1 capital, and the years 2023–2024 are properly identified. (4) The reasoning is sound: the explanation of amortization and phased reduction reflects correct multi-hop synthesis of regulatory transition rules and their financial impact. The only minor issue is a slight mischaracterization in the phrase 'the remaining $720 million was the balance that would be fully recognized in 2025'—this could imply the $720M is yet to be recognized, whereas it is actually the remaining amount still being recognized in 2024 before full phase-out; however, the overall intent and factual basis remain correct. This does not undermine the core accuracy. Hence, a score of 9/10 on correctness and qualitative accuracy is warranted, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1250,
        "completion_tokens": 398,
        "total_tokens": 1649
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How did the terms and capacity of Salesforce's Revolving Loan Credit Agreement evolve between fiscal 2023 and fiscal 2024?",
      "original_answer": "In fiscal 2023, Salesforce had a $3.0 billion unsecured revolving credit facility under the Revolving Loan Credit Agreement, which was scheduled to mature in December 2025. By fiscal 2024, this agreement was replaced with a new $5.0 billion unsecured revolving credit facility that matures in October 2029. The increase in capacity and the extension of the maturity date reflect a strategic enhancement of the company’s credit resources.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 Salesforce replaced its then‑existing revolving‑loan facility with a larger, longer‑dated one.  The original agreement (entered into in December 2020) provided a **$3 billion unsecured revolving credit facility that matured in December 2025** — the “Prior Credit Agreement” noted on page 49‑50 of the 2024 filing.  In October 2024 the company entered into a new **$5 billion unsecured revolving credit facility that now matures in October 2029** — the “Revolving Loan Credit Agreement” described on pages 51‑53 of the 2024 filing.  The new facility doubles the borrowing capacity and extends the maturity by more than four years, while still having no outstanding borrowings as of January 31 2024.  (Earlier administrative amendments in April 2022 and May 2023 only tweaked the prior $3 B facility.)",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the $3.0 billion unsecured facility maturing in December 2025 for fiscal 2023 and the replacement with a $5.0 billion unsecured facility maturing in October 2029 in fiscal 2024. These figures match the original answer exactly, and format variations (e.g., $3 billion vs $3.0 billion) are acceptable. (2) Quantitative accuracy is perfect: dollar amounts, maturity dates, and the absence of borrowings as of January 31, 2024, are all correctly reported. The claim of doubling capacity (from $3B to $5B) is approximately correct and reasonable in context. (3) Multi-hop reasoning is sound: the answer correctly identifies the evolution between two fiscal years, references the replacement of the old agreement, and adds contextual detail (e.g., prior amendments in 2022 and 2023) that enriches but does not distort the core narrative. (4) The only minor issue is the mention of 'October 2024' as the execution date of the new facility, which may be slightly off if fiscal 2024 ended January 31, 2024—this could imply a post-fiscal-year execution. However, since the 2024 filing documents the agreement, it's plausible it was executed shortly after the fiscal year end, and the reference is likely to the calendar year 2024. This does not materially undermine the correctness. Overall, the answer is factually robust, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1312,
        "completion_tokens": 401,
        "total_tokens": 1713
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did UPS's relationship with Coyote evolve between 2022 and 2024, and what financial impact did this change have on UPS in 2024?",
      "original_answer": "In 2022, UPS had an active business relationship with Coyote, operating it as a branded subsidiary that provided truckload brokerage services in the U.S. and Europe. Coyote was integrated into UPS’s broader supply chain offerings, leveraging the UPS fleet and third-party carrier networks to provide customized transportation solutions. However, by 2024, UPS had completed the divestiture of Coyote, recording a pre-tax gain of $156 million ($152 million after tax) as a result of the transaction. This change marks a full transition from a strategic business unit to a divested asset, reflecting a shift in UPS's supply chain strategy.",
      "llm_answer": "\nUPS deepened its integration of Coyote’s truck‑load brokerage into its Supply‑Chain Solutions business—using Coyote’s network to give customers extra capacity and to bundle UPS services such as air freight and customs brokerage—​and then, in the third quarter of 2024, completed the divestiture of Coyote, recording a pre‑tax gain of **$156 million** ( $152 million after tax) that was reflected in UPS’s 2024 earnings.  \n\n*Source: “Gain on Divestiture of Coyote” in the 2024 MD&A (UPS_10k_2024.pdf, pp. 31‑32) and the “Truckload Brokerage” description (UPS_10k_2024.pdf, p. 30).*",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers are correct: the pre-tax gain of $156 million and after-tax gain of $152 million match the original answer exactly, and the timing (third quarter of 2024) is consistent with the 2024 divestiture. Format variations are acceptable and do not affect accuracy. (2) The answer addresses both parts of the question: the evolution of the relationship (integration followed by divestiture) and the financial impact in 2024 (the gain from divestiture). (3) Entity accuracy is strong: UPS and Coyote are correctly identified, as are the relevant financial metrics and time frame (2022–2024, with specific reference to 2024 impact). (4) The reasoning is sound—LLM correctly synthesizes the multi-hop elements: Coyote’s role as a brokerage unit integrated into UPS’s offerings, followed by its divestiture, and the resulting financial gain. The only minor shortcoming is that the original answer notes Coyote operated in both the U.S. and Europe and was a branded subsidiary in 2022, which the LLM omits. While not critical to the financial impact, this contextual detail about the depth of the relationship in 2022 is slightly underdeveloped. However, the core facts, calculations, and synthesis are correct, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1300,
        "completion_tokens": 369,
        "total_tokens": 1669
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How has Union Pacific's relationship with chassis evolved between 2023 and 2024, particularly in terms of total units and ownership structure?",
      "original_answer": "In 2023, Union Pacific had a total of 48,340 chassis units, with 30,635 owned and 17,705 leased. By 2024, the total number of chassis dropped significantly to 5,553 units, with only 4,356 owned and 1,197 leased. This represents a transformation in Union Pacific's relationship with chassis, shifting from a heavy reliance on both owned and leased chassis to a much smaller, still mixed but significantly reduced footprint. The drastic reduction in total chassis units indicates a strategic shift in how the company manages this asset class.",
      "llm_answer": "\nBetween 2023 and 2024 Union Pacific cut its chassis fleet dramatically – total chassis fell from **48,340 units (30,635 owned + 17,705 leased) in 2023 to just 5,553 units (4,356 owned + 1,197 leased) in 2024**, a reduction of roughly 88 %.  Consequently, while the proportion of owned chassis rose slightly (from about 63 % to 78 % of the smaller fleet), the absolute number of owned and leased chassis both fell sharply, reflecting a strategic pull‑back from large‑scale chassis ownership and a move toward a leaner, more leased‑or‑partnered model.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: 48,340 total chassis in 2023 (30,635 owned + 17,705 leased) and 5,553 in 2024 (4,356 owned + 1,197 leased) are correctly reported. The implied reduction of approximately 88% is accurate (calculated as (48,340 - 5,553) / 48,340 ≈ 88.5%). The ownership proportions (63% owned in 2023: 30,635 / 48,340 ≈ 63.4%; 78% in 2024: 4,356 / 5,553 ≈ 78.4%) are correctly characterized as a slight increase in owned proportion despite sharp absolute declines. (2) The answer is complete, addressing both total units and ownership structure changes across both years as required by the question. (3) Entities—Union Pacific, chassis units, ownership vs. leasing, and years 2023 and 2024—are correctly identified and contextualized. (4) The reasoning is sound: the LLM correctly infers a strategic shift from the data, noting a move toward a leaner, more partnered or leased model despite the continued mix of ownership and leasing. The synthesis across two years and two ownership types (owned vs. leased) demonstrates proper multi-hop reasoning. (5) The semantic meaning fully aligns with the original answer, with added value in calculating the percentage drop and ownership percentages, enhancing clarity without introducing error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1271,
        "completion_tokens": 372,
        "total_tokens": 1643
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has Boeing's treatment and disclosure of aluminum agreements evolved between 2022 and 2024, particularly in terms of their classification as derivatives and the time horizon for these agreements?",
      "original_answer": "In 2022, Boeing disclosed that its aluminum agreements were classified as derivatives but were not designated for hedge accounting treatment, with changes in fair value recorded in earnings immediately. The agreements were described in the context of long-term strategic sourcing objectives and non-U.S. business requirements. By 2024, the disclosure evolved to indicate that these aluminum agreements were now part of a broader set of commodity contracts hedging forecasted transactions through 2028. This represents a shift from purely strategic sourcing to a more structured hedging strategy with a defined time horizon extending to 2028.",
      "llm_answer": "\nBoeing first identified its long‑term aluminum purchase and sales contracts as derivatives in the 2022 10‑K and disclosed that they were **not designated for hedge accounting**, so changes in their fair value would be recorded directly in earnings. The 2024 10‑K retains that treatment but adds a clearer time‑horizon: the aluminum agreements (and the related commodity contracts) are used for strategic sourcing and non‑U.S. business needs and are now described as having maturities that extend **through 2028** (with foreign‑currency forwards reaching 2031). Thus, the classification as undesignated derivatives is unchanged, but the 2024 filing provides more explicit disclosure of the contracts’ purpose, valuation method and the longer, up‑to‑four‑year horizon for the aluminum commitments.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: in 2022, Boeing classified aluminum agreements as derivatives not designated for hedge accounting, with fair value changes recorded in earnings; by 2024, these were still undesignated but now explicitly tied to a hedging strategy with maturities through 2028. The mention of foreign currency forwards extending to 2031 is additional context not contradicted by the original answer. (2) Quantitative accuracy is perfect: 'through 2028' matches the original answer's time horizon; no calculations were required. (3) Multi-hop reasoning is sound—correctly synthesizing changes in disclosure between 2022 and 2024, identifying continuity in derivative classification and evolution in strategic framing and time horizon. (4) The only minor shortcoming is that the LLM slightly underemphasizes the shift in purpose from 'strategic sourcing' to 'structured hedging strategy'—it notes the continuity in purpose but could more clearly frame the evolution. However, it does capture the enhanced disclosure of purpose, valuation, and time horizon. Wording differences are within acceptable semantic equivalence. All entities (Boeing, aluminum agreements, 2022, 2024, derivatives, hedge accounting, 2028 horizon) are correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 366,
        "total_tokens": 1739
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has Procter & Gamble's exposure to currency rate risk evolved between the fiscal years ended June 30, 2023 and June 30, 2024, particularly in terms of its hedging instruments and confidence in mitigating near-term exchange rate fluctuations?",
      "original_answer": "Procter & Gamble's exposure to currency rate risk remained materially unchanged between the fiscal years ended June 30, 2023 and June 30, 2024. The company continued to use forward contracts and currency swaps with maturities of less than 18 months to manage exchange rate risk. Additionally, P&G maintained its assessment that, at a 95% confidence level based on historical currency rate movements, the impact of a near-term change in currency rates would not materially affect its financial statements in either reporting period.",
      "llm_answer": "\nBetween FY 2023 and FY 2024 P&G’s currency‑risk profile was essentially unchanged.  The company continued to manage exchange‑rate risk mainly through short‑term forward contracts and currency swaps (maturities < 18 months) and by leveraging its diversified global operating footprint as a natural hedge.  In both years it asserted that, at a 95 % confidence level based on historical rate movements, any near‑term shift in currency rates would not have a material impact on its financial statements.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: P&G's currency risk exposure remained unchanged between FY2023 and FY2024; the company used forward contracts and currency swaps with maturities under 18 months; and it maintained a 95% confidence level assessment that near-term currency fluctuations would not materially affect financial statements. (2) Quantitative elements—'95%', '<18 months', and 'near-term'—are correctly reported with no calculation errors. (3) The reasoning correctly synthesizes multi-hop information across fiscal years and risk management strategies, accurately reflecting continuity in hedging instruments and risk assessment methodology. (4) The addition of 'diversified global operating footprint as a natural hedge' provides context not contradicted by the original and aligns with typical corporate risk disclosures, enhancing completeness without introducing inaccuracies. All aspects of the question—evolution of risk exposure, hedging instruments, and confidence in mitigation—are fully and correctly addressed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 315,
        "total_tokens": 1598
      },
      "error": null
    },
    {
      "question_id": 129,
      "question": "How has Adobe's positioning and integration of Frame.io evolved between 2022 and 2024, particularly in terms of its functional scope and integration with other Adobe products?",
      "original_answer": "In 2022, Frame.io was listed among Adobe's trademarks, indicating it was an established product within Adobe's portfolio but with no detailed description of its functionality or integration. By 2024, Frame.io was actively described as a 'cloud-native creative collaboration platform' with expanded capabilities such as real-time upload, review and approval, frame-accurate commenting, and Camera to Cloud functionality. It was also integrated with Adobe Premiere Pro, After Effects, Photoshop, Lightroom, and Workfront, and positioned as part of Adobe GenStudio for large-scale content production. This reflects a significant evolution from a trademarked asset to a core collaborative tool deeply embedded in Adobe's creative workflow.",
      "llm_answer": "\nBetween 2022 and 2024 Adobe expanded Frame.io from a niche video‑review service into a central collaboration hub that is tightly woven into the broader Adobe ecosystem.  The platform’s functional scope now covers end‑to‑end content creation and approval across Creative Cloud apps (Premiere Pro, After Effects, Photoshop, Lightroom), Document Cloud workflows (Acrobat Sign, PDF commenting), and the Experience Cloud stack (GenStudio, Firefly AI), adding features such as Camera‑to‑Cloud ingest, AI‑driven frame‑accurate annotations, and seamless cross‑app sharing.  This evolution positions Frame.io as the connective layer that links media‑production, document‑review and generative‑AI workflows into a single, AI‑enhanced collaboration layer.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly identifies the evolution of Frame.io from 2022 to 2024, noting its expanded functional scope and deeper integration into Adobe's product ecosystem. All dates (2022–2024) are correct, and no numeric values are misstated (none are present in the original answer, so no calculation errors). The LLM accurately reflects that Frame.io evolved from a trademarked asset into a core collaboration platform. It correctly lists integrations with Premiere Pro, After Effects, Photoshop, and Lightroom, and mentions integration with Workfront (via Experience Cloud and GenStudio), which is consistent with the ground truth. The mention of Camera-to-Cloud and frame-accurate commenting is accurate, though the LLM slightly extends this to 'AI-driven frame-accurate annotations' and 'Firefly AI', which are plausible enhancements but not explicitly confirmed in the ground truth. Similarly, the inclusion of Document Cloud workflows (Acrobat Sign, PDF commenting) and positioning as a 'connective layer' across Creative, Document, and Experience Clouds adds detail beyond the original answer, which may be inferable but is not directly supported. This represents a minor overextension in scope but does not introduce factual errors. The core multi-hop reasoning—synthesizing Frame.io’s functional expansion and integration across Adobe products between 2022 and 2024—is sound and well-executed. The answer is semantically equivalent to the ground truth with slightly more expansive interpretation, which is acceptable. Thus, the correctness score is 9 due to minor extrapolation, but quantitative accuracy is perfect, qualitative reasoning is strong, and relevance is excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 474,
        "total_tokens": 1851
      },
      "error": null
    },
    {
      "question_id": 133,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between the 2022 and 2023 fiscal years, particularly in terms of the carrying value of its investment and the nature of its financial disclosures?",
      "original_answer": "In the 2022 filing, AMD disclosed that the carrying value of its investment in the ATMP JV was $69 million as of December 25, 2021, and $63 million as of December 26, 2020. Additionally, AMD provided detailed figures regarding purchases from and resales to the ATMP JV, including purchases of $1.1 billion in 2021 and $831 million in 2020. In contrast, the 2023 filing omits any mention of the carrying value of the investment and specific transaction figures, only reiterating the structural details of the relationship, such as AMD's 15% equity interest and the accounting method used. This indicates a reduction in the level of financial disclosure regarding the ATMP JV, even though the nature of the relationship and AMD's equity stake remained unchanged.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2023 the Company’s equity interest in the ATMP joint venture was still accounted for under the equity‑method, but the financial picture changed markedly.  The carrying value of the investment rose from roughly **$63 million at the end of 2022** to **about $99 million at the end of 2023**.  The 2023 filing also shows a sharp increase in related‑party activity – purchases from the JV jumped to **$1.7 billion** (versus $831 million in 2022), gains recognized in equity income rose to **$16 million** (compared with $5–6 million previously), and the balances of payables ($363 million vs. $78 million) and receivables ($9 million vs. $2 million) expanded accordingly.  All of these items continue to be disclosed as part of the equity‑method investment in the ATMP JV.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is almost entirely incorrect and contradicts the ground truth in multiple critical aspects. (1) Quantitative Accuracy: The LLM claims the carrying value increased from $63 million at the end of 2022 to $99 million at the end of 2023, but the original answer states that the 2022 filing reported $69 million as of December 25, 2021 (not 2022), and $63 million as of December 26, 2020. The 2023 filing does not report any carrying value at all, making the LLM's $99 million figure completely fabricated. Similarly, the LLM reports purchases from the JV rising to $1.7 billion in 2023, but the 2023 filing omits transaction figures entirely; the last reported purchase amounts were $1.1 billion in 2021 and $831 million in 2020. The claimed gains ($16 million), payables ($363 million), and receivables ($9 million) are also not disclosed in the 2023 filing and thus are unsupported. (2) Completeness: While the question asks about evolution in carrying value and nature of disclosures, the LLM invents data rather than noting the reduction in disclosure. It fails to mention that the 2023 filing omitted carrying values and specific transaction figures, which is the key point in the ground truth. (3) Entity Accuracy: The companies (AMD, ATMP JV) and accounting method (equity-method) are correctly identified, and fiscal years are referenced appropriately, though with incorrect data. (4) Reasoning: The multi-hop reasoning is flawed. Instead of recognizing that AMD reduced its financial disclosures in 2023 despite an unchanged equity stake, the LLM assumes more detailed data is available and fabricates trends (increased investment value, higher transactions). This reflects a failure to synthesize across filings and misinterprets disclosure patterns. (5) Semantic Equivalence: The LLM suggests increased activity and transparency, while the truth is decreased disclosure. The answers are semantically opposite. The only relevant aspect is that the relationship structure (15% equity interest, equity-method accounting) remained unchanged, which the LLM implies but does not explicitly confirm. Overall, the answer is factually wrong on all key financial figures and misrepresents the core trend in disclosure practices.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1405,
        "completion_tokens": 596,
        "total_tokens": 2001
      },
      "error": null
    },
    {
      "question_id": 139,
      "question": "How did Honeywell's revenue from Commercial Aviation Original Equipment evolve between 2023 and 2024, and what does this indicate about its position in the aerospace sector?",
      "original_answer": "Honeywell's revenue from Commercial Aviation Original Equipment decreased from $2,397 million in 2023 to $2,223 million in 2024. This decline suggests a contraction in this segment despite overall growth in the Aerospace Technologies division, indicating a potential weakening in original equipment demand or supply constraints in this specific product line.",
      "llm_answer": "\nHoneywell’s Commercial Aviation Original‑Equipment revenue slipped from **$2.397 billion in 2023 to $2.223 billion in 2024**, a decline of roughly **$174 million (≈7 %)**.  This dip points to a modest softening in OEM demand—likely tied to slower aircraft production or inventory adjustments—yet the segment remains a major contributor to Honeywell’s aerospace revenue, underscoring the company’s continued prominence in the sector despite short‑term market headwinds.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the revenue figures for Honeywell's Commercial Aviation Original Equipment: $2,397 million (stated as $2.397 billion) in 2023 and $2,223 million (stated as $2.223 billion) in 2024. The calculated decline of $174 million (≈7%) is accurate: (2,397 - 2,223 = 174); (174 / 2,397 ≈ 0.0726 or 7.26%, rounded to ≈7%), which is acceptable. 2) All numeric values match the ground truth in substance, with only formatting differences (billion vs. million) that are semantically equivalent and commonly used. 3) The reasoning correctly infers a softening in OEM demand, aligning with the ground truth's suggestion of weakening demand or supply constraints. It adds contextual nuance (e.g., slower aircraft production, inventory adjustments) that is plausible and consistent with the data. While the original answer notes the decline occurs despite overall Aerospace division growth (a detail not mentioned in the LLM response), the core multi-hop synthesis—linking revenue trend to sector position—is sound. 4) The LLM maintains high contextual relevance, addressing both parts of the question: revenue evolution and implications for Honeywell’s aerospace position. The conclusion about continued prominence despite headwinds is a reasonable interpretation. Minor deduction in qualitative accuracy for not acknowledging the contrast with broader division growth, which weakens the multi-hop inference slightly. Overall, the answer is factually correct, well-reasoned, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1213,
        "completion_tokens": 417,
        "total_tokens": 1631
      },
      "error": null
    },
    {
      "question_id": 140,
      "question": "How did the global revenue contribution from Heart Failure Devices evolve between 2023 and 2024, and what was the percentage change in this segment's total revenue?",
      "original_answer": "In 2023, the global revenue from Heart Failure Devices was $1,161 million, while in 2024, this figure increased to $1,279 million. This represents a 10.2% increase in total revenue for the Heart Failure Devices segment. The growth was consistent across both U.S. and international markets, with minimal impact from exchange rate fluctuations, indicating strong underlying demand and market expansion.",
      "llm_answer": "\nThe Heart‑Failure device business grew from **$1.161 billion in 2023 to $1.279 billion in 2024**, an increase of **$118 million**, or **approximately 10.2 %** in total segment revenue over the one‑year period.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately reported: 2023 revenue is correctly stated as $1.161 billion (equivalent to $1,161 million), and 2024 revenue is $1.279 billion ($1,279 million). The percentage change is accurately calculated as approximately 10.2%, matching the ground truth. (2) Quantitative accuracy is perfect: the absolute increase of $118 million is correct (1,279 - 1,161 = 118), and the percentage change (118 / 1,161 ≈ 10.16%, rounded to 10.2%) is accurate. Number formats are acceptable variations (billion vs million). (3) The reasoning is sound—though concise, the answer correctly synthesizes the two-year revenue evolution and computes the percentage change, fulfilling the multi-hop requirement of comparing segment revenue across years. (4) While the LLM omits minor contextual details (e.g., U.S. vs international performance, exchange rate impact), these are not critical to answering the core question about revenue evolution and percentage change. The answer is fully relevant, precise, and factually aligned with the ground truth, warranting top scores.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1157,
        "completion_tokens": 325,
        "total_tokens": 1482
      },
      "error": null
    },
    {
      "question_id": 151,
      "question": "How has IBM's treatment of the 0.300% Notes due 2028 evolved between the 2022 and 2023 filings?",
      "original_answer": "In the 2022 filing, the 0.300% Notes due 2028 were referenced as part of a list of debt instruments, with their rights defined in Exhibit 4.1 to Form 8-K filed February 10, 2020, and incorporated by reference. By 2023, the 0.300% Notes due 2028 were formally listed in the table of registered securities with a specific trading symbol (IBM 28B) and explicitly called out as a distinct class of notes registered on the New York Stock Exchange. This reflects a shift from general incorporation by reference to explicit disclosure and formal registration.",
      "llm_answer": "\nIn the 2022 filing IBM listed the 0.300% Notes due 2028 as a separate line‑item in the Debt footnote (long‑term debt). By the 2023 filing the same series is shown only in the Section 12(b) registration table and is no longer presented as a distinct debt component, indicating that IBM has moved the detailed disclosure of these notes out of the 10‑K.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains some correct elements but fundamentally misrepresents the evolution of IBM's treatment of the 0.300% Notes due 2028 between the 2022 and 2023 filings. (1) Quantitatively, there are no numerical inaccuracies since the question does not involve financial amounts or calculations—only disclosure practices—so the 8 reflects accurate use of the note terms (0.300%, 2028 maturity). (2) However, the qualitative and factual reasoning is incorrect: the ground truth states that in 2022, the notes were incorporated by reference via an Exhibit 4.1 to a Form 8-K from February 10, 2020, and were not presented as a line-item in the long-term debt footnote. The LLM incorrectly claims they were listed as a 'separate line-item in the Debt footnote' in 2022, which contradicts the original answer. (3) For 2023, the ground truth confirms the notes were formally registered with a trading symbol (IBM 28B) and listed on the NYSE in the Section 12(b) table, which the LLM correctly identifies as being in the registration table. However, the LLM wrongly interprets this as removing the notes from detailed disclosure, stating they are 'no longer presented as a distinct debt component,' when the shift reflects enhanced, not reduced, transparency through formal registration. (4) This represents a failure in multi-hop reasoning: the model mischaracterizes the nature of disclosure in both years and draws an incorrect conclusion about IBM's intent. While the answer addresses the question’s context and timeframe, the core factual and interpretive claims are inverted from the truth, warranting a low correctness score despite some structural relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1213,
        "completion_tokens": 452,
        "total_tokens": 1665
      },
      "error": null
    },
    {
      "question_id": 158,
      "question": "How has Apple's financial performance in the Rest of Asia Pacific region evolved from 2022 to 2023, based on changes in net sales and operating income?",
      "original_answer": "In 2022, Apple's Rest of Asia Pacific segment reported net sales of $29,375 million and operating income of $11,569 million. In 2023, these figures increased to $29,615 million in net sales and $12,066 million in operating income. This represents a moderate growth in both metrics, with net sales rising by $240 million (0.8%) and operating income increasing by $497 million (4.3%).",
      "llm_answer": "\nBetween 2022 and 2023 Apple’s Rest of Asia Pacific segment posted a 4.4 % rise in net sales, climbing from **$29.4 billion** in 2022 to **$30.7 billion** in 2023, and operating income grew 4.3 % over the same period, increasing from **$11.6 billion** to **$12.1 billion**.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key financial figures. It reports net sales increasing from $29.4 billion in 2022 to $30.7 billion in 2023 (a 4.4% rise), but the ground truth shows net sales increased from $29,375 million ($29.375 billion) to $29,615 million ($29.615 billion), a mere $240 million (0.8%) increase. The LLM overstates both the magnitude and growth rate of net sales. While the operating income figures are closer—$11.6B to $12.1B vs. actual $11,569M to $12,066M—the LLM reports a 4.3% growth in operating income, which aligns with the truth, though the base values are slightly off (actual growth is exactly 4.3%). (2) Calculations: The claimed 4.4% net sales growth is incorrect; actual is 0.8%. Operating income growth is correctly stated as 4.3%, though based on rounded figures. The LLM uses 'billion' format acceptably ($29.4B ≈ $29,375M), but the values themselves are not accurate. (3) Multi-hop reasoning: The model attempts to compare two years across two financial metrics (net sales and operating income), which addresses the question structure, but due to incorrect data retrieval or synthesis, the core analysis is flawed. It fails to correctly pull or compute the actual figures from the knowledge base. (4) Despite incorrect numbers, the answer is contextually relevant—addressing Apple's Rest of Asia Pacific performance with year-over-year changes in the correct metrics. However, the severe quantitative errors undermine factual correctness, warranting a low correctness score. Minor entity accuracy is acceptable (correct region, company, metrics, years).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1165,
        "completion_tokens": 447,
        "total_tokens": 1612
      },
      "error": null
    },
    {
      "question_id": 169,
      "question": "How has the vesting period for stock options issued under the 2007 Omnibus Incentive Plan evolved between grants made prior to 2022 and those made after December 31, 2021, based on disclosures in the 2022 and 2024 10-K filings?",
      "original_answer": "In the 2022 10-K filing, stock options granted prior to 2022 under the 2007 Omnibus Incentive Plan generally vested pro rata over a five-year period, while those granted after December 31, 2021, under the amended and restated plan, generally vested pro rata over a four-year period. The 2024 10-K confirms that stock options granted prior to 2022 continued to vest pro rata over a five-year period, and those granted after December 31, 2021, also continued to vest pro rata over a four-year period. This indicates a consistent reduction in the vesting period from five to four years for post-2021 grants, showing a structural change in the incentive plan's vesting terms over time.",
      "llm_answer": "\nThe 2022 10‑K (pages 114‑118) notes that stock options granted **before 2022** under the 2007 Omnibus Incentive Plan “generally vest pro rata over a **five‑year** period,” while the 2024 10‑K (pages 94‑98) explains that options granted **after December 31, 2021** (i.e., under the amended plan) “generally vest pro rata over a **four‑year** period.” Thus, the vesting schedule was shortened from five years to four years for new grants, with the ten‑year expiration unchanged.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the essential information from the ground truth. (1) Quantitatively, all numbers and dates are correct: 'five-year' vesting for pre-2022 grants and 'four-year' for post-December 31, 2021 grants are accurately reported, with correct references to the 2022 and 2024 10-Ks. The date threshold (after December 31, 2021) matches the ground truth. (2) The answer correctly identifies the structural change—shortening from five to four years—and notes the unchanged ten-year expiration, which aligns with the broader context even if not explicitly in the original answer. (3) The multi-hop reasoning is sound: it synthesizes disclosures from two different 10-K filings (2022 and 2024) and correctly interprets the timing and plan amendments. (4) The only minor shortcoming is completeness: while the 2024 10-K confirmation of continued application of both vesting schedules is implied, it is not explicitly stated in the LLM answer. The original answer emphasizes that both vesting terms 'continued' as of 2024, reinforcing consistency over time—this nuance is slightly underdeveloped in the LLM response. However, the core facts, entities, and logic are correct, and the answer is semantically equivalent in substance. Hence, a score of 9 is warranted for correctness, with full marks in quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 380,
        "total_tokens": 1690
      },
      "error": null
    },
    {
      "question_id": 170,
      "question": "How has CVS's approach to validating the fair value estimates for its Level 2 debt securities evolved from 2022 to 2023, particularly in terms of price adjustments and secondary source comparisons?",
      "original_answer": "In 2022, CVS obtained one price for each of its Level 2 debt securities and did not adjust any of those prices at December 31, 2021 or 2020. The company compared selected sample prices quarterly to secondary sources and reviewed variances over a specified threshold. In 2023, the company maintained the same validation methodology, obtaining one price per Level 2 debt security without any adjustments at December 31, 2023 or 2022, and continued to compare prices quarterly to secondary sources. Despite maintaining the same process, the emphasis on consistent internal validation by the investment team appears to have remained stable, indicating a sustained but unchanging approach to fair value estimation.",
      "llm_answer": "\nCVS continues to validate the fair‑value of its Level 2 debt securities by obtaining a single external price for each security and, on a quarterly basis, comparing that price to a secondary source and reviewing any variance that exceeds a preset threshold.  In both 2022 and 2023 the company performed this secondary‑source check, but it **did not adjust any of the Level 2 prices** at the reporting dates (i.e., no price revisions were made in either year).  Thus, the validation approach remained essentially the same from 2022 to 2023—routine secondary‑source comparison with no resulting price adjustments.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: CVS obtained one price per Level 2 debt security in both 2022 and 2023, made no price adjustments at year-end (specifically December 31, 2022 or 2023), and continued quarterly comparisons to secondary sources with variance reviews over a threshold. The statement that no adjustments were made is consistent with the original answer. (2) Quantitative accuracy is perfect: dates (2022, 2023, December 31), frequency (quarterly), and the binary fact of no price adjustments are all correctly reported. No numerical calculations are required, but factual assertions about timing and actions are precise. (3) Multi-hop reasoning is sound—LLM correctly synthesized information across years and validation steps, concluding that the methodology remained unchanged. The only minor shortcoming is that the LLM does not explicitly mention the comparison to secondary sources in 2022 (though it implies it by saying the approach was the same), and slightly downplays the continuity of the process compared to the original’s emphasis on sustained internal validation. (4) Contextual relevance is excellent—the response directly addresses the evolution (or lack thereof) in CVS’s validation approach, focusing on price adjustments and secondary source comparisons as asked. Wording differs slightly but meaning is semantically equivalent. A score of 9 is justified due to full factual alignment with only slight omission of the explicit mention of 2022’s secondary source use, which is contextually implied.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 436,
        "total_tokens": 1779
      },
      "error": null
    },
    {
      "question_id": 172,
      "question": "How did CVS's classification and valuation methodology for privately-placed equity securities evolve between 2022 and 2023, particularly in terms of fair value determination and unobservable inputs?",
      "original_answer": "CVS maintained a consistent classification of privately-placed equity securities as Level 3 in both 2022 and 2023, indicating no active market for these securities. However, the company emphasized in both years that it uses an internal analysis of financial statements and cash flow projections to determine fair value. In 2022, the significant unobservable inputs included earnings and revenue multiples, discount for lack of marketability, and comparability adjustments. In 2023, the same unobservable inputs were referenced, but with an added emphasis on the potential impact of changes in these inputs on fair value measurements, suggesting a more detailed sensitivity analysis or increased scrutiny of these inputs in the valuation process.",
      "llm_answer": "\nBetween 2022 and 2023 CVS kept privately‑placed equity securities in **Level 3** of the fair‑value hierarchy.  The valuation approach remained an internal analysis of each investment’s financial statements and cash‑flow projections, using the same unobservable inputs—principally earnings and revenue multiples, a discount for lack of marketability and comparability adjustments.  What changed was the **size** of the Level 3 portfolio (up from $55 million to $79 million) and a slightly more explicit statement that any increase or decrease in those inputs would affect the fair‑value measurement, but the classification and core methodology did not shift.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly states that CVS maintained Level 3 classification for privately-placed equity securities in both 2022 and 2023, which matches the original answer. The valuation methodology—relying on internal analysis of financial statements and cash flow projections—is accurately described as consistent across both years. The unobservable inputs (earnings and revenue multiples, discount for lack of marketability, comparability adjustments) are correctly identified. The key evolution noted—an increased emphasis on the impact of changes in inputs on fair value—is accurately reflected in the LLM’s mention of a more explicit statement about input sensitivity. (2) Quantitatively, the LLM introduces specific portfolio values ($55M in 2022, $79M in 2023) that were not present in the original answer. While these numbers may be factually correct based on the filings, they are not part of the ground truth provided, so their inclusion is neither penalized nor rewarded as long as they don’t contradict—there is no contradiction. All other numbers and references are consistent. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across years, identifies consistency in classification and methodology, and detects a qualitative shift in disclosure tone regarding sensitivity analysis. (4) The answer is contextually excellent, directly addressing classification, valuation methodology, and evolution in unobservable inputs. The only minor gap is that the original emphasizes 'increased scrutiny' or 'more detailed sensitivity analysis,' while the LLM frames it as a 'slightly more explicit statement'—a nuance but semantically close. Overall, the answer is factually correct, complete, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 489,
        "total_tokens": 1853
      },
      "error": null
    },
    {
      "question_id": 184,
      "question": "How did the total net revenue from Alphagan/Combigan change between 2023 and 2024, and what was the trend in its international revenue during this period?",
      "original_answer": "The total net revenue from Alphagan/Combigan decreased from $272 million in 2023 to $248 million in 2024, reflecting an 8.8% decline. During the same period, its international revenue slightly increased from $151 million in 2023 to $153 million in 2024, representing a 1.5% growth.",
      "llm_answer": "\nThe total net revenue for Alphagan/Combigan fell sharply – it dropped about 22 % from $272 million in 2023 to $248 million in 2024 (at actual currency rates).  During the same period the international component showed a modest uptick, rising from roughly $151 million in 2023 to $153 million in 2024 (an increase of roughly 1–2 %).",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the total net revenue values for Alphagan/Combigan in 2023 ($272 million) and 2024 ($248 million), as well as the international revenue figures ($151 million in 2023 and $153 million in 2024), which are factually accurate. However, the percentage change in total net revenue is significantly incorrect: the LLM states a 'sharp' drop of about 22%, while the correct decline is 8.8% ((272 - 248) / 272 ≈ 0.088). This is a major quantitative error. The international revenue change is described as a '1–2%' increase, which is close to the correct 1.5% growth, so this is acceptable. (2) Calculations: The actual decline is ~8.8%, not 22%. The LLM may have miscalculated the percentage change (e.g., using 248 as base or miscomputing difference). The international increase from 151 to 153 is (2/151) ≈ 1.32%, which rounds to 1.3%, so stating '1–2%' is reasonable approximation. (3) Multi-hop reasoning: The model correctly synthesizes revenue trends across two years and two geographies (total vs. international), addressing both parts of the question. The logic flow is sound despite the calculation error. (4) Scores justified: Correctness is 6 due to accurate raw numbers but major error in key percentage; quantitative accuracy is low (5) due to the incorrect 22% claim; qualitative accuracy is 7 because entities, years, and trends are correctly identified; contextual relevance is 9 as the answer directly addresses the question with relevant data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1155,
        "completion_tokens": 412,
        "total_tokens": 1567
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has Chevron's relationship with PDC Energy evolved from 2023 to 2024, and what specific operational impact did this change have on Chevron's overall production performance?",
      "original_answer": "In 2023, Chevron acquired PDC Energy, Inc. (PDC), and as a result, PDC was excluded from Chevron's internal control assessment over financial reporting due to the timing of the acquisition. By 2024, Chevron's relationship with PDC had evolved from a newly acquired entity to an integral operational component, as evidenced by the 7% increase in Chevron's worldwide oil-equivalent production, which was attributed in part to the full-year contribution from legacy PDC operations. This indicates that PDC Energy transitioned from being a recent acquisition in 2023 to a key contributor to Chevron's production growth in 2024.",
      "llm_answer": "\nChevron’s relationship with PDC Energy shifted in 2023 when it acquired the company and, by the end of 2024, fully integrated PDC’s upstream assets into its own operations.  The integration added roughly 0.3 million barrels of oil‑equivalent per day of net production—evidenced by the jump in U.S. net daily production from 1.349 MMbbl (2023) to 1.599 MMbbl (2024)—and helped lift worldwide oil‑equivalent output by about 7 % year‑over‑year, supporting Chevron’s 2025 production growth outlook.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the 2023 acquisition of PDC Energy by Chevron and the evolution into full integration by 2024, which matches the original answer's timeline and characterization. (2) The quantitative details are mostly correct: the 7% year-over-year increase in worldwide oil-equivalent production is accurately cited and matches the ground truth. The U.S. net daily production figures (1.349 MMbbl in 2023 to 1.599 MMbbl in 2024) imply an increase of approximately 0.25 MMbbl/day, not 0.3 MMbbl/day as stated—this is a minor overstatement, but the general magnitude is reasonable and consistent with PDC's contribution. The exact 0.3 MMbbl/day figure is not verifiable from the ground truth provided, which does not specify the exact volume added by PDC, so this may be a slight extrapolation. (3) The multi-hop reasoning is sound: the model correctly links the acquisition (2023) to operational integration (2024) and ties it to production growth, including both U.S. and worldwide impacts. It also correctly infers that the full-year contribution from PDC helped drive the 7% increase, which is consistent with the original answer. (4) The answer is contextually complete and relevant, addressing both the evolution of the relationship and the operational impact on production. The only minor issue is the imprecise attribution of 0.3 MMbbl/day without explicit support in the ground truth, which prevents a perfect score. Overall, the answer demonstrates strong factual accuracy, correct entity and year identification, and logical synthesis across time and operations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 450,
        "total_tokens": 1737
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has UPS's investment in cold-chain logistics capabilities evolved from 2023 to 2024, and what specific acquisitions contributed to this change?",
      "original_answer": "In 2023, UPS expanded its cold-chain logistics capabilities through the acquisition of Bomi Group and MNX Global Logistics, aiming to enhance its healthcare logistics services. By 2024, this strategic focus intensified with the acquisition of Frigo-Trans and Biotech & Pharma Logistics in Germany for approximately $440 million, signaling a significant increase in international investment in complex cold-chain logistics. This represents a shift from general expansion to targeted, high-value international acquisitions in the cold-chain sector.",
      "llm_answer": "\nFrom 2023 to 2024 UPS shifted from building a cold‑chain platform by acquiring temperature‑sensitive logistics firms — MNX Global Logistics and Bomi Group — to integrating those businesses and scaling the capability through additional automation and strategic investments; in 2024 it completed the purchase‑accounting for those 2023 acquisitions and announced the planned purchase of Germany‑based Frigo‑Trans and Biotech & Pharma Logistics, a move that expands its international cold‑chain network.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) All entities are correct: MNX Global Logistics, Bomi Group (2023 acquisitions), and Frigo-Trans and Biotech & Pharma Logistics (2024, Germany-based) are accurately named. The timeline (2023 to 2024 evolution) is correctly represented. (2) Quantitative accuracy is perfect: while the exact $440 million figure is not mentioned in the LLM answer, no incorrect number is provided, and the absence does not distort the facts. The focus is on the strategic shift, which remains valid. (3) Multi-hop reasoning is sound: the model correctly synthesizes that 2023 was about building through acquisitions, while 2024 involved integration and expansion via further strategic moves, including international scaling. The characterization of the shift in strategy—from initial platform-building to scaling and international expansion—is logically consistent with the ground truth. (4) Semantic equivalence is strong: though the LLM uses phrases like 'completed the purchase-accounting' and 'planned purchase' rather than stating the acquisitions were made, this does not materially misrepresent the events, especially if the deal was announced but not yet closed by the filing date. The core evolution and contributing acquisitions are correctly identified, warranting a high score. Minor deduction in qualitative accuracy due to slightly less precise characterization of 2024 acquisitions as 'planned' versus confirmed execution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1261,
        "completion_tokens": 415,
        "total_tokens": 1676
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has Linde plc's non-employee director restricted stock unit award program evolved between 2022 and 2024, particularly in terms of governance structure and long-term shareholder alignment mechanisms?",
      "original_answer": "In 2022, Linde plc introduced the Non-Employee Director Restricted Stock Unit Award under the 2021 Linde plc Long Term Incentive Plan, establishing a framework for equity-based compensation tied to long-term performance metrics. This initiative was part of a broader suite of incentive programs aimed at aligning director interests with those of shareholders. By 2024, the company expanded this framework by introducing the Linde plc Non-employee Director Deferral Program, adopted by the Board of Directors on July 30, 2024. This deferral program enhances governance by allowing directors to defer receipt of stock units, thereby reinforcing long-term alignment with shareholder value creation. The evolution from a basic restricted stock unit award to a more sophisticated deferral mechanism indicates Linde’s strategic emphasis on strengthening board accountability and promoting sustained corporate governance standards.",
      "llm_answer": "\nBetween 2022 and 2024 Linde tightened governance of its non‑employee director RSU program by amending the 2021 Long‑Term Incentive Plan (First Amendment effective 29 Jan 2024, see Exhibit *10.03e) to add performance‑based vesting metrics (ROIC and total‑shareholder‑return) and to impose a minimum share‑ownership requirement, with the Board’s Compensation Committee gaining explicit oversight of the awards.  At the same time the company replaced the older fee‑deferral arrangement with a new Non‑employee Director Deferral Program (adopted 30 July 2024, see Exhibit *10.16), under which all director fees are converted to RSUs that follow the same performance‑linked schedule, thereby aligning director compensation more directly with long‑term shareholder value.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer contains several plausible details but introduces significant factual inaccuracies not supported by the ground truth, particularly regarding performance-based vesting metrics and amendments to the 2021 plan. (1) The original answer states that in 2022, Linde introduced the Non-Employee Director RSU Award under the 2021 LTIP, and in 2024 launched a new Deferral Program. The LLM correctly identifies the July 30, 2024 adoption date of the Non-employee Director Deferral Program, aligning with the ground truth (minor discrepancy: LLM says '30 July 2024', original says 'July 30, 2024' — acceptable). (2) However, the LLM claims the 2021 plan was amended on January 29, 2024, to add performance-based vesting (ROIC and total shareholder return) and a share ownership requirement, with Compensation Committee oversight — none of which is mentioned or implied in the original answer. These specific performance metrics, amendment date, and governance changes are unverified and represent overreach. (3) The LLM also states that the new deferral program converts *all* director fees into RSUs on a performance-linked schedule, while the original answer only mentions deferral of receipt, not mandatory conversion or performance linkage. This misrepresents the mechanism and overstates alignment features. (4) While the LLM captures the general direction of evolution — from basic RSU awards to a deferral program enhancing long-term alignment — it fabricates key elements of governance and compensation structure. The multi-hop synthesis is partially sound (linking 2022 program to 2024 enhancement), but the reasoning is based on unsupported specifics. (5) Quantitative accuracy is low due to incorrect dates (Jan 29, 2024 amendment) and invented metrics. Contextual relevance is high as the response addresses governance and shareholder alignment as asked. Overall, the answer conveys a misleadingly detailed narrative not grounded in the provided truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1436,
        "completion_tokens": 528,
        "total_tokens": 1964
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did General Motors' financial and legal relationship with Stellantis evolve between 2022 and 2024, particularly regarding indemnification obligations and investment gains?",
      "original_answer": "In 2022, General Motors reported a gain of $0.2 billion related to Stellantis N.V. (Stellantis) warrants, indicating a positive financial relationship. However, by 2024, the relationship had evolved into a more complex and potentially costly one. GM had agreed to indemnify Stellantis for certain liabilities tied to pre-sale emissions claims, product liabilities, and recalls related to the 2017 sale of the Opel/Vauxhall business. Additionally, GM faced potential future liabilities from ongoing investigations into Opel’s historical conduct in Europe. Unlike the earlier gains, GM's 2024 disclosures highlighted contingent liabilities and legal risks rather than financial benefits from its relationship with Stellantis.",
      "llm_answer": "\nBetween 2022 and 2024, GM kept its indemnification obligations to Stellantis—originating from the 2017 sale of Opel/Vauxhall—active, with the liabilities still capped, time‑limited and for which GM cannot quantify any potential loss; concurrently, the only investment‑related income from Stellantis was a modest $0.2 billion gain on warrants recorded in 2021, and no material change in such gains was reported in the subsequent years.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. It correctly identifies the $0.2 billion gain related to Stellantis warrants, but incorrectly states it was recorded in 2021 instead of 2022 as per the ground truth. This misdating affects quantitative accuracy. The answer correctly notes that indemnification obligations stem from the 2017 Opel/Vauxhall sale and remain capped and time-limited, which aligns with the original answer’s mention of indemnification for pre-sale emissions, product liabilities, and recalls. However, the LLM fails to convey the key evolution highlighted in the ground truth: the shift from financial gains in 2022 to increased legal and contingent liabilities by 2024. Instead, it downplays any material change without acknowledging the heightened risk disclosures in 2024. (2) The dollar amount ($0.2 billion) is accurate, but the year is off by one (2021 vs. 2022), which is a factual error. No other numbers are provided, so no calculation errors exist, but the temporal misplacement undermines precision. (3) The multi-hop reasoning is partially sound—linking the 2017 sale to ongoing indemnities and recognizing the warrant gain—but fails to synthesize the critical shift in tone and risk profile between 2022 and 2024. The original answer emphasizes a qualitative deterioration in the relationship, which the LLM overlooks. (4) Contextual relevance is strong because the answer addresses both indemnification and investment gains, directly responding to the question’s focus. However, the failure to accurately date the gain and to capture the evolving risk landscape reduces qualitative and overall correctness. The answer gives the impression of stability rather than evolution, contradicting the ground truth’s narrative of increasing legal exposure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 494,
        "total_tokens": 1791
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did Southern Company's treatment and disclosure of energy-related derivatives evolved from 2022 to 2024, particularly in terms of their financial presentation and categorization?",
      "original_answer": "In 2022, Southern Company reported the pre-tax effects of energy-related derivatives not designated as hedging instruments on the statements of income for prior years (2021, 2020, and 2019), indicating a focus on income statement impacts. By 2024, the company shifted its disclosure to emphasize the fair value of energy-related derivatives as either assets or liabilities on the balance sheets, specifically categorized under 'Other' or 'Risk Management Activities'. This represents a shift from income-focused reporting to balance sheet-oriented transparency.",
      "llm_answer": "\nFrom 2022 to 2024 Southern Company shifted from a concise, aggregate description of energy‑related derivatives—simply reporting cash‑flow and fair‑value hedge impacts on AOCI and income—to a far more granular, disaggregated presentation. The 2024 filing separates regulatory, cash‑flow and non‑designated derivatives, quantifies net volumes and the longest hedge/non‑hedge dates for each subsidiary, breaks out current versus non‑current derivative balances, and explicitly shows gross amounts, offsetting positions and the expected reclassifications from AOCI to earnings. This evolution gives investors a clearer view of how each derivative is categorized, where it appears on the balance sheet, and what financial effect it is expected to have.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains some accurate directional insights about increased disclosure granularity in Southern Company's derivative reporting from 2022 to 2024, but diverges significantly from the ground truth in key factual and qualitative aspects. (1) The original answer states that in 2022, Southern focused on income statement impacts (pre-tax effects of non-designated derivatives on prior years), while in 2024 the focus shifted to balance sheet presentation (fair value categorized under 'Other' or 'Risk Management Activities'). The LLM answer instead claims a shift from 'aggregate description' to 'disaggregated presentation' with specific details like 'net volumes', 'longest hedge dates', 'current vs non-current balances', 'gross amounts', and 'offsetting positions'—none of which are mentioned or supported in the ground truth. (2) There are no numeric values in either answer, so quantitative accuracy is neutral; however, the LLM invents detailed disclosures (e.g., expected reclassifications from AOCI, subsidiary-level breakdowns) not present in the original, suggesting fabricated precision. (3) The multi-hop reasoning is partially sound in identifying a shift in disclosure emphasis, but fails to correctly characterize the nature of the evolution—specifically misrepresenting it as increased disaggregation and operational detail rather than a shift from income statement to balance sheet focus. (4) While the answer is contextually relevant and addresses the general theme of evolving derivative disclosures, it introduces unsupported specifics and misses the core factual shift described in the ground truth. Thus, the correctness score is low due to factual overreach and misrepresentation of the actual disclosure changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 473,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did GILD's strategic relationship with Arcus evolve between 2023 and 2024, particularly in terms of equity ownership and governance influence?",
      "original_answer": "In 2023, GILD owned approximately 19.9% of Arcus' issued and outstanding voting stock and had two designees on Arcus' board of directors. In January 2024, GILD made an additional $320 million equity investment in Arcus, increasing its ownership to 33%, and expanded its board representation to three designees. This represents a significant increase in both financial commitment and governance influence over Arcus within a year.",
      "llm_answer": "\nBetween 2023 and early 2024 Gilead’s stake in Arcus grew sharply—from roughly 20 % (≈14.8 million shares, or 19.9 % of voting stock) after its mid‑2023 purchase to about 33 % following the January 2024 $320 million equity investment, which also triggered the payment of the $100 million fourth‑anniversary option fee.  At the same time, governance influence expanded: Arcus added a third Gilead‑appointed designee to its board, and the amended Collaboration Agreement gave Gilead additional opt‑in rights, milestone‑payment structures and a 50/50 U.S. profit‑share on co‑developed programs, cementing a deeper strategic and board‑level partnership.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in GILD's relationship with Arcus between 2023 and 2024. (1) Quantitatively, it correctly states that GILD's ownership increased from approximately 19.9% (rounded to ~20%) in 2023 to 33% following a $320 million equity investment in January 2024—matching the ground truth. The mention of 14.8 million shares adds detail not in the original but does not contradict it. However, the reference to a $100 million fourth-anniversary option fee, while contextually plausible from broader knowledge of the GILD-Arcus deal, is not part of the provided ground truth and introduces unverified information, slightly reducing quantitative accuracy. (2) The governance expansion—from two to three Gilead designees on the board—is correctly reported. (3) The qualitative reasoning is strong: the answer synthesizes equity ownership, board representation, and strategic rights (opt-ins, profit-sharing) to show deepening influence, demonstrating sound multi-hop logic across financial and governance dimensions. (4) Contextual relevance is excellent—it directly addresses both equity ownership and governance influence as asked. The only minor overreach is the inclusion of the $100M fee and 50/50 profit-share, which, while factually correct in broader public filings, are not in the provided ground truth and thus slightly dilute fidelity. Overall, the answer is semantically equivalent and factually robust, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1269,
        "completion_tokens": 407,
        "total_tokens": 1677
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the maturity date and borrowing capacity of the 2021 Multicurrency Credit Facility evolved between 2022 and 2023?",
      "original_answer": "In 2022, the 2021 Multicurrency Credit Facility had a maximum borrowing capacity of $6.0 billion with a maturity date of June 30, 2025. By 2023, the borrowing capacity remained at $6.0 billion, but the maturity date was extended to July 1, 2026. This reflects a one-year extension of the facility’s term without any increase in the total commitment amount, indicating a strategic move to maintain financial flexibility over a longer horizon.",
      "llm_answer": "\nBetween the end of 2022 and the end of 2023 the 2021 Multicurrency Credit Facility was first extended in the December 8 2021 amendment to a maturity of **June 30 2025** with a total commitment of **$6.0 billion** (including a $3.5 billion multicurrency sub‑limit). A further amendment on **June 29 2023** pushed the maturity out to **July 1 2026** and replaced the LIBOR benchmark with SOFR, while the **overall borrowing capacity remained $6.0 billion** (the multicurrency sub‑limit stayed at $3.5 billion). Thus, the facility’s maturity was extended by roughly one year and its borrowing limits were unchanged, though the interest‑rate structure was updated.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the 2022 maturity date is correctly stated as June 30, 2025, and the 2023 maturity date is accurately updated to July 1, 2026; the borrowing capacity remains $6.0 billion in both years, matching the original answer. Minor additional details (e.g., $3.5 billion multicurrency sub-limit, SOFR transition) are factually consistent and add context without contradicting the ground truth. (2) Quantitative accuracy is perfect: all dates and dollar amounts match or are equivalent in meaning ($6.0 billion, June 30, 2025 → July 1, 2026). The mention of the June 29, 2023 amendment is a precise detail not in the original answer but does not conflict with it. (3) Multi-hop reasoning is sound: the model correctly synthesizes changes over time (2022 vs 2023) for the same facility, tracking both maturity and capacity. The conclusion that maturity was extended by about a year with no change in borrowing capacity is logically derived. (4) The only reason for not scoring a 10 is that the original answer emphasizes the strategic implication (maintaining financial flexibility), which the LLM omits, though it does note the unchanged capacity and extension. The LLM adds procedural details (amendment dates, benchmark changes) that are relevant but not required. Overall, the answer is factually complete, contextually appropriate, and semantically equivalent to the ground truth with excellent reasoning and precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1269,
        "completion_tokens": 416,
        "total_tokens": 1685
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has Chevron's utilization of imported crude oil in U.S. refining operations evolved between 2023 and 2024, and what changes in refinery capacity utilization accompanied this trend?",
      "original_answer": "Chevron's reliance on imported crude oil in U.S. refining operations remained consistent at approximately 60% of refinery inputs in both 2023 and 2024. However, the utilization of U.S. refineries changed: in 2023, crude unit distillation capacity utilization averaged 90.8%, while in 2024 it decreased to 86.6%. This indicates that while the company's dependency on imported crude oil remained stable, the overall operational intensity of its U.S. refineries declined slightly in 2024.",
      "llm_answer": "\nChevron’s share of imported crude in its U.S. refinery feedstocks stayed essentially steady—about 60 percent of inputs in both 2023 and 2024. What did change was the refinery utilization rate: average crude‑unit distillation capacity utilization fell from roughly 90.8 percent in 2023 to about 86.6 percent in 2024 (and from 89.8 percent to 87.9 percent for the consolidated U.S. system), indicating a noticeable drop in overall refinery capacity utilization over that period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Chevron's imported crude oil share remained at ~60% in both 2023 and 2024, and U.S. crude unit distillation capacity utilization decreased from 90.8% in 2023 to 86.6% in 2024—these numbers match the original answer exactly. (2) The LLM adds slightly more detail by referencing '89.8 percent to 87.9 percent for the consolidated U.S. system,' which is not in the ground truth but does not contradict it and may reflect additional context from the source; however, since the question specifically asks about Chevron's U.S. refining operations and the original answer focuses on crude unit distillation (a Chevron-specific metric), this addition is extraneous but not incorrect. (3) The multi-hop reasoning is sound: the model correctly identifies both the stability in imported crude reliance and the decline in refinery utilization, synthesizing two trends across years. (4) Semantic equivalence is maintained—wording differs slightly but meaning is preserved. The only minor issue is the inclusion of an unverified additional data point, which doesn't detract significantly from accuracy. Hence, full marks for quantitative accuracy and contextual relevance, a 9 for qualitative accuracy due to slight over-elaboration, and a 9 overall for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1250,
        "completion_tokens": 376,
        "total_tokens": 1626
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How did UPS's hedging position in British Pound Sterling evolve between 2023 and 2024, and what does this shift indicate about the company's currency risk management strategy?",
      "original_answer": "In 2023, UPS reported a British Pound Sterling (GBP) hedge position of 663 million units, which decreased to 536 million units in 2024. This represents a reduction of 127 million units, or approximately 19.15%. The decrease indicates a strategic move to reduce exposure to GBP, suggesting that UPS may have reassessed its currency risk related to the British Pound and opted for a more conservative hedging approach or a lower anticipated risk in that currency during the later year.",
      "llm_answer": "\nUPS trimmed the size of its financial hedge on British‑Pound exposure.  In the 2023 “Outstanding Positions” table the company reported GBP notional contracts of **$663 million**, but by the 2024 filing that figure had fallen to **$536 million** – a reduction of roughly **$127 million (about 19 %)**.  \n\nThis pull‑back in the GBP hedge shows that UPS is actively re‑balancing its currency‑risk program.  Rather than maintaining a static, fully‑hedged position, the company appears to be scaling the derivative coverage down as its forecasted GBP‑denominated cash flows change (e.g., shifting volume, pricing adjustments, or a lower exposure to Euro‑area shipments).  The move also suggests a greater reliance on operational hedging tools such as freight‑rate adjustments and fuel‑surcharge mechanisms, while still retaining a modest derivative hedge to protect against residual GBP volatility.  In short, the reduction signals a more dynamic, exposure‑driven approach to foreign‑currency risk management.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the hedging positions for UPS in British Pound Sterling for both 2023 ($663 million) and 2024 ($536 million), matching the ground truth. The reduction of $127 million is accurately calculated, and the approximate percentage decrease (19%) is consistent with the ground truth (19.15%), with only a minor rounding difference that is acceptable. All numeric values and calculations are factually correct, satisfying quantitative accuracy.\n\n2) The answer fully addresses both parts of the question: the evolution of the hedging position (quantitative change) and the strategic implication of the shift. It correctly attributes the change to a dynamic risk management strategy, noting reduced derivative usage and potential reliance on operational hedges like freight-rate adjustments—insights that go beyond the ground truth but are reasonable and contextually sound.\n\n3) Entities are accurate: UPS is the correct company, the currency is correctly identified as GBP, and the years (2023 to 2024) are properly referenced. The use of 'notional contracts' aligns with typical hedging disclosures in 10-K filings.\n\n4) The reasoning is strong and demonstrates multi-hop synthesis: it connects the numerical reduction in hedge size to strategic shifts in risk management, infers changes in anticipated cash flows, and introduces complementary mechanisms (operational hedging), which, while not explicitly stated in the ground truth, are plausible and enhance the explanation without contradicting facts. The conclusion about a more dynamic, exposure-driven approach is logically supported by the data.\n\n5) Semantic equivalence is maintained: the core information matches the ground truth, and the additional interpretation adds depth without introducing inaccuracies. The minor rounding of 19.15% to 19% does not affect correctness. Overall, the answer is factually precise, contextually relevant, and demonstrates high-quality reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 530,
        "total_tokens": 1909
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the fair value of money market investments held by Bank of America evolved between 2023 and 2024, and what does this shift indicate about the company's short-term investment strategy?",
      "original_answer": "The fair value of money market investments held by Bank of America increased from $1.2 billion at December 31, 2023, to $1.3 billion at December 31, 2024. This indicates a modest growth in the company's short-term investment holdings, suggesting a slight expansion in liquidity management or short-term capital deployment strategies over the year.",
      "llm_answer": "\nThe fair‑value of Bank of America’s money‑market holdings grew from **$1.2 billion at the end of 2023 to $1.3 billion at the end of 2024** (an increase of roughly $0.1 billion, or about 8 %).  \n\nThis modest rise shows that the company is **maintaining a larger cushion of short‑term, low‑risk assets**, likely to capture slightly higher yields in a higher‑interest‑rate environment while preserving liquidity for funding and regulatory requirements. In other words, the shift signals a cautious short‑term investment strategy that emphasizes safety and liquidity over longer‑term or higher‑risk placements.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly reports the fair value of money market investments for Bank of America as $1.2 billion at the end of 2023 and $1.3 billion at the end of 2024, matching the ground truth exactly. The increase of $0.1 billion (approximately 8%) is accurately calculated: (1.3 - 1.2) / 1.2 ≈ 8.33%, which rounds to about 8%, so the percentage is reasonably stated.\n\n2) All entities are correct: 'Bank of America' is the right company, the years 2023 and 2024 are accurate, and the metric 'fair value of money market investments' is properly identified. The time points ('end of 2023' and 'end of 2024') align with the ground truth's reference to December 31 of each year.\n\n3) The reasoning is sound and adds context beyond the ground truth, such as referencing higher interest rate environments and regulatory liquidity needs. While the original answer notes a 'modest growth' and 'slight expansion in liquidity management', the LLM elaborates with plausible strategic rationale (yield capture, safety, liquidity) that is consistent with and enriches the ground truth without contradicting it. This shows strong qualitative reasoning.\n\n4) The answer fully addresses both parts of the question: the evolution of fair value (quantitative change) and what the shift indicates (strategic interpretation). The synthesis across time points is correct and the conclusion is contextually appropriate.\n\nThe only reason for not giving a perfect 10 is that the original answer emphasizes 'modest growth' and 'slight expansion', while the LLM interprets this as a strategy emphasizing 'safety and liquidity over longer-term or higher-risk placements'—a reasonable inference but slightly more interpretive than the more neutral tone of the ground truth. However, this does not make it factually inaccurate, hence the high scores.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1249,
        "completion_tokens": 494,
        "total_tokens": 1744
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the maximum expected volume of natural gas subject to physical supply contracts with sell-back options changed across Southern Company's subsidiaries between 2022 and 2024?",
      "original_answer": "In 2022, the maximum expected volume of natural gas subject to such contracts was 26 million mmBtu for Southern Company as a whole, with individual volumes of 6 million mmBtu for Alabama Power, 8 million mmBtu for Georgia Power, 4 million mmBtu for Mississippi Power, and 8 million mmBtu for Southern Power. By 2024, this volume had decreased to 15 million mmBtu company-wide, with corresponding reductions in each subsidiary's volume: 4 million mmBtu for Alabama Power, 6 million mmBtu for Georgia Power, 2 million mmBtu for Mississippi Power, and 3 million mmBtu for Southern Power. This represents a consistent reduction across all entities.",
      "llm_answer": "\nThe “sell‑back” feature that can be triggered on physical natural‑gas supply contracts fell sharply – from a total of **26 million mmBtu** across Southern Company’s subsidiaries in 2022 (6 mmBtu for Alabama Power, 8 mmBtu for Georgia Power, 4 mmBtu for Mississippi Power and 8 mmBtu for Southern Power) to **15 million mmBtu** in 2024 (4 mmBtu for Alabama Power, 6 mmBtu for Georgia Power, 2 mmBtu for Mississippi Power and 3 mmBtu for Southern Power).  In other words, the maximum expected sell‑back volume dropped by roughly **11 million mmBtu** (about a 42 % reduction) over the two‑year period.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) All numeric values for 2022 and 2024 are accurate: total volumes (26 million mmBtu in 2022, 15 million mmBtu in 2024) and subsidiary breakdowns (Alabama Power: 6→4, Georgia Power: 8→6, Mississippi Power: 4→2, Southern Power: 8→3) are exactly correct. (2) The calculation of the 11 million mmBtu decrease (26 - 15 = 11) and the ~42% reduction (11/26 ≈ 42.3%) are accurate and appropriately contextualized. (3) The multi-hop reasoning—aggregating data across subsidiaries and years, identifying the trend, and synthesizing the change—is sound and complete. (4) The answer addresses all parts of the question: it reports the change over time, provides entity-level detail, and correctly identifies the consistent reduction across all subsidiaries. Minor formatting differences (e.g., 'mmBtu' vs 'million mmBtu') do not affect meaning and are semantically equivalent. The answer is concise, factually precise, and fully aligned with the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 300,
        "total_tokens": 1620
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the integration and application of the Firefly Vector Model evolved across Adobe's product suite between 2023 and 2024?",
      "original_answer": "In 2023, the Firefly Vector Model was integrated into Adobe Express, enabling users to generate custom images and text effects from text prompts in over 100 languages. By 2024, the Firefly Vector Model had expanded its application beyond Adobe Express and was now also integrated into Adobe Illustrator, powering features like Generative Recolor, which allows users to create different color palettes using text prompts and apply them to vector graphics. This represents a significant expansion of the Firefly Vector Model’s functionality and reach within Adobe’s creative tools, moving from a single-app integration to becoming a core AI-driven feature across multiple professional-grade applications.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 Adobe expanded the Firefly Vector Model from a limited feature in Illustrator / Express into a core, cross‑product AI engine that is now natively embedded across Photoshop, Illustrator, Express, Acrobat, Stock and the Creative Cloud All‑Apps subscription.  The model’s capabilities were broadened (e.g., Generative Fill, Expand, Recolor), credit allocations were increased with paid‑credit plans, and enterprise‑grade indemnification and custom‑model services were added, allowing the Vector Model to drive end‑to‑end generative workflows throughout Adobe’s suite.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general trend of Firefly Vector Model's expansion across Adobe's product suite from 2023 to 2024, which aligns with the ground truth. However, there are significant factual inaccuracies that reduce correctness. The original answer states that in 2023, the model was integrated into Adobe Express (not Illustrator), and only in 2024 did it expand to Illustrator with Generative Recolor. The LLM incorrectly claims the model was already in both Illustrator and Express in 2023, reversing the timeline and misrepresenting the evolution. Additionally, the LLM overstates the integration by listing Photoshop, Acrobat, Stock, and Creative Cloud All-Apps as having the Firefly Vector Model, which is not supported by the ground truth. While 'Generative Recolor' is correctly mentioned, 'Generative Fill' and 'Expand' are not attributed to the Vector Model in the original (they are typically associated with Firefly's image model, not vector). The addition of credit plans and indemnification, while plausible, are not mentioned in the ground truth and introduce unsupported details. Quantitatively, there are no explicit numbers to verify, so accuracy is moderate based on consistency with timeframes. Qualitatively, the reasoning is partially sound in identifying expansion, but the multi-hop synthesis is flawed due to incorrect product-timeline mapping. Contextually, the answer is relevant and addresses the evolution question, but with significant factual overreach.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 409,
        "total_tokens": 1728
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the commercial significance of Biktarvy evolved for GILD from 2023 to 2024, and what implications does this have for the company's HIV business strategy?",
      "original_answer": "In 2023, Biktarvy was a major revenue driver for GILD, generating $11,850 million in total product sales globally, representing a growth from $10,390 million in 2022. By 2024, although Biktarvy remained central to GILD's HIV portfolio, the company highlighted increased risks around its reliance on HIV products, particularly those containing TAF like Biktarvy, due to potential shifts in treatment paradigms and growing generic competition. This indicates that while Biktarvy continued to be a key asset, GILD faced mounting pressure to diversify or innovate within its HIV pipeline to sustain revenue growth.",
      "llm_answer": "\nBiktarvy’s sales rose sharply—from **$10.4 bn in 2022 to $11.9 bn in 2023**, and its share of total HIV revenue grew from roughly **61 % to about 65 %**—showing that the drug has become an even more dominant source of GILD’s HIV cash flow.  This accelerating contribution reinforces the company’s strategy of protecting and expanding Biktarvy’s market position (through pricing power, line‑extension and label‑expansion efforts) while using its strong commercial platform to fund next‑generation HIV R&D and mitigate competitive and reimbursement pressures.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reports Biktarvy's 2023 sales as $11.9 billion (matching the ground truth of $11,850 million, rounded appropriately) and accurately references the 2022 figure as $10.4 billion (vs. $10,390 million). These numbers are quantitatively accurate within acceptable rounding. However, the LLM introduces a new metric—Biktarvy’s share of total HIV revenue increasing from 61% to 65%—which is not present in the original answer and cannot be verified from the provided data, making it an unsupported addition. (2) The calculation of growth from $10.4B to $11.9B is consistent with the ground truth, but the percentage share claim lacks sourcing and introduces potential inaccuracies in completeness and reasoning. (3) The reasoning correctly infers that Biktarvy’s growing sales reinforce its strategic importance, but it omits the key forward-looking risk highlighted in the original answer: increasing vulnerability due to generic competition and shifting treatment paradigms in 2024. This is a significant omission in the multi-hop synthesis, as the question asks about evolution into 2024 and strategic implications. Instead, the LLM emphasizes R&D funding and label expansion without acknowledging the heightened risks that shape GILD’s strategic response. (4) The contextual relevance is high because the answer addresses Biktarvy’s commercial significance and ties it to strategy, but the qualitative accuracy is reduced due to missing critical risk factors in 2024 and the introduction of unverified percentage shares. The correctness score is 7 because core financial data is accurate and the strategic role of Biktarvy is reasonably interpreted, but the answer fails to fully capture the nuanced shift in 2024 that is central to the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 484,
        "total_tokens": 1780
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did the status and financial structure of the Series 2018-1A Securities evolve between 2022 and 2023, particularly in terms of outstanding principal and interest rate?",
      "original_answer": "In 2022, the Series 2018-1A Securities had an aggregate principal amount of $500.0 million and an interest rate of 3.652%. By 2023, the outstanding principal had slightly decreased to $496.8 million, while the interest rate remained unchanged at 3.652%. This indicates a minor reduction in the principal amount over the year without any modification to the interest rate.",
      "llm_answer": "\nBetween the end of 2022 and the end of 2023 the Series 2018‑1A Securities kept the same fixed coupon of **3.652 %**; the balance rose only slightly from **≈ $496.1 million** (2022) to **≈ $496.8 million** (2023), reflecting modest interest accrual but no principal repayments or structural changes. Consequently, the securitization’s financial structure remained unchanged – the same 10‑year expected life and March 2048 final repayment date persisted, with the outstanding principal essentially stable over the two years.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors in the quantitative data. According to the ground truth, the 2022 outstanding principal was $500.0 million, but the LLM incorrectly states it was approximately $496.1 million. Additionally, the LLM claims the balance 'rose' to $496.8 million in 2023, implying an increase, whereas the ground truth shows a decrease from $500.0 million to $496.8 million. The interest rate is correctly reported as 3.652% in both years. (2) The calculation and direction of principal change are wrong: the principal decreased by $3.2 million, but the LLM suggests a slight increase due to 'interest accrual', which contradicts typical amortizing securitization behavior and the ground truth. There is no support for 'no principal repayments' in the original answer, and the claim of balance increase due to interest is financially implausible for a fixed-rate amortizing note. (3) The multi-hop reasoning is flawed because the model fails to correctly retrieve and compare the two principal amounts across years. It synthesizes an incorrect trend (increase vs. actual decrease), undermining the core of the question about evolution in financial structure. While it correctly identifies the interest rate stability, the principal trajectory is misrepresented. (4) Despite the incorrect numbers and reasoning, the answer is contextually relevant—addressing the right security, time frame, and metrics (principal and interest rate). Hence, contextual relevance is high, but quantitative accuracy is severely compromised, leading to a low overall correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1229,
        "completion_tokens": 441,
        "total_tokens": 1670
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did UPS's relationship with Coyote evolve from 2023 to 2024 in terms of financial impact and strategic direction?",
      "original_answer": "In 2023, UPS recorded a $111 million impairment charge related to the Coyote trade name due to declining market conditions and a strategic evaluation of the business. By 2024, this strategic evaluation culminated in the September 2024 divestiture of Coyote, which significantly impacted UPS's Supply Chain Solutions revenue, contributing to a decrease primarily driven by Coyote's exit. This marks a clear evolution from impairment and strategic review in 2023 to full divestiture in 2024.",
      "llm_answer": "\nFrom 2023 to 2024 UPS moved from testing and impairing the Coyote trade‑name—recording a $111 million impairment charge in 2023 after reviewing strategic alternatives—to completing its divestiture in 2024, which generated a $156 million gain and eliminated Coyote’s revenue and expenses from the consolidated results. This sale signals a strategic shift away from the truckload‑brokerage unit toward expanding UPS’s Logistics and broader supply‑chain businesses.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the $111 million impairment charge in 2023 related to the Coyote trade name, which matches the ground truth. However, it introduces a $156 million gain from the 2024 divestiture that is not present in the original answer or supported by the provided ground truth, making this a significant factual inaccuracy. The original answer only states that the divestiture contributed to a revenue decrease due to Coyote's exit, with no mention of a gain. (2) The dates (2023 and 2024) and sequence of events (impairment followed by divestiture) are accurate. The $111 million figure is correctly cited. The $156 million gain is unverified and contradicts the ground truth’s emphasis on negative financial impact (revenue decrease), so quantitative accuracy is reduced. (3) The multi-hop reasoning is mostly sound: the model correctly links the 2023 impairment and strategic review to the 2024 divestiture, showing evolution in strategic direction. It also correctly infers a strategic shift toward logistics and supply chain solutions, which aligns with the original answer’s implication of strategic realignment. However, the incorrect financial impact (gain vs. revenue decline) undermines full reasoning accuracy. (4) The answer is contextually relevant and addresses both financial impact and strategic direction. Despite the incorrect gain figure, the core narrative of strategic evolution from impairment to divestiture is preserved, warranting a 7 for overall correctness. The qualitative and contextual scores reflect strong reasoning and relevance, while quantitative accuracy is penalized for the unsupported $156M gain.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1230,
        "completion_tokens": 455,
        "total_tokens": 1686
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did Linde plc's structure of Performance Share Unit Awards evolve between 2022 and 2024, particularly in terms of the performance metrics used for grants beginning in 2019?",
      "original_answer": "In 2022, Linde plc disclosed two forms of Performance Share Unit Awards under the Amended and Restated 2009 Praxair, Inc. Long Term Incentive Plan: one with Return on Capital performance metrics (Exhibit 10.11k) and another with Total Shareholder Return performance metrics (Exhibit 10.11l). By 2024, these same forms of Performance Share Unit Awards remained in place, as evidenced by Exhibits 10.10l and 10.10m, which correspond directly to the 2019 grants with the same performance metrics. This indicates that the company maintained the same dual structure for Performance Share Unit Awards tied to 2019 grants, without introducing new metrics or eliminating existing ones.",
      "llm_answer": "\nLinde plc’s Performance Share Unit awards that began in 2019 were originally tied to two metrics—Return on Capital (ROC) and Total Shareholder Return (TSR)—as specified in the Amended and Restated 2009 Praxair Long‑Term Incentive Plan (Exhibits 10.11N‑O). The 2021 LTIP retained those same ROC and TSR criteria, and the plan was subsequently amended in January 2024 (*10.03e) and again in March 2024 (*10.10c) to revise the performance‑metric definitions and thresholds—adding adjusted‑ROC and a modified TSR hurdle—while preserving the overall structure of the PSU awards.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The original answer states that in 2022, Linde plc used Exhibits 10.11k (ROC) and 10.11l (TSR), but the LLM incorrectly cites Exhibits 10.11N-O, which do not match the ground truth. In 2024, the correct exhibits are 10.10l and 10.10m, not *10.03e and *10.10c as claimed. Furthermore, the LLM asserts that the plan was amended in January and March 2024 to introduce 'adjusted-ROC' and a 'modified TSR hurdle', which contradicts the ground truth stating that the same dual structure remained in place without new metrics or eliminations. (2) The dates (2019, 2022, 2024) are correct in context, but the exhibit numbers and amendment details are wrong. There is no mention in the ground truth of amendments in January or March 2024, nor any changes to metric definitions or thresholds. (3) The multi-hop reasoning is flawed: the LLM incorrectly infers evolution in the structure by citing non-existent amendments and altered metrics, when the actual data shows stability in structure and metrics from 2022 to 2024 for grants beginning in 2019. The model fails to correctly synthesize across years and documents, instead fabricating changes. (4) While the initial identification of ROC and TSR as the two metrics is correct, the conclusion about structural evolution is false. The answer is partially relevant but fundamentally incorrect on the core point—there was no evolution in the structure, contrary to the LLM's claim. Hence, low scores for correctness, quantitative, and qualitative accuracy; moderate relevance due to correct mention of base metrics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 445,
        "total_tokens": 1766
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has the regulatory status of Trodelvy evolved between 2023 and 2024, and what does this indicate about its development trajectory?",
      "original_answer": "In 2023, Trodelvy was indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer, hormone receptor-positive/HER2-negative breast cancer, and urothelial cancer. By 2024, the FDA granted Trodelvy a Breakthrough Therapy designation for the treatment of extensive-stage small cell lung cancer in patients whose disease has progressed after platinum-based chemotherapy. This indicates a strategic expansion of Trodelvy’s development into new oncology indications with high unmet medical need.",
      "llm_answer": "\nBetween 2023 and 2024 Trodelvy progressed from the FDA approvals it already had for metastatic triple‑negative and HR⁺/HER2⁻ breast cancers (and for UC) to a **Breakthrough‑Therapy designation in 2024 for extensive‑stage small‑cell lung cancer** (the second such designation for the drug).  This regulatory advance—moving from standard approvals in solid‑tumor indications to a Breakthrough‑Therapy status in a new cancer type—signals that the company’s development trajectory is expanding Trodelvy into additional oncology indications and that the FDA views its clinical data as sufficiently promising to accelerate further review.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that in 2023, Trodelvy was approved for triple-negative breast cancer, HR+/HER2-negative breast cancer, and urothelial cancer (UC), and notes the 2024 Breakthrough Therapy designation (BTD) for extensive-stage small cell lung cancer (ES-SCLC). The mention of 'second such designation' is plausible context not in the original but not contradicted by it. (2) All dates (2023, 2024) and indications are factually correct; no numerical errors present. (3) The multi-hop reasoning is sound: it synthesizes prior approvals with the new BTD to infer an expansion into new oncology areas with unmet need, accurately reflecting the development trajectory. (4) The answer is contextually excellent—directly addresses both the regulatory evolution and its implications. Only minor deduction from qualitative accuracy due to the unsupported claim about it being the 'second' BTD (not confirmed in ground truth), but this does not affect overall correctness. Semantic equivalence is strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 306,
        "total_tokens": 1599
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the role of the Vertex AI platform within Google Cloud evolved from 2023 to 2024, particularly in terms of its capabilities and integration with generative AI models?",
      "original_answer": "In 2023, the Vertex AI platform was described as a tool that allowed developers to train, tune, augment, and deploy applications using generative AI models and services such as Enterprise Search and Conversations. By 2024, the platform had evolved to specifically support Gemini and other leading generative AI models, offering developers the ability to train, tune, augment, test, and deploy applications with additional services like vector search, grounding, and distillation to improve model cost and quality. This reflects a shift toward more advanced and optimized generative AI integration.",
      "llm_answer": "\nFrom 2023 to 2024 Vertex AI shifted from a generic generative‑AI development platform—where developers could train, tune and deploy models such as Enterprise Search and Conversations—to a Gemini‑centric, multimodal hub that natively supports Gemini, Gemini 2.0, Imagen and Veo and supplies pre‑packaged AI agents for coding, testing, cybersecurity and other tasks. This expansion gives developers tighter integration with Google’s latest foundation models, broader multimodal capabilities, and seamless use across Google Cloud and Google Workspace.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution of Vertex AI from 2023 to 2024 with accurate qualitative details. It correctly identifies the shift from general generative AI support (e.g., Enterprise Search and Conversations) in 2023 to a more advanced, Gemini-centric platform in 2024. The mention of Gemini, Imagen, and Veo aligns with Google's expanded foundation model integration, and the inclusion of pre-packaged AI agents for coding, testing, and cybersecurity reflects broader capabilities. However, the original answer emphasizes specific technical enhancements like vector search, grounding, and distillation for improving model cost and quality—details that are missing in the LLM response. While 'Gemini-centric' and 'multimodal hub' convey the direction of evolution, the LLM adds 'Gemini 2.0' which is not mentioned in the ground truth, introducing a minor inaccuracy or over-specificity. There are no numerical values to verify, so quantitative accuracy is scored as 10. Contextual relevance is perfect—the answer directly addresses the question about Vertex AI’s evolution in capabilities and integration. The reasoning is sound and reflects multi-hop understanding across years and features, though slight overreach in naming unspecified models (Gemini 2.0) and omission of key services (vector search, grounding) prevents a top score in qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 385,
        "total_tokens": 1679
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the treatment and valuation of weather derivatives changed in SO's financial disclosures from 2022 to 2024, particularly in terms of the amounts considered immaterial and excluded from derivative valuations?",
      "original_answer": "In 2022, SO disclosed that the premium and intrinsic value associated with weather derivatives were immaterial for all periods presented, but did not specify exact amounts. By 2024, SO continued to exclude the premium and intrinsic value of weather derivatives as immaterial, but also provided more specific context by disclosing that cash collateral held in broker margin accounts was $17 million and $62 million at the end of 2024 and 2023, respectively. This suggests a more detailed and structured approach to derivative disclosures over time, even though the weather derivative component remained immaterial.",
      "llm_answer": "\nSouthern Company’s filings from 2022 through 2024 continue to treat weather‑related derivatives as immaterial, omitting their premium and intrinsic value from the reported fair‑value of derivatives. The only quantitative change is a modest increase in the cash‑collateral required for these contracts—from about $3 million in earlier disclosures to roughly $17 million in the 2024 filings—while the premium and intrinsic component remains deemed immaterial and is still excluded from derivative valuations.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies, particularly in quantitative details. (1) It incorrectly states that cash collateral increased from 'about $3 million in earlier disclosures' to $17 million in 2024; the ground truth specifies $62 million in 2023 and $17 million in 2024, indicating a decrease, not an increase, and no mention of $3 million in prior years. This misrepresents both the direction and magnitude of change. (2) The answer fabricates a 'modest increase' and a $3 million figure not present in the original, undermining quantitative accuracy. (3) While the LLM correctly identifies that weather derivatives' premium and intrinsic value were consistently treated as immaterial and excluded from valuations in both 2022 and 2024, it fails to mention the absence of specific amounts in 2022 disclosures, missing a key contrast in disclosure detail over time. (4) The multi-hop reasoning is partially sound—linking immateriality treatment across years—but fails to accurately incorporate the cash collateral trend (which decreased from $62M to $17M), leading to flawed synthesis. (5) The answer is contextually relevant and addresses the core theme of evolving disclosure practices, but the incorrect numbers and mischaracterization of trends severely limit factual correctness. Semantic equivalence is not achieved due to the invented data point and reversed trend.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 385,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the regulatory and market positioning of Biktarvy evolved between 2023 and 2024 based on GILD's disclosures?",
      "original_answer": "In 2023, Biktarvy was listed with a U.S. patent expiration year of 2033, indicating long-term market exclusivity protection in the U.S. In 2024, Biktarvy received an expanded regulatory indication from the FDA to treat people with HIV who have suppressed viral loads with known or suspected M184V/I resistance, a common form of treatment resistance. Additionally, the FDA approved an updated label with data reinforcing Biktarvy's safety and efficacy for use in pregnant people with HIV-1. This represents a shift from primarily patent protection in 2023 to expanded therapeutic application and broader patient eligibility in 2024.",
      "llm_answer": "\nBetween 2023 and 2024 Gilead’s disclosures show that Biktarvy’s **regulatory footprint was broadened** – in 2024 the FDA granted an expanded indication for patients with HIV who have M184V/I resistance and issued an updated label that includes safety and efficacy data for pregnant people, building on the product’s existing approval.  This label‑expansion work is part of a longer‑term lifecycle strategy that, together with its U.S. regulatory exclusivity (now set to expire in 2032) and patent protection that runs to 2033, helps sustain Biktarvy’s **market‑lead position** in the HIV arena despite the looming patent expiry, while the company continues to promote it as a cornerstone of its HIV portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the key developments in Biktarvy's regulatory and market positioning between 2023 and 2024. It correctly identifies the 2024 FDA expanded indication for patients with M184V/I resistance and the updated label including safety and efficacy data for pregnant people with HIV, which aligns with the ground truth. The answer also correctly references the U.S. patent protection extending to 2033. However, there is a minor discrepancy in stating that 'regulatory exclusivity' expires in 2032, which is not mentioned in the original answer and introduces a potentially conflicting date not present in the ground truth. While patent and regulatory exclusivity can differ, the original answer only specifies a 2033 patent expiration, so introducing 2032 for exclusivity creates a slight inaccuracy. This does not undermine the core correctness but affects quantitative precision. The reasoning is sound, synthesizing multi-hop information across years and regulatory actions. The answer addresses both regulatory evolution (expanded indications) and market positioning (sustained leadership, lifecycle strategy), fulfilling the question’s requirements. Wording differs but semantic meaning matches. Contextual relevance and qualitative reasoning are excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 361,
        "total_tokens": 1689
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did AMT's utilization of the 2021 Multicurrency Credit Facility change between 2022 and 2023, particularly in terms of borrowing amounts and facility amendments?",
      "original_answer": "In 2022, AMT made additional net borrowings of $850.0 million under the 2021 Multicurrency Credit Facility, which were used to repay existing indebtedness and for general corporate purposes. By 2023, the company borrowed an aggregate of $3.0 billion and repaid $6.1 billion under the same facility, including a significant repayment of 842.6 million EUR ($919.1 million). Additionally, the facility underwent amendments in 2023 that extended its maturity date to July 1, 2026, maintained a total commitment of $6.0 billion, and replaced the LIBOR pricing benchmark with SOFR. This reflects a significant transformation in the usage and structure of the facility.",
      "llm_answer": "\nBetween 2022 and 2023 AMT stepped up its use of the 2021 Multicurrency Credit Facility – it recorded roughly $850 million of net borrowings in 2022 (to fund acquisitions and repay maturing debt) and, after the facility was amended in June 2023, it added another $850 million of draws in early 2023, leaving a $723 million balance outstanding at year‑end 2023.  The June 2023 amendment kept the $6 billion commitment unchanged but extended the maturity to July 2026, added a $50 million swing‑line sub‑limit and replaced the LIBOR benchmark with SOFR‑based pricing, thereby increasing the facility’s flexibility and lowering financing costs even though the amount drawn remained modest relative to the available commitment.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. While it correctly notes the $850 million net borrowings in 2022, it incorrectly states that AMT made another $850 million in draws in early 2023 and had only a $723 million balance at year-end. The ground truth shows that in 2023, AMT borrowed $3.0 billion and repaid $6.1 billion, resulting in a net repayment of $3.1 billion—not additional borrowing. The LLM also omits the significant EUR 842.6 million ($919.1 million) repayment, which is a key detail. (2) The amendment details are partially correct: the maturity extension to July 1, 2026, the $6.0 billion commitment, and the LIBOR-to-SOFR transition are accurately reported. However, the LLM adds unverified details such as a '$50 million swing-line sub-limit' and claims about 'lowering financing costs' and 'increased flexibility' that are not in the original answer. The claim of 'modest amount drawn' contradicts the ground truth, which shows substantial borrowing and repayment activity. (3) The multi-hop reasoning is flawed: the model fails to synthesize the full scope of 2023 activity—especially the net repayment—and incorrectly implies continued borrowing. It conflates net and gross activity, misrepresenting the facility's utilization trend. (4) Despite these errors, the answer is contextually relevant and captures some correct elements (amendment timing, benchmark change, 2022 borrowing), warranting a moderate score for qualitative and contextual accuracy. However, the quantitative inaccuracies are severe enough to limit correctness to a 4.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 447,
        "total_tokens": 1798
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has the role of Google Ad Manager in Alphabet's advertising revenue recognition strategy evolved between 2023 and 2024, particularly in terms of its integration with revenue reporting models?",
      "original_answer": "In 2023, Google Ad Manager was directly tied to Alphabet's advertising revenue recognition on a gross basis, with the company reporting the full amount billed to customers as revenue for ads placed on Google Network properties. By 2024, the language around Google Ad Manager shifted, emphasizing a more nuanced control-based evaluation where Alphabet asserts its role as principal by controlling advertising inventory before transfer to customers, being primarily responsible to them, and having discretion over pricing. This reflects a strategic evolution from a transactional reporting model to a more control-driven justification for gross revenue recognition, reinforcing the centrality of Google Ad Manager in revenue operations.",
      "llm_answer": "\nBetween 2023 and 2024 Alphabet continued to record the advertising inventory sold through Google Ad Manager as part of its Google Network properties on a **gross‑basis**—the full amount billed to customers is recognized as revenue and payments to network partners are recorded as cost of revenue.  However, the 2024 filing shows that Ad Manager’s revenue is now **integrated into the company’s multi‑performance‑obligation framework**, with revenue allocated to the platform based on relative standalone selling prices and with a more refined principal‑vs‑agent assessment.  This evolution tightens the linkage between Ad Manager transactions and Alphabet’s overall advertising‑revenue recognition model, aligning the timing and measurement of Ad Manager proceeds with the broader performance‑fee and revenue‑allocation methodology.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of core facts: Alphabet continued gross-basis revenue recognition for Google Ad Manager in both 2023 and 2024, with the full amount billed recognized as revenue and partner payments as cost of revenue. The answer correctly identifies a strategic evolution in 2024, particularly around integration into a more sophisticated revenue recognition framework. It accurately reflects the shift toward a control-based, principal-vs-agent assessment and ties Ad Manager to performance obligations and standalone selling price allocations—key elements of ASC 606 compliance. However, the LLM introduces the term 'multi-performance-obligation framework' and 'performance-fee methodology,' which, while conceptually plausible under ASC 606, are not explicitly mentioned in the ground truth and slightly over-specify the nature of the change. The ground truth emphasizes a shift in *language* and *justification* (control-based reasoning) rather than structural integration into a new allocation model. Thus, while the qualitative direction is correct, the specific characterization of integration into a refined allocation system goes beyond the documented evolution. There are no numerical inaccuracies (quantitative accuracy is perfect), and the entities—Alphabet, Google Ad Manager, Google Network properties, gross-basis reporting—are all correctly identified and contextualized. The answer is highly relevant and captures the essence of the strategic evolution, meriting a high but not perfect score due to slight over-interpretation of the 2024 changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1404,
        "completion_tokens": 443,
        "total_tokens": 1847
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has UPS's financial exposure and strategic positioning regarding Roadie evolved between 2023 and 2024, particularly in terms of goodwill impairment and risk assessment?",
      "original_answer": "In 2023, UPS recorded a $56 million goodwill impairment charge related to Roadie, indicating financial concerns about its value. By 2024, although no further impairment was recorded, Roadie was identified among the reporting units with limited excess of fair value over carrying value, signaling ongoing financial risk. This evolution reflects a shift from active impairment to a cautious monitoring stance due to Roadie's continued sensitivity to cost of capital and performance forecasts.",
      "llm_answer": "\nBetween 2023 and 2024 UPS moved from an outright goodw​ill write‑down on Roadie—$56 million of impairment was recorded in 2023—to a 2024 impairment test that found Roadie’s fair value only marginally above its carrying amount, leaving the unit with “limited excess” and flagging it as one of three reporting units most at risk of future impairment.  No new impairment was taken in 2024, but the company explicitly warned that a modest reduction in projected cash flows or a 100‑basis‑point rise in the cost of capital could trigger an impairment charge, highlighting that Roadie’s strategic role in Supply‑Chain Solutions is now balanced against an increased financial exposure to goodwill impairment.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: the $56 million goodwill impairment in 2023 is accurately reported, and the 2024 status—no new impairment but identification of Roadie as a unit with 'limited excess' fair value over carrying value—is correctly conveyed. (2) Quantitative accuracy is perfect: the $56 million figure is correct in amount and year, and the 100-basis-point sensitivity to cost of capital is a precise detail consistent with the risk assessment in the original. (3) Multi-hop reasoning is sound: the answer synthesizes information across years (2023 vs 2024), financial concepts (impairment, fair value, cost of capital), and strategic implications, correctly inferring a shift from active impairment to ongoing risk monitoring. (4) The answer addresses all parts of the question: financial exposure (via impairment and sensitivity analysis) and strategic positioning (continued role in Supply Chain Solutions despite risks). Wording differs slightly but meaning is preserved, and the LLM adds context (e.g., being one of three at-risk units) that enhances completeness without introducing error. All metrics, entities, and years are accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 346,
        "total_tokens": 1651
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has Linde's relationship with helium evolved from 2022 to 2024, and what quantitative impact did this change have on the company's sales and operating profit?",
      "original_answer": "In 2022, helium was a supply component for Linde, indicating a positive or neutral role in operations. By 2024, helium had a negative impact on performance, with a 2% underlying sales decrease in the 'Other' segment primarily due to lower volumes in global helium and Linde Advanced Materials Technology (LAMT). Additionally, operating profit in the 'Other' segment saw increased costs related to helium, partially offset by an insurance recovery for LAMT. This reflects a shift from helium being a supply input to a source of cost pressure.",
      "llm_answer": "\nLinde’s helium business, which was a modest growth contributor in 2022, had become a drag by 2024, cutting the “Other” segment’s sales by about 2 % – roughly $32 million lower in 2024 – as helium volumes fell.  Despite that sales dip, operating profit in the segment still rose $19 million (≈44 %) in 2024, driven by an insurance recovery that more than offset the higher helium‑related cost pressure.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the core shift in Linde's helium relationship from neutral/growth contributor in 2022 to a cost pressure/drag in 2024, which aligns with the ground truth. It correctly identifies the 2% underlying sales decrease in the 'Other' segment due to lower helium volumes. However, it introduces a specific dollar figure of $32 million in lost sales that is not present in the original answer and cannot be verified from the provided ground truth, making it a fabricated quantitative claim. Additionally, the LLM states that operating profit rose by $19 million (≈44%) in 2024 despite helium cost pressure due to an insurance recovery. While the original answer mentions an insurance recovery partially offsetting higher helium costs, it does not state that operating profit increased—let alone by $19 million or 44%. Thus, this calculation and conclusion are unsupported and likely incorrect. (2) Quantitative accuracy is compromised: the 2% sales impact is correct, but the derived $32 million and the $19 million/44% operating profit increase are not in the ground truth and appear to be speculative. No basis is given for these numbers, and they may misrepresent the financial impact. (3) The multi-hop reasoning is partially sound—the model correctly infers a negative shift in helium’s role and links it to segment performance—but it overreaches by asserting precise profit growth unsupported by the source. It synthesizes the insurance recovery and cost pressure but draws an erroneous net conclusion. (4) Correctness is scored 6 due to correct directional analysis but significant quantitative inaccuracies. Quantitative accuracy is 5 due to one correct percentage but two unverified dollar amounts and a misleading growth claim. Qualitative accuracy is 7 because the conceptual evolution of the helium relationship is well captured. Contextual relevance is 9 as the answer directly addresses the question’s scope and evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1239,
        "completion_tokens": 530,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did the total value of loans covered under long-term credit protection agreements with FNMA and FHLMC evolve from 2023 to 2024, and what does this indicate about the Corporation's credit risk exposure on residential mortgage loans?",
      "original_answer": "In 2023, the Corporation had $8.7 billion in loans covered under credit protection agreements with FNMA and FHLMC, which decreased to $8.0 billion in 2024. This indicates a reduction in the Corporation's reliance on full credit protection for residential mortgage loans that become severely delinquent. Since these agreements provide full credit protection and the Corporation does not record an allowance for credit losses on these loans, the decline suggests a potential decrease in the volume of high-risk residential mortgage loans in their portfolio.",
      "llm_answer": "\nThe amount of loans covered by the long‑term credit‑protection agreements with FNMA and FHLMC slipped from roughly **$8.7 billion at the end of 2023 to about $8.0 billion at the end of 2024**.  Because these insured residential‑mortgage loans are fully guaranteed, the Corporation does not record an allowance for losses on them, so the decline signals a modest reduction in the volume of such protected exposure; however, the overall credit‑risk profile remains tied to the performance of the underlying insured portfolio, as reflected in stable non‑performing loan balances and only modest charge‑offs.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly reports the quantitative evolution of loans covered under credit protection agreements: $8.7 billion in 2023 decreasing to $8.0 billion in 2024, matching the ground truth exactly. The formatting variation (e.g., 'roughly', 'about') does not affect factual accuracy and is acceptable per evaluation guidelines.\n\n2) Quantitatively, both values are accurate and correctly attributed to the right years. The decrease of $0.7 billion is implied and numerically correct, though not explicitly calculated—this is not required for full credit as the values themselves are precise.\n\n3) The reasoning is largely sound: the LLM correctly identifies that these loans are fully guaranteed and that no allowance for credit losses is recorded, aligning with the ground truth. It also correctly infers that the decline represents a reduction in protected exposure. However, it adds a detail not present in the original answer—'stable non-performing loan balances and only modest charge-offs'—which, while plausible, is not supported by the provided ground truth and slightly extends beyond the evidence. This minor overreach prevents a perfect qualitative score.\n\n4) The answer addresses both parts of the question: the evolution of loan values (quantitative change) and the implication for credit risk exposure (qualitative interpretation). It synthesizes the correct entities (FNMA/FHLMC, residential mortgage loans, credit protection, no allowance for losses) and correctly links the decline to reduced reliance on full protection, which aligns with the ground truth's conclusion about reduced high-risk loan volume.\n\n5) Semantic equivalence is maintained: the core message—that declining protected loans suggest reduced exposure to high-risk residential mortgages—is preserved. The additional performance commentary slightly exceeds the original but does not contradict it. Overall, this is a highly accurate, well-reasoned response with only minor extrapolation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1312,
        "completion_tokens": 533,
        "total_tokens": 1845
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has Adobe's strategic positioning of Adobe Firefly evolved between 2023 and 2024, particularly in terms of competitive differentiation and associated regulatory risks?",
      "original_answer": "In 2023, Adobe positioned Adobe Firefly as a competitive differentiator by emphasizing its generative AI capabilities that are natively integrated into Adobe products and designed to be safe for commercial use. By 2024, Adobe continued to highlight Firefly's AI innovations but introduced new concerns around regulatory risks, particularly referencing the EU AI Act adopted in 2024, which could impose compliance costs, delay development, or require changes to AI development practices. This reflects a shift from purely competitive emphasis to a more risk-aware strategic positioning of the product.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 Adobe moved Firefly from a niche, “safe‑for‑commercial‑use” generative‑AI add‑on inside Creative Cloud toward a core, enterprise‑grade AI engine that is natively embedded across the broader Adobe Experience Cloud stack (e.g., Experience Manager, Sensei GenAI) and offered with IP‑indemnification for corporate customers.  This expansion deepens its competitive differentiation—native integration, cross‑app generative capabilities, and enterprise‑level governance—while simultaneously exposing Adobe to heightened regulatory risk, as emerging AI‑specific rules (such as the EU AI Act) impose new compliance, liability and indemnification obligations that the company must monitor and address.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution of Adobe Firefly's strategic positioning from 2023 to 2024: starting as a 'safe-for-commercial-use' generative AI tool (2023 focus on competitive differentiation via commercial safety and native integration) and expanding into a core enterprise AI engine embedded across Adobe Experience Cloud by 2024. The mention of IP indemnification for corporate customers adds valuable context not in the original but consistent with Adobe's real-world strategy, enhancing rather than distorting accuracy. (2) There are no numeric values, dates, or financial figures in the question or answers that require verification—both reference 2023 to 2024 and the EU AI Act adoption in 2024, which is factually correct. The LLM correctly identifies the EU AI Act as a regulatory driver without inventing specifics. (3) Multi-hop reasoning is sound: it synthesizes Firefly’s competitive differentiation (native integration, cross-app capabilities, governance) with increasing regulatory exposure (compliance, liability, indemnification under emerging rules like the EU AI Act), reflecting a shift from pure innovation emphasis to risk-aware positioning. (4) The only minor gap is that the original answer explicitly notes Adobe began referencing the EU AI Act as a risk factor in 2024 filings, while the LLM implies this more generally. However, the LLM does correctly frame regulatory risks as heightened due to emerging AI rules, maintaining semantic equivalence. No factual inaccuracies; slight augmentation with plausible detail (e.g., IP indemnification, Experience Cloud integration) strengthens completeness without overreach. Thus, high scores across all dimensions, with a 9 on correctness due to slightly more expansive claims than the original, though still within reasonable inference.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 509,
        "total_tokens": 1845
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did the financial performance and regulatory trajectory of Trodelvy evolve between 2023 and 2024?",
      "original_answer": "In 2023, Trodelvy generated total product sales of $1,063 million, reflecting a 56% increase compared to the previous year. By 2024, the regulatory landscape for Trodelvy advanced significantly with the FDA granting it a second Breakthrough Therapy designation, specifically for the treatment of adult patients with extensive-stage small cell lung cancer who have progressed after platinum-based chemotherapy. This indicates both strong financial growth and increased regulatory recognition of the drug's potential clinical impact.",
      "llm_answer": "\nBetween 2023 and 2024 Trodelvy’s sales surged — product revenue rose 56 % to **$1.063 billion** in 2023 and continued to climb in 2024, driving a 37 % jump in overall oncology sales and contributing to the company’s 1 % total‑revenue growth.  Regulatorily, the drug secured **European Commission approval as a monotherapy for HR⁺/HER2‑ negative metastatic breast cancer** (and later received U.S. FDA approval for the same indication), while also gaining a Breakthrough‑Therapy designation for advanced‑stage small‑cell lung cancer; however, its Phase 3 EVOKE‑01 trial in previously treated metastatic NSCLC failed to meet the primary overall‑survival endpoint, limiting further expansion in that setting.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. It correctly reports the 2023 product sales of $1.063 billion (equivalent to $1,063 million) and the 56% year-over-year increase, which matches the ground truth. However, it incorrectly implies that sales continued to climb in 2024 and contributed to a 1% total-revenue growth and 37% jump in oncology sales—details not present in the original answer and unsupported by the provided ground truth. (2) The quantitative accuracy is partially correct: the $1.063 billion and 56% increase are accurate and properly formatted. However, the additional financial claims for 2024 (e.g., 37% jump in oncology sales, 1% total-revenue growth) are not in the ground truth and appear fabricated or misattributed. (3) The qualitative accuracy suffers due to incorrect regulatory details: the ground truth states that in 2024, the FDA granted a *second* Breakthrough Therapy Designation (BTD) for extensive-stage small cell lung cancer (ES-SCLC), but the LLM incorrectly claims European Commission approval for HR+/HER2-negative metastatic breast cancer and subsequent U.S. FDA approval for the same, which is not mentioned in the original. Additionally, the mention of the failed EVOKE-01 trial in NSCLC is extraneous and contradicts the positive regulatory trajectory emphasized in the ground truth. (4) Contextual relevance is moderate—the answer addresses both financial performance and regulatory developments, aligning with the question’s scope, but introduces irrelevant or inaccurate details that distort the actual trajectory. The core financial data is correct, but the regulatory narrative is misleading. Thus, the answer is partially correct but contains significant factual and reasoning errors, warranting a correctness score of 4.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 492,
        "total_tokens": 1790
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How has Chevron's financial involvement and strategic positioning in Angola LNG evolved from 2022 to 2024, based on specific disclosures regarding its equity investments and affiliate transactions?",
      "original_answer": "In 2022, Chevron reported improved income from equity affiliates, including upstream-related earnings from Angola LNG, which contributed to an overall increase in income from equity affiliates to $5,657 million. By 2024, Chevron's specific interest in Angola LNG Limited was disclosed as a 36.4% ownership stake, with Angola LNG Limited described as a key entity that processes and liquefies natural gas produced in Angola for delivery to international markets. This evolution reflects a continued strategic emphasis on LNG as part of Chevron’s broader upstream portfolio, with a clear quantification of its stake in 2024, suggesting a more defined and stable long-term positioning compared to the more general mention of earnings contribution in 2022.",
      "llm_answer": "\nChevron’s equity investment in Angola LNG Limited fell modestly—from about **$1.86 billion at year‑end 2022 to $1.66 billion at year‑end 2024**—reflecting a gradual reduction in the carried‑investment balance.  At the same time, equity‑method earnings from the joint venture remained robust, posting **$1.86 billion in 2023 and $0.51 billion in 2024**, driven by higher upstream realizations and the absence of the 2020‑era impairments that had previously weighed on results.  The company’s 2024 MD&A explicitly cites “higher upstream‑related earnings from … Angola LNG” as a key factor behind the uplift in overall upstream performance, underscoring a continued strategic emphasis on the LNG JV despite the slight decline in book value.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that Chevron's income from equity affiliates (including Angola LNG) was $5,657 million in 2022, but the LLM claims specific earnings from Angola LNG alone were $1.86 billion in 2023 and $0.51 billion in 2024—numbers not supported by the original answer. There is no mention in the ground truth of Chevron's equity investment declining from $1.86 billion to $1.66 billion; these figures are entirely fabricated. Additionally, the original answer does not provide any year-end book value or carried-investment balance data for Angola LNG, so the LLM's quantitative claims about investment balances are unsupported. (2) The only correct qualitative point is the mention of 'higher upstream-related earnings from Angola LNG' in 2024, which aligns with the original answer’s reference to improved income from equity affiliates due to Angola LNG. However, the LLM misattributes this to 2024 earnings ($0.51B) without any such figure in the truth. (3) The multi-hop reasoning is flawed: the model incorrectly synthesizes non-existent financials for Angola LNG as a standalone entity, whereas the original answer only references Angola LNG as a contributor to a broader $5,657M total in 2022. The 36.4% ownership stake in Angola LNG Limited in 2024—a key fact in the ground truth—is completely omitted. (4) The contextual relevance is moderate because the answer addresses Chevron’s strategic positioning in Angola LNG and mentions upstream earnings, but the heavy reliance on invented numbers and absence of the disclosed ownership percentage severely undermines correctness. Quantitative accuracy is very low due to fabricated dollar amounts and lack of verification. Qualitative accuracy is slightly higher because of partial alignment on strategic emphasis, but core entity details and ownership stake are missing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 515,
        "total_tokens": 1900
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did the value and issuance activity of META's Fixed-Rate Senior Unsecured Notes evolve from 2023 to 2024?",
      "original_answer": "In 2023, META issued $8.46 billion of net proceeds from Fixed-Rate Senior Unsecured Notes in May. By the end of 2024, the total value of these Notes had increased to $29.0 billion, up from $18.50 billion at the end of 2023, with an additional $10.50 billion issued in August 2024. This reflects both continued reliance on this form of debt financing and a significant increase in the total outstanding amount over the two-year period.",
      "llm_answer": "\nFrom the end of 2023 to the end of 2024 Meta’s fixed‑rate senior unsecured notes grew sharply, rising from roughly **$18.5 billion** of outstanding principal to **$29 billion**.  This increase reflects new issuances of **$8.5 billion** of notes in May 2023 and a further **$10.5 billion** of notes issued in August 2024, expanding the total face amount and extending the maturity profile to 2027‑2064.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key facts: the outstanding value of META's Fixed-Rate Senior Unsecured Notes increased from $18.5 billion at the end of 2023 to $29.0 billion at the end of 2024, and an issuance of $10.5 billion occurred in August 2024. However, the May 2023 issuance is reported as $8.5 billion in the LLM answer, while the ground truth states $8.46 billion in net proceeds. This is a minor numerical discrepancy—likely due to rounding—but still affects quantitative precision. (2) The calculation of the total increase ($29.0B - $18.5B = $10.5B) aligns with the August 2024 issuance, which is accurate. The May 2023 issuance should be $8.46B, not $8.5B; though close, it's not exact. The total value evolution is correctly portrayed. (3) The multi-hop reasoning is sound: the model synthesizes data across 2023 and 2024, correctly attributes issuances to specific months/years, and links them to the growth in total outstanding notes. It also adds relevant context about maturity extension (2027–2064), which, while not in the original answer, does not contradict it and adds value. (4) The answer is contextually excellent, addressing both value evolution and issuance activity. The qualitative reasoning and entity accuracy (META, correct metric, correct years) are strong. The correctness score is 8 due to the minor inaccuracy in the May 2023 issuance amount; otherwise, the answer is comprehensive and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1199,
        "completion_tokens": 404,
        "total_tokens": 1604
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did LIN's financial exposure to helium as a raw material change from 2023, when it was categorized as a supply, to 2024, when it became a dependency, based on specific cost or sourcing disclosures?",
      "original_answer": "In 2023, LIN categorized helium as a supply, indicating it was a standard input with manageable sourcing dynamics, and reported helium costs at 4.2% of total raw material expenses. By 2024, the relationship shifted to 'depends_on,' signaling increased strategic importance, and helium costs rose to 6.8% of raw material expenses, reflecting a more critical role in operations and a corresponding increase in cost exposure.",
      "llm_answer": "\nIn the 2023 Form 10‑K (page 71 of LIN_10k_2023.pdf) helium is listed only as part of “Raw materials and supplies” with a $614 million balance and is characterized merely as a routine supply, with no special sourcing or price‑risk disclosures. The 2024 filing (page 61 of LIN_10k_2024.pdf) still reports helium under raw‑materials but reduces the inventory to $529 million and adds a risk‑factor statement that the company is now “highly dependent on external helium producers,” citing a double‑digit increase in purchase price and the need for long‑term supply agreements—signaling the shift from a simple supply to a critical dependency.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies in quantitative details, which undermines its correctness. The ground truth states that helium costs were 4.2% of total raw material expenses in 2023 and increased to 6.8% in 2024—this percentage-based metric is central to the question about financial exposure. However, the LLM instead cites absolute inventory balances ($614M in 2023 and $529M in 2024), which are not mentioned in the original answer and contradict the implied trend (cost exposure increased, but inventory value decreased). These dollar amounts may reflect inventory values, but they do not equate to cost percentages of raw material expenses, making the quantitative response incorrect. There is no mention of the key metric—percentage of raw material costs—which is essential for assessing financial exposure. Additionally, while the LLM correctly identifies a qualitative shift in language (from routine supply to 'highly dependent') and cites risk factors about price increases and supply agreements, this supports only the dependency shift, not the financial exposure change based on cost disclosures. The reasoning partially captures the conceptual shift from supply to dependency but fails to report the actual financial metrics (4.2% → 6.8%) that define the exposure change. Thus, while contextually relevant and showing some correct entity and document references (LIN, 2023/2024 10-Ks, helium sourcing), the answer misses the core quantitative evidence required. Multi-hop synthesis is attempted but flawed due to substitution of unrelated financial figures. The answer is semantically different because it uses inventory balances instead of cost percentages, leading to a misleading interpretation of exposure trends.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 474,
        "total_tokens": 1753
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did PayPal's utilization of European customer balances for credit activities evolve between 2022 and 2023, and what was the percentage change in the amount approved for such activities?",
      "original_answer": "In 2022, PayPal had $3.8 billion approved to fund credit activities, representing approximately 37% of European customer balances available for corporate use. In 2023, the approved amount decreased to $3.0 billion, representing approximately 39% of European customer balances. This indicates a reduction in the absolute amount approved for credit activities, even though the percentage slightly increased, signaling a more conservative approach to utilizing customer balances for credit funding.",
      "llm_answer": "\nBetween 2022 and 2023 the amount of European customer balances that PayPal could designate for credit activities fell from **$3.8 billion (≈ 37 % of European balances) in 2022 to $3.0 billion (≈ 39 % of European balances) in 2023**.  This represents a **year‑over‑year decline of roughly 21 %** in the approved credit‑activity funding amount.  The shift reflects a modest reduction in the absolute dollar amount approved, even as the proportion of balances made available for credit remained roughly stable.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly reports all key facts: the approved amounts ($3.8 billion in 2022 and $3.0 billion in 2023), the corresponding percentages of European customer balances (37% and 39%), and the correct year-over-year decline of approximately 21% (calculated as (3.8 - 3.0)/3.8 ≈ 21.05%). These values match the ground truth exactly in both magnitude and context.\n\n2) Quantitative accuracy is perfect: all dollar amounts, percentages, and the calculated percentage change are correct. The format variations (e.g., $3.8 billion vs $3.8 billion) are acceptable and do not affect clarity or correctness.\n\n3) The reasoning is sound and captures the nuance: the absolute amount approved decreased, while the relative percentage of balances used slightly increased, indicating a more conservative utilization strategy. The LLM correctly interprets this as a reduction in absolute terms with stable proportional use, aligning with the ground truth's implication of a more conservative approach.\n\n4) The only minor shortcoming is that the LLM describes the proportion as 'roughly stable' despite a 2-percentage-point increase from 37% to 39%, which may slightly underemphasize the nuance that the proportion increased while the absolute amount decreased. The original answer explicitly notes this contrast to highlight the conservative shift, which the LLM captures partially but less precisely in interpretation. However, this does not constitute a factual error.\n\nOverall, the answer is factually complete, quantitatively accurate, and contextually appropriate, warranting a high correctness score with only a slight deduction in qualitative accuracy for less precise interpretive nuance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1261,
        "completion_tokens": 461,
        "total_tokens": 1722
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did Starbucks' exposure to foreign currency - other instruments evolve between 2023 and 2024, particularly in terms of their fair value and the expected reclassification impact on earnings?",
      "original_answer": "In 2023, Starbucks reported a fair value of $1,164 million for foreign currency - other instruments, with a net gain of $39.6 million included in AOCI. By 2024, the fair value decreased to $920 million, and the net gain included in AOCI dropped to $11.5 million. Additionally, the amount expected to be reclassified from AOCI into earnings within 12 months declined from $55.3 million in 2023 to $9.5 million in 2024, indicating a reduced short-term earnings impact from these instruments.",
      "llm_answer": "\nBetween the end of fiscal 2023 (Oct 1 2023) and the end of fiscal 2024 (Sep 29 2024) Starbucks’ foreign‑currency‑other hedging program contracted sharply.  The cumulative gain that remained in AOCI fell from **$39.6 million to $11.5 million**, and the fair‑value of the related derivatives also dropped – prepaid‑expense assets fell from **$32 million to $1.9 million** while accrued‑liability balances stayed relatively flat – signalling a smaller notional exposure.  Consequently, the amount of that AOCI gain that is expected to be re‑classified into earnings over the next 12 months fell from **$23.6 million (2023) to $28.2 million (2024)**, indicating a reduced future earnings impact from foreign‑currency hedges.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "(1) The LLM answer contains several factual inaccuracies despite capturing the general trend of decreasing exposure. Key correct elements include the drop in AOCI net gain from $39.6 million to $11.5 million, which matches the ground truth. However, critical errors include: the fair value of foreign currency - other instruments being misrepresented — the ground truth reports $1,164 million (2023) and $920 million (2024), but the LLM incorrectly focuses on prepaid expenses ($32M to $1.9M) and accrued liabilities, which are not the fair value of the instruments themselves. Additionally, the amount expected to be reclassified into earnings is stated as $23.6M in 2023 and $28.2M in 2024 by the LLM, which contradicts the ground truth of $55.3M (2023) and $9.5M (2024). This is a major quantitative error, especially since the direction of change (increase vs. actual sharp decrease) is wrong. (2) Number verification: AOCI gain values are correct. Fair value numbers are entirely incorrect — LLM uses component balance sheet items rather than total fair value. Reclassification amounts are wrong: $23.6M and $28.2M vs. $55.3M and $9.5M. (3) Multi-hop reasoning is partially sound — the model recognizes that changes in AOCI and reclassification impact relate to future earnings and attempts to synthesize trends. However, it fails to correctly identify the primary metric (fair value of instruments) and uses incorrect proxy data, undermining the synthesis. (4) Correctness score is 4 due to partial factual accuracy on AOCI gains but major errors in fair value and reclassification figures. Quantitative accuracy is low (3) due to incorrect numbers and a wrong trend in reclassification impact. Qualitative accuracy is moderate (5) because reasoning structure is logical but based on incorrect data. Contextual relevance is high (8) as the answer addresses the right topic, time frame, and conceptual framework.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 515,
        "total_tokens": 1829
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did the fair value of energy-related derivatives held by Alabama Power and Georgia Power evolve from 2022 to 2023, and what was the directional change in their asset versus liability positions?",
      "original_answer": "In 2022, Alabama Power reported energy-related derivatives with a fair value of $55 million in assets and $11 million in liabilities, while Georgia Power reported $75 million in assets and $8 million in liabilities. By 2023, Alabama Power's energy-related derivatives decreased to $15 million in assets but increased significantly to $110 million in liabilities. Similarly, Georgia Power's derivatives were valued at $13 million in assets and $124 million in liabilities in 2023. This indicates a substantial shift toward liability exposure for both entities over the period.",
      "llm_answer": "\nFrom 2022 to 2023 the fair‑value of the energy‑related derivatives held by Alabama Power dropped from roughly **$55 million (asset) and $11 million (liability)** to **$15 million (asset) and $110 million (liability)**, while Georgia Power’s fell from about **$75 million (asset) and $8 million (liability)** to **$13 million (asset) and $124 million (liability)**. In each subsidiary the **asset side contracted** and the **liability side expanded**, moving both from a modest net‑asset/near‑zero position to a sizable net‑liability.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: Alabama Power's 2022 values ($55M assets, $11M liabilities) and 2023 values ($15M assets, $110M liabilities) are correctly reported; Georgia Power's 2022 ($75M assets, $8M liabilities) and 2023 ($13M assets, $124M liabilities) are also exact. Minor wording like 'roughly' or 'about' does not affect factual accuracy as the numbers themselves are precise. (2) The answer addresses both parts of the question: the evolution of fair value from 2022 to 2023 for both companies, and the directional change in asset vs. liability positions. (3) Entities (Alabama Power, Georgia Power), years (2022, 2023), and financial metrics (fair value of energy-related derivatives, asset/liability positions) are correctly identified. (4) The reasoning is sound: the LLM correctly synthesizes multi-hop data across two companies and two years, noting the contraction in assets and expansion in liabilities, and concludes the shift to net-liability positions, which aligns with the ground truth. The semantic meaning is equivalent to the original answer, with slightly more concise phrasing but no loss of information. All evaluation criteria are fully satisfied.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 354,
        "total_tokens": 1644
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did the asset allocation strategy for the U.S. Retiree Health Care Plan evolve from 2022 to 2023, particularly in terms of the percentage distribution between fixed income securities and equity securities?",
      "original_answer": "In 2022, the U.S. Retiree Health Care Plan allocated 65% to fixed income securities and cash equivalents and 35% to equity securities. By 2023, the allocation to fixed income securities increased to 80%, while equity securities decreased to 20%. This represents a shift toward a more conservative investment strategy in 2023 compared to 2022.",
      "llm_answer": "\nFrom 2022 to 2023 the U.S. Retiree Health Care plan shifted its asset mix markedly toward fixed‑income.  In 2022 the plan held about **65 % fixed‑income securities and 35 % equity securities** (≈ $182 m fixed‑income vs $98 m equity of a $280 m total).  By the end of 2023 the allocation was roughly **80 % fixed‑income and 20 % equity** (≈ $210 m fixed‑income vs $54 m equity of a $264 m total), moving the portfolio to the upper end of the plan’s target 65‑80 % fixed‑income range and the lower end of its 20‑35 % equity range.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the percentages for both years are accurate: 65% fixed income and 35% equity in 2022, shifting to 80% fixed income and 20% equity in 2023. The dollar amounts provided ($182M vs $98M in 2022, $210M vs $54M in 2023) are consistent with the total plan values ($280M in 2022, $264M in 2023) and the stated percentages—calculations are correct. (2) The answer is complete, addressing the evolution of asset allocation between the two years and specifically detailing the shift in percentage distribution between fixed income and equity securities as asked. (3) Entity accuracy is correct: the plan name (U.S. Retiree Health Care Plan), time periods (2022 and 2023), and financial categories (fixed income and equity securities) are all properly identified. (4) The reasoning is sound and adds contextual insight—correctly noting that the 2023 allocation moved to the upper end of the target range for fixed income (65–80%) and lower end for equities (20–35%), which demonstrates accurate multi-hop synthesis beyond just restating numbers. (5) The semantic meaning fully aligns with the original answer, with added precision (dollar values, target ranges) that enhance clarity without introducing error. Minor formatting variations (e.g., use of ≈, spacing in $210 m) are acceptable and do not affect accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1233,
        "completion_tokens": 387,
        "total_tokens": 1620
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How has the regulatory approval status of Trodelvy evolved between 2022 and 2023, and what new indications were granted in 2023?",
      "original_answer": "In 2022, Trodelvy was indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies and for metastatic urothelial cancer after platinum-based chemotherapy and a PD-1/PD-L1 inhibitor. By 2023, Trodelvy received additional approvals: it was granted EC approval and FDA approval for the treatment of adult patients with unresectable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. This represents a significant expansion of the drug’s therapeutic applications.",
      "llm_answer": "\nBetween 2022 and 2023 the regulatory footprint of Trodelvy expanded — in 2022 it held only accelerated‑approval indications for metastatic triple‑negative breast cancer and for platinum‑treated metastatic urothelial cancer — and by the end of 2023 the FDA granted a new, non‑accelerated approval for Trodelvy as a monotherapy in advanced HR⁺/HER2⁻ breast cancer (after endocrine therapy and at least two prior systemic regimens), while the European Commission also granted marketing authorization for that same breast‑cancer indication. This added a major solid‑tumor indication beyond the original TNBC and urothelial cancer approvals.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) It correctly identifies the 2022 indications for Trodelvy: metastatic triple-negative breast cancer (TNBC) and platinum-treated metastatic urothelial cancer. It also accurately describes the 2023 expansion to include HR+/HER2- breast cancer, with both FDA and European Commission (EC) approvals. (2) There are no numeric values requiring calculation, but all dates (2022, 2023) and regulatory bodies (FDA, EC) are correctly cited. The mention of 'endocrine therapy and at least two prior systemic regimens' matches the ground truth's 'endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.' (3) The multi-hop reasoning is sound: the model synthesizes changes over time (2022 to 2023), compares indications, and correctly attributes approvals to the relevant regulatory agencies. The only minor omission is that the original answer specifies the 2022 approvals included patients who had received 'two or more prior systemic therapies' for TNBC, which the LLM answer does not explicitly restate, though it implies prior treatment. Also, the LLM adds detail about the 2023 approval being 'non-accelerated,' which is not in the ground truth but is factually plausible and adds context without contradicting. (4) The answer is semantically equivalent, well-structured, and fully relevant to the question about regulatory evolution and new indications. The slight lack of full detail on prior therapy criteria in 2022 prevents a perfect 10, but overall accuracy is excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 438,
        "total_tokens": 1776
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Meta's disclosure regarding user perception as a risk factor evolve between 2023 and 2024, particularly in terms of the nature of risks highlighted and their potential impact on business operations?",
      "original_answer": "In 2023, Meta emphasized user perception risks related to privacy, safety, content quality, and regulatory changes, specifically noting concerns around decreased user sentiment and engagement due to data practices and content policies. In 2024, while user perception was still acknowledged, the focus shifted toward broader operational and financial risks, such as integration challenges from acquisitions, tax liabilities, and investor sentiment. The explicit mention of user perception as a direct risk factor was notably reduced in 2024, indicating a strategic shift in how Meta communicated its risk profile.",
      "llm_answer": "\nBetween the 2023 and 2024 filings the discussion of “user perception” moved from a broad warning that loss of users or engagement could hurt revenue (2023 Risk Factors – “If we fail to retain existing users… our revenue… may be significantly harmed”) to a more granular, multi‑dimensional risk statement.  In 2024 the company explicitly ties perceived problems—such as doubts about the platform’s usefulness, reliability, trustworthiness, data‑privacy practices, content‑moderation decisions, and the impact of new regulations (GDPR, DMA, DSA) or product changes (e.g., “subscription‑for‑no‑ads” in Europe)—to concrete business consequences: reduced user growth/engagement, lower ad‑impression volume, diminished advertiser demand, and ultimately a direct hit to revenue and financial results.  Thus, the 2024 disclosure deepens the risk by spelling out the specific trust‑related and regulatory drivers that can erode user perception and by linking those drivers more directly to operational and financial outcomes.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim about the evolution of Meta's risk disclosures. The ground truth states that Meta *reduced* its explicit discussion of user perception as a risk factor in 2024, shifting focus toward operational and financial risks like acquisition integration and tax liabilities. In contrast, the LLM claims the opposite: that Meta *deepened* and *expanded* its discussion of user perception risks in 2024 by linking them more directly to business outcomes. This misrepresents the direction of change. While the LLM accurately references regulatory frameworks (GDPR, DMA, DSA) and potential consequences like reduced engagement or ad revenue, these details are framed within an incorrect overarching narrative. There are no numerical inaccuracies (hence high quantitative score), but the qualitative reasoning is flawed—failing the multi-hop synthesis by drawing the wrong conclusion from the data. The answer is contextually relevant to the question and uses appropriate financial and regulatory terminology, but the central inaccuracy severely undermines correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1422,
        "completion_tokens": 313,
        "total_tokens": 1736
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How has the notional amount of Lockheed Martin's variable interest rate swaps evolved from 2021 to 2024, and what does this indicate about the company's interest rate risk management strategy?",
      "original_answer": "In 2021, the notional amount of Lockheed Martin's variable interest rate swaps was $500 million, while by 2024, it had increased to $1.3 billion. This indicates a significant shift in the company's interest rate risk management strategy, with a growing emphasis on converting fixed-rate borrowings to variable-rate borrowings, likely in response to changes in the interest rate environment and the company's borrowing profile over the period.",
      "llm_answer": "\nThe notional amount of Lockheed Martin’s outstanding variable‑rate interest‑rate swaps grew from **$0.5 billion at the end of 2021** (reported in the 2022 10‑K, p. 64‑65) to **$1.3 billion by the end of 2023 and again in 2024** (reported in the 2024 10‑K, p. 52‑53).  This expansion shows that the company has deliberately increased its use of interest‑rate swaps to hedge the fair‑value exposure of its fixed‑rate debt, indicating a more robust strategy for managing interest‑rate risk as rates have risen.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reports the notional amounts: $0.5 billion in 2021 (equivalent to $500 million in the ground truth) and $1.3 billion in 2024. The answer notes that the $1.3 billion amount was already in place by the end of 2023 and continued into 2024, which is consistent with available data and does not contradict the ground truth—it simply adds slightly more granular timing. (2) All numbers are accurate: $500 million in 2021 and $1.3 billion in 2024 are correctly stated, with acceptable format variation ($0.5 billion = $500 million). No calculations are required beyond comparison, and the directional change (increase) is correctly emphasized. (3) The multi-hop reasoning is sound: the LLM synthesizes data from different 10-K filings across years and correctly infers that the increase in variable-rate swaps reflects a strategic shift in interest rate risk management, specifically hedging fixed-rate debt. This aligns with the ground truth’s interpretation. (4) The only minor deviation is that the LLM frames the strategy as hedging 'fair-value exposure of fixed-rate debt'—which is technically accurate—but does not explicitly state the economic effect of converting fixed to variable rates, as the ground truth does. However, this is a nuance in phrasing rather than a factual error. Overall, the answer is factually correct, complete, and contextually appropriate, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1249,
        "completion_tokens": 394,
        "total_tokens": 1643
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did PayPal's approach to its Seller Protection Programs evolve between 2022 and 2023, particularly in terms of financial provisions for transaction losses?",
      "original_answer": "In 2022, PayPal acknowledged the risk of losses from its Seller Protection Programs and noted that historical loss rates ranged between 0.09% and 0.15% of TPV, with the potential for increased losses due to macroeconomic conditions such as the ongoing impacts of the COVID-19 pandemic. By 2023, PayPal provided more structured financial disclosures, showing that the allowance for transaction losses was $64 million (down from $66 million in 2022), indicating a slight decrease in expected losses. This shift reflects a more defined and quantified approach to managing seller protection risk in 2023 compared to the more qualitative risk assessment in 2022.",
      "llm_answer": "\nBetween 2022 and 2023 PayPal modestly raised the expense it records for seller‑protection losses—the provision for transaction and credit losses grew from **$1.17 billion to $1.19 billion**—while the year‑end allowance for transaction losses stayed essentially unchanged, moving from **$278 million to $282 million**. This indicates a slight, more conservative adjustment to the estimated cost of potential transaction losses, but the overall reserve level was kept steady.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both quantitative and qualitative aspects. (1) Quantitatively, the LLM states that PayPal's provision for transaction and credit losses increased from $1.17 billion to $1.19 billion and that the allowance for transaction losses rose from $278 million to $282 million. However, the ground truth states that the allowance for transaction losses was $64 million in 2023, down from $66 million in 2022—meaning both the values and the trend are wrong. The LLM's figures are off by more than a factor of four, indicating severe factual inaccuracy. (2) The original answer emphasizes a shift from qualitative risk disclosure in 2022 (mentioning historical loss rates of 0.09%–0.15% of TPV and macroeconomic risks) to a more structured, quantified approach in 2023 with specific allowance figures. The LLM completely omits this key evolution in disclosure strategy and instead fabricates large-scale financial figures unrelated to the actual data. (3) The reasoning is flawed: the LLM implies a conservative adjustment due to a rising provision, but the truth is a slight decrease in allowance, reflecting improved or more precise risk modeling. (4) The entities (PayPal, Seller Protection Programs, transaction losses) and time frame (2022–2023) are correct, and the general topic of financial provisioning is relevant, but the core facts, numbers, and synthesis are incorrect. Thus, while the context is partially relevant, the answer fails on correctness and accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 413,
        "total_tokens": 1699
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Starbucks' derivative asset and liability positions in foreign currency - other change from fiscal year 2023 to fiscal year 2024, and what was the magnitude of this change on the balance sheet?",
      "original_answer": "In fiscal year 2023, Starbucks reported a derivative asset of $1,164 million under 'Foreign currency - other.' By fiscal year 2024, this amount significantly decreased to $1.9 million in derivative assets under the same category. Additionally, the derivative liability for 'Foreign currency - other' increased from $2.0 million in 2023 to $4.7 million in 2024. This indicates a major reduction in the company's foreign currency derivative assets and a moderate increase in liabilities tied to foreign currency over this period.",
      "llm_answer": "\nThe foreign‑currency‑other derivative **asset** fell from **$32.0 million** at the end of fiscal 2023 to **$1.9 million** at the end of fiscal 2024, a **$30.1 million decrease**; the foreign‑currency‑other derivative **liability** rose from **$2.0 million** to **$4.7 million**, an **increase of $2.7 million**.  Consequently, the net derivative position shifted from a net asset of roughly **$30 million** to a net liability of about **$2.8 million**, representing a total balance‑sheet swing of roughly **$33 million** between FY 2023 and FY 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors in the reported derivative asset value for fiscal year 2023. According to the ground truth, Starbucks' derivative asset under 'Foreign currency - other' was $1,164 million in 2023, not $32.0 million as stated by the LLM. The 2024 asset value ($1.9 million) and both liability values ($2.0 million in 2023 and $4.7 million in 2024) are correct. (2) Due to the incorrect 2023 asset figure, all derived calculations are wrong: the decrease in assets is reported as $30.1 million instead of the correct $1,162.1 million ($1,164M - $1.9M); the net position in 2023 is incorrectly calculated as $30 million (using $32M - $2M) instead of the correct $1,162 million ($1,164M - $2M); and the claimed total balance-sheet swing of $33 million is vastly off from the actual swing of approximately $1,164.8 million (from +$1,162M net asset to -$2.8M net liability). (3) While the LLM correctly identifies the direction of change (decrease in assets, increase in liabilities) and attempts multi-hop reasoning by computing net positions and overall impact, the synthesis is based on incorrect input data, undermining the validity of the conclusion. (4) The contextual relevance is high because the answer addresses all aspects of the question—changes in asset, liability, and overall balance sheet impact—with appropriate terminology and structure. However, the quantitative accuracy is severely compromised by the incorrect 2023 asset figure, which appears to be a factual hallucination or data retrieval error. This major error propagates through all calculations, warranting a low correctness score despite partial accuracy on liability figures and qualitative trends.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 469,
        "total_tokens": 1752
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did the financial impact of energy-related derivatives on natural gas cost and revenue hedging positions evolve from 2022 to 2023?",
      "original_answer": "In 2022, energy-related derivatives had a negative impact of $117 million on natural gas revenues and a $27 million negative impact on the cost of natural gas. In 2023, the impact shifted positively with a $59 million gain on the cost of natural gas, while the revenue impact remained neutral at $0. This indicates a transformation in the role and effectiveness of these derivatives in managing natural gas exposure.",
      "llm_answer": "\nThe data show that the benefit from the natural‑gas‑related hedges collapsed between the two years.  In 2022 the company recorded a **$134 million gain** on the energy‑related cash‑flow hedge that boosted natural‑gas revenues and a **$15 million gain** on the hedge that reduced the cost of natural gas; by 2023 those same hedges produced a **$117 million loss** on revenues and a **$27 million loss** on cost (see the “Gain (loss) on energy‑related cash flow hedges (a)” and non‑designated‑hedge tables).  As a result, the net financial impact swung from a **$149 million positive effect** in 2022 to a **$144 million adverse effect** in 2023.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is almost entirely incorrect and contradicts the ground truth in both direction and magnitude of impacts. (1) Quantitative Accuracy: The LLM claims a $134 million gain on revenues in 2022, but the ground truth states a $117 million *loss* (negative impact). Similarly, the LLM reports a $15 million gain on cost in 2022, while the truth is a $27 million *loss*. In 2023, the LLM incorrectly states a $117 million loss on revenues and $27 million loss on cost, whereas the truth is a $59 million *gain* on cost and $0 impact on revenue. These are fundamental factual errors. (2) Calculations: The LLM’s derived net impact of $149 million positive in 2022 ($134 + $15) and $144 million adverse in 2023 are based on false inputs and are therefore invalid. (3) Qualitative Accuracy: The reasoning is flawed—instead of showing an improvement in cost hedging and neutral revenue impact in 2023, the LLM suggests a collapse in hedge performance, which is the opposite of the truth. (4) Contextual Relevance: While the answer addresses the general topic of energy derivatives and their financial impact over 2022–2023, the severe factual inaccuracies render it misleading. The multi-hop synthesis fails completely as the model misidentifies the sign, magnitude, and evolution of impacts. The answer does not reflect the actual transformation described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1262,
        "completion_tokens": 380,
        "total_tokens": 1643
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Walmart's treatment of its Deferred Compensation Matching Plan evolve between the 2023 and 2024 10-K filings, particularly in terms of its documentation status and effective date?",
      "original_answer": "In the 2023 10-K filing, the Deferred Compensation Matching Plan was newly introduced as 'Walmart Inc. Deferred Compensation Matching Plan, as amended and restated effective November 8, 2023.' By the 2024 10-K filing, the plan was no longer labeled as newly introduced but was instead referenced as being 'incorporated by reference' to the 2024 Annual Report on Form 10-K, indicating that it had become an established, ongoing plan. The effective date remained unchanged at November 8, 2023, suggesting no substantive changes to the plan’s implementation timeline, but its treatment shifted from being newly introduced to being formally integrated into the company's long-term compensation framework.",
      "llm_answer": "\nBetween the 2023 and 2024 10‑K filings Walmart continued to disclose its Deferred Compensation Matching Plan as an “amended and restated” arrangement with an effective date of **November 8, 2023**. In the 2023 filing the plan appeared as Exhibit 10.1 and was described as newly amended and restated, while in the 2024 filing the same language and exhibit reference were retained, confirming that the plan remained documented in the same manner and that its effective date did not change.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the key factual elements: the plan's name, the effective date of November 8, 2023, and its continued presence in both the 2023 and 2024 10-K filings with the same 'amended and restated' language and exhibit number (Exhibit 10.1). The quantitative accuracy is perfect—dates and documentation references are factually correct. However, the LLM misses a key qualitative shift emphasized in the ground truth: the change in *treatment* and *documentation status* of the plan from being newly introduced in 2023 to being 'incorporated by reference' in 2024, indicating institutionalization. The LLM incorrectly implies that the plan was described in the same way in both years by stating the 'same language and exhibit reference were retained,' which contradicts the ground truth that in 2024 it was no longer labeled as newly introduced and was instead referenced by incorporation. This reflects a failure in multi-hop reasoning to synthesize the evolution in disclosure practice, even if the underlying document date remained unchanged. While the core facts are accurate, the answer lacks the nuanced interpretation of how the plan’s status evolved from new to established, which is central to the question. Hence, correctness and qualitative accuracy are reduced, though not severely due to strong factual grounding.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 373,
        "total_tokens": 1680
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has the disclosure and treatment of LTIP Units evolved between 2023 and 2024, particularly in terms of their dilutive effect and accrual policy?",
      "original_answer": "In 2023, LTIP Units were described as potentially dilutive securities that are convertible into units and exchangeable for common stock, with no material dilutive effect reported for the years 2023, 2022, and 2021. The company stated it does not adjust net income attributable to common stockholders or weighted average shares outstanding due to no dilutive impact. In 2024, the disclosure simplified, stating that LTIP Units are potentially dilutive but again noting no material dilutive effect for the years 2024, 2023, and 2022. Additionally, the accrual policy remained consistent, stating that distributions are accrued when declared. The treatment of LTIP Units remained stable with no significant change in dilutive impact or accrual policy.",
      "llm_answer": "\nBetween 2023 and 2024 the company’s disclosures treat LTIP Units in the same way: they are identified as “potentially dilutive securities” that are exchangeable into common stock or operating partnership units, but they are explicitly stated to have **no material dilutive effect** for any of the years presented. Consequently, the company does **not adjust net income attributable to common stockholders or the weighted‑average share (or unit) count** for any income allocated to limited partners or LTIP holders, and it continues to **accrue dividends on LTIP Units only when they are declared**, a policy that has remained unchanged from 2023 through 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the original (ground truth) answer. (1) All key facts are accurately conveyed: LTIP Units are described as potentially dilutive but with no material dilutive effect in both 2023 and 2024; the company does not adjust net income or weighted average shares due to lack of dilutive impact; and the accrual policy remains unchanged—distributions are accrued only when declared. (2) There are no numeric values requiring calculation (e.g., percentages, dollar amounts), but the years referenced (2023, 2022, 2021 in 2023 disclosure; 2024, 2023, 2022 in 2024 disclosure) are correctly reflected in the context of reporting periods. (3) The multi-hop reasoning is sound—information from both years is synthesized correctly to show consistency in treatment and disclosure evolution (simplification in 2024 without substantive change). (4) The LLM captures the stability in both dilutive effect and accrual policy, directly addressing both parts of the question. Wording differs slightly but meaning is preserved with high precision. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 324,
        "total_tokens": 1676
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Meta's compliance approach to the EU-U.S. Data Privacy Framework (EU-U.S. DPF) evolved between 2023 and 2024, particularly in response to regulatory actions and decisions?",
      "original_answer": "In 2023, Meta was in the process of implementing steps to comply with corrective orders from the Irish Data Protection Commission (IDPC) following a EUR €1.2 billion fine and a directive to suspend unlawful data transfers to the U.S. under Standard Contractual Clauses (SCCs). At that time, the EU-U.S. DPF had just been finalized, and Meta viewed its implementation as a key milestone to address data transfer compliance. By 2024, Meta had implemented compliance measures with the corrective orders and was actively engaging with regulators on new compliance models, such as the 'subscription for no ads' alternative introduced in November 2023. In 2024, the European Commission opened formal proceedings into the compliance of this model with the Digital Markets Act (DMA), issuing preliminary findings in July 2024 that suggested non-compliance. This reflects a shift from foundational compliance with the EU-U.S. DPF framework to navigating more complex regulatory scrutiny around specific business models under evolving EU laws.",
      "llm_answer": "\nBetween 2023 and 2024 Meta moved from waiting for the EU‑U.S. Data Privacy Framework (DPF) to become operational to actively embedding it into its data‑transfer and compliance programmes.  In 2023 the company was still appealing the Irish Data Protection Commission’s €1.2 billion fine and corrective order that had invalidated its reliance on Standard Contractual Clauses, while publicly stating that the newly‑announced DPF‑adequacy decision would replace the expired Privacy‑Shield and SCC mechanisms.  By 2024 Meta had begun implementing the DPF’s safeguards—updating consent models, launching a “subscription‑for‑no‑ads” option, and aligning its advertising‑consent flows with the EU’s DMA and GDPR—while continuing to monitor the DPF’s legal resilience and preparing contingency plans in case the framework is later struck down.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core evolution of Meta's compliance approach to the EU-U.S. DPF between 2023 and 2024 with reasonable accuracy, but contains some inaccuracies and omissions that affect factual precision and completeness. (1) Quantitatively, the €1.2 billion fine is correctly cited, and the timeline (2023–2024) aligns with the ground truth. However, the LLM incorrectly states Meta was 'appealing' the IDPC decision in 2023—while Meta may have challenged aspects, the ground truth emphasizes implementation of corrective orders, not appeal. Also, the 'subscription for no ads' was introduced in November 2023, not in 2024 as implied by the phrasing 'by 2024 Meta had begun implementing...launching'. (2) The LLM omits the key 2024 development: the European Commission opening formal proceedings under the DMA and issuing preliminary findings of non-compliance in July 2024, which is a critical part of the regulatory evolution. (3) Reasoning is partially sound—LLM correctly links the shift from SCCs to DPF reliance and notes alignment with GDPR/DMA, but fails to fully synthesize the multi-hop progression: from foundational compliance (2023) to active regulatory scrutiny of new models (2024). (4) Contextually, the answer is relevant and addresses the broad trajectory of Meta’s compliance evolution. Wording differences are acceptable, but missing the DMA proceedings and misrepresenting the timeline of the subscription model launch reduces qualitative and quantitative accuracy. Overall, core facts are present but key regulatory developments and timing are misrepresented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1475,
        "completion_tokens": 434,
        "total_tokens": 1909
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Linde's approach to green hydrogen production evolved between 2023 and 2024, particularly in terms of production methods and emphasis on renewable energy sources?",
      "original_answer": "In 2023, Linde described green hydrogen as being produced primarily through electrolysis using renewable energy or from steam methane reforming of biomethane, and it was presented as one of the company's clean energy offerings alongside blue hydrogen. By 2024, the company had expanded its description to emphasize green hydrogen as 'renewable hydrogen' produced by electrolysis using renewable energy and water as feedstock, and it was clearly differentiated from low-carbon (blue) hydrogen. Additionally, in 2024, Linde placed more emphasis on the carbon intensity metric to differentiate production methods, indicating a more refined and strategic framing of green hydrogen within the broader context of clean energy solutions.",
      "llm_answer": "\nBetween 2023 and 2024 Linde moved from a general reference to “green hydrogen” produced by electrolysis using renewable energy (or biomethane) to a more explicit, metrics‑driven strategy.  The 2024 filing defines green hydrogen as electrolysis powered by renewable electricity and introduces a carbon‑intensity framework that distinguishes green from blue (low‑carbon) hydrogen made from fossil feedstocks with capture, while also noting that renewable hydrogen can be sourced from non‑fossil feedstocks.  This shift reflects a stronger emphasis on renewable‑energy‑driven production methods and positions green hydrogen as a central element of Linde’s clean‑energy portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in Linde's approach to green hydrogen between 2023 and 2024. It correctly identifies the shift from a broader definition in 2023—where green hydrogen included production via electrolysis using renewable energy or steam methane reforming of biomethane—to a more precise 2024 framing that emphasizes electrolysis powered exclusively by renewable electricity and water feedstock. The answer accurately notes the introduction of a carbon-intensity framework in 2024 to differentiate green (renewable) from blue (low-carbon) hydrogen, which aligns with the ground truth. It also correctly highlights the strategic repositioning of green hydrogen as central to Linde’s clean energy portfolio. The only minor shortcoming is that the LLM slightly downplays the explicit 2024 rebranding of green hydrogen as 'renewable hydrogen'—a nuance present in the original answer—but this does not detract significantly from the overall accuracy. There are no numerical inaccuracies (dates: 2023–2024 are correct), and the reasoning reflects sound multi-hop synthesis across time periods and conceptual developments. The answer is fully contextually relevant and conveys semantically equivalent information to the ground truth with high fidelity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 359,
        "total_tokens": 1717
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did Southern Company's relationship with Sequent evolve between 2022 and 2023, and what were the financial implications of this change?",
      "original_answer": "Southern Company's relationship with Sequent evolved from a business ownership relationship in 2022 to a completed divestiture in 2023. In 2022, Southern Company Gas completed the sale of Sequent to Williams Field Services Group for $159 million, recognizing a pre-tax gain of $121 million. Additionally, the sale resulted in $85 million of additional tax expense due to changes in state apportionment rates. By 2023, Sequent was no longer part of Southern Company's portfolio, and the financial impact of the sale was fully reflected in the company's financial statements, with the gain from the sale reported as a $121 million pre-tax benefit. This marked a complete transformation in the relationship, shifting from operational integration to full separation.",
      "llm_answer": "\nSouthern Company’s exposure to Sequent ended after the July 1 2021 divestiture; by 2022 the company no longer held any ownership or regulatory‑rate rights in Sequent, and in 2023 there was no remaining financial relationship.  The only financial effects of the transaction were the $121 million pre‑tax gain (≈ $92 million after‑tax) recorded in 2021 and a subsequent $85 million increase in tax expense arising from state‑apportionment changes—after which Sequent generated no further earnings, cash flows, or regulatory assets for Southern Company.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly regarding the timing of the divestiture. The ground truth states the sale occurred in 2022, but the LLM claims it happened on July 1, 2021, which is incorrect. This misalignment affects the entire temporal framing of the relationship evolution between 2022 and 2023. While the LLM correctly identifies the $121 million pre-tax gain and the $85 million additional tax expense due to state apportionment changes, it incorrectly attributes the gain to 2021 rather than 2022. (2) Quantitatively, the dollar amounts ($121M gain, $85M tax expense) are accurate and match the ground truth, but the dates are wrong—this severely undermines quantitative accuracy despite correct figures. The after-tax gain estimate of ~$92M is a reasonable approximation but not mentioned in the original answer, so it's extraneous but not erroneous. (3) The multi-hop reasoning is flawed because the model fails to correctly synthesize the timeline: it should have shown that in 2022 the sale occurred (not 2021), leading to financial impacts in that year, and by 2023 Sequent was fully divested. Instead, it asserts no relationship existed in 2022, contradicting the question’s premise about a 2022–2023 evolution. (4) Contextual relevance is moderate—the answer addresses the financial implications and the nature of the relationship change, but due to the incorrect timeline, the core narrative is factually unsound. The conclusion that there was no financial relationship in 2022–2023 is correct, but the reasoning leading to it is invalid. Thus, while some facts are right, the overall correctness is low due to critical errors in timing and causal sequence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 470,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Walmart's relationship with the Allswell brand evolved between 2023 and 2024, and what does this indicate about its strategic positioning within the company's private brand portfolio?",
      "original_answer": "In 2023, Walmart introduced the Allswell brand as part of its private brand offerings, indicating its initial entry into the market. By 2024, the brand was not only retained but explicitly listed among other mature private brands like 'bettergoods,' 'Equate,' and 'Great Value,' suggesting that Allswell has transitioned from a newly introduced brand to a more established part of Walmart's private label strategy. This evolution indicates that Allswell has likely gained traction and is being positioned as a core component of Walmart’s private brand portfolio.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 the company’s disclosures show that **Allswell remained on the list of Walmart‑owned private‑brand labels, but the 2024 filing expands the private‑brand narrative**—it is presented as a core component of a broader, deliberately curated portfolio that now also includes newer brands such as “bettergoods.”  The 2024 text emphasizes growing the assortment, margin contribution and strategic importance of these private‑brand lines, positioning Allswell as a key value‑oriented brand that reinforces Walmart’s everyday‑low‑price positioning while delivering higher‑margin, differentiated merchandise.  This evolution signals that Walmart is using Allswell (and the rest of its private‑brand suite) as a strategic lever to deepen its private‑brand portfolio and capture additional consumer trust and profitability.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns well with the ground truth. (1) It correctly states that Allswell remained in Walmart's private brand portfolio from 2023 to 2024 and was included in a broader strategic narrative in 2024, which matches the original answer's claim that Allswell transitioned from a new to an established brand. The mention of 'bettergoods' as a newer brand alongside Allswell is consistent with the ground truth listing. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—dates (2023 and 2024) are correct. (3) The multi-hop reasoning is sound: the model infers from the continued presence and repositioning of Allswell in disclosures that it has become a core brand, which is a valid interpretation of the evolution described in the ground truth. The added detail about margin contribution and strategic importance is a reasonable extrapolation from the 2024 emphasis on private brands, though slightly more interpretive than the original. (4) The answer is semantically equivalent and contextually relevant, capturing the strategic significance of Allswell’s retention and positioning. The only minor deviation is that the original emphasizes Allswell’s transition from new to established, while the LLM focuses more on strategic role; however, this does not detract from factual correctness. Hence, a high score of 9 is warranted.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 398,
        "total_tokens": 1762
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has the strategic importance of Embedded Processing products evolved from 2022 to 2023 based on TXN's revenue composition and strategic emphasis?",
      "original_answer": "In 2022, Embedded Processing products were described as one of two core segments, positioned alongside Analog as a key part of the business, though no specific revenue figures were disclosed. By 2023, Embedded Processing remained a strategic focus area, and notably, it partially offset a decline in Analog revenue, contributing to a $17.52 billion total revenue. This indicates that while Embedded Processing maintained its strategic importance, it also played a more pronounced compensatory role in the revenue mix during a year of overall revenue decline.",
      "llm_answer": "\nEmbedded‑Processing’s contribution to TI’s sales grew noticeably from 2022 to 2023: its revenue rose 3 % to $3.37 billion while total company revenue fell 12.5 %, pushing the segment’s share of total revenue up from roughly 16 % in 2022 to about 19 % in 2023.  The MD&A explicitly lists Embedded Processing as one of the company’s two core strategic focus areas and highlights a shift in product mix toward higher‑value devices, underscoring a stronger strategic emphasis on this business line and prompting increased capital investment to expand its capacity.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that no specific revenue figures for Embedded Processing were disclosed in 2022, but the LLM claims a 2022 revenue of approximately $3.27 billion (implied by 3% growth to $3.37B in 2023), which is unsupported. Additionally, the 16% and 19% revenue share figures are not present in the ground truth and appear to be fabricated or inferred incorrectly. The total company revenue decline of 12.5% and Embedded Processing growth of 3% are not corroborated by the original answer, which only notes that Embedded Processing partially offset Analog revenue declines and contributed to a $17.52B total revenue in 2023. (2) The quantitative inaccuracies are severe: the LLM introduces precise numbers (e.g., $3.37B, 16%, 19%, 12.5% decline) that do not appear in the ground truth and cannot be verified from the provided information. The calculation of revenue shares and growth rates is speculative and incorrect. (3) The reasoning partially captures the strategic emphasis—correctly identifying Embedded Processing as a core strategic area and noting increased investment—but incorrectly frames the evolution as one of growing revenue and share, whereas the ground truth emphasizes its compensatory role during a revenue decline without citing specific segment figures. The multi-hop synthesis fails because it invents data rather than relying on disclosed information. (4) Despite the factual errors, the answer is contextually relevant, addressing the evolution of strategic importance and referencing strategic focus and capital investment. However, the incorrect numbers undermine the qualitative insights, leading to a low correctness and quantitative accuracy score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1280,
        "completion_tokens": 479,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How has Chevron's involvement in Angola LNG evolved from 2022 to 2024, and what does this indicate about its strategic positioning in the LNG market?",
      "original_answer": "In 2022, Chevron's involvement in Angola LNG was referenced in the context of its production volumes, indicating operational participation. By 2024, Chevron's stake in Angola LNG Limited was explicitly stated as a 36.4% interest, highlighting a more defined and structured investment approach. This evolution suggests a strategic shift toward securing a stable position in the LNG market through formalized equity stakes.",
      "llm_answer": "\nChevron’s stake in Angola LNG remained a 36.4 % equity interest, but the 2022 10‑K (pp. 6‑10) shows the company reporting roughly 78 million barrels‑of‑oil‑equivalent of gas production from the project and emphasizing its role as a key African gas source. In the 2024 filing (pp. 83‑87) Chevron notes new long‑term natural‑gas delivery contracts through 2024 with variable, market‑linked pricing, positioning Angola LNG as a central pillar of its global LNG portfolio and underscoring a strategic shift toward securing high‑margin, long‑term LNG supply in Africa.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. While the 36.4% stake in Angola LNG is correctly stated for 2024 (matching the ground truth), the claim that this was also the stake in 2022 contradicts the original answer, which indicates that Chevron's involvement in 2022 was referenced only in terms of production volumes—not ownership percentage. Thus, asserting a 36.4% interest in 2022 is unsupported and incorrect. Additionally, the LLM introduces specific production data (78 million barrels-of-oil-equivalent) and page numbers (pp. 6-10, 83-87) not present in the ground truth, with no verification possible from the provided knowledge graph—these appear fabricated or hallucinated. The mention of 'long-term natural-gas delivery contracts through 2024 with variable, market-linked pricing' and characterization of Angola LNG as a 'central pillar' of Chevron's global LNG portfolio are qualitative expansions absent from the original answer and not corroborated by the ground truth. While the general strategic interpretation (shift toward securing position in LNG via equity stakes) aligns thematically, the LLM misrepresents the evolution: the original emphasizes a shift from operational participation (2022) to formalized equity stake (2024), whereas the LLM assumes the stake existed earlier. This undermines the multi-hop reasoning. Quantitative accuracy is low due to unverified numbers and incorrect temporal assignment of the 36.4% stake. Qualitative accuracy is partially met in framing strategic intent but penalized for unsupported claims. Contextual relevance is high as the response stays on topic and addresses the question's intent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1247,
        "completion_tokens": 460,
        "total_tokens": 1707
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How has the financial contribution and production status of the CH-53K program evolved between 2021 and 2024, and what does this indicate about its role within Lockheed Martin's RMS division?",
      "original_answer": "In 2021, the CH-53K program contributed to a $540 million increase in RMS net sales, driven by higher production volume alongside the Black Hawk and CRH programs. Additionally, it contributed to a $140 million increase in operating profit due to higher risk retirements and production volume. By 2024, the CH-53K program was described as being in a 'production ramp-up' phase, contributing $1.1 billion to higher product sales within RMS, indicating a shift from early-stage production and risk retirement to a more mature, high-volume production phase. This evolution shows that the CH-53K has transitioned from a developing program with growing financial impact to a key growth driver within RMS.",
      "llm_answer": "\nBetween 2021 and 2024 the CH‑53K evolved from a modest contributor to a headline growth driver for RMS.  In 2021 the program helped lift RMS net sales by $794 million (≈5 %) and added roughly $183 million (≈11 %) to operating profit, but by 2024 the 10‑K explicitly cites “higher production volume on the CH‑53K program” as a principal reason for the segment’s product‑sales increase.  This shift shows that the CH‑53K has become a core, high‑margin platform within Lockheed Martin’s Rotary and Mission Systems division, underpinning its longer‑term revenue and profit trajectory.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. According to the ground truth, in 2021 the CH-53K contributed to a $540 million increase in RMS net sales and a $140 million increase in operating profit. The LLM incorrectly states $794 million for net sales and $183 million for operating profit, which are not supported by the original data. These figures may conflate CH-53K with other programs like Black Hawk and CRH, but the LLM attributes them solely or predominantly to CH-53K, which is incorrect. In 2024, the ground truth states the program contributed $1.1 billion to higher product sales, but the LLM does not provide this specific figure, instead offering a vague citation of production volume as a driver—missing a key data point. (2) The percentages cited (5% and 11%) are not present in the original answer and cannot be verified without additional context (e.g., total RMS sales), making them potentially misleading. The calculation or sourcing of these percentages is unsupported. (3) Qualitatively, the LLM captures the correct directional evolution—CH-53K transitioning from a growing program to a key production and growth driver within RMS—and correctly identifies 'production ramp-up' as a theme by 2024, aligning with the 'mature, high-volume production phase' described in the ground truth. The reasoning about its increasing strategic importance is logically sound and reflects multi-hop synthesis of program status and financial impact over time. (4) Contextually, the answer is relevant and addresses both financial contribution and production status across the time period, as well as the program’s role in RMS. However, the incorrect numbers severely undermine factual reliability. While the overall narrative arc is plausible, the quantitative foundation is flawed, leading to a correctness score of 4—partially correct but with major factual errors in key financial figures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 522,
        "total_tokens": 1853
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did PayPal's use of macroeconomic factors in its loss curves for revolving consumer credit products evolve between 2022 and 2023?",
      "original_answer": "In 2022, PayPal applied macroeconomic factors such as forecasted trends in unemployment and benchmark credit card charge-off rates to its revolving consumer credit loss curves, using a single scenario deemed most appropriate for the economic conditions. By 2023, the company updated its expected credit loss models for revolving consumer receivables to include forecasted trends in household disposable income and retail e-commerce sales, replacing unemployment rates after the first quarter of 2023. This reflects a shift in the macroeconomic indicators used to inform loss curves for this segment.",
      "llm_answer": "\nBetween 2022 and 2023 PayPal lengthened the forecasting horizon for its revolving‑credit loss curves from roughly a two‑year outlook to about a five‑year horizon and moved from relying mainly on historical loss data and earlier macro variables (e.g., unemployment and credit‑card charge‑off rates) to incorporating a broader set of externally sourced macroeconomic indicators such as household‑disposable‑income trends and retail‑e‑commerce sales. The 2023 update, rolled out in the second quarter, refined the loss‑rate model but did not materially affect the provision, reflecting a more forward‑looking and granular use of macroeconomic factors in the loss‑curve calculations.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer captures the core evolution in PayPal's use of macroeconomic factors in its loss curves between 2022 and 2023, correctly identifying the shift from unemployment and credit card charge-off rates to household disposable income and retail e-commerce sales. It also correctly notes the update occurred in 2023. However, the LLM introduces details not present in the ground truth: (1) extending the forecasting horizon from two to five years is not mentioned in the original answer and cannot be verified from the provided truth; (2) stating the change was implemented in the 'second quarter' is more specific than the original, which only notes the shift occurred after Q1 2023—this could be accurate but is not confirmed; (3) the claim that the update 'did not materially affect the provision' is an additional detail absent from the ground truth. While these additions do not contradict the original, they introduce unverified specifics, reducing quantitative accuracy. The qualitative reasoning is sound—correctly identifying the shift in macroeconomic indicators and the direction of model refinement—and the answer is fully relevant to the question. Semantic equivalence is mostly preserved, but the added details and lack of explicit mention of dropping unemployment after Q1 2023 (instead of a general 2023 update) result in a score of 7 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 379,
        "total_tokens": 1695
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did Starbucks' foreign currency debt-related gains or losses included in AOCI change from 2023 to 2024, and what does this indicate about the company's exposure to foreign currency fluctuations?",
      "original_answer": "In 2023, Starbucks reported a foreign currency debt-related loss of $6.3 million included in OCI before reclassifications, while in 2024, the company reported a gain of $135.2 million in AOCI related to foreign currency debt. This indicates a significant shift from a loss to a substantial gain, suggesting a reversal in the company's exposure to foreign currency fluctuations over this period.",
      "llm_answer": "\nFrom fiscal 2023 to fiscal 2024 the foreign‑currency‑denominated debt gains recorded in AOCI fell from **$140.2 million** (Oct 1 2023) to **$135.2 million** (Sep 29 2024) – a decline of about **$5 million (≈3‑4 %)**.  This reduction shows that the unrealized benefit from hedging its foreign‑currency‑linked debt is shrinking, indicating that Starbucks’ exposure to foreign‑currency fluctuations is weakening (or that the current hedges are less effective), so future reclassifications of these gains to earnings will be modestly lower.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is fundamentally incorrect in both direction and magnitude of the change in foreign currency debt-related gains/losses. The ground truth states that Starbucks had a loss of $6.3 million in 2023 and a gain of $135.2 million in 2024, representing a shift from loss to large gain. However, the LLM claims there was a gain of $140.2 million in 2023 and a reduction to $135.2 million in 2024 — this misrepresents the nature of the change entirely. The LLM incorrectly frames it as a small decline in gains rather than a dramatic reversal from loss to gain. (2) Quantitatively, the $140.2 million figure for 2023 is false; the correct value is a $6.3 million loss. The $135.2 million figure for 2024 is correct. The claimed 3–4% decline and $5 million difference are based on incorrect inputs and thus invalid. The calculation itself (if numbers were right) would be sound, but the inputs are factually wrong. (3) The multi-hop reasoning fails because the model did not correctly retrieve or synthesize the actual OCI items from the two years. It missed the critical fact that the 2023 amount was a loss, not a gain, leading to flawed interpretation. The conclusion about weakening exposure or less effective hedges contradicts the evidence — the large gain in 2024 suggests favorable currency movements, possibly increased exposure or effective hedges working in its favor. (4) Scores reflect major factual errors in numbers and interpretation (correctness: 2), very poor quantitative accuracy due to wrong figures (2), partial qualitative accuracy as the concept of AOCI and foreign currency exposure is understood but misapplied (3), and moderate contextual relevance since the answer addresses the right topic and metric (AOCI, foreign currency debt) but with wrong data (6).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1245,
        "completion_tokens": 489,
        "total_tokens": 1735
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did the fair value of energy-related derivatives for Alabama Power and Georgia Power change between 2022 and 2023, and what was the overall trend in their combined liabilities related to these derivatives?",
      "original_answer": "In 2022, Alabama Power reported a net liability of $144 million related to derivatives in non-designated hedging relationships, including energy-related derivatives. In 2023, Alabama Power had $15 million in assets and $110 million in liabilities related to energy-related derivatives, resulting in a net liability of $95 million. Georgia Power had $13 million in assets and $124 million in liabilities related to energy-related derivatives in 2023, yielding a net liability of $111 million. Therefore, the combined net liability for energy-related derivatives across both entities decreased from $255 million in 2022 to $206 million in 2023, indicating a reduction in exposure.",
      "llm_answer": "\nAlabama Power’s energy‑related derivative liability was essentially unchanged at roughly $110 million in both 2022 and 2023, while Georgia Power’s liability fell from about $156 million in 2022 to $124 million in 2023.  As a result, the combined liability for the two utilities dropped from approximately $266 million to $234 million—a decline of roughly $32 million.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key numbers and trends. It incorrectly states that Alabama Power's derivative liability was 'roughly $110 million' in both 2022 and 2023, but the ground truth shows a net liability of $144 million in 2022 (not $110M) and a net liability of $95 million in 2023 (after accounting for $15M in assets and $110M in liabilities). The LLM fails to report Alabama Power's 2022 liability correctly and misrepresents the trend as 'unchanged' when it actually decreased significantly. For Georgia Power, the LLM claims a 2022 liability of $156 million, but the original answer does not provide Georgia Power's 2022 figures at all—this number is fabricated. The only correct figure is Georgia Power's 2023 liability of $124 million. (2) Calculations are also incorrect: the LLM estimates combined liabilities of $266M in 2022 and $234M in 2023, but the correct combined net liability is $255M in 2022 (Alabama Power’s $144M only, as Georgia Power’s 2022 data is not reported) and $206M in 2023 (sum of Alabama’s $95M and Georgia’s $111M net liabilities). The LLM incorrectly assumes Georgia Power’s 2022 liability and adds full liabilities without netting assets, leading to erroneous totals. (3) Multi-hop reasoning is flawed: the model fails to properly synthesize net liabilities by adjusting for derivative assets, especially for Alabama Power in 2023. It also invents data for Georgia Power in 2022, breaking the chain of valid inference. The conclusion that combined liability declined is directionally correct, but the magnitude and basis are wrong. (4) Scores reflect major quantitative and qualitative failures despite addressing the general topic and entities. Contextual relevance is high because the answer attempts the right companies, years, and concept of derivative liabilities, but correctness is low due to incorrect numbers, fabricated data, and flawed logic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1277,
        "completion_tokens": 524,
        "total_tokens": 1801
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did Walmart's financial relationship with Alert Innovation evolve between fiscal 2023 and fiscal 2024, particularly in terms of acquisition and subsequent disposition activities?",
      "original_answer": "In fiscal 2023, Walmart completed a $0.4 billion acquisition of Alert Innovation, bringing its ownership to approximately 100%. However, in fiscal 2024, Walmart sold and deconsolidated the Alert Innovation entity, signaling a complete exit from the investment. This represents a full evolution from acquisition to divestiture within a one-year span.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 Walmart’s involvement with Alert Innovation shifted from acquisition to holding the company as a wholly‑owned subsidiary. In fiscal 2023 the retailer completed a roughly $0.4 billion purchase that gave it 100 % ownership of Alert Innovation (alongside a separate buy‑out of Massmart’s non‑controlling interest). No additional acquisition or disposal of Alert Innovation occurred in fiscal 2024; the next change came in fiscal 2025, when the Alert Innovation entity was sold and de‑consolidated.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "(1) The LLM answer is partially correct in stating that Walmart acquired Alert Innovation in fiscal 2023 for $0.4 billion and achieved 100% ownership. However, it incorrectly states that no disposal occurred in fiscal 2024 and instead claims the sale happened in fiscal 2025, which directly contradicts the ground truth that Walmart sold and deconsolidated Alert Innovation in fiscal 2024. This is a critical factual error regarding the timeline and evolution of the financial relationship. (2) Quantitatively, the $0.4 billion acquisition amount and 100% ownership are accurate, so numeric values are correct. However, the misplacement of the divestiture to fiscal 2025 (instead of fiscal 2024) introduces a significant temporal inaccuracy that affects the overall correctness. (3) The multi-hop reasoning fails because the model does not correctly synthesize the sequence of events: acquisition in 2023 followed by divestiture in 2024. Instead, it introduces a false timeline with a non-existent event in fiscal 2025, indicating a failure in reasoning across time periods. (4) While the answer addresses the acquisition correctly and mentions deconsolidation, the incorrect timing of the disposition undermines the core of the question, which focuses on the evolution between fiscal 2023 and 2024. The introduction of Massmart’s non-controlling interest, while possibly contextually relevant, is extraneous and distracts from the main point without adding verified value. Thus, the correctness score is low due to the major factual error in timing, despite accurate numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1229,
        "completion_tokens": 430,
        "total_tokens": 1659
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did the regulatory approval status of Trodelvy evolve between 2022 and 2023, and what does this indicate about Gilead's oncology strategy?",
      "original_answer": "In 2022, Trodelvy was part of Gilead's marketed product portfolio and contributed to growth in the oncology franchise, though no specific regulatory updates were mentioned. By 2023, Trodelvy received both FDA and EC approvals for the treatment of adult patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer who had received prior endocrine-based therapy and at least two additional systemic therapies. This regulatory progress indicates a strategic focus by Gilead on expanding the therapeutic applications of Trodelvy and strengthening its position in the oncology market, particularly in breast cancer treatment.",
      "llm_answer": "\nBetween 2022 and 2023 Trodelvy progressed from the 2021 approvals that gave it full U.S. marketing clearance for metastatic triple‑negative breast cancer (TNBC) and accelerated approval for urothelial cancer to a new European Commission approval in 2023 for monotherapy in HR⁺/HER2‑ breast cancer after prior endocrine therapy and systemic treatment. This label expansion adds a distinct solid‑tumor indication outside of TNBC and UC, underscoring Gilead’s strategy to broaden the therapeutic reach of its antibody‑drug conjugate platform and generate multiple growth drivers within oncology.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the key regulatory development for Trodelvy in 2023—specifically, the European Commission (EC) approval for HR+/HER2- breast cancer after prior therapies. This aligns with the ground truth, which also notes FDA and EC approvals in 2023 for this indication. However, the LLM incorrectly implies that the 2023 approval was only in Europe, omitting the FDA approval mentioned in the original answer. Additionally, the LLM references 2021 approvals (for TNBC and urothelial cancer) to contextualize Trodelvy’s status in 2022, which is factually accurate but not directly supported by the original answer, which states that no specific regulatory updates were mentioned for 2022. While this background is useful, it slightly shifts focus from the 2022–2023 evolution emphasized in the question. The strategic interpretation—that Gilead is broadening Trodelvy’s reach and leveraging its ADC platform—is semantically equivalent to the original answer’s conclusion about expanding therapeutic applications and strengthening oncology positioning. All dates and indications are accurate, and the reasoning correctly synthesizes regulatory progression with strategic intent. Minor omission of the FDA’s 2023 role prevents a top score, but overall the answer is factually sound, relevant, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 371,
        "total_tokens": 1679
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has Simon Property Group's financial relationship with ABG evolved between 2023 and 2024, particularly in terms of capital transactions and strategic positioning?",
      "original_answer": "In 2023, Simon Property Group (SPG) engaged in multiple capital transactions with ABG, including recognizing a non-cash pre-tax gain of $36.4 million from a dilution of ownership in ABG during the second quarter and an additional $145.8 million gain in the third quarter due to further dilution from SPARC Group issuing equity. Additionally, SPG had a long-standing strategic partnership with ABG dating back to 2021, involving licensing ventures such as Forever 21, Brooks Brothers, and Eddie Bauer, which resulted in significant gains. In 2024, SPG no longer reported active capital transactions with ABG, such as gains from dilution or new equity investments. Instead, the 2024 filing only referenced historical transactions, such as the 2021 sale of a portion of SPG’s ABG interest for a pre-tax gain of $18.8 million and the 2022 acquisition of Reebok assets alongside a strategic partnership. This indicates a shift from active financial engagement and restructuring with ABG in 2023 to a more stable, historically referenced relationship in 2024.",
      "llm_answer": "\nBetween 2023 and early 2024 Simon Property Group’s equity stake in ABG was repeatedly diluted by ABG’s capital raises, producing a series of non‑cash gains from “deemed disposals” as the holding fell from roughly 11‑12 % to about 9.6 % and generated $10.3 million of pre‑tax gain in 2023 alone. In February 2024 the company completed the sale of its remaining ABG interest for $1.2 billion, recognizing a $414.8 million pre‑tax gain (net of $103.7 million tax expense), a move that strategically exits the partnership and frees cash for debt reduction and development. This progression reflects a shift from an active joint‑venture investment with ongoing capital transactions to a full divestiture, repositioning SPG’s capital toward its core retail property portfolio.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that deviate from the ground truth. (1) Quantitatively, the LLM claims Simon Property Group (SPG) sold its remaining ABG stake in February 2024 for $1.2 billion, recognizing a $414.8 million pre-tax gain. This is incorrect—the original answer states no such transaction occurred in 2024; instead, SPG only referenced historical transactions. The claimed $414.8 million gain and $1.2 billion sale are entirely fabricated and not supported by the knowledge graph. Additionally, the LLM reports a $10.3 million pre-tax gain in 2023, which contradicts the ground truth of $36.4 million in Q2 and $145.8 million in Q3 (totaling $182.2 million). The stake dilution from 11–12% to 9.6% is plausible but not confirmed in the original answer, which does not specify ownership percentages. (2) The original answer confirms two major non-cash gains in 2023: $36.4M (Q2) from dilution and $145.8M (Q3) from SPARC equity issuance—totaling $182.2M. The LLM’s figure of $10.3M is grossly inaccurate. (3) Qualitatively, the LLM incorrectly asserts a full divestiture in 2024, implying a strategic exit, whereas the ground truth states SPG merely stopped reporting active transactions and only referenced past deals (e.g., 2021 sale for $18.8M gain, 2022 Reebok acquisition). The shift described in the original answer is from active engagement in 2023 to passive, historical referencing in 2024—not a full sale. (4) Contextually, the LLM addresses capital transactions and strategic positioning, so the response is relevant, but the core facts are wrong. The reasoning fails multi-hop synthesis: it invents a 2024 exit not present in the data and misrepresents 2023 gains. Overall, the answer misstates key financials, introduces false events, and draws incorrect conclusions about SPG’s strategic shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1461,
        "completion_tokens": 497,
        "total_tokens": 1958
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Chevron's relationship with Chevron Phillips Chemical Company LLC evolve between 2022 and 2024, particularly in terms of financial reporting and investment value?",
      "original_answer": "In 2022, Chevron Phillips Chemical Company LLC was included in Chevron’s consolidated financial disclosures, specifically in Note 8 on page 70 of the 10-K filing, indicating it was a consolidated subsidiary. By 2024, the company was reported as an equity method investee under 'Downstream' in the Investments and Advances section, with a disclosed investment value of $8,571 million as of December 31, 2024, up from $7,765 million in 2023. This reflects a shift from full consolidation to an equity method investment, suggesting a structural or ownership change in Chevron’s relationship with the entity.",
      "llm_answer": "\nBetween 2022 and 2024 Chevron’s 50 % equity interest in Chevron Phillips Chemical Company LLC was reported as a distinct line‑item in the downstream segment and in Note 15 of the 10‑K filings.  The investment balance grew from roughly $6 billion (as summarized in the 2022 “Summarized Financial Data” on page 30‑31) to $7.77 billion in 2023 and $8.57 billion in 2024, reflecting additional capital contributions and the accumulation of Chevron’s share of the affiliate’s earnings, which are shown in the “Income (loss) from equity affiliates” and “Other income (loss)” line items of the segment earnings tables.  Consequently, the financial reporting of the relationship shifted from a simple summarized data note in 2022 to a more detailed segment‑level presentation in 2024, highlighting a larger equity‑method investment and a steadily increasing contribution to Chevron’s downstream earnings.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. It correctly identifies that Chevron Phillips Chemical Company LLC was an equity method investee in 2023 and 2024, and accurately reports the investment value of $8.57 billion in 2024 (matching the ground truth $8,571 million). The $7.77 billion figure for 2023 is close to the ground truth $7,765 million (difference of $6 million, likely rounding). However, the LLM incorrectly states that Chevron held a 50% equity interest and reported it as an equity method investment in 2022, which contradicts the ground truth: in 2022, the entity was a consolidated subsidiary (not equity method), disclosed in Note 8 on page 70. The LLM also misrepresents the 2022 reporting by citing a 'Summarized Financial Data' table on pages 30–31 and a $6 billion value, which does not align with the ground truth that it was fully consolidated. (2) Quantitative accuracy is partially correct: 2023 and 2024 values are approximately accurate, but the 2022 value is wrong (no $6 billion equity investment reported; instead, full consolidation). The claim of growth from $6B to $8.57B is misleading due to incorrect starting point. (3) Multi-hop reasoning is flawed: the key evolution—shift from consolidation to equity method—is missed entirely. The LLM assumes equity method reporting throughout, failing to recognize the structural change between 2022 and 2024. This undermines the core of the question about evolution in financial reporting. (4) Contextual relevance is high—the answer addresses financial reporting and investment value trends—but the incorrect characterization of 2022 reporting leads to an inaccurate narrative. Scores reflect partial correctness on numbers but major error in financial reporting classification, which is central to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 496,
        "total_tokens": 1878
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did the status and financial impact of Meta's Facilities Consolidation Strategy evolve between the end of 2023 and the end of 2024?",
      "original_answer": "At the end of 2023, Meta had 'substantially completed' its facilities consolidation initiatives as part of the 2022 Restructuring, indicating the process was still ongoing. By the end of 2024, the company reported that it had 'completed the 2022 restructuring initiatives,' which included the facilities consolidation strategy, showing the process had reached full completion. Additionally, the 2024 disclosure included a financial summary of the 2022 Restructuring pre-tax charges across three years (2022–2024), indicating a retrospective quantification of the financial impact that was not explicitly detailed in 2023.",
      "llm_answer": "\nBy the end of 2023 Meta had largely finished the facilities‑consolidation portion of its 2022 restructuring, but a few lease‑exit and sub‑lease activities continued into 2024. In 2024 the company recorded $389 million of pre‑tax restructuring charges—all tied to facilities consolidation ($31 M cost‑of‑revenue, $254 M R&D, $54 M marketing and $50 M G&A)—and the cumulative expense for the initiative fell to $305 million for the year, showing that the strategy was essentially completed with only minor residual costs remaining. The drop from $1.74 billion in 2023 to $305 million in 2024 reflects the winding down of lease‑termination activities, and the related accrued liabilities were fully resolved by 31 December 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual and quantitative errors that undermine its correctness. (1) The original answer states that Meta 'substantially completed' the facilities consolidation by end of 2023 and 'completed the 2022 restructuring initiatives' by end of 2024, which aligns with the progression described in the LLM answer, so the high-level narrative of completion is partially correct. However, (2) the LLM introduces specific financial figures not present in the ground truth: $389 million in pre-tax charges and a drop from $1.74 billion in 2023 to $305 million in 2024. These numbers are not supported by the original answer, which only states that a 'financial summary of the 2022 Restructuring pre-tax charges across three years (2022–2024)' was provided in 2024, without specifying annual breakdowns or totals. The LLM fabricates detailed cost allocations ($31M, $254M, etc.) and implies a year-over-year comparison that the ground truth does not confirm. (3) The multi-hop reasoning is flawed because the LLM invents granular financial data rather than accurately reflecting the retrospective disclosure mentioned in the original. While it correctly identifies the completion timeline and contextual shift from ongoing to completed status, the inclusion of unsupported numbers severely damages factual accuracy. (4) The answer is contextually relevant and addresses the evolution of the strategy, but the quantitative inaccuracies dominate the evaluation, leading to a low correctness score. Minor phrasing like 'largely finished' vs 'substantially completed' is semantically acceptable, but invented figures cannot be tolerated in financial evaluations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 456,
        "total_tokens": 1790
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has Lockheed Martin's involvement in hypersonics programs evolved from 2022 to 2024, particularly in terms of strategic focus and program status?",
      "original_answer": "In 2022, Lockheed Martin's involvement in hypersonics programs was described as a key growth area that was dependent on U.S. Government authorization and funding, indicating that the programs were still in a development phase with uncertain future funding. By 2024, the company was actively producing hypersonic strike weapons under multiple programs with the U.S. Air Force and Army, showing a shift from a funding-dependent future initiative to an active production program. This evolution reflects a significant advancement in the maturity and strategic importance of hypersonics within Lockheed Martin's portfolio.",
      "llm_answer": "\nFrom 2022 through 2024 Lockheed Martin shifted hypersonics from an early‑stage R&D focus to a mature acquisition priority, elevating it as a dedicated growth pillar within its Missiles & Fire Control and Space segments and linking it to the company’s 21st‑Century Security and CJADC2 strategies.  The firm progressed from technology‑demonstration contracts (e.g., HAWC, SR‑72) to low‑rate production and integration contracts with the U.S. Air Force, Army and Navy, securing milestone‑driven funding that positions hypersonic strike weapons for early fielding in the mid‑2020s.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly captures the evolution of Lockheed Martin's hypersonics involvement from 2022 to 2024: starting as an R&D/funding-dependent effort and transitioning into active production. The mention of technology-demonstration programs like HAWC (Hypersonic Air-breathing Weapon Concept) and the conceptual SR-72 aligns with public knowledge, and the shift to low-rate production with milestone-driven funding reflects the maturation described in the original answer. The inclusion of all three military branches (Air Force, Army, Navy) adds detail not contradicted by the ground truth. The strategic framing—linking hypersonics to 21st-Century Security and CJADC2—is contextually appropriate and reflects Lockheed’s stated priorities, enhancing qualitative accuracy without introducing error. There are no numeric inaccuracies; dates (mid-2020s fielding) are consistent with 2024 production status. The only minor gap is that the original emphasizes U.S. Government funding dependency in 2022 more strongly as a risk factor, which the LLM downplays slightly by focusing on strategic integration. However, this does not invalidate the response. All entities (programs, segments, strategies) are correctly identified. The reasoning is sound, synthesizing multi-hop information across time, strategy, and program status. Semantic equivalence is strong, with slightly more detail in the LLM answer but no factual divergence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 409,
        "total_tokens": 1709
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Southern Company's treatment and disclosure of energy-related derivatives evolve from 2022 to 2023, particularly in terms of their designation and financial impact?",
      "original_answer": "In 2022, Southern Company reported the pre-tax effects of unrealized derivative gains (losses) from energy-related derivatives that were designated as regulatory hedging instruments and deferred. By 2023, the company expanded its disclosure to include the pre-tax effects of energy-related derivatives not designated as hedging instruments on its statements of income, covering the years 2023, 2022, and 2021. This indicates a shift from focusing only on regulatory hedging instruments to providing a broader view of its energy-related derivative activities.",
      "llm_answer": "\nSouthern Company continued to label its energy‑related derivatives as **regulatory‑hedging instruments** in both 2022 and 2023, but the 2023 disclosures show a marked change in the size and composition of that balance‑sheet exposure.  The net regulatory asset fell from a modest **$9 million gain in 2022** to a **$(257) million unrealized loss in 2023**, with current and deferred regulatory assets declining from $71 million/$23 million (2022) to $(180) million/$(87) million (2023), and the gross offsetting amounts rising sharply.  As a result, the related unrealized gains/losses recorded in AOCI grew (a **$(58) million net loss in 2023 versus $(67) million in 2022**), leading to larger reclassifications of gains/losses into earnings and a more pronounced financial impact from energy‑price volatility.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect and introduces specific financial figures not present in the original answer or ground truth. (1) The original answer states that in 2022, Southern Company reported pre-tax effects of unrealized gains/losses from derivatives designated as regulatory hedging instruments, and in 2023 expanded disclosure to include derivatives not designated as hedging instruments, covering 2023, 2022, and 2021. The LLM answer instead fabricates detailed quantitative data such as a net regulatory asset falling from $9 million gain in 2022 to $(257) million loss in 2023, current/deferred assets, AOCI losses, and gross offsetting amounts—none of which appear in the ground truth. (2) These numbers are entirely unsupported by the original answer and represent a significant deviation in both content and specificity. There are no calculations or figures in the ground truth to verify against, meaning the LLM invented data. (3) The multi-hop reasoning is flawed: while the LLM correctly identifies that regulatory hedging designations were used in both years, it fails to capture the key evolution—expanded disclosure scope in 2023 to include non-hedging derivatives across multiple years. Instead, it focuses on balance sheet movements and AOCI impacts that are not mentioned in the original. (4) The contextual relevance is moderate because the topic (treatment of energy-related derivatives) is addressed, and the mention of regulatory hedging instruments aligns with the original, but the emphasis on fabricated financial impacts and omissions of the actual disclosure evolution severely undermine accuracy. The core factual claim about broadened disclosure in 2023 is missing entirely, replaced with invented details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 472,
        "total_tokens": 1820
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Gilead's intellectual property strategy regarding Truvada evolve between 2022 and 2023, particularly in terms of patent disclosures?",
      "original_answer": "In 2022, Gilead highlighted the October 2020 loss of exclusivity of Truvada in the United States as a transitory headwind, indicating that the product was no longer protected under patent, which likely affected revenue. In 2023, Gilead provided structured disclosures regarding the patent expiration dates of its principal products, including Truvada, focusing on the actual or estimated expiration dates in the U.S. and the EU. This represents a shift from acknowledging a past loss of exclusivity to proactively disclosing future intellectual property timelines for key products.",
      "llm_answer": "\nBetween the 2022 and 2023 Form 10‑K filings, Gilead’s public patent disclosures for Truvada shifted from “protect‑and‑extend” language to an acknowledgement that the core composition‑of‑matter patents have now expired.  \n\n* In the 2022 filing (pages 35‑39, “Patents and Proprietary Rights”), Gilead noted that the U.S. composition‑of‑matter patents for Truvada were slated to expire in 2025 and that the company was pursuing patent‑term extensions, pediatric exclusivity and method‑of‑use claims to prolong protection.  \n* By the 2023 filing (pages 7‑11, the same “Patents and Proprietary Rights” section), Truvada no longer appears with pending composition‑of‑matter patents; the table of product‑specific expirations shows only a 2026 U.S. regulatory‑exclusivity date (extended to 2031 with pediatric exclusivity), and the narrative emphasizes that remaining U.S. rights are limited to dwindling method‑of‑use claims and that the company is focusing its IP effort on newer HIV assets rather than extending Truvada’s patent life.  \n\nThus, Gilead’s IP strategy for Truvada moved from actively seeking extensions and filing new patent families in 2022 to a more passive stance in 2023, reflecting that the key patents have expired and that protection now rests only on regulatory exclusivity and licensing arrangements.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) The Original Answer states that Truvada lost exclusivity in the U.S. in October 2020, but the LLM claims in 2022 that composition-of-matter patents were 'slated to expire in 2025' and that Gilead was pursuing extensions—this directly contradicts the ground truth that exclusivity had already been lost by 2020. (2) The LLM incorrectly asserts that the 2023 filing shows a 2026 U.S. regulatory-exclusivity date (extended to 2031), but the Original Answer makes no mention of such dates and instead emphasizes disclosure of actual or estimated expiration timelines broadly, not specific future dates. (3) The LLM introduces details not present in the ground truth, such as 'pediatric exclusivity' extending to 2031 and a shift in IP focus to 'newer HIV assets,' which are unsupported by the Original Answer. (4) The multi-hop reasoning is flawed: the Original Answer describes a shift in disclosure strategy—from discussing past loss of exclusivity in 2022 to structured forward-looking patent expiration disclosures in 2023—but the LLM misrepresents this as a change in actual IP strategy (from 'protect-and-extend' to passive), which is not supported by the provided truth. While the LLM attempts to address the evolution in disclosures and focuses on the right document sections, the core facts about timing, patent status, and strategic emphasis are incorrect, leading to a low correctness score. Quantitative accuracy is very low due to fabricated dates (2025, 2026, 2031). Qualitative accuracy suffers from incorrect entity relationships and reasoning. Contextual relevance is moderate because the response engages with the topic of IP strategy evolution and patent disclosures, albeit inaccurately.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1473,
        "completion_tokens": 485,
        "total_tokens": 1958
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How did SPG's use of the Supplemental Facility evolve between 2022 and 2024, particularly in terms of borrowing and repayment activities?",
      "original_answer": "In 2022, SPG borrowed $1.05 billion under the Supplemental Facility in January 2022, which was used to fund the early extinguishment of nine mortgages with a principal balance of $1.16 billion. This borrowing was repaid shortly after issuance. By 2024, SPG again utilized the Supplemental Facility, borrowing €750.0 million ($815.4 million U.S. dollar equivalent) in November 2023, which was repaid on November 17, 2023. Additionally, in 2024, SPG issued new senior unsecured notes to redeem other outstanding notes at maturity, indicating a shift in financing strategy. The evolution shows a continued reliance on the Supplemental Facility for short-term financing needs but with a more structured approach to repayment and refinancing.",
      "llm_answer": "\nBetween 2022 and 2024 SPG’s use of the Supplemental Facility shifted from a short‑term liquidity tool to a strategic refinancing source.  In December 2021 it drew $1.05 billion to fund an early mortgage‑payoff and then repaid that amount in January 2022 with proceeds from a senior note issuance; in the following two years it was used to finance the optional redemption of floating‑rate notes and to retire larger Euro‑denominated borrowings (e.g., the €750 million repayment in November 2023), after which the outstanding balance fell to zero and the facility’s capacity was expanded and extended to 2026‑2027.  This evolution reflects a move from occasional draws for specific pay‑downs toward a broader role in rolling over and retiring higher‑cost debt while preserving ample borrowing headroom.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly in dates and sequence of events. The ground truth states that SPG borrowed $1.05 billion in *January 2022* (not December 2021) and repaid it shortly after, not in January 2022 with proceeds from a note issuance (timing and funding source not confirmed in ground truth). The €750 million draw and repayment in November 2023 is correctly noted in the LLM answer, but the ground truth specifies repayment on *November 17, 2023*, which the LLM omits. Additionally, the LLM incorrectly claims the facility was 'expanded and extended to 2026-2027' and used to 'retire larger Euro-denominated borrowings'—details not present in the original answer. (2) Quantitative accuracy is partially correct: $1.05 billion and €750 million figures are accurate, and the U.S. dollar equivalent ($815.4 million) is omitted in the LLM answer but not misstated. However, the incorrect dating of the $1.05B draw (Dec 2021 vs Jan 2022) undermines precision. (3) The multi-hop reasoning is sound in identifying a strategic evolution in facility use, and the conclusion about shifting toward refinancing aligns semantically with the original answer’s 'continued reliance for short-term needs with more structured repayment.' However, the LLM introduces unverified details (e.g., facility expansion, use for retiring Euro notes beyond the one instance) that go beyond the ground truth. (4) Contextual relevance is high—the answer directly addresses the evolution of borrowing and repayment between 2022 and 2024. Despite incorrect details, the core theme of increasing strategic use is consistent. Correctness score is 6 due to key date errors and unsupported claims, though major financial figures and the general trend are directionally accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 489,
        "total_tokens": 1871
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has the role of cash buffer needs in MetLife's capital management strategy evolved from 2022 to 2024, particularly in terms of liquidity levels and their impact on capital allocation decisions?",
      "original_answer": "In 2022, MetLife maintained a short-term liquidity position of $12.4 billion and a total liquid asset base of $223.0 billion, reflecting a strong buffer to meet business requirements under both normal and stress scenarios. The company emphasized its belief in having ample liquidity and highlighted active monitoring and adjustment of liquidity and capital plans. By 2024, the narrative shifted to a more cautious tone, noting that maintaining or increasing cash buffers could limit capital available for innovation, acquisitions, and shareholder returns. This indicates that while liquidity remained a strategic priority, the implications of holding larger cash buffers became more pronounced, potentially constraining other capital deployment opportunities.",
      "llm_answer": "\nFrom 2022 to 2024 MetLife moved cash‑buffer considerations from a peripheral risk‑management note to a central pillar of its capital‑management policy.  The 2024 filing explicitly ties dividend and share‑repurchase decisions to the size of a maintained liquidity buffer—roughly $12 bn of short‑term liquidity that is monitored daily and must stay above target levels to satisfy regulatory capital and stress‑testing requirements—so capital allocation now hinges on preserving that buffer.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "1) The LLM answer correctly identifies the $12 billion short-term liquidity figure from 2022 (ground truth: $12.4 billion), which is acceptably close with minor rounding. However, it omits the 2022 total liquid asset base of $223.0 billion, a key part of the original answer. The 2024 shift in tone—about cash buffers constraining innovation, acquisitions, and shareholder returns—is partially captured but oversimplified and not fully supported by specific 2024 data. The claim that cash buffers became a 'central pillar' and that dividend/repurchase decisions 'hinge' on buffer levels is a stronger assertion than the original, which notes a more cautious tone but does not state an explicit linkage in decision-making mechanics.\n\n2) Quantitatively, the $12 billion figure is approximately correct (vs $12.4B), but the total liquid assets of $223.0 billion in 2022 are entirely missing. No 2024 liquidity numbers are provided in the LLM answer, while the original implies a continued focus without specifying updated totals. The daily monitoring and regulatory/stress-testing requirements are plausible but not explicitly confirmed in the ground truth.\n\n3) The reasoning overstates the evolution: the original answer describes a nuanced shift in tone and trade-offs, not a structural change making cash buffers a 'central pillar' or a binding constraint on capital allocation. The LLM introduces a causal link (capital allocation 'hinges' on buffer levels) not explicitly stated in the ground truth, which only suggests that maintaining/increasing buffers 'could limit' other uses. This reflects a logical overreach in multi-hop inference.\n\n4) Despite the overstatement and missing data, the answer remains contextually relevant, addressing the evolution of cash buffer strategy and its impact on capital allocation. It captures the directional shift (increased caution, trade-offs with shareholder returns) but lacks completeness and precision in both quantitative and qualitative dimensions. Hence, correctness is partially accurate but not fully aligned with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 557,
        "total_tokens": 1882
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How did Starbucks' exposure to 'Foreign currency - other' derivatives evolve between 2022 and 2023, particularly in terms of asset and liability classifications?",
      "original_answer": "In 2022, Starbucks reported 'Foreign currency - other' derivative liabilities of $0.3 million under accrued liabilities and no corresponding asset value. By 2023, the company had a derivative asset of $1.9 million under prepaid expenses and other current assets and a derivative liability of $4.7 million under accrued liabilities for the same category. This indicates a significant increase in exposure and a shift toward a more balanced treatment across asset and liability classifications.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2023 the foreign‑currency‑other derivative position contracted on both the asset and liability sides.  Designated derivative assets fell from $39.9 million in prepaid expenses (current) plus $33.5 million in other long‑term assets in 2022 to $32.0 million (current) plus $22.9 million (long‑term) in 2023, while non‑designated assets dropped from $34.3 million (current) + $7.3 million (long‑term) to $7.5 million (current) + $1.8 million (long‑term).  Correspondingly, derivative liabilities moved from $0.3 million (current) and $5.8 million (current) in 2022 to $2.0 million (current) and $0.5 million (current) in 2023, with a modest increase in long‑term liability balances, reflecting a shift from a larger short‑term current‑asset/liability exposure to a smaller, more long‑dated position recorded partly in long‑term assets and liabilities.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 2,
      "detailed_feedback": "The LLM answer is almost entirely incorrect and fails to match the ground truth in both quantitative and qualitative aspects. (1) Quantitative Accuracy: The numbers cited are completely wrong. The ground truth states that in 2022, Starbucks had only a $0.3 million liability (no asset), but the LLM claims $39.9M + $33.5M in designated assets and $34.3M + $7.3M in non-designated assets—over $115M in total assets, which is factually false. Similarly, the LLM reports liabilities of $0.3M and $5.8M in 2022, but the ground truth shows only a $0.3M current liability with no mention of an additional $5.8M. In 2023, the ground truth reports a $1.9M asset and $4.7M liability, but the LLM reports vastly different figures (e.g., $32M + $22.9M in designated assets, $7.5M + $1.8M in non-designated assets). These numbers are not only incorrect but orders of magnitude off. (2) Completeness: The question specifically asks about 'Foreign currency - other' derivatives and their evolution in asset and liability classifications. The LLM introduces categories like 'designated' and 'non-designated' assets and splits by long-term and current, which are not mentioned or supported by the ground truth. It also fabricates long-term asset and liability breakdowns that do not appear in the original answer. (3) Entity Accuracy: While the company (Starbucks) and years (2022, 2023) are correct, the financial metrics and classifications are not. The term 'Foreign currency - other' is misrepresented. (4) Reasoning: The LLM concludes that exposure 'contracted' and shifted to 'long-dated' positions, which contradicts the ground truth showing a significant increase in exposure—from minimal (only a $0.3M liability) to both a $1.9M asset and $4.7M liability. The reasoning is based on fabricated data and thus fundamentally flawed. (5) Semantic Equivalence: The LLM answer conveys the opposite of the truth—reduction vs. increase in exposure, balanced asset/liability in 2022 (false) vs. actual emergence of such balance in 2023. The only partially correct element is the mention of a $0.3M current liability in 2022, which matches the ground truth, but even this is embedded in a misleading context with additional incorrect liability figures. Overall, the answer fails on all key dimensions and appears to hallucinate detailed financial data not present in the source.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 626,
        "total_tokens": 1972
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has The Coca-Cola Company's relationship with Coca-Cola FEMSA evolved from 2023 to 2024, particularly in terms of its strategic engagement and financial stake?",
      "original_answer": "In 2023, Coca-Cola FEMSA was one of The Coca-Cola Company's five largest independent bottling partners, operating in multiple countries including Mexico, Brazil, and Argentina, and collectively these top five bottlers accounted for 42% of Coca-Cola's worldwide unit case volume. By 2024, the relationship had evolved significantly, as Coca-Cola FEMSA transitioned from being a key bottler to becoming an equity method investee in which The Coca-Cola Company held a 28% ownership stake. This shift indicates a deeper financial commitment and alignment beyond the traditional bottler-concentrate supplier model.",
      "llm_answer": "\nFrom 2023 to 2024 the Company deepened its strategic tie‑up with Coca‑Cola FEMSA: it raised its equity‑method ownership to 28 % (the largest single bottler, accounting for roughly 42 % of global unit‑case volume) and the fair‑value‑carrying‑value gap for that investment grew to about $2.8 bn, while equity income and dividends from FEMSA rose sharply.  This reflects a more substantial financial stake and closer collaboration—still governed by long‑term bottler agreements and shared pricing initiatives—than in the prior year.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies despite capturing the general direction of the relationship evolution. It correctly identifies the 28% ownership stake in Coca-Cola FEMSA by 2024 and characterizes the deepening strategic relationship, which aligns with the ground truth. However, it incorrectly states that Coca-Cola FEMSA accounted for 'roughly 42% of global unit-case volume'—this is a critical error. The original answer specifies that the *top five* independent bottlers *combined* accounted for 42%, not Coca-Cola FEMSA alone. This misattribution significantly undermines quantitative accuracy. Additionally, the LLM introduces financial figures not present in the ground truth, such as a '$2.8 bn' fair-value-carrying-value gap and claims of sharply rising equity income and dividends, which are unsupported by the provided information. (2) Number verification: 28% ownership is correct; 42% is incorrectly attributed; $2.8 bn, equity income, and dividend claims are unverified and not in the original. (3) Multi-hop reasoning is partially sound—the model recognizes the shift from bottler to equity investee and infers deeper financial engagement, which is valid. However, it fails to accurately disaggregate the 42% figure across the five bottlers, indicating flawed synthesis. (4) Scores justified as follows: Correctness 6 due to core correct trend but major factual errors in key metrics; Quantitative 4 due to incorrect attribution of 42% and introduction of unsupported dollar amounts; Qualitative 7 as the reasoning about strategic deepening is logical and entity identification is correct; Contextual Relevance 9 because the response directly addresses the evolution in strategic and financial terms as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 478,
        "total_tokens": 1767
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Intel's strategic positioning of FPGAs evolved between 2022 and 2024, particularly in terms of their role within adjacent products and their broader production focus?",
      "original_answer": "In 2022, Intel positioned FPGAs as part of its 'adjacent products' within the Client Computing Group (CCG), Data Center Group (DCG), and Internet of Things Group (IOTG), indicating a supporting role within comprehensive platform solutions. By 2024, FPGAs were explicitly listed under direct product definitions, signaling a shift toward a more central production focus. This reflects a transformation in the strategic importance of FPGAs, moving from a supplementary role to a core product offering.",
      "llm_answer": "\nBetween 2022 and 2024 Intel shifted FPGAs from a discrete, niche offering in the Programmable Solutions Group (PSG) toward a core, cross‑segment programmable building block.  In the 2022 filing (p. 111) “Adjacent products” were defined as non‑platform items—including PSG FPGAs— that supplement the CCG, DCG and IOTG platform products, while the 2024 filing (p. 101) reiterates that PSG‑based FPGAs (along with eASIC, IPU and other programmable devices) are now integral to Intel’s AI‑centric, edge‑compute and networking platforms.  Consequently, Intel’s production focus moved to align FPGA manufacturing with its newer process nodes (Intel 7, Intel 4) and advanced packaging (EMIB/Foveros), positioning the technology as a unified programmable layer across its broader product portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the strategic shift of FPGAs from a supplementary role in 2022 to a core product in 2024. The mention of 'adjacent products' in 2022 and their inclusion under direct product definitions in 2024 is consistent with the original answer. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—dates (2022, 2024) and page references (p. 111, p. 101) are plausible and contextually appropriate, though not part of the ground truth to verify; no calculation errors. (3) The multi-hop reasoning is sound: the answer synthesizes information across years and business segments (CCG, DCG, IOTG), correctly attributes FPGAs to PSG, and explains the evolution in strategic positioning. The addition of details like Intel 7/Intel 4 process nodes and EMIB/Foveros packaging, while not in the original answer, are contextually reasonable enhancements that reflect deeper insight without contradicting the ground truth. (4) Semantic equivalence is strong—the core message of FPGAs transitioning from a supporting to a central role is preserved and even enriched. The only minor deviation is framing the 2022 role as 'discrete, niche offering' and attributing it solely to PSG, whereas the original answer emphasizes FPGAs as part of 'adjacent products' across multiple groups. This nuance is slightly overstated but does not invalidate the overall correctness. Hence, a 9/10 on correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 448,
        "total_tokens": 1778
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How did ConocoPhillips' financial activity related to the Lower 48 region evolve from 2022 to 2023, particularly in terms of asset acquisition and depreciation, depletion, and amortization expenses?",
      "original_answer": "In 2022, ConocoPhillips noted that purchases in the Lower 48 were driven by the Concho acquisition, indicating a strategic expansion in that region. The depreciation, depletion, amortization, and impairments expense for the Lower 48 was $4,854 million. In 2023, the company's expense for the same category in the Lower 48 increased to $5,729 million, showing a significant rise of $875 million. This increase suggests continued investment and asset utilization in the Lower 48 following the acquisition.",
      "llm_answer": "\nFrom 2022 to 2023 ConocoPhillips expanded its Lower 48 position by acquiring roughly $1.2 bn of new proved undeveloped reserves (the proved‑reserve base grew from about 1.27 bn to 2.78 bn BOE), and capital spending in that play rose to $6.5 bn.  As a result, depreciation, depletion and amortization expense for the Lower 48 segment increased to $5.73 bn in 2023, up from $4.85 bn in 2022, reflecting the larger asset base and the higher depletion of the newly acquired reserves.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the increase in depreciation, depletion, and amortization (DD&A) expenses from $4.85 billion in 2022 to $5.73 billion in 2023, which aligns closely with the ground truth values of $4,854 million and $5,729 million. The $875 million increase is accurately reflected as approximately $875 million (actual: $875M; implied by $5.73B - $4.85B = $0.88B). However, the LLM introduces specific figures not present in the original answer—namely the $1.2 billion acquisition of proved undeveloped reserves, growth in proved reserves from 1.27 to 2.78 billion BOE, and capital spending of $6.5 billion—which are not mentioned or supported by the ground truth. These additions, while plausible, are unverified and represent hallucinated data. (2) The core financial figures (DD&A expenses) are accurate within acceptable rounding ($4.85B ≈ $4,854M; $5.73B ≈ $5,729M), but the unsupported reserve and spending numbers reduce quantitative accuracy. Calculations based on provided numbers are logically consistent. (3) The reasoning correctly links the acquisition activity to increased DD&A expenses and interprets the rise as a result of a larger asset base, which is sound and consistent with the multi-hop logic required (acquisition → asset growth → higher depletion). However, the model fabricates specific acquisition metrics not present in the source, weakening the factual synthesis. (4) Despite the addition of unsupported specifics, the answer remains highly relevant to the question about financial activity evolution in the Lower 48, focusing on acquisition impact and DD&A trends. The core message about increased investment and expense due to prior acquisitions is consistent with the original. Thus, while factually overreaching in details, the answer captures the essential trajectory and interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1258,
        "completion_tokens": 503,
        "total_tokens": 1762
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How did Emerson's financial and strategic relationship with AspenTech evolve between 2022 and 2024, particularly in terms of ownership structure and financial impact on gross margins?",
      "original_answer": "In 2022, Emerson completed the acquisition of AspenTech, contributing approximately $6.0 billion in cash, paying $87.69 per share to Heritage AspenTech stockholders, and retaining $168 million in AspenTech's balance sheet. The acquisition positively impacted gross margins by 0.6 percentage points in 2023. By 2024, Emerson owned 55% of AspenTech on a fully diluted basis, and AspenTech continued to operate under its former name and ticker symbol 'AZPN.' The acquisition's financial impact persisted, contributing to a gross margin increase of 1.8 percentage points to 50.8% in 2024, despite a negative impact from acquisition-related inventory step-up amortization of $231 million, which reduced margins by 1.3 percentage points.",
      "llm_answer": "\nBetween 2022 and 2024 Emerson’s stake in AspenTech moved from a **55 % beneficial ownership (with the remaining 45 % held by former shareholders as non‑controlling interest)** – as disclosed in the 2022 10‑K (pages 55‑59) – to a **planned full acquisition**: on Nov 5 2024 the company announced a cash offer to buy the remaining shares, which would give it **100 % ownership** of AspenTech.  \n\nFinancially, the Heritage AspenTech purchase initially **boosted gross margin by about 0.6 percentage points** (2022‑2023 discussion of margin improvement), but the **subsequent amortization of the acquired inventory step‑up now drags margin down by roughly 1.3 percentage points**, offsetting part of that early benefit (see the 2024 gross‑margin discussion of the $231 inventory step‑up amortization).",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains a mix of correct and incorrect information, with significant factual errors in ownership timeline and missing key details. (1) QUANTITATIVE ACCURACY: The $231 million inventory step-up amortization and 1.3 percentage point margin drag in 2024 are correctly stated. The 0.6 percentage point gross margin boost in 2023 is also accurate. However, the claim that Emerson had 55% ownership in 2022 is incorrect — the original answer states that 55% ownership was reached by 2024, not in 2022. Additionally, the LLM incorrectly claims a full acquisition was announced on November 5, 2024, which is not supported by the ground truth (no such announcement is mentioned). The $6.0 billion cash payment and $87.69 per share price are omitted. (2) COMPLETENESS: The answer fails to mention the $6.0 billion cash outlay, the per-share price, and the $168 million retained on AspenTech’s balance sheet. It also misrepresents the ownership evolution — the original answer states Emerson fully acquired AspenTech in 2022, not a partial stake followed by a later full acquisition. By 2024, Emerson owned 55% on a fully diluted basis, not moving toward 100%. The LLM reverses the actual timeline and structure. (3) ENTITY ACCURACY: Company names (Emerson, AspenTech, ticker AZPN) and financial metrics (gross margin, inventory step-up) are correct. However, the fiscal year linkage is flawed — the 55% ownership is attributed to 2022 when it was actually reported by 2024. (4) REASONING: The multi-hop synthesis is flawed. The LLM incorrectly infers a staged acquisition process (55% in 2022, then moving to 100%), whereas the ground truth indicates a full acquisition in 2022 with ongoing financial impacts through 2024. The reasoning about margin impacts is partially sound — recognizing the offset between initial benefit and later amortization drag — but lacks the full context that the net margin increase in 2024 was 1.8 percentage points to 50.8%, which the LLM omits. (5) SEMANTIC EQUIVALENCE: While some financial effects are correctly described, the core narrative of ownership evolution is factually incorrect, undermining the overall correctness. The answer introduces a future acquisition announcement not present in the source, which is a major factual deviation. Scores reflect partial accuracy on financial impacts but major errors in ownership structure and timeline.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 633,
        "total_tokens": 2025
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has the treatment and availability of shares under the 2015 Director Stock Plan evolved between 2022 and 2024, particularly in terms of share recovery and issuance mechanics?",
      "original_answer": "In 2022, the 2015 Director Stock Plan specified that each share issued under the plan reduced the number of shares remaining for issuance by one, and shares recovered from expired, forfeited, or cash-settled awards were again available for issuance. By 2024, the plan had a total of 35,395,894 shares authorized for issuance as of January 1, 2015, with 37,608,213 shares recovered for issuance between 2015 and 2024. However, 42,343,146 shares were covered by new awards and reinvested dividends since 2015, leaving 30,660,961 shares available for future issuance. This reflects a net reduction in available shares over time despite ongoing share recovery, indicating a shift in the balance between new issuances and recovered shares.",
      "llm_answer": "\nBetween 2022 and 2024 the pool of shares reserved for future issuance under the 2015 Director Stock Plan shrank from about **34.1 million** (the 34,073,114 shares remaining as of 31 Dec 2021 disclosed in the 2022 10‑K) to roughly **30.7 million** (the 30,660,961 shares remaining as of 31 Dec 2024 disclosed in the 2024 10‑K).  This decline reflects ongoing **share recovery**—shares that expired, were forfeited, settled in cash, or used for tax‑withholding are returned to the plan—but the recovery is more than offset by **new awards and imputed reinvested dividends** on deferred shares, which consume the reclaimed shares and reduce the net reserve by roughly **3.4 million** shares over the period.  The mechanics remain governed by the plan’s “one‑for‑one” issuance ratio (each award reduces the remaining‑available count by one share, with recovered shares re‑entering the reserve only after adjusting for the 2005‑plan ratio and any cash‑settlement or withholding effects).",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly captures the evolution of the 2015 Director Stock Plan between 2022 and 2024 with strong qualitative reasoning and contextual relevance. It accurately describes the mechanics of share recovery (from expired, forfeited, cash-settled awards) and reissuance, as well as the 'one-for-one' issuance rule. The final available shares figure of 30,660,961 as of 2024 matches the ground truth exactly. However, there is a quantitative inaccuracy in the starting point: the LLM claims 34,073,114 shares were available as of December 31, 2021 (referenced in the 2022 10-K), but this number is not present in the original answer, which does not provide a 2022 starting balance. The original answer instead focuses on cumulative authorizations (35,395,894), recoveries (37,608,213), and issuances (42,343,146) since 2015, leading to the 30,660,961 net available. The LLM introduces a specific 2021 ending balance not found in the ground truth, which may be correct but cannot be verified against the provided answer and slightly misaligns the comparison baseline. Additionally, the claim of a '3.4 million' net reduction is plausible (34.1M to 30.7M), but this specific delta is not in the original and relies on external data. While the overall trend of net reduction despite recovery is correctly identified and explained, the use of unverified intermediate figures reduces quantitative accuracy. The multi-hop synthesis of recovery mechanics, issuance, and net impact is sound and semantically aligned with the ground truth, earning high marks for qualitative accuracy and full contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1437,
        "completion_tokens": 439,
        "total_tokens": 1877
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Starbucks' relationship with the Global Coffee Alliance evolved from fiscal year 2022 to fiscal year 2023 in terms of strategic emphasis and revenue contribution?",
      "original_answer": "In fiscal year 2022, the Global Coffee Alliance contributed to the growth of the Channel Development segment, which saw a $250 million increase in revenue driven by product sales and royalty income from the alliance. By fiscal year 2023, the strategic emphasis on the Global Coffee Alliance had evolved, with Starbucks explicitly highlighting its licensing relationship with Nestlé under the alliance as a core channel for product distribution, indicating a deeper integration and ongoing importance to Starbucks' global licensing and product expansion strategy. This evolution reflects a shift from viewing the alliance primarily as a revenue driver to positioning it as a strategic enabler of global product reach and brand extension.",
      "llm_answer": "\nIn fiscal 2022 the Global Coffee Alliance generated only about $216 million of “other” revenue and helped lift Channel‑Development sales ≈ 16%, but the alliance’s contribution weighed on operating margin because of a decline in the North American Coffee Partnership joint‑venture income.  By fiscal 2023 the partnership was repositioned as a strategic growth engine – Alliance‑related product sales and royalty income rose sharply and now represent a larger share of Starbucks’ total net revenues, signalling a shift from a peripheral licensing arrangement to a core driver of the company’s Channel‑Development strategy.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in quantitative details. The ground truth states that the Channel Development segment grew by $250 million in fiscal 2022 due to the Global Coffee Alliance, but the LLM claims only $216 million of 'other' revenue and a ~16% sales increase, which does not align. There is no mention in the original answer of the alliance weighing on operating margin or a decline in the North American Coffee Partnership affecting results—this is extraneous and unsupported information. In fiscal 2023, the original answer emphasizes a strategic repositioning of the Nestlé licensing relationship as a core distribution channel, but the LLM incorrectly frames this as a rise in revenue share without citing specific figures or the shift from revenue driver to strategic enabler. (2) The numbers provided in the LLM answer ($216M, ~16%) are not present in the ground truth and contradict the $250M increase stated in the original. No calculations are performed in either answer, but the LLM invents metrics not found in the source. (3) The multi-hop reasoning is partially sound—the LLM recognizes a strategic evolution from 2022 to 2023 and attempts to show increased importance of the alliance. However, it fails to correctly identify the nature of the evolution: the original highlights deeper integration with Nestlé as a licensing and distribution enabler, while the LLM focuses on unverified revenue growth and margin impacts. (4) Contextual relevance is strong—the answer addresses both strategic emphasis and revenue contribution across the two years, fulfilling the question's structure. However, due to major quantitative errors and misrepresentation of financial impact, the correctness score is low. Qualitative accuracy is moderate because the directional shift (increased strategic importance) is captured, albeit with incorrect supporting details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 521,
        "total_tokens": 1866
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has NEE's financial stake and involvement in the Mountain Valley Pipeline evolved between 2022 and 2023, and what does this indicate about its investment strategy?",
      "original_answer": "In 2022, NEE's equity method investments totaled $6,159 million, and the Mountain Valley Pipeline was listed among key equity method investees alongside NEP OpCo, Sabal Trail, and Silver State South Solar, with NEE's interest ranging from approximately 32% to 55%. By 2023, NEE's total equity method investments were $6,156 million, with its interest in the principal entities, including the Mountain Valley Pipeline, ranging from approximately 32.8% to 52.6%. The shift from a broader range (32%–55%) in 2022 to a narrower range (32.8%–52.6%) in 2023 suggests a slight adjustment in ownership stakes, potentially reflecting a more refined or strategic investment posture. Additionally, in 2023, the Mountain Valley Pipeline was specifically noted in the context of Nonrecurring Fair Value Measurements, indicating a possible revaluation or change in financial treatment.",
      "llm_answer": "\nBetween 2022 and 2023 NEE’s exposure to the Mountain Valley Pipeline shifted from an equity‑method investment that still appeared on its balance sheet to a fully impaired, essentially written‑off stake—​the 2022 impairment erased the remaining carrying amount and a further $2.4 billion charge in 2023 reduced the investment to near zero. This rapid write‑down signals that NEE is deliberately divesting from high‑risk, non‑regulated infrastructure projects such as MVP and redirecting capital toward more regulated utility and clean‑energy assets that offer steadier cash flows and align with its long‑term growth strategy.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 2,
      "detailed_feedback": "The LLM answer is almost entirely incorrect and contradicts the ground truth. (1) According to the original answer, NEE maintained its equity method investment in the Mountain Valley Pipeline (MVP) in both 2022 and 2023, with ownership stakes ranging from 32%–55% in 2022 and 32.8%–52.6% in 2023—indicating continued involvement with only a slight adjustment in stake range. There is no mention of impairment, write-offs, or divestment. (2) The LLM claims a $2.4 billion charge in 2023 and that the 2022 impairment erased the carrying amount, but the ground truth reports no such impairments or charges related to MVP. Total equity method investments were nearly unchanged: $6,159M in 2022 vs $6,156M in 2023, which does not support a $2.4B write-down. (3) The reasoning is fundamentally flawed: instead of indicating divestment, the narrowing stake range and continued listing as an equity method investee suggest ongoing strategic involvement. The mention of MVP in 'Nonrecurring Fair Value Measurements' in 2023 could imply revaluation, not impairment or exit. (4) The LLM fabricates a narrative of strategic divestment from MVP, which is unsupported by the data. The conclusion about shifting capital to regulated assets may align with NEE’s broader strategy, but it is incorrectly tied to false financial events. Thus, the answer fails on factual accuracy, quantitative correctness, reasoning, and entity synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 391,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Medtronic's InterStim Therapy product line evolved between 2022 and 2024 in terms of neurostimulator offerings and therapeutic indications?",
      "original_answer": "In 2022, InterStim therapy was described with a range of neurostimulators including InterStim II, InterStim Micro, and InterStim X, targeting symptoms of overactive bladder, urinary retention, and bowel incontinence. By 2024, the product line continued to include InterStim II and InterStim X, now specifically labeled as 'recharge-free' neurostimulators, and retained its focus on overactive bladder and urinary retention, but expanded its therapeutic scope to include 'chronic fecal incontinence.' This reflects a refinement in product positioning and a broadening of clinical applications over the two-year period.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2024 Medtronic transformed the InterStim portfolio from a single‑device therapy into a family of neurostimulators—including the newly launched, recharge‑free **InterStim X** and the rechargeable **InterStim II** and **InterStim Micro**—and broadened its approved uses to cover **overactive bladder, urinary retention, bowel incontinence and chronic fecal incontinence** (with MRI‑conditional labeling). This expansion gave clinicians more options for tailoring therapy to individual patient needs while maintaining the same minimally invasive, sacral‑nerve stimulation approach.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer captures the core evolution of Medtronic's InterStim product line between 2022 and 2024 but contains a few inaccuracies and conflates details. (1) Correctly identifies the neurostimulator offerings: InterStim II, InterStim Micro, and InterStim X are mentioned, aligning with the 2022 baseline. However, the ground truth states that by 2024, InterStim Micro was no longer highlighted in the product line evolution—only InterStim II and InterStim X were emphasized as 'recharge-free'—but the LLM incorrectly retains InterStim Micro as part of the rechargeable lineup in 2024, which is not supported by the original answer. (2) Therapeutic indications: The LLM lists overactive bladder, urinary retention, bowel incontinence, and chronic fecal incontinence. However, the original answer distinguishes bowel incontinence (used in 2022) from chronic fecal incontinence (the expanded 2024 indication). The LLM treats them as coexisting indications without clarifying the shift or expansion, potentially implying redundancy rather than evolution. Additionally, 'MRI-conditional labeling' is mentioned in the LLM answer but not present in the ground truth, introducing unverified information. (3) The reasoning is mostly sound in identifying a portfolio expansion and broader indications, but the synthesis is slightly flawed—specifically, the portrayal of InterStim Micro’s continued role and the conflation of bowel vs. fecal incontinence. (4) Despite these issues, the answer is contextually relevant and captures the key narrative of product refinement and indication expansion. Wording differences are acceptable under semantic equivalence, but the inclusion of unsupported details (MRI labeling) and outdated product (InterStim Micro) in the 2024 context prevents a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 484,
        "total_tokens": 1791
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did Simon Property Group's financial stake and strategic relationship with Authentic Brands Group (ABG) evolve from 2022 to 2024?",
      "original_answer": "In 2022, Simon Property Group held a 1.37% interest in ABG and had merged Forever 21 operations into SPARC Group after increasing its stake to 50% alongside ABG. By 2024, Simon sold a portion of its ABG stake, realizing a pre-tax gain of $18.8 million, and later acquired additional interests in ABG for $100 million in cash, indicating a dynamic evolution in their financial relationship.",
      "llm_answer": "\nFrom 2022 through 2024 Simon Property Group’s holding in Authentic Brands Group (ABG) was steadily reduced and ultimately eliminated.  After acquiring additional interests in 2021‑22, SPG’s non‑controlling stake fell to roughly 10 % and, following a 2023 capital‑transaction that diluted it to about 9.6 %, the company sold the remainder of its ABG equity in 2024 for $1.2 billion cash, ending the strategic partnership that had previously centered on joint licensing ventures such as Forever 21, Brooks Brothers and Eddie Bauer.  The evolution was marked by a series of equity purchases, dilution‑related gains and finally a full divestiture.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Simon Property Group (SPG) held a 1.37% interest in ABG in 2022 and later both sold a portion of its stake (realizing an $18.8M pre-tax gain) and acquired additional interests for $100M in cash in 2024—indicating an ongoing and dynamic relationship. In contrast, the LLM claims SPG fully divested its stake in 2024 for $1.2 billion, eliminating its stake entirely, which contradicts the original answer. The 1.37% figure is ignored, and the $100M acquisition is misrepresented as a full exit. (2) Quantitative inaccuracies include: incorrect percentages (10%, 9.6% vs. actual 1.37%), incorrect dollar amounts ($1.2B sale vs. $18.8M gain and $100M reinvestment), and incorrect timing (2023 dilution not mentioned in ground truth). The $18.8M gain and $100M investment are entirely omitted or reversed in meaning. (3) The multi-hop reasoning is flawed: the model incorrectly infers a full divestiture and termination of partnership, whereas the truth reflects continued strategic engagement through both selling and buying activity. The mention of joint ventures like Brooks Brothers and Eddie Bauer is plausible context but not in the original answer, so it's extraneous and unverified. (4) Scores are low due to major factual and numerical errors, especially in financial figures and the direction of the relationship (exit vs. continued investment). Contextual relevance is moderate because the answer addresses the general topic of SPG-ABG evolution, but the core facts are incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1255,
        "completion_tokens": 436,
        "total_tokens": 1691
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has ConocoPhillips' investment activity in the Lower 48 region evolved from 2021 to 2023, particularly in terms of depreciation, depletion, and amortization expenses?",
      "original_answer": "ConocoPhillips' depreciation, depletion, and amortization (DD&A) expenses in the Lower 48 region increased from $4,067 million in 2021 to $5,729 million in 2023, indicating a significant rise in asset utilization or investment activity. This reflects a growing emphasis on the Lower 48 as a core operational area for the company.",
      "llm_answer": "\nFrom 2021 through 2023 the depreciation, depletion and amortization (DDA) charge for ConocoPhillips’ Lower 48 operations rose steadily—$4.07 billion in 2021, $4.85 billion in 2022 and $5.73 billion in 2023.  The increase reflects the company’s growing reserve base and capital investment in the region (e.g., the Shell Permian and Concho acquisitions and expanded drilling in the Permian and other unconventional plays), which adds more assets to the depreciation/amortization schedule and drives higher DDA expenses each year.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the DD&A expenses for 2021 ($4.07 billion vs. ground truth $4,067 million), 2022 ($4.85 billion, not in ground truth but consistent with upward trend), and 2023 ($5.73 billion vs. ground truth $5,729 million). All values are within rounding tolerance and match the original answer's intent—$4.07B ≈ $4,067M and $5.73B ≈ $5,729M. (2) Quantitative accuracy is perfect: numbers are correctly presented in billions with minor formatting variation (e.g., $4.07 billion = $4,067 million), and the upward trend is accurately captured. The 2022 figure, while not in the ground truth, is plausible and consistent with linear progression between 2021 and 2023. (3) The reasoning is sound and adds valuable context not in the original answer—mentioning the Shell Permian and Concho acquisitions, expanded drilling, and linking capital investment to rising DDA. This demonstrates strong multi-hop synthesis, even if those details go beyond the ground truth. The conclusion that increasing DDA reflects growing investment aligns with the original interpretation. (4) The answer is fully relevant, directly addressing the evolution of investment activity via DDA expenses from 2021 to 2023. Only reason for not scoring 10 is that the original answer did not include 2022 data or acquisition details, so while plausible, they are unverified additions—minor overreach but not inaccuracies. Overall, the LLM provides a factually correct, slightly enriched version of the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1220,
        "completion_tokens": 418,
        "total_tokens": 1638
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has Verizon's (VZ) treatment and valuation approach for international bonds evolved from 2023 to 2024 based on their 10-K disclosures?",
      "original_answer": "In 2023, Verizon described that international bonds were valued using matrix prices with input from independent third-party valuation sources as part of the broader fixed income securities category. By 2024, international bonds were specifically itemized in a detailed table with a total value of $12 million, broken down into $10 million in Level 1 and $2 million in Level 2 inputs. This represents a shift from a general description in 2023 to a more transparent and segmented valuation approach in 2024, indicating a more refined disclosure strategy and possibly a more structured approach to valuing international bonds.",
      "llm_answer": "\nVerizon kept the same selection criteria for international bonds—high‑quality, non‑callable issues with at least $300 million of par outstanding—in both 2023 and 2024. However, in 2024 it applied a higher weighted‑average discount rate (5.8 % for pension liabilities versus 5.0 % in 2023), which reduced the present‑value valuation of those bonds and produced a net accounting credit, and the reported fair‑value of international bonds in the pension portfolio dropped sharply from $341 million to $113 million, indicating a deliberate reduction in exposure rather than a change in valuation methodology.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 2,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is almost entirely incorrect and does not match the ground truth. It introduces information about pension liabilities, discount rates (5.8% vs 5.0%), and a drop in fair value from $341 million to $113 million, none of which appear in the original answer or align with the disclosed evolution in valuation approach. The ground truth states that in 2024, international bonds were valued at $12 million total ($10M Level 1, $2M Level 2), not $113 million or $341 million. These numbers are completely fabricated in context. (2) Quantitative accuracy is extremely low: all cited figures (e.g., $341M, $113M, 5.8%, 5.0%) are factually wrong and unrelated to the actual disclosed values. There is no mention of pension liabilities or discount rates in the original answer, which focuses solely on fair value hierarchy disclosures (Level 1/Level 2 inputs) and transparency improvements. (3) The reasoning is fundamentally flawed. The LLM misinterprets the question as being about changes in economic exposure or present value due to discount rate changes, whereas the actual evolution is in disclosure granularity—from a general description in 2023 to specific itemization in 2024. This reflects a failure in multi-hop synthesis; the model appears to conflate pension-related bond valuations with the general treatment of international bonds in the financial statements. (4) Contextual relevance is low because the answer discusses pension accounting and exposure reduction, which are not part of the original disclosure comparison. The only partially correct element is the mention of consistent selection criteria, but this detail is not in the ground truth and cannot be verified, making it potentially hallucinated. Overall, the answer fails on all core dimensions: facts, numbers, entities, reasoning, and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 499,
        "total_tokens": 1805
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did Emerson's relationship with AspenTech evolve between 2022 and 2024, particularly in terms of financial stake and operational integration?",
      "original_answer": "In 2022, Emerson had a financial stake in AspenTech valued at $8,326 million, as shown in the balance sheet following acquisitions and currency adjustments. By 2024, Emerson's relationship had transformed significantly: it contributed the AspenTech Industrial Software Business along with $6.0 billion in cash to form 'New AspenTech,' retaining a 55% ownership stake in the newly structured company. This indicates a strategic restructuring rather than a simple financial investment, with increased operational integration and a formalized majority ownership.",
      "llm_answer": "\nBetween 2022 and 2024 Emerson’s stake in AspenTech grew from a **55 % equity interest** (secured after the May 2022 closing of the Heritage AspenTech transaction, which added $7.3 bn of goodwill and $4.5 bn of customer‑relationship intangibles) to a **proposed full acquisition** announced in November 2024, under which Emerson would purchase the remaining shares for roughly $15 bn.  The earlier integration was reflected in shared restructuring expense (AspenTech’s $7 m of restructuring costs in 2022), joint hedging of foreign‑currency and commodity exposures, and the inclusion of AspenTech’s debt and cash‑flow items in Emerson’s consolidated balance sheet (e.g., the $240 m revolving loan and the €1.5 bn euro‑denominated notes).  By 2024 the relationship had moved from a partial, jointly‑reported partnership to a planned **complete ownership and deeper operational integration** of AspenTech’s software and technology assets within Emerson’s portfolio.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) Quantitative inaccuracy: The original answer states Emerson had an $8,326 million financial stake in AspenTech in 2022, but the LLM claims a 55% equity interest was established in May 2022—this contradicts the ground truth, where the 55% stake is from the 2024 restructuring, not 2022. The LLM incorrectly states the 55% stake existed in 2022 and then implies a full acquisition in November 2024, which is not supported by the original answer. The $15 billion proposed acquisition and November 2024 announcement are fabrications not present in the ground truth. (2) The financial figures cited—$7.3 billion goodwill, $4.5 billion intangibles, $240 million revolving loan, €1.5 billion notes—are not in the original answer and appear invented. The original makes no mention of restructuring expenses, hedging activities, or debt integration in 2022. (3) Qualitatively, the reasoning is flawed: the evolution is misrepresented as a progression from 55% in 2022 to full acquisition in 2024, whereas the truth is that Emerson restructured its stake in 2024 by contributing assets and cash to form 'New AspenTech' and retained 55% ownership—this was not a new acquisition but a strategic reorganization. The LLM fails to mention the contribution of the Industrial Software Business and $6.0 billion in cash, a key part of the multi-hop synthesis. (4) Contextual relevance is moderate—the answer addresses financial stake and operational integration but does so with incorrect entities, dates, and events. The core transformation described in the original (from financial stake to majority control via restructuring) is overshadowed by fictional details. Overall, major factual and numerical errors result in a low correctness score despite some relevant thematic elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 501,
        "total_tokens": 1881
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did Starbucks' position in interest rate swaps evolve between 2022 and 2023, particularly in terms of their classification and associated liabilities?",
      "original_answer": "In 2022, Starbucks had an interest rate swap classified as a long-term liability with a value of $34.0 million. By 2023, the company's interest rate swaps were categorized under both current and long-term liabilities, with $0.4 million listed under accrued liabilities (current) and $19.2 million under other long-term liabilities. This reflects a shift in the classification and a net decrease in the overall liability associated with interest rate swaps from $34.0 million in 2022 to $19.6 million in 2023.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2023 Starbucks continued to treat its interest‑rate swaps as **designated fair‑value hedges of fixed‑rate debt**, but the size of the hedge contracted.  In the 2022 filing the swaps appeared as derivative liabilities of **$12 million in accrued liabilities and $34 million in other long‑term liabilities** (10‑K 2022, pp. 66‑67), with a cumulative fair‑value hedging adjustment of **$(52.3) million** recorded in the hedged long‑term debt.  By 2023 the same swaps were still classified as designated fair‑value hedges, yet the liability had fallen to **about $19 million in other long‑term liabilities** (and a much smaller accrued‑liability balance), and the cumulative adjustment in the debt balance dropped to **$(17.8) million**, reflecting a reduced notional amount and a lower fair‑value liability (10‑K 2023, pp. 70‑71).",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer contains significant quantitative inaccuracies that undermine its correctness. According to the ground truth, in 2022 Starbucks reported a single interest rate swap liability of $34.0 million classified entirely as a long-term liability. However, the LLM claims $12 million was in accrued liabilities (current) and $34 million in long-term liabilities in 2022, which contradicts the original data. This results in a total liability of $46 million in the LLM answer—$12 million more than the correct $34 million—indicating a major factual error. For 2023, the ground truth specifies $0.4 million in accrued liabilities and $19.2 million in long-term liabilities, totaling $19.6 million. The LLM vaguely states 'about $19 million' in long-term liabilities and mentions a 'much smaller accrued-liability balance' without specifying $0.4 million, leading to partial credit for directionally correct but incomplete and imprecise figures. The net decrease from $34.0 million to $19.6 million is accurate in the ground truth, but the LLM does not explicitly compute or confirm this. The qualitative aspects are stronger: the answer correctly identifies the continued use of fair-value hedges and references hedging adjustments in debt ($(52.3) million in 2022 and $(17.8) million in 2023), which aligns with multi-hop reasoning from the filings. However, these details were not part of the original question, which focused on classification and liability amounts, not hedging adjustments. While contextually relevant and well-structured, the answer introduces unsupported numbers and omits precise breakdowns required by the ground truth. Thus, despite sound reasoning framework and correct directional trend (decrease in liability), the factual inaccuracies in key financial figures significantly reduce the correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 494,
        "total_tokens": 1838
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did NextEra Energy Resources' financial commitment and involvement in the Mountain Valley Pipeline evolve from 2022 to 2023?",
      "original_answer": "In 2022, NextEra Energy Resources recorded an impairment charge of approximately $0.8 billion related to its equity method investment in the Mountain Valley Pipeline, which was fully written off due to the very low probability of pipeline completion. By 2023, despite the ongoing challenges, NEE's subsidiary NEER maintained a 32.8% equity investment in the joint venture and committed to a 20-year natural gas transportation agreement with an annual obligation of approximately $70 million, subject to the completion of construction.",
      "llm_answer": "\nFrom 2022 to 2023 NextEra Energy Resources moved from an active equity investment in the Mountain Valley Pipeline to a largely written‑off position with only modest, contingent financial ties. In 2022 the company recorded an ≈ $0.8 billion impairment charge that completely wrote down its equity‑method stake (≈ $0.6 billion carrying amount) and created a ≈ $0.2 billion liability for future ARO costs. By 2023 its exposure was limited to modest, contingent commitments—principally a 20‑year natural‑gas transportation agreement that obligates about $70 million per year and equity contributions of roughly $1 billion in 2024‑2026 (plus a $1.065 billion joint obligation with NEECH that tapers to $5 million by 2026)—while the pipeline’s future remains uncertain.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the core evolution of NextEra Energy Resources' (NEER) involvement in the Mountain Valley Pipeline (MVP) from 2022 to 2023 but introduces significant inaccuracies, particularly in quantitative details not present in the ground truth. (1) Correct elements: The $0.8 billion impairment charge in 2022 is accurate and correctly framed as a write-off due to low completion probability. The mention of a 20-year, ~$70 million annual transportation commitment in 2023 aligns with the original answer. (2) Quantitative inaccuracies: The LLM adds specific figures not in the ground truth—namely a $0.6 billion carrying amount, $0.2 billion ARO liability, $1 billion in future equity contributions (2024–2026), and a $1.065 billion joint obligation tapering to $5 million by 2026. These numbers are either fabricated or over-specified; the original answer states NEER maintained a 32.8% equity stake but does not mention future equity contributions or detailed liability breakdowns. (3) Multi-hop reasoning: The model correctly infers a shift from active investment to contingent exposure, showing sound qualitative reasoning. However, it fails to accurately represent the extent of financial commitment in 2023—portraying it as more substantial than stated in the ground truth, which emphasizes the transportation agreement as the primary ongoing obligation. (4) Entity and context accuracy: NEER, MVP, and NEECH are correctly identified, and the timeline (2022 vs. 2023) is properly structured. The answer is contextually relevant and addresses the evolution question, but the added numerical specifics reduce factual reliability. Due to major quantitative errors despite correct core narrative, the correctness score is 5—partially correct but with significant factual overreach.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 485,
        "total_tokens": 1805
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has The Coca-Cola Company's investment in equity and debt securities related to its captive insurance company reinsuring group annuity insurance contracts evolved between 2023 and 2024?",
      "original_answer": "In 2023, The Coca-Cola Company reported that its captive insurance company reinsuring group annuity insurance contracts held $1,643 million in equity and debt securities as part of its solvency capital funds. By 2024, this amount increased to $1,883 million, indicating a growth in the company's investment in these securities over the year.",
      "llm_answer": "\nBetween 2023 and 2024 the captive insurance company that backs the group‑annuity reinsurance saw its solvency‑capital portfolio expand markedly: equity securities rose from **$1.643 billion** (as of 31 Dec 2023) to **$1.883 billion** (as of 31 Dec 2024), and debt securities increased from **$1.378 billion** to **$1.643 billion** over the same period.  This growth reflects a larger investment base that the captive uses to fund the group‑annuity contracts, with both equity and debt components rising by roughly 14–19 % year‑over‑year.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. The original answer states that the total investment in equity and debt securities combined was $1,643 million in 2023 and $1,883 million in 2024. However, the LLM incorrectly breaks this down into separate figures for equity and debt securities, claiming equity rose from $1.643 billion to $1.883 billion and debt from $1.378 billion to $1.643 billion—these individual values are not supported by the ground truth and contradict it when summed (e.g., $1.643B equity + $1.378B debt in 2023 would exceed the total reported). There is no mention in the original answer of a split between equity and debt components, nor any percentage increases of 14–19%. The LLM fabricates granular data and performs incorrect multi-hop reasoning by introducing unsupported disaggregated figures. While the overall direction (increase in investment) is correct and the years are properly referenced, the core numerical claims are false. This represents a failure in both quantitative accuracy and qualitative reasoning. The answer is contextually relevant—addressing the right company, time frame, and general topic—but the invented specifics severely undermine correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1230,
        "completion_tokens": 350,
        "total_tokens": 1580
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has Intel's approach to the Intel 4 process node evolved from 2022 to 2024, particularly in terms of production status and strategic positioning within Intel's product roadmap?",
      "original_answer": "In 2022, Intel was incurring higher period charges related to the ramp-up of Intel 4, indicating early-stage production challenges and investment. By 2024, Intel 4 had transitioned to high-volume manufacturing in Ireland and became the process node for the high-volume Intel Core Ultra processor, marking its strategic importance in Intel's product roadmap. This evolution shows a shift from initial investment and production ramp-up in 2022 to full-scale production and product integration by 2024.",
      "llm_answer": "\nBetween 2022 and 2024 Intel moved the Intel 4 node from design and early risk‑reduction into full‑scale high‑volume manufacturing, with the node entering production at its Ireland fab in 2024 and already powering the Core Ultra Series 1 AI PCs and other 13th/14th‑gen Core processors. This makes Intel 4 a cornerstone of Intel’s roadmap—providing the flagship client and AI‑focused silicon while Intel 3 and the forthcoming Intel 18A node are positioned as the next‑generation process technologies for data‑center and future client products.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution of Intel 4 from early production stages in 2022 to high-volume manufacturing by 2024, noting the Ireland fab as the site—consistent with the original answer. (2) There are no numeric values (e.g., financial figures, percentages) in either answer, so quantitative accuracy is not compromised; dates (2022 to 2024) are correct. (3) The multi-hop reasoning is sound: the model synthesizes production status (ramp-up to volume manufacturing) and strategic positioning (use in Core Ultra and AI PCs) across time, correctly identifying Intel 4 as a cornerstone in the product roadmap. (4) The LLM adds slightly more detail than the ground truth (mentioning 13th/14th-gen processors and positioning of Intel 3 and Intel 18A), but this is contextually appropriate and does not introduce inaccuracies. The only minor gap is the absence of explicit mention of 'higher period charges' in 2022, which is a factual detail from the original about financial impact during ramp-up. However, the description of moving from early risk-reduction to volume manufacturing implies this transition. Overall, the answer is semantically equivalent, factually correct, and contextually rich.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1268,
        "completion_tokens": 356,
        "total_tokens": 1624
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did Emerson's strategic relationship with AspenTech evolve between 2022 and 2024, particularly in terms of ownership structure and financial integration?",
      "original_answer": "In 2022, AspenTech was described as a strategic partner of Emerson, with no mention of ownership stakes or integration into Emerson's financials. By 2024, Emerson had merged its industrial software business with AspenTech, creating 'New AspenTech,' and retained a 55% ownership stake in the newly formed entity. This marked a significant shift from a partnership to a partially owned subsidiary structure. Additionally, AspenTech's financials were now integrated into Emerson's results, with the acquisition positively impacting gross margins by 0.6 percentage points in 2023 and influencing SG&A expenses in 2024 due to the deeper integration.",
      "llm_answer": "\nBetween 2022 and 2024 Emerson’s stake in AspenTech moved from a **55 % equity interest** (secured in 2022 when it contributed two of its own industrial‑software businesses and about $6 billion of cash, giving Emerson a majority but still minority position) to a **proposed 100 % acquisition** announced in November 2024, under which Emerson would buy the remaining shares for $240 per share (implying a $15.3 billion fully‑diluted market value).  The 2024 proposal, to be financed with cash on hand and committed credit lines, marks a shift from an equity‑method investment to full consolidation, integrating AspenTech’s revenues, costs and cash flows into Emerson’s financial statements and giving Emerson complete control over its governance and strategic direction.  This evolution also reflects deeper financial integration, as Emerson’s earlier 55 % holding already provided board representation and collaborative product‑go‑to‑market initiatives, while the 2024 buy‑out would eliminate the remaining minority interest and fully absorb AspenTech into Emerson’s consolidated results.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that deviate from the ground truth. (1) QUANTITATIVE INACCURACY: The claim that Emerson held a 55% equity interest in AspenTech in 2022 is false — the original answer states that in 2022, AspenTech was only a strategic partner with no ownership stake. The $6 billion cash contribution and the structure of the deal are not mentioned in the ground truth. The November 2024 announcement of a 100% acquisition at $240 per share and $15.3 billion valuation is not supported by the provided truth, which only states that Emerson retained a 55% stake in 'New AspenTech' by 2024. (2) COMPLETENESS: The answer fails to correctly describe the evolution — it invents a future full acquisition not present in the truth, and omits the key fact that the 55% ownership began in 2024 (not 2022) as part of a merger of Emerson’s software business with AspenTech. (3) ENTITY & TEMPORAL INACCURACY: The timeline is incorrect — the 55% stake was established in 2024, not 2022. The financial integration described (impact on gross margins by 0.6 points in 2023 and SG&A in 2024) is entirely omitted. (4) REASONING: The multi-hop synthesis is flawed — instead of correctly tracing the shift from partnership (2022) to partial ownership (2024), it fabricates a narrative of increasing ownership culminating in a buyout. (5) SEMANTIC EQUIVALENCE: The overall meaning is not equivalent — the LLM suggests full acquisition is planned, while the truth indicates a 55% ownership and integration as of 2024. The financial integration details in the original answer are ignored. While the answer is relevant to the topic and attempts to address ownership and integration, the core facts are incorrect, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1435,
        "completion_tokens": 477,
        "total_tokens": 1913
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has Intel's approach to the Intel 4 process node evolved from 2022 to 2024, particularly in terms of its manufacturing readiness and performance improvements?",
      "original_answer": "In 2022, Intel 4 was newly introduced as part of a restructured naming convention for manufacturing process nodes, signaling its position as a next-generation node following Intel 7. By 2024, Intel 4 had transitioned from a conceptual roadmap item to a fully realized product, with high-volume manufacturing ramped up in Ireland. Intel 4, as the company's first EUV lithography node, delivered a 20% performance-per-watt improvement over Intel 7 and was used in the production of the Intel Core Ultra processor, which began shipping in 2023. This represents a significant evolution from its initial naming in 2022 to full-scale production and performance quantification by 2024.",
      "llm_answer": "\nFrom 2022 – when Intel 4 was still being qualified as the company’s first EUV‑based node – to 2024, Intel has taken the process from early development to full‑scale, high‑volume manufacturing in its Irish fabs.  The node now powers the Core Ultra Series 1 AI PCs and other products and delivers roughly 20 % higher performance‑per‑watt (and greater density) than the preceding Intel 7 node, making it a central pillar of Intel’s 2024‑2025 product roadmap.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, the 20% performance-per-watt improvement is correctly stated, and the timeline (2022 qualification to 2024 high-volume manufacturing) matches. The mention of EUV lithography and the use in Core Ultra processors (referred to as 'Core Ultra Series 1 AI PCs') is factually correct. (2) All numbers and dates are accurate: Intel 4 was introduced in 2022 as a roadmap item, entered high-volume manufacturing by 2024, and powers products shipping from 2023 onward. The 20% performance-per-watt gain over Intel 7 is correctly cited. (3) The multi-hop reasoning is sound: the answer synthesizes Intel's process node evolution across time, technology (EUV), manufacturing scale (Ireland fabs), and product integration (Core Ultra). (4) The only minor shortcoming is that the original answer specifies the Ireland ramp-up and the 2023 product shipment start, which the LLM answer omits but implies through context. The LLM mentions '2024–2025 product roadmap', which slightly deemphasizes the 2023 start but does not contradict it. Overall, the answer is semantically equivalent, factually correct, and contextually complete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 338,
        "total_tokens": 1626
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has the role and positioning of InterStim Micro evolved within MDT's Pelvic Health therapies between 2022 and 2024?",
      "original_answer": "In 2022, InterStim Micro was listed as one of several neurostimulators within MDT's Pelvic Health product portfolio, which also included InterStim X and InterStim II, used to treat overactive bladder, urinary retention, and fecal incontinence. By 2024, InterStim Micro was specifically highlighted as the rechargeable neurostimulator option, differentiated from the recharge-free InterStim X and InterStim II. This indicates a more defined strategic positioning of InterStim Micro as the rechargeable variant within the broader InterStim therapy lineup, with an emphasis on its continued global growth and adoption.",
      "llm_answer": "\nBetween 2022 and 2024 the InterStim Micro moved from being simply one of several InterStim neurostimulators for pelvic‑health indications to a deliberately highlighted, rechargeable “micro” option within Medtronic’s expanded InterStim platform.  In the 2022 filing it was listed alongside InterStim X and InterStim II as a rechargeable device for overactive‑bladder, urinary‑retention and fecal‑incontinence therapy, while the 2024 filing explicitly groups it with the new recharge‑free InterStim X/II systems and emphasizes its smaller form‑factor, MRI‑conditional capability, and role in providing a rechargeable solution for the same indications.  Thus, its positioning shifted to a premium, rechargeable micro‑therapy that complements—and is marketed in parallel with—a broader suite of both rechargeable and recharge‑free pelvic‑health devices.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: InterStim Micro was part of MDT's Pelvic Health portfolio in 2022 alongside InterStim X and II, and by 2024 it was explicitly positioned as the rechargeable option, contrasted with the recharge-free variants. The indications (overactive bladder, urinary retention, fecal incontinence) are correctly stated. (2) There are no numeric values requiring verification (e.g., financials, dates beyond years), and the years 2022 and 2024 are used appropriately and correctly. (3) The multi-hop reasoning is sound—LLM synthesizes changes in product positioning across two time points, correctly identifying the strategic repositioning of InterStim Micro as a rechargeable, compact, MRI-conditional device. It accurately infers a more defined market role without overreaching. (4) The LLM adds slightly more detail than the original (e.g., 'smaller form-factor', 'MRI-conditional capability', 'premium micro-therapy'), which are plausible enhancements based on typical product differentiation but not explicitly confirmed in the ground truth. This prevents a perfect 10, as these specifics, while reasonable, are not verifiable from the provided answer. However, they do not contradict the truth and enhance contextual understanding. Overall, the answer is factually correct, complete, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 388,
        "total_tokens": 1748
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has the disclosure around the dilutive effect of LTIP Units evolved from 2022 to 2024, particularly in terms of material impact across reporting periods?",
      "original_answer": "In 2022, the disclosure stated that LTIP units were exchangeable for common stock and that no securities had a material dilutive effect for the years ended December 31, 2021, 2020, and 2019. By 2024, the disclosure simplified to state that no securities had a material dilutive effect for the years ended December 31, 2024, 2023, and 2022, without explicitly referencing the exchangeability of LTIP units into common stock. This indicates a reduction in the level of detail provided about LTIP units' conversion features, while maintaining the same conclusion regarding dilution impact.",
      "llm_answer": "\nFrom 2022 through 2024 the footnote on diluted earnings‑per‑share (and per unit) consistently identifies LTIP units as potentially dilutive but explicitly states that, for each of the reported periods (2021‑2022 in the 2022 filing and 2022‑2024 in the 2024 filing), no such securities produced a material dilutive effect, so the EPS/unit calculations are not adjusted for them. The wording simply updates the reference years while reaffirming that LTIP‑unit dilution is considered immaterial across the successive reporting periods.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the consistent conclusion across 2022 and 2024 disclosures that LTIP units did not have a material dilutive effect in the reported periods, and accurately reflects the years covered in each filing (2019–2021 in 2022 filing; 2022–2024 in 2024 filing). The quantitative accuracy is high: years and the absence of material dilution are correctly stated, and the treatment of LTIP units as potentially dilutive but immaterial is factually sound. However, the LLM omits a key qualitative change noted in the ground truth: the removal of explicit disclosure about the exchangeability of LTIP units into common stock by 2024. This reduction in detail about the conversion mechanism represents an evolution in disclosure depth that the LLM answer fails to mention, weakening its qualitative accuracy. While the core conclusion about dilutive impact is correctly synthesized across years, the answer does not fully capture the change in disclosure granularity, which is central to the question about 'evolution' of disclosure. The reasoning is logically sound but incomplete in multi-hop synthesis—correctly tracking the dilution conclusion over time but missing the shift in descriptive detail. Contextual relevance is strong as the response directly addresses the question’s focus on dilutive impact over time.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 370,
        "total_tokens": 1653
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has MetLife's approach to managing cash buffer needs in relation to stock repurchases evolved from 2022 to 2024, particularly in terms of remaining repurchase authorization and liquidity considerations?",
      "original_answer": "In 2022, MetLife had $1.5 billion remaining under its $3.0 billion common stock repurchase authorization as of December 31, 2021, indicating a significant but partially utilized capacity for returning capital to shareholders. By 2024, the company emphasized increased caution around cash buffer needs, noting that maintaining or increasing liquidity buffers could limit capital available for repurchases, acquisitions, and innovation. This reflects a shift from a more active repurchase posture in 2022 to a more conservative liquidity strategy in 2024, influenced by regulatory, market, and internal capital considerations.",
      "llm_answer": "\nFrom the 2022 filing (pages 48‑52) MetLife had a $3 billion common‑stock repurchase authorization with roughly $1.5 billion still available at the end of 2021, and it repeatedly warned that legal‑regulatory limits and the need to preserve a cash buffer for claims and capital‑ratio requirements could curb future buy‑backs. The 2024 filing (pages 31‑35) shows that the remaining authorization had been reduced to about $0.8 billion and that any further repurchases are now explicitly conditioned on maintaining a strong liquidity buffer to meet claim‑paying, rating‑agency and regulatory capital needs, signalling a more conservative approach to stock repurchases.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $3.0 billion repurchase authorization and $1.5 billion remaining at the end of 2021 from the 2022 filing, which aligns with the ground truth. However, it introduces a new figure—$0.8 billion remaining authorization in 2024—that is not present in the original answer or supported by the provided ground truth. The original answer does not specify the exact remaining authorization in 2024, only noting increased caution and liquidity constraints. This incorrect quantitative claim reduces confidence in the numerical accuracy. (2) The dates and years referenced (2021, 2022, 2024) are contextually appropriate, and the $3B/$1.5B figures are accurate. But the unsupported $0.8B figure in 2024 is a significant deviation, especially since the original emphasizes a qualitative shift rather than providing updated numbers. No calculation is offered to justify this number, and it appears to be an overinference or hallucination. (3) The multi-hop reasoning is otherwise sound: the LLM correctly synthesizes the evolution from a more active repurchase stance in 2022 to a more conservative, liquidity-constrained approach in 2024. It accurately reflects the growing emphasis on regulatory, rating agency, and claim-paying obligations as constraints on capital deployment. This demonstrates good qualitative understanding of the strategic shift. (4) Contextual relevance is high—the response directly addresses the evolution of MetLife’s approach to cash buffers and stock repurchases across the specified time frame. While the core narrative of increased conservatism is correct, the inclusion of an unsupported specific dollar amount in 2024 undermines quantitative accuracy. Hence, correctness is partially compromised, warranting a 7. Qualitative accuracy is strong due to correct reasoning and entity identification, and contextual relevance is perfect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 515,
        "total_tokens": 1853
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How did Starbucks' foreign currency - other derivative asset and liability positions evolve from fiscal year 2022 to 2023, and what specific changes occurred in their balance sheet classifications?",
      "original_answer": "In fiscal year 2022, Starbucks reported foreign currency - other derivative assets of $103.9 million recognized in OCI before reclassifications and $22.0 million reclassified from AOCI to earnings. By fiscal year 2023, the foreign currency - other derivative assets on the balance sheet were reported as $1.9 million in prepaid expenses and other current assets and $1.7 million in other long-term assets as of October 1, 2023, while derivative liabilities were $4.7 million in accrued liabilities and $4.1 million in other long-term liabilities. This represents a significant reduction in asset positions compared to the prior year, with a shift in balance sheet classification.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2023 the foreign‑currency‑other derivative **asset** fell dramatically—from about **$74 million** ( $39.9 m recorded in “Prepaid expenses and other current assets” plus $33.5 m in “Other long‑term assets”) to roughly **$3.6 million** ( $1.9 m in current assets and $1.7 m in long‑term assets).  The corresponding **liability** balance also shrank, from roughly **$13 million** to about **$11 million**, with the current‑liability portion dropping from $7.5 m to $2.5 m and the long‑term‑liability portion from $5.4 m to $4.1 m.  The **balance‑sheet classifications did not change**—assets remained in “Prepaid expenses and other current assets” and “Other long‑term assets,” and liabilities in “Accrued liabilities” and “Other long‑term liabilities”—but the dollar amounts in each bucket shifted sharply, reflecting a much smaller current‑asset position and a modest re‑allocation between current and long‑term components.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in both asset and liability figures for fiscal year 2022. According to the ground truth, Starbucks did not report a foreign currency - other derivative asset of $74 million in 2022 broken down into $39.9M and $33.5M across balance sheet categories. Instead, the original answer states that in 2022, the asset was $103.9 million recognized in OCI before reclassifications, with $22.0 million reclassified from AOCI to earnings — information entirely missing from the LLM response. The LLM incorrectly assumes balance sheet line-item breakdowns for 2022 that are not present in the ground truth. For 2023, while the LLM correctly reports the $1.9M in prepaid expenses, $1.7M in other long-term assets, $4.7M in accrued liabilities, and $4.1M in other long-term liabilities, it misrepresents the prior-year data, leading to incorrect comparisons. (2) The liability figures for 2022 are also wrong: the LLM claims $13M total liabilities ($7.5M current + $5.4M long-term), but the ground truth does not provide these numbers for 2022 liabilities — making this fabrication. The original answer only specifies 2023 liability classifications, not 2022, so any comparison is unsupported. (3) The multi-hop reasoning is flawed because the model invents 2022 balance sheet allocations that are not in the source data, fails to mention OCI recognition and reclassifications which are central to the 2022 position, and incorrectly asserts that balance sheet classifications remained unchanged — while the ground truth highlights a 'shift in balance sheet classification' as a key development. (4) Despite these major errors, the answer is contextually relevant — it attempts to address the evolution of derivative positions and classifications — and correctly reports the 2023 balance sheet figures. However, due to severe quantitative inaccuracies and incorrect reasoning, the overall correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1421,
        "completion_tokens": 531,
        "total_tokens": 1952
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has Procter & Gamble's global cash management strategy evolved in relation to its restructuring activities and corporate-level financial performance between fiscal 2022 and fiscal 2024?",
      "original_answer": "In fiscal 2022, Procter & Gamble incurred restructuring costs within its historical range of $250 to $500 million before tax, with $147 million in restructuring accruals as of June 30, 2022. Corporate net earnings improved by $872 million to $485 million, partly due to tax benefits and lower restructuring charges. By fiscal 2024, restructuring costs increased significantly to $659 million before tax, including $216 million in non-cash foreign currency translation losses. Corporate net earnings decreased by $1.0 billion, largely due to the $1.4 billion impairment charge of the Gillette intangible asset and incremental restructuring charges. This indicates a shift toward more aggressive restructuring actions, particularly in Enterprise Markets like Nigeria, which impacted both cash flow and earnings. The global cash management strategy remained focused on liquidity and tax considerations, but faced increased pressure from these restructuring activities and impairment charges.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2024 P&G expanded its restructuring program – annual pre‑tax charges rose from the historic $250‑$500 million range to $659 million in FY 24, including a $216 million non‑cash foreign‑currency translation loss from the liquidation of certain enterprise markets – and funded these initiatives with the company’s strong operating cash flow (up 18 % to $19.8 billion in FY 24) and continued access to capital markets.  As a result, cash generation remained robust enough to sustain dividend growth, share‑repurchase activity and debt refinancing, but corporate‑level earnings deteriorated, falling from a $485 million profit in FY 22 to a $1.43 billion loss in FY 24 driven by the impairment charge and incremental restructuring costs.  Consequently, the global cash‑management strategy shifted from simply supporting growth to deliberately channeling cash to finance an intensified productivity‑and‑cost‑savings agenda while preserving liquidity through high‑quality cash flow and stable credit ratings.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of P&G's restructuring activities and their impact on financial performance and cash management strategy. It accurately notes the increase in restructuring costs from the historical range ($250–$500 million) in FY22 to $659 million in FY24, including the $216 million non-cash foreign currency translation loss. It also correctly identifies the deterioration in corporate-level earnings, though the exact FY22 corporate net earnings figure is misrepresented: the original answer states a $485 million profit in FY22 (an improvement of $872 million), while the LLM claims a $485 million profit in FY22 but then says it fell to a $1.43 billion loss in FY24. However, the original answer states that corporate net earnings *decreased by $1.0 billion* in FY24 due to the $1.4 billion impairment and restructuring charges, not that they reached a $1.43 billion loss. This is a significant quantitative error. (2) The LLM introduces an 18% increase in operating cash flow to $19.8 billion in FY24, which is not present in the original answer and cannot be verified from the provided ground truth — this is an unsupported addition. The original answer does not mention operating cash flow trends or dividend/share repurchase activity. (3) The qualitative reasoning is strong: the LLM correctly infers a shift in cash management strategy toward financing a more aggressive cost-savings agenda amid increased restructuring, particularly in Enterprise Markets like Nigeria (implied in original via 'liquidation of certain enterprise markets'). It synthesizes the tension between robust cash generation and declining earnings well, even if some specifics are extrapolated. (4) Contextual relevance is excellent — the answer directly addresses the evolution of cash management in relation to restructuring and financial performance across the specified period. Despite the incorrect cash flow and earnings figures, the core narrative aligns with the ground truth. Quantitative accuracy is reduced due to unsupported numbers and miscalculations, but qualitative and contextual accuracy remain high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1516,
        "completion_tokens": 576,
        "total_tokens": 2092
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has NVIDIA's positioning and application of Omniverse evolved between 2022 and 2023, particularly in terms of its integration with enterprise solutions and simulation technologies?",
      "original_answer": "In 2022, NVIDIA Omniverse was positioned primarily as a virtual world simulation and collaboration platform for 3D workflows, emphasizing its availability as a software subscription for enterprise use and free for individuals. It was highlighted in use cases such as virtual car showrooms, surgical training, and architectural walkthroughs, and was integrated with DRIVE Sim software for automotive simulation and validation. By 2023, Omniverse had evolved into a more robust development platform and operating system for building virtual world simulation applications. It was increasingly tied to industrial enterprises for digitalizing complex physical assets and processes, including digital twins of factories and real-time 3D product configurators. Additionally, it was more explicitly linked to NVIDIA's accelerated computing infrastructure both on-premises and in the cloud, indicating a broader integration with enterprise-grade simulation and AI workflows.",
      "llm_answer": "\nBetween 2022 and 2023 NVIDIA moved Omniverse from a primarily collaborative 3‑D design tool for creators and early‑stage enterprise pilots to a core enterprise‑grade simulation and digital‑twin platform.  The company began offering it as a paid subscription for large‑scale deployments while keeping a free tier, and it embedded Omniverse in its automotive stack (e.g., DRIVE Sim for self‑driving validation and Omniverse Avatar for real‑time conversational AI) and in industrial workflows that build digital twins of factories, products and autonomous robots, all powered by NVIDIA’s AI‑accelerated computing and the broader AI Enterprise software ecosystem.  This deepened integration positioned Omniverse as the backbone for enterprise‑level, AI‑driven virtual‑world testing, validation and real‑time collaboration across multiple industries.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of NVIDIA's Omniverse between 2022 and 2023. (1) It correctly identifies the shift from a collaborative 3D design tool to an enterprise-grade simulation and digital twin platform, aligning with the ground truth's emphasis on broader industrial use and integration with enterprise solutions. The mention of free vs. paid tiers matches the original answer. (2) There are no numeric values, dates, or financial figures in the question or answers that require verification—thus, quantitative accuracy is not compromised, scoring 10. (3) The LLM correctly synthesizes multi-hop information: it links Omniverse to DRIVE Sim for automotive validation, references digital twins of factories and autonomous robots, and ties the platform to NVIDIA’s AI-accelerated computing and AI Enterprise ecosystem—key points in the ground truth. The only minor omission is the absence of specific 2022 use cases like surgical training and architectural walkthroughs, and slightly less emphasis on the 'operating system for virtual worlds' framing in 2023. However, these are contextual nuances rather than factual errors. (4) The answer is fully relevant to the question about positioning, enterprise integration, and simulation technologies. Overall, the semantic meaning and factual content are nearly identical to the ground truth, warranting a 9/10 for correctness and qualitative accuracy, with full marks for contextual relevance and quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1462,
        "completion_tokens": 413,
        "total_tokens": 1875
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did AMT's financial commitments related to communications sites evolve from 2023 to 2024, particularly in terms of anticipated spending and future obligations?",
      "original_answer": "In 2023, AMT anticipated spending approximately $450 million related to data center assets as part of its construction plans for 2,500 to 3,500 communications sites globally. By 2024, the company disclosed a much larger financial commitment, with an estimated undiscounted future cash outlay of $4.5 billion for asset retirement obligations tied to leased sites hosting communications infrastructure. This indicates a significant increase in long-term financial exposure related to communications sites, shifting from near-term capital allocation planning in 2023 to a more mature and substantial obligation structure in 2024.",
      "llm_answer": "\nFrom 2023 to 2024 AMT trimmed its planned outlay for new communications‑site and data‑center infrastructure – 2023 capital spending was about **$1.8 billion**, while the company now projects **$1.545 billion–$1.655 billion** of total 2024 capital expenditures, with discretionary projects earmarked at **$790 million–$820 million** and ground‑lease purchases of only **$70 million–$90 million**.  At the same time, AMT’s future cash obligations have shifted toward larger debt‑service and lease commitments: it must meet **$3.69 billion of debt maturities in 2025** (rising to **$5.5 billion in 2027** and **$6.0 billion in 2028**) and **≈$1 billion of annual operating‑lease payments**, plus ongoing commitments for ground‑lease easements and potential acquisitions.  Thus, while 2024 spending on new sites is modestly lower than 2023, the company’s long‑term financial obligations for site‑related debt and lease payments remain substantial and are set to increase in the coming years.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and fails to align with the ground truth in both quantitative and qualitative aspects. (1) The numbers provided—such as $1.8 billion in 2023 capital spending and $1.545–1.655 billion projected for 2024—are not mentioned in the original answer and contradict the ground truth, which states AMT anticipated spending $450 million in 2023 related to data center assets for 2,500–3,500 communications sites. The LLM introduces figures about capital expenditures, debt maturities in 2025–2028, and annual lease payments of ~$1 billion, none of which appear in the original answer. (2) The key financial commitment highlighted in the original answer is the $4.5 billion in estimated undiscounted future cash outlays for asset retirement obligations (AROs) on leased communications sites in 2024—a critical multi-hop detail showing increased long-term liability. This is entirely missing from the LLM response. Instead, the model focuses on capital expenditures and debt maturities unrelated to AROs or site retirement, misrepresenting the nature of the financial commitment. (3) The reasoning is flawed: the original answer describes a shift from near-term construction spending (2023) to long-term asset retirement obligations (2024), indicating maturation of liabilities. The LLM incorrectly frames the evolution as a reduction in capital spending with rising debt and lease payments, which is not supported by the ground truth. (4) While the LLM attempts to address financial commitments related to communications sites, it does so with incorrect data and misaligned concepts (e.g., confusing capital expenditures with asset retirement obligations). The contextual relevance is moderate because it discusses financial obligations related to sites, but the core facts and multi-hop synthesis are incorrect, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1407,
        "completion_tokens": 504,
        "total_tokens": 1912
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has ExxonMobil's characterization of asset divestitures in relation to strategic objectives evolved between 2023 and 2024, particularly in terms of the language used to describe the proceeds from these transactions?",
      "original_answer": "In 2023, ExxonMobil described proceeds from asset sales as part of 'sales of subsidiaries, property, plant and equipment, and sales and returns of investments,' emphasizing a disciplined review process to ensure assets align with strategic goals. By 2024, the company refined its language, referring more broadly to 'proceeds from asset sales and returns of investments,' maintaining the same strategic alignment rationale but streamlining the description. This evolution indicates a more consolidated framing of divestiture proceeds without specific mention of subsidiaries or equipment sales, suggesting a possible shift toward a more generalized narrative around asset management.",
      "llm_answer": "\nIn the 2023 10‑K the discussion of asset‑sale proceeds was largely procedural – it simply noted that “proceeds associated with sales of subsidiaries, property, plant and equipment” are included in cash‑flow from operations and that a regular review ensures assets “contribute to the Corporation’s strategic objectives,” without tying the cash to any specific strategic use. By contrast, the 2024 10‑K frames those proceeds as the outcome of a “disciplined portfolio‑optimization process” that divests assets no longer meeting its strategic objectives or that are “worth considerably more to others,” explicitly describing the cash as a key source to fund strategic growth priorities and to support shareholder distributions. Thus, the language shifted from a neutral, mechanical reference to a purposeful, strategy‑aligned characterization of divestiture proceeds.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains no numeric data, so quantitative accuracy is not applicable; however, since there are no numbers to verify or miscalculate, it is scored as 10 by default. The contextual relevance is high because the response directly addresses the evolution of ExxonMobil's language around asset divestitures between 2023 and 2024. However, the qualitative accuracy is low due to significant factual discrepancies. The original answer states that in 2023, ExxonMobil described proceeds as part of 'sales of subsidiaries, property, plant and equipment, and sales and returns of investments,' with a focus on disciplined review for strategic alignment. In 2024, the language was streamlined to 'proceeds from asset sales and returns of investments,' consolidating the framing without specific categories. The LLM answer incorrectly claims that in 2024, the company explicitly tied proceeds to funding growth and shareholder distributions and used terms like 'disciplined portfolio-optimization process' and 'worth considerably more to others'—phrases not present in the ground truth. Additionally, the LLM attributes a shift in strategic narrative (from neutral to purposeful use of proceeds) that is unsupported by the original answer, which only notes a consolidation of terminology. This represents a failure in multi-hop reasoning: while the model attempts to infer strategic intent, it fabricates key elements not present in the source data. Thus, despite correct entity identification (ExxonMobil, 2023–2024) and addressing the question’s scope, the factual inaccuracies in language characterization severely undermine correctness, warranting a score of 4.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1405,
        "completion_tokens": 453,
        "total_tokens": 1858
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has Comcast's financial exposure to Universal Beijing Resort evolved from 2022 to 2023, based on the changes in consolidated asset and liability amounts?",
      "original_answer": "In 2022, Comcast's consolidated balance sheet included $9.7 billion in assets and $8.1 billion in liabilities related to Universal Beijing Resort. By 2023, these figures had decreased to $7.8 billion in assets and $7.2 billion in liabilities. This indicates a reduction in both the scale of assets and liabilities associated with the Universal Beijing Resort, suggesting either asset depreciation, debt repayment, or a strategic reduction in the resort's financial footprint within Comcast's consolidated statements.",
      "llm_answer": "\nFrom 2022 to 2023 the consolidated exposure to Universal Beijing Resort fell sharply: the resort’s assets on Comcast’s balance sheet dropped from about **$9.7 billion** (reported for 2021) to **$7.8 billion** by the end of 2023, while its liabilities fell from roughly **$8.1 billion** to **$7.2 billion**.  This reduction in both assets and liabilities reflects a lower financial exposure to the joint venture over the two‑year period.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly reports the asset and liability figures for Universal Beijing Resort: $9.7 billion in assets and $8.1 billion in liabilities in 2022, decreasing to $7.8 billion in assets and $7.2 billion in liabilities in 2023. These values match the ground truth. However, the LLM incorrectly references '2021' as the starting year for the $9.7 billion asset figure, when the question and ground truth clearly pertain to 2022–2023. This is a factual error in temporal attribution, though the numbers themselves are accurate. 2) All numeric values are correct in amount and format: $9.7B, $7.8B, $8.1B, $7.2B. Calculations implied (reductions in assets and liabilities) are accurate: asset decrease of $1.9B and liability decrease of $0.9B. 3) The reasoning is sound—reduction in both assets and liabilities indicates lower financial exposure, which aligns with the ground truth interpretation. The model correctly synthesizes the multi-hop concept of financial exposure via balance sheet items across years. 4) Despite the mislabeling of the year (2021 instead of 2022), the core data and conclusion are correct. The answer remains contextually relevant and conveys the intended trend. The error is minor but affects precision in entity (year) accuracy, warranting a slight deduction in correctness and qualitative accuracy. Semantic equivalence is largely preserved.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1241,
        "completion_tokens": 381,
        "total_tokens": 1622
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has the nature of Customer Demand Volatility as a risk factor for Caterpillar evolved between 2023 and 2024, particularly in relation to its impact on financial performance and supply chain stability?",
      "original_answer": "In 2023, Customer Demand Volatility was described as being primarily driven by economic uncertainties, including the lingering effects of a global pandemic, which led to inflationary pressures, supply chain disruptions, and labor inefficiencies, all of which limited Caterpillar's ability to meet customer demand. By 2024, while the risk remained, the focus shifted slightly to include broader commodity price changes, material price increases, and significant disruptions to supply chains or shortages of labor and material as key contributors to financial performance risks. This evolution indicates a broadening of the risk profile to include more systemic supply-side challenges alongside demand volatility.",
      "llm_answer": "\nBetween 2023 and 2024 the risk of customer‑demand volatility shifted from being framed mainly as a cyclical, commodity‑price‑driven swing that could curb orders and force inventory write‑downs, to a broader macro‑economic uncertainty amplified by inflation, higher interest rates and pandemic‑related supply‑chain disruptions.  This evolution means that demand fluctuations now directly pressure Caterpillar’s revenue and cash flow while also tightening the supply‑chain window for meeting orders, forcing the company to adopt more flexible production and inventory controls to protect financial performance.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is partially correct but contains key inaccuracies in the characterization of how Customer Demand Volatility evolved between 2023 and 2024. (1) Correct elements: The answer correctly identifies macroeconomic uncertainty, inflation, and supply-chain disruptions as relevant factors, and it appropriately links demand volatility to financial performance (revenue, cash flow) and supply chain stability. The contextual relevance is high, as it addresses the evolution of the risk and its impacts. (2) Quantitative accuracy is not applicable here—no specific numbers, percentages, or financial figures are involved in the question or ground truth, so no numeric errors exist. (3) Multi-hop reasoning is partially sound but flawed: the ground truth states that in 2023, the risk was driven by pandemic aftereffects, inflation, supply chain issues, and labor inefficiencies—all demand- and external shock-related. In 2024, the focus broadened to include supply-side factors like commodity price changes, material price increases, and labor/material shortages. However, the LLM incorrectly reverses the timeline by suggesting that in 2023 the risk was 'mainly cyclical, commodity-price-driven,' which contradicts the original answer (commodity prices were emphasized more in 2024). It also overemphasizes commodity prices early and underrepresents the shift toward systemic supply-side risks in 2024. (4) The answer misses the key evolution noted in the ground truth: the broadening from demand-side volatility (2023) to a combined demand-and-supply risk profile (2024). Instead, it frames the shift as one of intensification due to macro factors, not a structural expansion of risk drivers. Thus, while semantically plausible and contextually relevant, the qualitative inaccuracy in the causal drivers and their temporal assignment reduces correctness. Scores reflect mostly accurate reasoning but significant factual misalignment in the evolution narrative.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 528,
        "total_tokens": 1872
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did the fair value and valuation methodology of Net derivative assets (liabilities) evolve from 2022 to 2024?",
      "original_answer": "In 2022, the fair value of Net derivative assets (liabilities) was $19 million as of December 31, 2021, with changes in value primarily tied to derivative activity such as issuances ($68 million), settlements ($-37 million), and transfers ($6 million). By 2024, the fair value had increased significantly to $58 million as of December 31, 2023. Additionally, the valuation methodology shifted from being primarily based on realized and unrealized gains/losses reported in net income to being assessed using discounted cash flows with a focus on observable inputs like swap rates (3-5%, weighted average of 4%). This indicates both a material increase in value and a methodological shift toward more transparent and observable valuation techniques.",
      "llm_answer": "\nBetween 2022 and 2024 the reported fair‑value of net derivative assets (liabilities) grew from roughly **$5 million (2022)** to **$58 million (2023)** and **$69 million (2024)**, as shown in the Level‑3 roll‑forward tables.  This increase reflects larger notional positions and a greater share of the derivatives being classified as Level 3, but the underlying valuation methodology has not changed – Capital One continues to value these instruments with vendor‑based discounted‑cash‑flow models that use market‑observable inputs such as swap rates, yield curves, credit spreads and prepayment assumptions, supplemented only by unobservable assumptions when observable data are unavailable.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The original answer states that the fair value in 2022 was $19 million as of December 31, 2021 (i.e., reported in 2022), while the LLM incorrectly claims it was $5 million in 2022. The LLM also introduces a $69 million value for 2024, which is not present in the ground truth—the correct value is $58 million as of December 31, 2023 (reported in 2024). These numbers are materially off and unsupported by the original data. (2) The quantitative inaccuracies are severe: the LLM fabricates values ($5M, $69M) and misaligns reporting years. The ground truth does not mention Level-3 classifications or notional positions, nor does it state that the methodology remained unchanged—on the contrary, it explicitly notes a shift toward discounted cash flows with a focus on observable inputs, indicating an evolution in methodology. (3) The multi-hop reasoning is flawed. The LLM fails to correctly synthesize the evolution in both value and methodology. It incorrectly asserts that the valuation approach did not change, directly contradicting the original answer’s key point about a methodological shift toward more transparent, observable techniques. This undermines the core qualitative analysis. (4) While the LLM attempts to address both fair value trends and methodology, its responses are factually incorrect on both counts. The contextual relevance is moderate because it discusses the right topic (derivative valuation), but the substance is largely inaccurate. Due to major errors in numbers, dates, and reasoning—especially the denial of a methodology change—the correctness score is low at 3 out of 10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 459,
        "total_tokens": 1810
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has NVIDIA's GeForce NOW cloud gaming offering evolved from 2022 to 2023 in terms of its positioning within the company's broader GPU and cloud platform ecosystem?",
      "original_answer": "In 2022, GeForce NOW was positioned as a cloud platform enabling gamers to access interactive graphics applications from nearly any device, emphasizing its role in extending NVIDIA’s graphics leadership and ecosystem reach. It was mentioned alongside other cloud platforms like vGPU for enterprise use. By 2023, GeForce NOW was more specifically integrated into the broader NVIDIA accelerated computing platform narrative, and its positioning shifted to emphasize cloud gaming as part of a suite of GPU-driven services, including AI training platforms like NVIDIA DGX Cloud. This evolution reflects a more strategic alignment of GeForce NOW with NVIDIA’s expanding cloud infrastructure and software offerings, particularly in the context of gaming as a service.",
      "llm_answer": "\nFrom 2022 to 2023 NVIDIA reframed GeForce NOW from a stand‑alone game‑streaming service into a flagship showcase of its broader GPU‑accelerated cloud platform.  The service now streams RTX‑enabled, AI‑enhanced titles using the same data‑center GPUs, CUDA‑based software stack, and Omniverse‑derived technologies that power the company’s AI, professional‑visualization and automotive offerings, positioning cloud gaming as the consumer‑facing edge of NVIDIA’s full‑stack accelerated‑computing ecosystem.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution of GeForce NOW from 2022 to 2023: starting as a standalone game-streaming service and becoming more integrated into NVIDIA’s broader GPU-accelerated cloud platform. The emphasis on RTX, AI enhancements, data-center GPUs, CUDA, and Omniverse technologies reflects the correct technical and strategic context. (2) There are no numeric values in the question or answers, so quantitative accuracy is not applicable—no errors here. (3) The multi-hop reasoning is sound: the LLM synthesizes the shift in positioning with NVIDIA’s full-stack ecosystem, linking consumer-facing cloud gaming to enterprise AI and professional offerings like Omniverse and accelerated computing, which matches the ground truth’s emphasis on integration with DGX Cloud and the broader platform. (4) The only minor gap is that the LLM answer does not explicitly mention vGPU or the 2022 comparison with enterprise cloud platforms, which slightly reduces completeness in entity coverage. However, the core evolution in strategic positioning is accurately conveyed with richer technical detail. Wording differs but semantic meaning is equivalent and contextually appropriate. Hence, high scores across all dimensions with a 9 on correctness due to slight omission of 2022 comparative context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 380,
        "total_tokens": 1701
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did the revenue performance of Inlyta evolve between 2022 and 2023, and what factors influenced this change?",
      "original_answer": "In 2022, Inlyta had total global revenue of $1,003 million, while in 2023, its revenue increased to $1,036 million, representing a 3% growth. This growth was primarily driven by continued adoption of Inlyta in combination with immune checkpoint inhibitors for the first-line treatment of advanced renal cell carcinoma (RCC) in the U.S., and growth in emerging markets. However, this increase was partially offset by lower volumes and lower net prices in certain European markets.",
      "llm_answer": "\nInlyta’s worldwide revenue rose modestly from about **$1.00 billion in 2022 to $1.04 billion in 2023** (≈3–5 % growth). The increase was driven primarily by stronger uptake of Inlyta in combination with immune‑checkpoint inhibitors for first‑line treatment of advanced renal‑cell carcinoma in the United States and continued expansion in emerging markets, although this was partially offset by lower volumes and price reductions in certain European markets.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the revenue figures for Inlyta in 2022 and 2023, reporting approximately $1.00 billion and $1.04 billion, respectively. The ground truth specifies $1,003 million (i.e., $1.003 billion) in 2022 and $1,036 million ($1.036 billion) in 2023. The LLM's rounding to $1.00B and $1.04B is acceptable and common in financial reporting. The stated growth of '≈3–5%' slightly overestimates the exact 3% growth (calculated as (1,036 - 1,003)/1,003 ≈ 3.3%), but '≈3–5%' is a reasonable approximation and not factually incorrect. (2) All key qualitative factors influencing revenue change are accurately identified: increased U.S. adoption in combination with immune checkpoint inhibitors for first-line advanced RCC treatment, growth in emerging markets, and offsetting pressures from lower volumes and prices in Europe. (3) The multi-hop reasoning is sound—synthesizing revenue data across two years and integrating causal factors from different geographic markets. (4) The answer is semantically equivalent to the original, with minor rounding and phrasing differences that do not affect factual correctness. Thus, the answer is highly accurate, with only a slight deduction in quantitative accuracy due to the growth rate approximation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1225,
        "completion_tokens": 358,
        "total_tokens": 1583
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has the treatment and valuation of network location intangibles evolved from 2023 to 2024, particularly in terms of amortization assumptions and impairment review processes?",
      "original_answer": "In 2023, the company amortized network location intangibles on a straight-line basis over their estimated useful lives, with a weighted average amortization period of 15 years as of December 31, 2023. The focus was on the relationship between these intangibles and tower assets, particularly in terms of potential revenue growth from leasing excess capacity. By 2024, the company expanded its disclosures to include a more detailed impairment review process for network location intangibles, assessing impairment on an individual tower basis and identifying specific triggers such as lack of tenant leases or expenses exceeding revenues. Additionally, while amortization remained a key treatment, the company's broader discussion of asset retirement obligations in 2024, including a $470 million increase in liability due to revised settlement dates, indirectly impacts the valuation and useful life assumptions for these intangible assets.",
      "llm_answer": "\nFrom 2023 to 2024 the Company lengthened the amortization horizon for its network‑location intangibles—now tying them to the 30‑year useful life of towers and applying straight‑line amortization over that period, which reduced annual amortization expense (the weighted‑average amortization period is still reported around 15 years but is effectively extended). At the same time, the impairment review was sharpened to test each tower‑level intangible for recoverability using projected undiscounted cash flows and market‑based fair‑value comparisons, although the only intangible‑related impairments recorded in 2023 were the $322 M (India) and $80 M (Spain) goodwill charges, with no new network‑location intangible impairments reported in 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. The claim that the company 'lengthened the amortization horizon' to 30 years in 2024 is incorrect — the original answer states that amortization remained on a straight-line basis with a weighted average period of 15 years as of 2023, with no mention of extending it to 30 years. The LLM incorrectly implies a change in amortization period that is not supported by the ground truth. Additionally, the LLM introduces $322M (India) and $80M (Spain) goodwill impairments as 'intangible-related impairments,' but the original answer does not mention these figures or link them to network location intangibles; instead, it states there was no specific discussion of such impairments, but rather an enhanced process in 2024 focused on triggers like lack of leases or negative cash flow. These numbers are entirely fabricated in context. (2) Quantitative accuracy is low: the $322M and $80M figures are not in the original answer, and while the original mentions a $470 million increase in asset retirement obligations in 2024, the LLM omits this key number entirely. The 15-year weighted average amortization period is correctly cited, but the interpretation that it is 'effectively extended' is unsupported. (3) The multi-hop reasoning is partially sound — the LLM attempts to connect amortization treatment and impairment reviews across years — but fails to accurately represent the evolution described in the original. It invents a 30-year linkage to tower assets and introduces irrelevant goodwill impairments, breaking the logical chain. (4) Contextual relevance is high because the response addresses both amortization and impairment review processes and attempts to compare 2023 and 2024. However, due to significant factual and quantitative errors, especially the introduction of false numbers and incorrect assumptions about amortization period changes, the overall correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1429,
        "completion_tokens": 529,
        "total_tokens": 1958
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has ExxonMobil's strategic emphasis on Guyana evolved between 2023 and 2024, particularly in terms of its upstream growth portfolio and production capacity?",
      "original_answer": "In 2023, ExxonMobil highlighted Guyana as a key component of its upstream growth portfolio, noting four additional discoveries on the Stabroek Block and the startup of the Prosperity FPSO vessel, which brought production to nearly 440 kbd in the fourth quarter. By 2024, Guyana was formally categorized under 'Advantaged Assets' within the updated earnings drivers, reflecting its strategic elevation alongside the Permian and LNG projects as a core contributor to earnings through volume/mix growth. This shift indicates a transition from a discovery and early production phase in 2023 to a more mature, financially impactful asset in 2024.",
      "llm_answer": "\nBetween 2023 and 2024 ExxonMobil shifted from confirming the size of the Stabroek Block to actively developing it—four new discoveries were made in 2023 and the Prosperity FPSO reached name‑plate capacity in January 2024. The company now plans to have six FPSO vessels on the block by the end of 2027 and is seeking regulatory approval for a sixth project (Whiptail), positioning Guyana as a core component of its upstream growth portfolio and a key driver of rising oil‑equivalent production.",
      "correctness_score": 7,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures key elements of ExxonMobil's strategic evolution in Guyana between 2023 and 2024, including the four discoveries in 2023 and the startup of the Prosperity FPSO. However, it states that the Prosperity FPSO reached name-plate capacity in January 2024, while the ground truth specifies that production reached nearly 440 kbd in Q4 2023, with no mention of January 2024 as a milestone. This introduces a minor timing inaccuracy. Additionally, the LLM mentions plans for six FPSOs by 2027 and regulatory approval for Whiptail, which are factually consistent with ExxonMobil’s trajectory but not explicitly confirmed in the provided ground truth, making them plausible but unverified additions. (2) Quantitatively, the four discoveries in 2023 are correctly noted, and the production figure of ~440 kbd in late 2023 is indirectly acknowledged via the FPSO startup, though the LLM does not explicitly state the 440 kbd figure. The absence of this specific number and the imprecise timing of the capacity achievement reduce quantitative accuracy. (3) The multi-hop reasoning is generally sound—linking 2023 discoveries to 2024 development and strategic elevation—but misses the key qualitative shift in ExxonMobil’s internal classification of Guyana as an 'Advantaged Asset' in 2024, which is central to the ground truth. This omission reduces completeness and conceptual precision. (4) Despite missing the 'Advantaged Assets' reclassification and specific production figures, the LLM conveys the overall strategic elevation of Guyana in the upstream portfolio and correctly frames it as a core growth driver. Wording differs but meaning partially aligns. Hence, correctness is scored at 7 due to missing key details and minor factual inaccuracies, though the core narrative is directionally accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 496,
        "total_tokens": 1784
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has the X1 platform's integration with third-party streaming services evolved between 2022 and 2023, and what does this evolution indicate about Comcast's strategy in reducing cord-cutting and increasing average revenue per user (ARPU)?",
      "original_answer": "In 2022, the X1 platform integrated third-party streaming services such as Disney+ and Netflix, and provided access to Peacock's premium tier, with Comcast earning commission revenue from the sale of these services. By 2023, the X1 platform continued to support third-party integrations but now included Xumo Play, NBC, and Sky as part of the NOW TV service, which was specifically marketed to residential broadband customers. This expansion indicates a strategic pivot toward enhancing the value of broadband subscriptions and bundling streaming access to retain customers and potentially increase ARPU through deeper content integration and commission-generating partnerships.",
      "llm_answer": "\nBetween 2022 and 2023 Comcast moved the X1 platform from the Flex streaming device—limited to Peacock‑premium and a few third‑party apps on a commission basis—to the Xumo Stream Box (formerly Flex) and the launch of the box‑free NOW service, which directly integrates a wider range of DTC services (e.g., Peacock, Disney+, Netflix) and free streaming channels into the X1 user experience.  This deeper integration lets Comcast keep subscribers inside its own ecosystem, slowing cord‑cutting and generating additional revenue streams (commissions and upsold streaming tiers) that boost average revenue per user.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent in terms of dates (2022–2023 evolution) and correctly identifies key third-party streaming services integrated into the X1 platform, including Disney+, Netflix, and Peacock, as well as commission-based revenue models. It accurately reflects Comcast's strategic intent to reduce cord-cutting and increase ARPU through ecosystem retention and revenue from partnerships. However, there are notable discrepancies in entity accuracy and reasoning: the LLM incorrectly frames the evolution as a transition from 'Flex streaming device' to 'Xumo Stream Box' and 'NOW service', which is not supported by the ground truth. The original answer specifies that in 2023, Xumo Play, NBC, and Sky were integrated as part of NOW TV service for broadband customers, but the LLM misrepresents the device transition and overemphasizes a 'box-free NOW service' not mentioned in the ground truth. Additionally, the original answer highlights a strategic pivot toward enhancing broadband value through bundling, while the LLM focuses more on device shifts than the broader service integration strategy. Despite these issues, the core financial and strategic logic—deeper integration to retain users and generate commission revenue—is sound and contextually relevant. No numerical inaccuracies are present, hence perfect quantitative accuracy. The answer is semantically close but misses precise entity and platform evolution details, warranting a 7 for correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 412,
        "total_tokens": 1758
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has Caterpillar's relationship with FG Wilson evolved between 2023 and 2024 in terms of its distribution network coverage for electric power generation systems?",
      "original_answer": "In 2023, FG Wilson's electric power generation systems were distributed through a network of 110 distributors covering 109 countries. By 2024, this distribution network had slightly contracted to 108 distributors, now covering 158 countries. This indicates a minor reduction in the number of distributors but an expansion in the geographic reach of the network. The change suggests a strategic shift toward optimizing distributor efficiency while broadening market access.",
      "llm_answer": "\nBetween 2023 and 2024 Caterpillar trimmed the FG Wilson distributor base from **110 to 108** dealers, yet expanded the geographic reach of that network from **109 to 158 countries**.  This reflects a shift toward a more concentrated dealer lineup that still broadens market coverage for FG Wilson‑branded electric‑power‑generation systems.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) Quantitatively, all numbers are correct: the reduction from 110 to 108 distributors and expansion from 109 to 158 countries is accurately reported. No calculation errors. (2) The answer addresses all parts of the question—evolution of Caterpillar's relationship with FG Wilson in terms of distribution network coverage for electric power generation systems—by highlighting the change in distributor count and geographic reach. (3) Entity accuracy is strong: Caterpillar, FG Wilson, and the relevant time frame (2023–2024) are correctly identified. (4) The reasoning is sound: the model correctly infers a strategic shift toward concentration and broader market coverage, though it does not explicitly mention 'optimizing distributor efficiency' as in the original, which slightly reduces qualitative completeness. However, the semantic meaning and implication are equivalent. Wording differs but meaning aligns. Minor omission of the explicit 'strategic shift' terminology does not detract from factual correctness. Overall, the answer is factually complete, contextually relevant, and quantitatively precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1207,
        "completion_tokens": 338,
        "total_tokens": 1545
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How did Capital One's exposure to securitized debt obligations change between 2022 and 2024, particularly in terms of the carrying value and fair value of these obligations?",
      "original_answer": "In 2022, Capital One reported that the assets and liabilities of consolidated VIEs, including securitized debt obligations, were primarily composed of loan receivables and debt securities issued by the VIEs, with the liabilities reported under 'securitized debt obligations' on the consolidated balance sheets. By 2024, the carrying value of 'Securitized debt obligations' was $18,043 million, with a fair value of $18,067 million, all categorized under Level 2 of the fair value hierarchy. This indicates that Capital One maintained a significant exposure to securitized debt obligations, with a slight increase in fair value relative to carrying value, suggesting stable valuation and continued involvement in securitization activities.",
      "llm_answer": "\nBased on the 2022 10‑K (pages 177‑181) Capital One reported a carrying amount of securitized debt obligations of roughly **$15 billion** (with a fair‑value estimate of about **$15.2 billion**). In the 2024 10‑K (pages 218‑222) that carrying amount had fallen to **$14.264 billion**, and the fair‑value estimate to **$14.335 billion**. Thus, between 2022 and 2024 the exposure to securitized debt obligations declined modestly on both the recorded carrying value and the estimated fair value.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both quantitative and qualitative aspects. (1) Quantitative Accuracy: The ground truth states that in 2024, the carrying value of securitized debt obligations was $18,043 million ($18.043 billion), with a fair value of $18,067 million ($18.067 billion). The LLM incorrectly reports these as $14.264 billion and $14.335 billion, respectively. For 2022, the LLM claims a carrying value of $15 billion and fair value of $15.2 billion, but the original answer does not provide exact 2022 figures—only a qualitative description—and no such numbers are present in the ground truth. Thus, the LLM fabricates specific numerical values not supported by the source. (2) Completeness: While the question asks about changes between 2022 and 2024 in both carrying and fair value, the LLM invents precise numbers for 2022 that are not in the original answer and misreports the 2024 figures, failing to reflect the actual data. (3) Entity Accuracy: The company (Capital One) and metric (securitized debt obligations) are correctly identified, and the years (2022, 2024) are correct. (4) Reasoning: The LLM concludes that exposure 'declined modestly', but the ground truth indicates a continuation of significant exposure with a slight increase in fair value relative to carrying value—implying stability or possible growth, not decline. This misrepresents the trend. (5) Semantic Equivalence: The overall message contradicts the original—decrease vs. stable/maintained exposure—and uses false precision. The contextual relevance is moderate because it addresses the right topic and structure, but factual inaccuracies severely undermine correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 455,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has McDonald's use of line of credit agreements evolved between 2023 and 2024 in relation to its financing activities and cash flow management?",
      "original_answer": "In 2023, McDonald's cash used for financing activities totaled $4.4 billion, a decrease of $2.2 billion compared to 2022, primarily due to increased bond issuances. The company's cash and equivalents balance was $4.6 billion at the end of 2023, reflecting sufficient liquidity supported by cash from operations and access to commercial paper borrowings and line of credit agreements. In 2024, cash used for financing activities increased to $7.5 billion, a rise of $3.1 billion compared to 2023, driven by decreased bond issuances. The company's cash and equivalents balance dropped to $1.1 billion at year-end 2024, with the prior year's higher balance attributed to the timing of debt issuances that funded 2024's required cash outflows. The company continued to rely on its line of credit agreements and commercial paper to meet short-term funding needs. This indicates a shift from surplus liquidity and bond financing in 2023 to a more cash-constrained environment in 2024, with greater reliance on existing credit facilities.",
      "llm_answer": "\nBetween 2023 and 2024 McDonald’s refreshed its short‑term financing structure: the $15 bn borrowing authority that had been approved in 2022 was terminated and replaced with a new $15 bn multi‑year credit facility effective 2025, while the existing $4 bn committed line‑of‑credit was retained and continues to be the primary source for meeting day‑to‑day cash‑flow needs.  This line of credit, together with the commercial‑paper program, helped the company cover the rise in cash used for financing activities—$7.5 bn in 2024 versus $4.4 bn in 2023—as bond issuances declined, ensuring that financing outflows could still be funded without disrupting operations.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains several factual inaccuracies that significantly undermine its correctness. (1) The claim that McDonald's terminated its $15B borrowing authority and replaced it with a new $15B multi-year credit facility 'effective 2025' is not supported by the ground truth and introduces information not present in the original answer—specifically, no mention of a 2025 facility or termination of prior agreements exists in the ground truth. (2) The original answer does not state any structural changes to credit facilities between 2023 and 2024; instead, it emphasizes continuity in reliance on existing line of credit and commercial paper programs. (3) The quantitative data on cash used for financing activities—$4.4B in 2023 and $7.5B in 2024—is correctly reported, as is the contrast between decreased bond issuances in 2024 contributing to higher financing outflows. This supports a partial quantitative accuracy score. (4) The drop in cash and equivalents from $4.6B (2023) to $1.1B (2024), a key indicator of tightening liquidity, is omitted entirely in the LLM answer, which fails to mention the declining cash balance—a central point in the original answer’s conclusion about increased reliance on credit lines. (5) While the LLM correctly identifies that line of credit and commercial paper were used to meet short-term needs amid reduced bond issuance, it fabricates a refinancing event (the 2025 facility) that distorts the actual evolution of credit usage. (6) The reasoning is partially sound in linking increased financing outflows and reduced bond issuance to greater reliance on credit facilities, but the fabricated structural change breaks the multi-hop logic and leads to an incorrect narrative. (7) Contextually, the answer addresses financing activities and cash flow management relevance, hence a decent contextual relevance score. Overall, core financial figures are accurate, but critical omissions and invented details result in a partially incorrect synthesis, warranting a correctness score of 4.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1423,
        "completion_tokens": 544,
        "total_tokens": 1968
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has the role of the Worldwide Business Conduct Manual in reinforcing internal controls evolved between 2022 and 2024, and what does this indicate about Procter & Gamble's approach to governance?",
      "original_answer": "In 2022, the Worldwide Business Conduct Manual was described as reinforcing the company's commitment to conducting business with integrity and within the letter and spirit of the law, emphasizing its role in supporting internal controls through policies, segregation of duties, and employee development. In 2024, while the core description remained similar, the manual was more specifically tied to governance frameworks such as the oversight activities of the Global Leadership Council and the responsibilities of the Disclosure Committee in evaluating significant business activities. This indicates a shift toward emphasizing structured governance mechanisms alongside ethical conduct, suggesting a more integrated approach to internal control over time.",
      "llm_answer": "\nThe Worldwide Business Conduct Manual shifted from a broad‑brush statement of commitment in the 2022 filing to a concrete, system‑level component of P&G’s control framework in the 2024 filing—explicitly linking the Manual to written policies, segregation of duties, the annual Control Self‑Assessment program, and the oversight functions of the Global Leadership Council, Disclosure Committee and Audit Committee.  This evolution shows that P&G now treats the Manual as a central, risk‑based governance tool that embeds ethical conduct and control discipline across the enterprise, reinforcing a proactive and transparent approach to internal‑control oversight.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: the 2022 description emphasizes commitment to integrity, policies, segregation of duties, and employee development; the 2024 evolution ties the Manual more explicitly to governance bodies like the Global Leadership Council and Disclosure Committee. The LLM correctly identifies these entities and their roles. (2) There are no numeric values, dates, or calculations in the question or answers, so quantitative accuracy is not applicable—scored as 10 by default. (3) The multi-hop reasoning is sound: the model synthesizes changes in the Manual’s role across two years and infers a strategic shift toward integrated governance. The LLM adds value by referencing the Control Self-Assessment program and Audit Committee, which are consistent with the direction of the ground truth and reflect plausible extensions of the governance framework, though the original answer does not explicitly mention the Audit Committee or the Self-Assessment program. This minor addition does not contradict but slightly extends the source, which keeps the answer within acceptable bounds of inference. (4) The semantic meaning fully captures the evolution and its implications—shifting from ethical commitment to a system-level governance tool—demonstrating strong contextual relevance and qualitative accuracy. The answer is slightly more detailed than the original but remains factually aligned. Hence, a correctness score of 9 is warranted, with full marks for contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 431,
        "total_tokens": 1799
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Exxon's strategic positioning in Guyana evolved between 2023 and 2024, as reflected in its long-lived asset disclosures and earnings driver definitions?",
      "original_answer": "In 2023, Exxon disclosed $9,689 million in long-lived assets in Guyana, indicating it was already a significant contributor among non-U.S. assets. By 2024, Guyana was explicitly named as part of Exxon's 'Advantaged Assets' under the new 'Advantaged Volume Growth' earnings driver, which includes key growth projects like Guyana and LNG. This evolution shows that Guyana transitioned from being a quantitatively notable asset in 2023 to a strategically emphasized growth engine in 2024.",
      "llm_answer": "\nBetween 2023 and 2024 Exxon’s long‑lived‑asset schedule shows Guyana‑related assets jump from **$6.8 bn to $9.7 bn**, signalling a marked rise in capital investment and production capacity in that basin.  In the 2024 earnings‑driver framework the company explicitly groups Guyana (together with Permian and LNG) under “Advantaged Assets,” positioning it as a core, high‑return growth pillar, and the surge in PP&E additions (including the non‑cash Pioneer acquisition) reinforces this strategic shift toward Guyana as a central element of Exxon’s upstream growth strategy.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "(1) The LLM answer contains significant quantitative inaccuracies: it states Guyana-related assets increased from $6.8 billion in 2023 to $9.7 billion in 2024, while the ground truth reports $9,689 million (i.e., $9.689 billion) in 2023—meaning there was no increase from 2023 to 2024 as implied, and the starting value is incorrect. The $6.8 billion figure does not appear in the ground truth and is factually wrong. (2) The qualitative elements are mostly accurate: the LLM correctly identifies that in 2024, Guyana was grouped under 'Advantaged Assets' within the 'Advantaged Volume Growth' earnings driver, alongside Permian and LNG, reflecting a strategic elevation. This aligns with the ground truth’s characterization of Guyana becoming a strategically emphasized growth engine. (3) The multi-hop reasoning is partially sound—the model connects asset disclosures with earnings driver reclassification, showing synthesis across financial statements and strategic framing. However, the flawed asset numbers undermine the conclusion about a 'jump' in assets. (4) Contextually, the answer is relevant and addresses both parts of the question—asset disclosures and earnings driver definitions—though the incorrect numbers distort the evolution narrative. The mention of the 'Pioneer acquisition' is extraneous and not in the ground truth, introducing irrelevant information. Overall, core strategic reasoning is correct but undermined by critical numerical errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1268,
        "completion_tokens": 402,
        "total_tokens": 1670
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Capital One's reliance on securitized debt obligations as a funding source evolved from 2022 to 2024, based on the disclosed figures and descriptions?",
      "original_answer": "In 2022, Capital One identified securitized debt obligations as part of its diversified funding mix, which also included deposits, senior and subordinated notes, federal funds purchased, and FHLB advances. While no specific dollar value was disclosed in 2022, the company emphasized the strategic importance of securitized debt obligations in maintaining access to wholesale funding. By 2024, Capital One disclosed that its securitized debt obligations had a carrying value of $14,264 million and an estimated fair value of $14,335 million. This represents a concrete quantification of the instrument's role in the company's capital structure, showing an increased transparency and continued use of this funding source.",
      "llm_answer": "\nCapital One continued to treat securitized debt as a core funding source from 2022 through 2024, issuing $6.25 billion of such obligations in 2021 (the latest figure disclosed in the 2022 filing) and, after accounting for maturities, achieving a net $2.4 billion increase in total long‑term debt by the end of 2021 that was driven largely by securitization activity.  The company’s outstanding securitized‑debt balance rose to $14.3 billion by year‑end 2024, and its shelf‑registration filings still permit up to $25 billion of credit‑card and $20 billion of auto‑loan securitizations, indicating a stable but modestly expanded reliance on this funding channel compared with the 2022 baseline.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. The ground truth states that no specific dollar value for securitized debt obligations was disclosed in 2022, but the LLM incorrectly claims that $6.25 billion was issued in 2021 (with a net $2.4 billion increase in long-term debt), which is not supported by the provided original answer. Furthermore, the LLM states that the outstanding balance rose to $14.3 billion by end-2024, which is close to the ground truth carrying value of $14,264 million (i.e., $14.264 billion), so this figure is approximately correct (rounding to $14.3B is acceptable). However, the introduction of shelf-registration capacity ($25B for credit card, $20B for auto) is not mentioned in the original answer and thus introduces unverified information. (2) The calculation of a net $2.4 billion increase in long-term debt driven by securitization is not present in the ground truth and cannot be verified; no such calculation or attribution is made in the original answer. The use of 2021 data to infer 2022 baseline conditions is misleading, especially since the question focuses on 2022–2024 evolution. (3) The multi-hop reasoning is partially sound in that the model attempts to trace the evolution of securitized debt over time, but it fails to accurately represent the lack of disclosed figures in 2022 and fabricates supporting data. The conclusion of 'stable but modestly expanded reliance' is speculative and not directly supported by the original answer, which emphasizes increased transparency rather than expansion. (4) The contextual relevance is high because the answer addresses the evolution of securitized debt as a funding source and correctly identifies it as a continuing component of Capital One’s funding mix. However, due to major quantitative inaccuracies and unsupported claims, the correctness score is low. The qualitative accuracy is moderate because the general direction (continued use, increased disclosure) aligns with the original, but reasoning is flawed. Quantitative accuracy is poor due to incorrect figures and unsupported calculations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 580,
        "total_tokens": 1936
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has NVIDIA's Omniverse platform evolved in terms of its positioning and enterprise adoption between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, Omniverse was described as 'real-time 3D design collaboration and virtual world simulation software' aimed at empowering creators to collaborate across leading design applications. By fiscal year 2023, Omniverse had evolved into a more robust enterprise-focused development platform and operating system for building virtual world simulation applications. It was made available as a software subscription for enterprise use and offered free for individual users, with industrial enterprises adopting its 3D and simulation technologies to digitalize complex physical assets and environments, including digital twins of factories and real-time 3D product configurators. This indicates a strategic shift from a creative collaboration tool to a broader enterprise simulation and digital twin platform.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2023 NVIDIA moved Omniverse from a newly introduced real‑time 3D collaboration and simulation platform (launched in 2022 as a free‑for‑individual service) to a fully‑monetized enterprise offering, positioning it as a subscription‑based software stack for building digital twins, industrial metaverses and collaborative design workflows.  During that period enterprise adoption accelerated sharply—automotive, industrial and design companies began using Omniverse (e.g., for DRIVE Sim vehicle‑simulation and Omniverse‑based cockpit development), the ecosystem of partners and developers expanded, and the platform’s subscription revenue grew as more large‑scale customers signed up for the enterprise tier.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of NVIDIA's Omniverse platform between fiscal years 2022 and 2023. (1) It correctly identifies the shift from a free, creator-focused collaboration tool in 2022 to a monetized, enterprise-oriented subscription platform in 2023. The description of Omniverse evolving into a platform for digital twins, industrial metaverses, and simulation aligns with the ground truth's emphasis on enterprise adoption for digital twins of factories and real-time 3D configurators. (2) There are no numeric values, dates, or financial figures in either answer that conflict—both correctly reference fiscal years 2022 and 2023, and while the LLM mentions 'subscription revenue grew,' this is a reasonable inference from 'offered as a software subscription for enterprise use' in the original. No calculations are required, and all temporal references are accurate. (3) The multi-hop reasoning is sound: the LLM synthesizes positioning changes and adoption trends across the two fiscal years, correctly inferring increased enterprise adoption and ecosystem expansion. It adds specific examples like DRIVE Sim and cockpit development, which are plausible and contextually consistent with the ground truth, though not explicitly mentioned in the original. (4) The only minor gap is that the original explicitly notes Omniverse was 'free for individual users'—a detail the LLM mentions ('free-for-individual service') but slightly less clearly in the context of the 2023 model. Overall, the answer is semantically equivalent, well-reasoned, and fully relevant to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 441,
        "total_tokens": 1826
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Pfizer's financial relationship with Viatris evolved between 2022 and 2023, particularly in terms of net amounts due under their various agreements?",
      "original_answer": "In 2022, the net amounts due to Viatris under the agreements were $94 million as of December 31, 2022. By 2023, this amount had decreased to $33 million as of December 31, 2023. This indicates a significant reduction in the net financial obligations between the two companies over the period, suggesting a winding down or stabilization of transitional financial arrangements established post-separation.",
      "llm_answer": "\nBetween 2022 and 2023 the inter‑company balance that Pfizer held under the post‑spin‑off agreements shifted from a modest receivable to a small payable.  At December 31 2022 Pfizer was owed **$94 million** from Viatris under the interim TSAs/MSAs, but by December 31 2023 the balance had reversed, with Pfizer **owing $33 million** to Viatris.  This decline (and eventual reversal) reflects the winding‑down of the transitional services and manufacturing arrangements that were established when the Upjohn business was spun off to form Viatris, with the related cash flows recorded in operating cash flow and the final settlement of those amounts.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $94 million amount due to Pfizer from Viatris as of December 31, 2022, and the $33 million amount due to Viatris from Pfizer as of December 31, 2023, which aligns with the ground truth in magnitude and direction of change. However, the original answer states that the net amounts were 'due to Viatris' in both years, while the LLM incorrectly frames the 2022 amount as Pfizer being owed (i.e., receivable), and 2023 as Pfizer owing (payable), implying a reversal in liability direction. The ground truth indicates that the amounts due *to Viatris* decreased from $94M to $33M — meaning Viatris was a net creditor in both years, not that the balance flipped from receivable to payable for Pfizer. This is a critical misinterpretation of the financial relationship. (2) Quantitatively, the numbers and dates are accurate ($94M and $33M, December 31, 2022 and 2023), satisfying numerical precision. (3) The multi-hop reasoning is partially sound — the model recognizes the post-separation context and infers winding-down transitional arrangements, which is consistent with the original answer. However, the flawed interpretation of the direction of cash flows undermines the reasoning: it incorrectly suggests a reversal in net position rather than a reduction in the same directional obligation. (4) Contextual relevance is high — the answer addresses the evolution of financial obligations and ties it to the spin-off context. Due to the significant error in interpreting who owes whom — a core aspect of the financial relationship — the correctness score is reduced to 6 despite accurate numbers and good contextual framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 458,
        "total_tokens": 1723
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has ExxonMobil's strategic emphasis on Guyana evolved between 2023 and 2024, and what specific changes in project activity or classification reflect this evolution?",
      "original_answer": "In 2023, ExxonMobil's operations in Guyana were characterized by active exploration and development, with 12.6 net exploratory and development wells completed, and key projects such as Payara, Yellowtail, and Uaru underway. By 2024, Guyana was formally classified as part of ExxonMobil's 'Advantaged Assets' under the 'Advantaged Volume Growth' earnings driver, signaling a strategic elevation of its importance alongside the Permian Basin and LNG. This reclassification reflects a shift from operational reporting to strategic prioritization, indicating increased emphasis on Guyana as a core growth asset.",
      "llm_answer": "\nBetween 2023 and 2024 ExxonMobil shifted Guyana from a frontier exploration target to a core, high‑return growth pillar.  In 2023 the focus was on securing a 4.6 million‑acre offshore position and drilling 12.6 net exploratory/development wells, culminating in the start‑up of the Payara development and the funding of the Uaru project; by 2024 those assets were classified as “Advantaged Assets” and featured in the “Advantaged Volume Growth” earnings driver, signalling that Guyana’s projects are now being treated as production‑ready, earnings‑driving components of the company’s strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in ExxonMobil's strategic emphasis on Guyana between 2023 and 2024. (1) Quantitatively, the 12.6 net exploratory and development wells in 2023 are correctly reported. However, the claim of securing a '4.6 million-acre offshore position' is not present in the ground truth and cannot be verified; this is a minor factual overreach or addition not supported by the original answer. All other numbers and classifications are correct. (2) The reclassification of Guyana into 'Advantaged Assets' under the 'Advantaged Volume Growth' earnings driver in 2024 is accurately reported and correctly framed as a strategic elevation. (3) The multi-hop reasoning is sound: the model correctly synthesizes operational activity in 2023 (wells, project developments) with the strategic reclassification in 2024, inferring a shift from exploration to core growth status. (4) Semantically, the LLM conveys the same strategic shift as the ground truth—elevating Guyana from active development to a prioritized, production-ready growth pillar alongside Permian and LNG—though it adds slightly more detail (e.g., 'frontier exploration target') not in the original. The answer fully addresses both parts of the question: evolution of strategy and specific changes in project activity/classification. The only deduction is for the unverified 4.6 million-acre claim, which may be contextually accurate but is not in the ground truth, lowering quantitative accuracy slightly. Otherwise, reasoning, entity accuracy (ExxonMobil, Guyana, Payara, Uaru, 2023–2024), and relevance are excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 443,
        "total_tokens": 1749
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did the weighted-average interest rate and face value of senior notes with maturities greater than 10 years evolve from 2022 to 2023?",
      "original_answer": "In 2022, the weighted-average interest rate for senior notes with maturities greater than 10 years was 3.67%, with a face value of $54.536 billion. In 2023, the interest rate remained unchanged at 3.8%, but the face value slightly decreased to $53.4 billion. This indicates a slight reduction in long-term debt in this category, while the interest rate stayed stable.",
      "llm_answer": "\nThe weighted‑average interest rate on Comcast’s senior notes that mature after 10 years was 3.8 % at the end of 2022 and remained 3.8 % at the end of 2023, so it was essentially unchanged.  At the same time, the outstanding face value of those notes grew from **$52.8 billion** (2022) to **$53.4 billion** (2023), an increase of about $0.6 billion (roughly 1 %).  This reflects a modest expansion in the size of the long‑dated debt issuance while the borrowing cost stayed flat.",
      "correctness_score": 4,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key numeric values. According to the ground truth, the 2022 weighted-average interest rate was 3.67%, not 3.8% as stated in the LLM answer. While the 2023 rate of 3.8% is correct, the claim that it remained unchanged from 2022 is false, as it actually increased from 3.67% to 3.8%. Additionally, the face value in 2022 is incorrect: the LLM reports $52.8 billion, whereas the ground truth is $54.536 billion. The 2023 face value of $53.4 billion is correct. (2) Calculations: The LLM incorrectly states that the face value increased by $0.6 billion, but with incorrect starting values. In reality, the face value decreased from $54.536B to $53.4B, a reduction of $1.136B (~2.1%), contradicting the LLM's claim of growth. (3) Multi-hop reasoning: The model correctly identifies the need to compare both interest rates and face values across 2022 and 2023 for senior notes with maturities over 10 years, showing appropriate conceptual understanding. However, due to incorrect data retrieval, the synthesis is flawed. (4) The contextual relevance is high because the structure and intent of the response match the question, and the qualitative reasoning about stability in rates and changes in debt size is logically framed—just based on wrong numbers. Thus, while the narrative flow is sound, the factual foundation is partially incorrect, leading to a correctness score of 4.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1209,
        "completion_tokens": 401,
        "total_tokens": 1610
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did the nuclear decommissioning trusts managed by Alabama Power and Georgia Power shift their domestic equity investment allocations and valuation methodologies between 2023 and 2024, particularly in terms of Level 1 and Level 2 input classifications?",
      "original_answer": "In 2023, Alabama Power reported $396 million in domestic equity investments under Level 1 inputs and $169 million under Level 2 inputs, totaling $565 million. Georgia Power reported $255 million in Level 1 and $1 million in Level 2, totaling $256 million. By 2024, Alabama Power’s domestic equity investments increased to $443 million in Level 1 and $208 million in Level 2, totaling $651 million. Georgia Power saw its Level 1 domestic equity investments rise to $321 million while Level 2 remained at $1 million, totaling $322 million. This indicates a strategic shift toward higher allocations in domestic equities, particularly through more actively traded (Level 1) instruments, which may reflect a more transparent or liquid investment approach in line with evolving trust management strategies.",
      "llm_answer": "\nIn 2023 the domestic‑equity holdings of the Alabama Power and Georgia Power nuclear decommissioning trusts were reported almost entirely under Level 2 (e.g., $443 million for Alabama Power and $321 million for Georgia Power) with only a small Level 3 component; by 2024 a portion of those equities was re‑classified as Level 1, showing that the trusts moved from valuation based primarily on significant observable inputs to using quoted market prices (Level 1) from external vendors, thereby reducing the relative weight of Level 2 inputs.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in terms of factual content. It claims that in 2023, Alabama Power and Georgia Power reported domestic equity investments 'almost entirely under Level 2', which directly contradicts the ground truth: in 2023, Alabama Power had $396M in Level 1 (not Level 2) and only $169M in Level 2, while Georgia Power had $255M in Level 1 and just $1M in Level 2. The LLM incorrectly states that Alabama Power had $443M in Level 2 in 2023, but $443M was actually Alabama Power's 2024 Level 1 amount. Similarly, it misattributes $321M to Georgia Power in 2023 as Level 2, but $321M is Georgia Power's 2024 Level 1 value. These are major factual and numerical errors. (2) All quantitative values cited by the LLM are wrong or misplaced across years and classification levels. There is no evidence in the ground truth that Level 3 inputs were involved, yet the LLM mentions a 'small Level 3 component', which is unsupported. The reclassification narrative (from Level 2 to Level 1) is backwards: both companies increased Level 1 holdings from 2023 to 2024, but they already had dominant Level 1 allocations in 2023, not Level 2. (3) The multi-hop reasoning is flawed: the model fails to correctly extract and compare the time-series data across companies and classification levels. It inverts the actual trend by suggesting a shift from Level 2 to Level 1 due to reclassification, when the real trend is growth in both Level 1 and Level 2 (especially Level 1), consistent with increased investment, not reclassification. (4) Despite the factual inaccuracies, the answer is contextually relevant—it addresses the right topic (nuclear decommissioning trusts, Level 1/Level 2 shifts, valuation methodologies) and attempts to interpret the strategic implication of moving toward more observable inputs. However, because the underlying data is completely incorrect, the reasoning and conclusion are invalid. Correctness and quantitative accuracy are severely penalized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 538,
        "total_tokens": 1901
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has NVIDIA's strategic positioning of CUDA evolved from 2022 to 2023 in terms of its role within the company's full-stack computing platform and its integration across different end markets?",
      "original_answer": "In 2022, CUDA was positioned as a fundamental building block of NVIDIA's accelerated computing platform, supporting a variety of end markets such as Gaming, Data Center, Professional Visualization, and Automotive through a unified underlying architecture. It was described as essential for leveraging GPU capabilities across these markets. By 2023, CUDA's role had evolved into being the foundational programming model within NVIDIA's full-stack computing infrastructure, extending its integration beyond traditional markets into domain-specific verticals such as healthcare, telecom, automotive, and manufacturing. Additionally, in 2023, CUDA was positioned as the base layer supporting hundreds of domain-specific software libraries, SDKs, and APIs, which were not explicitly emphasized in 2022. This indicates a strategic shift from CUDA being a foundational component to becoming the core enabler of a broader, more vertically integrated software stack aimed at accelerating deployment across computationally intensive workloads.",
      "llm_answer": "\nFrom 2022 to 2023 NVIDIA deepened CUDA’s role from a GPU‑programming model into the core of a **full‑stack computing platform** that spans data‑center, automotive, professional‑visualization and gaming markets.  The 2023 filing positions CUDA as the unifying software layer that ties together NVIDIA’s hardware (GPUs, DPUs, Grace CPUs), AI frameworks, Omniverse, and the DRIVE autonomous‑driving stack, enabling a single programmable architecture to serve diverse end‑markets and power everything from cloud AI services to real‑time 3D simulation.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of CUDA's strategic positioning from 2022 to 2023 as described in the ground truth. It correctly identifies that CUDA evolved from a foundational GPU programming model into the central, unifying software layer of NVIDIA's full-stack computing platform. The answer accurately reflects the integration across end markets (gaming, data center, automotive, professional visualization) and correctly emphasizes the expansion into domain-specific applications by referencing DRIVE, Omniverse, and AI frameworks. It also correctly conveys that CUDA ties together hardware (GPUs, DPUs, Grace CPUs) and software, supporting a unified architecture—aligning with the ground truth's emphasis on full-stack integration. The only minor omission is that the 2023 evolution's emphasis on CUDA enabling 'hundreds of domain-specific software libraries, SDKs, and APIs'—a key indicator of vertical software expansion—is not explicitly mentioned. However, the reference to AI frameworks, Omniverse, and DRIVE implies this broader software ecosystem. There are no numerical inaccuracies (quantitative accuracy is perfect as no numbers are misstated), and all entities (NVIDIA, CUDA, Omniverse, DRIVE, Grace CPUs, DPUs) are correctly identified with appropriate context. The reasoning is sound, demonstrating multi-hop synthesis across product lines and strategic shifts. The answer is fully contextually relevant, directly addressing the evolution in strategic positioning. Thus, the answer is semantically equivalent to the ground truth with only a slight gap in completeness regarding the explicit mention of SDKs/libraries, warranting a 9/10 on correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1407,
        "completion_tokens": 469,
        "total_tokens": 1876
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did Pfizer's financial obligations and contractual relationships with Viatris evolve from 2022 to 2023, particularly in terms of transitional service agreements and net amounts owed?",
      "original_answer": "In 2022, Pfizer disclosed that amounts recorded under transitional service agreements (TSAs) and master services agreements (MSAs) with Viatris were not material to operations, and the TSA services were largely completed by the end of 2022. By 2023, services under the TSAs were fully completed as of December 31, 2023, and the net amounts due to Viatris under the agreements decreased from $94 million in 2022 to $33 million in 2023. This reflects a reduction in intercompany financial obligations and the winding down of transitional support following the 2020 spin-off of the Upjohn Business into Viatris.",
      "llm_answer": "\nFrom 2022 to 2023 Pfizer’s transitional‑service agreements (TSAs) with Viatris were wound down – by the end of 2023 the TSAs were essentially completed, leaving only a modest $33 million balance (down from $94 million owed at the end of 2022).  The successor manufacturing and supply agreement (MSA) that replaced the TSAs remains in force for an initial three‑year term (with two‑year extensions), but Pfizer recorded no material amounts under either the TSAs or the MSA in 2023, indicating that the contractual financial obligations had largely been settled.  (Pages 67‑68 of the 2023 10‑K show the $33 million receivable as of 12/31/23, the $94 million balance as of 12/31/22, and note that TSAs were completed as of 12/31/23.)",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers and dates are correct: the $94 million balance as of December 31, 2022, and the reduction to $33 million as of December 31, 2023, are accurately reported. The claim that TSAs were completed as of December 31, 2023, matches the original answer. (2) The calculation of a $61 million decrease in net amounts owed is implied and correct, though not explicitly stated. (3) The qualitative reasoning is sound: the winding down of TSAs, the completion by end of 2023, and the non-materiality of amounts in 2023 are all correctly synthesized. The mention of the successor MSA (master services agreement) adds context not in the original answer but is consistent with plausible contractual evolution and does not contradict the ground truth. (4) The only minor deviation is the introduction of the MSA’s three-year term with extensions, which is not present in the original answer and cannot be verified from the provided ground truth. However, this does not undermine the core facts and may reflect additional filing details. Overall, the answer addresses all parts of the question—transitional service agreements, net amounts owed, and evolution from 2022 to 2023—with high fidelity. Semantic equivalence is maintained, and the citation of specific 10-K pages reinforces accuracy. Thus, a score of 9 is warranted due to the slight addition of unverified MSA term details, but quantitative and contextual accuracy remain excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 419,
        "total_tokens": 1764
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has the relationship between retail deregulation pressures and Duke Energy's environmental regulation compliance costs evolved from 2022 to 2023?",
      "original_answer": "In 2022, Duke Energy highlighted that retail deregulation could result in unrecovered costs, including those related to above-market purchased power commitments from qualifying facilities (QFs) under PURPA, which could hinder the recovery of environmental compliance costs through regulatory rate structures. By 2023, the company noted increased regulatory emphasis on environmental compliance, including EPA regulations on CO2 emissions and cooling water intake structures, as well as new state-level carbon reduction goals more aggressive than the company’s own plans. These developments suggest that deregulation pressures have compounded the challenge of recovering rising environmental compliance costs, as competitive market conditions limit the ability to pass on these expenses to customers.",
      "llm_answer": "\nFrom 2022 to 2023 the filings show that deregulation risk remained a stand‑alone threat to stranded‑cost recovery, but the 2023 filing explicitly ties that threat to the company’s growing environmental‑compliance burden.  In the 2022 10‑K (pages 26‑30) the risk discussion notes that deregulation could create unrecovered costs and that environmental rules require “significant capital expenditures” that could be “prohibitively expensive,” while the 2023 10‑K (pages 24‑28) expands this linkage by warning that new climate‑related and CCR‑related regulations will raise compliance costs and that “regulatory changes could also result in generation facilities being retired earlier,” thereby magnifying the financial impact if retail markets were to be deregulated.  Consequently, the relationship has evolved from two separate risk categories into a compounded exposure where deregulation pressures now amplify the cost of meeting stricter environmental standards.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the original ground truth. (1) All factual elements are correct: the 2022 filing identifies retail deregulation as a risk to cost recovery and notes environmental compliance requires significant capital, while the 2023 filing strengthens the linkage by showing how deregulation could amplify financial risks from rising environmental compliance costs and early retirements due to new regulations. The evolution from separate risks to a compounded exposure is correctly identified. (2) There are no numeric values (e.g., dollar amounts, percentages, dates) in either the original or LLM answer, so quantitative accuracy is not compromised—score is 10 by default. (3) Multi-hop reasoning is sound: the LLM synthesizes information across two years of 10-K filings, correctly identifying the shift in Duke Energy’s risk framing. It references specific pages (26–30 in 2022, 24–28 in 2023), which adds precision, though the ground truth does not require page numbers. The only minor shortcoming is that the LLM does not explicitly mention PURPA or state-level carbon goals being more aggressive than Duke’s plans—details present in the original. However, the core synthesis about compounding risks is preserved. (4) Contextual relevance is excellent: the answer directly addresses how the relationship evolved, uses appropriate financial and regulatory terminology, and maintains focus on Duke Energy, retail deregulation, and environmental compliance costs. The slight omission of PURPA and state-level ambition prevents a perfect 10, but the answer remains substantially correct and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1442,
        "completion_tokens": 449,
        "total_tokens": 1891
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How did the retail share of Skoal oral tobacco products change between 2023 and 2024, and how does this contrast with the pricing strategy applied to Skoal during 2023?",
      "original_answer": "The retail share of Skoal oral tobacco products decreased from 9.3% in 2023 to 7.6% in 2024, reflecting a decline in market presence. This contrasts with the pricing strategy in 2023, where multiple price increases were applied to Skoal products, including a $0.11 per can increase effective January 23, 2024 (announced in 2023), following earlier increases of $0.09, $0.09, and $0.08 per can in May, February, and January 2022, respectively. The cumulative effect of these increases may have impacted consumer demand, contributing to the drop in retail share.",
      "llm_answer": "\nBetween 2023 and 2024 Skoal’s retail‑share slipped from about **9.3 % to 7.6 %** (a decline of roughly 1.7 percentage points).  This erosion took place even though Altria/USSTC kept raising Skoal’s list price throughout 2023—​$0.09‑$0.10 per‑can increases were applied in January, April, July and August—so the price hikes did not stop the share loss.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM correctly identifies the decline in Skoal's retail share from 9.3% in 2023 to 7.6% in 2024, which matches the ground truth. However, the pricing details are partially inaccurate: the LLM claims four price increases in 2023 (January, April, July, August) of $0.09–$0.10 per can, but the ground truth states that the 2023-announced price increase was $0.11 effective January 23, 2024, and that prior increases occurred in 2022 (not 2023). Thus, the LLM incorrectly assigns recent price hikes to 2023 and misrepresents their amounts and timing.\n\n2) Quantitative accuracy is compromised: while the 9.3% to 7.6% drop is correct (1.7 percentage point decline), the dollar amounts and dates of price increases are wrong. The ground truth specifies a single 2023-announced increase ($0.11) effective in early 2024, not multiple 2023 increases. The LLM invents four 2023 increases not present in the source, with approximate values that do not align.\n\n3) Qualitatively, the reasoning is sound in noting a contrast between declining market share and aggressive pricing, which aligns with the ground truth’s implication that price increases may have hurt demand. The synthesis of market performance versus pricing strategy is logically valid, even if the pricing data is flawed.\n\n4) Contextual relevance is excellent—the response directly addresses both parts of the question: the change in retail share and its contrast with pricing strategy. It attempts multi-hop reasoning by linking pricing actions to market outcomes, though based on incorrect data.\n\nOverall, the core fact (share decline) is correct and the conceptual contrast is well-framed, but significant errors in pricing details reduce quantitative accuracy, warranting a score of 7 for overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1233,
        "completion_tokens": 480,
        "total_tokens": 1714
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How did Amgen's investment in 'Other short-term interest-bearing securities' evolve between 2023 and 2024, and what does this indicate about the company's short-term investment strategy?",
      "original_answer": "Amgen's investment in 'Other short-term interest-bearing securities' remained unchanged at $138 million in both 2023 and 2024. This stability suggests that the company maintained a consistent approach to this segment of its short-term investment portfolio over the two-year period.",
      "llm_answer": "\nBetween 2023 and 2024 Amgen’s “other short‑term interest‑bearing securities” fell modestly from $138 million to $135 million (about a 2 % decline).  The reduction is part of a broader reallocation of its short‑term cash into larger money‑market fund and Treasury‑bill positions, signalling that the company is trimming its exposure to that specific instrument in favor of more liquid, lower‑risk investments.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that Amgen's investment in 'Other short-term interest-bearing securities' decreased from $138 million to $135 million. The ground truth confirms the amount remained unchanged at $138 million in both years. This fundamental error undermines the entire response. (2) The quantitative inaccuracies are severe: the claimed $3 million decrease and 2% decline are both false. The correct data shows no change, so any calculation based on a reduction is invalid. (3) The reasoning is flawed because it infers a strategic reallocation from a non-existent decline. While the idea of shifting to more liquid instruments could be plausible, it is not supported by the data provided in the ground truth, which indicates stability, not reallocation. The model introduces unverified claims about broader portfolio changes not present in the source. (4) Despite the factual errors, the answer is contextually relevant—it addresses the right metric, company, and time frame, and attempts to interpret strategic implications, which aligns with the question's intent. However, the core factual inaccuracy in numbers and trend severely limits correctness. Minor formatting like '$138 million' is acceptable, but directional changes must be accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1182,
        "completion_tokens": 362,
        "total_tokens": 1544
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the nature of General Dynamics' involvement in Abrams Main Battle Tank Upgrades evolved from 2022 to 2024, particularly in terms of contract scope and value?",
      "original_answer": "In 2022, General Dynamics received a $360 million contract from the Army for Abrams main battle tank upgrades, mission control units, and systems technical support. By 2024, the company's involvement had evolved to include both production and support services, as evidenced by a $350 million contract for Abrams upgrades, engineering and logistics support, and system and sustainment technical support services. Additionally, a separate $285 million contract was awarded for producing Abrams tanks in the SEPv3 configuration for Romania. This indicates a shift from primarily upgrade-focused contracts to a broader scope that includes both upgrades and production of new configurations, with an increase in total contract value.",
      "llm_answer": "\nFrom FY 2022 through FY 2024 General Dynamics’ Abrams‑upgrade work shifted from a relatively narrow $360 million contract that covered only tank upgrades and mission‑control units to a larger, $350 million (plus option) award that now includes engineering, logistics and sustainment support services.  This expanded scope is reflected in the Combat Systems segment’s total estimated contract value, which rose from $6.2 billion at the end of 2023 to $8.6 billion at the end of 2024, indicating a broader and higher‑value involvement in Abrams upgrades.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies. While it correctly identifies a $360 million contract in 2022 for Abrams upgrades and related work, it misrepresents the 2024 contract value and scope. The LLM states a '$350 million (plus option)' contract but omits the key fact that in 2024, General Dynamics received not one but two major contracts: a $350 million contract for upgrades and support services, and a separate $285 million contract for producing Abrams SEPv3 tanks for Romania. The LLM fails to mention the Romania production contract entirely, which is a significant omission in assessing the evolution of contract scope and value. Additionally, the LLM introduces figures not present in the ground truth—namely, the Combat Systems segment’s total estimated contract value rising from $6.2 billion to $8.6 billion—which are unsupported by the original answer and likely conflated from other data. (2) Quantitative accuracy is compromised: while $360M and $350M figures are correct, the $285M Romania contract is missing, and the $6.2B/$8.6B figures are incorrect and not part of the ground truth. There is no indication in the original answer that the $350M contract had an option. (3) The reasoning partially captures the evolution in scope—from upgrades to include support services—but fails the full multi-hop synthesis by missing the shift into new production (SEPv3 for Romania), which is central to the scope expansion. The conclusion about increased total value is plausible but based on incorrect aggregate data. (4) Contextual relevance is high as the answer addresses the evolution of contract scope and value over time, but factual correctness is undermined by omissions and extraneous, inaccurate figures. The core idea of broadening scope is partially correct, but completeness and quantitative accuracy drag down the overall score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 507,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How did AIG's financial relationship with Corebridge evolve from 2023 to 2024, particularly in terms of borrowing arrangements and income recognition?",
      "original_answer": "In 2023, AIG disclosed that Corebridge had the ability to continue borrowing through February 25, 2025, indicating an ongoing financial arrangement. By 2024, AIG's relationship with Corebridge had transformed, as AIG began recognizing equity method income tied to Corebridge’s stock price changes and dividends received since June 9, 2024. This shift reflects a change from a borrowing-based relationship to one focused on equity-based returns.",
      "llm_answer": "\nFrom 2023 to 2024 AIG moved from being the primary guarantor of Corebridge’s borrowing – providing a reimbursement guarantee, collateral‑backed support and directly issuing debt on Corebridge’s behalf (e.g., the DDTL facility and Corebridge senior notes) – to a passive equity holder after Corebridge was de‑consolidated on June 9 2024.  Consequently, AIG no longer records Corebridge’s debt on its balance sheet; instead it recognizes income from the retained equity‑method investment (dividends and fair‑value changes, $601 million in 2024) and from the sale of Corebridge shares ($282 million gain in Q4 2024), while the earlier guarantee and collateral obligations now apply only to any remaining limited exposure.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and provides a detailed, correct evolution of AIG's financial relationship with Corebridge from 2023 to 2024. (1) It correctly identifies the shift from a borrowing/guarantee-based relationship in 2023 to an equity-method investment in 2024, with de-consolidation occurring on June 9, 2024—matching the ground truth date. (2) Quantitatively, it introduces two specific figures not in the original answer: $601 million in equity-method income and a $282 million gain from share sales in Q4 2024. While these numbers are plausible and consistent with public filings, they are not present in the ground truth, which does not mention specific income amounts. This introduces a minor over-precision but does not contradict known facts. The date June 9, 2024, is correctly cited. (3) The multi-hop reasoning is sound: the model synthesizes the end of direct borrowing support, removal of Corebridge debt from AIG’s balance sheet, and the start of equity-method accounting including dividends and fair value changes. It accurately reflects the transformation from guarantor to equity holder. (4) The answer exceeds the original in detail and context (e.g., mentioning DDTL facility, reimbursement guarantees), but all added information is factually consistent with SEC filings. The core shift described—borrowing to equity income—is fully aligned with the ground truth. Minor deduction in quantitative accuracy only because it adds specific dollar figures not in the verified truth, though they are not implausible.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 422,
        "total_tokens": 1713
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has Tesla's approach to the Solar Roof product evolved between 2022 and 2024, particularly in terms of production challenges and strategic dependencies?",
      "original_answer": "In 2022, Tesla was actively selling the Solar Roof and improving installation efficiency through collaboration with real estate developers and builders. The company emphasized its engineering efforts to combine aesthetics, durability, and power generation. By 2024, however, Tesla's 10-K highlights that the future of the Solar Roof (alongside other products) 'depends in large part' on overcoming production ramp challenges, including bottlenecks, supplier risks, and cost control. This reflects a shift from product development and sales emphasis to a more complex production and dependency landscape.",
      "llm_answer": "\nBetween 2022 and 2024 Tesla shifted the Solar Roof from a pilot‑scale, installer‑dependent offering to a more vertically‑integrated, builder‑partnered rollout that relies on its own in‑house glass‑tile production and tighter integration with Powerwall and its proprietary solar‑inverter; however, the product still hinges on a limited set of high‑purity glass suppliers and on the same battery‑cell supply chain that underpins its energy‑storage business.  Early‑stage production bottlenecks—particularly low yields in stamping and curing the solar tiles and the need for custom installation hardware—slowed deployment in 2022, and while 2024 saw added automation and sequential design changes that improved yields and reduced installation time, the company continues to depend on those specialized suppliers and on the scaling of its battery‑cell manufacturing to meet demand.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in its qualitative description of Tesla's evolving approach to the Solar Roof between 2022 and 2024, with accurate emphasis on production challenges and strategic dependencies. It correctly identifies ongoing issues such as production bottlenecks (e.g., low yields in stamping and curing), reliance on specialized suppliers (high-purity glass), and integration with Powerwall and proprietary inverters. The mention of automation improvements and design changes by 2024 aligns with the general direction of progress. However, the original answer from the knowledge graph does not mention specific details like 'pilot-scale, installer-dependent offering', 'in-house glass-tile production', 'custom installation hardware', or 'tighter integration with Powerwall' as explicit 2022–2024 evolution points. These additions, while plausible, go beyond the documented 10-K disclosures in the ground truth and introduce granular technical details not present in the source. The shift described in the ground truth is more general—framing the 2024 outlook as increasingly dependent on overcoming production ramp challenges—without specifying vertical integration or hardware changes. There are no numerical values in the question or answers, so quantitative accuracy is not applicable but assumed perfect (10). The reasoning is sound and contextually relevant, but the LLM adds unverified specifics not supported by the provided ground truth, reducing qualitative accuracy. Thus, while the core evolution—increased focus on production challenges and supply chain dependencies—is correctly captured, the added detail lowers the score to 7 for correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 461,
        "total_tokens": 1834
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the retail share of Skoal in the U.S. oral tobacco market changed between 2023 and 2024, and what does this indicate about its competitive positioning?",
      "original_answer": "In 2023, Skoal held a 9.3% retail share in the U.S. oral tobacco market, which decreased to 7.6% in 2024. This decline indicates a weakening in Skoal's competitive positioning within the oral tobacco segment over this period. The drop in market share for Skoal contrasts with the growth seen in other products like on!, which increased from 6.8% to 8.3% during the same timeframe.",
      "llm_answer": "\nSkoal’s U.S. oral‑tobacco retail share slipped from **9.3 % in 2023 to 7.6 % in 2024** (a decline of roughly 1.7 percentage points). This loss of share—while the overall oral‑tobacco category’s share fell even more sharply (from 42.5 % to 37.5 %)—signals that Skoal is ceding ground to competing brands (notably on! and Copenhagen) and to the faster‑growing oral‑nicotine‑pouch segment, weakening its competitive positioning in the market.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly reports Skoal's retail share in 2023 (9.3%) and 2024 (7.6%), matching the ground truth exactly. The 1.7 percentage point decline is accurately calculated (9.3 - 7.6 = 1.7). These numbers are factually correct and properly contextualized.\n\n2) Quantitatively, all figures are accurate: the starting and ending market shares, the direction and magnitude of change. The additional context about the overall oral-tobacco category declining from 42.5% to 37.5% is not in the original answer but does not contradict it and may come from broader knowledge; it doesn't detract from accuracy.\n\n3) The LLM correctly identifies the implication of the decline—worsening competitive positioning—and supports it with reasoning, including competition from on! and Copenhagen and the rise of oral nicotine pouches. While the original answer specifically contrasts Skoal’s decline with on!’s growth (6.8% to 8.3%), the LLM captures the same competitive dynamic by naming on! as a growing competitor, showing sound multi-hop reasoning.\n\n4) The answer is semantically equivalent in conveying the core facts and interpretation. The only minor shortcoming is that it doesn’t explicitly quantify on!’s growth as the original does, which slightly reduces completeness in comparative context. However, the conclusion about weakening competitive positioning is fully supported and aligns with the ground truth. Wording differences are acceptable and do not affect meaning.\n\nOverall, the answer is highly accurate, well-reasoned, and relevant, meriting a 9/10 due to the slight omission of on!’s specific market share numbers, though the competitive contrast is still effectively communicated.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1208,
        "completion_tokens": 462,
        "total_tokens": 1670
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the risk associated with the concentration of device share among premium tier companies evolved between 2023 and 2024, particularly in terms of its potential impact on Qualcomm's pricing power and revenue stability?",
      "original_answer": "In 2023, Qualcomm highlighted that the concentration of device share among a few premium tier companies was contributing to a trend of deriving a significant portion of revenues from a small number of customers, particularly Chinese OEMs. This concentration was noted to potentially result in lower prices for Qualcomm's products due to the purchasing power of these companies. In 2024, the risk factor remained present, but the emphasis shifted slightly to underscore the broader implications of this concentration, including the potential for even greater pricing pressure and revenue fluctuation due to the timing and success of customer product introductions. The continued reliance on a small group of customers, especially those developing their own integrated circuits or using competitors, suggests that the risk has not only persisted but potentially intensified, increasing its impact on Qualcomm's pricing power and revenue stability.",
      "llm_answer": "\nThe 2024 filing makes clear that the concentration of premium‑tier device share remains a material risk and, if anything, has become more pronounced—citing not only the ongoing “concentration of device share among a few companies” but also concrete developments such as Apple’s in‑house modem program, the revocation of export licenses to Huawei, and China’s “Made‑in‑China 2025” push that is driving OEMs to vertically integrate. Because these customers now wield even greater purchasing power and can dictate lower prices or shift volumes through their own product cycles, Qualcomm’s pricing power and the stability of its revenue streams are increasingly vulnerable to the fortunes of a handful of premium‑tier OEMs.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the original (ground truth) answer. It correctly identifies that the risk associated with concentration of device share among premium-tier companies has persisted from 2023 to 2024 and has potentially intensified. The answer captures the core implications for Qualcomm's pricing power and revenue stability, noting increased vulnerability due to customer purchasing power and product cycle dependencies. While the original answer emphasizes the shift in emphasis in 2024 toward broader implications like timing of product introductions and vertical integration, the LLM answer enhances this with specific examples—Apple’s in-house modem program, Huawei’s export license revocation, and China’s 'Made-in-China 2025' initiative—that are contextually plausible and consistent with the risk evolution, even if not explicitly detailed in the ground truth. These additions do not contradict but rather enrich the explanation, assuming they are supported in the actual 2024 filing. There are no numerical figures to verify, so quantitative accuracy is scored as 10. The reasoning is sound, multi-hop synthesis is appropriate, and the entities (Apple, Huawei, Chinese OEMs, Qualcomm) and timeframes (2023–2024) are correctly referenced. The only reason for not scoring a perfect 10 is that the LLM slightly shifts focus toward specific geopolitical and competitive developments not explicitly mentioned in the ground truth, which may go beyond the scope of the provided knowledge graph. However, these are reasonable inferences and do not detract from factual correctness. Overall, the answer is semantically equivalent and contextually excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1435,
        "completion_tokens": 460,
        "total_tokens": 1895
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "Given Amgen's approach to managing short-term liquidity, how did its allocation to money market mutual funds evolve between 2023 and 2024?",
      "original_answer": "Amgen's allocation to money market mutual funds remained unchanged at $10,266 million in both 2023 and 2024. The disclosed investment values for money market mutual funds under available-for-sale investments were identical in both years, indicating no shift in this portion of the company's short-term investment strategy.",
      "llm_answer": "\nAmgen’s short‑term liquidity was primarily held in money‑market mutual funds, which rose sharply from **$2.66 billion (amortized cost) as of 31 Dec 2023** to **$10.35 billion (amortized cost) as of 31 Dec 2024**—an increase of roughly **$7.7 billion (about a 290 % jump)**.  This expansion reflects a deliberate shift toward a larger, more liquid cash buffer, driving the total available‑for‑sale investment balance up from $4.34 billion to $11.49 billion over the same period.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in nearly all quantitative aspects. According to the ground truth, Amgen's allocation to money market mutual funds was unchanged at $10,266 million in both 2023 and 2024. However, the LLM claims it increased from $2.66 billion in 2023 to $10.35 billion in 2024—a dramatic rise that contradicts the original data. The reported increase of $7.7 billion and a 290% jump are therefore entirely inaccurate. Additionally, the LLM references 'amortized cost' and total available-for-sale investments rising from $4.34B to $11.49B, which are not supported by the ground truth and introduce false context. (2) Number verification: Ground truth states $10,266 million (~$10.27B) for both years; LLM reports $2.66B (2023) and $10.35B (2024), both incorrect. The calculation of a $7.7B increase and 290% growth is mathematically plausible given those numbers but based on wrong inputs, so the calculation itself is invalid. (3) Multi-hop reasoning: The model fails to correctly synthesize the data across years. Instead of identifying stability in allocation, it invents a significant strategic shift. There is no evidence in the ground truth of a change in strategy or portfolio rebalancing. (4) Scores justified: Correctness is 1 due to fundamental factual errors. Quantitative accuracy is 1 because all key numbers are wrong. Qualitative accuracy is 2 because while the answer addresses liquidity management and uses relevant financial terms, the reasoning is flawed. Contextual relevance is 6 because the topic (liquidity, money market funds, AFS investments) is appropriate, but the substance is misleading.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1198,
        "completion_tokens": 452,
        "total_tokens": 1650
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has General Dynamics' participation in the Capital Construction Fund evolved between 2022 and 2024, particularly in terms of the amount of U.S. government accounts receivable pledged to the fund?",
      "original_answer": "In 2022, General Dynamics had U.S. government accounts receivable pledged to the Capital Construction Fund (CCF) of $295 million as of December 31, 2021. By 2024, the amounts pledged to the CCF had increased to $315 million on December 31, 2023, and $333 million on December 31, 2024. This indicates a steady increase in GD's participation in the CCF over the period, reflecting a growing utilization of the tax deferral benefits offered by the program.",
      "llm_answer": "\nGeneral Dynamics’ pledged U.S. government accounts receivable in the Capital Construction Fund rose modestly over the period.  The 2022 filing notes a balance of **$295 million** (the same amount reported as pledged as of Dec 31 2021/2020), the 2023 filing shows the balance increased to **$315 million**, and the 2024 filing reports **$333 million** pledged as of Dec 31 2024.  Thus, participation has expanded incrementally, with the pledged amount growing from roughly $295 M in 2022 to $333 M by the end of 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key figures: $295 million as of December 31, 2021 (referenced in the 2022 filing), $315 million as of December 31, 2023 (2023 filing), and $333 million as of December 31, 2024 (2024 filing). These match the ground truth exactly in value and timing. (2) All numeric values are accurate and properly contextualized by year and filing. The progression from $295M to $315M to $333M is correctly presented, with no calculation or date errors. Format variations (e.g., $295 million vs $295M) are acceptable and do not affect accuracy. (3) The multi-hop reasoning is sound: the model synthesizes data across three annual filings (2022, 2023, 2024) to show a trend over time, correctly interpreting that the pledged amounts are reported in each year’s filing for the prior or current year-end. The conclusion of 'incremental expansion' aligns with the ground truth's 'steady increase'. (4) The only minor shortcoming is that the LLM slightly conflates reporting year with reference date by stating the 2022 filing reports $295M 'as of Dec 31 2021/2020' — while the $295M is correct for Dec 31, 2021, the inclusion of '2020' is not supported in the ground truth and introduces a small inaccuracy. Otherwise, the answer is factually complete, contextually relevant, and semantically equivalent to the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1255,
        "completion_tokens": 379,
        "total_tokens": 1634
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did AIG's financial relationship with Corebridge evolve between 2023 and 2024, particularly in terms of its tax implications and investment income following the IPO and subsequent deconsolidation?",
      "original_answer": "In 2023, AIG's ownership in Corebridge dropped below 80% after Corebridge's IPO on September 19, 2022, resulting in the tax deconsolidation of Corebridge from AIG’s U.S. federal income tax group. This deconsolidation had significant tax implications, including restrictions on future consolidated tax filings for five years and the retention of Corebridge's net operating losses and tax credit carryforwards by Corebridge entities. By 2024, AIG no longer consolidated Corebridge's financials, and instead, AIG reported its investment in Corebridge under the equity method, recognizing $X in equity method income for the period from June 10, 2024, to December 31, 2024, based on dividends received and changes in Corebridge's stock price. This marks a shift from a consolidated tax and financial reporting relationship to a more arms-length investment relationship.",
      "llm_answer": "\nBetween 2023 and 2024 AIG’s ownership of Corebridge fell from just under 80 % to about 23 % after a series of secondary offerings and the June 2024 deconsolidation, which removed Corebridge from AIG’s consolidated U.S. federal tax group and left Corebridge’s net‑operating‑loss carryforwards and tax credits with the standalone entity, creating stranded tax effects that required a valuation allowance.  Consequently, AIG now records its remaining stake under the equity‑method, recognizing investment income from dividends and changes in the Corebridge stock price (e.g., a $282 million gain on the sale of 120 million shares in Q4 2024) while the 2024 deconsolidation generated a $4.8 billion after‑tax loss that is reflected in discontinued operations.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly in quantitative details. The claim that AIG's ownership dropped to 23% by 2024 due to a 'June 2024 deconsolidation' is not supported by the ground truth, which states deconsolidation occurred after the September 2022 IPO when ownership fell below 80%, triggering tax deconsolidation in 2023. The mention of a 'June 2024 deconsolidation' is incorrect and introduces a false timeline. The $282 million gain on sale of shares and $4.8 billion after-tax loss in discontinued operations are specific figures not present in the original answer and cannot be verified against the ground truth; these appear to be hallucinated or misattributed. The original answer mentions 'X' as a placeholder for equity method income, but does not specify any gain on sale or deconsolidation loss. (2) The original answer does not provide exact percentages or dollar figures beyond 'X', so the LLM’s inclusion of precise numbers like $282M and $4.8B cannot be considered accurate without corroboration. The 23% ownership figure and June 2024 deconsolidation date are not mentioned in the ground truth and contradict the stated timeline. (3) The multi-hop reasoning is partially sound—LLM correctly identifies the shift from consolidation to equity method accounting and links deconsolidation to tax consequences such as stranded NOLs and tax credits. It also correctly notes the change in reporting to equity method income. However, it misattributes the timing and cause of deconsolidation, failing to correctly synthesize that the tax deconsolidation was triggered in 2023 due to post-IPO ownership drop, not a 2024 event. (4) Despite the hallucinated numbers and incorrect timeline, the LLM captures the core conceptual evolution: tax deconsolidation, loss of consolidated filing benefits, retention of tax attributes by Corebridge, and shift to equity method reporting. This preserves some qualitative and contextual accuracy, warranting moderate scores in those areas. However, the quantitative inaccuracies significantly undermine the correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1418,
        "completion_tokens": 568,
        "total_tokens": 1986
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Tesla's approach to Solar Roof production and its dependencies evolved from 2022 to 2024, particularly in terms of operational strategy and supply chain challenges?",
      "original_answer": "In 2022, Tesla emphasized improving Solar Roof installation capabilities by onboarding and training new installers and collaborating with real estate developers to reduce installation time and costs. The company also highlighted the need to maintain adequate battery cell supply and hire additional skilled electricians to support the ramp. By 2024, Tesla's focus had shifted to broader manufacturing and supply chain risks, with Solar Roof production now described as being dependent on the company's ability to manage global component procurement, avoid bottlenecks, and maintain cost-effective production amid potential supplier failures and inflationary pressures. The evolution reflects a shift from localized installer development to systemic supply chain and production scalability concerns.",
      "llm_answer": "\nFrom 2022 through 2024 Tesla shifted Solar Roof from a largely outsourced, installer‑driven rollout to a more vertically‑integrated production model that leans on its own battery‑cell supply and a growing, trained installer workforce. The 2022 filing notes that “maintaining adequate battery‑cell supply … and hiring additional personnel, particularly skilled electricians, to support the ramp of Solar Roof” was essential, and the 2024 filing adds that the company is “improving installation capabilities and price efficiencies … by on‑boarding and training new installers, as well as collaborating with real‑estate developers and builders to reduce installation time and costs.” Nevertheless, both years stress that the effort remains constrained by global component shortages, raw‑material price volatility and the need to scale skilled‑labor pipelines, making supply‑chain reliability a persistent dependency.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer contains no numeric data, so quantitative accuracy is not applicable in a traditional sense; however, since there are no incorrect numbers or miscalculations, it is scored as 10. Contextual relevance is high because the response directly addresses Tesla's Solar Roof production evolution from 2022 to 2024. However, the qualitative accuracy is low due to significant misrepresentation of the timeline and strategic evolution. The LLM incorrectly attributes the quote about onboarding and training installers and collaborating with real estate developers to the 2024 filing, when in fact this language comes from the 2022 filing. Conversely, the 2024 filing emphasizes systemic supply chain risks—global component procurement, supplier failures, inflationary pressures—which the LLM downplays. The LLM also incorrectly frames the shift as moving toward vertical integration with battery-cell supply, which is not supported in the ground truth; battery-cell supply was a 2022 concern linked to ramping production, not a 2024 strategic shift. The core idea of ongoing supply chain and labor constraints is partially correct, but the synthesis across years is flawed, reversing the progression of priorities. Instead of showing a shift from installer development (2022) to systemic supply chain management (2024), the LLM suggests both strategies are emphasized in both years, missing the evolution entirely. This constitutes a critical error in multi-hop reasoning, as the temporal progression and changing focus are central to the question. Therefore, while some elements are factually present, the overall narrative misaligns with the ground truth, warranting a correctness score of 6 for partial accuracy with major conceptual and factual misalignment in the synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1434,
        "completion_tokens": 482,
        "total_tokens": 1916
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Duke Energy's estimated total cost to permanently close all coal ash basins in North Carolina and South Carolina evolved from 2022 to 2023, and what does this indicate about the company's progress under the Coal Ash Act?",
      "original_answer": "In 2022, Duke Energy estimated the total cost to permanently close all coal ash basins in North Carolina and South Carolina to be approximately $8 billion to $9 billion. By 2023, this estimate had decreased to approximately $7 billion to $8 billion, indicating a downward adjustment in projected costs. Additionally, the amount already spent on these closures increased from approximately $3.1 billion through 2021 (as reported in 2022) to approximately $4 billion through 2023. This evolution suggests that Duke Energy has made measurable progress in implementing closure plans under the Coal Ash Act, with more basins excavated and cost estimates refined over time.",
      "llm_answer": "\nFrom the 2022 10‑K the company estimated that permanently closing all of its North Carolina and South Carolina coal‑ash basins would cost **about $8 billion – $9 billion**, of which **≈ $3.1 billion** had already been spent (through 2021).  \nThe 2023 filing revises that outlook to a **total cost of roughly $7 billion – $8 billion**, with **≈ $4 billion** spent through 2023—an increase of roughly $0.9 billion in expenditures and a modest reduction in the overall cost estimate.  \n\nThis shift shows that Duke Energy has **advanced its excavation and capping work**, spending more than originally projected while also refining its cost estimate downward, demonstrating measurable progress toward meeting the Coal Ash Act’s closure requirements.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: the 2022 total cost estimate of $8B–$9B and $3.1B spent through 2021 are correctly reported; the 2023 update of $7B–$8B total cost and $4B spent through 2023 is also correct. The implied increase in spending (~$0.9B) is logically sound ($4B - $3.1B = $0.9B). (2) The answer is complete, addressing both the evolution of cost estimates and what it indicates about progress under the Coal Ash Act. (3) Entities—Duke Energy, coal ash basins, North Carolina and South Carolina, and the Coal Ash Act—are correctly identified and contextualized. (4) The reasoning is sound: the downward revision in total cost alongside increased spending indicates progress through completed work and improved cost forecasting, which aligns with the multi-hop synthesis required. The LLM correctly infers that more basins have been excavated and that cost estimates have been refined. (5) Semantic equivalence is maintained—wording differs slightly but meaning is identical to the original answer. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1373,
        "completion_tokens": 325,
        "total_tokens": 1698
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did the retail share of the 'on!' oral tobacco product evolved between 2023 and 2024, and what does this indicate about its market position relative to the overall oral tobacco product segment during this period?",
      "original_answer": "The retail share of the 'on!' oral tobacco product increased from 6.8% in 2023 to 8.3% in 2024. This indicates that 'on!' gained market share during this period. In contrast, the total oral tobacco product segment saw a decline in retail share, dropping from 42.5% in 2023 to 37.5% in 2024. This divergence suggests that 'on!' strengthened its position within the broader oral tobacco market between these years.",
      "llm_answer": "\nThe “on!” oral‑tobacco brand’s retail‑share rose from **6.8 % in 2023 to 8.3 % in 2024** (an increase of about 1.5 percentage points).  At the same time the overall oral‑tobacco segment’s share of the U.S. market fell from **42.5 % to 37.5 %**, meaning the category’s total volume was contracting while “on!” was capturing a larger slice of it.  This trend shows that “on!” is gaining momentum relative to the broader oral‑tobacco market, positioning it as a growing, albeit still niche, player within the segment.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: 'on!' retail share increased from 6.8% in 2023 to 8.3% in 2024, and the total oral tobacco segment declined from 42.5% to 37.5%, as confirmed in both answers. The implied calculation of a 1.5 percentage point increase is correct (8.3 - 6.8 = 1.5). (2) The answer is complete, addressing both parts of the question: the evolution of 'on!''s retail share and its market position relative to the overall segment. (3) Entity accuracy is perfect: the product name 'on!' is correctly identified, time periods (2023–2024) are accurate, and the metric (retail share) is properly contextualized. (4) The reasoning is sound and reflects multi-hop synthesis: the LLM correctly infers that while the overall category is contracting, 'on!' is gaining share, indicating relative strength. The conclusion that 'on!' is gaining momentum and strengthening its position aligns semantically with the ground truth's interpretation. Minor wording differences (e.g., 'gaining momentum' vs. 'strengthened its position') do not affect factual equivalence. All criteria are met at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1249,
        "completion_tokens": 336,
        "total_tokens": 1585
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Qualcomm's reliance on Chinese OEMs for revenue evolved from 2023 to 2024, and what implications does this have for its business stability?",
      "original_answer": "In 2023, Qualcomm derived a significant portion of its revenues from a small number of Chinese OEMs, highlighting its dependency on their device share growth in China and other regions. By 2024, this dependency persisted, with the company continuing to emphasize that it derives a significant portion of its revenues from these same OEMs. This ongoing reliance indicates that any political, economic, or market shifts affecting Chinese OEMs could continue to pose a risk to Qualcomm's revenue stability, particularly given the persistent U.S./China trade and national security tensions mentioned in both filings.",
      "llm_answer": "\nFrom 2023 to 2024 Qualcomm’s exposure to Chinese OEMs remained large, but a pivotal development occurred in fiscal 2024: the U.S. revoked its export licence to Huawei, eliminating roughly $560 million of product revenue that had been generated that year and underscoring how quickly geopolitical actions can cut off sales to a key Chinese customer base. At the same time, heightened U.S.–China trade and national‑security tensions have spurred many Chinese OEMs to pursue their own integrated‑circuit solutions (e.g., the “Made‑in‑China 2025” agenda), accelerating the shift away from Qualcomm’s chips. As a result, the company’s revenue stability is now more vulnerable to these political and competitive pressures, making diversification and risk‑mitigation increasingly critical.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces specific claims not present in the ground truth, most notably that the U.S. revoked an export license to Huawei in fiscal 2024, resulting in a $560 million loss in product revenue. This information is not supported by the original answer and cannot be verified from the provided ground truth. The original answer states only that Qualcomm continued to derive significant revenue from Chinese OEMs in both 2023 and 2024, with no mention of revenue loss, Huawei license revocation, or specific dollar impacts. (2) The $560 million figure is a precise quantitative claim absent from the ground truth and thus factually unsupported in this context, leading to a low quantitative accuracy score. There are no calculations in the original answer to validate or refute, but the introduction of an incorrect specific figure significantly undermines factual correctness. (3) The qualitative reasoning partially aligns with the ground truth in identifying ongoing reliance on Chinese OEMs and the risk posed by U.S.-China tensions. However, the LLM adds unsupported causal dynamics (e.g., Huawei license revocation, 'Made-in-China 2025' driving design-outs) that go beyond the source material. While the general concern about geopolitical risk and business stability is consistent, the multi-hop synthesis includes speculative or extraneous elements not grounded in the provided data. (4) Contextual relevance is high because the answer addresses the evolution of reliance and implications for business stability as asked. However, correctness is significantly reduced due to the inclusion of unverified facts and numbers, resulting in a score of 4: partially correct on core themes but with major factual inaccuracies that alter the factual basis of the response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 487,
        "total_tokens": 1836
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did Amgen's composition of total available-for-sale investments evolve between 2022 and 2023, particularly in terms of specific security types held?",
      "original_answer": "In 2022, Amgen reported total available-for-sale investments of $4,335 million, which included $1,676 million in marketable securities alongside $2,659 million in cash and cash equivalents. By 2023, Amgen no longer held any marketable securities or U.S. Treasury bills, and instead, the entire $10,404 million in total available-for-sale investments was composed of $10,266 million in money market mutual funds and $138 million in other short-term interest-bearing securities. This reflects a strategic shift toward more liquid and short-term interest-bearing instruments.",
      "llm_answer": "\nBetween 2022 and 2023 Amgen essentially eliminated its U.S. Treasury‑bill holdings and expanded its cash‑equivalent position.  In 2022 the portfolio consisted of about $1.7 bn of Treasury bills and $2.7 bn of money‑market mutual funds (with negligible other securities), whereas in 2023 it held virtually no Treasury bills, $10.3 bn of money‑market funds, and a small $138 m position in other short‑term interest‑bearing securities.  This shift reflects a move toward a larger, more liquid money‑market allocation and away from Treasury‑security exposure.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies in the quantitative details. It states that in 2022, Amgen held $1.7 billion in Treasury bills and $2.7 billion in money-market mutual funds. However, the ground truth indicates that in 2022, Amgen held $1,676 million in marketable securities (not specifically identified as Treasury bills) and $2,659 million in cash and cash equivalents — not money-market mutual funds. The ground truth does not state that money-market funds were held in 2022; those only appear in 2023. Thus, the LLM incorrectly attributes the 2023 composition (money-market funds) retroactively to 2022 and mislabels marketable securities as U.S. Treasury bills. Additionally, the LLM reports $10.3 billion in money-market funds in 2023, while the correct figure is $10,266 million ($10.266 billion), which is close but still inaccurate. (2) The only correct numbers are the $138 million in other short-term interest-bearing securities in 2023 and the general direction of the shift. However, the total available-for-sale investments in 2022 ($4,335 million) and 2023 ($10,404 million) are omitted, weakening completeness and quantitative accuracy. (3) The reasoning correctly identifies a strategic shift toward more liquid instruments and away from Treasury securities, which aligns with the ground truth’s conclusion. However, the multi-hop synthesis is flawed because it misrepresents the 2022 portfolio composition by conflating 'marketable securities' with 'Treasury bills' and incorrectly assigning money-market funds to 2022. (4) Despite these errors, the answer is contextually relevant and captures the high-level trend — a shift to more liquid, short-term instruments — which supports a moderate score. The qualitative reasoning is sound in direction but based on incorrect premises. Therefore, the correctness score is reduced due to significant quantitative inaccuracies, even though the overall narrative trend is partially correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 535,
        "total_tokens": 1818
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has the presence of Shake Shack as a tenant evolved across SPG's premium outlet properties between 2022 and 2023?",
      "original_answer": "In 2022, Shake Shack was listed as a tenant at Woodbury Common Premium Outlets in New York. By 2023, Shake Shack not only remained at Woodbury Common but also expanded its presence to Las Vegas Outlets North Premium in Nevada. This indicates a strategic expansion of Shake Shack’s footprint within SPG's portfolio of properties over the two years.",
      "llm_answer": "\nIn the 2022 and 2023 SEC filings, Shake Shack is not listed among the tenants of any of SPG’s premium‑outlet properties, so the brand’s presence was essentially unchanged—there were no additions or removals of a Shake Shack location across the portfolio between the two years.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect. (1) According to the ground truth, Shake Shack was present at Woodbury Common Premium Outlets in New York in 2022 and expanded to Las Vegas Outlets North Premium in Nevada in 2023, indicating growth in SPG's portfolio. The LLM claims Shake Shack was not listed as a tenant in any SPG premium outlet in either 2022 or 2023, which directly contradicts the verified facts. (2) There are no numeric values in this response to evaluate for quantitative accuracy, but the core factual assertions about presence/absence are wrong. (3) The reasoning is flawed: the model fails to recognize the multi-hop nature of the question—comparing tenant presence across two years and two properties—and incorrectly concludes no change occurred. (4) Contextual relevance is low because the answer asserts no presence instead of documenting expansion, but it does attempt to address the timeframe and topic. The answer reflects a complete failure to retrieve or synthesize the correct information from the knowledge base.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1148,
        "completion_tokens": 297,
        "total_tokens": 1445
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did the classification of retirement annuity contracts within the fair value hierarchy evolve between 2022 and 2024, and what does this indicate about GD's valuation methodology for these assets?",
      "original_answer": "In 2022, retirement annuity contracts were part of Level 3 assets, indicating that their fair value was determined using unobservable inputs. By 2024, these contracts remained in Level 3, but the disclosure noted that investments valued using net asset value (NAV) as a practical expedient were now included in the tables for reconciliation to total plan assets, which was not explicitly stated in 2022. This suggests a refinement in disclosure practices rather than a change in hierarchy classification, indicating that while the valuation methodology remained complex and less observable, GD improved transparency in how these assets are reported.",
      "llm_answer": "\nBetween 2022 and 2024 the retirement‑annuity contracts moved out of the Level 3 category of the fair‑value hierarchy.  In the 2021 and 2022 disclosures they were listed under “Significant Unobservable Inputs (Level 3),” but the 2023 and 2024 tables explicitly state that “we had no Level 3 investments” and that these assets are now “measured using NAV as a practical expedient” – i.e., they are excluded from the hierarchy altogether.  This shift shows that GD has revised its valuation approach so that retirement annuities are now priced using observable market‑based inputs or third‑party NAV valuations rather than unobservable estimates, reflecting a more transparent and reliable fair‑value methodology.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that retirement annuity contracts moved out of Level 3 between 2022 and 2024. The ground truth confirms they remained in Level 3 throughout this period. The claim that 'we had no Level 3 investments' in 2023 and 2024 is false according to the original answer, which explicitly states the contracts stayed in Level 3. (2) There are no numeric values (e.g., dollar amounts, percentages) to verify, but the dates (2021–2024) are correctly referenced in context. However, the interpretation of disclosures for those years is inaccurate. (3) The multi-hop reasoning fails: the model incorrectly infers a reclassification out of Level 3 and misinterprets the role of NAV as a practical expedient. In reality, assets measured at NAV are not classified in the fair value hierarchy but are reconciled to total plan assets — a nuance the model misunderstands, leading to a false conclusion about methodology improvement. The original answer clarifies that the valuation methodology did not change, only the transparency in disclosure. (4) The contextual relevance is moderate because the answer addresses the right topic (fair value hierarchy, NAV, Level 3) and attempts to interpret changes over time, but the core factual error — movement out of Level 3 — undermines the entire response. The conclusion about improved reliability and use of observable inputs is unsupported and incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 399,
        "total_tokens": 1753
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did AIG's financial relationship with Corebridge evolve between 2023 and 2024, particularly in terms of potential equity dilution and income recognition?",
      "original_answer": "In 2023, AIG had a stake in Corebridge that included a potential equity dilution mechanism tied to Blackstone's right to exchange its ownership interest in Corebridge for AIG common shares, which would have introduced up to 24.1 million additional shares in 2022 (and 4.4 million in 2023) had the IPO not occurred before 2024. However, since the IPO occurred on September 19, 2022, this exchange right was terminated. By 2024, AIG's relationship with Corebridge had shifted from a stakeholding to an equity method investment, where AIG reported income based on dividends received and changes in Corebridge's stock price from June 9, 2024 onwards. This reflects a transformation from a potential equity dilution scenario to a post-divestiture equity income model.",
      "llm_answer": "\nBetween 2023 and 2024 AIG’s stake in Corebridge fell from 52.2 % (the ownership level reported at 31 Dec 2023) to 22.7 % after a series of secondary offerings, share‑repurchases and the June 9 2024 de‑consolidation; the only remaining source of equity dilution – a Blackstone option to exchange its Corebridge holding for AIG shares – had already been terminated after the 2022 IPO, so no further dilution was possible.  Following the de‑consolidation AIG elected the fair‑value option for its retained interest and now accounts for it as an equity‑method investment, recognizing dividends and changes in Corebridge’s stock price in net‑investment income (which contributed $601 million of equity‑method income for the June‑Dec 2024 period) and a $282 million gain on the sale of 120 million Corebridge shares to Nippon in Dec 2024.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the shift in AIG's relationship with Corebridge from a controlling stake to an equity-method investment, and notes the termination of Blackstone's exchange right post-IPO, which aligns with the ground truth. However, there are key quantitative inaccuracies: the IPO date is stated as September 19, 2022 in the ground truth, but the LLM implies the dilution mechanism was still relevant in 2023, which contradicts the fact that the exchange right was terminated at IPO in 2022. The LLM incorrectly suggests dilution was still a consideration in 2023 by referencing a 4.4 million share potential, but the ground truth clarifies that because the IPO occurred in 2022, the mechanism was already terminated before 2023. (2) The ownership percentages (52.2% in 2023 and 22.7% in 2024) and the $601 million equity-method income for June–Dec 2024 and $282 million gain in Dec 2024 are not present in the original answer and cannot be verified against the ground truth; these appear to be hallucinated or sourced from outside the provided knowledge. The de-consolidation date of June 9, 2024 is correct and matches the shift in accounting treatment. (3) The multi-hop reasoning is partially sound: the model correctly infers a transition from potential dilution to income recognition, but fails to emphasize that the dilution mechanism was already defunct before 2023 due to the 2022 IPO, which is a critical point in the original answer. (4) Despite strong contextual relevance and correct overall narrative arc, the inclusion of unverified numbers and the misstatement about the timing of the exchange right termination reduce quantitative and overall correctness. The answer captures the qualitative transformation but introduces unsupported specifics, warranting a score of 7 for correctness, 6 for quantitative accuracy, 8 for qualitative reasoning, and 10 for relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 518,
        "total_tokens": 1920
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has Comcast's financial exposure to Universal Beijing Resort evolved from 2022 to 2024, based on its debt disclosures and consolidation treatment?",
      "original_answer": "In 2022, Comcast disclosed that Universal Beijing Resort had $3.6 billion in debt as of December 31, 2021, and $2.5 billion as of December 31, 2020. By 2024, Comcast clarified that Universal Beijing Resort had $3.4 billion in debt outstanding as of December 31, 2024, and $3.5 billion as of December 31, 2023. This indicates that the debt levels stabilized after earlier reductions, and Comcast now consolidates Universal Beijing Resort as a variable interest entity (VIE), with its assets and liabilities fully included in Comcast’s consolidated balance sheets at $7.3 billion in assets and $7.0 billion in liabilities as of 2024.",
      "llm_answer": "\nFrom 2022 through 2024 Comcast’s debt exposure to Universal Beijing Resort fell modestly—​the resort’s outstanding borrowings dropped from roughly **$3.6 billion (as of the 2021/2022 reporting)** to **$3.4 billion (reported in the 2024 filing)**, with the term‑loan component falling from about $3.1 billion to $3.0 billion.  The resort has remained a **consolidated variable‑interest entity** throughout the period, so the full amount of that debt continues to appear on Comcast’s consolidated balance sheet, but the absolute level of exposure has been gradually reduced.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies in numbers and dates. The ground truth states that as of December 31, 2021, Universal Beijing Resort had $3.6 billion in debt, and as of December 31, 2023, it had $3.5 billion, decreasing to $3.4 billion by December 31, 2024. The LLM incorrectly frames the timeline as a continuous decline from '2021/2022' to 2024, omitting the increase from $3.6B (2021) to $3.5B (2023), which contradicts the 'gradual reduction' narrative. The LLM also introduces a term-loan component of $3.1B to $3.0B not present in the original answer, adding unverified detail. (2) The quantitative inaccuracies include misrepresenting the debt trajectory—debt actually increased slightly from 2021 to 2023 before dropping in 2024, but the LLM implies a steady decline. Additionally, the 2024 debt is correctly cited as $3.4B, but the prior figure is misrepresented as being from 2022 instead of 2021. (3) The qualitative reasoning is partially sound: the model correctly identifies Universal Beijing Resort as a consolidated VIE throughout the period, which is key to understanding Comcast’s financial exposure. However, it fails to mention the full consolidation of assets and liabilities ($7.3B assets, $7.0B liabilities in 2024), a critical part of the original answer and relevant to financial exposure. (4) Contextual relevance is high—the answer addresses debt levels and consolidation treatment—but due to incorrect numerical sequencing and missing key data points, the overall correctness is compromised. The answer gives a plausible but factually incomplete and partially misleading picture of the debt evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1302,
        "completion_tokens": 453,
        "total_tokens": 1755
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has the structure of aircraft trade-in commitments changed between 2022 and 2023, particularly in terms of customer eligibility and risk exposure?",
      "original_answer": "In 2022, the Aerospace segment had outstanding options with 'some customers' to trade in aircraft as partial consideration for new aircraft purchases, indicating a broader or less-specific customer eligibility. By 2023, the eligibility was narrowed to 'some Gulfstream customers,' suggesting a more specific subset of customers was offered trade-in options. Additionally, while both years acknowledged the risk associated with adverse market changes affecting trade-in values, 2023 introduced a more specific framing by highlighting Gulfstream, a key business jet brand, which may indicate a strategic focus or increased risk concentration in that segment. Despite these structural changes, both years reported that the estimated change in fair market values from the commitment date was 'not material.'",
      "llm_answer": "\nThe 2023 filing narrows the trade‑in program from “some customers” (2022) to “some **Gulfstream** customers” who hold the options, and it describes the commitments as often being **structured to guarantee a pre‑determined trade‑in price** rather than simply establishing fair‑market value 45 days before delivery.  Because eligibility is now limited to Gulfstream customers, the company’s exposure to market‑value declines is greater – any excess of the guaranteed price over the aircraft’s fair market value at delivery must be recorded as a reduction of new‑aircraft revenue, whereas the earlier structure exposed the company only to modest market fluctuations that were deemed immaterial.  \n\n*Source: GD_10k_2022.pdf pp. 75‑78 (2022 description) and GD_10k_2023.pdf pp. 77‑80 (2023 description).*",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the narrowing of customer eligibility from 'some customers' in 2022 to 'some Gulfstream customers' in 2023, which aligns with the ground truth. It also correctly notes that both years consider the impact of market changes on trade-in values and that the overall effect is deemed immaterial. However, the LLM introduces significant factual inaccuracies in qualitative reasoning: it claims that in 2023, trade-in commitments were 'structured to guarantee a pre-determined trade-in price' and that this creates greater exposure because any excess over fair market value reduces new-aircraft revenue. This detail is not present in the original answer or implied by the ground truth, which only states that the risk from adverse market changes was acknowledged in both years and that the change in fair value was 'not material.' The original does not mention guaranteed prices, pricing mechanisms (e.g., 45 days before delivery), or changes in accounting treatment. These additions represent a substantial overinterpretation or hallucination of contractual terms and financial impacts not supported by the ground truth. While the entity (Gulfstream), years (2022 vs 2023), and general trend in eligibility are correct, the reasoning about risk exposure is therefore flawed. Quantitative accuracy receives full marks because there are no numerical values to assess, and the textual details that are present (e.g., customer scope) are factually aligned. Contextual relevance is high as the response directly addresses the question’s focus on eligibility and risk exposure. The qualitative accuracy is low due to incorrect inference about pricing structure and risk accounting, undermining the correctness score despite partial accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 477,
        "total_tokens": 1879
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has Tesla's approach to the Tesla Semi evolved between 2022 and 2024, particularly in terms of its production status and strategic positioning within Tesla's product lineup?",
      "original_answer": "In 2022, Tesla had only announced the Tesla Semi as part of its planned electric vehicles, indicating it was in the conceptual and development phase. By 2024, Tesla had moved the Tesla Semi into 'pilot production' at its Nevada facility, signaling a significant advancement in its development and a step closer to commercialization. This evolution reflects Tesla's strategic shift from merely planning the vehicle to actively preparing it for market entry.",
      "llm_answer": "\nBetween 2022 and 2024 Tesla moved the Semi from a purely announced concept to a vehicle in **pilot production** at its Nevada factory, signaling that limited manufacturing readiness had been achieved but full‑scale volume production was still pending.  The Semi is still positioned as a **strategic commercial‑vehicle offering** within Tesla’s lineup—intended to leverage the company’s battery, powertrain and autonomous‑driving technologies alongside upcoming models such as the Cybertruck and next‑generation platforms—while remaining secondary to the consumer‑focused models (e.g., Model Y, Cybercab) in the overall rollout schedule.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly states that Tesla moved the Semi from a conceptual/announced phase in 2022 to 'pilot production' in 2024 at the Nevada facility, matching the key evolution in production status. The strategic positioning as a commercial-vehicle offering leveraging Tesla's core technologies is consistent with the original answer. (2) There are no numeric values (e.g., dates, dollar amounts) in the question or ground truth beyond the years 2022 and 2024, which are correctly used—thus quantitative accuracy is perfect. (3) The multi-hop reasoning is sound: the model synthesizes the timeline (2022 vs 2024), production status evolution, and strategic context within Tesla’s broader product lineup, including correct reference to related models (Cybertruck, next-gen platforms) and prioritization relative to consumer vehicles. (4) The only minor gap is that the original answer emphasizes the shift from 'planning' to 'preparing for market entry' more explicitly, while the LLM answer adds some forward-looking context (e.g., full-scale production pending, rollout schedule) not in the ground truth—but this is reasonable inference and not factually incorrect. Overall, the answer is semantically equivalent, factually correct, and contextually complete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1281,
        "completion_tokens": 368,
        "total_tokens": 1649
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did the valuation allowance related to Altria's investment in Cronos evolve between 2022 and 2024, and what does this indicate about the company's expectations regarding the realizability of associated deferred tax assets?",
      "original_answer": "Between 2022 and 2024, the valuation allowance related to Altria's investment in Cronos increased from $379 million in 2022 to $402 million in 2024. This indicates that Altria continued to maintain significant uncertainty regarding the realizability of deferred tax assets associated with the Cronos investment, as the company still did not expect the temporary difference to reverse in the foreseeable future. The steady increase in the allowance suggests a cautious stance by Altria in recognizing the full value of these assets.",
      "llm_answer": "\nThe valuation allowance recorded for the deferred‑tax assets tied to Altria’s Cronos investment rose only slightly—from roughly **$379 million in 2022 to $397 million in 2023 and $402 million in 2024**.  This modest increase shows that management continues to view the Cronos‑related tax assets as **more likely than not to remain unrealized** and therefore keeps a full valuation allowance on them.  In other words, Altria is signaling that it does not expect sufficient future taxable earnings from the Cronos stake to realize those deferred‑tax benefits.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the valuation allowance amounts for 2022 ($379 million) and 2024 ($402 million), matching the ground truth. It also includes an intermediate value for 2023 ($397 million), which, while not present in the original answer, does not contradict the ground truth and may reflect additional data from the filings. All numeric values are accurate and properly formatted. (2) Quantitative accuracy is perfect: the starting and ending figures match exactly, and the progression is logically consistent. There are no calculation errors. (3) The reasoning is sound—LLM correctly infers that the increasing allowance reflects Altria's continued doubt about the realizability of deferred tax assets, using appropriate terminology such as 'more likely than not to remain unrealized' and linking it to insufficient future taxable earnings. This aligns with the ground truth’s interpretation of 'significant uncertainty' and 'temporary difference not reversing in the foreseeable future.' (4) The answer is fully relevant, addressing both parts of the question: the evolution of the allowance and its implication for deferred tax asset realizability. The only minor limitation is the inclusion of a 2023 figure not in the original, but this enhances rather than detracts from the response, assuming it's from the actual filing. Overall, the answer is factually correct, well-reasoned, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 405,
        "total_tokens": 1697
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did the financial treatment and valuation impact of Amgen's investment in BeiGene evolve between 2023 and 2024?",
      "original_answer": "In 2023, Amgen changed the accounting method for its investment in BeiGene from the equity method to fair value, resulting in gains recognized in connection with this revaluation. By 2024, the investment contributed net unrealized losses within Amgen's Other income (expense), net, reflecting a shift from gains in 2023 to losses in 2024 due to market or valuation changes. This evolution shows a reversal in the financial benefit derived from the BeiGene investment over the two years.",
      "llm_answer": "\nBetween 2023 and 2024 Amgen’s accounting for its BeiGene stake shifted from the equity‑method to a fair‑value measurement with changes in fair value recognized directly in earnings. In 2023 the re‑measurement produced net gains that boosted “Other income (expense), net,” but in 2024 the same fair‑value approach generated net unrealized losses on the BeiGene investment, turning that line item negative and dampening overall earnings. Consequently, the financial impact of the BeiGene investment moved from a positive, gain‑driven contribution in 2023 to a drag on results in 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) It correctly identifies the change in accounting method from equity method to fair value in 2023, and the resulting gains recognized in that year, followed by net unrealized losses in 2024. (2) There are no numeric values requiring calculation (e.g., dollar amounts or percentages), but the temporal markers (2023 and 2024) are correct and consistently applied. (3) The multi-hop reasoning is sound: the model correctly synthesizes the evolution of the investment treatment over two years, linking the accounting change to its financial impact (gains turning to losses) and the effect on 'Other income (expense), net'. (4) The answer fully addresses the question about the evolution of financial treatment and valuation impact, with precise terminology and logical flow. All entities—Amgen, BeiGene, the relevant accounting methods, and financial statement impacts—are accurately represented. Minor wording differences (e.g., 'boosted' vs 'dampening') do not affect factual correctness and enhance clarity. Thus, all scores are perfect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 318,
        "total_tokens": 1578
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the positioning and market strategy for Disney+ Hotstar evolved between 2023 and 2024, particularly in terms of its regional branding and service structure?",
      "original_answer": "In 2023, Disney+ Hotstar was described as a DTC service primarily in India that offered general entertainment, family, and sports programming. It was positioned as a distinct regional brand within Disney’s broader Direct-to-Consumer portfolio. By 2024, while still branded as Disney+ Hotstar in India and Southeast Asia, the company had merged its previously separate Star+ and Disney+ services in Latin America into a single Disney+ product offering by the end of June 2024. This indicates a strategic shift toward consolidating regional streaming services under the Disney+ brand umbrella, streamlining offerings, and possibly enhancing content integration across markets.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 Disney re‑positioned Disney+ Hotstar from a stand‑alone, India‑focused DTC service that carried general‑entertainment, family and sports content to a distinct regional brand that is kept out of the company’s multi‑product bundles.  In 2023 the filing described Hotstar simply as “a DTC service primarily in India that offers general entertainment, family and sports programming,” whereas the 2024 filing notes that the former Star+ offering in Latin America was merged into a single Disney+ product and that Disney+ Hotstar remains a separate service (outside the U.S. and Canada) with its own branding and subscriber reporting.  Thus, Hotstar’s market strategy evolved to preserve its separate regional identity while the broader Disney+ portfolio was consolidated under a unified brand.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth. It accurately captures that Disney+ Hotstar remained a distinct regional brand in India and Southeast Asia, offering general entertainment, family, and sports content. It correctly notes the 2024 merger of Star+ and Disney+ in Latin America into a single Disney+ product, which reflects the strategic consolidation under the Disney+ brand. The answer correctly identifies that Disney+ Hotstar remains separate outside the U.S. and Canada with its own branding and subscriber reporting, preserving its regional identity. However, the LLM slightly mischaracterizes the evolution by implying that the shift was toward keeping Hotstar 'out of multi-product bundles'—a detail not present or implied in the original answer. The original emphasizes brand consolidation in Latin America (Star+ merged into Disney+) while maintaining Hotstar’s regional branding, but does not mention bundling strategy. This is a minor omission in nuance rather than a factual error. All dates (2023 to 2024), entities (Disney+ Hotstar, Star+, Latin America, India), and strategic moves are correctly identified. There are no numerical inaccuracies (quantitative accuracy is perfect as no calculations or figures are involved). The reasoning is sound and synthesizes the multi-hop elements (regional branding changes across years and geographies). The answer is contextually relevant and addresses both regional branding and service structure evolution. Minor deduction in qualitative accuracy due to the unsupported mention of bundling; otherwise, the response is strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 441,
        "total_tokens": 1818
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How did PayPal's approach to its Protection Programs evolve between 2023 and 2024, particularly in terms of risk exposure and loss recovery mechanisms?",
      "original_answer": "In 2023, PayPal disclosed that the costs associated with its protection programs were recorded in 'transaction and credit losses' during the period the payment transaction was completed, and it did not provide a separate service to customers under these programs. By 2024, PayPal introduced more detailed disclosures around its protection programs, highlighting that it incurs substantial losses from these programs due to customer disputes and faces challenges in recovering losses from merchants, especially in cases involving fraud or merchant insolvency. Additionally, PayPal noted that it may face increased exposure due to evolving fraud schemes and potential regulatory changes affecting chargeback requirements. This indicates a shift toward more explicit risk acknowledgment and a broader understanding of potential financial impact.",
      "llm_answer": "\nBetween 2023 and 2024 PayPal kept protection‑program costs on the books as a provision for transaction and credit losses, but the 2024 disclosure sharpened the focus on risk.  The company now reports a more granular loss‑rate metric, expands the scope of transactions covered by purchase‑and‑seller protection, and introduces new recovery tools—such as forward‑flow sales of BNPL receivables and tighter merchant‑recovery initiatives—while still noting that full recovery of disputed losses remains uncertain and can be affected by regulatory changes.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general direction of PayPal's evolving approach to protection programs between 2023 and 2024, correctly noting increased risk disclosure and challenges in loss recovery. It accurately reflects that costs were recorded under transaction and credit losses in 2023 and that 2024 brought more detailed risk acknowledgment. However, several key details in the LLM response are not supported by the original answer: (1) There is no mention in the ground truth of a 'more granular loss-rate metric' or expansion of coverage scope for purchase-and-seller protection; (2) The introduction of 'forward-flow sales of BNPL receivables' and 'tighter merchant-recovery initiatives' as new recovery tools is not present in the original answer and appears to be fabricated or inferred beyond available evidence; (3) While the original answer notes challenges in recovering losses from merchants due to fraud or insolvency, it does not mention any new recovery mechanisms. The LLM adds speculative operational enhancements not found in the source. The core evolution—increased transparency, recognition of substantial losses, merchant recovery difficulties, and exposure to fraud and regulation—is partially correct, but the addition of unverified mechanisms reduces factual accuracy. Quantitative accuracy is high because there are no specific numbers that conflict (the answer avoids citing figures), but qualitative accuracy suffers due to incorrect synthesis and unsupported additions. Contextual relevance is strong as the response stays on topic and addresses risk exposure and loss recovery as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 440,
        "total_tokens": 1790
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has NextEra Energy's relationship with solar generation facilities evolved from 2022 to 2024, particularly in terms of ownership structure and financial exposure?",
      "original_answer": "In 2022, NextEra Energy Resources was actively divesting ownership stakes in solar generation facilities, including the sale of a 100% ownership interest in a 100 MW solar facility in Arizona and the sale of a 90% ownership interest in a portfolio that included four solar facilities. These transactions resulted in significant cash proceeds and the recognition of gains. By 2024, the company's relationship had transformed into a more complex structure involving equity stakes and consolidated variable interest entities (VIEs). For example, NextEra consolidated eight VIEs owning solar generation facilities with approximately 765 MW of capacity and held a 10% direct ownership interest in additional solar facilities. This shift indicates a strategic move from outright ownership and divestiture to a more diversified and financially leveraged stake through VIEs, with increased financial exposure through guarantees and credit support.",
      "llm_answer": "\nFrom 2022 through 2024 NextEra shifted most solar assets from direct ownership to a “Class B‑membership” structure in which it retained a controlling interest but sold the economic upside (and, in some cases, redemption rights) to third‑party investors; these interests are reported as non‑controlling or, when redemption features exist, as redeemable non‑controlling interests on the balance sheet.  Because the projects are now consolidated variable‑interest entities, NextEra’s financial exposure is limited to contingent obligations—such as the potential repurchase of sold assets or return of proceeds (up to roughly $668 million) and payments tied to the achievement of commercial‑operation dates or a solar production‑tax‑credit—rather than to full equity ownership.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the strategic shift from direct ownership to a more complex structure involving variable interest entities (VIEs) and retained controlling interests while selling economic rights, which aligns with the ground truth. It accurately describes the financial reporting treatment (non-controlling and redeemable non-controlling interests) and notes contingent obligations as part of financial exposure. However, it omits specific 2022 divestiture examples cited in the original answer—namely, the 100% sale of a 100 MW Arizona solar facility and the 90% sale in a portfolio of four solar facilities—which are key factual anchors for the evolution narrative. (2) The LLM introduces a specific dollar figure of approximately $668 million related to potential repurchase obligations. This number does not appear in the original answer and cannot be verified against the provided ground truth, representing a potential hallucination or unsupported specificity. The original answer mentions 'significant cash proceeds' and 'gains' in 2022 but provides no dollar amounts. Thus, the quantitative accuracy is compromised by this unverified figure. (3) The multi-hop reasoning is sound: the model synthesizes changes in ownership structure (from full ownership to VIE consolidation with minority economic stakes) and infers correct implications for financial exposure and balance sheet treatment. It correctly identifies the shift in strategy and the use of VIEs by 2024. However, it fails to explicitly reference the 765 MW of solar capacity across eight VIEs consolidated by NextEra in 2024—a key quantitative benchmark in the original answer. (4) Despite missing specific examples and introducing an unsupported number, the LLM conveys the core strategic evolution and structural shift accurately. The answer is contextually relevant and semantically close to the original, earning high marks for qualitative reasoning and relevance, but loses points on quantitative accuracy due to the unverified $668 million figure and omission of key metrics like 100 MW, 90%, and 765 MW from the original.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1433,
        "completion_tokens": 571,
        "total_tokens": 2004
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How did ACN's investment in Mutual Fund Debt Securities evolve from 2022 to 2023, and what was the change in valuation methodology as reflected in the fair value hierarchy levels?",
      "original_answer": "In 2022, ACN reported Mutual Fund Debt Securities valued at $379,989 with the entire amount categorized under Level 2 of the fair value hierarchy. In 2023, this investment decreased to $253,025, and the valuation remained entirely under Level 2. The decrease in value indicates a reduction in exposure to Mutual Fund Debt Securities over the year, while the valuation methodology remained consistent, relying on observable market data.",
      "llm_answer": "\nFrom fiscal 2022 to fiscal 2023 the balance of ACN’s mutual‑fund debt‑security holdings in its non‑U.S. defined‑benefit plans was essentially unchanged – $379,989 million (shown as a Level 2 item) in both years – indicating only a modest, flat evolution of the position.  The valuation methodology did not shift; the securities remained classified as Level 2 in the fair‑value hierarchy, continue to be measured using quoted prices for similar instruments in active markets.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that the balance was 'essentially unchanged' and reported as $379,989 million in both years. The original answer shows a decrease from $379,989 in 2022 to $253,025 in 2023. The LLM incorrectly claims the amount remained the same and adds 'million' (i.e., thousands vs. millions), which grossly misrepresents the scale. This is a critical quantitative error. (2) The numbers are not accurate: the 2023 value is wrong (claims $379,989 million instead of $253,025), and the unit 'million' is erroneously appended to the 2022 figure (which is already in thousands or dollars, not millions). The difference of over $126,000 is ignored. (3) The reasoning is flawed: the LLM concludes 'flat evolution' when the actual data shows a significant decrease (~33%). While it correctly notes that valuation remained in Level 2, it fails to acknowledge the reduction in exposure, which is a key point in the original answer. (4) Contextual relevance is moderate because it addresses the right topic (Mutual Fund Debt Securities, Level 2 classification), but the core quantitative facts and trend interpretation are wrong, undermining the answer's validity. The valuation methodology part is accurate, but this does not compensate for the major factual inaccuracies in the financial values and trend analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1235,
        "completion_tokens": 378,
        "total_tokens": 1613
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has Chevron's financial stake and involvement in Tengizchevroil evolved between 2022 and 2023?",
      "original_answer": "In 2022, Chevron's carrying value of its investment in Tengizchevroil was $23,727 million with a reported equity in earnings of $1,238 million. By 2023, Chevron disclosed that its carrying value was approximately $80 million higher than its underlying equity in Tengizchevroil's net assets, indicating a more complex valuation approach. Additionally, Chevron highlighted that it provided a loan of $4,500 million to Tengizchevroil to fund the Future Growth Project and Wellhead Pressure Management Project (FGP/WPMP). This shows a significant deepening of Chevron's financial involvement and strategic commitment to the partnership in 2023 compared to 2022.",
      "llm_answer": "\nChevron’s equity stake in Tengizchevroil remained at 50 percent, but the carrying value of its investment rose from **$26.5 bn (2022)** to **$26.9 bn (2023)**, and the share of earnings generated by the affiliate increased from **$2.83 bn (2022)** to **$3.38 bn (2023)**.  This growth reflects a modest increase in the loan to TCO (still about $4.5 bn) and higher earnings from the Tengiz and Korolev fields, underscoring a deepening financial involvement in the joint venture over the two years.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key financial figures. According to the ground truth, in 2022, Chevron's carrying value was $23,727 million (~$23.7B), not $26.5B as stated. The reported equity in earnings was $1,238 million ($1.238B), not $2.83B. The 2023 figures in the LLM answer ($26.9B carrying value, $3.38B earnings) are also incorrect and not supported by the original data. The only correct quantitative element is the $4.5 billion loan to Tengizchevroil for the FGP/WPMP projects, which matches the ground truth. (2) Calculations and comparisons are therefore flawed: the LLM reports a rise in earnings from $2.83B to $3.38B, implying a ~19% increase, whereas the actual increase was from $1.238B to an unspecified 2023 amount (the ground truth does not provide 2023 earnings, only a valuation difference). The carrying value increase from $23.7B to ~$23.8B (implied by 'approximately $80 million higher') is misrepresented as a jump to $26.9B. (3) The multi-hop reasoning is partially sound in that the LLM attempts to show evolution in financial involvement and correctly notes the continued 50% equity stake and the $4.5B loan. However, it fabricates or misreports earnings and carrying values, undermining the synthesis. The ground truth emphasizes a shift in valuation methodology in 2023 (carrying value $80M above equity in net assets), which the LLM omits entirely, missing a key qualitative insight. (4) Correctness is severely penalized due to major numerical errors. Quantitative accuracy is very low (2/10) because most numbers are wrong. Qualitative accuracy is moderate (4/10) as the structure and intent are reasonable but lack fidelity. Contextual relevance is high (7/10) because the answer addresses the evolution of involvement and includes relevant elements like the loan and earnings trend, albeit with incorrect data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1276,
        "completion_tokens": 511,
        "total_tokens": 1788
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has Disney's relationship with ABC Network evolved between 2023 and 2024, particularly in terms of its strategic positioning within Disney's broader entertainment ecosystem?",
      "original_answer": "In 2023, ABC Network was positioned as a core component of Disney's 'Linear Networks' within the Entertainment segment, specifically highlighting its domestic footprint through eight owned ABC television stations and its role in content distribution. By 2024, ABC Network's role had evolved, with its programming becoming more integrated into Disney's direct-to-consumer platforms, such as Hulu and Disney+. Specifically, content from ABC Network was made available on Hulu's SVOD service one day after its linear airing. This shift indicates a strategic move toward digital integration and away from traditional linear distribution. Additionally, while ABC Network was still referenced in the context of affiliate fees in 2023, 2024 emphasized its contribution to streaming services rather than standalone linear revenue.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 Disney has tightened ABC Network’s role as the primary broadcast outlet for its sports content, explicitly funding ESPN’s programming on ABC and positioning the network to carry the upcoming joint‑venture sports‑DTC service (Venu Sports) and a 2025 live‑stream offering of ESPN channels.  At the same time, ABC continues to generate strong affiliate‑fee and advertising revenue, reinforcing its status as a strategic bridge that links Disney’s traditional linear‑network business to its expanding direct‑to‑consumer and multi‑platform entertainment ecosystem.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and fails to align with the ground truth. (1) It incorrectly emphasizes ABC's role in sports programming and the Venu Sports DTC service, which is not supported by the original answer and introduces entities (e.g., Venu Sports, 2025 live-stream offering) not mentioned in the ground truth. (2) There are no numeric values to verify, but the temporal claims (fiscal 2023–2024 evolution) are misaligned—the ground truth highlights a shift toward digital integration via Hulu and Disney+, not sports expansion. (3) The multi-hop reasoning is flawed: the original answer stresses ABC’s transition from linear distribution (with affiliate fees in 2023) to digital content pipeline (2024 integration with Hulu), whereas the LLM focuses on sports and affiliate revenue continuity, missing the core strategic shift. (4) While ABC being part of Disney’s broader ecosystem is contextually relevant, the LLM misrepresents the nature of the evolution—emphasizing linear continuity rather than digital transition. Key points like day-after availability on Hulu and reduced emphasis on affiliate fees in 2024 are entirely omitted. Thus, despite some contextual plausibility, the answer is factually and strategically incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 353,
        "total_tokens": 1714
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has General Dynamics' positioning of the ASCOD vehicle within its Land Systems portfolio evolved between 2022 and 2023, and what does this indicate about potential shifts in production focus or investment allocation?",
      "original_answer": "In 2022, General Dynamics explicitly stated it was 'producing and upgrading' the ASCOD vehicle, indicating active development and enhancement of the platform. By 2023, the company's disclosure shifted to simply 'offering' the ASCOD, without specific mention of production or upgrades. This change in language suggests a potential shift in focus away from active investment or development of the ASCOD platform, possibly reallocating resources to other vehicle programs like the Piranha 5 and AJAX, which are explicitly called out in both years with continued production and international deployments.",
      "llm_answer": "\nBetween 2022 and 2023 General Dynamics shifted the ASCOD from a peripheral “offered” tracked vehicle in the European Land Systems lineup to a highlighted, export‑focused centerpiece of that portfolio—explicitly calling it a “highly versatile tracked combat vehicle” and tying it to the company’s broader investment in robotic/autonomous platforms.  This emphasis, together with the rise in Combat Systems revenue (military‑vehicle sales up from $4.7 B in 2021 to $5.0 B in 2023) and the growing backlog of vehicle programs, signals that GD is reallocating production capacity and R&D spend toward tracked combat‑vehicle development (including ASCOD and related variants) to capture export growth and modernize its land‑systems focus.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth. (1) It claims that General Dynamics elevated the ASCOD vehicle from a 'peripheral' to a 'highlighted' position between 2022 and 2023, describing it as a 'centerpiece' with increased investment. However, the original answer shows the opposite: in 2022, GD was 'producing and upgrading' ASCOD, but in 2023 only 'offering' it, indicating a reduction in active development. This misrepresents the core factual evolution. (2) The LLM cites a rise in Combat Systems revenue from $4.7B (2021) to $5.0B (2023) and links it to ASCOD investment, but this data is not in the ground truth and cannot be verified from the provided context. The years referenced (2021–2023) do not align with the 2022–2023 focus of the question, and no revenue figures were mentioned in the original answer. (3) The multi-hop reasoning is flawed: instead of recognizing the downgrading of ASCOD’s status, the model incorrectly infers increased focus and investment, drawing opposite conclusions from the evidence. It also introduces unverified programs and strategic priorities (e.g., robotic/autonomous platforms, export growth) not supported by the ground truth. (4) While the answer addresses the question's structure and discusses production focus and investment allocation, its factual foundation is inverted, leading to a misleading interpretation. The contextual relevance is moderate because it engages with the topic of portfolio evolution and investment shifts, but the qualitative and quantitative inaccuracies severely undermine correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 434,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has PayPal's utilization of European customer balances for credit activities evolved between 2023 and 2024, and what does this shift indicate about the company's credit funding strategy?",
      "original_answer": "In 2023, PayPal had approved $3.0 billion of European customer balances for credit activities, representing approximately 39% of balances made available for corporate use. By 2024, the approved amount had decreased to $2.0 billion, or 26% of European customer balances. This indicates a strategic shift toward reducing reliance on customer balances for credit funding, potentially in favor of external financing sources, as evidenced by PayPal's multi-year agreement to sell consumer installment receivables, which saw $20.8 billion in loans sold in 2024 compared to $5.5 billion in 2023.",
      "llm_answer": "\nBetween 2023 and 2024 the pool of European customer balances that PayPal can earmark for credit‑funding fell sharply—from about **$3.0 billion (≈ 39 % of European balances)** in 2023 to **$2.0 billion (≈ 26 % of European balances)** in 2024.  This reduction shows that PayPal is pulling back on its reliance on internal customer deposits as a source of credit capital and is instead leaning more on external financing (e.g., debt issuances, partnership funding) to support its loan and advance portfolios.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: the approved amounts of European customer balances for credit activities were $3.0 billion (39%) in 2023 and $2.0 billion (26%) in 2024—matching the original answer exactly. Number formats are consistent and acceptable. (2) Quantitative accuracy is perfect: values, percentages, and years are all correctly reported. (3) The reasoning is sound—correctly identifying a strategic shift away from internal customer balances toward external financing. However, the LLM omits a specific piece of evidence mentioned in the ground truth: PayPal’s multi-year agreement to sell consumer installment receivables, with $20.8 billion sold in 2024 versus $5.5 billion in 2023. This is a notable omission in the qualitative synthesis, slightly weakening the support for the external financing claim, though the conclusion is still logically plausible. (4) Despite this omission, the answer remains contextually relevant, directly addressing both parts of the question—evolution between 2023 and 2024 and the strategic implication. The core message is semantically equivalent to the original. Minor deduction from qualitative accuracy due to missing evidentiary detail, but no error in logic or facts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1284,
        "completion_tokens": 359,
        "total_tokens": 1643
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How did the valuation and categorization of equity securities within NEE's Special Use Funds evolve between 2022 and 2024, and what does this indicate about changes in transparency or investment composition?",
      "original_answer": "In 2022, NEE's Special Use Funds reported equity securities at a carrying amount of $906 million (with an estimated fair value of $907 million) for NEE and $672 million (with an estimated fair value of $672 million) for FPL, without detailed categorization by valuation levels. By 2024, the equity securities in the Special Use Funds had grown significantly, with NEE holding $2,614 million in Level 1 equity securities and FPL holding $1,028 million in Level 1 equity securities, alongside more granular disclosures that included Level 2 and Level 3 valuations. This indicates a substantial increase in equity investments and a shift toward more transparent and detailed reporting of asset valuation methodologies.",
      "llm_answer": "\nBetween the 2022 filing (which reports the 2021 year‑end balances) and the 2024 filing (which reports the 2024 year‑end balances), equity securities held in NEE’s Special Use Funds remained classified almost entirely as Level 1 or Level 2 in 2022—$2,538 M and $2,973 M for NEE, and $862 M and $2,690 M for FPL, with $0 M in Level 3. By 2024 the same funds showed a non‑zero Level 3 balance of $229 M for NEE and $204 M for FPL, while total equity holdings grew modestly (e.g., NEE’s equity securities rose from $5,511 M to $6,164 M).  \n\nThe emergence of a Level 3 component indicates that a larger share of the fund’s equity investments is now valued using unobservable inputs and significant management judgment, reflecting a shift toward more complex, less‑transparent assets in the fund’s composition.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and misrepresents both the time periods and financial figures from the ground truth. (1) QUANTITATIVE INACCURACY: The LLM claims that in 2022, NEE held $2,538M in Level 1 and $2,973M in Level 2 equity securities, but the ground truth states that in 2022, NEE reported a total carrying amount of $906M (fair value $907M) without breakdown by valuation levels—meaning the LLM's numbers are fabricated and overstate holdings by more than 5x. Similarly, FPL's 2022 equity securities were $672M total, not the $862M and $2,690M cited. The LLM also claims total equity holdings grew from $5,511M to $6,164M for NEE, which contradicts the ground truth that NEE's 2024 Level 1 equity securities alone were $2,614M—far below the claimed totals. (2) ENTITY/TIMING ERROR: The LLM incorrectly states that the 2022 filing reports 2021 year-end balances, when the question and ground truth clearly refer to 2022 and 2024 year-end data. This misalignment invalidates the comparison. (3) REASONING FLAW: The LLM concludes that the emergence of Level 3 assets indicates a shift toward less transparent investments, but the ground truth emphasizes increased transparency due to more granular disclosures (including Level 2 and Level 3), not reduced transparency. The presence of Level 3 does not inherently imply less transparency if properly disclosed. (4) COMPLETENESS: The LLM fails to mention that 2022 had no categorization by level (Level 1/2/3), which is a key point in the evolution toward transparency. Instead, it falsely asserts that 2022 already had Level 1/2 classifications. (5) CONTEXTUAL RELEVANCE: While the answer addresses valuation levels and attempts to interpret transparency implications, the severe factual errors undermine its validity. The core conclusion is inverted from the ground truth: the actual trend is toward greater transparency and more detailed reporting, not less. Minor credit is given for addressing the right topic (valuation levels and transparency).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1395,
        "completion_tokens": 544,
        "total_tokens": 1939
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How did the scope and utilization of Accenture's share purchase program evolve from fiscal 2022 to fiscal 2023, particularly in terms of shares acquired under the public program versus those acquired through employee-related transactions?",
      "original_answer": "In fiscal 2022, Accenture purchased 1,964,612 Class A ordinary shares under the publicly announced open-market share purchase program for an aggregate price of $576 million. Additionally, 97,251 shares were acquired through employee-related transactions, such as share withholding for payroll tax obligations, which do not affect the aggregate available authorization. In fiscal 2023, there is no mention of shares purchased under the public program, but the company continued acquiring shares through employee-related transactions under equity share plans. This indicates a shift where the public share purchase program saw reduced or no activity, while employee-related share acquisitions remained consistent.",
      "llm_answer": "\nFrom fiscal 2022 to fiscal 2023 the company broadened the scope of its share‑repurchase authority – the open‑market program’s available authorization rose from $3.1 bn (as of Aug 2022) to about $6.1 bn after the September 2022 Board approval and continued to expand in FY 2023 – and increased the volume of purchases executed under that public program (≈2.0 million shares in Q4 FY 2023 versus 1.96 million shares in Q4 FY 2022).  At the same time, shares acquired through employee‑related transactions remained a tiny, separate slice of the total (roughly 0.1 million shares each year, acquired incidentally for payroll‑tax withholding and not part of the announced program).  Consequently, the public repurchase program’s utilization grew markedly, while employee‑related acquisitions stayed minimal and unchanged.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth in both quantitative and qualitative aspects. (1) Quantitatively, the LLM claims that Accenture increased share purchases under the public program in fiscal 2023 (e.g., '≈2.0 million shares in Q4 FY2023'), but the original answer states there is 'no mention of shares purchased under the public program' in fiscal 2023—meaning no such purchases were reported. The LLM also incorrectly states that the open-market authorization rose to $6.1B after a September 2022 Board approval, which is not supported by the ground truth and introduces unverified data. The only accurate number is the ~97,000 employee-related shares in FY2022, which the LLM rounds to '0.1 million'—this is acceptable. (2) The claim that 'purchases executed under that public program' increased is false; the ground truth indicates a reduction or cessation of public program activity. (3) Qualitatively, the reasoning is flawed: the LLM infers increased utilization of the public program and growing repurchase activity, while the correct interpretation is a shift *away* from the public program. The model fails to recognize the absence of public program activity in FY2023 as a key signal. (4) Contextually, the answer addresses the right topic (share purchase programs) and distinguishes between public and employee-related transactions, so relevance is moderate. However, the core conclusion is the opposite of the truth: it reports expansion and increased utilization, while the correct answer is reduced or no public program activity. This fundamental reversal results in a very low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1405,
        "completion_tokens": 447,
        "total_tokens": 1852
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How did Chevron's financial reporting relationship with Chevron Phillips Chemical Company LLC evolve between 2022 and 2023, particularly in terms of its consolidation status and investment accounting approach?",
      "original_answer": "In 2022, Chevron Phillips Chemical Company LLC was consolidated into Chevron’s financial statements, as indicated by the inclusion of 'Note 8: Summarized Financial Data - Chevron Phillips Chemical Company LLC' among other consolidated subsidiaries. However, in 2023, Chevron explicitly stated that its investment in Chevron Phillips Chemical Company LLC was accounted for using the equity method, and it was no longer consolidated under Chevron U.S.A. Inc.'s financial data. This reflects a significant structural change where Chevron transitioned from consolidating the entity to reporting its investment under the equity method, altering how its financial performance is reflected in Chevron’s consolidated results.",
      "llm_answer": "\nBetween 2022 and 2023 Chevron continued to treat Chevron Phillips Chemical Company LLC (CPChem) as an **equity‑method investment**—it was never consolidated into Chevron’s financial statements.  The company’s share of CPChem’s earnings fell from **$1.662 billion in 2022 to $1.173 billion in 2023**, and the carrying amount of the investment reflected this change (CPChem’s net equity rose from $13.569 bn to $14.683 bn), but the reporting approach and consolidation status remained unchanged.",
      "correctness_score": 2,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 2,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is fundamentally incorrect in its core claim about consolidation status. According to the ground truth, Chevron Phillips Chemical Company LLC (CPChem) was consolidated in 2022 but switched to equity method accounting in 2023. The LLM incorrectly states that CPChem was always an equity-method investment and never consolidated, which contradicts the original answer and misrepresents the evolution of the financial reporting relationship. (2) Quantitatively, the LLM provides specific numbers: Chevron’s share of CPChem earnings ($1.662B in 2022, $1.173B in 2023) and CPChem’s net equity ($13.569B to $14.683B). While these figures may be factually accurate within the dataset, they are irrelevant or misleading because they assume equity-method accounting applied in both years, which contradicts the 2022 consolidation status per the ground truth. Thus, the numbers are potentially accurate but applied in the wrong context, leading to incorrect interpretation. (3) The multi-hop reasoning is flawed. The question requires understanding a change in accounting treatment over time—specifically, a shift from consolidation to equity method. The LLM fails this synthesis, asserting no change occurred when the ground truth confirms a significant structural change. This indicates a failure to correctly interpret or retrieve the consolidation status in 2022 (via Note 8 indicating consolidation) versus the explicit 2023 disclosure of equity method use. (4) Contextual relevance is moderate—the response addresses the right entity (CPChem), time frame (2022–2023), and topic (accounting treatment)—but the central factual claim is inverted. Due to the severity of the error in consolidation status, which is the primary focus of the question, the correctness score is low despite some accurate numerical data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 498,
        "total_tokens": 1816
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the role of Hydra-70 rockets in General Dynamics' Combat Systems segment evolved from 2022 to 2023, particularly in terms of contract involvement and production capacity expansion?",
      "original_answer": "In 2022, General Dynamics received a $175 million contract for the production of Hydra-70 rockets as part of its Combat Systems segment. By 2023, the company's role had evolved significantly, with OTS (Orbital Technologies Corporation, part of Combat Systems) maintaining a market-leading position in the supply of Hydra-70 rockets and expanding its production capacity. Specifically, OTS received awards to increase metal parts production capacity for munitions from 18,000 to 86,000 rounds per month by 2025, which includes Hydra-70 rockets as part of its broader munitions portfolio.",
      "llm_answer": "\nFrom 2022 into 2023 the Hydra‑70 rocket line moved from a single, modest $175 million production award (recorded in the 2021 Combat Systems contract list) to a strategic growth area for General Dynamics.  In 2023 OTS received new awards that explicitly expand its metal‑parts production from 18 k to 86 k rounds per month by 2025 and its propellant capacity from 4 M to 16 M lb/yr by 2028, signaling a deeper contract involvement and a planned scale‑up of Hydra‑70 output to meet rising Army and international demand.  This reflects a shift from a one‑off contract to an ongoing, capacity‑expansion‑focused commitment within the Combat Systems segment.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $175 million contract in 2022 (though it incorrectly references '2021 Combat Systems contract list' despite the event occurring in 2022 per ground truth). It accurately reports the expansion of metal parts production capacity from 18,000 to 86,000 rounds per month by 2025, which aligns with the original answer. However, it introduces new information not present in the ground truth: an expansion of propellant capacity from 4M to 16M lb/yr by 2028. This detail is absent in the original answer and cannot be verified from the provided knowledge graph, constituting a factual overreach. (2) Quantitative accuracy is mostly correct—$175M, 18k to 86k rounds/month by 2025 are accurate. The erroneous inclusion of propellant capacity figures reduces precision. (3) The multi-hop reasoning is strong: the model correctly infers an evolution from a production contract to strategic capacity expansion, synthesizing contract awards with production scaling. It correctly identifies OTS as part of Combat Systems and links it to Hydra-70 rockets. (4) Despite the addition of unverified propellant data, the core facts, timeline, and strategic interpretation match the ground truth. The answer addresses both contract involvement and production capacity, fulfilling the question's requirements. The score is reduced due to unsupported quantitative claims, but the overall reasoning and relevance remain high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 402,
        "total_tokens": 1723
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has PayPal's treatment of the Global Restricted Stock Unit Award Grant Notice evolved between the 2023 and 2024 filings, particularly in terms of its documentation status and associated agreements?",
      "original_answer": "In the 2023 filing, the Global Restricted Stock Unit Award Grant Notice was listed as Exhibit 10.07+ and was associated with the PayPal Holdings, Inc. 2015 Equity Incentive Award Plan, with its form incorporated by reference from 10-12B/A filed on May 14, 2015. By 2024, the same form of the Global Restricted Stock Unit Award Grant Notice (Exhibit 10.07+) remained in place, still referencing the 2015 plan and incorporated by reference from the same 10-12B/A filing on May 14, 2015. However, in the 2024 filing, there was an updated form of the Global Performance Based Restricted Stock Unit Award Grant Notice (Exhibit 10.08+), which was now filed under the amended and restated plan and was linked to a more recent 10-Q filing on April 30, 2024. This indicates that while the base RSU grant notice remained unchanged, the performance-based variant saw active revision and documentation updates in 2024.",
      "llm_answer": "\nIn the 2023 Form 10‑K the Global Restricted Stock Unit Award Grant Notice was disclosed only as Exhibit 10.07+, a form that had been originally filed in 2015 and incorporated by reference; the notice itself was not separately reproduced in the 2023 filing. By the 2024 filing the same exhibit remains, but it is now presented as part of the “PayPal Holdings, Inc. 2015 Equity Incentive Award Plan, as Amended and Restated” (Exhibit 10.03+) and is accompanied by a new Exhibit 10.08+ for performance‑based RSUs, showing that the grant‑notice language has been formally updated and explicitly incorporated into the current plan documentation.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core factual elements correctly: the Global Restricted Stock Unit Award Grant Notice remains as Exhibit 10.07+ in both years and was originally incorporated by reference from the 2015 filing. It correctly notes the continued use of the 2015 plan and identifies the introduction of a new Exhibit 10.08+ for performance-based RSUs in 2024. However, there are inaccuracies in the description of how the exhibit is presented in the 2024 filing. The LLM claims that Exhibit 10.07+ is now 'presented as part of the PayPal Holdings, Inc. 2015 Equity Incentive Award Plan, as Amended and Restated (Exhibit 10.03+)', which implies reintegration or restructuring that is not supported by the ground truth. The original answer states that the base RSU notice remains unchanged and still incorporated by reference from the same 2015 10-12B/A filing, with no indication it was refiled or newly linked to the amended plan document in 2024. Additionally, while the LLM mentions the new Exhibit 10.08+, it fails to specify that it was linked to a 10-Q filing on April 30, 2024, a key detail indicating active updating. The reasoning is partially sound but overstates integration with the amended plan. Quantitative accuracy is high—no incorrect dates or exhibit numbers—but the qualitative synthesis contains a subtle but important misrepresentation of documentation status. Contextual relevance is strong as the response directly addresses the evolution of the grant notice between filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1400,
        "completion_tokens": 411,
        "total_tokens": 1812
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the role of Opdivo within Bristol-Myers Squibb's portfolio evolved from 2022 to 2024, based on its revenue performance and new regulatory approvals?",
      "original_answer": "In 2022, Opdivo generated $7,523 million in revenue, indicating it was a major contributor to Bristol-Myers Squibb's oncology portfolio. By 2024, Opdivo received a new FDA approval in March 2024 for use in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. This regulatory expansion demonstrates a strategic evolution in Opdivo’s therapeutic application and reinforces its continued importance in the company's oncology pipeline, despite not showing a significant revenue increase from earlier years.",
      "llm_answer": "\nOpdivo’s sales have risen steadily—from $6.99 bn in 2020 to $7.52 bn in 2021 and continued double‑digit growth through 2022‑2024—while the brand accumulated a series of new regulatory milestones (FDA approval of the subcutaneous formulation Opdivo Qvantig in Dec 2024, EC approval of the Opdivo + Yervoy first‑line colorectal‑cancer combo, Japan approvals for urothelial‑cancer and other indications, and expanded uses in melanoma, NSCLC and renal cancer).  These approvals broadened Opdivo’s therapeutic footprint and cemented its position as BMS’s flagship immuno‑oncology franchise and a primary growth engine within the company’s portfolio.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The revenue figures cited ($6.99B in 2020, $7.52B in 2021) are not supported by the ground truth, which only provides 2022 revenue of $7,523 million (approximately $7.52B). The claim of 'continued double-digit growth through 2022–2024' is incorrect and unsupported—no data for 2023 or 2024 revenue is provided in the ground truth, and the original answer explicitly notes no significant revenue increase. Additionally, the LLM claims an FDA approval for Opdivo Qvantig in December 2024, but the ground truth states the key approval was in March 2024 for urothelial carcinoma in combination with cisplatin and gemcitabine. Other approvals mentioned (EC approval for colorectal cancer, Japan approvals, melanoma, NSCLC, renal cancer) are not in the ground truth and are therefore unverified or incorrect. (2) Quantitative accuracy is low: the LLM fabricates revenue data for 2020 and 2021 and misrepresents growth trends. The only correct number is approximately $7.52B for 2022 (matching $7,523 million), but even this is attributed to 2021 in the LLM answer. The 2024 approval date is also wrong—March 2024 vs. December 2024. (3) Multi-hop reasoning is flawed: the LLM fails to correctly synthesize the evolution of Opdivo based on verified revenue and regulatory milestones. Instead, it invents a narrative of continuous growth and multiple approvals not present in the ground truth. The core insight from the original answer—that Opdivo remains strategically important due to new indications despite stagnant revenue—is missed. (4) Contextual relevance is moderate because the answer discusses Opdivo’s role in BMS’s portfolio and regulatory approvals, which is relevant, but the incorrect data and fabricated approvals severely undermine factual correctness. The answer appears plausible but is largely inaccurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1312,
        "completion_tokens": 511,
        "total_tokens": 1823
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did Chevron's financial involvement and strategic support for Chevron Phillips Chemical Company LLC evolve between 2022 and 2023, particularly in terms of project funding and investment structure?",
      "original_answer": "In 2022, Chevron highlighted its 50% ownership in Chevron Phillips Chemical Company LLC (CPChem), emphasizing ongoing investments in global manufacturing facilities and expansion projects, such as the planned 1-hexene unit in Old Ocean, Texas, and a C3 splitter at Cedar Bayou, with targeted start-ups in 2023. By 2023, Chevron's involvement had evolved to include a direct loan of $387 million to fund a portion of the Golden Triangle Polymers Project in Orange, Texas, in which CPChem owns 51%. This indicates a shift from general equity ownership and project announcements in 2022 to more direct financial support and structured investment in specific projects in 2023.",
      "llm_answer": "\nChevron’s equity stake in Chevron Phillips Chemical Company LLC grew from $6.84 billion at the end of 2022 to $7.77 billion in 2023, reflecting an incremental capital infusion.  This additional funding was directed toward the two flagship CPChem projects that received final investment decisions in 2021—a 266 kt/yr on‑purpose 1‑hexene unit at Old Ocean, Texas, and a new C3 splitter at Cedar Bayou, Texas—both slated for start‑up in 2023.  Chevron kept its 50 % ownership structure but expanded the investment mix to include extra equity contributions and project‑specific loans to support these downstream petrochemical expansions.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in quantitative details. The claim that Chevron's equity stake in CPChem grew from $6.84 billion to $7.77 billion is not supported by the ground truth, which does not mention these specific equity values or an increase in ownership stake. The 50% ownership is correctly noted, but the financial figures for equity are fabricated or misstated. Additionally, while the 1-hexene unit and C3 splitter projects are correctly identified with their locations and 2023 start-up targets, the LLM incorrectly states that funding came through 'incremental capital infusion' and 'extra equity contributions,' whereas the ground truth specifies a $387 million direct loan for a different project—the Golden Triangle Polymers Project. (2) The $387 million loan to fund part of the Golden Triangle Polymers Project (in which CPChem owns 51%) is entirely missing from the LLM answer, and instead, it invents equity growth numbers not present in the original. This is a major quantitative and factual error. The project start-up dates and locations (Old Ocean, Cedar Bayou) are consistent and correct. (3) The multi-hop reasoning is partially sound—linking Chevron to CPChem, identifying key projects, and noting evolution in support—but fails the critical synthesis: it misses the shift from general equity-backed investment in 2022 to a specific, direct loan structure in 2023. Instead, it implies continued equity funding, contradicting the ground truth. (4) Contextual relevance is high as the answer addresses financial involvement, project funding, and investment structure over the two years. However, due to major factual and numerical inaccuracies, especially the invented equity values and omission of the $387M loan, the correctness and quantitative accuracy scores are low. The qualitative accuracy is moderate because some entities and projects are correctly identified, but the reasoning and financial mechanisms are misrepresented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 542,
        "total_tokens": 1882
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did PayPal's protection programs evolve between 2023 and 2024 in terms of financial commitments and disclosures regarding transaction loss reserves?",
      "original_answer": "In 2023, PayPal disclosed that it estimated and recorded costs associated with protection programs in transaction and credit losses, but did not specify the exact amounts for the allowance for transaction losses or negative customer balances. In 2024, PayPal provided more detailed disclosures, including specific figures: the allowance for transaction losses increased from $64 million in 2023 to $86 million in 2024, and the allowance for negative customer balances rose from $218 million to $256 million. This indicates a significant increase in PayPal's financial commitments and potential risk exposure under its protection programs in 2024 compared to the prior year.",
      "llm_answer": "\nBetween 2023 and 2024 PayPal’s protection‑program reserves grew substantially – the allowance for transaction losses rose from **$64 million (2023) to $86 million (2024)** and the allowance for negative customer balances increased from **$218 million to $256 million**.  The 2024 filing now provides a detailed roll‑forward table (beginning balance, provision, realized losses, recoveries, ending balance) that explicitly discloses these movements and notes that the costs are recorded as transaction and credit losses at the time each payment is completed, reflecting both a larger financial commitment to covering potential losses and more transparent quantitative disclosures.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: the allowance for transaction losses increased from $64 million in 2023 to $86 million in 2024, and the allowance for negative customer balances rose from $218 million to $256 million—both figures exactly match the original answer. (2) The answer is complete, addressing both the financial commitments (increased reserves) and disclosures (new roll-forward table in 2024), which reflects the evolution in transparency and reporting detail. (3) Entity accuracy is correct—PayPal is the subject, and the years 2023 and 2024 are properly referenced with appropriate financial metrics. (4) The reasoning is sound: the LLM correctly infers that the increased allowances indicate a larger financial commitment and that the introduction of a roll-forward table signifies improved disclosure transparency. The multi-hop synthesis—comparing disclosures and reserve levels across two years—is accurately executed. (5) The semantic meaning is equivalent to the original answer, with slightly enhanced detail (e.g., mentioning the roll-forward table structure), which adds value without introducing error. All criteria are met at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 351,
        "total_tokens": 1691
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has McDonald's strategic framing of its relationship with franchisees changed between 2022 and 2024, particularly in terms of franchising as a core business model and the role of franchisee co-investment?",
      "original_answer": "In 2022, McDonald's described its relationship with franchisees in neutral, structural terms, emphasizing the division of responsibilities such as franchised arrangements and license agreements, and presenting franchisees as co-participants in operating restaurants. By 2024, the framing evolved significantly, with franchising being described as 'paramount' to delivering food quality, customer experience, and profitability. The 2024 filing also emphasized the importance of franchisee co-investment, noting that it enables McDonald's to achieve high restaurant performance. This represents a shift from a descriptive to a more strategic and value-laden framing of the franchisee relationship.",
      "llm_answer": "\nBetween 2022 and 2024 McDonald’s continued to present franchising as the core of its business, but the way it described the franchise‑franchisee relationship grew more strategic.  In the 2022 filing the company merely noted that it “may co‑invest with franchisees to fund improvements” and that the heavily franchised model “generates stable and predictable revenue,” whereas the 2024 filing explicitly frames co‑investment as a deliberate partnership tool that “accelerates implementation of initiatives, modernizes restaurants and drives shared growth,” positioning franchising not just as a revenue source but as a collaborative platform for long‑term value creation.  This shift underscores a move from a descriptive view of co‑investment to a proactive, strategic emphasis on partnership‑driven expansion.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in McDonald's strategic framing between 2022 and 2024. It correctly identifies the shift from a more neutral, structural description in 2022—highlighting stable revenue and potential co-investment—to a more strategic, value-laden emphasis in 2024, where co-investment is framed as a tool for accelerating modernization and shared growth. The dates (2022 and 2024) and entities (McDonald's, franchisees) are correct, and there are no numerical inaccuracies (the question does not involve specific financial figures, so quantitative accuracy is based on correct use of qualitative descriptors, which are consistent with the ground truth). The reasoning is sound and reflects multi-hop synthesis: it contrasts language across filings and infers a strategic shift in framing. The only minor shortcoming is that the LLM does not explicitly use the term 'paramount'—a key descriptor from the 2024 filing in the ground truth—nor does it directly mention food quality or customer experience as outcomes tied to franchising. However, it effectively conveys the strategic elevation of franchising and co-investment as central to performance and growth, which aligns semantically. Thus, while slightly less detailed than the original answer on specific value drivers, the LLM response is factually correct, contextually relevant, and demonstrates strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1392,
        "completion_tokens": 394,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the FDA's authorization of Marlboro HeatSticks evolved between 2022 and 2023, and what does this indicate about Altria's regulatory progress with heated tobacco products?",
      "original_answer": "In 2022, the FDA had not yet authorized Marlboro HeatSticks and was considering them on a case-by-case basis regarding graphic health warnings. By 2023, the FDA had authorized PMTAs for three new tobacco-flavored varieties of Marlboro HeatSticks in January 2023, marking a significant regulatory milestone. This indicates that Altria made notable progress in securing FDA approval for its heated tobacco product line, which is a key part of its innovation strategy.",
      "llm_answer": "\nThe FDA’s stance on Marlboro HeatSticks shifted markedly between 2022 and 2023.  In the 2022 filing (MO 10‑K 2022, pp. 35‑39) the company notes that, after the September 2021 ITC cease‑and‑desist order that removed the product from the U.S. market, the FDA **authorized in March 2022 three new tobacco‑flavored HeatStick PMTAs** and extended the IQOS 3 marketing order as a Modified‑Risk Tobacco Product.  The 2023 filing (MO 10‑K 2023, pp. 33‑37) reports that the FDA **continued to recognize IQOS 3 as an MRTP and granted post‑market surveillance approvals**, reinforcing the earlier 2022 authorizations.  \n\nTogether, these actions show that Altria moved from a regulatory setback to securing FDA marketing authorizations for its heated‑tobacco products, indicating tangible regulatory progress in getting Marlboro HeatSticks back onto the U.S. market.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, the FDA did *not* authorize any Marlboro HeatSticks PMTAs in March 2022; instead, in 2022, the FDA was still considering them on a case-by-case basis. The actual authorization of three new tobacco-flavored Marlboro HeatSticks occurred in *January 2023*, not March 2022. The LLM incorrectly backdates a key regulatory milestone, reversing the timeline of progress. Additionally, the mention of an 'ITC cease-and-desist order in September 2021' removing the product from the market is contextually relevant but not part of the original answer and may conflate legal and regulatory timelines. (2) Quantitative accuracy is low: the date 'March 2022' is incorrect (should be January 2023), and the claim of three PMTAs being authorized in 2022 is false. The 2023 authorization is correctly noted in the ground truth but misattributed in timing and context in the LLM answer. (3) The multi-hop reasoning is partially sound—linking Altria’s regulatory progress across years and interpreting FDA actions as indicators of strategic advancement—but it is built on incorrect foundational facts. The synthesis between 2022 and 2023 filings is present, but the conclusion is undermined by the erroneous timeline. (4) Contextual relevance is high because the answer addresses the evolution of FDA authorization and its implication for Altria’s regulatory strategy. However, due to major factual and chronological errors, the correctness score is low despite appropriate framing and structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 434,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did the valuation of mutual fund equity securities held by ACN evolve between 2022 and 2023, and what does this shift indicate about the company's investment positioning in this category?",
      "original_answer": "In 2022, ACN reported $239,293 (in millions) in mutual fund equity securities. By 2023, this figure decreased to $196,226 (in millions), indicating a reduction of $43,067 (in millions). This decline suggests a strategic shift or reallocation away from mutual fund equity securities during the period.",
      "llm_answer": "\nThe fair‑value of ACN’s mutual‑fund equity securities rose from **$239 million at the end of fiscal 2022 to $274 million at the end of fiscal 2023**, an increase of roughly **14 %**. This jump reflects a deliberate shift toward a larger equity allocation in the company’s defined‑benefit pension portfolio, moving the assets closer to the 2023 target of **27 % equity** for non‑U.S. plans and signalling a strategic emphasis on growth‑oriented investments within that asset class.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both direction and magnitude of the valuation change. According to the ground truth, ACN's mutual fund equity securities decreased from $239,293 million in 2022 to $196,226 million in 2023, a reduction of $43,067 million. The LLM incorrectly states an increase from $239 million to $274 million (a 14% rise), which is factually wrong on all key metrics. The LLM also introduces unrelated concepts such as 'defined-benefit pension portfolio', '2023 target of 27% equity for non-U.S. plans', and 'growth-oriented investments', which are not supported by the original answer and appear to be hallucinated. The entity (ACN) and years (2022–2023) are correct, and the topic (mutual fund equity securities) is relevant, but the numerical data, trend direction, calculations, and reasoning are entirely inaccurate. The answer fails the multi-hop requirement by not correctly synthesizing the actual reported figures and misrepresenting the strategic implication. While the format of numbers is acceptable (e.g., $239 million vs $239,293 million), the values themselves do not match and the calculation is based on false premises. Thus, the correctness and quantitative accuracy are extremely low. Contextual relevance is slightly higher only because the general subject area and company are correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1206,
        "completion_tokens": 370,
        "total_tokens": 1576
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has Chevron's involvement in Angola LNG Limited evolved from 2022 to 2023, particularly in terms of its operational focus and investment emphasis?",
      "original_answer": "In 2022, Chevron operated and held a 36.4% interest in Angola LNG Limited, emphasizing its role in processing and liquefying associated natural gas from multiple fields and operators in Angola. The company was also involved in developing non-associated gas resources to supply the Angola LNG plant. By 2023, Chevron continued to hold the same 36.4% interest, but the disclosure shifted focus to its broader portfolio of equity affiliates and non-equity investments, with Angola LNG Limited being listed alongside other major investments like Tengizchevroil and Chevron Phillips Chemical Company LLC. This indicates a shift in disclosure emphasis from operational development to financial stake and integration within Chevron’s global portfolio.",
      "llm_answer": "\nChevron’s 36.4 % interest in Angola LNG Limited was unchanged from 2022 to 2023, but the company’s focus moved from simply keeping the Soyo plant running to actively developing the offshore gas that feeds it. In 2022 the emphasis was on sustaining plant throughput and tying in associated gas; by 2023 the emphasis shifted to investing in non‑associated gas discoveries and related infrastructure (e.g., the SLGC tie‑in project) to boost feedstock volume and expand LNG export capacity.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "1) The LLM correctly states that Chevron maintained a 36.4% interest in Angola LNG Limited from 2022 to 2023, which matches the ground truth. This satisfies quantitative accuracy. However, the qualitative description of the shift in operational focus diverges from the original answer. The LLM claims the 2023 focus shifted to 'investing in non-associated gas discoveries and related infrastructure (e.g., the SLGC tie-in project)' to expand LNG capacity. In contrast, the ground truth indicates that by 2023, the disclosure emphasis shifted to Chevron's broader portfolio of equity affiliates, with Angola LNG mentioned alongside Tengizchevroil and Chevron Phillips — suggesting a change in reporting focus from operational development to financial integration, not an acceleration in infrastructure investment. 2) All numbers (36.4%) and years (2022–2023) are accurate. No calculations were required. 3) The multi-hop reasoning is flawed: while the LLM correctly identifies the continuity of ownership, it infers an operational investment shift not supported by the ground truth. Instead of citing a change in disclosure strategy or portfolio-level reporting, it fabricates project-specific emphasis (SLGC tie-in) not present in the original. This reflects a failure to synthesize the correct reasoning across time and reporting context. 4) Despite accurate numbers and relevance to Chevron’s Angola LNG involvement, the core qualitative claim about evolving operational focus is incorrect. The answer introduces unsupported specifics (SLGC project) and misses the actual shift in disclosure emphasis. Hence, correctness is partially compromised, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 455,
        "total_tokens": 1764
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did MMM's investment in Certificates of Deposit/Time Deposits evolve from 2022 to 2023, and what was the magnitude of this change?",
      "original_answer": "In 2022, MMM held $14 million in Certificates of Deposit/Time Deposits, as disclosed in the fair value measurements. By 2023, this amount increased to $49 million, indicating a significant growth in this category of investment. This represents an increase of $35 million, or approximately 250%, from the prior year.",
      "llm_answer": "\nFrom 2022 to 2023 the amount of 3M’s investment in certificates of deposit/time deposits rose from **$21 million** (2022) to **$49 million** (2023).  This reflects an **increase of $28 million**, or roughly a **130 %‑140 % jump** in the size of the holding.",
      "correctness_score": 4,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the quantitative values. According to the ground truth, MMM's investment in Certificates of Deposit/Time Deposits was $14 million in 2022, not $21 million as stated by the LLM. The 2023 value of $49 million is correct in both answers. Therefore, the calculated change is incorrect: the actual increase is $35 million (from $14M to $49M), not $28 million. The percentage increase is approximately 250% (35/14 ≈ 2.5), not 130–140% as claimed. (2) Number verification: 2022 value wrong ($21M vs $14M), 2023 value correct ($49M), change magnitude wrong ($28M vs $35M), percentage wrong (130–140% vs 250%). Calculations based on incorrect inputs lead to erroneous results despite correct methodology. (3) Multi-hop reasoning: The model correctly identifies the need to compare two years and compute change, but fails at retrieving the correct 2022 value, undermining the synthesis. The structure of the response shows understanding of the required comparison, but the foundational data is flawed. (4) Scores justified as follows: Correctness at 4 due to partial correctness (right direction, correct 2023 value) but major errors in key figures; Quantitative accuracy at 4 due to multiple incorrect numbers and miscalculations; Qualitative accuracy at 5 because reasoning framework is sound but based on wrong data; Contextual relevance at 9 because the answer addresses the exact question with appropriate structure and terminology.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1140,
        "completion_tokens": 414,
        "total_tokens": 1554
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of the percentage of franchised restaurants between 2021 and 2024?",
      "original_answer": "In 2021, 93% of McDonald's restaurants were franchised, while by 2024, this percentage increased to approximately 95%. This indicates a slight but deliberate shift toward further reliance on franchisees to operate McDonald's restaurants, reinforcing the company's strategic emphasis on franchising as a core business model.",
      "llm_answer": "\nBetween 2021 and 2024 the proportion of McDonald’s restaurants operated by franchisees grew modestly—from roughly **93 % of the system at the end of 2021 to about 95 % by the end of 2024**. This slight increase shows that McDonald’s has continued to expand its franchise model as the dominant ownership structure across its worldwide network.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) Quantitatively, the percentages (93% in 2021 and 95% by 2024) are accurately reported, matching the original answer exactly. The time frame (2021 to 2024) is correctly referenced. (2) The answer addresses all parts of the question—specifically, the evolution of McDonald's relationship with franchisees in terms of franchised restaurant percentage over the specified period. (3) Entity accuracy is correct: McDonald's is the focus, and the metric (percentage of franchised restaurants) and years (2021 and 2024) are properly identified. (4) The reasoning is sound: the slight increase from 93% to 95% is correctly interpreted as a continued strategic shift toward franchising, demonstrating accurate multi-hop synthesis of temporal data and strategic implication. Minor wording differences (e.g., 'modestly' vs 'slight but deliberate') do not affect factual equivalence. All criteria are met with high precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1164,
        "completion_tokens": 286,
        "total_tokens": 1450
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did the effective date and structure of the 2015 Stock Compensation Plan for Non-Employee Directors evolve between 2022 and 2023?",
      "original_answer": "In 2022, the 2015 Stock Compensation Plan for Non-Employee Directors was described as 'amended and restated effective March 31, 2021.' By 2023, the plan was further amended and restated, with a new effective date of 'October 26, 2022.' This indicates that the plan underwent at least one additional amendment during the 2022–2023 period, reflecting a structural or procedural update to the plan’s terms.",
      "llm_answer": "\nThe 2015 Stock Compensation Plan for Non‑Employee Directors was originally adopted in 2015 and restated with an effective date of October 28 2015.  In the 2022 filing the plan was again amended and restated, this time effective October 26 2022, which updated the share‑reserve language and other administrative provisions.  By the 2023 filing the plan remained the same but the remaining shares available under the reserve fell from 703,256 (at the end of 2022) to 589,927 (at the end of 2023), reflecting the shares used for prior awards.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. It correctly identifies the October 26, 2022 effective date for the amended plan in the 2022 filing, which aligns with the ground truth. However, it incorrectly states that the plan was amended and restated in 2022 with that date, while the ground truth indicates that the 2022 filing still referenced the March 31, 2021 amendment, and the October 26, 2022 date only appeared in the 2023 filing as a new amendment. The LLM backdates the awareness of the October 2022 amendment to the 2022 filing, which contradicts the evolution timeline. (2) The share reserve numbers (703,256 and 589,927) are plausible but not mentioned in the ground truth, making them unverifiable; their inclusion adds detail not supported by the original answer and may reflect hallucination. The original answer does not mention share reserves or usage, so this is extraneous. (3) The multi-hop reasoning is partially sound—tracking changes across years—but fails on the core point: the evolution of the effective date between 2022 and 2023. The LLM implies the October 26, 2022 date was already in effect in 2022, when the ground truth shows it was only reflected in the 2023 filing, indicating a failure in accurately synthesizing the timeline. (4) The contextual relevance is high because the answer addresses the plan’s structure and evolution, but factual inaccuracies in key dates and unsupported numerical details reduce correctness. The qualitative score is moderate due to flawed reasoning on the amendment timeline. Quantitative accuracy is compromised by unverified numbers and misaligned dates.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1232,
        "completion_tokens": 454,
        "total_tokens": 1687
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did Accenture's financial relationship with Duck Creek Technologies evolve between fiscal years 2022 and 2023, particularly in terms of investment valuation and reported financial impact?",
      "original_answer": "In fiscal 2022, Accenture's investment in Duck Creek Technologies was valued at $223,166 (approximately 16% ownership), with a carrying amount of $138,902, and was accounted for using the equity method. By fiscal 2023, the investment resulted in a $253 million gain, which was specifically called out in the financial statements as impacting the adjusted earnings per share and effective tax rate calculations. This indicates a shift from a long-term equity stake to a more active financial realization event.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2023 Accenture’s equity‑method investment in Duck Creek Technologies moved from a carrying amount of **$138.9 million** (with an estimated fair value of **$223.2 million** at the end of FY 2022) to a higher fair‑value position that enabled the company to record a **$253 million investment gain** in FY 2023 (shown in other income).  The higher valuation lifted the stake’s carrying amount and generated a non‑operating profit that boosted adjusted earnings per share, illustrating how the financial relationship evolved from a modest, un‑realized gain to a material, recognized gain in the 2023 results.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key financial figures: the FY 2022 carrying amount ($138.9 million vs. ground truth $138,902,000), fair value ($223.2 million vs. $223,166,000), and the $253 million gain in FY 2023. These are accurate within reasonable rounding and format variation (e.g., $138.9 million = $138,900,000, very close to $138,902,000). (2) Quantitative accuracy is excellent—numbers match ground truth with only negligible rounding differences, well within acceptable tolerance. The $253 million gain is reported exactly as in the original. (3) The reasoning is sound: the answer correctly identifies the shift from an equity-method investment with unrealized gains in FY 2022 to a realized $253 million gain in FY 2023, highlighting its impact on adjusted EPS and positioning it as a non-operating item. It infers the financial evolution accurately, even if it doesn't explicitly mention the 16% ownership or the impact on the effective tax rate—minor omissions that do not undermine the core financial narrative. (4) The answer is contextually relevant, directly addressing the evolution in Accenture’s financial relationship with Duck Creek Technologies. The qualitative score is 9 due to the omission of the 16% ownership stake and the specific mention of the tax rate impact, which are present in the ground truth and add depth. However, the central financial transformation is correctly and clearly conveyed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 401,
        "total_tokens": 1698
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has the therapeutic application of Breyanzi evolved between 2022 and 2024, and what specific new indications were approved in 2024 that expand its market potential?",
      "original_answer": "In 2022, Breyanzi was indicated for the treatment of adult patients with certain types of relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. By 2024, Breyanzi received two new approvals: in March 2024 for the treatment of adult patients with relapsed or refractory CLL or SLL who have received at least two prior lines of therapy, and in May 2024 for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior lines of systemic therapy. These new indications significantly expand the patient populations eligible for Breyanzi treatment.",
      "llm_answer": "\nBetween 2022 and 2024 Breyanzi’s use moved beyond its original 2021 launch for relapsed or refractory large‑B‑cell lymphoma and began targeting additional hematologic cancers.  In 2024 the FDA granted accelerated approvals for three new indications—relapsed or refractory chronic lymphocytic leukemia/small‑lymphocytic lymphoma, mantle‑cell lymphoma, and follicular lymphoma—each requiring prior therapy with a BTK inhibitor and/or a BCL‑2 inhibitor—thereby widening the patient population that can be treated with Breyanzi and expanding its commercial market potential.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. It correctly identifies that Breyanzi expanded beyond large B-cell lymphoma and gained new indications in 2024 for CLL/SLL and follicular lymphoma, which aligns with the ground truth. However, it incorrectly states *three* new indications, adding 'mantle-cell lymphoma'—which is not mentioned in the original answer and is factually incorrect based on the provided knowledge. Additionally, the LLM introduces specific prior therapy requirements involving BTK and BCL-2 inhibitors, which are not present in the ground truth and may reflect overgeneralization or confusion with other therapies. (2) The dates of approval—March and May 2024 for CLL/SLL and FL—are omitted in the LLM answer, reducing quantitative precision. While the year 2024 is correct, the lack of specific months and the addition of a false third indication harm quantitative accuracy. The number of approvals (3 vs 2) is incorrect. (3) The reasoning shows partial multi-hop synthesis—recognizing expansion of indications over time and linking it to market potential—but fails in entity accuracy by introducing a non-existent approval. This undermines the qualitative reasoning. (4) The answer is contextually relevant and addresses the evolution and market expansion, but factual errors in entities and numbers reduce correctness. The core idea of expanded use is right, but key details are wrong, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 408,
        "total_tokens": 1716
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has 3M's approach to estimating and recording insurance receivables related to legal proceedings under ASC 450 evolved between 2022 and 2023, particularly in relation to respirator mask/asbestos litigation?",
      "original_answer": "In 2022, 3M referenced its compliance with ASC 450 for recording liabilities related to legal proceedings but did not specifically mention the methodology for estimating insurance receivables. By 2023, the company explicitly described applying the loss recovery and/or gain contingency models under ASC 450 and ASC 610-30 to estimate insurance receivables, including analysis of policy terms, case law, and claim nature. Additionally, the number of individual claimants in respirator mask/asbestos litigation increased from approximately 4,028 in 2022 to 4,042 in 2023, indicating a growing exposure that likely influenced the more detailed approach to insurance receivables in 2023.",
      "llm_answer": "\nBetween 2022 and 2023 3M’s procedure for estimating insurance recoveries under ASC 450‑ASC 610‑30 was unchanged – it bases the receivable on policy language, historical claim experience and external expert analyses, and only records a receivable when a liability has been accrued.  In 2023 the company increased its accrual for respirator‑mask/asbestos liabilities by $57 million (to $574 million, excluding Aearo) and paid $88 million of related defense and settlement costs, yet the offsetting insurance‑recovery receivable remained immaterial, reflecting that recoveries were still not considered probable or estimable enough to recognize.  Thus, while the size of the accrued liability grew, the method of estimating and recording the related insurance receivable stayed consistent, with recognition only when recovery became reasonably estimable.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth. (1) The core claim—that 3M's procedure for estimating insurance receivables was 'unchanged' between 2022 and 2023—is factually wrong. The original answer states that in 2022, 3M did not specify its methodology for estimating insurance receivables under ASC 450, but in 2023, it explicitly adopted the loss recovery and/or gain contingency models under ASC 450 and ASC 610-30, incorporating analysis of policy terms, case law, and claim nature. This represents a significant evolution in methodology, directly contradicting the LLM's assertion of no change. (2) The LLM introduces specific dollar figures—$57 million increase in accrual, $574 million total liability, $88 million in payments—which are not present in the ground truth and cannot be verified. These numbers are likely fabricated or misattributed, failing quantitative accuracy. (3) The LLM claims the insurance receivable remained 'immaterial' and 'not considered probable or estimable enough to recognize,' implying no receivable was recorded. However, the original answer discusses a more detailed estimation approach being applied, suggesting increased recognition efforts, not continued non-recognition. (4) The multi-hop reasoning fails: the LLM does not connect the increase in claimants (from 4,028 to 4,042) to the evolving methodology, which is a key point in the ground truth. Instead, it invents financial data and draws incorrect conclusions about consistency in approach. While the answer is relevant to the topic of insurance receivables and litigation, the factual inaccuracies and flawed reasoning severely undermine correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1399,
        "completion_tokens": 455,
        "total_tokens": 1855
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How did PepsiCo's relationship with Naked evolve between 2022 and 2023, particularly in terms of its operational involvement and financial stake?",
      "original_answer": "In 2022, PepsiCo sold its Tropicana, Naked, and other select juice brands to PAI Partners while retaining a 39% noncontrolling interest in a newly formed joint venture, The Beachbody Company (TBG), which operates across North America and Europe. Additionally, PepsiCo acted as the exclusive distributor for TBG's portfolio of brands, including Naked, for small-format and foodservice customers via chilled direct-store-delivery. By 2023, PepsiCo no longer directly distributed Naked products and instead primarily disclosed its relationship through its retained 39% noncontrolling interest in TBG, with no further operational involvement in the distribution of Naked products. This represents a shift from active distribution to a purely financial stake.",
      "llm_answer": "\nBetween 2022 and 2023 PepsiCo moved from full ownership of the Naked juice brand to selling it (along with Tropicana and other select juice brands) to PAI Partners, while retaining a 39 percent non‑controlling equity stake in the newly formed joint‑venture TBG that now owns those brands. Operationally, PepsiCo remains the exclusive U.S. distributor for TBG’s portfolio—using its chilled direct‑store‑delivery network to serve small‑format and food‑service customers—so it continues to handle sales, marketing and logistics for the former Naked products. Financially, PepsiCo records its 39 % share of TBG’s results as a non‑controlling interest, meaning it receives equity earnings and cash returns from the venture while PAI Partners owns the remaining 61 % of the business.",
      "correctness_score": 4,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "1) The LLM answer is partially correct in stating that PepsiCo sold Naked and other juice brands to PAI Partners and retained a 39% noncontrolling interest in TBG. This numeric and entity information is accurate. However, the key error lies in the operational involvement: the LLM claims PepsiCo 'remains the exclusive U.S. distributor' and continues handling sales, marketing, and logistics via its chilled DSD network in 2023, which directly contradicts the ground truth. According to the original answer, by 2023, PepsiCo no longer directly distributed Naked products and had ceased operational involvement in distribution. This is a major factual and reasoning error.\n\n2) Quantitative accuracy is high: the 39% stake is correctly stated, and the joint venture structure with PAI Partners owning 61% is consistent with the ground truth. Dates (2022 transaction) are correct. No calculation errors.\n\n3) The multi-hop reasoning fails because the model does not correctly track the evolution over time. It conflates the 2022 arrangement (when PepsiCo did act as distributor) with the 2023 status, failing to recognize the shift from operational to purely financial involvement. This undermines the core of the question about how the relationship evolved.\n\n4) Contextual relevance is fair—the answer addresses both operational and financial aspects as asked, and focuses on the right entities and timeline. However, due to the critical error in depicting ongoing distribution in 2023, the qualitative accuracy and overall correctness are significantly reduced. The answer misrepresents the nature of the evolution, which is the central point of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 451,
        "total_tokens": 1834
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has the accounting treatment or disclosure around the ExtraBucks Rewards program evolved between 2023 and 2024, particularly regarding the recognition of revenue and the determination of performance obligations?",
      "original_answer": "In 2023, the ExtraBucks Rewards program was described as creating an additional performance obligation at the time of the initial transaction, with revenue allocated based on relative standalone selling prices that consider historical redemption patterns. Revenue was recognized as the rewards were redeemed, and unredeemed rewards were reflected as a contract liability. In 2024, the disclosure remained consistent in terms of revenue recognition timing and contract liability treatment, but the language around performance obligations became more refined, emphasizing that the determination of an additional performance obligation was specifically tied to customers who accumulate ExtraBucks based on historical spending levels. The 2024 filing also included more structured language around how the Company allocates transaction prices and evaluates standalone selling prices, suggesting a more mature and formalized approach to the program’s accounting treatment.",
      "llm_answer": "\nThe company continues to treat ExtraBucks Rewards as a distinct performance obligation that is identified at the time the customer makes the initial purchase, allocating the transaction price between the underlying sale and the rewards based on relative standalone‑selling‑price estimates that rely on historical redemption patterns. Revenue from the rewards is recognized only when the points are actually redeemed, while any unredeemed balance is carried as a contract‑liability (breakage), a practice that was already described in the 2023 filing and remains unchanged in the 2024 disclosure. Consequently, there is no material evolution in the accounting treatment or disclosure of ExtraBucks Rewards between 2023 and 2024.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually consistent with the ground truth in terms of quantitative and entity accuracy—there are no incorrect numbers, dates, or financial terms, and the core accounting treatment (performance obligation, revenue recognition upon redemption, contract liability, breakage) is correctly described for both 2023 and 2024. However, the LLM incorrectly concludes that there is 'no material evolution' in the accounting treatment or disclosure, which directly contradicts the ground truth. The original answer specifies that while the core accounting remained consistent, the 2024 filing included more refined language linking the performance obligation to customers who accumulate ExtraBucks based on historical spending levels and introduced more structured disclosures around transaction price allocation and standalone selling price evaluation—indicating a more mature and formalized approach. The LLM answer fails to recognize or report this qualitative evolution in disclosure and reasoning, thus missing a key aspect of the multi-hop comparison between years. This omission constitutes a significant qualitative inaccuracy in reasoning and completeness, even though all stated facts are correct. Hence, the correctness and qualitative accuracy scores are moderate, while quantitative accuracy is perfect and contextual relevance is high due to appropriate focus on the right program and accounting concepts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1440,
        "completion_tokens": 393,
        "total_tokens": 1833
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has Netflix's reliance on integrated payment partners evolved between 2023 and 2024, based on the specific details provided in the cost of revenues section for each year?",
      "original_answer": "In 2023, Netflix specifically mentioned that payment processing fees paid to integrated payment partners were part of other operating costs within the cost of revenues. In 2024, the company continued to reference payment processing fees paid to integrated payment partners as part of other operating costs, but the overall structure of the cost of revenues section was streamlined, removing some of the granular details about these fees. This indicates that while the relationship persisted, the level of explicit detail about the financial impact of integrated payment partners decreased, suggesting a shift in disclosure strategy rather than a substantive discontinuation of the relationship.",
      "llm_answer": "\nBoth 2023 and 2024 list payment‑processing fees paid to integrated partners as part of “other operating costs” within cost of revenues, but the share of total cost of revenues devoted to these fees dropped from 58 % of revenues in 2023 to 54 % in 2024—suggesting that, while absolute spending likely grew, Netflix’s relative reliance on integrated payment partners decreased between the two years.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies, particularly in quantitative claims. The ground truth states that Netflix mentioned payment processing fees as part of 'other operating costs' in both 2023 and 2024, with a noted reduction in disclosure detail in 2024—indicating a change in reporting transparency, not a change in financial reliance. However, the LLM introduces a specific numerical claim that these fees were 58% of revenues in 2023 and 54% of revenues in 2024, which is not supported by the original answer or implied in the context. There is no mention of percentages or relative shares in the ground truth, making this a fabricated metric. This severely undermines quantitative accuracy. While the LLM correctly identifies that payment processing fees related to integrated partners were included in 'other operating costs' within cost of revenues in both years (demonstrating partial entity and contextual accuracy), it misrepresents the nature of the evolution—framing it as a decrease in 'relative reliance' due to changing percentages, whereas the original answer emphasizes a shift in disclosure strategy, not economic dependence. The reasoning is therefore flawed: it invents a trend based on non-existent data rather than interpreting changes in reporting granularity. The answer is contextually relevant to the question about evolution in reliance and focuses on the correct section and cost category, but the incorrect numerical assertions and mischaracterization of the underlying change reduce its overall correctness. Multi-hop synthesis is attempted but based on false premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1280,
        "completion_tokens": 441,
        "total_tokens": 1721
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has 3M's approach to managing PFAS contamination in Minnesota evolved from 2022 to 2023, particularly in response to regulatory changes and new health-based standards?",
      "original_answer": "In 2022, 3M had substantially completed remediation work at the Cottage Grove site and was continuing operational and maintenance activities at Oakdale and Woodbury sites in Minnesota under the May 2007 Settlement Agreement and Consent Order. The company was also addressing PFAS discharges at its Decatur, Alabama facility under a 2020 interim Consent Order with ADEM, which included obligations for on-site and off-site investigations and future capital improvements. By 2023, the Minnesota Department of Health issued updated, more stringent Health Based Values (HBVs) for PFOA and PFOS in January 2024, prompting 3M to evaluate the potential impact on its obligations under the SACO. Additionally, MPCA issued a Notice of Violation in March 2023 alleging PFAS in stormwater discharge at 3M’s Hutchinson facility, and in December 2022, MPCA issued an order addressing stormwater from the Cottage Grove facility. In January 2024, MPCA proposed a new Clean Water Act permit for Cottage Grove with significantly revised, often below-quantification-level limits on PFAS, indicating a tightening regulatory environment that 3M is actively engaging with.",
      "llm_answer": "\nFrom 2022 through 2023 3M moved beyond the baseline remediation required by the 2007 Minnesota Settlement/Consent Order and began tailoring its PFAS‑management program to a series of tighter state health‑based standards.  The Minnesota Department of Health issued updated, more stringent health‑based values (HBVs) for PFOA and PFOS, and the Minnesota Pollution Control Agency (MPCA) released a draft Clean Water Act permit (January 2024) that imposes significantly lower PFAS limits—including limits below the analytical detection threshold—while also issuing a March 2023 Notice of Violation for storm‑water discharges at the Hutchinson facility.  In response, 3M expanded groundwater and storm‑water monitoring, accelerated treatment and alternative‑water supplies where levels exceed the new HBVs or HRLs, and entered into negotiations to adjust its SACO obligations and related consent orders to reflect the stricter regulatory limits, while also increasing its accruals for PFAS‑related environmental liabilities to cover the broader remediation and compliance costs.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the evolution of 3M's PFAS management approach in Minnesota from 2022 to 2023 with strong alignment to the ground truth. It correctly identifies the updated, more stringent Health Based Values (HBVs) issued by the Minnesota Department of Health for PFOA and PFOS, though it references the January 2024 issuance date without explicitly noting that the impact assessment began in 2023—this is a minor temporal nuance but does not distort the timeline. The mention of the MPCA’s draft Clean Water Act permit in January 2024 with significantly lower PFAS limits, including below detection thresholds, is accurate and correctly reflects the tightening regulatory environment. The March 2023 Notice of Violation for stormwater discharges at the Hutchinson facility is correctly cited. The LLM also accurately notes 3M’s response actions: expanded monitoring, accelerated treatment, alternative water supplies, and negotiations to adjust SACO obligations. It appropriately infers increased accruals for environmental liabilities, which is consistent with 3M’s financial disclosures in this period. One minor issue: the original answer notes a December 2022 MPCA order on Cottage Grove stormwater, which the LLM omits—this is a small completeness gap but does not undermine the core multi-hop synthesis. The LLM correctly synthesizes across regulatory actions (MPCA, MDH), timelines (2022–2024), and corporate responses (operational, financial, legal). All entities (3M, MPCA, MDH, SACO), locations (Cottage Grove, Hutchinson), and regulatory instruments (Consent Order, Clean Water Act permit) are correctly identified. Quantitative accuracy is high: dates (March 2023, January 2024) are correct; no numerical figures are misstated. The reasoning is sound—3M’s shift from baseline remediation to proactive adaptation under tightening standards is logically and factually supported. The answer is fully contextually relevant, directly addressing how 3M’s approach evolved in response to regulatory and health-based changes. Overall, this is a semantically equivalent, well-reasoned response with only minor omissions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1562,
        "completion_tokens": 575,
        "total_tokens": 2137
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How did PepsiCo's use of foreign currency derivatives evolve between 2022 and 2023, and what does this indicate about its foreign exchange risk management strategy?",
      "original_answer": "In 2022, PepsiCo reported a total notional value of $3.0 billion for its foreign currency derivatives, while in 2023, this value increased to $3.8 billion. This indicates a strategic expansion in the use of foreign currency derivatives to manage foreign exchange risk, likely in response to increased exposure or volatility in international markets. Additionally, the company emphasized the use of these derivatives to offset changes in the underlying hedged items, resulting in no material net impact on earnings in 2023.",
      "llm_answer": "\nBetween the end of 2022 and the end of 2023 the notional amount of PepsiCo’s foreign‑currency derivatives grew from roughly **$3.0 billion to $3.8 billion** (the company reports $3.0 bn of foreign‑currency derivatives as of Dec 31 2022 and $3.8 bn as of Dec 30 2023).  This increase shows that PepsiCo is expanding its hedge book—using more forward contracts and net‑investment hedges—to lock in exchange rates for its global operations and investments.  The move signals a more proactive foreign‑exchange risk‑management strategy aimed at mitigating currency‑driven margin pressure amid a larger, more diversified international footprint.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the notional value of PepsiCo's foreign currency derivatives in 2022 ($3.0 billion) and 2023 ($3.8 billion), matching the ground truth exactly. The dates (Dec 31, 2022 and Dec 30, 2023) are consistent with fiscal year-end reporting, and minor variations in end-of-year dates are acceptable per SEC filing conventions. 2) Quantitatively, all numbers are accurate: the increase from $3.0B to $3.8B is correctly stated, and no calculations (e.g., percentage change) are required or misstated. 3) The reasoning is sound: the increase in notional amount is correctly interpreted as an expansion in hedging activity, indicating a more proactive FX risk management strategy. The mention of forward contracts and net-investment hedges aligns with typical instruments used, though the original answer emphasizes the 'no material net impact on earnings' outcome, which the LLM omits. This is a minor gap in completeness but does not undermine the core conclusion. 4) The LLM synthesizes the evolution across two years and infers strategic intent correctly, demonstrating strong multi-hop reasoning. The answer is contextually relevant, directly addressing both parts of the question: the quantitative evolution and its strategic implication. The only reason for not scoring a 10 is the omission of the 'no material net impact on earnings' point, which is part of the original conclusion about risk management effectiveness. However, the core facts, numbers, and strategic interpretation are fully aligned with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 425,
        "total_tokens": 1720
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has ExxonMobil's approach to capitalizing on improving living standards evolved between 2022 and 2023, particularly in terms of chemical production capacity additions and geographic focus?",
      "original_answer": "In 2022, ExxonMobil highlighted the completion of a joint venture ethane cracker near Corpus Christi, Texas, and plans for up to 500,000 metric tons annually of advanced recycling capacity in Baytown, Texas, by 2026, as part of its strategy to meet growing demand driven by improving living standards. By 2023, the company shifted focus toward expanding performance polymers and linear alpha olefins capacity in Baytown, Texas, and advancing a 100% foreign-owned petrochemical complex in Dayawan, China, with over 2.5 million metric tons per year of polyethylene and polypropylene capacity. This reflects a strategic evolution from domestic advanced recycling and integrated U.S. projects to high-performance product expansions and significant foreign investment in China to meet local demand.",
      "llm_answer": "\nBetween 2022 and 2023 ExxonMobil moved from a U.S.-centric growth push to a broader, geography‑focused strategy. In 2022 it was completing the Corpus Christi ethane‑cracker and restarting Gulf‑Coast projects (Baytown, Baton Rouge) while planning advanced‑recycling capacity, but by 2023 it had added two new chemical lines at Baytown—a 400 kt/yr performance‑polymers unit and a 350 kt/yr linear‑alpha‑olefins unit— and broke ground on a multi‑billion‑dollar petrochemical complex in China’s Dayawan park that will deliver >2.5 million t/yr of polyethylene/polypropylene capacity to capture China’s rising demand. This reflects a shift from primarily U.S. Gulf‑Coast capacity additions toward a dual focus on expanding U.S. Gulf‑Coast output while establishing a major foothold in China to capitalize on improving living standards there.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in ExxonMobil's strategy between 2022 and 2023. (1) Correctly identifies the 2022 Corpus Christi ethane cracker completion and advanced recycling plans in Baytown (with correct 500,000 metric tons target by 2026, though the LLM rounds to 'planning advanced-recycling capacity' without specifying the 500k number—minor omission). (2) Accurately reports the 2023 Baytown expansions: 400 kt/yr performance polymers and 350 kt/yr linear alpha olefins, which aligns with the ground truth's mention of expanding these capacities (though original does not specify exact tonnages; LLM adds precision not in ground truth, but plausibly inferred). (3) Correctly identifies the Dayawan, China petrochemical complex as 100% foreign-owned, >2.5 million t/yr polyethylene/polypropylene capacity, matching ground truth. (4) The strategic shift from U.S.-focused 2022 projects to dual U.S./China focus in 2023 is correctly synthesized and well-reasoned. (5) Minor issue: LLM implies the 400kt and 350kt Baytown units were completed in 2023, while the original answer states the company 'shifted focus toward expanding'—suggesting planning/advancement, not completion. This overstates progress slightly. Also, the 500k advanced recycling capacity by 2026 is mentioned in original but only vaguely referenced in LLM. Otherwise, all entities, years, and strategic logic are correct. Quantitative accuracy is high—only minor omission of 500k figure and slight overprecision on timing. Reasoning and contextual relevance are excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1419,
        "completion_tokens": 431,
        "total_tokens": 1850
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How did 3M's investment in Certificates of Deposit/Time Deposits evolve from 2022 to 2023, and what does this shift indicate about the company's short-term investment strategy?",
      "original_answer": "In 2022, 3M held $21 million in Certificates of Deposit/Time Deposits, which increased to $49 million in 2023 — more than doubling. This indicates a strategic shift toward increasing liquidity or reallocating short-term cash holdings into more stable or higher-yielding instruments within this category.",
      "llm_answer": "\nFrom 2022 to 2023 the balance of 3M’s certificates‑of‑deposit/time‑deposits rose from **$21 million to $49 million** (an increase of roughly $28 million, or more than 130 %).  This growth reflects a deliberate shift toward allocating a larger share of the company’s short‑term cash to short‑duration, low‑risk instruments, likely to capture higher yields in the current higher‑interest‑rate environment while preserving liquidity and flexibility.  (See NOTE 11 “Marketable Securities” in the 2022 and 2023 Form 10‑K filings.)",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the values $21 million in 2022 and $49 million in 2023 are accurately reported. The increase of $28 million and the percentage increase (more than 130%) are correctly calculated: (49 - 21) / 21 ≈ 1.33 or 133%, which justifies 'more than 130%'. (2) The answer addresses both parts of the question: the evolution of the investment (increase from $21M to $49M) and the strategic implication (shift toward low-risk, short-duration instruments for higher yields while maintaining liquidity). (3) Entities are correct: 3M, Certificates of Deposit/Time Deposits, and the years 2022 and 2023 are all accurately referenced. (4) The reasoning is sound and reflects proper multi-hop synthesis: the model infers a strategic shift based on numerical changes, aligning with the higher interest rate environment — a logical and contextually appropriate interpretation consistent with the ground truth's mention of 'higher-yielding instruments' and 'liquidity'. The reference to NOTE 11 in the 10-K filings adds contextual support. (5) Semantic equivalence is maintained: while the LLM provides slightly more detail (e.g., percentage increase, rationale about interest rates), the core information and meaning match the original answer exactly. No factual, numerical, or interpretive errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1214,
        "completion_tokens": 383,
        "total_tokens": 1597
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has Mastercard's approach to proprietary insights evolved from 2022 to 2023, particularly in terms of data responsibility and trust-building language?",
      "original_answer": "In 2022, Mastercard described its proprietary insights as being based on the 'principled use of consumer and merchant data.' By 2023, the language evolved to emphasize 'principled and responsible use of secure consumer and merchant data.' This shift indicates a stronger emphasis on data security and trust as a core component of their proprietary insights strategy. The change in phrasing reflects a broader narrative around cybersecurity and stakeholder confidence in how Mastercard manages sensitive data.",
      "llm_answer": "\nFrom 2022 to 2023 Mastercard’s language shifted from simply noting that its “value‑added services…provide proprietary insights” to explicitly describing those insights as coming from the company’s “principled use of consumer and merchant data” and emphasizing trust‑building.  The 2023 filing therefore introduces a clear responsibility framing—highlighting that the insights are derived responsibly and are meant to reinforce confidence among all ecosystem participants—whereas the 2022 discussion did not contain this explicit data‑responsibility language.  This evolution signals a more deliberate focus on data ethics and stakeholder trust in Mastercard’s proprietary‑insights strategy.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of Mastercard's language around proprietary insights from 2022 to 2023. It accurately identifies that in 2022, Mastercard referenced 'principled use of consumer and merchant data,' and that by 2023, the language evolved to include stronger emphasis on responsibility and trust. The answer correctly captures the shift toward data responsibility and stakeholder trust, which is the core of the ground truth. However, it does not explicitly mention the addition of 'secure' in 'secure consumer and merchant data'—a key detail in the 2023 description that underscores the heightened focus on data security. While the LLM infers a 'responsibility framing' and 'data ethics,' it omits the specific lexical addition of 'secure,' which is part of the factual change in wording. There are no numerical inaccuracies (quantitative accuracy is perfect by default, as no numbers are involved), and the reasoning is sound and contextually relevant. The omission of 'secure' prevents a top score, but the overall qualitative and semantic accuracy remains high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 322,
        "total_tokens": 1624
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How did the factors influencing the accounting estimates for pension and retiree medical plans evolve between 2022 and 2023, and what does this indicate about the changing external environment affecting these plans?",
      "original_answer": "In 2022, the accounting estimates for pension and retiree medical plans were influenced by uncertainties related to the ongoing impacts of the COVID-19 pandemic. By 2023, this had evolved, and the estimates were instead influenced by business and economic uncertainty stemming from the ongoing conflicts in Ukraine and the Middle East, as well as a high interest rate and inflationary cost environment. This indicates a shift in the external risk factors affecting the company's pension and retiree medical plans from health-related disruptions to broader macroeconomic and geopolitical concerns.",
      "llm_answer": "\nBetween 2022 and 2023 the estimated effect of pension and retiree‑medical assumptions on PepsiCo’s ROIC grew from a modest drag of roughly 0.1‑0.2 percentage points to a larger drag of about 0.1‑0.3 percentage points.  This widening impact signals that the external environment—especially rising interest rates, inflationary cost pressures and heightened economic uncertainty—is forcing the company to revise discount‑rate, mortality and health‑care‑cost assumptions, thereby amplifying the sensitivity of its pension and retiree‑medical accounting estimates.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect in both factual content and reasoning. (1) The original answer states that in 2022, pension and retiree medical estimates were influenced by the ongoing impacts of the COVID-19 pandemic, and in 2023 by geopolitical conflicts (Ukraine and Middle East) and macroeconomic conditions (high interest rates and inflation). The LLM instead introduces a specific quantitative claim about PepsiCo's ROIC being affected by 0.1–0.2 pp in 2022 and 0.1–0.3 pp in 2023, which is not present in the ground truth and cannot be verified from the provided information. (2) There are no numbers in the original answer to support the ROIC drag or any PepsiCo-specific financial metric—this is a hallucination. The quantitative accuracy is very low because the numbers are fabricated. (3) The multi-hop reasoning fails: the question asks about evolving factors influencing accounting estimates, not their impact on ROIC. The LLM shifts focus to a different metric (ROIC) and company (PepsiCo), which is not mentioned in the original answer. (4) While the LLM correctly identifies high interest rates and inflation as part of the 2023 environment, it misses the key shift from health-related (COVID-19) to geopolitical and macroeconomic risks, which is the core of the original answer. The contextual relevance is moderate because it discusses related themes (pension assumptions, inflation, interest rates) but misrepresents the entities, data, and primary conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 406,
        "total_tokens": 1713
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has ExxonMobil's undeveloped acreage position in the Other Americas region evolved between 2022 and 2023, and what does this indicate about the company's exploration potential in that region?",
      "original_answer": "ExxonMobil's undeveloped acreage in the Other Americas region decreased from 25,096 gross and 11,977 net thousands of acres in 2022 to 24,221 gross and 11,548 net thousands of acres in 2023. This indicates a reduction in the total acreage under evaluation, suggesting that some properties may have been relinquished or transitioned to developed status, while the company continues to focus on properties with higher exploration potential.",
      "llm_answer": "\nBetween year‑end 2022 and year‑end 2023 ExxonMobil’s undeveloped acreage in the Canada/Other Americas segment fell sharply – gross undeveloped acres dropped from **≈37.8 million to ≈30.8 million** (‑≈19 %) and net undeveloped acres from **≈18.98 million to ≈15.01 million** (‑≈21 %).  This contraction reflects the company’s decision to relinquish or convert a portion of that land base, indicating that it is focusing the remaining undeveloped holdings on the most prospective targets rather than maintaining a broad, low‑return acreage inventory.  Consequently, the decline signals that ExxonMobil perceives its exploration upside in the region as being concentrated in a smaller, higher‑potential set of prospects.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies. The original answer states that ExxonMobil's undeveloped acreage in the 'Other Americas' region decreased from 25,096 gross and 11,977 net thousands of acres in 2022 to 24,221 gross and 11,548 net thousands of acres in 2023. The LLM incorrectly reports values in the tens of millions (e.g., 37.8 million and 30.8 million gross acres), which are not only numerically wrong but also misrepresent the scale by a factor of over 1,000. These numbers appear to conflate 'Other Americas' with a broader 'Canada/Other Americas' category not mentioned in the original answer, introducing an incorrect geographic scope. (2) The quantitative values are entirely incorrect: the correct gross acreage decreased by 875,000 acres (25,096k to 24,221k), not ~7 million as implied by the LLM. Similarly, net acreage decreased by 429,000 acres (11,977k to 11,548k), not ~4 million. The percentages cited (19%, 21%) are therefore also wrong. (3) The reasoning about focusing on higher-potential prospects is semantically aligned with the original answer’s interpretation, showing some correct qualitative logic. However, the multi-hop synthesis fails because the LLM uses incorrect data and potentially conflates regions, undermining the validity of the conclusion. (4) The correctness score is low due to severe numerical inaccuracies. Quantitative accuracy is near-zero because all key figures are factually wrong. Qualitative accuracy is slightly higher because the interpretation of strategic focus is plausible and directionally consistent. Contextual relevance is moderate since the answer addresses the right topic and offers a reasonable explanation, albeit based on false data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 472,
        "total_tokens": 1773
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How did the treatment and financial impact of non-functional currency denominated items evolve from 2022 to 2023, particularly in terms of the use of foreign currency contracts not designated in hedging relationships?",
      "original_answer": "In 2022, MMM used foreign exchange forward and option contracts not designated in hedging relationships to offset the impacts of changes in value of various non-functional currency denominated items, including certain intercompany financing balances, with a gross notional amount of $3.7 billion. By 2023, the company continued to use such contracts for the same purpose but shifted focus to derivatives not designated as hedging instruments, with fair value gains and losses directly impacting earnings. This indicates a shift from primarily designated hedging strategies to a more direct financial exposure management approach.",
      "llm_answer": "\nFrom 2022 to 2023 3M continued to employ foreign‑currency forwards and options that were **not designated in hedge accounting** to offset the earnings effect of non‑functional‑currency items (e.g., intercompany financing balances).  In 2022 these contracts produced a **$76 million pre‑tax loss** recorded directly in the income statement, while in 2023 the loss narrowed to only **about $9 million**, reflecting reduced volatility and the runoff of prior hedge balances.  Under U.S. GAAP, such non‑designated derivatives are marked‑to‑market each period, with the resulting gains or losses recognized immediately in earnings rather than being routed through other comprehensive income.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness, despite addressing the right topic and showing relevant reasoning structure. (1) The original answer states that in 2022, MMM used non-designated foreign exchange contracts with a gross notional amount of $3.7 billion, but the LLM answer omits this key quantitative detail and instead introduces financial results (a $76 million pre-tax loss in 2022 and $9 million in 2023) that are not present in the ground truth and cannot be verified from the provided information. These specific loss figures are therefore incorrect or hallucinated. (2) The LLM claims a narrowing of losses from $76M to $9M, implying improved performance due to reduced volatility and runoff of prior hedge balances—this entire causal explanation is absent from the original and introduces unsupported details. (3) While the LLM correctly identifies the use of non-designated derivatives whose gains/losses impact earnings directly (aligning with U.S. GAAP treatment), this qualitative point is partially accurate but not uniquely insightful, as it's standard accounting knowledge. (4) The original answer emphasizes a strategic shift from designated hedging relationships to a more direct exposure management approach using non-designated instruments, which the LLM fails to capture clearly. Instead, it focuses on unverified P&L impacts. (5) Multi-hop reasoning is attempted—linking instrument type, accounting treatment, and year-over-year change—but the synthesis is flawed because it builds on incorrect numerical data. In summary, while the LLM stays contextually relevant and shows understanding of derivative accounting concepts, it fails on core factual accuracy, especially regarding the quantitative aspects and the actual evolution described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 494,
        "total_tokens": 1841
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has the role and emphasis of Cyber and Intelligence Solutions evolved within Mastercard's value proposition between 2022 and 2023?",
      "original_answer": "In 2022, Cyber and Intelligence Solutions were mentioned as part of a broader list of value-added services, grouped alongside consulting fees, loyalty programs, gateway services, and other payment-related offerings. This suggests a supporting role within the company's portfolio. By 2023, the Cyber and Intelligence Solutions were more prominently positioned as a core component of Mastercard’s value proposition, explicitly described as enabling secure, easy, and confident transactions across the global payments ecosystem. This indicates a strategic shift toward elevating the importance of cybersecurity within Mastercard’s overall service offering.",
      "llm_answer": "\nBetween 2022 and 2023 Mastercard moved cyber‑and‑intelligence solutions from a peripheral “other‑revenue” line item to a strategic growth pillar. In the 2022 filing (pages 79‑83) the services were merely listed alongside other value‑added offerings, but the 2023 filing (pages 47‑51) explicitly calls them “products and services offered to prevent, detect and respond to fraud… and supports open‑banking and digital‑identity capabilities,” positioning them as a core differentiator and a key driver of the company’s value proposition.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns closely with the ground truth. It correctly identifies the evolution of Cyber and Intelligence Solutions within Mastercard's value proposition from 2022 to 2023. In 2022, the service was listed as a minor component among other value-added offerings, and by 2023, it was elevated to a core strategic pillar, explicitly tied to fraud prevention, detection, response, and support for digital identity and open banking—consistent with the original answer's claim of increased prominence. The LLM cites specific page ranges (79–83 in 2022, 47–51 in 2023), which, while not verifiable without document access, are plausible and contextually appropriate. There are no numerical inaccuracies (quantitative accuracy is perfect as no calculations or financial figures are misstated). The reasoning is sound: it infers a strategic shift based on changes in presentation and language across filings, demonstrating correct multi-hop synthesis between years and documents. The only minor shortcoming is that the original answer emphasizes the broader conceptual framing—'enabling secure, easy, and confident transactions'—which the LLM does not quote directly, though it captures the essence through 'core differentiator' and 'key driver.' This slight omission in nuance prevents a perfect 10, but the answer remains highly accurate, complete, and relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 384,
        "total_tokens": 1678
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has the treatment or disclosure of Income Tax Expense and Accruals evolved in the list of critical accounting policies between 2022 and 2023?",
      "original_answer": "In 2022, 'income tax expense and accruals' was explicitly listed as one of the critical accounting policies and estimates, indicating its significance in financial reporting. By 2023, while still listed as a critical accounting policy, it was moved to a subsection under 'Our Critical Accounting Policies and Estimates' with a more structured presentation of related notes, such as Note 5 - Income Taxes, which provided deeper transparency into tax-related disclosures. This evolution reflects a shift toward more detailed and organized reporting of tax-related matters in 2023.",
      "llm_answer": "\nBetween 2022 and 2023 the SEC‑filing’s “Income Tax Expense and Accruals” entry kept the same core language – it continues to stress that the annual tax rate is derived from income, statutory rates and transfer‑pricing arrangements, that significant judgment is required to set the rate and evaluate tax positions, and that reserves (and related interest) are adjusted as facts and circumstances change.  The 2023 version adds no new substantive disclosures or structural changes; it merely repeats the 2022 wording (including the reference to “Item 1A. Risk Factors”) without expanding the description of the accounting policy.  Consequently, the treatment and disclosure of income‑tax expense and accruals remain materially unchanged across the two years.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim, directly contradicting the ground truth. The original answer states that in 2023, 'Income Tax Expense and Accruals' was moved to a subsection under 'Our Critical Accounting Policies and Estimates' and linked to more detailed disclosures such as Note 5 - Income Taxes, indicating a structural and presentational evolution toward greater transparency. In contrast, the LLM claims there were 'no new substantive disclosures or structural changes' and that the 2023 version 'merely repeats the 2022 wording,' which is false according to the ground truth. While the LLM correctly identifies that the treatment involves judgment in setting tax rates and adjusting reserves (qualitatively accurate elements), it fails the multi-hop reasoning by not recognizing the organizational and disclosural evolution in the 2023 filing. There are no numeric values to assess, so quantitative accuracy is not applicable but assumed correct by default. Contextually, the answer addresses the right topic and section of the filing, but the conclusion is misleading. Thus, the correctness and qualitative accuracy scores are low due to a fundamental error in characterizing the evolution of disclosure practices.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 348,
        "total_tokens": 1681
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has Intel's development and positioning of the Universal Chiplet Interconnect Express standard evolved between 2023 and 2024 in the context of its broader systems of chips strategy?",
      "original_answer": "In 2023, Intel introduced the Universal Chiplet Interconnect Express (UCIe) standard and demonstrated it in silicon, marking the initial phase of its strategic push to enable optimized systems of chips. By 2024, Intel had progressed beyond the demonstration phase and was actively producing based on this standard, integrating it into its broader advanced semiconductor assembly and test offerings. This evolution reflects Intel's deepening commitment to the UCIe standard as a core component of its systems of chips strategy, aimed at enhancing system performance and accelerating customer designs through advanced packaging technologies and system-level standards.",
      "llm_answer": "\nBetween 2023 and 2024 Intel moved the Universal Chiplet Interconnect Express (UCIe) from a proof‑of‑concept to a core element of its “systems‑of‑chips” strategy. In 2023 the company demonstrated UCIe in silicon and began embedding the standard in its Open‑System Foundry model, signing early design‑win agreements with ARM and Synopsys and promoting UCIe as the baseline interconnect for chiplet‑based AI and other workloads. By 2024 Intel had deepened that positioning—integrating UCIe into the IFS Accelerator ecosystem, securing additional design wins on the advanced 18A process, and framing the standard as a key enabler for customers to build optimized, multi‑chip modules across Intel’s foundry and packaging capabilities.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly identifies the evolution of Intel's UCIe standard from 2023 to 2024: in 2023, Intel demonstrated UCIe in silicon and began integrating it into its Open-System Foundry model, which matches the 'demonstrated in silicon' milestone in the original answer. By 2024, the LLM notes active integration into Intel's IFS Accelerator ecosystem and production on the 18A process, which reflects the 'actively producing based on this standard' and integration into 'advanced semiconductor assembly and test offerings' described in the ground truth. The mention of design wins with ARM and Synopsys, while adding detail not in the original, is plausible and contextually consistent. There are no numerical inaccuracies (quantitative accuracy is perfect), and all dates and entities (Intel, UCIe, IFS, ARM, Synopsys, 18A) are correct. The reasoning is sound, showing a logical progression from demonstration to production and strategic embedding. The answer captures the core intent of the question—evolution within the systems-of-chips strategy—with strong semantic equivalence, though slightly more detailed than the original. One minor point preventing a perfect 10 is the addition of specific partners (ARM, Synopsys) and the 'Open-System Foundry model' which, while reasonable, are not in the verified ground truth and could represent inference beyond the source data. Otherwise, the answer is complete, relevant, and factually solid.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 414,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has the accounting treatment and completion timeline of CVS's Accelerated Share Repurchase (ASR) transactions evolved between the 2023 and 2024 10-K filings?",
      "original_answer": "In 2023, CVS completed a $2.0 billion ASR with Citibank, receiving 17.4 million shares initially (80% of the notional amount) and an additional 5.4 million shares in February 2023, concluding the transaction. The forward contract portion was reclassified from capital surplus to treasury stock upon completion. In 2024, CVS completed a $3.0 billion ASR with Morgan Stanley, initially receiving 31.4 million shares (85% of the notional amount) and an additional 8.3 million shares in March 2024. Similar to 2023, the forward contract was reclassified from capital surplus to treasury stock after the final shares were received. The accounting treatment remained consistent, but the scale and timeline of completion evolved, with the 2024 ASR taking two months to conclude compared to one month in 2023.",
      "llm_answer": "\nIn the 2023 10‑K the company disclosed the three ASR transactions (Morgan Stanley $3 bn, Citibank $2 bn and Barclays $1.5 bn) as initial treasury‑stock purchases with a forward contract recorded in capital surplus, and it noted that the Morgan Stanley ASR was still pending final settlement and could deliver up to 73.9 million shares. The 2024 10‑K shows that the Morgan Stanley ASR was completed in March 2024 after the company received the remaining 15 % of the notional amount (≈8.3 million shares), at which point the forward contract was re‑classified from capital surplus to treasury stock, and the balance of the 2021 repurchase‑program authorization fell to $1.5 bn.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that in the 2023 10-K, CVS disclosed *three* ASR transactions, including a $3B Morgan Stanley ASR and a $1.5B Barclays ASR, which are not mentioned in the ground truth. According to the original answer, only a $2.0B ASR with Citibank occurred in 2023. The $3.0B ASR with Morgan Stanley was completed in 2024, but the LLM incorrectly implies it was initiated earlier and part of 2023 disclosures. Additionally, the LLM claims the Morgan Stanley ASR 'could deliver up to 73.9 million shares,' which is unsupported by the ground truth (initial 31.4M + 8.3M = 40.7M total). (2) Quantitative accuracy is poor: while the 8.3 million final shares in March 2024 and the 15% final delivery are approximately correct (85% initial implies 15% final), the total share numbers and dollar amounts for multiple ASRs are fabricated. The $1.5B remaining authorization is mentioned in the LLM answer but not in the ground truth, making it unverifiable and potentially misleading. (3) Multi-hop reasoning is flawed: instead of comparing the accounting treatment and timeline of the 2023 and 2024 ASRs as described in the ground truth, the LLM invents additional transactions and misattributes them across years. It fails to mention the 2023 Citibank ASR details (17.4M initial, 5.4M additional) and falsely presents the Morgan Stanley ASR as ongoing in 2023 when it appears to be a 2024-only transaction in the truth. (4) Contextual relevance is moderate because the answer discusses ASR accounting and reclassification correctly (forward contract reclassified from capital surplus to treasury stock), which aligns with the ground truth. However, due to major factual and entity errors, the overall correctness is low. The core evolution—scale increasing from $2B to $3B and completion time from one to two months—is missed entirely due to incorrect framing. Thus, scores are low on correctness and quantitative accuracy, slightly higher on qualitative due to correct mention of reclassification, and moderate on relevance for addressing ASR mechanics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1373,
        "completion_tokens": 570,
        "total_tokens": 1943
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How did UPS's financial exposure and reporting approach related to the Central States Pension Fund evolve from 2022 to 2023, particularly in terms of actuarial estimates and sensitivity analysis?",
      "original_answer": "In 2022, UPS disclosed a $2.3 billion pre-tax actuarial loss related to potential coordinating benefits for the Central States Pension Fund, as part of broader pension obligation disclosures. By 2023, the company's reporting shifted focus to sensitivity analysis, referencing a 25 basis point change in expected and actual returns on assets as a key assumption affecting pension liabilities, with an explicit cross-reference to Note 5 for details on the Central States Pension Fund liability. This indicates a shift from quantifying a specific obligation to emphasizing the sensitivity of returns on the overall liability.",
      "llm_answer": "\nFrom 2022 to 2023 UPS’s exposure to the Central States Pension Fund flipped: the 2022 filing (which reflects the 2021 actuarial calculations) recorded a **$5.1 bn pre‑tax gain** from coordinating benefits, whereas the 2023 filing shows a **$2.3 bn pre‑tax loss** on the same coordinating‑benefit estimate, indicating a reversal in the liability position.  UPS continues to disclose this liability in Note 5 of its 10‑K and applies the same sensitivity analysis—e.g., a 25‑basis‑point change in the discount rate would adjust the projected benefit obligation by roughly **$1.5 bn**—while updating the actuarial assumptions (discount rate, demographic factors, actual experience) each year.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual errors. The ground truth states that in 2022, UPS disclosed a $2.3 billion pre-tax actuarial *loss* related to potential coordinating benefits for the Central States Pension Fund. However, the LLM incorrectly claims a $5.1 billion pre-tax *gain* in 2022 (referencing 2021 actuarial calculations), which contradicts the original answer. It then states a $2.3 billion pre-tax loss in 2023, implying a reversal, but the original answer does not state that the loss occurred in 2023 — rather, the $2.3B loss was part of the 2022 disclosure (for prior period estimates). Thus, the timing, direction (gain vs loss), and magnitude of the reported items are incorrect. (2) The LLM introduces a 25-basis-point change in the *discount rate* affecting PBO by $1.5B, but the original answer specifies a 25-basis-point change in *expected and actual returns on assets* as the sensitivity factor, not the discount rate. This misrepresents a key assumption in the sensitivity analysis. Additionally, the $1.5B sensitivity figure is not mentioned in the ground truth, making it an unsupported addition. (3) The multi-hop reasoning is flawed: the original answer describes a shift in reporting *emphasis* from quantifying a specific actuarial loss in 2022 to focusing on sensitivity analysis in 2023, particularly around return on assets. The LLM instead frames this as a reversal in financial position due to a gain turning into a loss, which is not supported by the ground truth and reflects a misinterpretation of the evolution in reporting. (4) While the LLM correctly identifies Note 5 as the location of disclosures and mentions annual updates to actuarial assumptions, these correct contextual elements do not compensate for the core factual inaccuracies in numbers, timing, and reasoning. The answer is contextually relevant in topic and structure but fails on primary facts and synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 522,
        "total_tokens": 1862
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Mastercard's positioning and emphasis on its Cyber and Intelligence Solutions evolved between 2022 and 2023, particularly in terms of the value proposition communicated to stakeholders?",
      "original_answer": "In 2022, Mastercard described its Cyber and Intelligence Solutions as part of its value-added services that 'allow all parties to transact easily and with confidence' and emphasized principled use of consumer and merchant data. By 2023, the company expanded this messaging, positioning the solutions as central to enabling secure transactions and confidence in the payments ecosystem, while also linking them to strategic investments in new networks like open banking and digital identity. This reflects a broader integration of cyber solutions into the company's overall infrastructure narrative.",
      "llm_answer": "\nBetween 2022 and 2023 Mastercard moved the discussion of its Cyber and Intelligence Solutions from a peripheral “value‑added service” that simply “allows all parties to transact easily and with confidence” (2022 10‑K) to a strategic growth pillar that is explicitly linked to revenue expansion, digital‑identity/open‑banking investments and proprietary data insights (2023 10‑K).  In the later filing the company stresses that these solutions “enable secure, easy and confident transactions” while delivering “proprietary insights” and are highlighted as a primary driver of net‑revenue growth and shareholder value, underscoring a stronger, more value‑focused positioning for stakeholders.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: in 2022, Cyber and Intelligence Solutions were described as value-added services enabling confident transactions, with emphasis on principled data use (implied in 'proprietary insights' and consistent with 'principled use' in original). By 2023, the positioning evolved to a more strategic role, linked to secure transactions, open banking, digital identity, and revenue growth—accurately reflected in the LLM's description of the solutions as a 'strategic growth pillar' and 'primary driver of net-revenue growth'. (2) There are no numeric values, dates, or calculations in the question or answers, so quantitative accuracy is not applicable in a numerical sense, but all years (2022, 2023) and document references (10-K filings) are correctly attributed—scored as 10. (3) The multi-hop reasoning is sound: the model correctly synthesizes the evolution of messaging across two years, identifies the shift from peripheral to central positioning, and connects it to broader strategic initiatives (open banking, digital identity, data insights). The only minor gap is that the original emphasizes 'confidence in the payments ecosystem' and 'integration into overall infrastructure narrative', which the LLM captures semantically via 'strategic growth pillar' and 'driver of net-revenue growth', though slightly more focused on financial outcomes than systemic infrastructure. (4) The answer is fully contextually relevant, directly addressing the evolution in value proposition to stakeholders. Wording differs but meaning is substantively equivalent. No factual errors—only a slight lean toward financial impact over structural integration prevents a perfect 10 on qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 486,
        "total_tokens": 1820
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How did PepsiCo's presentation of the 4.450% Senior Note due 2046 evolve between its 2022 and 2023 SEC filings, particularly in terms of exhibit referencing and associated documentation dates?",
      "original_answer": "In the 2022 filing, the 4.450% Senior Note due 2046 was listed as Exhibit 4.12, incorporated by reference from PepsiCo's Form 8-K filed on October 14, 2015. In the 2023 filing, the same note was reclassified as Exhibit 4.13 and referenced the Form 8-K filed on February 24, 2016. This indicates a shift in how PepsiCo organized or updated its capital structure disclosures, potentially reflecting revised documentation or administrative reclassification over time.",
      "llm_answer": "\nIn the 2022 Form 10‑K the 4.450 % Senior Note due 2046 was listed as Exhibit 4.11 (and also repeated as Exhibit 4.13) with a citation to the original 8‑K filing of October 14 2015 (and a secondary reference to a February 24 2016 filing). In the 2023 Form 10‑K the same note appears under a new exhibit number — Exhibit 4.60 — and the reference is updated to a more recent 8‑K filing dated February 15 2023, showing that the company re‑numbered the exhibit and updated the documentation date for the note.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in the 2022 filing, the 4.450% Senior Note due 2046 was listed as Exhibit 4.12 (not 4.11 or 4.13 as stated), referencing the Form 8-K filed on October 14, 2015. The LLM incorrectly claims it was listed as both Exhibit 4.11 and 4.13, which contradicts the original answer. In the 2023 filing, the note was reclassified as Exhibit 4.13 (not Exhibit 4.60 as claimed), and referenced the Form 8-K filed on February 24, 2016 (not February 15, 2023). The LLM invents a new exhibit number and a completely incorrect date not present in the ground truth. (2) Quantitative accuracy is very low: all exhibit numbers (4.11, 4.13, 4.60) and the 2023 8-K date (February 15, 2023) are incorrect. Only the October 14, 2015 date is correctly mentioned, but it is misrepresented as having a secondary reference in 2016. (3) The multi-hop reasoning is flawed — the model fails to correctly track the exhibit renumbering from 4.12 to 4.13 and instead fabricates a shift to Exhibit 4.60 with a 2023 filing, suggesting a misunderstanding of the disclosure evolution. The conclusion about 'updated documentation' is speculative and based on false premises. (4) Contextual relevance is moderate because the answer addresses exhibit referencing and documentation dates as asked, but the incorrect data renders the response misleading. Due to major factual and numerical errors, the correctness score is low at 2.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1253,
        "completion_tokens": 411,
        "total_tokens": 1665
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Intel's relationship with Positive Technologies evolved between 2023 and 2024, particularly in terms of their engagement under OFAC licensing following the U.S. sanctions?",
      "original_answer": "In 2023, Intel disclosed that it had communicated with Positive Technologies regarding IT security research and coordinated disclosure of vulnerabilities, and that it resumed such communications under an OFAC license following the sanctions. By 2024, Intel's relationship had evolved from mere disclosure of past communication to an explicit statement of intent to continue these interactions in accordance with the OFAC license. While both years clarify that there were no gross revenues or net profits associated with these activities, the 2024 filing reflects a more forward-looking and sustained partnership posture with Positive Technologies under the sanctioned conditions.",
      "llm_answer": "\nBetween 2023 and 2024 Intel’s contact with Positive Technologies remained narrowly focused on coordinating IT‑security research and vulnerability disclosures.  Both the 2023 and 2024 10‑K filings note that, after the U.S. Treasury designated Positive Technologies as a sanctioned entity, Intel resumed those communications only under an OFAC general‑license (General License 1B) and that no revenue or profit is derived from the interaction.  Consequently, Intel’s relationship with Positive Technologies has not changed materially—it continues to engage under the same OFAC‑authorized license, with no commercial transactions and a stated intent to keep the communications going in 2024.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of key facts: Intel's engagement with Positive Technologies is limited to IT security research and vulnerability disclosure; communications resumed under an OFAC license (correctly specifying General License 1B, which is consistent with public filings); no revenue or profit is generated from the interaction; and the 2024 filing indicates an intent to continue. Quantitatively, there are no numerical inaccuracies—dates (2023, 2024), the absence of financial gain, and the licensing framework are all accurately represented. The answer is contextually relevant and addresses all parts of the question. However, the LLM understates the evolution in the relationship by stating that 'the relationship has not changed materially,' which contradicts the ground truth's emphasis on a shift from retrospective disclosure in 2023 to a forward-looking, sustained partnership posture in 2024. This mischaracterization affects the qualitative accuracy, as it fails to fully capture the nuanced progression in tone and intent between the two years, despite correctly reporting the facts. Thus, while the core information is correct, the synthesis and interpretation of the evolution are slightly off, warranting a score of 8 rather than 9 or 10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 365,
        "total_tokens": 1715
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has the balance of CVS's 4.78% Senior Notes due March 2038 evolved between 2023 and 2024, and what does this indicate about the company's long-term debt structure?",
      "original_answer": "The balance of CVS's 4.78% Senior Notes due March 2038 remained stable at $5,000 million in both 2023 and 2024, indicating that the company did not retire or issue additional amounts of this particular debt instrument during the period. This stability contrasts with other senior notes, such as the 2.7% senior notes due August 2040, which decreased from $1,250 million in 2023 to $367 million in 2024, suggesting selective debt management and refinancing activity in other long-term obligations.",
      "llm_answer": "\nThe $4.78 % senior notes maturing in March 2038 remained at a $5 billion outstanding balance in both the 2023 and 2024 borrowings tables, showing no change in the amount of that specific tranche over the two years. This stability indicates that CVS is keeping a large, long‑dated fixed‑rate pillar in its capital structure while it refinances shorter‑dated and higher‑coupon notes through newer issuances and early‑extinguishment activities.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly states that the balance of CVS's 4.78% Senior Notes due March 2038 remained unchanged at $5 billion (equivalent to $5,000 million) in both 2023 and 2024, matching the ground truth exactly. All numeric values—interest rate (4.78%), maturity date (March 2038), dollar amount ($5 billion), and years (2023–2024)—are accurate. (2) Quantitative accuracy is perfect: $5 billion = $5,000 million, and no incorrect calculations were made. The LLM correctly identifies stability in this debt tranche. (3) The reasoning is sound and aligns with the ground truth: the stability of this long-term note suggests CVS maintained this fixed-rate debt as a 'pillar' in its capital structure. The LLM appropriately infers selective refinancing activity, referencing early extinguishment and new issuances, which is consistent with the ground truth's mention of the decrease in the 2.7% senior notes due 2040 (though the LLM does not explicitly cite that specific example). This constitutes a minor omission in completeness but does not undermine the validity of the inference. (4) The answer is contextually fully relevant, directly addressing both parts of the question: the evolution (no change) and what it indicates (strategic stability in long-term debt structure amid broader refinancing). The qualitative score is 9 instead of 10 because the LLM does not explicitly contrast this note’s stability with changes in other tranches (e.g., the 2.7% notes), which was a key element in the original answer’s comparative analysis. However, the core multi-hop reasoning—linking stable debt balances to strategic capital structure management—is correctly and insightfully conveyed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1239,
        "completion_tokens": 462,
        "total_tokens": 1702
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has the status of the 0.835% Notes due 2032 evolved between the 2022 and 2024 SEC filings for Exxon Mobil Corporation?",
      "original_answer": "In the 2022 filing, the 0.835% Notes due 2032 were listed among other notes with distinct trading symbols, including the 0.142% Notes due 2024 (XOM24B), indicating a broader set of publicly traded debt instruments. By 2024, the 0.835% Notes due 2032 remained listed with the trading symbol XOM32, but the 0.142% Notes due 2024 no longer appeared in the 2024 filing, suggesting that the 2024 notes were either redeemed or no longer publicly traded. Therefore, while the 0.835% Notes due 2032 remained a consistent part of Exxon Mobil's publicly disclosed debt structure, the removal of the 2024 notes indicates a change in the company's short-to-intermediate term debt composition.",
      "llm_answer": "\nThe 0.835 % Notes due 2032 remained a registered security of Exxon Mobil in both filings. In the 2022 Form 10‑K (page 1) the notes were listed as “0.835 % Notes due 2032 – XOM32 – New York Stock Exchange,” and the 2024 Form 10‑K (page 1) continues to show the same issue with the identical ticker and exchange listing, indicating no change in its registration or status between the two years.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually correct regarding the status of the 0.835% Notes due 2032, accurately stating that they remained listed with the same trading symbol (XOM32) and exchange (NYSE) in both the 2022 and 2024 filings. All quantitative details—interest rate (0.835%), maturity year (2032), ticker (XOM32)—are correct and match the ground truth. However, the LLM answer is incomplete in scope. The original question asks how the status of the notes evolved *between* the 2022 and 2024 filings, which requires a comparative analysis. The ground truth highlights not only the continuity of the 2032 notes but also contrasts it with the disappearance of the 0.142% Notes due 2024 (XOM24B) in the 2024 filing, indicating a shift in ExxonMobil’s debt composition. This comparative insight is missing in the LLM response, which focuses only on the stability of the 2032 notes without addressing the broader context of changes in the company's debt structure. While the core facts about the 0.835% Notes are accurate, the lack of synthesis across both filings—particularly the absence of reasoning about what changed (e.g., removal of 2024 notes)—reduces the qualitative accuracy. The answer is contextually relevant and correctly interprets the data available, but fails to fully execute the multi-hop reasoning required to explain the evolution of the debt instrument within the larger portfolio. Hence, correctness is partially impacted due to omission of key comparative context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1262,
        "completion_tokens": 406,
        "total_tokens": 1668
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has American Express's investment strategy toward U.S. Government treasury obligations evolved between 2022 and 2024, particularly in terms of fair value allocation and maturity distribution?",
      "original_answer": "In 2022, American Express held U.S. Government treasury obligations exclusively in short-term instruments with a fair value of $477 million and no long-term exposure. By 2024, the company shifted its strategy to include both short-term ($189 million) and intermediate-term ($98 million) treasury obligations, indicating a more diversified maturity profile. This reflects a transformation in the company's investment approach, expanding beyond less than 12-month instruments to include holdings maturing within 1 to 5 years.",
      "llm_answer": "\nAmerican Express trimmed its U.S. government‑treasury book from a cost of $1.68 bn (fair value $1.704 bn) in 2021 to just $0.289 bn (fair value $0.287 bn) by the end of 2024.  The maturity profile moved from a laddered stance—about $832 m maturing within one year and $862 m maturing after one but within five years in 2021—to a front‑end‑biased mix where roughly $189 m matures within one year and $98 m matures after one to five years, with virtually no exposure beyond five years in 2024.  This shift reflects a strategic emphasis on shorter‑duration, lower‑interest‑rate risk, and the fair‑value position changed from a modest $25 m unrealized gain in 2021 to a near‑break‑even status with only a $2 m unrealized loss by 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, American Express held $477 million in short-term U.S. Treasury obligations with no long-term exposure. However, the LLM incorrectly references 2021 data (e.g., $1.68B cost, $1.704B fair value) not mentioned in the original answer and irrelevant to the 2022–2024 timeframe asked. The 2024 figures for short-term ($189M) and intermediate-term ($98M) are correct and align with the ground truth, but the LLM misrepresents the evolution by comparing 2021 to 2024 instead of 2022 to 2024. (2) The quantitative inaccuracies are severe: the $477M short-term holding in 2022 is completely omitted and replaced with incorrect 2021 figures. The LLM introduces cost basis and unrealized gains/losses ($25M gain in 2021, $2M loss in 2024), which are not in the original answer and cannot be verified against the ground truth. These numbers, while possibly from actual filings, contradict the provided knowledge graph. (3) The multi-hop reasoning is flawed because the model fails to correctly identify the starting point (2022) and instead extrapolates backward to 2021, which distorts the strategic evolution. The conclusion about a 'front-end-biased mix' and reduced duration risk may be plausible, but it is based on incorrect data inputs and timeframes. (4) Contextual relevance is moderate because the answer discusses fair value, maturity distribution, and strategic shift—key elements of the question—but the incorrect temporal scope and numerical foundation severely undermine factual correctness. The synthesis does not match the ground truth, leading to a low correctness score despite partial alignment on 2024 figures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 471,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did Amazon's introduction and subsequent treatment of the 2.500% Note due 2050 evolve between 2022 and 2024?",
      "original_answer": "In 2022, the 2.500% Note due 2050 was introduced as part of an Officers' Certificate dated June 3, 2020, and was listed alongside other notes in Exhibit 4.5. By 2024, the 2.500% Note due 2050 was reintroduced in Exhibit 4.6, which was an exact replication of Exhibit 4.5 from 2020, indicating that Amazon continued to maintain this long-term debt instrument without modification. The reintroduction in 2024 reaffirmed the note's role in Amazon's capital structure.",
      "llm_answer": "\nBetween 2022 and 2024 Amazon continued to carry the 2.500 % Note due 2050 unchanged in its financial statements. The note was first disclosed in the 2020 debt issuance (June 3 2020) and, in the 2022 10‑K, was presented as an outstanding unsecured senior obligation with no redemptions or covenant changes; the 2024 10‑K still lists the same 2.500 % Note due 2050 in the indenture schedule and reports no modifications, repayments, or amendments, indicating that its terms and status remained the same throughout the period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: the 2.500% Note due 2050 was originally issued on June 3, 2020, and remained unchanged through 2022 and 2024. The LLM correctly states that there were no modifications, repayments, or amendments to the note during this period. (2) Quantitative accuracy is perfect: the interest rate (2.500%), maturity year (2050), and issuance date (June 3, 2020) match the original answer exactly. (3) The multi-hop reasoning is sound—LLM synthesizes information across 2022 and 2024 filings to conclude the note remained unchanged, correctly inferring continuity in Amazon's capital structure. While the original answer references Exhibits 4.5 and 4.6, the LLM captures the same meaning by noting the note's continued listing in the indenture schedule without explicitly naming the exhibits. This is a minor omission but does not affect factual correctness. (4) The answer is highly relevant, directly addressing the evolution (or lack thereof) of the note between 2022 and 2024. The conclusion that terms and status remained the same aligns perfectly with the ground truth's assertion of 'reintroduction without modification.'",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1238,
        "completion_tokens": 344,
        "total_tokens": 1582
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did the number of amendments to the Citibank, N.A. Co-Branded Credit Card Agreement evolve between 2022 and 2023?",
      "original_answer": "In 2022, the most recent amendment to the Citibank, N.A. Co-Branded Credit Card Agreement was the Eighth Amendment, filed on March 10, 2022. By 2023, the agreement had undergone further modifications, with the Twelfth Amendment being filed on October 11, 2023, indicating a total of four additional amendments during this period. This demonstrates a continued evolution and refinement of the agreement terms over the 12-month period.",
      "llm_answer": "\nBetween the 2022 filing (which listed the Eighth Amendment as the latest) and the 2023 filing, four new amendments—Ninth, Tenth, Eleventh and Twelfth—were added to the Citibank, N.A. Co‑Branded Credit Card Agreement, raising the total count of amendments from eight to at least twelve by the end of 2023. This shows a steady increase of four additional amendments during that one‑year period.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) It accurately states that the Eighth Amendment was the latest in 2022 and that the Twelfth Amendment was reached by 2023, indicating four additional amendments (Ninth through Twelfth), which matches the original answer. (2) All quantitative details are correct: the progression from the 8th to the 12th amendment implies exactly four new amendments, and the time frame of one year is correctly interpreted. No specific dates (e.g., March 10, 2022, or October 11, 2023) are missing in a way that affects factual accuracy, as the question focuses on the evolution in number, not exact filing dates. (3) The multi-hop reasoning—comparing the latest amendment in 2022 to the latest in 2023 and calculating the difference—is sound and correctly executed. (4) The answer addresses all parts of the question: it identifies the starting and ending amendment numbers, the period, and the net change, with accurate entity names (Citibank, N.A. Co-Branded Credit Card Agreement). Wording differs slightly but conveys the same factual content. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1199,
        "completion_tokens": 331,
        "total_tokens": 1530
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has NVIDIA's approach to CUDA evolved between 2022 and 2024, particularly in terms of its integration with new computing architectures and software ecosystems?",
      "original_answer": "In 2022, NVIDIA emphasized CUDA as a foundational building block across its target markets, including Gaming, Data Center, Professional Visualization, and Automotive, highlighting its role in enabling accelerated computing and deep learning. CUDA was positioned as a core component of the company's unified architecture, supporting a wide range of applications through internal and third-party software stacks. By 2024, NVIDIA had significantly expanded the scope of CUDA's integration, describing it as part of a broader full-stack computing platform that includes the CUDA-X collection of acceleration libraries, APIs, SDKs, and domain-specific application frameworks. Additionally, CUDA was now explicitly tied to NVIDIA's expanded data center platform, which now includes CPUs (introduced in fiscal 2024) alongside GPUs and DPUs, showing a strategic evolution toward deeper integration with heterogeneous computing architectures and enterprise-grade AI ecosystems.",
      "llm_answer": "\nBetween 2022 and 2024 NVIDIA broadened CUDA from a GPU‑only parallel programming model into a full‑stack, hardware‑agnostic platform that runs on its newest architectures—Hopper (H100), Ada‑Lovelace and the forthcoming Blackwell GPUs—as well as on new CPUs (Grace), DPUs and Mellanox‑based networking.  This expansion was coupled with a richer software ecosystem (CUDA‑X libraries, AI Enterprise, NIM/NeMo/AI Blueprints, Omniverse, DRIVE software) that lets developers deploy AI workloads across data‑center, edge and automotive systems using a single, unified CUDA programming interface.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution of CUDA from a GPU-centric model in 2022 to a full-stack, heterogeneous computing platform by 2024. The mention of integration with CPUs (Grace), DPUs, and networking (Mellanox) reflects NVIDIA's strategic expansion into heterogeneous architectures, consistent with the introduction of CPUs in fiscal 2024. The software ecosystem components—CUDA-X, AI Enterprise, NIM/NeMo, Omniverse, DRIVE—are accurately cited as part of the broader platform, matching the 'domain-specific application frameworks' and 'acceleration libraries' described in the original answer. (2) There are no numeric values, dates, or financial figures in either answer, so quantitative accuracy is not applicable in a traditional sense; however, the reference to Hopper (H100), Ada-Lovelace, and Blackwell GPUs is factually correct for the 2022–2024 timeframe and aligns with known product rollouts. (3) The multi-hop reasoning is sound: the LLM synthesizes CUDA’s architectural evolution with new hardware (GPUs, CPUs, DPUs) and software ecosystems across data center, edge, and automotive domains—exactly as described in the ground truth. (4) The only minor shortcoming is that the LLM slightly overreaches by calling CUDA 'hardware-agnostic,' which may imply it runs on non-NVIDIA hardware, whereas the original answer emphasizes integration within NVIDIA’s own heterogeneous platforms (GPUs, CPUs, DPUs), not cross-vendor hardware support. This nuance is important and slightly affects qualitative accuracy. Otherwise, the answer is semantically equivalent, comprehensive, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1393,
        "completion_tokens": 458,
        "total_tokens": 1851
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did Pfizer's financial relationship with Paxlovid evolve between 2023 and 2024, particularly in terms of revenue recognition and contractual obligations?",
      "original_answer": "In 2023, Paxlovid generated $1.279 billion in revenue, but this figure was significantly impacted by a non-cash revenue reversal of $3.5 billion due to the expected return of 6.5 million treatment courses of EUA-labeled U.S. government inventory. By 2024, this reversal was adjusted favorably by $771 million as only 5.1 million treatment courses were actually returned, and an additional $442 million in revenue was recorded in connection with the creation of the U.S. Strategic National Stockpile (SNS). Furthermore, as of December 31, 2024, Pfizer reported approximately $1 billion in remaining performance obligations related to Paxlovid supply contracts, indicating ongoing but reduced commercial activity compared to the prior year. This evolution reflects a shift from a high-volume, government-driven revenue model in 2023 to a more stable, contracted future delivery model in 2024.",
      "llm_answer": "\nBetween 2023 and 2024 Pfizer’s Paxlovid revenue collapsed – it fell from **$1.28 bn in 2023** to **$5.72 bn in 2024**, the latter figure incorporating a **$442 m gain from new commercial sales** and a **$771 m favorable adjustment to the $3.5 bn non‑cash revenue reversal recorded in Q4 2023**.  At the same time the company shifted the product from government‑procured EUA supply to a commercial market, cutting the **deferred‑revenue balance from $5.1 bn (2023) to $2.2 bn (2024)**, and the **remaining performance obligations under long‑term supply contracts now total roughly $1 bn of contracted revenue to be recognized through 2028**.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual and quantitative errors. Most critically, it states that Paxlovid revenue 'fell from $1.28 bn in 2023 to $5.72 bn in 2024', which is incorrect — the 2024 revenue is not $5.72 billion, and revenue did not increase. In fact, the original answer indicates that 2023 revenue was $1.279 billion, but this was after a $3.5 billion non-cash reversal; the $5.72 billion figure appears to be a misinterpretation of cumulative adjustments. The LLM incorrectly presents $5.72 billion as 2024 revenue, when in reality, the $771 million favorable adjustment and $442 million SNS revenue are additions to prior adjustments, not total annual revenue. (2) The $442 million gain from SNS creation and $771 million favorable adjustment are mentioned, but their context is misrepresented — they are not components of 2024 revenue in the way implied. Additionally, the deferred revenue balances of $5.1 billion (2023) and $2.2 billion (2024) are fabricated and not supported by the original answer. The remaining performance obligations of $1 billion are correctly cited, though the extension to 2028 is an addition not present in the original and potentially speculative. (3) The multi-hop reasoning is flawed: the model fails to correctly track the evolution of revenue recognition, conflating reversals, adjustments, and actual sales. It incorrectly infers a revenue collapse when the original describes a normalization after a large non-cash adjustment. The shift from government to commercial model is partially correct but overstated. (4) Despite the severe quantitative inaccuracies, the answer addresses the right topic and attempts to discuss revenue recognition and contractual obligations, hence a moderate contextual relevance. However, the core financial narrative is inverted or distorted, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 506,
        "total_tokens": 1892
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has the availability and structure of shares under the 2003 Incentive Program evolved between 2022 and 2024?",
      "original_answer": "In 2022, the 2003 Incentive Program had 65,754,069 shares available for award. By 2024, the total maximum number of shares that could be issued under the program was increased to 220 million, with 47 million remaining available for awards by the end of 2024. This indicates a significant expansion in the program's capacity, although actual usage had grown moderately over time, with restricted stock units granted increasing from 9,392 thousand in 2022 to 10,393 thousand in 2024.",
      "llm_answer": "\nBetween 2022 and the end of 2024 the number of shares left available for future grants under the 2003 Incentive Program fell sharply—from about **65.8 million shares** noted in the 2022 filing to roughly **47 million shares** remaining as of December 31 2024 (Note 15).  The decline reflects the issuance of roughly **10.5 million restricted‑stock units in 2024**, including the conversion of Pioneer RSUs, as well as the vesting and forfeiture of earlier awards, while the program’s overall ceiling of **220 million shares** stays the same but is now much closer to being exhausted.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. It correctly identifies the 65.8 million shares available in 2022 (matching the ground truth 65,754,069, rounded appropriately) and the 47 million shares remaining available by the end of 2024. It also correctly notes the 220 million share ceiling in 2024. However, it incorrectly frames the evolution as a 'decline' in available shares due to issuances, implying no increase in the total authorized cap over time. The ground truth states that the total maximum number of shares was *increased* to 220 million by 2024, indicating an expansion of the program, which the LLM omits entirely. This misrepresents the structural evolution of the program. (2) The LLM claims '10.5 million restricted-stock units in 2024', but the ground truth reports 10,393 thousand (i.e., ~10.4 million) granted over the entire period from 2022 to 2024, not in 2024 alone. The LLM incorrectly attributes nearly all the change to 2024 grants and conversion activity, introducing a factual error in both magnitude and timing. (3) The multi-hop reasoning is flawed: the model fails to synthesize the key point that the program underwent a significant expansion (from ~65.8M to 220M total authorized shares), which is central to the 'evolution' of the program's structure. Instead, it assumes the cap remained static, leading to an incorrect narrative of depletion. (4) While the answer includes relevant context and correct numbers for availability at two points in time, the absence of the program's expansion and the misstatement of grant volumes reduce factual accuracy. Scores reflect partial correctness on numbers but major errors in reasoning and completeness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1257,
        "completion_tokens": 470,
        "total_tokens": 1727
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has AdSense's role within Google's advertising revenue streams evolved between 2022 and 2024, particularly in relation to the company's broader advertising technology portfolio?",
      "original_answer": "In 2022, AdSense was explicitly cited as a key growth driver within the Google Network, contributing to an $8.6 billion year-over-year revenue increase alongside AdMob and Google Ad Manager. By 2024, while AdSense remained part of the Google Network, it was no longer specifically quantified as a growth lever. Instead, newer AI-powered advertising products like Demand Gen and Performance Max were highlighted as central to advertiser success, suggesting a strategic shift where AdSense became a more foundational, mature offering within Google's broader advertising technology stack.",
      "llm_answer": "\nBetween 2022 and 2024 AdSense moved from being a distinct line‑item within the “Google Network” (which in 2022 showed a $8.6 billion revenue lift driven by AdMob, Ad Manager and AdSense) to a core, AI‑enabled layer of Google’s overall advertising stack.  By 2024 it is tightly integrated with products such as Performance Max, Gemini and the broader Google Ads platform, feeding third‑party inventory into AI‑driven performance and brand‑advertising tools and accounting for a larger share of Google’s total ad revenue.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of AdSense from a highlighted growth driver in 2022 to a more integrated component by 2024, which aligns with the ground truth. Quantitatively, it correctly references the $8.6 billion year-over-year revenue increase in the Google Network in 2022 and attributes it to AdSense, AdMob, and Ad Manager—this matches the original answer and is accurate. However, the LLM incorrectly implies that AdSense's integration with AI tools like Performance Max and Gemini led to it accounting for a 'larger share of Google’s total ad revenue'—a claim not supported by the original answer, which states AdSense was no longer specifically quantified as a growth lever by 2024 and instead became a mature, foundational offering. This misrepresents the strategic shift: the original emphasizes reduced emphasis on AdSense as a standalone growth driver, while the LLM suggests increased importance via revenue share, which is a significant factual overreach. The reasoning is partially sound in identifying integration with broader ad tech, but the conclusion about increased revenue share introduces unsupported inference. Entity accuracy (AdSense, AdMob, Ad Manager, Performance Max, Google Network) and timeframes (2022–2024) are correct. Contextually, the answer is relevant and addresses the evolution question, but the erroneous claim about growing revenue share undermines the qualitative accuracy. Thus, while the quantitative foundation is solid, the incorrect interpretation of AdSense’s strategic role reduces overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1285,
        "completion_tokens": 428,
        "total_tokens": 1713
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How did the UPS Retirement Plan's benefit accrual structure evolve between 2022 and 2023, and what specific changes were made to future benefit accruals for non-union participants?",
      "original_answer": "In 2022, the UPS Retirement Plan was described as noncontributory and covering substantially all eligible employees hired before July 1, 2016, who were not part of a collective bargaining unit or certain employees covered by a collective bargaining agreement. The plan provided retirement benefits based on average compensation and was subject to IRS limits. It was also disclosed that the plan would cease accruals of additional benefits for future service and compensation for non-union participants effective January 1, 2023. In 2023, this cessation of accruals was confirmed as effective, and the plan was described with the same eligibility and benefit structure but explicitly stated that no further accruals would occur for non-union participants. This marks a transformational change in the plan's structure, as the accrual freeze was implemented as planned, shifting the plan from an active benefit-accruing structure to a closed one for non-union employees. The change represents a significant strategic shift in UPS's retirement benefit policy.",
      "llm_answer": "\nBetween 2022 and 2023 the UPS Retirement Plan moved from an open‑ended defined‑benefit accrual for non‑union employees to a freeze of future benefit credits—effective January 1 2023 the plan (and its Excess Coordinating Benefit component) stopped accruing any additional benefits for that group. At the same time the plan was revised so that non‑union participants would receive a retirement contribution of 5 %–8 % of eligible compensation to the UPS 401(k) Savings Plan (up from the prior 3 %–8 % schedule for employees hired after July 1 2016), replacing the former defined‑benefit accrual. These changes are outlined in the “U.S. Pension Benefits” section of Note 6 in the 2023 filing.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies, particularly regarding the nature of the changes to the UPS Retirement Plan. While it correctly identifies that benefit accruals for non-union participants ceased effective January 1, 2023, it incorrectly states that non-union participants began receiving increased 401(k) contributions of 5%–8% of eligible compensation, replacing the defined benefit. The ground truth does not mention any such increase in 401(k) contributions or a shift to a 5%–8% range. The original answer confirms only the freeze of future accruals and does not reference any new or revised 401(k) contributions as a replacement. This is a major factual error that undermines the correctness of the response. The date (January 1, 2023) is accurate, and the identification of the affected group (non-union participants) is correct. The reference to Note 6 in the 2023 filing is plausible but not verifiable from the ground truth provided. The reasoning partially captures the structural change (closure of accruals), but the addition of the 401(k) enhancement is unsupported and incorrect, indicating a failure in multi-hop synthesis or misinterpretation of source material. While the answer addresses the evolution of the plan and the specific change to future accruals, the inclusion of unverified quantitative details (5%–8%) severely compromises quantitative accuracy. Contextually, the answer is well-structured and relevant to the question, hence a higher relevance score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1444,
        "completion_tokens": 413,
        "total_tokens": 1857
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has Amazon's utilization and structure of its short-term credit facilities evolved between 2022 and 2024, particularly in terms of credit capacity, interest rate terms, and outstanding borrowings?",
      "original_answer": "In 2022, Amazon had a $7.0 billion unsecured revolving credit facility with an interest rate of benchmark rate plus 0.50% and a commitment fee of 0.04%, and no borrowings were outstanding under this facility. Additionally, Amazon had $7.2 billion in unused letters of credit as of December 31, 2021. By 2024, Amazon had significantly expanded its credit capacity by entering into a new $15.0 billion unsecured revolving credit facility with a lower interest rate of benchmark rate plus 0.45% and a reduced commitment fee of 0.03%. In addition, Amazon introduced a new $5.0 billion unsecured 364-day revolving credit facility in October 2024, which also carried a rate of SOFR plus 0.45% and a 0.03% commitment fee. Notably, there were still no borrowings outstanding under the main Credit Agreement or the Short-Term Credit Agreement as of December 31, 2024. However, Amazon had $147 million and $151 million in borrowings under other short-term credit facilities as of December 31, 2023 and 2024, respectively, which were included in 'Accrued expenses and other.' The company also increased its unused letters of credit to $8.3 billion by the end of 2024.",
      "llm_answer": "\nBetween 2022 and 2024 Amazon expanded and reshaped its short‑term liquidity lines: it grew its unsecured revolving capacity from the $7 billion facility that was set to expire in 2023 to a $15 billion revolving agreement that now runs until 2028 (interest = benchmark + 0.45 % with a 0.03 % commitment fee), and it added a new $5 billion 364‑day revolving facility (SOFR + 0.45 % and a 0.03 % fee) that matures in 2025.  At the same time it terminated its $1 billion secured revolving facility that had been used for seller‑receivable collateral, and it doubled the size of its commercial‑paper program to $20 billion while bringing outstanding commercial‑paper borrowings to essentially zero.  Consequently, short‑term borrowings under these facilities fell from about $800 million at the end of 2021 to virtually none by the end of 2024, reflecting a shift toward larger, longer‑dated facilities and lower‑cost financing terms.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains several significant factual inaccuracies that undermine its correctness despite addressing the general theme of Amazon's evolving credit facilities. (1) Quantitative inaccuracies: The original answer states Amazon had a $7.0 billion unsecured revolving credit facility in 2022 with no borrowings outstanding, but the LLM incorrectly claims a $1 billion secured revolving facility was terminated—this is not mentioned in the ground truth. The LLM also introduces a 'commercial-paper program' doubled to $20 billion and mentions 'about $800 million' in borrowings at end of 2021, which contradicts the ground truth stating $7.2 billion in unused letters of credit (not borrowings) as of December 31, 2021, and only $147 million in short-term borrowings under other facilities by end of 2023. The claim that short-term borrowings fell from $800 million in 2021 to virtually none by 2024 is false—the ground truth shows increasing borrowings under other short-term facilities ($147M in 2023, $151M in 2024). (2) The LLM fabricates details not present in the original: the secured revolving facility, commercial paper program expansion, and seller-receivable collateral usage are absent from the ground truth. (3) While the LLM correctly identifies the new $15 billion facility (benchmark + 0.45%, 0.03% fee) and the $5 billion 364-day facility (SOFR + 0.45%, 0.03% fee), it misrepresents their timing and context—e.g., claiming the old $7B facility was set to expire in 2023 when the original does not specify expiration. (4) The ground truth emphasizes no borrowings under the main Credit Agreement or Short-Term Credit Agreement, but borrowings exist under 'other' short-term facilities—this nuance is lost in the LLM’s broad statement of 'virtually none.' (5) The increase in letters of credit from $7.2B (2021) to $8.3B (2024) is omitted entirely. Overall, while the answer captures the direction of change (larger, cheaper facilities), it fails on key facts, calculations, and entity accuracy, resulting in a partially correct but misleading response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1535,
        "completion_tokens": 555,
        "total_tokens": 2090
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has Costco's use of variable-priced contracts for energy purchases evolved between 2022 and 2023, and what does this indicate about its commodity price risk management strategy?",
      "original_answer": "In 2022, Costco entered into variable-priced contracts for some purchases of electricity and natural gas, as well as fuel for its gas stations, on an index basis. These contracts met the definition of derivatives but generally qualified for the 'normal purchases and normal sales' exception, requiring no mark-to-market adjustment. By 2023, Costco continued this approach but specifically called out natural gas and fuel for gas stations as key components of its variable-priced contract usage. This indicates a continued reliance on variable-priced contracts as part of its commodity price risk management, with no significant shift away from index-based pricing mechanisms. The strategy remains consistent, showing stability in how Costco manages exposure to energy price fluctuations.",
      "llm_answer": "\nBetween 2022 and 2023 Costco’s disclosures show a modest shift toward greater reliance on variable‑priced, index‑linked contracts for electricity, natural‑gas and fuel.  The 2022 filing (pp. 29‑33) describes a mixed strategy—fixed‑price agreements for many warehouses complemented by variable‑price purchases for some energy uses—whereas the 2023 filing (pp. 45‑49) emphasizes that the company now “enters into variable‑priced contracts for some purchases of electricity and natural gas… and does not intend to engage in speculative transactions,” indicating that it is leaning more heavily on index‑based pricing to absorb commodity volatility rather than locking in fixed rates.  This evolution reflects a risk‑management approach that seeks to pass price fluctuations on to members while avoiding the need for mark‑to‑market adjustments on derivative instruments.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains no explicit numerical data (e.g., dollar amounts, percentages), so quantitative accuracy is not applicable in a traditional sense; however, since no numbers were misstated, it receives full credit. The contextual relevance is high because the response directly addresses the evolution of Costco's variable-priced contracts and its risk management strategy. However, the qualitative accuracy is lower due to a significant misrepresentation of the evolution between 2022 and 2023. The ground truth states that Costco's approach remained consistent—using variable-priced contracts with no significant shift. In contrast, the LLM claims a 'modest shift' and 'leaning more heavily' on variable pricing, which is not supported by the original answer. The 2023 filing does not indicate increased reliance but rather reaffirms the continuation of prior practices, specifically highlighting natural gas and fuel for gas stations—already covered in 2022. The LLM incorrectly infers strategic intensification where none was stated, introducing a false narrative of evolution. This mischaracterization undermines the multi-hop reasoning: while the model correctly identifies the use of index-based contracts and the normal purchases exception (implied via no mark-to-market), it fails to accurately synthesize the continuity between years. Thus, despite correct entity identification (Costco, energy types, years) and relevant context, the conclusion about strategic evolution is factually incorrect, warranting a partial correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1422,
        "completion_tokens": 424,
        "total_tokens": 1846
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has the strategic positioning and commercial role of NVIDIA AI Enterprise evolved within NVIDIA's data center offerings between 2022 and 2024?",
      "original_answer": "In 2022, NVIDIA AI Enterprise was introduced as part of the Compute & Networking segment, indicating its foundational role in NVIDIA's AI and accelerated computing strategy. By 2024, the product had evolved into a more prominent commercial offering, described as a 'comprehensive suite of enterprise-grade AI software' that is actively licensed and integrated into broader data center solutions. This shift reflects NVIDIA's move from positioning it as a strategic initiative to a key monetization vehicle within its full-stack data center platform, alongside offerings like NVIDIA DGX Cloud and the expansion into CPUs and DPUs.",
      "llm_answer": "\nBetween 2022 and 2024, NVIDIA AI Enterprise shifted from a supplemental, license‑based software add‑on for enterprise AI workloads to a core, subscription‑oriented platform that forms the backbone of the company’s data‑center stack.  It now integrates AI software, networking and services (e.g., NIM, NemO, AI Blueprints) and is bundled with offerings such as DGX Cloud, positioning AI Enterprise as the primary recurring‑revenue engine for enterprise AI adoption within NVIDIA’s data‑center portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly captures the evolution of NVIDIA AI Enterprise from a foundational or supplemental offering in 2022 to a core, monetized platform by 2024. The shift toward a subscription-based, recurring revenue model is consistent with the original answer's emphasis on commercialization and licensing. The mention of integration with DGX Cloud and the role as a backbone of the data center stack reflects the 'full-stack' positioning described in the ground truth. Specific components like NIM, NemO, and AI Blueprints, while not explicitly named in the original, are plausible extensions of the enterprise software suite and do not contradict the source. The only minor gap is the absence of explicit reference to the 'Compute & Networking segment' in 2022, which slightly weakens the multi-hop linkage to NVIDIA’s segment structure. However, the overall reasoning, entity identification (NVIDIA, DGX Cloud, data center offerings), and timeline (2022 to 2024) are correct. No numerical inaccuracies exist—dates are correct, no erroneous figures are introduced, and the qualitative transformation is logically and accurately portrayed. The answer is semantically equivalent and contextually fully relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 356,
        "total_tokens": 1639
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How did Pfizer's contractual obligations related to Paxlovid evolve between 2023 and 2024, and what does this indicate about the company's future revenue expectations for the product?",
      "original_answer": "In 2023, Pfizer had a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter related to the expected return of an estimated 6.5 million treatment courses of Paxlovid labeled under Emergency Use Authorization (EUA) from the U.S. government. This indicated uncertainty and potential decline in demand for Paxlovid. By 2024, however, remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, signaling a stabilization and expectation of future revenue from existing contracts. This shift from a large revenue reversal to a defined forward-looking contractual obligation suggests improved demand forecasting and a more stable outlook for Paxlovid in 2024 compared to the uncertainty in 2023.",
      "llm_answer": "\nBetween 2023 and 2024 Pfizer’s Paxlovid contracts shifted from U.S. government EUA supply—where large revenue reversals were recorded when the government reclaimed inventory—to commercial‑market agreements with negotiated pricing and copay‑assistance programs; in 2024 the company recorded a $771 million favorable adjustment to the prior reversal and recognized $442 million from a new U.S. SNS supply, while disclosing roughly $1 billion of remaining performance‑obligation revenue to be recognized from 2025 through 2028. This signals that Pfizer expects only modest, declining future revenue from Paxlovid as demand moves from government stockpiling to commercial sales and the bulk of the product’s sales horizon extends only to the latter half of the decade.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect quantitative details. The ground truth states that Pfizer recorded a $3.5 billion non-cash revenue reversal in Q4 2023 due to expected returns of 6.5 million treatment courses under EUA. The LLM answer does not mention this key $3.5 billion reversal, instead stating a $771 million favorable adjustment to a prior reversal and $442 million from a new U.S. SNS supply—figures not present in the original answer and potentially conflating different disclosures. The only correct quantitative point is the $1 billion in remaining performance obligations as of December 31, 2024, which matches the ground truth. (2) The LLM introduces specific figures ($771M, $442M) and a timeline (revenue to be recognized from 2025–2028) that are not in the original answer and may reflect overextrapolation or misattribution. These numbers, while plausible, are not supported by the provided ground truth, making them factually inaccurate in this context. (3) The qualitative reasoning is partially sound: the shift from government EUA-based supply to commercial agreements and the interpretation of $1 billion in remaining obligations as a sign of stabilization are consistent with the original answer’s conclusion. However, the LLM infers 'modest, declining future revenue' and 'sales horizon extends only to the latter half of the decade,' which goes beyond the original answer’s more neutral 'stabilization and expectation of future revenue' and 'improved demand forecasting.' This introduces a bearish interpretation not explicitly supported in the ground truth. (4) Contextual relevance is high—the answer addresses the evolution of contractual obligations and links it to revenue expectations. However, due to significant quantitative inaccuracies and unsupported inferences, the correctness score is limited to 6, reflecting partial accuracy with key factual gaps and distortions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 524,
        "total_tokens": 1912
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "Compare and contrast how Google's exposure to new regulatory costs in international markets evolved between 2022 and 2024, particularly in terms of the scope and nature of regulatory challenges described?",
      "original_answer": "In 2022, Google highlighted that an evolving foreign policy landscape could subject the company to 'new regulatory costs and challenges,' specifically mentioning data transfers between the EU and the UK, as well as new customer requirements. By 2024, the scope of regulatory challenges expanded significantly. The 2024 filing not only reiterated the exposure to 'new regulatory costs and challenges' but also introduced elements like 'uncertainty regarding regulatory outcomes' and the risk of 'other liabilities under local laws that may not offer due process or clear legal precedent.' This indicates a shift from primarily data-related regulatory concerns in 2022 to broader, more unpredictable regulatory risks in 2024, reflecting an increased complexity in Google's international regulatory environment.",
      "llm_answer": "\nBetween 2022 and 2024 the company’s description of regulatory risk moved from a vague reference to “new and evolving products… raise ethical, legal and regulatory challenges” and a general warning that “increasing regulations” could pressure margins, to a concrete focus on specific cross‑border obligations—e.g., EU‑UK data‑transfer rules, anti‑corruption statutes, sanctions‑related foreign‑policy changes and heightened privacy‑ and content‑moderation compliance. Thus, the scope of exposure shifted from an unspecified regulatory threat to a detailed set of jurisdiction‑specific costs that Google now expects to incur to meet new international regulatory requirements.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in direction and captures the evolution in Google's regulatory risk disclosures between 2022 and 2024, but diverges from the ground truth in key qualitative details. (1) Correct elements: the shift from general to more specific regulatory concerns is accurately portrayed, and the mention of EU-UK data transfers aligns with the original answer. The contextual relevance is high, as the response directly addresses the question’s focus on scope and nature of regulatory challenges. (2) Quantitative accuracy is perfect—no numerical data is misstated, and no incorrect dates or financial figures are introduced (the years 2022 and 2024 are correctly used). (3) However, the qualitative accuracy is partially compromised: the LLM incorrectly characterizes Google’s 2022 language as referring to 'new and evolving products… raise ethical, legal and regulatory challenges,' which is not the emphasis in the ground truth. The original answer specifies that in 2022, Google focused on 'new regulatory costs and challenges' related to data transfers and customer requirements—not product-related ethical issues. Additionally, the LLM introduces elements not present in the ground truth, such as 'anti-corruption statutes,' 'sanctions-related foreign-policy changes,' and 'content moderation,' which are not mentioned in the original answer. (4) The multi-hop reasoning is sound in structure—comparing the evolution of risk disclosures over time—but synthesizes slightly inaccurate source details. The core conclusion about increasing specificity and scope of regulatory exposure is consistent with the ground truth, warranting a correctness score of 7. Minor but notable deviations in entity focus and introduced noise reduce the score despite strong overall alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 485,
        "total_tokens": 1870
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has UPS's approach to funding postretirement medical benefits evolved between 2022 and 2023, particularly in terms of the sources used for expected benefit payments?",
      "original_answer": "In 2022, UPS indicated that expected benefit payments for postretirement medical benefits would be paid from both plan trusts and corporate assets. In 2023, the language remained unchanged, indicating continuity in the funding approach. Therefore, there was no change in the sources used for expected benefit payments for postretirement medical benefits between the two years.",
      "llm_answer": "\nBetween 2022 and 2023 UPS continued to fund its post‑retirement medical benefits from **both plan trusts and corporate assets**, but the cash‑flow schedule and the amount contributed to the trusts changed.  In the 2022 filing the company expected $229 million of benefit payments in 2022 (and $219 million in 2023) with an employer contribution of $177 million to the trusts.  The 2023 filing revises the outlook, showing payments of $216 million in 2024, $206 million in 2025, etc., and reduces the planned trust contribution to $74 million for 2024, indicating a modest shift toward relying more on corporate assets while still using the same two‑source funding approach.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in its core claim. The original answer (ground truth) states that UPS's funding approach for postretirement medical benefits did not change between 2022 and 2023—the sources (plan trusts and corporate assets) remained the same, and there was no shift in policy or approach. However, the LLM answer incorrectly asserts a 'modest shift toward relying more on corporate assets' based on changes in contribution amounts and payment schedules. This interpretation is not supported by the ground truth, which emphasizes continuity in language and approach. While the LLM provides specific numbers (e.g., $229M payments in 2022, $177M contribution, $74M for 2024), these figures are not present in the original answer and cannot be verified against the ground truth; thus, their accuracy is questionable. More critically, the reasoning misinterprets numerical changes in projected payments and contributions as evidence of a strategic shift in funding sources, which contradicts the explicit statement that the language and approach remained unchanged. The model fails the multi-hop reasoning test by drawing an unsupported conclusion from isolated data points without confirming consistency in disclosure language. Although the answer is contextually relevant and addresses the right topic and entities (UPS, postretirement medical benefits, plan trusts, corporate assets), the factual and logical errors severely undermine correctness. Minor formatting variations in numbers would be acceptable, but here the numbers themselves appear fabricated or misattributed, and the central conclusion is false.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1268,
        "completion_tokens": 443,
        "total_tokens": 1712
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has the role and scope of NVIDIA AI Enterprise evolved from its introduction in 2022 to its broader supply and integration in 2024?",
      "original_answer": "In 2022, NVIDIA AI Enterprise was introduced as part of the Compute & Networking segment, described as a software suite aimed at simplifying the deployment of AI applications across data centers and enterprise environments. By 2024, the platform had evolved into a more comprehensive and integrated solution, including components such as NVIDIA NIM, NVIDIA NeMo, and AI Blueprints, with specific performance improvements like a 2.5x increase in token throughput. This reflects a shift from a foundational offering to a full-stack, production-grade generative AI platform with enhanced capabilities and broader deployment options.",
      "llm_answer": "\nFrom its launch in 2022, NVIDIA AI Enterprise was positioned as a software‑only suite that extended the company’s GPU‑accelerated AI stack to enterprise customers, offering tools such as AI Enterprise, vGPU licensing and DGX Cloud. By 2024 the offering had broadened into a full‑stack platform that now spans GPU, DPU and CPU hardware, integrates the Blackwell architecture, and is delivered through services like NIM, NeMo and AI Blueprints, reflecting a wider supply base and deeper integration across NVIDIA’s hardware, networking and software ecosystem.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the evolution of NVIDIA AI Enterprise from a software suite in 2022 to a full-stack, integrated platform by 2024. It correctly identifies the initial positioning as a software offering for enterprise AI deployment and notes the expansion into broader integration across hardware (GPU, DPU, CPU) and services like NIM, NeMo, and AI Blueprints—aligning with the ground truth. The mention of Blackwell architecture and vGPU licensing adds contextual detail not in the original answer but is plausible and does not contradict known facts. However, the original answer specifies a key quantitative improvement—'2.5x increase in token throughput'—which is missing in the LLM response, representing a minor omission in completeness. Additionally, the LLM groups 'AI Enterprise' as a tool within itself, which is slightly inaccurate (likely a wording error). There are no incorrect numbers or dates; all years and product names (NIM, NeMo, AI Blueprints) are accurate. The reasoning is sound, showing multi-hop synthesis across time and product evolution. The answer is highly relevant and conveys the core transformation accurately, warranting a high correctness score despite missing one specific performance metric.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 350,
        "total_tokens": 1644
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has ExxonMobil's proved reserves through equity companies evolved from 2022 to 2024, and what does this indicate about its strategic positioning in different regions?",
      "original_answer": "In 2022, ExxonMobil's total proved reserves from equity companies amounted to 14 million barrels gross (1 million net) across the United States, Europe, Africa, and Asia. By 2024, these reserves had significantly increased to 467 million barrels of crude oil, 120 million barrels of natural gas liquids, and 5,367 billion cubic feet of natural gas, with the majority of this growth concentrated in Asia. This indicates a major strategic shift toward strengthening its upstream presence in the Asia region through equity companies.",
      "llm_answer": "\nFrom 2022 to 2024 the proved reserves that ExxonMobil holds through equity‑company joint ventures rose from roughly **1.3 billion oil‑equivalent barrels to 1.48 billion barrels** (an increase of about 150 million boe).  The bulk of this growth occurred in **Asia** (e.g., added reserves in Iraq, Kazakhstan and other Asian PJVs) and, to a smaller extent, in **Africa**, while the share of equity reserves in the Americas remained essentially flat.  \n\nThis pattern shows that ExxonMobil is deliberately concentrating its partnership‑based resource base in high‑potential, growth‑oriented regions—particularly Asia and Africa—while maintaining a stable footprint in the mature Americas, underscoring a strategic shift toward leveraging equity ventures to secure future production growth in those emerging areas.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies. According to the ground truth, in 2022, ExxonMobil's total proved reserves from equity companies were 14 million barrels gross (1 million net), not 1.3 billion boe as claimed. By 2024, the reserves increased to 467 million barrels of crude oil, 120 million barrels of natural gas liquids, and 5,367 billion cubic feet of natural gas—none of which are accurately reflected in the LLM answer. The LLM incorrectly reports a rise to 1.48 billion boe, which is over 10 times higher than the actual crude oil equivalent implied by the ground truth (even when converting gas to boe). (2) The quantitative inaccuracies are severe: the 2022 baseline is off by two orders of magnitude (1.3 billion vs 14 million), and the 2024 figures are entirely fabricated. The LLM invents a 150 million boe increase without basis. Additionally, the ground truth specifies that the 2022 reserves were across multiple regions but does not support the LLM's claim of growth in Africa or specific countries like Iraq and Kazakhstan. (3) The multi-hop reasoning is flawed. While the LLM correctly infers a strategic shift toward Asia based on growth there, this conclusion is drawn from incorrect data. The ground truth does confirm a major strategic shift toward Asia, so the qualitative direction is partially aligned, but the reasoning is unsound due to fabricated inputs. (4) The contextual relevance is moderate because the answer addresses the question's structure—discussing evolution and strategic implications—and correctly identifies Asia as a focus area. However, due to gross numerical errors and invented data, the correctness and quantitative accuracy scores are very low. The qualitative accuracy is slightly higher because the general strategic interpretation aligns with the ground truth, albeit for wrong reasons.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 506,
        "total_tokens": 1847
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has the financial relationship with Google Network Partners evolved between 2022 and 2024, particularly in terms of their role in revenue generation and cost structure?",
      "original_answer": "In 2022, Google Network Partners played a central role in the revenue generation process as Google acted as the principal for ads placed on Google Network properties, reporting advertising revenues on a gross basis, with payments to partners recorded as cost of revenues. By 2024, Google continued to pay Google Network partners, but the focus of the financial reporting shifted to emphasize the net cash flow impact, noting that payments to these partners were a primary use of cash from operating activities. This reflects a more cost-centric framing of the relationship in the later year.",
      "llm_answer": "\nBetween 2022 and 2024 the amount Google pays to its Network Partners (recorded as traffic‑acquisition costs, or TAC) rose in absolute dollars—reflecting higher ad volume and expanded inventory on partner sites—but this cost grew more slowly than total advertising revenue, keeping the TAC‑to‑revenue ratio roughly stable (around 23‑24 % of revenue). As a result, while Google continues to report the full gross amount billed to advertisers as revenue, the expense paid to Network Partners has increased, pressuring the margin on that segment; however, the higher revenue base has still driven a net rise in Google Services operating income, showing that Network Partners remain a significant but increasingly efficient component of the cost structure.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces specific quantitative claims—such as the TAC-to-revenue ratio being 'around 23-24%' and that TAC grew more slowly than advertising revenue—that are not present in the original answer and cannot be verified from the provided ground truth. The original answer does not include any numerical data, percentages, or trends about cost growth or ratios, so these additions are unsupported. (2) There are no verifiable calculations in the original answer to assess against, but the LLM fabricates a level of quantitative precision (e.g., exact TAC percentage) that is absent from the source, making the quantitative accuracy low. (3) The multi-hop reasoning is partially sound in that it attempts to connect Google Network Partners to revenue and cost dynamics across years, but it misrepresents the evolution described in the ground truth. The original answer emphasizes a shift in financial reporting perspective—from gross revenue recognition with partners as a cost of revenue in 2022 to a focus on cash flow impact in 2024—whereas the LLM focuses on margin pressure and efficiency gains not mentioned in the truth. The core evolution (a change in financial framing and reporting emphasis) is missed. (4) While the LLM stays contextually relevant by discussing the role of Network Partners in revenue and cost structure over time, it substitutes the actual qualitative shift in reporting with a fabricated narrative about cost efficiency and margin trends. Thus, despite relevant framing, the factual core is incorrect, warranting a moderate score for contextual relevance but low for correctness and quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 453,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has UPS's foreign currency exchange risk management strategy evolved between 2022 and 2023, particularly in terms of the financial impact of undesignated foreign currency forward contracts on earnings volatility?",
      "original_answer": "In 2022, UPS disclosed that foreign currency exchange forward contracts were used to economically offset foreign currency remeasurement and settlement risk for certain balance sheet assets and liabilities, and that changes in their fair value affected earnings directly. For 2023, UPS expanded the disclosure to emphasize that undesignated derivative settlements are now explicitly linked to earnings volatility, with a specific focus on how these contracts impact income statement recognition. The 2023 filing also introduced a more structured presentation of fair value changes and settlements for these contracts, with amounts for both 2023 and 2022 now reported side-by-side in millions, indicating a more transparent and systematic approach to disclosing the financial effects of these instruments.",
      "llm_answer": "\nUPS moved away from using non‑designated foreign‑currency forward contracts as a primary hedge, cutting the notional amount of those contracts from roughly $1 million (shown in other current assets in 2022) to essentially zero by the end of 2023.  Consequently, the earnings impact of the resulting fair‑value adjustments fell dramatically—recording only a $7 million loss in 2023 versus a $69 million loss in 2022—showing that the company’s foreign‑exchange risk‑management strategy reduced earnings volatility in 2023.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect and misrepresents the evolution of UPS's foreign currency exchange risk management strategy between 2022 and 2023. (1) The ground truth states that UPS continued using undesignated foreign currency forward contracts and enhanced its disclosure transparency in 2023, with a more structured presentation of fair value changes and settlements for both years. There is no indication in the original answer that UPS reduced or eliminated these contracts. (2) The LLM introduces specific numerical claims—$1 million notional amount in 2022, reduced to zero in 2023, and $69M loss in 2022 vs $7M loss in 2023—that are not present in the ground truth and cannot be verified from the provided information. These figures are factually unsupported and contradict the original answer, which does not mention notional amounts or specific losses. (3) The reasoning is flawed: the LLM concludes that UPS reduced earnings volatility by cutting undesignated contracts, but the original answer emphasizes that UPS improved disclosure practices and explicitly linked undesignated derivative settlements to earnings volatility in 2023, not that it reduced their use. (4) While the LLM addresses the topic of earnings volatility and foreign exchange risk, it fabricates quantitative details and mischaracterizes the strategic evolution. The contextual relevance is moderate because it discusses the right topic (foreign currency forwards and earnings impact), but the factual inaccuracies severely undermine correctness. Semantic equivalence is not achieved due to invented data and incorrect causal claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 441,
        "total_tokens": 1790
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has the role of the membership format in Costco's profitability strategy evolved between 2022 and 2023, particularly in terms of its impact on member loyalty and fee revenue?",
      "original_answer": "In 2022, the membership format was described as 'an integral part of our business and has a significant effect on our profitability,' with an emphasis on growth in the membership base, increasing Executive member penetration, and sustaining high renewal rates as key drivers of profitability. By 2023, the language evolved to underscore that the membership format 'is an integral part of our business and profitability,' indicating a more consolidated role in the company's financial model. Additionally, in 2023, Costco introduced a new concern about the potential adverse impact of lower renewal rates in newer markets on the worldwide renewal rate, which was not explicitly mentioned in 2022. This suggests that while the membership model remained central to profitability, the company faced emerging challenges in sustaining renewal rates as it expanded into newer markets.",
      "llm_answer": "\nIn 2022 the membership model was presented as a core profitability engine, with fee revenue climbing 9 % to $4.2 bn as new sign‑ups, Executive‑membership upgrades and strong renewal rates reinforced member loyalty. By 2023 the company still regarded the format as integral, but it warned that paid‑membership growth and renewal rates could be constrained by openings in existing markets and lower renewal rates in newer markets, indicating a more nuanced evolution of its role.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the core evolution of Costco's membership format in its profitability strategy between 2022 and 2023, correctly identifying the continued centrality of the model and the emerging concern in 2023 about renewal rates in newer markets. However, it introduces a specific figure—'fee revenue climbing 9% to $4.2 bn'—that is not present in the original ground truth answer and cannot be verified from the provided context. This undermines quantitative accuracy. (2) The original answer does not include any numerical data on fee revenue growth or dollar amounts, so the inclusion of '$4.2 bn' and '9%' is an unsupported addition, likely hallucinated or inferred beyond the source material. These figures may be factually correct in reality, but since they are absent from the ground truth derived from the knowledge graph, they count as inaccuracies in this evaluation context. (3) The qualitative reasoning is strong: the LLM correctly synthesizes the shift in tone from 2022 to 2023, noting the continued importance of the membership model and the new caution about renewal rates in newer markets. It also correctly identifies the strategic concerns around market expansion affecting membership metrics. This shows sound multi-hop reasoning across years and strategic dimensions. (4) Contextual relevance is high, as the answer directly addresses the evolution of the membership model’s role in profitability, member loyalty, and fee revenue. Despite the unsupported numbers, the overall narrative aligns well with the ground truth. The correctness score is 7 due to accurate conceptual and strategic synthesis but docked for introducing unverified quantitative claims not present in the source.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 471,
        "total_tokens": 1818
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has NVIDIA's approach to CUDA evolved between 2022 and 2024, particularly in terms of its integration within the broader data center platform and software ecosystem?",
      "original_answer": "In 2022, CUDA was primarily positioned as a key component of NVIDIA's AI ecosystem, with nearly 3 million developers using CUDA and other software tools to deploy AI and accelerated computing technologies. It was described as central to NVIDIA's partnerships and developer programs, including the Deep Learning Institute and Inception program. By 2024, CUDA had evolved into a more deeply integrated part of a full-stack computing platform, specifically within the data center. It was described as the foundation of the CUDA-X collection of acceleration libraries, APIs, SDKs, and domain-specific frameworks, emphasizing its role in enabling end-to-end optimized computing across GPUs, CPUs, and DPUs. This reflects a strategic shift from promoting CUDA as a developer-focused tool to positioning it as a core infrastructure layer for enterprise-scale computing solutions.",
      "llm_answer": "\nBetween 2022 and 2024 NVIDIA moved CUDA from a stand‑alone parallel‑programming layer for GPUs into the core of an end‑to‑end data‑center stack, tightly coupling it with new hardware blocks (DPUs introduced in 2022 and the Grace CPU launched in 2024) and with a unified software ecosystem that now includes AI Enterprise, NIM, NeMo, AI Blueprints and DGX Cloud services.  This full‑stack approach lets CUDA‑based AI workloads span training, inference, simulation and over‑the‑air updates across GPUs, CPUs, networking and DPUs, delivering a seamless, scalable platform for generative‑AI and other data‑intensive applications.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly captures the evolution of CUDA from a GPU programming framework to a core component of a full-stack data center platform between 2022 and 2024. The mention of DPUs (introduced in 2022) and the Grace CPU (launched in 2024) is factually correct and supports the narrative of deeper hardware integration. The integration with software offerings like AI Enterprise, NIM, NeMo, AI Blueprints, and DGX Cloud is consistent with NVIDIA's 2024 ecosystem expansion. While the original answer emphasizes CUDA-X libraries and developer programs (Deep Learning Institute, Inception), the LLM answer focuses more on enterprise and cloud services, which is a valid interpretation but omits explicit mention of CUDA-X and the 3 million developer milestone. However, this omission does not undermine the core factual accuracy of the transformation. All dates and technological developments are correctly contextualized. The reasoning is sound, demonstrating multi-hop synthesis across hardware, software, and strategic positioning. The answer is semantically equivalent in conveying the strategic shift, even if the emphasis differs slightly. No numerical inaccuracies are present, and all entities are correctly identified.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 359,
        "total_tokens": 1740
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has Pfizer's financial commitment and contractual obligations related to Paxlovid evolved from 2023 to 2024, particularly in terms of expected future revenue and product delivery timelines?",
      "original_answer": "In 2023, Pfizer had a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter related to the expected return of an estimated 6.5 million treatment courses of EUA-labeled Paxlovid from U.S. government inventory. By the end of 2024, Pfizer reported remaining performance obligations for Paxlovid at approximately $1 billion, with expected product delivery and revenue realization scheduled from 2025 through 2028, indicating a shift from uncertain returns and revenue reversals to a more defined forward-looking revenue outlook based on firm contracts.",
      "llm_answer": "\nFrom 2023 to 2024 Pfizer’s Paxlovid revenue collapsed as the U.S. government wound down its EUA‑labeled supply, prompting a $3.5 bn non‑cash revenue reversal in Q4 2023 that was later softened by a $771 m favorable adjustment in Q1 2024 after 5.1 million treatment courses were returned.  The company now reports only about $1 bn of remaining contracted revenue for Paxlovid, to be recognized on deliveries scheduled from 2025 through 2028 under long‑term agreements (including a U.S. Strategic National Stockpile commitment that extends through 2028), with future volumes subject to renegotiation as the product transitions to commercial‑market sales.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in Pfizer's financial commitment and contractual obligations for Paxlovid from 2023 to 2024. (1) Quantitatively, it correctly states the $3.5 billion non-cash revenue reversal in Q4 2023, which aligns with the ground truth. It adds a specific detail not in the original answer — a $771 million favorable adjustment in Q1 2024 after 5.1 million treatment courses were returned — which is factually consistent with Pfizer’s public disclosures and provides additional context without contradicting the ground truth. The remaining contracted revenue of $1 billion is accurately reported, as are the delivery timelines from 2025 through 2028. (2) The mention of the U.S. Strategic National Stockpile commitment extending through 2028 adds contextual precision and supports the forward-looking contractual nature of the obligations. (3) The qualitative reasoning is sound: the answer correctly frames the shift from uncertain government returns and revenue reversals in 2023 to a more stable, contract-based revenue outlook in 2024, reflecting multi-hop synthesis across time periods and contractual developments. (4) The only minor deviation from the original answer is the use of the phrase 'revenue collapsed,' which is somewhat hyperbolic but contextually defensible given the magnitude of the reversal. However, this does not undermine factual accuracy. All key entities (Pfizer, Paxlovid, EUA-labeled supply, U.S. government) and timeframes (2023–2028) are correct. The answer fully addresses the question’s focus on financial commitments, contractual obligations, revenue expectations, and delivery timelines. Thus, the answer is semantically equivalent and highly accurate, warranting a 9/10 due to the slight editorialization but no material factual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 492,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has ExxonMobil's strategic emphasis on Guyana evolved between 2022 and 2024, based on its disclosures around reserves development and advantaged asset reporting?",
      "original_answer": "In 2022, ExxonMobil reported that Guyana was a key contributor to extensions and discoveries, adding approximately 1.3 billion oil-equivalent barrels (GOEB) of proved undeveloped reserves. By 2024, Guyana was explicitly listed as one of the core 'Advantaged Assets' in the company's updated earnings drivers, signaling a strategic shift to highlight Guyana's role in driving earnings through volume growth. This evolution reflects a transition from Guyana being primarily a reserves growth region to being a recognized source of advantaged production and earnings visibility.",
      "llm_answer": "\nExxonMobil’s view of Guyana shifted from a frontier, undeveloped reserve base — the 2022 filing listed roughly 1.3 billion oil‑equivalent barrels of proved undeveloped reserves in “Other Americas” and noted $8 billion of investment to move those reserves toward development — to a core “advantaged asset” that is now explicitly counted in the company’s earnings‑driver framework.  By 2024 the 10‑K’s “Advantaged Volume Growth” definition cites Guyana (alongside the Permian and LNG) as a key source of future production, signalling that the company has moved from planning to active development and expects Guyana to deliver significant volume‑mix earnings growth.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, the 1.3 billion oil-equivalent barrels of proved undeveloped reserves in Guyana from 2022 is correctly reported. While the $8 billion investment figure is not present in the original answer, it does not contradict the ground truth and may reflect additional context from the 10-K; its inclusion is plausible and does not degrade accuracy. (2) The evolution in strategic emphasis is correctly captured: Guyana transitions from a reserves growth story in 2022 to being named a core 'advantaged asset' in 2024, explicitly tied to earnings and volume growth. (3) The multi-hop reasoning is sound—linking 2022 reserve disclosures to 2024 advantaged asset reporting demonstrates synthesis across years and reporting frameworks. (4) The LLM uses slightly different phrasing (e.g., 'Other Americas' to refer to Guyana’s regional classification, 'volume-mix earnings growth') but maintains semantic equivalence. The only minor gap is that the original emphasizes 'earnings visibility' and 'strategic shift' more explicitly, which the LLM implies but doesn’t fully mirror. No factual errors; minor point deduction for potential overreach on $8B investment detail not in ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 353,
        "total_tokens": 1668
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How did the planned utilization of the ATR 72-600F aircraft evolve from 2022 to 2024, and what does this indicate about its role in the company's fleet strategy?",
      "original_answer": "In 2022, the ATR 72-600F was projected to have a decreasing role in the company's fleet, with planned units dropping from 11 in 2023 to just 1 by 2026. By 2024, however, the company's projections showed a shift, with ATR 72-600F units remaining steady at 7 for 2025 and declining only slightly to 3 by 2026. This indicates that while the aircraft was initially expected to phase out more rapidly, it continued to play a more sustained, albeit reduced, role in the fleet strategy.",
      "llm_answer": "\nFrom the 2022 note on purchase commitments the company had scheduled 24 ATR 72‑600F aircraft (11 in 2023, 6 in 2024, 6 in 2025 and 1 in 2026). By the 2024 update the commitment had fallen to only 10 aircraft (7 slated for delivery in 2025 and 3 in 2026), a reduction of more than half. This pull‑back signals that FedEx is de‑emphasizing the ATR 72‑600F in its fleet strategy, shifting instead toward larger, more fuel‑efficient jet freighters (B777F/B767F) and newer turboprops such as the Cessna SkyCourier for regional service.",
      "correctness_score": 4,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in numbers and timeline. According to the ground truth, in 2022 the plan was for ATR 72-600F units to drop from 11 in 2023 to 1 by 2026, but the LLM incorrectly states there were 24 total planned deliveries (11 in 2023, 6 in 2024, 6 in 2025, 1 in 2026), which misrepresents both the total and the annual breakdown. The 2024 update in the ground truth shows 7 units in 2025 and 3 in 2026, which the LLM correctly reports as 7 in 2025 and 3 in 2026, but incorrectly frames this as a reduction from 24 to 10, when the original plan was not 24 units. (2) Calculations are flawed: the LLM claims a reduction of 'more than half' from 24 to 10, but the actual shift in projections (from 11 in 2023 declining to 1 by 2026, to a flatter 7 in 2025 and 3 in 2026) reflects a strategic stabilization, not a simple reduction. The LLM mischaracterizes the trend by inflating initial numbers. (3) Multi-hop reasoning is partially sound—the model identifies a shift in fleet strategy and infers a move toward larger jets and other turboprops—but this conclusion contradicts the ground truth, which indicates a *less rapid phaseout*, not a de-emphasis. The ground truth shows the ATR 72-600F's role became more sustained than initially planned, whereas the LLM claims it is being de-emphasized. (4) Contextual relevance is high—the answer addresses fleet strategy evolution and draws inferences—but due to incorrect quantitative foundations and reversed interpretation of the trend, the overall correctness is low. The qualitative reasoning is logical but based on false premises. Scores reflect major quantitative errors and incorrect synthesis despite relevant framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1256,
        "completion_tokens": 470,
        "total_tokens": 1726
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has NVIDIA's approach to offering Omniverse evolved between 2022 and 2024, particularly in terms of its integration with other AI and simulation platforms?",
      "original_answer": "In 2022, NVIDIA Omniverse was primarily described as a virtual world simulation and collaboration platform for 3D workflows, available as a software subscription for enterprise use and free for individual use. It was highlighted as being integrated with VR and AR in enterprise applications such as virtual car showrooms and surgical training. By 2024, NVIDIA's offering of Omniverse had evolved into a more comprehensive development platform and operating system for building and running virtual world simulation applications. It was now emphasized as being used by industrial enterprises to digitalize complex physical assets and processes—such as building digital twins of factories and testing autonomous robots and vehicles—powered by NVIDIA's accelerated computing infrastructure both on-premises and in the cloud. This represents a shift from general 3D collaboration to a more specialized, enterprise-focused simulation and digital twin platform.",
      "llm_answer": "\nBetween 2022 and 2024 NVIDIA transformed Omniverse from a stand‑alone 3‑D collaboration and simulation tool into the backbone of its AI‑driven simulation ecosystem.  In 2022 it was offered as a subscription‑based enterprise platform (with a free individual tier) for digital‑twin and industrial‑design workflows, and it began powering automotive validation via the DRIVE Constellation simulation suite.  By 2024 the company had deepened integration, using Omniverse to generate synthetic data and run AI‑powered testing pipelines (e.g., DRIVE Sim), embedding it in AI services such as NIM, NeMo, AI Blueprints and the ACE avatar engine, and exposing it through cloud‑based enterprise subscriptions that tie directly to NVIDIA’s broader AI and accelerated‑computing stack.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution of NVIDIA's Omniverse from a 3D collaboration tool in 2022 to a core component of an AI-driven simulation ecosystem by 2024. Key points such as the subscription model (enterprise with free tier for individuals) and use in automotive simulation (DRIVE Constellation/DRIVE Sim) are factually consistent. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—dates (2022, 2024) are correct. (3) The multi-hop reasoning is sound: the LLM synthesizes information about platform evolution, integration with AI tools (NeMo, NIM, AI Blueprints, ACE), and cloud-based enterprise offerings, reflecting a deeper integration with NVIDIA’s broader AI and accelerated computing stack. This matches the ground truth’s emphasis on a shift toward digital twins, industrial simulation, and cloud/on-prem infrastructure. (4) Minor deduction in qualitative accuracy due to slightly more technical emphasis (e.g., naming specific AI services like ACE and NIM) that, while plausible and consistent with NVIDIA's direction, are not explicitly confirmed in the ground truth. However, these details do not contradict it and fall within reasonable inference. The answer is semantically equivalent and contextually fully relevant, capturing the strategic shift accurately.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1434,
        "completion_tokens": 397,
        "total_tokens": 1831
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has the role of Google Play in generating non-advertising revenue evolved between 2022 and 2023?",
      "original_answer": "In 2022, Google Play was introduced as part of the company's broader strategy to expand non-advertising revenues, specifically through the sales of apps, in-app purchases, and digital content. By 2023, Google Play had transitioned into a more defined revenue stream under 'platforms,' where it was explicitly tied to revenues from app sales and in-app purchases. This evolution indicates a strategic shift toward solidifying Google Play’s role as a key monetization platform rather than just a component of diversification. The change reflects a more structured categorization and likely a stronger contribution to revenue stability within the ecosystem.",
      "llm_answer": "\nBetween 2022 and 2023 the share of Google Play in Alphabet’s non‑advertising revenue grew noticeably.  The “Google Subscriptions, Platforms, and Devices” line—of which Google Play’s app‑sale and in‑app‑purchase proceeds are a key component—helped drive the $19 billion (8 %) rise in Google Services revenue and contributed to the overall increase in non‑advertising revenues, which expanded faster than advertising and now carries a larger weight in the company’s revenue mix, albeit at lower margins.",
      "correctness_score": 5,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces specific quantitative claims—such as an $19 billion (8%) rise in Google Services revenue—that are not present in the original answer and cannot be verified from the provided ground truth. These figures may be factually accurate in context but are not supported by the knowledge graph excerpt, making them potentially misleading or hallucinated. The original answer does not include any numerical data, so the LLM's inclusion of precise dollar amounts and percentages undermines quantitative accuracy. (2) There is no verification possible for the $19B increase or 8% growth since the ground truth contains no numbers. Thus, these specifics fail the quantitative accuracy test, even if they reflect real-world data, because the evaluation is based solely on alignment with the provided ground truth. (3) Qualitatively, the LLM captures the general direction of evolution—Google Play’s growing role in non-advertising revenue and its inclusion in a broader segment (Subscriptions, Platforms, and Devices)—which aligns with the original answer’s mention of Google Play transitioning into a more defined revenue stream under 'platforms.' This shows partial multi-hop reasoning, recognizing Google Play’s integration into a monetization strategy. However, it misses the strategic nuance emphasized in the original answer: the shift from diversification component to a structured, stabilizing monetization platform. (4) Contextually, the answer is relevant and addresses the evolution of Google Play’s role in non-advertising revenue. While it adds unverified numbers, the overall thrust about increased importance and categorization within platforms is consistent. The score is limited by unsupported quantification and incomplete capture of the strategic repositioning described in the original.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1277,
        "completion_tokens": 496,
        "total_tokens": 1774
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has AIG's use of expected loss ratio methods in workers' compensation reserving evolved between 2022 and 2023, particularly in relation to guaranteed cost and excess of deductible business?",
      "original_answer": "In 2022, AIG generally gave significant weight to expected loss ratio methods for guaranteed cost business only in the most recent accident year, while for excess of deductible business, these methods were given significant weight in the most recent five accident years. The company also noted that changes in claims strategy and loss mitigation efforts were accelerating settlements, increasing paid losses along the latest diagonals. In 2023, the reserving methodology remained broadly consistent, with AIG continuing to use a combination of loss development, frequency/severity, and expected loss ratio methods. However, the 2023 filing emphasized that incurred and paid losses were now presented net of reinsurance and undiscounted, which may reflect a refinement in reporting transparency rather than a change in reserving philosophy. Additionally, the increased proportion of large deductible business continued to slow the reporting pattern of claims in 2023, consistent with the trend noted in 2022.",
      "llm_answer": "\nBetween 2022 and 2023 AIG kept the expected‑loss‑ratio approach as the primary tool for its **guaranteed‑cost** workers‑compensation business, but it continued to apply it **only to the most recent accident year**—i.e., it did not broaden the weighting of the method beyond the latest year.  For **excess‑of‑deductible** (and the growing share of large‑deductible) business, the company **expanded the use of expected‑loss‑ratio estimates to the most recent five accident years** and incorporated higher tail‑factor assumptions to reflect the slower emergence of claims and longer medical‑development patterns.  This shift was driven by the increasing proportion of high‑deductible and excess‑of‑deductible policies, which lengthened reporting cycles and required more frequent updates to loss‑trend and inflation assumptions in the 2023 reserving process.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains a significant factual inaccuracy regarding the evolution of AIG's use of expected loss ratio methods between 2022 and 2023. According to the ground truth, the use of expected loss ratio methods for excess of deductible business already included the most recent five accident years in 2022 — not a change introduced in 2023. The LLM incorrectly states that AIG 'expanded' the use of these methods in 2023 to five years, implying a methodological change, which contradicts the original answer stating that the methodology 'remained broadly consistent' between years. This is a critical error in reasoning and timeline accuracy. Additionally, the ground truth does not mention 'higher tail-factor assumptions' or 'more frequent updates to loss-trend and inflation assumptions' in 2023, which are unsupported additions by the model. On the positive side, the LLM correctly notes that expected loss ratio methods were applied only to the most recent accident year for guaranteed cost business in both years, and it accurately reflects the impact of large deductible business on claims reporting patterns. The answer is contextually relevant and addresses the core aspects of the question (guaranteed cost vs. excess of deductible), but the incorrect portrayal of a methodological expansion in 2023 undermines the correctness. Quantitative accuracy is moderate — while no explicit numbers are wrong (no figures are cited), the temporal and methodological claims are misaligned with the source. Qualitative accuracy suffers due to flawed multi-hop reasoning: the model fails to recognize that the 2023 approach was a continuation, not an evolution, of prior practice. Contextual relevance is high as the structure and focus align well with the question's intent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1477,
        "completion_tokens": 480,
        "total_tokens": 1958
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has Cisco's product category segmentation evolved between fiscal 2022 and fiscal 2024, particularly in relation to the Collaboration category?",
      "original_answer": "In fiscal 2022, Cisco introduced a product revenue segmentation that included 'Collaboration' as one of six distinct categories, which also included Secure, Agile Networks; Internet for the Future; End-to-End Security; Optimized Application Experiences; and Other Products. By fiscal 2024, Cisco restructured its product categories into four main areas, retaining 'Collaboration' but now grouping it alongside Networking, Security, and a new category called Observability. This indicates a consolidation and realignment of product offerings, with the introduction of Observability as a distinct area and the removal or reclassification of Optimized Application Experiences and Internet for the Future.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2024 Cisco reshaped how it reports product revenue. In 2022 the company introduced a six‑category taxonomy that placed **Collaboration** as a distinct segment (alongside Secure Agile Networks, Internet for the Future, End‑to‑End Security, Optimized Application Experiences and Other Products). By fiscal 2024 the taxonomy was streamlined to four broader groups—**Networking, Security, Collaboration, and Observability**—and historical revenue was restated to fit this new structure. Consequently, the Collaboration category remained a separate line item, but its surrounding classification shifted: earlier it was one of several niche buckets, while in 2024 it sits alongside a “Networking” bucket that consolidates switching, routing, wireless and servers, and an “Observability” bucket that includes ThousandEyes/Splunk‑related offerings. Revenue trends show a 5 % decline in Collaboration in 2022, a 9 % drop in 2023, and a modest 2 % rebound in 2024.",
      "correctness_score": 7,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the evolution of Cisco's product segmentation from six categories in fiscal 2022 to four in fiscal 2024, accurately noting that Collaboration was retained as a distinct category and that Observability was newly introduced. It also correctly names the new groupings (Networking, Security, Collaboration, Observability) and references the consolidation of earlier categories like Secure Agile Networks into Networking. However, the LLM introduces revenue trend data—5% decline in 2022, 9% drop in 2023, 2% rebound in 2024—that is not present in the original answer and cannot be verified from the provided ground truth. This constitutes a significant quantitative inaccuracy. (2) The original answer contains no financial figures or performance metrics, so the inclusion of percentage changes in Collaboration revenue is an unsupported addition. These numbers may be factually incorrect or taken from external knowledge not in the knowledge graph. (3) The multi-hop reasoning is otherwise sound: the model correctly synthesizes the structural changes across fiscal years, understands the reclassification and consolidation of product lines, and correctly identifies the continuity of Collaboration as a standalone category. The explanation of Observability incorporating ThousandEyes/Splunk is plausible context but not in the original answer; while reasonable, it slightly extends beyond the ground truth. (4) The correctness score is 7 because the core structural evolution is accurately described, but the addition of unverified quantitative data reduces factual accuracy. Quantitative accuracy is low (4) due to the unsupported percentages. Qualitative accuracy is high (8) as the reasoning and entity identification are strong. Contextual relevance is excellent (9) as the response directly addresses the question’s focus on category evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1421,
        "completion_tokens": 511,
        "total_tokens": 1933
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has Amgen's disclosure regarding the 3.125% 2025 Notes evolved from 2022 to 2023 in terms of financial presentation and associated interest rate framework?",
      "original_answer": "In 2022, Amgen reported a carrying value of $1,000 million for the 3.125% 2025 Notes within its debt table, but no specific interest rate framework was disclosed. By 2023, Amgen included the 3.125% 2025 Notes in a new table that explicitly outlined the interest rate mechanism, identifying it as SOFR + 2.1%. This evolution reflects a shift from a purely quantitative disclosure in 2022 to a more detailed qualitative and quantitative presentation in 2023, including the interest rate benchmark and spread.",
      "llm_answer": "\nIn the 2022 filing the 3.125 % 2025 Notes were presented with a $1 billion carrying amount and disclosed that a related interest‑rate swap had converted the fixed coupon to a floating rate of **LIBOR + 1.8 %**, noting that the effective rate was essentially the same as the coupon. By the 2023 filing the note still carries a $1 billion balance, but the swap framework has been updated to reference **SOFR**, giving an effective rate of **SOFR + 2.1 %**, and the disclosure now provides detailed information on the SOFR‑based swap, its notional amount, and the associated hedge accounting, while still indicating that the coupon and effective rates remain closely aligned.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, Amgen did not disclose any specific interest rate framework for the 3.125% 2025 Notes. However, the LLM incorrectly claims that in 2022, an interest-rate swap converted the fixed coupon to LIBOR + 1.8%, which is not supported by the original data. Additionally, the ground truth confirms no interest rate framework was disclosed in 2022, making this a major factual error. In 2023, the ground truth states the rate was disclosed as SOFR + 2.1%, which the LLM correctly identifies. However, the LLM adds unsupported details such as the existence of a swap in 2022 tied to LIBOR, hedge accounting, notional amount, and alignment of coupon and effective rates—none of which are in the original answer. (2) Quantitatively, the $1 billion carrying amount is correct (equivalent to $1,000 million), so that element is accurate. The percentages (SOFR + 2.1%) match in 2023, but the 2022 LIBOR + 1.8% figure is fabricated. There is no mention of LIBOR or swaps in the ground truth, so these numbers are incorrect. (3) The multi-hop reasoning is flawed because the LLM invents a narrative about interest rate swaps and transition from LIBOR to SOFR, implying a continuity that is not present in the original data. The actual evolution is from no interest rate framework disclosure to a new SOFR-based disclosure—there is no indication of a prior LIBOR-based swap. The model fails to accurately synthesize the disclosed information across years and instead constructs a plausible but factually incorrect explanation. (4) Contextual relevance is moderate because the answer addresses the evolution of disclosure and focuses on the correct instrument and years, but the invented financial mechanics undermine correctness. The qualitative and quantitative scores are low due to major factual and numerical errors, especially regarding the non-existent 2022 swap and LIBOR spread.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 533,
        "total_tokens": 1831
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2022 to 2024, and what does this indicate about the company's strategic positioning in that geographic area?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure had decreased to 296 billion cubic feet. This indicates a reduction in the company's natural gas holdings in the region over the two-year period, suggesting a potential strategic shift or divestment in that geographic area.",
      "llm_answer": "\nFrom 2022 through 2024 the company’s **own (consolidated) proved natural‑gas reserves in the Asia‑Pacific/Middle‑East region slipped only modestly – from about 326 billion cubic feet (bcf) in 2022 to 312 bcf in 2023 and 296 bcf in 2024, a decline of roughly 9 %**.  By contrast, reserves held through **equity‑affiliated assets in the same region were far larger and showed a dip in 2023 (≈5,275 bcf) followed by a rebound to ≈5,870 bcf in 2024**.  This pattern indicates that ConocoPhillips is positioning its growth and market presence in the Asia‑Pacific/Middle‑East not through expanding its standalone reserve base, but by leveraging strategic joint‑venture and equity partnerships that provide a substantial and increasingly stable gas resource base.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 2022 (326 bcf) and 2024 (296 bcf) natural gas reserve figures from the ground truth, which are accurate. However, it introduces a 2023 value of 312 bcf that is not present in the original answer, and while this number may be plausible, it is unverified and adds unsupported detail. The 9% decline calculation is approximately correct (326 to 296 bcf is a ~9.2% drop), so this is acceptable. (2) The major factual error lies in the introduction of 'equity-affiliated assets' with reserves of ~5,275 bcf in 2023 and ~5,870 bcf in 2024—these figures are entirely absent from the original answer and not supported by the ground truth. There is no mention of equity-affiliated reserves in the provided data, making this a significant fabrication. (3) The reasoning is flawed due to this unsupported data. While the LLM attempts multi-hop synthesis by distinguishing between consolidated and equity-affiliated reserves, this distinction is not present in the original information and leads to an incorrect strategic interpretation. The original answer suggests a potential strategic shift or divestment due to declining reserves, while the LLM concludes growth via partnerships—this is a contradictory inference based on invented data. (4) The contextual relevance is high because the answer addresses the evolution of reserves and attempts to interpret strategic positioning. However, the correctness score is low due to the inclusion of unverified numbers and entities, undermining factual reliability. Quantitative accuracy is partially correct but penalized for unsupported figures. Qualitative accuracy suffers from incorrect reasoning based on fabricated data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 467,
        "total_tokens": 1757
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How did the repurchase activity of Class C Capital Stock by Alphabet change between 2022 and 2023, and what does this indicate about the company's capital allocation strategy?",
      "original_answer": "In 2022, Alphabet repurchased $59.3 billion of Class A and Class C shares, while in 2023, the repurchase amount increased to $62.2 billion. Additionally, in April 2023, the Board authorized an additional $70.0 billion for share repurchases, with $36.3 billion remaining available as of December 31, 2023. This indicates a continued and expanding emphasis on returning capital to shareholders through share repurchases, with a notable increase in the scale of buybacks year-over-year.",
      "llm_answer": "\nBetween 2022 and 2023 Alphabet repurchased roughly **450 million Class C shares for about $52.9 billion**, compared with **469 million shares for $52.6 billion in 2022** – a slight reduction in the number of shares bought back but a modest increase in total dollars spent. This modest pull‑back in share volume, coupled with continued heavy spending, shows that the company is still prioritizing share‑repurchase as a core element of its capital‑allocation strategy, but it is becoming more selective and price‑aware when executing those buybacks.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Alphabet repurchased $59.3 billion in 2022 and $62.2 billion in 2023, representing an increase in dollar terms. However, the LLM claims $52.6 billion in 2022 and $52.9 billion in 2023, which is incorrect. Additionally, the LLM introduces specific share counts (450 million and 469 million), which are not present in the original answer and appear to be fabricated or misattributed. The ground truth does not break down repurchases by share class (Class C only), but rather states combined repurchases of Class A and Class C shares. (2) The quantitative inaccuracies are severe: the dollar amounts are off by over $6 billion for 2022 and nearly $10 billion for 2023. The LLM also fails to mention the additional $70.0 billion authorization in April 2023 or the $36.3 billion remaining as of year-end 2023—key facts that indicate the scale and strategic direction of the buyback program. (3) The reasoning is partially sound in interpreting that share repurchases reflect a capital return strategy, but the conclusion that Alphabet is 'becoming more selective and price-aware' due to a 'slight reduction in share volume' is based on incorrect data and is not supported by the ground truth, which shows an increase in total repurchase spending. The multi-hop synthesis fails because the model does not correctly integrate the year-over-year increase in repurchase value or the expanded authorization. (4) The contextual relevance is moderate because the answer addresses the general topic of repurchase activity and capital allocation, but the factual foundation is flawed, leading to an incorrect interpretation of trends and strategy. Due to major errors in numbers, missing key facts, and flawed reasoning based on incorrect data, the correctness score is low at 2.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 506,
        "total_tokens": 1771
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has AIG's use of frequency/severity methods evolved between 2022 and 2023, particularly in terms of the lines of business where they are applied and the reasoning behind their usage?",
      "original_answer": "In 2022, AIG primarily used frequency/severity methods for short-tail classes such as U.S. Property, and explicitly avoided using them for aviation exposures due to the high severity and varying mix of claims year to year. By 2023, AIG expanded the application of frequency/severity methods to include U.S. Workers' Compensation, a long-tail line of business, as part of a combination of methods that also included loss development and expected loss ratio methods. This reflects a strategic shift toward using frequency/severity methods in more complex, long-tail environments, especially where risk-sharing features and large deductible business have increased.",
      "llm_answer": "\nBetween 2022 and 2023 AIG continued to reserve short‑tail property business (U.S. Property and the property‑portion of its program segments) with frequency‑severity techniques, but it tightened the scope of those methods.  The 2023 filing makes clear that frequency‑severity is **not** applied to high‑severity, long‑tail lines such as aviation, aerospace, and excess‑casualty—areas where the company now relies on loss‑development and expected‑loss‑ratio approaches—because the nature of those claims (large, infrequent, and heavily influenced by evolving judicial and market trends) makes the frequency‑severity assumptions unreliable.  For program business the 2023 methodology still uses frequency‑severity for property classes but adopts the casualty‑style methods described for liability classes, reflecting a more segmented and risk‑appropriate reserving practice.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains some correct elements regarding AIG's use of frequency/severity methods in 2022 for short-tail property lines, which aligns with the ground truth. However, it fundamentally misrepresents the evolution between 2022 and 2023. The original answer states that AIG *expanded* the use of frequency/severity methods in 2023 to include U.S. Workers' Compensation—a long-tail line—marking a strategic broadening into more complex areas. In contrast, the LLM claims AIG *tightened the scope* and explicitly avoided frequency/severity in long-tail lines like aviation and excess casualty, which contradicts the direction of change described in the ground truth. While the LLM correctly notes that frequency/severity is not used for high-severity, infrequent claims like aviation, it fails to acknowledge the key development: the method's new application to Workers' Compensation in 2023. This omission and reversal of trend (narrowing vs. expanding) represent a major factual error in reasoning and synthesis. There are no numerical values to verify, so quantitative accuracy is scored based on absence of incorrect numbers (hence 8). Qualitative accuracy is low due to incorrect multi-hop reasoning and failure to capture the strategic shift. Contextual relevance is moderate because the answer discusses relevant lines of business and methods but mischaracterizes the evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1393,
        "completion_tokens": 384,
        "total_tokens": 1777
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has Amgen's financial relationship with BeiGene evolved from 2022 to 2023, particularly in terms of cost recovery, product sales, and profit and loss sharing?",
      "original_answer": "In 2022, Amgen recovered $199 million in R&D costs from BeiGene, recorded product sales of $64 million, and recognized $53 million in profit and loss sharing expenses. In 2023, these figures changed to $109 million in cost recovery, $125 million in product sales, and $40 million in profit and loss sharing expenses. This indicates a decrease in cost recovery and profit-sharing expenses, but a significant increase in product sales to BeiGene. The shift suggests a maturation of the collaboration, with more product sales occurring in 2023, while the level of R&D cost sharing declined.",
      "llm_answer": "\nFrom 2022 to 2023 Amgen’s oncology partnership with BeiGene showed a clear shift: cost recoveries dropped sharply—from $199 million in 2022 to $109 million in 2023—while product sales to BeiGene grew—from $64 million in 2022 to $125 million in 2023—and profit‑and‑loss sharing expenses fell—from $53 million in 2022 to $40 million in 2023 (with related receivables declining to $16 million for sales and $44 million for cost/recovery settlements).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key financial figures from the ground truth: $199M to $109M in cost recovery, $64M to $125M in product sales, and $53M to $40M in profit and loss sharing expenses. These numbers are accurate and match the original answer exactly, with acceptable formatting variations (e.g., $199 million). (2) Quantitative accuracy is perfect—each dollar amount and year is correct, and the directional changes (decrease in cost recovery and P&L sharing, increase in product sales) are accurately described. The additional detail about receivables ($16M for sales and $44M for cost/recovery settlements) is not present in the ground truth but does not contradict it and may reflect supplementary data from the filings; it does not detract from correctness. (3) The multi-hop reasoning is sound: the model synthesizes data across two years and three financial dimensions (cost recovery, product sales, P&L sharing), correctly identifying the shift in the nature of the collaboration. The interpretation of a maturing partnership is implied and logically supported, though slightly less explicit than the original’s concluding sentence. (4) The answer is fully contextually relevant, directly addressing the evolution of the financial relationship as requested. The only minor shortcoming is the lack of an explicit concluding interpretation (e.g., 'suggests maturation of the collaboration'), which slightly reduces qualitative accuracy, but the factual and quantitative core is complete and correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1262,
        "completion_tokens": 423,
        "total_tokens": 1685
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2022 to 2024, and what specific changes occurred in terms of revisions, production, and purchases during this period?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure decreased slightly to 296 billion cubic feet. During this period, revisions in 2023 added 9 billion cubic feet, but production subtracted 25 billion cubic feet in 2024. Additionally, there were no purchases reported directly affecting this region in 2024, indicating a reduction in active reserve growth strategies compared to earlier years.",
      "llm_answer": "\nAt year‑end 2022 the company held 326 billion cubic feet of proved natural‑gas reserves in the Asia‑Pacific/Middle‑East, which declined to 312 BCF in 2023 and 296 BCF by the end of 2024 (a net reduction of roughly 30 BCF).  The drop reflects net downward revisions of about 26 BCF in 2024 (downward 81 BCF offset by upward technical revisions of 55 BCF) and roughly 90 BCF in 2023, while production removed approximately 24 BCF of reserves in 2023 and 51 BCF in 2024; purchases were limited to a small affiliate‑interest acquisition in 2022 with no material purchases thereafter.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in numbers and events compared to the ground truth. While the starting (326 BCF in 2022) and ending (296 BCF in 2024) reserve figures match, the intermediate 2023 value is incorrectly stated as 312 BCF, which is not supported by the original answer (which does not provide a 2023 total). More critically, the LLM claims 90 BCF of production in 2023 and 51 BCF in 2024, whereas the ground truth states only 25 BCF subtracted in 2024 with no 2023 production figure provided—certainly not 90 BCF. The revisions are also completely misrepresented: the LLM reports net downward revisions of 26 BCF in 2024 and 90 BCF in 2023, while the original answer states that revisions in 2023 *added* 9 BCF, with no mention of 2024 revisions. The LLM invents a detailed breakdown of downward 81 BCF and upward 55 BCF revisions in 2024, which is not in the source. Additionally, the LLM claims a small purchase in 2022 and no material purchases thereafter, while the original answer states there were no purchases directly affecting the region in 2024, without commenting on 2022 or affiliate acquisitions. (2) Calculations are therefore invalid: the claimed net reduction of 30 BCF is close (actual is 30 BCF: 326 → 296), but the attribution to production and revisions is entirely incorrect. (3) Multi-hop reasoning fails: the model synthesizes non-existent data across years and misattributes changes, failing to correctly link revisions, production, and purchases to the correct years and magnitudes. (4) Despite these major errors, the answer is contextually relevant—it addresses the right company (COP), region (Asia Pacific/Middle East), metric (natural gas reserves), and time frame (2022–2024), and attempts to break down changes by revisions, production, and purchases. However, the severe quantitative and qualitative inaccuracies drastically reduce correctness. Hence, low scores for correctness (3), quantitative accuracy (2), and qualitative accuracy (3), with moderate contextual relevance (7).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1277,
        "completion_tokens": 555,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did FedEx's planned usage of the B767F aircraft evolve from 2022 to 2024, and what does this indicate about its strategic fleet planning?",
      "original_answer": "In 2022, FedEx projected using 14 B767F aircraft in both 2023 and 2024, with a planned reduction to 10 by 2025. By 2024, the projections had changed, showing a decrease to 11 B767F aircraft for 2025 and only 3 by 2026. This indicates a strategic shift toward a more accelerated reduction in the planned use of B767F aircraft, reducing reliance on this model over time.",
      "llm_answer": "\nFrom the 2022 10‑K FedEx owned 114 B767F freighters and had purchase commitments for 38 additional B767Fs – 14 to be delivered in 2023, 14 in 2024 and 10 in 2025. The 2024 10‑K revises that schedule, showing only 11 B767Fs slated for delivery in 2025 and a further 3 in 2026, effectively cutting the near‑term commitment by roughly two‑thirds. This pull‑back indicates that FedEx is tempering its aggressive B767F expansion, instead relying on its existing fuel‑efficient fleet and shifting growth to other aircraft types (e.g., B777F) while managing capital outlays more conservatively.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in numbers and dates compared to the ground truth. The original answer states that FedEx *projected using* 14 B767F aircraft in 2023 and 2024 (operational fleet size), with reductions to 10 by 2025, then revised to 11 in 2025 and only 3 by 2026. However, the LLM misrepresents this as *deliveries* and *purchase commitments*, claiming 14 deliveries in 2023, 14 in 2024, and 10 in 2025 — which is not supported by the ground truth. The ground truth does not mention delivery schedules or ownership numbers like '114 B767F freighters owned' or '38 additional purchase commitments' — these figures are fabricated or misattributed. (2) The quantitative inaccuracies are severe: the LLM invents delivery numbers and ownership data absent from the original answer. While it correctly identifies a reduction trend (from 11 to 3 between 2025 and 2026), this is framed as deliveries rather than projected usage/fleet size, distorting the meaning. The 'two-thirds cut' claim lacks grounding in the provided truth. (3) The reasoning partially captures the strategic implication — a shift away from B767F reliance and more conservative capital management — which aligns with the original answer’s conclusion about accelerated reduction. It also correctly infers a strategic pivot toward other aircraft like B777F, which is a reasonable qualitative extension. However, the multi-hop synthesis is flawed because it conflates *planned usage* (the actual metric in the question) with *purchase commitments and deliveries*, failing to correctly interpret the nature of the data. (4) Despite incorrect numbers and mischaracterized data types, the LLM captures the directional strategic shift, earning moderate scores in qualitative accuracy and contextual relevance. The core idea of de-emphasizing B767F is correct, but the factual foundation is unsound, warranting a correctness score of 6 — partially correct but with major quantitative errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1237,
        "completion_tokens": 539,
        "total_tokens": 1776
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did AIG's use of Expected Loss Ratio Methods evolve between 2022 and 2023, particularly in terms of the lines of business and the reasoning behind their application?",
      "original_answer": "In 2022, AIG used Expected Loss Ratio Methods primarily for the latest accident year and in combination with other methods like loss development for aviation exposures, due to the high severity nature of claims and varying mix across years. By 2023, AIG applied Expected Loss Ratio Methods more broadly, particularly in U.S. Workers' Compensation, a long-tail line of business, where they used a combination of methods including Expected Loss Ratio, to account for extended loss emergence periods and complex risk-sharing features in policies. This reflects a shift from a focus on short-term forecasting in high-severity contexts to a broader application in long-tail, structurally complex lines.",
      "llm_answer": "\nBetween 2022 and 2023 AIG expanded and refined its use of Expected‑Loss‑Ratio (ELR) techniques. In 2022 the ELR method was applied chiefly to the U.S. Property and U.S. Special‑Risk lines for the latest accident year, using ground‑up claim projections and inflation‑adjusted loss‑trend assumptions because those lines have low‑frequency, high‑severity patterns and limited development data. By 2023 the Company broadened ELR to additional lines—including U.S. Excess Casualty, U.S. Workers’ Compensation and U.S. Personal Insurance—and incorporated more sophisticated weighting (e.g., Cape‑Cod/Bornhuetter‑Ferguson) and explicit adjustments for reinsurance and macro‑economic trends, reflecting a shift toward relying on ELR as the primary reserve driver for any line where development is slow, unreliable, or heavily influenced by severity‑driven factors.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent in terms of dates (2022 to 2023) and correctly identifies a broadening of AIG's use of Expected Loss Ratio (ELR) methods, which aligns with the ground truth. There are no numeric values (e.g., percentages, dollar amounts) in either the original or LLM answer, so quantitative accuracy is not compromised—scored 10 by default. The LLM correctly captures the evolution in reasoning: from use in low-frequency, high-severity lines with limited data to broader application where loss development is slow or unreliable. However, there are discrepancies in the specific lines of business cited. The original answer specifies aviation exposures in 2022 and U.S. Workers’ Compensation in 2023 as key examples, with an emphasis on long-tail characteristics and risk-sharing complexity. The LLM mentions U.S. Property and U.S. Special Risk in 2022 (not in original) and adds U.S. Excess Casualty and U.S. Personal Insurance in 2023—details not present in the ground truth. While some expansion is accurate, the specific lines introduced are not supported by the original, suggesting possible overgeneralization or hallucination. The LLM also introduces technical methods like Cape-Cod/Bornhuetter-Ferguson and adjustments for reinsurance and macroeconomic trends, which, while plausible, are not mentioned in the original answer, adding unsupported detail. The core evolution—broader use in 2023, especially in long-tail lines like Workers’ Compensation—is correct and reflects sound multi-hop reasoning. Thus, the answer is mostly accurate in direction and reasoning but includes unverified specifics, warranting a 7 for correctness and qualitative accuracy. Contextual relevance is high as all content directly addresses the question’s focus on evolution, lines of business, and reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 491,
        "total_tokens": 1885
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How has Cisco's positioning around Enterprise Data Center Transformation evolved between 2022 and 2024, particularly in relation to its strategic alliances and competitive landscape?",
      "original_answer": "In 2022, Cisco highlighted that the enterprise data center was undergoing a fundamental transformation due to the convergence of technologies like computing, networking, storage, and software, with strategic alliance partners sometimes acquiring or aligning with competitors, reducing business with Cisco. By 2024, Cisco continued to emphasize this transformation but expanded its focus on strategic alliances aimed at industry advancement and new market creation, while also updating its competitive landscape to include new entrants like Nvidia Corporation, signaling a shift in market dynamics and alliance strategies.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2024 Cisco moved enterprise‑data‑center transformation from a peripheral, channel‑focused theme to a core strategic pillar, embedding it in its growth narrative and tying it to a new wave of strategic alliances (e.g., deeper integrations with VMware, Microsoft Azure Stack, Nvidia and cloud hyperscalers such as AWS and Google).  This alliance‑driven approach was designed to deliver end‑to‑end hardware‑software‑observability solutions that could compete with both traditional networking rivals (Arista, Juniper, HPE) and the expanding data‑center offerings of the major cloud providers, which now also provide integrated stacks.  Consequently, Cisco’s positioning evolved to emphasize outcome‑based, software‑centric data‑center services backed by partnership ecosystems, while the competitive landscape intensified with more direct competition from the same alliance partners and from hyperscale vendors.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of Cisco's evolving positioning around Enterprise Data Center Transformation from 2022 to 2024. It accurately captures the shift in strategic focus toward deeper alliances and a more software- and outcome-centric approach. The mention of key partners like VMware, Microsoft Azure Stack, AWS, Google, and notably Nvidia is consistent with the 2024 expansion of alliances and recognition of new competitive dynamics. The competitive landscape is correctly updated to include cloud hyperscalers and traditional rivals, reflecting intensified competition. However, the LLM adds specific alliance examples (e.g., VMware, Azure Stack) and characterizes the shift as moving from 'peripheral' to 'core strategic pillar,' which, while plausible, goes beyond the specificity of the original answer and introduces interpretive language not present in the ground truth. The original answer emphasizes that in 2022, alliances with partners were challenged due to those partners aligning with competitors, and by 2024, Cisco responded by focusing on alliances that create new markets—this nuance about partner conflict and market creation is underemphasized in the LLM response. There are no numerical inaccuracies (quantitative accuracy is perfect), and all years (2022–2024) are correctly referenced. The reasoning is sound and multi-hop, connecting alliance strategy with competitive shifts. Contextual relevance is excellent, directly addressing the evolution in positioning, alliances, and competition. The answer is semantically close but slightly over-interprets the depth of alliance integration, warranting a high but not perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1399,
        "completion_tokens": 464,
        "total_tokens": 1863
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did the effective interest rate and notional amount associated with the 3.125% 2025 Notes evolve between 2022 and 2023?",
      "original_answer": "In 2022, the 3.125% 2025 Notes were part of a $5.2 billion principal amount on which new interest rate swaps were entered into after the termination of previous swaps, indicating a dynamic hedging strategy due to low interest rates. By 2023, the notional amount of the 3.125% 2025 Notes under interest rate swaps had decreased to $1.0 billion, with an effective interest rate of SOFR + 2.1%. This reflects a reduction in the hedged notional exposure and a shift in the interest rate environment.",
      "llm_answer": "\nBetween 2022 and 2023 the 3.125 % 2025 Notes kept the same outstanding notional amount of **$1 billion** (1,000 million).  However, the benchmark used to calculate the effective rate changed: in 2022 the notes bore interest at **LIBOR + 1.8 %**, while by the end of 2023 they were priced at **SOFR + 2.1 %**.  Thus, the notional stayed constant while the effective interest rate shifted to a slightly higher SOFR‑based spread.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors in both quantitative and qualitative aspects. (1) Quantitative inaccuracy: The notional amount in 2022 was $5.2 billion (not $1 billion), as stated in the ground truth, which notes that new interest rate swaps were entered on a $5.2 billion principal. The LLM incorrectly claims the notional amount remained constant at $1 billion in both years. The only correct numeric value is the 2023 effective rate of SOFR + 2.1%. The 2022 rate is stated as LIBOR + 1.8%, but the ground truth does not specify this rate—instead, it references a broader hedging strategy without giving a precise spread, making the LLM's figure unsupported. (2) Completeness: The answer fails to mention the reduction from $5.2 billion to $1.0 billion in notional under swap hedging, which is a key evolution. It also omits the rationale tied to changing interest rate environments and hedging strategy dynamics. (3) Entity and reasoning accuracy: The LLM incorrectly assumes the outstanding notional of the notes themselves changed, whereas the ground truth refers to the portion of the notes hedged via swaps (a multi-hop nuance). The shift from LIBOR to SOFR is plausible contextually (due to benchmark transition), but the specific rates and their attribution to the notes are not supported by the source. (4) Semantic equivalence: The core message—that hedged exposure and rates evolved—is in the right direction, but the incorrect numbers and missing scale of change (over 80% reduction in hedged notional) undermine correctness. The answer is contextually relevant but factually flawed in key dimensions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1224,
        "completion_tokens": 444,
        "total_tokens": 1669
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has Cisco's strategic positioning of AppDynamics within its product portfolio evolved from 2022 to 2024, particularly in terms of its emphasis within observability offerings?",
      "original_answer": "In 2022, Cisco explicitly introduced AppDynamics as a key component of its full-stack observability strategy, positioning it alongside Intersight and ThousandEyes to provide application performance monitoring capabilities. However, by 2024, Cisco restructured its product revenue reporting to include a new category called 'Observability,' which subsumed offerings like AppDynamics. This shift indicates a more formalized and integrated strategic emphasis on observability as a standalone pillar within Cisco's broader portfolio.",
      "llm_answer": "\nFrom 2022 through 2024 Cisco moved AppDynamics from a niche application‑performance‑monitoring (APM) add‑on into the center of its **Observability** strategy.  In the 2022 filing the company highlighted AppDynamics as part of a “full‑stack observability” push that also included ThousandEyes and security analytics, but by 2024 it was grouped under a dedicated **Observability product category** whose revenue grew 27 % YoY, driven largely by the Observability Suite (which incorporates AppDynamics) and by the Splunk‑based observability offering.  This evolution reflects a shift from merely selling an APM tool to positioning AppDynamics as a core, revenue‑generating pillar of Cisco’s end‑to‑end observability portfolio that spans network, application and infrastructure insights.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution of AppDynamics from a component of full-stack observability in 2022 to a core part of a dedicated 'Observability' product category by 2024. The integration of AppDynamics into a formalized observability pillar is accurately described. (2) The LLM introduces a specific quantitative claim—'revenue grew 27% YoY'—that is not present in the original answer. While this figure may be factually correct based on Cisco's 2024 filings, it is not part of the ground truth derived from the knowledge graph, making it an unverifiable addition. This prevents a perfect score despite likely accuracy. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across years (2022 to 2024), identifies the strategic shift in positioning (from APM tool to central observability pillar), and references related technologies (ThousandEyes, Splunk integration) to contextualize the evolution. (4) Entity accuracy is strong—Cisco, AppDynamics, ThousandEyes, and the Observability category are all correctly named and contextualized. The answer is semantically equivalent to the original, with slightly more detail (e.g., mentioning Splunk), which enhances context without distorting facts. The 27% revenue growth, while plausible, is the only unsupported addition, hence the 9/10 on correctness and quantitative accuracy. Qualitative accuracy and contextual relevance are excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 411,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How did the effective interest rate and notional amount associated with the 4.663% 2051 Notes evolve from 2022 to 2023?",
      "original_answer": "In 2022, the 4.663% 2051 Notes were part of a $5.2 billion principal amount of notes that were hedged using interest rate swaps, with the swaps terminated and replaced at then-current interest rates. In 2023, the notional amount of the 4.663% 2051 Notes was $1.5 billion, and the effective interest rate was SOFR + 4.3%. This indicates a continuation of the hedging strategy but with updated interest rate terms and a more specific disclosure of the notional amount and rate for the 2051 Notes.",
      "llm_answer": "\nThe 4.663% 2051 Notes kept essentially the same outstanding balance – about **$1.5 billion** of notional – in both 2022 and 2023.  Their effective yield was unchanged at roughly **5.6 %**; it was originally structured as LIBOR + 4.1% (reflecting a 5.6 % effective rate) and, after the 2023 swap reset, became SOFR + 4.3%, still delivering an effective rate close to 5.6 %.  Thus, neither the notional amount nor the effective interest rate materially changed from 2022 to 2023.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partial correctness but significant factual inaccuracies. The notional amount of $1.5 billion in 2023 matches the ground truth, which is correct. However, the claim that the notional amount was also $1.5 billion in 2022 is incorrect — the original answer states that in 2022, the 4.663% 2051 Notes were part of a $5.2 billion principal amount of hedged notes, not $1.5 billion specifically for the 2051 Notes. This misrepresents the 2022 notional amount. (2) Regarding the effective interest rate, the LLM claims it remained unchanged at roughly 5.6%, with a transition from LIBOR + 4.1% to SOFR + 4.3%. However, the ground truth does not mention LIBOR or a 5.6% effective rate in 2022; it only states that interest rate swaps were terminated and replaced at then-current rates. The 2023 effective rate of SOFR + 4.3% is correctly reported, but the inference of a stable 5.6% rate is unsupported by the original data. There is no confirmation in the ground truth that SOFR + 4.3% equals approximately 5.6%, nor that the prior rate was equivalent. (3) The multi-hop reasoning is flawed: the model assumes continuity in notional amount and effective rate without evidence from the source. It synthesizes a narrative of stability that is not present in the original answer, which emphasizes a restructuring (swap termination and replacement) and more specific disclosure in 2023, not consistency. (4) The contextual relevance is high because the answer addresses the evolution of rate and notional amount as asked. However, correctness is low due to unsupported numerical claims and incorrect synthesis. Quantitative accuracy is moderate due to the correct $1.5B 2023 figure but incorrect 2022 figure and unverified rate equivalence. Qualitative accuracy is low due to incorrect reasoning and assumption of rate equivalence without evidence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1236,
        "completion_tokens": 508,
        "total_tokens": 1744
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has AIG's use of expected loss ratio methods evolved between 2022 and 2023, particularly in terms of the lines of business and segmentation criteria applied?",
      "original_answer": "In 2022, AIG referenced the use of expected loss ratio methods in a general sensitivity analysis related to loss reserve assumptions, without specifying detailed segmentation or particular lines of business. By 2023, AIG explicitly applied expected loss ratio methods to U.S. Workers' Compensation, a long-tail line of business, and introduced more granular segmentation criteria such as risk-sharing features, state and industry subsets, deductible size, and claim handling entities. This indicates a more structured and detailed application of the method in 2023 compared to 2022.",
      "llm_answer": "\nBetween 2022 and 2023 AIG moved from a focused, trend‑driven use of expected‑loss‑ratio methods on a few long‑tail, excess‑of‑deductible lines (principally U.S. Excess Casualty and U.S. Financial Lines) to a systematic, company‑wide application of the same technique.  In 2023 the method is applied across many more lines of business—including U.S. Workers’ Compensation, U.S. Other Casualty and even short‑tail lines—and the segmentation criteria have been sharpened: ratios are now tied to recent accident‑year premiums and adjusted for inflation, rate changes and market conditions, and are segmented by deductible vs. guaranteed‑cost, by underlying primary carrier and by the Company’s reportable segments.  This broader, more granular deployment reflects a shift from relying mainly on loss‑cost‑trend assumptions to using explicit expected‑loss‑ratio estimates as a core driver of reserve projections.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies compared to the ground truth. (1) The original answer states that in 2022, AIG only generally referenced expected loss ratio methods in sensitivity analysis without specifying lines of business, whereas the LLM claims AIG applied the method to specific lines like U.S. Excess Casualty and U.S. Financial Lines—this is incorrect and unsupported by the ground truth. (2) The LLM asserts a shift to 'company-wide application' across many lines including short-tail lines in 2023, but the ground truth only confirms explicit application to U.S. Workers’ Compensation, a long-tail line, with no mention of short-tail lines or broader expansion. (3) The segmentation criteria cited by the LLM—such as recent accident-year premiums, inflation adjustments, rate changes, underlying primary carrier, and reportable segments—do not match the ground truth, which specifies segmentation by risk-sharing features, state and industry subsets, deductible size, and claim handling entities. (4) The reasoning is flawed: the LLM fabricates a multi-hop evolution that is more expansive and systematic than what the evidence supports. While the mention of U.S. Workers’ Compensation in 2023 aligns with the truth, the broader narrative of transformation is overstated and factually incorrect. Quantitative accuracy is low due to the absence of verifiable numbers and the reliance on incorrect qualitative descriptors presented as facts. Contextual relevance is moderate because the answer addresses the general topic of methodological evolution in expected loss ratios, but the specifics are largely invented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 447,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did PepsiCo's engagement with the 2.850% Senior Notes due 2026 evolve between 2023 and 2024, particularly in terms of its broader debt issuance strategy as reflected in the additional notes introduced in 2024?",
      "original_answer": "In 2023, PepsiCo referenced the 2.850% Senior Notes due 2026 as part of a broader set of debt instruments, including other senior notes with varying interest rates and maturity dates. By 2024, the company introduced a significantly expanded range of senior notes, including higher-yielding instruments such as the 7.00% Senior Notes due 2029 and the 5.50% Senior Notes due 2035, indicating a more diversified and long-term debt issuance strategy. This evolution suggests that PepsiCo not only maintained its commitment to the 2.850% Senior Notes due 2026 but also broadened its capital structure by incorporating a wider spectrum of debt instruments with different risk-return profiles.",
      "llm_answer": "\nIn the 2023 filing the 2.850 % Senior Notes due 2026 appear in the Board‑of‑Directors resolutions (Exhibit 4.64) that authorized a suite of senior notes, showing that PepsiCo was maintaining a laddered, fixed‑rate issuance schedule to manage near‑term maturities. By 2024 the company expanded that schedule—adding several new long‑dated and floating‑rate senior notes (e.g., the 2027‑2034 tranches disclosed in Exhibits 4.64‑4.66 and the Singapore‑vehicle indentures of February 2024)—while still keeping the 2.850 % 2026 notes in the lineup, indicating a strategic shift toward diversifying funding sources and extending the overall maturity profile of its debt.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of core facts and reasoning. (1) It accurately reflects that PepsiCo maintained the 2.850% Senior Notes due 2026 in both 2023 and 2024, which is consistent with the original answer. It also correctly identifies the expansion of the debt issuance strategy in 2024. (2) Quantitatively, the LLM does not specify exact new note rates like the 7.00% due 2029 or 5.50% due 2035 from the ground truth, instead referring more generally to 'new long-dated and floating-rate senior notes (e.g., the 2027–2034 tranches)' and Singapore vehicle indentures. While these details may be factually present in the filings, they do not precisely match the specific instruments cited in the original answer, leading to a minor shortfall in quantitative specificity. (3) The multi-hop reasoning is sound: the model correctly infers a strategic evolution in debt issuance—maintaining existing instruments while broadening the maturity and structure profile—based on document evidence (Exhibits 4.64–4.66). However, it omits explicit mention of the higher-yielding nature of the new notes, a key qualitative point in the original answer indicating risk-return diversification. (4) Contextual relevance is excellent—the response directly addresses the evolution of engagement with the 2026 notes and ties it to broader debt strategy. Overall, the answer captures the essence and direction of the strategy accurately but lacks full precision on the specific new instruments introduced in 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 423,
        "total_tokens": 1777
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has Cisco's exposure to channel partner financing guarantees evolved between fiscal years 2022 and 2024, and what does this indicate about the company's financial risk management strategy?",
      "original_answer": "In fiscal year 2022, Cisco disclosed that the volume of channel partner financing was $27.9 billion, with a balance of financing subject to guarantees amounting to $1.4 billion as of July 30, 2022. By fiscal year 2024, while the company continued to provide financing guarantees, the specific volume of channel partner financing and the balance subject to guarantees were no longer explicitly quantified in the disclosures. This shift indicates a potential strategic move toward reducing transparency around these financial commitments, which may reflect a broader risk management approach to limit visibility into contingent liabilities. However, the absence of updated figures prevents definitive conclusions about the actual change in exposure.",
      "llm_answer": "\nCisco’s exposure to channel‑partner financing guarantees grew only modestly between fiscal 2022 and fiscal 2024 – the guaranteed financing balance rose from roughly $1.3 billion to about $1.4 billion, and the maximum potential future payments increased from $155 million to $188 million, while the overall channel‑partner financing volume stayed near $27‑$28 billion.  This limited, tightly‑controlled growth shows that Cisco deliberately caps its credit‑risk exposure, offsetting guarantees with deferred revenue and collateral arrangements rather than expanding its risk footprint.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in fiscal year 2022, Cisco's channel partner financing volume was $27.9 billion with $1.4 billion subject to guarantees as of July 30, 2022. However, by fiscal year 2024, the company no longer disclosed specific figures for either the volume or the guaranteed balance. The LLM incorrectly states that the guaranteed balance rose from $1.3 billion to $1.4 billion and that maximum potential payments increased from $155 million to $188 million—these numbers are not supported by the original answer and contradict the key point that 2024 figures were no longer quantified. Additionally, the claim that financing volume stayed near $27–$28 billion in 2024 is unsupported due to lack of disclosure. (2) Quantitative accuracy is very low: the only correct number is the $1.4 billion guarantee balance in 2022 (close to the reported $1.4 billion), but the $1.3 billion figure for 2022 is incorrect (ground truth is $1.4 billion), and all 2024 numbers are fabricated. There is no evidence of updated figures in the original answer. (3) The multi-hop reasoning is flawed—the original answer emphasizes the absence of updated disclosures as a key point, indicating reduced transparency. The LLM instead assumes continuity and precise growth, failing to recognize the shift in disclosure policy. It draws strong conclusions about risk management based on non-existent data. (4) Contextual relevance is moderate because the answer addresses channel partner financing and risk management strategy, but the incorrect data undermines the analysis. The conclusion about 'tightly-controlled growth' and risk mitigation via deferred revenue and collateral is speculative and not present in the original answer. Overall, the LLM invents data and misses the central theme: declining transparency in disclosures between 2022 and 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 518,
        "total_tokens": 1862
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has the status and interest rate structure of the 2.45% 2030 Notes evolved between 2022 and 2023?",
      "original_answer": "In 2022, Amgen disclosed that it had entered into interest rate swap contracts with an aggregate notional amount of $1.0 billion with respect to the 2.45% 2030 Notes, effectively converting the fixed-rate interest to a floating LIBOR-based coupon. By 2023, the 2.45% 2030 Notes remained outstanding with a notional amount of $1.0 billion, but the interest rate structure had transitioned from LIBOR to SOFR, now stated as SOFR + 1.3%. This reflects a continuation of the note's existence but with a modified floating-rate benchmark.",
      "llm_answer": "\nBetween 2022 and 2023 the 2.45 % 2030 Notes remained outstanding with the same $1.25 billion principal amount (carrying value $1,250 million in both years).  However, the effective interest rate on that tranche shifted from a fixed‑coupon of 2.45 % to a floating rate: in 2021 the company had entered into interest‑rate swaps that tied the effective rate to **LIBOR + 1.0 %** (notional $1 billion), and by the end of 2023 those swaps had been reset to **SOFR + 1.3 %** (still on a $1 billion notional).  Thus, while the notes’ maturity (2030) and principal size did not change, their interest‑rate structure moved from a fixed 2.45 % coupon to a floating benchmark‑plus‑spread rate.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core evolution of the interest rate structure from fixed to floating and the transition from LIBOR to SOFR, which aligns with the ground truth. However, there are significant quantitative inaccuracies: the principal amount is stated as $1.25 billion, while the ground truth specifies $1.0 billion; the carrying value is repeated as $1,250 million in both years, which is inconsistent with the correct notional amount. Additionally, the LLM claims the swaps were entered into in 2021 (not 2022 as per the original answer), introducing a timing error. The floating rate spread is also incorrect: the ground truth states that the swaps converted the fixed rate to a LIBOR-based coupon (without specifying +1.0%), but the LLM adds a '+1.0%' spread not present in the original disclosure. By 2023, the shift to SOFR + 1.3% is correctly noted, but again, the ground truth does not specify the spread in 2022, making the LLM’s precise '+1.0%' claim unsupported. While the reasoning correctly identifies the multi-hop elements—existence of swaps, change in benchmark—the synthesis includes unsupported specifics. The context and structure of the answer are highly relevant and logically organized, hence high contextual relevance. Overall, the answer is partially correct but contains key factual and numerical errors that reduce its correctness and quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 384,
        "total_tokens": 1676
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How has FedEx's relationship with Pass-Through Certificates evolved between 2022 and 2023, particularly regarding its financial guarantees and obligations?",
      "original_answer": "In 2022, FedEx Express had issued $970 million of Pass-Through Certificates, Series 2020-1AA, which were fully and unconditionally guaranteed by FedEx. These certificates were secured by 19 Boeing aircraft with a net book value of $1.8 billion. However, in 2023, FedEx clarified that pass-through certificates associated with leveraged operating leases were not direct obligations of, nor guaranteed by, FedEx or FedEx Express. This indicates a shift from direct financial guarantees in 2022 to a position of no direct financial obligation in 2023.",
      "llm_answer": "\nBetween 2022 and 2023 FedEx kept the same $970 million Series 2020‑1AA pass‑through certificate program, but the wording of the guarantee changed.  The 2022 filing said the certificate payments were “fully and unconditionally guaranteed by FedEx,” whereas the 2023 filing clarified that the certificates are **not** direct obligations of FedEx and that the guarantee is provided only through the leveraged operating leases that secure them (the underlying collateral fell from about $1.8 billion to $1.7 billion).  Consequently, the financial guarantee remained in place but evolved from an explicit, unconditional guarantee to a contingent guarantee tied to lease‑derived cash flows, with updated disclosures of the secured aircraft value.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core evolution in FedEx's relationship with Pass-Through Certificates between 2022 and 2023 but introduces significant inaccuracies that affect factual correctness. (1) Quantitatively, the $970 million amount and reference to Series 2020-1AA are correct, aligning with the ground truth. However, the claim that the net book value of secured aircraft dropped from $1.8 billion to $1.7 billion is not supported by the original answer, which only states the 2022 value ($1.8 billion) and does not provide a 2023 figure—this is an unsupported addition. (2) The answer incorrectly implies that the financial guarantee 'remained in place' but evolved into a 'contingent guarantee tied to lease-derived cash flows.' In contrast, the ground truth states that in 2023, FedEx clarified these certificates were *not* direct obligations nor guaranteed by FedEx or FedEx Express—indicating a removal of guarantee language, not a transformation into a contingent form. This misrepresents the nature of the shift. (3) The multi-hop reasoning is partially sound—comparing disclosures across years—but misinterprets the legal and financial implications of the changed wording. The LLM assumes continuity of guarantee through collateral, while the ground truth emphasizes disavowal of obligation. (4) Despite these issues, the answer is contextually relevant and addresses the evolution in disclosure and financial stance. Wording differences are acceptable, but the introduction of incorrect figures and mischaracterization of the guarantee's status reduces correctness. Hence, partial credit is given for accurate identification of the certificate series and the directional change in disclosure, but major deductions apply for factual and interpretive errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 479,
        "total_tokens": 1803
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did Mastercard's use of risk mitigation arrangements to manage gross settlement exposure evolve from 2023 to 2024, and what does this indicate about the company's risk management strategy?",
      "original_answer": "In 2023, Mastercard had $75,023 million in gross settlement exposure, with $12,167 million covered by risk mitigation arrangements. By 2024, gross settlement exposure increased to $78,385 million, and the company applied $13,466 million in risk mitigation arrangements, reflecting an increase in both total exposure and the amount mitigated. This indicates that Mastercard's risk management strategy became more robust over time, as it increased its use of mitigation tools in response to growing settlement exposure.",
      "llm_answer": "\nMastercard’s gross settlement exposure grew from **$75.0 bn (2023) to $78.4 bn (2024)**, and the amount of risk‑mitigation arrangements it applied rose from **$12.2 bn to $13.5 bn** over the same period, pushing net exposure up slightly from **$62.9 bn to $64.9 bn**.  This shows the company is proactively scaling its collateral and credit‑enhancement programs in line with expanding settlement risk, reflecting a continuous, data‑driven risk‑management strategy that monitors exposure and adjusts mitigation measures as needed.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of Mastercard's risk mitigation arrangements from 2023 to 2024 with accurate figures, albeit rounded: $75,023 million gross exposure in 2023 is reported as $75.0 bn (correct within rounding); $78,385 million in 2024 is reported as $78.4 bn (also correct within rounding). Similarly, risk mitigation amounts are accurately rounded: $12,167 million → $12.2 bn, and $13,466 million → $13.5 bn. The net exposure calculation (gross minus mitigated) is implied and correctly estimated at $62.9 bn (2023) and $64.9 bn (2024), which matches ground truth when calculated: 75,023 - 12,167 = 62,856 ≈ $62.9 bn; 78,385 - 13,466 = 64,919 ≈ $64.9 bn. (2) All quantitative values are correct within acceptable rounding conventions used in financial reporting. No calculation errors. (3) The multi-hop reasoning is sound: the model correctly synthesizes two data points across years, compares both gross exposure and mitigation levels, and infers a strategic trend in risk management. The conclusion that Mastercard is 'proactively scaling' mitigation tools aligns semantically with the ground truth's assertion of a 'more robust' risk management strategy. (4) Minor deduction in quantitative accuracy due to rounding up of $13,466 million to $13.5 bn (slightly overstated by $34 million), but this is within typical reporting tolerance. Qualitative accuracy is high as reasoning and entity identification (Mastercard, gross settlement exposure, risk mitigation, years 2023–2024) are fully correct. Contextual relevance is perfect—answer directly addresses both parts of the question: evolution of use and strategic implication.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1273,
        "completion_tokens": 457,
        "total_tokens": 1731
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did Nike's liabilities related to foreign exchange forwards and options designated as hedging instruments change between 2022 and 2024, and what does this indicate about the company's exposure or strategy?",
      "original_answer": "In 2022, Nike reported $37 million in liabilities for foreign exchange forwards and options designated as hedging instruments under accrued liabilities, and $11 million under deferred income taxes and other liabilities, totaling $48 million. By 2024, the liability under accrued liabilities for the same category increased to $110 million, while the amount under deferred income taxes and other liabilities decreased to $5 million, resulting in a total of $115 million. This represents a significant increase in total liabilities for designated hedging instruments related to foreign exchange forwards and options, indicating a potential increase in Nike's foreign exchange risk exposure or a strategic shift in hedging activity.",
      "llm_answer": "\nBetween 2022 and 2024 the liability for foreign‑exchange forwards and options that Nike has formally designated as hedging instruments grew from **$37 million** (2022) to **$110 million** (2024) – an increase of roughly **$73 million**.  This jump shows that Nike has expanded the scale of its designated FX‑hedge program, using larger notional amounts to lock in rates and mitigate the earnings impact of currency fluctuations across its global operations.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the increase in liabilities under accrued liabilities from $37 million in 2022 to $110 million in 2024, which matches the ground truth. However, it omits the portion of liabilities reported under deferred income taxes and other liabilities—$11 million in 2022 and $5 million in 2024. As a result, the total hedging-related liabilities were $48 million in 2022 and $115 million in 2024, but the LLM only reports $37M and $110M, leading to an incomplete and slightly misleading quantitative picture. The calculation of a $73 million increase is based only on the accrued liabilities line and ignores the net change in the full liability structure. (2) The numbers cited for accrued liabilities are accurate, but the total liability figures are not fully represented. The LLM fails to mention the decrease in the second liability category, which is a relevant detail for understanding the full change in Nike's position. (3) The reasoning about increased hedging activity and potential strategy shift is logically sound and aligns with the trend in the primary liability component. However, because the model does not synthesize both liability components (accrued liabilities and deferred income taxes/other liabilities), the multi-hop reasoning is incomplete. A full analysis requires aggregating both buckets as per the original answer. (4) Despite missing part of the financial data, the LLM captures the main directional trend and provides a reasonable interpretation, earning high marks for qualitative reasoning and relevance. The omission of a material portion of the liability breakdown prevents a higher score on quantitative and overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1312,
        "completion_tokens": 464,
        "total_tokens": 1776
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did the representation of Bounty within P&G's Baby, Feminine & Family Care segment evolve between the 2022 and 2023 10-K filings, and what does this suggest about its brand visibility?",
      "original_answer": "In the 2022 10-K filing, Bounty was mentioned as part of P&G's Family Care business within the Baby, Feminine & Family Care segment, but it was not explicitly listed among the key brands. In contrast, the 2023 10-K filing explicitly included Bounty among the major brands under the Family Care category. This change suggests an increase in Bounty's brand visibility within P&G's portfolio, though the filings do not provide specific market share or sales figures to quantify this shift. The explicit mention in 2023 indicates a possible strategic move to highlight Bounty's role, though no direct strategic intent is stated in the evidence provided.",
      "llm_answer": "\nIn the 2022 filing the Baby, Feminine & Family Care segment represented about 25 % of net sales and 23 % of earnings, and Bounty was listed as one of the segment’s key brands with “North America market shares … over 40 %” for the Bounty paper‑towel line. The 2023 filing shows the same segment’s share shifting slightly to roughly 24 % of net sales and 25 % of earnings, while Bounty remains among the segment’s major brands and still carries the “over 40 %” North‑American market‑share reference. Thus, Bounty’s placement and prominence within the segment stayed consistent, and its relative importance even edged up modestly as the segment’s contribution to the company’s overall sales and earnings grew.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both factual content and reasoning. According to the ground truth, Bounty was *not* explicitly listed as a key brand in the 2022 10-K, but the LLM claims it was. In 2023, Bounty was newly included among major brands—indicating a change in visibility—but the LLM incorrectly states that Bounty's placement and prominence 'stayed consistent.' The LLM fabricates specific quantitative data: it claims Bounty had 'over 40% market share' in North America in both years and provides segment-level financials (25% of net sales, 23% of earnings in 2022; 24%, 25% in 2023), none of which appear in the ground truth. The original answer explicitly states that no sales or market share figures were provided in the filings. (2) All numeric values in the LLM response—25%, 23%, 24%, 25%, and 'over 40%'—are factually unsupported by the ground truth and thus quantitatively inaccurate. There are no calculations in the ground truth to verify, but the LLM invents comparative metrics without basis. (3) The multi-hop reasoning fails: the core of the question is about a change in *brand representation* (from unlisted to explicitly named), which reflects evolving visibility. The LLM misses this entirely, asserting consistency instead of change, and substitutes fabricated metrics for qualitative analysis. (4) Contextual relevance is moderate because the LLM addresses the right segment and brand and attempts to compare years, but it replaces the actual insight (increased visibility via explicit mention) with false precision and invented data, undermining the entire response. Correctness is severely compromised by hallucinated numbers and misrepresentation of the filings’ content.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 470,
        "total_tokens": 1820
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How has Oracle's approach to its hardware business, particularly Oracle Engineered Systems, evolved between fiscal 2022 and fiscal 2023 in terms of revenue recognition and strategic emphasis?",
      "original_answer": "In fiscal 2022, Oracle's hardware business, which includes Oracle Engineered Systems, was described in terms of its contractual activities and revenue recognition, with an emphasis on the timing of revenue recognition for cloud and license contracts. By fiscal 2023, Oracle introduced a more detailed explanation of how hardware and related software are treated as a combined performance obligation, with revenue recognized at the point in time of delivery and ownership transfer. Additionally, in 2023, Oracle emphasized ongoing R&D investments to improve and develop new hardware products and services, which was not explicitly mentioned in 2022. This indicates a shift toward a more strategic focus on innovation and integration of hardware and software components within the hardware business.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2023 Oracle kept the same revenue‑recognition mechanics for its hardware business—product sales are recorded when control is transferred at shipment, and hardware‑support fees are recognized ratably over the contract term.  However, the company’s strategic emphasis moved away from treating Engineered Systems and other hardware as a growth driver and toward positioning them as part of a broader cloud‑and‑license offering, with greater focus on recurring support and services; as a result, the proportion of total revenue coming from hardware slipped slightly and Oracle highlighted that future growth would be driven more by cloud subscriptions and support rather than new engineered‑system shipments.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains some correct elements but significantly misrepresents Oracle's strategic emphasis and revenue recognition changes between fiscal 2022 and 2023. While it correctly notes that product revenue is recognized upon shipment (control transfer) and support fees are recognized ratably, this level of detail was not present in the original answer and does not align with the key evolution described in the ground truth. The original answer emphasizes a new, more detailed 2023 approach to treating hardware and software as a combined performance obligation, with point-in-time revenue recognition upon delivery—this nuance is missing in the LLM response. Instead, the LLM incorrectly frames the shift as a de-emphasis on hardware growth, positioning it as part of a cloud-and-license offering, which contradicts the ground truth that Oracle increased strategic focus on R&D and integration, indicating continued investment rather than de-prioritization. (2) There are no explicit numbers (e.g., revenue figures, percentages) in either the question or original answer, so no quantitative inaccuracies are present—hence a high score on quantitative accuracy. (3) The multi-hop reasoning is flawed: the LLM fails to synthesize the correct evolution—increased integration of hardware/software revenue recognition and renewed R&D emphasis—instead inferring a strategic retreat from hardware that is not supported by the ground truth. This represents a failure in qualitative accuracy despite using plausible financial terminology. (4) Contextual relevance is moderate: the answer addresses revenue recognition and strategic emphasis as required, but with incorrect interpretation of the strategic direction, reducing its factual alignment with the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 486,
        "total_tokens": 1880
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did the sales performance of the product ERLEADA evolve between 2022 and 2023, and what does this indicate about its market trajectory?",
      "original_answer": "In 2022, ERLEADA generated $1,881 million in sales, and by 2023, its sales increased to $2,387 million, representing a 26.9% growth. This indicates a strong upward trajectory for ERLEADA in the market, suggesting increased adoption or improved commercial performance over the period.",
      "llm_answer": "\nERLEADA’s worldwide sales jumped from **$1.88 billion in 2022 to $2.39 billion in 2023**, a **≈27 % increase** (26.9 % total change, 27.5 % operational growth). This double‑digit rise—driven by continued label expansions, share‑gain momentum in metastatic castration‑resistant prostate cancer and favorable market dynamics—signals a **robust upward trajectory** for the product, suggesting accelerating adoption and growing demand despite competitive pressures.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all key aspects. (1) Quantitatively, the sales figures are accurate: $1.88 billion in 2022 (equivalent to $1,881 million) and $2.39 billion in 2023 (equivalent to $2,387 million), with a stated growth of ≈27% and a precise 26.9% increase, matching the ground truth calculation. The additional detail of 27.5% operational growth is contextually consistent and does not contradict the overall growth figure. (2) The answer addresses both parts of the question: the sales evolution (increase from 2022 to 2023) and the market trajectory (robust upward trend). (3) Entities are correct—ERLEADA, the years 2022 and 2023, and the financial metric (sales) are all accurately referenced. (4) The reasoning is sound and enhances the ground truth by providing context (label expansions, market share gains in mCRPC), which supports the conclusion of accelerating adoption and strong market performance. These details are plausible and consistent with the upward trajectory. (5) Semantic equivalence is maintained: the core facts, numbers, and interpretation align perfectly with the original answer, with only minor, acceptable elaboration. All scores are maximized due to full factual accuracy, correct multi-hop synthesis, and relevant contextual enrichment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1184,
        "completion_tokens": 365,
        "total_tokens": 1550
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has the nature of CMCSA's relationship with local broadcast television stations evolved from 2023 to 2024, particularly in terms of competitive positioning and dependency for content distribution?",
      "original_answer": "In 2023, CMCSA's Media segment directly competed with local broadcast television stations for viewers' attention and advertising revenue. By 2024, the relationship shifted to a more interdependent one, where CMCSA's linear television networks became reliant on local broadcast television stations for retransmission consent, which is necessary for distributing broadcast network programming to video service customers. This marks a shift from competition to dependency, reflecting a strategic and operational evolution in how CMCSA interacts with local broadcast stations.",
      "llm_answer": "\nFrom 2023 to 2024 the company’s ties to local broadcast affiliates stayed centered on securing affiliation and retransmission‑consent agreements that are essential for delivering its broadcast‑network programming nationwide; any failure to obtain or renew these deals would shrink its audience reach and cut revenue.  At the same time, the competitive landscape intensified—local stations now compete with streaming services, OTT platforms and other content providers for both audience share and the rights to carry programming—so CMCSA’s positioning increasingly depends on negotiating favorable carriage terms and on the ability to offset rising programming‑cost pressures from those stations.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the shift in CMCSA's relationship with local broadcast television stations toward greater dependency on retransmission consent for content distribution, which aligns with the ground truth. It accurately notes the importance of affiliation and retransmission-consent agreements for delivering broadcast programming and the risk of audience and revenue loss if agreements are not renewed—key elements from the original answer. However, it omits the explicit contrast between 2023 and 2024: the original answer emphasizes that in 2023, CMCSA competed with local broadcast stations for viewers and ad revenue, while by 2024, the relationship evolved into dependency due to retransmission needs. This competitive-to-dependent shift is central to the question and is not clearly articulated in the LLM response. While the LLM mentions increased competition from streaming and OTT platforms, it frames the competition as coming from those platforms rather than highlighting the prior direct competition between CMCSA and local stations. There are no numerical values in the question or answer, so quantitative accuracy is not applicable—scored as 10 by default. The reasoning is logically sound and contextually relevant, but the failure to fully capture and synthesize the multi-hop evolution (competition in 2023 → dependency in 2024) reduces qualitative accuracy. The answer remains relevant and factually grounded in the dynamics of retransmission and content distribution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 412,
        "total_tokens": 1743
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How did the value of Held-to-Maturity (HTM) securities held by MA evolve between 2023 and 2024, and what does this shift indicate about the company's investment strategy?",
      "original_answer": "In 2023, MA held $306 million in HTM securities, but by 2024, this amount dropped significantly to $38 million. This indicates a major shift in MA's investment strategy, with a sharp reduction in long-term held securities, likely reflecting a move toward more liquid or short-term investment positions.",
      "llm_answer": "\nThe company’s Held‑to‑Maturity (HTM) securities fell sharply from **$306 million at the end of 2023** to only **$38 million at the end of 2024** – a decline of roughly **$268 million (≈ 88 %)**.  \n\nThis reduction shows that Mastercard deliberately unwound most of its short‑term, low‑yield time‑deposit holdings, freeing cash to support other strategic priorities such as growth initiatives, debt management, or longer‑duration investments, indicating a clear shift away from maintaining a large HTM portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the HTM values for MA in 2023 ($306 million) and 2024 ($38 million), matching the ground truth exactly. The calculated decline of $268 million and approximate 88% reduction are accurate and correctly derived. 2) Quantitatively, all numbers, dates, and calculations are correct. The drop from $306M to $38M is indeed a $268M decrease, which is approximately 87.6%, rounded reasonably to 88%. 3) The reasoning is largely sound: the sharp reduction in HTM securities is correctly interpreted as a strategic shift. However, the LLM incorrectly characterizes the HTM holdings as 'short-term, low-yield time-deposit holdings'—the original answer does not specify the nature of the securities, so this detail is an unsupported addition. This minor over-interpretation slightly affects qualitative accuracy. 4) The answer fully addresses both parts of the question: the quantitative change and its strategic implication. The conclusion about shifting away from a large HTM portfolio aligns semantically with the ground truth's interpretation of a move toward more liquid or short-term positions. Despite the minor speculative detail, the core facts, calculations, and overall interpretation are correct and relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1209,
        "completion_tokens": 348,
        "total_tokens": 1557
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has the positioning of the Always brand within Procter & Gamble's Baby, Feminine & Family Care segment evolved between 2022 and 2023, particularly in terms of its product categorization and associated sub-categories?",
      "original_answer": "In 2022, Always was categorized under Feminine Care within the Baby, Feminine & Family Care segment, which included sub-categories like Adult Incontinence and Feminine Care. By 2023, the brand remained part of the same reportable segment but was more specifically aligned with 'Menstrual Care' under the updated Feminine Care sub-category, reflecting a more targeted positioning. This evolution indicates a strategic shift in how Always is being categorized to emphasize its core focus area.",
      "llm_answer": "\nBetween 2022 and 2023 the Always brand stayed inside the **Baby, Feminine & Family Care** segment, but the way it is labeled within that segment was refined.  \n- In the 2022 filing the segment’s table lists a single “Feminine Care (Adult Incontinence, Feminine Care)” sub‑category and names **Always** (along with Tampax) as a major brand.  \n- In the 2023 filing the same sub‑category is renamed “Feminine Care (Adult Incontinence, Menstrual Care)”, still placing **Always** (and its adult‑incontinence extension, Always Discreet) there, while the broader “Family Care” sub‑category continues to cover paper‑towel and tissue brands.  \n\nThus, Always’s product categorization remained within the Feminine Care umbrella, with the 2023 update providing a clearer split between menstrual‑care and adult‑incontinence products under that same segment.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that Always remained within the Baby, Feminine & Family Care segment from 2022 to 2023 and accurately describes the reorganization of sub-categories. In 2022, Feminine Care included 'Adult Incontinence, Feminine Care', while in 2023 it was updated to 'Adult Incontinence, Menstrual Care', with Always specifically associated with Menstrual Care. The mention of Always Discreet as an adult incontinence extension adds contextual accuracy. (2) There are no numeric values requiring calculation, but the years (2022, 2023) and brand names (Always, Tampax, Always Discreet) are correct. (3) The multi-hop reasoning is sound—comparing the segment disclosures across two years and synthesizing changes in categorization. The LLM correctly infers that the rebranding of the sub-category reflects a more targeted positioning, even if it doesn't use the exact phrase 'strategic shift'. (4) The only minor shortcoming is that the LLM does not explicitly state that this change reflects a 'strategic shift' or 'more targeted positioning' as emphasized in the original answer, but the implication is clearly conveyed through the explanation of the sub-category refinement. Thus, the answer is semantically equivalent with only slight nuance missing, warranting a 9/10 on correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 386,
        "total_tokens": 1739
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has Oracle's positioning and financial contribution of Oracle Engineered Systems evolved between 2022 and 2023, particularly in terms of revenue recognition and strategic emphasis?",
      "original_answer": "In 2022, Oracle Engineered Systems were disclosed as part of hardware revenues, but no specific percentage of total revenue was provided. Revenue recognition for hardware products, including Engineered Systems, was described as occurring at the point in time when the product and related software were delivered. By 2023, Oracle explicitly stated that the hardware business, which includes Engineered Systems, represented 6% of total revenues in both fiscal 2023 and fiscal 2024, indicating a clearer and more consistent measurement of the product line's contribution. Additionally, in 2023, Oracle emphasized ongoing R&D investments to improve hardware offerings and introduced more detailed factors affecting hardware revenue predictability, such as manufacturing partner performance and competitive positioning against cloud infrastructure offerings. This reflects both quantitative and strategic evolution in how Oracle presents and manages the Engineered Systems product line.",
      "llm_answer": "\nOracle still records revenue from Engineered Systems and other hardware at the point‑in‑time when the product and its software are delivered, while hardware‑support contracts are recognized ratably over the support term.  The hardware segment’s contribution stayed roughly flat at about 6 % of total revenue in fiscal 2022 and fiscal 2023, but its strategic emphasis has receded as Oracle’s cloud‑and‑license business grew to 84 % of total revenue in fiscal 2024 (up from 83 % in fiscal 2023), signalling a shift toward cloud‑centric growth and a more modest, support‑driven role for Engineered Systems.  (Pages 72‑76 of the 2022 10‑K describe the hardware business and its revenue‑recognition model; pages 41‑45 of the 2023 10‑K show the 6 % revenue share and the rising cloud‑revenue proportion.)",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual error regarding the hardware segment's revenue contribution in fiscal 2022. The original answer (ground truth) states that no specific percentage of total revenue was provided for hardware (including Engineered Systems) in 2022, whereas the LLM claims it was 'roughly flat at about 6% in fiscal 2022 and fiscal 2023.' This is incorrect for 2022 and misrepresents Oracle's disclosures. The 6% figure is only confirmed for fiscal 2023 and 2024 in the 2023 10-K, not 2022. (2) The LLM correctly identifies the 6% revenue share in fiscal 2023 and the point-in-time revenue recognition for hardware products, which aligns with the ground truth. It also accurately references the shift toward cloud revenue (84% in fiscal 2024 vs 83% in 2023), though this is more context than direct answer to the question. (3) The reasoning is partially sound: the LLM correctly infers a strategic shift toward cloud and a reduced emphasis on hardware, which is consistent with the increased R&D and competitive positioning disclosures. However, it incorrectly assumes continuity in the 6% figure for 2022, failing the multi-hop requirement to compare what was disclosed in each year—specifically, that 2022 lacked a quantified percentage while 2023 introduced it. (4) Despite the major quantitative error, the answer captures the strategic evolution and revenue recognition model accurately, and it cites relevant sections of the 10-Ks. Hence, correctness is reduced to 6 due to the critical misstatement about 2022 revenue share, which undermines the quantitative accuracy (scored 5), while qualitative reasoning and contextual relevance remain strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1454,
        "completion_tokens": 462,
        "total_tokens": 1916
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has Comcast's relationship with representation firms evolved in terms of advertising sales strategy between 2023 and 2024?",
      "original_answer": "In 2023, Comcast worked with representation firms as an extension of its sales force to sell a portion of the advertising units allocated to them, recording revenue net of agency commissions. By 2024, Comcast had evolved this relationship into formal representation agreements under which they sell advertising on behalf of third parties, indicating a deeper strategic alignment and expanded role for these firms. This reflects a shift from a co-selling model to a more formalized representation structure.",
      "llm_answer": "\nComcast’s handling of representation firms in its ad‑sales model has not changed materially from 2023 to 2024 – in both years the company records advertising revenue on a gross basis and then offsets the fees paid to third‑party representation firms as a cost in “other operating and administrative expenses,” using those firms as an extension of its own sales force to sell a portion of the allocated ad inventory. The 2024 filing repeats the same description that appears in the 2023 filing, indicating a consistent strategy rather than a new evolution. (See 2023 CMCSA_10k_2023.pdf pages 73‑74 and 2024 CMCSA_10k_2024.pdf pages 72‑73 under “Advertising”.)",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that Comcast's relationship with representation firms did not change between 2023 and 2024, directly contradicting the ground truth. According to the original answer (ground truth), there was a strategic evolution: in 2023, Comcast used representation firms as an extension of its sales force, recording revenue net of agency commissions (implying net revenue recognition). By 2024, it shifted to formal representation agreements where it sells advertising on behalf of third parties, indicating a deeper strategic role. However, the LLM claims Comcast recorded revenue on a gross basis in both years and treated fees as operating expenses, which contradicts the 'net of agency commissions' revenue treatment described in the ground truth. This misrepresents the accounting treatment and the nature of the relationship. The LLM cites consistent language across filings as evidence of no change, but the ground truth indicates a qualitative shift in strategy and structure, suggesting the LLM may have relied on surface-level textual similarity without detecting strategic evolution. Quantitatively, no specific numbers are misstated (hence a score of 8), but the qualitative reasoning is flawed—the model fails to recognize the multi-hop nuance between revenue recognition method, agency relationship type, and strategic intent. The answer is contextually relevant to advertising sales strategy but fundamentally incorrect in its conclusion, hence a low correctness score of 2.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 419,
        "total_tokens": 1705
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has Oracle's approach to its industry-specific hardware offerings evolved between fiscal 2022 and fiscal 2023, particularly in terms of revenue recognition and strategic emphasis?",
      "original_answer": "In fiscal 2022, Oracle described its hardware business as including industry-specific hardware and recognized hardware revenues at the point in time when products and related software were delivered to customers. By fiscal 2023, Oracle introduced a more detailed explanation of revenue recognition for hardware, stating that revenues for combined performance obligations (hardware plus related software) are generally recognized at the point in time of delivery and ownership transfer. Additionally, in 2023, Oracle emphasized ongoing investments in R&D to improve existing hardware offerings and develop new products, signaling a more strategic focus on innovation in this area compared to 2022, where the description was more general and focused on the breadth of offerings.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2023 Oracle’s industry‑specific hardware business continued to record product sales at the point of delivery and to recognize hardware‑support revenue ratably over the contract term (see ORCL_10K_2022.pdf pp. 103‑107).  However, the FY 2023 filing shows a modest decline in hardware revenue (down from $3.36 bn to $3.18 bn) and a lower margin, and management explicitly describes hardware as a smaller, lower‑margin, and more volatile line that is now overseen mainly through indirect channels while the company shifts strategic focus toward expanding its cloud‑and‑license offerings (see ORCL_10K_2023.pdf pp. 41‑45).",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly notes that hardware revenue recognition occurs at delivery, it incorrectly frames Oracle's strategic direction as a shift away from hardware toward cloud, which contradicts the ground truth that Oracle increased strategic emphasis on hardware innovation in 2023 through R&D investments. The ground truth highlights a more detailed revenue recognition policy and enhanced strategic focus on hardware in 2023, whereas the LLM claims hardware is now a smaller, lower-margin business being deemphasized. (2) Quantitatively, the LLM introduces revenue figures ($3.36B to $3.18B) and margin decline not present in the original answer, which does not mention specific revenue amounts or trends. These numbers may be factually correct in context but are not part of the ground truth derived from the knowledge graph, and their inclusion misdirects the answer’s focus. (3) The multi-hop reasoning is flawed: the LLM fails to identify the evolution in revenue recognition language (from general to more detailed treatment of combined performance obligations) and misinterprets strategic emphasis, drawing an opposite conclusion from the evidence. (4) Contextual relevance is moderate because the answer addresses revenue recognition and strategy, but the conclusions are factually misaligned with the ground truth. The answer introduces external data and inferences not supported by the provided truth, leading to a low correctness score despite some structural relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1365,
        "completion_tokens": 427,
        "total_tokens": 1793
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How did the sales performance of IMBRUVICA (ibrutinib) evolve between 2022 and 2023, and what factors contributed to this change?",
      "original_answer": "IMBRUVICA sales decreased from $3.784 billion in 2022 to $3.264 billion in 2023, a decline of 13.7%. In 2022, the growth of IMBRUVICA was already being offset by competitive pressures from novel oral agents and market dynamics related to the pandemic, such as delays in new patient starts. By 2023, this downward trend continued, with the product experiencing a significant drop in sales, reflecting sustained competitive pressures and likely increased market saturation or treatment shifts in the oncology space.",
      "llm_answer": "\nIMBRUVICA (ibrutinib) sales fell sharply from $3.78 billion in 2022 to $3.26 billion in 2023, a decline of roughly 13‑14 %. The drop was attributed to heightened competitive pressure from newer oral therapies and COVID‑19‑related market dynamics—including delays in new‑patient starts—that limited growth despite the drug’s continued share leadership.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the sales decline of IMBRUVICA from $3.78 billion in 2022 to $3.26 billion in 2023, which aligns with the ground truth values of $3.784 billion and $3.264 billion (rounded appropriately). The calculated decline of 'roughly 13–14%' matches the actual 13.7% drop. 2) Quantitatively, all figures are accurate within acceptable rounding: $3.784B → $3.78B and $3.264B → $3.26B are standard approximations. The percentage decline is correctly characterized as ~13–14%, which is semantically equivalent to 13.7%. 3) The reasoning is sound: the LLM correctly attributes the sales decline to competitive pressures from newer oral therapies and pandemic-related delays in new patient starts, which are key factors mentioned in the original answer. It also notes the drug’s continued market leadership, a nuance consistent with the ground truth. However, the LLM does not explicitly mention the continuation of the downward trend into 2023 or factors like market saturation or treatment shifts in oncology, which slightly reduces completeness in qualitative synthesis. 4) The answer is contextually fully relevant, directly addressing both parts of the question—sales evolution and contributing factors—with accurate, concise, and well-synthesized information. Minor omission of 'sustained' nature of trend and 'market saturation' prevents a perfect 10, but overall fidelity is very high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1212,
        "completion_tokens": 390,
        "total_tokens": 1602
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has Comcast's involvement with Universal Beijing Resort evolved from 2023 to 2024 in terms of debt levels, ownership structure, and financial risk exposure?",
      "original_answer": "In 2023, Universal Beijing Resort had $3.5 billion of debt outstanding, including a $3.1 billion term loan, and was consolidated by Comcast, which owns a 30% interest. By 2024, the debt level slightly decreased to $3.4 billion, with the term loan principal reducing to $3.0 billion. Comcast continues to consolidate Universal Beijing Resort as a VIE, maintaining its 30% ownership stake. The maximum financial risk exposure for Comcast remains limited to its 30% equity interest, indicating a stable risk profile despite the slight reduction in debt. This evolution reflects a minor decrease in leverage but no change in ownership or governance structure.",
      "llm_answer": "\nFrom 2023 to 2024 Comcast’s ownership in Universal Beijing Resort remained essentially unchanged at about a 30 % equity interest, but the resort’s debt burden slipped modestly—from roughly $3.5 billion of outstanding borrowings in 2023 to about $3.4 billion by the end of 2024, reflecting scheduled repayments on its ¥29.7 billion RMB term‑loan. Because the resort is a consolidated variable‑interest entity with no direct guarantees or other liquidity commitments from Comcast, the company’s financial‑risk exposure is limited to its equity stake and the covenant‑compliant debt already recorded on its balance sheet.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) Quantitatively, the debt levels are correctly reported: $3.5 billion in 2023 and $3.4 billion in 2024, matching the original answer. The term loan reduction is implied through 'scheduled repayments' and aligns with the drop from $3.1B to $3.0B, though the exact term loan figure is not restated—this is a minor omission. The 30% ownership stake is correctly maintained. (2) The mention of a ¥29.7 billion RMB term loan introduces a detail not in the ground truth; while not incorrect per se (could be equivalent to ~$3.1B USD), it adds specificity not confirmed in the original and slightly deviates from the source's USD framing. (3) Qualitatively, the reasoning is sound: Comcast continues to consolidate the resort as a VIE, and financial risk is correctly limited to its equity interest, with no guarantees. This reflects proper multi-hop synthesis of ownership, consolidation, and risk exposure. (4) The answer addresses all three components of the question—debt levels (slight decrease), ownership (stable at 30%), and financial risk (unchanged, limited to equity). Only the absence of explicit mention of 'maximum financial risk exposure' and the exact term loan principal values prevents a perfect 10. Contextual relevance is excellent, focusing precisely on the evolution across the specified dimensions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 388,
        "total_tokens": 1710
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How did the financial commitment related to future lease payments for build-to-suit facilities and equipment evolve from 2022 to 2023, and what does this indicate about FedEx's leasing strategy?",
      "original_answer": "In 2022, FedEx disclosed future undiscounted payments of approximately $3.4 billion for build-to-suit facilities that had not yet commenced, with expected commencement dates from 2023 to 2024. By 2023, the company reported a significant reduction in these future commitments, with undiscounted payments dropping to approximately $0.9 billion for build-to-suit facilities and equipment, with commencement dates expected from 2025 to 2027. This indicates a strategic shift toward fewer long-term build-to-suit lease commitments and a more extended timeline for asset utilization.",
      "llm_answer": "\nFrom 2022 to 2023 the undiscounted future lease obligations for build‑to‑suit facilities and equipment fell sharply—from about **$3.4 billion** of commitments disclosed in the 2022 filing to roughly **$0.9 billion** in the 2023 filing.  This reduction reflects that many of those planned build‑to‑suit projects either began operating during the year (moving out of the “future‑payment” pipeline into recorded right‑of‑use assets) or were cancelled, signaling that FedEx is scaling back new build‑to‑suit leasing and relying more on existing lease arrangements and other financing sources.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the key financial figures: $3.4 billion in 2022 and $0.9 billion in 2023 for future undiscounted lease payments related to build-to-suit facilities and equipment, matching the ground truth exactly. The years and amounts are accurate, and the sharp reduction is correctly highlighted. 2) Quantitatively, all numbers are correct and properly contextualized. The format variation ($3.4 billion vs $3.4B) is acceptable and semantically equivalent. No calculations are required beyond comparison, which is accurately described. 3) The reasoning is sound: the LLM correctly infers that the drop likely reflects either project commencements (moving into right-of-use assets) or cancellations, which aligns with the implication in the original answer. It accurately captures the strategic shift toward fewer long-term build-to-suit commitments. However, it omits the updated timeline for commencement (2025–2027) mentioned in the 2023 filing, which adds context about extended asset utilization planning. This minor omission prevents a perfect qualitative score. 4) The answer is highly relevant, directly addressing both parts of the question—evolution of financial commitment and implications for leasing strategy. The conclusion about scaling back new commitments and relying more on existing leases is consistent with the ground truth. Overall, the answer is factually correct, well-reasoned, and only slightly less complete than the original due to missing the forward-looking commencement window.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 419,
        "total_tokens": 1723
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has Mastercard's relationship with Dynamic Yield LTD evolved between 2023 and 2024, and what does this indicate about the company's strategic focus during this period?",
      "original_answer": "In 2023, Mastercard disclosed that it had acquired Dynamic Yield LTD in April 2022 for $325 million, with $200 million of goodwill attributed to synergies expected after the acquisition. By 2024, the relationship is described as stable, with no new investments or acquisitions involving Dynamic Yield reported during the year. This indicates that the integration of Dynamic Yield was largely completed by 2023, and Mastercard shifted focus to newer acquisitions like Recorded Future in 2024, signaling a strategic pivot toward cybersecurity and threat intelligence.",
      "llm_answer": "\nMastercard finalized the purchase‑accounting for its 2022 acquisition of Dynamic Yield in 2023, recording $200 million of goodwill and integrating the target’s technology and intangible assets, thereby moving the relationship from a one‑time transaction to an integrated capability. By 2024 the company’s disclosures no longer treat Dynamic Yield as a separate acquisition but cite it as part of a broader push into data‑driven, high‑margin value‑added services—evidenced by later purchases such as Recorded Future—signaling that Mastercard’s strategic focus shifted toward leveraging AI‑enabled personalization and analytics to fuel growth.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that Mastercard acquired Dynamic Yield in 2022 and finalized purchase accounting in 2023, recording $200 million of goodwill, which matches the ground truth. There are no new investments or developments with Dynamic Yield in 2024, accurately reflecting a stable, post-integration phase. The strategic pivot toward cybersecurity is correctly inferred through the mention of Recorded Future as a later acquisition, aligning with the ground truth's indication of a shift in focus. (2) All numeric values—$200 million in goodwill and the implied 2022 acquisition—are factually correct. The original answer notes the total acquisition cost was $325 million, which the LLM omits, but this detail is not critical to the core question about the evolution of the relationship and strategic focus. The absence of the $325M figure is a minor omission, not a factual error. (3) The multi-hop reasoning is sound: the model connects the integration of Dynamic Yield in 2023 to the absence of new activity in 2024 and links this to newer acquisitions like Recorded Future, correctly inferring a strategic shift. The conclusion that Mastercard is focusing on data-driven, high-margin services and AI-enabled personalization is semantically consistent with the ground truth’s emphasis on cybersecurity and threat intelligence, though it generalizes slightly—the ground truth specifies cybersecurity as the new focus, while the LLM emphasizes AI/analytics. This is a nuanced difference but does not invalidate the overall accuracy. (4) The answer is highly relevant, directly addressing both the evolution of the relationship and the strategic implications. The scores reflect near-perfect factual accuracy, with only minor completeness gaps in financial details and slight generalization in strategic interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 500,
        "total_tokens": 1808
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has the Severance Plan for Senior Officers at Lowe's evolved between 2022 and 2024, particularly in terms of the most recent amendment dates and associated filings?",
      "original_answer": "In 2022, the Severance Plan for Senior Officers was described as 'amended and restated May 29, 2020' and was filed on August 26, 2020 (Exhibit 10.29). By 2024, the plan had been further amended and restated on May 26, 2022, with the updated version filed on November 27, 2024 (Exhibit 10.28). This indicates that Lowe's updated its Severance Plan for Senior Officers at least once between 2022 and 2024, with the most recent amendment occurring in mid-2022 and formally disclosed in late 2024.",
      "llm_answer": "\nThe Severance Plan for Senior Officers was last amended and restated on **May 26 2022** (identified as Exhibit 10.28). That amendment was filed in Lowe’s **2024 Form 10‑K on November 27 2024**, and the company’s filings from 2022 through 2024 do not disclose any later amendment to the plan. Consequently, the May 26 2022 revision remains the most recent update to the plan within the period covered.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and aligns perfectly with the ground truth. (1) All key facts are accurately reported: the most recent amendment date (May 26, 2022), the filing date (November 27, 2024), and the exhibit number (10.28) match the original answer. The prior version (amended May 29, 2020, filed August 26, 2020, as Exhibit 10.29) is implicitly acknowledged by correctly identifying the 2022 amendment as the next update. (2) Quantitative accuracy is perfect: dates and exhibit numbers are correct and properly associated. (3) The reasoning is sound—by noting no later amendments were disclosed between 2022 and 2024, the LLM correctly infers the May 26, 2022 amendment is the most recent, consistent with the multi-hop synthesis required. (4) The answer is contextually relevant, directly addressing the evolution of the plan, amendment dates, and associated filings. Though slightly more concise than the original, it preserves all critical information with semantic equivalence. No errors or omissions affect correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1229,
        "completion_tokens": 296,
        "total_tokens": 1525
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the fair value of Netflix's 6.375% Senior Notes change between December 31, 2021, and December 31, 2023, and what does this evolution indicate about market perceptions of the company's debt over this period?",
      "original_answer": "The fair value of Netflix's 6.375% Senior Notes increased from $999 million as of December 31, 2021, to $872 million as of December 31, 2023. This indicates a decrease in the fair value of the notes over the two-year period, suggesting a potential decline in market confidence or an increase in required yields for this debt instrument.",
      "llm_answer": "\nThe 6.375 % Senior Notes were quoted at a fair‑value of **$999 million on December 31 2021** (Level 2 market price) and fell to **$872 million on December 31 2023**.  That is a decline of roughly **$127 million (about 13 %)** over the two‑year span.  \n\nThe price drop shows that market participants were demanding a higher yield on Netflix’s debt—reflecting tighter credit conditions, rising interest‑rate expectations, and/or a perceived increase in the company’s credit risk—so the evolution signals a more cautious or less favorable view of the 6.375 % notes over the period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the fair value of Netflix's 6.375% Senior Notes as $999 million on December 31, 2021, and $872 million on December 31, 2023, matching the ground truth exactly. The calculated decline of $127 million (approximately 13%) is accurate: (999 - 872) = 127, and (127 / 999) ≈ 12.7%, which rounds to 13%. These values and calculations are factually correct.\n\n2) The answer addresses both parts of the question: the change in fair value and the interpretation of what this indicates about market perceptions. It correctly notes the decrease in fair value and links it to higher required yields, tighter credit conditions, rising interest rate expectations, and/or increased credit risk—consistent with the ground truth's implication of declining market confidence.\n\n3) All entities are accurate: Netflix, 6.375% Senior Notes, and the correct dates (December 31, 2021, and December 31, 2023) are used. The financial metric (fair value) is correctly applied.\n\n4) The reasoning is sound and reflects proper multi-hop synthesis: the model infers from the declining fair value that market participants demand higher yields, which aligns with standard bond pricing principles (inverse relationship between price and yield). The interpretation goes slightly beyond the ground truth by specifying possible macroeconomic and firm-specific factors (interest rate expectations, credit risk), but these are reasonable and contextually appropriate, not speculative.\n\n5) The only reason for not giving a perfect 10 is a minor wording issue: the ground truth states the fair value 'increased from $999M to $872M', which is a factual error (it decreased), but the LLM correctly interprets this as a decline. However, the LLM contradicts the ground truth’s erroneous 'increased' claim by accurately describing the change as a 'fall'—which is correct. Thus, the LLM is factually right where the ground truth appears to have a typo. This strengthens the LLM’s accuracy.\n\nOverall, the answer is quantitatively precise, contextually relevant, and qualitatively strong, with excellent multi-hop reasoning connecting price changes to market sentiment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1246,
        "completion_tokens": 578,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the sales performance of IMBRUVICA evolve between 2022 and 2023, and what does this indicate about its market position in the oncology segment?",
      "original_answer": "IMBRUVICA's sales decreased from $4,369 million in 2022 to $3,264 million in 2023, representing a decline of 25.2%. This indicates a weakening market position for IMBRUVICA within the oncology segment, especially as other products like DARZALEX and ERLEADA experienced significant growth during the same period.",
      "llm_answer": "\nIMBRUVICA’s revenue slipped 13.7 % year‑over‑year, falling from $3.78 billion in 2022 to $3.26 billion in 2023 (J&J 2023 10‑K, “Oncology” table).  The decline occurred even though the overall oncology franchise grew 10.5 % in 2023, highlighting that IMBRUVICA is losing market share to newer agents and heightened competitive pressure in the oncology segment.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. According to the ground truth, IMBRUVICA's sales were $4,369 million in 2022, not $3.78 billion as stated in the LLM answer. The 2023 figure of $3.26 billion is correct (matching $3,264 million). This leads to an incorrect year-over-year decline: the LLM reports a 13.7% drop based on $3.78B to $3.26B, but the actual decline is from $4,369M to $3,264M, which is a 25.2% drop. The calculation error is substantial and materially affects the interpretation of performance. (2) The entity names (IMBRUVICA, oncology segment) and years (2022–2023) are correct, and the reference to J&J’s 10-K is plausible. However, the revenue figures do not match the ground truth data, indicating either incorrect sourcing or misreading of the document. (3) The reasoning is partially sound: the LLM correctly infers that IMBRUVICA is losing market share amid overall oncology growth, which aligns with the ground truth’s implication of weakening market position due to competition from DARZALEX and ERLEADA. This shows appropriate multi-hop reasoning—comparing IMBRUVICA’s performance against broader segment trends. (4) While the qualitative insight about competitive pressure is relevant and contextually appropriate, the incorrect baseline revenue and miscalculated decline undermine the factual foundation. The answer would be more accurate if it used correct figures and reflected the steeper 25.2% decline, which strengthens the argument about market erosion. Thus, the correctness score is 5 due to partial factual accuracy and a major numerical error, despite reasonable logic and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1169,
        "completion_tokens": 454,
        "total_tokens": 1623
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did LOW's inventory shrink reserve and LCNRV reserve evolve between 2022 and 2024, and what were the implications for net earnings?",
      "original_answer": "Between 2022 and 2024, LOW's inventory shrink reserve increased from $414 million to $427 million, while the LCNRV reserve increased from $168 million to $222 million. In 2024, a 10% change in either the amount of inventory subject to markdown or the weighted average estimated loss rate used in the LCNRV reserve calculation would have affected net earnings by approximately $17 million, and a 10% change in the estimated shrinkage rate would have impacted net earnings by approximately $32 million. These changes indicate a growing need for reserves, particularly for shrinkage, and highlight the increasing sensitivity of net earnings to inventory valuation assumptions.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2024 the inventory‑shrink reserve grew from roughly **$414 million to $427 million** (an increase of about $13 million), reflecting higher estimated shrinkage losses that would modestly drag down net earnings; a 10 % change in that reserve would have altered earnings by roughly **$32 million** in 2024.  Conversely, the LCNRV (lower‑of‑cost‑or‑net‑realizable‑value) reserve fell from **$168 million at the end of 2022 to $222 million at the end of 2024**, a decline of about $23 million that reduced the reserve and therefore **added roughly $17 million to net earnings** (the amount a 10 % shift would affect earnings).  In sum, the rising shrink reserve slightly pressured profitability, while the shrinking LCNRV reserve provided a modest earnings boost.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a critical factual error in describing the LCNRV reserve trend: it incorrectly states that the LCNRV reserve 'fell from $168 million to $222 million', when in fact it increased from $168 million to $222 million. This misrepresents the direction of change and leads to an incorrect conclusion that the reserve reduction 'added roughly $17 million to net earnings'. In reality, an increase in the LCNRV reserve would put downward pressure on earnings, not boost them. The shrink reserve evolution is correctly reported ($414M to $427M), as is the $32 million earnings sensitivity to a 10% change in shrinkage. The $17 million sensitivity to LCNRV assumptions is correctly cited, but the interpretation is flawed due to the directional error. (2) Quantitative accuracy is partially correct: all dollar amounts are accurate ($414M, $427M, $168M, $222M, $32M, $17M), and the $13M increase in shrink reserve is correctly implied. However, the claim of a '$23 million decline' in LCNRV is wrong—it was an increase of $54 million. (3) Multi-hop reasoning is partially sound: the model connects inventory reserves to earnings impact correctly in structure, but the flawed directional logic for LCNRV undermines the synthesis. It fails to recognize that increasing reserves (both shrink and LCNRV) generally reduce net earnings, not increase them. (4) Contextual relevance is high—the answer addresses both reserves and earnings implications as asked, and uses appropriate financial logic, but the core conclusion is misleading due to the reversed LCNRV trend. Correctness score is 4 due to major factual and interpretive errors despite correct citation of numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 462,
        "total_tokens": 1825
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did Qulipta's status and financial contribution evolve from 2022 to 2023, particularly in terms of its development and commercialization progress?",
      "original_answer": "In 2022, Qulipta was among the products that contributed to the reclassification of $1.0 billion of indefinite-lived research and development intangible assets to developed product rights upon receiving regulatory approvals. By 2023, Qulipta had transitioned from development to commercialization, generating $405 million in revenue in the United States and $3 million internationally, indicating a significant shift from a developmental asset to a revenue-generating product.",
      "llm_answer": "\nFrom 2022 to 2023 Qulipta moved from a pre‑launch product with essentially no sales (no revenue reported in 2021) to modest U.S. sales of about **$158 million in 2022**, and then to **$405 million in U.S. net revenue in 2023** (with additional early international sales emerging in the same year).  This jump was driven by regulatory milestones: the FDA approved Qulipta for the preventive treatment of chronic migraine in adults in **April 2023**, and the European Commission followed with approval of “Aquipta” (the same Qulipta formulation) in **August 2023**, enabling the company to launch the drug in the EU and generate its first international revenue.  Consequently, Qulipta’s contribution to AbbVie’s neuroscience portfolio grew more than **100 %** year‑over‑year, underscoring its transition from a pipeline asset to a commercially‑launched, revenue‑generating product.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness, despite capturing the general narrative of Qulipta's transition from development to commercialization. (1) Quantitative Accuracy: The LLM incorrectly states that Qulipta generated $158 million in U.S. sales in 2022, which contradicts the ground truth that makes no mention of 2022 revenue and instead highlights a $1.0 billion reclassification of R&D assets upon regulatory approval. More critically, the FDA approval date is wrong — Qulipta was approved by the FDA in **September 2021**, not April 2023. The European Commission approval in August 2023 for 'Aquipta' is factually correct and aligns with the international launch. However, the claim of 100%+ year-over-year growth is unsupported by the ground truth, which does not provide 2022 revenue for comparison. (2) The ground truth emphasizes that in 2022, Qulipta's key milestone was the accounting reclassification of intangible assets, not sales generation. The LLM omits this entirely and instead fabricates 2022 revenue, misrepresenting its 2022 status. (3) Qualitative Accuracy: While the model correctly identifies the shift from development to commercialization and notes international expansion, it fails to mention the critical 2022 accounting event (reclassification of $1.0 billion in R&D assets), which is central to Qulipta’s 2022 status per the original answer. This omission breaks the multi-hop synthesis required between 2022 regulatory/accounting impact and 2023 revenue performance. (4) Contextual Relevance is high because the answer addresses the evolution of Qulipta’s status and financial contribution, discusses U.S. and international revenue, and attempts to explain regulatory drivers. However, due to major factual errors in dates and financial figures, the correctness score is limited to 5 — partially correct but with significant inaccuracies affecting reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 521,
        "total_tokens": 1861
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How has Honeywell's financial dependency on the Resideo subsidiary for environmental liabilities evolved between 2022 and 2023, and what does this indicate about the company's risk exposure?",
      "original_answer": "Honeywell's financial dependency on the Resideo subsidiary for environmental liabilities remained consistent between 2022 and 2023, with Resideo's subsidiary still obligated to pay 90% of Honeywell's annual net spending on environmental matters at specified sites, up to a maximum of $140 million per year. This ongoing arrangement indicates that Honeywell continues to rely on Resideo's payments to offset a significant portion of its environmental costs, suggesting that the risk mitigation strategy through this indemnification agreement has not changed over the two years.",
      "llm_answer": "\nBetween 2022 and 2023 Honeywell’s annual cash reimbursement from the Resideo‑owned subsidiary remained fixed at **$140 million**, but the **recorded receivable for the 90 % reimbursement grew from about $157 million (2022) to $187 million (2023)**. This shows that while the cash inflow is capped, the portion of environmental spending that Honeywell expects to recover is rising, leaving a larger share of net liabilities uncovered once the $140 million cap is reached. Consequently, the company’s **risk exposure to unreimbursed environmental costs is increasing**.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that Resideo's subsidiary is obligated to pay 90% of Honeywell's annual net spending on environmental matters, up to a maximum of $140 million per year, and this arrangement remained consistent between 2022 and 2023. However, the LLM claims the recorded receivable grew from $157M to $187M, implying increasing expected recoveries and rising risk exposure—information not present in the original answer and unsupported by the provided truth. There is no mention of a growing receivable or increasing environmental spending in the ground truth. (2) The quantitative inaccuracies are severe: the $157M and $187M figures are fabricated; the original answer does not provide any receivable balances for either year. While the $140M cap is correctly referenced, the LLM misrepresents it as actual annual cash reimbursement, whereas the original specifies it as a maximum liability coverage, not guaranteed cash inflow. (3) The multi-hop reasoning is flawed. The LLM infers increasing risk exposure due to a growing gap between spending and the cap, but the original answer explicitly states the arrangement and risk mitigation strategy 'has not changed' over the two years. This contradicts the LLM's conclusion. The model fails to recognize that consistency in the indemnification terms implies stable risk exposure. (4) Despite addressing the right entities (Honeywell, Resideo, environmental liabilities) and time frame (2022–2023), the LLM introduces false data and incorrect conclusions, leading to a low correctness score. The contextual relevance is moderate because the answer attempts the right topic and structure, but factual divergence undermines validity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 478,
        "total_tokens": 1775
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How has Target's definition or treatment of 'original maturity' for cash equivalents evolved between 2022 and 2024, and what does this indicate about potential changes in their cash management strategy?",
      "original_answer": "In 2022, Target defined cash equivalents as highly liquid investments with an original maturity of three months or less, with no additional context or clarification. By 2024, the company maintained the same three-month threshold for original maturity but added a broader discussion around fair value measurements for other short-term assets and liabilities, suggesting a more comprehensive approach to short-term financial instruments. This evolution indicates a potential refinement in how Target evaluates and manages its cash and near-cash assets within a broader financial framework.",
      "llm_answer": "\nTarget has kept the same definition of cash equivalents – highly liquid investments that mature in three months or less from the date of purchase – through both the 2022 and 2024 Form 10‑K filings.  What has changed is the size of that bucket: cash‑equivalent balances fell from about **$5.9 billion in 2022** to roughly **$4.8 billion in 2024**, driven by a smaller portfolio of short‑term investments and a tighter roll‑forward of receivables.  This contraction suggests Target is being more conservative with its short‑term liquidity, possibly to guard against higher interest‑rate volatility or to re‑allocate cash toward other uses.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect in both factual content and reasoning. (1) The original answer states that Target maintained the same definition of 'original maturity' (three months or less) from 2022 to 2024 and added more discussion around fair value measurements in 2024, indicating a refinement in financial reporting. The LLM instead claims that the definition remained unchanged—which is correct—but then introduces financial data (cash-equivalent balances of $5.9B in 2022 and $4.8B in 2024) that are not present in the ground truth and were not part of the question. These numbers are unverified and appear fabricated. (2) The quantitative accuracy is very low because the dollar amounts and portfolio changes (e.g., 'tighter roll-forward of receivables') are not supported by the original answer and introduce false specifics. (3) The qualitative reasoning is flawed: the original answer points to an evolution in disclosure and framing (more comprehensive fair value discussion), while the LLM incorrectly infers a strategic shift based on unsupported balance changes. The LLM fails to identify the actual evolution—enhanced disclosure context in 2024—and instead invents a narrative around cash balance trends. (4) Contextual relevance is moderate because the answer addresses the definition correctly and attempts to discuss strategy, but it misses the core point about disclosure maturity and fair value context, focusing instead on irrelevant balance fluctuations. The multi-hop synthesis is incorrect: the model should have compared the qualitative depth of disclosures across years, not invented numerical trends.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 444,
        "total_tokens": 1764
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the valuation and classification of NVDA's 3.50% Notes Due 2040 evolve between 2023 and 2024, and what does this indicate about the company's long-term debt strategy?",
      "original_answer": "In 2023, the 3.50% Notes Due 2040 were listed under liabilities with a carrying value of $851 million as of January 28, 2024, and were categorized as Level 2 in the pricing hierarchy. By 2024, the valuation of the same notes increased to $1,000 million as of January 26, 2025, with a more detailed breakdown including an effective interest rate of 3.54% and a remaining term of 15.2 years. This indicates a strategic emphasis on long-term financing with stable interest rate structures.",
      "llm_answer": "\nBetween fiscal‑year 2023 (January 29 2023) and fiscal‑year 2024 (January 28 2024) NVIDIA’s 3.50 % Notes Due 2040 stayed in the Level 2 tier of the fair‑value hierarchy, but their reported fair value slipped modestly from **$870 million** to **$851 million**, reflecting the impact of higher market interest rates on the bond’s price. The securities continued to be carried at amortized cost (net of discount and issuance costs) and, as disclosed in Note 10, have a remaining maturity of about 15 years, underscoring the company’s strategy of financing its long‑term growth through stable, senior unsecured debt rather than short‑term borrowings.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. According to the ground truth, in 2023 the carrying value was $851 million as of January 28, 2024, not $870 million as stated by the LLM. The LLM incorrectly claims the value 'slipped' from $870M to $851M, implying a decrease, but the ground truth shows an increase from $851M in 2023 (as of Jan 2024) to $1,000M in 2024 (as of Jan 2025). This is a critical error in both direction and magnitude. Additionally, the LLM fails to mention the updated effective interest rate of 3.54% and the precise remaining term of 15.2 years reported in 2024, which are key details in the original answer. (2) The dates referenced are partially correct—fiscal years ending January 28, 2024 (2023) and January 26, 2025 (2024)—but the LLM mislabels them as 'fiscal-year 2023 (January 29 2023)' which is inconsistent with the reporting date of the 2023 data (which corresponds to Jan 28, 2024). (3) The qualitative reasoning about NVIDIA’s long-term debt strategy is sound and aligns with the ground truth—emphasizing stable senior unsecured debt for long-term financing—but this conclusion is based on flawed data, weakening the multi-hop synthesis. The classification as Level 2 is correctly maintained across years, which is accurate. (4) The contextual relevance is high because the answer addresses both valuation evolution and strategic implications. However, due to major numerical errors and omission of updated valuation and interest rate details, the correctness score is limited to 5. Quantitative accuracy is low (4) due to wrong values and incorrect trend interpretation. Qualitative accuracy is moderate (6) because reasoning and entity identification (NVDA, notes due 2040, Level 2) are correct, but missing key synthesized metrics. Contextual relevance is strong (9) as all question components are addressed in intent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 512,
        "total_tokens": 1802
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the financial performance of Venclexta evolve between 2022 and 2023, particularly in terms of total global revenue and the growth rate?",
      "original_answer": "In 2022, Venclexta generated a total global revenue of $2,009 million, with a growth rate of 10.4%. In 2023, the total global revenue from Venclexta increased to $2,288 million, representing a growth rate of 13.9%. This indicates an upward trend in both absolute revenue and growth rate year-over-year.",
      "llm_answer": "\nVenclexta’s worldwide net sales rose from **$2.01 billion in 2022 to $2.29 billion in 2023**, representing an increase of roughly **14 %–15 %** year‑over‑year.  The growth was driven by a modest 7.8 % rise in U.S. sales (to $1.09 bn) and a stronger 20 %‑plus increase abroad (to $1.20 bn), pushing total global revenue up by about **14 %** between 2022 and 2023.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is mostly correct but contains minor inaccuracies in the reported revenue figures and growth rate. The ground truth states that Venclexta generated $2,009 million (i.e., $2.009 billion) in 2022 and $2,288 million ($2.288 billion) in 2023, representing a growth rate of 13.9% in 2023. The LLM rounds these to $2.01 billion and $2.29 billion, which is acceptable in format but slightly over-rounds the 2023 figure (closer to $2.29B than $2.288B, but within tolerance). However, the calculated growth rate in the LLM answer is stated as 'roughly 14%–15%' and later 'about 14%', while the exact growth rate from $2,009M to $2,288M is (2,288 - 2,009)/2,009 = 13.89%, which rounds to 13.9% — the precise figure in the original answer. Reporting it as '14%' is a minor overstatement but common in rounding. (2) The breakdown into U.S. and international sales ($1.09B and $1.20B) is not part of the original answer and cannot be verified from the provided ground truth, suggesting potential hallucination or use of external data; however, since the question did not ask for this breakdown, it does not invalidate the response but adds unverified detail. (3) The multi-hop reasoning is sound in comparing two years of revenue and deriving a growth trend. The core metrics — increasing revenue and accelerating growth rate (from 10.4% in 2022 to 13.9% in 2023) — are correctly reflected in spirit, though the LLM does not explicitly mention the 2022 growth rate, omitting one part of the original answer. (4) Despite minor numerical approximations and omission of the prior-year growth rate, the LLM captures the upward trend in both absolute revenue and growth rate, fulfilling the intent of the question. Hence, the correctness score is 8 due to slight inaccuracies in precision and omission of one data point, but high marks for qualitative reasoning and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1165,
        "completion_tokens": 511,
        "total_tokens": 1676
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How has Netflix's approach to executive severance and retention incentives evolved between the 2022 and 2023 SEC filings, particularly in terms of plan amendments and their effective dates?",
      "original_answer": "In 2022, the filing referenced the 'Amended and Restated Executive Severance and Retention Incentive Plan' with a filing date of September 10, 2021, indicating that the plan had undergone revisions by that date. By 2023, the filing showed further evolution, introducing the 'Executive Severance and Retention Incentive Plan as Amended and Restated effective January 1, 2024,' with a filing date of December 8, 2023. This demonstrates Netflix’s ongoing adjustments to executive compensation frameworks, with a forward-looking amendment effective in 2024.",
      "llm_answer": "\nIn the 2022 Form 10‑K Netflix disclosed its **Amended and Restated Executive Severance and Retention Incentive Plan**, which had been adopted on **September 10 2021** (the plan’s effective date).  \nThe 2023 filing shows that this plan was **amended and restated again**, with the amendment becoming **effective on January 1 2024** and filed on **December 8 2023**, updating the severance and retention provisions.  \nSeparately, the company also adopted an **Amended and Restated Performance Bonus Plan** in **December 2022**, further refining its executive incentive structure.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the 2022 filing references the 'Amended and Restated Executive Severance and Retention Incentive Plan' effective September 10, 2021, and the 2023 filing introduces a further amendment effective January 1, 2024, filed on December 8, 2023—dates and events match exactly. (2) Quantitative accuracy is perfect: all dates (September 10, 2021; December 8, 2023; January 1, 2024) are correctly reported with no errors. (3) The multi-hop reasoning is sound—comparing the 2022 and 2023 filings to show evolution in the plan is well executed. (4) The only minor issue is the mention of the 'Amended and Restated Performance Bonus Plan' adopted in December 2022, which, while potentially true, is not part of the original answer’s scope and slightly diverges from the specific focus on the Severance and Retention Incentive Plan. However, it does not contradict any facts and adds context about executive incentives broadly. Thus, the answer is factually correct and comprehensive, warranting a 9/10 for correctness and qualitative accuracy due to the slight expansion beyond the core topic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 333,
        "total_tokens": 1626
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did Lowe's documentation and structure of its Benefit Restoration Plan evolve from 2022 to 2024, and what does this indicate about the company's approach to employee retirement benefits?",
      "original_answer": "In 2022, Lowe's maintained the Benefit Restoration Plan as part of its defined contribution retirement offerings, supplementing benefits under the 401(k) Plan for employees affected by IRS limitations. The plan included both employee salary deferrals and employer contributions in the form of a Company Match. By 2024, the company formally introduced an updated and restated version of the Benefit Restoration Plan, effective January 1, 2025, as evidenced by the new exhibit filing (10.3) in the 2024 10-K. This indicates a deliberate effort to formalize and likely enhance the structure of the plan, signaling a more strategic and forward-looking approach to managing executive and high-earner compensation through improved documentation and alignment with long-term benefit policies.",
      "llm_answer": "\nFrom 2022 to 2024 Lowe’s moved from a brief, generic description of the Benefit Restoration Plan in the 2022 10‑K (Note 12) to a formally **amended and restated plan** disclosed in the 2024 filing (Exhibit 10.3, “Lowe’s Companies Benefit Restoration Plan, as amended and restated as of January 1 2025”).  The 2024 exhibit adds detailed provisions on eligibility, matching formulas, contribution limits and vesting schedules that were not spelled out in the earlier filing, indicating that the company has **updated and clarified the plan’s structure**—likely to reflect regulatory changes, improve fiscal efficiency, and keep the benefit package competitive.  This evolution shows that Lowe’s is proactively refining its retirement‑benefit framework to attract and retain employees while maintaining compliance and fiscal discipline.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the evolution from a generic description in the 2022 10-K (Note 12) to a formally amended and restated plan in the 2024 10-K (Exhibit 10.3), effective January 1, 2025, is correctly identified. The date and exhibit number match the ground truth. (2) There are no numeric values requiring calculation, but the dates (2022, 2024, and effective January 1, 2025) are accurately reported. (3) The multi-hop reasoning is sound—comparing the level of detail between the 2022 and 2024 disclosures shows synthesis across filings. The LLM correctly infers that increased documentation (eligibility, matching formulas, vesting) indicates a more structured and strategic approach. (4) The LLM adds slight interpretive depth (e.g., 'fiscal efficiency', 'competitive benefit package') not explicitly in the ground truth, but these are reasonable inferences and do not contradict it. The only minor gap is that the ground truth emphasizes the plan’s role in supplementing high-earners/executives and alignment with long-term policy, which the LLM implies but doesn’t explicitly state. Overall, the answer is factually correct, contextually relevant, and semantically equivalent with excellent qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1415,
        "completion_tokens": 363,
        "total_tokens": 1778
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did NVDA's financial obligations related to the 0.584% Notes Due 2024 evolve between fiscal years 2023 and 2024?",
      "original_answer": "In fiscal year 2023, NVDA reported a liability of $1,185 million for the 0.584% Notes Due 2024. By fiscal year 2024, this obligation was fully repaid, as stated in the 2024 10-K filing. This indicates a complete resolution of this specific debt obligation over the two-year period.",
      "llm_answer": "\nBetween fiscal 2023 (ended January 29 2023) and fiscal 2024 (ended January 28 2024) NVIDIA’s 0.584% Notes Due 2024 remained outstanding but their market‑value estimate rose modestly—from roughly **$1.185 billion** to **$1.228 billion**, an increase of about **$43 million**.  The notes continued to be carried on the balance sheet throughout FY 2024; they were fully repaid in the following fiscal year (FY 2025), as indicated in the 2025 disclosures.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors. While it correctly identifies the $1.185 billion liability in fiscal 2023 (matching the ground truth), it incorrectly states that the liability increased to $1.228 billion in fiscal 2024 and remained outstanding. The ground truth explicitly states that the obligation was fully repaid by fiscal year 2024, as per the 2024 10-K. The LLM incorrectly claims repayment occurred in FY 2025 based on '2025 disclosures,' which is not supported by the original answer and contradicts the provided truth. (2) Quantitative accuracy is partially correct for the 2023 figure ($1.185 billion), but the $1.228 billion figure for 2024 is incorrect—no increase occurred, and the debt was extinguished. The $43 million increase is therefore factually wrong. (3) The multi-hop reasoning fails: the model should have synthesized that the debt was present in FY2023 and fully resolved in FY2024, but instead it extends the timeline incorrectly to FY2025 and misrepresents the evolution. (4) Contextual relevance is moderate because the answer addresses the right financial instrument and time frame, but the core conclusion about the debt's status is incorrect, severely undermining the response. The answer misrepresents the key event—repayment timing—making it largely inaccurate despite some correct initial data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1175,
        "completion_tokens": 379,
        "total_tokens": 1555
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did the global revenue performance of Mavyret evolve between 2022 and 2023, and what were the trends in its United States and international markets during this period?",
      "original_answer": "In 2022, Mavyret generated total global revenue of $1,541 million, with $755 million from the United States and $786 million from international markets. By 2023, total revenue from Mavyret decreased to $1,430 million, driven by a decline in both U.S. and international markets. Specifically, U.S. revenue dropped to $659 million, a decrease of 12.7%, while international revenue slightly declined to $771 million, a marginal decrease of 1.9%. This indicates a contraction in Mavyret's market performance across both regions, with a more pronounced decline in the U.S. market.",
      "llm_answer": "\nBetween 2022 and 2023 worldwide sales of Mavyret fell about 12–13 %, declining to roughly $1.43 billion in total. In the United States sales dropped 12.7 % (from $755 M to $659 M), whereas internationally they slipped only ~2 % in nominal terms (from $786 M to $771 M) but were essentially flat when adjusted for constant‑currency effects (a modest ~1 % increase).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key financial figures from the ground truth: 2022 U.S. revenue ($755M), 2023 U.S. revenue ($659M), 2022 international revenue ($786M), 2023 international revenue ($771M), and total 2023 revenue ($1.43 billion). The percentage declines (12.7% in the U.S., ~2% internationally) are accurate. The total global revenue drop of 12–13% is consistent with the actual decline from $1,541M to $1,430M (a 7.2% drop), though this specific percentage is not in the original answer; however, the LLM may be referring to U.S. decline or mischaracterizing the total drop, which is a minor inaccuracy. (2) All numeric values match the ground truth exactly, with acceptable format variations (e.g., $1.43 billion = $1,430 million). Calculations for percentage changes are correct: (755 - 659)/755 ≈ 12.7%, (786 - 771)/786 ≈ 1.9% ≈ 2%. (3) The multi-hop reasoning is sound—LLM synthesizes U.S. and international figures to describe global trends and correctly identifies the more pronounced U.S. decline. The addition of 'constant-currency effects' and a 'modest ~1% increase' internationally is extra information not present in the ground truth; while plausible and potentially from external knowledge, it introduces unverified context. However, it does not contradict the core facts. (4) The answer is highly relevant, addressing all parts of the question: global performance, U.S. and international trends. The only minor issues are the slightly overstated global decline percentage and the introduction of currency-adjusted data not in the source. Overall, factual accuracy is excellent, with only slight overinterpretation in qualitative reasoning, warranting a 9/10 on correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1241,
        "completion_tokens": 469,
        "total_tokens": 1710
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How did Netflix's compliance with covenant limitations related to its Senior Notes evolve between 2022 and 2024, particularly in terms of repayment obligations and the scope of restrictions?",
      "original_answer": "In 2022, Netflix was in compliance with all covenant limitations tied to its Senior Notes, which included restrictions on creating liens, entering into sale and lease-back transactions, incurring additional indebtedness by certain subsidiaries, and merging or transferring substantial assets. These notes included various euro-denominated tranches with principal amounts totaling €5,170 million. By 2024, Netflix remained in compliance with these covenants, but the scope of limitations had slightly evolved—specifically, certain Senior Notes no longer referenced restrictions on sale and lease-back transactions, suggesting a narrowing of covenant scope for some notes. Additionally, in 2024, Netflix repaid $400 million of its 5.750% Senior Notes upon maturity, indicating active debt management and a shift in its debt composition.",
      "llm_answer": "\nBetween 2022 and 2024 Netflix remained in full compliance with the covenants governing its senior unsecured notes, but the nature and scope of those covenants evolved.  In 2024 the company replaced its prior $1 billion revolving facility with a new $3 billion, five‑year agreement that added a quantitative covenant requiring a minimum consolidated EBITDA‑to‑interest‑expense ratio of 3.0 to 1.0 and reinforced existing negative covenants on subsidiary indebtedness, sale‑leaseback transactions, and mergers—covenants that had previously applied only to the outstanding notes.  While the 2024 repayment of the $400 million 5.750 % senior note marked the first major note maturity in that period, the company continued to satisfy all change‑of‑control repayment triggers, lien restrictions, and other covenants governing its senior debt, with no reported breaches.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) It incorrectly states that Netflix replaced a $1 billion revolving facility with a $3 billion facility in 2024, introducing a new quantitative covenant (EBITDA-to-interest ratio of 3.0 to 1.0). This is not supported by the ground truth and introduces financial instruments (revolving facility) and covenants not mentioned in the original answer. (2) The ground truth notes that by 2024, certain Senior Notes had *narrowed* in scope—specifically, some no longer included restrictions on sale and lease-back transactions—indicating a relaxation, not reinforcement, of covenants. The LLM incorrectly claims that such covenants were reinforced and expanded. (3) While the LLM correctly identifies the $400 million repayment of the 5.750% Senior Notes in 2024, it mischaracterizes it as the 'first major note maturity,' which is not confirmed in the ground truth. (4) The original answer emphasizes that covenant compliance continued but the *scope of restrictions evolved by narrowing*, whereas the LLM suggests the opposite—increased restrictions and new covenants—demonstrating flawed multi-hop reasoning. (5) The ground truth focuses on euro-denominated tranches totaling €5,170 million, a detail entirely omitted in the LLM response. Overall, while the answer is contextually relevant and correctly notes ongoing compliance and the $400M repayment, it fabricates key financial arrangements and misrepresents the evolution of covenants, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1435,
        "completion_tokens": 427,
        "total_tokens": 1862
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How did Honeywell's approach to the Safety and Retail product line evolve between 2022 and 2023, and what structural change was introduced in 2023 that reflects this evolution?",
      "original_answer": "In 2022, Honeywell reported the Safety and Retail business unit as a standalone component under the Safety and Productivity Solutions segment, generating $2,387 million in revenue. By 2023, the company had realigned its organizational structure, merging the Safety and Retail unit with the Advanced Sensing Technologies unit to form a new business unit called Sensing and Safety Technologies. This structural change, introduced in July 2022 but reported in the 2023 filing, reflects a strategic shift toward integrating sensing capabilities with safety solutions to enhance technological offerings and streamline operations.",
      "llm_answer": "\nBetween 2022 and 2023 Honeywell moved away from treating “Safety and Retail” as a separate business unit and instead combined it with its Advanced Sensing Technologies group to create a single “Sensing and Safety Technologies” line‑up within the Safety and Productivity Solutions segment.  The 2023 restructuring—documented in the 2022 notes (realignment disclosed on page 66) and reflected in the 2023 revenue tables (page 67)—re‑organized the former Safety and Retail unit into this new sub‑segment, signaling a strategic shift to integrate safety‑related and sensing products under one reporting line.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) It correctly identifies that Honeywell merged the Safety and Retail unit with Advanced Sensing Technologies to form Sensing and Safety Technologies, reflecting the strategic evolution. (2) Quantitatively, the LLM does not include the $2,387 million revenue figure from 2022, which is present in the original answer—this is a minor omission but not a factual error. The mention of the July 2022 realignment being disclosed in 2022 notes and reflected in 2023 reporting aligns with the timeline, though the exact month (July) is omitted in the LLM answer—this is a small detail but does not undermine correctness. (3) The reasoning is sound: it correctly synthesizes the structural change and its implications across years and units, demonstrating proper multi-hop understanding (from 2022 structure to 2023 change, including documentation timing). (4) Semantic equivalence is strong—wording differs but meaning matches. The LLM references page numbers (66, 67), which may be filing-specific details not in the ground truth, but they do not contradict it. Overall, the answer is factually correct, contextually relevant, and only slightly less complete due to missing the exact revenue figure. Hence, a 9/10 for correctness, with high scores in all categories.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 375,
        "total_tokens": 1689
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has the status and role of Class B-2 Common Stock evolved between 2023 and 2024, particularly in terms of its convertibility and impact on corporate governance?",
      "original_answer": "In 2023, Class B-2 Common Stock was described as part of a structure that would become convertible into Class A Common Stock, with potential dilutive effects on voting power and market price. It also played a role in approving significant corporate actions, indicating a governance influence. By 2024, no shares of Class B-2 Common Stock were outstanding prior to the Class B-1 Common Stock exchange offer, suggesting a strategic shift in equity structure. This indicates a transformation in the role of Class B-2 Common Stock, moving from an active governance and conversion position to a non-outstanding status, reducing its influence on corporate decisions.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 the Class B‑2 common shares went from “non‑existent” to a convertible class that can be exchanged into Class A common stock under Visa’s U.S. and Europe retrospective‑responsibility plans; the conversion is scheduled to be completed no later than 2028 (subject to a hold‑back for pending claims).  This conversion increases the total number of Class A shares outstanding, dilutes the voting power of existing Class A holders, and gives Class B‑2 (and B‑1) shareholders limited voting rights on certain corporate actions—meaning the evolution of Class B‑2 directly reshapes Visa’s capital structure and governance dynamics.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth in multiple critical aspects. (1) The claim that Class B-2 Common Stock went from 'non-existent' in 2023 to convertible in 2024 is false: the original answer states that Class B-2 was active in 2023 and had convertibility features, but by 2024, no shares were outstanding—indicating a phase-out, not an introduction. The LLM reverses the timeline and status. (2) The mention of 'Visa’s U.S. and Europe retrospective-responsibility plans' and a conversion scheduled for completion by 2028 is unsupported by the ground truth and introduces fabricated programs and dates. The original answer does not mention Visa, any such plans, or a 2028 timeline. (3) The LLM incorrectly attributes limited voting rights to Class B-2 (and B-1) shareholders as a new development, while the ground truth indicates that in 2023, Class B-2 already had governance influence, which was eliminated by 2024 due to no shares being outstanding. (4) The multi-hop reasoning fails: instead of recognizing the discontinuation of Class B-2, the model invents its emergence and future conversion. (5) Entity accuracy is poor—Visa is not mentioned in the original context, and the 'retrospective-responsibility plans' are not real entities in the provided data. (6) Despite being factually wrong, the answer is contextually relevant in discussing convertibility and governance, hence a moderate relevance score. Overall, the answer misrepresents the evolution, timeline, entities, and corporate actions, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1332,
        "completion_tokens": 430,
        "total_tokens": 1762
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has The Home Depot's approach to enhancing the ease of shopping experience evolved between 2023 and 2024, particularly in terms of digital and in-store capabilities?",
      "original_answer": "In 2023, The Home Depot focused on improving the ease of shopping experience by investing in mobile app-enabled store navigation, electronic shelf labels, reconfigured service desks, and enhanced self-checkout options. These efforts were aimed at improving store navigation, convenience, and checkout speed. By 2024, the company expanded its focus to include more personalized digital experiences, such as customer product review summaries and enhanced product content, while continuing to invest in digital platforms to improve navigation and 'shopability.' The 2024 strategy placed greater emphasis on leveraging customer data to meet personalized expectations, indicating a shift toward deeper integration of data-driven insights into the shopping journey.",
      "llm_answer": "\nBetween 2023 and 2024 Home Depot deepened its omnichannel model by expanding BOPIS, curbside and same‑day delivery, and by rolling out more “shopable” mobile features, enhanced search, personalized marketing and inventory‑visibility tools (e.g., computer‑vision and Sidekick assistance).  At the same time it invested $3.5 billion in capital to upgrade store layouts, self‑checkout, associate‑productivity systems and to open new locations, while also broadening Pro‑focused capabilities—acquiring SRS, adding showroom space, expanding Pro Xtra loyalty and credit, and improving order‑management—to make the in‑store experience faster, more customized and tightly linked to its digital shopping journey.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures some correct themes about The Home Depot's efforts to enhance the shopping experience through digital and in-store improvements, but diverges significantly from the ground truth in key details and emphasis. (1) Correct elements include mentions of self-checkout, store layout upgrades, digital navigation tools, and integration of digital with in-store experiences. However, the original answer emphasizes mobile app-enabled store navigation, electronic shelf labels, reconfigured service desks, and personalized digital experiences like product review summaries and enhanced content—none of which are mentioned in the LLM response. Instead, the LLM introduces specific initiatives not present in the ground truth, such as BOPIS expansion, curbside delivery, Sidekick assistance, computer vision, and the acquisition of SRS—details not supported by the provided knowledge base. (2) The $3.5 billion capital investment is a specific figure not present in the original answer, making it unverifiable against the ground truth; this lowers quantitative accuracy despite plausible formatting. (3) The reasoning partially reflects a multi-hop synthesis of digital and in-store evolution, but incorrectly shifts focus toward Pro-specific expansions and unmentioned technologies, indicating flawed or unsupported inference. (4) While contextually relevant and addressing the general theme of shopping experience evolution, the LLM answer substitutes verified 2023–2024 priorities with extraneous details, missing the core shift from operational convenience (2023) to data-driven personalization (2024) emphasized in the original. Thus, the answer is partially accurate but contains significant factual deviations, warranting a mid-range correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 478,
        "total_tokens": 1850
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has the structure of the Target Corporation Long-Term Incentive Plan evolved from 2022 to 2024, particularly in terms of the specific forms of equity awards included under the plan?",
      "original_answer": "In 2022, the Long-Term Incentive Plan included forms such as Non-Qualified Stock Options, Restricted Stock Units, Performance-Based Restricted Stock Units, Performance Share Units, Price-Vested Stock Options, Non-Employee Director Non-Qualified Stock Options, and Non-Employee Director Restricted Stock Units. By 2024, the plan introduced new forms of equity awards, including the Cliff-Vested Restricted Stock Unit Agreement and the Performance Award Performance Share Unit Agreement, indicating an expansion in the types of equity compensation vehicles available under the plan.",
      "llm_answer": "\nFrom 2022 through 2024 Target’s Long‑Term Incentive Plan remained anchored in the 2020 LTIP, but the company refined and expanded the equity‑award structure. In the 2022 filing the plan was documented with three “SPP” statements (I, II, III) and the existing award forms (stock options, RSUs, PSUs, performance‑share units, director RSUs). By the 2024 filing the plan’s exhibit list added new, specifically‑named agreements—​a cliff‑vested RSU agreement, a performance‑award PSU agreement, and updated forms for RSUs, performance‑RSUs, performance‑share units, and director RSUs—showing a more granular carve‑out of award types while still operating under the same 2020 LTIP framework.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. It correctly identifies that the Target Corporation Long-Term Incentive Plan (LTIP) has evolved from 2022 to 2024 by introducing new, more specific forms of equity awards under the same 2020 LTIP framework. The key additions—Cliff-Vested Restricted Stock Unit Agreement and Performance Award Performance Share Unit Agreement—are accurately reflected, even if phrased as 'cliff-vested RSU agreement' and 'performance-award PSU agreement,' which are semantically equivalent. The original answer notes the 2022 award forms (e.g., Non-Qualified Stock Options, RSUs, PSUs, etc.), and while the LLM does not list every single type from 2022, it correctly references the major categories (stock options, RSUs, PSUs, director RSUs) and implies continuity from 2022. The mention of 'SPP statements' and 'exhibit list' changes aligns with document-level evidence of structural refinement. There are no numerical inaccuracies (quantitative accuracy is perfect), and all dates (2022, 2024) are correct. The reasoning is sound: it recognizes that the plan operates under the 2020 LTIP but has expanded in granularity, which reflects proper multi-hop synthesis across filings. The only minor shortcoming is the omission of explicit mention of 'Performance-Based Restricted Stock Units' and 'Price-Vested Stock Options' from 2022, which slightly affects completeness but does not distort the overall evolution narrative. Thus, the answer is factually correct, contextually relevant, and well-reasoned, warranting a 9/10 for correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 446,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How did Qulipta's commercial performance evolve from its FDA approval in 2021 through 2023, based on AbbVie's financial disclosures?",
      "original_answer": "Qulipta was approved by the FDA in September 2021 for the preventive treatment of episodic migraine in adults, marking its entry into the market. By 2023, Qulipta had generated $405 million in U.S. revenue and $3 million internationally, totaling $408 million. This indicates a significant commercial trajectory following its approval, especially considering it had no revenue in 2021 and only $158 million in U.S. revenue in 2022. The product demonstrated strong growth, suggesting robust market adoption and positioning within AbbVie's portfolio.",
      "llm_answer": "\nAfter the September 2021 FDA approval for episodic migraine, Qulipta’s sales were modest but began to accelerate once the label was expanded to chronic migraine (FDA approval in April 2023) and the EU granted a similar indication in August 2023.  Consequently, AbbVie disclosed that net revenues from Qulipta grew by **more than 100 % in 2023**, helping lift the overall Neuroscience portfolio and offset declines in legacy products such as Humira.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "(1) The LLM answer contains partial factual correctness but misses key quantitative details and introduces potentially inaccurate growth claims. While it correctly notes Qulipta's September 2021 FDA approval for episodic migraine, it adds that sales accelerated due to a label expansion for chronic migraine with FDA approval in April 2023 and EU approval in August 2023—this contextual detail is absent from the ground truth and cannot be verified from the provided knowledge graph, making it speculative. (2) Quantitatively, the claim of 'more than 100% growth in 2023' is problematic. Ground truth shows U.S. revenue increased from $158M in 2022 to $405M in 2023, which is a 156% increase—so this figure is directionally accurate. However, the LLM fails to report the actual dollar amounts ($405M U.S., $3M international, $408M total), which are central to assessing commercial performance. The absence of these figures significantly reduces completeness and quantitative accuracy. (3) The reasoning is partially sound in linking label expansion to growth, but this inference is not supported in the original answer and represents an unsupported assumption. The multi-hop synthesis is weak—while the model attempts to explain growth drivers, it omits the core evolution of revenue over time (no revenue in 2021, $158M in 2022, $408M in 2023), which is essential to answering how performance evolved. (4) Contextually, the answer is relevant and addresses commercial trajectory and impact on AbbVie’s portfolio. However, the lack of specific financial figures and reliance on unverified label expansion as a driver reduces factual accuracy. A score of 5 reflects partial correctness: directional growth is right, but missing key data and introducing unverified causal factors limit overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1245,
        "completion_tokens": 487,
        "total_tokens": 1732
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How has Netflix's treatment and disclosure of the 2020 Stock Plan evolved between the 2022 and 2024 SEC filings, particularly in terms of its structural description and associated equity compensation activities?",
      "original_answer": "In 2022, the 2020 Stock Plan was referenced primarily through its inclusion in the exhibit list as a filed document (Def 14A, filed April 22, 2020), with no detailed description of its provisions or activities. In contrast, by 2024, the 2020 Stock Plan was not only explicitly described in detail but also linked to specific equity compensation activities, including the granting of incentive stock options, nonstatutory stock options, and restricted stock units (RSUs) with defined vesting schedules and performance-based criteria. This represents a significant shift from mere documentation to a more comprehensive disclosure of the plan's operational role in equity compensation.",
      "llm_answer": "\nIn the 2022 Form 10‑K the 2020 Stock Plan was mentioned only in passing—as a stock‑holder‑approved plan that permits stock‑option and other equity grants—without any detailed breakdown of award types or quantitative activity. By contrast, the 2024 filing expands the disclosure to explicitly list the plan’s components (incentive and non‑statutory options, stock‑appreciation rights, restricted stock and RSUs), and it provides detailed tables of option grants, exercises, expirations, intrinsic value, unrecognized compensation expense and RSU/PSU activity, reflecting a far more granular and transparent treatment of the plan’s structure and related equity‑compensation actions.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution in Netflix's disclosure of the 2020 Stock Plan between 2022 and 2024: from minimal, high-level mention in 2022 to detailed structural and operational disclosure in 2024. The key elements—such as the shift from passive reference to active description, inclusion of specific award types (incentive and non-statutory stock options, RSUs), and expanded reporting on equity activities—are all factually correct. (2) There are no numeric values (e.g., dollar amounts, dates, percentages) in either the original or LLM answer that conflict; the LLM correctly avoids fabricating numbers and sticks to qualitative descriptors that match the ground truth. The mention of 'detailed tables' and specific metrics like 'unrecognized compensation expense' and 'intrinsic value' is consistent with enhanced disclosure practices in 2024 filings, even if not explicitly listed in the ground truth. (3) The multi-hop reasoning is sound: the model synthesizes changes in disclosure depth over time, connects the plan to specific equity instruments, and infers increased transparency—all supported by the original answer. (4) The only minor gap is that the LLM mentions 'stock-appreciation rights' and 'PSU activity' not explicitly referenced in the ground truth, which slightly overextends the detail. However, this does not contradict the core facts and falls within reasonable inference given the context of expanded disclosures. Overall, the answer is semantically equivalent, factually correct, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 442,
        "total_tokens": 1799
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did the company's approach to aluminum purchase agreements evolve between 2022 and 2023, particularly in terms of their classification and strategic use of derivative instruments?",
      "original_answer": "In 2022, the company described its aluminum purchase agreements as derivative instruments entered into for long-term strategic sourcing objectives and non-U.S. business requirements. By 2023, the company continued to use these agreements but provided additional clarity that the quantities of aluminum in these contracts offset each other and are priced at prevailing market prices. This evolution indicates a more refined strategy around market pricing alignment and potentially reduced exposure through offsetting positions.",
      "llm_answer": "\nBetween 2022 and 2023 the company continued to treat its aluminum purchase agreements as derivatives that **do not qualify for hedge accounting**—they are held for long‑term strategic sourcing and are marked‑to‑market, with resulting gains or losses recorded directly in earnings.  The 2023 filing shows a **larger aggregate notional amount for these non‑hedge commodity contracts (≈ $115 million in 2023 versus about $412 million in 2022)** and a more explicit statement that the agreements “offset and are priced at prevailing market prices” to meet sourcing objectives, indicating an expanded strategic use of the instruments while the classification and accounting treatment remain the same.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies, particularly in the quantitative data. It claims the aggregate notional amount of non-hedge commodity contracts was approximately $115 million in 2023 versus about $412 million in 2022, which directly contradicts the ground truth—there is no mention of these figures in the original answer, and the direction of change (decrease from $412M to $115M) is unsupported and likely incorrect. These numbers are critical and completely fabricated or misattributed, severely undermining factual correctness. (2) The original answer does not provide any dollar amounts related to the aluminum purchase agreements, so introducing specific figures like $115M and $412M constitutes a serious quantitative error. There is no basis for these numbers in the ground truth, and they distort the actual evolution of the company’s strategy. (3) On qualitative aspects, the LLM correctly identifies that aluminum purchase agreements are treated as derivatives not qualifying for hedge accounting and are used for strategic sourcing, which aligns with the 2022 description. It also correctly notes increased clarity in 2023 about offsetting positions and pricing at prevailing market rates—this matches the multi-hop insight about refined strategy and reduced exposure. However, the erroneous numerical comparison undermines the reasoning. (4) Contextually, the response addresses the right topic—evolution in classification and strategic use of derivatives—and attempts synthesis across years. Despite incorrect numbers, it captures the conceptual shift toward market pricing alignment and offsetting. However, due to the severe quantitative inaccuracies, the overall correctness score is low. The model appears to hallucinate financial data not present in the source, which is a critical failure in financial reasoning tasks.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 507,
        "total_tokens": 1821
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How has the disclosure or treatment of the Directors' Code of Conduct evolved between 2023 and 2024, particularly in terms of its accessibility and scope?",
      "original_answer": "In 2023, the Directors' Code of Conduct was explicitly referenced and posted on the company's website at a specific URL: https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/inv relations/directors-code-of-conduct.pdf. In 2024, the URL for the Directors' Code of Conduct changed to https://www.bny.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-ofconduct.pdf, indicating a shift in how the document is categorized or accessed. Additionally, in 2024, the company introduced a new section titled 'INSIDER TRADING POLICIES AND PROCEDURES,' which was not present in 2023, suggesting an expanded focus on compliance mechanisms beyond the Code itself. These changes reflect a transformation in the presentation and accessibility of the Directors' Code of Conduct, as well as an increased emphasis on insider trading compliance.",
      "llm_answer": "\nBetween 2023 and 2024 the company’s filing shifted from a generic reference to a “Directors’ Code of Conduct” that was merely noted as posted on the website, to a more explicit statement that the code is posted at a dedicated URL and that any future amendments or waivers will be disclosed there.  The 2024 filing also clarifies that the code applies to all directors and ties the disclosure promise directly to the corporate‑governance discussion, making the document more readily accessible and signalling a broader, more transparent scope of governance oversight.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies a shift in the disclosure approach between 2023 and 2024, noting increased specificity in the 2024 filing regarding the URL and disclosure of amendments or waivers. It also correctly highlights improved accessibility and a broader governance scope, which aligns with the ground truth's emphasis on changes in presentation and accessibility. However, the LLM answer misses key factual details from the ground truth: (1) it does not mention the actual URL changes between 2023 and 2024, which is a central part of the evolution in accessibility; (2) it fails to note the introduction of the new 'INSIDER TRADING POLICIES AND PROCEDURES' section in 2024, a significant expansion in scope. Instead, it introduces a claim about 'future amendments or waivers' being disclosed, which is not present in the ground truth and cannot be verified. While the reasoning around improved transparency and governance oversight is plausible, it substitutes specific factual changes with inferred enhancements. The answer is contextually relevant and semantically aligned in direction, but lacks critical specifics and adds unverified content, reducing its qualitative accuracy. Quantitative accuracy is high because there are no numerical errors—dates (2023, 2024) are correct and no incorrect figures are cited.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 368,
        "total_tokens": 1726
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How has the structure and value of HD's 4.95% Senior Notes evolved between 2023 and 2024, and what does this indicate about the company's long-term debt strategy?",
      "original_answer": "In 2023, HD issued $750 million of 4.95% senior notes due September 30, 2026, at a discount of $1.6 million. By 2024, the carrying amount of these 4.95% senior notes due September 2026 was $747 million as of February 2, 2025, and the company also reported $980 million in 4.95% senior notes due September 2052. This indicates that while the original 2026 notes remained outstanding with only a slight reduction in carrying value, HD expanded its 4.95% senior note structure to a much longer maturity in 2052, suggesting a strategy of extending debt maturities and potentially locking in fixed interest rates over a longer horizon.",
      "llm_answer": "\nThe $750 million, 4.95 % senior notes that were issued in November 2023 (maturing September 2026) had a net carrying amount of $744 million at the end of fiscal 2023; by the end of fiscal 2024 that amount had risen modestly to $747 million, reflecting the amortization of the original discount and the absence of any principal repayment.  This small increase occurs as Home Depot has been shifting from short‑term commercial‑paper borrowing toward a series of larger, longer‑dated senior‑note issuances (including the 2024‑2025 tranches), using the 4.95 % notes as part of a broader strategy to lock in fixed‑rate, long‑term financing and fund its acquisition‑driven growth while reducing reliance on revolving credit facilities.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct elements but also key inaccuracies. It correctly identifies the issuance of $750 million in 4.95% senior notes in 2023 with a discount, and reports a carrying amount of $747 million by the end of fiscal 2024, which aligns closely with the ground truth. However, it incorrectly states the net carrying amount at the end of fiscal 2023 as $744 million, while the original answer notes a $1.6 million discount on a $750 million issue, implying a carrying amount of $748.4 million initially, not $744 million. The LLM’s figure of $744 million is thus factually incorrect. Additionally, the LLM completely omits the critical fact that HD issued $980 million in 4.95% senior notes due in 2052, a major component of the long-term debt strategy. This omission severely undermines the completeness and correctness of the answer. (2) The date of issuance is vaguely cited as 'November 2023'—the ground truth specifies September 30, 2026 as the maturity, but does not specify the issuance month, so this is acceptable. However, the carrying amount discrepancy is a material quantitative error. The increase from $744M to $747M suggests amortization, but with an initial discount of only $1.6M, the amortized value should not drop to $744M initially. (3) The reasoning about shifting toward long-term fixed-rate financing is sound and contextually appropriate, and the mention of reducing reliance on commercial paper and revolving credit aligns with strategic interpretation. However, the failure to mention the 2052 notes—central to the multi-hop inference about extending maturities—represents a breakdown in synthesis. The model infers a correct strategic direction but fails to support it with the key evidence (the 2052 issuance). (4) The contextual relevance is high because the answer addresses the evolution of the notes and attempts to interpret strategy. Qualitative reasoning is partially sound but based on incomplete data. Quantitative accuracy is compromised by the incorrect initial carrying value. Correctness score is 6 due to partial factual accuracy but major omission of a key debt tranche and incorrect financial figure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 585,
        "total_tokens": 1929
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did Intel's financial treatment and valuation of its investment in Beijing Unisoc Technology Ltd. evolve between 2021 and 2023, particularly in terms of observable price adjustments and net book value?",
      "original_answer": "In 2021, Intel recognized $471 million in observable price adjustments in its investment in Beijing Unisoc Technology Ltd. By the end of 2023, Intel was accounting for its interest in Unisoc as a non-marketable equity security, with a net book value of $1.1 billion as of December 30, 2023 (the same as December 31, 2022). This indicates that while Intel continued to hold the investment without marketability, the valuation remained stable over the two-year period despite the earlier price adjustment.",
      "llm_answer": "\nBetween 2021 and 2023 Intel recorded a $471 million observable‑price adjustment to its non‑marketable equity stake in Beijing Unisoc Technology Ltd. in the first quarter of 2021, which lifted the investment’s carrying amount.  By the end of 2023 the net book value of the holding had settled at roughly $1.1 billion—essentially the same level reported at the end of 2022—indicating that subsequent price‑adjustment or impairment activity was minimal and the valuation remained stable after the 2021 adjustment.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $471 million observable price adjustment in 2021 and the $1.1 billion net book value at the end of 2023 (matching December 30, 2023, and December 31, 2022, values from the ground truth). All key financial figures are accurate and properly contextualized. (2) Quantitative accuracy is perfect: the $471 million adjustment and $1.1 billion net book value are correctly reported with acceptable formatting variations (e.g., $1.1 billion = $1.1 billion). The timing of the adjustment is specified as Q1 2021, which is consistent with the original answer’s 2021 reference. (3) The reasoning is sound: the LLM correctly infers that the stable net book value from 2022 to 2023 implies minimal subsequent adjustments or impairments, aligning with the ground truth’s conclusion of valuation stability post-2021 adjustment. It accurately characterizes the investment as a non-marketable equity security, though it does not explicitly state this accounting classification until contextually implied. (4) The answer is semantically equivalent to the original, with only minor omission of the explicit phrase 'accounting for its interest as a non-marketable equity security'—but the term 'non-marketable equity stake' is used, preserving entity and classification accuracy. The synthesis across 2021 and 2023 data points is correct and logically presented. Minor deduction in qualitative accuracy due to slightly less explicit framing of the accounting treatment evolution, but overall reasoning and completeness remain strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1268,
        "completion_tokens": 431,
        "total_tokens": 1699
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did AbbVie's engagement with Qulipta evolve from 2022 to 2023, particularly in terms of its regulatory and commercial development status?",
      "original_answer": "In 2022, Qulipta was part of a group of products that received regulatory approvals, leading to the reclassification of $1.0 billion of indefinite-lived research and development intangible assets to developed product rights. By 2023, AbbVie had introduced Qulipta with specific regulatory milestones: it received FDA approval in April 2023 for the preventive treatment of chronic migraine in adults and EC approval in August 2023 for the preventive treatment of migraine in adults with four or more migraine days per month. This evolution reflects a shift from asset reclassification to active regulatory and commercial advancement.",
      "llm_answer": "\nFrom 2022 to 2023 AbbVie moved Qulipta from an investigational migraine‑prevention therapy to an approved, commercially‑launched product.  The FDA granted approval for Qulipta in April 2023, and the European Commission followed with approval (under the name Aquipta) in August 2023, after which the drug generated its first sales—$405 million in U.S. revenue and $408 million internationally in 2023—signaling a full regulatory and commercial transition.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key regulatory milestones for Qulipta in 2023—FDA approval in April and EC approval in August—which aligns with the ground truth. It also correctly frames the evolution from investigational to approved status, capturing the commercial launch. However, it omits the critical 2022 context provided in the original answer: the reclassification of $1.0 billion in R&D intangible assets due to regulatory progress, which is central to the 'evolution' asked in the question. (2) The LLM introduces financial figures—$405 million U.S. revenue and $408 million international revenue in 2023—that are not present in the ground truth and are likely incorrect or at least unverified by the source knowledge. These numbers significantly misrepresent the answer’s quantitative accuracy. There is no mention of revenue in the original answer, so introducing specific figures constitutes a factual overreach. (3) The multi-hop reasoning is partially sound: the model connects regulatory approvals to commercialization, but fails to synthesize the 2022 asset reclassification, which is a key part of the two-year evolution. This missing link weakens the qualitative and overall correctness. (4) Contextual relevance is high because the answer addresses regulatory and commercial development as required. However, the inclusion of unsupported revenue numbers severely undermines quantitative accuracy, warranting a low score there. The qualitative accuracy is moderate due to correct entity and timeline identification but incomplete reasoning. The overall correctness is reduced to 6 due to the introduction of unverified data and omission of a key 2022 fact.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1270,
        "completion_tokens": 463,
        "total_tokens": 1733
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How has Boeing's framing and strategic emphasis on 'upgrades and conversions' within the Global Services segment evolved between 2022 and 2023, based on the language used in the 10-K filings?",
      "original_answer": "In 2022, 'upgrades and conversions' were listed as part of a broader set of services under the Global Services segment, grouped alongside supply chain logistics, engineering, maintenance, spare parts, training systems, technical documents, and digital services. The description was general and lacked strategic framing. In 2023, while the service was still included, the context shifted subtly: it was now positioned within a more structured narrative that emphasized the full spectrum of sustaining aerospace platforms and systems, indicating a more integrated and strategic role within the segment. This evolution suggests a more deliberate positioning of 'upgrades and conversions' as a core capability rather than a general service offering.",
      "llm_answer": "\nBoth the 2022 and 2023 Form 10‑Ks list “upgrades and conversions” as one of the core services in the Global Services segment—alongside maintenance, modifications, spare parts, training and digital services—that sustain commercial and defense platforms. The 2023 filing keeps the same wording but ties “upgrades and conversions” more directly to data‑analytics and digital‑service language, reflecting a strategic shift toward framing these activities as technology‑driven growth levers rather than solely traditional maintenance offerings.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but introduces a detail not present in the ground truth, affecting factual accuracy. (1) Correct elements: Both years mention 'upgrades and conversions' as part of the Global Services segment alongside similar service offerings (maintenance, spare parts, training, digital services), and the 2023 framing is described as more strategically positioned—this aligns with the original answer’s claim of a more integrated narrative. (2) Quantitative accuracy: There are no numerical values in the question or answers, so this aspect is not applicable; no errors in dates or financial figures. (3) Multi-hop reasoning: The model correctly identifies the presence of 'upgrades and conversions' in both years and attempts to compare the strategic framing, which requires synthesis across filings. However, it incorrectly states that the 2023 filing 'ties upgrades and conversions more directly to data-analytics and digital-service language'—this specific technological linkage and characterization as 'technology-driven growth levers' is not supported by the ground truth, which only notes a subtle shift toward positioning the service within a broader, more structured narrative about sustaining aerospace platforms. This addition reflects an overinterpretation or inference beyond the provided evidence. (4) The answer is contextually relevant and addresses the evolution question, but the unsupported claim about digital integration and strategic reframing as 'growth levers' reduces qualitative accuracy. While the direction of increased strategic emphasis is correct, the specific rationale (data analytics/digital framing) is not corroborated, leading to a partial correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1332,
        "completion_tokens": 465,
        "total_tokens": 1798
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did Intel's financial relationship with Beijing Unisoc Technology Ltd. evolve between 2021 and 2023, particularly in terms of the valuation and recognition of this investment?",
      "original_answer": "Intel's financial relationship with Beijing Unisoc Technology Ltd. remained consistent in terms of total net book value, which stayed at $1.1 billion as of both December 25, 2021 (from the 2022 filing) and December 30, 2023 (from the 2023 filing). However, in 2021, Intel recognized $471 million in observable price adjustments related to its investment in Unisoc, indicating a revaluation event during that year. This type of valuation adjustment was not explicitly mentioned in the 2023 filing, suggesting a stabilization of the investment's value over time or a lack of significant observable price changes in 2023 compared to 2021.",
      "llm_answer": "\nBetween 2021 and 2023 Intel’s stake in Beijing Unisoc Technology Ltd. remained classified as a non‑marketable equity security, but its reported carrying amount grew sharply and then stabilized.  In 2020 the investment was recorded at roughly **$658 million**; by the end of 2021 it had risen to **$1.1 billion**, driven by a **$471 million** observable‑price adjustment recognized during that year.  Subsequent filings show the book value held steady at **about $1.1 billion** for both 2022 and 2023, indicating that the valuation achieved in 2021 was maintained thereafter.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $471 million observable-price adjustment in 2021 and the $1.1 billion book value in 2021, 2022, and 2023, which aligns with the ground truth. However, it introduces a figure of $658 million for 2020, which is not mentioned in the original answer or supported by the provided ground truth (the ground truth only confirms values for 2021 and 2023). This extrapolation, while plausible, is not verifiable from the given data and constitutes a minor factual overreach. (2) The key numbers—$1.1 billion book value in 2021 and 2023, and the $471 million adjustment in 2021—are accurate and correctly contextualized. The calculation of the increase from ~$658M to $1.1B via a $471M adjustment is mathematically reasonable ($658M + $471M = $1.129B ≈ $1.1B), but since the $658M figure is not in the ground truth, the quantitative accuracy is slightly reduced. (3) The multi-hop reasoning is sound: the model correctly infers that the investment value stabilized after 2021 and connects the observable-price adjustment to the valuation change. It synthesizes the lack of further adjustments in 2022 and 2023 into a conclusion of stabilization, which is consistent with the original answer. (4) The answer is highly relevant and captures the core evolution of the financial relationship. The inclusion of unverified 2020 data prevents a top score, but the overall factual and logical structure is strong, warranting a correctness score of 8.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 410,
        "total_tokens": 1721
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the role of Self-Service Lockers evolved within Home Depot's interconnected shopping experience between 2023 and 2024?",
      "original_answer": "In 2023, Self-Service Lockers were described as part of Home Depot's investments to improve the customer shopping experience, specifically to enable convenient online order pickup options alongside other features like wayfinding signage and electronic shelf labels. By 2024, Self-Service Lockers were positioned more strategically as part of the company's broader fulfillment network, specifically referenced in the context of leveraging stores as 'convenient customer pickup, return, and delivery fulfillment locations' under interconnected retail programs such as BOSS, BOPIS, BODFS, and BORIS. Additionally, in 2024, approximately 50% of U.S. online orders were fulfilled through a store, highlighting a more integrated and operationally significant role for Self-Service Lockers in the fulfillment process. This reflects a shift from a convenience-focused feature to a core component of the omnichannel delivery strategy.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 Home Depot turned self‑service lockers from a modest “front‑entrance” convenience into a central node of its omnichannel journey.  The lockers are now embedded in the BOPIS/BODFS/BORIS network (with additional locations, including a pilot in Mexico) and helped fulfill roughly 50 % of U.S. online orders in 2024, linking online ordering, in‑store inventory and curb‑side delivery into a seamless, frictionless shopping experience.  This evolution reflects the retailer’s broader push to integrate physical‑store pickup with digital channels for both DIY and professional customers.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of Self-Service Lockers at Home Depot from 2023 to 2024. (1) Quantitatively, the 50% figure for U.S. online orders fulfilled through stores in 2024 is correctly stated and matches the ground truth. No other numerical data is present, and all references to years (2023, 2024) are accurate. (2) The answer correctly identifies the shift from a convenience feature to a central part of the omnichannel strategy, aligning with the ground truth's emphasis on integration into BOSS, BOPIS, BODFS, and BORIS. The mention of a pilot in Mexico is an additional detail not in the original answer; however, it does not contradict the ground truth and may reflect supplementary knowledge. (3) The multi-hop reasoning is sound: the model synthesizes the functional evolution of lockers with their operational role in fulfillment networks and connects them to broader retail programs. (4) The answer is contextually relevant and directly addresses how the role of lockers evolved. The only minor shortcoming is that the original answer emphasizes the 2023 context more explicitly (e.g., wayfinding signage, electronic shelf labels) as part of the customer experience investments, which the LLM answer omits. While not required for correctness, this slight reduction in completeness prevents a perfect 10. Overall, the semantic meaning and factual content are equivalent, with excellent qualitative and quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 405,
        "total_tokens": 1784
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the level of detail and specificity in Costco's disclosure regarding the estimation methods for Insurance/Self-insurance Liabilities evolved from 2023 to 2024?",
      "original_answer": "In 2023, Costco provided a general description of its self-insurance practices and risk management mechanisms, including the use of a captive insurance subsidiary and a reinsurance program, but did not specify the factors used in estimating liabilities. In 2024, the company significantly expanded its disclosure, detailing that liabilities are estimated using historical claims experience, demographic factors, severity factors, and other actuarial assumptions. Additionally, 2024's disclosure included a discussion of the unpredictability of claim costs and the potential for significant differences between actual and recorded liabilities, which was not present in 2023. This represents a meaningful increase in transparency and specificity.",
      "llm_answer": "\nThe 2024 filing expands the self‑insurance note with concrete detail: it lists the specific claim types covered, explains that liabilities are **not discounted** and are **estimated using historical claims experience together with demographic and severity factors**, and even quantifies the balances ($1.612 bn in 2024 vs. $1.513 bn in 2023) while highlighting how future claim trends could materially change the estimate. In contrast, the 2023 disclosure only gave a broad statement that liabilities were “estimated using historical claims experience and actuarial assumptions,” without naming demographic/severity factors, the captive‑reinsurance structure, or providing the actual liability amounts. Thus, the 2024 description is markedly more granular and specific.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that the 2023 disclosure was general, mentioning only 'historical claims experience and actuarial assumptions,' while the 2024 filing added specificity such as demographic and severity factors—details absent in 2023. This matches the original answer’s claim of increased transparency. (2) Quantitatively, the LLM provides exact liability amounts: $1.612 billion in 2024 vs. $1.513 billion in 2023. These figures are precise and consistent with typical SEC filing data (and format variations like 'bn' are acceptable). The note about liabilities not being discounted and the inclusion of claim types and future trend risks add valuable context not contradicted by the ground truth. (3) The multi-hop reasoning is sound: the model compares disclosures across two years, synthesizes differences in detail level, and supports the conclusion of increased specificity with concrete examples. The only minor gap is that the original answer mentions the 'captive insurance subsidiary and reinsurance program' as newly detailed in 2024, which the LLM mentions briefly ('captive-reinsurance structure') but could have elaborated slightly more. However, it is still acknowledged, so the omission is not significant. (4) The answer is fully relevant, directly addressing the evolution in disclosure detail from 2023 to 2024. Overall, the response demonstrates strong factual accuracy, excellent quantitative precision, and clear reasoning, warranting a 9/10 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 428,
        "total_tokens": 1811
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How did the financial impact of the Aldevron acquisition on inventory-related costs evolve from 2022 to 2023?",
      "original_answer": "In 2022, the Aldevron acquisition contributed to a $59 million increase in cost of sales due to fair value adjustments to inventory. By 2023, this specific acquisition-related cost associated with Aldevron was no longer present; instead, a new $87 million charge emerged in the second quarter, primarily related to excess inventory in the Biotechnology segment due to reduced demand. This indicates a shift from acquisition-driven inventory adjustments to operational inventory challenges.",
      "llm_answer": "\nFrom 2022 into 2023 the drag of the Aldevron purchase on inventory‑related costs shifted from essentially settled fair‑value adjustments (the $59 million charge that showed up in 2021 and was largely absorbed by 2022) to a new, explicit $87 million inventory charge recorded in cost of sales in the second quarter of 2023.  That 2023 charge—attributable to excess inventory in the Biotechnology (Aldevron) segment as demand fell—significantly increased the inventory‑related cost impact compared with the prior year.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly regarding the timing of the $59 million charge. The original answer states this occurred in 2022, but the LLM claims it 'showed up in 2021 and was largely absorbed by 2022', which misrepresents the timeline and downplays its presence in 2022. This is a critical error in both year attribution and interpretation. The $87 million charge in Q2 2023 is correctly identified in amount and timing. (2) Quantitatively, the $87 million figure is accurate and correctly placed in Q2 2023. However, the $59 million charge is misattributed to 2021 rather than 2022, and the claim that it was 'largely absorbed by 2022' contradicts the ground truth, which clearly states the impact was present in 2022. This undermines the quantitative accuracy despite correct dollar amounts. (3) The reasoning partially captures the shift from acquisition-related to operational inventory costs, correctly identifying that the 2023 charge was due to excess inventory in the Biotechnology (Aldevron) segment from reduced demand. However, the multi-hop synthesis is flawed because it incorrectly frames the 2022 cost as residual from 2021 rather than a current-year impact of the acquisition, weakening the comparative analysis. (4) Contextual relevance is high—the answer addresses the evolution of inventory-related costs and focuses on the correct company and segment. However, due to the misstatement of key facts and timeline, the overall correctness is reduced to a 6, reflecting partial accuracy with significant factual shortcomings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1242,
        "completion_tokens": 438,
        "total_tokens": 1680
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has the treatment and recognition of shop card liabilities evolved between 2023 and 2024, and what does this indicate about Costco's approach to unclaimed balances?",
      "original_answer": "In both 2023 and 2024, Costco recognized revenue from shop cards upon redemption and accounted for outstanding balances as a liability, net of estimated breakage based on redemption data. However, the specific mention of 'estimated breakage' and the methodology tied to redemption data became more emphasized in 2024, indicating a more refined or formalized approach to tracking and accounting for unclaimed shop card balances. This evolution suggests Costco improved its estimation techniques for unclaimed balances, aligning its liability reporting more closely with actual redemption behavior over time.",
      "llm_answer": "\nCostco’s accounting for proprietary shop‑card liabilities was unchanged from 2023 to 2024: revenue is recognized only when the card is actually redeemed, and the remaining outstanding balances are recorded as a liability — net of an estimated breakage amount based on historical redemption patterns. This consistent treatment shows that Costco takes a conservative approach to unclaimed balances, deferring revenue recognition until the card is used and only estimating the portion that will ultimately go unredeemed.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate in its description of Costco's accounting treatment of shop card liabilities in both 2023 and 2024: revenue is recognized upon redemption, outstanding balances are recorded as a liability, and breakage is estimated based on historical redemption patterns. All entities (Costco, shop-card liabilities, breakage) and years (2023, 2024) are correct, and there are no numerical inaccuracies (though no specific dollar amounts are mentioned, which is consistent with the original answer). The reasoning is sound and reflects proper multi-hop synthesis across the two years. However, the LLM states the treatment was 'unchanged,' which slightly underrepresents the evolution noted in the ground truth — specifically, the increased emphasis on 'estimated breakage' and refinement of methodology in 2024. The original answer highlights a more nuanced shift toward a formalized or improved estimation process, suggesting evolution in approach even if core principles remained. The LLM answer misses this subtlety, portraying the practice as static when the ground truth indicates a qualitative enhancement. This omission affects completeness and reasoning depth but does not introduce factual errors, warranting a high but not perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 353,
        "total_tokens": 1640
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has Intel's Foundry Services offering evolved from 2022 to 2023 in terms of strategic partnerships and customer engagement, based on the specific initiatives and agreements mentioned in those years?",
      "original_answer": "In 2022, Intel introduced its Foundry Services as part of the IDM 2.0 strategy, emphasizing plans to build a world-class foundry business with differentiated offerings, including leading-edge packaging and process technology, committed capacity in the US and Europe, and a strong IP portfolio. By 2023, Intel had significantly advanced this offering by securing four design wins on Intel 18A, including a major high-performance computing customer, and five new design wins in advanced packaging, particularly for AI-related designs. Additionally, Intel expanded its IFS Accelerator Ecosystem Alliance program to over 40 strategic agreements and entered into multigenerational agreements with ARM and Synopsys to enable optimized SoC design on Intel 18A. These developments indicate a shift from strategic intent in 2022 to concrete customer engagements and ecosystem partnerships in 2023.",
      "llm_answer": "\nIn 2022 Intel launched its IFS Accelerator Ecosystem Alliance, announced a commercial agreement with Tower, and secured early design wins on the 18A node while expanding RAMP‑C collaborations with the U.S. Department of Defense, laying the groundwork for an external foundry business. By 2023 that initiative had more than doubled to over 40 partners, added a multigenerational ARM agreement and a definitive Synopsys partnership, deepened RAMP‑C ties with high‑profile customers such as Nvidia, IBM, Microsoft, Boeing and Northrop Grumman, and began using its New Mexico fab to provide foundry capacity for advanced‑analog chips.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. While it correctly identifies the expansion of the IFS Accelerator Ecosystem to over 40 partners and the multigenerational agreements with ARM and Synopsys in 2023, it introduces several inaccuracies. The claim that Intel 'launched' the IFS Accelerator in 2022 is not supported in the ground truth, which only mentions the broader IDM 2.0 strategy and intent. The 'commercial agreement with Tower' and 'RAMP-C collaborations with DoD' are not mentioned in the original answer and appear to be hallucinated or misattributed. Similarly, the assertion that Intel began using its New Mexico fab for advanced-analog chips is not in the ground truth. The mention of Nvidia, IBM, Microsoft, Boeing, and Northrop Grumman as RAMP-C customers is unsupported in the provided truth. (2) Quantitatively, the 'over 40 partners' figure matches the ground truth, which is correct. However, the original answer does not specify the number of design wins in 2022, so claiming 'early design wins on 18A' in 2022 is speculative—ground truth states four 18A design wins were secured in 2023. The doubling of the ecosystem is an inference not directly supported. (3) The multi-hop reasoning is partially sound—there is an attempt to show evolution from 2022 to 2023 in partnerships and customer engagement. However, the synthesis relies on unverified or incorrect data points, undermining the logical chain. The ground truth emphasizes a shift from strategic intent (2022) to concrete wins (2023), which the LLM attempts to reflect but distorts with fabricated details. (4) Correctness is scored 6 due to partial factual alignment on key 2023 partnerships but significant hallucinations. Quantitative accuracy is 5 due to one correct number but unsupported claims about timing and scale. Qualitative accuracy is 6 because reasoning structure is logical but based on incorrect entities. Contextual relevance is 9—response stays on topic and addresses the evolution question directly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1393,
        "completion_tokens": 549,
        "total_tokens": 1943
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How did the financial impact of DHR's relationship with Aldevron evolve between 2022 and 2023, particularly in terms of goodwill and net cash consideration?",
      "original_answer": "In 2022, DHR preliminarily recorded approximately $6.1 billion of goodwill related to the Aldevron Acquisition. By 2023, the net cash consideration for Aldevron increased to $9.561 billion, indicating a more detailed or revised financial assessment of the acquisition. This evolution shows a significant increase in the financial commitment to the Aldevron relationship, particularly in terms of cash outlay, beyond the initial goodwill estimate provided in 2022.",
      "llm_answer": "\nIn the 2022 filing (pages 81‑85) Danaher recorded roughly **$6.1 billion of goodwill** and **$9.6 billion of total cash consideration** for the Aldevron acquisition (≈ $9.56 billion net cash after non‑cash adjustments). The 2023 filing (pages 72‑76) shows **no additional goodwill or cash outlay for Aldevron**—the $6.1 billion goodwill remains unchanged, with only routine measurement‑period adjustments that are not material to the current period results.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that contradict the ground truth. (1) Quantitatively, while the $6.1 billion goodwill figure from 2022 is correct, the LLM incorrectly states that the total cash consideration was $9.6 billion (≈$9.56 billion net) in 2022, whereas the original answer indicates that the $9.561 billion net cash consideration was reported in 2023, not 2022. This misplacement of the cash figure across years is a critical error. (2) The LLM claims that in 2023, there was 'no additional goodwill or cash outlay' and that the goodwill remained unchanged, which directly contradicts the original answer stating that the net cash consideration increased to $9.561 billion in 2023, implying a revised or more complete financial assessment. (3) The qualitative reasoning is flawed: the model fails to recognize the evolution between years, instead asserting stability, which misrepresents the financial trajectory. It also introduces 'routine measurement-period adjustments' not mentioned in the ground truth, adding unsupported detail. (4) Contextually, the answer addresses the right entities (DHR, Aldevron, goodwill, cash consideration) and time frame (2022–2023), so it is relevant, but the core financial narrative is incorrect. The multi-hop synthesis fails because the model does not correctly track how the financials evolved from 2022 to 2023. Overall, the answer inverts the dynamic described in the ground truth, resulting in a mostly incorrect assessment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1232,
        "completion_tokens": 411,
        "total_tokens": 1644
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the maturity date of the AT&T Inc. 1.800% Global Notes changed between the 2022 and 2024 SEC filings, and what does this indicate about the company's debt structure evolution?",
      "original_answer": "In the 2022 SEC filing, the AT&T Inc. 1.800% Global Notes were due on September 5, 2026. In the 2024 filing, the same class of notes is listed with a maturity date of September 14, 2039. This indicates a significant shift in the company's debt structure, extending the maturity of this particular note by over 13 years.",
      "llm_answer": "\nIn the 2022 filing the 1.800 % Global Notes were scheduled to mature on **September 5, 2026**, but in the 2024 filing the same series is listed with a maturity of **September 14, 2039**—an extension of roughly 13 years. This shift shows that AT&T is deliberately lengthening the average maturity of its debt, reducing near‑term refinancing risk and signaling a more durable, longer‑term capital‑structure strategy.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the maturity dates are accurate: September 5, 2026 (2022 filing) and September 14, 2039 (2024 filing), with the extension correctly described as approximately 13 years (actual difference is ~13 years and 9 days). Minor formatting (e.g., spaces in dates) does not affect correctness. (2) The answer addresses both parts of the question: the change in maturity date and its implication for AT&T's debt structure. (3) Entity accuracy is perfect: correct company (AT&T Inc.), correct instrument (1.800% Global Notes), and correct years (2022 and 2024 filings). (4) The reasoning is sound and adds appropriate qualitative insight—extending maturities reduces refinancing risk and signals a more stable capital structure—consistent with the implications in the ground truth. The multi-hop synthesis across two filings is correctly executed, and the conclusion is logically derived. All criteria are met at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1192,
        "completion_tokens": 290,
        "total_tokens": 1483
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has Target's compliance with its debt leverage covenant evolved between 2023 and 2024, and what changes in credit facility structure may have influenced this compliance?",
      "original_answer": "In 2023, Target stated that it was, and expected to remain, in compliance with its debt leverage covenant, which was part of a $1.0 billion 364-day credit facility that would expire in October 2024, along with a $3.0 billion five-year facility expiring in October 2028. By 2024, Target had renewed its 364-day credit facility, extending its expiration to October 2025, while maintaining the same $3.0 billion five-year facility. The company continued to assert compliance with the debt leverage covenant. The renewal of the 364-day facility likely provided continued flexibility, supporting Target’s ability to remain compliant with the covenant.",
      "llm_answer": "\nTarget’s debt‑leverage covenant was still comfortably satisfied in 2024.  Total long‑term debt (including finance‑lease liabilities) fell from about **$16.0 bn** as of January 28 2023 to **$14.9 bn** as of February 3 2024, keeping the leverage ratio well under the covenant threshold that is tied to secured‑debt levels in its credit agreements.  The October 2023 entry into a new **$1 bn 364‑day revolving credit facility** and the amendment that **extended the existing $3 bn five‑year facility to an October 2028 maturity** added extra borrowing capacity but did not change the covenant’s limits, allowing Target to maintain compliance even as its leverage improved.  (Pages 52‑56 of the 2023 Form 10‑K and pages 33‑37 of the 2024 Form 10‑K).",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth, but has minor discrepancies in quantitative precision and completeness. (1) Correct elements: The LLM correctly identifies Target's continued compliance with its debt leverage covenant in both 2023 and 2024, notes the renewal of the $1.0 billion 364-day facility (entered October 2023, expiring October 2024 → extended to October 2025), and confirms the $3.0 billion five-year facility extended to October 2028. It also correctly observes that the covenant limits were unchanged and that improved leverage (via lower debt) supported compliance. (2) Quantitative accuracy: The reported long-term debt figures ($16.0 billion as of Jan 28, 2023, and $14.9 billion as of Feb 3, 2024) are accurate per Target’s 10-K filings and support the narrative of improved leverage. However, the ground truth does not mention these specific debt amounts or the leverage ratio — while factually correct, their inclusion introduces detail beyond the original answer, which focused on covenant compliance and facility structure. This does not reduce accuracy but slightly diverges from the scope. (3) Multi-hop reasoning: The LLM synthesizes information across the 2023 and 2024 10-Ks correctly, linking facility renewals to covenant compliance. It accurately infers that maintaining credit capacity supports compliance, even though the covenant terms themselves were unchanged. (4) Minor gap: The original answer emphasizes that in 2023, Target expected to remain compliant and that the renewal of the 364-day facility 'likely provided continued flexibility' — a forward-looking nuance slightly underemphasized in the LLM’s more backward-looking phrasing. However, the core multi-hop logic — facility renewal supports compliance — is sound. Overall, the answer is factually accurate, contextually relevant, and well-reasoned, warranting a high score with a small deduction for slight over-elaboration on debt figures not in the ground truth and minor softening of forward-looking language.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 547,
        "total_tokens": 1902
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has Intel's approach to expanding digital readiness for global populations evolved from 2022 to 2023, particularly in relation to its RISE strategy and external collaboration initiatives?",
      "original_answer": "In 2022, Intel committed to expanding digital readiness through its RISE strategy, focusing on collaborative initiatives with other technology companies via the Alliance for Global Inclusion to create an Inclusion Index with unified goals and metrics. By 2023, this effort had matured into the publication of the third global inclusion index survey, which transitioned into an index system where organizations scoring 50% or higher were formally recognized. Intel was among the 18 recognized organizations out of 27 respondents, indicating a more structured and outcome-focused approach to digital readiness and inclusion. This evolution reflects a shift from establishing collaborative frameworks to measuring and recognizing performance against defined benchmarks.",
      "llm_answer": "\nFrom 2022 to 2023 Intel shifted from launching isolated digital‑readiness pilots (e.g., AI for Youth and AI for Workforce) toward embedding those efforts within a broader **RISE** framework that explicitly ties inclusive skills development to its RISE strategy.  In 2023 the company deepened external collaboration by forming the **Alliance for Global Inclusion**, expanding partnerships with governments, universities and HBCUs, and linking RISE‑related metrics to executive compensation—thereby scaling digital‑readiness initiatives for millions of people while coordinating industry‑wide standards and accountability.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and misrepresents key aspects of Intel's evolution from 2022 to 2023 regarding digital readiness and the RISE strategy. (1) Incorrectly states that the Alliance for Global Inclusion was formed in 2023, when the original answer indicates it was already active in 2022 as part of the initial collaborative effort. (2) Falsely claims that isolated pilots like 'AI for Youth' and 'AI for Workforce' were launched in 2022 and then integrated into RISE, which is not supported by the ground truth—no such pilots are mentioned, nor is there evidence of a shift from isolated to integrated efforts. (3) Introduces new, unverified details such as linking RISE metrics to executive compensation and expanding partnerships with HBCUs and governments, which are absent from the original answer and not corroborated by the knowledge graph. (4) Omits the core factual progression: the development and publication of the third global inclusion index survey, the establishment of a 50% benchmark for recognition, and Intel being one of 18 recognized organizations out of 27 respondents—critical quantitative and qualitative milestones. (5) While the answer correctly references the RISE strategy and external collaboration, it fabricates the nature and timeline of initiatives rather than accurately reflecting the shift from framework-building to performance measurement. The contextual relevance is moderate because it addresses digital readiness and collaboration, but the reasoning is unsound due to invented details and failure to report the actual multi-hop evolution documented in the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 448,
        "total_tokens": 1806
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How did Emerson's relationship with Micromine evolve between 2023 and 2024, and what financial implications were associated with this change?",
      "original_answer": "In 2023, Emerson (via its AspenTech subsidiary) entered into an agreement to acquire Micromine for AU$900 (approximately $623 USD), but later terminated the agreement due to uncertainty around Russian regulatory approval. This led to a mark-to-market gain of $24 in 2023 related to foreign currency forward contracts tied to the Micromine acquisition. By 2024, AspenTech had terminated all outstanding foreign currency forward contracts associated with the Micromine deal. The termination of the Micromine acquisition represented a shift from a strategic expansion effort in 2023 to a full withdrawal from the transaction, with no further financial commitments or exposures to Micromine reported in 2024.",
      "llm_answer": "\nBetween 2023 and 2024 the link to Micromine shifted from a planned acquisition to a terminated deal.  AspenTech (the vehicle through which Emerson had been pursuing Micromine) announced on August 1 2023 that it was ending the AU $900 (~ $623 USD) acquisition because the required Russian regulatory approval could not be secured, and it did **not** pay any termination fee.  As a result, Emerson incurred no additional financial penalty or liability from the collapse of the transaction—only the prior, already‑recorded costs (e.g., foreign‑currency hedging gains/losses) were resolved, leaving no material net financial impact on Emerson.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the key evolution of Emerson's relationship with Micromine from a planned acquisition to termination due to lack of Russian regulatory approval. The financial implications are accurately summarized, including the absence of a termination fee and no material net financial impact. Quantitatively, the AU$900 (~$623 USD) acquisition amount and the reason for termination are correct. However, the LLM omits the specific $24 mark-to-market gain in 2023 from foreign currency forward contracts, which is a notable financial implication mentioned in the ground truth. While it references 'prior, already-recorded costs (e.g., foreign-currency hedging gains/losses)', it does not specify the gain amount, reducing completeness. Additionally, the ground truth notes that AspenTech terminated all outstanding foreign currency forward contracts in 2024, a detail absent in the LLM response. These omissions affect completeness and precision but do not invalidate the core correctness. The entity identification (Emerson, AspenTech, Micromine) and timeline (2023–2024) are accurate. The reasoning is sound, correctly linking the failed regulatory approval to deal termination and financial consequences. The answer is highly relevant and synthesizes multi-hop information appropriately, though with minor gaps in financial detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 378,
        "total_tokens": 1712
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How did the availability of shares under The Home Depot's U.S. Employee Stock Purchase Plan (ESPP) and the average purchase price of shares during the fiscal year change from 2022 to 2023?",
      "original_answer": "In 2022, there were approximately 17 million shares available under the U.S. ESPP, and associates purchased approximately one million shares at an average price of $305.14. In 2023, the number of shares available under the U.S. ESPP decreased to 15 million, and associates again purchased approximately one million shares, but at a lower average price of $277.19. This indicates a reduction in share availability and a notable decrease in the average purchase price during the fiscal year.",
      "llm_answer": "\nThe U.S. ESPP had about 17 million shares available at the close of fiscal 2022, but that pool shrank to roughly 15 million shares by the end of fiscal 2023.  At the same time, the average price paid for shares under the plan fell from approximately $305 per share in fiscal 2022 to about $277 per share in fiscal 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the essential information from the ground truth. (1) It correctly states that shares available under The Home Depot's U.S. ESPP decreased from approximately 17 million in fiscal 2022 to 15 million in fiscal 2023. The average purchase price is reported as ~$305 in 2022 and ~$277 in 2023, which aligns closely with the exact figures of $305.14 and $277.19—minor rounding is acceptable and common in financial reporting. (2) All numeric values are factually correct within reasonable approximation; no calculation errors are present. The answer captures the directional changes (decrease in availability and lower purchase price) accurately. (3) The multi-hop reasoning—comparing availability and pricing across two fiscal years—is sound and well-synthesized. (4) While the LLM omits the detail that approximately one million shares were purchased in each year, this does not undermine the core of the question, which focuses on share availability and average price. The omission is minor and does not affect the overall correctness. Wording differs slightly but maintains semantic equivalence. Thus, the answer is factually robust, contextually relevant, and logically coherent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1212,
        "completion_tokens": 342,
        "total_tokens": 1554
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has the pattern of impairment triggers and associated charges across DHR's business segments evolved between the 2022 and 2023 filings, and what does this indicate about shifting risks in its intangible asset portfolio?",
      "original_answer": "In the 2022 filing, DHR reported impairment triggers only in the Diagnostics segment during the first quarter of 2021, resulting in a $10 million impairment charge. In contrast, the 2023 filing identified impairment triggers in multiple segments: the Biotechnology segment in the second quarter of 2023, the Diagnostics and Biotechnology segments in the fourth quarter of 2023, and again in the Diagnostics segment in the first quarter of 2021 (which was included for comparative purposes). The impairment charges increased significantly, from $10 million in 2021 (reported in the 2022 filing) to $77 million in 2023 (reported in the 2023 filing). This indicates a notable expansion in both the scope and magnitude of impairment activity, particularly affecting the Biotechnology segment in 2023, which was not previously a focus of impairment events. This evolution suggests growing risks in DHR’s intangible asset portfolio, especially in its Biotechnology segment.",
      "llm_answer": "\nBetween the 2022 and 2023 filings the pattern of impairment triggers moved from isolated events in the Diagnostics and Environmental & Applied Solutions segments—​which generated $10 M and $22 M charges in 2021 and no charges in 2022—to new triggers in the Biotechnology segment (second‑quarter 2023) and a repeat trigger in Diagnostics (fourth‑quarter 2023) that together produced $77 M of impairment charges in 2023.  This shift shows that the company now perceives higher risk of impairment in its Biotechnology‑related finite‑lived intangibles, indicating a re‑allocation of exposure from the older Diagnostics/EAS assets to the newer Biotechnology portfolio.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that there were impairment triggers in both the Diagnostics and Environmental & Applied Solutions (EAS) segments in 2021, with $10M and $22M charges respectively. However, the ground truth confirms only a $10M charge in the Diagnostics segment in Q1 2021—there is no mention of EAS or a $22M charge in 2021. Additionally, the LLM claims there were no charges in 2022, which may be true, but this was not explicitly confirmed in the ground truth. More critically, the LLM misattributes the $77M total 2023 charge to both Biotechnology and Diagnostics in Q4 2023, but fails to note that the 2023 filing reported multiple triggers: Biotechnology in Q2 2023, both Diagnostics and Biotechnology in Q4 2023, and a repeat mention of Diagnostics in Q1 2021 for comparative purposes. The $77M figure itself matches the ground truth, but the breakdown is not verified and appears oversimplified. (2) Quantitative accuracy is low: the $22M charge in EAS is entirely fabricated, and the attribution of charges across quarters and segments lacks precision. The correct evolution is from a single $10M charge (in 2021, reported in 2022 filing) to $77M in new charges in 2023 (reported in 2023 filing), with Biotechnology emerging as a new risk. (3) The multi-hop reasoning is partially sound—the model identifies a shift from Diagnostics to Biotechnology as a growing risk, which aligns with the ground truth. However, it introduces a false entity (EAS) and incorrect historical charges, undermining the synthesis. The conclusion about shifting risk to newer Biotechnology assets is plausible but based on flawed premises. (4) Contextual relevance is high because the answer addresses the evolution of impairment triggers, segments involved, and implications for intangible asset risk. However, due to major factual errors in numbers and entities, the correctness score is low despite relevant framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1427,
        "completion_tokens": 534,
        "total_tokens": 1961
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did the value of outstanding letters of credit related to trade contracts change between 2022 and 2023, and what does this indicate about the company's involvement in business transactions tied to trade contracts?",
      "original_answer": "The value of outstanding letters of credit related to trade contracts increased from $362 million in 2022 to $598 million in 2023. This significant increase indicates a growing involvement or expansion in business activities tied to trade contracts during this period.",
      "llm_answer": "\nThe company’s outstanding letters of credit that are tied to trade contracts grew from **$362 million at the end of fiscal 2022** to **$598 million at the end of fiscal 2023**—an increase of roughly **$236 million (about 65 %)**. This jump shows that Home Depot has become more involved in trade‑related transactions, using a larger volume of letters of credit to support its contractual commitments.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the values of $362 million in 2022 and $598 million in 2023 are accurately reported. The increase of $236 million is correct (598 - 362 = 236), and the calculated percentage increase of approximately 65% is accurate (236 / 362 ≈ 0.6519, or 65.19%). Minor rounding to 65% is acceptable. (2) The answer addresses both parts of the question: the change in value between 2022 and 2023, and the implication regarding the company's involvement in trade-related transactions. (3) Entity accuracy is correct—the company (implied as Home Depot, consistent with context), metric (outstanding letters of credit related to trade contracts), and fiscal years (2022 and 2023) are all correctly identified. (4) The reasoning is sound: the increase in letters of credit is logically interpreted as a sign of growing involvement in trade-related business activities, which aligns with the ground truth. The LLM correctly synthesizes multi-hop information (change in value over time and its business implication). (5) Semantic equivalence is maintained—wording differs slightly but conveys the same factual and interpretive content. No errors in facts, calculations, or logic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1185,
        "completion_tokens": 350,
        "total_tokens": 1535
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How has the status of the 0.300% Notes due 2028 evolved between the 2023 and 2024 SEC filings, and what does this indicate about IBM's financial instruments disclosures?",
      "original_answer": "In the 2023 filing, the 0.300% Notes due 2028 were disclosed as part of IBM's instruments defining the rights of holders, with specific reference to Exhibit 4.1, filed on February 10, 2020. In the 2024 filing, the 0.300% Notes due 2028 are listed as actively issued financial instruments under the trading symbol IBM28B, registered on the New York Stock Exchange. This indicates a shift from merely disclosing the existence of the instrument in 2023 to formally recognizing it as an actively traded financial instrument in 2024, suggesting increased market engagement or liquidity for this instrument.",
      "llm_answer": "\nThe 0.300 % Notes due 2028 continued to be listed as an outstanding series of IBM debt in both the 2023 and 2024 Form 10‑K filings; the 2024 filing again includes them in the “Title of each class” table and reiterates the same indenture and supplemental indenture (Exhibit 4 to the 2016 Form 8‑K) as the governing documents. This unchanged presentation shows that IBM’s disclosures of its financial instruments remain stable and that no material amendment, redemption, or new issuance of these notes was reported between the two fiscal years.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth. (1) It claims the 0.300% Notes due 2028 were presented unchanged between the 2023 and 2024 filings, with identical disclosures and governing documents (Exhibit 4 to the 2016 8-K), but the ground truth states that in 2023 the notes were referenced under Exhibit 4.1 filed on February 10, 2020, and in 2024 they were newly listed as actively traded under symbol IBM28B on the NYSE—indicating a material change in disclosure status. (2) The quantitative elements (interest rate: 0.300%, maturity: 2028) are correct, but the document references (Exhibit 4 to 2016 8-K) are factually wrong per ground truth, which cites Exhibit 4.1 from 2020. There are no calculations in this question, so accuracy hinges on correct document dates and exhibit numbers, which the LLM fails to provide. (3) The multi-hop reasoning is flawed: the question asks about the evolution of the note's status and what it indicates about disclosure practices. The LLM concludes there was no change, missing the key shift from passive disclosure to active recognition as a traded instrument, which implies greater market visibility or liquidity. (4) Contextual relevance is moderate because the answer addresses IBM’s financial instruments and the notes in question, but it fails to capture the evolution or its implications, rendering it substantively incorrect. The answer reflects a failure to synthesize the correct cross-year changes in disclosure status.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 410,
        "total_tokens": 1702
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How has IBM's treatment of the 1.750% Notes due 2031 evolved between 2023 and 2024, particularly in terms of disclosure and registration on stock exchanges?",
      "original_answer": "In 2023, IBM disclosed the 1.750% Notes due 2031 in its 10-K filing, indicating that the instrument defining the rights of the holders was incorporated by reference as part of an exhibit filed on January 30, 2019. By 2024, the 1.750% Notes due 2031 were not only still referenced but also explicitly registered under a trading symbol (IBM31) on the New York Stock Exchange, reflecting a shift from mere disclosure to formal recognition and active listing on a financial market platform.",
      "llm_answer": "\nBetween 2023 and 2024 IBM kept the 1.750% Notes due 2031 listed on the New York Stock Exchange under the ticker IBM31. In the 2023 10‑K the registration details appeared in the “Item 1. Business” table on pages 18‑22, whereas the 2024 10‑K moves that table to the front (pages 1‑5) and adds an explicit reference to the governing indenture, but the notes remain registered and disclosed in the same manner.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains several inaccuracies that significantly deviate from the ground truth. (1) It incorrectly states that the 1.750% Notes due 2031 were already listed on the New York Stock Exchange under ticker IBM31 in 2023, while the original answer clarifies that in 2023 the notes were only disclosed (with rights incorporated by reference from a 2019 filing), not formally registered or listed. The key evolution—shift from disclosure to active listing—was missed. (2) The claim that registration details appeared in the 'Item 1. Business' table on pages 18–22 in the 2023 10-K and were moved to pages 1–5 in 2024 lacks verification and introduces specific page numbers not present in the ground truth; such granular detail is unsupported and potentially misleading. (3) The assertion that the notes 'remain registered and disclosed in the same manner' contradicts the original answer’s central point: there was a material change in status—from disclosure via incorporation to explicit registration and formal listing under a trading symbol. (4) While the LLM correctly identifies the note’s existence and the ticker IBM31 in 2024, it fails the multi-hop reasoning required to contrast the two years accurately. The core evolution—transition from passive disclosure to active market recognition—is misrepresented. Quantitative accuracy is moderate: percentages and ticker symbol are correct, but no incorrect calculations are made (only mischaracterizations). Contextual relevance is high as the response stays on topic. However, qualitative accuracy is low due to flawed reasoning and incorrect synthesis across years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1225,
        "completion_tokens": 443,
        "total_tokens": 1669
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did Eli Lilly's financial relationship with Zyprexa evolve between 2023 and 2024, particularly in terms of revenue recognition and business model approach?",
      "original_answer": "In 2023, Eli Lilly generated $1.45 billion from the sale of the rights for the olanzapine portfolio, including Zyprexa, outside the U.S., indicating a direct revenue stream from product sales. By 2024, the company no longer reported Zyprexa as part of product sales; instead, revenue from the 2023 sale of rights was included in collaboration and other arrangements revenue, signaling a shift from direct product sales to revenue recognition through licensing and collaboration agreements. This change reflects a transformation in the financial relationship from active product sales to post-sale royalty or profit-sharing arrangements.",
      "llm_answer": "\nBetween 2022 and 2023 Eli Lilly’s Zyprexa‑related revenue jumped from roughly $337 million to about $1.69 billion – the latter figure reflects the one‑time sale of the olanzapine portfolio rights rather than ongoing drug sales.  That transaction is reported as collaboration/other revenue (and contributes to acquired IPR&D), so the company no longer records recurring product‑sale revenue from Zyprexa; by 2024 the only Zyprexa‑related amounts are residual references to the previously sold rights, indicating a shift from a product‑sales model to a licensing‑style, lump‑sum revenue recognition.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the shift in Eli Lilly's financial relationship with Zyprexa from direct product sales to licensing/royalty-based revenue recognition between 2023 and 2024, which aligns with the ground truth. It accurately notes that the large revenue increase in 2023 was due to the one-time sale of rights to the olanzapine portfolio (including Zyprexa) and that this is classified under collaboration/other revenue, not product sales. By 2024, the absence of recurring product sales and presence of residual references is correctly interpreted as a shift to a licensing-style model. (2) However, there are quantitative inaccuracies: the ground truth states $1.45 billion from the sale of rights in 2023, but the LLM claims $1.69 billion, which is incorrect. Additionally, the LLM references 2022 revenue of $337 million, which is not mentioned in the original answer and introduces data not supported by the ground truth. These deviations affect factual precision. (3) The multi-hop reasoning is sound—LLM connects the change in revenue classification (from product sales to collaboration revenue) with a strategic shift in business model, correctly inferring the post-sale royalty/profit-sharing arrangement. This demonstrates good synthesis across time and financial categories. (4) Despite strong qualitative reasoning and contextual relevance, the correctness score is reduced due to incorrect figures and introduction of unsupported data (2022 revenue), warranting a 7. Quantitative accuracy is penalized more heavily (6) due to the significant dollar amount discrepancy ($1.45B vs $1.69B).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 447,
        "total_tokens": 1758
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How did the treatment and financial impact of the Mobility Preferred Interests evolve from 2023 to 2024, particularly in terms of redemption obligations and their effect on earnings per share calculations?",
      "original_answer": "In 2023, AT&T reclassified the Mobility Preferred Interests from equity to a liability due to the certainty of redemption, recording $2,670 in current liabilities and $2,670 in noncurrent liabilities. The company ultimately repurchased all remaining interests in April 2023 for $5,414, including accrued distributions. By 2024, the Mobility Preferred Interests were fully retired, and the focus shifted to their impact on earnings per share calculations, where under ASU 2020-06, the ability to settle these interests in stock was reflected in the diluted earnings per share computation for periods prior to the repurchase. This indicates a shift from active financial obligations to retrospective accounting treatment.",
      "llm_answer": "\nFrom 2022 through early 2023 the Mobility II Preferred Interests were treated as redeemable equity that could be put to AT&T or redeemed by the company, and because they were potentially settleable in stock they were included in the diluted‑EPS denominator (72 million shares in 2022).  In April 2023 AT&T repurchased the remaining 213 million interests (plus the earlier 105 million put) for about $5.4 billion, re‑classified the instruments as liabilities, and settled all redemption obligations; consequently, no Mobility Preferred Interests remained outstanding at the end of 2023 and there was no longer any dilutive share count to adjust EPS.  By the 2024 reporting period the former interests have been fully retired, so they no longer affect either the redemption liability or the calculation of basic or diluted earnings per share.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth, with only minor discrepancies in quantitative details. (1) Correctly identifies the reclassification of Mobility Preferred Interests from equity to liability in 2023 due to redemption certainty, the full repurchase in April 2023, and the retirement of the instrument by 2024. It accurately notes the shift in EPS treatment: inclusion in diluted EPS prior to repurchase (due to potential stock settlement under ASU 2020-06) and removal post-retirement. (2) Quantitatively, the LLM states the repurchase was for 'about $5.4 billion', which matches the ground truth amount of $5,414 million (i.e., $5.414 billion); this is acceptable as a rounded figure. However, it introduces specific numbers not in the original—213 million and 105 million interests—which are plausible but not confirmed in the ground truth, and the 72 million diluted shares in 2022, while contextually reasonable, are not present in the original answer. These additions do not contradict but go beyond the provided truth. (3) The multi-hop reasoning is sound: it connects the accounting treatment (reclassification to liability), the redemption event, and the subsequent impact on EPS calculations across 2023 and 2024. It correctly infers that once retired, the interests no longer affect basic or diluted EPS. (4) The answer is contextually complete and directly addresses the evolution of treatment and financial impact over time. The only reason for not scoring a 10 is the introduction of unverified granular share numbers, though they do not appear factually incorrect. Overall, the semantic meaning and financial logic match the ground truth very closely.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1404,
        "completion_tokens": 463,
        "total_tokens": 1867
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has IBM's treatment and disclosure of the 0.875% Notes due 2030 evolved between 2023 and 2024, particularly in terms of its listing and registration status?",
      "original_answer": "In 2023, the 0.875% Notes due 2030 were disclosed as part of a list of instruments incorporated by reference to Exhibit 4.1 to Form 8-K filed on February 8, 2022. By 2024, the 0.875% Notes due 2030 were explicitly listed in the table of registered securities with a trading symbol (IBM30A) and registered on the New York Stock Exchange. This indicates a shift from a referenced disclosure to a fully listed and registered financial instrument.",
      "llm_answer": "\nIn the 2023 Form 10‑K the 0.875 % Notes due 2030 were listed on the NYSE (ticker IBM30A) and were included in the table of securities registered under Section 12(b), with the governing indenture incorporated by reference from a 2022 Form 8‑K. The 2024 filing retains that listing and registration but adds a specific reference to a February 2 2024 Form 8‑K amendment to the indenture, confirming that the notes remain listed, registered, and that the amendment is incorporated by reference.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) According to the ground truth, in 2023 the 0.875% Notes due 2030 were *not* explicitly listed in the table of registered securities or shown with a trading symbol—instead, they were disclosed by incorporation by reference to a February 8, 2022 Form 8-K. However, the LLM claims they were already listed on the NYSE with ticker IBM30A in the 2023 Form 10-K, which contradicts the original answer. (2) The LLM states that the 2024 filing 'retains that listing and registration' and adds a reference to a February 2, 2024 Form 8-K amendment. The ground truth does not mention any such amendment or Form 8-K filing on February 2, 2024, nor does it indicate that the 2023 filing included NYSE listing details. This introduces fabricated information. (3) The core evolution—shift from referenced disclosure in 2023 to explicit listing in 2024—is reversed in the LLM’s account, failing the multi-hop reasoning requirement. (4) While the entities (IBM, 0.875% Notes due 2030, NYSE, Form 8-K) are correct, the timeline and status attribution across years are incorrect. The contextual relevance is moderate because the answer addresses the right topic and structure, but factual errors dominate. Quantitative accuracy is low due to incorrect dates (Feb 2 vs Feb 8, 2022 vs 2024) and unsupported claims about registration status. Qualitative accuracy suffers from flawed synthesis and incorrect inference.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1237,
        "completion_tokens": 408,
        "total_tokens": 1645
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did the structure and distribution terms of the Telco Preferred Interests evolve from 2023 to 2024, and what does this indicate about AT&T's approach to financing through preferred equity instruments?",
      "original_answer": "In 2023, the Telco Preferred Interests consisted of $2,000 of Class A-1 preferred interests issued in September 2020, paying a 4.25% annual distribution, and $5,250 of Class A-2 and A-3 preferred interests issued in April 2023, paying a 6.85% annual distribution. By 2024, the total Telco Preferred Interests had grown to $7,250, with the Class A-1 preferred interests still at 4.25% and the Class A-2 and A-3 interests remaining at 6.85%, both subject to reset every seven years. Additionally, in 2024, AT&T clarified that failure to pay distributions would not restrict cash movements or its ability to pay dividends or repurchase shares. The structure remained consistent in terms of redemption rights and noncontrolling interest classification, but the expansion of the instrument in 2024 suggests a continued reliance on preferred equity as a financing strategy.",
      "llm_answer": "\nThe Telco LLC preferred‑equity structure was broadened in 2024.  In 2023 the company had three cumulative series – Class A‑1 (4.25 % initial distribution, reset every 7 years) and Classes A‑2/A‑3 (6.85 % initial distribution, reset on 1 Nov 2027 and every 7 years thereafter).  In 2024 AT&T issued an additional $2.25 bn of Class A‑4 preferred interests that carry a 5.94 % initial distribution, a reset on 1 Nov 2028 (and every 4 years thereafter) and a call option beginning 1 Nov 2028; the proceeds are earmarked to fund the redemption of earlier preferred securities.  \n\nThis evolution shows that AT&T is actively managing its preferred‑equity financing—adding new tranches with different rate‑reset schedules and call features to optimize cost, maintain liquidity flexibility, and support the orderly redemption of older preferred issues while still preserving unrestricted access to dividends and share‑repurchaseauthorities.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) Quantitatively, the LLM claims AT&T issued $2.25 billion of Class A-4 preferred interests in 2024 at 5.94%, with reset and call dates in 2028. However, the ground truth states that by 2024, the total Telco Preferred Interests were $7,250 (consistent with the 2023 total of $7,250: $2,000 Class A-1 + $5,250 Class A-2/A-3), with no new issuance or new class (e.g., Class A-4) mentioned. The $2.25 billion figure appears to be a miscalculation (possibly $7,250 - $5,250 = $2,000, not $2,250), and the 5.94% rate, 2028 reset, and 4-year reset cycle are all fabricated. (2) The ground truth confirms no structural change in 2024 other than a clarification on distribution payment flexibility—specifically, that failure to pay does not restrict dividends or share repurchases. The LLM invents new securities, terms, and redemption plans not present in the original. (3) While the LLM correctly notes the 4.25% and 6.85% distributions and 7-year reset for existing classes, it incorrectly implies evolution through new issuance rather than continuity. (4) The reasoning about AT&T managing preferred equity is plausible but based on false premises, reducing qualitative accuracy. The answer is contextually relevant to the question about financing strategy but fails on core facts and multi-hop synthesis, as it does not accurately reflect the lack of structural change beyond expanded clarity on payment flexibility.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1464,
        "completion_tokens": 412,
        "total_tokens": 1876
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How has Capital One's involvement in multifamily commercial real estate loans evolved between 2022 and 2023, particularly in terms of risk exposure under loss sharing agreements with government-sponsored enterprises?",
      "original_answer": "In 2022, Capital One originated multifamily commercial real estate loans with the intent to sell them to GSEs, entering into loss sharing agreements, which resulted in a liability of $82 million. By 2023, the company continued this practice but the liability recognized on the consolidated balance sheets for these loss sharing agreements increased to $137 million, indicating a significant increase in risk exposure. This evolution reflects a growing involvement in these types of loans and a corresponding rise in the financial obligations tied to their loss sharing agreements.",
      "llm_answer": "\nBetween 2022 and 2023 Capital One continued to originate multifamily commercial‑real‑estate loans that it sells to government‑sponsored enterprises under loss‑sharing agreements.  The liability recorded for these loss‑sharing arrangements rose from **$82 million (2022) to $137 million (2023)**, reflecting a larger pool of originated loans and therefore greater risk exposure.  Moreover, since 2020 the company has applied the **fair‑value option** to new loss‑sharing agreements, so unrealized gains and losses are now recognized in non‑interest income rather than being amortized, which makes the risk exposure more visible in the financial statements.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: the liability increased from $82 million in 2022 to $137 million in 2023, and these values match the original answer exactly. There are no calculation errors. (2) The answer is complete, addressing both the continuation of Capital One's involvement in multifamily CRE loans and the increase in risk exposure via loss sharing agreements. (3) Entity accuracy is strong: 'Capital One', 'government-sponsored enterprises (GSEs)', 'loss-sharing agreements', and the correct years (2022–2023) are all properly identified. (4) The reasoning is sound and adds value by including the detail about the fair-value option applied since 2020, which, while not in the original answer, is factually consistent and enhances the explanation by clarifying how risk exposure is now accounted for in financial statements. This additional context does not contradict the ground truth and supports the conclusion of increased visibility in risk exposure. The only reason for not scoring a 10 is that the original answer did not include the fair-value option detail, so it's an augmentation rather than a strict synthesis from the provided truth; however, it doesn't detract from accuracy. Overall, the LLM demonstrates correct multi-hop reasoning across time periods and financial implications, with excellent contextual relevance and factual precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 398,
        "total_tokens": 1725
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did Amazon's co-branded credit card programs shift in strategic significance and associated regulatory risks from 2022 to 2023, particularly in terms of new compliance obligations and their potential impact on operating results?",
      "original_answer": "In 2022, Amazon introduced co-branded credit card programs as part of its payment offerings, highlighting the risk that renewal on less favorable terms or termination could adversely affect operating results. The regulatory risks at that time included compliance with payment card association rules such as data security and certification requirements. By 2023, Amazon expanded its offerings and emphasized additional compliance obligations, including data localization rules, which were not mentioned in 2022. This indicates that the co-branded credit card programs became subject to a broader set of regulatory risks, particularly in international jurisdictions, which could increase compliance costs and operational complexity. The potential impact on operating results grew as Amazon now faced risks not only from traditional payment regulations but also from evolving data governance laws, particularly regarding cross-border data transfers tied to these credit card programs.",
      "llm_answer": "\nFrom the 2022 filing Amazon treated its co‑branded credit‑card partnerships as a modest but growing revenue stream that reinforced the attractiveness of its ecosystem, and it disclosed only the ordinary payment‑processor fees and standard consumer‑protection compliance that such programs entail. In contrast, the 2023 10‑K notes that the strategic importance of these programs has risen sharply while the regulatory landscape has tightened—new mandates for enhanced authentication, stricter data‑security and privacy rules, and heightened antitrust/consumer‑protection scrutiny now impose additional compliance costs and create a real risk of termination or renewal on less‑favorable terms. Consequently, the company warns that any deterioration in the economics of these agreements or failure to meet the expanded compliance obligations could lower interchange‑fee income and increase operating expenses, directly pressuring future operating results.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of strategic shift and increased regulatory risks from 2022 to 2023. It accurately captures that Amazon's co-branded credit card programs grew in strategic importance and faced heightened regulatory scrutiny, including new compliance obligations that could impact operating results. The mention of 'enhanced authentication,' 'stricter data-security and privacy rules,' and 'antitrust/consumer-protection scrutiny' aligns with the broader regulatory expansion noted in the original answer, including data localization and cross-border data transfer concerns. While the LLM does not explicitly mention 'data localization rules'—a specific new obligation highlighted in the ground truth—it does generalize the increased compliance burden accurately, which supports a high but not perfect qualitative accuracy score. There are no numerical values in the question or answers, so quantitative accuracy is scored as 10 by default (no errors). The answer is contextually fully relevant, addressing both strategic significance and regulatory risks, and correctly synthesizing changes across years. The minor omission of 'data localization' as a specific new requirement prevents a top score in qualitative accuracy, but the overall reasoning and multi-hop synthesis (comparing 2022 vs 2023 disclosures) are sound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1505,
        "completion_tokens": 382,
        "total_tokens": 1887
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How has PM's financial relationship with RBH evolved between 2022 and 2024, particularly regarding the consolidation status and valuation considerations of RBH within PM's financial statements?",
      "original_answer": "In 2022, RBH was deconsolidated from PM's financial statements due to CCAA proceedings initiated in 2019, with its financial results excluded since that time. Additionally, PM faced potential material impacts from unresolved Canadian tobacco litigation, including a CAD 3.1 billion allocation of compensatory damages against RBH. By 2024, PM's relationship with RBH had evolved into holding an equity investment, which required impairment analysis. The audit process emphasized significant judgment around the fair value estimate of the investment, including assumptions on discount rates, sales volumes, operating margins, and the tax treatment of a potential global settlement. This reflects a shift from a deconsolidated subsidiary to a valued equity stake requiring ongoing impairment evaluation.",
      "llm_answer": "\nSince the March 2019 deconsolidation of Rothmans, Benson & Hedges Inc. (RBH), the company has not been consolidated in PMI’s financial statements; by 2022 it was carried as an equity security without a readily determinable fair value, and in 2024 PMI performed an impairment review that concluded the investment was impaired, resulting in a $2.3 billion non‑cash charge that reduced the carrying amount to an estimated fair value of $714 million.  The 2024 valuation relied on a discounted‑cash‑flow model and assumptions about the allocation of global settlement amounts and tax deductibility, introducing significant judgment into the fair‑value estimate.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the key evolution in PM's financial relationship with RBH from 2022 to 2024, including the deconsolidation, shift to equity investment, and impairment analysis. However, there are some quantitative discrepancies: the original answer does not mention a $2.3 billion impairment charge or a $714 million fair value estimate; these specific figures are absent from the ground truth, making their inclusion in the LLM answer factually unsupported. The original answer notes that by 2024, PM held an equity investment requiring impairment analysis with significant judgment around valuation assumptions (discount rates, sales volumes, margins, tax treatment), which the LLM correctly identifies, including the use of a discounted cash flow model and global settlement assumptions. The deconsolidation date is correctly cited as 2019 (not 2022), and the LLM accurately reflects that RBH was not consolidated in 2022. The mention of 'equity security without readily determinable fair value' aligns with accounting standards for such investments. The LLM adds specificity (e.g., exact impairment amount and resulting carrying value) not present in the ground truth, which weakens quantitative accuracy. There is no mention in the original answer of the CAD 3.1 billion litigation allocation being directly tied to the 2024 valuation, so the LLM’s focus on global settlement and tax deductibility, while plausible, slightly overreaches without confirming that link. Nonetheless, the reasoning is sound, entities (PM, RBH, CCAA context implied via deconsolidation) are correct, and the multi-hop synthesis across years and accounting treatments is well executed. The answer is highly relevant and conveys the core transformation in the financial relationship.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 485,
        "total_tokens": 1861
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did the financial performance and strategic positioning of Baqsimi evolve between 2023 and 2024, particularly in terms of revenue contribution and its role within LLY's product portfolio?",
      "original_answer": "In 2023, Baqsimi contributed $677.6 million in total revenue, with $645.7 million from the U.S. and $31.9 million from outside the U.S., indicating it was still a growing product within LLY's portfolio. By 2024, Baqsimi was no longer reported as a direct revenue contributor through product sales; instead, it was disclosed as part of a collaboration and other arrangements, specifically under the 2023 sale of rights. This shift suggests that LLY transitioned Baqsimi from an internally commercialized product to a divested asset, impacting its strategic focus and revenue model. The absence of Baqsimi from direct product revenue in 2024 reflects a significant change in its role and contribution to LLY's financials.",
      "llm_answer": "\nIn 2023 Baqsimi produced $677.6 million of total revenue—up from only $139.3 million in 2022—largely because Lilly recognized a $579 million one‑time gain from the sale of its rights and modest ongoing sales; however, by the 2024 reporting period that figure represented just a small slice of Lilly’s $45 billion consolidated revenue, underscoring a strategic pivot away from Baqsimi as a growth driver toward higher‑volume, higher‑margin franchises such as Mounjaro, Jardiance and Verzenio.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly states Baqsimi's 2023 total revenue as $677.6 million, it incorrectly attributes a $579 million one-time gain from the sale of rights as the primary reason for the revenue increase, which is not supported by the ground truth. The ground truth indicates that Baqsimi generated $645.7 million in U.S. sales and $31.9 million outside the U.S., implying that the $677.6 million reflects actual product sales, not a one-time gain. There is no mention of a $579 million gain in the original answer. Additionally, the LLM introduces a comparison to 2022 revenue ($139.3 million), which is not part of the provided ground truth, making this addition unsupported. (2) The quantitative accuracy is low because the model misrepresents the composition of 2023 revenue and fabricates a one-time gain figure not present in the source. The $45 billion consolidated revenue for 2024 is plausible but not verifiable from the ground truth and distracts from the core issue: Baqsimi’s removal from direct product sales. (3) The reasoning partially captures the strategic shift—Baqsimi was indeed transitioned out of direct reporting in 2024 due to the divestiture—but misattributes the financial mechanism (one-time gain vs. ongoing collaboration income). The model correctly infers a strategic pivot but bases it on incorrect financial causality. (4) Contextual relevance is moderate because the answer addresses revenue evolution and strategic positioning, aligning with the question’s intent, but fails in factual fidelity. The mention of Mounjaro, Jardiance, and Verzenio adds context but is speculative and not in the ground truth. Overall, the answer is partially correct in direction but flawed in key facts and calculations, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 499,
        "total_tokens": 1813
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How has the composition of Union Pacific's Total Highway Revenue Equipment changed from 2022 to 2024, particularly in terms of the ratio of owned versus leased containers and chassis?",
      "original_answer": "In 2022, Union Pacific owned 78,837 units and leased 16,004 units of Total Highway Revenue Equipment, with containers making up the majority of owned assets and chassis being heavily leased. By 2024, the company significantly reduced both owned and leased equipment, with owned units dropping to 50,731 and leased units to 1,485. The most notable change was in leased containers, which fell from 1,856 in 2022 to just 288 in 2024, and owned chassis decreased from 29,875 to 4,356. This indicates a strategic shift toward owning fewer assets and leasing even fewer, especially in chassis.",
      "llm_answer": "\nFrom 2022 to 2024 the container portion of Union Pacific’s highway‑revenue equipment became almost entirely owned – owned containers rose from 48,962 (≈96 % of the 50,818 total) with only 1,856 leased, to 46,375 owned and just 288 leased (≈99.4 % owned), shifting the owned‑to‑leased ratio from roughly 26 : 1 to about 161 : 1.  The chassis fleet also moved toward greater ownership, with owned units increasing from 29,875 (≈68 % of the 44,023 total) and 14,148 leased to 4,356 owned and 1,197 leased (≈78 % owned), cutting the leased share from roughly one‑third to about one‑five and improving the owned‑to‑leased ratio from ~2.1 : 1 to ~3.6 : 1.  Overall, both container and chassis equipment became markedly more heavily owned between 2022 and 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors in both direction and magnitude of changes in Union Pacific's equipment composition from 2022 to 2024, despite addressing the right topic. (1) Quantitative inaccuracies: The LLM claims owned containers increased from 48,962 to 46,375, but the ground truth states total owned units dropped from 78,837 to 50,731 overall, with no breakdown suggesting an increase in owned containers. More critically, the LLM incorrectly states that owned chassis increased from 29,875 to 4,356 — this is a decrease, not an increase. It also misrepresents leased chassis: ground truth shows total leased units dropped from 16,004 to 1,485, but the LLM cites 14,148 leased in 2022 and 1,197 in 2024, which does not align with the known total leased containers (1,856) and implies incorrect chassis leasing figures. (2) Calculations are based on incorrect inputs: the LLM computes ownership ratios using fabricated totals (e.g., 50,818 total containers in 2022), which do not match the ground truth sum of owned and leased equipment (78,837 + 16,004 = 94,841 total units). (3) Multi-hop reasoning fails: the conclusion that Union Pacific shifted toward greater ownership of chassis is factually wrong — the ground truth shows a sharp reduction in both owned and leased chassis (owned chassis fell from 29,875 to 4,356), indicating asset divestment, not increased ownership. Similarly, leased containers dropped from 1,856 to 288, but the LLM incorrectly frames this as a proportional improvement in ownership ratio without acknowledging the broader drawdown. (4) The answer is contextually relevant and attempts correct analysis (ratios, trends), but the core data is misaligned with the knowledge graph, leading to an inverted understanding of the trend. Thus, while the structure and intent are sound, the factual foundation is flawed, resulting in a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 512,
        "total_tokens": 1857
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did Capital One's use of securitized debt obligations evolve between 2022 and 2023, particularly in terms of their role within the company's overall funding structure?",
      "original_answer": "In 2022, securitized debt obligations were explicitly described as one of the company's key funding sources alongside deposits, senior and subordinated notes, federal funds purchased, and FHLB advances. By 2023, while still present in the funding structure at $18.043 billion in carrying value, securitized debt obligations were categorized under Level 2 in the fair value hierarchy, indicating a shift toward more standardized valuation methods. This evolution suggests a more structured and possibly less volatile role for securitized debt obligations in Capital One's funding strategy.",
      "llm_answer": "\nBetween the end of 2022 and the end of 2023 Capital One’s securitized‑debt balance rose from about **$16.97 billion to $18.04 billion** – an increase of roughly **$1 billion** driven by net new issuances in its securitization programs (see Table 16.6, “Securitized debt obligations” carrying values).  This modest growth added to the firm’s overall funding mix, but securitized debt still represents only **≈4‑5 %** of total funding, serving as a supplemental source that complements deposit growth and other debt issuances within Capital One’s broader funding structure.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer is largely correct in its quantitative claims: the increase in securitized debt obligations from $16.97 billion in 2022 to $18.043 billion in 2023 is accurate (within rounding), and the $1 billion increase is approximately correct. The percentage of total funding (≈4–5%) is a reasonable inference if derived from total funding sources, though this specific percentage is not confirmed in the ground truth. 2) Quantitatively, the numbers align well with the ground truth: the 2023 carrying value of $18.043 billion is correctly cited (rounded to $18.04 billion), and the 2022 value of $16.97 billion is consistent with the implied starting point. However, the original answer does not mention the 2022 carrying value explicitly, so the LLM may have pulled that from a source outside the provided ground truth—this introduces a minor discrepancy in provenance, though the number itself is likely correct. 3) Qualitatively, the LLM captures the continued role of securitized debt as a supplemental funding source, which aligns with the original answer’s implication of a stable but structured role. However, it omits the key qualitative evolution noted in the ground truth: the reclassification to Level 2 in the fair value hierarchy, which signals a shift toward standardized valuation methods and a more structured risk management approach. This is a significant omission in the evolution narrative. 4) Contextually, the answer is highly relevant, addressing both the quantitative change and the role within the funding structure. The synthesis of securitized debt as a complementary, modest component of funding is sound and responsive to the question. However, the failure to mention the fair value hierarchy shift—a core part of the evolution—reduces the qualitative accuracy score. Overall, the answer is factually strong but misses a key conceptual development, warranting a correctness score of 8.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 516,
        "total_tokens": 1812
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did the nature of LLY's revenue from Zyprexa evolve between 2023 and 2024, particularly in terms of the source and recognition method of that revenue?",
      "original_answer": "In 2023, Zyprexa revenue was primarily derived from the sale of the rights for the olanzapine portfolio. By 2024, the revenue associated with Zyprexa was recognized as part of collaboration and other arrangements, specifically stemming from the 2023 sale of rights for the olanzapine portfolio, and was included in collaboration revenue rather than product sales. This reflects a shift in how Zyprexa-related revenue was categorized and recognized in 2024 compared to 2023.",
      "llm_answer": "\nBetween 2023 and 2024 the revenue stream from Zyprexa shifted from ongoing product sales to a one‑time gain on the sale of the olanzapine portfolio rights. In 2023 the $79.4 million Zyprexa amount reflected the recognition of the rights‑sale proceeds (recorded in “collaboration and other revenue” under Note 4), whereas prior years it had been reported as regular net product revenue from drug sales; by 2024 there is no continuing Zyprexa product revenue, so the only Zyprexa‑related proceeds are the 2023 one‑off gain.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual error regarding the timing and nature of the revenue recognition. The original answer states that in 2023, Zyprexa revenue was primarily from the sale of rights, and in 2024, revenue was recognized as part of collaboration and other arrangements stemming from that 2023 sale. However, the LLM incorrectly claims that the $79.4 million in 2023 reflected the recognition of the sale proceeds, implying a one-time gain was recorded in 2023. This contradicts the ground truth, which indicates that the shift in recognition method occurred in 2024, not that the entire gain was recognized in 2023. Furthermore, the LLM suggests there was no continuing revenue in 2024 because the gain was a '2023 one-off,' which misrepresents the ongoing recognition of revenue from collaboration arrangements post-sale. (2) The $79.4 million figure is introduced by the LLM but not present in the original answer; there is no verification that this number is accurate, and its inclusion without support from the ground truth constitutes a quantitative inaccuracy. No other numbers are mentioned in the original, so this unsupported figure reduces quantitative accuracy. (3) The reasoning partially captures the multi-hop nature of the shift in revenue recognition—from product sales to collaboration revenue—but misattributes the timing and accounting treatment. It correctly identifies that the source of revenue changed due to the sale of rights, but incorrectly frames the accounting impact as a one-time 2023 gain rather than a shift in categorization that became evident in 2024. (4) Contextually, the answer is relevant and addresses the evolution of revenue source and recognition method. The qualitative accuracy is moderate because the core idea of a shift is present, but the execution contains key errors. The correctness score is reduced primarily due to the incorrect assertion about when the revenue was recognized and the introduction of an unsupported dollar amount.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1250,
        "completion_tokens": 544,
        "total_tokens": 1795
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has the valuation methodology and classification of Federal Government Securities in the pension plan evolved from 2022 to 2024?",
      "original_answer": "In 2022, Federal Government Securities were valued under the 'Significant Other Observable Inputs (Level 2)' category and totaled $742 million. By 2024, the company clarified that these securities are valued using a bid evaluation process with bid data from independent pricing sources and are explicitly classified as Level 2 investments. This reflects a continuation in classification but adds specificity in methodology explanation.",
      "llm_answer": "\nFrom 2022 through 2024 the plan continued to value Federal Government Securities by a bid‑evaluation process using independent pricing sources, and they remained classified as Level 2 fair‑value measurements.  The only change was the size of the exposure – the fair‑value amount fell from roughly $742 million (reported in the 2021/2022 tables) to about $150 million (reported in the 2024 table) – reflecting a strategic shift toward a larger target debt allocation (70‑80 % of assets) while the valuation methodology and hierarchy level stayed the same.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly states that Federal Government Securities remained classified as Level 2 from 2022 to 2024, it incorrectly claims the value dropped from $742 million to $150 million. The ground truth only confirms the $742 million figure for 2022 and does not provide a 2024 value, so the $150 million figure is unsupported. Additionally, the original answer makes no mention of a strategic shift toward a larger target debt allocation (70–80%), which is an unsupported addition. (2) Quantitative accuracy is low: the $150 million figure is not in the ground truth, and no 2024 dollar amount is provided for comparison. The drop in exposure and percentage allocation are fabrications. (3) The reasoning is partially sound in noting continuity in classification and methodology, and the mention of bid-evaluation using independent pricing sources aligns with the 2024 clarification. However, the model introduces a multi-hop inference about strategic allocation and asset size changes not supported by the original answer, failing in accurate synthesis. (4) Contextual relevance is high because the answer addresses valuation methodology and classification over time, which is the core of the question, but the inclusion of unverified financial figures and strategic rationale reduces correctness. The model captures the qualitative continuity but adds unsupported quantitative and strategic details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1244,
        "completion_tokens": 407,
        "total_tokens": 1651
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How did Capital One's credit score data utilization for product segmentation decisions evolve from 2022 to 2023, and what does this indicate about their credit risk modeling strategy?",
      "original_answer": "In 2022, Capital One used credit score data for product segmentation decisions based on historical credit score distributions from 2020 to 2021, as shown in Table 21. In 2023, the company updated its data to reflect credit score distributions from 2022 to 2023 in the same table. This shift indicates a more current and dynamic credit risk modeling strategy, with product segmentation decisions being informed by the most recent borrower behavior and risk profiles, suggesting a proactive approach to managing credit risk in evolving economic conditions.",
      "llm_answer": "\nFrom 2022 to 2023 Capital One moved from a peripheral reference to credit‑score data to an explicit, systematic use of those scores for product segmentation.  The 2022 filing only notes that scores are “used … in some cases to drive product segmentation decisions,” whereas the 2023 filing expands the description, highlights refreshed monthly FICO data, and shows a more detailed score distribution (e.g., a higher share of >660 scores for auto loans and a slightly lower share of >660 scores for credit‑card loans).  This evolution signals that the firm is integrating granular, up‑to‑date credit‑score information into its risk‑based pricing and portfolio‑design models, using scores not just for subprime classification but as a core driver of how it segments products and tailors offerings to distinct credit‑risk groups.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies compared to the ground truth. While both mention Capital One and the evolution of credit score usage from 2022 to 2023, the LLM incorrectly claims that in 2022 the company only used credit scores 'in some cases' and that usage was peripheral, whereas the ground truth states that credit score data was actively used based on historical distributions from 2020–2021. The LLM also fabricates specific details not present in the original answer, such as 'refreshed monthly FICO data', 'higher share of >660 scores for auto loans', and 'slightly lower share of >660 scores for credit-card loans'—none of which appear in the ground truth. These are significant quantitative and factual errors. (2) There are no verifiable numbers in the original answer to cross-check (e.g., percentages or exact score thresholds), so the LLM’s inclusion of such specifics is unsupported and misleading. The original answer references Table 21 and a shift in time periods (2020–2021 to 2022–2023), which the LLM omits entirely, instead inventing granular data points. (3) The multi-hop reasoning is partially sound in that it identifies a strategic shift toward more dynamic use of credit data, which aligns with the ground truth’s conclusion about a 'more current and dynamic credit risk modeling strategy'. However, the LLM fails to correctly represent the nature of the data update (from older to newer distributions in the same table) and instead constructs a narrative of increasing explicitness and granularity not fully supported by the source. (4) The contextual relevance is high because the answer addresses product segmentation, credit risk modeling, and temporal evolution. However, due to fabricated quantitative details and misrepresentation of the 2022 practice, the correctness and quantitative accuracy scores are low. The qualitative accuracy is moderate because the general direction of the strategic shift is plausible, but the reasoning is based on incorrect premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 545,
        "total_tokens": 1900
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has Amazon's strategic positioning of AWS evolved from 2022 to 2023 in terms of its role within the company's broader business segments and investment priorities?",
      "original_answer": "In 2022, AWS was positioned primarily as a key area of investment within Amazon's broader technology and content spending, with an emphasis on supporting geographic expansion, new product categories, and internal operational efficiencies. The document highlighted that Amazon was investing in AWS alongside initiatives to build and deploy innovative software and electronic devices, indicating a strategic alignment with internal growth and infrastructure enhancement. By 2023, AWS had evolved into one of Amazon's three core business segments—alongside North America and International—reflecting its elevated strategic importance. The 2023 filing explicitly states that AWS serves developers and enterprises by offering a broad set of on-demand technology services, including compute, storage, database, analytics, and machine learning, and is now a distinct and central pillar of Amazon’s business model. This shift demonstrates a transformation in AWS's role from a strategic investment area to a standalone, mission-critical business segment.",
      "llm_answer": "\nFrom 2022 to 2023 Amazon’s view of AWS shifted from a key component of its broader “technology and content” investment—used to fund the infrastructure that powers its retail and fulfillment operations—to a distinct business segment that the company explicitly treats as a primary growth engine.  Accordingly, capital‑expenditure priorities moved toward expanding AWS’s cloud‑service portfolio (e.g., AI/ML, analytics, and additional data‑center capacity) and scaling its infrastructure, positioning AWS as a central driver of revenue diversification and cross‑segment synergies.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in AWS's strategic positioning from 2022 to 2023 as described in the ground truth. It correctly identifies that in 2022, AWS was part of Amazon's broader 'technology and content' investment area, supporting internal infrastructure. It also accurately reflects the shift by 2023, where AWS became a distinct and central business segment, now positioned as a primary growth engine. The mention of capital expenditure shifting toward AI/ML, analytics, and data-center expansion aligns with the ground truth's emphasis on AWS offering on-demand services like machine learning and database solutions. The only minor omission is that the original answer explicitly names the three core segments (North America, International, AWS), which the LLM answer does not mention—though it does convey AWS’s elevated status as a standalone segment. There are no numerical inaccuracies (quantitative accuracy is perfect as no specific numbers are involved and time periods are correct). The reasoning is sound, demonstrating proper multi-hop synthesis across years and strategic priorities. The answer is semantically equivalent and contextually fully relevant, with only a slight reduction in completeness due to the missing detail about the three-segment structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1411,
        "completion_tokens": 365,
        "total_tokens": 1776
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has Philip Morris International's financial relationship with Rothmans, Benson & Hedges Inc. (RBH) evolved between 2022 and 2024, particularly in terms of its accounting treatment and potential financial exposure?",
      "original_answer": "In 2022, RBH was deconsolidated from Philip Morris International’s financial statements due to its CCAA restructuring, and its financial results were no longer included in PMI’s consolidated financials. At that time, there was a comprehensive stay of Canadian tobacco litigation until March 31, 2022, and no loss accruals were made due to the inability to estimate potential losses. By 2024, PMI’s relationship with RBH had shifted from deconsolidation to an equity investment model. A proposed settlement of CAD 32.5 billion in the Canadian tobacco litigation emerged, prompting PMI to assess its investment in RBH for impairment. As a result, PMI recorded a non-cash impairment charge of $2,316 million in 2024, reflecting a decline in the estimated fair value of its investment. This marks a significant evolution from a deconsolidated entity with uncertain liabilities to a recognized equity investment with a quantified impairment.",
      "llm_answer": "\nBetween 2022 and 2024 PMI’s accounting treatment of Rothmans, Benson & Hedges Inc. shifted from full consolidation (prior to 2019) to de‑consolidation, with the remaining exposure now reflected only in PMI’s equity investment and related hedging activities; the 2022 10‑K notes that RBH’s financial results were de‑consolidated as of 22 Mar 2019, and the 2024 10‑K records the equity investment in RBH at a reduced carrying amount after a $2.3 bn non‑cash impairment charge (see Note 6 and the $27 m of derivative gains that may be re‑classified to earnings).  Consequently, PMI’s potential financial exposure to RBH is now limited to the carrying value of that equity stake, the possible re‑classification of hedging gains/losses in accumulated other‑comprehensive losses, and contingent liabilities arising from the ongoing CCAA proceedings and the proposed CAD 32.5 bn settlement, which could materially affect PMI’s results if realized.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the shift in accounting treatment from deconsolidation to equity investment and notes the $2.3 billion impairment charge in 2024, which aligns with the ground truth's $2,316 million (approx. $2.3B). However, it incorrectly states that deconsolidation occurred on March 22, 2019, while the ground truth specifies the deconsolidation was due to CCAA restructuring in 2022. This is a significant factual error in timing and context. (2) The numeric values are mostly accurate: $2.3 billion impairment is acceptably close to $2,316 million, and CAD 32.5 billion settlement amount is correctly cited. The mention of $27 million in derivative gains is not contradicted by the ground truth, though not included in the original answer, so it may be extraneous but not necessarily incorrect. The key error is the 2019 deconsolidation date, which contradicts the 2022 deconsolidation in the ground truth. (3) The multi-hop reasoning is partially sound: the model correctly infers that deconsolidation led to equity-method accounting and that the proposed litigation settlement triggered an impairment. However, it fails to correctly link the 2022 CCAA restructuring as the cause of deconsolidation, instead citing a 2019 event not mentioned in the ground truth, undermining the chronological evolution. (4) Despite the date error, the answer captures the core evolution in financial exposure and accounting treatment, hence a correctness score of 7. Quantitative accuracy is penalized due to the incorrect deconsolidation date and lack of precision on the exact impairment amount ($2,316M vs rounded $2.3B), though the latter is acceptable. Qualitative and contextual scores remain high because the overall logic and relevance are strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1487,
        "completion_tokens": 483,
        "total_tokens": 1970
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has the commercial significance of Biktarvy evolved for GILD from 2022 to 2024, considering both its revenue contribution and associated product risks?",
      "original_answer": "In 2022, Biktarvy was a major revenue driver for GILD, generating $8,624 million in total product sales globally, indicating its strong market position in the HIV treatment segment. By 2024, while specific revenue figures are not provided, the company's risk disclosures highlight Biktarvy's ongoing importance but also emphasize heightened risks related to the HIV product class, particularly concerning the reliance on TAF-based therapies and potential shifts in treatment paradigms. This evolution suggests that although Biktarvy remains central to GILD's revenue, its commercial outlook has become more vulnerable to competitive and regulatory pressures.",
      "llm_answer": "\nBetween 2022 and 2024 Biktarvy’s sales grew from about **$8.6 billion** to roughly **$9.8 billion**, making it Gilead’s single largest product and accounting for **≈30 % of total revenue** (and roughly one‑third of total product sales) by the end of 2024.  At the same time, its commercial outlook is exposed to heightened risk: looming **generic competition**, aggressive **price‑cutting and rebate pressures** from Medicare‑negotiation and the Inflation‑Reduction Act, and the possibility of **market‑share erosion** as HIV treatment paradigms shift toward newer regimens and alternative therapies.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in quantitative claims. The ground truth states that Biktarvy generated $8,624 million ($8.624 billion) in 2022, which the LLM approximates correctly as $8.6 billion. However, the LLM claims revenue grew to $9.8 billion by 2024—this figure is not supported by the original answer, which explicitly states that 'specific revenue figures are not provided' for 2024. Thus, the $9.8 billion figure is fabricated. Additionally, the claim that Biktarvy accounted for ≈30% of total revenue and one-third of product sales by 2024 is unsupported in the provided ground truth and cannot be verified. (2) The original answer does not provide any 2024 revenue data, so the LLM’s calculation or projection of growth to $9.8 billion lacks basis. The only confirmed number is the 2022 revenue, which the LLM reports with acceptable rounding. All other financial percentages and figures are speculative and incorrect. (3) The qualitative aspects partially align: the LLM correctly identifies that Biktarvy remains commercially significant and highlights relevant risks such as generic competition, pricing pressures (e.g., Inflation Reduction Act), and shifting treatment paradigms. These risks are consistent with the ground truth’s mention of 'heightened risks related to the HIV product class' and 'reliance on TAF-based therapies.' However, the LLM overreaches by implying quantifiable market share and revenue growth without evidence. (4) The contextual relevance is high because the response addresses both revenue contribution and product risks as asked. The reasoning structure is logical and covers the right themes, but the inclusion of unverified numerical data severely undermines factual correctness. Due to major quantitative errors despite some correct qualitative insights, the correctness score is 4 out of 10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 513,
        "total_tokens": 1830
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has Union Pacific Railroad's financial stake and operational relationship with TTX evolved from 2022 to 2024, particularly in terms of investment value and car hire expenses?",
      "original_answer": "Union Pacific Railroad's financial stake in TTX increased from $1.6 billion in 2021 (referenced in the 2022 filing) to $1.9 billion in 2024. Additionally, UPRR's car hire expenses rose from $375 million in 2021 to $432 million in 2024. These increases indicate a growing financial and operational involvement with TTX over the period.",
      "llm_answer": "\nFrom 2022 through 2024 Union Pacific’s equity stake in TTX grew modestly – the carrying value of its investment rose from about **$1.6 billion** (reported for 2021) to **$1.9 billion** by the end of 2024, reflecting the slight increase in ownership share (≈36.8 % to ≈37 %).  At the same time, the amount it pays TTX for rail‑car rentals (car‑hire expense) has risen steadily – $375 million in 2021, $402 million in 2022, $399 million in 2023 and **$432 million in 2024** – showing a growing operational reliance on TTX’s pooled rail‑car fleet.  Thus, both the financial investment and the car‑hire costs have expanded over the 2022‑2024 period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key numbers are correct: the investment value increased from $1.6 billion (2021, referenced in 2022 filing) to $1.9 billion in 2024, and car hire expenses rose from $375 million in 2021 to $432 million in 2024. The LLM adds granular detail by including intermediate values ($402M in 2022, $399M in 2023), which are consistent with a rising trend and do not contradict the ground truth. (2) Quantitative accuracy is perfect—dollar amounts, years, and percentages (≈36.8% to ≈37%) are correctly reported or reasonably estimated. (3) The reasoning is sound: the LLM correctly synthesizes multi-hop information (financial stake and operational expenses over time) and infers growing reliance on TTX, which matches the original conclusion. The slight expansion of ownership percentage is a reasonable inference from increased investment value, assuming proportional equity. (4) The answer is contextually complete and relevant, addressing both investment value and car hire expenses across the requested timeframe. The only minor limitation is the introduction of inferred intermediate-year data not present in the ground truth, but this does not reduce accuracy—it enhances clarity without contradiction. Thus, the answer earns a 9/10 for correctness, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1253,
        "completion_tokens": 385,
        "total_tokens": 1638
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How did Tesla's approach to scaling Solar Roof production change from 2022 to 2023, particularly regarding installer training initiatives and supply chain risk management?",
      "original_answer": "In 2022, Tesla emphasized expanding Solar Roof production by on-boarding and training new installers, collaborating with real estate developers, and reducing installation time and costs. The company also highlighted its need to hire additional personnel, particularly skilled electricians, to support the ramp. By 2023, Tesla's focus had shifted toward addressing broader supply chain risks and production ramp challenges, with language indicating that Solar Roof production now depended more on managing supplier reliability, global component constraints, and cost-effective manufacturing processes. The 2023 filing also noted that delays in production ramps could harm the business, signaling a shift from installer-focused growth to a more risk-averse strategy centered on supply chain resilience.",
      "llm_answer": "\nFrom 2022 to 2023 Tesla moved Solar‑Roof scaling from a pilot‑phase of onboarding new installers and partnering with builders toward a formalized training pipeline that expands certification programs and enlarges the pool of certified electricians to meet higher deployment volumes.  At the same time, its supply‑chain risk management shifted from relying mainly on external battery‑cell suppliers to building internal cell production capacity, diversifying suppliers and maintaining larger inventory buffers and raw‑material contracts to blunt the impact of component shortages on Solar‑Roof output.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains significant factual inaccuracies in the qualitative details, particularly regarding Tesla's supply chain focus. (1) Correct elements: The shift from pilot-phase installer onboarding in 2022 to a more structured training and certification pipeline in 2023 aligns with the ground truth’s emphasis on expanding installer training initiatives. The mention of expanding the pool of certified electricians matches Tesla’s 2022 need to hire skilled personnel. (2) Quantitative accuracy is high because no specific numbers (dates, dollar amounts, percentages) are misstated—the answer avoids numeric claims, so no errors exist in that domain. (3) However, the reasoning is flawed in the supply chain section: the original answer states Tesla’s 2023 focus shifted to managing supplier reliability, global component constraints, and cost-effective manufacturing processes broadly for Solar Roof production. The LLM incorrectly narrows this to battery-cell suppliers and internal cell production, which relates more to Tesla’s Powerwall or vehicle operations, not Solar Roof. Solar Roof supply chain issues pertain to roofing components, tiles, and general electronics—not battery cells. The mention of 'larger inventory buffers and raw-material contracts' is plausible but not stated in the original and misdirects the core risk from component constraints to battery-specific strategy. (4) Contextual relevance is strong because the answer addresses both installer training and supply chain risk as asked, and the structure follows the timeline. However, the misattribution of battery supply chain efforts to Solar Roof undermines the qualitative accuracy. The answer synthesizes a reasonable narrative but fails on key factual grounding in the source material, especially in multi-hop reasoning linking Solar Roof to battery supply chains, which is unsupported. Thus, correctness is only partially achieved.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 523,
        "total_tokens": 1879
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has The Coca-Cola Company's relationship with fountain retailers evolved between 2022 and 2023, particularly regarding the manufacturing and distribution of fountain syrups in the United States?",
      "original_answer": "In 2022, The Coca-Cola Company stated that U.S. bottlers were generally not authorized to manufacture fountain syrups, and instead, the Company itself manufactured and sold fountain syrups directly to authorized fountain wholesalers (including some bottlers) and certain fountain retailers. By 2023, the Company clarified that it continues to manufacture fountain syrups in the U.S., but now explicitly states that it sells these syrups to both fountain retailers and authorized fountain wholesalers or bottling partners who then distribute them to fountain retailers. This indicates a more explicit acknowledgment of a tiered distribution model involving bottling partners in 2023, suggesting a potential expansion of their distribution network or clarification of roles.",
      "llm_answer": "\nBetween 2022 and 2023 the Company’s U.S. fountain‑syrup model was unchanged: it continues to be the sole manufacturer of the syrups and sells them directly to fountain retailers (or to authorized fountain wholesalers who then supply the retailers).  The 2023 filing simply re‑classifies these sales under the North America operating segment, but the underlying relationship—no bottling partner is authorized to produce fountain syrups in the United States—remains the same as described for 2022.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct in stating that The Coca-Cola Company remains the sole manufacturer of fountain syrups in the U.S. and that bottling partners are not authorized to produce them—this aligns with the original answer for both 2022 and 2023. However, the LLM incorrectly asserts that the model was 'unchanged' between 2022 and 2023. The original answer highlights a key evolution: in 2023, the Company explicitly acknowledged selling fountain syrups not only to authorized wholesalers but also directly to bottling partners who then distribute to fountain retailers, indicating a more defined or expanded tiered distribution model. The LLM dismisses this shift as merely a 're-classification' under the North America segment, which is not supported by the ground truth and contradicts the documented clarification of distribution roles. While there are no numerical inaccuracies (hence high quantitative accuracy), the qualitative reasoning is flawed—the model failed to recognize the significance of the 2023 clarification as an evolution in the distribution relationship. The answer is contextually relevant and addresses the core topic, but misses the nuanced yet important shift in how distribution roles were described, leading to an incomplete and misleading conclusion about continuity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 363,
        "total_tokens": 1693
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has IBM's treatment and disclosure of the 0.950% Notes due 2025 evolved from 2022 to 2024, particularly in terms of its financial instrument classification and registration details?",
      "original_answer": "In 2022, the 0.950% Notes due 2025 were disclosed as part of IBM's exhibits in Form 8-K filings, specifically referenced under Exhibit 4.1 filed on May 22, 2017. By 2024, the 0.950% Notes due 2025 were not only still present but were actively listed as a financial instrument with a trading symbol 'IBM25B' on the New York Stock Exchange. This evolution indicates a shift from merely disclosing the instrument to formally registering and listing it for trading.",
      "llm_answer": "\nIn the 2022 filing (pages 28‑32) IBM disclosed the 0.950 % Notes due 2025 as a registered debt security (ticker IBM25B) under the Securities Act of 1933, merely noting its registration without extensive classification language. The 2024 Form 10‑K (pages 1‑5) continues to list the same instrument in the securities table, identifying it as a “0.950 % Notes due 2025 (IBM25B)” on the NYSE, confirming that its financial‑instrument classification has remained unchanged—only the presentation of the registration details has been updated to the standard 10‑K securities table.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) QUANTITATIVE ACCURACY: The LLM claims the 0.950% Notes due 2025 were already registered with ticker 'IBM25B' in the 2022 filing, but the ground truth states that in 2022 the notes were only disclosed as part of an Exhibit 4.1 in a May 22, 2017 Form 8-K — not in a 2022 filing. The LLM incorrectly cites 'pages 28–32' of a 2022 filing and implies the ticker was already in use then, which contradicts the ground truth. The 2024 listing on NYSE with symbol 'IBM25B' is correctly noted, but the timeline is distorted. (2) COMPLETENESS: The question asks about the evolution from 2022 to 2024, but the LLM misrepresents the 2022 state — claiming registration and ticker usage that the ground truth does not support until 2024. The evolution is misrepresented as a change in presentation rather than a shift from disclosure to active listing. (3) ENTITY ACCURACY: The financial instrument and percentage (0.950%) are correct, and 'IBM25B' is correctly identified as the ticker. However, the Form type and filing date in 2022 are wrong — the ground truth references a 2017 8-K, not a 2022 10-K. (4) REASONING: The multi-hop reasoning fails because the model incorrectly assumes the instrument was already registered and listed in 2022, thus missing the core evolution: from passive disclosure (in a prior year’s exhibit) to active listing in 2024. The conclusion that 'classification has remained unchanged' is unsupported, as the ground truth implies a progression in status. (5) SEMANTIC EQUIVALENCE: While the final state (2024 listing) is correctly described, the initial state is not, so the overall narrative is factually flawed. The answer is contextually relevant and well-structured, hence a moderate contextual relevance score, but factual errors severely reduce correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1268,
        "completion_tokens": 504,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has GILD's strategic positioning of Biktarvy evolved from 2022 to 2024, particularly in terms of its financial risk exposure and competitive differentiation within the HIV treatment market?",
      "original_answer": "In 2022, Biktarvy was listed among GILD’s key marketed products, indicating its central role in the company's HIV portfolio and suggesting strong commercial positioning. By 2024, the company highlighted increasing financial risk tied to its reliance on nucleoside-based therapies like Biktarvy, particularly due to the potential shift in HIV treatment paradigms away from TAF-based regimens. This evolution reflects a growing concern over Biktarvy’s long-term competitive differentiation and its ability to sustain revenue, especially in the face of rising generic competition and changing therapeutic preferences.",
      "llm_answer": "\nFrom 2022 through 2024 Gilead has treated Biktarvy as a cash‑generating anchor, using the strong operating cash flow it produces (e.g., $11.4 bn of cash from operations in 2021 and comparable levels in the 2024 filing) to fund dividends, share‑repurchases and R&D while keeping new debt to a minimum, thereby lowering its reliance on external financing and reducing revenue‑concentration risk.  At the same time, Biktarvy’s once‑daily single‑tablet regimen, high resistance barrier and favorable renal‑safety profile give it a distinct clinical and commercial edge that lets Gilead sustain pricing power and market share against generic and competing HIV regimens, reinforcing its competitive differentiation in the HIV treatment market.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains some correct contextual elements but diverges significantly from the ground truth in key aspects. (1) Correctly identifies Biktarvy as a central product for GILD and mentions its competitive clinical profile (single-tablet regimen, renal safety), which aligns with its commercial strength. However, it fails to reflect the core evolution highlighted in the original answer: the increasing financial risk due to reliance on TAF-based therapies and potential paradigm shifts away from them. Instead, the LLM claims Gilead is reducing 'revenue-concentration risk,' which contradicts the ground truth that GILD's dependence on Biktarvy creates growing financial risk. (2) Quantitatively, the $11.4 billion cash from operations in 2021 is mentioned, but the question focuses on 2022–2024 evolution; the reference to 'comparable levels in the 2024 filing' is vague and not directly supported in the ground truth. No actual 2024 cash flow figure is provided or verified, and the use of 2021 data to represent 2024 trends weakens accuracy. (3) The multi-hop reasoning is flawed: while the LLM synthesizes financial strategy and product differentiation, it misses the critical shift from strong positioning in 2022 to heightened risk in 2024. It omits the threat of generic competition and changing treatment paradigms explicitly noted in the original answer. (4) The answer emphasizes risk mitigation and sustained differentiation, whereas the ground truth stresses increasing vulnerability and erosion of long-term differentiation. This fundamental contradiction in narrative leads to a low correctness score despite some accurate descriptive elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 453,
        "total_tokens": 1803
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How did Lockheed Martin's approach to defined contribution retirement savings plans evolve between 2022 and 2023, particularly in terms of pension obligation transfers and associated financial impacts?",
      "original_answer": "In 2022, Lockheed Martin transferred $4.3 billion of gross defined benefit pension obligations through group annuity contracts, recognizing a noncash pension settlement charge of $1.5 billion. In 2023, instead of another annuity purchase, the company made $414 million in settlement payments to approximately 6,500 former employees who had not yet started receiving benefits. This shift indicates a strategic evolution from transferring large blocks of pension obligations to insurers (as in 2022) to directly settling smaller portions of obligations with individual participants in 2023.",
      "llm_answer": "\nBetween 2022 and 2023 Lockheed Martin accelerated its shift from a qualified defined‑benefit pension regime to an enhanced defined‑contribution retirement savings plan by completing two large annuity‑driven obligation transfers—$4.3 billion of defined‑benefit liabilities were off‑loaded in Q2 2022 (which generated a $1.5 billion non‑cash settlement charge) and a $414 million lump‑sum settlement in 2023—thereby cutting accrued pension liabilities and the balance in accumulated other‑comprehensive loss and eliminating future funding obligations.  These moves reduced the company’s long‑term pension cash‑flow risk and allowed it to rely on the defined‑contribution plan (with matching contributions) as the primary retirement vehicle for employees, while the settlement charges were recorded as non‑operating pension expenses that impacted earnings and AOCL.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains mostly correct information but misrepresents the 2023 action as an 'annuity-driven obligation transfer' and a 'lump-sum settlement' in the same context as the 2022 annuity purchase, which is inaccurate. According to the ground truth, in 2023 Lockheed Martin did *not* use an annuity contract but instead made $414 million in settlement payments directly to about 6,500 former employees who had not yet started benefits. The LLM incorrectly frames this as a continuation of annuity-driven transfers, stating 'two large annuity-driven obligation transfers,' which is factually wrong—only the 2022 transaction involved an annuity. (2) Quantitatively, the dollar amounts ($4.3 billion in 2022, $1.5 billion noncash charge, and $414 million in 2023) are accurate and correctly attributed. Dates (Q2 2022) are plausible though not fully specified in the ground truth. However, the mischaracterization of the $414 million as an annuity or lump-sum settlement within an annuity framework undermines quantitative context. (3) The reasoning is partially sound—LLM correctly identifies a strategic shift toward reducing pension liabilities and reliance on defined-contribution plans—but fails the multi-hop synthesis by conflating two distinct types of transactions (annuity buyout vs. individual settlement payments). The evolution in strategy—from large insurer transfers to direct participant settlements—is missed. (4) Contextual relevance is high, as the answer addresses pension obligation transfers, financial impacts (settlement charges, AOCL, cash-flow risk), and the broader shift to defined-contribution plans. However, due to the key factual error in characterizing the 2023 transaction, the correctness score is limited to 6—partially correct with significant inaccuracies in entity and process identification.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 501,
        "total_tokens": 1878
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has the composition of IBM's debt instruments maturing in 2025 evolved between 2022 and 2024, particularly regarding the 2.875% Notes due 2025?",
      "original_answer": "In 2022, IBM listed the 2.875% Notes due 2025 (IBM 25A) among other Notes due in 2025, including the 0.950% Notes due 2025 (IBM 25B) and the 0.875% Notes due 2025 (IBM 25C). By 2024, the 2.875% Notes due 2025 (IBM25A) remained, but the 0.875% Notes due 2025 (IBM 25C) were no longer listed, indicating a shift in the debt composition for that year. The 2.875% Notes due 2025 continued to be a key part of IBM's debt structure in 2024, suggesting a strategic decision to maintain this specific financial instrument while retiring or restructuring others.",
      "llm_answer": "\nBetween 2022 and 2024 the set of securities that mature in 2025 stayed the same – the 2.875 % Notes (IB 25A), the 0.950 % Notes (IB 25B) and the 7.00 % Debentures (IB 25) – but the smaller‑size 0.300 % Notes that also matured in 2022 were dropped and replaced by a 0.300 % issue due in 2026. Consequently, the 2.875 % Notes remain the largest‑percentage component of IBM’s 2025‑maturing debt, while the overall mix shifted toward a higher relative weight for that series after the 0.300 % 2025 tranche was removed.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in terms of factual content. According to the ground truth, in 2022, IBM had three debt instruments maturing in 2025: the 2.875% Notes (IBM 25A), the 0.950% Notes (IBM 25B), and the 0.875% Notes (IBM 25C). By 2024, the 0.875% Notes (IBM 25C) were no longer listed, while the 2.875% and 0.950% Notes remained. However, the LLM incorrectly states that the 7.00% Debentures (IB 25) were part of the 2025 maturity set and claims a 0.300% Notes issue maturing in 2025 was dropped — none of which is supported by the original answer. The 0.300% Notes are not mentioned in the ground truth, nor is any replacement with a 2026 issue. (2) Quantitative accuracy is poor: the percentages 2.875%, 0.950%, and 0.875% are partially correct, but the LLM introduces false instruments (7.00% Debentures, 0.300% Notes) and incorrect maturities. The claim that the 2.875% Notes are the 'largest-percentage component' is speculative and not in the original answer. (3) Multi-hop reasoning fails: the model does not correctly identify the change in composition (removal of IBM 25C), instead fabricating changes involving non-existent tranches. It misses the key point that the 0.875% Notes disappeared by 2024. (4) Contextual relevance is moderate because the answer addresses IBM's 2025 debt and the 2.875% Notes, but the incorrect entities and dynamics severely undermine accuracy. The conclusion about the 2.875% Notes remaining significant is partially aligned, but based on flawed premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1267,
        "completion_tokens": 420,
        "total_tokens": 1687
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has the strategic importance and risk profile of Biktarvy within Gilead's HIV portfolio evolved from 2022 to 2024, particularly in light of competitive pressures and changes in the treatment paradigm?",
      "original_answer": "In 2022, Biktarvy was positioned as a key growth driver for Gilead, with the company noting its 'continued growth in all geographies' and attributing part of the 11% revenue increase to its performance. By 2024, however, the strategic importance of Biktarvy appears more precarious. The 2024 10-K highlights increased risks around Gilead's HIV franchise, noting that 'many of our HIV products contain TAF' and that any shift away from nucleoside-based therapies could materially impact sales. This suggests that while Biktarvy was a growth asset in 2022, by 2024 it was increasingly seen as vulnerable to paradigm shifts in HIV treatment, representing a change in both strategic positioning and risk exposure.",
      "llm_answer": "\nBetween 2022 and 2024, Biktarvy shifted from being the chief growth engine that recaptured market share after the 2020 loss of exclusivity of Truvada/Atripla to a more mature, high‑margin cornerstone of Gilead’s HIV franchise.  At the same time, its risk profile intensified as the market introduced competing long‑acting regimens and generic pressure, prompting Gilead to expand its label (e.g., pediatric low‑dose) and bolster its pipeline to defend the product’s position.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but misses key elements from the ground truth, particularly regarding the evolution of Biktarvy's risk profile due to treatment paradigm shifts. (1) Correct aspects: The answer correctly identifies Biktarvy as a major growth driver for Gilead and notes increased competitive pressures by 2024, including long-acting regimens and generics. It also appropriately references label expansions (e.g., pediatric use) as a defensive strategy. (2) Quantitative accuracy: There are no specific numbers (e.g., percentages, dollar amounts) in either the LLM or original answer that conflict; the LLM does not introduce any incorrect figures, so quantitative accuracy is high. (3) Multi-hop reasoning: The LLM fails to incorporate the critical 2024 risk highlighted in the ground truth—namely, that Biktarvy’s reliance on TAF makes it vulnerable to a shift away from nucleoside-based therapies, which would materially impact sales. This is a central point in the original answer and reflects a deeper strategic risk beyond just competition or generics. The LLM focuses on external competitive threats but overlooks the internal structural vulnerability tied to the drug’s composition. (4) The answer is contextually relevant and well-phrased, but lacks the key insight about the changing treatment paradigm (from daily oral to potential non-nucleoside or long-acting therapies) that redefines Biktarvy’s risk profile. Thus, while the general trajectory from growth engine to mature asset is accurate, the reasoning behind the increased risk is incomplete, leading to a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 441,
        "total_tokens": 1752
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How did the balance of the U.S. litigation escrow account evolve between the end of fiscal year 2022 and the end of fiscal year 2023, and what were the specific deposit contributions during each period?",
      "original_answer": "The balance of the U.S. litigation escrow account increased significantly from $1,449 million at the end of fiscal year 2022 to $3,089 million at the end of fiscal year 2023. During this time, deposits into the account rose from $1,000 million in fiscal year 2022 to $1,500 million in fiscal year 2023.",
      "llm_answer": "\nThe U.S. litigation escrow account balance grew from **$1.45 billion at the end of fiscal 2022** to **$1.76 billion at the end of fiscal 2023**.  During that period the Company added **$850 million** to the escrow in fiscal 2022 and **$1.0 billion** in fiscal 2023, while net payments to opt‑out merchants (after interest) of **$685 million** were made in fiscal 2023, resulting in the higher ending balance.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ending balance for fiscal year 2023 is wrong: the ground truth states $3,089 million ($3.089 billion), but the LLM reports $1.76 billion, which is off by over $1.3 billion. The starting balance is approximately correct ($1.45 billion vs. $1,449 million), though slightly rounded. Deposit contributions are also incorrect: the LLM states $850 million in fiscal 2022 and $1.0 billion in fiscal 2023, whereas the ground truth reports $1,000 million in fiscal 2022 and $1,500 million in fiscal 2023. Additionally, the LLM introduces 'net payments to opt-out merchants of $685 million' and interest, which are not mentioned or supported in the original answer, suggesting fabricated or extraneous information. (2) Quantitative accuracy is very low: both deposit figures are wrong, the final balance is severely underestimated, and unsupported calculations involving payments are introduced. Even allowing for formatting variations (e.g., billion vs. million), the numbers do not align—$1.45B to $1.76B implies a $310M increase, but the LLM claims $1.85B in deposits and $685M in payments, which would imply a decrease, contradicting the stated increase. This indicates flawed arithmetic and data synthesis. (3) The multi-hop reasoning is unsound. The model fails to correctly synthesize the evolution of the escrow account balance and deposits across fiscal years 2022 and 2023. Introducing unmentioned outflows (payments to merchants) without basis in the ground truth shows a failure in logical inference and source fidelity. (4) Contextual relevance is moderate—the response addresses the right topic (U.S. litigation escrow account evolution and deposits) and time frame (fiscal 2022–2023), so it is on-topic. However, due to severe factual and numerical errors, the answer misrepresents the situation. Correctness score is low due to major quantitative and qualitative inaccuracies despite addressing the general subject.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1191,
        "completion_tokens": 538,
        "total_tokens": 1730
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has the role of fountain syrups in Coca-Cola's North America operating segment evolved between 2022 and 2023, particularly regarding the company's manufacturing and distribution responsibilities?",
      "original_answer": "In 2022, Coca-Cola explicitly stated that it manufactured fountain syrups in the United States and sold them directly to fountain retailers or to authorized fountain wholesalers or bottling partners for further distribution. By 2023, the company's description shifted: while it still referenced selling fountain syrups in the North America segment, it also indicated that outside the U.S., bottling partners were authorized to manufacture fountain syrups using company concentrates. This suggests a nuanced evolution where Coca-Cola may be emphasizing a more decentralized, authorization-based model, particularly outside the U.S., while maintaining direct control within the U.S. There is no explicit mention of a change in manufacturing responsibilities within North America itself, indicating operational continuity there.",
      "llm_answer": "\nBetween 2022 and 2023 the company continued to **manufacture fountain syrups in the United States**, but the **distribution responsibility moved from direct sales to bottling partners and authorized wholesalers**. In the 2022 filing the North America operating segment was described as Coca‑Cola selling the syrups to fountain retailers (or to wholesalers who then sold them on), whereas the 2023 filing notes that those syrup sales are now “included in our North America operating segment” through the bottling‑partner network, indicating a shift toward a partner‑driven distribution model. This change is also reflected in the revenue mix, with concentrate operations (which include fountain syrups) rising from 56 % of net operating revenue in 2022 to 58 % in 2023.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains a mix of accurate and inaccurate claims, with significant issues in reasoning and factual synthesis. (1) Correct elements: The statement that Coca-Cola manufactured fountain syrups in the U.S. in both years aligns with the ground truth. The mention of distribution through bottling partners and wholesalers is partially correct, as the original answer confirms sales to authorized wholesalers and bottling partners. (2) Quantitative accuracy: The claim that concentrate operations rose from 56% to 58% of net operating revenue is not supported by the ground truth, which does not mention this percentage change. This introduces a specific numerical claim without evidence, reducing quantitative accuracy. (3) Multi-hop reasoning flaws: The LLM incorrectly infers a shift in *distribution responsibility* from direct sales to partner-driven models as a change between 2022 and 2023. However, the ground truth states there was no explicit change in manufacturing or distribution responsibilities *within North America*—the 2023 update refers to authorization of bottling partners *outside the U.S.*, not a shift in North America. The LLM misattributes a global policy nuance to a North America-specific operational change. (4) The answer creates a narrative of evolution (direct → partner-driven) not substantiated by the original answer, which emphasizes continuity in North America. While the response is relevant and structured well, the core reasoning misrepresents the scope and nature of the change, leading to a moderate correctness score due to partial factual alignment but significant interpretive error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1411,
        "completion_tokens": 445,
        "total_tokens": 1856
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has the composition of IBM's debt instruments maturing in 2025 evolved between 2022 and 2024, particularly regarding the 0.950% Notes due 2025?",
      "original_answer": "In 2022, IBM had three sets of notes maturing in 2025: the 2.875% Notes due 2025 (IBM 25A), the 0.950% Notes due 2025 (IBM 25B), and the 0.875% Notes due 2025 (IBM 25C). By 2024, the 0.875% Notes due 2025 were no longer listed, leaving only the 2.875% Notes due 2025 (IBM 25A) and the 0.950% Notes due 2025 (IBM 25B). This indicates a reduction in the diversity of interest rate profiles for debt maturing in 2025, with the removal of the 0.875% instrument.",
      "llm_answer": "\nBetween the 2022 and 2024 Form 10‑K filings the roster of securities that mature in 2025 was unchanged: the company still has three separate 2025‑maturing issues on its register – the 2.875 % Notes (IBM 25A), the 0.950 % Notes (IBM 25B) and the 7.00 % Debentures (IBM 25).  The 0.950 % Notes due 2025 appear in both tables (as IBM 25B) with no indication of a new issuance, redemption, or re‑classification, showing that its place in the 2025 maturity bucket remained the same over the two years.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that the composition of IBM's debt instruments maturing in 2025 remained unchanged between 2022 and 2024. According to the ground truth, in 2022 there were three notes: 2.875% (IBM 25A), 0.950% (IBM 25B), and 0.875% (IBM 25C). By 2024, the 0.875% Notes (IBM 25C) were no longer listed, leaving only two instruments. However, the LLM incorrectly claims that three instruments still exist in 2024, including a '7.00% Debentures (IBM 25)', which is not mentioned in the ground truth and appears to be fabricated or confused with another instrument. The 0.950% Notes (IBM 25B) are correctly identified as present in both years, which is accurate. (2) Quantitatively, the interest rates of 2.875% and 0.950% are correct, but the introduction of a '7.00% Debentures' is a major factual error with no supporting evidence in the original answer. The removal of the 0.875% Notes is a key quantitative and qualitative change that the model fails to recognize. (3) The multi-hop reasoning is flawed: the question requires comparing IBM’s debt composition across two time points (2022 and 2024) and identifying changes in the 2025 maturity bucket. The model fails this synthesis, asserting no change when there was a clear reduction in the number and diversity of instruments. It also misidentifies the specific instruments, breaking the chain of correct inference. (4) The contextual relevance is moderate because the answer addresses the right topic (IBM's 2025-maturing debt) and references the correct filing type (Form 10-K), but the core conclusion about stability is contradicted by the ground truth. Due to major factual inaccuracies and failure to detect a key change, the correctness score is low despite partial recognition of existing notes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1238,
        "completion_tokens": 490,
        "total_tokens": 1728
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has Disney's strategic approach to cruise ships evolved between 2022 and 2024 based on disclosures in their 10-K filings?",
      "original_answer": "In 2022, Disney mentioned cruise ships as part of its broader travel and resort experiences, indicating that their success depended on consumer demand for out-of-home entertainment and travel. By 2024, Disney had elevated its approach, explicitly stating plans to 'expand investment in our Experiences segment' and 'additional expansion of our fleet of cruise ships.' This evolution reflects a shift from general dependence on consumer demand to an active investment and growth strategy in cruise ship operations. The 2024 filing also notes that new offerings, such as additional cruise ships, come with increased costs and uncertain returns, signaling a more capital-intensive and strategic focus compared to the more passive mention in 2022.",
      "llm_answer": "\nBetween 2022 and 2024 Disney moved from a modest, single‑ship expansion focus to a more integrated, multi‑ship growth strategy anchored by its new private island at Lighthouse Point.  The 2022 filing highlighted the upcoming Disney Wish and the 2024 opening of the island as a destination‑enhancement, while the 2024 filing emphasized ordering additional cruise ships, tying the fleet’s itineraries to the island year‑round, and leveraging the island to drive occupancy and cross‑sell Disney Vacation Club and resort stays.  In short, Disney’s cruise‑ship strategy evolved from “add a flagship and a destination” to a broader, destination‑centric fleet expansion that ties the private island to sustained, high‑occupancy cruising.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains several factual inaccuracies and introduces unverified details not present in the ground truth. (1) The 2022 filing does not mention the 'Disney Wish' or 'Lighthouse Point' specifically, nor does it reference a private island opening in 2024—these details are absent from the original answer and cannot be confirmed from the provided ground truth. (2) The claim that Disney moved from a 'single-ship expansion' to a 'multi-ship growth strategy' is unsupported; the original answer states only that Disney mentioned cruise ships as part of travel experiences in 2022 and by 2024 announced plans to expand investment and the cruise fleet, without specifying prior or future ship counts. (3) The integration of the private island with year-round itineraries, cross-selling with Disney Vacation Club, and occupancy strategies are not mentioned in the ground truth and represent speculative elaboration. (4) While the general direction of strategic evolution—from passive dependence on demand to active investment—is correctly inferred, the LLM overreaches in specificity and introduces multi-hop elements (e.g., island-cruise integration, DVC cross-selling) not present in the source. (5) Quantitative accuracy is low because specific dates (e.g., 2024 island opening) and implied timelines are not corroborated. (6) Contextual relevance is moderate because the answer addresses strategic evolution in cruise ships, but the added details reduce factual fidelity. The core idea of increased strategic focus is aligned, but the lack of grounding in actual disclosures significantly undermines correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 441,
        "total_tokens": 1805
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How did Lockheed Martin's approach to pension risk transfer transactions evolve from 2022 to 2023, particularly in terms of financial impact and strategic intent?",
      "original_answer": "In 2022, Lockheed Martin detailed a specific pension risk transfer transaction from August 3, 2021, where $4.9 billion of gross defined benefit pension obligations were transferred via group annuity contracts (GACs), resulting in a noncash pension settlement charge of $1.7 billion. The company also noted that since December 2018, it had transferred approximately $11.6 billion in pension obligations, eliminating volatility for around 95,000 retirees. By 2023, the company reiterated its strategic intent to continue evaluating such transactions but shifted focus toward the broader financial and risk implications, including potential future contributions to the pension trust and the possibility of additional noncash settlement charges. The 2023 filing also introduced a nuanced risk: while most GACs relieve Lockheed of pension obligations, some could leave the company liable if the insurer defaults. This reflects a more cautious framing of pension risk transfer, acknowledging residual liability exposure not emphasized in 2022.",
      "llm_answer": "\nFrom 2022 through 2023 Lockheed Martin broadened its pension‑risk‑transfer program, moving from the single $4.9 bn group‑annuity purchase in August 2021 to a series of incremental annuity purchases funded by the master retirement trust that now cover roughly 95 k retirees and cut annual PBGC premiums by about $69 m. Each additional transfer reduces the accrued benefit liability and, while generating a non‑cash settlement charge in the period it occurs, is intended to smooth earnings and free cash flow for the business, making pension‑risk management a recurring strategic lever rather than a one‑time event.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. It correctly references the $4.9 billion group annuity transaction and the 95,000 retirees, which aligns with the ground truth. However, it misrepresents the timing by stating that transfers occurred 'from 2022 through 2023' and describes 'a series of incremental annuity purchases' during this period, while the original answer only confirms a single transaction from August 3, 2021, with no new transfers reported in 2022 or 2023. The claim of cutting PBGC premiums by $69 million is not present in the ground truth and appears fabricated. (2) Quantitative accuracy is partially correct: $4.9 billion and 95,000 retirees are accurate, but the $69 million PBGC savings figure has no support in the original data and cannot be verified. The noncash settlement charge of $1.7 billion in 2022 is omitted entirely in the LLM answer, a significant factual gap. (3) The reasoning is flawed in its portrayal of pension risk transfer as an ongoing 'recurring strategic lever' with multiple new transactions, whereas the original answer emphasizes that while Lockheed continues to evaluate such transactions, no new large-scale transfers are reported in 2022–2023. Instead, the strategic evolution is in risk framing—particularly the acknowledgment of residual liability due to insurer default risk in 2023, which the LLM answer completely misses. This reflects a failure in multi-hop synthesis: the model extrapolated activity not stated in the filings. (4) Contextual relevance is high—the answer addresses financial impact and strategic intent as asked—but the factual inaccuracies and invented details reduce correctness. The omission of the key 2023 nuance about potential ongoing liability if insurers default severely undermines qualitative accuracy. Overall, the answer gives a plausible but factually incomplete and partially incorrect picture.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1416,
        "completion_tokens": 520,
        "total_tokens": 1937
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has Tesla's relationship with its financing partners evolved between 2022 and 2023, particularly in terms of accounts receivable management and leasing program risks?",
      "original_answer": "In 2022, Tesla disclosed that accounts receivable from financing partners could take up to approximately two weeks to settle based on contractual payment terms, directly impacting the company's short-term liquidity and balance sheet fluctuations. By 2023, Tesla highlighted increased complexity and risk in managing its financing programs, noting that its leasing business depends on securing adequate financing or partners, and that residual value risks from leased vehicles could negatively affect profitability. This indicates a shift from a focus on operational cash flow timing in 2022 to a broader concern over credit, compliance, and residual value risks in 2023 as the leasing program scaled.",
      "llm_answer": "\nBetween 2022 and 2023 Tesla’s disclosures show that it continued to depend on financing partners to fund customer loans and direct‑lease arrangements, but the company’s risk commentary grew more detailed.  In the 2022 filing it pointed out that accounts‑receivable balances can swing by tens of millions from quarter‑to‑quarter as payments from financing partners clear (often within two weeks) and as long‑term government rebates are collected, prompting the establishment of an allowance for doubtful accounts.  By 2023 the discussion broadened to stress the credit‑risk of those partners, the volatility of residual‑value guarantees and lease‑return values, and the potential for substantial credit losses or impairments if partners under‑perform or if a downturn reduces customer payment ability.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that in 2022, Tesla noted accounts receivable from financing partners could take up to approximately two weeks to settle, impacting short-term liquidity—this matches the original answer's emphasis on settlement timing and balance sheet fluctuations. The mention of 'tens of millions' in swings is consistent with known volatility, though not explicitly quantified in the ground truth, it is a reasonable inference and does not contradict. (2) In 2023, the LLM correctly captures the expanded risk discussion: credit risk of partners, residual value volatility, and potential credit losses—directly reflecting the original answer’s focus on increased complexity, residual value risks, and dependence on financing partners. (3) The multi-hop reasoning is sound: it synthesizes Tesla’s evolving disclosures across two years, correctly identifying a shift from operational cash flow timing (2022) to broader financial and credit risks (2023). (4) All entities (Tesla, financing partners, leasing programs), years (2022, 2023), and financial concepts (accounts receivable, residual value risk, credit risk) are accurate and contextually appropriate. The only minor gap is that the LLM does not explicitly mention 'compliance' risks noted in the original answer, but this is a secondary detail. Overall, the answer is factually correct, semantically equivalent, and contextually complete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 407,
        "total_tokens": 1788
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "What changes occurred in Coca-Cola's fountain syrup distribution strategy between 2022 and 2023, and how did the roles of bottlers and fountain wholesalers evolve during this period?",
      "original_answer": "In 2022, Coca-Cola manufactured and sold fountain syrups directly to authorized fountain wholesalers (including certain authorized bottlers), who then sold or delivered the syrups to retailers. Bottlers in the U.S. were generally not authorized to manufacture fountain syrups. By 2023, the strategy evolved such that outside the United States, bottlers were typically authorized to manufacture fountain syrups using Coca-Cola concentrates, which they could sell to fountain retailers or authorized fountain wholesalers. This represents a shift from a more centralized syrup distribution model to a more integrated one, where bottlers play a more active role in the fountain syrup supply chain, particularly in international markets.",
      "llm_answer": "\nBetween 2022 and 2023 Coca‑Cola altered the way it gets fountain syrup to the market: it stopped authorising bottlers to **manufacture** fountain syrups and instead **sold the syrups directly to a network of approved fountain‑wholesalers** (some of which are bottlers) that then distribute the product to restaurants and other retailers.  \n\nAs a result, the **bottlers’ role shifted** from being producers and distributors of fountain syrup to a more limited, wholesale‑distribution or purchasing role, while **fountain‑wholesalers assumed the primary responsibility for delivering syrup to end‑users**. This change gave the Company tighter control over pricing, terms and supply‑chain logistics for fountain‑syrup sales.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its description of Coca-Cola's fountain syrup distribution strategy changes between 2022 and 2023. According to the ground truth, in 2022 Coca-Cola sold syrups directly to authorized fountain wholesalers (including some bottlers), with bottlers generally not authorized to manufacture fountain syrups in the U.S. By 2023, the model shifted such that *outside the United States*, bottlers were typically authorized to *manufacture* fountain syrups using Coca-Cola concentrates—representing an expansion of bottlers' roles internationally. The LLM answer incorrectly states the opposite: that Coca-Cola stopped authorizing bottlers to manufacture syrups and instead took over direct sales, which misrepresents the actual shift toward greater bottler involvement internationally. There are no numeric values in the question or answer, so quantitative accuracy is not applicable (score of 10 by default due to absence of errors). The qualitative accuracy is very low because the core reasoning and entity roles (bottlers, wholesalers) are reversed. Contextual relevance is moderate—the answer addresses the general topic of distribution strategy and roles of bottlers and wholesalers—but the factual direction of change is wrong, undermining the response. The multi-hop synthesis failed: the model did not correctly interpret the geographic distinction (U.S. vs. international) or the shift toward integration with bottlers rather than away from them.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 409,
        "total_tokens": 1781
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between 2023 and 2024, particularly in terms of receivables and new investment activities?",
      "original_answer": "In 2023, AMD had receivables from the ATMP JV of $9 million, and there was no mention of any direct investment or loan made by AMD to the JV. By 2024, AMD's receivables from the ATMP JV increased to $12 million, and the company entered into a new $100 million one-year term loan agreement with one of the ATMP JVs to support its general corporate purposes. This marks a significant shift from a purely transactional relationship in 2023 to a more financially integrated one in 2024, where AMD is not only a customer but also a creditor and strategic supporter of the JV.",
      "llm_answer": "\nBetween 2023 and 2024 AMD’s exposure to the ATMP joint venture grew modestly but strategically.  Receivables from the JV rose from about $9 million (2023) to roughly $12 million (2024), while payables increased from $363 million to $476 million, reflecting a larger volume of inventory transactions.  In addition, AMD made a new $100 million term‑loan to the JV, contributed an extra $17 million of equity (raising the investment’s carrying value from $99 million to $149 million), and began recognizing higher equity‑income gains ($33 million in 2024 versus $16 million in 2023).  These actions show a deepening financial relationship and a shift from passive purchaser to active investor in the ATMP JV.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies not present in the ground truth. While it correctly identifies the increase in receivables from $9 million (2023) to $12 million (2024), it introduces additional financial figures—such as payables increasing from $363M to $476M, a $17M equity contribution, carrying value rising from $99M to $149M, and equity income of $33M in 2024 vs $16M in 2023—that are not mentioned or supported in the original answer. Most critically, the original answer states there was no direct investment or loan by AMD in 2023, and only in 2024 did AMD enter a $100 million term loan. The LLM incorrectly adds an equity investment and misrepresents the nature of AMD's involvement. (2) Quantitative accuracy is low because while the $9M, $12M, and $100M loan figures are correct, the other numbers (e.g., $17M equity, $149M carrying value, $33M equity income) are fabricated or hallucinated. There is no indication in the ground truth that AMD made equity contributions or recognized such income. (3) The multi-hop reasoning is partially sound in identifying a deepening financial relationship, but the conclusion is based on incorrect data. The original answer emphasizes a shift from transactional to financially integrated due to the new loan, while the LLM overstates this with unsupported claims of equity investment and income. (4) Contextual relevance is high because the answer addresses the evolution of the financial relationship and focuses on receivables and new investments. However, the inclusion of unverified metrics significantly undermines factual correctness, leading to a low overall correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 456,
        "total_tokens": 1776
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did Lockheed Martin's approach to managing its nonqualified defined benefit pension plans evolve between 2022 and 2023, particularly in terms of pension obligation settlements and associated financial impacts?",
      "original_answer": "In 2022, Lockheed Martin purchased group annuity contracts to transfer $4.3 billion of gross defined benefit pension obligations and recognized a noncash pension settlement charge of $1.5 billion. In 2023, the company continued its strategy of reducing pension liabilities by making voluntary settlement payments of $414 million to approximately 6,500 former employees, significantly smaller in scale compared to the 2022 transaction. This indicates a shift from large-scale pension obligation transfers to a more targeted approach involving smaller settlements with former employees who had not yet started receiving benefits.",
      "llm_answer": "\nBetween 2022 and 2023 Lockheed Martin moved from a period of large, non‑cash settlement charges—$1.5 billion was recognized in 2022 after purchasing group annuities that transferred $4.3 billion of defined‑benefit obligations—to a stage where the remaining pension‑obligation reductions were executed as relatively small, cash‑settlement payments ($414 million in the fourth quarter of 2023) with no additional settlement charge recorded.  This shift reflects a deliberate strategy to off‑load non‑qualified pension liabilities through annuity purchases and lump‑sum offers, resulting in a much lower earnings impact (only the $414 million cash outflow and a corresponding reduction in accrued pension liabilities/AOCL) rather than the multi‑billion‑dollar charges seen in the prior year.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: in 2022, Lockheed Martin transferred $4.3 billion in pension obligations via group annuities and recognized a $1.5 billion noncash settlement charge. In 2023, it made $414 million in voluntary settlement payments to about 6,500 former employees. These numbers match the original answer exactly, with acceptable formatting (e.g., $4.3 billion = $4.3B). (2) The quantitative accuracy is perfect—dollar amounts, timing (2022 vs 2023), and scale comparison are all correct. (3) The reasoning is sound: the LLM correctly infers a strategic shift from large-scale annuity transfers (with significant noncash charges) to smaller cash settlements with minimal earnings impact. It accurately notes no additional settlement charge was recorded in 2023, which is consistent with the nature of smaller, voluntary payments not triggering full plan settlements. (4) The only minor shortcoming is that the LLM specifies the $414 million payment occurred in the 'fourth quarter of 2023,' while the original answer does not specify the quarter—this adds detail not confirmed in the ground truth, but does not contradict it. Also, the original emphasizes the shift to a 'targeted approach involving former employees who had not yet started receiving benefits,' a nuance slightly underemphasized in the LLM response. However, the core multi-hop synthesis—comparing two years of pension strategy, financial impact, and strategic evolution—is correctly executed. The answer is contextually excellent, directly addressing the evolution in approach and financial implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1370,
        "completion_tokens": 451,
        "total_tokens": 1822
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did AMD's financial relationship with the ATMP JV evolve between 2023 and 2024, particularly in terms of its investment and equity income?",
      "original_answer": "In 2023, AMD recorded $16 million in equity income from the ATMP JV and had a carrying value of $99 million as of the end of the year. In 2024, AMD contributed an additional $17 million to the JV, increasing its investment's carrying value to $149 million by the end of the year. Equity income also rose to $33 million. This indicates a significant increase in both AMD's investment stake and the returns it received from the ATMP JV.",
      "llm_answer": "\nBetween 2023 and 2024 AMD’s stake in the ATMP joint venture expanded both in size and earnings contribution.  The carrying value of its equity‑method investment rose from roughly **$99 million (as of Dec 30 2023)** to **about $149 million (as of Dec 28 2024)**, driven in part by a **$17 million additional equity contribution in August 2024**.  Accordingly, AMD’s share of the JV’s earnings—recorded as “equity income in investee”—more than doubled, climbing from **$16 million in 2023 to $33 million in 2024**.  The relationship also deepened through a **$100 million term loan** to the JV and higher payable/receivable balances, but the key evolution was the larger equity investment and the resulting increase in equity‑income earnings.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key financial figures from the ground truth: the 2023 equity income ($16M), 2024 equity income ($33M), 2023 carrying value ($99M), 2024 carrying value ($149M), and the $17M additional contribution in August 2024. These match the original answer exactly, with acceptable formatting variations (e.g., 'about $149 million' is semantically equivalent). (2) Quantitative accuracy is perfect: all numbers are correct, and the implied calculation (99 + 17 = 116, with the remainder of the increase attributed to equity income and other adjustments) is consistent with accounting principles, even though the full $33M income isn't added to carrying value (which is correct under equity method accounting). The $100M term loan is an additional detail not in the ground truth, but it does not contradict it and may reflect supplementary data; however, since it's not in the original answer, it introduces unverified information, slightly affecting qualitative accuracy. (3) Multi-hop reasoning is sound: the model correctly links the increased investment to higher equity income and interprets the evolution of the financial relationship. It synthesizes investment changes and income trends across years, fulfilling the multi-hop requirement. (4) The answer is highly relevant, directly addressing AMD's investment and equity income evolution. The only minor issue is the introduction of the $100M loan, which, while plausible, isn't part of the verified ground truth and slightly dilutes qualitative accuracy. Overall, the answer is factually correct, complete, and well-reasoned, warranting a 9/10 correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 454,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did Johnson & Johnson's financial stake and ownership relationship with Kenvue evolve between 2023 and 2024, particularly in terms of retained equity and associated gains or losses?",
      "original_answer": "In 2023, Johnson & Johnson retained a 9.5% ownership stake in Kenvue valued at $4.3 billion following the exchange offer, which resulted in a non-cash gain of $21.0 billion, including a $2.8 billion gain on the retained shares. By the end of 2024, the company completed a Debt-for-Equity Exchange of its remaining 182,329,550 shares of Kenvue Common Stock, thereby eliminating its ownership stake and incurring a loss of approximately $0.4 billion in the process. This marks a full exit from Kenvue after initially reducing its stake significantly in 2023.",
      "llm_answer": "\nBetween 2023 and 2024 Johnson & Johnson’s stake in Kenvue collapsed from roughly 89.6 % (after the May 2023 IPO) to about 9.5 % following the August 2023 exchange offer, and was fully eliminated in May 2024 when the remaining 182 million shares were swapped for commercial paper, resulting in a ≈ $0.4 billion loss and no retained equity. The 2023 exchange generated a one‑time $21 billion pre‑tax gain (including a $2.8 billion gain on the shares J&J kept), but the 2024 debt‑for‑equity transaction produced a modest loss, ending J&J’s ownership in Kenvue.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth with only minor discrepancies in phrasing and one non-critical detail. (1) Quantitatively: The key numbers are correct — the 9.5% retained stake in 2023, $21 billion pre-tax gain (matching the $21.0 billion in the original), $2.8 billion gain on retained shares, the disposal of 182,329,550 shares (correctly rounded to ~182 million), and the ≈$0.4 billion loss in 2024. The IPO timing (May 2023) and exchange offer (August 2023) are accurate. The full exit in May 2024 is consistent. (2) The only minor inaccuracy is the mention of an '89.6%' stake post-IPO, which, while plausible contextually, is not present in the original answer and introduces a detail not confirmed by the ground truth — this slightly affects quantitative accuracy but does not undermine correctness. (3) Qualitatively, the reasoning is sound: the two-step divestment process (partial exit with gain in 2023, full exit with loss in 2024) is correctly synthesized, and the financial implications (gain vs. loss) are properly contrasted. The use of 'debt-for-equity exchange' is accurately paraphrased as 'swapped for commercial paper', reflecting the nature of the transaction. (4) The answer fully addresses the evolution of ownership, retained equity, and gains/losses across both years, demonstrating strong multi-hop reasoning across time and financial events. Semantic equivalence is maintained despite rewording. Contextual relevance is perfect — focused, precise, and directly responsive.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1288,
        "completion_tokens": 426,
        "total_tokens": 1714
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How did AT&T's financial guarantee relationship with Southwestern Bell Telephone Co. evolve between 2022 and 2023, particularly in terms of its inclusion in guarantee agreements?",
      "original_answer": "AT&T's financial guarantee relationship with Southwestern Bell Telephone Co. remained consistent between 2022 and 2023, with the company continuing to guarantee certain obligations of Southwestern Bell Telephone Co. in both years. In 2022, the guarantee was listed in Exhibit 4-c, which included multiple entities such as Southwestern Bell Telephone Company. In 2023, the guarantee was again referenced in Exhibit 4-c, maintaining the same inclusion of Southwestern Bell Telephone Co. within the list of guaranteed entities. This indicates no change in the nature or scope of the guarantee.",
      "llm_answer": "\nIn the 2022 filing AT&T still listed a guarantee of certain Southwestern Bell obligations among its contingent‑liability disclosures, but the 2023 filing no longer included that guarantee in its guarantee‑agreement disclosures—effectively ending the parent‑company guarantee relationship that had been reported the prior year.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect. According to the ground truth, AT&T's financial guarantee relationship with Southwestern Bell Telephone Co. remained consistent between 2022 and 2023, with the guarantee included in Exhibit 4-c in both years. The LLM incorrectly claims that the 2023 filing no longer included the guarantee, implying termination of the relationship—this contradicts the original answer. There are no numeric values to verify, but the qualitative and reasoning errors are severe: the model fails to correctly synthesize the multi-hop information across years and misrepresents the continuity as a termination. The entity names and years are correctly identified, but the conclusion about the evolution of the relationship is entirely wrong. Contextual relevance is moderate because the answer addresses the right entities and topic, but factual correctness is critically flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1237,
        "completion_tokens": 261,
        "total_tokens": 1499
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has Lockheed Martin's involvement in hypersonics programs evolved from 2022 to 2023, particularly in terms of strategic positioning and program development responsibilities?",
      "original_answer": "In 2022, Lockheed Martin's involvement in hypersonics programs was described as a growth area that was dependent on U.S. Government authorization and funding, and was listed among other key development areas like classified programs and next-generation franchise programs. By 2023, the company's role had evolved significantly, with hypersonics programs now explicitly listed among major programs under the Space segment, indicating a more concrete and active role in designing, developing, and building hypersonic strike weapons for the U.S. Army and Navy. This reflects a shift from a potential growth area to a clearly defined and active program portfolio.",
      "llm_answer": "\nFrom 2022 to 2023 Lockheed Martin shifted its hypersonics effort from a pure research‑and‑development posture—highlighted in the 2022 filing as “several programs with the U.S. Air Force and Army to design, develop and build hypersonic strike weapons” under undefinitized contract actions—to a concrete production‑transition role.  The 2023 filing notes that “multiple hypersonics programs are expected to enter early production phases through 2026,” signaling that the company is now positioning itself as the lead integrator for both Air Force and Navy hypersonic strike weapons and taking on broader program‑management and production responsibilities as the initiatives move toward fielding.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of Lockheed Martin's hypersonics involvement from R&D toward production, which aligns with the direction of the ground truth. It correctly identifies movement into early production phases by 2026 and mentions both the Air Force and Navy, which is consistent with the Original Answer’s reference to the U.S. Army and Navy. However, there are key discrepancies: (1) The Original Answer states that in 2022, hypersonics was described as a growth area dependent on government funding and authorization, not yet an active program, whereas the LLM Answer incorrectly claims that in 2022, Lockheed Martin was already under contract to 'design, develop and build hypersonic strike weapons'—this contradicts the ground truth, which positions it more tentatively. (2) The LLM Answer cites the Air Force as a primary customer in both years, but the Original Answer specifies the Army and Navy in 2023, with no explicit mention of the Air Force. This misrepresents the customer base. (3) The shift in strategic positioning—from potential growth area (2022) to active program under Space segment (2023)—is not reflected in the LLM Answer, missing a core element of the multi-hop reasoning. While the LLM correctly infers increased responsibility and production transition, it fabricates specifics about 2022 contract status and misidentifies key military branches. Quantitative accuracy is high because there are no numerical errors (dates like 2026 are plausible and not contradicted), but qualitative accuracy suffers due to incorrect entity mapping and flawed reasoning about the nature of 2022 involvement. Contextual relevance is strong as the response stays focused on program evolution and strategic positioning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 474,
        "total_tokens": 1820
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How did the balance of the U.S. litigation escrow account evolve from fiscal year 2022 to fiscal year 2023, and what were the respective amounts deposited into the account during those years?",
      "original_answer": "The balance of the U.S. litigation escrow account increased significantly from $1.4 billion as of September 30, 2022, to $3.089 billion as of September 30, 2023. During fiscal year 2022, $850 million was deposited into the account, while in fiscal year 2023, $1.0 billion was deposited.",
      "llm_answer": "\nThe U.S. litigation escrow account balance rose from **$1.449 billion at the end of fiscal 2022** to **$1.764 billion at the end of fiscal 2023**.  During fiscal 2023 the company **deposited $1.0 billion** into the escrow account (offset by $685 million of payments), producing the net increase reflected in the year‑end balance.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the reported balance amounts. The ground truth states the balance increased from $1.4 billion (Sept 30, 2022) to $3.089 billion (Sept 30, 2023), but the LLM reports $1.449 billion and $1.764 billion, which are both incorrect. The deposit amount for fiscal year 2023 is correctly stated as $1.0 billion, but the fiscal year 2022 deposit is omitted entirely—ground truth specifies $850 million was deposited in FY2022. (2) Quantitative accuracy is low: the ending balance for 2023 is off by over $1.3 billion, and the starting balance is slightly inflated. The $1.0 billion deposit in FY2023 is correct, but the mention of $685 million in payments is unsupported in the ground truth and introduces unverified information. No calculation in the LLM answer aligns with the actual net increase of $1.689 billion ($3.089B - $1.4B), suggesting flawed or incomplete data sourcing. (3) The reasoning is partially sound in that it attempts to explain the change in escrow balance through deposits and payments, but it fails the multi-hop requirement by not correctly synthesizing the full two-year evolution and missing key inputs (e.g., FY2022 deposit). The omission of the actual large increase in the account balance suggests a failure to access or interpret the correct data points across both years. (4) Contextual relevance is fair because the answer addresses the right topic (U.S. litigation escrow account), time frame (fiscal years 2022–2023), and direction of change (increase), but the incorrect figures and missing data severely undermine factual correctness. The inclusion of unverified payments further reduces reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1165,
        "completion_tokens": 464,
        "total_tokens": 1629
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has the role and positioning of Outdoor Garden within HD's product strategy evolved from 2022 to 2024, based on its classification and performance metrics?",
      "original_answer": "In 2022, Outdoor Garden was disclosed as a distinct product line with $10,317 million in net sales, accounting for 6.8% of total net sales, indicating its importance as a standalone category. By 2024, Outdoor Garden was grouped under the broader 'Hardlines' merchandising department, suggesting a strategic integration into a larger product segment. This shift reflects a change in how HD positions Outdoor Garden within its overall product portfolio, moving from a separate focus area to a component of a consolidated category.",
      "llm_answer": "\nFrom fiscal 2022 through fiscal 2024 Outdoor Garden has remained classified under the **Hardlines** merchandising department within HD’s single reportable “Primary” segment, with its sales holding steady around **$10.3 billion** each year—representing roughly **6.5 %–6.8 %** of total net sales.  The only structural change was a 2024 realignment of merchandising departments that re‑sequenced the categorization but did not move Outdoor Garden to a different segment or product line, underscoring its continued role as a core, stable contributor to HD’s hard‑goods portfolio.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, Outdoor Garden was a distinct product line, but by 2024 it was grouped under the broader 'Hardlines' department, indicating a strategic repositioning. However, the LLM claims Outdoor Garden was classified under Hardlines in both 2022 and 2024, which contradicts the original answer and misrepresents the evolution. This is a critical error in entity classification over time. (2) Quantitatively, the LLM reports sales of ~$10.3 billion and 6.5%–6.8% of total net sales, which aligns approximately with the 2022 figure of $10,317 million (i.e., $10.3 billion) and 6.8%. However, the ground truth does not confirm that sales remained steady in 2024 or that the percentage range applies across both years—this extrapolation is unsupported. The LLM introduces a 'structural change' in 2024 involving 're-sequenced categorization' not mentioned in the original, adding speculative detail. (3) The multi-hop reasoning is flawed: the question asks about evolution in role and positioning based on classification and performance. The LLM fails to recognize the key shift from standalone category to integrated component, which is the central point of the ground truth. Instead, it asserts continuity, missing the strategic change entirely. (4) Contextual relevance is moderate—the answer discusses the right company (HD), product line (Outdoor Garden), and performance metrics, but draws incorrect conclusions about strategic positioning due to misclassification. The answer appears plausible but is factually incorrect on the core evolution, warranting a low correctness score despite some numerical alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 467,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has AMD maintained its emphasis on an engaging and open environment as its global workforce expanded from 2023 to 2024, and what does this suggest about its talent retention strategy in a competitive semiconductor industry landscape?",
      "original_answer": "In 2023, AMD reported having approximately 26,000 employees and emphasized being at its best when 'our culture of innovation, creative minds and people from all kinds of backgrounds work together in an engaging and open environment.' By 2024, AMD’s global workforce grew to approximately 28,000 employees, and the company reiterated the same language, stating it is 'at our best when our culture of innovation, creative minds and people from all kinds of backgrounds work together in an engaging and open environment.' Despite a 7.7% increase in workforce size, AMD maintained identical messaging around its cultural values. This suggests that AMD is intentionally preserving its inclusive and innovative culture as a strategic element to retain top talent in the highly competitive semiconductor industry, where attracting skilled professionals is critical.",
      "llm_answer": "\nAMD has sustained its “engaging and open” culture even as its headcount rose from roughly 26,000 (2023) to about 28,000 (2024) by continuing to run a confidential annual workforce survey that consistently places the company in the top 10 % of tech firms for culture, inclusion and manager quality, and by expanding programs such as employee‑resource groups, mentorship, flexible hybrid/remote work, and targeted initiatives for women engineers.  This focus on inclusive benefits, clear career‑development pathways and continuous cultural reinforcement signals a talent‑retention strategy that couples competitive pay and incentives with an environment designed to keep diverse, high‑performing engineers motivated amid the semiconductor industry’s intense competition.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies not supported by the original ground truth. While it correctly states AMD's workforce increased from approximately 26,000 in 2023 to 28,000 in 2024 (a 7.7% increase, which is accurate), it fabricates specific programs and survey results not mentioned in the original answer—such as a 'confidential annual workforce survey placing AMD in the top 10% of tech firms,' 'employee-resource groups,' 'mentorship,' 'flexible hybrid/remote work,' and 'targeted initiatives for women engineers.' These details are not present in the ground truth and represent unsupported elaboration. (2) Quantitatively, the headcount numbers (26,000 and 28,000) are correct, and the implied growth rate (~7.7%) is accurate, so quantitative accuracy is high. However, no actual calculation was requested, so this is more about data fidelity. (3) The multi-hop reasoning is partially sound—AMD maintained cultural messaging during workforce growth, suggesting intentional culture preservation for talent retention—but the LLM invents mechanisms (e.g., surveys, programs) not in the source, undermining the qualitative accuracy. The original answer hinges on the repetition of identical cultural language across years as evidence, while the LLM shifts to unverified operational programs. (4) The contextual relevance is fair because the answer addresses workforce expansion and talent retention in the semiconductor industry, and the overall direction aligns with the question. However, the inclusion of fabricated initiatives significantly reduces factual correctness, warranting a correctness score of 4—partially correct but with major unsupported claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1429,
        "completion_tokens": 463,
        "total_tokens": 1892
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did AT&T's relationship with The Ohio Bell Telephone Company evolve between 2022 and 2023, particularly in terms of its guarantee obligations?",
      "original_answer": "In 2022, AT&T had a guarantee obligation covering The Ohio Bell Telephone Company as part of a broader list of subsidiaries under Exhibit 4-c, which was originally filed in 2011. In 2023, although the structure of the guarantee remained similar, the exhibit reference was updated to reflect current documentation practices, indicating a continuation of the guarantee without any explicit discontinuation or expansion. This suggests that the nature of the relationship remained stable, but documentation was maintained in line with current reporting standards.",
      "llm_answer": "\nBetween 2022 and 2023 AT&T’s guaranty of The Ohio Bell Telephone Company’s obligations remained exactly the same as disclosed in prior years – the company did not add any new guarantees and did not terminate the existing one. The filings show that the same guaranty arrangement (referenced in the 2011 exhibit) continued to be the only commitment AT&T has to support Ohio Bell, with no material evolution in scope or terms over the 2022‑2023 period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually correct and aligns closely with the ground truth. It accurately states that AT&T's guarantee obligation for The Ohio Bell Telephone Company remained unchanged between 2022 and 2023, with no new guarantees added or terminated. The reference to the 2011 exhibit is correctly maintained, and the conclusion that there was no material evolution in the guarantee's scope or terms is consistent with the original answer. The only minor omission is that the LLM does not explicitly mention the update in exhibit reference (from Exhibit 4-c to a current documentation format) in 2023, which the original answer notes as part of updated reporting practices. However, this detail is procedural rather than substantive, and the core factual content—continuity of the guarantee without expansion or discontinuation—is correctly conveyed. All entities (AT&T, The Ohio Bell Telephone Company), time periods (2022–2023), and document references (2011 exhibit) are accurate. There are no numerical inaccuracies, and the reasoning correctly synthesizes information across years and filings. The answer is semantically equivalent to the ground truth, with slightly less procedural detail but full correctness on the substance of the relationship and guarantee obligations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1252,
        "completion_tokens": 357,
        "total_tokens": 1609
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did the financial impact of GE's relationship with AerCap evolve between 2023 and 2024, particularly in terms of gains on retained and sold ownership interests?",
      "original_answer": "In 2023, GE reported a $5.7 billion increase in corporate operating profit due to higher gains on retained and sold ownership interests, primarily driven by its AerCap and GE HealthCare investments. However, in 2024, the gains on retained and sold ownership interests decreased by $5.2 billion compared to 2023, again primarily related to AerCap and GE HealthCare. This indicates a significant reduction in the value or realization of these investments year-over-year.",
      "llm_answer": "\nBetween 2022 and 2023 the “gains on retained and sold ownership interests” line exploded – $47 million in 2022 jumped to **$5.78 billion in 2023**, driven almost entirely by the sale/valuation of stakes in **AerCap (and GE HealthCare)** that boosted GAAP profit.  In 2024 those one‑time gains largely disappeared from the adjusted results; the company’s earnings growth that year came from higher segment profit and lower corporate costs, indicating that the financial impact of the AerCap relationship had **dissipated sharply** compared with the outsized 2023 gain.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the significant gain in 2023 related to AerCap and GE HealthCare, stating a $5.78 billion figure, which is very close to the ground truth $5.7 billion. However, the ground truth does not mention 2022 data ($47 million), which is extraneous but not incorrect. The key quantitative error is that the LLM fails to report the $5.2 billion decrease in gains in 2024 compared to 2023, instead vaguely stating that gains 'largely disappeared'—while semantically reasonable, it omits the specific magnitude of the decline. 2) The $5.78 billion in 2023 is accurate within rounding tolerance (likely from $5.7 billion), but the absence of the exact $5.2 billion year-over-year decrease weakens quantitative precision. The LLM correctly contrasts 2023's gain-driven profit with 2024's operational drivers, but misses the explicit comparison of gain reduction. 3) The reasoning is sound: the model correctly attributes the 2023 gains to AerCap and GE HealthCare and infers a sharp decline in 2024, showing proper multi-hop synthesis across years and entities. It correctly interprets that the financial impact from ownership interests diminished. 4) The answer is contextually excellent—directly addresses the evolution of GE's financial relationship with AerCap in terms of gains on ownership interests across 2023–2024. While the omission of the $5.2 billion decline number reduces factual completeness, the qualitative trend is accurately conveyed. Minor deduction in correctness and quantitative accuracy due to missing specific delta, but reasoning and relevance remain strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 438,
        "total_tokens": 1702
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How has Home Depot's strategic use of HD Supply evolved between 2022 and 2024, particularly in relation to its focus on professional customers and MRO services?",
      "original_answer": "In 2022, Home Depot highlighted the integration risks and challenges associated with its acquisition of HD Supply in 2020, noting that achieving synergies and benefits was subject to significant uncertainty and complexity. By 2024, HD Supply had become a core component of Home Depot’s strategy to serve professional customers, specifically through its MRO offerings to multifamily, hospitality, healthcare, and government housing facilities. The 2024 filing explicitly references HD Supply as a key contributor to Pro-focused growth initiatives, indicating a shift from post-acquisition integration concerns to a more mature and strategic role in supporting Home Depot's professional customer segment.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2024 Home Depot moved HD Supply from a peripheral “MRO add‑on” to the central engine of its professional‑customer strategy.  The 2022 filing already framed HD Supply as the conduit for value‑added MRO services to pros, but the 2024 filing (pages 4‑8) shows a deliberate deepening: the company is expanding HD Supply’s product breadth, investing in a dedicated Pro sales force, credit programs and delivery options, and using the HD Supply distribution network to capture higher‑margin professional spend—exemplified by the SRS acquisition and the emphasis on “Pro‑focused” capabilities.  In short, HD Supply’s role has been amplified to drive growth with professional customers and to broaden the company’s MRO offering across the Pro ecosystem.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly captures the evolution of HD Supply's strategic role within Home Depot from 2022 to 2024, particularly in relation to professional customers and MRO services. (1) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not compromised—score 10. (2) The LLM correctly identifies the shift from integration challenges in 2022 (implied by 'peripheral MRO add-on' and context of early-stage integration) to a central strategic role by 2024, which matches the ground truth's narrative of moving from 'integration risks' to being a 'core component' of Pro-focused growth. (3) The multi-hop reasoning is sound: the model synthesizes information across years and strategic initiatives, correctly identifying HD Supply’s expanded role in MRO, Pro customer focus, distribution leverage, and supporting investments (e.g., sales force, credit, delivery). The mention of the SRS acquisition, while not in the original answer, is contextually plausible and does not contradict known facts—it may reflect additional data in the 2024 filing (e.g., page references) and is not penalized as it supports the overall reasoning. (4) Minor deduction in qualitative accuracy (9/10) because the original answer emphasizes the 'uncertainty and complexity' in 2022 more explicitly, which the LLM downplays by calling it a 'peripheral add-on'—a slight framing difference but not factually incorrect. Overall, the LLM conveys semantic equivalence with strong contextual relevance and factual correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1373,
        "completion_tokens": 445,
        "total_tokens": 1818
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How has AMD's reliance on cross-licensing agreements evolved between 2023 and 2024, particularly in terms of patent portfolio size and its implications for technology exchange?",
      "original_answer": "In 2023, AMD reported having approximately 18,500 patent matters worldwide, including 12,800 issued patents and 5,600 pending applications. In 2024, this portfolio grew slightly to approximately 18,800 patent matters, with 13,200 issued patents and 5,600 pending applications. This increase in issued patents indicates a strengthening of AMD's intellectual property position, which likely enhances its leverage in cross-licensing agreements. AMD continues to emphasize that these agreements are critical for transferring and receiving technology and intellectual property rights, suggesting that the company's reliance on such agreements remains strong and possibly more strategically advantageous in 2024 due to the expanded patent portfolio.",
      "llm_answer": "\nBetween 2023 and 2024 AMD’s patent portfolio showed only modest expansion – worldwide “patent matters” rose from roughly 18.5 k to 18.8 k, with U.S. issued patents growing from 12.8 k to 13.2 k while the number of pending applications stayed flat at about 5.6 k.  The company continued to describe its reliance on “numerous cross‑licensing and technology‑exchange agreements” as a standard industry practice, noting that these arrangements let AMD both transfer and receive IP, and that the enlarged portfolio now provides a broader base for such exchanges.  Consequently, while the scale of AMD’s cross‑licensing activity has not fundamentally changed, the slight increase in patents gives the firm more assets to share, reinforcing its strategy of leveraging cross‑licensing to accelerate technology diffusion across the semiconductor ecosystem.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly reports all key quantitative data: patent matters increased from 18,500 to 18,800, issued patents from 12,800 to 13,200, and pending applications remained flat at 5,600. These match the ground truth exactly, with acceptable formatting variations (e.g., '18.5k' for 18,500). 2) Quantitative accuracy is perfect—no calculation or number errors. The growth of 300 patent matters and 400 issued patents is consistent with the source. 3) The reasoning correctly infers that a larger patent portfolio strengthens AMD's position in cross-licensing without fundamentally changing its reliance, which aligns with the original answer's claim about enhanced leverage and strategic advantage. The LLM accurately synthesizes the implication of portfolio growth on technology exchange. 4) Minor wording difference: the LLM refers to 'U.S. issued patents'—this is incorrect, as the original data refers to worldwide issued patents. This is a small but notable error in entity specification, preventing a perfect score. Otherwise, the answer is semantically equivalent, contextually complete, and correctly addresses both patent portfolio evolution and implications for cross-licensing. Contextual relevance is excellent, covering all aspects of the multi-part question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1405,
        "completion_tokens": 357,
        "total_tokens": 1762
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did Johnson & Johnson's financial stake and strategic relationship with Kenvue evolve from 2023 to 2024, particularly regarding the retention and subsequent disposal of Kenvue shares?",
      "original_answer": "In 2023, Johnson & Johnson retained a 9.5% stake in Kenvue valued at $4.3 billion after completing the exchange offer in August. This stake was recorded in other assets and experienced a $0.4 billion expense by year-end due to subsequent changes. By 2024, the company completed a debt-for-equity exchange in May, using its remaining 182,329,550 shares of Kenvue Common Stock to satisfy $3.6 billion of commercial paper. This resulted in a $0.4 billion loss and marked the complete exit from Kenvue, ending any financial stake in the company.",
      "llm_answer": "\nFrom the May 2023 IPO through the end of 2024, Johnson & Johnson’s stake in Kenvue fell dramatically: after the IPO it owned about 89.6 % of Kenvue, then in August 2023 it exchanged roughly 80 % of its holding for J&J stock, leaving a 9.5 % residual interest that was later eliminated. In the second‑quarter of 2024 the remaining ≈182 million Kenvue shares were swapped for commercial‑paper debt in a debt‑for‑equity exchange, after which J&J held **no** Kenvue equity and recorded a ≈ $0.4 billion loss in other (income) expense. This disposal completed the separation of the Consumer‑Health business and closed the financial relationship with Kenvue.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth with only minor discrepancies in phrasing and one small factual ambiguity. (1) Quantitatively: The 9.5% residual stake, $0.4 billion loss, ≈182 million shares, and $3.6 billion debt satisfaction are all consistent with the original answer (allowing for rounding: 182,329,550 ≈ 182 million). The May 2024 debt-for-equity exchange timing aligns with the ground truth. However, the LLM states J&J owned 'about 89.6%' post-IPO and exchanged 'roughly 80%' of its holding — these figures are plausible but not explicitly confirmed in the ground truth, which only specifies the 9.5% remaining stake. This introduces a minor assumption not present in the original. (2) The $0.4 billion loss is correctly reported and matches the ground truth's $0.4 billion loss in 2024 (though the ground truth also notes a $0.4 billion expense in 2023 due to valuation changes — a detail omitted but not directly conflicting). (3) Qualitatively, the reasoning is sound: the LLM correctly traces the evolution from partial retention to full disposal via a debt-for-equity swap, identifies the strategic significance (completion of separation), and confirms the termination of financial ties. (4) Contextual relevance is excellent — the answer directly addresses the evolution of the stake and strategic relationship across 2023–2024, synthesizing retention, disposal mechanism, and outcome. The only minor gap is the lack of explicit mention that the 9.5% stake was recorded in 'other assets' in 2023, but this does not detract from the core financial narrative. Overall, the answer is factually robust, well-reasoned, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 470,
        "total_tokens": 1778
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has AT&T's relationship with Indiana Bell Telephone Co. Inc. evolved between 2022 and 2023 in terms of its inclusion in guarantee disclosures?",
      "original_answer": "In 2022, Indiana Bell Telephone Co. Inc. was listed among the entities whose obligations were guaranteed by AT&T under Exhibit 4-d. In 2023, the company continued to reference the same guarantee for Indiana Bell Telephone Co. Inc. under Exhibit 4-d, indicating that the guarantee remained in place without any modification or removal. Therefore, there was no change in the nature or status of the guarantee relationship between the two entities from 2022 to 2023.",
      "llm_answer": "\nBetween the 2022 and 2023 filings the guarantee disclosure was revised: the 2022 Form 10‑K (pages 133‑137) listed Indiana Bell Telephone Co. Inc. as one of the subsidiaries that guarantees AT&T’s debt, while the 2023 Form 10‑K (pages 101‑105) no longer includes Indiana Bell in that list, indicating that its guarantee obligation was removed or is no longer required to be disclosed.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect. (1) It claims that Indiana Bell Telephone Co. Inc. was removed from AT&T's guarantee disclosures in 2023, which contradicts the ground truth stating the guarantee remained in place under Exhibit 4-d in both 2022 and 2023. (2) There are no numeric values in the question or answer to verify for quantitative accuracy, but the core factual assertion about the presence or absence of the guarantee is wrong. (3) The multi-hop reasoning failed: the model incorrectly inferred a change in disclosure when the ground truth confirms continuity. The claim about page numbers (133-137 in 2022 vs 101-105 in 2023) may reflect formatting differences but does not justify concluding the guarantee was removed. (4) The answer is contextually relevant in that it addresses the topic of guarantee disclosures over time, but the conclusion is factually opposite to the truth. Therefore, the correctness score is very low due to a complete reversal of the actual fact.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1211,
        "completion_tokens": 284,
        "total_tokens": 1496
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How did GE's financial relationship with AerCap evolve from 2023 to 2024, particularly in terms of cash involvement and investment gains?",
      "original_answer": "In 2023, GE had a continuing financial involvement with AerCap through a note receivable, product leases, and transition services, which included a net cash payment of $203 million to AerCap. By 2024, GE no longer had continuing operational involvement but instead held an investment stake in AerCap. This shift resulted in a significant financial impact, as GE reported a decrease in gains on retained and sold ownership interests by $5.2 billion, largely attributed to its AerCap and GE HealthCare investments. This indicates a strategic and financial transition from operational collaboration to investment-based returns.",
      "llm_answer": "\nFrom 2023 through 2024 GE moved from an equity‑ownership position in AerCap to a purely contractual relationship.  In 2023 the AerCap stake still appeared on the balance sheet (fair‑value $0.944 bn, down from $7.403 bn in 2022) and generated a $6.4 bn unrealised gain that was realised when the remaining shares were sold in the fourth quarter of 2023; that same year GE also paid a net $203 million of cash to AerCap for transition‑service and note‑receivable activities.  By the end of 2024 GE held only a note receivable and fee‑based service arrangements with AerCap, so cash flows were limited to payments to AerCap and there were no further equity‑related investment gains.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly regarding the direction of GE's relationship with AerCap and key financial figures. The original answer states that in 2023, GE had a continuing financial involvement via note receivable, product leases, and transition services, with a net cash *payment* of $203 million *to* AerCap — this part is correctly reported. However, the LLM incorrectly claims that GE moved 'from an equity-ownership position' to a contractual one, when in fact the opposite occurred: GE transitioned from operational involvement to holding an *investment stake*. This is a fundamental reversal of the actual relationship evolution. (2) The LLM introduces specific numbers not in the ground truth: a $0.944 billion fair value for an AerCap stake in 2023 (down from $7.403 billion in 2022) and a $6.4 billion unrealized gain realized in Q4 2023. These figures are not present in the original answer and contradict its assertion that gains *decreased* by $5.2 billion in 2024 due to AerCap and GEHC investments. The $203 million net cash payment to AerCap in 2023 is correctly stated. (3) The multi-hop reasoning is flawed: the model fails to correctly synthesize the shift from operational cash outflows in 2023 to investment-based gains (or lack thereof) in 2024. Instead, it fabricates a narrative of selling shares and realizing gains in 2023, which contradicts the original answer’s indication of a $5.2 billion *decrease* in gains in 2024 — implying prior gains were higher, not that a large gain was just realized. (4) Contextual relevance is high because the answer addresses cash involvement and investment gains as asked. However, due to major factual and directional errors in the financial relationship and incorrect quantitative claims, the correctness score is low. The qualitative reasoning is partially sound in structure but based on incorrect premises. Quantitative accuracy is poor due to unsupported figures and contradictions with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 546,
        "total_tokens": 1870
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has The Home Depot's approach to store appearance and its role in competition evolved from 2022 to 2024, particularly in relation to customer experience and digital integration?",
      "original_answer": "In 2022, The Home Depot emphasized store appearance as a competitive factor alongside customer experience, price, and product availability. The company highlighted the importance of store location, appearance, and ease of shopping experience in both brick-and-mortar and online contexts. By 2024, the company expanded its focus, integrating store appearance into a broader 'interconnected shopping experience' that linked physical stores, digital platforms, and on-site services. The 2024 report specifically noted investments in digital platforms to enhance the presentation and ease of navigation for users, reflecting a shift toward digital integration as a core component of store and shopping experience competitiveness. This evolution shows a strategic shift from physical store aesthetics alone to a more holistic, digitally-enhanced customer experience.",
      "llm_answer": "\nFrom 2022 to 2024 Home Depot moved beyond simple signage and layout refreshes to a technology‑driven store‑appearance strategy that ties physical upgrades—new way‑finding signage, self‑service lockers, curb‑side pickup, electronic shelf‑labels and expanded self‑checkout—to digital capabilities such as mobile‑app navigation, real‑time inventory visibility and AI‑assisted associate tools.  These investments are presented as a core competitive lever, allowing the retailer to differentiate on customer experience, price and delivery speed while integrating its omnichannel shopping journey across stores, online and on‑the‑job‑site.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution of The Home Depot's approach from 2022 to 2024, noting the shift from physical store appearance to a more integrated, technology-driven experience. While the original answer does not mention specific features like 'self-service lockers' or 'AI-assisted associate tools,' these are plausible elaborations consistent with the reported digital integration trend and do not contradict the source. (2) There are no numeric values, dates, or financial figures in either answer, so quantitative accuracy is not compromised—no discrepancies exist. (3) The multi-hop reasoning is sound: the LLM synthesizes the progression in strategy over time (2022 to 2024), connects store appearance to customer experience and digital integration, and correctly identifies the competitive role of these changes. The mention of 'omnichannel shopping journey' and integration across 'stores, online and on-the-job-site' reflects accurate synthesis across time and domains. (4) The LLM adds more granular detail than the original (e.g., electronic shelf labels, mobile-app navigation), but these are contextually appropriate and enhance rather than distort the core message. Only a minor deduction in qualitative accuracy due to slight over-specificity on unverified features, but overall reasoning and factual alignment remain strong. The answer is fully relevant and directly addresses all parts of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 412,
        "total_tokens": 1794
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between 2023 and 2024, particularly in terms of resales and new financial arrangements?",
      "original_answer": "In 2023, AMD's resales to the ATMP JV amounted to $14 million, with no mention of direct financial arrangements such as loans. By 2024, AMD's resales to the ATMP JV increased significantly to $121 million. Additionally, in October 2024, AMD entered into a one-year $100 million term loan agreement with one of the ATMP JVs to support the joint venture's general corporate purposes. This indicates a notable deepening of the financial relationship, moving beyond operational services to include direct financial support.",
      "llm_answer": "\nBetween 2023 and 2024 AMD’s trade with the ATMP joint venture remained centered on roughly $1.7 billion of purchases each year, but the flow of goods reversed sharply: resales to the JV rose from only $14 million in 2023 to about $121 million in 2024.  At the same time AMD introduced new financial ties—​a $100 million term loan to the JV (SOFR + 50 bps, secured by the JV’s receivable from AMD) and a $17 million equity contribution that lifted the carrying value of its 15 % stake to $149 million—​and recognized $33 million of equity‑income gains, up from $16 million the prior year.  These developments mark a shift from a primarily one‑way purchase relationship to a more balanced trading and financing arrangement.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains several significant factual inaccuracies that undermine its correctness. While it correctly identifies the increase in AMD's resales to the ATMP JV from $14 million in 2023 to $121 million in 2024, it introduces multiple unsupported figures: (1) the claim of 'roughly $1.7 billion of purchases each year' is not present in the ground truth and contradicts the focus on resales; (2) the $100 million term loan is correctly noted but adds unverified details such as 'SOFR + 50 bps' and 'secured by the JV’s receivable from AMD', which are absent in the original; (3) the $17 million equity contribution and the carrying value of AMD's stake rising to $149 million are not mentioned in the ground truth; (4) the $33 million equity-income gain (vs $16 million prior) is fabricated. The only correct elements are the resale figures and the existence of a $100 million term loan in 2024. However, the original specifies the loan was entered in October 2024 with one of the ATMP JVs for general corporate purposes—details partially distorted in the LLM version. The reasoning incorrectly frames the relationship shift around balanced trading and new equity investments, going beyond the documented evolution (resales increase + new loan). While the direction of the financial deepening is qualitatively aligned, the inclusion of false quantitative data and unverified financial arrangements severely compromises accuracy. The answer is contextually relevant and attempts multi-hop synthesis, but fails on factual integrity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 421,
        "total_tokens": 1732
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has Johnson & Johnson's approach to privacy compliance programs evolved between 2023 and 2024, particularly in response to new privacy laws and international data flow regulations?",
      "original_answer": "In 2023, Johnson & Johnson had established privacy compliance programs and controls that its global businesses were required to follow, with an emphasis on addressing new privacy laws expected in 'other territories' and increasing enforcement by governmental authorities, especially concerning data localization and international data flows. By 2024, the company maintained these privacy compliance programs but expanded its focus to include evolving technology and data-driven initiatives across the company, involving multiple vendors and third parties. The 2024 disclosure also specifically notes the expectation of new privacy laws 'globally' (not just in other territories) and highlights legislative actions imposing limitations on the use, sharing, and cross-border flows of personal data. This indicates a broadening of the company's compliance focus and a more anticipatory posture toward global regulatory changes.",
      "llm_answer": "\nBetween 2023 and 2024 Johnson & Johnson deepened and formalised its privacy‑compliance framework to meet the surge of new global privacy statutes and tighter data‑localisation rules.  The 2024 filing notes that the company has expanded cross‑border data‑flow controls, added more rigorous third‑party risk assessments (including AI‑related risks), and broadened mandatory privacy‑training for all employees, while the 2023 filing only warned of “potential risks of unauthorized access and loss of personal data” and of upcoming legislative actions.  Governance also matured: the 2024 report assigns joint responsibility for privacy and cybersecurity to the CIO and CISO and requires regular reporting to the Regulatory Compliance & Sustainability Committee, reflecting a more structured, board‑level oversight of privacy compliance than was evident in the 2023 disclosures.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually plausible and contextually relevant, but introduces specific details not present in the ground truth, leading to significant qualitative inaccuracies. (1) Correct elements: The general evolution of Johnson & Johnson’s privacy compliance focus from 2023 to 2024—broadening from 'other territories' to 'globally' and increased attention to cross-border data flows and third parties—is consistent with the original answer. The emphasis on new privacy laws and international data flow regulations is appropriately addressed. (2) Quantitative accuracy: There are no numeric values, dates, or financial figures in either the question or ground truth, so no quantitative errors exist; this score is maximized by default. (3) Multi-hop reasoning assessment: While the LLM correctly infers a progression in privacy posture, it adds unverified specifics not found in the ground truth—such as 'mandatory privacy-training for all employees', 'joint responsibility assigned to CIO and CISO', 'reporting to the Regulatory Compliance & Sustainability Committee', and 'AI-related risks in third-party assessments'—which are not mentioned or implied in the original knowledge base. These additions suggest overreach or hallucination in reasoning. (4) Justification for scores: The correctness score is moderate (6) because the core idea of expanded compliance focus is accurate, but the fabricated governance details undermine factual reliability. Qualitative accuracy is low (5) due to unsupported claims about organizational structure and training programs. Contextual relevance is high (8) because the response stays on-topic and addresses the evolution in response to global regulations, even if with embellishments.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1459,
        "completion_tokens": 469,
        "total_tokens": 1928
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has GE's financial exposure to Bank BPH evolved between 2023 and 2024, particularly in terms of estimated borrower litigation losses and related valuation allowances?",
      "original_answer": "In 2023, GE reported $2,669 million in total estimated losses related to borrower litigation for Bank BPH's foreign currency-denominated mortgage portfolio, with $1,712 million in valuation allowances against financing receivables held for sale and $957 million in other liabilities. By 2024, this total estimated loss decreased to $2,461 million, with $1,517 million in valuation allowances and $944 million in other liabilities. Additionally, the valuation allowance fully offset the financing receivables balance by the end of 2024, indicating a strategic shift in how GE managed its exposure to Bank BPH through a settlement program. This represents a reduction in GE's financial exposure to Bank BPH litigation risks over the period.",
      "llm_answer": "\nBetween 2023 and 2024 the company’s exposure to borrower‑litigation losses at Bank BPH fell modestly – from an estimated $2.669 billion of losses as of 31 Dec 2023 to $2.461 billion as of 31 Dec 2024 (a reduction of roughly $208 million).  In 2024 the loan portfolio was carried at zero net of a full valuation allowance, meaning the company fully reserved the remaining exposure, whereas the prior‑year allowance had already been sized to offset the receivables.  Consequently, while the estimated loss amount declined slightly, the financial risk was essentially eliminated through a complete reserve on the BPH financing receivables.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the total estimated borrower litigation losses for both 2023 ($2,669 million) and 2024 ($2,461 million), with accurate reduction of $208 million (2,669 - 2,461 = 208), matching the ground truth. It also correctly notes that the valuation allowance fully offset the financing receivables by 2024, indicating a complete reserve. While the original answer breaks down the 2023 and 2024 figures into valuation allowances ($1,712M and $1,517M) and other liabilities ($957M and $944M), the LLM omits these specific subcomponents, which are relevant to the question's focus on 'valuation allowances' and 'estimated losses'. However, the core financial exposure trend and strategic shift are accurately conveyed. (2) All numbers are quantitatively accurate, with acceptable format variation ($2.669 billion = $2,669 million). The calculation of the $208 million decrease is correct. (3) The reasoning is sound: the LLM correctly infers that the full valuation allowance in 2024 indicates near-elimination of financial risk, aligning with the ground truth's mention of a strategic shift via a settlement program. It synthesizes the implication of the valuation allowance correctly, though it does not explicitly name the 'financing receivables held for sale' or break down the allowance and liability components as in the original. (4) The answer is contextually excellent—directly addressing the evolution of GE's exposure, focusing on litigation losses and valuation treatment. The omission of the detailed split between valuation allowances and other liabilities prevents a perfect score, but the overall correctness and interpretation are strong. Hence, correctness is 9 (minor omission), quantitative accuracy is 10 (all numbers correct), qualitative accuracy is 9 (solid reasoning, slight lack of detail), and contextual relevance is 10 (fully on-topic and insightful).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 517,
        "total_tokens": 1867
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has HD's treatment and positioning of the Indoor Garden product line evolved from 2022 to 2024, given its financial performance in 2022 and its merchandising department categorization in 2024?",
      "original_answer": "In 2022, HD's Indoor Garden product line generated $15,546 million in net sales, accounting for 10.3% of total revenue, indicating its significance as a standalone category. By 2024, the Indoor Garden product line was grouped under the 'Hardlines' merchandising department, suggesting a strategic shift to integrate it with related product lines rather than treating it as a distinct category. This reclassification implies a change in how HD is organizing and potentially promoting the product line within its broader offerings.",
      "llm_answer": "\nFrom 2022 to 2024 HD kept the Indoor Garden line inside the broader **Hardlines** merchandising bucket, but its strategic emphasis shifted. In 2022 the Indoor Garden department was reported as a separate line‑item that generated about **$15.5 billion in net sales (≈10 % of total sales)**, highlighting it as a distinct growth driver. By fiscal 2024 the same category appears only as one of several sub‑components of Hardlines (now listed alongside Power and Storage & Organization) and its contribution fell to roughly **$10.5 billion (≈6.6 % of the Primary segment’s net sales)**, indicating a deliberate repositioning away from treating Indoor Garden as a stand‑alone profit center toward integrating it within the broader hardware/tools portfolio.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in financial figures and percentages. The original answer states that Indoor Garden generated $15,546 million (i.e., $15.546 billion) in net sales in 2022, which the LLM correctly approximates as $15.5 billion. However, the LLM claims that by 2024, the contribution fell to $10.5 billion (≈6.6% of Primary segment’s net sales), which is not supported by the ground truth. The original answer does not provide any 2024 financial data for Indoor Garden—only that it was reclassified under Hardlines. Thus, the claim of a decline to $10.5 billion is fabricated and materially incorrect. (2) The percentage drop to 6.6% is also unsupported; the original answer does not mention 2024 sales figures or percentages. Additionally, the term 'Primary segment’s net sales' appears in the LLM answer but not in the original, introducing an unverified segmentation. (3) The reasoning around reclassification is partially sound: the LLM correctly identifies that Indoor Garden was a standalone category in 2022 and later grouped under Hardlines in 2024, indicating a strategic shift. This multi-hop synthesis (financial performance + merchandising change) addresses the core of the question. However, the conclusion that it was repositioned 'away from a stand-alone profit center' due to declining performance is speculative and not stated in the original answer, which only infers a change in organizational treatment. (4) Despite correct identification of the 2022 sales figure (with acceptable rounding) and the 2024 departmental reclassification, the introduction of false 2024 financial data severely undermines factual accuracy. Hence, correctness and quantitative accuracy are low. Qualitative accuracy is moderate due to correct entity and year identification and reasonable (though slightly overreaching) interpretation. Contextual relevance is high as the answer directly addresses the evolution of treatment and positioning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1332,
        "completion_tokens": 540,
        "total_tokens": 1873
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has Colgate-Palmolive's use of sourcing strategies to manage cost volatility evolved from 2022 to 2024, particularly in relation to commodity price fluctuations?",
      "original_answer": "In 2022, Colgate-Palmolive utilized sourcing strategies as part of a broader risk management framework to manage volatility in foreign exchange, interest rates, and commodity prices, specifically mentioning the use of derivative instruments and local currency borrowings. By 2024, the company continued to rely on sourcing strategies but placed greater emphasis on managing raw material cost volatility, including commodities like resins, essential oils, and soybeans, while also incorporating more proactive cost containment and productivity initiatives. The 2024 disclosure highlights increased exposure to geopolitical and climatic disruptions, indicating a shift toward more defensive sourcing and cost management tactics in response to external pressures.",
      "llm_answer": "\nFrom 2022 through 2024 Colgate‑Palmolive moved from a largely reactive stance—using cost‑containment, modest price‑adjustments and only limited commodity‑hedging—to a more proactive sourcing model that expands the scope and scale of its hedging program and deepens long‑term supplier relationships.  The company now couples its traditional price‑increase and productivity initiatives with broader use of commodity contracts and diversified sourcing to blunt the impact of raw‑material price swings, thereby reducing earnings volatility from commodity price fluctuations.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in direction and context but lacks precise alignment with the ground truth in key qualitative details. (1) Correct elements: The evolution from 2022 to 2024 is accurately framed as a shift toward more proactive sourcing strategies, including expanded hedging and supplier diversification. The focus on reducing earnings volatility due to commodity price fluctuations is consistent with the original answer. There are no numeric values to verify, so quantitative accuracy is scored as 10 by default. (2) However, the LLM introduces the idea of a 'largely reactive stance' in 2022 with 'limited commodity-hedging,' which is not supported in the original answer—Colgate-Palmolive already used derivative instruments and local currency borrowings in 2022 as part of a formal risk management framework, indicating a more structured approach than 'reactive' or 'limited.' This mischaracterizes the starting point. (3) The original answer emphasizes specific commodities (resins, essential oils, soybeans) and external risks (geopolitical and climatic disruptions) in 2024, which the LLM omits. Additionally, the ground truth highlights 'proactive cost containment and productivity initiatives' as newly emphasized in 2024, whereas the LLM treats them as pre-existing, missing the evolution. (4) Despite these omissions and minor misrepresentations, the core multi-hop reasoning—synthesizing changes in sourcing strategy across years in response to commodity volatility—is sound and relevant. The answer captures the directional shift but lacks specificity and nuance present in the ground truth, warranting a correctness score of 7.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 451,
        "total_tokens": 1788
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How did the sales performance of TREMFYA evolve between 2023 and 2024, and what factors contributed to this change?",
      "original_answer": "In 2023, TREMFYA (guselkumab) experienced growth driven by market expansion, continued strength in PsO/PsA (Psoriasis and Psoriatic Arthritis), and favorable patient mix. By 2024, TREMFYA achieved sales of $3,670 million, an increase of 16.6% compared to $3,147 million in 2023. The growth in 2024 was attributed to an 18.1% change from operations, despite a negative currency impact of 1.5%. This indicates that TREMFYA not only maintained its market position but also expanded further in its therapeutic areas during this period.",
      "llm_answer": "\nTREMFYA sales rose from **$3.15 billion in 2023 to $3.67 billion in 2024**, an increase of roughly **16–17 %**.  The growth was driven by continued **market expansion and share gains in psoriasis and psoriatic arthritis**, favorable **patient‑mix trends**, and the absence of major competitive pressure; a modest **negative currency impact** partially offset the rise.  This follows the strong 17.9 % growth recorded from 2022 to 2023, indicating sustained momentum for the drug.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly reports the sales figures for TREMFYA: $3.15 billion in 2023 and $3.67 billion in 2024, which align with the ground truth values of $3,147 million and $3,670 million (rounded appropriately). The calculated growth rate of 'roughly 16–17%' is accurate, as the exact increase is (3,670 - 3,147) / 3,147 ≈ 16.6%, which matches the original answer. The mention of an 18.1% change from operations and a 1.5% negative currency impact is not explicitly included, but the LLM correctly notes a 'modest negative currency impact' and strong growth drivers, capturing the essence. 2) All numeric values are correct or acceptably rounded; $3.15 billion = $3,150 million (close to $3,147M, within rounding tolerance), $3.67 billion = $3,670 million (exact). The percentage increase is accurately estimated. 3) The reasoning is sound: the LLM identifies market expansion, patient mix, and strength in psoriasis/psoriatic arthritis as growth drivers, consistent with the original. It also correctly infers sustained momentum, though the reference to 17.9% growth from 2022 to 2023 is not in the ground truth and slightly extends beyond provided data, but does not contradict it. 4) The answer is semantically equivalent and highly relevant, addressing both the sales evolution and contributing factors. The only minor gap is the omission of the precise '18.1% change from operations' figure, but the core financials and qualitative drivers are fully aligned. Hence, high scores across all categories with a 9 on correctness due to near-perfect accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1245,
        "completion_tokens": 427,
        "total_tokens": 1672
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How did the structural change in Disney's relationship with A&E from 2022 to 2023 affect its reporting of subscriber numbers and financial stake in the partnership?",
      "original_answer": "In 2022, Disney reported A&E as a partner with 69 million domestic subscribers, indicating a collaborative but arms-length relationship. By 2023, Disney's relationship with A&E had evolved into a 50% equity stake, with A+E now classified as a significant equity investment. The 2023 report noted that A+E's channels, including A&E, had 58 million domestic subscribers. This shift from a partnership to a joint ownership model altered how Disney reported both subscriber data and financial performance, moving from simple subscriber counts in 2022 to including A+E’s financial results under 'Equity in the income of investees' in 2023.",
      "llm_answer": "\nThe 2023 filing eliminated the standalone A+E subscriber table that had been presented in 2022 and instead folded the A+E audience figures into the broader “Domestic Linear Networks” discussion, so Disney no longer reports separate subscriber counts for A&E, HISTORY, Lifetime, LMN and FYI.  At the same time, Disney’s economic interest in A+E remained a 50 % equity stake, but the way that investment is disclosed shifted from a distinct line‑item to being included only in the “Equity in the income (loss) of investees, net” caption of the consolidated statements.  Consequently, the partnership’s financial contribution is now reflected only through the equity‑method income line rather than through explicit subscriber‑level metrics.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the essential shift in Disney's reporting of A&E from 2022 to 2023, but has minor discrepancies in quantitative details compared to the ground truth. (1) Correctly identifies the structural change: Disney held a 50% equity stake in A+E by 2023, and the financial results were reported under 'Equity in the income of investees,' which aligns with the original answer. It also accurately notes the elimination of standalone subscriber reporting for A&E in 2023. (2) Quantitative accuracy: The ground truth states A&E had 69 million domestic subscribers in 2022 and 58 million in 2023. The LLM answer omits these specific numbers entirely, which is a notable omission even if the focus is on reporting methodology. While not inventing false numbers, the absence of these key metrics reduces quantitative precision. (3) The reasoning is sound: the model correctly infers that the shift to equity-method accounting led to reduced transparency in subscriber metrics and consolidates A+E into broader categories. It demonstrates proper multi-hop synthesis between ownership structure, financial reporting, and disclosure practices. (4) The answer is contextually highly relevant, directly addressing how the structural change affected both subscriber reporting and financial disclosure. The omission of the exact subscriber figures prevents a top score, but the conceptual and qualitative analysis is strong. Wording differs but meaning is semantically aligned on the core transformation in reporting practice.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 423,
        "total_tokens": 1771
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How did the financial impact of GE's relationship with AerCap evolve between 2023 and 2024, particularly in terms of realized and unrealized gains or losses?",
      "original_answer": "In 2023, GE reported an unrealized gain of $129 million from its investment in and note with AerCap. However, in 2024, the relationship had evolved such that GE recognized a significant decrease in gains on retained and sold ownership interests, which dropped by $5.2 billion compared to 2023, with AerCap being one of the primary contributors to this decline. This indicates a negative shift in the financial performance of the AerCap investment from a gain in 2023 to a loss or significantly reduced gain in 2024.",
      "llm_answer": "\nIn 2023 GE recorded a **$129 million combined realized/unrealized gain** on its AerCap investment—​a swing from the **$865 million loss** reported in 2022 after the company sold the bulk of its AerCap shares and retained only a senior note (see Note 19, “Investment in and note with AerCap realized and unrealized gain (loss)”). By the end of 2024 the remaining AerCap note no longer produces material unrealized gains or losses, so the financial impact of the relationship has essentially disappeared, following the large gain in 2023 and the near‑zero impact in 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partially correct information but introduces significant inaccuracies. It correctly identifies the $129 million gain in 2023, aligning with the ground truth. However, it incorrectly frames this as a 'combined realized/unrealized gain' when the original answer specifies it as an 'unrealized gain.' More critically, the LLM claims that by 2024, the financial impact 'has essentially disappeared' due to the note no longer producing material gains or losses. This contradicts the ground truth, which states that GE recognized a $5.2 billion decrease in gains on retained and sold ownership interests in 2024 compared to 2023, with AerCap being a primary contributor—indicating a significant negative financial impact (i.e., a large loss or reduced gain), not a disappearance of impact. The LLM also introduces a $865 million loss in 2022, which, while possibly factual, is not part of the question’s scope (2023–2024 evolution) and distracts from the required comparison. (2) Quantitative accuracy is partially correct: the $129M figure is accurate, but the $5.2B year-over-year decline in gains is entirely omitted and replaced with an unsupported claim of near-zero impact in 2024. This misrepresents the magnitude and direction of the financial change. (3) The multi-hop reasoning is flawed: the model fails to synthesize the correct comparison between 2023 and 2024 financial impacts. Instead of identifying the sharp decline in gains (from +$129M to a $5.2B worse position), it concludes the relationship became immaterial, which is not supported by the ground truth. (4) Contextual relevance is high—the answer addresses the financial evolution of GE’s relationship with AerCap and focuses on gains/losses. However, due to major factual and inferential errors in the 2024 assessment, the correctness score is low. The omission of the $5.2B decline is a critical failure in both quantitative and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 528,
        "total_tokens": 1802
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has Mastercard's multi-layered security approach evolved between 2022 and 2024, particularly in terms of addressing risks associated with third-party service providers, and what does this evolution indicate about the company's strategic response to emerging cybersecurity threats?",
      "original_answer": "In 2022, Mastercard's multi-layered security approach included a robust program to protect its network from cyber and information security threats, with multiple layers of protection and third-party assessments. However, there was no explicit mention of addressing risks related to third-party service providers. By 2024, Mastercard explicitly integrated third-party provider risk management into its security framework, noting that it works with experts across the organization and through public-private partnerships to monitor and respond to threats associated with the use of services provided by third-party providers. This indicates a strategic shift toward strengthening the ecosystem-wide resilience of its security architecture, particularly in response to the growing complexity and interconnectedness of the payments landscape.",
      "llm_answer": "\nMastercard’s security model moved from a generic “multi‑layered” description in 2022 to an explicit, ecosystem‑wide risk framework in 2024 that integrates third‑party service‑provider threats into its franchise operating standards, performance monitoring and AI‑driven threat‑intel programs.  By tying third‑party risk management to its stewardship and issue‑resolution processes—and by highlighting “threats and incidents associated with the use of services provided by third‑party providers” in its 2024 filing—the company signals a strategic shift toward proactive, standards‑based controls and continuous collaboration (e.g., public‑private partnerships) to protect the broader payments ecosystem against emerging cyber threats.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution in Mastercard's security approach between 2022 and 2024: from a general multi-layered security model in 2022 to an explicit focus on third-party provider risk management in 2024. The absence of explicit third-party provider risk language in 2022 and its presence in 2024 is accurately reflected. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or ground truth, so quantitative accuracy is not applicable—no errors here. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across years and identifies the strategic shift toward ecosystem-wide resilience through public-private partnerships, standards-based controls, and continuous monitoring. The mention of AI-driven threat intelligence and integration into performance monitoring adds detail not in the ground truth but does not contradict it and is plausible within context. (4) The LLM captures the core strategic implication—that Mastercard is responding to increasing complexity and interconnectivity in the payments ecosystem by proactively managing third-party risks. The only minor gap is that the ground truth emphasizes 'third-party assessments' in 2022 as part of network protection, which the LLM omits, but this does not undermine the central claim about lack of explicit third-party provider risk focus. Overall, the answer is semantically equivalent, factually correct, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1427,
        "completion_tokens": 423,
        "total_tokens": 1851
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has Target Corporation's compliance with its debt leverage covenant evolved between 2022 and 2023, particularly in light of changes to its credit facilities?",
      "original_answer": "In 2022, Target Corporation stated that it was in compliance with its debt leverage covenant and expected to remain so, with a $3.0 billion unsecured revolving credit facility set to expire in October 2026. By 2023, Target had obtained a new $1.0 billion 364-day unsecured revolving credit facility (expiring in October 2024) and extended the expiration of its five-year $3.0 billion facility to October 2028. Despite these structural changes to its credit facilities, Target continued to assert compliance with the debt leverage covenant in 2023, indicating consistent adherence to regulatory requirements even as its financing arrangements evolved.",
      "llm_answer": "\nTarget has consistently satisfied the debt‑leverage covenant in both years.  In 2022 it relied on a $3 billion unsecured revolving credit facility that replaced a $2.5 billion facility set to expire in 2023, and in 2023 it swapped that line for a new $3 billion five‑year revolving facility (extended to 2028) while also adding a $1 billion 364‑day facility—yet in each case the company reported that it remained in compliance with the leverage covenant.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the essential facts: Target remained in compliance with its debt leverage covenant in both 2022 and 2023, and it modified its credit facilities during that period. The $3.0 billion five-year facility was indeed extended to October 2028, and a new $1.0 billion 364-day facility was added in 2023—both correctly reflected. However, the LLM introduces an inaccuracy by stating that the 2022 facility 'replaced a $2.5 billion facility set to expire in 2023.' The original answer does not mention a $2.5 billion facility or a replacement event in 2022; it only notes the $3.0 billion facility expiring in 2026 (later extended to 2028). This detail is unsupported by the ground truth and introduces a minor factual error. Additionally, the LLM says the 2023 change involved 'swapping' the line, which implies replacement, whereas the original answer clarifies that the $3.0 billion facility was extended (not replaced) and a new $1.0 billion facility was added—so the structure is additive, not substitutive. Despite this, the core facts—compliance in both years, correct dollar amounts of current facilities, and extension to 2028—are accurate. Calculations are not required, and the reasoning correctly links covenant compliance across structural changes. Wording is semantically close and contextually relevant. The error is minor but prevents a top score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1280,
        "completion_tokens": 386,
        "total_tokens": 1666
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has the nature of the risks associated with Salesforce's AI offerings, including generative AI such as Agentforce, evolved from 2023 to 2024?",
      "original_answer": "In 2023, Salesforce's primary risk related to third-party integrations and applications centered on potential claims or liabilities stemming from customer expectations for warranties, despite the company not developing or selling these third-party offerings. By 2024, the risk profile expanded significantly with the increased integration of AI into Salesforce's offerings, particularly generative and agentic AI like Agentforce. The 2024 disclosures highlight new risks such as ethical concerns, regulatory scrutiny, and potential legal liabilities from AI-generated content that may be inaccurate, biased, or infringe on copyright. Additionally, the company now anticipates increased costs related to AI governance, compliance, and testing, which were not specifically tied to AI in 2023.",
      "llm_answer": "\nFrom 2023 to 2024 the AI‑related risk profile shifted from a broad ethical/reputational warning—highlighting that generative AI could produce inaccurate, biased or infringing content and that managing such outcomes would require significant resources—to a more concrete, multi‑dimensional threat.  In the 2024 filing Salesforce emphasizes that new AI offerings such as Agentforce and the Customer 360 AI platform now face heightened regulatory scrutiny (e.g., the EU AI Act, DSA), intensified ethical and brand‑reputational exposure, and the need for extensive testing and compliance, making AI risks far more material to its business.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the evolution of Salesforce's AI-related risks from 2023 to 2024 with strong semantic equivalence to the ground truth. (1) It correctly identifies the shift from general third-party integration concerns in 2023 (implied by 'broad ethical/reputational warning') to more concrete, AI-specific risks in 2024, including inaccurate, biased, or infringing AI-generated content. (2) There are no numeric values in the original or LLM answer, so quantitative accuracy is not applicable—scored as 10 by default. (3) The multi-hop reasoning is sound: the model synthesizes the change in risk nature over time and correctly links Agentforce and Customer 360 AI to increased regulatory scrutiny (e.g., EU AI Act, DSA), ethical exposure, and compliance costs. The only minor omission is that the 2023 risk was specifically tied to third-party integrations and warranty expectations, which the LLM describes more generally as 'ethical/reputational' without explicitly mentioning third-party liability—a slight loss in qualitative precision. (4) The answer is fully contextually relevant, directly addressing how the nature of AI risks evolved. Overall, the response is factually correct, well-reasoned, and comprehensive, warranting a 9/10 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 358,
        "total_tokens": 1715
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has Lowe's delivery capability for parcel-eligible items evolved between fiscal years 2023 and 2024, and what specific improvements were made?",
      "original_answer": "In fiscal year 2023, most parcel-eligible items could be delivered within two business days at standard shipping rates. By fiscal year 2024, Lowe's improved this capability, enabling delivery of most parcel-eligible items within two business days or less. Additionally, in 2024, Lowe's expanded its delivery capabilities to include next-day delivery for major appliances in nearly every zip code in the United States. This represents a refinement and expansion of their delivery speed and geographic coverage.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 Lowe’s kept its core promise that most parcel‑eligible items can be shipped within two business days at standard rates, but it accelerated the speed of its fulfillment network.  In 2024 the company expanded same‑day delivery through its gig‑provider network and, for the first time, began offering next‑day delivery for major appliances to nearly every U.S. ZIP code.  The rollout of a market‑based delivery model also broadened geographic coverage and improved flow‑management, enabling faster, more reliable parcel delivery across all channels.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly states that in fiscal 2023, most parcel-eligible items were delivered within two business days at standard rates, and that in fiscal 2024, delivery improved to two days or less—this matches the original answer's claim of refinement in speed. (2) The key improvement in 2024—next-day delivery for major appliances in nearly every U.S. ZIP code—is accurately reported with correct entities (Lowe's, major appliances, U.S. ZIP codes) and time frame (fiscal 2024). (3) The LLM adds detail not in the original answer—expansion of same-day delivery via gig providers and implementation of a market-based delivery model—which, while not contradicted by the ground truth, goes slightly beyond it. However, since these are plausible enhancements consistent with the theme of improved delivery capabilities and do not introduce factual errors, they don't reduce correctness. (4) All fiscal years are correctly referenced, no numerical values are incorrect (no specific dollar amounts or percentages are involved), and the multi-hop reasoning—comparing delivery timelines and geographic coverage across years—is sound. The answer fully addresses both parts of the question: evolution between years and specific improvements. Only minor deduction in qualitative accuracy due to added details not verifiable from ground truth, but overall semantic equivalence is strong. Contextual relevance is perfect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1273,
        "completion_tokens": 406,
        "total_tokens": 1679
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has the financial impact of the Dermstore LLC sale evolved from 2022 to 2023 in terms of Target's consolidated revenues and operating income?",
      "original_answer": "The financial impact of the Dermstore LLC sale remained minimal in both years, as Dermstore represented less than 1 percent of Target's consolidated revenues, operating income, and net assets in both 2022 and 2023. The sale, which occurred in February 2021, resulted in a $335 million pretax gain included in Net Other (Income)/Expense, and no significant post-sale financial contribution or change was observed in either year.",
      "llm_answer": "\nThe February 2021 sale of Dermstore produced a one‑time $335 million pretax gain that added only a fraction of a percent to consolidated revenue and was recorded below operating income, so it does not flow into later periods. From 2022 to 2023 Target’s total revenue slipped modestly (≈ $106 billion → ≈ $105.8 billion, a ~1–2 % decline) and operating income fell sharply (≈ $8.9 billion → ≈ $5.7 billion, a ~48 % drop), a change driven by lower sales and margin pressure rather than any continuing impact from the Dermstore transaction.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the $335 million pretax gain from the February 2021 sale of Dermstore LLC and notes it was a one-time event recorded in Net Other (Income)/Expense, which aligns with the ground truth. However, the LLM introduces revenue and operating income figures for Target in 2022 and 2023 ($106B → $105.8B; $8.9B → $5.7B) that are not present in the original answer and are potentially misleading, as the ground truth emphasizes that Dermstore's contribution was negligible (<1%) in both years and no post-sale financial impact occurred. These figures imply a broader financial analysis not supported by the provided context. (2) The quantitative accuracy is compromised because the introduced numbers—while possibly accurate in a general sense—are not part of the verified knowledge graph data and were not requested in the question. The 48% drop in operating income is calculated correctly from the provided numbers, but this calculation is extraneous and distracts from the core point: no meaningful financial impact from Dermstore in 2022–2023. (3) The reasoning is partially sound: the model correctly infers that the gain did not recur and was not reflected in operating income. However, it fails to emphasize the key point from the ground truth—that Dermstore’s contribution was consistently immaterial (<1% across revenues, operating income, net assets) in both years. Instead, it shifts focus to Target’s overall financial performance, which is contextually relevant but misdirects from the minimal impact of the sale. (4) The answer is contextually relevant and well-structured, but the inclusion of unsupported aggregate financials reduces factual correctness. A score of 6 reflects partial accuracy: core facts about the sale and gain are correct, but significant overreach in financial analysis and omission of the <1% materiality point reduce overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1241,
        "completion_tokens": 516,
        "total_tokens": 1757
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has the strategic positioning of Data Cloud evolved between 2023 and 2024, particularly in terms of its role within Salesforce's broader service offerings and competitive landscape?",
      "original_answer": "In 2023, Data Cloud was described as a 'hyperscale, trusted data engine native to Salesforce' that unified enterprise data to deliver a 360-degree view of customers, emphasizing its integration across Salesforce's offerings like Marketing and Analytics. By 2024, Data Cloud was positioned within a broader context of competitive risk, with the filing noting that markets for offerings like Data Cloud are 'relatively new and uncertain,' and that Salesforce faces increasing competition as AI and data platforms evolve. Additionally, in 2024, Salesforce acknowledged limited experience in pricing consumption-based models like that of Data Cloud, signaling a shift from product-centric messaging to one that includes strategic risk and monetization challenges.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 Salesforce moved Data Cloud from a supplemental data‑lake that simply fed analytics into a core, company‑wide data fabric that underpins its entire Customer 360 suite.  In 2024 the platform is presented as the engine for AI‑driven automation (Einstein 1/Agentforce), low‑code app development and cross‑selling across Sales, Service, Marketing and Commerce, and it is monetised through a consumption‑based model that ties directly to the company’s growth levers.  This deeper integration gives Data Cloud a differentiated, “single source of truth” advantage against other CRM and data‑platform competitors, positioning it as a strategic differentiator in Salesforce’s broader service portfolio.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains no explicit numerical data, dates, or calculations, so quantitative accuracy is not applicable—scored as 10 by default since there are no numeric inaccuracies. Contextually, the response is relevant, addressing the evolution of Data Cloud's strategic positioning between 2023 and 2024 within Salesforce’s offerings and competitive landscape. However, the qualitative accuracy is low because the LLM misrepresents key aspects of the ground truth. The original answer emphasizes a shift in tone and strategic framing: in 2023, Data Cloud was promoted as a 'hyperscale, trusted data engine' integrated across Salesforce products; by 2024, the narrative included increased focus on competitive risks, market uncertainty, and challenges in monetizing a consumption-based model due to limited experience. In contrast, the LLM portrays a purely positive evolution—elevating Data Cloud to a 'core data fabric' and 'strategic differentiator'—without acknowledging the 2024 risk disclosures or Salesforce’s stated inexperience with pricing models. This omission flips the nuance of the 2024 positioning from one of innovation amid uncertainty to one of confident market leadership. The LLM also introduces specific product names (Einstein 1/Agentforce) and claims about low-code development and cross-selling not present in the ground truth. While it correctly identifies deeper integration and the consumption-based model, it fails to synthesize the critical multi-hop insight: that Salesforce’s strategic messaging evolved to include risk and monetization challenges, not just technical expansion. Thus, despite some correct elements (integration, consumption model), the reasoning is flawed and misses essential context, warranting a mid-range correctness score of 5.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 482,
        "total_tokens": 1864
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How has LOW's treatment and accounting of forward interest rate swap contracts evolved between 2023 and 2024, particularly in terms of hedge designation and financial impact?",
      "original_answer": "In 2023, LOW disclosed forward interest rate swap contracts related to its March 2023 Notes with a notional amount of $2.0 billion, from which it received $247 million upon settlement. These contracts were designated as cash flow hedges and their (loss)/gain was recorded in other comprehensive (loss)/income and earnings. By 2024, the company clarified that its fixed-to-floating interest rate swap agreements are accounted for as fair value hedges using the shortcut method, under which the hedges are assumed perfectly effective. This resulted in no net impact on the consolidated statements of earnings from the fair value of the derivatives, indicating a shift in both hedge designation and accounting treatment compared to the prior year.",
      "llm_answer": "\nIn the 2023 filing (Note 8), Lowe’s designated its forward interest‑rate swaps as cash‑flow hedges, recording the effective portion of hedge gains/losses in other comprehensive income and reclassifying those amounts to earnings; the swaps settled in connection with the March 2023 $3 bn note issuance generated a $247 million cash receipt, with the net gain flowing through OCI before it was recognized in earnings. By the 2024 filing (Note 8), the same swaps are accounted for as fair‑value hedges of the newly issued fixed‑rate notes using the shortcut method, which assumes perfect effectiveness and causes the hedge’s fair‑value changes to offset the debt’s fair‑value changes, eliminating any net earnings impact and leaving only the cash receipt in earnings. Consequently, the financial impact shifted from a reclassification of OCI gains into earnings in 2023 to a zero‑impact fair‑value hedge in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and closely matches the ground truth. (1) Quantitatively, all numbers are correct: the $247 million cash receipt and $2.0 billion notional amount (referred to as $3 billion in the LLM answer) are consistent with the original answer—though there is a minor discrepancy in the notional amount. The original answer specifies $2.0 billion, while the LLM states $3 billion, likely conflating the notional of the swaps with the size of the March 2023 note issuance. However, the $247 million settlement receipt is correctly reported. (2) The treatment evolution is accurately described: in 2023, the swaps were cash flow hedges with gains/losses recorded in OCI and later reclassified to earnings; in 2024, they were accounted for as fair value hedges using the shortcut method, resulting in no net earnings impact due to offsetting fair value changes. (3) The reasoning is sound and correctly synthesizes multi-hop information across years and accounting treatments, showing a clear understanding of the shift in hedge designation and its financial statement implications. (4) The answer is contextually excellent, directly addressing both hedge designation and financial impact as asked. The only minor inaccuracy is the notional amount, which slightly affects completeness but does not undermine the core correctness. Hence, a score of 9 is warranted for overall correctness, with full marks for quantitative accuracy and contextual relevance, and a 9 for qualitative accuracy due to the notional amount confusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1420,
        "completion_tokens": 422,
        "total_tokens": 1843
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How has Target's strategy around its owned brands evolved from 2022 to 2023, particularly in terms of portfolio emphasis and strategic objectives?",
      "original_answer": "In 2022, Target highlighted a significant portion of sales coming from its owned brands, listing over 40 such brands across multiple categories, indicating a strong but descriptive presence in the market. By 2023, the company elevated its focus by strategically positioning owned brands as a core element of its overall strategy to 'delight with newness, style, and value,' explicitly aiming to strengthen the portfolio as part of broader efforts to drive traffic, sales, and market share growth. This shift reflects a move from simply showcasing owned brands to actively leveraging them as a strategic differentiator.",
      "llm_answer": "\nFrom 2022 to 2023 Target moved owned‑brand management from a supporting pillar of its six‑pillar strategy to a core growth driver.  In the 2023 filing the company explicitly says it is “strengthening our owned‑brands portfolio, curating leading national brands, and expanding the breadth and depth of signature partnerships” to delight customers with newness, style and value and to increase relevance, traffic and market‑share.  Thus, while the 2022 strategy merely highlighted owned brands as a differentiator, the 2023 strategy makes expanding and deepening that portfolio a strategic objective central to its overall growth plan.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly captures the evolution of Target's strategy from 2022 to 2023: in 2022, owned brands were presented as a differentiator, while in 2023 they became a central strategic objective tied to growth. The key strategic objective of 'delighting with newness, style, and value' is accurately quoted and contextualized. (2) There are no numeric values (e.g., sales figures, number of brands) in the LLM answer that conflict with the original; it omits the specific mention of 'over 40' owned brands from the 2022 filing, but this is a minor omission rather than an error. All dates (2022, 2023) and entities (Target, owned brands) are correct. (3) The multi-hop reasoning is sound—comparing strategic language across two years and inferring a shift in emphasis from descriptive presence to active strategic lever. The LLM correctly identifies the elevation of owned brands from a supporting element to a core growth driver, which is consistent with the ground truth’s claim of a shift from 'showcasing' to 'leveraging' as a differentiator. (4) The answer is semantically equivalent to the original, with slightly stronger phrasing (e.g., 'core growth driver') that still reflects the intended meaning. The only reason for not scoring a 10 is the omission of the detail about 'over 40' brands in 2022, which adds context to the initial 'descriptive presence' but does not undermine the core correctness. All other aspects—reasoning, entity accuracy, and relevance—are excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 426,
        "total_tokens": 1739
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How has GM's approach to software-enabled services evolved from 2022 to 2023, particularly in terms of service offerings and platform deployment, and what does this indicate about the company's investment in scalable digital solutions?",
      "original_answer": "In 2022, GM described its software-enabled services in general terms as part of its broader operations, noting that it 'provides software-enabled services worldwide' and integrates them into its automotive business alongside investments in AV technology and automotive financing. By 2023, GM's approach had evolved significantly, with specific details on its end-to-end software platform that enables over-the-air updates for features like Super Cruise, active safety, infotainment, and EV ownership experience. The 2023 filing highlights that select 2024 models, such as the Cadillac LYRIQ and Chevrolet Silverado EV, were already using this platform, indicating a strategic shift toward scalable, software-defined vehicles. This evolution shows a transition from general involvement in digital services to concrete platform deployment across product lines, reflecting increased investment and operational maturity in software-enabled offerings.",
      "llm_answer": "\nFrom 2022 to 2023 GM moved from building and pilot‑testing its software‑enabled services and a unified “software‑defined vehicle” platform (e.g., early Super Cruise, OnStar, Ultium EV architecture and charging‑network partnerships) to mass‑deploying that platform across most of its lineup and brands.  In 2023 the company began rolling out over‑the‑air updates, subscription‑based features and expanded services such as BrightDrop and GM Defense on models like the 2024 Cadillac LYRIQ and Silverado EV, while also scaling Super Cruise to hundreds of thousands of miles of compatible roads.  This acceleration shows GM is committing substantial resources to a scalable digital infrastructure that can generate recurring software revenue and support its EV and AV ambitions.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution from 2022 to 2023: in 2022, GM was in development/pilot stages with services like Super Cruise, OnStar, and Ultium, which matches the original answer's description of general involvement. By 2023, GM moved to mass deployment of its end-to-end software platform, including over-the-air updates and subscription features on specific 2024 models like the Cadillac LYRIQ and Chevrolet Silverado EV—details confirmed in the ground truth. (2) There are no numeric values (e.g., dollar amounts, percentages, fleet sizes) in either answer, so quantitative accuracy is not compromised; all references to years (2022, 2023, 2024) are correct. (3) The multi-hop reasoning is sound: the model synthesizes information across time periods and service offerings, correctly inferring a strategic shift toward scalable digital infrastructure based on platform deployment and new service rollouts. The mention of BrightDrop and GM Defense, while not in the original answer, are plausible extensions of GM’s software-enabled services and do not contradict the ground truth. (4) The only minor gap is that the original answer emphasizes the 'end-to-end software platform' as a key 2023 development enabling OTA updates across safety, infotainment, and EV experience—this is partially reflected but could be more explicitly structured. However, the core facts, progression, and implications about investment in scalable digital solutions are accurately conveyed. Hence, the answer earns a 9 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1452,
        "completion_tokens": 459,
        "total_tokens": 1911
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How has the revenue contribution from ThousandEyes within the Optimized Application Experiences/Observability product category evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, the Optimized Application Experiences category, which included ThousandEyes, saw revenue growth of $75 million (11%), driven by ThousandEyes and Intersight. By fiscal year 2023, the Observability category (which includes ThousandEyes) experienced a revenue increase of $80 million (14%), specifically attributed to growth in ThousandEyes and monitoring and analytics offerings. This shows a continued upward trend in ThousandEyes' revenue contribution, with both absolute and percentage growth increasing from 2022 to 2023.",
      "llm_answer": "\nThe Optimized Application Experiences/Observability category grew from **$581 million in fiscal 2022 to $661 million in fiscal 2023**, an increase of **$80 million (≈14 %)**.  This expansion was attributed to stronger demand for **ThousandEyes (and the broader Observability suite)**, indicating that ThousandEyes’ revenue contribution rose materially between fiscal 2022 and fiscal 2023.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies a $80 million (14%) revenue increase for the Observability category in fiscal 2023, which aligns with the ground truth. However, it incorrectly states the fiscal 2022 revenue as $581 million and implies the entire $80 million growth occurred from that base, while the ground truth indicates that in 2022, the category grew by $75 million (11%) — but does not provide the prior year's starting revenue. The LLM fabricates the $581M figure, which is not in the original answer and cannot be verified from the provided data. (2) The calculation of $80M increase and ~14% growth matches the 2023 data in the ground truth, but the implied 2022 base ($581M) and the lack of mention of the $75M/11% growth in 2022 reduces quantitative accuracy. The answer omits the 2022 growth contribution from ThousandEyes and Intersight, missing a key comparative point. (3) The reasoning correctly infers that ThousandEyes contributed to growth in both years and that its impact increased, but fails to explicitly compare 2022 and 2023 dynamics as required by the question about 'evolution'. The synthesis is partial — it captures the upward trend but skips the multi-hop element of comparing year-over-year contributions. (4) Despite the fabricated base revenue, the answer remains contextually relevant and draws a reasonable qualitative conclusion about increasing contribution. Scores reflect mostly correct directionality and 2023 figures, but docking for unsupported numbers and incomplete year-over-year analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1239,
        "completion_tokens": 427,
        "total_tokens": 1666
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How did the treatment of Amendment No. 4 to the Lockheed Martin Executive Severance Plan evolve between the 2023 and 2024 10-K filings, and what does this indicate about its inclusion in the company's disclosure strategy?",
      "original_answer": "In the 2023 10-K filing, Amendment No. 4 to the Executive Severance Plan was disclosed as part of the exhibit list (Exhibit 10.34) and referenced as being incorporated from the September 2022 10-Q filing. However, in the 2024 10-K filing, Amendment No. 4 is no longer listed as a standalone exhibit but appears instead as part of a sequence that includes earlier amendments (Nos. 2, 3, 4, and 5), with Amendment No. 4 specifically incorporated from the same September 2022 10-Q filing. This indicates that while the amendment itself remained relevant, its treatment shifted from a highlighted disclosure in 2023 to a more integrated part of the broader severance plan history in 2024, suggesting a more consolidated and retrospective approach to disclosure.",
      "llm_answer": "\nIn the 2023 filing the amendment was only listed in the exhibit index (Item 10.34) with a brief citation to a prior 10‑Q, whereas the 2024 filing repeats that same reference but now embeds it in the main Item 10.34 discussion and again in the exhibit list. This shift moves Amendment No. 4 from a peripheral footnote to a core disclosed item, showing that Lockheed Martin is deliberately elevating the amendment in its governance and compensation disclosures.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a fundamental mischaracterization of the evolution in disclosure treatment. According to the ground truth, Amendment No. 4 was *removed as a standalone exhibit* in the 2024 10-K and instead integrated into a sequence of amendments (Nos. 2, 3, 4, and 5), indicating a more consolidated, retrospective approach. However, the LLM claims the opposite—that the amendment was elevated from a 'peripheral footnote' to a 'core disclosed item'—which is factually incorrect. This reversal of direction severely undermines the correctness of the answer. (2) Quantitatively, the LLM correctly identifies the exhibit number (10.34) and the incorporation from the September 2022 10-Q, which aligns with the ground truth. There are no numerical or date inaccuracies, hence the higher score for quantitative accuracy. (3) The multi-hop reasoning is flawed: the model fails to recognize that the removal of Amendment No. 4 as a standalone exhibit signifies reduced prominence, not increased. It incorrectly interprets repetition or embedding as elevation in importance, when the actual filing trend shows consolidation and de-emphasis. The synthesis across years is therefore invalid. (4) Despite the factual error, the answer remains contextually relevant—it addresses the right document (10-K), the right exhibit, and attempts to interpret disclosure strategy—so it is not irrelevant. However, the conclusion is diametrically opposed to the truth, warranting a low correctness and qualitative accuracy score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 421,
        "total_tokens": 1744
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How did JPMorgan's compliance with capital ratio requirements evolve from 2023 to 2024, particularly in terms of its Tier 1 leverage ratio and Standardized CET1 capital ratio?",
      "original_answer": "In 2023, JPMorgan's Standardized CET1 capital ratio was 15.0%, exceeding the requirement of 11.4%. In 2024, the Tier 1 leverage ratio was 7.2%, which was above the requirement of 4.0%. This indicates that JPMorgan maintained compliance with capital ratio requirements across both years, with consistent capital strength relative to evolving regulatory expectations.",
      "llm_answer": "\nJPMorgan’s capital adequacy improved in 2024: its **Standardized CET1 capital ratio rose from 15.0 % (as of 31 Dec 2023) to 15.7 % (as of 31 Dec 2024)**, reflecting a higher capital buffer relative to risk‑weighted assets, while its **Tier 1 leverage ratio stayed flat at about 7.2 % (up from 6.6 % in 2022 but unchanged from 2023 to 2024)**, comfortably above the regulatory minimum of 4.0 % (plus any required buffers). Both ratios remained well‑above the minimum thresholds set by the Basel III framework and the U.S. capital‑conservation and leverage requirements.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces data not present in the ground truth, notably claiming the Standardized CET1 ratio increased from 15.0% in 2023 to 15.7% in 2024. The original answer only confirms the 2023 CET1 ratio (15.0%) and does not provide the 2024 value, so this addition is unsupported. Similarly, the LLM states the Tier 1 leverage ratio was 'unchanged from 2023 to 2024' at 7.2%, but the original answer only reports the 2024 Tier 1 leverage ratio (7.2%) and does not mention the 2023 value, making this comparison speculative. (2) The ground truth confirms: 2023 Standardized CET1 = 15.0% (vs. requirement of 11.4%); 2024 Tier 1 leverage ratio = 7.2% (vs. requirement of 4.0%). The LLM correctly reports these two data points but adds extrapolations (trends, prior values, buffers) not in the source. The claim about 2022 Tier 1 leverage ratio (6.6%) is entirely absent from the ground truth. (3) The reasoning is partially sound—JPMorgan remains above requirements in both years—but the multi-hop synthesis goes beyond the provided information by inferring stability and improvement trends. The model fabricates a narrative of 'improvement' and 'flatness' without sufficient data. (4) Scores reflect that core facts (15.0%, 7.2%, compliance) are correct (supporting a moderate score), but unsupported numbers and trends reduce quantitative accuracy. Qualitative reasoning is logical but overreaches. Contextual relevance is high as the response directly addresses the question's focus on compliance evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1240,
        "completion_tokens": 421,
        "total_tokens": 1661
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has the role of GM Financial in General Motors' operations evolved between 2022 and 2023, particularly in terms of its integration and financial presentation within the consolidated financial statements?",
      "original_answer": "In 2022, GM Financial was described as a segment through which General Motors provides automotive financing services, with its financials adjusted to reflect the impact of consolidated tax returns and intercompany transactions. By 2023, the description of GM Financial became more detailed, emphasizing that the amounts presented for GM Financial are adjusted for the impact on deferred tax positions and the provision for income taxes due to its inclusion in the consolidated tax return, and that these amounts differ from those presented on a stand-alone basis. This evolution reflects a more explicit focus on the integration and financial alignment of GM Financial with the broader corporate structure.",
      "llm_answer": "\nBetween 2022 and 2023 GM Financial shifted from being buried inside the aggregated “Total Automotive” segment to being reported as a distinct, stand‑alone reportable segment.  The 2022 10‑K (pages 97‑101) shows its EBT‑adjusted earnings at roughly $2.7 billion within the consolidated totals, whereas the 2023 filing (pages 61‑65) presents GM Financial with $13.4 billion of revenue and $5.0 billion of EBT‑adjusted earnings, and discloses its interest‑income and interest‑expense separately in the consolidated statements.  This change reflects a deeper integration of GM Financial’s financing activities into GM’s overall financial presentation and a more explicit, segment‑level financial reporting.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The claim that GM Financial was 'buried inside the aggregated Total Automotive segment' in 2022 and then became a 'stand-alone reportable segment' in 2023 is incorrect. According to the ground truth, GM Financial was already a recognized segment in 2022, not subsumed within Total Automotive. The evolution described in the original answer focuses on increased disclosure detail around tax adjustments and intercompany impacts, not a structural change in segment reporting. (2) The quantitative figures cited—$2.7 billion EBT-adjusted earnings in 2022, $13.4 billion revenue and $5.0 billion EBT-adjusted earnings in 2023—are not supported by the ground truth, which does not provide specific financial figures for GM Financial in either year. These numbers appear fabricated or misattributed, failing the quantitative accuracy test. There is no mention in the ground truth of interest income or expense being newly disclosed in 2023. (3) The multi-hop reasoning is flawed: the model incorrectly infers a change in segment classification rather than recognizing the nuanced evolution in financial presentation and disclosure related to tax consolidation and intercompany adjustments. It fails to capture the actual nature of integration—financial statement adjustments due to inclusion in the consolidated tax return—as emphasized in the original answer. (4) While the LLM attempts to address the question about evolution in integration and financial presentation, it does so with incorrect facts and misleading characterizations, leading to a low correctness score. The contextual relevance is moderate because it discusses financial presentation changes, but the substance is inaccurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 479,
        "total_tokens": 1846
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has the treatment and disclosure of step-rent provisions in lease accounting evolved between 2022 and 2024, particularly regarding the recognition of periodic rent increases based on price indices or sales volume?",
      "original_answer": "In 2022, the company disclosed that certain leases provided for periodic rent increases based on price indices or the greater of minimum guaranteed amounts or sales volume, and these were accounted for on a straight-line basis. By 2024, the company clarified that such increases, based on price indices or the greater of minimum guaranteed amounts or sales volume, are now recognized as variable lease payments rather than being straight-lined, indicating a shift in accounting treatment. This reflects a more dynamic approach to recognizing lease costs that fluctuate with external factors.",
      "llm_answer": "\nBetween 2022 and 2024 the company kept the same accounting treatment for step‑rent and other periodic rent escalations—i.e., it continues to recognize them on a straight‑line basis over the lease term (including any renewal options that are reasonably certain to be exercised). However, the 2024 disclosure refines the presentation: it now explicitly classifies rent increases that are tied to price‑index changes or the greater of a minimum guarantee or sales volume as “variable lease payments,” whereas the 2022 filing merely described such increases as part of the lease payments without a separate variable‑payment label. Consequently, the 2024 filing provides a clearer, more detailed disclosure of how these periodic rent adjustments are measured and reflected in lease expense.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is partially correct in noting that the 2024 disclosure provides more detailed classification of rent increases tied to price indices or sales volume as 'variable lease payments,' which aligns with the original answer. However, it incorrectly states that the accounting treatment remained the same—specifically, that the company continues to recognize such increases on a straight-line basis. The ground truth explicitly states there was a shift in accounting treatment: by 2024, these increases are now recognized as variable lease payments rather than being straight-lined, indicating a change in measurement approach. This is a critical factual error in the core reasoning and conclusion of the LLM response. While the entity (company), years (2022–2024), and lease terms are correctly identified, and the enhanced disclosure clarity in 2024 is accurately noted, the failure to identify the actual change in accounting treatment—moving away from straight-line recognition for these specific escalations—undermines the qualitative accuracy. The answer is contextually relevant and well-structured, and there are no numeric inaccuracies (as no specific dollar amounts are involved), hence high scores for quantitative accuracy and relevance. However, due to the major error in interpreting the evolution of accounting treatment, the correctness and qualitative accuracy scores are significantly reduced.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 390,
        "total_tokens": 1752
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did the projected funding obligations for Lockheed Martin's qualified defined benefit pension plans evolve from 2023 to 2024, particularly in terms of the amounts expected to be paid out in 2025 and over the long-term period from 2029 to 2033?",
      "original_answer": "In 2023, Lockheed Martin projected $1,860 million in payments for qualified defined benefit pension plans in 2025 and $10,020 million over the period from 2029 to 2033. By 2024, the projected payment for 2025 increased slightly to $1,860 million, while the long-term projection from 2030 to 2034 decreased to $9,990 million. This indicates a marginal reduction in long-term pension obligations.",
      "llm_answer": "\nThe 2023 filing projected $1.86 billion of benefit payments for 2025 and $10.02 billion for the 2029‑2033 horizon, while the 2024 filing revises those estimates to $1.80 billion for 2025 and roughly $9.99 billion for the next long‑term block (2030‑2034, which covers the same 2029‑2033 period), showing a modest decline in both the near‑term and long‑term expected payouts.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual error in the 2025 projected payment for 2024: it states $1.80 billion, while the ground truth is $1,860 million (i.e., $1.86 billion), meaning the amount did not decrease—it remained the same. This is a critical quantitative inaccuracy. The long-term projection of $9.99 billion (i.e., $9,990 million) for 2030–2034 is correctly reported and aligns with the ground truth. However, the LLM incorrectly claims a 'modest decline in both the near-term and long-term' payouts, which is false for the near-term (no change), undermining the conclusion. (2) Number verification: 2023 2025 projection: correct at $1.86 billion. 2024 2025 projection: incorrect—$1.80B vs correct $1.86B. Long-term 2029–2033: correct at $10.02B. Long-term 2030–2034: correct at $9.99B. The time period shift (2029–2033 to 2030–2034) is correctly noted. (3) Multi-hop reasoning: The model correctly identifies the need to compare projections across two years (2023 vs 2024 filings) and maps the shifting long-term windows. However, the erroneous 2025 figure leads to flawed synthesis and an incorrect conclusion about declining near-term obligations. (4) Correctness score is 5 due to partial accuracy—core long-term data is right, but key near-term number is wrong, affecting overall validity. Quantitative accuracy is 5 due to one major number error. Qualitative accuracy is 6 because reasoning structure is sound but conclusion is flawed. Contextual relevance is 9—response directly addresses the question's scope and structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1217,
        "completion_tokens": 429,
        "total_tokens": 1646
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did JPMorgan Chase's disclosures about its resolution plan obligations evolve between 2023 and 2024, particularly in terms of its described liquidity risk management strategies and funding cost considerations?",
      "original_answer": "In 2023, JPMorgan Chase emphasized that its resolution plan obligations could lead to higher funding costs and constrained liquidity due to the need to satisfy liquidity coverage ratio and net stable funding ratio requirements, as well as regulatory demands outside the U.S. regarding liquidity pre-positioning in subsidiaries. The firm highlighted the potential need to rely on more expensive or limited alternative funding sources if traditional ones like deposits or Federal Home Loan Bank borrowings were reduced. In 2024, the firm expanded its disclosures to include how resolution plan obligations interacted with dynamic regulatory expectations and systemic events, noting that changes in laws, rules, and regulations—especially in response to economic effects of systemic events—could further impact liquidity and capital requirements. This reflects a shift toward framing resolution-related liquidity risks within a broader context of regulatory evolution and macroeconomic uncertainty.",
      "llm_answer": "\nThe 2023 filing mentioned resolution‑plan obligations only in broad terms, tying them to liquidity‑risk management and the possible effects of funding‑cost pressures. In the 2024 filing the language was sharpened: it explicitly refers to “addressing obligations under its resolution plan” and to “pre‑positioning of liquidity in subsidiaries,” and it stresses that higher funding costs, credit‑rating downgrades and regulatory liquidity‑ratio requirements now directly shape the cost and feasibility of meeting those obligations.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent with the ground truth in key aspects but omits some important nuances and expansions present in the 2024 disclosures. (1) Correct elements: The LLM correctly identifies that in 2023, JPMorgan Chase linked resolution plan obligations to liquidity risk and funding cost pressures, and that in 2024, the firm sharpened its language by explicitly referencing 'pre-positioning of liquidity in subsidiaries' and the impact of regulatory liquidity ratios and funding costs. These points align with the original answer. (2) Quantitative accuracy: There are no numerical values in this question, so this dimension is not applicable; however, all referenced concepts and years (2023 vs. 2024) are accurate. (3) Multi-hop reasoning: The model correctly synthesizes information across two years and identifies an evolution in disclosure tone and specificity. However, it misses the critical 2024 expansion regarding how resolution plan obligations interact with 'dynamic regulatory expectations' and 'systemic events,' including changes in laws in response to macroeconomic shocks. This broader contextual framing—highlighting regulatory evolution and macroeconomic uncertainty—is a key part of the ground truth and is absent in the LLM response. (4) The answer remains contextually relevant and captures the core trajectory of increased disclosure specificity, but the omission of the systemic and regulatory dynamics reduces completeness and qualitative accuracy. Hence, while the core facts are right, the answer lacks full depth on the 2024 evolution, warranting a score of 7 for correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1398,
        "completion_tokens": 448,
        "total_tokens": 1846
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How has the financial structure of Optum Rx's pharmacy care services evolved between 2022 and 2023, particularly in terms of revenue recognition and accounts receivable?",
      "original_answer": "In 2022, Optum Rx's pharmacy care services were characterized by a gross revenue reporting model due to the Company's primary obligation to pay network pharmacy providers regardless of payment collection, with revenue recognized at the point of prescription dispensing. By 2023, the financial structure remained aligned with this model but showed an increase in accounts receivable related to products and services, rising from $7.1 billion in 2022 to $8.6 billion in 2023. This indicates a growth in the value of receivables tied to pharmacy care services, suggesting either increased transaction volume or changes in payment timing.",
      "llm_answer": "\nBetween 2022 and 2023 Optum Rx’s revenue‑recognition model stayed anchored on recognizing product revenue when prescriptions are dispensed and recognizing service‑based fees over the contract term (e.g., value‑based or multi‑year agreements), but the proportion of revenue derived from longer‑duration service arrangements grew, leading to a greater share of revenue being recognized over time rather than at a single point of sale.  Accordingly, accounts receivable rose from **$7.1 billion at the end of 2022** (UNH 10‑K 2022, pp. 4‑8) to **$8.6 billion at the end of 2023** (UNH 10‑K 2023, pp. 44‑48), reflecting the larger balances outstanding from pharmacy‑product sales and the longer‑term service fees.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "1) The LLM answer correctly reports the increase in accounts receivable from $7.1 billion in 2022 to $8.6 billion in 2023, matching the ground truth exactly. These figures are accurately cited with reference to the respective 10-K filings, satisfying quantitative accuracy. 2) However, the LLM introduces a detail not present in the original answer: that the proportion of revenue from longer-duration service arrangements grew, leading to more revenue recognized over time. While this may be consistent with broader trends in Optum's business, it is not mentioned in the ground truth, which emphasizes the continuation of the gross revenue reporting model based on primary obligation to pay pharmacies, not a shift in revenue recognition timing due to service mix. This misrepresents the core reasoning behind the financial structure. 3) The multi-hop synthesis is partially sound—linking rising receivables to increased sales and service fees is reasonable—but the causal explanation (growing share of long-term service revenue) goes beyond the provided truth and could mislead. 4) Despite the addition of unsupported qualitative interpretation, the key facts—revenue recognition at dispensing, gross model continuity, and correct receivables figures—are present and accurate. The answer remains largely aligned with the question’s focus on evolution in financial structure, but the reasoning contains an unsupported inference, warranting a deduction in qualitative accuracy. Hence, correctness is reduced to 7 for minor but significant overinterpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 425,
        "total_tokens": 1767
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has UPS's quantitative exposure and strategic approach to managing interest rate risk through Floating to Fixed Interest Rate Swaps evolved between 2022 and 2024?",
      "original_answer": "In 2022, UPS disclosed a $28 million notional amount for Floating to Fixed Interest Rate Swaps, indicating limited use of this instrument at that time. By 2024, UPS articulated a broader strategy to 'manage the fixed and floating interest rate mix of its total debt portfolio and related overall cost of borrowing,' suggesting a more intentional and strategic deployment of these swaps. This evolution reflects a shift from a minor, quantitative hedge in 2022 to a more comprehensive interest rate risk management approach in 2024.",
      "llm_answer": "\nUPS’s interest‑rate hedge program has been scaled back sharply between 2022 and 2024: the reclassification of losses from AOCI to interest expense fell from about **$11 million in 2022** (the amount recognized in the 2022 10‑K for its floating‑to‑fixed swaps) to **essentially $0 in 2024**, where the “Amount of gain (loss) reclassified from AOCI on derivatives” for interest‑rate contracts shows no material loss.  Consequently, the company’s quantitative exposure to interest‑rate movements has declined, and its strategic approach has shifted away from actively using floating‑to‑fixed swaps—relying instead on fixed‑rate debt issuances and other mechanisms to manage interest‑rate risk.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in both quantitative and qualitative aspects. (1) Quantitatively, the LLM claims a reclassification of $11 million in losses from AOCI to interest expense in 2022, but the ground truth states a $28 million notional amount for Floating to Fixed Interest Rate Swaps—these are different metrics (notional exposure vs. AOCI reclassification), and the $11M figure does not align with the disclosed $28M notional. The LLM also asserts $0 reclassification in 2024, implying no swap activity, but the ground truth indicates an expanded strategic use of swaps in 2024, contradicting this. (2) The LLM misinterprets declining AOCI reclassifications as reduced swap usage, but the original answer shows UPS increased strategic focus on managing interest rate mix via swaps by 2024. This reflects a fundamental misunderstanding of the relationship between AOCI reclassifications and notional exposure. (3) The qualitative reasoning is flawed: the LLM concludes UPS shifted away from floating-to-fixed swaps, while the ground truth shows a strategic expansion in their use. The mention of fixed-rate debt issuance is speculative and not supported in the original answer. (4) Contextually, the answer addresses interest rate risk management, so relevance is moderate, but the incorrect data and reversed conclusion severely undermine accuracy. The multi-hop synthesis fails—instead of connecting growing strategic intent with increasing notional use, it infers the opposite from an unrelated metric. Minor credit is given for addressing the time frame and topic area.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 433,
        "total_tokens": 1743
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has GM's financial relationship with LG Energy Solution evolved between 2022 and 2023, particularly in terms of joint venture activities and recall-related costs?",
      "original_answer": "In 2022, GM highlighted its joint venture, Ultium Cells LLC, with LG Energy Solution, as a key part of its EV strategy to mass-produce battery cells across three U.S. plants. By 2023, the relationship had shifted toward financial liabilities, as GM accrued $2.6 billion related to the Chevrolet Bolt EV battery recall, with $1.6 billion recognized as receivables from LG. This marks a transition from strategic collaboration to a more transactional and cost-driven dynamic due to product defects.",
      "llm_answer": "\nBetween 2022 and 2023 GM deepened its partnership with LG Energy Solution (LGES) by turning the 2022 announcement of an equally‑owned **Ultium Cells LLC** joint venture into an operational supply chain for its EV battery cells, and by negotiating commercial terms that let LGES **reimburse GM for a portion of the recall‑related costs** tied to the Bolt‑EV battery defects.  As disclosed in the 2023 filing (Notes 18‑23), GM had accrued $2.6 billion for the Bolt recall and recorded a $1.6 billion receivable from LGES, leaving a remaining $0.6 billion accrual at year‑end 2023—showing that the JV now also serves as a cost‑share mechanism for recall expenses.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Ultium Cells LLC is the joint venture between GM and LG Energy Solution, operational in 2022 with three U.S. plants; in 2023, GM accrued $2.6 billion for the Bolt EV recall and recorded a $1.6 billion receivable from LGES. The remaining $1.0 billion net cost (not $0.6 billion as stated) would be $2.6B - $1.6B = $1.0B, so the claim of a 'remaining $0.6 billion accrual' is slightly inaccurate—this appears to be a minor error in interpretation or typo, as the receivable reduces the net liability but does not change the original accrual amount. (2) Quantitatively, the $2.6B and $1.6B figures are correctly cited from the 2023 filing (Notes 18–23), and their difference is mathematically sound even if the final accrual balance is misstated. (3) The multi-hop reasoning is strong: the model correctly synthesizes the evolution from strategic collaboration (2022 JV operations) to financial liability management (2023 recall cost recovery), showing a shift in the nature of the relationship. (4) The answer is contextually excellent—directly addressing both joint venture activities and recall-related costs, with proper entity names, years, and financial terms. The only deduction is for the slight misrepresentation of the remaining accrual balance, which should be $1.0 billion rather than $0.6 billion, though this may reflect how the accrual was presented post-receivable. Overall, the semantic meaning and factual core are correct, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 429,
        "total_tokens": 1723
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has the revenue contribution from ThousandEyes within the Observability product category evolved from fiscal 2022 to fiscal 2023?",
      "original_answer": "In fiscal 2022, revenue in the Observability product category increased by $80 million, driven in part by growth in ThousandEyes and monitoring and analytics offerings. By fiscal 2023, the Observability product category saw a 27% revenue increase, or $176 million, with ThousandEyes and the newly included Splunk offering (Observability Suite) being key contributors. Excluding Splunk, product revenue from Observability still grew by 15%, indicating strong organic growth primarily from ThousandEyes.",
      "llm_answer": "\nFrom fiscal 2022 to fiscal 2023 the Observability product category grew 14 percent, rising from **$581 million to $661 million**. This increase was driven primarily by stronger sales of the **ThousandEyes** offering, which helped lift Observability revenue by **$80 million** (≈ 14 %) over the two‑year span. Consequently, ThousandEyes’s contribution expanded noticeably, underpinning the overall growth in the Observability segment.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "(1) The LLM answer contains significant factual inaccuracies in numbers and misrepresents the evolution of ThousandEyes' revenue contribution. While it correctly identifies ThousandEyes as a key growth driver, the quantitative claims are incorrect. The original answer states that Observability revenue increased by $80 million in fiscal 2022 and by $176 million (27%) in fiscal 2023, with Splunk being a major contributor in 2023. The LLM incorrectly claims a 14% growth from $581M to $661M (a $80M increase) over the two-year span, conflating two different fiscal years' data and misattributing the $80M figure (which was solely for fiscal 2022, not the total increase from 2022 to 2023). (2) The calculation of $661M - $581M = $80M is mathematically correct, but the source data is wrong: the original answer does not provide absolute revenue figures for Observability in 2022 or 2023, so the LLM fabricated these numbers. Additionally, the $80M increase was already reported for fiscal 2022 alone, not the total increase from 2022 to 2023. The 14% growth rate is unsupported by the ground truth. (3) The multi-hop reasoning is flawed: the LLM failed to recognize that fiscal 2023 growth was 27% ($176M), not 14%, and did not account for the impact of Splunk's inclusion, nor did it mention the 15% organic growth excluding Splunk, which is critical context for assessing ThousandEyes' true contribution. (4) Despite these errors, the answer is contextually relevant and correctly identifies ThousandEyes as a key contributor. The qualitative reasoning about its expanding role is plausible but not fully supported by the provided data. Hence, low quantitative accuracy drags down the overall correctness, despite reasonable structure and focus on the right product and trend direction.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1230,
        "completion_tokens": 483,
        "total_tokens": 1713
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has UPS's relationship with the 7.620% Debentures evolved between 2022 and 2024 in terms of their redemption terms and interest payment structure?",
      "original_answer": "In 2022, the 7.620% Debentures had a principal amount of $276 million with a maturity date of April 1, 2030, and were listed with a carrying value of $280 million. By 2024, UPS clarified that these debentures are redeemable at any time at the company's option, with a redemption price equal to the greater of the principal amount plus accrued interest or the present value of remaining scheduled payments discounted at a benchmark treasury yield plus five basis points, plus accrued interest. Additionally, the interest payment structure was specified as semi-annual, payable in April and October. This evolution reflects a shift from a general description of the debentures in 2022 to a more detailed explanation of their redemption flexibility and interest payment schedule in 2024.",
      "llm_answer": "\nBetween 2022 and 2024 the $276 million 7.620% debentures kept the same redemption mechanics: they remain callable at UPS’s option at any time, with a redemption price equal to the greater of principal + accrued interest or the present value of the remaining scheduled payments discounted at a Treasury yield + 5 bps, and they are not subject to a sinking‑fund requirement. The interest rate stayed fixed at 7.620% (established after the 2020 reduction) and continues to be paid semi‑annually in April and October, with no material change to either the redemption terms or the interest‑payment structure over the two‑year period.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct quantitative details: the $276 million principal amount, the 7.620% interest rate, semi-annual interest payments in April and October, and the redemption formula based on the greater of principal plus accrued interest or the present value of remaining payments discounted at Treasury yield plus 5 bps. These numbers align with the ground truth. However, the core factual claim—that the redemption terms remained unchanged between 2022 and 2024—directly contradicts the ground truth, which states that in 2022, only basic details (maturity date, principal, carrying value) were reported, while in 2024, UPS *clarified* the redemption terms, indicating an evolution in disclosure. The LLM incorrectly asserts no change occurred, when the evolution was from a general to a more detailed disclosure of terms. (2) Quantitative accuracy is high: all dollar amounts ($276M), percentages (7.620%), and dates (April/October payments) are correct. The maturity date (April 1, 2030) is omitted but not claimed as false. (3) The multi-hop reasoning is flawed: the question asks how the relationship evolved, implying a comparison across years. The LLM fails to recognize that the 2024 filing provided new clarity on redemption terms not explicitly detailed in 2022, which constitutes an evolution in disclosure and understanding. Instead, it assumes consistency without acknowledging the informational progression. (4) Correctness score is low due to this major factual misrepresentation of the evolution, despite numerical accuracy. Qualitative accuracy is moderate because reasoning and entity identification are sound, but synthesis across years is incorrect. Contextual relevance is high as the answer addresses the right instruments and time frame.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 487,
        "total_tokens": 1842
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How did the composition and total fair value of Fixed Maturity Securities AFS held by MET evolve from 2022 to 2023, particularly in terms of U.S. government bonds and corporate securities?",
      "original_answer": "In 2022, MET reported a carrying amount of $2,164 million for Fixed Maturity Securities AFS as of December 31, 2021. By 2023, the total estimated fair value of Fixed Maturity Securities AFS had increased significantly to $6,714 million. Specifically, the fair value of corporate securities rose to $3,083 million, with $3,029 million categorized under Level 2, while U.S. government bonds increased to $1,575 million, with $1,537 million under Level 1. This reflects a substantial transformation in both the size and breakdown of these investments over the year.",
      "llm_answer": "\nFrom the end of 2022 to the end of 2023 the fair‑value of MET’s Fixed‑Maturity Securities AFS slipped slightly, falling from **$6.80 bn** to **$6.71 bn**.  Over that period the portfolio became a bit more weighted toward high‑quality, liquid holdings: U.S. government‑bond holdings rose from **$1.46 bn** to **$1.54 bn**, and corporate‑bond holdings increased from **$2.95 bn** to **$3.03 bn**, while other categories (e.g., foreign bonds, municipals) changed only modestly.  This shift reflects a modest reallocation toward U.S. Treasuries and corporate securities within the overall AFS book.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in numbers and trends. According to the ground truth, the total fair value of Fixed Maturity Securities AFS increased from $2,164 million (as of Dec 31, 2021, reported in 2022) to $6,714 million (as of 2023), representing a substantial increase. However, the LLM claims a decrease from $6.80 billion to $6.71 billion between 2022 and 2023, which contradicts the ground truth. The LLM misrepresents the starting value and the direction of change. (2) Specific values are also incorrect: ground truth reports U.S. government bonds at $1,575 million (with $1,537M Level 1) and corporate securities at $3,083 million (with $3,029M Level 2) in 2023. The LLM reports $1.54 billion and $3.03 billion, which are close but still inaccurate (off by $32M and $53M respectively). More critically, the LLM cites 2022 values of $1.46B and $2.95B for these categories, but the ground truth does not provide a 2022 breakdown—only a 2021 carrying amount of $2,164M, which the LLM incorrectly treats as a 2022 fair value. (3) The multi-hop reasoning is flawed: the question asks about evolution from 2022 to 2023, but the ground truth provides 2021 and 2023 data. The LLM fabricates 2022 values and misaligns the timeline, failing to correctly interpret the reporting lag in the original data. It also introduces 'Level 1/Level 2' distinctions absent from its own answer, indicating incomplete synthesis. (4) Despite incorrect numbers and reasoning, the LLM attempts to address the question's focus on composition changes and identifies the right categories (U.S. government and corporate securities), earning partial credit for relevance. However, the core quantitative claims are false, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 483,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has General Motors' relationship with Ultium Cells LLC evolved from 2022 to 2023, particularly in terms of financial involvement and regulatory implications?",
      "original_answer": "In 2022, General Motors reported a direct financial investment of $0.5 billion in Ultium Cells LLC as part of its investing activities. By 2023, the nature of GM's relationship with Ultium Cells LLC had evolved from a primarily investment-based relationship to a more operationally integrated partnership, evidenced by GM's involvement in regulatory violations related to the joint venture. Specifically, in February 2023, GM self-disclosed potential violations of the Toxic Substances Control Act (TSCA) related to Ultium Cells LLC to the EPA, which resulted in a November 2023 settlement involving joint civil penalties estimated at approximately $5.1 million. This indicates a shift from a passive investment to a more active and operationally entangled partnership with associated regulatory responsibilities.",
      "llm_answer": "\nFrom 2022 to 2023 GM deepened its financial stake in Ultium Cells LLC – the 2022 10‑K (pages 40‑44) records an additional ~ $1 billion of equity and a $5.2 billion multi‑year revolving credit line that became available to the JV through 2024, pushing GM’s cumulative investment to roughly $2 billion.  In 2023 the relationship was marked by regulatory action: GM self‑disclosed and settled EPA TSCA violations tied to imports into the JV, agreeing to about $5.1 million in civil penalties that are shared jointly with Ultium Cells LLC (see the 2023 10‑K, pages 26‑30).",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. The ground truth states GM's 2022 investment was $0.5 billion, but the LLM claims an additional ~$1 billion in equity and a $5.2 billion credit line, pushing cumulative investment to $2 billion—this is unsupported by the original answer and introduces figures not present in the ground truth. The $5.1 million civil penalty is correctly reported. (2) The dates (February 2023 self-disclosure, November 2023 settlement) are not mentioned in the LLM answer, though the regulatory event (EPA TSCA violations) and outcome (joint $5.1M penalty) are correctly identified. (3) The qualitative reasoning is sound in identifying a shift from financial investment to operational entanglement via regulatory responsibility, which aligns with the original answer’s core thesis. The LLM correctly synthesizes that GM self-disclosed and settled EPA violations related to Ultium Cells LLC, indicating deeper operational involvement. However, it overstates the financial commitment with unverified figures. (4) Contextually, the answer is highly relevant, addressing both financial and regulatory dimensions of the GM–Ultium relationship. While the direction of evolution is correctly interpreted, the incorrect investment amounts undermine factual accuracy, warranting a moderate correctness score. Minor formatting differences in dollar amounts are acceptable, but invented figures like $2B cumulative investment and $5.2B credit line are not. Thus, quantitative accuracy is low, qualitative accuracy is fair, and relevance is high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 437,
        "total_tokens": 1787
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has the company's use of variable-priced contracts for natural gas and fuel purchases evolved between 2022 and 2024?",
      "original_answer": "In 2022, the company entered into variable-priced contracts for some purchases of natural gas and fuel for its gas stations on an index basis, though the specific volume or value of these contracts was not disclosed. By 2024, the company continued using variable-priced contracts for similar purchases and explicitly noted that these contracts met the characteristics of derivative instruments but generally qualified for the 'normal purchases and normal sales' exception, requiring no mark-to-market adjustment. This indicates a more formalized or strategic use of variable-priced contracts by 2024, aligning them with accounting frameworks for derivatives, suggesting a shift in how these contracts are managed or accounted for.",
      "llm_answer": "\nBetween 2022 and 2024 the company continued to rely on variable‑priced, index‑based contracts for its natural‑gas and fuel purchases, treating them as “normal purchases and normal sales” that are exempt from mark‑to‑market accounting.  The filings show no substantive change in the nature or extent of these contracts—​the same index‑based approach is described in both years, indicating a consistent use of variable‑priced agreements over the period.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually consistent in describing the use of variable-priced, index-based contracts for natural gas and fuel purchases in both 2022 and 2024, and correctly notes the application of the 'normal purchases and normal sales' exception from mark-to-market accounting. Quantitatively, there are no numbers or calculations to verify, so the score is 10 by default. However, the key discrepancy lies in the interpretation of evolution: the original answer identifies a meaningful shift by 2024—namely, that the company explicitly recognized these contracts as having characteristics of derivatives, indicating a more formalized or strategic accounting treatment. The LLM answer incorrectly concludes there was 'no substantive change' and 'consistent use,' which contradicts the ground truth that suggests an evolution in how these contracts are managed or accounted for, even if the operational use remained similar. This reflects a failure in multi-hop reasoning to infer the significance of the derivative characteristics and accounting alignment mentioned in 2024 but not in 2022. Thus, while contextually relevant and factually accurate on surface details, the LLM misses the qualitative evolution, leading to a partially correct assessment. Hence, correctness and qualitative accuracy are moderate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 364,
        "total_tokens": 1653
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has Cisco's financial reporting approach for the APJC segment evolved between fiscal 2022 and fiscal 2023, particularly in terms of the expense categories excluded from segment performance measurement?",
      "original_answer": "Cisco's financial reporting for the APJC segment maintained a consistent exclusion of key expense categories from segment performance measurement in both fiscal 2022 and fiscal 2023. In fiscal 2022, the company explicitly excluded research and development, sales and marketing, and general and administrative expenses from segment financial decisions and resource allocations. This approach remained unchanged in fiscal 2023, with the same categories of expenses—along with amortization and impairment of acquisition-related intangible assets, share-based compensation expense, significant litigation settlements, and charges related to asset impairments and restructurings—not being allocated to the gross margin for each segment. The consistency in exclusions indicates no change in how APJC's performance was internally measured across the two fiscal years.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2023 Cisco kept the same set of expense items excluded from the APJC segment’s performance measurement.  In both years the company does **not** allocate – and therefore does not include in segment gross‑margin – research‑and‑development, sales‑and‑marketing, and general‑and‑administrative costs, as well as amortization and impairment of acquisition‑related intangible assets, share‑based compensation expense, significant litigation settlements and other contingencies, restructuring‑related charges, and certain other charges.  No new categories were added or removed; the exclusion list remained unchanged across the two periods.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the original (ground truth) answer. (1) It accurately states that Cisco's financial reporting approach for the APJC segment remained unchanged between fiscal 2022 and 2023, with consistent exclusions from segment performance measurement. (2) There are no numeric values requiring calculation (e.g., dollar amounts, percentages), but the fiscal years (2022 and 2023) are correctly referenced. (3) The multi-hop reasoning is sound: the model correctly synthesizes that the same expense categories were excluded in both years, including research and development, sales and marketing, general and administrative expenses, amortization and impairment of intangible assets, share-based compensation, litigation settlements, restructuring charges, and other contingencies. The LLM even includes 'other contingencies' and 'certain other charges' which align with the broader category mentioned in the ground truth. (4) All entities (Cisco, APJC segment, fiscal years) are correct, and the answer directly addresses the evolution (or lack thereof) in reporting approach. No factual inaccuracies, omissions, or misstatements are present. The answer is concise, complete, and factually precise, warranting top scores across all dimensions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1396,
        "completion_tokens": 359,
        "total_tokens": 1755
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has UNH's approach to managing medical cost trends evolved from 2022 to 2023, particularly in terms of strategies to address rising outpatient procedure costs for seniors?",
      "original_answer": "In 2022, UNH expressed concern over increased medical care costs due to deferred care during the pandemic and the potential for higher demand for services, especially among individuals with chronic conditions. The company emphasized the importance of accurate cost prediction and effective management under risk-based arrangements. By 2023, UNH specifically identified rising outpatient procedure costs for seniors as a persistent trend, expecting it to continue into 2024 and beyond. In response, the company shifted toward more proactive strategies, such as engaging physicians and consumers with data-driven insights to guide clinical decisions and promote affordable, high-quality care. This represents a shift from general concern in 2022 to targeted intervention in 2023.",
      "llm_answer": "\nFrom 2022 to 2023 UnitedHealth shifted from a broad‑based cost‑containment model—relying on underwriting criteria, product design and competitive provider contracts—to a more targeted approach that explicitly addresses the rise in senior outpatient utilization. In 2023 the company emphasized engaging physicians and senior members with data‑driven information and care‑management tools, expanding value‑based payment arrangements and clinical engagement to steer high‑cost outpatient procedures toward lower‑cost, high‑quality settings, while still using underwriting and contract negotiations but now coupled with consumer‑focused strategies to curb senior outpatient cost growth.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution from 2022 to 2023: in 2022, UNH used broad cost-containment strategies (underwriting, product design, provider contracts), which matches the original answer's emphasis on risk-based arrangements and cost prediction. By 2023, the shift to targeted interventions—specifically data-driven engagement with physicians and consumers, value-based payments, and steering care to lower-cost settings—is accurately described and consistent with the original answer’s focus on data-driven insights and clinical engagement. (2) There are no numeric values, dates, or financial figures in the question or answers that require verification; all time references (2022 to 2023) are correct. (3) The multi-hop reasoning is sound: the model synthesizes UNH’s changing strategy across two years and correctly identifies the specific focus on senior outpatient costs as a developing trend requiring new approaches. The mention of value-based arrangements and clinical engagement reflects accurate entity and concept mapping. (4) While the original answer emphasizes 'concern over deferred care' in 2022 and 'expectation of continuation into 2024' in 2023, the LLM answer omits the forward-looking 2024 expectation, which is a minor omission but does not undermine the core accuracy. Otherwise, the semantic meaning and factual content are equivalent. Wording differs slightly but conveys the same strategic shift. Hence, a score of 9 is justified—excellent accuracy with only minor contextual detail missing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 436,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has UPS's approach to time-definite delivery services evolved between 2022 and 2024, particularly in terms of service scope and network integration?",
      "original_answer": "In 2022, UPS emphasized its integrated global air and ground network as the foundation for time-definite delivery services, highlighting its ability to combine all packages within a single network for operational efficiency. By 2024, UPS expanded its time-definite delivery offerings by insourcing the final delivery of non-urgent, lightweight residential shipments previously handled by the USPS through UPS SurePost, giving it greater control over service quality. Additionally, in 2024, UPS offered same-day pickup seven days a week and expanded returns services across approximately 150 countries, reflecting a broader and more customer-centric service scope compared to 2022.",
      "llm_answer": "\nBetween 2022 and 2024 UPS broadened the scope of its time‑definite portfolio—adding more guaranteed same‑day, next‑day and day‑definite international options—while deepening network integration through RFID‑enabled “Smart Package” facilities and a shift from a scanning to a sensing network that ties pick‑up, transportation and final‑mile delivery into a single, tightly coordinated flow.  At the same time the company reshaped the network to focus on higher‑yielding B2B, healthcare and SMB volume, divesting non‑core brokerage assets (e.g., Coyote) and insourcing final‑mile delivery (UPS SurePost), thereby consolidating pick‑up points via the UPS Access Point system and improving overall asset utilization.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general direction of UPS's evolution in time-definite delivery services between 2022 and 2024, particularly around network integration and service expansion, but introduces unverified details not present in the ground truth. Correct elements include the insourcing of final-mile delivery (UPS SurePost), which aligns with the 2024 shift for greater control, and the emphasis on network integration and asset utilization. However, the LLM adds specific technological claims—such as RFID-enabled 'Smart Package' facilities and a shift from 'scanning to sensing network'—that are not supported in the original answer and cannot be verified from the provided knowledge. Additionally, the mention of divesting 'non-core brokerage assets (e.g., Coyote)' and focusing on 'B2B, healthcare and SMB volume' introduces strategic moves not referenced in the ground truth, making them potentially misleading. While the core idea of broadening time-definite services is correct, the original answer emphasizes same-day pickup seven days a week and expanded returns in 150 countries—key customer-facing enhancements—missing entirely in the LLM response. The LLM also omits the specific point about integrating all packages into a single network in 2022 as the foundation. Quantitatively, no hard numbers (e.g., dollar amounts, percentages) are present in either answer, so accuracy is neutral; dates (2022–2024) are correctly framed. Contextually, the answer is relevant and addresses service scope and network integration, but the reasoning is partially unsound due to unsupported additions, weakening the multi-hop synthesis. Thus, while the answer is plausible and directionally accurate, it lacks fidelity to the source data in key qualitative aspects.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 478,
        "total_tokens": 1828
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How did Lowe's Companies, Inc.'s treatment or recognition of its 2.50% Notes maturing in April 2026 evolve between the 2022 and 2023 annual filings?",
      "original_answer": "In the 2022 filing, the 2.50% Notes maturing in April 2026 were referenced as part of the Thirteenth Supplemental Indenture dated April 20, 2016, but were described in the context of historical documentation. By the 2023 filing, these same notes were explicitly recognized as issued instruments under the same indenture, indicating a shift in disclosure treatment. This reflects a procedural or administrative transition from planning or documentation phase in 2022 to a more active recognition of the notes as part of the company's outstanding debt structure in 2023, even though the core terms (interest rate of 2.50%, maturity in April 2026) remained unchanged.",
      "llm_answer": "\nIn the 2022 Form 10‑K the 2.50 % Notes due April 2026 were shown as a separate tranche of senior unsecured debt in the supplemental indenture (Exhibit 4.14) and were carried at amortized cost on the balance‑sheet with a disclosed interest‑rate description. By the 2023 filing the company no longer listed the 2.50 % series individually; instead the notes were folded into the broader “Notes maturing in 2026” disclosure, with only a consolidated reference to the 2026 maturity schedule and no separate carrying‑amount detail for the 2.50 % tranche.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth. (1) According to the original answer, the 2.50% Notes maturing in April 2026 were referenced in the 2022 filing as part of the Thirteenth Supplemental Indenture in a historical/documentation context and were then explicitly recognized as issued instruments in the 2023 filing—indicating increased specificity and active recognition. However, the LLM claims the opposite: that the notes were individually disclosed in 2022 but 'folded into' a broader category in 2023 with less detail. This misrepresents the evolution entirely, suggesting a reduction in disclosure when the truth is an enhancement. (2) Quantitatively, while the interest rate (2.50%) and maturity (April 2026) are correctly stated, the LLM incorrectly implies a change in accounting treatment (e.g., 'carried at amortized cost') and consolidation of disclosures, for which there is no support in the ground truth. There is no mention in the original answer of amortized cost or Exhibit 4.14, introducing unverified details. (3) The multi-hop reasoning fails: instead of identifying a procedural transition from documentation to active recognition, the model fabricates a narrative of disaggregation to consolidation, which is factually wrong. (4) Contextual relevance is moderate because the answer discusses the right instrument (2.50% Notes, April 2026) and general disclosure trends, but the core conclusion about the direction of change is inverted. Thus, despite some correct surface-level details, the substantive claim is false, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 438,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has the impact of sovereign debt crises on Costco's merchandise sourcing and cost structure evolved from 2022 to 2024?",
      "original_answer": "In 2022, sovereign debt crises were mentioned as part of a broader set of macroeconomic factors that could adversely affect demand for Costco's products and services, influence the cost or ability to purchase inventory, and require a change in product mix. The document highlighted that the degree of exposure depended on the type of goods, tariff rates, and timing, with the potential for higher tariffs to impact results. By 2024, the framing had shifted, with sovereign debt crises now explicitly stated to 'negatively impact' Costco's business, financial condition, and results of operations. The 2024 filing emphasized a broader set of supply chain risks, including supplier adherence to standards, supply constraints, and geopolitical instability, suggesting a heightened concern over the cascading effects of sovereign debt crises on both sourcing and cost predictability.",
      "llm_answer": "\nFrom 2022 to 2024 the 10‑K filings treat sovereign‑debt crises as part of a broader set of macro‑economic shocks that can curb member demand, alter product mix and raise the cost of acquiring inventory.  In the 2022 filing the reference is brief—sovereign‑debt crises are listed among “general economic factors” that *could* affect demand and cost of goods.  By 2024 the discussion is more explicit: the same section links sovereign‑debt turmoil (along with tariffs, inflation and commodity‑price volatility) to the *ability to purchase quality merchandise at competitive prices* and to “the cost of or ability to purchase inventory,” indicating that such external debt‑related stresses have become a more concrete driver of sourcing decisions and cost‑structure pressure for Costco.  In short, the risk has moved from a general possibility in 2022 to a recognized, ongoing factor shaping Costco’s merchandise sourcing and cost management by 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: the evolution from a general mention in 2022 as part of macroeconomic risks to a more explicit and concrete risk in 2024 is accurately portrayed. The LLM correctly identifies that in 2022, sovereign debt crises were listed among 'general economic factors' that could affect demand and inventory costs, and by 2024, they are linked more directly to the ability to source quality merchandise at competitive prices. (2) There are no numerical values to verify, so quantitative accuracy is scored as 10 since no numbers were misstated. (3) The multi-hop reasoning is sound—LLM synthesizes changes in tone, framing, and implication across two years of 10-K filings, correctly inferring an escalation in perceived risk severity. The only minor shortcoming is that the LLM does not explicitly mention the 2024 emphasis on 'supplier adherence to standards, supply constraints, and geopolitical instability' as part of the broader supply chain risks, which slightly reduces completeness. However, it captures the core shift in risk characterization. (4) The answer is fully contextually relevant, directly addressing how the impact on sourcing and cost structure evolved. Wording differs but semantic meaning matches the original answer. Thus, correctness is 9 due to a minor omission in contextual detail, but all key points are present and accurately conveyed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1450,
        "completion_tokens": 403,
        "total_tokens": 1854
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has the number of shares available for future grants under the 2020 Stock Incentive Plan changed between 2021 and 2023, and what does this indicate about UnitedHealth Group's capacity for issuing new share-based awards?",
      "original_answer": "In 2021, UnitedHealth Group had 64 million shares available for future grants under the 2020 Stock Incentive Plan. By 2023, this number had decreased to 53 million shares. This indicates a reduction in the company's available capacity to issue new share-based awards over this period.",
      "llm_answer": "\nThe 2020 Stock Incentive Plan had about **64 million shares** available for future grants at the end of 2021, but by the end of 2023 that pool had shrunk to roughly **53 million shares**—a decline of roughly **11 million shares**. This reduction shows that UnitedHealth Group has nearly exhausted the shares originally reserved for share‑based compensation and now has limited remaining capacity to issue new awards unless the share reserve is expanded through shareholder approval.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the number of shares available in 2021 (64 million) and 2023 (53 million), matching the ground truth exactly. The calculated decrease of 11 million shares is accurate. 2) All numeric values and the implied calculation (64M - 53M = 11M) are correct. Format variations (e.g., '64 million' vs '64 million') are acceptable and do not affect accuracy. 3) The reasoning is sound: the reduction in available shares is correctly interpreted as a decline in capacity to issue new awards. The addition that UnitedHealth Group 'has nearly exhausted' the pool and has 'limited remaining capacity' is a reasonable qualitative inference, though slightly stronger than the neutral tone of the original answer. However, it does not contradict the ground truth. 4) The answer fully addresses both parts of the question: the change in shares (quantitative) and what it indicates about future award capacity (qualitative). The entities (UnitedHealth Group, 2020 Stock Incentive Plan, years 2021 and 2023) are correct. The only minor overstatement is the phrase 'nearly exhausted'—while 53M is a significant reduction, it does not imply near exhaustion, so this slightly affects qualitative precision. Overall, the answer is factually correct, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1211,
        "completion_tokens": 362,
        "total_tokens": 1573
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did the expiration date and contribution significance of the IAM National Pension Fund / National Pension Plan relationship with UPS evolve between 2022 and 2024?",
      "original_answer": "In 2022, the IAM National Pension Fund / National Pension Plan had a collective bargaining agreement expiration date of July 31, 2024, and UPS had contributed more than 5% of the total plan contributions from all employers for the years 2019 through 2021. By 2024, the expiration date for this specific plan was extended to July 31, 2029, and UPS continued to be a significant contributor, providing more than 5% of total contributions for the plan years 2022 through 2024. This indicates a notable extension in the contractual relationship and sustained significance of UPS's contributions over time.",
      "llm_answer": "\nBetween 2022 and 2024 the IAM National Pension Fund/National Pension Plan’s collective‑bargaining agreement was extended: the 2022 filing listed a July 31 2024 expiry, while the 2024 filing shows the new expiry date is July 31 2029.  During that time UPS’s required contributions to the plan rose from roughly $48 million (the latest amount reported for 2021 in the 2022 filing) to $53 million in 2024, underscoring the plan’s growing significance in UPS’s multi‑employer pension funding despite remaining a red‑zone, underfunded plan that operates under a rehabilitation plan and currently incurs no surcharge.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. While it correctly identifies the extension of the expiration date from July 31, 2024, to July 31, 2029, it introduces dollar amounts ($48 million in 2021 and $53 million in 2024) that are not present in the ground truth. The original answer states that UPS contributed more than 5% of total plan contributions for 2019–2021 and continued to do so for 2022–2024, but does not provide specific dollar figures. These invented numbers severely undermine quantitative accuracy. (2) The dates (July 31, 2024, and July 31, 2029) are correct and match the ground truth, but the contribution amounts are unverified and not supported by the original answer, making the quantitative claims misleading. There is no indication in the ground truth that contributions 'rose' from $48M to $53M; the only metric provided is the >5% threshold, which is qualitative. (3) The multi-hop reasoning is partially sound—the model correctly synthesizes the change in expiration date between 2022 and 2024 filings and infers ongoing significance of UPS’s role. However, it fails to accurately represent the nature of 'significance' (i.e., >5% of total contributions) and instead substitutes unsupported dollar figures, indicating a failure in precise information retrieval or synthesis. (4) Contextual relevance is high because the answer addresses the evolution of the expiration date and UPS’s contribution significance over time, which directly responds to the question. However, the introduction of false quantitative data and omission of the correct >5% metric significantly reduces correctness and qualitative accuracy. The mention of the plan being in the 'red zone' and under rehabilitation, while potentially true, is extraneous and not in the ground truth, further deviating from the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 502,
        "total_tokens": 1810
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did the terms and availability under LOW's 2020 Credit Agreement evolve between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, the 2020 Credit Agreement had a maturity date of March 2025 and provided $2.0 billion in availability. By fiscal year 2023, the 2020 Credit Agreement was amended and restated in September 2023 into the 2023 Credit Agreement, which extended the maturity date to September 2028 while maintaining the same $2.0 billion availability. Additionally, in 2023, the combined availability under both the 2023 Credit Agreement and the Third Amended and Restated Credit Agreement remained at $4.0 billion, consistent with the total availability reported in 2022.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2023 the Company extended the maturity of its revolving credit facilities and reshaped their structure.  In September 2023 it amended and restated the $2 bn 2020 Credit Agreement, pushing the final maturity from March 2025 (and the earlier third‑amended agreement’s December 2026 maturity) out to **September 2028**, while keeping the $2 bn per‑agreement capacity (with a combined $4 bn availability and an optional $1 bn expansion).  The amendment also introduced a new 2023 Credit Agreement that mirrors the same $2 bn, five‑year revolving commitment, so the key evolution was a **later maturity date and the replacement of the prior facility with a new, similarly‑sized agreement that matures in 2028**.  No borrowings were outstanding under either agreement during the periods reported.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the key evolution in LOW's credit agreement terms between fiscal years 2022 and 2023. (1) Quantitatively, all numbers and dates are correct: the original 2020 Credit Agreement had a March 2025 maturity and $2.0 billion availability, which was amended in September 2023 to extend maturity to September 2028 while maintaining $2.0 billion availability. The combined $4.0 billion total availability (from both the 2023 Credit Agreement and the Third Amended and Restated Credit Agreement) is correctly noted as consistent with 2022 levels. (2) The mention of an 'optional $1 billion expansion' is not present in the ground truth and is a minor addition not confirmed by the original answer, slightly affecting completeness and precision. However, this does not contradict the ground truth but adds peripheral detail. (3) The reasoning is sound: the LLM correctly identifies the amendment and restatement of the 2020 agreement into the 2023 agreement, recognizes the extension of maturity, and notes the continuity of per-agreement and total availability. (4) The entity identification (LOW, 2020 and 2023 Credit Agreements) and fiscal years are accurate. The answer is contextually relevant and fully addresses the question about how terms and availability evolved. The only reason for not scoring a 10 is the inclusion of the unverified optional expansion feature, which, while plausible, was not part of the ground truth. Overall, the answer is factually correct, well-reasoned, and semantically equivalent to the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 430,
        "total_tokens": 1769
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did MDLZ's use of Net Investment Hedge Derivative Contracts evolve between 2022 and 2024, particularly in terms of their notional amounts?",
      "original_answer": "In 2022, MDLZ reported a notional amount of $3,915 million for Net Investment Hedge Derivative Contracts as of December 31, 2021, and $4,551 million as of December 31, 2020. By 2024, the notional amount for these contracts had increased significantly to $8,647 million as of December 31, 2024, up from $7,456 million in 2023. This indicates a growing reliance on such contracts over the two-year period.",
      "llm_answer": "\nMDLZ’s net‑investment‑hedge derivative program more than doubled in size.  The notional amount of the cross‑currency swaps and forwards rose from roughly **$3.9 billion** (as of Dec 31 2021, disclosed in the 2022 10‑K) to **$8.6 billion** (as of Dec 31 2024, disclosed in the 2024 10‑K), representing an increase of over 120 % and signalling a substantial expansion of the company’s hedging of non‑U.S. investments between 2022 and 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the essential evolution of MDLZ's Net Investment Hedge Derivative Contracts between 2022 and 2024. (1) It correctly identifies the notional amount as $3.9 billion as of December 31, 2021 (disclosed in the 2022 10-K), matching the ground truth of $3,915 million (rounded appropriately). It also correctly reports $8.6 billion as of December 31, 2024 (disclosed in the 2024 10-K), aligning with the ground truth $8,647 million. (2) The intermediate values for 2023 ($7,456 million) and 2020 ($4,551 million) are not mentioned, but the question focuses on the evolution between 2022 and 2024, so their omission does not undermine the core response. The percentage increase (over 120%) is approximately correct: (8,647 - 3,915) / 3,915 ≈ 120.9%, so the calculation is sound. (3) The reasoning is logically sound—correctly identifying the growth trend and interpreting it as increased reliance on hedging. The use of 'cross-currency swaps and forwards' as specific instruments is consistent with typical net investment hedges, though not explicitly detailed in the ground truth; this is a reasonable inference. (4) The answer is contextually relevant, directly addressing the evolution in notional amounts and correctly synthesizing data across filings. The only minor shortcoming is the lack of mention of the 2023 figure, which would have strengthened completeness, but it does not detract significantly from the overall correctness. Hence, a score of 9 is appropriate—excellent accuracy with near-complete synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1209,
        "completion_tokens": 426,
        "total_tokens": 1635
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How has Microsoft 365's integration with AI technologies evolved between 2022 and 2024, and what specific new capabilities were introduced in 2024 to enhance its role in productivity and collaboration?",
      "original_answer": "In 2022, Microsoft 365 was described as integrating Office 365, Windows, and Enterprise Mobility + Security with AI-backed tools to empower employees, focusing on creativity, collaboration, and innovation. By 2024, Microsoft 365 had evolved into an 'AI first platform,' introducing Copilot for Microsoft 365, which combines AI with business data from the Microsoft Graph and Microsoft 365 applications. Additionally, role-specific extensions such as Copilot for Sales, Copilot for Service, and Copilot for Finance were introduced to streamline business processes. These developments reflect a significant enhancement in AI integration aimed at delivering more personalized and intelligent productivity tools.",
      "llm_answer": "\nBetween 2022 and 2024 Microsoft 365 moved from offering generic “AI‑backed” perks to a dedicated Copilot layer that embeds a large‑language‑model assistant directly into Office apps, Teams and Windows, using Microsoft Graph to pull in user‑specific data.  In 2024 the company introduced **Copilot for Microsoft 365** (AI‑enhanced Office suite), **Copilot Studio** (a low‑code tool for customers to create or customize their own Copilot agents), and **Copilot Pro** (a subscription that delivers richer AI assistance), along with AI‑driven features in Windows 11 and Power Platform that further automate collaboration and productivity tasks.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly captures the evolution of Microsoft 365's AI integration from 2022 to 2024, noting the shift to an 'AI-first' platform. The key 2024 introduction of Copilot for Microsoft 365 is accurately described, along with its integration with Microsoft Graph and Office apps. The LLM adds specific details not in the original answer—Copilot Studio and Copilot Pro—which are factually correct and reflect real 2024 developments, thus enhancing completeness rather than introducing errors. The mention of AI-driven features in Windows 11 and Power Platform is contextually appropriate and consistent with Microsoft's broader AI strategy. The original answer highlights role-specific extensions (Copilot for Sales, Service, Finance), which the LLM omits, representing a minor gap in completeness. However, this does not undermine the core accuracy. All dates (2022–2024) are correct, no numerical data is incorrect, and the reasoning across time periods and product evolution is sound. The answer is semantically equivalent and contextually rich, demonstrating strong multi-hop synthesis between product strategy, AI integration, and new capabilities. The minor omission prevents a perfect 10, but the answer is otherwise excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 362,
        "total_tokens": 1713
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How has 3M's approach to PFAS discharge characterization in its wastewater permits evolved between its Decatur, Alabama facility disclosures in 2022 and 2024?",
      "original_answer": "In 2022, 3M disclosed that it had not fully characterized its PFAS discharge in its NPDES permit for the Decatur facility and had submitted an application to ADEM to add additional PFAS to the permit. By 2024, the Company had installed and was upgrading wastewater treatment controls specifically designed to address PFAS at the Decatur facility, and the controls were being optimized, though ADEM had not yet acted on the permit modification request. This evolution shows a shift from identifying the issue and initiating corrective actions to implementing and refining treatment solutions while awaiting regulatory approval.",
      "llm_answer": "\nBetween 2022 and 2024 3M moved from simply acknowledging—under the 2022 disclosures—that its NPDES permit for the Decatur, Alabama plant did not fully characterize its PFAS discharges and from temporarily idling the affected processes, to actively pursuing a formal permit amendment to add the missing PFAS, installing and optimizing dedicated wastewater‑treatment controls, and committing to ongoing analytical studies and monitoring under the interim Consent Order.  This reflects a shift from a reactive admission of an incomplete characterization to a proactive, comprehensive approach to defining, treating, and reporting PFAS discharges.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that in 2022, 3M acknowledged incomplete PFAS discharge characterization in its NPDES permit for the Decatur facility and had submitted a permit amendment request—consistent with the original answer. It also accurately states that by 2024, 3M was installing and optimizing wastewater treatment controls specifically for PFAS, while regulatory approval from ADEM was still pending. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), but the years (2022 and 2024) are correctly used and contextually appropriate. (3) The multi-hop reasoning is sound: the model synthesizes information across time points (2022 to 2024), locations (Decatur, AL), regulatory frameworks (NPDES, ADEM), and corporate actions (permit application, treatment upgrades, monitoring). The mention of the 'interim Consent Order' and 'temporarily idling processes' adds contextual detail not in the original answer but consistent with plausible regulatory context; however, these specifics are not confirmed in the ground truth, which slightly affects qualitative precision. (4) Despite minor elaboration beyond the original, the core evolution—from identification to implementation while awaiting approval—is correctly conveyed with strong semantic equivalence. The answer is fully relevant, directly addressing the evolution of 3M’s approach. Minor deduction in qualitative accuracy due to unverified details (e.g., Consent Order, idling), but no impact on overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 434,
        "total_tokens": 1755
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did Lowe's Companies, Inc.'s issuance of the 4.550% Notes evolve between 2022 and 2023?",
      "original_answer": "In 2022, the 4.550% Notes were first introduced in the Fifteenth Supplemental Indenture dated April 5, 2019, and were due April 5, 2049. In 2023, the same 4.550% Notes continued to be referenced under the same Fifteenth Supplemental Indenture, with no changes to the terms or maturity date. Therefore, while the 4.550% Notes were still in effect in 2023, there was no modification or new issuance related to this specific instrument during that year.",
      "llm_answer": "\nBetween 2022 and 2023 Lowe’s did not issue any new 4.550 % notes; the series was originally created in the Fourteenth Supplemental Indenture (April 5 2019) with a 2049 maturity.  The subsequent 21st Supplemental Indenture (September 8 2022) and 22nd Supplemental Indenture (March 30 2023) added newer tranches—such as 4.400 % notes due 2025 (2022) and 4.800 % notes due 2026 (2023)—but left the existing 4.550 % notes unchanged, so the evolution of that specific issuance was simply its continued presence in the indenture without any fresh issuance or amendment during 2022‑2023.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that there was no new issuance or amendment to the 4.550% Notes between 2022 and 2023, which aligns with the ground truth. However, it contains significant factual errors in the supporting details. The original 4.550% Notes were issued under the Fifteenth Supplemental Indenture, not the Fourteenth as claimed. Additionally, the LLM references the 21st and 22nd Supplemental Indentures in 2022 and 2023, which are not mentioned in the ground truth and appear to be fabricated or misattributed. While the core conclusion about no change to the 4.550% Notes is correct, the reasoning is based on incorrect entity details. (2) Quantitatively, the maturity date (2049) and interest rate (4.550%) are correct, but the dates and numbers of the supplemental indentures (Fourteenth, 21st, 22nd) are inaccurate. The ground truth specifies the Fifteenth Supplemental Indenture dated April 5, 2019, while the LLM incorrectly cites the Fourteenth and later indentures. (3) The multi-hop reasoning is partially sound in that the model infers no change to the specific note series from the absence of amendments in later indentures, but it fails to correctly identify the originating document and introduces unrelated indentures, undermining the validity of the synthesis. (4) The contextual relevance is high because the answer addresses the evolution (or lack thereof) of the 4.550% Notes directly. However, due to key factual inaccuracies in the legal documents and issuance history, the correctness score is reduced to 6, reflecting partial accuracy with significant errors in entity identification and source attribution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1244,
        "completion_tokens": 453,
        "total_tokens": 1697
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did MDLZ's financial relationship with KDP evolve between 2022 and 2024, particularly in terms of gains recognized from changes in accounting for the investment?",
      "original_answer": "In 2022, MDLZ recognized a pre-tax gain of $71 million (or $54 million after-tax) during the first quarter related to the sale of KDP shares, which reduced its ownership interest. By 2024, the company recorded a significantly larger pre-tax gain of $493 million ($368 million after-tax) due to a change in accounting for its investment in KDP. This indicates a substantial evolution in the financial impact of MDLZ's relationship with KDP over the two-year period.",
      "llm_answer": "\nBetween 2022 and 2024 MDLZ’s stake in Keurig Dr Pepper shifted from an equity‑method investment to a marketable‑security and then to a full exit. In 2022 the company still held roughly a 13 % interest and accounted for it under the equity method (no new gain was disclosed that year). In 2023, once its ownership fell below the 5 % threshold, MDLZ re‑classified the holding to “marketable securities”; it recorded a $493 million pre‑tax gain on the equity‑method remeasurement before the change, and then realized a total $606 million gain on the subsequent sale of those securities ( $593 million on the sale plus $13 million of dividend/other income). By 2024 the remaining KDP shares were sold, eliminating any further equity exposure and leaving only the $606 million gain recognized in 2023 as the final financial effect of the investment’s accounting evolution.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual and quantitative errors that undermine its correctness. (1) In 2022, the LLM claims 'no new gain was disclosed,' but the ground truth states MDLZ recognized a $71 million pre-tax gain ($54 million after-tax) in Q1 2022 from the sale of KDP shares—this is a direct contradiction and a major omission. (2) The LLM incorrectly attributes the $493 million pre-tax gain to 2023, while the original answer clearly states this gain was recorded in 2024 due to a change in accounting for the investment. This misplacement of timing is a critical error. (3) The LLM invents a $606 million total gain in 2023 from the sale of securities, including $593 million on sale and $13 million in dividend/other income, which is not supported by the ground truth. The original answer does not mention any such sale or total gain in 2023, nor does it reference dividend income. (4) The claim that MDLZ fully exited its KDP position by 2024 is plausible but not confirmed in the ground truth, which only discusses the $493 million gain in 2024 from accounting changes, not a full sale. (5) The qualitative reasoning about reclassification below a 5% threshold and shift from equity method to marketable securities may reflect plausible accounting treatment but is not present in the original answer and distracts from the actual reported gains. (6) The multi-hop synthesis fails because the model misaligns key events across years and introduces unsupported financial figures. While the answer attempts to provide a narrative evolution, it contradicts the ground truth on core facts—especially the timing and magnitude of gains. Quantitative accuracy is very low due to incorrect amounts and years. Contextual relevance is moderate because the answer addresses the general topic of MDLZ's changing relationship with KDP, but factual fidelity is poor.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 504,
        "total_tokens": 1842
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How has the scale and positioning of Xbox Game Pass evolved between 2022 and 2024, based on the number of titles available and Microsoft's strategic emphasis?",
      "original_answer": "In 2022, Xbox Game Pass offered access to a curated library of over 100 first- and third-party titles, and was positioned as a key part of Microsoft's broader gaming strategy focused on content, community, and cloud services. By 2024, the service had expanded significantly, offering access to over 400 first- and third-party titles, and was described as the 'cornerstone' of Microsoft's gaming platform, reflecting a stronger strategic emphasis on subscriptions and community growth. This indicates a significant transformation in both scale and strategic importance.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2024 the Xbox Game Pass library grew dramatically—from “a curated library of over 100 first‑ and third‑party titles” in 2022 to “a subscription service with access to over 400 first‑ and third‑party console and PC titles” by 2024.  This expansion reflects Microsoft’s strategic shift to position Game Pass as the central hub of its gaming ecosystem, emphasizing a broad content portfolio, deeper studio acquisitions (e.g., Activision Blizzard), and cross‑device delivery through cloud streaming and subscription models.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, the numbers are correct: 'over 100' titles in 2022 and 'over 400' in 2024 match the original answer exactly. The time frame (2022 to 2024) is correctly referenced, and no calculations are required beyond the implied scale increase, which is accurately conveyed. (2) The answer addresses both parts of the question: the scale (number of titles) and Microsoft's strategic emphasis. It correctly notes the growth from over 100 to over 400 titles and characterizes the strategic shift, describing Game Pass as the 'central hub'—semantically equivalent to 'cornerstone' in the original. (3) Multi-hop reasoning is sound: the answer synthesizes information about library size, strategic positioning, and supporting initiatives like studio acquisitions (Activision Blizzard) and cloud streaming, which are consistent with Microsoft's broader strategy even if not explicitly stated in the ground truth. (4) The only minor deviation is the addition of 'PC titles' and 'cloud streaming' as specifics not present in the original answer, but these are contextually appropriate and do not contradict the ground truth. The core facts, numbers, and strategic evolution are correctly captured, warranting a high correctness score of 9. Quantitative accuracy is perfect (10), qualitative accuracy is slightly marked down (9) due to slight elaboration beyond the source, and contextual relevance is full (10).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 407,
        "total_tokens": 1690
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has the structure or disclosure of Deferred Stock Unit Award Agreements for non-employee directors under the 3M Company 2016 Long-Term Incentive Plan evolved from 2022 to 2024, based on the referenced filings?",
      "original_answer": "The Deferred Stock Unit Award Agreement for non-employee directors was first referenced in the 2022 10-K filing as part of the 3M Company 2016 Long-Term Incentive Plan, applicable to grants on or after January 1, 2019. By 2024, the agreement continued to be disclosed in the 10-K filing, still referencing grants on or after January 1, 2019, indicating no change in the effective date or structure of the agreement over this period. However, the 2024 disclosure reflects an updated incorporation by reference from the 2023 10-K, showing the ongoing maintenance of the plan through amendments as of May 8, 2023.",
      "llm_answer": "\nThe 2022 filing (MMM 10‑K, pp. 129‑133) first disclosed the **form of Deferred Stock Unit Award Agreement** for non‑employee directors under the 2016 Long‑Term Incentive Plan – a performance‑based grant that vests over a three‑year cycle and settles in 3M common stock (or cash) upon termination of service. In the 2024 filing (MMM 10‑K, pp. 115‑119) the same agreement is still the governing document, but the disclosure has been updated to reflect the **post‑spin‑off structure**: the agreement now provides for settlement in shares of the newly created Solventum (or cash) and the table of equity awards lists **230 deferred stock units** outstanding for non‑employee directors as of 2024. Thus, while the core vesting and performance criteria remain unchanged, the 2024 wording clarifies the settlement method and unit count in light of the separation of Solventum.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that deviate from the ground truth. (1) The claim that the Deferred Stock Unit Award Agreement was 'first disclosed' in the 2022 filing is partially correct per the original answer, but the LLM incorrectly adds details not present in the ground truth: specifically, that the grant is 'performance-based' and 'vests over a three-year cycle' — this information is not mentioned in the ground truth and cannot be assumed. (2) The most critical error is the assertion that the 2024 agreement provides for settlement in 'Solventum' shares due to a spin-off. The ground truth makes no mention of Solventum, a spin-off, or any change in settlement method; instead, it states there was no change in the structure or effective date of the agreement. This introduces a major factual distortion. (3) The LLM cites '230 deferred stock units outstanding' as of 2024 — a specific quantitative claim — but this number is not present in the ground truth and cannot be verified, making it likely fabricated or misattributed. (4) The reasoning fails on multi-hop synthesis: rather than identifying continuity with updated incorporation by reference (as per ground truth), the model invents structural changes based on a corporate event (spin-off) not referenced in the original answer. (5) While the answer attempts to address the evolution of disclosure, it does so with incorrect entities (Solventum), fabricated metrics (230 units), and unsupported details about vesting and performance conditions. The core conclusion — that the core structure remains unchanged — aligns weakly with the ground truth, but the supporting details overwhelmingly contradict it. Thus, despite some contextual relevance in discussing disclosure updates, the answer is largely incorrect in both quantitative and qualitative dimensions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 499,
        "total_tokens": 1886
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has the composition of Charles Schwab Bank's First Mortgages and HELOCs portfolio evolved between 2023 and 2024, particularly in terms of origination costs and geographic concentration in California?",
      "original_answer": "In 2023, the First Mortgages and HELOCs portfolio included $100 million in unamortized premiums, discounts, and direct origination costs, with 43% of the portfolio concentrated in California. By 2024, these costs increased to $112 million, while the California concentration slightly decreased to 42%. This indicates a slight shift in geographic risk exposure and an increase in loan origination activity or associated costs over the year.",
      "llm_answer": "\nBetween 2023 and 2024 the First‑Mortgage portfolio modestly expanded (current balance rose from $26.1 billion to $27.3 billion) while the HELOC portfolio slipped slightly (from $0.48 billion to $0.42 billion).  The Company’s direct origination‑cost balance grew from about $100 million at the end of 2023 to roughly $112 million at the end of 2024, reflecting higher new‑loan production expenses.  Geographic concentration in California remained very high, holding steady at roughly 42‑43 percent of the combined First‑Mortgage and HELOC portfolio in both years.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the $100 million origination costs in 2023 and $112 million in 2024, matching the ground truth exactly. It also accurately reflects the California concentration as 'roughly 42-43 percent' in both years, which aligns with the 43% in 2023 and 42% in 2024 in the original answer. While the LLM adds extra detail about portfolio balances ($26.1B to $27.3B for First Mortgages, $0.48B to $0.42B for HELOCs), these are factually consistent with typical reporting and do not contradict the ground truth. (2) All numeric values related to origination costs and geographic concentration are correct. The slight rewording of California's concentration as a range (42-43%) is semantically equivalent to stating 43% in 2023 and 42% in 2024. No calculation errors are present. (3) The multi-hop reasoning is sound: the model correctly synthesizes data across time (2023 vs 2024), metric type (origination costs, geographic concentration), and product lines (First Mortgages and HELOCs). It infers increased loan production expenses from rising origination costs, which is a reasonable interpretation. (4) The answer is highly relevant and complete, addressing both origination costs and geographic concentration over time. The only minor shortcoming is that it does not explicitly note the 'slight decrease' in California concentration from 43% to 42%, instead characterizing it as 'holding steady'—a slight softening of the trend, but not factually incorrect given the small change. This justifies a 9/10 on correctness and qualitative accuracy, but full marks on quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 451,
        "total_tokens": 1715
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has Nike's strategic emphasis on the Dri-FIT technology evolved between fiscal 2023 and fiscal 2024, based on the language in Nike's product research and development sections?",
      "original_answer": "Nike's strategic emphasis on the Dri-FIT technology remained stable between fiscal 2023 and fiscal 2024. In both years, Dri-FIT was listed among key technologies such as Nike Air, Zoom, Free, Flyknit, FlyEase, ZoomX, Air Max, and React, indicating consistent strategic importance. The exact same language was used in both the 2023 and 2024 10-K filings, showing no change in the description or emphasis of Dri-FIT's role in Nike’s innovation strategy.",
      "llm_answer": "\nIn the FY 2023 filing the Dri‑FIT technology is mentioned only as one item in a list of “Nike Air, Zoom, Free, Dri‑FIT, Flyknit…​ technologies,” which signals that it was still being pursued but without a separate, highlighted strategic focus. By contrast, the FY 2024 filing expands the language, describing the “proliferation” of Dri‑FIT and positioning it as a core platform that the company leverages across product categories and consumer experiences, indicating that Nike has elevated Dri‑FIT from a peripheral innovation to a more central, strategic emphasis.",
      "correctness_score": 1,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim. The original answer (ground truth) states that the language describing Dri-FIT in Nike's 10-K filings was *identical* between fiscal 2023 and fiscal 2024, with no change in emphasis or description. The LLM incorrectly asserts that the FY2024 filing 'expands the language' and describes 'proliferation' of Dri-FIT, positioning it as a 'core platform'—a characterization not supported by the source data. There are no numerical values in the question or answers, so quantitative accuracy is not applicable beyond correct referencing of fiscal years (which the LLM got right). However, the qualitative inaccuracy is severe: the model fabricates a shift in strategic emphasis and textual evolution that did not occur, failing the multi-hop reasoning by misrepresenting the consistency of language as a change. The contextual relevance is low because the answer invents details not present in the filings, fundamentally misrepresenting Nike’s disclosed strategy. The model likely hallucinated enhanced language due to common corporate narrative patterns, but in this case, the actual filings used the exact same wording, so no evolution occurred.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1262,
        "completion_tokens": 335,
        "total_tokens": 1598
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has Mondelez International's investment in backup and disaster recovery evolved from 2022 to 2024, particularly in response to increasing cybersecurity threats?",
      "original_answer": "In 2022, Mondelez was on heightened alert regarding cybersecurity risks, dedicating focused resources to backup and disaster recovery as part of its response to increased global cybersecurity threats, especially during the pandemic. By 2024, the company significantly expanded its efforts, explicitly stating that it continues to invest and augment its cybersecurity program with enhanced backup and disaster recovery solutions, among other measures, to address increasingly sophisticated threats including those from state-sponsored actors and emerging technologies like artificial intelligence.",
      "llm_answer": "\nFrom 2022 to 2024 Mondelez moved beyond basic backup and disaster‑recovery safeguards to a far more robust, proactive cyber‑resilience program.  The company increased funding for network‑security monitoring, 24/7 security‑operations centers, multi‑factor authentication and advanced threat‑detection tools, and it tied those investments to its broader disaster‑recovery and incident‑response capabilities to keep pace with rising cyber threats.  As a result, backup and disaster‑recovery are now a core, continuously‑enhanced component of its strategy rather than a peripheral function.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually consistent with the ground truth in terms of the evolution of Mondelez International's investment in backup and disaster recovery from 2022 to 2024, particularly in response to increasing cybersecurity threats. While no specific dollar amounts or percentages are mentioned in either answer, the qualitative progression is accurately portrayed: in 2022, Mondelez was already focused on cybersecurity and disaster recovery due to heightened threats, and by 2024, the company had expanded its efforts significantly. The LLM correctly captures the shift toward a more integrated, proactive, and continuously enhanced cybersecurity posture that includes backup and disaster recovery as core components. It appropriately references advanced measures such as 24/7 security operations centers, multi-factor authentication, and threat detection tools, which align with the idea of augmenting cybersecurity programs in response to sophisticated threats, including state-sponsored actors and AI-driven risks. However, the LLM answer does not explicitly mention 'state-sponsored actors' or 'artificial intelligence' as cited in the original answer, which are key specifics from the ground truth. While the general direction and reasoning are sound and semantically aligned, the absence of these precise threat vectors slightly reduces qualitative accuracy. There are no numerical inaccuracies (quantitative accuracy is perfect by default, as no conflicting numbers are present), and the response is fully contextually relevant, directly addressing the evolution of investment in backup and disaster recovery over the specified time frame.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1300,
        "completion_tokens": 450,
        "total_tokens": 1750
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has Microsoft's financial commitment and engagement with Black and African American-owned suppliers evolved from fiscal year 2022 to fiscal year 2024?",
      "original_answer": "In fiscal year 2022, Microsoft reported that it had enriched its supplier pipeline, reaching more than 90% of its goal to spend $500 million with double the number of Black and African American-owned suppliers. By fiscal year 2024, Microsoft had not only achieved its $500 million spending goal but also expanded its financial commitments by allocating $150 million to Minority Depository Institutions and funds supporting Black and African American-owned small businesses. This evolution indicates a deepening of Microsoft's strategic focus on supplier diversity and community economic development over time.",
      "llm_answer": "\nBetween fiscal years 2022 and 2024 Microsoft moved from reporting that it had reached roughly 90 percent of its $500 million goal for spending with Black‑ and African‑American‑owned suppliers to actually meeting that target—effectively doubling the number of such suppliers it contracts with.  The company also broadened its financial engagement by increasing transaction volumes and deposits with Black‑owned financial institutions, signaling a deepening commitment to the Black‑owned supplier ecosystem.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution in Microsoft's financial commitment to Black and African American-owned suppliers from FY2022 to FY2024. It accurately states that in FY2022, Microsoft had reached about 90% of its $500 million spending goal and that by FY2024, it had met the target while doubling the number of such suppliers—this aligns with the ground truth. However, the LLM omits the specific $150 million allocation to Minority Depository Institutions and funds supporting Black-owned small businesses, which is a key quantitative and strategic detail in the original answer. While the LLM mentions 'increasing transaction volumes and deposits with Black-owned financial institutions,' this is a more general statement and does not precisely reflect the $150 million committed, leading to a minor loss in quantitative accuracy. The entity identification (Microsoft, Black- and African American-owned suppliers), time frame (fiscal years 2022–2024), and reasoning about deepening commitment are all accurate and logically sound. The answer is contextually relevant and synthesizes multi-hop information correctly across years and initiatives, but the omission of a major financial figure prevents a top score. Semantic equivalence is mostly preserved, though the specificity of the $150 million expansion is missing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1280,
        "completion_tokens": 374,
        "total_tokens": 1655
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has the availability of common shares for future issuance under the Abbott Laboratories Employee Stock Purchase Plan for Non-U.S. Employees evolved from 2022 to 2023, and what does this indicate about Abbott's stock-based incentive strategy?",
      "original_answer": "In 2022, as of December 31, 2021, an aggregate of 10,638,639 common shares were available for future issuance under the Employee Stock Purchase Plan. In 2023, as of December 31, 2023, this number had decreased to 8,565,087 common shares. This indicates a reduction in the number of shares available for future issuance, suggesting a potential tightening or adjustment in Abbott's stock-based incentive strategy for non-U.S. employees.",
      "llm_answer": "\nThe tables in the 2022 and 2023 Form 10‑K filings show that the reserve of Abbott common shares available for future issuance under the Employee Stock Purchase Plan for Non‑U.S. Employees fell from **≈10.6 million shares at the end of 2022** to **≈8.565 million shares at the end of 2023** – a reduction of about 2 million shares (≈19%).  This shrinkage of the ESPP pool signals that Abbott is scaling back the shares earmarked for that plan, likely reallocating them to other equity‑based incentive programs or corporate uses, reflecting a more focused or conservative stock‑based compensation strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) Quantitatively, the LLM correctly reports the available shares as approximately 10.6 million at the end of 2022 (actual: 10,638,639) and 8.565 million at the end of 2023 (actual: 8,565,087), with minor rounding that is acceptable. The reduction of about 2 million shares and the ≈19% decrease are accurate calculations (difference: 2,073,552 shares; 2,073,552 / 10,638,639 ≈ 19.49%). (2) The answer addresses both parts of the question: the evolution of available shares (from 2022 to 2023) and the implication for Abbott's stock-based incentive strategy. (3) Entity accuracy is correct: Abbott Laboratories, Employee Stock Purchase Plan for Non-U.S. Employees, and the correct years (availability as of end of 2022 and end of 2023) are properly referenced. (4) The reasoning is sound: the reduction in available shares is correctly interpreted as a sign of scaling back or tightening the stock-based incentive strategy, with plausible speculation about reallocation to other programs. The only minor shortcoming is that the original answer specifies the 2022 figure is as of December 31, 2021 (i.e., reported in the 2022 10-K), while the LLM refers to 'end of 2022'—a slight ambiguity in timing reference that does not materially misrepresent the data. Overall, the answer is factually correct, well-reasoned, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1284,
        "completion_tokens": 395,
        "total_tokens": 1680
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has Nike's treatment of Nike Air technology evolved in its product development strategy between fiscal years 2023 and 2024?",
      "original_answer": "In fiscal 2023, Nike Air was described as part of a list of technologies that 'typifies our dedication to designing innovative products,' indicating it was still being actively proliferated across product lines. By fiscal 2024, Nike Air was again listed among key technologies, but now embedded alongside mature technologies like Zoom, Free, and React, suggesting that Nike Air had become a standard component of Nike’s broader innovation platform rather than a distinct growth driver. This reflects a strategic shift from emphasizing Nike Air as an emerging innovation to treating it as an integrated, foundational offering within Nike’s product development framework.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 Nike moved from treating Air technology as a niche footwear innovation to making it a cross‑category platform for product development.  The company expanded the use of Air‑Sole components—leveraging its dedicated Air Manufacturing Innovation facilities and integrating Air Max, ZoomX, React and related Air technologies into apparel, equipment and digital experiences—so that Air‑based performance and comfort became a core element of its overall design strategy rather than a standalone footwear feature.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains significant inaccuracies in reasoning and entity representation compared to the ground truth. (1) Correct elements: The general idea that Nike Air evolved in strategic importance is contextually relevant, and there are no numeric values to conflict with quantitative accuracy (thus scored 10). (2) However, the LLM introduces unsupported claims: it states Nike moved Air from a 'niche footwear innovation' to a 'cross-category platform' including apparel, equipment, and digital experiences—this is not supported by the original answer, which only discusses Nike Air becoming a mature, integrated technology alongside Zoom, Free, and React within product development, not expansion into new categories. The mention of 'Air Manufacturing Innovation facilities' and integration of 'ZoomX' with Air technologies is speculative or fabricated. (3) Multi-hop reasoning is flawed: the original answer draws a nuanced distinction between Nike Air being an innovative differentiator in 2023 and a foundational component in 2024; the LLM overstates this as a transformation into a broad platform across non-footwear domains, which is not evidenced. The core shift—from emerging innovation to mature, integrated technology—is misrepresented as a strategic expansion rather than a maturation. (4) Despite this, the answer remains contextually relevant to the question about strategic evolution, hence a contextual relevance score of 8. Qualitative accuracy is low due to incorrect synthesis and entity relationships, but not entirely wrong—hence correctness score of 5.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 437,
        "total_tokens": 1735
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has Abbott's positioning of Osmolite within its Nutritional Products segment evolved between 2022 and 2023, particularly in terms of its enteral feeding portfolio and associated product line strategy?",
      "original_answer": "In 2022, Osmolite was listed among Abbott's enteral feeding products used in healthcare institutions, alongside Jevity®, Glucerna® 1.2 Cal, Glucerna® 1.5 Cal, Oxepa®, Freego™, Nepro®, and Vital®. By 2023, Osmolite continued to be included in the enteral feeding portfolio, but Abbott's product listing in this category remained largely consistent, indicating a stable strategic positioning of Osmolite within the institutional enteral nutrition segment. There is no indication of Osmolite being newly introduced, discontinued, or significantly repositioned relative to other products in this category during this period.",
      "llm_answer": "\nBetween 2022 and 2023 Abbott shifted Osmolite from being listed merely as one of several enteral‑feeding formulas to positioning it as a flagship adult nutrition product that is promoted as part of an integrated solution—emphasizing its compatibility with the Freego™ enteral pump and its role as the standard isotonic formula for hospital and long‑term‑care patients. This reflects a product‑line strategy that bundles Osmolite with delivery devices and focuses on expanding its use within Abbott’s institutional enteral‑feeding portfolio.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect in its characterization of Abbott's positioning of Osmolite between 2022 and 2023. According to the ground truth, Osmolite's strategic positioning remained stable during this period, with no significant repositioning, bundling, or promotional shifts. The original answer explicitly states that the product listing remained largely consistent and that there was no indication of Osmolite being newly introduced, discontinued, or repositioned. However, the LLM claims a strategic shift positioning Osmolite as a 'flagship adult nutrition product' and part of an 'integrated solution' with the Freego™ pump—information not supported by the source. While Freego™ is mentioned in both years as part of the enteral portfolio, there is no evidence in the ground truth of a new bundling strategy or elevated flagship status for Osmolite. The answer fabricates a narrative of strategic evolution that contradicts the documented stability. Quantitatively, there are no numerical claims to assess, so no errors in that regard. Contextually, the response addresses the right segment and product line, but the reasoning is flawed and not grounded in the data. Thus, the correctness and qualitative accuracy scores are low due to significant factual inaccuracies and unsupported synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 364,
        "total_tokens": 1668
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has 3M's regulatory engagement and remediation obligations related to PFAS discharge evolved between 2022 and 2024, particularly in Minnesota and Alabama?",
      "original_answer": "In 2022, 3M was actively working under a 2007 Settlement Agreement and Consent Order with the MPCA to address PFAS contamination in Minnesota, with remediation substantially completed at the Cottage Grove site and ongoing operational and maintenance activities at multiple locations. In Alabama, the Company had entered into a July 2020 Interim Consent Order with ADEM, which included obligations for PFAS-related wastewater discharges and air emissions, and had completed installation of a multilayer cap at the Decatur facility. By 2024, regulatory scrutiny had intensified. In Minnesota, MPCA issued a draft Clean Water Act permit for the Cottage Grove facility with significantly revised effluent limits for certain PFAS compounds, some below current quantification levels, and the Company submitted public comments in August 2024. Additionally, in 2024, MPCA published a revised draft permit in December after considering stakeholder input, which could have a significant adverse impact on the Cottage Grove facility's operations. In Alabama, while the 2020 Interim Consent Order remained in effect, the Company's obligations under ongoing investigations and potential future remediation were still expected to involve additional operating costs and capital expenditures over multiple years. The regulatory landscape evolved to include more stringent standards, such as updated HBVs from MDH in January 2024 and proposed HRLs in October 2024, further complicating 3M's compliance path.",
      "llm_answer": "\nBetween 2022 and 2024, 3M’s Minnesota PFAS program shifted from the largely‑completed remedial work required by the 2007 Settlement Agreement and Consent Order to a phase of active compliance‑driven actions: the company is installing and optimizing PFAS‑specific wastewater‑treatment systems, responding to a March 2023 MPCA notice of violation, and negotiating a revised draft Clean Water Act permit that imposes markedly stricter effluent limits and new health‑based water‑quality standards.  \n\nIn Alabama, the firm moved from the 2009 TSCA consent order and the 2020 interim Consent Order—under which it capped former sludge areas and committed to monitoring—to a more enforcement‑focused regime that includes a 2022 EPA‑ADEM administrative consent order for drinking‑water sampling, a September 2024 RCRA consent agreement (with an immaterial penalty) and ongoing negotiations to add additional PFAS to its NPDES permit, all under heightened scrutiny from a federal grand‑jury subpoena and continued EPA/ADEM oversight of its Decatur facility.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of 3M's regulatory engagement and remediation obligations related to PFAS in Minnesota and Alabama between 2022 and 2024, but contains several factual inaccuracies that reduce its correctness. In Minnesota, the answer correctly notes the shift from completed remediation under the 2007 Settlement Agreement to compliance-driven actions, including stricter effluent limits and a draft Clean Water Act permit. However, it incorrectly states that a notice of violation was issued in March 2023—this detail is not present in the ground truth, which instead emphasizes the 2024 draft permit and 3M's August 2024 public comments. Additionally, the ground truth highlights that MPCA issued a revised draft permit in December 2024 after stakeholder input, which the LLM omits. The mention of 'health-based water-quality standards' is partially accurate but conflates timelines: MDH updated HBVs in January 2024 and proposed HRLs in October 2024, which the LLM does not specify. In Alabama, the LLM incorrectly references a '2009 TSCA consent order'—the ground truth only cites a July 2020 Interim Consent Order with ADEM. The claim about a 'September 2024 RCRA consent agreement' with an immaterial penalty is unsupported by the original answer, which makes no mention of such an agreement or penalty. Similarly, the reference to a 'federal grand-jury subpoena' and 'EPA-ADEM administrative consent order for drinking-water sampling in 2022' introduces details absent from the ground truth. While the core idea—that regulatory scrutiny intensified and obligations expanded—is consistent, these specific inaccuracies in dates, entities, and regulatory actions reduce quantitative and qualitative accuracy. The answer is contextually relevant and synthesizes across time and locations, but fails to accurately represent key regulatory milestones and documents, particularly in Alabama. Minor formatting differences (e.g., 'multilayer cap' vs 'capped former sludge areas') are acceptable under semantic equivalence, but invented events (e.g., RCRA agreement, grand jury) are not. Thus, the answer is partially correct with significant factual gaps and errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1637,
        "completion_tokens": 584,
        "total_tokens": 2222
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has The Coca-Cola Company's financial relationship with Coca-Cola HBC AG evolved between 2022 and 2024, particularly in terms of investment classification and stake percentage?",
      "original_answer": "In 2022, Coca-Cola HBC AG was among the listed equity method investees, though the specific ownership percentage was not disclosed in the provided evidence. By 2024, Coca-Cola HBC AG remained an equity method investee, and the company explicitly stated a 22% ownership stake as of December 31, 2024. This indicates a formalization and quantification of the relationship, with Coca-Cola now specifying the exact percentage of ownership, which was absent in the 2022 disclosures.",
      "llm_answer": "\nThe Coca‑Cola Company’s interest in Coca‑Cola HBC AG remained classified as an equity‑method investment from 2022 to 2024, but the ownership stake grew from roughly 19 % in 2022 to 22 % by the end of 2024. This change is disclosed in the 2024 10‑K (pages 85‑89), which reports a 22 % stake and a carrying value of $1.147 bn versus a fair‑value of $2.675 bn.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual error regarding the ownership percentage in 2022. The original answer (ground truth) states that the ownership percentage was not disclosed in 2022, whereas the LLM claims it was 'roughly 19%,' which is unsupported by the evidence. The 22% stake in 2024 is correct and matches the ground truth. The carrying value ($1.147 billion) and fair value ($2.675 billion) figures are accurate per the 2024 10-K and correctly cited, but these were not part of the original question or ground truth answer, so their inclusion, while factually plausible, does not compensate for the incorrect 2022 percentage. (2) Quantitative accuracy is compromised due to the fabricated 19% figure; no such number appears in the evidence for 2022. The 22% figure and dollar amounts are correct, but the comparison (growth from 19% to 22%) is invalid because the starting point is incorrect. (3) The reasoning partially captures the multi-hop aspect by noting consistent equity-method classification across years and identifying a change in disclosure specificity. However, it incorrectly infers a numerical increase in stake due to lack of disclosed data in 2022, failing to recognize that the absence of a disclosed percentage does not imply a lower or known percentage. The synthesis is flawed at this critical point. (4) Contextual relevance is high—the answer addresses investment classification and stake percentage over time, cites the correct document (2024 10-K), and includes relevant financial data. However, the incorrect 2022 percentage undermines the core factual basis, leading to a moderate correctness score. The answer would have scored higher if it had acknowledged the lack of disclosed percentage in 2022 instead of inventing one.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1217,
        "completion_tokens": 485,
        "total_tokens": 1702
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has Oracle's strategic emphasis on hybrid deployments evolved between fiscal 2022 and fiscal 2024, particularly in terms of product development investment and deployment model integration?",
      "original_answer": "In fiscal 2022, Oracle emphasized hybrid deployments as part of its broader deployment model strategy, investing $7.2 billion in research and development to enhance existing offerings and develop new technologies, including hybrid solutions like Oracle Cloud@Customer. By fiscal 2024, Oracle further integrated hybrid deployments into its core offerings, positioning them as a standard deployment choice alongside on-premise and cloud-based models, and reinforcing its commitment to interoperability and customer choice. This reflects a strategic evolution from a development-focused approach to a more mature, integrated deployment model.",
      "llm_answer": "\nOracle has shifted its hybrid‑cloud strategy from offering hybrid as a optional add‑on to making hybrid deployment the core integration point across its cloud, license, hardware and services businesses.  In FY 2022 the company invested $7.2 billion in R&D to build hybrid‑ready technologies, and the 2024 filing shows continued, higher‑level funding and explicit engineering focus on embedding hybrid capabilities—such as Cloud@Customer, interoperable SaaS/OCI and migration programs—directly into its product road‑maps, signaling a deeper, more integrated commitment to hybrid deployments.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, the $7.2 billion R&D investment in FY2022 is correctly stated, and while the exact FY2024 R&D figure isn't provided in the original answer, the LLM's reference to 'continued, higher-level funding' is consistent with Oracle's increasing strategic emphasis and does not contradict the ground truth. (2) The entities—Oracle, hybrid deployments, Cloud@Customer, FY2022, FY2024—are all correct. (3) The reasoning accurately captures the multi-hop evolution: from initial investment in hybrid technologies in 2022 to deeper integration into core product roadmaps by 2024. The shift from 'optional add-on' to 'core integration point' mirrors the original answer's progression from development focus to integrated deployment model. (4) The LLM adds slightly stronger language (e.g., 'core integration point across its cloud, license, hardware and services businesses') not explicitly in the original, but this is a reasonable interpretation and does not introduce factual errors. The answer fully addresses both product development investment and deployment model integration. Only a minor deduction in qualitative accuracy due to slight extrapolation beyond the original's wording, but overall semantic equivalence is maintained. Contextual relevance is perfect—directly responsive to the question's scope and intent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 388,
        "total_tokens": 1707
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has the filing status of the Mandatory Clawback Policy evolved between the 2023 and 2024 SEC 10-K disclosures for Wells Fargo & Company?",
      "original_answer": "In 2023, the Mandatory Clawback Policy was filed directly as part of the 10-K filing under Exhibit 97. In 2024, instead of being filed directly, it was incorporated by reference to Exhibit 97 from the previous year's 10-K filing. This indicates a procedural change in how the policy is disclosed rather than a substantive change to the policy itself.",
      "llm_answer": "\nIn the 2023 Form 10‑K the Mandatory Clawback Policy was listed as **Exhibit 97 and noted as “incorporated by reference”** to the prior filing. In the 2024 Form 10‑K the same policy appears as **Exhibit 97 but is now described as “filed herewith,”** indicating that the policy is directly included in the 2024 filing rather than merely referenced from an earlier report. This shift reflects the policy’s transition from a prior‑year incorporation to a current‑year, stand‑alone exhibit.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is completely incorrect and inverts the actual facts. According to the ground truth, in 2023 the Mandatory Clawback Policy was filed directly as Exhibit 97 (i.e., 'filed herewith'), while in 2024 it was incorporated by reference to the prior year’s filing. The LLM answer states the opposite: that in 2023 it was 'incorporated by reference' and in 2024 it was 'filed herewith.' This reversal of facts constitutes a fundamental error in both quantitative and qualitative accuracy. The entities (Wells Fargo, Exhibit 97, years 2023 and 2024) are correctly identified, and the response addresses the procedural change in filing status, so there is partial contextual relevance. However, the core reasoning and factual basis are flawed, failing the multi-hop synthesis requirement. No calculations are involved, but the misrepresentation of filing methods ('incorporated by reference' vs 'filed herewith') makes the answer factually wrong. Therefore, the correctness and accuracy scores are very low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1207,
        "completion_tokens": 288,
        "total_tokens": 1496
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How did Thermo Fisher's relationship with CorEvitas, LLC evolve between 2023 and 2024, and what specific financial implications were associated with this change?",
      "original_answer": "In 2023, Thermo Fisher invested $0.91 billion to acquire CorEvitas, LLC, a U.S.-based provider of regulatory-grade, real-world evidence for medical treatments. By 2024, this relationship had evolved from an investment into a full acquisition, as CorEvitas was integrated into the Laboratory Products and Biopharma Services segment. The acquisition in 2023 was part of a broader strategy that included significant capital expenditures and financing activities, such as issuing $5.94 billion in senior notes and repurchasing $3.00 billion of company stock. In 2024, the company began amortizing the definite-lived intangible assets from CorEvitas over a weighted average period of 18 years, reflecting the long-term strategic value of the acquisition.",
      "llm_answer": "\nThermo Fisher acquired CorEvitas, LLC in August 2023 and integrated it into its Laboratory Products & Biopharma Services segment, a move that lifted that segment’s income and margin and continued to drive growth into 2024. The $0.9 bn cash purchase added $627 million of goodwill and $260 million of customer‑related intangibles (amortized over ~18 years), increased the company’s debt and net interest expense, and the related amortization is added back in the reconciliation to adjusted operating income.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution and financial implications of Thermo Fisher's relationship with CorEvitas, LLC. (1) Quantitatively, the $0.9 billion acquisition cost is correctly reported (matches ground truth $0.91 billion, acceptable rounding). The $627 million goodwill and $260 million customer-related intangibles are factually correct and align with the knowledge graph. The 18-year amortization period is accurately stated. The mention of increased debt and interest expense is consistent with the 2023 financing activities (issuance of $5.94 billion in senior notes), though exact note amounts are not repeated—this is acceptable as the LLM focuses on direct implications of the acquisition. (2) The date 'August 2023' is more specific than the ground truth (which only says 2023), but does not contradict it and may reflect additional precision. (3) Qualitatively, the integration into the Laboratory Products & Biopharma Services segment is correctly identified, and the strategic impact—driving segment income, margin, and growth into 2024—is a valid inference. The note about amortization being added back in adjusted operating income reflects proper understanding of financial reporting treatment. (4) The answer addresses both parts of the question: the evolution (acquisition and integration) and financial implications (goodwill, intangibles, amortization, debt impact). One minor omission is the lack of explicit mention of the broader 2023 capital activities (stock repurchase, note issuance) as context for financing, but the focus remains on direct financial implications of CorEvitas, which is appropriate. Overall, the answer demonstrates sound multi-hop reasoning, correctly linking the acquisition to segment integration, intangible asset accounting, and financial statement impacts. Semantic equivalence is strong, with no factual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 510,
        "total_tokens": 1828
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How did RTX's flight hour payment obligations under its 2012 agreement with Rolls-Royce evolve between 2022 and 2023, particularly in terms of the timing and capitalization treatment of these payments?",
      "original_answer": "In 2022, RTX disclosed that flight hour payments to Rolls-Royce were contingent upon each hour flown through June 2027 by V2500-powered aircraft in service as of the acquisition date, and these payments were considered in 'Other commercial aerospace commitments' and capitalized as collaboration intangible assets as payments were made. In 2023, RTX reiterated the same contingent payment structure tied to flight hours through June 2027 and maintained that these payments would continue to be capitalized as collaboration intangible assets. There was no indication of a change in the magnitude or timing of these obligations between the two years, suggesting a stable commitment structure.",
      "llm_answer": "\nUnder the 2012 Rolls‑Royce acquisition agreement, RTX’s flight‑hour payments to Rolls‑Royce remain contingent on hours flown on V2500‑powered aircraft through June 2027, but the company’s disclosed commitment schedule shows a lower future outflow—“Other commercial aerospace commitments” fell from $11.0 bn (2022) to $10.0 bn (2023), with the 2022‑2023 payment windows shifted to later years (2024‑2028). These payments are accounted for as collaboration intangible assets and are capitalized when the cash outflow occurs, rather than being expensed, so the revised schedule only changes the timing and amount of the capitalized intangible assets.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states there was no change in the magnitude or timing of RTX's payment obligations between 2022 and 2023, but the LLM claims a reduction in 'Other commercial aerospace commitments' from $11.0 bn (2022) to $10.0 bn (2023) and a shift in payment windows from 2022–2023 to 2024–2028—information not supported by the original answer. These specific dollar amounts and timing shifts are entirely fabricated or misattributed. (2) The quantitative inaccuracies are severe: the $1.0 bn decrease and reallocation of payment periods are not mentioned in the ground truth, which explicitly states there was 'no indication of a change in the magnitude or timing' of obligations. These numbers contradict the original answer and introduce false precision. (3) While the LLM correctly identifies the contingent nature of payments tied to flight hours on V2500-powered aircraft through June 2027 and the capitalization of payments as collaboration intangible assets, it fails the multi-hop reasoning by incorrectly inferring a change in commitment levels over time. The model synthesizes non-existent trends from what the ground truth describes as a stable structure. (4) Contextually, the answer addresses the right topic and accounting treatment, hence a moderate relevance score, but the core claim about evolving payment obligations is factually wrong, dragging down correctness and quantitative accuracy. The qualitative score reflects partial understanding of the mechanism but flawed evolution analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 435,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has The Coca-Cola Company's financial relationship with fairlife evolved from 2022 to 2024, particularly regarding contingent payments tied to performance milestones?",
      "original_answer": "In 2022, Coca-Cola's acquisition-related disclosures referenced the 2020 acquisition of the remaining ownership interest in fairlife, with no mention of ongoing contingent payments. By 2024, the company disclosed that there was a remaining milestone payment related to the 2020 acquisition of fairlife, contingent on fairlife achieving certain financial targets through 2024, with the payment scheduled for 2025. This indicates that Coca-Cola's relationship with fairlife has evolved from a completed acquisition in 2020 to one where a performance-linked financial obligation remains active through 2024.",
      "llm_answer": "\nFrom 2022 through 2024 Coca‑Cola has continued to carry the contingent consideration that arose from its 2020 acquisition of the remaining interest in fairlife; the payment is tied to fairlife achieving specified financial performance milestones by the end of 2024, with any earned amount scheduled for settlement in 2025.  The company re‑measures this liability each quarter, and the 2024 filing shows its fair‑value has risen to roughly $6.1 billion (up from about $3.0 billion in 2023), reflecting updated expectations of milestone achievement.  Thus, while the structural milestone‑based payment remains in place, the estimated financial obligation has evolved upward as the company updates its fair‑value estimates.",
      "correctness_score": 3,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies, particularly in quantitative details. The ground truth states that Coca-Cola disclosed a remaining milestone payment tied to fairlife's performance through 2024, with payment due in 2025, but does not mention any specific dollar amount, let alone $6.1 billion or $3.0 billion. These figures are entirely fabricated and grossly misrepresent the financial obligation. There is no indication in the original answer that the contingent liability was re-measured quarterly or that its fair value increased. (2) The numbers cited—$6.1 billion and $3.0 billion—are not present in the ground truth and are implausible for a contingent payment related to fairlife, especially given Coca-Cola's overall financial context. This severe quantitative inaccuracy undermines the entire response. (3) While the LLM correctly identifies the multi-hop structure—linking the 2020 acquisition to ongoing contingent payments through 2024 and a 2025 payout—it incorrectly implies ongoing financial revaluation and growing liability, which is not supported by the original answer. The reasoning is partially sound in tracking the timeline and structure of the contingent payment, but the added financial details reflect a failure in synthesis. (4) The contextual relevance is high because the answer addresses the evolution of the financial relationship and the nature of contingent payments. However, the correctness score is low due to the invention of large-scale financial data not present in the source, making the answer misleading despite some structural accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 442,
        "total_tokens": 1779
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has Oracle's strategic positioning of Oracle Cloud Services evolved between 2022 and 2024, particularly in terms of integration with enterprise applications and infrastructure technologies?",
      "original_answer": "In 2022, Oracle emphasized the transformational potential of Oracle Cloud Services, particularly highlighting the Oracle Autonomous Database as a key OCI offering that utilized machine learning to enable leaner business processes and automation. The focus was on flexibility, interoperability, and customer choice across deployment models, including cloud-based, hybrid, and on-premise environments. By 2024, Oracle expanded this positioning by describing Oracle Cloud Services (including SaaS and OCI) as comprehensive and integrated offerings that provide customers with a full suite of applications and infrastructure services. The 2024 filing explicitly frames Oracle Cloud Services as enabling customers to 'choose the best option that meets their specific business needs,' indicating a more mature and customer-centric strategic approach. This evolution reflects a shift from promoting individual innovations (e.g., Autonomous Database) to positioning Oracle Cloud Services as a holistic, integrated platform for enterprise IT transformation.",
      "llm_answer": "\nBetween fiscal 2022 and 2024 Oracle moved from positioning its Cloud Services mainly as a flexible, choice‑driven complement to on‑premise and hybrid deployments toward a tightly‑integrated, end‑to‑end cloud platform.  The company now markets Oracle Cloud SaaS (e.g., Fusion ERP, HCM, SCM) as native services that run on Oracle Cloud Infrastructure (OCI), using technologies such as the Autonomous Database and OCI‑based engineering to embed application‑level functionality directly within the infrastructure layer, and it has launched programs that encourage customers to migrate existing on‑premise licenses and workloads to the cloud.  This evolution is reflected in the growing share of cloud services and license‑support revenue (≈ 71 % of total revenue) and in sustained R&D and acquisition spending aimed at deepening the coupling of enterprise applications with OCI‑based infrastructure.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly captures Oracle's strategic evolution from 2022 to 2024: starting with a focus on flexibility and deployment choice (hybrid, on-premise) and progressing toward a more integrated, end-to-end cloud platform. The mention of Oracle Cloud SaaS (Fusion ERP, HCM, SCM) running natively on OCI and leveraging Autonomous Database and OCI-based engineering reflects the correct integration of enterprise applications and infrastructure, as emphasized in the 2024 positioning. The claim about encouraging migration of on-premise workloads to the cloud is consistent with Oracle's customer-centric, full-suite narrative. The quantitative figure of ~71% of total revenue coming from cloud services and license-support is factually plausible and consistent with Oracle's reported trends, though the exact percentage is not present in the ground truth; however, since the original answer does not provide revenue figures, this addition does not contradict it and reflects reasonable inference from public trends. No calculation errors are present. The reasoning is sound, demonstrating multi-hop synthesis across time (2022 vs 2024), product layers (applications and infrastructure), and strategic themes (integration, migration programs). The LLM slightly exceeds the original by adding revenue context and specific SaaS product names, but these enhance rather than distort the answer. Semantic equivalence is strong: both answers describe a shift from promoting standalone innovations to a holistic, integrated platform. The only minor deduction is for introducing a specific revenue percentage not in the source, though it is contextually reasonable. All entities (Oracle, OCI, Autonomous Database, Fusion apps) and years (2022–2024) are correct. The answer is fully relevant and directly addresses the evolution in strategic positioning as requested.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1497,
        "completion_tokens": 517,
        "total_tokens": 2015
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How has the treatment or status of the Key/Specified Employee Policy evolved between the 2023 and 2024 SEC filings, particularly in terms of its documentation and incorporation by reference?",
      "original_answer": "In the 2023 filing, the Key/Specified Employee Policy was introduced as part of the company's disclosures, specifically incorporated by reference to Exhibit 10(v) from the Annual Report on Form 10-K for the year ended December 31, 2018. By 2024, the policy was no longer newly introduced but was instead announced as a continuing policy, still relying on the same Exhibit 10(v) from the 2018 filing. This indicates that while the policy remained in place, there were no new amendments or updates to its documentation during this period.",
      "llm_answer": "\nThe Key/Specified Employee Policy continues to be disclosed only as Exhibit 10(r)* and is incorporated by reference to the same 2018 filing (Exhibit 10(v) of the 2018 Form 10‑K) in both the 2023 and the 2024 SEC filings. Neither filing adds a new standalone document or amends the incorporation method—the policy remains referenced solely through that exhibit number, indicating a stable, unchanged treatment between the two years.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is mostly correct in terms of factual content and conveys that the Key/Specified Employee Policy was consistently incorporated by reference to Exhibit 10(v) from the 2018 Form 10-K in both 2023 and 2024, with no new amendments or standalone documents added. This aligns with the ground truth regarding the stable documentation and incorporation method. However, there is a discrepancy in exhibit labeling: the LLM refers to 'Exhibit 10(r)*' as the current exhibit reference, while the original answer and ground truth only mention Exhibit 10(v) from the 2018 filing being reused by reference. This inconsistency raises questions about exhibit numbering accuracy, potentially confusing the reader about whether the exhibit label changed or if there's a typo. While the core reasoning about continuity and lack of updates is sound and the dates (2018, 2023, 2024) are correct, the introduction of 'Exhibit 10(r)*' not present in the ground truth constitutes a minor factual error in entity accuracy. The answer correctly identifies the multi-hop element—that the same historical exhibit continues to be referenced across two recent filings—but slightly misrepresents the exhibit identifier, which affects precision. Wording and semantic meaning are otherwise equivalent, and the conclusion about unchanged treatment is valid.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1253,
        "completion_tokens": 370,
        "total_tokens": 1623
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How did the aggregate principal balance of the 6.700% notes due 2028 evolve between 2022 and 2023, and what does this indicate about RTX's debt management strategy?",
      "original_answer": "In 2022, the aggregate principal balance of the 6.700% notes due 2028 was $115 million. By 2023, this amount increased significantly to $285 million. This indicates that RTX increased its outstanding debt related to this particular note, suggesting a strategic decision to retain or expand exposure to this fixed-rate debt instrument.",
      "llm_answer": "\nThe 6.700 % notes maturing in 2028 showed essentially no change in outstanding principal between the end of 2022 and the end of 2023 – the balance remained $285 million in both years.  This follows the company’s earlier repayment of $115 million of the issue in 2021, after which the remaining tranche was carried at a modest level and was not refinanced with a new 2028‑dated series.  The flat‑line balance reflects RTX’s strategy of retiring higher‑cost legacy debt and managing its overall leverage by letting older tranches amortize rather than issuing new comparable notes.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in both direction and magnitude. The ground truth states the aggregate principal balance increased from $115 million in 2022 to $285 million in 2023, indicating an increase of $170 million. The LLM claims the balance was $285 million in both years, implying no change, which contradicts the ground truth. (2) Quantitative accuracy is severely lacking: the LLM misstates both the 2022 value (claims $285M vs. correct $115M) and asserts no change when there was a significant increase. The mention of a $115M repayment in 2021 is not supported by the provided ground truth and introduces unverified information. (3) The multi-hop reasoning is flawed: instead of recognizing the increase as a strategic expansion of fixed-rate debt, the LLM incorrectly infers a strategy of debt retirement and non-refinancing, based on false premises. (4) Contextual relevance is partially present as the answer discusses RTX's debt management, but the reasoning is built on incorrect data, leading to an invalid conclusion. The answer fails on correctness due to major factual and numerical errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1232,
        "completion_tokens": 322,
        "total_tokens": 1554
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How did the carrying value and effective interest rate of TMO's 1.95% 12-Year Senior Notes evolve between 2023 and 2024?",
      "original_answer": "In 2023, the carrying value of the 1.95% 12-Year Senior Notes was $773 million with an effective interest rate of 2.08%. In 2024, the carrying value decreased to $725 million, and the effective interest rate slightly declined to 2.07%. This indicates a reduction in the financial liability associated with these notes and a marginal improvement in the effective borrowing cost.",
      "llm_answer": "\nBetween the end of 2023 and the end of 2024 the company’s 1.95 % 12‑year senior notes (due 7/24/2029, euro‑denominated) saw their carrying amount fall from **$773 million to $725 million**—a reduction of roughly **$48 million**.  At the same time the effective interest rate attached to those notes slipped slightly from **2.08 % to 2.07 %**.  This decline reflects both the amortization of the note discount (and related issuance costs) and the modest change in the underlying market rates that determine the effective rate.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: the carrying value decreased from $773 million in 2023 to $725 million in 2024, and the effective interest rate declined from 2.08% to 2.07%. The $48 million reduction is correctly calculated ($773M - $725M = $48M). (2) The answer addresses both parts of the question—evolution of carrying value and effective interest rate—over the specified time period (2023 to 2024), demonstrating completeness. (3) Entity accuracy is correct: TMO's 1.95% 12-Year Senior Notes are properly identified, and the time frame aligns with the question. The mention of the euro-denomination and maturity date (7/24/2029) adds contextual detail not required but factually consistent. (4) The reasoning is sound: the explanation that the decline reflects amortization of discount/issuance costs and minor market rate changes is a reasonable qualitative interpretation supported by accounting principles for debt instruments, even if not in the original answer. This shows strong multi-hop synthesis and understanding. (5) Semantic equivalence is achieved—the LLM conveys the same core facts and implications as the original answer, with enhanced detail. All scores are maximized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1219,
        "completion_tokens": 357,
        "total_tokens": 1576
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "What are the corporate governance implications of the change in how BNY Mellon presents its Directors' Code of Conduct between its 2022 and 2024 SEC filings?",
      "original_answer": "In 2022, BNY Mellon explicitly detailed the availability of the Directors' Code of Conduct on its website with a direct URL link, and it was referenced within the broader context of corporate governance disclosures and ethics policies. By 2024, the Code was listed among other governance materials—such as committee charters and by-laws—without a direct link or specific mention of updates or amendments. This shift in presentation may signal a more streamlined or consolidated approach to governance disclosures, potentially reducing the visibility of the Code as a standalone document. While the Code remains accessible, the change could affect transparency and stakeholder engagement with the specific ethical expectations for directors, which may influence perceptions of governance accountability.",
      "llm_answer": "\nThe 2022 filing listed the Directors’ Code of Conduct as a separate, downloadable PDF and expressly pledged to post any amendments or waivers of that code on the company website, whereas the 2024 filing merges the directors’ code into the broader “Code of Ethics” and removes the separate waiver disclosure language. This consolidation signals a shift toward a more streamlined governance disclosure that centralises board‑level standards under a single ethics document, potentially reducing the visibility of board‑specific rules and any future waivers. From a corporate‑governance perspective, the change may reflect a move to simplify reporting but could be seen as lowering the transparency of board‑level conduct and the company’s commitment to publicly disclose board‑specific modifications.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but introduces significant factual inaccuracies not present in the ground truth. (1) Correct elements: The answer correctly identifies a change in presentation between 2022 and 2024 filings and discusses potential governance implications around transparency and visibility. The years (2022 and 2024) are accurate, and the focus on disclosure practices is relevant. (2) Quantitative accuracy: There are no numeric values to verify, but the temporal references (2022 vs. 2024) are correct. (3) Multi-hop reasoning: The model attempts to synthesize changes across filings, but the reasoning is based on incorrect premises. Crucially, the ground truth states that the Directors' Code of Conduct remains a distinct document in 2024, merely listed among other governance materials without a direct link. The LLM incorrectly claims that the code was 'merged into the broader Code of Ethics' and that it is no longer separate—this is a major factual error. Additionally, the ground truth does not mention any removal of 'waiver disclosure language,' nor does it state the code was available as a 'separate downloadable PDF' in 2022; it only mentions a direct URL and explicit reference. These are fabrications or misrepresentations. (4) The answer is contextually relevant and raises valid governance concerns about transparency and accountability, but the flawed factual foundation undermines the qualitative accuracy. The conclusion about reduced visibility is partially aligned with the ground truth, but the reasoning is based on incorrect consolidation claims. Thus, while the direction of analysis is reasonable, the factual inaccuracies significantly reduce correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1402,
        "completion_tokens": 462,
        "total_tokens": 1865
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has Amazon's Short-Term Credit Agreement evolved between 2023 and 2024, particularly in terms of facility size, maturity date, and the timing of its establishment?",
      "original_answer": "In 2023, Amazon entered into a $5.0 billion unsecured 364-day revolving credit facility (Short-Term Credit Agreement) in November, replacing the prior agreement from November 2022, with a maturity date in October 2024. In 2024, Amazon again entered into a new $5.0 billion unsecured 364-day revolving credit facility in October, replacing the 2023 agreement, with a maturity date in October 2025. The facility size remained the same at $5.0 billion, but the establishment date shifted from November to October, and the maturity date moved forward by one year, indicating a procedural renewal rather than a substantive change in the credit structure.",
      "llm_answer": "\nBetween 2023 and 2024 Amazon replaced its 364‑day revolving credit facility twice. The first $5 billion facility was entered into in November 2023 and was set to mature in October 2024; it was then swapped for a second $5 billion 364‑day revolving facility in October 2024, which now matures in October 2025 (with a one‑year extension option) and was established later in the year. Thus, the commitment size stayed at $5 billion, but the maturity date was pushed forward by roughly one year and the new agreement was launched in October 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the essential information from the ground truth. (1) All key facts are correct: the $5.0 billion facility size in both years, the November 2023 establishment and October 2024 maturity, and the October 2024 renewal with a maturity in October 2025. The shift in timing from November to October is correctly noted. (2) Quantitative accuracy is perfect: dollar amounts ($5 billion), dates (November 2023, October 2024, October 2025), and the 364-day term are all correctly reported. The optional one-year extension mentioned in the LLM answer is a minor addition not in the original answer, but it does not contradict it and may reflect supplementary knowledge; however, since it's not in the ground truth, it slightly affects qualitative precision. (3) Multi-hop reasoning is sound: the model correctly synthesizes the renewal pattern across 2023 and 2024, compares facility size, timing, and maturity, and infers procedural renewal. (4) The answer is contextually relevant and fully addresses the question’s focus on evolution in facility size, maturity, and establishment timing. The only minor deviation is the mention of a 'one-year extension option' not present in the original, which slightly reduces qualitative accuracy but does not undermine correctness. Overall, the answer is factually aligned and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 385,
        "total_tokens": 1688
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has AMD's APU strategy evolved from 2022 to 2024 in terms of product integration and target markets, and what implications does this shift have for its revenue potential in the AI PC segment?",
      "original_answer": "In 2022, AMD emphasized external GPU-based solutions for AI and HPC workloads, particularly through the Instinct MI200 series and Radeon PRO V620 GPUs, focusing on data center and cloud applications. By 2024, AMD had shifted toward integrating dedicated AI acceleration directly into client devices, becoming the first company to include a dedicated neural processing unit (NPU) on the same SoC as an x86 CPU for AI PCs. This strategic pivot toward integrated APUs with NPU cores indicates a move to capture revenue growth in the emerging AI PC market, where on-device AI processing is becoming critical. This evolution likely enhances AMD's revenue potential by positioning it as a differentiated player in the AI PC segment, moving beyond traditional CPU-GPU combinations.",
      "llm_answer": "\nFrom 2022 to 2024 AMD shifted its APU roadmap from a pure CPU‑GPU balance aimed at mainstream consumer and gaming notebooks toward a heterogeneous‑compute platform that adds a dedicated neural‑processing unit, AI‑optimized software (ROCm, FidelityFX) and tighter integration with Zen 5/Zen 5‑based cores and 3‑D V‑Cache.  This integration expands the target market from traditional desktops and laptops to “AI‑PC” and commercial segments—including enterprise laptops, data‑center‑adjacent workloads and semi‑custom designs—while preserving the cost‑efficiency of a single‑chip solution.  Consequently, AMD can tap a higher‑margin, rapidly growing AI‑PC opportunity, but it also faces stiffer competition and must secure software‑ecosystem adoption to translate the broader market reach into sustainable revenue growth.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of AMD's strategic shift from 2022 to 2024. It accurately captures the evolution from CPU-GPU integration in APUs to incorporating dedicated NPUs for AI acceleration, which reflects the core of AMD's pivot toward AI PCs. The mention of Zen 5 and 3D V-Cache, while more detailed than the original answer, is consistent with AMD's 2024 roadmap and adds context without introducing inaccuracies. There are no numeric values in the question or answers, so quantitative accuracy is scored as 10 by default. The answer correctly identifies the shift in target markets—from consumer and gaming to AI-PC and commercial segments—matching the ground truth's emphasis on enterprise and on-device AI. However, the LLM omits the specific contrast in 2022 strategy being focused on external GPUs (Instinct MI200, Radeon PRO V620) for data center/cloud, which is a key multi-hop element in the original answer. While it implies a shift, it does not explicitly state that AMD previously relied on discrete GPUs rather than integrated NPUs, slightly weakening the comparative reasoning. The implications for revenue potential are well-articulated, noting higher-margin opportunities and competitive challenges, which complements the original answer’s point about enhanced revenue potential through differentiation. Overall, the answer is semantically equivalent in intent and mostly accurate in reasoning, but loses minor points for not fully synthesizing the 2022 external-GPU focus as a contrast to 2024’s integrated NPU strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1410,
        "completion_tokens": 435,
        "total_tokens": 1846
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has the treatment of Irish income tax liability for U.S. shareholders receiving dividends from Medtronic evolved between 2023 and 2024, particularly in relation to the Irish dividend withholding tax?",
      "original_answer": "In both 2023 and 2024, dividends paid by Medtronic were generally subject to Irish dividend withholding tax at a rate of 25 percent unless an exemption applied. For U.S. residents, exemptions were available based on residency documentation, such as a valid U.S. Certification of Residence (Form 6166) or Irish Non-Resident Form V2. In both years, a U.S. resident who met the exemption criteria and did not hold shares through an Irish branch generally had no Irish income tax liability. Additionally, if a U.S. shareholder was subject to the 25% withholding tax, the payment discharged any Irish income tax liability, provided the shareholder submitted the required statement to the Irish Revenue authorities. There was no change in the tax rate or in the conditions for exemption between the years, indicating a stable regulatory framework.",
      "llm_answer": "\nThe 2024 10‑K contains essentially the same Irish‑tax framework that was set out in the 2023 filing: Irish dividends remain subject to a 25 % withholding tax, but U.S. shareholders can avoid that tax if they satisfy the DTC‑address or Form 6166/V2 certification requirements, and the withholding payment then discharges any Irish income‑tax liability.  No new exemptions, rates, or procedural changes were introduced between fiscal years 2023 and 2024—the treatment of Irish dividend withholding tax for U.S. shareholders stayed consistent.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same essential information as the ground truth. (1) All key facts are correct: the 25% Irish dividend withholding tax rate is accurately stated, and the availability of exemptions for U.S. shareholders via Form 6166 or Irish Form V2 is correctly noted. The statement that withholding tax discharge eliminates further Irish income tax liability is consistent with the original. (2) Quantitative accuracy is perfect: the 25% rate is correct, and no erroneous numbers are introduced. (3) The reasoning is sound—LLM correctly identifies that there was no change between 2023 and 2024 in tax treatment, reflecting stable policy, which aligns with the multi-hop requirement to compare across years. It synthesizes the continuity of rules across filings. (4) Minor point: the mention of 'DTC-address' is not in the original and slightly narrows the exemption criteria—while likely referring to depository-level processing, it’s not as clearly tied to individual certification as in the ground truth. However, this does not materially distort the outcome. Overall, the answer is semantically equivalent, highly relevant, and factually correct, warranting a 9 due to slight imprecision in describing exemption mechanisms.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 352,
        "total_tokens": 1711
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has the risk disclosure around new products and services evolved between 2022 and 2024, particularly regarding the company's platforms operating model initiative?",
      "original_answer": "In 2022, BNY Mellon highlighted that new lines of business, new products and services, or transformational or strategic project initiatives subject the company to new or additional risks. By 2024, this risk disclosure evolved to specifically include the 'transition to a platforms operating model' as a new source of uncertainty. The 2024 filing explicitly states that the company 'may not realize some or all of the expected benefits of our transition to a platforms operating model,' indicating a more focused risk related to this specific strategic initiative. This evolution shows a shift from general strategic risk language to a more concrete acknowledgment of platform-specific implementation risks.",
      "llm_answer": "\nBetween the 2022 and 2024 Form 10‑K filings, BNY Mellon’s risk discussion shifted from a brief, generic reference to “new lines of business, new products and services or transformational or strategic project initiatives” (2022) to a more explicit, dedicated risk factor that highlights the **platforms operating‑model transformation** and the specific dangers of failing to execute it (2024).  The 2024 filing expands the language to note that the company may not realize the expected benefits of the platforms operating model and that any shortfall could materially affect its results of operations, reflecting a heightened focus on the risks tied to new products, services and the ongoing platform redesign.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: the 2022 risk disclosure is accurately described as generic, referencing new business lines, products, services, and strategic initiatives; the 2024 evolution is correctly identified as including the 'platforms operating model' as a specific risk, with the added detail that expected benefits may not be realized. (2) There are no numeric values (e.g., dollar amounts, percentages) in the original or LLM answer, so quantitative accuracy is not applicable—scored as 10 by default since no errors exist. (3) The multi-hop reasoning is sound: the model correctly synthesizes risk disclosures across two years and identifies the shift from general to specific risk language around the platforms operating model. The LLM adds a relevant detail—'materially affect its results of operations'—which is consistent with typical 10-K risk language and plausible in context, though not explicitly mentioned in the ground truth. This addition does not contradict but slightly extends the original answer. (4) The answer is contextually fully relevant, directly addressing the evolution of risk disclosures regarding new products/services and the platforms operating model. The only reason for not scoring a perfect 10 is that the LLM slightly over-enhances by adding the 'material effect' clause without explicit confirmation in the ground truth, though this is a minor issue. Overall, the semantic meaning, entity accuracy (BNY Mellon, 2022, 2024, platforms operating model), and reasoning are excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 438,
        "total_tokens": 1797
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has Amazon's relationship with the 3.600% Note due 2032 evolved between 2023 and 2024, particularly in terms of its debt instrument disclosures?",
      "original_answer": "In 2023, the 3.600% Note due 2032 was disclosed as part of a Supplemental Indenture dated April 13, 2022, among Amazon.com, Inc., Wells Fargo Bank, National Association (as prior trustee), and Computershare Trust Company, National Association (as successor trustee). In 2024, the same note was referenced under the same Supplemental Indenture, but the trustee structure now only referenced Computershare Trust Company, National Association, as successor trustee, indicating a formal transition away from Wells Fargo Bank. This reflects a procedural evolution in the administration of the note, with no changes to the note’s terms or interest rate, but a shift in the trustee relationship.",
      "llm_answer": "\nBetween 2023 and 2024 Amazon continued to disclose the 3.600 % Note due 2032 in the same location—Exhibit 4.2 of its Form 10‑K filings—where it is presented as part of the Supplemental Indenture dated April 13 2022.  The company made no material change to the note’s terms or outstanding balance; the 2024 filing simply updates the exhibit list and re‑incorporates the identical disclosure by reference, confirming that the 3.600 % Note remains outstanding without any amendment or new issuance.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the 3.600% Note due 2032 and its inclusion under the Supplemental Indenture dated April 13, 2022, with consistent disclosure in Amazon's 10-K filings between 2023 and 2024. The note’s terms, interest rate, and lack of amendment are accurately conveyed. However, the LLM omits a key qualitative evolution highlighted in the ground truth: the trustee transition from Wells Fargo Bank, National Association (prior trustee) to Computershare Trust Company, National Association (successor trustee), and the fact that by 2024, only Computershare is referenced, indicating a formal administrative shift. This procedural change in trustee relationship is a central part of the 'evolution' asked in the question. (2) Quantitatively, all dates (April 13, 2022), percentages (3.600%), and years (2032 maturity) are correct. No calculations are required, and the LLM accurately references Exhibit 4.2 and Form 10-K filings. (3) The reasoning is sound in recognizing continuity in disclosure and absence of changes to the note’s terms, but it fails to synthesize the multi-hop detail about the trustee transition, which requires connecting information across the 2023 and 2024 disclosures regarding the parties to the indenture. This is a significant omission in the qualitative evolution of the relationship. (4) The answer is contextually relevant and well-structured, focusing on the right document and exhibit, but the missing trustee detail reduces completeness and qualitative accuracy, preventing a higher score. The core facts are correct, but the full scope of the relationship evolution is not addressed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 450,
        "total_tokens": 1746
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How did MDLZ's treatment and disclosure of net investment hedge derivative contracts evolve from 2023 to 2024, particularly in terms of their financial impact and presentation within the financial statements?",
      "original_answer": "In 2023, MDLZ disclosed the fair value of derivative assets and liabilities associated with net investment hedge contracts, with $1,347 million and $377 million in other current assets and $250 million and $413 million in other assets as of December 31, 2023 and 2022, respectively. By 2024, the focus shifted to the income statement impact, where the company noted that 'Other income, net' included amounts excluded from the assessment of hedge effectiveness related to these contracts, indicating a change in emphasis from balance sheet valuation to income volatility effects.",
      "llm_answer": "\nIn the 2023 filing the net‑investment hedge derivatives were shown only as part of the overall derivative balances—$163 million of asset derivatives and $382 million of liability derivatives at fair value—with their periodic gains/losses recorded in accumulated other‑comprehensive income and re‑classified to earnings only when the hedged investment was settled. By the 2024 filing the same contracts are disclosed in a dedicated “Net investment hedge derivative contracts” table, reporting a much smaller liability ($50 million) and a larger asset ($305 million) at fair value, and the note now explicitly breaks out the after‑tax OCI gain/loss, the Level 1/2 valuation inputs, and the amount that will be re‑classified to earnings, providing a clearer view of hedge effectiveness and financial impact.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in numbers and misrepresents the evolution of MDLZ's disclosure. The ground truth states that in 2023, MDLZ reported $1,347 million and $377 million in other current assets and $250 million and $413 million in other assets as of December 31, 2023 and 2022 respectively — none of which are reflected in the LLM answer. Instead, the LLM claims $163 million in asset derivatives and $382 million in liability derivatives for 2023, which contradicts the ground truth. For 2024, the LLM reports a $305 million asset and $50 million liability, but the original answer does not provide 2024 balance sheet values at all — so this cannot be verified and appears fabricated. (2) Quantitative accuracy is very low: none of the dollar amounts match the ground truth, and there is no mention of the correct figures such as $1,347 million or $250 million. The LLM invents a 'dedicated table' and specific fair values not supported by the original. (3) The qualitative reasoning partially captures a shift in disclosure focus — from balance sheet presentation in 2023 to income statement impact in 2024 — which aligns with the ground truth’s emphasis on a change from balance sheet valuation to income volatility effects. However, the LLM incorrectly frames the 2023 data as being 'only part of overall derivative balances' and introduces details like 'Level 1/2 valuation inputs' and 'after-tax OCI gain/loss' that are not in the original answer, suggesting over-interpretation or hallucination. (4) Contextual relevance is moderate because the answer attempts to address the evolution of disclosure and financial impact, but fails on factual correctness. The core idea of increased transparency and changing emphasis has some merit, but the lack of accurate data and incorrect specifics severely undermines the response. Correctness score is low due to major quantitative errors and unsupported claims, despite a partially correct directional insight.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1361,
        "completion_tokens": 541,
        "total_tokens": 1902
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has the Abrams Main Battle Tank's modernization strategy evolved from 2023 to 2024, particularly in terms of technological development and international demand?",
      "original_answer": "In 2023, General Dynamics was focused on delivering the System Enhancement Package version 3 (SEPv3) for the Abrams tank, which included upgrades in communications, power generation, fuel efficiency, optics, and armor. Additionally, GD announced the development of the M1E3 Abrams, a more significant engineering change aimed at future threats, featuring the latest systems architecture for quicker upgrades and reduced sustainment footprint. By 2024, the company emphasized continued capability enhancement of the Abrams to counter current and potential threats, with increased international demand reflected in a growing installed base across Europe, the Middle East, North Africa, and the Indo-Pacific. While 2023 focused on the technical roadmap (SEPv3 and M1E3), 2024 highlighted the global strategic relevance and procurement momentum of the Abrams platform.",
      "llm_answer": "\nFrom 2023 to 2024 the Abrams modernization moved from introducing the SEPv3 “system‑enhancement package” – which adds upgraded communications, power generation, fuel‑efficiency, optics and armor – and launching the next‑generation M1E3 engineering‑change variant aimed at faster tech refreshes and lower sustainment costs – to a sustained focus on meeting strong overseas demand.  The 2024 disclosures highlight that NATO allies and partners in Europe, the Middle East, North Africa and the Indo‑Pacific are increasingly procuring and upgrading Abrams tanks, reinforcing the program’s international market and prompting continued production of SEPv3 upgrades and further development of the M1E3 configuration.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the SEPv3 upgrades (communications, power generation, fuel efficiency, optics, armor) and the M1E3's purpose (faster tech refreshes, reduced sustainment) are accurately described. The shift from 2023's technical roadmap to 2024's focus on international demand across Europe, the Middle East, North Africa, and the Indo-Pacific is correctly captured. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages, unit counts), so quantitative accuracy is not compromised—no errors in dates (2023 vs 2024) or program names. (3) Multi-hop reasoning is sound: the model synthesizes the evolution of modernization strategy across two years, linking technological development (SEPv3 and M1E3) with shifting emphasis toward global procurement trends. (4) The only minor shortcoming is that the LLM does not explicitly mention the 'latest systems architecture for quicker upgrades' as a feature of the M1E3, which is in the original answer—this is a small omission in technical detail, but the essence (faster tech refreshes) is conveyed. Overall, the answer is semantically equivalent, well-structured, and fully relevant to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1398,
        "completion_tokens": 353,
        "total_tokens": 1751
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has AMD's role in the development and positioning of APUs evolved between 2022 and 2024, particularly in terms of their market segmentation and strategic emphasis?",
      "original_answer": "In 2022, APUs were discussed as part of AMD's broader Enterprise, Embedded and Semi-Custom product portfolio, which included CPUs, GPUs, and customized SoC products. They were described in general terms without specific market segmentation or strategic emphasis. By 2024, APUs were explicitly included in two of AMD's four reportable segments: the Data Center segment and the Client segment. In the Data Center segment, APUs were listed alongside AI accelerators, CPUs, GPUs, and DPUs, indicating a strategic shift to position APUs as part of data center solutions. In the Client segment, APUs were specifically tied to desktop and notebook CPUs and chipsets, showing a more defined and segmented approach to their market positioning. This evolution reflects a more structured and strategic integration of APUs into AMD's core business segments.",
      "llm_answer": "\nBetween 2022 and 2024 AMD expanded the APU’s role from a primarily client‑segment, value‑oriented solution for mainstream and commercial notebooks (integrated CPU‑GPU chips for cost‑effective PCs) to a heterogeneous‑computing platform that spans client, commercial‑PRO, embedded and even data‑center markets.  The company increasingly positioned APUs as AI‑ready, RDNA 2‑based graphics engines and as the core of semi‑custom designs (e.g., PlayStation 5, Xbox Series X/S, Steam Deck), emphasizing balanced CPU‑GPU performance and software ecosystems across all segments.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of AMD's APU strategy but introduces significant inaccuracies and unsupported claims not present in the ground truth. (1) Correct elements: The idea that APUs expanded beyond client devices and are used in semi-custom designs (e.g., gaming consoles) aligns broadly with AMD's product scope. Mentioning integration of CPU and GPU and use in notebooks/desktops is consistent. (2) Quantitative accuracy: There are no specific numbers (dates, dollar amounts, percentages) in either answer, so no factual numeric errors—score is 10. (3) Multi-hop reasoning issues: The ground truth states that in 2022, APUs were part of a broader 'Enterprise, Embedded and Semi-Custom' category without specific segmentation, and by 2024 were explicitly included in the Data Center and Client segments. The LLM answer overreaches by claiming APUs expanded into 'data-center markets' and are 'AI-ready' platforms, which is not supported by the original answer—APUs were listed in the Data Center segment alongside AI accelerators but not explicitly positioned as AI accelerators themselves. Also, 'RDNA 2-based graphics engines' and 'commercial-PRO' are specific technical and market claims absent from the source. (4) The answer adds plausible but unverified details (e.g., Steam Deck, RDNA 2, AI-ready) not in the original, reducing qualitative accuracy. While the direction of evolution (broader strategic role, segmentation) is partially correct, the specific market segmentation and strategic emphasis described in the LLM answer do not match the documented shift in reportable segments. Thus, correctness is partially accurate but contains significant embellishments, warranting a 6.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 464,
        "total_tokens": 1823
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has Medtronic's disclosure regarding the implications of the Financial Transfers Act 1992 on financial transfers between Ireland and third countries evolved from 2023 to 2024?",
      "original_answer": "In 2023, Medtronic disclosed that the Financial Transfers Act 1992 allowed the Irish Minister for Finance to impose restrictions on financial transfers with certain third countries, and that the list of such countries was subject to ongoing change. By 2024, the company continued to disclose the same regulatory framework but no longer emphasized the dynamic nature of the list of restricted countries, suggesting a potential shift in focus or a stabilization in the regulatory environment affecting these transfers.",
      "llm_answer": "\nFrom 2023 to 2024 Medtronic’s description of the Irish Financial Transfers Act 1992 remained essentially the same – the company noted that the Act lets the Irish Minister for Finance restrict capital movements between Ireland and certain third‑country jurisdictions, that a list of those jurisdictions is maintained and “subject to ongoing change,” and that any transfers involving sanctioned governments or entities may be limited.  The 2024 filing did not introduce new restrictions; instead it reiterated the prior position and clarified that, as of the 2024 filing, the list of restricted third countries had not been expanded since the 2023 filing and continues to be monitored for future updates.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the core regulatory framework under the Financial Transfers Act 1992 and accurately states that Medtronic disclosed the Irish Minister for Finance's authority to restrict transfers to certain third countries. It correctly notes that the list of such countries is maintained and subject to change, and that transfers involving sanctioned entities may be limited—this aligns with the 2023 disclosure in the ground truth. However, the LLM introduces a detail not present in the original answer: that in 2024, the list 'had not been expanded since the 2023 filing and continues to be monitored.' While this may seem consistent, the ground truth does not state that the list remained unchanged—only that the company no longer emphasized its dynamic nature, suggesting a shift in disclosure tone or focus. This addition represents an overinterpretation or unsupported inference. The ground truth emphasizes a qualitative shift in emphasis (from 'ongoing change' to less focus on dynamism), whereas the LLM frames it as a factual stabilization with monitoring, which is not explicitly supported. Thus, while the key entities, years, and regulatory context are correct (ensuring high quantitative and contextual scores), the qualitative reasoning slightly misrepresents the nature of the evolution in disclosure, missing the nuance of reduced emphasis versus confirmed stability. This results in a correctness score of 7—core facts are accurate, but the synthesis of the change over time is partially incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 421,
        "total_tokens": 1734
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How did the status and production outlook of the G700 aircraft evolve from 2023 to 2024 based on GD's disclosures?",
      "original_answer": "In 2023, the G700 was described as the next model to join the Gulfstream lineup, with expectations for it to enter service following FAA certification in early 2024. By 2024, the G700 had begun deliveries in the second quarter, indicating that it successfully completed certification and transitioned from development to active production and customer delivery. This marks a clear evolution from a future product to a realized and delivered aircraft model.",
      "llm_answer": "\nThe 2023 filing positioned the G700 as an upcoming ultra‑large‑cabin jet slated to enter service “following FAA certification in early 2024.” By the 2024 filing the aircraft had already been certified and was in production ramp‑up, with deliveries beginning in the second quarter of 2024 and contributing to a noticeable increase in inventories and customer deposits for new Gulfstream models. This shift shows the G700 moved from a planned 2024 entry‑into‑service to an actual, revenue‑generating product in GD’s portfolio.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and fully aligned with the ground truth. (1) It correctly states that in 2023, the G700 was expected to enter service following FAA certification in early 2024, and by 2024, deliveries began in Q2—matching the original answer's timeline. (2) There are no numerical values requiring calculation, but the dates (early 2024 certification, Q2 2024 deliveries) are consistent with the ground truth. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of disclosures to show progression from 'planned' to 'delivered' status, correctly inferring the successful completion of certification and the start of production and deliveries. (4) The LLM adds contextual detail (e.g., impact on inventories and customer deposits) that is plausible and enhances the narrative without contradicting the ground truth. Semantic equivalence is maintained, with slightly richer elaboration. All entities—G700, GD (Gulfstream), FAA, 2023 and 2024 timeframes—are accurately referenced. The answer fully addresses the evolution in status and production outlook as required by the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1237,
        "completion_tokens": 321,
        "total_tokens": 1558
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has the nature of PMI's relationship with KT&G evolved from 2023 to 2024, particularly in terms of strategic dependency and product commercialization?",
      "original_answer": "In 2023, PMI announced a long-term collaboration with KT&G to commercialize KT&G's smoke-free devices and consumables on an exclusive, worldwide basis (excluding South Korea), under a 15-year agreement running through January 29, 2038. This partnership granted PMI exclusive access to KT&G's smoke-free brands and product pipeline, including offerings for low- and middle-income markets. By 2024, this relationship had evolved into a more integrated dependency, as KT&G's heat-not-burn products were explicitly referenced as part of PMI's heat-not-burn product portfolio, indicating a shift from exclusive distribution to inclusion within PMI's broader smoke-free product strategy. This evolution reflects a deeper strategic alignment and operational integration of KT&G's offerings into PMI's product ecosystem.",
      "llm_answer": "\nFrom 2023 to 2024 the PMI‑KT&G tie‑up shifted from the January 2023 renewal of a 15‑year, exclusive worldwide licence (ex‑South Korea) to an active commercialisation phase.  The agreement now runs on a series of three‑year performance‑review cycles that tie confirmed volume targets to continued exclusivity, giving PMI sustained access to KT&G’s smoke‑free brands and product‑innovation pipeline for low‑ and middle‑income markets while requiring PMI to obtain market‑specific regulatory approvals.  As a result, PMI’s strategic dependence on KT&G has deepened – the partnership is now a core driver of PMI’s smoke‑free growth strategy and the primary source of new heated‑tobacco and related products outside South Korea.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of the PMI-KT&G relationship from 2023 to 2024 and correctly identifies the strategic deepening and commercialization focus. However, there are significant factual inaccuracies that reduce correctness. (1) The original agreement was signed on January 29, 2023, and runs through January 29, 2038 — a 15-year term — but the LLM incorrectly states it now operates on 'three-year performance-review cycles,' which is not supported by the ground truth. This misrepresents the contractual structure. (2) The LLM claims exclusivity is 'tied' to volume targets and regulatory approvals, introducing conditions absent in the original answer, thus adding unverified operational mechanics. (3) While the original answer notes KT&G's products were integrated into PMI's portfolio by 2024, the LLM overstates this by calling the partnership the 'primary source' of new heated-tobacco products outside South Korea — a claim not explicitly made in the ground truth. (4) The core facts — exclusivity, global rights (ex-South Korea), 15-year term, access to product pipeline, focus on low- and middle-income markets — are mostly correct, and the direction of evolution (from distribution to deeper integration) is accurately inferred. (5) The reasoning shows multi-hop synthesis (linking 2023 agreement to 2024 strategic role), but introduces unsupported details that compromise quantitative and qualitative accuracy. Wording differences are acceptable, but invented contractual terms and performance mechanisms constitute material errors. Hence, partial credit is given for correct direction and key facts, but significant deductions for fabrication of structural details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 461,
        "total_tokens": 1847
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has AMD's approach to semi-custom SoC products evolved from 2022 to 2024, particularly in terms of their strategic positioning and integration with broader product ecosystems?",
      "original_answer": "In 2022, AMD's semi-custom SoC products were described as being dependent on third-party product success, with revenue tied to both non-recurring engineering fees and the incorporation of AMD's SoCs into customer devices. There was a clear emphasis on the risks associated with this dependency, including the lack of control over third-party marketing and the uncertainty of revenue realization. By 2024, AMD's approach had evolved significantly, with semi-custom SoCs being positioned as core components of a broader, more integrated product ecosystem that includes AI accelerators, CPUs, GPUs, and APUs. The 2024 filing highlights strategic integration with AI capabilities, such as the inclusion of a dedicated neural processing unit (NPU) on the same SoC as an x86 CPU for AI PCs, and the use of semi-custom SoCs in gaming, cloud services, and embedded systems across multiple industries. This reflects a shift from a dependency model to a more proactive, integrated product leadership strategy.",
      "llm_answer": "\nFrom 2022 to 2024 AMD moved away from a single‑foundry, near‑exclusive wafer‑capacity deal (the 2021‑2025 WSA with GF) toward a more flexible, non‑exclusive sourcing model that lets it spread semi‑custom SoC production across multiple fabs—including TSMC’s 7 nm and newer nodes—while still honoring the minimum annual capacity commitments that run through 2025.  This shift lets AMD tie its semi‑custom SoC roadmap directly to the broader “adaptive‑computing” ecosystem it is building, linking the SoCs used in gaming consoles and handhelds to its expanding AI‑focused data‑center, client‑PC and embedded product lines, so that design wins and revenue are contingent on the success of those downstream platforms.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains some accurate contextual elements but diverges significantly from the ground truth in key aspects of strategic evolution. (1) Correct elements include the mention of semi-custom SoCs being linked to broader product lines and design wins depending on downstream platform success, which aligns loosely with the 2024 integration theme. However, the core of the LLM response focuses on foundry strategy (e.g., shift from GlobalFoundries to TSMC, WSA details), which is not mentioned in the original answer and is irrelevant to the question about strategic positioning and ecosystem integration. (2) Quantitatively, the LLM references a '2021-2025 WSA with GF' and '7 nm nodes'—while plausible details, they are not present in the ground truth and cannot be verified from the provided context; no actual numbers (revenue, dates, percentages) from the original answer are included or contradicted, so quantitative accuracy is partially acceptable. (3) The multi-hop reasoning is flawed: instead of tracing the evolution from dependency on third-party success (2022) to integrated ecosystem leadership with AI/NPU integration (2024), the model fabricates a narrative around supply chain and manufacturing partnerships. This misrepresents the strategic shift entirely. (4) Contextual relevance is moderate because it discusses semi-custom SoCs and ecosystem linkage, but the focus on wafer supply agreements and fabrication nodes distracts from the actual evolution in product strategy, AI integration, and ecosystem design highlighted in the original. The absence of any mention of NPUs, AI PCs, or the shift from risk-laden dependency to proactive integration severely undermines qualitative and overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1436,
        "completion_tokens": 469,
        "total_tokens": 1905
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has the treatment of Irish income tax on dividends paid to U.S. residents evolved between 2023 and 2024, particularly regarding exemptions and withholding tax obligations?",
      "original_answer": "In 2023, Medtronic noted that U.S. residents who are exempt from Irish dividend withholding tax generally would not be subject to Irish income tax on dividends unless they had a connection to Ireland beyond shareholding. Additionally, non-residents subject to withholding tax typically had no further Irish income tax liability. In 2024, the company clarified that U.S. residents who qualify for a withholding tax exemption and do not hold shares through an Irish branch generally will not have Irish income tax liability, and those subject to withholding can discharge any further liability by furnishing a statement to Irish Revenue. The 25% withholding tax rate remained unchanged, but the 2024 disclosure provided more structured conditions for exemption and clarified post-withholding tax procedures.",
      "llm_answer": "\nThe 2024 filing confirms that U.S.‑resident shareholders who hold their Medtronic shares through DTC and have a U.S. address on record (or who supply a valid U.S. certification of residence (Form 6166) or Irish Non‑Resident Form V2) are exempt from the 25 % Irish dividend‑withholding tax—exactly the same exemption that applied in 2023.  What changed between the years is mainly clarification: the 2024 disclosure explicitly states that the withholding tax is discharged once the shareholder provides a statement to the Irish Revenue authorities and notes that reliance on the U.S.–Ireland tax treaty is generally unnecessary because the statutory exemption is so broad.  Thus, the practical tax treatment of Irish dividends paid to U.S. residents has not shifted substantively; only the documentation requirements and procedural wording have been refined.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: the 25% Irish dividend withholding tax rate remained unchanged between 2023 and 2024, U.S. residents can be exempt if they meet certain conditions, and those subject to withholding can discharge further liability—consistent with the original answer's note about furnishing a statement to Irish Revenue. The LLM correctly identifies that the core treatment did not change substantively, but procedural clarifications were made in 2024. (2) Quantitatively, the 25% rate is accurately reported, and no incorrect numbers or dates are present. (3) The multi-hop reasoning is sound: the model synthesizes information across years (2023 vs 2024) and entities (Medtronic, Irish tax law, U.S. residents), correctly identifying continuity in tax treatment and evolution in procedural clarity. The mention of Form 6166 and Irish Non-Resident Form V2 adds specificity not in the original answer but is contextually plausible and does not contradict it. (4) The only minor shortcoming is that the original answer emphasizes the 'connection to Ireland beyond shareholding' as a liability trigger, which the LLM omits. While the LLM focuses on documentation and procedural updates, it slightly underrepresents the substantive condition for tax liability in the absence of withholding. However, this does not undermine the overall correctness. Wording differences are within acceptable semantic equivalence. The answer is fully relevant and directly addresses the evolution in exemptions and withholding obligations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1423,
        "completion_tokens": 437,
        "total_tokens": 1860
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How did General Dynamics' financial performance and strategic focus in ship construction change from 2023 to 2024, particularly regarding cost pressures on the Virginia-class and DDG-51 programs and the revenue outlook for the Columbia-class submarine initiative?",
      "original_answer": "In 2023, General Dynamics' Marine Systems segment experienced a 110 basis point decline in operating margin due to supply chain disruptions affecting the Virginia-class submarine schedule and cost overruns on the DDG-51 guided-missile destroyer program. Despite these challenges, revenue from U.S. Navy ship construction rose, driven by increased activity on the Columbia-class submarine program. By 2024, the company projected revenue for the Marine Systems segment to rise to $12.8–12.9 billion with an expected operating margin of approximately 7.6%, suggesting a strategic effort to stabilize and improve profitability. This indicates a shift from cost-driven margin pressure in 2023 to a more optimistic outlook in 2024, likely supported by improved program execution and growth in the Columbia-class program.",
      "llm_answer": "\nFrom 2023 to 2024 General Dynamics’ Marine Systems segment saw revenue jump ≈ 13 % in 2023, driven largely by higher volume on the Columbia‑class submarine program and related Virginia‑class and DDG‑51 work, but operating margin slipped about 110 basis points because supply‑chain cost pressures inflated the estimated costs of the Virginia‑class submarine schedule and the Arleigh Burke‑class (DDG‑51) destroyer program.  The 2024 outlook projects Marine Systems revenue of roughly $12.8‑12.9 billion with an operating margin near 7.6 %, indicating that revenue growth from the Columbia‑class submarine initiative will continue even as the company works to contain cost overruns on the Virginia‑class and DDG‑51 contracts.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth with only minor differences in emphasis. (1) Quantitatively, the LLM correctly states the 110 basis point decline in operating margin in 2023, the $12.8–12.9 billion revenue projection for 2024, and the ~7.6% operating margin target. The ≈13% revenue increase in 2023 is not explicitly in the original answer but is a reasonable inference given the context and does not contradict it. (2) The dollar amounts, percentages, and timeframes are accurate and match the ground truth. Format variations (e.g., $12.8–12.9 billion) are acceptable. (3) The multi-hop reasoning is sound: the LLM correctly links cost pressures on Virginia-class and DDG-51 programs to margin decline in 2023, identifies the Columbia-class program as the key revenue driver, and projects improved outlook in 2024 based on revenue growth and margin stabilization. (4) The answer fully addresses all parts of the question: financial performance changes, cost pressures, and revenue outlook. The only minor shortcoming is that the original answer emphasizes a 'strategic effort to stabilize profitability' more explicitly, which the LLM implies but does not state directly. However, the semantic meaning and factual content are equivalent. No factual errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1413,
        "completion_tokens": 368,
        "total_tokens": 1782
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How has BKNG's financial dependency on Booking.com evolved between 2022 and 2023 based on the proportion of revenue derived from accommodation reservations?",
      "original_answer": "BKNG's financial dependency on Booking.com has remained high but slightly increased between 2022 and 2023. In 2022, Booking.com's accommodation reservations contributed 89% of BKNG's total revenues. This percentage remained unchanged in 2023, indicating BKNG continues to heavily rely on Booking.com for its revenue base. The consistent 89% contribution in both years shows a sustained and concentrated dependency on Booking.com's core service offering.",
      "llm_answer": "\nBetween 2022 and 2023, the share of Booking Holdings’ total revenue that comes from accommodation‑reservation services stayed essentially unchanged—about 89 % of revenue in both years (the 2023 filing notes that “approximately 89 % of the Company’s revenues for the years ended December 31, 2023 and 2022 relate to online accommodation‑reservation services,” up only slightly from 87 % in 2021). Thus, BKNG’s financial reliance on Booking.com for accommodation bookings remained very high and stable, with only a marginal increase in the proportion of revenue derived from those reservations from 2022 to 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and closely aligns with the ground truth. (1) Quantitatively, it correctly states that 89% of BKNG's revenue came from accommodation reservations in both 2022 and 2023, matching the original answer. It adds context from 2021 (87%), which is factually correct and enhances understanding, though not required. (2) The answer addresses all parts of the question: it evaluates the evolution (or lack thereof) in financial dependency between 2022 and 2023 and focuses on the proportion of revenue from accommodation reservations. (3) Entity accuracy is strong: BKNG is correctly identified, Booking.com is appropriately referenced as the source of the revenue (implied through context), and the years 2022 and 2023 are correctly used. (4) Reasoning is sound: the conclusion of 'stable' and 'very high' reliance with only a marginal increase is logically supported by the unchanged 89% figure. The slight discrepancy is that the original answer claims the percentage 'remained unchanged' at 89%, while the LLM suggests it was 'up slightly' from 87% in 2021, which could imply a change from 2022 to 2023, but the LLM explicitly states it was 89% in both years, so the core comparison is correct. This minor ambiguity prevents a perfect 10. Overall, the answer is factually correct, well-reasoned, and contextually complete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1268,
        "completion_tokens": 373,
        "total_tokens": 1642
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How did the company's position with respect to its Swiss Franc note evolve between 2023 and 2024, and what does this indicate about its foreign currency obligations?",
      "original_answer": "In 2023, the company disclosed a Swiss Franc note obligation of $299 million, which was completely removed by the end of 2024. This indicates that the company either repaid or restructured this foreign currency obligation over the year, reflecting a strategic shift in managing its Swiss Franc exposure.",
      "llm_answer": "\nBetween 2023 and 2024 the company’s Swiss‑franc‑denominated debt was eliminated.  In the 2023 long‑term‑debt schedule the firm listed a CHF note of $299 million (1.625 % due 2024), but the 2024 schedule shows that line as “‑”, indicating the note was fully repaid (or written‑off) by year‑end 2024.  This reduction signals that PMI deliberately shortened its foreign‑currency exposure, using cash or other financing to retire the Swiss‑franc obligation and thereby lower its overall foreign‑currency debt burden.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately reported: the $299 million Swiss Franc note in 2023 and its complete removal by 2024. The notation of '1.625% due 2024' adds contextual detail consistent with typical debt disclosures and does not contradict the ground truth. (2) Quantitative accuracy is perfect: the $299 million figure matches exactly, and the interpretation of the dash ('-') in the 2024 schedule as full repayment or elimination is correct and reasonable. (3) The multi-hop reasoning is sound—comparing the debt schedules across two years to infer the elimination of the obligation demonstrates proper synthesis. The conclusion that the company reduced its foreign currency exposure aligns with the ground truth's interpretation of a 'strategic shift.' (4) The answer addresses both parts of the question: the evolution of the Swiss Franc note (from $299M to zero) and the implication for foreign currency obligations (reduced exposure). Wording differs slightly but meaning is identical. No factual, numerical, or logical errors present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1208,
        "completion_tokens": 317,
        "total_tokens": 1526
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How did Goldman Sachs' treatment of Non-Employee Director RSU Award Agreements evolve between the 2023 and 2024 10-K filings, particularly in terms of introduced or modified agreements?",
      "original_answer": "In the 2023 10-K filing, Goldman Sachs referenced the 'Form of Non-Employee Director RSU Award Agreement (pre-2015)' as Exhibit 10.8, indicating that the existing documentation pertained to agreements prior to 2015. In the 2024 filing, the company not only retained the reference to the pre-2015 RSU Award Agreement but also introduced a new exhibit titled 'Amendments to Certain Non-Employee Director Equity Award Agreements' as Exhibit 10.18, which was not present in the 2023 filing. This indicates that Goldman Sachs expanded its disclosures to include amendments to these agreements, suggesting a more comprehensive or updated treatment of non-employee director equity arrangements in 2024.",
      "llm_answer": "\nBetween the 2023 and 2024 10‑K filings Goldman Sachs replaced the older “pre‑2015” Non‑Employee Director RSU Award Agreement language (referenced in the 2023 filing as Exhibit 10.8) with a set of newer, more detailed award templates.  The 2024 filing adds dedicated exhibits for a cash‑settled director RSU agreement (Exhibit 10.32), a fully‑vested one‑time/year‑end RSU agreement (Exhibit 10.35), and updated base/supplemental RSU forms (Exhibits 10.36‑10.38), indicating that the company introduced and refined award structures—including cash‑settlement options and clearer vesting conditions—while retiring the earlier pre‑2015 versions.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and introduces significant factual inaccuracies not present in the ground truth. (1) It claims that Goldman Sachs 'replaced' the pre-2015 RSU Award Agreement in the 2024 filing, which contradicts the original answer stating that the pre-2015 form was retained (Exhibit 10.8) and a new exhibit (10.18) was added. The LLM incorrectly asserts that the older version was retired. (2) The LLM invents multiple exhibits (10.32, 10.35, 10.36–10.38) that are not mentioned in the ground truth; the original answer only references Exhibit 10.18 as the new addition. These exhibit numbers and descriptions (e.g., 'cash-settled director RSU agreement', 'fully-vested one-time/year-end RSU agreement') are fabricated. (3) The multi-hop reasoning is flawed: instead of identifying the retention of the old agreement and the introduction of amendments, the model incorrectly infers a full replacement and expansion with new templates not supported by the data. (4) While the answer addresses the general topic of evolution in RSU agreements and is framed around the correct company and time period, the core factual claims about what changed are unsupported and inaccurate. The contextual relevance is moderate because it attempts to answer the right question, but the content is factually unsound. Minor formatting variations in numbers are not at issue here, but the complete misrepresentation of exhibits and changes results in a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 405,
        "total_tokens": 1749
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How did PM's financial relationship with Swedish Match AB evolve between 2023 and 2024, particularly in terms of long-term debt obligations tied to the acquisition?",
      "original_answer": "In 2023, the long-term debt obligations related to the Swedish Match AB acquisition totaled $6,121 million, while in 2024, this amount decreased to $2,610 million. This indicates a significant reduction in the debt tied to the acquisition, suggesting that PM made substantial repayments or refinanced during the period. The decrease supports the idea that PM's financial dependency or exposure linked to the Swedish Match acquisition lessened over time.",
      "llm_answer": "\nBetween 2023 and 2024 PMI completed the cash‑consideration phase of its acquisition of Swedish Match AB: it paid the $1.7 billion (plus 6 % interest) that had been scheduled for July 2023, recording the amount in “other assets” on its 2023 balance sheet, and it had originally financed the deal with a €5.5 billion senior unsecured term‑loan (a €3 billion tranche due 2025 and a €2.5 billion tranche due 2027). In November 2024 PMI used cash and the proceeds of newly‑issued bonds to pre‑pay the entire €3 billion 2025 tranche, eliminating that portion of the long‑term debt tied to the acquisition while the remaining €2.5 billion tranche (due 2027) and its interest obligations remain on the books. The acquisition also continues to be reflected in the Swedish Match reporting unit’s goodwill and intangible‑asset balances, which are subject to ongoing impairment testing.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies in key quantitative figures related to long-term debt obligations, which are central to the question. The ground truth states that PM's long-term debt tied to the Swedish Match AB acquisition was $6,121 million in 2023 and decreased to $2,610 million in 2024. However, the LLM claims the financing involved a €5.5 billion term loan (approx. $5.9B at 2023 exchange rates), and that only the €3 billion tranche was prepaid in 2024, leaving €2.5 billion outstanding—implying a 2024 debt level of about $2.7B. While this is close to the $2,610M in the original answer, it does not match exactly and relies on unverified assumptions about currency conversion and debt structure. More critically, the LLM fails to report the actual reported debt figures ($6,121M and $2,610M), instead reconstructing the debt based on assumed financing instruments not confirmed in the ground truth. Additionally, the $1.7 billion payment with 6% interest is not mentioned in the original answer and appears fabricated. The timeline (July 2023 payment, November 2024 prepayment) is specific but unsupported by the ground truth, which only provides year-end debt balances. While the LLM correctly infers a reduction in debt and attributes it to repayment, the reasoning is based on incorrect or unverified financial details. The entities (PM, Swedish Match AB) and time frame (2023–2024) are correct, and the answer is contextually relevant, attempting to explain the evolution of debt. However, the quantitative inaccuracies—especially the incorrect starting debt amount and unsupported payment schedule—severely undermine factual correctness. The model also introduces granular financial instruments (tranches, bond issuances) not present in the ground truth, reflecting overconfident synthesis. Thus, while the directional conclusion (debt decreased) is correct, the specific numbers and mechanisms are not, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 530,
        "total_tokens": 1867
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How did BMY's strategic positioning around KRAS inhibition evolve from 2023 to 2024, particularly in relation to the acquisition of Mirati and the development trajectory of Krazati?",
      "original_answer": "In 2023, BMY had not yet acquired Mirati, and Krazati was not part of its portfolio. However, by 2024, BMY completed the acquisition of Mirati for $4.8 billion, gaining full rights to Krazati, a KRAS G12C inhibitor. Krazati had already received FDA approval for second-line NSCLC and was in clinical development for first-line NSCLC in combination with a PD-1 inhibitor. Additionally, in 2024, Krazati was also FDA approved for advanced or metastatic KRAS-mutated colorectal cancer with cetuximab, expanding its therapeutic footprint. This acquisition marked a significant evolution in BMY’s oncology strategy, positioning it more strongly in the KRAS inhibition space.",
      "llm_answer": "\nFrom 2023 through early 2024 BMS moved from a largely internal, pipeline‑focused effort on KRAS‑driven oncology to a decisive strategic acquisition: it bought Mirati Therapeutics in January 2024, gaining commercial rights to the KRAS‑G12C inhibitor **Krazati** (already approved for second‑line NSCLC and KRAS‑mutant colorectal cancer) and a deep‑stage PRMT5 inhibitor (MRTX‑1719) plus other KRAS‑adjacent assets.  The deal gave BMS an immediate commercial foothold in KRAS inhibition and a clear development path to expand Krazati into first‑line NSCLC combinations and additional tumor types, positioning the asset as a cornerstone of its oncology growth strategy for the next several years.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in BMY's (Bristol-Myers Squibb's) strategic positioning around KRAS inhibition from 2023 to 2024. It correctly identifies the acquisition of Mirati Therapeutics in January 2024, which aligns with the timeline in the ground truth (implied completion in 2024), and notes that Krazati became part of BMY's portfolio post-acquisition. The answer accurately states that Krazati was already FDA approved for second-line NSCLC and mentions its approval in KRAS-mutant colorectal cancer—consistent with the ground truth, though it omits the detail about cetuximab combination, which is a minor omission. It also correctly highlights the ongoing development of Krazati in first-line NSCLC in combination with a PD-1 inhibitor (implied in 'combinations') and references additional pipeline assets like MRTX1719, which strengthens the qualitative assessment of BMY’s expanded KRAS strategy. The $4.8 billion acquisition price is missing from the LLM answer, which is a quantitative shortcoming, hence the deduction in quantitative accuracy. However, no incorrect numbers are stated—only one omitted—so the error is partial. The reasoning is sound, demonstrating multi-hop synthesis: connecting the pre-acquisition state (2023), the acquisition event, and the resulting strategic shift in oncology. The entity names (Mirati, Krazati, KRAS G12C, NSCLC) and years are correct. The answer is fully contextually relevant, directly addressing how BMY’s positioning evolved. Overall, the answer conveys semantically equivalent information with only minor omissions, warranting a high correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 448,
        "total_tokens": 1798
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Goldman Sachs' disclosure and positioning of the Restricted Partner Compensation Plan evolved between 2023 and 2024, particularly in relation to newer compensation governance policies introduced during this period?",
      "original_answer": "In 2023, the Restricted Partner Compensation Plan was listed as Exhibit 10.3 and appeared early in the exhibit list, indicating a prominent position among compensation-related disclosures. By 2024, while the plan itself (still referenced as Exhibit 10.4) remained substantively unchanged, its relative placement shifted later in the exhibit list. Notably, in 2024, the firm introduced the Clawback Policy (Exhibit 10.1), signaling a new emphasis on compensation accountability and governance reforms. This suggests a strategic repositioning of compensation-related disclosures to prioritize risk mitigation and regulatory alignment alongside traditional partner compensation frameworks.",
      "llm_answer": "\nBetween 2023 and 2024 the firm shifted the Restricted Partner Compensation Plan from a brief exhibit citation in the 2023 10‑K to a formally amended and restated governance document (listed as Exhibit 10.4 in the 2024 filing) and placed it alongside the newly adopted 2023 Clawback Policy. This re‑positioning signals a more explicit governance framing and heightened disclosure of partner‑compensation terms as part of the firm’s updated compensation‑oversight framework.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general direction of change in disclosure positioning and correctly identifies the introduction of the Clawback Policy in 2024 (though mislabels it as the '2023 Clawback Policy'). However, it contains significant inaccuracies: (1) It incorrectly states that the Restricted Partner Compensation Plan was 'amended and restated' in 2024, while the ground truth confirms it remained substantively unchanged; (2) It misrepresents the 2023 disclosure as only a 'brief exhibit citation,' whereas the original answer notes it was listed as Exhibit 10.3 and prominently positioned early in the exhibit list; (3) It falsely claims the plan was moved to be 'alongside' the Clawback Policy, when the key point is its relative demotion in the exhibit list despite the Clawback Policy being prioritized as Exhibit 10.1. Quantitatively, exhibit numbers (10.3 in 2023, 10.4 in 2024) are mostly correct, though the LLM omits the 2023 exhibit number. The reasoning is partially sound in linking disclosure order to governance emphasis, but flawed in implying formal amendment and closer integration with the Clawback Policy. The answer is contextually relevant and addresses the evolution question, but with key factual errors that undermine the multi-hop synthesis. Semantic equivalence is partially achieved but undermined by incorrect characterization of changes to the plan and its placement.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 387,
        "total_tokens": 1696
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Philip Morris International's approach to heat-not-burn products evolved from 2022 to 2023, particularly in terms of product categorization and business integration?",
      "original_answer": "In 2022, Philip Morris described its heat-not-burn products as part of its Reduced-Risk Products (RRPs) portfolio, emphasizing their role in a smoke-free future and highlighting the IQOS Platform 1 device and various heated tobacco units (HTUs) such as HEETS and Marlboro HeatSticks. These products were positioned as a key part of the company's long-term strategy to replace traditional cigarettes. By 2023, the categorization had evolved, with heat-not-burn products now explicitly grouped under 'smoke-free products' alongside e-vapor and oral nicotine products, as well as wellness and healthcare offerings. Additionally, in 2023, PMI explicitly stated that its heat-not-burn products include licensed KT&G heat-not-burn products, indicating a broader integration and expansion of the product line beyond internally developed offerings.",
      "llm_answer": "\nFrom 2022 to 2023 PMI re‑classified heat‑not‑burn as a distinct sub‑category within its “smoke‑free products excluding wellness and healthcare” segment, reporting a 27 % revenue increase (to $12.5 bn) and a 14.7 % rise in heated‑tobacco unit shipments. At the same time the company integrated HNB into its broader smoke‑free portfolio—linking it to the IQOS Platform 1, expanding the brand suite (HEETS, Marlboro Dimensions, TEREA, licensed KT&G products) and tying its growth to the Swedish Match acquisition—so that HNB is now managed as a core, integrated component of PMI’s smoke‑free business rather than a standalone product line.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer includes several factual inaccuracies, particularly in quantitative details not present in the original answer. The original ground truth does not mention any revenue figures ($12.5 bn), percentage increases (27%, 14.7%), or specific business developments like the Swedish Match acquisition. These numbers, while plausible, are not supported by the provided ground truth and appear to be hallucinated or inferred beyond the source material. (2) Quantitative accuracy is low because the LLM introduces specific financial metrics and growth rates that are not in the original answer, making them factually unverifiable against the ground truth. The original answer focuses on categorization and integration changes, not performance metrics. (3) Qualitatively, the LLM captures the correct direction of evolution—heat-not-burn products being more integrated into the broader smoke-free portfolio and expanded to include licensed KT&G products. It correctly identifies IQOS, HEETS, Marlboro HeatSticks (as Marlboro Dimensions), and the shift toward integration. However, it misrepresents the 2023 categorization by implying a sub-category 'excluding wellness and healthcare,' whereas the original states that smoke-free products now include wellness and healthcare offerings. (4) Contextual relevance is high because the response directly addresses the evolution in product categorization and business integration from 2022 to 2023, using appropriate terminology and structure. Despite incorrect numbers, the core conceptual shift is acknowledged, warranting a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 442,
        "total_tokens": 1818
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How did Bristol-Myers Squibb's approach to business risk governance evolve between 2023 and 2024 in relation to SEC Consent Order compliance, particularly regarding the role of the business risk and disclosure group?",
      "original_answer": "In 2023, Bristol-Myers Squibb established the business risk and disclosure group specifically to comply with the SEC Consent Order. This included implementing a formal review and certification process for SEC filings, retaining an outside consultant to re-engineer accounting and financial reporting processes, and introducing a governance mechanism to escalate and resolve compliance-related questions. By 2024, the company had fully integrated this group into its ongoing compliance framework, with no indication of modifications or reductions in scope, suggesting that the group remained a central component of financial governance under the Consent. The continued reference to the group in 2024 filings indicates that the company maintained its enhanced risk governance structure without significant changes.",
      "llm_answer": "\nBetween 2023 and 2024 the company moved from simply **creating a “business risk and disclosure group”** as one of the remedial measures required by the 2004 SEC Consent Order to **embedding that group within a broader, formally documented governance framework**.  In the 2023 filing the group was mentioned only as part of the list of compliance actions; by 2024 the firm described a **company‑wide policy** that incorporates the group’s work, adds a **structured escalation process** for any questions or concerns, and mandates **regular monitoring of compliance**.  Thus, the evolution is a shift from a one‑time establishment to an ongoing, integrated risk‑governance mechanism that directly oversees adherence to the Consent’s sales‑limitation and disclosure requirements.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in its characterization of the evolution of Bristol-Myers Squibb's business risk and disclosure group between 2023 and 2024, with accurate qualitative details and no numeric inaccuracies (quantitative accuracy is 10). The dates (2023 and 2024) and entity (Bristol-Myers Squibb, SEC Consent Order) are correct. However, there is a critical factual error: the LLM incorrectly states that the SEC Consent Order was from 2004, which is not supported by the original answer or context. The original answer does not specify the year of the Consent Order, but the LLM introduces a false detail (2004), which undermines the qualitative accuracy. Despite this, the core reasoning about the group’s evolution—from creation in 2023 to integration into a broader governance framework in 2024—is consistent with the ground truth. The answer correctly identifies the shift from initial implementation to ongoing, structured compliance with escalation processes and monitoring, aligning with the original answer’s claim of full integration and sustained role. The multi-hop synthesis across years and governance changes is sound, and the answer addresses all parts of the question. The error in referencing the 2004 Consent Order is significant but does not completely derail the explanation of the group’s evolving role. Hence, correctness is reduced to 7 due to this factual inaccuracy, though the rest of the reasoning and structure remains strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1414,
        "completion_tokens": 403,
        "total_tokens": 1818
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has UNP's treatment of the relationship between its pension plan's expected return and its asset allocation mix evolved between 2023 and 2024?",
      "original_answer": "In 2023, UNP explicitly stated that the expected return on plan assets was based on the asset allocation mix, historical returns, and market conditions, and included a specific actual return of 6% for that year. By 2024, the language shifted to indicating that the expected return 'depends on' the asset allocation mix, with no explicit mention of historical returns or market conditions, and no disclosure of the actual return for 2024. This represents a shift from a more comprehensive explanation of factors influencing returns to a narrower focus on the asset allocation mix alone.",
      "llm_answer": "\nBetween 2023 and 2024 UNP moved from a de‑risking “equity‑to‑debt” shift that culminated in a 25 % equity / 75 % debt target by the end of 2023 to a more explicit linkage of its long‑term expected return assumption to that higher‑weight debt allocation.  In the 2024 filing the company stresses that the 5.25 % long‑term return forecast is now driven primarily by the 70‑80 % debt exposure (with equity limited to 20‑30 %), whereas the 2023 discussion simply noted the completion of the shift to the 25 %‑equity target and the use of a 5‑year smoothed return to calculate pension expense.  Thus, the relationship evolved from a general “expected return is tied to asset allocation” statement to a concrete, debt‑heavy allocation that directly shapes the expected‑return assumption.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and introduces information not present in the ground truth. (1) Quantitative Accuracy: The LLM claims UNP had a 25% equity / 75% debt target by end of 2023 and a long-term expected return of 5.25% in 2024, but the ground truth states only that the actual return was 6% in 2023 and makes no mention of any expected return assumption (like 5.25%) or asset allocation percentages (e.g., 70-80% debt) in 2024. These specific numbers and targets are not supported by the original answer and appear fabricated. (2) Completeness: The question asks about the evolution in how UNP treats the relationship between expected return and asset allocation — specifically, the change in disclosure language. The LLM focuses instead on a detailed shift in allocation strategy and return assumptions that are not in the ground truth, missing the actual evolution in disclosure tone and scope (from broader factors to only asset mix). (3) Entity Accuracy: While UNP and years (2023, 2024) are correct, the financial metrics (5.25%, 25%/75%, 70-80%) are incorrect or unverified. (4) Reasoning: The multi-hop reasoning is flawed — the LLM infers a strategic evolution based on unsupported numerical claims rather than analyzing the actual shift in narrative emphasis described in the ground truth. (5) Semantic Equivalence: The LLM describes a concrete, data-driven evolution in investment policy, while the ground truth describes a change in disclosure language and transparency. These are semantically distinct. The answer is contextually relevant to pension plan assumptions but misrepresents the nature and content of the evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 454,
        "total_tokens": 1795
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How did BNY Mellon's disclosure approach to the Directors' Code of Conduct evolve between 2022 and 2023, particularly in terms of its accessibility and integration within corporate governance reporting?",
      "original_answer": "In 2022, BNY Mellon explicitly stated that the Directors' Code of Conduct was posted on its website and outlined its applicability to all directors. The document was referenced in the context of broader corporate governance disclosures, including Board Meetings and Committee Information. By 2023, the Directors' Code of Conduct was no longer just referenced but was specifically listed among the governance materials 'available on our website,' alongside key governance documents like the Corporate Governance Guidelines and committee charters. This evolution indicates a more structured and centralized approach to governance disclosures, with the Code being more directly tied to the company's overall governance framework in the 2023 filing.",
      "llm_answer": "\nBetween 2022 and 2023 BNY Mellon shifted the presentation of its Directors’ Code of Conduct from a peripheral reference in the Proxy statement to a dedicated, explicitly‑linked disclosure in the 10‑K’s governance section.  In the 2023 filing the code is posted on the company’s website with a clear statement that any future amendments or waivers will be disclosed there, and this information is embedded in Item 10 alongside other governance details—making it far more accessible and integrated into the firm’s corporate‑governance reporting than in the 2022 filing, which only mentioned the code in passing.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of BNY Mellon's disclosure approach to the Directors' Code of Conduct between 2022 and 2023. It accurately captures the shift from a more peripheral mention in 2022 to a more prominent, structured, and accessible presentation in 2023. The claim that in 2023 the Code was 'posted on the company’s website with a clear statement that any future amendments or waivers will be disclosed there' is consistent with enhanced accessibility and integration, though this specific detail about amendments and waivers is not present in the original answer and cannot be verified from the ground truth provided. However, this addition does not contradict the original and is a plausible extension of improved disclosure practices. The LLM correctly identifies the integration of the Code into Item 10 of the 10-K and its co-location with other governance documents, reflecting a more centralized governance framework. While the original answer emphasizes the Code being 'specifically listed among the governance materials,' the LLM interprets this as a 'dedicated, explicitly-linked disclosure,' which is semantically reasonable. The reasoning is sound and reflects appropriate multi-hop synthesis across years and disclosure formats. All entities (BNY Mellon, Directors' Code of Conduct, 2022 vs 2023, 10-K, Proxy) are accurate, and there are no factual inaccuracies in dates or document types. The answer is fully contextually relevant. Minor deduction in qualitative accuracy due to the unverified addition about amendment disclosures, and in correctness for slightly overstating the specificity of the 2023 disclosure beyond the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 469,
        "total_tokens": 1822
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has Oracle's strategic positioning of Oracle Database evolved between 2023 and 2024 in terms of deployment flexibility and integration with engineered systems, and what does this indicate about the company's approach to cloud migration and hybrid IT environments?",
      "original_answer": "In 2023, Oracle emphasized the flexibility of running Oracle Database across multiple deployment models, including on-premise, Oracle Cloud, and multicloud environments, with specific offerings like Oracle Exadata Cloud@Customer and Oracle Roving Edge Infrastructure. These options were framed around enabling customers to securely run Oracle Database behind their firewalls while being managed by Oracle. By 2024, Oracle shifted toward deeper integration of Oracle Database within Oracle Engineered Systems, such as the Oracle Exadata Database Machine, which combines database, storage, operating system, and networking hardware into a single optimized platform. This system was highlighted as being available across on-premise, OCI cloud, and hybrid deployments. The evolution from flexible deployment of standalone database services to tightly integrated engineered systems suggests a strategic shift toward offering more holistic, performance-optimized solutions that align with enterprise needs for scalability, security, and simplified maintenance. This indicates a maturation of Oracle's cloud migration strategy, focusing not only on deployment flexibility but also on delivering comprehensive, high-performance infrastructure packages.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 Oracle broadened the deployment options for its Oracle Database by making it available not only on public OCI but also through on‑premise and hybrid models—most notably via engineered‑system offerings such as **Exadata Cloud@Customer, OCI Dedicated Region and OCI Sovereign Cloud**.  These options are tightly integrated with Oracle’s engineered systems (e.g., Exadata Database Machine) that combine database, storage, and middleware in a single, optimized appliance, giving customers a consistent platform that can be run in any IT environment.  This evolution signals Oracle’s strategy of **facilitating cloud migration and hybrid‑IT deployments**, allowing customers to move workloads fluidly between on‑premise and the cloud while protecting existing investments.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of strategic evolution, deployment models, and integration with engineered systems. It accurately identifies key offerings such as Exadata Cloud@Customer and mentions hybrid and on-premise deployment flexibility in both 2023 and 2024. The mention of OCI Dedicated Region and OCI Sovereign Cloud, while not in the original answer, are contextually accurate extensions of Oracle's hybrid cloud strategy and do not contradict the ground truth. The core shift from deployment flexibility to tighter integration with engineered systems (e.g., Exadata Database Machine) is correctly captured, though the original answer emphasizes a clearer evolution from standalone database deployment to holistic engineered systems as a strategic maturation. The LLM slightly underemphasizes the 2024 shift toward performance-optimized, integrated infrastructure as a strategic evolution and instead frames it more as an expansion of deployment options. There are no numerical inaccuracies (quantitative accuracy is perfect, hence 10), and all entities (Oracle, OCI, Exadata) and timeframes (2023–2024) are correct. The reasoning is sound and synthesizes multi-hop concepts—deployment models, engineered systems, cloud migration strategy—though the conclusion could more explicitly reflect the 'maturation' of strategy as stated in the original. Contextual relevance is excellent, directly addressing all parts of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1540,
        "completion_tokens": 408,
        "total_tokens": 1949
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has the implementation of the formal review and certification process of annual and quarterly SEC reports evolved between 2023 and 2024, particularly in terms of compliance monitoring and governance procedures?",
      "original_answer": "In 2023, the company established a formal review and certification process of SEC filings as part of the Consent agreement, which included governance procedures to escalate potential compliance concerns to appropriate management levels and regular monitoring of compliance. By 2024, the company continued to emphasize the implementation of these governance procedures, noting that compliance with the policy was consistently monitored and that the process was integrated into company-wide sales policies to ensure adherence to inventory and sales limitations. The evolution reflects a shift from initial implementation in 2023 to sustained enforcement and integration into broader operational frameworks in 2024.",
      "llm_answer": "\nBetween 2023 and 2024 the company’s formal review and certification of its annual and quarterly SEC reports remained rooted in the 2004 Consent, but the 2024 filing added a more detailed governance structure—specifically a dedicated business‑risk and disclosure group and a systematic, escalation‑based monitoring process that requires management‑level review of compliance questions and regular documentation of the certification workflow. This evolution reflects a more formalized and ongoing oversight of the review process and enhanced compliance monitoring.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. First, it incorrectly references a '2004 Consent' as the basis for the review and certification process, while the ground truth states the process was established in 2023 as part of a Consent agreement—there is no mention of 2004 in the original answer, making this a critical error. Second, the LLM introduces specific new entities not present in the ground truth, such as a 'dedicated business-risk and disclosure group' and a 'systematic, escalation-based monitoring process' with 'regular documentation of the certification workflow,' which are not mentioned in the original answer. While the general idea of enhanced governance and monitoring in 2024 aligns thematically with the ground truth, the specific mechanisms described are fabricated. The original answer emphasizes integration into company-wide sales policies and inventory/sales limitations, which the LLM answer omits entirely. Instead, the LLM invents structural changes without grounding in the source material. The evolution described—shifting from implementation to integration and sustained enforcement—is partially in line with the ground truth, giving some contextual relevance. However, due to the incorrect date, invented entities, and failure to reflect the actual integration into sales policies and compliance monitoring as described, the answer is largely incorrect. Quantitative accuracy is low due to the wrong year (2004 vs 2023), and qualitative accuracy suffers from flawed reasoning and unsupported details. The answer does address the question's focus on evolution in governance and compliance, so it retains moderate contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 464,
        "total_tokens": 1800
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Philip Morris International's approach to heat-not-burn products evolved from 2022 to 2023, particularly in terms of their market positioning and product categorization?",
      "original_answer": "In 2022, Philip Morris International (PMI) positioned heat-not-burn products as part of its broader Reduced-Risk Products (RRPs) portfolio, emphasizing their potential to present less harm to smokers who switch from traditional cigarettes. These products, including the Platform 1 device and its consumables, were described as being in various stages of development, scientific assessment, and commercialization. By 2023, PMI had refined its categorization, explicitly including heat-not-burn products within the smoke-free product segment, alongside e-vapor and oral nicotine products. Additionally, PMI began including licensed KT&amp;G heat-not-burn products in its portfolio, indicating a broader market approach and potential expansion of partnerships or offerings. This evolution shows a strategic shift from internal development focus to a more integrated and commercialized product positioning.",
      "llm_answer": "\nBetween 2022 and 2023 PMI elevated heat‑not‑burn (HTU) from a niche emerging line to a central pillar of its “smoke‑free products” portfolio, reporting a 14.7 % increase in HTU shipments and a 26 % jump in smoke‑free net revenue (from $9.9 bn to $12.5 bn).  The 2023 filing begins to separate HTU revenue within the broader smoke‑free category—grouping it with e‑vapor, oral nicotine, Swedish Match and the newly added Wellness & Healthcare business—thereby positioning the products as a premium, reduced‑risk offering and the primary growth engine of PMI rather than a peripheral adjunct to combustible tobacco.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly in quantitative claims not supported by the ground truth. The 14.7% increase in HTU shipments and 26% jump in smoke-free net revenue (from $9.9B to $12.5B) are specific numerical assertions absent from the original answer and cannot be verified from the provided ground truth. These figures may be plausible but are not part of the knowledge graph data provided, making them potentially hallucinated. Additionally, the mention of 'Wellness & Healthcare' as a newly added segment in 2023 is not mentioned in the original answer and represents an unsupported expansion. (2) The original answer does not provide any financial figures or growth metrics, so the inclusion of such detailed numbers undermines quantitative accuracy. There is no mention of Swedish Match integration into the heat-not-burn category in the ground truth; while PMI acquired Swedish Match, the original answer does not link it to heat-not-burn product categorization. (3) Qualitatively, the LLM captures the correct directional evolution: heat-not-burn products moved from being part of RRPs in 2022 to being more centrally positioned within the smoke-free segment in 2023. It correctly identifies a strategic elevation in product positioning. The inclusion of licensed KT&G products is omitted, which is a notable detail from the original answer, but the general trend toward broader commercialization and integration is reasonably inferred. (4) Contextual relevance is high because the response directly addresses the evolution in market positioning and categorization over the two years, using appropriate terminology and structure. However, the addition of unverified metrics and entities reduces factual reliability. The reasoning shows understanding of strategic shifts but overreaches with unsupported data. Thus, while the qualitative insight is partially sound, the incorrect numbers significantly reduce overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 535,
        "total_tokens": 1922
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Oracle's strategic positioning of Oracle Database evolved between 2023 and 2024 in terms of deployment flexibility and integration with other Oracle technologies?",
      "original_answer": "In 2023, Oracle emphasized the deployment flexibility of Oracle Database across cloud-based, on-premise, or other IT environments, highlighting its perpetual licensing model and the company's strategy to provide customer choice. By 2024, Oracle Database's role had evolved to become a foundational component within broader engineered systems, such as Oracle Exadata Database Machine, which integrates the database with storage, operating system software, and hardware components for optimized performance. This shift indicates a move toward deeper integration with Oracle's infrastructure technologies, positioning Oracle Database not just as a standalone product but as a core element of Oracle Engineered Systems, available in on-premise, cloud (OCI), and hybrid cloud deployments.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 Oracle broadened the ways customers can run Oracle Database, moving from a primarily on‑premise license model to a fully flexible, hybrid‑cloud approach.  The 2024 filing highlights that Database can now be deployed on‑premise, in Oracle Cloud public regions, in dedicated or sovereign OCI instances, or through Exadata Cloud@Customer, and it is tightly integrated with the rest of the Oracle Cloud stack—including Autonomous Database, Java, Middleware, Engineered Systems, and OCI AI/Analytics services.  This evolution gives customers choice of deployment location while embedding the Database more deeply within Oracle’s complementary cloud offerings, driving the shift toward cloud‑centric licensing and higher cloud‑services revenue.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution of Oracle Database's strategic positioning from 2023 to 2024, noting increased deployment flexibility and deeper integration with Oracle technologies. The shift from a primarily on-premise/perpetual licensing model in 2023 to a hybrid-cloud, multi-deployment approach in 2024 is accurately described. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the LLM synthesizes deployment models (on-premise, cloud, hybrid) and integration with Oracle technologies (Exadata, Autonomous Database, OCI, AI/Analytics), correctly identifying the strategic shift toward cloud-centric integration and engineered systems. The mention of Exadata Cloud@Customer and dedicated OCI instances adds detail consistent with Oracle’s 2024 positioning. (4) The only minor gap is that the LLM answer emphasizes 'cloud-centric licensing and higher cloud-services revenue'—a reasonable inference but not explicitly stated in the ground truth. Conversely, the original answer highlights Oracle Database becoming a 'foundational component' within engineered systems like Exadata, which the LLM mentions but could emphasize more. Despite this slight difference in emphasis, the core facts, entities (Oracle, Exadata, OCI, Autonomous Database), and timeline (2023 vs 2024) are correct. Semantic equivalence is maintained. Contextual relevance is excellent as all parts of the question are addressed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1393,
        "completion_tokens": 445,
        "total_tokens": 1839
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has BMY's strategic relationship with Krazati evolved from 2023 to 2024, and what specific financial commitments were made in 2024 that reflect this evolution?",
      "original_answer": "In 2023, Krazati was mentioned as part of BMY's oncology portfolio, demonstrating a strategic fit into their offerings. By 2024, BMY had acquired Mirati for $4.8 billion, obtaining the rights to Krazati, which had received FDA and EMA approvals for second-line NSCLC and was in clinical development for first-line NSCLC. Additionally, BMY committed $1.0 billion in contingent value rights tied to the development of PRMT5 Inhibitor, further signaling long-term investment in the acquired assets.",
      "llm_answer": "\nFrom 2023 to 2024 BMY moved Krazati from a partner‑licensed asset (via the Mirati option/ collaboration) to a fully owned product after closing the $4.8 billion acquisition of Mirati in January 2024; the deal comprised $4.6 billion cash for shares, $205 million for equity awards and a $248 million fair‑value estimate of contingent‑value‑right payments that could total up to $1 billion, while $640 million of the purchase price was specifically allocated to the Krazati product‑rights and $3.5 billion to other IPRD assets. This financial commitment reflects the strategic evolution from a non‑controlling partnership to complete ownership of Krazati within BMY’s oncology portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the evolution of BMY's relationship with Krazati from 2023 to 2024, correctly identifying the transition from a collaborator/licensee to full ownership via the Mirati acquisition. The $4.8 billion acquisition figure is correct and broken down into $4.6 billion cash for shares, $205 million for equity awards, and a contingent value right (CVR) with a fair value of $248 million that could total up to $1 billion—this aligns with the ground truth, which confirms the $1 billion contingent commitment. The allocation of $640 million to Krazati and $3.5 billion to other IPRD assets adds detail not in the original answer but does not contradict it and is plausible within the context. The January 2024 acquisition timing is accurate. The strategic evolution—from partnership to full ownership—is correctly framed and supported by financial commitments. Minor point: the original answer emphasizes FDA/EMA approvals and clinical development in first-line NSCLC as part of the strategic rationale, which the LLM omits, slightly reducing completeness. However, the core multi-hop reasoning—linking the acquisition to ownership of Krazati and long-term investment via CVRs—is sound and well-supported. All entities (BMY, Mirati, Krazati), years (2023 to 2024), and financial terms are correct. Number formats are consistent and accurate. The answer is semantically equivalent and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 397,
        "total_tokens": 1696
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has the treatment or status of the 6.244% Fixed-to-Floating Rate Normal Preferred Capital Securities of Mellon Capital IV evolved between 2022 and 2023 based on BK's SEC filings?",
      "original_answer": "In 2022, the 6.244% Fixed-to-Floating Rate Normal Preferred Capital Securities of Mellon Capital IV were introduced as securities registered under Section 12(b) of the Act and were listed on the New York Stock Exchange under the trading symbol BK/P, fully and unconditionally guaranteed by The Bank of New York Mellon Corporation. In 2023, the same securities remained registered under Section 12(b) of the Act, retained the same trading symbol BK/P, and continued to be listed on the New York Stock Exchange with the same guarantee structure. Therefore, there was no change in the treatment or status of these securities between the two years.",
      "llm_answer": "\nThe 6.244 % Fixed‑to‑Floating Rate Normal Preferred Capital Securities of Mellon Capital IV were listed on the NYSE under the symbol BK/P and remained fully and unconditionally guaranteed by The Bank of New York Mellon Corporation in both the 2022 Form 10‑K (covering 2021) and the 2023 Form 10‑K (covering 2023).  No change in the securities’ terms, classification, or listing status was reported; the only evolution noted was an updated market‑value figure and the revised outstanding‑share count for the underlying common stock.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth. It accurately states that the 6.244% Fixed-to-Floating Rate Normal Preferred Capital Securities of Mellon Capital IV were listed on the NYSE under symbol BK/P and were fully and unconditionally guaranteed by The Bank of New York Mellon Corporation in both 2022 and 2023. The key facts—listing status, trading symbol, guarantee structure—are consistent with the original answer, and it correctly concludes there was no change in treatment or status. However, there is a minor inaccuracy in the LLM's reference to the '2022 Form 10-K (covering 2021)', which mischaracterizes the reporting period: the 2022 Form 10-K covers fiscal year 2022, not 2021. This introduces a small error in temporal reasoning, though the substantive information about the securities is correct. The mention of 'updated market-value figure' and 'revised outstanding-share count for the underlying common stock' is not present in the ground truth and may introduce extraneous detail not confirmed by the original data, though it does not contradict it. Quantitative accuracy is high—percentage (6.244%), symbol (BK/P), and entity names are correct. The reasoning is sound in concluding no change occurred, but the misstatement about the 10-K coverage year slightly undermines qualitative accuracy. Contextual relevance is excellent, as the response directly addresses the evolution (or lack thereof) of the securities between 2022 and 2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 407,
        "total_tokens": 1710
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has the capacity and utilization of PMI's short-term credit arrangements changed from 2022 to 2023, and what does this shift suggest about their near-term liquidity posture?",
      "original_answer": "The capacity of PMI's short-term credit arrangements increased from $1.9 billion at the end of 2022 to $2.7 billion at the end of 2023, while the actual utilization decreased slightly from $295 million to $283 million. This indicates that PMI has expanded its available liquidity buffer without increasing its drawdown, suggesting a more conservative approach to short-term financing and working capital management.",
      "llm_answer": "\nFrom 2022 to 2023 PMI’s short‑term credit **capacity grew markedly** – the uncommitted credit lines available to its subsidiaries rose from about **$1.9 billion at the end of 2022 to roughly $2.7 billion at the end of 2023**.  At the same time, **outstanding borrowings under those facilities slipped slightly**, falling from **≈ $295 million in 2022 to ≈ $283 million in 2023**.  \n\nThe combination of a larger credit pool and lower utilization signals that PMI now has a **substantially stronger near‑term liquidity buffer**, using far less of its short‑term borrowing capacity than it did a year earlier.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately reported: short-term credit capacity increased from $1.9 billion in 2022 to $2.7 billion in 2023, and utilization decreased from $295 million to $283 million. These figures match the original answer exactly, with acceptable formatting variations (e.g., '≈' and 'about' used appropriately). (2) Quantitative accuracy is perfect—no calculation errors, and all numbers align with the ground truth. (3) The reasoning is sound: the model correctly synthesizes the increase in capacity and decrease in utilization to infer a stronger liquidity buffer and more conservative liquidity posture, which is a valid interpretation of the data. (4) The answer addresses all parts of the question—changes in capacity and utilization, and the implication for near-term liquidity—demonstrating strong multi-hop reasoning by connecting numerical changes to strategic financial behavior. Wording differs slightly (e.g., 'substantially stronger near-term liquidity buffer' vs. 'more conservative approach'), but the meaning is equivalent. No omissions or inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 327,
        "total_tokens": 1590
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has Oracle's positioning of the Autonomous Database evolved between 2023 and 2024, particularly in terms of integration with other cloud services and automation capabilities?",
      "original_answer": "In 2023, Oracle positioned the Autonomous Database as part of its broader Oracle Cloud Infrastructure (OCI) offerings, emphasizing its automated database operations and the ability to run in cloud, on-premise, or hybrid environments. It was described as a service that Oracle runs, manages, upgrades, and supports on behalf of the customer, with a focus on reducing IT process time and resources. By 2024, Oracle expanded its positioning to highlight deeper integration with other Oracle Cloud services, such as Java Cloud and Oracle APEX low-code service, and emphasized open interfaces and native machine learning capabilities. The 2024 filing also introduced a stronger focus on automation powered by machine learning, including diagnostics, fault prediction, error handling, and automatic threat detection. Additionally, 2024 emphasized the Autonomous Database's role in enabling modern cloud-native application development and analytics, including data lake houses and real-time analysis of transactional data.",
      "llm_answer": "\nBetween 2023 and 2024 Oracle has moved the Autonomous Database from a stand‑alone, self‑driving DB service on OCI to the central engine of its cloud stack.  In 2024 the company emphasizes tight integration of the database with other cloud services—such as Fusion SaaS (ERP, HCM, EPM), Java Cloud, APEX low‑code, Analytics Cloud and OCI AI—while adding richer automation (ML‑driven tuning, automatic threat detection/remediation, consumption‑based elastic scaling) and new deployment options (Exadata Cloud@Customer, OCI Dedicated Region, Sovereign Cloud) that let customers run the database in their own data centers yet still have it fully managed by Oracle.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the evolution in Oracle's positioning of the Autonomous Database from 2023 to 2024 with strong factual alignment to the ground truth. It correctly identifies the shift from a self-managed, automated database service to a more integrated and central component of Oracle's cloud ecosystem. The mention of integration with Java Cloud, APEX low-code, and analytics/AI services aligns with the 2024 emphasis on deeper integration with Oracle Cloud services. The description of enhanced automation via machine learning—such as ML-driven tuning, automatic threat detection, and diagnostics—matches the ground truth's focus on ML-powered automation for fault prediction and error handling. The LLM also adds specific deployment options (Exadata Cloud@Customer, OCI Dedicated Region, Sovereign Cloud) that are consistent with Oracle’s hybrid and fully managed offerings, even if not explicitly detailed in the original answer; these represent valid extensions of the 'on-premise or hybrid' mention in 2023 and do not contradict it. The only minor gap is that the original answer highlights 'open interfaces' and 'data lake houses' and 'real-time analysis of transactional data' as part of the 2024 positioning, which the LLM does not explicitly mention. However, these are contextually implied in the reference to Analytics Cloud and modern application development. There are no numerical inaccuracies (quantitative accuracy is 10), and all entities (Oracle, OCI, APEX, Java Cloud, etc.) are correctly identified. The reasoning is sound, showing multi-hop synthesis across years and services. The answer is fully relevant and directly addresses the question about integration and automation evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1426,
        "completion_tokens": 471,
        "total_tokens": 1898
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How did GM's financial relationship with Ultium Cells Holdings LLC evolve between 2023 and 2024, particularly in terms of its capital involvement and strategic positioning?",
      "original_answer": "In 2023, GM's relationship with Ultium Cells Holdings LLC was characterized by contingent capital commitments, with a committed contribution of $0.8 billion, and the entity was classified as a variable interest entity (VIE) where GM lacked voting control. By 2024, GM's involvement evolved into a more direct investment of $0.7 billion, indicating a shift from a potential future obligation to a realized investment stake. This transformation suggests a strategic realignment, providing GM with potentially greater influence over Ultium Cells' operations while stabilizing its financial exposure.",
      "llm_answer": "\nBetween 2023 and 2024 GM’s capital involvement with Ultium Cells Holdings LLC changed only modestly: the company recorded a $0.7 billion cash outflow for an equity investment in 2024 (the same amount as in 2023) and its committed capital contribution fell from $1.4 billion at the end of 2022 to $0.8 billion at the end of 2023.  GM continues to treat Ultium Cells as a non‑consolidated VIE—without voting control—so its exposure is limited to the equity investment and the modest committed funding, while using the partnership mainly as a strategic link to its EV‑battery supply chain rather than as a source of direct financing.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. Most critically, it claims GM made a $0.7 billion equity investment in 2024 'the same amount as in 2023'—but the ground truth states that in 2023, GM had a $0.8 billion *committed* contribution (not an actual investment), and no actual investment occurred in 2023. The LLM incorrectly implies a realized $0.7B investment in both years, which contradicts the ground truth where 2023 was contingent and 2024 was actual. Additionally, the LLM references a $1.4B commitment at the end of 2022, which is not mentioned in the ground truth and introduces unverified data. (2) Quantitative accuracy is partially correct: the $0.8B committed contribution in 2023 and $0.7B actual investment in 2024 are correctly stated in magnitude, but the LLM misattributes timing and nature (committed vs. actual). The $1.4B figure has no support in the ground truth and is a significant error. (3) Multi-hop reasoning is flawed: the LLM fails to capture the strategic evolution from contingent obligation to direct investment, instead suggesting minimal change. It also misses the implication of increased strategic influence in 2024, incorrectly stating GM 'continues' to treat Ultium as a non-consolidated VIE without noting any shift in control or influence. The ground truth emphasizes a strategic realignment, which the LLM overlooks. (4) Contextual relevance is high—the answer addresses capital involvement and strategic positioning as asked—but due to factual and reasoning errors, the qualitative and correctness scores are low. The answer synthesizes some correct elements but draws incorrect conclusions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 454,
        "total_tokens": 1767
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has the financial impact of the Litigation Management Deed evolved between 2022 and 2024, particularly in terms of the amount of as-converted value released and the number of series A preferred shares issued during the anniversary releases?",
      "original_answer": "In 2022, as part of the sixth anniversary release assessment required by the Litigation Management Deed, Visa released $3.5 billion of as-converted value and issued 176,655 shares of series A preferred stock. In 2024, during the eighth anniversary release, the company released $2.7 billion of as-converted value and issued 99,264 shares of series A preferred stock. This indicates a decrease in both the value released and the number of shares issued, suggesting a reduction in the financial burden associated with the VE territory covered litigation over time.",
      "llm_answer": "\nBetween the sixth‑anniversary release in 2022 and the eighth‑anniversary release in 2024, the Litigation Management Deed unlocked less of the preferred‑stock protection: the Company released **$3.5 billion** of as‑converted value in 2022 versus **$2.7 billion** in 2024.  Accordingly, the number of series A preferred shares issued fell from **176,655 shares** (2022) to **99,264 shares** (2024), with cash payments of $3 million and $5 million respectively to cover any fractional shares.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key factual information: $3.5 billion and $2.7 billion as-converted value released in 2022 and 2024, respectively, and 176,655 and 99,264 series A preferred shares issued in those years. These match the ground truth exactly. The mention of $3 million and $5 million cash payments for fractional shares is an additional detail not present in the original answer; however, it does not contradict the ground truth and may reflect supplementary information from the filing. (2) Quantitative accuracy is perfect: all numbers, years, and financial figures are correct and properly attributed to the respective years. Format variations (e.g., $3.5 billion vs $3.5B) are acceptable and semantically equivalent. (3) The multi-hop reasoning is sound—LLM correctly synthesizes data across two time points (2022 and 2024) and compares both the as-converted value and shares issued, capturing the trend of decreasing financial impact. The conclusion about reduced burden is implied correctly. (4) The only minor shortcoming is that the LLM introduces cash payments not mentioned in the original answer, which, while plausible, slightly deviates from the provided ground truth without confirmation. This does not reduce correctness significantly but prevents a full 10. Overall, the answer is factually accurate, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 386,
        "total_tokens": 1674
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How did the financial and strategic relationship between 3M and the Aearo Entities evolve between 2023 and 2024, particularly in terms of litigation impact and business segment adjustments?",
      "original_answer": "In 2023, 3M reconsolidated the Aearo Entities following the dismissal of their bankruptcy filings, lifting the stay on litigation related to Combat Arms Earplugs and entering into the CAE Settlement to resolve existing and future claims. This reconsolidation had an immaterial income statement impact. By 2024, the Aearo Entities were referenced in the context of divestiture and acquisition impacts in the Transportation and Electronics segment, where their deconsolidation in 2022 and reconsolidation in 2023 were each reflected separately as divestiture and acquisition effects. This indicates a shift from litigation-focused involvement in 2023 to a more strategic financial treatment in 2024.",
      "llm_answer": "\nBetween 2023 and 2024 the relationship shifted from a period of legal separation to a coordinated settlement and reporting realignment.  After the Aearo Entities filed for Chapter 11 in July 2022, 3M funded a $1.2 bn pre‑tax charge (including a $1 bn cash election for the $1 bn equity portion of the later CAE Settlement) and, following the dismissal of the bankruptcy case in June 2023, re‑consolidated the entities in Q2 2023, increasing its accrual for Combat‑Arms‑Earplug litigation to $5 bn and recording a $4.2 bn pre‑tax charge in Q3 2023 for the $6 bn settlement (paid $10 m + $147 m + $250 m + $253 m).  The settlement, finalized in August 2023 and amended in January 2024 to require cash payment for the equity portion, resolved the bulk of the earplug litigation and eliminated the need for ongoing Chapter 11 stays.  At the same time, 3M’s segment reporting was updated in Q2 2024 (post‑Solventum separation) to reflect the three‑segment structure (Safety & Industrial, Transportation & Electronics, Consumer) and to re‑classify litigation‑related special items—previously shown in Safety & Industrial and Corporate—into the appropriate segment totals, thereby adjusting segment operating‑income margins and disclosures.  These changes illustrate how the litigation settlement reshaped both the financial exposure (large accruals and charges) and the strategic presentation of 3M’s business segments.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of the financial and strategic relationship between 3M and the Aearo Entities, correctly identifying the reconsolidation in 2023 after dismissal of bankruptcy and the shift toward strategic financial reporting in 2024. However, significant quantitative inaccuracies undermine the correctness. The LLM claims a $1.2B pre-tax charge in 2022, a $5B accrual increase, and a $4.2B pre-tax charge in Q3 2023 for a $6B settlement — none of which are supported by the ground truth, which states only that reconsolidation had an immaterial income statement impact. The detailed payment breakdown ($10M + $147M + $250M + $253M) and the $6B settlement figure are not present in the original answer and appear fabricated. The mention of a January 2024 amendment requiring cash payment for equity is also absent from the ground truth. While the LLM correctly notes the reconsolidation in 2023 and the reflection of deconsolidation/reconsolidation as divestiture/acquisition effects in the Transportation and Electronics segment in 2024, it overcomplicates and distorts the financial impact. The qualitative reasoning about segment reporting changes in Q2 2024 post-Solventum separation adds context not contradicted by the ground truth but goes beyond what is stated. The core multi-hop synthesis — linking litigation resolution to financial reconsolidation and then to segment reporting adjustments — is logically sound and contextually relevant, but the inclusion of unsupported financial figures severely reduces factual accuracy. Thus, while the narrative arc is plausible and addresses both litigation and strategic adjustments, the answer is partially incorrect due to invented numbers and unverified events.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1538,
        "completion_tokens": 472,
        "total_tokens": 2011
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has the financial treatment or structure of Class C Common Stock evolved between 2022 and 2024, particularly in terms of its relationship to other stock classes and its earnings per share performance?",
      "original_answer": "In 2022, Class C Common Stock was described in the context of its voting rights and potential influence on corporate actions, particularly in mergers or strategic decisions, with an emphasis on how its holders—typically financial institution clients—might have divergent interests from Class A Common Stockholders. By 2024, Class C Common Stock had a significantly higher earnings per share ($33.17 basic EPS and $33.13 diluted EPS) compared to Class A ($8.29 basic EPS and $8.28 diluted EPS), indicating a shift in its financial performance relative to other stock classes, even though its governance role appeared unchanged.",
      "llm_answer": "\nBetween 2022 and 2024 the **Class C common stock remained authorized (≈1.1 billion shares)** but its **effective share count and conversion dynamics changed**.  A 2024 exchange of class B‑1 shares for class C shares and the periodic “anniversary releases” of series B and C preferred stock adjusted the conversion rates, reducing the number of as‑converted class A shares and altering the earnings‑allocation that feeds Class C’s EPS calculation.  Consequently, the **EPS attributable to Class C rose sharply**—from **$28.03 (basic) in 2022 to $33.17 in 2023 and $38.97 in 2024**—driven by higher allocated net income and a relatively small weighted‑average share base (≈16 million shares in each year).  Class C therefore continues to have **limited voting rights** (similar to Class B) and **no automatic conversion to Class A**, but its EPS performance is now tied to the litigation‑driven conversion‑rate adjustments and the 2024 exchange that created new Class C shares.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant quantitative inaccuracies that undermine its correctness. According to the ground truth, Class C EPS in 2024 was $33.17 (basic) and $33.13 (diluted), while Class A EPS was $8.29 (basic) and $8.28 (diluted). However, the LLM claims Class C EPS rose to $38.97 in 2024 and was $33.17 in 2023—values not supported by the original answer, which does not mention 2023 EPS at all. Additionally, the LLM incorrectly states that Class C EPS was $28.03 in 2022, which is not present in the ground truth; the original answer does not provide any EPS figures for Class C in 2022. These numerical discrepancies are critical because they misrepresent the financial performance trend. The LLM introduces specific mechanisms like 'anniversary releases' and a '2024 exchange of class B-1 shares for class C shares' that are not mentioned in the original answer, implying a level of structural change unsupported by the ground truth. While the original answer notes a shift in financial performance (higher EPS for Class C in 2024 vs Class A), it does not attribute this to conversion dynamics or share exchanges. The qualitative reasoning about governance (limited voting rights, no conversion to Class A) aligns broadly with the original mention of voting rights and influence, but the LLM overextends with unverified structural details. The answer is contextually relevant—addressing evolution in financial treatment, relationship to other classes, and EPS performance—but the factual foundation is flawed. Multi-hop synthesis is attempted (linking share structure to EPS), but based on incorrect data. Thus, while the direction of the conclusion (Class C outperforming Class A in EPS) is consistent, the specific numbers, causal mechanisms, and year-by-year progression are inaccurate or invented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1415,
        "completion_tokens": 490,
        "total_tokens": 1905
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has Qualcomm's involvement in the development and commercialization of ADAS/AD technology evolved from fiscal 2022 to fiscal 2024, based on the specific changes in their strategic activities and revenue categorization?",
      "original_answer": "In fiscal 2022, Qualcomm was actively investing in and developing ADAS/AD technologies as part of its broader innovation and strategic investment initiatives, particularly through its QSI segment and Qualcomm Ventures, with an emphasis on expanding opportunities for its technologies beyond mobile handsets. By fiscal 2024, Qualcomm's engagement had evolved from development to commercialization, as evidenced by the explicit inclusion of ADAS/AD under revenue streams categorized under 'automotive' products. This indicates that ADAS/AD transitioned from a technology under development and investment in 2022 to a revenue-generating product line by 2024.",
      "llm_answer": "\nFrom fiscal 2022 to fiscal 2024 Qualcomm shifted ADAS/AD from a generic “emerging automotive” mention in its R&D narrative to a concrete, revenue‑producing line‑item. In the 2022 filing the company only referenced automotive (and IoT) as a future application area, but the 2024 10‑K explicitly breaks out automotive revenue to include “connectivity, digital cockpit **and ADAS/AD**,” isolating ADAS/AD as a distinct sub‑category of QCT sales. This reflects a strategic evolution from early‑stage investment to measurable commercialization of ADAS/AD technologies within Qualcomm’s semiconductor business.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and closely aligns with the ground truth. It correctly identifies the evolution of Qualcomm's ADAS/AD involvement from R&D/future application in fiscal 2022 to explicit commercialization by fiscal 2024, with ADAS/AD called out as a distinct sub-category under automotive revenue in the 2024 10-K. The key entities (Qualcomm, ADAS/AD, automotive segment, QCT) and timeframes (fiscal 2022 to 2024) are correct. The reasoning is sound: it traces a multi-hop progression from strategic investment to revenue categorization, supported by changes in disclosure language. The only minor limitation is that it does not explicitly mention Qualcomm Ventures or the QSI segment, which are part of the original answer’s detail on 2022 investment activities. However, the core factual trajectory—shift from development to commercialization via revenue recognition—is accurately captured. All dates and categorizations are correct; no numerical inaccuracies exist (non-numeric question). The answer is highly contextually relevant and semantically equivalent to the ground truth, with slightly less detail on early-stage investment mechanisms.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 328,
        "total_tokens": 1662
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How has Visa's U.S. Retrospective Responsibility Plan evolved between 2022 and 2024, particularly in terms of its mechanisms for addressing liability in covered litigation, and what does this evolution suggest about the company's approach to managing litigation risk?",
      "original_answer": "In 2022, Visa's U.S. Retrospective Responsibility Plan was described as a mechanism to address monetary liabilities from settlements or final judgments in U.S. covered litigation, utilizing a U.S. litigation escrow account, though the accrual for liabilities could differ from the escrow balance. By 2024, the plan had become significantly more structured and detailed, introducing a suite of interrelated mechanisms including a U.S. litigation escrow agreement, a conversion feature for Class B common stock, makewhole agreements related to the Class B-1 exchange offer, indemnification obligations from Visa U.S.A. members, an interchange judgment sharing agreement, a loss sharing agreement, and an omnibus agreement. These additions indicate a more comprehensive and layered strategy to manage litigation risk, suggesting Visa has moved toward a more proactive and diversified approach to mitigate potential financial exposure from ongoing or future litigation outcomes.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2024 Visa deepened the financial‑engineered safeguards of its U.S. Retrospective Responsibility Plan: the litigation‑escrow account was expanded (balances rose to $3.1 bn in 2024) and the plan’s conversion‑feature and makewhole provisions were tightened so that any additional escrow deposits automatically dilute the class‑B conversion rate, thereby linking share‑structure changes directly to funding needs.  At the same time, the loss‑sharing and interchange‑judgment‑sharing agreements were broadened to cover newly‑identified opt‑out and future U.S.‑covered matters, and the omnibus‑agreement amendments formalised a 66.7 % / 33.3 % split of any settlement or judgment liability.  Together, these refinements show that Visa manages litigation risk through a structured, pre‑funded escrow buffer, contractual share‑conversion adjustments, and layered indemnity arrangements that collectively cap and isolate potential monetary exposure.",
      "correctness_score": 7,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core evolution of Visa's U.S. Retrospective Responsibility Plan from 2022 to 2024 with strong qualitative accuracy, correctly identifying key mechanisms such as the litigation escrow account, conversion features, makewhole agreements, loss sharing, interchange judgment sharing, and the omnibus agreement. It accurately reflects the trend toward a more structured, layered, and proactive approach to litigation risk management, which aligns with the ground truth. However, the quantitative accuracy is compromised by the introduction of specific figures not present in the original answer—namely, the $3.1 billion escrow balance in 2024 and the 66.7%/33.3% liability split. These numbers, while plausible, are not supported by the ground truth and represent overprecision or hallucination. The original answer notes that the accrual may differ from escrow balance but provides no dollar amounts or exact liability splits. Additionally, the claim that 'additional escrow deposits automatically dilute the class-B conversion rate' adds mechanistic detail not confirmed in the source. While the overall direction of increased structuring and risk isolation is correct, these unsupported specifics reduce factual reliability. The answer is contextually relevant and addresses all parts of the question, synthesizing multi-hop elements (evolution over time, mechanisms, risk implications), but the inclusion of unverified quantitative details prevents a higher correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1516,
        "completion_tokens": 411,
        "total_tokens": 1928
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How did Merck's financial stake in Lynparza evolve between 2023 and 2024, and what indicators suggest changes in the product's performance or strategic importance during this period?",
      "original_answer": "In 2023, Merck reported a $1.5 billion net intangible asset related to Lynparza as part of its collaboration with AstraZeneca. By 2024, although the financial stake amount was not explicitly stated, there was a 9% growth in alliance revenue linked to Lynparza, driven by increased demand in most international markets. Additionally, in January 2025, Lynparza received approval in China for an adjuvant treatment in early breast cancer, indicating expanded market potential. This suggests that while the initial asset value was substantial in 2023, 2024 marked a period of performance-driven growth and regulatory expansion, enhancing its strategic importance.",
      "llm_answer": "\nBetween 2023 and 2024 Merck’s alliance‑revenue share from Lynparza grew from **$1.199 billion to $1.311 billion**—an approximate **9 % increase**—driven by higher international demand and new regulatory approvals (e.g., the 2025 Chinese NMPA approval for adjuvant use in BRCA‑mutated breast cancer).  The product is also reflected as a **$1.5 billion net intangible asset** in Merck’s 2023 balance sheet, underscoring its strategic importance, and the company continues to expand its collaboration with AstraZeneca, indicating that Lynparza’s performance and strategic value are rising.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 9% growth in alliance revenue from Lynparza between 2023 and 2024, with specific figures of $1.199 billion in 2023 and $1.311 billion in 2024, which aligns with the 9% increase stated in the ground truth. The $1.5 billion net intangible asset in 2023 is accurately reported. The January 2025 China approval for adjuvant use in early breast cancer is correctly mentioned, though the regulator is referred to as 'NMPA' (accurate) rather than generically as 'approval in China'—a minor enhancement, not an error. (2) Quantitatively, the calculation from $1.199B to $1.311B is approximately 9.3%, which rounds to the reported 9%—acceptable given typical reporting conventions. All dollar amounts and percentages are consistent with the ground truth, though the original answer did not specify the exact revenue figures, only the 9% growth. The LLM added precision not in the original, but plausibly derived. (3) The multi-hop reasoning is sound: it connects Merck’s financial stake (intangible asset), revenue growth, regulatory developments, and strategic collaboration with AstraZeneca. It correctly infers rising strategic importance from performance and expansion. (4) The only minor deviation is that the original answer notes the 2024 financial stake was *not explicitly stated*, while the LLM provides exact revenue numbers—this is a slight overprecision but not factually incorrect, as such figures could be inferred from filings. This prevents a perfect 10. Otherwise, the answer is factually correct, complete, and contextually excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 438,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How did Skoal's market position and competitive performance within Altria's oral tobacco products segment evolve between 2022 and 2024, particularly in relation to its key competitor brands?",
      "original_answer": "In 2022, Skoal was one of the premium oral tobacco brands under Altria, alongside Copenhagen and on!, with a retail share of 9.3%. By 2024, Skoal's retail share had declined to 7.6%, indicating a weakening market position. This decline occurred alongside a broader contraction in Altria's oral tobacco segment, which saw total retail share fall from 42.5% in 2023 to 37.5% in 2024. Notably, Copenhagen, Altria's leading brand, also experienced a drop from 23.5% to 19.1% over the same period, while on! oral nicotine pouches gained traction, rising from 6.8% to 8.3%. These shifts suggest that Skoal not only lost market share overall but also underperformed relative to both its primary brand (Copenhagen) and the newer product category (on!).",
      "llm_answer": "\nBetween 2022 and 2024 Skoal’s volume fell from roughly 170 million units (about 10 % of the oral‑tobacco market) to 147 million units, and its retail‑share slipped from the low‑single‑digit‑percent range to 7.6 %. Its longtime rival Copenhagen also lost ground (≈23 % → 19 % share), while the newer on! brand grew to 8.3 % share, intensifying competition and further eroding Skoal’s position in the oral‑tobacco segment.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the core trend—Skoal's declining market position and retail share loss from 2022 to 2024—and correctly identifies competitive dynamics with Copenhagen and on!. However, there are key quantitative inaccuracies. The original answer states Skoal's 2022 retail share was 9.3%, but the LLM says it was in the 'low-single-digit-percent range,' which is factually incorrect and underrepresents the brand's initial position. The LLM introduces volume figures (170M to 147M units) not present in the ground truth, which may be plausible but are unsupported and distract from the verified retail share metric. The 2024 Skoal share (7.6%) and Copenhagen’s drop (from ~23% to 19%) are approximately correct, though the original specifies 23.5% to 19.1%. The on! growth to 8.3% is accurately reflected. (2) The calculation of Skoal’s 2022 share is wrong: 'low single digits' (e.g., <9%) contradicts 9.3%. Volume data cannot be verified and appears fabricated. (3) The reasoning is sound in interpreting market dynamics and relative performance—Skoal weakened, Copenhagen declined, on! grew—but fails to note that Altria’s overall segment share fell from 42.5% to 37.5%, a key contextual point for industry contraction. (4) Scores reflect mostly correct qualitative trends and competitive analysis (8), moderate quantitative errors in key percentages (6), full relevance to the question (10), and an overall correctness of 7 due to accurate directionality but flawed specifics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1302,
        "completion_tokens": 414,
        "total_tokens": 1716
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How has the revenue contribution from Dynamics 365 within Microsoft Cloud evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, Dynamics 365 contributed to the $91.2 billion Microsoft Cloud revenue, with Dynamics products and cloud services revenue growing 25%, driven by a 39% increase in Dynamics 365. By fiscal year 2023, the Microsoft Cloud revenue had increased to $111.6 billion, which includes Dynamics 365 as a component. Although the exact growth percentage for Dynamics 365 in 2023 is not explicitly stated, its continued inclusion in the Microsoft Cloud breakdown indicates sustained growth and integration within the broader cloud portfolio.",
      "llm_answer": "\nIn fiscal 2022 Dynamics‑related revenue (recorded as “Dynamics products and cloud services”) was $5.44 billion, and it grew to $6.48 billion in fiscal 2023 – an increase of roughly $1.04 billion, or about 19%.  Because total Microsoft Cloud revenue rose from $91.4 billion to $111.6 billion over the same period, the share of Dynamics 365 within the cloud portfolio slipped slightly, from around 6 % of cloud revenue to about 5.8 %.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth does not provide exact revenue figures for Dynamics 365 in fiscal years 2022 or 2023—only that 'Dynamics products and cloud services' grew 25% in FY2022 with Dynamics 365 up 39%. The LLM fabricates specific revenue numbers: $5.44 billion in FY2022 and $6.48 billion in FY2023. These figures are not present in the original answer and cannot be derived from the provided data. Additionally, the LLM claims a 19% growth rate, which contradicts the 39% growth for Dynamics 365 in FY2022 stated in the ground truth. The Microsoft Cloud revenue is slightly misstated as $91.4 billion in FY2022 (vs. $91.2 billion in the original), though $111.6 billion in FY2023 is correct. (2) Calculations are internally consistent (e.g., $6.48B - $5.44B = $1.04B; ~19% increase), but since the inputs are fabricated, the results are incorrect. The share calculations (6% to 5.8%) are based on false inputs and thus invalid. (3) The reasoning is structurally sound—attempting to track revenue evolution and market share shift—but fails on multi-hop synthesis because it invents data rather than acknowledging the limits of the original information. The original answer explicitly states that the exact FY2023 growth for Dynamics 365 is not provided, but the LLM assumes precise figures. (4) Contextual relevance is fair because the answer addresses the evolution of Dynamics 365’s contribution within Microsoft Cloud, but the fabrication of numbers severely undermines correctness. The qualitative reasoning would be stronger if it reflected uncertainty or lack of explicit data in FY2023, as the original does.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1237,
        "completion_tokens": 459,
        "total_tokens": 1696
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How has Merck's approach to managing foreign exchange exposure through its Balance Sheet Risk Management Program evolved from 2023 to 2024, particularly in terms of the instruments used and the scope of hedging activities?",
      "original_answer": "In 2023, Merck primarily used forward exchange contracts to offset the effects of exchange on exposures when economically beneficial, focusing on the euro, Swiss franc, Japanese yen, and Chinese renminbi. These contracts were not designated as hedges and were marked to market through Other (income) expense, net. By 2024, the company expanded its approach under a more structured balance sheet risk management program, continuing to use forward contracts but also introducing a broader framework that included purchased local currency put options and collar options. Additionally, the 2024 disclosure highlights a more strategic layering of hedges over time, increasing the portion of forecasted sales hedged as the expected dates approach, based on cost-benefit assessments.",
      "llm_answer": "\nFrom 2023 to 2024 Merck expanded and refined its Balance‑Sheet Risk Management program by markedly increasing the notional volume of foreign‑exchange forwards used to hedge both monetary‑asset translations and its net‑investment in overseas operations, and by designating a larger share of those forwards as cash‑flow hedges (using purchased‑put options, collars and a layered “layer‑in” approach that extends up to two years into the future).  It also broadened its interest‑rate hedge book, raising the number of swaps and the notional amount covering its fixed‑rate notes from $1 bn to $1.5 bn.  As a result, the program now relies on a more layered mix of designated and non‑designated FX derivatives and a larger interest‑rate swap program to manage foreign‑exchange exposure.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains several significant factual inaccuracies and introduces information not present in the ground truth, particularly regarding notional volumes, hedge designations, and interest rate swaps. (1) The claim that Merck increased the 'notional volume' of forwards and designated more as cash-flow hedges is unsupported by the original answer, which states that in 2023 forwards were *not* designated as hedges and marked to market through income, and while 2024 introduced a more structured program, there is no mention of formal hedge designation or increased notional amounts. (2) The introduction of 'purchased local currency put options and collar options' in 2024 is correct and aligns with the ground truth, as is the concept of a 'layered' approach based on timing and cost-benefit—though the LLM incorrectly names it a 'layer-in' approach extending two years, which is not specified in the original. (3) Most critically, the LLM falsely claims Merck expanded its *interest-rate* hedge book from $1B to $1.5B in swaps, which is entirely absent from the original answer—this question was about foreign exchange exposure, not interest rate risk, making this a major factual deviation. (4) The original answer does not mention hedging of net investments or monetary-asset translations explicitly, nor does it reference a change in hedge accounting treatment (e.g., cash-flow hedge designation), so the LLM overreaches in its reasoning. While the answer correctly identifies an evolution toward more structured hedging with options and layering, it fails on key quantitative and qualitative points, especially by introducing irrelevant interest rate swap data. Thus, despite some correct directional insights (use of options, broader framework), the inclusion of fabricated metrics and mischaracterization of hedge accounting leads to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1408,
        "completion_tokens": 505,
        "total_tokens": 1914
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How has PayPal's involvement with merchant receivables evolved between 2022 and 2024, particularly in terms of its credit loss provisions and direct investment in merchant financing products?",
      "original_answer": "In 2022, PayPal disclosed its methodology for estimating credit losses on merchant receivables, applying macroeconomic forecasts and historical loss data to calculate allowances, with a principal and interest coverage ratio of approximately 9% as of December 31, 2021, down from 23% in 2020. By 2024, PayPal had significantly expanded its direct involvement by purchasing approximately $1.8 billion in merchant receivables during the year, with an outstanding balance of $1.5 billion as of December 31, 2024, up from $1.2 billion in 2023. This represents a shift from primarily disclosing credit risk exposure to actively investing in and managing merchant receivables through products like PPWC and PPBL, indicating a more strategic and operational role in merchant finance.",
      "llm_answer": "\nPayPal’s merchant‑receivable business expanded materially from 2022 through 2024, with purchases of merchant receivables rising to **$1.8 billion in 2024** (up from $1.7 billion in 2023) and the outstanding portfolio growing to **$1.5 billion** (net of the partner‑institution participation interest), compared with $1.2 billion at the end of 2023.  Consequently, the **allowance for credit losses on these assets fell sharply**—from **$160 million at the end of 2023 to $113 million at the end of 2024**—and **provisions declined to $79 million in 2024 versus $162 million in 2023**, while charge‑offs also dropped to **$156 million from $300 million**.  This evolution reflects PayPal’s direct investment in merchant‑financing products (PPWC and PPBL), under which it purchases receivables from a partner institution, services them, and records the related fees as deferred revenue (see PYPL 10‑K 2022 pp. 52‑56 and PYPL 10‑K 2024 pp. 99‑103).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key quantitative figures, particularly around the allowance for credit losses and provisions, which are not supported by the ground truth. The original answer states no specific allowance or provision amounts for 2022–2024, only referencing a coverage ratio of 9% as of December 31, 2021, down from 23% in 2020. However, the LLM claims allowances fell from $160M (2023) to $113M (2024), provisions dropped from $162M to $79M, and charge-offs from $300M to $156M—none of which appear in the ground truth. These numbers are entirely fabricated or misattributed, severely undermining factual correctness. Additionally, the LLM incorrectly states that receivables purchases were $1.7B in 2023, while the ground truth only provides the 2024 purchase amount ($1.8B) and outstanding balances ($1.2B in 2023, $1.5B in 2024), with no mention of 2023 purchase volume. (2) The only correct quantitative elements are the $1.8B in receivables purchased in 2024 and the $1.5B outstanding as of December 31, 2024, matching the ground truth. The $1.2B outstanding at end of 2023 is also correct. However, the claim of $1.7B purchases in 2023 is unsupported and likely incorrect. (3) The qualitative reasoning partially captures the shift from risk disclosure to active investment, correctly identifying PPWC and PPBL as part of PayPal’s strategy and noting increased direct involvement. This reflects some correct multi-hop synthesis between product offerings and balance sheet activity. However, the erroneous financials distort the narrative of credit loss trends, making the conclusion about 'sharply falling' allowances misleading. The ground truth does not support any such trend post-2021. (4) Contextually, the answer addresses the evolution of PayPal’s role and ties it to specific products and financial activities, which is relevant. But due to major quantitative errors in credit loss metrics and unsupported year-over-year comparisons, the correctness score is low. The answer creates a false impression of improving credit quality based on invented data, despite correctly identifying the strategic shift in merchant financing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1441,
        "completion_tokens": 588,
        "total_tokens": 2030
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How has the financial significance of smokeable products to MO evolved from 2022 to 2024, considering both goodwill allocation and operating income performance?",
      "original_answer": "In 2022, the goodwill allocated to smokeable products was $99 million, indicating a relatively small portion of MO's overall asset valuation, with total goodwill at $5,177 million. By 2024, although no updated goodwill figure is disclosed specifically for smokeable products, their operating income contribution rose to $10,821 million in 2024 from $10,670 million in 2023, showing sustained profitability. This suggests that while the strategic asset valuation (via goodwill) remained stable or undisclosed, the operational significance of smokeable products remained high and slightly increased in terms of earnings. The lack of updated goodwill allocation in 2024 filings for this segment implies a potential shift in reporting focus toward performance metrics rather than asset valuations.",
      "llm_answer": "\nFrom 2022 through 2024 the amount of goodwill assigned to Altria’s **smokeable‑products segment has been essentially flat at about $99 million**—a figure that represents only a tiny slice of the company’s total goodwill ($5.18 billion) and has not changed materially across the three years.  At the same time, the **operating‑income contribution of that segment has remained the company’s primary profit driver**, edging upward from roughly **$10.5 billion in 2022 to $10.82 billion in 2024** (with $10.67 billion recorded in 2023), underscoring that despite unchanged goodwill, smokeable products continue to generate the bulk of Altria’s earnings.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the $99 million goodwill allocation to smokeable products in 2022 and maintains it as flat through 2024, consistent with the ground truth which notes no updated goodwill figure is disclosed for 2024—thus, stating it as 'essentially flat' is a reasonable interpretation. The total goodwill is accurately reported as $5.18 billion (vs. $5,177 million in 2022), a negligible rounding difference. Operating income figures are precisely aligned: $10.5 billion in 2022 (approximation of $10,670M in 2023 and implied ~$10.5B in 2022 based on trend), $10.67 billion in 2023, and $10.82 billion in 2024—all matching the ground truth. (2) Quantitative accuracy is excellent: all dollar amounts, years, and trends are correct or acceptably rounded for clarity (e.g., $10.5B as approximation). No calculation errors. (3) Multi-hop reasoning is sound—LLM synthesizes goodwill allocation (asset valuation) and operating income (performance) across three years, correctly inferring that despite stagnant or undisclosed goodwill, operational profitability increased slightly, reinforcing the financial significance. It captures the implied shift in reporting focus by emphasizing performance over valuation. (4) The only minor shortcoming is that the original answer notes the lack of updated goodwill disclosure may indicate a shift in reporting focus, a nuance slightly underemphasized in the LLM response, though the core conclusion about sustained earnings importance is well-supported. Overall, the answer is factually correct, comprehensive, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1364,
        "completion_tokens": 441,
        "total_tokens": 1805
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How has the revenue contribution from the commercial portion of LinkedIn within Microsoft Cloud evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, the Microsoft Cloud revenue, which includes the commercial portion of LinkedIn, was reported at $91.2 billion. By fiscal year 2023, this figure had increased to $111.6 billion, indicating a significant growth in the commercial cloud segment that includes LinkedIn. This increase suggests a stronger revenue contribution from LinkedIn's commercial services within the broader Microsoft Cloud portfolio.",
      "llm_answer": "\nThe commercial portion of LinkedIn contributed roughly **$13.6 billion** to Microsoft Cloud in fiscal 2022 and **$15.0 billion** in fiscal 2023, reflecting an increase of about **$1.4 billion (≈10 %)** over that one‑year period.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its quantitative claims. The ground truth states that Microsoft Cloud revenue (which includes the commercial portion of LinkedIn) was $91.2 billion in FY2022 and $111.6 billion in FY2023. The LLM incorrectly reports LinkedIn's standalone commercial contribution as $13.6B and $15.0B for those years, which is not supported by the original answer or any public disclosure in the knowledge graph. There is no breakdown in the ground truth that isolates LinkedIn’s commercial revenue at this level of precision. Additionally, the claimed $1.4 billion increase (≈10%) in LinkedIn's contribution is speculative and not derivable from the provided data. The original answer only discusses the total Microsoft Cloud revenue including LinkedIn, not a separate figure for LinkedIn’s commercial portion. Thus, the LLM fabricates specific numbers that are not present in the source, failing the multi-hop reasoning task. While the direction of growth (increase) aligns qualitatively, the core financial figures are entirely inaccurate, leading to a very low correctness score. Contextual relevance is moderate because the answer addresses the right topic (LinkedIn's commercial revenue within Microsoft Cloud) and timeframe, but with false specificity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1161,
        "completion_tokens": 357,
        "total_tokens": 1518
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How did the commercialization and market expansion of Lynparza evolve between 2023 and 2024, particularly in terms of geographic approvals and revenue growth?",
      "original_answer": "In 2023, Lynparza received FDA and Japan's MHLW approvals for treating BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) in combination with abiraterone and prednisone or prednisolone, based on the PROpel trial. By 2024, alliance revenue related to Lynparza grew by 9%, largely due to higher demand in most international markets. Additionally, in January 2025, Lynparza received China's NMPA approval for adjuvant treatment of germline BRCA-mutated, HER2-negative high-risk early breast cancer, based on the OlympiA trial, indicating a significant geographic and therapeutic area expansion.",
      "llm_answer": "\nBetween 2023 and 2024 Lynparza’s geographic footprint expanded primarily through the FDA’s May 2023 approval for BRCA‑mutated mCRPC and the subsequent August 2023 Japan MHLW approval for the same indication, after which the drug was marketed in both the United States and Japan.  In 2024 the product’s commercial reach broadened further, generating a 9 % rise in alliance revenue (driven by stronger demand across multiple international markets) even though no additional major regulatory approvals were recorded during that year.  This revenue growth reflects the deepening market penetration of the drug beyond its initial U.S. and Japanese launches.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 2023 FDA and Japan MHLW approvals for BRCA-mutated mCRPC, specifying the correct indication and timing (May 2023 and August 2023), which aligns with the ground truth. It accurately reports the 9% growth in alliance revenue in 2024, attributing it to increased international demand. However, it omits the January 2025 China NMPA approval for adjuvant treatment in early breast cancer, which is a key part of the commercialization and market expansion narrative, particularly for geographic and therapeutic expansion. While the omission does not invalidate the rest of the answer, it represents a significant missing element in completeness. (2) All quantitative elements are correct: the 9% revenue growth is accurately cited, and the dates (May 2023, August 2023) are consistent with the ground truth. No calculations are required, and all numbers are presented accurately. (3) The reasoning is sound in linking regulatory approvals to market expansion and using revenue growth as an indicator of international uptake. The model correctly synthesizes information across time and geography for 2023–2024, though it fails to incorporate the forward-looking but relevant 2025 China approval that was included in the original answer as part of the evolution trajectory. (4) The answer is highly contextually relevant, directly addressing geographic approvals and revenue trends. The scores reflect high accuracy with a moderate deduction for incompleteness on a key multi-hop fact (China approval) that was part of the original answer’s conclusion about expansion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 442,
        "total_tokens": 1761
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How did RTX's financial treatment of the Powder Metal Matter evolve between 2023 and 2024, particularly in terms of its impact on future income tax benefits?",
      "original_answer": "In 2023, the Powder Metal Matter was noted as a reduction in sales, indicating a negative financial impact. By 2024, the Powder Metal Matter was specifically listed under future income tax benefits at $455 million, down from $644 million in 2023, showing a shift in its financial treatment from a sales reduction to a recognized tax benefit. This represents a decrease of $189 million, or about 29.3%, in its value contribution to future tax benefits.",
      "llm_answer": "\nBetween 2023 and 2024 the deferred‑tax asset that RTX had recorded for the Powder Metal Matter fell sharply—from **$644 million** in 2023 to **$455 million** in 2024.  This decline reflects the amortization/realization of the temporary difference created by the matter and means the company will have **less future income‑tax benefit** to draw on from that item.  Consequently, the tax‑related advantage of the Powder Metal Matter is diminishing, reducing the amount of tax savings RTX can expect in upcoming periods.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: the deferred-tax asset decreased from $644 million in 2023 to $455 million in 2024, matching the original answer. The implied decrease of $189 million is accurate, though the LLM does not explicitly state the percentage drop (29.3%), which is a minor omission. (2) The entity (RTX), the subject (Powder Metal Matter), and the years (2023–2024) are correctly identified. (3) The reasoning is sound: the shift from a sales reduction in 2023 to a future tax benefit in 2024 is correctly interpreted as a change in financial treatment, and the explanation that the declining deferred-tax asset reduces future tax benefits is logically and factually correct. The LLM correctly infers amortization/realization as the cause, which is consistent with accounting principles, even if not explicitly stated in the ground truth. (4) The answer is contextually relevant and directly addresses the evolution in financial treatment and its impact on future income tax benefits. The only minor shortcoming is the lack of explicit mention of the 29.3% decrease, which slightly affects completeness but does not detract from the core correctness. Hence, a score of 9 is justified for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1245,
        "completion_tokens": 383,
        "total_tokens": 1628
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How did the borrowing capacity and terms of the Paidy Credit Agreement evolve from 2022 to 2024?",
      "original_answer": "In 2022, the Paidy Credit Agreement provided a secured revolving credit facility of approximately $198 million, with $98 million outstanding as of December 31, 2021. By 2024, the Paidy Credit Agreement had been modified to increase the borrowing capacity to ¥90.0 billion (approximately $574 million as of December 31, 2024), and it was restructured as an unsecured facility. The interest rate also changed from unspecified terms in 2022 to a rate based on the Tokyo Interbank Offered Rate plus a margin ranging from 0.40% to 0.60% in 2024. The maturity date was set for February 2027, and the agreement now includes a financial covenant requiring a maximum consolidated leverage ratio.",
      "llm_answer": "\nFrom 2022 through 2024 the Paidy Credit Agreement grew from an initial unsecured revolving line of ¥60 billion (≈ $574 million) that was expanded in September 2022 by an additional ¥30 billion, bringing total capacity to ¥90 billion (≈ $574 million); by the end of 2024 the full ¥90 billion had been drawn, leaving essentially no remaining borrowing capacity. The facility bears interest at the Tokyo Interbank Offered Rate plus a 0.40 %–0.60 % margin and matures in February 2027, at which point all outstanding balances must be repaid unless the agreement is terminated earlier. (PYPL 10‑K 2022, pp. 48‑52; PYPL 10‑K 2024, pp. 103‑107)",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that the initial facility in 2022 was ¥60 billion (≈$574 million) and unsecured, while the ground truth indicates a $198 million secured facility in 2022. The LLM also claims the full ¥90 billion was drawn by end-2024 with no remaining capacity, but the original answer does not state this—only that the capacity increased to ¥90 billion (≈$574 million). The LLM misrepresents the 2022 terms by claiming the facility was unsecured from the start, whereas it was secured in 2022 and became unsecured only after restructuring in 2024. (2) Quantitative errors include the incorrect initial amount ($198M vs. claimed ¥60B), wrong conversion (¥90B ≈ $574M as of 2024 is correct, but claiming ¥60B ≈ $574M is mathematically inconsistent), and erroneous assertion that the full amount was drawn. The $98M outstanding as of Dec 31, 2021, is omitted entirely. (3) The multi-hop reasoning is partially sound in tracking changes over time and citing correct maturity (Feb 2027) and interest rate (TIBOR + 0.40%-0.60%), but fails to accurately represent the evolution because it misstates the initial 2022 terms and omits the shift from secured to unsecured. The restructuring nature of the change is misrepresented as a simple expansion. (4) Contextual relevance is high—the answer addresses borrowing capacity, terms, interest rate, maturity, and timeline—but factual correctness is severely compromised by key number and attribute errors, warranting a low correctness and quantitative accuracy score despite relevant structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 442,
        "total_tokens": 1760
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How has Altria's reliance on long-term senior unsecured notes as part of its capital resources evolved between 2022 and 2024?",
      "original_answer": "In 2022, Altria's capital resources included access to credit markets through the issuance of long-term senior unsecured notes, along with $4.5 billion in cash and cash equivalents. By 2024, Altria continued to rely on long-term senior unsecured notes as a key source of capital, but its cash and cash equivalents decreased to $3.1 billion. While the company maintained its $3.0 billion Credit Agreement and continued to use similar capital instruments, the reduction in cash reserves suggests a potentially increased reliance on external financing mechanisms, including long-term senior unsecured notes, to support its operations and strategic initiatives such as dividend payments, share repurchases, and debt repayment.",
      "llm_answer": "\nAltria’s use of long‑term senior unsecured notes has steadily declined from the peak seen in 2021‑2022.  After issuing $5.5 bn of notes in February 2021 and carrying about $28 bn of total debt at the end of 2021, the company repaid roughly $5 bn of those notes in 2021‑2022 and, by the end of 2024, had reduced long‑term debt to $24.9 bn (down from $26.2 bn in 2023) and relied more on internal cash flows, commercial‑paper borrowings and its $3 bn revolving credit facility for financing.  Consequently, new senior‑note issuances after 2021 have been smaller and purpose‑specific (e.g., the $1 bn February 2025 issuance to refinance near‑term maturities), reflecting a deliberate de‑leveraging of its capital structure.  (Pages 47‑51 of MO_10k_2024; Note 9 and Capital Markets discussion.)",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth. (1) The original answer states that Altria continued to rely on long-term senior unsecured notes as a key capital source in 2024, with only a reduction in cash reserves suggesting potentially increased reliance on such notes. In contrast, the LLM claims a 'steady decline' in use of these notes and a shift toward de-leveraging and internal cash flows, which is not supported by the ground truth. (2) Quantitatively, the LLM introduces specific figures not present in the original answer: $5.5B issuance in 2021, $28B debt in 2021, $5B repayment, $24.9B debt in 2024, and $26.2B in 2023. These numbers are not in the ground truth and cannot be verified against it; more importantly, they imply a detailed debt reduction narrative absent from the correct answer. The original answer only provides cash and cash equivalents ($4.5B in 2022, $3.1B in 2024) and mentions a $3.0B credit agreement—none of which are contradicted by the LLM, but the added quantitative detail is extraneous and misleading. (3) The reasoning is flawed: the LLM infers a strategic de-leveraging and reduced reliance on senior unsecured notes, while the ground truth suggests stable reliance on such notes and a possible increase due to lower cash reserves. This misrepresents the evolution of Altria’s capital structure. (4) Contextual relevance is moderate—the answer discusses capital resources and financing instruments relevant to the question—but the core conclusion about evolving reliance is factually wrong. The LLM fails the multi-hop synthesis by not connecting the decrease in cash to a potential increase in external financing reliance, instead asserting the opposite. Overall, major factual and directional errors result in a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1373,
        "completion_tokens": 487,
        "total_tokens": 1860
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How did RTX's financial treatment of the Powder Metal Matter evolve between 2023 and 2024, and what does this indicate about its impact on future income tax benefits?",
      "original_answer": "In 2023, the Powder Metal Matter contributed $644 million to RTX's future income tax benefits. By 2024, this amount decreased to $455 million, indicating a reduced financial benefit from the Powder Metal Matter over time. This decline suggests a diminishing positive impact on RTX's tax position related to this factor.",
      "llm_answer": "\nIn 2023 RTX took a $5.4 bn net‑sales charge and a $2.5 bn reduction in cost of sales related to the Powder Metal Matter, which sharply lowered pretax earnings; the resulting large pretax loss gave the 2023 effective tax rate a roughly 4 % boost as the loss generated a disproportionate tax benefit. By 2024 that Matter no longer drives earnings, and the 2024 tax rate is now shaped by recurring items such as audit settlements, R&D credits, FDII benefits and other tax adjustments, indicating that the one‑time tax advantage from the Powder Metal Matter has been exhausted and future income‑tax benefits will come from those ongoing credit and settlement items rather than the Matter itself.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in terms of quantitative details. The ground truth states that the Powder Metal Matter contributed $644 million to RTX's future income tax benefits in 2023 and $455 million in 2024, showing a decline. However, the LLM claims a $5.4 billion net-sales charge and a $2.5 billion reduction in cost of sales—figures not present in the ground truth—and frames the tax benefit as a one-time boost to the effective tax rate due to a loss, which contradicts the original answer’s focus on future income tax benefits. There is no mention in the ground truth of pretax losses, effective tax rate impacts, or the specific charges cited. (2) The numbers provided in the LLM answer ($5.4B, $2.5B, 4%) are entirely inconsistent with the ground truth and unsupported by it. The correct values are $644M (2023) and $455M (2024), with a decrease of $189M indicating reduced future tax benefits. The LLM fails to report these actual figures or the trend they represent. (3) The reasoning is flawed: while the LLM attempts multi-hop synthesis by linking financial events to tax implications, it invents a narrative around earnings charges and loss-driven tax benefits rather than reporting the stated reduction in future tax benefits. It incorrectly concludes the tax advantage was 'exhausted' and replaced by recurring items, whereas the ground truth only indicates a reduction, not elimination, in the benefit from the Powder Metal Matter. (4) Despite incorrect facts, the answer is contextually relevant—it addresses the evolution of the Powder Metal Matter’s tax impact and attempts to explain future implications. However, due to major factual and quantitative errors, the correctness score is low. The qualitative reasoning shows some understanding of tax dynamics but misapplies it, warranting partial credit.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1257,
        "completion_tokens": 500,
        "total_tokens": 1758
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has PayPal's utilization of the Paidy Credit Agreement evolved between 2022 and 2024, particularly in terms of borrowing capacity and actual drawdown?",
      "original_answer": "In 2022, PayPal had approximately $198 million in borrowing capacity under the Paidy Credit Agreement, with $98 million outstanding as of December 31, 2021, leaving about $100 million available. By 2024, the borrowing capacity had increased to approximately $574 million (¥90.0 billion), and the full amount was drawn down, leaving no borrowing capacity available. This reflects a significant increase in both the scale of the facility and PayPal's reliance on it over the period.",
      "llm_answer": "\nBetween 2022 and 2024 PayPal expanded the Paidy Credit Agreement’s capacity dramatically—​the facility was increased in February 2022 from roughly $100 million (the amount outstanding as of 12/31/21) to a total of ¥90 billion, or about $574 million, as of 12/31/24. By the end of 2024 the company had drawn the full ¥90 billion (≈ $574 million), leaving essentially no borrowing capacity left under the agreement. This represents a shift from a modest, partially‑used $100 million line in 2021‑22 to a fully‑utilized $574 million facility by 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth, with only a minor discrepancy in the interpretation of 2022 borrowing capacity. (1) Quantitatively: The LLM states that the facility was increased in February 2022 from roughly $100 million (outstanding as of 12/31/21) to ¥90 billion (~$574M) by end of 2024. However, the original answer clarifies that in 2022, the borrowing capacity was ~$198M, not $100M, with $98M drawn and ~$100M available. The LLM conflates 'available capacity' ($100M) with 'total capacity' in 2022, which is a subtle but notable error. The 2024 figures are correct: ¥90.0 billion ≈ $574M fully drawn. (2) Completeness: The answer addresses both borrowing capacity evolution and actual drawdown across 2022–2024, satisfying the multi-part question. (3) Entity accuracy: PayPal, Paidy Credit Agreement, years (2022, 2024), and financial metrics are correctly identified. (4) Reasoning: The synthesis across time points is logical—showing expansion and full utilization—but slightly misrepresents the 2022 starting capacity. (5) Semantic equivalence: Despite the capacity confusion, the overall trend (significant increase and full drawdown) is correctly conveyed. Minor deduction in quantitative accuracy due to the $198M vs implied $100M total capacity in 2022. Contextual relevance is perfect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 376,
        "total_tokens": 1635
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has the ownership structure and equity relationship between Accenture plc and Accenture Canada Holdings Inc. evolved from 2023 to 2024, particularly regarding noncontrolling interests and exchangeable shares?",
      "original_answer": "In 2023, the noncontrolling ownership interests in Accenture Canada Holdings Inc. held by certain current and former members of Accenture Leadership were less than 1% as of August 31, 2024. By 2024, the structure had evolved to include detailed provisions around Accenture Canada Holdings Inc. exchangeable shares, which can be exchanged for Accenture plc Class A ordinary shares on a one-for-one basis or redeemed for cash. Additionally, Accenture plc Class X ordinary shares were tied directly to these exchangeable shares, with a restriction ensuring the number of Class X shares does not fall below the number of exchangeable shares held. This indicates a more formalized and structured equity relationship in 2024 compared to the simpler noncontrolling interest disclosure in 2023.",
      "llm_answer": "\nFrom 2023 to 2024 the equity linkage between Accenture plc and Accenture Canada Holdings Inc. remained essentially unchanged: the Canadian entity is still a wholly‑owned subsidiary, but a tiny non‑controlling stake—less than 1 % of its equity as of 31 August 2024—is held by certain current and former members of Accenture Leadership.  Holders of Accenture Canada Holdings Inc. exchangeable shares can still exchange them one‑for‑one for Accenture plc Class A ordinary shares (or, at our option, receive cash), and these exchangeable shares continue to carry the same distribution rights and Class X share features (no dividends, redeemable at par, subject to redemption limits).  Consequently, while the legal structure and the exchange‑share mechanism persisted, the non‑controlling interest stayed immaterial and did not experience a material change in size or composition over the 2023‑2024 period.",
      "correctness_score": 6,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually accurate in terms of quantitative details: the less than 1% noncontrolling interest as of August 31, 2024, the one-for-one exchangeability of Accenture Canada Holdings Inc. exchangeable shares into Accenture plc Class A ordinary shares, and the cash redemption option are all correctly reported. The dates and percentages match the ground truth, satisfying quantitative accuracy. However, the qualitative reasoning and completeness are flawed. The original answer emphasizes an evolution in the ownership structure from 2023 to 2024—specifically, a shift toward a more formalized equity framework involving Class X shares and structural safeguards (e.g., the restriction that Class X shares must not fall below the number of exchangeable shares). The LLM answer incorrectly asserts that 'the equity linkage... remained essentially unchanged' and that 'the legal structure and exchange-share mechanism persisted,' which contradicts the ground truth's emphasis on structural evolution and formalization. This misrepresents the multi-hop synthesis required: the model fails to recognize that the introduction or explicit disclosure of Class X share mechanics and structural restrictions constitutes a meaningful change in the equity relationship, not merely a continuation. While the LLM mentions Class X shares and their features, it frames them as pre-existing and unchanged, missing the nuance of structural maturation. Thus, despite correct numbers and entities, the reasoning and interpretation are partially incorrect, leading to a moderate correctness score. Contextual relevance is high because the answer addresses ownership, noncontrolling interests, exchangeable shares, and the 2023–2024 timeframe directly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1438,
        "completion_tokens": 472,
        "total_tokens": 1910
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has Merck's approach to managing balance sheet risk through forward exchange contracts evolved between 2022 and 2024, particularly in terms of the currencies and cost-benefit considerations?",
      "original_answer": "In 2022, Merck explicitly outlined a balance sheet risk management program that involved the use of forward exchange contracts to offset exposures in both developed and developing country currencies, with a specific mention of the Chinese renminbi. The decision to hedge developing country currencies was based on a cost-benefit analysis considering exposure magnitude, exchange rate volatility, and hedging instrument cost. By 2024, while the balance sheet risk management program was still referenced, the detailed discussion around cost-benefit analysis and the specific mention of the Chinese renminbi in the context of developing countries was omitted. This suggests a shift in emphasis or a potential simplification of the decision-making framework for hedging non-developed market exposures.",
      "llm_answer": "\nBetween 2022 and 2024 Merck broadened and systematized its forward‑exchange hedging program.  It kept hedging forecasted sales in the euro, Japanese yen and Chinese renminbi, but added a dedicated balance‑sheet layer that uses forwards for monetary‑asset exposures in developed currencies and, when a cost‑benefit analysis shows the exposure is large enough, for developing‑currency items; the company also began designating forwards as net‑investment hedges and often pairs them with euro‑denominated debt, always layering new hedges over time and weighing the size of the exposure, exchange‑rate volatility and the cost of the hedge before entering the contract.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and misrepresents the evolution of Merck's approach to balance sheet risk management between 2022 and 2024. (1) The original answer indicates that in 2022, Merck used forward exchange contracts for both developed and developing country currencies, specifically mentioning the Chinese renminbi, with a cost-benefit analysis guiding the decision. By 2024, the detailed discussion of cost-benefit analysis and specific mention of the renminbi were omitted, suggesting a simplification or shift in emphasis. In contrast, the LLM answer incorrectly claims that Merck 'broadened and systematized' its program and added a 'dedicated balance-sheet layer,' which is not supported by the ground truth. It also falsely states that hedging of developing currencies occurs 'when a cost-benefit analysis shows the exposure is large enough' in 2024, while the original answer notes the removal of such detailed rationale in the later period. (2) There are no explicit numerical values to verify, so quantitative accuracy is based on structural elements like time periods and currency names. While currencies mentioned (euro, yen, renminbi) are plausible, the LLM adds euro-denominated debt and net-investment hedge designations not present in the original, introducing unsupported details. (3) The multi-hop reasoning is flawed: instead of identifying a reduction in transparency or detail about the cost-benefit framework from 2022 to 2024, the model invents an expansion and operational refinement of the program. This reverses the actual trend suggested by the ground truth. (4) Contextual relevance is moderate because the answer discusses forward contracts, currencies, and cost-benefit considerations as required, but the synthesis is incorrect. Overall, the LLM fabricates program enhancements rather than reporting the documented shift in disclosure emphasis, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 522,
        "total_tokens": 1900
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "What does the change in RTX's disclosure about the Powder Metal Matter between 2023 and 2024 suggest about its ongoing financial impact on future income tax benefits?",
      "original_answer": "In 2023, the Powder Metal Matter was disclosed as having a net sales charge of $5.3 billion, which negatively impacted net products sales at Pratt & Whitney and contributed to a decline in overall revenue. By 2024, the Powder Metal Matter was listed under future income tax benefits with a value of $455 million, down from $644 million in 2023. This shift indicates that while the matter continues to carry financial significance, its treatment has evolved from a direct operational loss to a deferred tax asset, suggesting a reduction in its immediate negative impact and a potential long-term recovery or resolution.",
      "llm_answer": "\nThe 2024 filing shows the deferred‑tax asset that had been recorded for the Powder Metal matter falling sharply—from about $644 million in 2023 to roughly $455 million in 2024—and the associated valuation allowance being trimmed by a comparable amount.  This reduction indicates that the tax credit generated by the matter is being exhausted (or fully reserved) and that RTX no longer expects any significant future income‑tax benefit from that item.  In short, the ongoing financial impact of the Powder Metal matter on future tax benefits is now minimal.",
      "correctness_score": 4,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer is partially correct in terms of quantitative accuracy: it correctly reports the decrease in the deferred tax asset from $644 million in 2023 to $455 million in 2024, which aligns with the ground truth. These numbers are accurate and properly attributed to the Powder Metal Matter and RTX, satisfying entity and numerical correctness. However, the qualitative reasoning and interpretation are flawed. The ground truth states that the shift from a $5.3 billion net sales charge in 2023 to a future income tax benefit of $455 million in 2024 indicates a change in treatment from an operational loss to a deferred tax asset, suggesting reduced immediate impact and potential long-term resolution. In contrast, the LLM interprets the decline in the deferred tax asset as evidence that the tax benefit is being exhausted and that there is now minimal future impact. This misinterprets the significance: a reduction in the deferred tax asset value does not necessarily mean the benefit is exhausted or that no future value remains—it may reflect recognition or reassessment, not elimination. The LLM incorrectly concludes 'minimal ongoing financial impact,' while the original answer suggests continued significance as a deferred tax asset. This represents a failure in multi-hop reasoning: the model fails to connect the shift in disclosure category (from operational loss to tax asset) as a sign of evolving financial treatment and recovery trajectory. While the context and entities are relevant and mostly accurate, the core inference about future income tax benefits is contradicted by the ground truth, leading to a low correctness score despite strong quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 458,
        "total_tokens": 1757
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How has PayPal's involvement in the merchant receivables space evolved between 2022 and 2024, particularly in terms of its relationship with partner institutions and the scale of its merchant finance offerings?",
      "original_answer": "In 2022, PayPal described its U.S. merchant finance products (PPWC and PPBL) as being provided under a program agreement with WebBank, where PayPal could purchase the related receivables and also sell back a participation interest in the pool of receivables to WebBank. PayPal accounted for this arrangement as a sale and derecognized the portion of participation interests for which control was surrendered. By 2024, PayPal's relationship with partner institutions had evolved, with PayPal now purchasing approximately $1.8 billion in merchant receivables in 2024 (up from $1.7 billion in 2023), and the total outstanding balance in the pool of merchant loans, advances, and interest and fees receivable reached $1.5 billion as of December 31, 2024 (up from $1.2 billion as of December 31, 2023). Additionally, the participation interest sold to the partner institution increased to $53 million in 2024 from $44 million in 2023, indicating a growing level of investment in and collaboration around merchant receivables.",
      "llm_answer": "\nBetween 2022 and 2024 PayPal’s merchant‑finance business grew substantially in size—purchasing about $1.8 billion of merchant receivables in 2024 (up from $1.7 billion in 2023) and holding a $1.5 billion portfolio (versus $1.2 billion in 2023)—while still relying on the same partnership model.  In the United States the credit is originated by WebBank, which PayPal purchases and services, and the risk is shared through a participation‑interest arrangement; internationally the company extends similar advances through its Luxembourg and Australian subsidiaries.  At the same time, PayPal has tightened its underwriting and credit‑loss monitoring, as evidenced by a lower allowance for credit losses on merchant receivables in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All quantitative figures are correct: $1.8 billion in receivables purchased in 2024 (up from $1.7 billion in 2023), $1.5 billion portfolio balance as of December 31, 2024 (vs. $1.2 billion in 2023), and the increase in participation interest is implied through context though not explicitly stated as rising from $44M to $53M. However, this specific dollar increase in participation interest is omitted, which is a minor gap in completeness. (2) The numbers match exactly with the original answer, and no calculation errors are present. Format variations are acceptable and clear. (3) The multi-hop reasoning is sound: the LLM correctly synthesizes PayPal’s ongoing relationship with WebBank, the structure of the program (origination by WebBank, purchase by PayPal, participation interest), and the growth trajectory from 2023 to 2024. It adds context about international operations via Luxembourg and Australia, which is consistent with PayPal’s model though not in the original answer—this is a reasonable expansion, not a factual error. (4) The mention of tightened underwriting and lower allowance for credit losses is not in the original answer and introduces new information not supported by the ground truth, slightly affecting qualitative accuracy. However, it does not contradict the original and may reflect related trends, so the impact is minimal. Overall, the answer is factually correct, comprehensive, and contextually appropriate, missing only one specific data point (participation interest amounts) for full completeness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1454,
        "completion_tokens": 441,
        "total_tokens": 1896
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How did Merck's alliance revenue from Lynparza evolve between 2022 and 2024, and what factors contributed to the change?",
      "original_answer": "In 2022, Merck's alliance revenue from Lynparza was $989 million. By 2024, this revenue grew by 9%, driven by increased demand in most international markets. The growth reflects Lynparza's expanding adoption and new approvals, such as in China in January 2025 for adjuvant treatment in early breast cancer based on the OlympiA trial.",
      "llm_answer": "\nAlliance revenue from Lynparza rose steadily – $1.12 billion in 2022, $1.20 billion in 2023 and $1.31 billion in 2024 – reflecting a series of growth‑driving factors.  The increase was powered by stronger global demand (especially outside the United States), new label expansions such as the 2025 adjuvant‑breast‑cancer approval in China and ongoing pricing advantages within the AstraZeneca collaboration, which shares profits net of cost‑of‑sales and commercialization expenses.  These dynamics offset any pressure from generic competition and drove the upward trajectory through 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in numbers and timeline. According to the ground truth, Merck's alliance revenue from Lynparza was $989 million in 2022, but the LLM claims $1.12 billion, which is a substantial overstatement (~13% higher). The LLM also provides figures for 2023 ($1.20B) and 2024 ($1.31B), implying a 33% growth from 2022 to 2024, whereas the ground truth states a 9% growth from 2022 to 2024. This results in major quantitative errors. Additionally, the LLM references a 2025 approval in China as a factor influencing 2024 revenue, but the ground truth notes the approval occurred in January 2025, which would not contribute to 2024 performance—this is a forward-looking event not yet realized in the 2024 data. (2) Calculations: The ground truth implies 2024 revenue = $989M * 1.09 = ~$1.078B, but the LLM reports $1.31B, which is 21% higher than even the correct projected value. The LLM’s year-by-year figures are unsupported and inconsistent with the source. (3) Multi-hop reasoning: While the LLM correctly identifies international demand and label expansion (China approval) as growth drivers, it misattributes timing and magnitude. It also mentions 'pricing advantages within the AstraZeneca collaboration' and 'ongoing pricing advantages,' which are not mentioned in the ground truth and introduce unverified factors. The synthesis of revenue trend and drivers is partially logical but based on incorrect data. (4) Despite incorrect numbers and timeline issues, the LLM captures the general direction (growth due to international demand and new approvals) and addresses both parts of the question (evolution and contributing factors), hence moderate qualitative and relevance scores. However, the severe numerical inaccuracies severely undermine factual correctness, warranting a low overall score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1223,
        "completion_tokens": 504,
        "total_tokens": 1728
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has PayPal's involvement in merchant receivables evolved between 2022 and 2024, particularly in terms of its financial exposure and operational role?",
      "original_answer": "In 2022, PayPal's involvement in merchant receivables was primarily framed in terms of credit losses and net charge-offs, indicating a focus on risk management and accounting treatment under CECL standards. By 2024, PayPal had significantly expanded its direct involvement through active purchases of merchant receivables—$1.8 billion in 2024 compared to $1.7 billion in 2023—and reported a growing outstanding balance of $1.5 billion, up from $1.2 billion. Additionally, PayPal took on full servicing responsibilities for these receivables, signaling a deeper operational engagement in merchant finance through products like PPWC and PPBL.",
      "llm_answer": "\nBetween 2022 and 2024 PayPal’s merchant‑receivable exposure shifted from a largely on‑balance‑sheet loan book to an asset‑light, fee‑based model.  The company now originates PPWC/PPBL advances through partner lenders and sells eligible receivables under a forward‑flow agreement, so that the allowance for merchant credit losses fell from about $160 million in 2023 to $113 million in 2024 and gross charge‑offs dropped sharply.  Operationally, PayPal’s role has become that of a service provider that underwrites, monitors credit quality and collects repayments, while the bulk of the financial risk and capital is borne by the partner institutions and the sold‑receivable facility.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth in both direction and magnitude of PayPal's evolution in merchant receivables. (1) Quantitatively, the LLM claims a decline in allowance for credit losses from $160M (2023) to $113M (2024) and cites a shift to an 'asset-light' model, but the ground truth states PayPal *increased* its direct financial exposure—purchasing $1.8B in receivables in 2024 (up from $1.7B in 2023) and reporting a growing outstanding balance of $1.5B (up from $1.2B). This indicates a move toward *greater* on-balance-sheet involvement, not less. The LLM’s numbers (e.g., $160M, $113M) are unsupported by the original answer and contradict the trend. (2) The LLM incorrectly asserts that PayPal now uses partner lenders and sells receivables under a forward-flow agreement, shifting risk off-balance sheet. In contrast, the ground truth confirms PayPal is *actively purchasing* receivables and taking on *full servicing responsibilities*, indicating deeper financial and operational involvement. (3) The qualitative reasoning is flawed: the multi-hop synthesis fails because the LLM infers a de-risking strategy when the truth is an expansion of direct engagement. The mention of PPWC and PPBL is correct contextually, but the role (service provider vs. risk bearer) is inverted. (4) Contextual relevance is moderate—terms like credit losses, servicing, and product names are relevant—but the overall narrative misrepresents the evolution. The answer fails on correctness due to major factual and directional errors in financial exposure and operational role.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1332,
        "completion_tokens": 437,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has Merck's involvement in the development and commercialization of Lynparza evolved from 2022 to 2024, particularly in terms of regulatory progress and revenue growth?",
      "original_answer": "In 2022, Merck was awaiting FDA decision on a supplemental NDA for Lynparza for the adjuvant treatment of BRCA-mutated, HER2-negative high-risk early-stage breast cancer, based on the OlympiA trial, with a PDUFA date in Q1 2022. By 2024, Lynparza had not only maintained its approvals but also expanded its regulatory footprint, with a new approval in China in January 2025 for the same indication, indicating continued global regulatory momentum. Additionally, alliance revenue related to Lynparza grew by 9% in 2024 due to increased demand in international markets, showing a measurable increase in commercial success.",
      "llm_answer": "\nFrom 2022 through 2024 Merck moved Lynparza forward with a series of regulatory milestones: the FDA accepted a supplemental NDA for an adjuvant breast‑cancer indication in Nov 2021 and awarded it Priority Review, delivering a Q1 2022 PDUFA decision that resulted in U.S. approval; the EU continued its review for a metastatic castration‑resistant prostate‑cancer label, and China’s NMPA granted approval in Jan 2025 (announced after the 2024 fiscal year).  Commercially, alliance revenue from Lynparza rose steadily—$1.116 billion in 2022, $1.199 billion in 2023 and $1.311 billion in 2024—reflecting growing demand and expanded use across its approved cancer indications.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key regulatory milestones for Lynparza from 2022 to 2024, including the FDA's acceptance of the sNDA with Priority Review and the PDUFA date in Q1 2022, which aligns with the ground truth. It also accurately notes the January 2025 approval in China, though this falls just outside the 2024 timeframe, it is correctly framed as post-2024 and consistent with the original answer’s forward-looking indication of continued momentum. However, the LLM introduces a new indication — metastatic castration-resistant prostate cancer (mCRPC) in the EU — that is not mentioned in the ground truth and is therefore extraneous or potentially incorrect. (2) Quantitatively, the LLM provides specific revenue figures: $1.116B (2022), $1.199B (2023), and $1.311B (2024). From these, the year-over-year growth in 2024 is (1.311 - 1.199)/1.199 ≈ 9.34%, which rounds to the 9% growth cited in the ground truth. This is a strong match, though the original answer does not provide annual breakdowns, so the precision of these numbers cannot be fully verified. Their inclusion enhances detail but introduces risk if unverified. (3) The multi-hop reasoning is sound: the LLM connects regulatory progress across years and geographies and links increasing revenues to commercial growth, correctly inferring sustained momentum. However, the addition of the EU mCRPC review not present in the ground truth reflects either overextrapolation or use of external knowledge, slightly undermining qualitative accuracy. (4) Despite minor overreach on one indication, the LLM captures the core evolution — regulatory expansion and revenue growth — with strong numerical support and appropriate context. The answer is highly relevant and mostly factually aligned, warranting a high correctness score with a slight deduction for unverified details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 505,
        "total_tokens": 1835
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How has Boeing's strategy with commodity purchase contracts evolved between 2022 and 2024, particularly in terms of risk management horizon and financial exposure?",
      "original_answer": "In 2022, Boeing disclosed that a 10% change in commodity prices would impact unrealized losses by $46 million, and the company used commodity swaps and purchase contracts to hedge against price volatility, neutralizing material market risk. By 2024, Boeing extended the scope of its hedging strategy, indicating the use of commodity purchase contracts and derivatives to manage exposure through 2031. This represents a shift toward longer-term risk management aligned with extended production planning cycles. The expansion from a general hedging approach in 2022 to a multi-decade horizon in 2024 suggests Boeing is proactively securing cost predictability for strategic business stability.",
      "llm_answer": "\nBetween 2022 and 2024 Boeing shifted from relying mainly on cash‑flow‑hedged commodity purchase contracts—used to offset price swings for production‑related commodities with a multi‑year (through 2028) horizon and modest exposure (e.g., a 10 % price move would alter unrealized losses by roughly $46 million)—to a broader approach that adds longer‑term aluminum purchase and sales agreements for strategic sourcing and non‑U.S. operations.  These newer contracts include both hedge‑accounted derivatives and non‑hedge agreements, increasing the notional volume and the amount of losses expected to be re‑classified from AOCI ($≈ $64 pre‑tax over the next 12 months), thereby expanding the overall financial exposure while still targeting price‑risk mitigation.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. It correctly identifies the $46 million exposure in 2022 related to a 10% change in commodity prices and acknowledges Boeing's use of hedging instruments like purchase contracts and derivatives. However, it incorrectly states that Boeing's hedging horizon extended only through 2028 in 2022, which is not supported by the original answer (the 2022 disclosure did not specify a 2028 horizon). More critically, the original answer states that by 2024 Boeing extended its hedging strategy through 2031, but the LLM answer fails to mention 2031 and instead introduces vague 'longer-term aluminum purchase and sales agreements' without specifying the new horizon. Additionally, the LLM introduces a new figure—$64 million in losses expected to be reclassified from AOCI—which is not present in the ground truth and appears fabricated or misattributed. (2) Quantitative accuracy is partially correct: the $46 million figure is accurate and properly contextualized, but the $64 million number is unsupported and incorrect. The 2028 and 2031 dates are critical to the evolution of Boeing’s strategy, and the LLM’s failure to accurately report the 2031 horizon significantly undermines factual correctness. (3) The multi-hop reasoning is flawed: while the model attempts to compare 2022 and 2024 strategies, it misrepresents the time horizons and introduces unverified financial exposure data. The conclusion about increased financial exposure due to notional volume and AOCI reclassification is not aligned with the original answer, which emphasizes enhanced cost predictability and strategic stability, not increased exposure. (4) Despite these issues, the answer is contextually relevant and addresses the core question about strategic evolution in commodity risk management. It correctly frames the shift toward longer-term contracts and strategic sourcing, showing understanding of the general direction of Boeing’s strategy, even if specifics are inaccurate. Hence, partial credit is given for qualitative reasoning and relevance, but significant deductions apply for factual and quantitative errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 583,
        "total_tokens": 1951
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How did Schwab's exposure to PALs and the associated credit risk evolve between 2021 and 2024, particularly in terms of collateralization and allowance for credit losses?",
      "original_answer": "In 2021, all PALs were fully collateralized by securities with fair values exceeding borrowings, and therefore no allowance for credit losses was required. In contrast, by 2024, although PALs experienced slight growth overall, Schwab observed a decrease in the allowance for credit losses due to lower projected loss rates and improved credit quality metrics. This reflects a shift from a focus on full collateralization as the primary risk mitigant to a broader assessment of credit quality and loss projections.",
      "llm_answer": "\nSchwab’s Pledged‑Asset Line (PAL) portfolio was fully collateralized at both December 31 2021 and December 31 2024, with the pledged securities’ fair value exceeding the outstanding PAL borrowings, so no allowance for credit losses was recorded for PALs in either year. The PAL balance grew from about $12.7 billion in 2021 to roughly $17 billion in 2024, but the collateral coverage remained sufficient, leaving the credit risk essentially unchanged and the allowance at zero.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains partially correct quantitative information but fundamentally misrepresents the evolution of Schwab's credit risk and allowance for credit losses between 2021 and 2024, contradicting the ground truth. (1) Correct elements: The PAL growth from $12.7B in 2021 to ~$17B in 2024 is consistent with the knowledge graph, and the statement that PALs were fully collateralized in 2021 is accurate. (2) Quantitative accuracy: The dollar amounts and years are approximately correct, though 'about $12.7 billion' and 'roughly $17 billion' are acceptable approximations. However, the claim that no allowance was recorded in 2024 conflicts with the ground truth, which states that an allowance *was* recorded due to a shift in risk assessment methodology—even if the allowance decreased due to improved credit quality. (3) Multi-hop reasoning failure: The LLM incorrectly asserts that because collateral coverage remained sufficient, the allowance remained at zero in both years. This contradicts the original answer, which emphasizes a strategic shift by 2024 toward using projected loss rates and credit quality metrics—implying an active allowance framework was in place. The model fails to recognize that the absence of an allowance in 2021 (due to full collateralization) vs. a *decreasing* allowance in 2024 (despite sufficient collateral) reflects a change in accounting and risk assessment approach. (4) The answer is contextually relevant and addresses the question’s focus on collateralization and credit risk, but the core qualitative inaccuracy—denying any allowance in 2024—undermines the correctness. This misstatement suggests no evolution in credit risk management, directly opposing the ground truth. Hence, while numbers are mostly right, the reasoning and factual synthesis are significantly flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1253,
        "completion_tokens": 493,
        "total_tokens": 1746
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How did Boeing's financial treatment and strategic positioning of the 777X program evolve between 2022 and 2024, given the changes in cost impacts and research & development investments?",
      "original_answer": "In 2022, the 777X program negatively impacted Boeing's financials, contributing to higher charges and a cost of sales increase, partly due to a 'reach-forward loss' on the program. By 2024, the program had transitioned to being a strategic investment priority, as evidenced by a $435 million increase in R&D spending in 2024 compared to 2023, following a $525 million increase in 2023 over 2022, indicating a shift from a cost burden to a focal point for future product development.",
      "llm_answer": "\nBetween 2022 and 2024 Boeing’s 777X program moved from a phase of heavy R&D outlays but relatively modest cost‑of‑sales pressure to a stage in which the company began booking sizable reach‑forward losses on the type.  In 2022 the program absorbed about $2.85 billion of R&D expense, and cost of sales represented roughly 94‑95 % of revenue; by 2023 the cost‑of‑sales share had fallen to 90 % as revenues grew, but development charges remained, and R&D spending rose to $3.38 billion.  In 2024 a $1.77 billion reach‑forward loss on the 777X (and related 767 charges) pushed cost of sales up to 103 % of revenue, while R&D expense kept climbing to $3.81 billion—signaling a strategic shift toward accepting higher expenditures and losses to complete certification and bring the 777X into production.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. The ground truth states that Boeing increased R&D spending by $525 million in 2023 over 2022 and by $435 million in 2024 over 2023, but the LLM fabricates precise R&D figures ($2.85B, $3.38B, $3.81B) and year-over-year increases that do not align with the original data. There is no mention in the ground truth of specific R&D totals or cost-of-sales percentages (e.g., 94-95%, 90%, 103%), nor of a $1.77 billion reach-forward loss in 2024. The original answer does not specify exact loss amounts or cost-of-sales ratios, making these LLM-provided numbers unsupported. (2) The calculation of R&D increases implied by the LLM—$530M from 2022 to 2023 and $430M from 2023 to 2024—is close in magnitude to the ground truth ($525M and $435M), but since the base figures are invented, this appears coincidental rather than accurate. The $1.77B loss and its attribution (including 767 charges) are not in the original and contradict the more general 'higher charges' mentioned without specifics. (3) The multi-hop reasoning is partially sound in that the LLM identifies a shift from financial burden to strategic investment, which aligns with the original's narrative of moving from cost impacts to increased R&D focus. However, it misrepresents the nature and timing of the shift—portraying rising losses in 2024 as part of the strategy, whereas the ground truth emphasizes increased R&D investment as evidence of strategic prioritization, not worsening losses. (4) The contextual relevance is fair because the answer addresses the evolution of financial treatment and strategic positioning, but the qualitative accuracy is low due to fabricated metrics. The correctness score is low (3) because the core financial narrative is distorted by incorrect numbers and misleading specifics, undermining trust in the synthesis. While the directional shift (cost burden to investment) is partially captured, the reasoning is built on false quantitative foundations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 555,
        "total_tokens": 1885
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How has Schwab's exposure to and risk management of Portfolio Against Loans (PALs) evolved between 2022 and 2024, particularly in terms of credit loss allowance methodology and portfolio growth?",
      "original_answer": "In 2022, Schwab applied the practical expedient for PALs due to their collateralized nature and over-collateralization requirements, which limited inherent credit loss. The company monitored collateral daily and maintained strict maintenance levels based on the type of security pledged. By 2024, PALs had contributed to the growth of the average loan portfolio, although there was a slight decrease in 2023. The overall decrease in the allowance for credit losses as a ratio to year-end loans in 2024 was attributed to improved credit quality metrics and lower projected loss rates, indicating a reduced risk profile for PALs despite portfolio growth.",
      "llm_answer": "\nBetween 2022 and 2024 Schwab’s PAL exposure grew sharply—​the balance of pledged‑asset lines rose from roughly $13 billion at year‑end 2022 to about $17 billion by the end of 2024.  The credit‑loss allowance for PALs has remained anchored in the same practical‑expedient that bases the allowance on daily collateral‑maintenance thresholds and over‑collateralization, but in 2024 the company refined the estimation by incorporating updated macro‑economic forecasts and a more formal quantitative assessment, keeping the resulting allowance immaterial relative to the larger portfolio.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces specific dollar amounts ($13B in 2022, $17B in 2024) that are not present in the original answer (ground truth), and there is no mention of a 'sharp growth' or exact portfolio balances in the truth. These numbers are unverified and likely incorrect, making the quantitative claims unsupported. The original answer notes portfolio growth and a slight decrease in 2023 but does not provide exact figures. (2) The claim that Schwab 'refined the estimation by incorporating updated macro-economic forecasts and a more formal quantitative assessment in 2024' is not present in the ground truth. While the truth mentions improved credit quality and lower projected loss rates, it does not state any methodology changes beyond the continued use of the practical expedient. This introduces a factual inaccuracy regarding methodology evolution. (3) The LLM correctly identifies the ongoing use of the practical expedient, daily collateral monitoring, and over-collateralization as risk controls, which aligns with the 2022 methodology in the original. It also correctly links portfolio growth with a relatively stable or immaterial allowance, which is consistent with the decreasing allowance ratio mentioned in the truth. However, it fails to mention the decrease in allowance ratio as a percentage of year-end loans and misattributes the reason by adding unsupported methodological refinements. (4) The contextual relevance is high because the answer addresses exposure, portfolio growth, and allowance methodology. However, the quantitative accuracy is low due to fabricated numbers and unsupported specifics. The qualitative accuracy is moderate—core concepts are present but with overreach in detail. Correctness is partially compromised by these additions, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 494,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How did MDLZ's value of British pound sterling notes change from 2022 to 2023, and what does this shift indicate about the company's foreign exchange risk management strategy?",
      "original_answer": "In 2022, MDLZ reported a value of $3 million for British pound sterling notes. By 2023, this value had increased significantly to $45 million. This shift indicates a substantial change in MDLZ's foreign exchange risk management strategy, suggesting an increased exposure to the British pound sterling, which could reflect either a strategic decision to hedge more in this currency or an increase in operational activities tied to the UK market.",
      "llm_answer": "\nThe company’s notional holding of British‑pound‑denominated debt that was used as a net‑investment hedge fell from **$360 million at the end of 2022** (shown in the “Non‑U.S. dollar debt designated as net‑investment hedges” table for 2022) to **essentially zero by the end of 2023**—the 2023 table lists only euro, Swiss‑franc and Canadian‑dollar debt and does not include any British‑pound amount.  \n\nThis reduction indicates that Mondelez International deliberately trimmed its GBP‑specific foreign‑exchange hedge, reallocating the hedge program toward other currencies (euro, Swiss franc, Canadian dollar) and reflecting a strategic shift in how it manages FX risk across its international operations.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both quantitative and qualitative aspects. (1) Quantitatively, it states that MDLZ's British pound sterling notional holding decreased from $360 million in 2022 to zero in 2023, which directly contradicts the ground truth: the actual value increased from $3 million in 2022 to $45 million in 2023. These numbers are entirely different and not within any reasonable margin of error. (2) The LLM references a 'Non-U.S. dollar debt designated as net-investment hedges' table and claims the 2023 report lists only euro, Swiss franc, and Canadian dollar debt—this contradicts the ground truth data and introduces unverified document details not present in the original answer. (3) Qualitatively, the reasoning is flawed: instead of identifying an increase in GBP exposure, the LLM claims a reduction and reallocation to other currencies, which is the opposite of the truth. This misrepresents MDLZ's foreign exchange risk management strategy. (4) Contextually, while the answer attempts to address FX risk strategy, it does so based on fabricated or misread data. The conclusion about strategic reallocation is unsupported by the ground truth. The answer fails on all core dimensions: numbers are wrong, entities and years are misused, reasoning is invalid, and the overall message contradicts the correct interpretation. Minor relevance is given only because it discusses FX risk management in a general sense.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 398,
        "total_tokens": 1693
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "Compare the interest rate disclosures for Amgen's 3.125% 2025 Notes in the 2022 and 2024 filings, and explain what this reveals about the company's approach to debt financing for this instrument.",
      "original_answer": "In the 2022 filing, Amgen disclosed a fixed interest rate of 3.125% for the 2025 Notes with no mention of variable rate terms. However, by the 2024 filing, Amgen disclosed that the interest rate for the same 3.125% 2025 Notes was tied to SOFR (Secured Overnight Financing Rate) plus 2.1%. This indicates a shift from a purely fixed-rate structure to a floating-rate mechanism, suggesting Amgen may have refinanced or repriced the notes to adapt to changing market conditions and interest rate environments.",
      "llm_answer": "\nThe 2022 filing disclosed that the 3.125% 2025 Notes carried a fixed coupon of 3.125 % but, because of interest‑rate swaps, their effective financing cost was LIBOR + 1.8 % (a floating‑rate exposure of roughly $1 bn of swap notional). The 2024 filing revises this to an effective rate of SOFR + 2.1 % (still on a $1 bn swap notional) and notes the transition from LIBOR‑based to SOFR‑based swaps, together with the related fair‑value hedge adjustments.  \n\nThis shift shows that Amgen deliberately hedges the note’s fixed‑rate liability with interest‑rate swaps to lower its funding cost and manage interest‑rate risk, and that it updates the hedge structure as market benchmarks change—demonstrating a proactive, market‑responsive approach to financing this instrument.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces information not present in the ground truth—specifically, the use of interest-rate swaps with $1 billion notional and effective rates tied to LIBOR and SOFR as hedged rates. The original answer states that in 2022, the note was disclosed as a fixed 3.125% with no variable rate mentioned, but by 2024, the rate itself was described as SOFR + 2.1%, indicating a structural change in the instrument (e.g., refinancing), not a hedge. The LLM incorrectly frames the floating-rate exposure as the result of hedges (swaps), whereas the ground truth implies a change in the actual terms of the debt. This is a significant factual divergence. (2) Quantitatively, the 3.125% fixed rate is correct for 2022, and SOFR + 2.1% appears in both answers for 2024. However, the $1 billion swap notional, LIBOR + 1.8%, and the characterization of these as 'effective' rates are not in the ground truth and cannot be verified—these numbers are likely fabricated or misattributed. (3) The multi-hop reasoning is partially sound—comparing disclosures across years and interpreting a shift in rate structure—but it misattributes the cause. Instead of recognizing a possible refinancing or repricing of the note (a direct change in debt terms), the LLM assumes an unchanged fixed-rate note with dynamic hedging, which changes the interpretation of Amgen’s financing strategy. This undermines the qualitative accuracy. (4) Contextual relevance is high because the answer addresses the comparison across years, discusses benchmark transitions (LIBOR to SOFR), and draws a conclusion about Amgen’s financing approach. However, due to the incorrect mechanism (hedging vs. actual rate change), the conclusion about a 'proactive, market-responsive approach' is based on flawed premises. Thus, while the direction of reasoning is relevant, the factual foundation is unsound, leading to a correctness score of 4—partially correct but with major factual errors in the explanation of how the rate change occurred.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 544,
        "total_tokens": 1875
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How has Schwab's reliance on its Commercial Paper Issuance Program evolved between 2022 and 2024 in response to market disruptions and rising interest rates?",
      "original_answer": "In 2022, Schwab introduced its Commercial Paper Issuance Program as one of several potential sources of external financing, alongside unsecured bank credit lines and a universal shelf registration, to address liquidity needs during market disruptions. The company emphasized that while these tools were available, access to financing could still be constrained due to credit market volatility and potential credit rating downgrades. By 2024, Schwab's reliance on the program had increased as a complement to other funding mechanisms like FHLB advances and repurchase agreements, particularly in response to rising short-term interest rates in 2022 and 2023, which led to higher client cash outflows. The company noted that these outflows, outpacing cash generated from maturities and paydowns, required supplemental funding sources, including the commercial paper program, to manage liquidity under more costly and constrained conditions.",
      "llm_answer": "\nBetween 2022 and 2024 Schwab’s use of its Commercial Paper Issuance Program receded sharply.  In the 2022 filing (pages 21‑25) the company still described the CP program as a regular source of short‑term funding, but it warned that “rising market rates and recent credit‑market disruptions have made commercial‑paper financing more costly.”  By the 2024 filing (pages 14‑18) Schwab reported that it had “largely curtailed CP issuances and now relies on alternative secured sources—such as bank credit lines, Federal Home Loan Bank advances and repo facilities—to meet liquidity needs, using the CP program only on an opportunistic, as‑needed basis.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its core claim: it states that Schwab's use of the Commercial Paper (CP) Issuance Program 'receded sharply' and that issuances were 'largely curtailed' by 2024, which directly contradicts the ground truth. According to the original answer, Schwab's reliance on the CP program actually *increased* between 2022 and 2024 as a response to rising interest rates and client cash outflows. The LLM incorrectly frames the trend as a reduction in reliance, when the truth is an increased use of the program as a complement to other funding sources. There are no numeric values (e.g., dollar amounts, percentages, dates) in either answer that can be compared for quantitative accuracy, but the temporal framing (2022 vs 2024) is correct in terms of entity and year identification. However, the reasoning is flawed: the LLM misinterprets the cause-effect relationship, suggesting that higher costs led to reduced use, while the ground truth indicates that despite higher costs and constrained conditions, the program was used more due to greater liquidity demands. The mention of alternative sources like FHLB advances and repo facilities is consistent with the original, but the synthesis is incorrect—these are described as complements, not replacements. The answer is contextually relevant in discussing funding mechanisms and market conditions, but the conclusion is factually inverted. Thus, the correctness score is low due to a major factual and directional error in the central claim.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1399,
        "completion_tokens": 417,
        "total_tokens": 1817
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How has the status and interest rate structure of the 3.625% Notes evolved from 2022 to 2024, and what does this indicate about the company's debt management strategy?",
      "original_answer": "In 2022, the 3.625% 2024 Notes had a carrying value of $1,400 million with a fixed interest rate of 3.625%. By 2024, these notes were fully paid off, as indicated by the $0 notional amount, and were replaced with floating interest rates tied to SOFR (Secured Overnight Financing Rate). This shift from fixed to floating rate debt indicates a strategic change in Amgen's debt management, aligning with broader market conditions and potentially reducing interest costs in a declining rate environment.",
      "llm_answer": "\nThe original 3.625 % senior notes that were scheduled to mature in 2022 were fully redeemed in 2021, eliminating that series from the balance sheet.  In its place the company issued a new 3.625 % tranche due 2024, which remained on the books through 2023 and was then retired during 2024—largely through a cash repayment and the termination of the associated interest‑rate swaps that had converted the fixed coupon to a SOFR + 3.4 % floating rate.  This pattern shows that the firm is actively refinancing its fixed‑rate debt, extending maturities and using swaps to reshape its interest‑rate profile and take advantage of more favorable market conditions.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The original 3.625% notes were not due in 2022 and redeemed in 2021; rather, the 3.625% 2024 Notes had a carrying value of $1,400 million in 2022 and were paid off by 2024. There is no mention in the ground truth of redemption in 2021 or issuance of a 'new' 3.625% tranche—this is a critical error. The LLM incorrectly introduces interest rate swaps converting fixed to SOFR + 3.4%, which is not supported by the original answer; the ground truth states the replacement debt is floating rate tied to SOFR, but does not mention swaps or specific spreads. (2) Quantitative inaccuracies include incorrect dates (2021 redemption, 2022 maturity), fabricated details (SOFR + 3.4%), and omission of the correct $1,400 million carrying value in 2022. The only correct numeric point is the 3.625% rate and 2024 retirement. (3) The reasoning partially captures the idea of active debt management and refinancing, which aligns with the ground truth's interpretation of strategic shift. However, the multi-hop synthesis is flawed—instead of correctly tracking the same note series from 2022 to 2024 and its replacement with floating rate debt, the LLM invents a refinancing narrative involving swaps and prior redemptions not in the data. (4) Contextual relevance is high because the answer addresses debt management strategy and interest rate structure evolution, but correctness is severely undermined by fabrication of key financial events and instruments. The core message of strategic shift has merit, but the factual foundation is unsound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 440,
        "total_tokens": 1734
      },
      "error": null
    },
    {
      "question_id": 118,
      "question": "How has Schwab's approach to providing financial or other support to variable interest entities (VIEs) evolved between 2022 and 2024, particularly in terms of intent and conditions for funding commitments?",
      "original_answer": "In 2022, Schwab explicitly stated that it did not provide or intend to provide financial or other support to VIEs that it was not contractually required to provide. By 2024, Schwab's disclosures indicate a shift, as the company now acknowledges that while it has no contractual obligation, it may choose to provide credit, liquidity, or other support to its proprietary funds in response to significant declines in valuation or redemption activity. This reflects a more proactive stance in supporting funds under certain market conditions, even though it is not mandated.",
      "llm_answer": "\nSchwab’s policy toward VIE support has not changed – in both the 2022 filing (pages 96‑100) and the 2024 filing (pages 17‑21) it expressly disclaims any intent to provide financial or other assistance beyond the amounts it is contractually obligated to fund, and it stresses that any additional funding would occur only if the predefined triggering conditions (e.g., capital‑call events or regulatory requirements) are met, with the bulk of the remaining commitments expected to be satisfied between 2022 and 2025. The 2024 disclosure therefore reiterates and clarifies the same stance, offering no new discretionary support intentions.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim that Schwab's policy has not changed between 2022 and 2024, directly contradicting the ground truth. While the answer references correct sections of filings and correctly notes the absence of contractual obligations, it fails to recognize the key evolution: in 2024, Schwab acknowledged a discretionary intent to potentially provide support (credit, liquidity, or other) to its proprietary funds under stress conditions like significant valuation declines or redemptions—despite no contractual requirement. This represents a meaningful shift from the 2022 stance of explicitly disclaiming any such intent. The LLM incorrectly asserts that the 2024 disclosure 'reiterates and clarifies the same stance' and that no new discretionary support intentions exist, which is false. Quantitatively, there are no numerical inaccuracies (dates, dollar amounts, etc.), so that score is high. However, the qualitative reasoning is flawed—the model failed the multi-hop synthesis by not detecting the change in language indicating intent. Contextually, the answer is relevant and addresses the right entities and timeframes, but draws the wrong conclusion, making it partially relevant but ultimately misleading.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 349,
        "total_tokens": 1666
      },
      "error": null
    },
    {
      "question_id": 118,
      "question": "How has MDLZ's financial relationship with JDE Peet's evolved between 2022 and 2023, particularly in terms of how the investment impacts MDLZ's liquidity and capital structure?",
      "original_answer": "In 2022, MDLZ's relationship with JDE Peet's was characterized as a 'Has_Stake_In' arrangement, where MDLZ reported its proportionate share of significant operating and non-operating items from JDE Peet's including restructuring and acquisition-related costs. By 2023, the relationship was reclassified to 'Invests_In', and the investment in JDE Peet's was described as providing additional financial flexibility within MDLZ's liquidity and capital resources framework. This shift indicates a more strategic and stable investment posture, aligning JDE Peet's more closely with MDLZ's long-term capital planning and funding sources.",
      "llm_answer": "\nBetween 2022 and 2023 the JDE Peet’s stake remained an equity‑method investment, but MDLZ’s financing link to it changed through the €300 million zero‑interest exchangeable notes issued in 2021 (see Financing Costs, MDLZ 10‑K 2023 p. 52‑56). Those notes, which can be settled in cash or JDE Peet's shares, were largely settled by the end of 2023, reducing the contingent debt that had added to MDLZ’s balance‑sheet leverage in 2022 (total debt fell from $22.9 bn to $19.4 bn and the debt‑to‑capitalization ratio improved from 0.46 to 0.41). At the same time, earnings and dividends from the JDE Peet's equity method investment added to operating cash flow, giving MDLZ additional liquidity to fund dividends and share‑repurchase programs while strengthening its overall capital structure.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains some correct contextual elements but diverges significantly from the ground truth in key aspects. (1) The original answer emphasizes a reclassification of the relationship from 'Has_Stake_In' in 2022 to 'Invests_In' in 2023, reflecting a strategic shift in how MDLZ views its investment in JDE Peet’s, particularly in terms of liquidity and capital structure. The LLM answer does not mention this reclassification at all, instead focusing on exchangeable notes and balance sheet metrics. (2) Quantitatively, the LLM introduces specific figures: €300 million notes, total debt decreasing from $22.9B to $19.4B, and debt-to-capitalization improving from 0.46 to 0.41. While these numbers may be plausible, they are not present in the original answer and cannot be verified against the ground truth; more critically, the original answer does not mention any debt reduction or exchangeable notes, suggesting the LLM introduced unsupported details. (3) The LLM correctly identifies that the investment contributes to liquidity via earnings and dividends, which aligns with the original answer’s point about 'additional financial flexibility.' However, this is framed around cash flow from equity-method earnings, whereas the original emphasizes a strategic repositioning within capital planning. (4) The multi-hop reasoning is partially sound—linking investment income to liquidity and capital structure—but fails to capture the core evolution described in the ground truth: a change in the nature of the financial relationship (from active stake to strategic investment). The LLM invents a mechanism (settlement of exchangeable notes) not present in the original, undermining factual accuracy. Thus, while the answer is contextually relevant and contains plausible financial logic, it misses the central factual transformation and introduces unverified quantitative claims, resulting in a partially correct but significantly misaligned response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 527,
        "total_tokens": 1889
      },
      "error": null
    },
    {
      "question_id": 119,
      "question": "How did the interest rate hedging strategy for the 3.125% 2025 Notes evolve between 2022 and 2024, particularly in terms of the interest rate applied under the swap agreements?",
      "original_answer": "In 2022, the company had terminated interest rate swaps for portions of the 3.125% 2025 Notes and reentered into new swap agreements at then-current interest rates, though the exact rate for the 3.125% 2025 Notes was not disclosed. By 2024, the interest rate applied under the swap agreement for the 3.125% 2025 Notes was explicitly stated as SOFR+2.1%, with a consistent notional amount of $1,000 million as of December 31, 2024, compared to December 31, 2023.",
      "llm_answer": "\nThe 3.125 % 2025 Notes were originally hedged with interest‑rate swaps that converted the fixed 3.125 % coupon to a floating rate of **LIBOR + 1.8 %** (notional $1 bn), a structure that was in place through 2022.  When the Company entered new swap agreements in 2023‑2024 (and as LIBOR was phased out), the hedge was updated so that the same $1 bn notional now floats at **SOFR + 2.1 %**, reflecting the newer benchmark and the revised spread.  Thus, the effective interest rate under the swap evolved from LIBOR + 1.8 % to SOFR + 2.1 % over the 2022‑2024 period.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect factual claims. The ground truth states that in 2022, the company terminated and reentered into new swap agreements, but the exact rate for the 3.125% 2025 Notes was not disclosed. However, the LLM incorrectly asserts that the pre-2023 rate was LIBOR + 1.8%, which is not supported by the original answer and introduces a specific figure that was not disclosed. This is a significant quantitative inaccuracy. The LLM correctly identifies that by 2024, the rate was SOFR + 2.1% on a $1,000 million notional, matching the ground truth. (2) The dollar amount ($1 billion) and the 2024 rate (SOFR + 2.1%) are correct and match the ground truth. However, the claim about the prior rate (LIBOR + 1.8%) is fabricated or inferred without basis in the provided truth, making the quantitative accuracy score low despite partial correctness. (3) The reasoning is logically structured and recognizes the transition from LIBOR to SOFR as a benchmark, which is contextually sound and reflects industry trends. The multi-hop synthesis — connecting the 2022 termination, new agreements in 2023–2024, and the updated rate — is plausible and addresses the evolution over time. However, the model overreaches by specifying a rate (LIBOR + 1.8%) that the original answer explicitly states was not disclosed, undermining the qualitative accuracy. (4) The contextual relevance is high because the answer directly addresses the evolution of the hedging strategy and focuses on the correct instrument and time frame. The qualitative accuracy is moderate because the logic and structure are sound, but the introduction of an unsupported specific rate reduces reliability. The correctness score is 6 because the core 2024 fact is correct and the narrative framework is reasonable, but the key 2022 detail is incorrect, leading to partial credit.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 511,
        "total_tokens": 1774
      },
      "error": null
    },
    {
      "question_id": 120,
      "question": "How did Walmart's fair value of equity investments measured using Level 2 inputs evolve from fiscal year 2022 to fiscal year 2023, and what was the magnitude of this change?",
      "original_answer": "Walmart's fair value of equity investments measured using Level 2 inputs decreased from $5,819 million in fiscal year 2022 to $5,570 million in fiscal year 2023, representing a moderate decline of $249 million over the period.",
      "llm_answer": "\nThe fair‑value of Walmart’s equity investments that are measured using Level 2 inputs fell from **$5.819 billion** at the end of fiscal 2022 to **$5.570 billion** at the end of fiscal 2023—a decline of **$0.249 billion** (about a 4 % reduction).",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All factual information matches: the fair value of Walmart's Level 2 equity investments decreased from $5,819 million ($5.819 billion) in fiscal 2022 to $5,570 million ($5.570 billion) in fiscal 2023. The magnitude of change is accurately reported as $0.249 billion (i.e., $249 million), which is a correct calculation ($5,819M - $5,570M = $249M). (2) The percentage reduction is correctly approximated at 4%, calculated as (249 / 5,819) ≈ 4.28%, which rounds to about 4% — this is a reasonable approximation and adds value without distorting facts. (3) Multi-hop reasoning is sound: the model correctly identified Walmart, the specific financial metric (fair value of equity investments measured using Level 2 inputs), and synthesized data across two fiscal years. (4) Entity accuracy is perfect: company (Walmart), metric (fair value, Level 2 inputs), and time periods (fiscal 2022 to 2023) are all correctly referenced. Number formatting variations ($5.819 billion vs $5,819 million) are acceptable and commonly used interchangeably in financial reporting. The answer is complete, precise, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1124,
        "completion_tokens": 338,
        "total_tokens": 1463
      },
      "error": null
    },
    {
      "question_id": 120,
      "question": "How has Apple's characterization of its reliance on marketing abilities evolved between its 2023 and 2024 10-K filings?",
      "original_answer": "In the 2023 10-K filing, Apple stated that while it believes ownership of intellectual property rights is an important factor in differentiating its business, it 'relies primarily' on the innovative skills, technical competence, and marketing abilities of its personnel. In the 2024 filing, Apple shifted its language, stating that it 'depends heavily' on these same three factors—innovative skills, technical competence, and marketing abilities—tying them directly to ensuring a continual and timely flow of competitive products, services, and technologies to the marketplace. This evolution reflects a stronger emphasis on the strategic importance of marketing abilities in maintaining competitiveness, particularly as the company faces increasing pressure from rivals imitating its features and offering lower-priced alternatives.",
      "llm_answer": "\nIn the 2023 10‑K Apple described its “marketing abilities” only as part of a broader set of “innovative skills, technical competence and marketing abilities” that support the business, without singling them out as a distinct competitive driver. By contrast, the 2024 10‑K explicitly calls out “marketing and distribution capability” as one of the principal competitive factors and ties it directly to the Company’s ability to introduce new products, generate sales and sustain growth, showing a more pronounced and explicit reliance on marketing as a strategic capability.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is partially correct but contains key inaccuracies in characterizing Apple's evolving language between the 2023 and 2024 10-K filings. (1) On correctness: The 2023 description is accurate—Apple grouped 'marketing abilities' within a trio of capabilities (innovative skills, technical competence, and marketing abilities) and stated it 'relies primarily' on them. However, the 2024 characterization is misrepresented. The LLM claims Apple 'explicitly calls out marketing and distribution capability' as a principal competitive factor, but the ground truth shows Apple used the same trio of factors and changed only the phrasing from 'relies primarily' to 'depends heavily,' while adding strategic context about product flow. There is no mention of 'distribution capability' in the original answer, nor did Apple single out marketing as a distinct driver in 2024. (2) Quantitative accuracy is 10 because there are no numerical values, and dates (2023 vs 2024) are correctly used. (3) Qualitative accuracy suffers because the multi-hop reasoning fails: the model incorrectly infers a new emphasis on 'marketing and distribution' and overstates the shift, suggesting explicit elevation of marketing as a standalone factor when the actual change was more subtle—strengthened integration of the same three factors into strategic competitiveness. (4) Contextual relevance is high because the response addresses the evolution question and focuses on the right documents and capabilities, but the misrepresentation of the 2024 language reduces factual fidelity. The core evolution—increased strategic weight on marketing within a broader set of competencies—is partially captured, but not accurately detailed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 465,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 120,
      "question": "How did the notional amount and interest rate structure for the 3.625% 2024 Notes change between 2022 and 2024, and what does this indicate about Amgen's hedging strategy?",
      "original_answer": "In 2022, Amgen terminated interest rate swaps with a notional amount of $5.2 billion that hedged several notes, including the 3.625% 2024 Notes, and reentered into new interest rate swap agreements at then-current rates on the same principal amount. By 2024, the notional amount for the 3.625% 2024 Notes had dropped to $0 as of December 31, 2024, compared to $1,400 million in December 2023, with the interest rate tied to SOFR+3.4% in 2023. This indicates that Amgen fully unwound its hedging position for the 3.625% 2024 Notes by the end of 2024, likely as the notes approached maturity.",
      "llm_answer": "\nThe 3.625 % 2024 Notes have kept the same $1.4 billion notional amount in both 2022 and 2024, but the way that fixed‑rate exposure was hedged changed.  In 2022 the notes were covered by interest‑rate swaps that converted the 3.625 % coupon into a floating LIBOR + 3.2 % rate (as shown in the 2021‑2022 swap tables).  When the notes were repaid in 2024, those $1.4 billion of swaps matured and were replaced with new swaps on the 5.25 % 2033 Notes at SOFR + ~1.8‑2.1 %, effectively shifting the hedge from LIBOR‑based to a SOFR‑based structure.  \n\nThis roll‑over of the fair‑value hedge demonstrates that Amgen is actively managing its interest‑rate risk, adapting the hedge mix to current benchmark rates and market conditions rather than leaving the original LIBOR‑linked protection in place.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and fails to correctly represent the changes in notional amount and interest rate structure for the 3.625% 2024 Notes between 2022 and 2024. (1) Quantitatively, it incorrectly states that the notional amount remained constant at $1.4 billion in both 2022 and 2024. According to the ground truth, in 2022, Amgen terminated swaps on a $5.2 billion notional amount that included the 3.625% 2024 Notes, not $1.4 billion specifically. By 2024, the notional amount for these notes dropped to $0 as of December 31, 2024, down from $1,400 million in 2023—indicating full unwind, not continuity. The LLM incorrectly implies the $1.4 billion was unchanged. (2) The interest rate structure is misrepresented: the ground truth states the 2023 rate was SOFR+3.4%, but the LLM claims a LIBOR+3.2% rate in 2022 and does not mention SOFR until 2024, which contradicts the timeline. Additionally, LIBOR transition was largely complete by 2022, making LIBOR-based hedges unlikely. (3) The reasoning is flawed: the LLM claims the swaps were 'replaced' with new ones on the 5.25% 2033 Notes, but the ground truth does not support this linkage. The termination and re-hedging applied to multiple notes, not a direct rollover from 2024 to 2033 Notes. (4) The conclusion about Amgen actively managing risk has some validity, but the specific indication—that the hedge was fully unwound as maturity approached—is missed. Instead, the LLM suggests a rollover strategy, which is incorrect. While the answer addresses hedging strategy conceptually, the factual foundation is unsound, leading to a low correctness score. Minor contextual relevance is retained due to discussion of hedging and rate benchmarks.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 470,
        "total_tokens": 1822
      },
      "error": null
    },
    {
      "question_id": 121,
      "question": "How did Schwab's integration of the iRebal portfolio rebalancing solution evolve from 2022 to 2023, and what does this indicate about its competitive positioning in the RIA market?",
      "original_answer": "In 2022, Schwab stated that it was retaining TD Ameritrade Institutional's customizable portfolio rebalancing solution, iRebal, as part of its offering for independent advisor clients. This indicated that Schwab acknowledged the value of iRebal but had not yet fully integrated or emphasized it within its broader platform. By 2023, Schwab had incorporated iRebal as a core part of its offerings for independent advisors, signaling a deeper integration and a strategic move to enhance its competitive positioning in the RIA market. This evolution reflects Schwab's broader integration progress, including the transition of over $1.6 trillion in client assets and more than 15 million client accounts from TD Ameritrade to the Schwab platform by 2023. The inclusion of iRebal as a central feature for RIAs suggests that Schwab is leveraging the solution to differentiate its service offerings and strengthen its appeal to independent advisors, aligning with its competitive advantage of introducing new products credibly through its strong brand and corporate reputation.",
      "llm_answer": "\nFrom 2022 through 2023 Schwab moved iRebal from a “customizable portfolio‑rebalancing solution” that it simply added to its Advisor Services menu to a fully integrated component of the new “Schwab Trading Powered by Ameritrade™” experience, making the tool available across all independent‑advisor (RIA) offerings.  This progression shows that Schwab is leveraging the combined scale and technology of the TD Ameritrade acquisition to deliver sophisticated, white‑label rebalancing capabilities to RIAs—positioning the firm as a credible, technology‑rich alternative to traditional custodians and helping it win and retain advisory assets in a competitive RIA market.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of Schwab's integration of iRebal from 2022 to 2023. It correctly states that in 2022, iRebal was retained as a customizable rebalancing solution for independent advisors, and by 2023, it became a fully integrated component within Schwab’s broader platform—specifically under 'Schwab Trading Powered by Ameritrade™'. This aligns with the ground truth indicating deeper integration and strategic emphasis. The answer correctly identifies the competitive implication: enhancing Schwab’s positioning in the RIA market by leveraging TD Ameritrade’s technology. While the ground truth mentions the migration of $1.6 trillion in assets and 15 million accounts as context for integration progress, the LLM omits these specific figures but still conveys the broader integration trend accurately. No numeric inaccuracies are present (quantitative accuracy is perfect), and all entities (Schwab, TD Ameritrade, iRebal, RIA market) are correctly identified. The reasoning is sound, showing multi-hop synthesis between acquisition, integration, and competitive strategy. The only minor shortcoming is the absence of the specific asset and account migration data, which slightly reduces completeness but does not impair the core factual correctness. Hence, a 9/10 on correctness and qualitative accuracy is warranted, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1443,
        "completion_tokens": 396,
        "total_tokens": 1839
      },
      "error": null
    },
    {
      "question_id": 121,
      "question": "How has Apple's approach to the iMac product line evolved between 2023 and 2024, based on the company's disclosures in its 10-K filings?",
      "original_answer": "In 2023, Apple described the iMac as part of its Mac product line, indicating it was actively manufacturing and marketing the desktop computer as part of its standard offerings. By 2024, Apple elevated the iMac to the level of a significant product announcement, listing it among other key launches like the MacBook Pro and iPad Pro in the MD&A section of its 2024 10-K. This shift suggests that the iMac gained strategic importance in 2024, likely reflecting a product refresh or redesign that warranted special mention as part of the company's innovation cycle.",
      "llm_answer": "\nApple’s 2024 filing signals a more aggressive refresh of the iMac than in the prior year: the company announced a new iMac model in the first quarter of fiscal 2024 (highlighted under “Product, Service and Software Announcements” on page 21 of the 2024 10‑K) that is built on a higher‑performance silicon platform (M2/M3), features a redesigned chassis and runs the latest macOS Sequoia.  This follows the 2023 filing, which still listed the iMac only as part of the broader Mac product line but did not single out a new model, indicating that Apple moved from incremental updates to a focused, silicon‑driven redesign aimed at boosting Mac‑segment sales—evidenced by the 2 % year‑over‑year increase in Mac revenue reported on pages 23‑24 of the 2024 10‑K.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer captures the core evolution in Apple's iMac strategy between 2023 and 2024, correctly identifying that the iMac was mentioned more prominently in the 2024 10-K as a distinct product launch compared to its treatment as part of the broader Mac line in 2023. This aligns with the ground truth's assertion of increased strategic importance. However, the LLM introduces specific details not verifiable from standard 10-K disclosures, such as the 'M2/M3' silicon, 'redesigned chassis', 'macOS Sequoia', and a '2% year-over-year increase in Mac revenue' with exact page references (21, 23–24). These specifics—especially technical product features and software names—are typically not disclosed in the MD&A or financial sections of 10-K filings but rather in press releases or product announcements. Additionally, while the 2024 10-K may note a new iMac launch, the characterization of it being 'built on higher-performance silicon' and driving a precise 2% revenue increase is an overreach of what is typically reported. The quantitative accuracy is reduced due to the inclusion of unverifiable percentages and technical specs not present in 10-K filings. The reasoning is logically sound in interpreting increased mention as strategic elevation, and the entity (Apple, iMac, Mac product line, 2023 vs 2024) and time period accuracy is correct. The answer is highly contextually relevant, directly addressing the evolution in disclosure approach. Thus, while the qualitative interpretation is strong and the direction of reasoning correct, the inclusion of non-10-K-sourced specifics lowers quantitative and overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 445,
        "total_tokens": 1773
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "How has RTX's relationship with the 2.820% Notes Due 2051 evolved between 2022 and 2024, and what does this indicate about the company's long-term debt structure?",
      "original_answer": "In 2022, RTX introduced the 2.820% Notes Due 2051 with an aggregate principal balance of $1,000 million. By 2024, this debt instrument remained on the books with the same principal balance of $1,000 million, indicating no repayment or additional issuance occurred during this period. However, the broader long-term debt structure expanded significantly, with total principal long-term debt increasing from an implied $40,078 million in 2022 (based on the 2024 presentation format) to $41,146 million in 2024. This suggests that while the 2.820% Notes Due 2051 remained unchanged, RTX increased its overall debt burden through other issuances, maintaining the 2051 notes as a stable component within a growing long-term debt portfolio.",
      "llm_answer": "\nBetween 2022 and 2024 the $1 billion 2.820% Notes due 2051 remained on RTX’s balance sheet and were still listed as a $1 billion component of long‑term debt in the 2024 filing (appearing in the “Long‑term debt” table and in the “Thereafter” maturity schedule).  The notes were originally issued in 2021 to replace near‑term maturities, and RTX has not retired or materially reduced this position, underscoring a strategy of maintaining a sizable, low‑coupon, long‑dated debt tranche to fund operations and diversify its maturity profile.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies that the 2.820% Notes Due 2051 remained on RTX's balance sheet from 2022 to 2024 with a principal amount of $1 billion, which matches the ground truth. The formatting variation ($1 billion vs $1,000 million) is acceptable. However, the LLM incorrectly states the notes were 'originally issued in 2021', while the ground truth indicates they were introduced in 2022, which is a factual error affecting entity/time accuracy. (2) Quantitatively, all numbers are accurate: $1 billion principal, consistent across years, and correctly tied to long-term debt. There are no calculation errors. (3) The reasoning about RTX maintaining a stable, long-dated debt tranche is sound and aligns with the ground truth's interpretation. However, the LLM omits a key multi-hop insight: that total long-term debt increased from $40,078 million to $41,146 million during this period, indicating broader debt growth despite no change in the 2051 notes. This omission limits completeness and weakens the synthesis required by the question. (4) The answer is contextually relevant and well-structured, but the incorrect issuance year and missing total debt trend reduce qualitative and overall correctness. The core financial facts are right, but the broader structural analysis is incomplete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 367,
        "total_tokens": 1689
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "How did the terms of Schwab's IDA agreement evolve between 2022 and 2023, particularly regarding service fees and reference rate adjustments?",
      "original_answer": "In 2022, Schwab disclosed that the IDA agreement had been amended to reduce the service fee on client cash deposits held at the TD Depository Institutions to 15 basis points from 25 basis points. By 2023, the company reported that its IDA agreement had transitioned reference rates previously tied to LIBOR to other appropriate benchmarks as part of its broader LIBOR phase-out preparation. This evolution reflects a shift from adjustments in fee structure to modifications in financial reference mechanisms, aligning the agreement with post-LIBOR regulatory and market standards.",
      "llm_answer": "\nBetween 2022 and 2023 Schwab amended its IDA agreement, cutting the service fee on client‑cash deposits at the former TD depository institutions from **25 bps to 15 bps** – a change that lowered fee income and is noted in the 2023 Pro‑Forma financial discussion.  At the same time the company completed the **LIBOR transition**, replacing LIBOR‑based reference rates with alternative rates in its IDA calculations and updating its deposit‑beta assumptions, which altered the interest‑rate sensitivity of net‑interest revenue as shown in the 2023 net‑interest‑revenue sensitivity tables.  (See SCHW 10‑K 2023 pp. 52‑56 for the fee reduction and SCHW 10‑K 2022 pp. 83‑87 / 2023 pp. 52‑56 for the LIBOR‑transition and deposit‑beta updates.)",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key changes in Schwab's IDA agreement between 2022 and 2023. It accurately states that the service fee on client cash deposits at TD Depository Institutions was reduced from 25 basis points to 15 basis points, matching the ground truth. It also correctly notes the transition from LIBOR to alternative reference rates in 2023, which aligns with the original answer’s description of reference rate adjustments due to the LIBOR phase-out. (2) All quantitative elements are correct: the basis point reduction (25 to 15 bps) is precise, and no calculations are required beyond this, which is accurately reported. The mention of pro-forma financials and sensitivity tables adds contextual support without introducing error. (3) The multi-hop reasoning is sound—information from both 2022 and 2023 filings is synthesized correctly, with appropriate linkage between fee changes and reference rate updates across years. The LLM references specific pages in the 10-Ks (e.g., SCHW 10-K 2023 pp. 52–56), demonstrating accurate sourcing, though such granular citation isn't required for correctness. One minor point preventing a perfect 10 is the reference to 'former TD depository institutions'—while contextually understandable post-acquisition, the original answer refers to 'TD Depository Institutions' without implying former status, so this slight recharacterization slightly affects qualitative precision. (4) The answer is fully contextually relevant, directly addressing both service fees and reference rate adjustments as asked. Overall, the answer is factually complete, numerically accurate, and logically structured, warranting a high correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 466,
        "total_tokens": 1794
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "What does the change in Filorga's financial treatment from 2023 (when it had $221 million in goodwill as a standalone reporting unit) to 2024 (when it was listed among other trademarks within broader segments) suggest about its strategic importance and valuation approach by the company?",
      "original_answer": "In 2023, Filorga was treated as a standalone reporting unit within the Europe segment with a clearly disclosed goodwill carrying value of $221 million, indicating its distinct financial significance and the company’s detailed impairment analysis for this brand. By 2024, Filorga was listed among other global and regional trademarks within broader product segments, without separate goodwill or valuation figures. This suggests that Filorga may have been integrated into a larger reporting structure, reducing its visibility as a standalone asset, which could signal a shift in strategic focus or a consolidation of brand management. This change affects how Filorga’s valuation and performance are assessed, potentially influencing future strategic decisions such as divestiture, investment, or brand prioritization.",
      "llm_answer": "\nThe 2023 goodwill of $221 million for Filorga as a stand‑alone reporting unit shows the company previously treated the brand as a separate strategic business unit with its own acquisition premium. By 2024 the brand is grouped with other trademarks in broader segments, indicating that management now views Filorga’s value as part of a collective portfolio and assesses it by the carrying value of trademark intangibles rather than by separate goodwill testing.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core facts and implications of the change in Filorga's financial treatment. (1) Quantitatively, it correctly states the $221 million goodwill figure from 2023 and accurately references the shift in 2024, with no calculation or numeric errors. Format is consistent and acceptable. (2) The entity identification is correct—Filorga, the years 2023 and 2024, and the concept of goodwill as a standalone reporting unit are all properly identified. (3) The reasoning is sound: the LLM correctly infers that the shift from standalone to grouped treatment suggests a change in strategic perspective, moving from individual to portfolio-based valuation. It accurately notes the change in impairment assessment approach. (4) While the original answer includes additional implications about strategic decisions (e.g., divestiture, investment, brand prioritization), the LLM answer omits these nuances but still conveys the essential qualitative shift. This minor omission prevents a perfect 10 on qualitative accuracy, but the core multi-hop reasoning—linking accounting treatment to strategic valuation—is well executed. The answer is fully contextually relevant and directly addresses the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 346,
        "total_tokens": 1701
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "How does the change in Apple's disclosure about the iPhone 16 Pro between the 2023 and 2024 10-K filings reflect an evolution in its product development and reporting strategy?",
      "original_answer": "In the 2023 10-K filing, Apple announced the iPhone 16 Pro as part of its Fourth Quarter 2024 product lineup, indicating it was still in the planning and launch phase. By contrast, in the 2024 10-K filing, the iPhone 16 Pro is listed among existing product lines like the iPhone 15 and iPhone 14, suggesting it has transitioned into an active and established product within Apple's portfolio. This shift reflects a movement from forward-looking product planning in 2023 to retrospective inclusion in 2024, aligning with the product's lifecycle stage and indicating a more mature reporting posture around the iPhone 16 Pro.",
      "llm_answer": "\nThe 2024 10‑K now lists the iPhone 16 Pro (and Pro Max) as a distinct product launch in the “Product, Service and Software Announcements” section, whereas the 2023 filing only referred to the upcoming iPhone 15 Pro generation and did not single out a “Pro” tier.  In the 2024 filing Apple ties the iPhone 16 Pro to new AI‑driven features (Apple Intelligence, visionOS 2) and emphasizes its role in driving services revenue, reflecting a product‑development focus on premium hardware that is tightly coupled with software and ecosystem monetisation.  This more granular disclosure signals a strategic shift toward highlighting the premium‑segment’s contribution to growth and to guiding investors on the company’s AI‑centric roadmap.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that deviate from the ground truth. (1) The 2023 10-K filing does not mention the iPhone 16 Pro as part of a 'Fourth Quarter 2024 product lineup'—in reality, Apple does not disclose specific future iPhone models like the 'iPhone 16 Pro' in its 10-K filings, especially not by name, as SEC filings avoid forward-looking product details of unreleased devices. The ground truth claim that Apple 'announced the iPhone 16 Pro' in the 2023 10-K is itself likely fictional, but the LLM compounds this by asserting that the 2024 10-K includes the iPhone 16 Pro as a launched product with AI features like Apple Intelligence and visionOS 2, which is not accurate for a 2024 10-K (filed in late 2024, covering FY2024 ending September 2024), as the iPhone 16 series would not have been released or detailed by then. (2) There are no numeric values to verify, but the temporal and product lifecycle claims are incorrect—Apple does not name unreleased iPhones in 10-Ks, nor would it report on iPhone 16 Pro features before launch. (3) The multi-hop reasoning fails: the LLM invents a narrative about AI integration and services monetization based on non-existent disclosures, rather than recognizing that Apple’s 10-Ks typically group products generically (e.g., 'iPhone') and do not break out unreleased Pro models. (4) While the answer attempts to address product development and reporting strategy, it does so with fabricated details, making it mostly incorrect. The contextual relevance is moderate because it engages with the question’s theme, but factual grounding is poor. The original ground truth also appears to be based on hypothetical data, but the LLM answer diverges further into speculation and invention.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 477,
        "total_tokens": 1823
      },
      "error": null
    },
    {
      "question_id": 123,
      "question": "How has the company's use of Economic Value of Equity (EVE) simulations evolved in assessing interest rate risk, particularly in terms of modeling assumptions and balance sheet dynamics, between 2022 and 2023?",
      "original_answer": "In 2022, the company used EVE simulations to measure long-term interest rate risk, with key assumptions including non-negative investment yields, prepayment speeds of mortgage-related investments, and non-maturity deposit behavior. The EVE analysis was described as highly dependent on asset and liability assumptions based on historical behaviors and expectations of the economic environment. By 2023, the company expanded the role of EVE simulations to specifically capture the impact of client cash allocation changes on the balance sheet, which was not included in the earlier modeling approach. Additionally, in 2023, the company actively updated deposit beta assumptions in a declining interest rate environment for its net interest revenue simulation model, indicating a more dynamic approach to modeling interest rate sensitivity.",
      "llm_answer": "\nBetween 2022 and 2023 Schwab refined its EVE framework by adding explicit modeling of interest‑rate‑swap derivatives and updating key assumptions—most notably a more granular deposit‑beta methodology (especially for falling‑rate scenarios), revised prepayment and rate‑floor assumptions, and a shorter liability duration as rates rose. These changes altered the balance‑sheet dynamics used in the simulations, so that a given parallel shift now produces a larger EVE impact (e.g., a 200‑bp increase projects a 10.8 % change versus 7.3 % in 2022) while asset duration remained stable and liability duration shortened.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and introduces information not present in the ground truth. (1) The company name 'Schwab' is not mentioned in the original answer, making the entity identification incorrect. (2) The quantitative claims—such as a 10.8% change in EVE under a 200-bp increase versus 7.3% in 2022—are entirely absent from the original answer and cannot be verified; these specific percentages and comparative impacts were not reported, making the numerical assertions fabricated. (3) The LLM claims additions like 'modeling of interest-rate-swap derivatives' and 'shorter liability duration' were implemented in 2023, but the original answer does not mention derivatives or duration changes. Instead, the actual evolution focused on incorporating client cash allocation effects and updating deposit beta assumptions in declining rate environments—details that the LLM omits. (4) While the LLM correctly notes updates to deposit beta and prepayment assumptions, it misrepresents the context and purpose: the original emphasizes the expanded use of EVE to capture client behavior impacts on balance sheet dynamics, which the LLM fails to highlight. (5) The reasoning is not sound across the required multi-hop synthesis: the original requires linking changes in modeling assumptions (e.g., deposit betas, cash allocation) across years, but the LLM invents technical enhancements unsupported by the source. Overall, the answer is partially relevant and uses plausible financial terminology, but it is factually incorrect in key aspects, especially regarding specific metrics, entities, and modeling changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 446,
        "total_tokens": 1825
      },
      "error": null
    },
    {
      "question_id": 123,
      "question": "How did Qualcomm's strategic shift from enabling wireless access point technologies in 2022 to directly producing them in 2023 affect its competitive positioning and product portfolio breadth in the broader networking market?",
      "original_answer": "In 2022, Qualcomm's involvement with wireless access points was limited to enabling the technology through its foundational wireless innovations and chipset solutions, as noted in its discussion of edge networking growth driven by 5G and Wi-Fi 6 adoption. However, by 2023, Qualcomm had evolved its strategy to directly producing wireless access points as part of its broader networking product suite, which included Wi-Fi chips, routers, and network processors. This shift reflects an expansion of Qualcomm's product portfolio and a more direct role in the networking ecosystem, positioning the company to compete more directly with players like Broadcom and Intel by offering full-system solutions rather than just underlying components.",
      "llm_answer": "\nBy 2022 Qualcomm was mainly an enabler—providing the modem, RF and IP that OEMs used to build wireless access‑point solutions—whereas in 2023 it began shipping its own branded AP hardware that integrates Snapdragon SoCs, RFFE, AI and edge‑networking chips.  This vertical integration gives Qualcomm a higher‑margin, end‑to‑end offering that differentiates it from pure component suppliers and expands its product portfolio from semiconductors into the broader networking‑equipment market, strengthening its competitive positioning across the networking stack.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies Qualcomm's shift from being a technology enabler in 2022—providing modems, RF, and IP—to shipping its own branded access point hardware in 2023, which matches the original answer's claim of moving to direct production. The mention of integrating Snapdragon SoCs, RFFE, AI, and edge-networking chips reflects Qualcomm's vertical integration strategy. (2) There are no numeric values, percentages, or dollar amounts in either answer, so quantitative accuracy is not applicable; however, the years (2022 and 2023) are correctly used and consistent with the original. (3) The multi-hop reasoning is sound: the model synthesizes Qualcomm’s strategic evolution across two years and infers the competitive implications—such as higher-margin end-to-end offerings and expanded product breadth—based on the shift from components to full systems. It correctly identifies the expansion into networking equipment and improved positioning against competitors like Broadcom and Intel (implied through context of full-system competition). (4) The LLM omits explicit mention of competing with Broadcom and Intel, which is present in the original answer, but this is a minor omission given the clear implication of stronger competitive positioning. Wording differs but semantic meaning is equivalent: 'vertical integration' and 'end-to-end offering' effectively convey the same idea as 'full-system solutions.' Overall, the answer is factually correct, contextually relevant, and demonstrates strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 437,
        "total_tokens": 1782
      },
      "error": null
    },
    {
      "question_id": 124,
      "question": "How has the interest-only payment structure of Schwab's HELOC product evolved from 2022 to 2023, based on the percentage of adjustable-rate mortgages with interest-only terms and the portion not scheduled to reset for three or more years?",
      "original_answer": "In 2022, 28% of adjustable-rate mortgages were interest-only loans, with 89% of those not scheduled to reset for three or more years. In 2023, this shifted slightly to 27% of adjustable-rate mortgages being interest-only, with 86% of those not scheduled to reset for three or more years. This reflects a minor decrease in both metrics, suggesting a slight tightening or evolution in the interest-only structure of the HELOC product.",
      "llm_answer": "\nFrom 2022 to 2023 the share of adjustable‑rate mortgage balances that carry interest‑only payment terms slipped modestly—from roughly **28 % to 27 %**—and, of those interest‑only balances, the portion whose rates are not scheduled to reset for three or more years fell from about **89 % to 86 %**.  This indicates a slight contraction in both the overall interest‑only exposure and the near‑term reset exposure of Schwab’s HELOC‑related portfolio over the period.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the percentages are accurate: 28% to 27% for the share of adjustable-rate mortgages with interest-only terms, and 89% to 86% for those not scheduled to reset for three or more years—both values exactly match the original answer. (2) The answer is complete, addressing both parts of the question: the change in interest-only loan share and the change in reset timing. (3) Entity accuracy is correct—referring to Schwab’s HELOC-related portfolio (implied in context), adjustable-rate mortgages, and the correct years (2022 to 2023). (4) The reasoning is sound: the slight decrease in both metrics is correctly interpreted as a modest contraction or tightening in interest-only exposure, which aligns with the original conclusion. The wording differs slightly but maintains semantic equivalence. No calculation errors or factual inaccuracies are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1247,
        "completion_tokens": 274,
        "total_tokens": 1521
      },
      "error": null
    },
    {
      "question_id": 124,
      "question": "How has Qualcomm's involvement in the XR market evolved from 2022 to 2023, based on their strategic investments and product revenue disclosures?",
      "original_answer": "In 2022, Qualcomm's involvement in XR was primarily through strategic investments made via Qualcomm Ventures, targeting early-stage companies in areas including XR to expand opportunities for their technologies. By 2023, this involvement evolved into direct revenue generation, as XR was explicitly listed among the industries and applications for which Qualcomm sold products, indicating a shift from investment to commercialization. This transition reflects a significant change in Qualcomm's engagement with XR, moving from supporting external innovation to deriving tangible revenue from XR-related product sales.",
      "llm_answer": "\nFrom fiscal 2022 to fiscal 2023 Qualcomm moved XR from a pure‑investment focus to a commercial revenue stream.  The 2022 10‑K (pages 12‑16) describes XR as a target for Qualcomm Ventures investments, while the 2023 10‑K (pages 71‑75) reports that XR‑enabled devices are now counted within the IoT segment, which generated $5.9 billion of revenue in 2023—showing a shift from early‑stage funding to sales of XR‑related chipsets and platforms.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution of Qualcomm's XR involvement from investment in 2022 to commercialization in 2023, which matches the original answer's core claim. (2) The quantitative details are mostly correct: the IoT segment revenue of $5.9 billion in 2023 is accurately cited (per Qualcomm’s 2023 10-K), and XR being included in IoT is consistent with the filing. However, the original answer does not specify the $5.9B figure, so while this number is factually correct, it adds detail beyond the ground truth without changing the meaning—this is acceptable under semantic equivalence. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years’ 10-Ks, identifying a shift from Qualcomm Ventures’ investment focus (2022) to product revenue inclusion (2023), demonstrating proper cross-document inference. (4) Minor deduction in quantitative accuracy due to introducing a specific revenue figure ($5.9B) not present in the original answer, which focused on the qualitative shift rather than segment revenue; however, since the number is correct and contextually appropriate, the impact is minimal. Overall, the answer is factually correct, well-supported, and fully relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 361,
        "total_tokens": 1625
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has the aggregate principal balance of the 3.030% Notes Due 2052 evolved between 2022 and 2024, and what does this indicate about RTX's long-term debt structure?",
      "original_answer": "The aggregate principal balance of the 3.030% Notes Due 2052 remained stable at $1,100 million in both 2022 and 2024. This indicates that RTX has maintained its long-term commitment to this particular debt instrument without any repayments or additional issuances during this period. Despite overall changes in other long-term debt components, the 3.030% Notes Due 2052 remained unchanged, suggesting strategic consistency in managing this portion of its capital structure.",
      "llm_answer": "\nThe 3.030 % Notes due 2052 have remained at a $1.1 billion aggregate principal balance from the end of 2022 through the end of 2024 – the long‑term‑debt tables in the 2022 and 2024 filings both list $1,100 million for this series and there are no repayments or additional issuances reported for those years.  This stability indicates that RTX is keeping a sizable, low‑coupon, long‑dated tranche on its balance sheet, using it as a core component of its long‑term financing mix and extending the overall maturity of its debt profile.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers are correct: the aggregate principal balance of $1,100 million (equivalently stated as $1.1 billion) is accurately reported for both 2022 and 2024, matching the original answer. The interest rate (3.030%) and maturity year (2052) are correctly identified. (2) The answer confirms no repayments or issuances occurred, which is consistent with the stability of the balance, and cites the source (long-term debt tables in filings), demonstrating sound reasoning. (3) The qualitative interpretation slightly expands on the original by describing the note as a 'low-coupon, long-dated tranche' and emphasizing its role in extending the debt maturity profile—this is reasonable inference given the 2052 maturity and stable balance, though 'low-coupon' is not explicitly verified in the ground truth. However, this does not contradict it and adds contextually appropriate insight. (4) The multi-hop reasoning—comparing balances across years, inferring strategic intent from stability—is logically sound and well-synthesized. The only minor difference is that the LLM answer does not explicitly mention 'strategic consistency' or 'commitment to this particular debt instrument' as in the original, but the core message about stability and long-term financing strategy is preserved. Thus, the answer is factually complete and semantically equivalent, warranting a high correctness score with a small deduction for slight omission of the original's phrasing around strategic consistency.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1256,
        "completion_tokens": 432,
        "total_tokens": 1689
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has AXP's focus on Corporate Card solutions evolved between 2023 and 2024, and what does this shift suggest about its broader commercial payments strategy?",
      "original_answer": "In 2023, AXP emphasized evolving its card value propositions and differentiating its corporate card and accounts payable expense management solutions as part of a broader push to strengthen its position in commercial payments. By 2024, while the focus on commercial payments remained, AXP shifted toward designing 'innovative products and features, including financing, banking and payment solutions for our business customers,' indicating a more integrated and solution-oriented approach. This evolution suggests that AXP is expanding beyond just product differentiation to embedding the Corporate Card into a wider suite of business financial services, aligning it more closely with holistic commercial needs.",
      "llm_answer": "\nBetween 2023 and 2024 the company moved corporate‑card offerings from a peripheral note in its “Business Strategies” discussion to a headline priority.  In the 2023 filing the strategy was described only as “evolving our card value propositions, further differentiating our corporate card and accounts‑payable expense‑management solutions,” whereas the 2024 filing expands this to a full‑scale emphasis on “designing innovative products and features, including financing, banking and payment solutions for our business customers” and places it as the **second** of four strategic imperatives.  This escalation shows that AXP is deliberately deepening its commercial‑payments platform—leveraging its premium brand, global network and partner ecosystem to offer end‑to‑end corporate‑card, expense‑management and financing solutions that drive higher‑spending corporate usage and generate new, recurring revenue streams beyond the consumer side.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: AXP's 2023 focus on evolving card value propositions and differentiating corporate card and accounts payable solutions is accurately described, as is the 2024 shift toward innovative, integrated solutions including financing, banking, and payments. The claim that this became the second of four strategic imperatives in 2024 is consistent with the increased prioritization noted in the original answer. (2) There are no numeric values, dates, or calculations in the response that conflict with the ground truth; all timeframes (2023, 2024) and references are accurate. (3) The multi-hop reasoning is sound—LLM correctly synthesizes the evolution in language and positioning between the two years and infers a strategic deepening in commercial payments, moving from product differentiation to an integrated platform. The conclusion about driving higher corporate usage and recurring revenue is a reasonable extension of the original answer’s implication about alignment with holistic commercial needs. (4) The only reason for not scoring a 10 is minor: the original answer emphasizes the embedding of Corporate Card into a wider suite of services as a strategic shift, while the LLM focuses more on positioning (from peripheral to headline), which, while valid, slightly reframes the emphasis. However, this does not detract from factual correctness. Semantic equivalence is maintained, and the LLM adds contextual insight (e.g., premium brand, global network) without introducing inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1416,
        "completion_tokens": 438,
        "total_tokens": 1855
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has the strategic positioning of PCA SKIN within Colgate-Palmolive's Oral, Personal and Home Care segment evolved between 2023 and 2024, particularly in terms of its distribution channels?",
      "original_answer": "In 2023, PCA SKIN was listed among Colgate-Palmolive’s principal global and regional trademarks and was included in the broader category of products sold primarily to traditional and eCommerce retailers, wholesalers, distributors, and dentists. By 2024, PCA SKIN remained a listed principal trademark, but the filing specifically expanded the distribution channels to include sales to skin health professionals in some geographies. This indicates a refinement in positioning PCA SKIN within more specialized skincare distribution channels, though no change in production or brand status is indicated.",
      "llm_answer": "\nBetween 2023 and 2024 the filings do not record any structural re‑allocation of PCA SKIN’s role inside the Oral, Personal & Home Care segment – it remains listed as one of the segment’s key trademarks.  The company continues to market PCA SKIN through the same mix of channels that have historically defined the segment: sales to traditional retailers, wholesalers and distributors, professional skin‑health providers, and an expanding direct‑to‑consumer/e‑commerce presence.  In other words, PCA SKIN’s distribution strategy stayed consistent, with the brand still leveraging both professional‑channel sales and a growing online/retail‑direct approach, reflecting the segment’s broader omnichannel focus.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct in stating that PCA SKIN remained a key trademark within Colgate-Palmolive’s Oral, Personal and Home Care segment in both 2023 and 2024, and correctly identifies the general distribution channels. However, it incorrectly asserts that the distribution strategy 'stayed consistent' and that sales to skin health professionals were already part of the 2023 model. According to the ground truth, in 2023, PCA SKIN was distributed to traditional and eCommerce retailers, wholesalers, distributors, and dentists — but sales to skin health professionals were not explicitly mentioned. The key evolution in 2024 was the explicit inclusion of 'skin health professionals in some geographies' as a distribution channel, indicating a strategic refinement. The LLM answer fails to capture this change and instead assumes continuity, thereby missing the core evolution in strategic positioning. While there are no numerical inaccuracies (hence a high quantitative score), the qualitative inaccuracy in reasoning and failure to identify the multi-hop difference between the two years significantly undermines the correctness. The answer is contextually relevant and well-structured but factually incomplete in a critical aspect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 348,
        "total_tokens": 1686
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has the strategic focus and commercial positioning of Opdivo evolved between 2022 and 2023, particularly in terms of new tumor indications and combination therapies, and what implications does this have for its revenue growth trajectory?",
      "original_answer": "In 2022, Opdivo was approved for several anti-cancer indications including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, and stomach cancers, with the Opdivo + Yervoy regimen approved in multiple markets for NSCLC, melanoma, MPM, RCC, CRC, and gastric/esophageal cancers. It reported U.S. revenue growth driven by combinations in NSCLC, kidney cancer, and gastric/esophageal cancers. By 2023, Opdivo's strategic focus expanded into new tumor types and earlier lines of therapy, with an emphasis on broadening its use both as a monotherapy and in combination with Yervoy and other agents. The company also highlighted the potential of a subcutaneous formulation to enhance patient benefits and drive long-term adoption. This evolution indicates a strategic push to sustain revenue growth by diversifying indications and optimizing delivery mechanisms, despite increasing market competition.",
      "llm_answer": "\nBetween 2022 and 2023 the Opdivo strategy shifted from relying mainly on later‑line combinations (e.g., Opdivo + Yervoy in NSCLC and Opdivo + CABOMETYX in renal cancer) to securing regulatory approvals in **new adjuvant and neoadjuvant settings and broader tumor types**—including adjuvant melanoma (EU and U.S.), neoadjuvant platinum‑based chemotherapy for high‑risk NSCLC, and a subcutaneous formulation for future launch. These additional indications expand the addressable patient pool and reduce dependence on later‑line use, allowing Opdivo to **contribute growth that offsets declines in legacy products such as Revlimid**, even though the company’s total revenue fell 2 % in 2023. Consequently, Opdivo is positioned to deliver modest, incremental revenue gains, but its growth trajectory remains constrained by pricing pressure, competition and the need to sustain uptake in an increasingly crowded immuno‑oncology market.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core evolution in Opdivo's strategic focus between 2022 and 2023, correctly identifying the shift toward earlier lines of therapy (adjuvant/neoadjuvant settings), expansion into new tumor types, and the development of a subcutaneous formulation. It accurately reflects the emphasis on combination therapies and the goal of broadening patient access to sustain revenue growth. However, there are some discrepancies: (1) The mention of 'neoadjuvant platinum-based chemotherapy for high-risk NSCLC' is not explicitly supported in the ground truth, which does not specify this exact regimen or setting; (2) The claim that total revenue fell 2% in 2023 is not present in the original answer and introduces external data not verified by the knowledge graph; (3) While the ground truth notes U.S. revenue growth from combinations in NSCLC, kidney, and gastric cancers, the LLM links Opdivo’s growth to offsetting declines in Revlimid—a plausible inference but not directly stated. The qualitative reasoning is sound in direction but includes some extrapolations beyond the provided facts. Quantitatively, no hard numbers (e.g., revenue amounts) are misstated, but the 2% revenue decline is an unsupported addition. Contextually, the answer remains highly relevant, addressing all key aspects of strategic focus, new indications, combinations, and revenue implications with strong semantic alignment on the main points.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1484,
        "completion_tokens": 395,
        "total_tokens": 1879
      },
      "error": null
    },
    {
      "question_id": 126,
      "question": "How did American Express's investment in foreign government bonds and obligations evolve between 2023 and 2024 in terms of fair value and maturity distribution?",
      "original_answer": "In 2023, American Express held $549 million in foreign government bonds and obligations with all of it maturing in 12 months or more and a gross unrealized loss of $1 million. By 2024, the fair value of these investments increased significantly to $765 million, with $764 million maturing within one year and only $1 million maturing after one year but within five years. This indicates a substantial increase in exposure to foreign government bonds, primarily in short-term maturities.",
      "llm_answer": "\nBetween the 2023 and 2024 reporting periods the fair‑value of American Express’s foreign‑government‑bond portfolio was essentially flat—$770 million in 2023 versus $765 million in 2024 (a negligible decline).  The maturity profile stayed the same: almost the entire position (about $768 million) matures within one year, with only a modest $2 million portion scheduled to mature after one year but within five years, and no material exposure beyond that.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, American Express held $549 million in foreign government bonds in 2023, not $770 million as stated by the LLM. In 2024, the correct fair value is $765 million, which the LLM correctly reports. However, the 2023 figure is grossly overstated, leading to an incorrect conclusion of 'essentially flat' when in fact there was a substantial increase from $549M to $765M (a 39% increase). (2) Maturity distribution is also incorrect: in 2023, 100% of the $549M matured in 12 months or more, but the LLM claims $768M matured within one year in 2023—this is factually wrong and contradicts the source. In 2024, the LLM correctly identifies that $764M matures within one year and $1M after one year, though it rounds up to $2M, which is inaccurate. (3) The multi-hop reasoning is flawed: the model fails to recognize the dramatic shift in both volume and maturity profile—from long-term in 2023 to predominantly short-term in 2024. Instead, it claims the maturity profile 'stayed the same,' which is the opposite of the truth. (4) Contextual relevance is acceptable because the answer addresses fair value and maturity as asked, but due to severe quantitative and qualitative errors, the overall correctness score is low. The answer misrepresents both the magnitude of change and the directional shift in investment strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1238,
        "completion_tokens": 393,
        "total_tokens": 1632
      },
      "error": null
    },
    {
      "question_id": 126,
      "question": "How has Walmart's use of intercompany financing arrangements evolved between 2022 and 2024, particularly regarding the amount of cash not freely transferable to the U.S. and the conditions under which such transfers occur?",
      "original_answer": "In 2022, Walmart reported $4.3 billion in cash and cash equivalents that may not be freely transferable to the U.S., with $2.2 billion of that amount subject to approval by Flipkart minority shareholders. By 2024, the amount of cash not freely transferable decreased slightly to $3.3 billion, and the language indicates that these transfers are now generally subject to approval from noncontrolling interest shareholders, rather than specifically tied to Flipkart. This reflects a slight reduction in the magnitude of restricted cash and a broader framing of the conditions under which such transfers occur, suggesting a shift in the structure or focus of intercompany financing arrangements.",
      "llm_answer": "\nWalmart’s “cash that cannot be freely transferred to the U.S.” fell from roughly **$4.3 billion as of January 31 2022** to about **$3.5 billion as of January 31 2024** (≈$3.3 billion in the 2025 filing).  The company continues to use intercompany financing to move cash to where it is needed at the lowest cost, but the **conditions for repatriation have broadened** – whereas in 2022 roughly $2.2 billion of that amount could be accessed only through dividends or intercompany financing that required the **approval of Flipkart’s minority shareholders**, by 2024 the same cash is described as being **subject to the approval of the relevant non‑controlling interest shareholders** (i.e., the same Flipkart minority owners but with a more flexible, approval‑based mechanism).  This evolution reflects tighter local legal restrictions but also a shift toward using shareholder‑approval‑driven intercompany financing as the primary route for moving the restricted cash back to the U.S.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer is mostly correct in its factual content and captures the key evolution in Walmart's intercompany financing arrangements between 2022 and 2024. It correctly identifies the decrease in cash not freely transferable to the U.S. from $4.3 billion in 2022 to a figure close to $3.5 billion in 2024, with a note that the 2025 filing reports $3.3 billion. However, the original answer specifies $3.3 billion as the 2024 amount, while the LLM states $3.5 billion as of January 31, 2024, and then references $3.3 billion in the 2025 filing—this introduces a minor discrepancy in timing. The ground truth ties $3.3 billion directly to 2024, not to the subsequent year’s filing. 2) Quantitatively, the $4.3 billion figure for 2022 is accurate. The $2.2 billion subject to Flipkart minority shareholder approval in 2022 is also correct. The shift to $3.5 billion (vs. $3.3 billion) in 2024 is a small but notable overstatement. The explanation that the 2024 amount is reported in the 2025 filing is technically accurate due to fiscal reporting lags (Walmart’s fiscal year ends January 31), but the LLM conflates the reporting date with the fiscal year, leading to potential confusion. 3) The qualitative reasoning is strong: the LLM correctly identifies the broadening of transfer conditions from being specifically tied to Flipkart to a more general reference to noncontrolling interest shareholders, indicating a shift in framing and possibly structure. The interpretation that this reflects a move toward shareholder-approval-driven mechanisms is reasonable and aligns with the original answer. 4) Contextual relevance is excellent—the response directly addresses both parts of the question: the change in restricted cash amount and the evolving conditions for transfer. The synthesis across years and entities (Walmart, Flipkart, noncontrolling interests) is sound. The minor quantitative inaccuracy prevents a top score, but the overall answer is factually robust and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1438,
        "completion_tokens": 534,
        "total_tokens": 1972
      },
      "error": null
    },
    {
      "question_id": 126,
      "question": "How did the composition of Texas Instruments' U.S. Retiree Health Care Plan assets evolve between the 2023 and 2024 filings, particularly in terms of fixed income securities and equity securities allocation?",
      "original_answer": "The composition of Texas Instruments' U.S. Retiree Health Care Plan assets remained completely unchanged between the 2023 and 2024 filings. In both years, the plan held $210 million in fixed income securities and cash equivalents, and $54 million in equity securities, resulting in a total of $264 million in plan assets. The fixed income allocation represented approximately 79.5% of the total plan assets, while equity securities represented approximately 20.5% in both years. The identical figures across both filings indicate no evolution in the asset allocation strategy for this plan during the reported period.",
      "llm_answer": "\nBetween the 2023 and 2024 filings the U.S. Retiree Health‑Care plan’s asset mix stayed essentially unchanged: roughly 80 % of the portfolio was held in fixed‑income securities and cash equivalents and about 20 % in equity securities. In 2023 the plan held $210 million of fixed‑income assets (≈79.5 % of total $264 million) and $54 million of equities (≈20.5 %); by 2024 the corresponding figures were $198 million of fixed‑income (≈79.8 % of $248 million) and $50 million of equities (≈20.2 %). Thus the allocation remained stable within the plan’s target ranges (75‑85 % fixed income, 15‑25 % equity).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its numerical claims. According to the ground truth, the asset values and allocations for Texas Instruments' U.S. Retiree Health Care Plan were identical in 2023 and 2024: $210 million in fixed income and $54 million in equities, totaling $264 million in both years. However, the LLM incorrectly states that in 2024, fixed income dropped to $198 million and equities to $50 million, with a total of $248 million—numbers not supported by the data. These errors directly contradict the ground truth of no change. (2) The percentages cited in the LLM answer (e.g., 79.8% and 20.2%) are miscalculated based on incorrect totals and do not align with the correct 79.5% and 20.5% in both years. While the approximate 80/20 split description is directionally reasonable, the specific figures are wrong. (3) The reasoning fails on multi-hop synthesis: the model should have identified that the same values appear in both years’ filings, indicating no evolution, but instead fabricated a change. The mention of target allocation ranges (75–85% fixed income, 15–25% equity) is contextually relevant but not present in the original answer and does not compensate for factual inaccuracies. (4) Despite incorrect numbers, the answer addresses the right plan, company, and time frame, and attempts to compare allocations—hence partial credit for qualitative and contextual accuracy. However, the core failure in quantitative fidelity results in a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 416,
        "total_tokens": 1736
      },
      "error": null
    },
    {
      "question_id": 127,
      "question": "How did Honeywell's 2006 Stock Plan for Non-Employee Directors evolve between 2022 and 2024 in terms of the specific forms of award agreements offered, and what might this suggest about changes in the company's non-employee director compensation structure?",
      "original_answer": "In 2022, Honeywell's 10-K filing listed both the 'Form of Option Agreement' (Exhibit 10.30) and the 'Form of Restricted Unit Agreement' (Exhibit 10.32) as part of the 2006 Stock Plan for Non-Employee Directors. By 2024, while the 'Form of Option Agreement' was still referenced (Exhibit 10.29), the 'Form of Restricted Unit Agreement' was no longer explicitly mentioned in the exhibit list. This suggests a shift in the types of equity awards offered to non-employee directors, potentially signaling a strategic move toward emphasizing stock options over restricted units in director compensation.",
      "llm_answer": "\nBetween 2022 and 2024 Honeywell refreshed the awards it grants under the 2006 Stock Plan for Non‑Employee Directors by swapping the 2021‑era option and RSU templates for revised ones that (i) add performance‑based vesting and change‑in‑control acceleration language, (ii) replace the prior cash‑settlement of notional shares with full‑share issuance, and (iii) incorporate updated expiration and holding‑period provisions (see Exhibit 10.52‑10.53 for the 2021 forms and Exhibit 10.55‑10.56 for the 2023‑2024 updates).  This shift toward more performance‑linked, share‑based awards indicates that the company is tightening the link between director compensation and long‑term shareholder value and reducing reliance on simple time‑based options.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contains significant factual and entity errors. (1) The 2006 Stock Plan for Non-Employee Directors was not updated with '2021-era' or '2023-2024' forms as claimed; the ground truth shows that in 2022, Honeywell referenced Exhibit 10.30 (Option Agreement) and Exhibit 10.32 (Restricted Unit Agreement), and in 2024, only Exhibit 10.29 (Option Agreement) was listed, with no mention of a Restricted Unit Agreement. The LLM incorrectly invents exhibits (10.52–10.56) and mislabels them as part of a 2021–2024 update, which contradicts the actual exhibit numbering and content in the filings. (2) There is no evidence in the ground truth of performance-based vesting, change-in-control acceleration, or shifts from cash-settled notional shares to full-share issuance—these are fabricated details. (3) The reasoning is flawed: the ground truth suggests a potential shift from restricted units to options, but the LLM claims a move toward performance-linked awards and away from 'simple time-based options,' which is the opposite of what the evidence implies. (4) The answer fails the multi-hop requirement: it does not accurately track the evolution of specific award forms between 2022 and 2024 as documented in the 10-K exhibits. Instead, it introduces non-existent documents and reformulations. While the general direction of analyzing compensation structure changes is contextually relevant, the factual foundation is entirely unsound, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 413,
        "total_tokens": 1776
      },
      "error": null
    },
    {
      "question_id": 127,
      "question": "How did Walmart's strategic position regarding its ownership stake in Flipkart evolve between 2022 and 2024, particularly in terms of financial implications and potential exposure to regulatory risks?",
      "original_answer": "In 2022, Walmart received $3.2 billion in equity funding related to Flipkart, which reduced its ownership stake from 83% to 75%. This signaled a partial financial exit while maintaining majority control. By 2024, however, Walmart disclosed ongoing regulatory scrutiny in India, including a show cause notice issued in July 2021 and subsequent information requests related to alleged violations of India's Foreign Direct Investment rules during the period 2009–2015—prior to Walmart's acquisition of Flipkart in 2018. Despite the reduced ownership stake, Walmart remained exposed to potential regulatory consequences, including share ownership restrictions, and noted its inability to reasonably estimate potential losses or indemnification proceeds from prior shareholders. The evolution reflects a shift from active financial participation to managing legacy risks tied to Flipkart's pre-acquisition history.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2024 Walmart’s Flipkart stake was trimmed when the company participated in a $3.2 billion equity funding that cut its ownership from about 83 % to roughly 75 % and generated a large cash inflow, reducing the carrying value of its investment.  Since that transaction the remaining minority stake has been exposed to intensified Indian regulatory scrutiny—including a foreign‑direct‑investment notice, an antitrust probe by the Competition Commission of India and related enforcement actions—creating potential liabilities, possible forced divestiture or operational constraints that could materially affect Walmart’s earnings and cash flow.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $3.2 billion equity funding event and the reduction in Walmart's ownership stake from 83% to 75%, which aligns with the ground truth. The financial implication of a cash inflow and reduced carrying value is accurately conveyed. However, the LLM omits the specific timing of the regulatory actions—namely that the show cause notice was issued in July 2021 (prior to 2022), and that the alleged FDI violations occurred between 2009–2015, before Walmart’s 2018 acquisition. While the LLM correctly notes ongoing regulatory scrutiny and potential risks, it does not clarify that these issues predate Walmart’s ownership, which is a key nuance in assessing Walmart’s exposure and liability. (2) Quantitatively, all numbers are accurate: $3.2 billion, 83% to 75% stake reduction—no calculation errors. Date formatting uses 'fiscal 2022–2024' which is acceptable as a proxy for calendar years in absence of explicit fiscal year discrepancies. (3) The multi-hop reasoning is largely sound: the model connects the equity event to financial implications and then links continued exposure to regulatory risks. However, it fails to fully synthesize the critical point that the regulatory risks stem from Flipkart’s pre-acquisition history, weakening the precision of the risk attribution. This affects qualitative accuracy but not core correctness. (4) The answer remains highly contextually relevant, addressing both financial implications and regulatory exposure as asked. The omission of the pre-2018 timeline detail prevents a perfect score, but the core facts and synthesis are strong, warranting a correctness score of 8.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1408,
        "completion_tokens": 456,
        "total_tokens": 1865
      },
      "error": null
    },
    {
      "question_id": 128,
      "question": "How did the composition and strategic emphasis of HON's U.S. cash balances evolve between 2022 and 2024, particularly in terms of total cash holdings and geographic distribution of funds?",
      "original_answer": "In 2022, HON reported holding $11.5 billion of cash and cash equivalents as of December 31, 2021, with an emphasis on safety of principal and diversification among counterparties. By 2024, the company held $11.0 billion in total cash and equivalents as of December 31, 2024, but specifically noted that $8.0 billion of that amount was held in non-U.S. subsidiaries. This represents a shift in geographic distribution, with a larger portion of liquidity positioned outside the U.S., while maintaining the same strategic emphasis on safety and diversification.",
      "llm_answer": "\nBetween 2022 and 2024 Honeywell’s overall cash pool remained roughly in the low‑teens of billions of dollars, but the **geographic split shifted markedly toward non‑U.S. balances**.  In the 2024 filing the company reports about **$8 billion (≈73 %) of its cash, cash equivalents and short‑term investments held in subsidiaries outside the United States**, leaving only roughly **$3 billion of U.S.–based cash** – down from an estimated $3½–$4 billion of U.S. cash in 2022.  This evolution reflects a strategic emphasis on using the larger overseas cash pool to fund acquisitions, capital‑expenditure programs and share‑repurchase initiatives, while keeping only a modest amount of cash onshore to meet domestic liquidity needs.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies in numbers and time references. The ground truth states that the $11.5 billion cash balance was as of December 31, 2021 (reported in the 2022 filing), while the LLM incorrectly implies this figure is from 2022. Similarly, the $11.0 billion total cash for 2024 is correct, but the LLM misattributes the $8 billion non-U.S. portion to 'cash, cash equivalents and short-term investments' rather than just 'cash and equivalents' as per the original answer. Additionally, the LLM estimates $3.5–$4 billion of U.S. cash in 2022, which is not supported by the ground truth—no such breakdown was provided for 2022, only total cash of $11.5 billion with no geographic split. The 73% calculation ($8B / $11B) is mathematically correct but misleading since the original answer does not claim this percentage. (2) The LLM introduces 'short-term investments' not mentioned in the original answer, conflating the metric. It also invents a strategic rationale—funding acquisitions, capex, buybacks with overseas cash—which is not present in the ground truth. While the shift toward non-U.S. holdings is correctly identified, the reasoning behind it is speculative. (3) The multi-hop reasoning partially works: the model identifies a change in geographic distribution between two years and attempts to infer implications. However, it fails to accurately represent what was known in each year—especially the lack of geographic data for 2022—and thus overinterprets. (4) The contextual relevance is high because the answer addresses both total cash and geographic distribution, and the strategic emphasis is partially aligned (though extended beyond the source). Due to significant quantitative errors and unsupported inferences, the correctness score is limited to 6 despite capturing the general trend.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 500,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 128,
      "question": "How did the financial treatment and liability estimation methodology for the Membership Rewards program evolve from 2023 to 2024, particularly in terms of deferred fees and liability modeling assumptions?",
      "original_answer": "In 2023, the company recognized deferred fees related to Membership Rewards program participants, indicating a focus on the deferral aspect of fee revenue associated with the program. By 2024, the disclosures provided a much more detailed explanation of the liability estimation methodology, including the use of the Ultimate Redemption Rate (URR) and the weighted average cost (WAC) per point. The 2024 filing also quantified the sensitivity of the liability to changes in assumptions, noting that a 25 basis point increase in URR would raise the liability by $197 million, and a 1 basis point increase in WAC per point would increase it by $220 million. This reflects a shift from a simpler mention of deferred fees to a comprehensive, model-driven approach to estimating future redemption liabilities.",
      "llm_answer": "\nThe 2024 filing continues to record Membership‑Rewards expense by establishing a liability equal to the best estimate of future redemption cost, using an actuarially‑derived Ultimate Redemption Rate (URR) and a 12‑month weighted‑average cost‑per‑point (WAC) that is updated each year from actual redemptions and adjusted for known partner‑contract changes.  Compared with 2023, the 2024 methodology refines the URR model—explicitly allocating future payments first to interest and fees before principal—and adds a disclosed sensitivity analysis (≈ $197 million increase for a 25‑basis‑point rise in URR and ≈ $220 million for a 1‑basis‑point rise in WAC), indicating a more granular, statistically‑driven estimation of the liability.  The liability is now presented net of membership‑cancellation reserves within the “Deferred card and other fees, net” line, providing a clearer separation of deferred fees from the rewards obligation.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the shift from deferred fees in 2023 to a more detailed liability modeling approach in 2024 is accurately described. The use of Ultimate Redemption Rate (URR) and weighted average cost (WAC) per point in 2024 is correctly identified. (2) Quantitative accuracy is perfect: the sensitivity figures—$197 million increase for a 25-basis-point rise in URR and $220 million for a 1-basis-point rise in WAC—are exactly as stated in the original answer, with acceptable formatting (≈ used appropriately). (3) The multi-hop reasoning is sound: the model correctly infers an evolution in methodology between 2023 and 2024, synthesizing the increased granularity and disclosure of actuarial methods and sensitivity analysis. (4) The LLM adds slightly more detail than the original (e.g., mentioning allocation of payments to interest/fees before principal and net presentation within 'Deferred card and other fees, net'), which is consistent with plausible enhancements in disclosure but not explicitly confirmed in the ground truth. This extra detail does not contradict but slightly exceeds the original, warranting a 9 instead of 10 for qualitative accuracy due to potential over-attribution of specifics not in the source. Overall, the answer is factually correct, comprehensive, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1449,
        "completion_tokens": 387,
        "total_tokens": 1837
      },
      "error": null
    },
    {
      "question_id": 128,
      "question": "How has Adobe's strategic positioning and integration of Frame.io evolved between 2022 and 2024, particularly in terms of its alignment with Adobe's broader product ecosystem?",
      "original_answer": "In 2022, Adobe described the integration of Frame.io as part of its Digital Media reportable segment, emphasizing its role as a cloud-based video collaboration platform acquired for $1.18 billion, with integration efforts just beginning. By 2024, Frame.io had transitioned from being a newly acquired integration to being positioned as a core component of Adobe's creative collaboration suite, directly integrated with key applications such as Adobe Premiere Pro, After Effects, Photoshop, and Workfront. Additionally, in 2024, Frame.io was included as part of Adobe GenStudio, indicating a deeper strategic alignment with Adobe's broader content production and collaboration ecosystem. This evolution reflects a shift from initial integration to full ecosystem incorporation.",
      "llm_answer": "\nBetween fiscal 2022 and 2024 Adobe deepened Frame.io’s role inside its Creative Cloud and Experience Cloud stacks, positioning the platform as the native collaboration layer that ties together video‑centric apps such as Premiere Pro, After Effects and Adobe Express while also feeding into Document Cloud workflows and AI‑driven features like Firefly.  The 2024 filing treats Frame.io’s recurring revenue as part of the Digital Media ARR metric and emphasizes that its integration accelerates subscription growth and reinforces Adobe’s broader strategy of unifying creative, document and customer‑experience tools into a single, subscription‑based ecosystem.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the strategic evolution of Frame.io within Adobe's ecosystem between 2022 and 2024. (1) Quantitatively, there are no specific numerical inaccuracies—the answer does not repeat the $1.18B acquisition figure from the original, but it does not misstate any numbers, and correctly references recurring revenue being included in Digital Media ARR in 2024, which is consistent with the knowledge graph. No incorrect calculations are made. (2) The entity accuracy is strong: Adobe, Frame.io, Premiere Pro, After Effects, and Adobe Express are correctly named; fiscal years 2022 and 2024 are appropriately used; and the Digital Media segment (via ARR) is correctly referenced. (3) The reasoning is sound and reflects multi-hop synthesis: the answer captures the shift from initial integration to deeper ecosystem embedding, highlights integration with key Adobe apps, and connects Frame.io to broader strategic goals like AI (Firefly), subscription growth, and unification across Creative Cloud, Experience Cloud, and Document Cloud. However, it omits specific mention of Workfront and GenStudio—two key integrations highlighted in the ground truth—which slightly weakens completeness and qualitative accuracy. (4) Despite these omissions, the answer conveys the core strategic trajectory accurately and uses semantically equivalent language (e.g., 'native collaboration layer' reflects 'core component'). Contextual relevance is excellent, directly addressing the evolution of strategic positioning and ecosystem alignment. The answer earns a high score but not perfect due to missing GenStudio and Workfront references, which are material to full ecosystem integration as defined in the original.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 480,
        "total_tokens": 1846
      },
      "error": null
    },
    {
      "question_id": 129,
      "question": "How did the composition of private alternative investments, specifically equity-like funds, evolve between 2022 and 2023 in terms of fair value measurements using significant unobservable inputs (Level 3)?",
      "original_answer": "In 2022, equity-like funds under private alternative investments had a fair value of $5.5 million measured using significant unobservable inputs (Level 3). In 2023, this value increased significantly to $25.4 million. This indicates a fivefold increase in the portion of equity-like funds valued using Level 3 inputs, suggesting a shift toward more opaque or complex valuation methodologies for these investments.",
      "llm_answer": "\nBetween the end of 2022 and the end of 2023 the amount of equity‑like private‑alternative investments that was classified as Level 3 (i.e., measured using significant unobservable inputs) fell modestly—from **$25.4 million** in the 2022 fair‑value hierarchy to **$25.1 million** in the 2023 hierarchy, a decline of about $0.3 million (roughly 1 %).  At the same time the overall equity‑like fund assets grew (from $4,014.1 million to $4,093.7 million), but the share valued through Level 3 inputs slipped slightly, indicating a modest shift toward more observable‑input pricing for that segment.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is almost entirely incorrect and contradicts the ground truth. (1) Quantitatively, it states that Level 3 equity-like fund values decreased from $25.4 million in 2022 to $25.1 million in 2023, while the original answer shows an increase from $5.5 million in 2022 to $25.4 million in 2023. This reverses both the direction and magnitude of change. The LLM also introduces overall fund sizes ($4,014.1M and $4,093.7M) not present in the ground truth, which may be fabricated or misattributed. (2) Calculations are incorrect: the LLM claims a 1% decline, but the actual change per ground truth is a ~362% increase (from $5.5M to $25.4M). (3) Qualitatively, the reasoning is flawed—the LLM concludes a shift toward more observable inputs (i.e., away from Level 3), while the truth indicates a significant increase in Level 3 usage, implying more opaque valuations. (4) Contextually, the answer addresses the right topic (evolution of Level 3 equity-like funds), so it maintains some relevance, but all key facts and conclusions are wrong. Multi-hop synthesis failed completely: the model either accessed incorrect data or misattributed values across years. The reversal of values between years suggests a critical error in data retrieval or reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1267,
        "completion_tokens": 351,
        "total_tokens": 1618
      },
      "error": null
    },
    {
      "question_id": 130,
      "question": "How has Adobe's integration and positioning of Frame.io within its Digital Media offerings evolved between 2022 and 2024?",
      "original_answer": "In 2022, Adobe had just acquired Frame.io in October 2021 and was beginning to integrate it into the Digital Media segment as a cloud-based video collaboration platform. By 2024, Frame.io had become a core part of Adobe’s creative collaboration tools, being directly integrated with Adobe Premiere Pro, After Effects, Photoshop, Lightroom, and Workfront, and was also included in Adobe GenStudio for scalable content production. This reflects a strategic evolution from initial integration to deeper ecosystem embedding.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2024 Adobe moved Frame.io from a newly‑acquired, stand‑alone video‑collaboration platform (acquired in Q4 FY2021 and first reported in the 2022 10‑K as being “integrated into the Digital Media reportable segment”) to a core, tightly‑woven component of its Digital Media portfolio.  The 2022 filing notes the initial integration effort, while the 2024 filing describes deep product‑level integration—Frame.io’s collaboration tools are now embedded directly in flagship Creative Cloud apps (e.g., Premiere Pro, After Effects, Photoshop) and are promoted alongside Creative Cloud and Document Cloud as a key driver of ARR growth and subscription uptake.  This evolution reflects a shift from “adding a new service” to positioning Frame.io as a central hub that enhances the end‑to‑end creative workflow across Adobe’s Digital Media offerings.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Frame.io was acquired in October 2021 (Q4 FY2021), integration began in 2022, and by 2024 it was deeply embedded in Adobe's Digital Media offerings. The timeline and fiscal year references are accurate. (2) Quantitative accuracy is perfect: no numerical errors, and the use of 'Q4 FY2021' and reporting in the 2022 10-K matches the source. (3) Multi-hop reasoning is sound—correctly synthesizing information across 2022 and 2024 filings to show evolution from initial integration to core component. The LLM correctly infers strategic positioning from integration depth. (4) The only minor omission is that the original answer specifically mentions integration with Lightroom and Workfront and inclusion in Adobe GenStudio, which the LLM answer does not include. While the LLM mentions 'flagship Creative Cloud apps' and gives correct examples, the absence of GenStudio and the specific callout of Workfront and Lightroom slightly reduces completeness. However, the semantic meaning and strategic evolution are accurately conveyed. Wording differs but meaning is equivalent. Contextual relevance is excellent—directly addresses the evolution of integration and positioning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 356,
        "total_tokens": 1697
      },
      "error": null
    },
    {
      "question_id": 130,
      "question": "How has CVS's approach to Medication Management evolved between 2022 and 2024, particularly in terms of clinical programs and digital tools aimed at improving medication adherence and cost efficiency?",
      "original_answer": "In 2022, CVS emphasized formulary management through its National Pharmacy and Therapeutics Committee, promoting the use of generic drugs and offering real-time benefit information to guide members toward lower-cost alternatives. The company also operated mail order and specialty pharmacies, and provided clinical programs focused on medication adherence and utilization management, including an industry-leading approach to limit opioid prescriptions to seven-day supplies for acute cases. By 2024, CVS had expanded its Medication Management offerings with the introduction of digital tools like the NovoLogix preauthorization platform and enhanced analytics for identifying lower-cost drug alternatives. The company also launched the CVS Weight Management program, integrating GLP-1 medication optimization with lifestyle coaching, and expanded its value-based care initiatives through Oak Street Health, operating 239 primary care centers across 27 states to better manage chronic conditions and medication use. These developments reflect a shift from primarily cost-containment strategies to a more integrated, digitally enabled, and clinically proactive model of medication support.",
      "llm_answer": "\nBetween 2022 and 2024 CVS moved from a largely formulary‑ and utilization‑management‑only approach to a fully digital, AI‑enabled medication‑management ecosystem.  The company added real‑time benefits and “Health Engagement Engine” analytics, the Canopy platform, and point‑of‑care EHR integration that deliver personalized adherence and cost‑saving recommendations, while expanding clinical programs such as Pharmacy Advisor, disease‑specific management, GLP‑1 weight‑management and tighter opioid controls.  These tools are now embedded within broader value‑based and home‑care initiatives (e.g., Signify Health in‑home evaluations, Oak Street Health clinics), creating a more granular, data‑driven strategy to improve adherence and lower drug‑spend.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core evolution in CVS's Medication Management approach from 2022 to 2024 with accurate qualitative direction and strong contextual relevance. It correctly identifies the shift from formulary/utilization management to a more integrated, digital, and clinically proactive model. Quantitatively, there are no specific numbers (e.g., 239 clinics, 27 states) mentioned in the LLM response, but it does not fabricate any incorrect figures—thus, quantitative accuracy is high due to absence of errors. However, the LLM introduces unverified program names such as 'Health Engagement Engine', 'Canopy platform', and 'Pharmacy Advisor' that are not present in the ground truth, which undermines entity and qualitative accuracy. While the mention of GLP-1 weight management and Oak Street Health is correct and aligned with the original answer, the integration with Signify Health and 'in-home evaluations' is not mentioned in the ground truth, representing an unsupported expansion. The original answer specifies NovoLogix as the preauthorization platform and highlights real-time benefit tools and analytics for lower-cost alternatives—concepts echoed in the LLM answer but rebranded with unverified names. The reasoning is logically sound in framing the strategic shift, but the use of non-grounded tool names and programs reduces factual precision. Overall, the answer is semantically close and contextually strong, but loses points for introducing unverified entities and missing specific, verifiable 2024 initiatives like the NovoLogix platform and the exact scope of Oak Street Health's footprint.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1498,
        "completion_tokens": 441,
        "total_tokens": 1940
      },
      "error": null
    },
    {
      "question_id": 131,
      "question": "How has Adobe's integration and positioning of Frame.io within its Creative Cloud ecosystem evolved from 2022 to 2024, and what specific enhancements were made to its collaboration features during this period?",
      "original_answer": "In 2022, Adobe acquired Frame.io and began integrating its cloud-based video collaboration platform into Adobe Creative Cloud, with initial enhancements focused on deeper integration into Premiere Pro and After Effects to deliver native collaborative workflows for video editing. By 2024, Frame.io had evolved into a more comprehensive cloud-native creative collaboration platform, offering real-time upload, review, and approval features not only for video but also for still images, design files, and PDFs. It expanded its integration across Adobe Photoshop, Lightroom, and Workfront, and introduced Camera to Cloud functionality, enabling automatic upload of footage directly into Frame.io from cameras on set. These enhancements reflect a strategic shift from a video-specific collaboration tool to a broader creative asset production and review platform within Adobe’s ecosystem.",
      "llm_answer": "\nFrom fiscal 2022 through 2024 Adobe moved Frame.io from a recent acquisition into the central collaboration layer of Creative Cloud, first embedding its review‑and‑approval workflow directly into Premiere Pro and After Effects and then broadening that integration across the suite.  During this period Adobe added native, frame‑accurate commenting, “Camera‑to‑Cloud” automatic upload, browser‑based editing, and tighter links to Creative Cloud Express, Adobe Firefly and the Document Cloud AI services, giving users real‑time, cross‑app collaboration, AI‑enhanced content‑credential tracking, and a unified workflow that positions Frame.io as the collaborative backbone of Creative Cloud.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly identifies the timeline (2022–2024) and the strategic integration of Frame.io into Creative Cloud post-acquisition. Key enhancements such as deeper integration with Premiere Pro and After Effects, Camera-to-Cloud, real-time collaboration, and expansion to other apps are accurately reported. The mention of integration with Photoshop, Lightroom, and Workfront in the original is partially reflected in the LLM’s reference to broader suite integration and links to Creative Cloud Express and Document Cloud, though Workfront is not explicitly named. The LLM adds specific features not in the original—such as browser-based editing and AI-enhanced content-credential tracking via Adobe Firefly and Document Cloud AI—which are plausible enhancements but not confirmed in the ground truth; this introduces minor overreach but does not contradict known facts. All dates and entities (Adobe, Frame.io, Creative Cloud, Premiere Pro, After Effects) are correct. No numerical inaccuracies exist, and the reasoning correctly synthesizes multi-hop information across time and product lines. The answer captures the strategic evolution from video-specific tool to central collaboration layer, matching the core insight of the original. Thus, it scores a 9 for correctness and qualitative accuracy due to slight extrapolation, but full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1409,
        "completion_tokens": 403,
        "total_tokens": 1812
      },
      "error": null
    },
    {
      "question_id": 132,
      "question": "How has the use of recently executed transactions in the valuation of loans and other assets evolved from 2023 to 2024, particularly in terms of their role in fair value determination?",
      "original_answer": "In 2023, recently executed transactions were a key input for determining the fair value of corporate loans and contingent lending commitments, often used alongside market price quotations, implied yields, and proprietary valuation models. By 2024, the role of recently executed transactions remained significant but was more specifically tied to the held-for-sale category of loans and lending commitments, and also extended to the valuation of other assets such as other investments, where they were used in conjunction with discounted cash flow models and comparable company multiples. This reflects a more targeted application of transaction data in valuation practices.",
      "llm_answer": "\nFrom 2023 to 2024 the Firm continued to use prices of recently executed transactions—such as comparable‑bond or loan trades—as a key observable input for fair‑value measurement of loans and other assets, classifying those inputs as Level 2 when market prices are unavailable and as Level 3 when the inputs become unobservable.  The 2024 disclosures note that no material revisions were made to this approach, indicating that the methodology for incorporating recent market trades into fair‑value estimates remained essentially unchanged.  Consequently, the role of those transaction‑derived prices in determining fair value was stable, serving both to supplement quoted market prices and to provide the basis for valuation adjustments (e.g., credit‑spread, prepayment, and discount‑rate inputs) across the loan and securities portfolios.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually consistent in its description of valuation inputs and fair value hierarchy levels (Level 2/Level 3), and no numbers are incorrect—hence full marks for quantitative accuracy. However, it contradicts the ground truth regarding the evolution of the use of recently executed transactions from 2023 to 2024. The original answer states that while transaction data remained significant, its application became more targeted in 2024—specifically emphasized for held-for-sale loans and extended to other assets like investments using DCF and comparable multiples. In contrast, the LLM claims the methodology 'remained essentially unchanged' with 'no material revisions,' which directly conflicts with the ground truth’s implication of a meaningful shift in scope and application. This misrepresents the qualitative evolution of the practice. While the LLM correctly identifies the general role of transaction data in fair value measurement and its interaction with other models, it fails to capture the nuanced expansion and re-targeting described in the original answer, resulting in partial correctness. Contextual relevance is high as the response stays focused on fair value determination and inputs, but the reasoning is flawed in synthesizing the change over time, undermining the multi-hop aspect of tracking methodological evolution across years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 379,
        "total_tokens": 1766
      },
      "error": null
    },
    {
      "question_id": 132,
      "question": "How has Adobe's approach to the Substance 3D Stager product evolved between 2022 and 2024, particularly in terms of its positioning within the broader Substance 3D ecosystem?",
      "original_answer": "In 2022, Substance 3D Stager was listed among Adobe's trademarks, indicating it was an established product within the company's portfolio but without detailed information about its functionality or strategic positioning. By 2024, Adobe introduced a more comprehensive view of Substance 3D as an ecosystem, where Stager is specifically described as a tool for building and assembling 3D scenes. This evolution reflects a strategic shift from simply offering the product to integrating it into a broader suite of 3D tools, including Painter, Sampler, Designer, and Modeler, emphasizing its role in enabling end-to-end 3D content creation workflows.",
      "llm_answer": "\nBetween 2022 and 2024 Adobe reframed Substance 3D Stager from a stand‑alone desktop app for assembling 3‑D scenes into the central, cloud‑connected hub of its Substance 3D ecosystem.  The 2024 disclosures stress that Stager now works natively with the other Substance 3D tools (Painter, Designer, Sampler, Modeler) and with Creative Cloud, offering cross‑device, AI‑enhanced workflows that tie 3‑D content creation to Adobe’s broader digital‑experience and generative‑AI (Firefly) platform.  Consequently, Stager is positioned not just as a scene‑building utility but as the integrated staging layer that links asset creation, collaboration and delivery across Adobe’s Creative Cloud and Experience Cloud offerings.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of Adobe's positioning of Substance 3D Stager between 2022 and 2024. It accurately captures the shift from a standalone tool to a more integrated component within the broader Substance 3D ecosystem. The mention of integration with other Substance 3D tools (Painter, Designer, Sampler, Modeler) and Creative Cloud is factually consistent with the original answer. The emphasis on cloud connectivity, AI enhancements via Firefly, and linkage to Experience Cloud adds detail not explicitly in the ground truth but is plausible and contextually relevant, reflecting Adobe’s broader strategic direction. However, the claim that Stager became the 'central, cloud-connected hub' and 'integrated staging layer' across Creative Cloud and Experience Cloud goes slightly beyond the original answer, which describes Stager as a tool for building and assembling 3D scenes within an end-to-end workflow but does not elevate it to a central hub or explicitly tie it to Experience Cloud. This represents a minor overstatement in strategic positioning. There are no numerical values in the question or answers, so quantitative accuracy is not applicable—scored as 10 by default. The reasoning is sound and reflects appropriate multi-hop synthesis across time and product ecosystem data. The answer is fully contextually relevant. Thus, while the core facts and evolution are correctly conveyed, the slight over-extension in Stager’s strategic role prevents a perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 425,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 133,
      "question": "How did GE's strategic positioning regarding grid-scale batteries evolve from 2022 to 2023, particularly in terms of their role in the company's energy transition strategy and level of strategic reliance?",
      "original_answer": "In 2022, GE mentioned grid-scale batteries as part of a broader set of emerging technologies that 'may become more important over time' in achieving deep decarbonization goals, indicating GE was considering them as a potential future investment. By 2023, GE explicitly listed grid-scale batteries as one of the key technologies 'that may become more important over time' and integrated them into the company’s strategic narrative as a dependency, noting that achieving decarbonization goals would 'depend in part' on such technologies. This reflects a shift from viewing grid-scale batteries as a speculative investment to a more central component of GE's energy transition strategy.",
      "llm_answer": "\nFrom 2022 to 2023 GE moved grid‑scale batteries from a peripheral, “emerging‑technology” opportunity in its renewable‑energy portfolio to a core strategic pillar of the newly created GE Vernova energy business.  In the 2022 filing the company described battery storage only as a potential growth area with modest near‑term commercial traction, but by 2023 the separation plan positioned large‑scale storage as essential to the decarbonization roadmap of the spun‑off energy unit, indicating a much higher level of strategic reliance and a commitment of capital and resources to develop and commercialize grid‑scale battery projects.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies a strategic shift in GE's positioning on grid-scale batteries from 2022 to 2023, aligning with the ground truth's core narrative of increased strategic reliance. It accurately reflects that in 2022, batteries were seen as an emerging technology with limited near-term traction, and by 2023, they became more central to decarbonization goals. However, the LLM introduces specific details not present in the original answer: (1) the claim that grid-scale batteries became a 'core strategic pillar' of GE Vernova, and (2) that the 2023 positioning was tied to the 'separation plan' and 'spun-off energy unit'. While GE did spin off GE Vernova, the original answer does not explicitly link the heightened strategic reliance on batteries to the structural separation or the new entity’s roadmap. The original answer emphasizes a rhetorical shift—from 'may become more important' to 'depend in part'—indicating deeper integration into strategic dependency language, but does not confirm the level of commitment such as 'commitment of capital and resources' or 'develop and commercialize grid-scale battery projects'. These additions, while plausible, go beyond the documented evidence in the ground truth. There are no numerical inaccuracies (quantitative accuracy is high), and the answer is contextually relevant and well-reasoned, but the qualitative leap in specificity reduces its factual precision. Thus, the answer is partially correct with minor overstatement, warranting a 7 for correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 425,
        "total_tokens": 1768
      },
      "error": null
    },
    {
      "question_id": 133,
      "question": "How has CVS's disclosure regarding the use of broker quoted debt securities in its fair value measurements evolved between 2022 and 2024, particularly in terms of its presence or impact on financial reporting?",
      "original_answer": "In 2022, CVS explicitly stated that it did not have any broker quoted debt securities for the years ended December 31, 2021, and 2020, and that it only used internal pricing for certain private placements. By 2024, the company continued to disclose that it had no broker quoted debt securities for the years ended December 31, 2024 and 2023, indicating a consistent absence of such securities in its portfolio. However, the 2024 disclosure no longer mentions any negative impact or specific review process related to broker quoted debt securities, suggesting a reduced emphasis or relevance of this topic in the company's fair value measurement disclosures over time.",
      "llm_answer": "\nBetween 2022 and 2024 CVS consistently reports that it does **not** use broker‑quoted prices for any debt securities that fall under Level 3 of its fair‑value hierarchy—​the 2022 filing notes “no broker‑quoted debt securities” for 2021‑2020, and the 2024 filing repeats the same statement for 2024‑2023. As a result, broker‑quoted debt securities have remained absent from its fair‑value measurements, and they have had no discernible impact on its financial reporting during this period.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly identifies the key fact that CVS did not use broker-quoted debt securities in its fair value measurements for both the 2022 and 2024 reporting periods, with accurate references to the years covered (2021–2020 in the 2022 filing and 2023–2024 in the 2024 filing). The quantitative accuracy is perfect: dates and the absence of broker-quoted securities are correctly reported, and no incorrect numbers are introduced. The entity accuracy is also correct—CVS is the right company, and the context of Level 3 fair value hierarchy is appropriately referenced. However, the LLM answer omits a key qualitative nuance present in the original answer: the 2024 disclosure no longer mentions any negative impact or specific review process related to broker-quoted debt securities, which indicates a reduced emphasis over time. This evolution in disclosure tone and detail is a critical part of the question about how the disclosure 'evolved.' While the LLM captures the consistency in the absence of such securities, it fails to note the change in disclosure language and emphasis, which weakens the multi-hop synthesis aspect. Thus, while factually correct and contextually relevant, the answer lacks completeness in capturing the full evolution of the disclosure, particularly the reduced narrative focus in 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 368,
        "total_tokens": 1673
      },
      "error": null
    },
    {
      "question_id": 134,
      "question": "How did the composition of BlackRock's Equity Securities at FVTNI change between 2023 and 2024, particularly in terms of equity securities/mutual funds and equity method investments?",
      "original_answer": "In 2023, BlackRock reported $1,211 million in equity securities/mutual funds under Equity Securities at FVTNI, while equity method investments totaled $1,895 million. By 2024, the value of equity securities/mutual funds increased to $1,950 million, and equity method investments rose to $2,783 million. This reflects a significant increase in both categories, indicating a strategic expansion in these investment areas.",
      "llm_answer": "\nBetween 2023 and 2024 the “Equity securities / mutual funds” line in BlackRock’s FVTNI portfolio expanded sharply – fair‑value holdings rose from **$1.585 bn to $1.950 bn** (an increase of roughly **$0.365 bn or 23 %**).  By contrast, the aggregate “Equity‑method” investment balance grew only modestly, moving from **about $2.756 bn to $2.783 bn** (a gain of roughly **$27 m**).  Thus, the composition shifted toward a larger share of publicly‑traded equity securities/mutual funds, while equity‑method investments remained essentially flat.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies in the reported values for both equity securities/mutual funds and equity method investments. According to the ground truth, in 2023, equity securities/mutual funds were $1,211 million, but the LLM incorrectly states $1.585 billion. The 2024 value of $1,950 million is correct. For equity method investments, the LLM reports $2.756 billion in 2023, whereas the correct value is $1,895 million—this is a significant overstatement. The 2024 value of $2.783 billion is accurate. (2) Calculations based on incorrect inputs are also wrong: the LLM computes a $0.365 billion increase in equity securities, but the actual increase is $739 million ($1,950M - $1,211M), not $365M. The percentage increase is thus about 61%, not 23%. The equity method increase is reported as $27 million, which aligns roughly with the true increase of $888 million ($2,783M - $1,895M), but due to the incorrect base, even this small change is misrepresented. (3) The multi-hop reasoning is partially sound in structure—comparing two categories across two years—but fails due to reliance on incorrect data. The conclusion that equity securities grew significantly while equity method investments remained flat is misleading; in reality, both categories increased substantially, with equity method investments growing by nearly 47%. (4) The contextual relevance is high because the answer addresses the right categories and time frame, and attempts comparative analysis. However, the quantitative accuracy is very low due to incorrect core data, dragging down correctness and qualitative accuracy. Despite proper terminology and structure, the answer misrepresents the actual changes, leading to an incorrect interpretation of BlackRock’s strategic shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1249,
        "completion_tokens": 487,
        "total_tokens": 1736
      },
      "error": null
    },
    {
      "question_id": 134,
      "question": "How did UnitedHealth Group's evaluation and treatment of credit-related impairments for available-for-sale debt securities evolve from 2022 to 2024, particularly in terms of unrealized losses and the allowance for credit losses?",
      "original_answer": "In 2022, UnitedHealth Group reported that unrealized losses in its available-for-sale debt securities were primarily driven by interest rate increases and not credit deterioration, with no significant credit deterioration observed since purchase. The allowance for credit losses was noted to be not material as of December 31, 2021. By 2024, the company's evaluation methodology remained consistent in terms of assessing present value of expected cash flows, issuer credit condition, and fair value relative to amortized cost. However, the allowance for credit losses is now explicitly described as being recorded as a separate component through an allowance account, with credit-related impairments impacting investment and other income, indicating a more structured recognition of credit risk. This evolution shows a shift from a qualitative, low-risk assessment to a more formalized impairment accounting framework.",
      "llm_answer": "\nUnitedHealth Group’s review of credit‑related impairments for its available‑for‑sale debt securities showed essentially the same approach in 2022 and 2024: it evaluates each security’s expected cash‑flows and credit ratings and determines that the unrealized losses are driven by market‑interest‑rate movements rather than any deterioration in issuer credit quality. Consequently, the company continued to carry **no material allowance for credit losses** on those securities, indicating that its methodology and conclusion about credit‑related impairments remained stable across the 2022‑2024 period.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that UnitedHealth Group attributed unrealized losses to interest rate movements rather than credit deterioration in both 2022 and 2024, which aligns with the ground truth. It also correctly notes that the allowance for credit losses was not material, which matches the 2021 year-end disclosure referenced in the original answer. However, the LLM answer incorrectly asserts that the methodology and conclusions remained 'stable' across 2022–2024, directly contradicting the ground truth, which identifies a key evolution: by 2024, the company had adopted a more formalized framework where credit-related impairments are recognized through a separate allowance account, with impacts on investment income. This shift from a qualitative to a structured accounting approach is a central point in the original answer and is entirely missed by the LLM. (2) There are no numerical values requiring calculation, but the dates (2022, 2024) and entity (UnitedHealth Group) are accurate. The term 'available-for-sale debt securities' is correctly used. (3) The multi-hop reasoning fails because the LLM does not synthesize the change in accounting treatment over time. It treats the two periods as static, failing to recognize the evolution in disclosure and accounting practice from qualitative assessment to formal allowance recognition. (4) While the LLM captures part of the factual context, it misses the core analytical point of the question—how the evaluation and treatment evolved. This omission severely undermines the correctness despite surface-level accuracy, warranting a score of 4 for correctness and qualitative accuracy. Quantitative accuracy is higher due to correct use of terms and absence of numerical errors. Contextual relevance is moderate as the response addresses the topic but not the evolution asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1400,
        "completion_tokens": 504,
        "total_tokens": 1905
      },
      "error": null
    },
    {
      "question_id": 135,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between 2022 and 2023, particularly in terms of investment value and equity income?",
      "original_answer": "In 2022, AMD's carrying value of its investment in the ATMP JV was $83 million, and it recorded $14 million in equity income from the JV. By 2023, the carrying value increased to $99 million, and equity income rose to $16 million. This indicates a growing financial stake and increased profitability from the joint venture over the two-year period.",
      "llm_answer": "\nBetween 2022 and 2023 AMD’s equity investment in the ATMP joint venture grew from roughly **$69 million to $99 million**, driven by a jump in purchases of ATMP‑produced inventory (from $1.1 bn to $1.7 bn) and larger balances of payables and receivables.  As a result of this larger stake, the equity‑method income recognized in “Equity income in investee” increased from **$6 million in 2022 to $16 million in 2023**.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key financial figures. According to the ground truth, AMD's carrying value of its investment in the ATMP JV was $83 million in 2022, but the LLM incorrectly states it was $69 million. Similarly, the equity income in 2022 is reported as $6 million by the LLM, whereas the correct figure is $14 million. The 2023 figures ($99 million carrying value and $16 million equity income) are correctly stated. (2) Quantitative accuracy is low: two out of four core numbers are wrong, and the magnitude of the error is substantial (e.g., $69M vs $83M is a 17% deviation; $6M vs $14M is a 57% underreporting). The increase in inventory purchases and payables/receivables is not part of the original answer and introduces unverified causal reasoning. (3) While the LLM attempts multi-hop reasoning by linking investment growth to operational activity (inventory, payables), this synthesis is not supported by the ground truth and distracts from the actual trend—steady growth in both carrying value and equity income. The core evolution—increasing investment value and rising equity income—is partially captured, but with incorrect baselines. (4) Contextual relevance is high because the answer addresses the financial relationship, investment value, and equity income over time. However, the incorrect numbers undermine the conclusion. The qualitative accuracy is moderate because the direction of change (increasing investment and income) is correct, but the reasoning and figures are flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1191,
        "completion_tokens": 427,
        "total_tokens": 1619
      },
      "error": null
    },
    {
      "question_id": 135,
      "question": "How has UnitedHealth Group's exposure to tort claims evolved between 2022 and 2024, particularly in terms of the nature of the claims and the potential financial impact?",
      "original_answer": "In 2022, UnitedHealth Group specifically highlighted self-insured liabilities related to medical malpractice claims against affiliated physicians and the potential for actual losses to significantly exceed recorded liabilities. The document emphasized increasing legal actions alleging medical malpractice and general professional liabilities, with litigants seeking recoveries under new theories of liability that might not be subject to damage caps. By 2024, while tort claims remained a concern, the focus shifted slightly to broader legal risks tied to the delivery of health care services, including claims related to clinical quality and patient safety standards. The 2024 filing also emphasized the potential for reputational harm and adverse effects on business relationships, indicating a broader and more systemic risk profile compared to the more narrowly defined exposure in 2022.",
      "llm_answer": "\nBetween 2022 and 2024 UnitedHealth Group’s exposure to tort claims remained anchored in medical‑malpractice and other liability claims arising from the services of its affiliated physicians, hospitals and health‑care providers, but the filing notes that the volume of such claims and the size of potential settlements have increased.  The company continues to self‑insure these risks and records reserves for estimated losses, yet it acknowledges that actual costs could substantially exceed those estimates, potentially materially affecting its results of operations, financial position and cash flows.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that UnitedHealth Group faces tort claims primarily related to medical malpractice involving affiliated providers and that the company self-insures these risks, with potential losses exceeding recorded reserves—this aligns with the 2022 ground truth. It also notes increasing claim volume and settlement sizes, which is consistent with the trend of rising legal actions mentioned in the original. However, the LLM fails to capture the evolution in the *nature* of the claims between 2022 and 2024. Specifically, the 2024 shift toward broader legal risks—including clinical quality, patient safety standards, and reputational harm—is missing. This omission limits completeness and weakens the multi-hop synthesis across years. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not compromised; the score of 10 is justified as no numbers are misstated. (3) The reasoning is sound in linking self-insured liabilities to potential financial impact and acknowledging uncertainty in estimates, but it does not fully reflect the qualitative shift in risk profile from 2022 to 2024. The answer treats exposure as relatively static, whereas the ground truth emphasizes a broadening of risk scope over time—a key multi-hop insight. (4) Contextual relevance is high because the answer addresses tort claims, financial impact, and self-insurance, all central to the question. The correctness score is 7 because core facts are accurate, but a significant portion of the evolution—especially the expanded risk dimensions in 2024—is omitted, reducing completeness and qualitative accuracy despite strong contextual alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 475,
        "total_tokens": 1855
      },
      "error": null
    },
    {
      "question_id": 136,
      "question": "How has the structure and capacity of Boeing's three-year revolving credit agreement evolved between 2023 and 2024, and what does this indicate about the company's liquidity strategy?",
      "original_answer": "In 2023, Boeing had a legacy three-year revolving credit agreement expiring in August 2025 with $3.0 billion of total commitments. In 2024, this agreement remained in effect, but Boeing also entered into a new $4.0 billion five-year revolving credit agreement expiring in May 2029 while terminating two other credit facilities. This evolution indicates a strategic shift to enhance liquidity capacity and extend maturity timelines, reinforcing Boeing's financial flexibility and commitment to managing corporate borrowing needs.",
      "llm_answer": "\nBetween 2023 and 2024 Boeing replaced its expiring $3.2 bn five‑year revolving facility (which was set to end in October 2024) with a new $4.0 bn five‑year line (maturing May 2029), while retaining its $3.0 bn three‑year revolving agreement (due August 2025) and a $3.0 bn five‑year line (due August 2028).  This increased the total revolving‑credit commitment from roughly $6 bn in 2023 to about $10 bn in 2024, leaving approximately $10 bn of unused borrowing capacity.  The expansion reflects Boeing’s intent to broaden and strengthen its liquidity back‑stop, reducing reliance on cash‑flow from operations and providing greater flexibility to meet financing needs.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2023 Boeing had a single $3.0 billion three-year revolving credit agreement expiring in August 2025. However, the LLM claims there was a $3.2 billion five-year facility expiring in October 2024 and also mentions a $3.0 billion five-year line due August 2028 — neither of which are present in the original answer. These additional facilities are entirely fabricated. The only correct numeric detail is the new $4.0 billion five-year agreement in May 2029. (2) The calculation of total commitments increasing from $6 billion to $10 billion is incorrect because the ground truth only confirms a $3.0 billion legacy facility and a new $4.0 billion one, totaling $7.0 billion, not $10 billion. The LLM incorrectly assumes two $3.0 billion facilities in 2023 and retains both in 2024, leading to inflated totals. (3) The multi-hop reasoning is flawed: the LLM fails to recognize that Boeing terminated two other credit facilities in 2024 as part of the restructuring, which is a key point in the original answer. Instead, it suggests Boeing retained multiple large facilities, contradicting the strategic simplification and replacement described in the ground truth. (4) While the general direction of the conclusion — that Boeing is strengthening liquidity — aligns with the original, the reasoning is based on false premises. The contextual relevance is high because the answer addresses structure, capacity, and liquidity strategy, but the factual foundation is weak, warranting a low correctness and quantitative accuracy score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 447,
        "total_tokens": 1755
      },
      "error": null
    },
    {
      "question_id": 136,
      "question": "How did the financial impact of the 2017 Performance-based Options evolve between 2023 and 2024, particularly in terms of the fair value of options vested and the intrinsic value of options exercised?",
      "original_answer": "In 2023, the fair value of the 2017 Performance-based Options that vested was $56 million, and the intrinsic value of options exercised was $44 million. By 2024, the fair value of the options vested decreased slightly to $52 million, but the intrinsic value of options exercised saw a significant increase to $373 million. This indicates that while the value of options vesting declined slightly in 2024, the actual financial benefit realized from exercised options increased substantially compared to the prior year.",
      "llm_answer": "\nBetween 2023 and 2024 the 2017 performance‑based options saw a modest decline in the fair‑value of the portions that vested—$56 million in 2023 versus $52 million in 2024—while the intrinsic value realized on exercised options rose sharply, from $44 million in 2023 to $373 million in 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately reported: the fair value of vested options was $56 million in 2023 and $52 million in 2024, and the intrinsic value of exercised options was $44 million in 2023 and $373 million in 2024. (2) Quantitative accuracy is perfect—numbers match exactly, with only acceptable formatting differences (e.g., using ' ' as a thousands separator). (3) The multi-hop reasoning is sound: the model correctly synthesizes data across two years and two financial metrics (fair value of vesting vs. intrinsic value of exercises) related to the same instrument (2017 Performance-based Options). (4) The answer addresses both parts of the question—evolution of fair value and intrinsic value—and captures the contrast between slight decline in vesting value versus sharp increase in exercise benefit. Wording is concise but complete, and the conclusion implied by the data is logically presented. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1215,
        "completion_tokens": 299,
        "total_tokens": 1515
      },
      "error": null
    },
    {
      "question_id": 136,
      "question": "How did AMD's approach to estimating adjustments for product return rights evolve between 2022 and 2023, and what specific changes were made in the methodology used for these estimates?",
      "original_answer": "In 2022, AMD estimated adjustments for product return rights using trended actual historical product return rate information, adjusted for known information or events. By 2023, AMD maintained the use of historical data but placed additional emphasis on 'rights of return and rebates' as part of variable consideration under ASC 606-10-32-8 through 14, explicitly stating that these estimates were based on the 'most likely amount' of consideration expected after adjustments for returns, rebates, and price protection. This reflects a more structured and codified approach to estimating returns, aligning more closely with specific accounting standards.",
      "llm_answer": "\nBetween 2022 and 2023 AMD moved from a broad, historical‑average estimate of return‑right adjustments to a more granular, data‑driven model.  In 2023 it explicitly uses trended, actual quarterly return‑rate data, adjusts those rates for known supply‑chain or economic events, and separately quantifies OEM versus distributor returns, allowing discretionary overrides when contractual percentages are exceeded.  This refined approach adds forward‑looking market data and a clearer distinction between baseline contractual limits and event‑specific adjustments.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains some correct elements but introduces significant inaccuracies and fabricates details not present in the ground truth. (1) Correctly identifies that AMD used historical data in both years and that there was a refinement in methodology from 2022 to 2023. However, the ground truth does not mention 'quarterly return-rate data', 'OEM versus distributor returns', 'discretionary overrides', or 'contractual percentages'—these are unsupported additions. (2) No numeric values (percentages, dollar amounts) are present in either answer, so quantitative accuracy is neutral—no errors but no verifiable numbers to assess. The LLM's description of a 'data-driven model' and 'forward-looking market data' is not corroborated by the original answer, which emphasizes a shift toward ASC 606 guidance and use of the 'most likely amount' method under variable consideration. (3) The multi-hop reasoning is partially sound—AMD did evolve its approach—but the LLM mischaracterizes the nature of the change: it frames the evolution as operational and segmentation-based (OEM vs. distributor), while the ground truth describes a more accounting-standard-aligned shift focused on ASC 606 and variable consideration. (4) The answer is contextually relevant and addresses the question's intent, but the factual misrepresentation of the methodology change reduces correctness. The core improvement—greater structure and alignment with ASC 606—is omitted and replaced with fabricated operational details, leading to a low qualitative and overall correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 427,
        "total_tokens": 1740
      },
      "error": null
    },
    {
      "question_id": 137,
      "question": "How did the number of shares under option for the 2017 Performance-based Options evolve from 2023 to 2024, and what does this indicate about the exercise and forfeiture trends of these options?",
      "original_answer": "The number of shares under option for the 2017 Performance-based Options decreased significantly from 1,549,080 shares at the end of 2023 to 625,825 shares at the end of 2024. This indicates that a large portion of these options were exercised (905,219 shares) and some were forfeited (18,036 shares) during 2024, showing a trend of completion in the lifecycle of these options as they approached their final vesting date.",
      "llm_answer": "\nThe 2017 performance‑based options fell sharply – from **1,549,080 shares outstanding at 31 Dec 2023** to **625,825 shares outstanding at 31 Dec 2024**.  The reduction of roughly **923 k shares** is almost entirely due to **exercises of about 905 k options** (with only ~18 k shares forfeited), showing that the performance hurdles were satisfied, the options became in‑the‑money, and were largely converted into common stock rather than being left to expire.  This reflects a strong exercise trend and a low forfeiture rate for the 2017 performance‑based options.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key numbers: 1,549,080 shares at the end of 2023 and 625,825 at the end of 2024, matching the ground truth. It accurately states that approximately 905,000 shares were exercised and about 18,000 forfeited, which aligns with the ground truth values of 905,219 and 18,036, respectively. The minor rounding (e.g., '905k' instead of 905,219) is acceptable and common in financial communication. (2) The calculation of the total reduction (1,549,080 - 625,825 = 923,255) is correct, and the LLM correctly attributes most of this to exercises (~905k) and a small portion to forfeitures (~18k), which is consistent with the ground truth breakdown. (3) The reasoning is sound: the LLM correctly infers that the sharp decline indicates completion of the option lifecycle, with most options being exercised rather than forfeited, and links this to performance hurdles being met and options becoming in-the-money. This reflects accurate multi-hop synthesis of the data and its implications. (4) The only minor shortcoming is that the LLM does not explicitly mention the 'final vesting date' as a reason for the trend, which is included in the ground truth and adds contextual completeness. However, the core conclusion about exercise trends and low forfeitures is well-supported. Overall, the answer is factually accurate, contextually appropriate, and semantically equivalent to the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1258,
        "completion_tokens": 400,
        "total_tokens": 1658
      },
      "error": null
    },
    {
      "question_id": 137,
      "question": "How has the role and scope of Optum Rx's Pharmacy Care Services evolved between 2022 and 2024, particularly in terms of its service offerings and strategic positioning within UnitedHealth Group's broader health care ecosystem?",
      "original_answer": "In 2022, Optum Rx was described as managing $112 billion in pharmaceutical spending, including $45 billion in specialty pharmaceutical spending, and was positioned as a provider of pharmacy care services through a network of over 67,000 retail pharmacies, home delivery, specialty pharmacies, and infusion services. It emphasized clinical programs, digital tools, and medication management to help clients reduce costs and improve health outcomes. By 2024, Optum Rx was more strategically integrated into Optum’s broader vision of creating a 'value-oriented and more connected approach to health care,' with an emphasis on leveraging 'data and analytics, pharmacy care services, health care operations, population health and health financial services' to improve the overall health system performance. While specific spending figures were not provided in 2024, the service was elevated as a core component of Optum’s mission to enhance affordability, quality, and patient experience across the health care continuum.",
      "llm_answer": "\nBetween 2022 and 2024 Optum Rx expanded the breadth of its pharmacy‑care platform—from a focus on retail and specialty drug management to a full‑service model that now includes infusion services, rare‑disease and gene‑therapy support, behavioral‑health integration, and pharmacist‑led, whole‑patient care.  During the same period the volume of pharmaceutical spend it manages grew sharply (from about $112 billion to $178 billion total, with specialty spend rising from $45 billion to $74 billion), underscoring its scale.  This evolution positions Rx as a core, data‑driven hub that links pharmacy, medical and behavioral health within UnitedHealth Group’s end‑to‑end ecosystem, enabling UnitedHealthcare and other payers to coordinate care, control costs and improve outcomes.",
      "correctness_score": 4,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "(1) The LLM answer contains significant factual inaccuracies, particularly in quantitative claims. While the original answer states that in 2022, Optum Rx managed $112 billion in pharmaceutical spending (including $45 billion in specialty spending), the LLM incorrectly asserts that by 2024, total spending grew to $178 billion and specialty spending to $74 billion. These figures are not supported by the ground truth, which explicitly notes that 'specific spending figures were not provided in 2024.' Therefore, the LLM fabricates precise 2024 numbers without evidence. (2) The calculation of growth from $112B to $178B and $45B to $74B is entirely speculative and incorrect. No such data exists in the original answer for 2024, making the quantitative accuracy very low. (3) Qualitatively, the LLM captures the direction of evolution—expanded service offerings (infusion, gene therapy, behavioral health integration) and deeper strategic positioning within UnitedHealth’s ecosystem—though these specifics (e.g., 'gene therapy support', 'behavioral-health integration') are not explicitly mentioned in the ground truth. The core idea of Optum Rx becoming a more integrated, data-driven component of a connected healthcare system aligns with the 2024 description, so the reasoning reflects a plausible interpretation of strategic evolution, albeit overstated. (4) Contextually, the answer is highly relevant, addressing both service offerings and strategic positioning across the two years. However, the inclusion of fabricated metrics undermines overall correctness. The answer appears confident and logically structured but fails on factual fidelity, especially in unsupported numerical claims. Thus, while the qualitative trajectory is partially accurate, the invention of data severely penalizes correctness and quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1468,
        "completion_tokens": 495,
        "total_tokens": 1964
      },
      "error": null
    },
    {
      "question_id": 138,
      "question": "How did the composition and valuation of BlackRock's Equity Securities at FVTNI change between 2023 and 2024, particularly in terms of investments held for deferred cash compensation plans?",
      "original_answer": "In 2023, BlackRock reported $9 million invested in Equity Securities at FVTNI as part of the investments held to economically hedge deferred cash compensation plans. By 2024, this specific category was no longer listed under Equity Securities at FVTNI but instead appeared under 'Investments related to deferred cash compensation plans' within the Equity Method section with a value of $173 million. This indicates a reclassification or realignment of how these investments were categorized and reported in the financial statements, reflecting a significant change in the composition of Equity Securities at FVTNI.",
      "llm_answer": "\nBetween 2023 and 2024 the fair‑value carrying amount of BlackRock’s Equity Securities at FVTNI rose sharply—from **$1.585 billion to $1.950 billion**—driven by higher market prices and additional purchases.  The slice of that portfolio that is dedicated to **deferred cash‑compensation plans** stayed relatively small: the filings list **$14 million** of the FVTNI equity as being held for those plans (with a similar $9 million held in “other investments”), a figure that is unchanged from the 2023 disclosure.  Consequently, while the overall FVTNI equity position grew by roughly $365 million, the composition of the deferred‑compensation‑related holdings remained proportionally constant, consisting of about $14 million in FVTNI equity and $9 million in other investments within the broader $241 million equity‑method allocation.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in both quantitative and qualitative aspects. (1) Quantitatively, the LLM states that $14 million of Equity Securities at FVTNI were held for deferred cash compensation plans in 2024, unchanged from 2023, but the ground truth indicates that in 2023 the amount was $9 million under FVTNI and in 2024 it was no longer reported under FVTNI at all—instead, it was reclassified to the Equity Method section with a value of $173 million. The LLM incorrectly claims the amount remained unchanged and still present in FVTNI, which contradicts the reclassification. Additionally, the LLM introduces a total FVTNI value increase from $1.585 billion to $1.950 billion, which is not mentioned or supported by the original answer and appears fabricated. (2) The calculation of a $365 million increase in overall FVTNI securities is irrelevant and unsupported by the ground truth, which focuses solely on the deferred compensation component. (3) Qualitatively, the LLM fails to recognize the key multi-hop insight: the reclassification of the deferred compensation investments from FVTNI to the Equity Method section, which is the central point of the original answer. Instead, it assumes continuity in categorization, missing the structural change in reporting. (4) Contextually, the answer addresses the topic of deferred compensation investments and attempts to compare years, so it remains relevant in theme, but the core factual and reasoning errors severely undermine accuracy. Minor details like 'other investments' and 'equity-method allocation' are mentioned without alignment to the ground truth's emphasis on reclassification. Overall, the answer misrepresents the data, contains unsupported figures, and misses the primary analytical point.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1373,
        "completion_tokens": 479,
        "total_tokens": 1852
      },
      "error": null
    },
    {
      "question_id": 138,
      "question": "How has the aggregate available authorization for Accenture's open-market share purchase program changed between 2022 and 2024, and what does this indicate about the company's capital allocation strategy?",
      "original_answer": "The aggregate available authorization for Accenture's open-market share purchase program decreased from $3,129,296 in 2022 to $2,694,281 in 2024. This indicates a reduction in the company's capital allocated for share repurchases over this period, suggesting a more conservative approach to capital deployment or a strategic shift in how the company is managing its equity structure.",
      "llm_answer": "\nThe open‑market share‑purchase authorization fell from **$3.13 billion as of August 31 2022** to **$2.69 billion as of August 31 2024**, a reduction of roughly **$435 million (≈14 %)**.  This decline shows that Accenture has either used up a portion of its previously authorized repurchase capacity or deliberately scaled back the program, indicating a shift toward conserving cash and focusing capital on other priorities such as dividend growth and strategic investments rather than aggressive share‑buybacks.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the decrease in aggregate available authorization from $3.13 billion in 2022 to $2.69 billion in 2024, which aligns with the ground truth values of $3,129,296 and $2,694,281 (rounded appropriately). The calculated difference of $435 million and the approximate 14% reduction are accurate. (2) All numeric values are correct when accounting for standard rounding: $3,129,296 ≈ $3.13 billion, $2,694,281 ≈ $2.69 billion, and the difference is $435,015, which rounds to $435 million. The percentage change is (435,015 / 3,129,296) ≈ 13.9%, correctly stated as ≈14%. Dates (August 31, 2022 and 2024) are consistent with typical fiscal year-ends for Accenture and match the context. (3) The multi-hop reasoning is sound: the model correctly infers that a reduction in authorization suggests a strategic shift in capital allocation, possibly toward dividends or investments, which is a reasonable interpretation of the trend. The original answer mentions a 'more conservative approach' or 'strategic shift,' which the LLM captures well, though it adds slight interpretive detail (e.g., 'dividend growth') not explicitly in the ground truth—this is plausible but slightly extends beyond the provided conclusion. (4) Scores reflect near-perfect quantitative accuracy, excellent contextual relevance, and strong qualitative reasoning with only minor extrapolation, not error. Thus, correctness is 9 (not 10) due to slight interpretive addition, but all facts and calculations are precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1238,
        "completion_tokens": 421,
        "total_tokens": 1660
      },
      "error": null
    },
    {
      "question_id": 139,
      "question": "How has the treatment and disclosure around Accenture Canada Holdings Inc. Exchangeable Shares evolved between 2022 and 2024, particularly in terms of share repurchase activity and shareholder rights?",
      "original_answer": "In 2022, Accenture disclosed its intention to use a significant portion of cash generated from operations for share repurchases during fiscal 2023, including purchases and redemptions of Accenture Canada Holdings Inc. exchangeable shares. The company noted that the number of shares repurchased would depend on various factors such as share price and market conditions. By 2024, the disclosures had evolved to include more detailed descriptions of the rights associated with Accenture Canada Holdings Inc. exchangeable shares, particularly their exchangeability on a one-for-one basis for Accenture plc Class A ordinary shares, and the company's commitment to align the number of Class X ordinary shares with outstanding exchangeable shares. Additionally, as of August 31, 2024, the company had a specific remaining authorization of $2,694,281 for share repurchase programs, indicating a more structured and quantified approach compared to the more general intentions expressed in 2022.",
      "llm_answer": "\nBetween 2022 and 2024 the disclosure moved from a brief structural note that Accenture Canada Holdings Inc. exchangeable shares could be exchanged one‑for‑one for Class A ordinary shares (and might be redeemed) to a detailed, quantitative shareholder‑rights description.  The 2024 filing spells out a $2.69 bn repurchase authorisation (later raised to $6.69 bn), reports actual purchases of 47,752 exchangeable shares ( $15.3 m ) during the year, and explicitly states that holders may exchange the shares for cash or Class A stock, receive the same distributions as ordinary shareholders, and that the Board may suspend or accelerate the program at any time—showing a clear evolution toward transparent, rights‑focused repurchase activity.",
      "correctness_score": 4,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in quantitative details. While the general direction of evolution in disclosure is correctly identified—increased transparency and detail around shareholder rights and repurchase activity—many specific numbers do not align with the ground truth. The $2.69 billion repurchase authorization is incorrect; the original answer states $2,694,281 (approximately $2.7 million, not billion). The claim that this was 'later raised to $6.69 billion' is unsupported by the ground truth, which mentions no such increase. The report of 47,752 exchangeable shares purchased for $15.3 million is entirely absent from the original answer and thus fabricated. (2) The ground truth only confirms a remaining authorization of $2,694,281 as of August 31, 2024, with no mention of actual purchases or dollar amounts spent during the year. The LLM incorrectly presents these as facts. Additionally, the one-for-one exchange right was already noted in 2022 per the original answer, so characterizing it as a 2024 development is misleading. (3) The multi-hop reasoning is partially sound—the model correctly infers an evolution toward greater transparency and structured repurchase programs—but fails to accurately synthesize the actual data points across years. It invents specific transaction volumes and program expansions not present in the source. (4) Correctness is scored low due to major quantitative errors and invented figures. Qualitative accuracy is moderate because the conceptual trend is correctly identified. Contextual relevance is high as the response stays focused on the question’s themes of disclosure evolution, repurchases, and shareholder rights.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1445,
        "completion_tokens": 471,
        "total_tokens": 1917
      },
      "error": null
    },
    {
      "question_id": 139,
      "question": "How did the global revenue from Electrophysiology Devices evolve between 2023 and 2024, and what was the percentage change in this revenue, excluding the impact of foreign exchange fluctuations?",
      "original_answer": "In 2023, the global revenue from Electrophysiology Devices was $2,195 million, which increased to $2,467 million in 2024. This represents a total change of 12.3%, with the change excluding the impact of foreign exchange fluctuations being 14.4%.",
      "llm_answer": "\nThe Electrophysiology Devices segment generated about **$2.195 billion in 2023**, which rose to **$2.467 billion in 2024**.  Excluding the effect of foreign‑exchange movements, this increase corresponds to a **14.4 % growth** in global revenue over the two‑year period.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately reported: 2023 revenue is correctly stated as $2.195 billion ($2,195 million), and 2024 revenue is $2.467 billion ($2,467 million). The percentage change excluding foreign exchange impact is correctly given as 14.4%. (2) Quantitative accuracy is perfect: the numbers match exactly (allowing for unit formatting: billion vs million), and the implied calculation of growth (2,467 - 2,195) / 2,195 ≈ 12.3% total growth is consistent with the ground truth, even though the LLM did not explicitly state the 12.3% total change. However, the question specifically asks for the percentage change excluding FX impact, which is correctly provided as 14.4%. (3) The reasoning is sound and synthesizes the correct multi-hop data points: revenue figures across two years and the FX-adjusted growth rate. (4) The answer is contextually complete and relevant, directly addressing both parts of the question: revenue evolution and the FX-excluded growth rate. The omission of the 12.3% total change does not detract from correctness since the question emphasizes the FX-excluded figure, which is provided accurately. All entities (Electrophysiology Devices, 2023–2024 timeframe) are correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1140,
        "completion_tokens": 359,
        "total_tokens": 1500
      },
      "error": null
    },
    {
      "question_id": 140,
      "question": "How has Accenture's financial relationship with Duck Creek Technologies evolved between fiscal 2022 and fiscal 2024, particularly in terms of investment valuation and its impact on financial performance?",
      "original_answer": "In fiscal 2022, Accenture's investment in Duck Creek Technologies was valued at $223,166 (approximately 16% ownership), with the investment accounted for under the equity method. By fiscal 2024, this investment resulted in a $253 million gain, indicating a significant increase in value and a shift in how the investment contributed to Accenture's financial performance. This demonstrates both a quantitative increase in the investment's value and a qualitative change in its impact on Accenture's earnings.",
      "llm_answer": "\nAccenture has maintained a roughly 16 % equity stake in Duck Creek Technologies and continues to account for it under the equity‑method; the investment’s carrying amount grew modestly from $138.9 million as of August 31 2022 (reported in the 2022 10‑K) to about the same level in the 2024 filing, while its estimated fair value rose to roughly $223 million.  A $253 million gain from the investment was recorded in fiscal 2023, boosting adjusted earnings‑per‑share, but thereafter the investment’s earnings are reflected only in “other income (expense), net,” so its contribution to overall operating performance remains limited.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. Most critically, it misstates the 2022 investment value: the original answer reports $223,166 (not $138.9 million), while the LLM claims a carrying amount of $138.9 million as of August 31, 2022, which contradicts the ground truth. Additionally, the LLM incorrectly states that the fair value rose to $223 million by 2024, when in fact the original answer indicates the $223,166 was the 2022 value and the investment had appreciated significantly by 2024, resulting in a $253 million gain. The $253 million gain is correctly attributed to fiscal 2023 in the LLM answer, which aligns with the original answer’s implication of a major valuation increase by 2024, though the original does not specify the exact year of the gain. (2) The LLM reverses the meaning of the numbers: it treats $223 million as the 2024 fair value, but in the ground truth, $223,166 is the 2022 carrying value. This is a major quantitative error. The gain of $253 million is correctly cited, but its timing (fiscal 2023) is not in the original answer, making this an unsupported addition. (3) The multi-hop reasoning is partially sound—the LLM attempts to track the investment over time and discusses changes in accounting impact (e.g., shift to 'other income')—but it fails to correctly synthesize the valuation evolution due to incorrect base figures. The qualitative point about increased impact on earnings is partially supported by mentioning the gain boosting EPS, but the conclusion that the contribution remains 'limited' contradicts the original answer’s emphasis on a 'significant increase in value' and 'qualitative change in impact'. (4) The contextual relevance is high as the answer addresses investment valuation and financial performance impact over time. However, due to major numerical inaccuracies and a flawed understanding of the valuation trajectory, the correctness score is reduced to 5. The qualitative accuracy is moderate because the structure and intent are sound, but the reasoning is based on incorrect data. Quantitative accuracy is low due to the significant dollar amount and valuation timeline errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 583,
        "total_tokens": 1881
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How has the composition and scale of Union Pacific's retention share and unit awards changed between 2022 and 2023, and what does this indicate about the company's executive compensation strategy?",
      "original_answer": "In 2022, Union Pacific disclosed that 389,207 retention shares were outstanding under the 2021 Stock Incentive Plan as of December 31, 2021. By 2023, the company disclosed that 954,405 retention shares had been issued and were outstanding, along with 366,046 retention units that do not have an exercise price. This represents a significant increase in the number of outstanding retention instruments, indicating a shift toward greater use of retention-based compensation. The introduction of retention units in 2023 suggests a possible expansion or refinement of the company's long-term incentive strategy for executives.",
      "llm_answer": "\nBetween 2022 and 2023 the size of the time‑vested retention‑share grants fell modestly (approximately 300 k shares granted in 2022 versus about 297 k shares in 2023), while the number of performance‑linked stock units rose sharply (from roughly 77 k performance units in 2022 to about 227 k in 2023).  At the same time, the total unrecognized compensation expense for retention awards dropped from roughly $87 million at the end of 2022 to about $16 million at the end of 2023.  This shift shows that Union Pacific is moving away from fixed‑term retention awards and toward a higher‑percentage of performance‑contingent equity, signaling a strategic emphasis on tying executive pay more directly to measurable performance metrics and controlling overall equity‑compensation costs.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and fails to align with the ground truth in both quantitative and qualitative aspects. (1) Quantitatively, the LLM reports approximately 300k and 297k retention shares granted in 2022 and 2023, respectively, and performance units increasing from 77k to 227k. However, the ground truth states that 389,207 retention shares were outstanding as of December 31, 2021 (reported in 2022), and by 2023, 954,405 retention shares and 366,046 retention units were outstanding. The LLM confuses granted amounts with outstanding amounts, uses incorrect figures, and introduces performance-linked units not mentioned in the original answer. Additionally, the claim about unrecognized compensation expense dropping from $87M to $16M is unsupported by the ground truth, which contains no such data. (2) The original answer focuses on outstanding retention shares and the introduction of retention units without exercise prices, while the LLM mischaracterizes the data by discussing performance-based units and cost reductions. (3) The reasoning is flawed: the LLM concludes a shift toward performance-based pay and cost control, but the ground truth indicates a significant increase in retention instruments (from ~389k to over 954k shares plus new units), suggesting a strategy of increased retention focus, not reduced equity cost. The introduction of retention units supports a refinement in long-term incentives, not a move toward performance-based metrics. (4) While the LLM attempts to interpret executive compensation strategy, its conclusions are based on fabricated or misinterpreted data, leading to a fundamentally incorrect assessment. The contextual relevance is moderate because it addresses executive compensation strategy, but the factual foundation is unsound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 485,
        "total_tokens": 1848
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How has MetLife's application of GAAP guidance for adjusted earnings evolved between 2023 and 2024, particularly in terms of the exclusions related to market volatility and asymmetrical accounting adjustments?",
      "original_answer": "In 2023, MetLife updated its calculation of adjusted earnings due to the adoption of LDTI, which led to the exclusion of certain adjustments related to the amortization of DAC, VOBA, and related intangibles, as well as changes in measurement of certain guarantees. Adjusted earnings excluded changes in fair value associated with MRBs, discount rate changes on annuitization guarantees, and asymmetrical accounting from in-force reinsurance. By 2024, MetLife continued to refine these exclusions, particularly expanding the scope of policyholder liability remeasurement gains (losses) to exclude asymmetrical accounting associated with in-force reinsurance. Additionally, in 2024, net investment income exclusions were expanded to include adjustments relating to joint ventures under the equity method, which was not explicitly mentioned in 2023. This reflects a more detailed and structured application of GAAP guidance over time.",
      "llm_answer": "\nBetween 2023 and 2024 MetLife moved from an early‑LDTI‑driven definition of adjusted earnings to a fully‑articulated, segment‑wide metric that systematically strips out market‑volatility effects and all forms of asymmetrical accounting.  In 2023 the exclusions were introduced as part of the LDTI implementation (e.g., removing DAC/VOBA amortization and certain embedded‑derivative remeasurements and noting that market‑volatility gains/losses and asymmetrical items such as in‑force‑reinsurance adjustments were omitted).  By 2024 the company formalized these carve‑outs, explicitly stating that adjusted earnings excludes net investment and derivative gains/losses, MRB remeasurements, goodwill impairments, and—most importantly—any market‑volatility‑driven fluctuations and asymmetrical accounting adjustments (including basis‑adjustment amortization, inflation‑indexed benefit tweaks, and in‑force‑reinsurance asymmetries) across all segments, with the tax impact of those exclusions calculated on a statutory‑rate basis.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution in MetLife's adjusted earnings exclusions between 2023 and 2024. It accurately identifies the 2023 adoption of LDTI as a catalyst, correctly noting exclusions such as DAC/VOBA amortization, embedded derivative remeasurements, and asymmetrical accounting from in-force reinsurance. It also correctly states that market volatility effects and asymmetrical adjustments were excluded. For 2024, the LLM correctly emphasizes formalization and expansion of exclusions, particularly around asymmetrical accounting. However, it adds details not present in the ground truth: while the original answer specifies the 2024 expansion to exclude policyholder liability remeasurement gains/losses and equity-method joint venture adjustments in net investment income, the LLM generalizes with broader terms like 'basis-adjustment amortization' and 'inflation-indexed benefit tweaks,' which are not mentioned in the original. It also omits the specific mention of 'discount rate changes on annuitization guarantees' and 'MRBs' (market risk benefits), though MRBs are partially covered. The LLM overgeneralizes and introduces plausible but unverified elements, slightly reducing qualitative accuracy. There are no numerical inaccuracies (dates are correct, no incorrect figures), so quantitative accuracy is perfect. The answer remains contextually relevant and conveys a semantically close evolution of MetLife's policy, earning a high but not full correctness score due to minor overreach in specificity beyond the source.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1505,
        "completion_tokens": 429,
        "total_tokens": 1934
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How has Accenture's approach to achieving compressed transformations evolved from 2022 to 2024, particularly in terms of the technologies leveraged and the scope of transformation services offered?",
      "original_answer": "In 2022, Accenture focused on using technologies like digital twins, AI, IoT, cloud/Edge, 5G, advanced robotics, and metaverse to help clients achieve compressed transformations by redefining product design, engineering, sourcing, manufacturing, and servicing. By 2024, the company expanded its technological toolkit to include generative AI, artificial reality / virtual reality, and advanced robotics, while also enhancing its own development of automation equipment and commercial hardware to support client operations. Additionally, the scope of transformation broadened to include digitally transforming capital projects such as plant and asset construction, public infrastructure, power grids, and data centers. This reflects a more integrated and advanced technological approach to compressed transformations over the two-year period.",
      "llm_answer": "\nFrom fiscal 2022 to fiscal 2024 Accenture shifted from a broad‑based transformation model that focused on building digital cores, optimizing operations and accelerating revenue growth through cloud, data and AI, to a deliberately “compressed transformation” approach that is now driven by generative AI, the SynOps platform and the AI Navigator suite and is embedded in strategic managed‑services engagements.  The scope has also expanded to encompass talent, sustainability, the metaverse and other emerging forces, delivering end‑to‑end, industry‑specific solutions across Strategy & Consulting, Technology, Operations, Industry X and Song.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the evolution of Accenture's transformation approach and correctly identifies the shift toward generative AI and advanced platforms by 2024, which aligns with the ground truth. However, it omits key technologies emphasized in 2022 (digital twins, IoT, 5G, Edge computing, metaverse) and incorrectly frames the 2022 approach as 'building digital cores, optimizing operations, and accelerating revenue growth'—a description not present in the original answer and not equivalent in focus to the 2022 technological toolkit. The LLM introduces 'SynOps platform' and 'AI Navigator suite' as new drivers, which are not mentioned in the ground truth and represent unverified specifics. While generative AI is correctly cited for 2024, the answer misses the expansion into capital projects (plant construction, infrastructure, power grids, data centers), a critical scope broadening in the original. Instead, it adds 'talent, sustainability, metaverse'—the latter was already present in 2022 per the original, so positioning it as a 2024 expansion is misleading. (2) There are no numeric values, dates, or calculations to verify; fiscal years 2022 and 2024 are correctly referenced, satisfying quantitative accuracy. (3) The multi-hop reasoning is partially sound—there is an attempt to compare 2022 and 2024 approaches—but the synthesis is flawed due to incorrect characterization of the 2022 strategy and introduction of unsupported tools (SynOps, AI Navigator). The scope evolution is inaccurately represented, failing to reflect the actual expansion into capital project transformation. (4) Correctness is scored 6 due to partial factual alignment: core idea of technological advancement and scope growth is present, but key details are missing or incorrect. Qualitative accuracy is 6 due to reasoning gaps and unsupported entities. Quantitative accuracy is 10 (no numbers, but years correct). Contextual relevance is 9—answer stays on topic and addresses the question’s intent, despite inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 547,
        "total_tokens": 1931
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How did Abbott's use of interest rate hedge contracts evolve between 2023 and 2024 in managing exposure to changes in the fair value of fixed-rate debt?",
      "original_answer": "In 2023, Abbott had interest rate hedge contracts totaling approximately $2.2 billion at December 31, 2023, to manage exposure to changes in the fair value of fixed-rate debt due to long-term benchmark interest rate fluctuations. These contracts were designated as fair value hedges, effectively converting fixed-rate debt to variable-rate debt. In 2024, Abbott continued to maintain interest rate hedge contracts with notional values totaling $2.2 billion, indicating a consistent strategy in hedging interest rate risk. However, the average interest rate on long-term debt increased from 3.6% in 2023 to 3.8% in 2024, suggesting a shift in the underlying debt structure or market interest rate conditions despite the stable hedge notional amount.",
      "llm_answer": "\nBetween 2023 and 2024 Abbott kept the size of its fair‑value interest‑rate hedge program essentially steady at about **$2.2 billion of notional contracts**, after having reduced the program from roughly **$2.9 billion in 2022** (the decline in 2022‑23 was driven by the maturity of $700 million of hedges and corresponding debt). The contracts continue to be designated as fair‑value hedges of fixed‑rate debt, are marked‑to‑market each reporting period, and the resulting gains or losses offset the changes in the fair value of the hedged fixed‑rate obligations. This reflects a shift from a shrinking hedge book in 2022‑23 to a stabilized hedge position in 2024 that continues to manage exposure to interest‑rate movements on Abbott’s fixed‑rate debt.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "(1) The LLM answer correctly states that Abbott maintained $2.2 billion in notional interest rate hedge contracts in both 2023 and 2024, which aligns with the ground truth. It also correctly identifies the designation of these contracts as fair value hedges and their purpose in managing exposure to interest rate changes on fixed-rate debt. However, the LLM introduces information not present in the ground truth: it claims the hedge program was reduced from $2.9 billion in 2022 due to $700 million of maturities, and describes a 'shrinking hedge book in 2022–23'. This data is absent from the original answer and cannot be verified against the provided ground truth, making it a significant factual overreach. (2) The quantitative accuracy is compromised because the $2.9 billion figure and $700 million reduction are not supported by the original answer, which only provides data for 2023 and 2024. While the $2.2 billion figure is correct for both years, the inclusion of unsupported prior-year numbers undermines numerical precision. (3) The reasoning is logically structured and correctly interprets the function of fair value hedges and their accounting treatment. The synthesis of the stable hedge notional amount reflecting a consistent strategy is reasonable and partially aligns with the ground truth’s observation of continuity. However, the model extrapolates backward in time beyond the scope of the question and ground truth, failing a strict multi-hop evaluation that should be limited to 2023–2024. (4) Contextual relevance is high because the answer addresses the evolution of Abbott’s hedging strategy and explains the mechanism and intent of the hedges. The core message of a stabilized hedge position is consistent with the ground truth, but the addition of unverified historical context reduces overall correctness. The ground truth also includes a key point missing in the LLM response: the increase in average interest rate on long-term debt from 3.6% to 3.8%, which indicates changing debt or market conditions despite stable hedges. This omission further reduces completeness and factual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 567,
        "total_tokens": 1944
      },
      "error": null
    },
    {
      "question_id": 142,
      "question": "How has MetLife's treatment and definition of Adjusted Earnings evolved between 2023 and 2024, particularly in relation to GAAP guidance and segment performance measurement?",
      "original_answer": "In 2023, MetLife updated its calculation of Adjusted Earnings due to the adoption of LDTI, removing certain adjustments related to the amortization of DAC, VOBA, and related intangibles, and instead adjusted for changes in measurement of certain guarantees. Adjusted Earnings in 2023 excluded changes in fair value associated with MRBs, discount rate changes on annuitization guarantees, and asymmetrical accounting from in-force reinsurance. By 2024, Adjusted Earnings remained the GAAP measure of segment performance, but the exclusions were more clearly delineated to include market volatility impacts, asymmetrical and non-economic accounting adjustments, revenues and costs from divested businesses, and results from discontinued operations. Specifically, 2024 Adjusted Earnings excluded net investment gains/losses, derivative gains/losses, MRB remeasurement gains/losses, and goodwill impairments, with more structured exclusions such as inflation-indexed benefit adjustments and non-economic losses from single premium annuity contracts. This represents a refinement and expansion of the exclusions introduced in 2023.",
      "llm_answer": "\nBetween 2023 and 2024 MetLife refined the way it calculates and presents **Adjusted Earnings** after the LDTI implementation: the metric is now explicitly identified as a **GAAP‑compliant measure of segment performance** that the CODM uses to evaluate profitability and allocate capital, and it is defined as adjusted revenues less adjusted expenses (net of tax) with a set of standardized exclusions (market‑volatility items such as investment and derivative gains/losses, MRB remeasurement, goodwill impairments, and specific asymmetrical accounting adjustments).  The 2024 disclosures also note that the calculation was updated to remove legacy amortization adjustments to DAC and VOBA and to exclude preferred‑stock redemption premiums, making the metric more consistent with GAAP segment‑reporting guidance while still serving the same performance‑evaluation purpose.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution in MetLife's Adjusted Earnings treatment between 2023 and 2024. It correctly identifies the impact of LDTI implementation in 2023, noting the removal of DAC and VOBA amortization adjustments, which aligns with the ground truth. It accurately states that Adjusted Earnings remains the GAAP measure of segment performance used by the CODM, consistent with 2024 disclosures. The exclusions mentioned—investment and derivative gains/losses, MRB remeasurement, goodwill impairments, and asymmetrical accounting—are factually correct and reflect both years' practices. The mention of preferred stock redemption premiums as a new exclusion in 2024 is plausible but not explicitly confirmed in the ground truth, representing a minor addition not present in the original. The answer omits specific details from the ground truth such as 'inflation-indexed benefit adjustments' and 'non-economic losses from single premium annuity contracts,' which were explicitly called out as structured exclusions in 2024. It also does not mention the exclusion of results from divested businesses and discontinued operations, which are part of the 2024 refinement. While the reasoning is sound and the synthesis across 2023 and 2024 is logical, these omissions prevent a top score. There are no numerical inaccuracies (dates: 2023–2024 correct; no incorrect figures), so quantitative accuracy is perfect. The answer is highly relevant to the question and conveys the essential evolution in definition and treatment. Thus, correctness is high but not complete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1506,
        "completion_tokens": 437,
        "total_tokens": 1943
      },
      "error": null
    },
    {
      "question_id": 142,
      "question": "How has the funding and utilization of Accenture's share purchase program evolved from 2022 to 2024, particularly in terms of available authorization and share acquisition methods?",
      "original_answer": "In 2022, Accenture reported an aggregate available authorization of $3,129,296 for its publicly announced open-market share purchase program and other related share purchase programs. This included acquisitions of Accenture plc Class A ordinary shares and Accenture Canada Holdings Inc. exchangeable shares held by current and former members of Accenture Leadership. By 2024, the company clarified that its open-market share purchase program applied specifically to Accenture plc Class A ordinary shares, which were held as treasury shares for employee benefits, such as equity awards. Additionally, in fiscal 2024, Accenture acquired Class A ordinary shares primarily through share withholding for payroll tax obligations tied to employee equity plans. These purchases did not impact the aggregate available authorization for the public share purchase programs, indicating a shift in acquisition methods while maintaining a focus on funding levels.",
      "llm_answer": "\nFrom fiscal 2022 to fiscal 2024 Accenture repeatedly expanded its repurchase authority—starting with a $3.13 billion authorization that was boosted by a $3 billion increase in September 2022 (raising total authority to $6.13 billion) and then, after using part of that capacity, adding another $4 billion in September 2024 (bringing total authority to $6.69 billion).  The company continued to fund purchases through the same three channels—open‑market purchases, other authorized purchase programs (including exchangeable‑share redemptions), and employee‑related share withholding—but the volume of shares acquired grew, rising from about 12.2 million shares for $4.1 billion in 2022 to roughly 13.9 million shares for $4.5 billion in 2024.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and fails to align with the ground truth. (1) Quantitative Accuracy: The reported $3.13 billion authorization in 2022 is close to the ground truth figure of $3,129,296 (approx. $3.13 million, not billion), but this is off by a factor of 1,000—indicating a critical error. The claimed $3 billion increase in September 2022 and $4 billion in September 2024 are not supported by the original answer, which does not mention any increases in authorization. The total authorities cited ($6.13B, $6.69B) are entirely fabricated. The share volumes (12.2M, 13.9M) and purchase values ($4.1B, $4.5B) are also not present in the ground truth and contradict it—since the original answer does not report such totals. (2) Completeness: The question asks about evolution in funding and utilization, particularly available authorization and acquisition methods. The LLM incorrectly emphasizes repeated expansions in authorization, which is not mentioned in the ground truth. It does correctly note employee-related share withholding as a method, but incorrectly frames it as part of a consistent three-channel approach without noting the shift emphasized in the original answer. (3) Entity Accuracy: Accenture is correct, and fiscal years 2022–2024 are appropriately referenced. However, the financial figures and program details are misattributed. (4) Reasoning: The multi-hop synthesis is flawed. The original answer highlights a shift in acquisition methods—specifically that in 2024, share withholding for tax obligations became a primary method that did not impact public program authorization—indicating a structural change. The LLM instead asserts continuity across three channels and fabricates authorization increases, missing the key nuance. (5) Semantic Equivalence: The LLM’s narrative of growing repurchase activity and expanding authority contradicts the ground truth, which focuses on stable funding levels and a methodological shift. While the mention of employee-related withholding aligns partially, the overall message is factually incorrect. The answer invents data not present in the source, leading to a very low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1431,
        "completion_tokens": 584,
        "total_tokens": 2015
      },
      "error": null
    },
    {
      "question_id": 143,
      "question": "How did MetLife's treatment and valuation methodology for Unit-linked Securities evolve from 2023 to 2024, particularly in terms of cost basis and fair value sensitivity?",
      "original_answer": "In 2023, MetLife described the cost basis for Unit-linked and FVO securities as primarily equity and fixed maturity securities, with cost representing original cost for equities and amortized cost for fixed maturities. By 2024, Unit-linked securities were included in Level 3 fair value measurements and subjected to valuation techniques involving significant unobservable inputs such as mortality rates, lapse rates, and equity volatility. Additionally, the 2024 disclosures emphasized sensitivity of fair value to changes in these inputs, indicating a more dynamic and assumption-driven valuation approach compared to the more static cost-based method described in 2023.",
      "llm_answer": "\nMetLife continues to record Unit‑linked and FVO securities at their original cost (reduced only by repayments and amortization of premium/discount for the fixed‑maturity portion) and measures them at fair value using Level 3 inputs; the 2024 roll‑forward shows the balance rising to about $1.19 bn (up from $0.787 bn in 2023) and adds a detailed quantitative sensitivity table that specifies the range of unobservable inputs—mortality, lapse, utilization, equity‑volatility and non‑performance spreads—and the directional impact of each on the fair‑value estimate. Thus, while the underlying cost‑basis methodology is unchanged, the 2024 disclosure refines and expands the fair‑value sensitivity analysis, providing more granular input ranges and quantified effects on the reported fair value.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer contains several inaccuracies that affect the correctness score, particularly in the description of cost basis and valuation methodology evolution. (1) The claim that MetLife 'continues to record Unit-linked and FVO securities at their original cost' contradicts the ground truth, which states that by 2024, these securities were included in Level 3 fair value measurements using significant unobservable inputs—indicating a shift away from a static cost-based approach. The original answer emphasizes a methodological evolution toward assumption-driven valuation, while the LLM implies the cost-basis methodology is unchanged, which is factually incorrect. (2) The quantitative figures ($1.19B in 2024 vs $0.787B in 2023) are not present in the ground truth and cannot be verified; the original answer does not include any dollar amounts for Unit-linked securities balances, so these numbers appear to be hallucinated or sourced incorrectly. This severely impacts quantitative accuracy. (3) While the LLM correctly identifies the inclusion of sensitivity analysis in 2024 and lists relevant unobservable inputs (mortality, lapse, equity volatility), it mischaracterizes the nature of the change—as an enhancement to disclosure rather than a substantive shift in valuation methodology. (4) The multi-hop reasoning is partially sound: it connects 2023 and 2024 disclosures and identifies sensitivity analysis expansion, but fails to recognize the core shift from cost-based/amortized cost treatment to Level 3 fair value with dynamic assumptions. (5) Contextual relevance is high—the response addresses the right topic, time frame, and type of securities, and uses appropriate financial terminology. However, due to key factual and methodological misrepresentations, especially regarding the persistence of cost basis and unsupported numerical claims, the overall correctness is only partially accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 515,
        "total_tokens": 1887
      },
      "error": null
    },
    {
      "question_id": 143,
      "question": "How has the structure and vesting timeline of market-based RSUs evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, market-based RSUs generally vested over four years and grantees could receive between 0% and 300% of the original grant based on total stockholder return (TSR) relative to an index group. By fiscal year 2023, while four-year vesting remained common, the company also introduced market-based RSUs that vested over five years, with vesting contingent on achieving stock price performance milestones. This indicates an expansion in the types of market-based RSUs offered, adding a new vesting structure based on specific stock price targets.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2023 the company’s market‑based RSU program shifted from a single four‑year vesting cycle that depended on a market‑performance metric (total stockholder return relative to an index and could result in 0 %–300 % of the original grant) to a two‑track approach: it continued to award four‑year market‑based RSUs but also began granting a new class of market‑based RSUs that vest over **five years** and are tied to specific stock‑price performance milestones.  The 2023 grants also incorporated a larger share pool (including RSUs assumed in the VMware merger) and a higher maximum payout, reflecting the expanded vesting horizon and more granular performance conditions.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly states that in fiscal 2022, market-based RSUs vested over four years with payouts from 0% to 300% based on TSR relative to an index group. In 2023, the company maintained the four-year vesting but introduced a new five-year vesting structure tied to stock price performance milestones—this matches the original answer. (2) All quantitative elements (0%–300% payout range, four-year and five-year vesting periods) are correct; no calculations were required. (3) The reasoning is sound: the model correctly synthesizes a multi-hop evolution in RSU structure across two fiscal years and identifies a shift from a single structure to a dual-track approach. (4) The only minor addition not present in the ground truth is the mention of a 'larger share pool' and 'higher maximum payout' due to the VMware merger—while plausible and contextually reasonable, these details are not confirmed in the provided ground truth and slightly extend beyond it. However, they do not contradict it. Overall, the answer is factually correct, complete, and semantically equivalent, warranting a high score with only a small deduction for the unverified contextual expansion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 347,
        "total_tokens": 1652
      },
      "error": null
    },
    {
      "question_id": 145,
      "question": "How did the phase-in treatment of the CECL standard's ongoing impact on regulatory capital evolve between 2023 and 2024, and what specific regulatory capital treatment applied during the phase-in period?",
      "original_answer": "In 2023, the CECL Transition Election allowed for the cumulative 'day 2' ongoing impact to be phased into regulatory capital at 25% per year from January 1, 2022, through December 31, 2024. By 2024, this phase-in treatment remained consistent, with the ongoing impact continuing to be phased in at 25% annually, indicating that the regulatory capital treatment under the CECL Transition Rule was applied uniformly across both years as part of the multi-year transition framework.",
      "llm_answer": "\nThe CECL transition rule lets a bank hold back the full capital effect of adopting CECL and then add it back to regulatory capital in a five‑year “phase‑in.”  \n\n* **2023:**  By the end of 2023 the company had already added back the entire $2.4 bn “day‑1” CECL impact that had been delayed, and under the rule it was required to phase in the remaining “day‑2” ongoing impact at a uniform 25 %‑per‑year rate.  The table in the 2023 filing shows that for 2023 the cumulative day‑2 impact was **50 % phased‑in**, which meant that only half of the estimated ongoing CECL allowance could be counted toward capital.  Consequently, the Company’s CET1 ratio reported under the transition rule was **12.9 %**, versus **12.6 %** on a fully‑phased‑in basis.  \n\n* **2024:**  The phase‑in continued at the same 25 %‑per‑year pace.  The remaining $1.2 bn of the delayed impact was scheduled to be added back in two installments of $600 m each, one in 2024 and the final $600 m in 2025.  As a result, by the end of 2024 the company had **75 % of the total delayed amount phased‑in** (the first $1.8 bn of the $2.4 bn had been incorporated).  This is reflected in the 2024 filing, which reports a CET1 ratio of **13.5 %** when the transition rule is applied, versus **13.3 %** on a fully‑phased‑in basis.  \n\n**Regulatory capital treatment during the phase‑in:**  \n- The “day‑1” CECL adoption impact was **delayed** and added back to regulatory capital in the year of adoption (2020) but could not be fully reflected until the phase‑in schedule allowed it.  \n- The “day‑2” ongoing impact was **approximated with a 25 % scaling factor** and then **phased into capital at 25 % per year** (i.e., 25 % of the remaining estimated impact could be added to capital each year).  \n- Thus, in 2023 the company could count 50 % of the cumulative day‑2 impact, and by 2024 it could count 75 % (with the final 100 % to be reached in 2025).  This phased‑in treatment directly raised the reported CET1 ratios as the company progressed from 50 % to 75 % of the delayed amount being incorporated.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness, despite addressing the right conceptual framework. (1) The original answer states that the CECL phase-in occurred at 25% per year from January 1, 2022, through December 31, 2024—meaning the phase-in period ended in 2024 with 100% implementation by 2025 not possible, as the rule concluded in 2024. However, the LLM claims the phase-in continued into 2025, which contradicts the ground truth. (2) The LLM introduces specific dollar amounts ($2.4B, $1.2B, $600M) and CET1 ratios (12.9%, 12.6%, 13.5%, 13.3%) that are not present in the original answer and cannot be verified from the provided context—these appear fabricated or misattributed. (3) The mention of 'day-1' impact being added back in 2020 and ongoing 'day-2' impact being phased in is conceptually aligned, but the execution misrepresents the timeline and magnitude. (4) The original answer emphasizes consistency between 2023 and 2024 in the application of the 25% annual phase-in, which the LLM captures in part but distorts by extending it beyond 2024. (5) Multi-hop reasoning is attempted—linking regulatory treatment to capital ratios and year-over-year changes—but fails due to incorrect numerical grounding and timeline extension. While the explanation of the 25% annual phase-in is directionally correct, the inclusion of unsupported figures and the erroneous extension of the phase-in to 2025 severely reduce factual accuracy. The answer is contextually relevant and structured well, but quantitatively and factually flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1649,
        "completion_tokens": 431,
        "total_tokens": 2081
      },
      "error": null
    },
    {
      "question_id": 146,
      "question": "How has Broadcom's relationship with Wilmington Trust, National Association evolved between 2022 and 2023 in terms of the types and terms of senior notes issued under their indentures?",
      "original_answer": "In 2022, Broadcom had an ongoing relationship with Wilmington Trust, National Association as trustee under indentures governing senior notes issued in January 2021, which included notes with interest rates as low as 1.950% (due 2028) and as high as 3.750% (due 2051). By 2023, the relationship had evolved to include new indentures dated April 18, 2022, and July 12, 2024, under which Broadcom issued higher-yielding senior notes, including a 4.926% note due 2037 and later, in October 2024, notes ranging from 4.150% (due 2028) to 4.800% (due 2034). This reflects a shift toward issuing longer-term debt with higher interest rates over time.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2023 Broadcom shifted from issuing senior notes under the April 2022 indenture – which included 4.00 % notes maturing 2029, 4.15 % notes maturing 2032 and 4.926 % notes maturing 2037 – to launching new series under later indentures (e.g., 5.05 % 2027, 4.15 % 2028, 4.35 % 2030, 4.55 % 2032 and 4.80 % 2034) with longer maturities and modestly higher coupons.  The change reflects a strategic evolution toward longer‑dated, higher‑yield debt while still using Wilmington Trust, National Association as trustee, and the new issuances were made under supplemental indentures that updated the covenant language and discount‑rate terms.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in dates, interest rates, and issuance timelines. It incorrectly states that the April 2022 indenture was active in fiscal 2022, while the ground truth specifies that the new indentures were dated April 18, 2022, and July 12, 2024 — the latter being in 2024, not 2022 or 2023. The LLM also fabricates a 5.05% note due 2027 and other series (4.35%, 4.55%) not mentioned in the original answer. The only correct rate mentioned is 4.926% due 2037, which aligns with the ground truth. However, the 4.15% 2028 and 4.80% 2034 notes are said to be issued in October 2024 in the original, but the LLM presents them as 2023 issuances without noting the correct future date. (2) Quantitative accuracy is low: multiple incorrect percentages (e.g., 5.05%, 4.35%, 4.55%) and maturities are introduced, and the timeline is distorted — the July 12, 2024 indenture cannot be part of 2023 activity. The original notes from January 2021 (1.950% to 3.750%) are entirely omitted in the LLM response, breaking the multi-hop comparison between 2022 and 2023 evolution. (3) Reasoning is partially sound in identifying a trend toward longer-term, higher-yield debt and maintaining Wilmington Trust as trustee, which shows correct qualitative synthesis. However, the failure to reference the earlier lower-rate notes from 2021 undermines the comparative evolution. The mention of supplemental indentures updating covenants and discount-rate terms introduces details not present in the ground truth, potentially hallucinated. (4) Contextual relevance is high — the answer addresses the relationship evolution, trustee continuity, and note terms — but factual correctness drags down the overall score. While the direction of the trend (higher yields, longer maturities) is correctly inferred, the specific data points and chronology are flawed, leading to a partially correct but misleading response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 525,
        "total_tokens": 1860
      },
      "error": null
    },
    {
      "question_id": 147,
      "question": "How did Capital One's regulatory capital add-back under the CECL Transition Rule evolve from 2023 to 2024, and what was the specific phase-in progression during this period?",
      "original_answer": "In 2023, Capital One had already added back $2.4 billion to its regulatory capital under the CECL Transition Rule, with a phase-in of 50% as of January 1, 2023. By January 1, 2024, the phase-in had progressed to 75%, indicating a 25 percentage point increase over the year. This reflects the structured five-year phase-in process under the CECL Transition Rule, where 25% of the cumulative impact was phased in annually after 2021.",
      "llm_answer": "\nUnder the CECL Transition Rule Capital One delayed the full CECL impact and began phasing it into regulatory capital at a 25 %‑per‑year rate. The “cumulative day‑2” impact was 25 % phased in during 2022, 50 % phased in by the end of 2023, and 75 % phased in by the end of 2024, with the remaining 25 % (≈ $600 million) scheduled to be added on January 1 2025. Thus, the regulatory‑capital add‑back grew from a 50 % phase‑in in 2023 to a 75 % phase‑in in 2024, completing the full 100 % phase‑in in 2025.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the phase-in progression from 50% in 2023 to 75% in 2024, which matches the ground truth. However, it introduces a claim not present in the original answer — that $600 million (≈25%) is scheduled to be added on January 1, 2025 — which is unsupported by the provided ground truth. The original answer states the phase-in was part of a five-year process starting after 2021, implying full phase-in by 2025, but does not specify the dollar amount of the remaining add-back. The $2.4 billion figure in the original answer corresponds to the 50% phase-in level as of 2023, meaning the full cumulative CECL impact would be $4.8 billion. Thus, 25% of that is $1.2 billion, not $600 million — making the LLM's implied calculation incorrect. (2) The phase-in percentages (50% in 2023, 75% in 2024) are accurate and correctly reflect a 25 percentage point increase. However, the dollar amount of the remaining add-back is wrong due to miscalculation. The LLM incorrectly assumes $600 million = 25%, which would imply a total CECL impact of $2.4 billion, but that was already the add-back at 50% phase-in. (3) The multi-hop reasoning is mostly sound — the model correctly tracks the phase-in schedule and applies the annual 25% increment. It correctly infers the structured phase-in pattern. However, it fails to reverse-calculate the total CECL impact from the 50% = $2.4 billion data point, leading to the erroneous $600 million estimate. (4) The contextual relevance is perfect — the answer directly addresses the evolution and phase-in progression. Qualitative accuracy is high due to correct logic and structure. Quantitative accuracy is reduced due to the incorrect dollar figure. Correctness score is 7 because core facts (percentages, timing, trend) are correct, but a significant numerical error affects completeness and precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1240,
        "completion_tokens": 509,
        "total_tokens": 1749
      },
      "error": null
    },
    {
      "question_id": 147,
      "question": "How did the treatment of VMware stock options for non-employee directors evolve between 2022 and 2023 following the Broadcom acquisition?",
      "original_answer": "In 2022, the 10-K filing stated that all outstanding in-the-money VMware stock options and RSU awards held by non-employee directors would be accelerated and converted into the right to receive cash and shares of Broadcom common stock, in equal parts, upon the completion of the acquisition. By 2023, this provision had been realized, with the statement confirming that these awards were indeed accelerated and converted into the right to receive cash and Broadcom shares. This reflects a transition from a planned conversion to an actualized event following the completion of the acquisition.",
      "llm_answer": "\nAfter the May 2022 merger agreement, Broadcom disclosed that **all outstanding in‑the‑money VMware stock options (and RSU awards) held by non‑employee directors would be accelerated and settled with a mixture of cash and Broadcom common stock, in equal parts**. When the transaction closed in November 2023, those options were fully settled—directors received the agreed‑upon cash‑and‑stock consideration and there were no remaining VMware equity awards for non‑employee directors.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and conveys the same core information as the ground truth. (1) It correctly identifies that in-the-money VMware stock options and RSUs for non-employee directors were accelerated and converted into equal parts cash and Broadcom common stock upon acquisition. (2) The dates are accurate: the merger agreement was disclosed in May 2022, and the transaction closed in November 2023—aligning with the transition from a planned to realized event between 2022 and 2023. (3) The multi-hop reasoning is sound: the answer synthesizes the change in treatment over time (from announcement in 2022 to execution in 2023), correctly reflecting the evolution of the stock option treatment. (4) Minor difference: the original answer emphasizes the 'transition from planned conversion to actualized event' more explicitly, while the LLM focuses on settlement mechanics. However, the LLM's statement that awards were 'fully settled' and 'no remaining VMware equity awards' captures the same outcome. All entities (VMware, Broadcom, non-employee directors, stock options, RSUs) and financial terms (cash and stock in equal parts) are correct. No calculation errors. Wording differs slightly but maintains semantic equivalence. Thus, high scores across all categories with a 9 on correctness due to slightly less emphasis on the conceptual evolution, though facts are fully accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1266,
        "completion_tokens": 386,
        "total_tokens": 1653
      },
      "error": null
    },
    {
      "question_id": 147,
      "question": "How has the therapeutic positioning of Vraylar evolved from 2022 to 2024 based on AbbVie's disclosures?",
      "original_answer": "In 2022, Vraylar was described as being evaluated in Phase 3 clinical trials as an adjunctive treatment for major depressive disorder (MDD), with one trial meeting its primary endpoint and the other showing numerical but not statistically significant improvement. By 2024, Vraylar was disclosed as being indicated for a broader range of psychiatric conditions, including acute and maintenance treatment of schizophrenia, acute treatment of manic or mixed episodes associated with bipolar disorder, acute treatment of depressive episodes associated with bipolar I disorder, and as an adjunctive treatment in major depressive disorder. This reflects a clear expansion and solidification of its therapeutic positioning over time.",
      "llm_answer": "\nFrom 2022 through 2024 AbbVie’s filings show that Vraylar’s approved uses did not shift to new disease areas; the company continued to promote the drug as a **dopamine‑D₃‑preferring partial agonist indicated for schizophrenia, for acute manic/mixed episodes of bipolar disorder, and as an adjunctive treatment for major depressive disorder**.  \n\nThe 2022 disclosure highlighted the Phase 3 data that secured the adjunctive‑MDD label, and the 2024 10‑K simply reiterated those same core indications—schizophrenia, bipolar depression and adjunctive MDD—while emphasizing the accumulated clinical evidence and revenue growth, indicating a **stable therapeutic positioning rather than a substantive expansion**.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains no numeric data, so quantitative accuracy is not applicable—scored as 10 by default since there are no incorrect numbers. However, the qualitative accuracy is low because it contradicts the ground truth regarding the evolution of Vraylar's therapeutic positioning. The original answer states that by 2024, Vraylar was indicated for a broader range of conditions, including acute and maintenance treatment of schizophrenia, acute treatment of manic/mixed and depressive episodes in bipolar I disorder, and adjunctive MDD—reflecting an expansion. In contrast, the LLM claims the positioning remained 'stable' with no shift to new disease areas, which is factually incorrect based on the disclosed expansion into bipolar depression as a distinct indication. The LLM also fails to mention the specific 2022 Phase 3 trial outcomes (one met primary endpoint, the other showed numerical but not statistically significant improvement), omitting key context about how the MDD indication was supported. While the LLM correctly identifies some core indications and the drug’s mechanism, it misrepresents the trajectory of therapeutic positioning as static rather than evolving, undermining the multi-hop reasoning required to assess change over time. Contextual relevance is moderate because the answer discusses the right drug and timeframe but draws an incorrect conclusion about its development. Thus, the correctness score is 4—partially correct on indications but significantly flawed in synthesis and interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 420,
        "total_tokens": 1767
      },
      "error": null
    },
    {
      "question_id": 148,
      "question": "How has GE's accounting policy for long-term services agreements evolved from 2022 to 2024, particularly in terms of revenue recognition method and contract billing estimates?",
      "original_answer": "In 2022, GE recognized revenue for long-term services agreements on a straight-line basis, primarily in the Healthcare and Renewable Energy segments, with periodic invoicing as services were provided. By 2024, GE shifted to using the percentage of completion method for revenue recognition, predominantly within the CES segment, based on costs incurred relative to total expected costs. Additionally, in 2024, GE reported a long-term services agreements net liability balance of $6.6 billion, representing approximately 4.1% of total estimated life of contract billings of $162 billion, indicating a more detailed and forward-looking estimation process involving asset utilization and cost improvements, which was not explicitly mentioned in 2022.",
      "llm_answer": "\nGE continued to recognize revenue on long‑term services agreements using the percentage‑of‑completion method based on costs incurred to date, but by 2024 it refined that approach to explicitly incorporate forward‑looking utilization forecasts and market‑trend data when estimating total expected costs and future billings; it also introduced a cumulative‑catch‑up adjustment for revised estimates. The 2024 policy further clarifies that billing is tied to asset utilization or specific maintenance events, which determines the timing of revenue recognition and the creation of contract‑asset/contract‑liability balances.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies and omissions compared to the ground truth. It incorrectly states that GE used the percentage-of-completion method in 2022, whereas the original answer clearly indicates that in 2022, GE used the straight-line basis for revenue recognition. This is a major factual error. The LLM also fails to mention the shift from straight-line to percentage-of-completion as a key evolution, which is central to the question. (2) Quantitatively, the LLM answer omits all specific numbers from the ground truth: the $6.6 billion net liability, the $162 billion total estimated life of contract billings, and the 4.1% ratio. These are critical data points that demonstrate the scale and sophistication of the 2024 estimation process. Their absence significantly undermines quantitative accuracy. (3) While the LLM correctly identifies that forward-looking estimates (e.g., utilization forecasts) were introduced in 2024 and that billing is tied to asset utilization, it misrepresents the timeline and method evolution. It also introduces the concept of 'cumulative-catch-up adjustment' which is not present in the original answer and cannot be verified. The reasoning around policy refinement is plausible but not fully aligned with the documented shift in methodology. (4) Contextually, the answer is relevant and addresses revenue recognition methods and billing estimates. However, due to the incorrect baseline for 2022 and missing quantitative benchmarks, the multi-hop synthesis across years and policies is flawed. The answer captures some qualitative aspects of the 2024 policy but fails to accurately contrast the before-and-after picture required by the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 468,
        "total_tokens": 1817
      },
      "error": null
    },
    {
      "question_id": 148,
      "question": "How has IBM's disclosure of the 1.250% Notes due 2027 evolved between the 2022 and 2023 10-K filings?",
      "original_answer": "In the 2022 10-K filing, IBM disclosed the 1.250% Notes due 2027 as part of a list of instruments defining the rights of holders, with Exhibit 4.3 to Form 8-K filed on January 30, 2019, referenced for the notes. In the 2023 10-K filing, the 1.250% Notes due 2027 are listed under registered securities with the trading symbol IBM 27B on the New York Stock Exchange. This evolution reflects a shift from referencing the instrument defining the rights to identifying the notes as a registered class of securities.",
      "llm_answer": "\nThe 1.250% Notes due 2027 were identified in both filings as “1.250% Notes due 2027 – IBM 27B” in the Section 12(b) securities table. In the 2022 10‑K they appeared in the table on pages 31‑32 toward the end of the document, whereas in the 2023 10‑K the same entry is placed on the cover pages (pages 1‑5) as part of the opening securities table. Thus, the wording and terms of the note did not change—only its location moved forward in the filing.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains some correct elements but significantly misrepresents the evolution of IBM's disclosure of the 1.250% Notes due 2027 between the 2022 and 2023 10-K filings. (1) Quantitatively, the percentage (1.250%), year (2027), and trading symbol (IBM 27B) are correctly identified, which supports a quantitative accuracy score of 8. However, the claim that the notes were listed in the Section 12(b) securities table in both years with the same name '1.250% Notes due 2027 – IBM 27B' is factually incorrect per the ground truth. In 2022, the notes were not presented as a registered security with a trading symbol but were instead referenced via Exhibit 4.3 to Form 8-K filed on January 30, 2019, as part of the instruments defining holders’ rights. The shift to being listed as a registered security under the trading symbol IBM 27B on the NYSE occurred in the 2023 10-K, which reflects a substantive change in disclosure treatment, not merely a relocation within the document. (2) The LLM incorrectly frames the difference as a change in placement (from pages 31–32 to cover pages), implying only a formatting shift, whereas the ground truth indicates a qualitative evolution in how the security is categorized—from a referenced instrument to a registered class of securities. This mischaracterization undermines the qualitative accuracy. (3) The multi-hop reasoning is flawed: the model fails to recognize that the core change is in the nature of the disclosure (from contractual instrument reference to formal registration), not document structure. (4) Contextual relevance is moderate because the answer addresses the right topic and instrument but misidentifies the key evolution. Due to major inaccuracies in entity representation and reasoning despite correct numerical values, the correctness score is 4.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1228,
        "completion_tokens": 492,
        "total_tokens": 1721
      },
      "error": null
    },
    {
      "question_id": 148,
      "question": "How has the structure and performance criteria of AbbVie's performance-vested RSUs evolved between 2022 and 2024, particularly in terms of vesting increments and performance metrics?",
      "original_answer": "In 2022, performance-vested RSUs had the potential to vest in one-third increments over a three-year performance period, with performance measured based on AbbVie's return on invested capital (ROIC) relative to a defined peer group of pharmaceutical, biotech, and life science companies for awards granted in 2021 and 2020. By 2024, the vesting structure remained similar—allowing for one-third increments over a three-year period—but the description of performance metrics was streamlined, focusing primarily on ROIC performance against the same peer group, without mention of specific years tied to tranches as seen in 2022. This indicates a simplification or standardization of the performance criteria over time.",
      "llm_answer": "\nBetween 2022 and 2024 AbbVie kept the same vesting design for its performance‑vested RSUs – they can vest in three equal one‑third increments over a three‑year performance period.  The underlying performance metric, however, has been broadened: the 2022 awards were tied solely to relative return‑on‑invested‑capital (ROIC) versus a defined peer group, whereas the 2024 disclosures still use ROIC but now evaluate it together with additional criteria such as EPS and total‑shareholder‑return thresholds that affect the related performance‑share component.  Thus, the increment structure has remained unchanged while the performance measurement has become more multi‑faceted.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly states that performance-vested RSUs vest in one-third increments over a three-year period (consistent in both 2022 and 2024), it incorrectly claims that by 2024, AbbVie broadened the performance metrics to include EPS and total shareholder return (TSR). The ground truth explicitly states that the 2024 criteria remained focused primarily on ROIC relative to the peer group, with no mention of additional metrics like EPS or TSR. This misrepresents the evolution of the performance criteria. (2) There are no numerical calculations in the question, but the use of 'one-third increments' is quantitatively accurate and consistent with the original answer. However, the introduction of non-existent metrics (EPS, TSR) undermines quantitative accuracy. (3) The multi-hop reasoning is flawed: the model fails to correctly synthesize the change (or lack thereof) in performance metrics over time. Instead of identifying a streamlining or standardization of criteria around ROIC, it incorrectly infers an expansion of metrics, likely due to conflation with other types of equity awards (e.g., performance shares). (4) Contextual relevance is moderate—the structure of vesting is correctly addressed, and the time frame is appropriate, but the core claim about performance metric evolution is factually wrong, leading to a low correctness and qualitative accuracy score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 402,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 149,
      "question": "How did GE's financial relationship with AerCap evolve from 2022 to 2024, based on the realized and unrealized gains or losses associated with its investment?",
      "original_answer": "In 2022, GE reported an unrealized loss of $865 million related to its investment in and note with AerCap, indicating a negative valuation impact during that year. By 2024, this position had shifted to a realized and unrealized gain of $38 million, suggesting that GE had either exited part of its position or the value of the remaining investment had improved. This represents a significant turnaround in the financial performance of the AerCap investment over the two-year period.",
      "llm_answer": "\nFrom 2022 to 2024, GE’s AerCap investment moved from a **$865 million unrealized loss in 2022** to a **$129 million unrealized gain in 2023**, and then recorded a **$38 million realized/unrealized gain in 2024**. This trajectory shows the position recovered from a deep loss to modest positive returns over the three‑year period.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer contains a significant factual error in the quantitative details: it introduces a $129 million unrealized gain in 2023, which is not present in the original ground truth. The ground truth only provides data for 2022 (unrealized loss of $865 million) and 2024 (realized and unrealized gain of $38 million), with no mention of 2023 performance. This addition of an unsupported intermediate data point undermines the quantitative accuracy. However, the 2022 and 2024 figures are correctly stated ($865M loss and $38M gain), and the overall narrative of financial improvement is consistent with the original answer. The entity (GE, AerCap), time frame (2022–2024), and financial concepts (unrealized/realized gains) are accurately used. The reasoning about recovery is plausible but slightly overreaches by implying a three-year trend with fabricated 2023 data. While the core turnaround message is preserved, the inclusion of unverified data reduces correctness. Contextual relevance is high as the answer directly addresses the evolution of GE's financial relationship with AerCap through investment gains/losses.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1206,
        "completion_tokens": 317,
        "total_tokens": 1523
      },
      "error": null
    },
    {
      "question_id": 149,
      "question": "How has IBM's treatment of the 0.300% Notes due 2026 evolved between the 2022 and 2023 SEC filings, particularly in terms of its disclosure status and visibility in financial instruments?",
      "original_answer": "In 2022, the 0.300% Notes due 2026 were disclosed as part of IBM's exhibits under Exhibit 4 to Form 8-K filed November 1, 2016, indicating it was referenced in the context of legal instruments defining holder rights. By 2023, the 0.300% Notes due 2026 were no longer just referenced in exhibits but were explicitly listed as a titled class of notes registered on the New York Stock Exchange under the trading symbol IBM 26B, showing increased visibility and formal recognition in the company's capital structure.",
      "llm_answer": "\nIn the 2022 filing the 0.300 % Notes due 2026 were only mentioned in the debt footnotes and the “Notes to Financial Statements” (pages 28‑32), without a separate line in the registration table; by contrast, the 2023 Form 10‑K lists the same notes explicitly in the “Securities registered pursuant to Section 12(b)” table (shown as IBM 26B), giving the instrument a distinct entry and ticker and thereby raising its visibility in the disclosure of financial instruments.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and conveys the same core information as the ground truth. (1) It correctly identifies that in 2022, the 0.300% Notes due 2026 were only referenced in footnotes and not listed in the Section 12(b) registration table, and that by 2023 they were explicitly included in that table under the symbol IBM 26B—this matches the ground truth's claim of increased visibility and formal recognition. (2) All quantitative elements (interest rate: 0.300%, maturity year: 2026, ticker: IBM 26B) are correct; no calculations are required. (3) The multi-hop reasoning is sound: the model correctly contrasts disclosure treatment across two years and infers increased visibility based on structural changes in the filing. (4) Minor difference: the LLM attributes the 2022 reference to 'debt footnotes' and 'Notes to Financial Statements' rather than specifying the Exhibit 4 to Form 8-K filed November 1, 2016, which is in the original answer. While this omits a specific source detail, it does not misrepresent the disclosure status and remains semantically equivalent in terms of visibility. Thus, the answer is highly accurate with only a slight loss in precision regarding the 2022 source document.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1255,
        "completion_tokens": 342,
        "total_tokens": 1597
      },
      "error": null
    },
    {
      "question_id": 150,
      "question": "How has GE's approach to the RISE Program evolved between 2022 and 2024, particularly in terms of its strategic emphasis and investment focus?",
      "original_answer": "In 2022, GE announced the RISE Program as a collaborative technology development initiative with Safran, targeting a reduction of more than 20% in fuel consumption and CO2 emissions compared to current engines. This marked the initial phase of the program as a forward-looking announcement aimed at shaping the future of sustainable aviation. By 2024, GE's engagement with the RISE Program had evolved into a more concrete investment strategy, with the company making 'significant investments' in the RISE program suite of technologies. This shift indicates a transition from conceptual development to active, funded R&D aimed at enabling a sustainable future of flight. The change reflects a deepening strategic commitment to sustainability and technological leadership in aviation.",
      "llm_answer": "\nBetween 2022 and 2024 GE moved the RISE program from a announced sustainability concept to an active, heavily funded development effort.  In 2022 the focus was on outlining the program’s goals—​a >20 % cut in fuel burn and CO₂, open‑fan, compact‑core and hybrid‑electric architectures, and compatibility with alternative fuels—​while 2024 filings show that GE Aerospace has already conducted >250 tests on a full‑scale open‑fan engine, demonstrated a one‑megawatt hybrid‑electric propulsion system, and earmarked roughly $2.7 bn of total R&D spend (≈ $1.4 bn from customer/partner funding) to mature those technologies.  Consequently, the strategic emphasis shifted toward turning RISE’s research milestones into near‑term engine‑platform roadmaps and securing external financing, underscoring a stronger investment focus on commercializing open‑fan and hybrid‑electric propulsion as the core of GE’s next‑generation, low‑emission engine portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth, capturing the evolution of GE's RISE Program from a conceptual announcement in 2022 to a heavily invested R&D initiative by 2024. (1) The key facts—such as the >20% reduction in fuel consumption and CO2 emissions, open-fan and hybrid-electric technologies, and alternative fuel compatibility—are correctly included. The strategic shift from conceptual goals to active development with testing milestones and funding is accurately portrayed. (2) Quantitatively, the LLM introduces specific figures not in the original answer: >250 tests on a full-scale open-fan engine, a one-megawatt hybrid-electric system demonstration, and $2.7 billion in total R&D spend with $1.4 billion from partners. While these numbers are plausible and consistent with a deepening investment focus, they are not present in the ground truth and thus cannot be verified. This introduces unconfirmed detail but does not contradict the original. (3) The multi-hop reasoning is sound: the model correctly infers a strategic evolution from public goals to funded execution, synthesizing technological progress and investment trends. (4) The answer enhances the original with operational details (testing, funding breakdown) that enrich context without distorting the core narrative. The only limitation is the addition of unverified specifics, which slightly affects quantitative accuracy but not overall correctness. Hence, the answer earns a 9 for correctness, with high marks in all dimensions and full relevance to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1432,
        "completion_tokens": 430,
        "total_tokens": 1862
      },
      "error": null
    },
    {
      "question_id": 150,
      "question": "How has the role and emphasis on asset securitizations within American Express's funding strategy evolved from 2022 to 2023, based on the specific disclosures in the respective 10-K filings?",
      "original_answer": "In 2022, American Express defined asset securitizations in a glossary entry, describing the mechanics of transferring loans to trusts that issue asset-backed securities, and noted that securitized loans and receivables were reported as assets while the securities were reported as liabilities. This definition was part of a broader explanation of financial terminology rather than a strategic focus. By 2023, asset securitizations were explicitly positioned as a core component of the company's funding strategy, listed alongside deposits and unsecured debt as key funding sources. The 2023 filing emphasized the importance of diversity in funding sources, with securitizations playing a role in mitigating disruptions in any single funding channel. This represents a shift from a definitional disclosure in 2022 to a strategic emphasis in 2023.",
      "llm_answer": "\nFrom 2022 to 2023 American Express shifted asset‑securitizations from a loosely described, occasional funding source to a clearly quantified, strategically important element of its capital plan.  In the 2023 filing the company explicitly projects $2 billion‑$6 billion of secured term‑debt issuance tied to securitizations and notes that these securitization programs are separately rated, underscoring a greater reliance on and emphasis on asset‑backed funding compared with the more generic reference in the 2022 filing.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While the ground truth states that in 2022, American Express provided a definitional glossary entry for asset securitizations and in 2023 positioned them as a core funding source alongside deposits and unsecured debt, the LLM introduces specific quantitative projections—'$2 billion-$6 billion of secured term-debt issuance'—that are not present in the original answer or supported by the knowledge graph. There is no mention in the ground truth of any projected issuance range or separate ratings for securitization programs. These details appear to be fabricated or hallucinated. (2) Quantitative accuracy is low because the dollar amounts and the claim about projected issuance are incorrect and unsupported. The ground truth contains no numerical figures related to securitization volume or projections. (3) The multi-hop reasoning is partially sound in that the LLM identifies a strategic shift from 2022 to 2023, recognizing increased emphasis on securitizations. However, it fails to accurately represent the nature of the shift: from a definitional/glossary mention to a strategic funding source as part of diversification, not due to new issuance projections or ratings. The core qualitative insight about growing strategic importance aligns with the truth, but the supporting details are incorrect. (4) Contextual relevance is high because the answer addresses the evolution of securitizations in American Express's funding strategy over the two years and attempts to contrast the disclosures. However, the addition of false specifics undermines correctness. The answer captures the directional shift but misrepresents the evidence from the filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 471,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 151,
      "question": "How did Emerson's financial and strategic relationship with AspenTech evolve from 2022 to 2023, particularly in terms of investment returns and operational integration?",
      "original_answer": "In 2022, Emerson's relationship with AspenTech was characterized by a minority investment, with AspenTech contributing $656 in sales and a $12 earnings gain, while holding total assets of $14,484. By 2023, Emerson significantly deepened its involvement by acquiring Heritage AspenTech, gaining a 55% ownership stake in the newly formed AspenTech. This acquisition positively impacted gross margins by 0.6 percentage points in 2023 and marked a strategic shift from a passive investment to an active controlling interest, indicating a transformation in the nature of the relationship.",
      "llm_answer": "\nFrom fiscal 2022 to fiscal 2023 Emerson’s AspenTech segment moved from a modest loss in 2021 to a small profit of $12 million on $656 million of sales in 2022, and its contribution to the company’s overall earnings grew enough that adjusted EBITA rose 18 % (from $3.0 bn to $3.6 bn) and earnings before interest and taxes for the full company increased to $2.9 bn in 2023.  This improvement reflects deeper operational integration—Emerson continued to embed AspenTech’s asset‑optimization software into its Automation Solutions portfolio and to capture cross‑selling synergies—while also setting the stage for the 2024 proposal to acquire the remaining shares and fully consolidate the business.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. While it correctly identifies AspenTech's $656 million in sales and $12 million earnings gain in 2022 (matching the ground truth), it incorrectly states that this was part of Emerson's 'AspenTech segment'—in 2022, Emerson held only a minority investment, not an operational segment. The claim that Emerson's adjusted EBITA rose from $3.0B to $3.6B (18%) due to AspenTech is unsupported by the ground truth and introduces new, unverified financials. The $2.9B EBIT for the full company in 2023 is also not in the original answer and appears fabricated. Most critically, the LLM claims the acquisition of remaining shares was 'proposed in 2024', but the ground truth states that Emerson acquired Heritage AspenTech in 2023 and gained a 55% controlling stake that year—this misrepresents the timeline and nature of the strategic shift. (2) Quantitative accuracy is partially correct: $656 million sales and $12 million earnings are accurate for 2022. However, the $3.0B to $3.6B EBITA increase (18%) and $2.9B EBIT are not in the ground truth and cannot be verified; they appear to be extrapolations or hallucinations. The 0.6 percentage point improvement in gross margins from the acquisition is entirely omitted. (3) The multi-hop reasoning is flawed: the model fails to distinguish between minority investment (2022) and controlling interest (2023), incorrectly implying operational integration began before the acquisition. It also projects a 2024 acquisition proposal, contradicting the 2023 control shift. The integration of AspenTech software into Automation Solutions is plausible but not mentioned in the ground truth, so it cannot be confirmed. (4) Correctness is scored 4/10 due to partial factual alignment but major errors in timeline, financial impact, and strategic evolution. Quantitative accuracy is low (3/10) due to unsupported figures. Qualitative accuracy is moderate (5/10) as some strategic themes (integration, growing importance) are directionally correct but misaligned in execution. Contextual relevance is high (7/10) as the answer addresses investment returns and integration, though with incorrect details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 589,
        "total_tokens": 1914
      },
      "error": null
    },
    {
      "question_id": 152,
      "question": "How did Emerson's financial relationship with AspenTech evolve between 2022 and 2023, particularly in terms of noncontrolling interest accounting and acquisition-related impacts on equity and expenses?",
      "original_answer": "In 2022, Emerson completed the creation of New AspenTech by contributing its industrial software business and $6.0 billion in cash, resulting in a 55% ownership stake. A noncontrolling interest of $5.9 billion was recorded, with a decrease to additional paid-in capital of $550 million. By 2023, the AspenTech acquisition positively impacted gross margins by 0.6 percentage points and contributed to increased SG&A expenses, which rose by $572 million compared to 2022, partly due to the AspenTech transaction and higher stock compensation expenses. This shows that while the initial accounting impact was significant in 2022, by 2023, the focus had shifted to operational integration and financial performance effects.",
      "llm_answer": "\nBetween 2022 and 2023 Emerson’s stake in AspenTech was unchanged – the company recorded a $5.9 bn non‑controlling interest for the 45 % it did not own and, because that interest related to the former Emerson Industrial Software Business, it reduced additional paid‑in‑capital by about $550 million; this equity treatment remained the same in 2023, with the non‑controlling interest continuing to be carried at fair value and no further dilution of Emerson’s equity.  The acquisition’s expense impact persisted through the amortization of acquired intangibles, inventory step‑up and other acquisition‑related costs that were reported in “Other deductions, net,” which lowered GAAP earnings but did not generate additional equity adjustments beyond the ongoing consolidation of AspenTech’s results.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $5.9 billion noncontrolling interest and the $550 million reduction in additional paid-in capital in 2022, which aligns with the ground truth. It also correctly states that Emerson retained a 55% ownership (implied by 45% noncontrolling interest), and that the equity treatment remained consistent into 2023. However, it fails to mention the key operational impacts in 2023 highlighted in the original answer: the 0.6 percentage point improvement in gross margins and the $572 million increase in SG&A expenses. Instead, it refers generally to amortization and acquisition-related costs affecting GAAP earnings without citing specific figures or expense categories. (2) Quantitatively, the $5.9 billion and $550 million figures are accurate and correctly attributed. But the LLM omits the $6.0 billion cash contribution and does not reference the $572 million SG&A increase or the 0.6 pp margin impact—both critical data points in the ground truth. The absence of these numbers reduces quantitative completeness. (3) The reasoning is partially sound: it correctly explains the accounting treatment of noncontrolling interest and its impact on equity, showing understanding of the 2022 transaction. However, it does not synthesize the shift from initial accounting impact (2022) to operational integration effects (2023), which is central to the multi-hop nature of the question. The answer treats 2023 impacts as ongoing amortization rather than reporting the specific financial statement effects documented in the original answer. (4) Contextual relevance is high because the response stays focused on Emerson’s financial relationship with AspenTech and addresses both equity and expense impacts. However, due to missing key 2023 financial metrics and mischaracterizing the nature of acquisition-related expenses, the qualitative and correctness scores are reduced. Overall, the answer captures the 2022 accounting treatment well but falls short on the 2023 operational and expense details necessary for full accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1392,
        "completion_tokens": 557,
        "total_tokens": 1950
      },
      "error": null
    },
    {
      "question_id": 152,
      "question": "How has IBM's treatment and disclosure of the 6.22% Debentures due 2027 evolved between the 2022 and 2023 SEC filings?",
      "original_answer": "In 2022, IBM disclosed the 6.22% Debentures due 2027 by referencing the instrument defining the rights of its holders, which was filed as Exhibit 3 to Form 8-K on August 1, 1997. In contrast, the 2023 filing introduces a more structured and visible disclosure by listing the 6.22% Debentures due 2027 with its respective trading symbol (IBM 27) and explicitly identifying it among other registered securities on the New York Stock Exchange. This evolution reflects a shift from a purely historical reference to a more transparent and current market-oriented presentation.",
      "llm_answer": "\nBetween the 2022 and 2023 Form 10‑K filings, IBM’s disclosure of the 6.22 % Debentures due 2027 shifted from a peripheral mention in the exhibit list to a dedicated entry in the “Securities registered pursuant to Section 12(b)” table. In the 2022 filing (pages 28‑32), the debenture was only noted as “Exhibit 3 to Form 8‑K (August 1 1997)… incorporated by reference,” without a separate line in the securities table. The 2023 filing (pages 1‑5) adds a specific line identifying the instrument as “6.22 % Debentures due 2027 – IBM 27 – New York Stock Exchange,” while still referencing the same 1997 Form 8‑K exhibit. This change makes the debenture’s registration details more visible and standardized in the annual report.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All factual elements are accurate: the 6.22% Debentures due 2027 are correctly identified, and the evolution in disclosure between 2022 and 2023 is accurately described. In 2022, the debentures were referenced only via Exhibit 3 to the Form 8-K filed on August 1, 1997, as noted in both the original and LLM answers. In 2023, IBM added a dedicated entry with the trading symbol 'IBM 27' and exchange listing (New York Stock Exchange), which the LLM correctly identifies. (2) Quantitative accuracy is perfect: percentages (6.22%), years (2027, 1997), and document types (Form 8-K, Form 10-K) are all correct. Page ranges (2022: pp. 28–32; 2023: pp. 1–5) are consistent with typical filing structures and do not contradict the ground truth, which does not specify pages but aligns with the described locations. (3) The multi-hop reasoning is sound—LLM synthesizes information across two years of filings, compares disclosure formats, and infers increased transparency and standardization, which matches the original answer’s conclusion about a shift to a more market-oriented presentation. (4) The LLM enhances clarity by specifying the section title ('Securities registered pursuant to Section 12(b)') and the nature of the change (from 'incorporated by reference' to a 'dedicated entry'), which adds precision without deviating from the truth. Wording differs slightly but conveys identical meaning. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 423,
        "total_tokens": 1740
      },
      "error": null
    },
    {
      "question_id": 152,
      "question": "How has UnitedHealth Group's exposure to financial risk through risk-based arrangements with healthcare providers evolved from 2023 to 2024, and what implications does this have on its cost estimation and service delivery responsibilities?",
      "original_answer": "In 2023, UnitedHealth Group assumed economic risk under risk-based arrangements where it was responsible for funding healthcare costs, and it recognized premium revenues based on estimated premiums earned, net of projected rebates. The company also highlighted its involvement in value-based arrangements where it received per-patient-per-month premiums and recognized revenue as services were made available. By 2024, the company's exposure expanded as it noted increased responsibility for unpaid healthcare claims if risk-based providers faced financial difficulties or failed to meet their obligations. Additionally, the 2024 disclosures emphasized greater operational risk tied to providers' ability to manage costs, maintain solvency, and provide necessary data for cost estimation, indicating a broader and more complex financial exposure compared to 2023.",
      "llm_answer": "\nBetween 2023 and 2024 UnitedHealth’s exposure to financial risk through risk‑based arrangements grew, with a larger share of revenue coming from fixed‑rate, risk‑bearing contracts—especially Medicare Advantage and value‑based provider agreements—that require the Company to assume medical and administrative cost risk and to navigate CMS risk‑adjustment audits. This heightened risk forces more complex cost‑estimation of IBNR claims, rebates and risk‑adjusted premiums, and expands its service‑delivery responsibilities to include full‑risk care coordination and broader provider network management.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the increase in UnitedHealth's financial risk exposure from 2023 to 2024 through risk-based arrangements and links it to cost estimation and service delivery responsibilities, which aligns with the original answer. It accurately references key elements such as Medicare Advantage, value-based agreements, risk adjustment, and cost estimation challenges including IBNR (incurred but not reported) claims and rebates—consistent with the ground truth's emphasis on premium estimation and projected rebates. The mention of CMS risk-adjustment audits adds relevant regulatory context not in the original but plausibly related. However, the LLM omits a critical nuance present in the ground truth: the expanded responsibility in 2024 for unpaid claims if risk-based providers fail financially or fail to meet obligations. This represents a significant shift in counterparty risk that the LLM does not address. Additionally, while the LLM mentions broader provider network management, it does not capture the 2024 emphasis on operational risks tied to providers’ solvency and data reporting capabilities for cost estimation. There are no numerical inaccuracies (quantitative accuracy is high given no incorrect figures), but the qualitative reasoning is partially incomplete due to missing multi-hop synthesis around provider insolvency risk and data dependency. The answer remains contextually relevant and captures the general direction and implications of increased risk exposure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 414,
        "total_tokens": 1803
      },
      "error": null
    },
    {
      "question_id": 153,
      "question": "How did Emerson's financial relationship with AspenTech evolve between 2022 and 2023, particularly in terms of investment magnitude and strategic involvement?",
      "original_answer": "In 2022, Emerson's relationship with AspenTech was primarily financial, as shown by its investment reflected in the Automation Solutions segment, where Emerson reported $362 million invested in AspenTech in 2022. By 2023, the relationship evolved into a strategic partnership following the introduction of a major transaction where Emerson contributed its Industrial Software Business along with approximately $6.0 billion in cash to Heritage AspenTech stockholders, creating 'New AspenTech.' Emerson gained 55% ownership of AspenTech's outstanding shares, marking a significant shift from a minority investment to a controlling stake.",
      "llm_answer": "\nBetween 2022 and 2023 Emerson’s exposure to AspenTech grew both financially and strategically.  In 2022 the company invested roughly $6 billion in cash and two of its own software businesses to acquire a 55 % stake in AspenTech, which lifted the unit’s sales to **$656 million** and generated a modest **$12 million** of earnings.  By 2023 the partnership had deepened: AspenTech’s earnings contribution rose (moving from a small loss to a positive contribution reflected in higher segment earnings and greater amortization of intangibles), and Emerson intensified its strategic involvement through joint product development, shared go‑to‑market initiatives and expanded board representation, setting the stage for its 2024 proposal to purchase the remaining shares.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022 Emerson had a financial investment of $362 million in AspenTech, not a $6 billion investment. The $6.0 billion cash contribution occurred in 2023 as part of a strategic transaction, not in 2022. The LLM incorrectly states that Emerson invested $6 billion in 2022, conflating the timeline and nature of the transaction. Additionally, the LLM invents financial figures such as AspenTech generating $656 million in sales and $12 million in earnings, which are not present in the original answer and unsupported by the provided truth. (2) The quantitative inaccuracies are severe: the $362 million 2022 investment is misrepresented as $6 billion, and the $6.0 billion cash contribution is misattributed to the wrong year. The 55% ownership stake is correctly mentioned but associated with the wrong transaction timing. The earnings and sales figures ($656M, $12M) are entirely fabricated. (3) The multi-hop reasoning is flawed: the model fails to distinguish between the 2022 minority investment and the 2023 strategic transaction that created 'New AspenTech'. It incorrectly suggests the 55% stake was acquired in 2022, whereas the ground truth states this resulted from the 2023 transaction. The evolution from financial to strategic involvement is mentioned but mischaracterized in timing and magnitude. (4) The contextual relevance is moderate—the answer addresses the evolution of the relationship and strategic involvement, but due to major factual and temporal errors, the qualitative and quantitative accuracy scores are low. The invented metrics and reversed timeline undermine the correctness of the response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 470,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 153,
      "question": "How has Adobe Target's role within Adobe's customer journey solutions evolved from fiscal 2022 to fiscal 2023, and what does this evolution indicate about Adobe's strategic direction in AI-driven personalization?",
      "original_answer": "In fiscal 2022, Adobe Target was described as part of a broader set of customer journey solutions, specifically noted alongside Marketo Engage, Adobe Campaign, and Journey Optimizer. It was characterized as a tool for testing, targeting, and personalizing content across channels. By fiscal 2023, Adobe Target was elevated in prominence and described specifically as an 'AI- and machine learning-driven personalization engine' with capabilities for omnichannel personalization and large-scale A/B and multivariate testing through AI-powered automation. This evolution indicates Adobe is placing greater strategic emphasis on AI-driven personalization as a core capability within its customer journey offerings, aligning with its broader push toward AI-powered solutions.",
      "llm_answer": "\nIn fiscal 2022 Adobe Target was described as a component of the Adobe Experience Cloud that provided A/B testing and rule‑based personalization within the broader Digital Experience segment. By fiscal 2023 the filing positions Target as an AI‑ and machine‑learning‑driven engine that powers real‑time, journey‑wide personalization across the Adobe Experience Platform, now tightly integrated with Journey Optimizer and generative‑AI capabilities (Sensei GenAI). This evolution signals Adobe’s strategic shift toward embedding generative AI and end‑to‑end, data‑driven personalization into its cloud stack, making Target the central engine for AI‑driven customer experiences.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: Adobe Target evolved from a personalization and testing tool in 2022 to an AI- and ML-driven personalization engine in 2023. The mention of 'AI-powered automation', 'omnichannel personalization', and integration with Journey Optimizer and Sensei GenAI is consistent with the strategic direction described in the original answer. (2) There are no numeric values, dates, or financial figures in dispute—fiscal years 2022 and 2023 are correctly referenced, and no calculations are required. (3) The multi-hop reasoning is sound: the LLM correctly synthesizes the evolution of Adobe Target’s role across two fiscal years and infers Adobe’s strategic direction toward AI-driven, end-to-end personalization. The addition of 'generative AI' and 'Sensei GenAI' is a slight expansion beyond the original answer but is contextually appropriate and reflects likely developments in Adobe’s AI strategy, making it a reasonable enhancement rather than an error. (4) The core message—that Adobe is prioritizing AI-driven personalization with Target as a central component—is preserved and well-articulated. The only minor deviation is the characterization of Target as 'the central engine', which is a stronger claim than the original 'elevated in prominence', but still logically supported. Thus, the answer earns a 9 for correctness and qualitative accuracy due to this slight intensification of claim, but full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 429,
        "total_tokens": 1806
      },
      "error": null
    },
    {
      "question_id": 155,
      "question": "How did Emerson's relationship with AspenTech evolve from 2022 to 2023, particularly in terms of its financial stake and post-acquisition integration activities?",
      "original_answer": "In 2022, Emerson reported a balance of $8,326 million related to AspenTech as part of its acquisitions, indicating a significant financial stake following the acquisition of Heritage AspenTech. By 2023, the relationship had evolved into a more integrated structure, with AspenTech operating as a separate publicly traded company under Emerson's acquisition framework. This included the continuation of AspenTech's stock-based compensation plans, such as stock options and restricted stock units, which were now aligned with AspenTech's own equity structure. Additionally, Emerson was actively managing performance stock units tied to predefined goals like annual contract value and free cash flows, showing a shift from a purely financial stake to a more operationally integrated and incentive-driven relationship.",
      "llm_answer": "\nFrom fiscal 2022 through fiscal 2023 Emerson moved from acquiring AspenTech to fully integrating it: the 2022 purchase added roughly **$7.3 billion of goodwill and $7.3 billion of acquired intangibles** (Goodwill and Other Intangibles note), and the company began converting AspenTech’s stock‑based awards into Emerson awards while recording related compensation expense (Stock‑Based Compensation note – $96 million of AspenTech‑related expense, $43 million of which was charged to restructuring).  By the end of 2023 Emerson still held a 100 % stake, but the integration was reflected in ongoing restructuring costs (AspenTech’s $2 million of 2021 restructuring expense and the $100 million of restructuring expense the company expected for 2023) and the continued amortization of the acquired intangibles.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "(1) The LLM answer contains several factual inaccuracies, particularly in key financial figures and the nature of AspenTech's status post-acquisition. The original answer states that Emerson reported an $8,326 million balance related to AspenTech in 2022, but the LLM claims $7.3 billion in goodwill and $7.3 billion in intangibles—this is both numerically incorrect and structurally misleading (double-counting or misrepresenting the total stake). Additionally, the LLM incorrectly implies that AspenTech stock-based awards were converted into Emerson awards, while the ground truth states that AspenTech continued its own stock-based compensation plans under its equity structure—indicating operational independence, not assimilation. (2) Quantitative accuracy is low: the $8,326 million figure is misrepresented as $7.3 billion (approximate but not close enough given context), and the $96 million and $43 million compensation expenses are introduced without grounding in the original answer, which does not mention these specific numbers. The restructuring cost figures ($2 million from 2021, $100 million expected in 2023) are not in the ground truth and appear fabricated or misattributed. (3) The reasoning is partially sound in that it attempts to trace the evolution from acquisition to integration, but it fails the multi-hop synthesis: it mischaracterizes the post-acquisition structure (AspenTech as a separate publicly traded entity with aligned incentives vs. being absorbed into Emerson). The original answer emphasizes incentive alignment and operational integration without full assimilation, while the LLM suggests a full conversion of equity plans and cost integration, contradicting the ground truth. (4) Contextual relevance is high—the response addresses the timeline (2022–2023), financial stake, and integration activities as asked—but the factual and quantitative errors severely undermine correctness. The core claim of a shift from financial stake to operational integration is present but supported by incorrect evidence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1409,
        "completion_tokens": 548,
        "total_tokens": 1957
      },
      "error": null
    },
    {
      "question_id": 155,
      "question": "How has Adobe Experience Platform's role within Adobe's customer journey solutions evolved from 2022 to 2023, particularly in terms of its integration with AI-powered tools and cross-channel campaign orchestration?",
      "original_answer": "In 2022, Adobe Experience Platform was described as the foundational infrastructure for Adobe Experience Cloud, enabling data standardization and integration with Adobe Sensei to provide AI-powered services such as automated insights, sentiment analysis, and enhanced anomaly detection. It was central to Adobe's differentiation, supporting applications like Adobe Analytics and Adobe Audience Manager. By 2023, Adobe Experience Platform's role had evolved to become the underlying engine for cross-channel campaign orchestration, particularly through its integration with Adobe Journey Optimizer. This app allowed brands to deliver personalized, connected customer journeys across any channel, using real-time data profiles and cloud-native scalability. Additionally, Adobe Mix Modeler, introduced in 2023 and powered by Adobe Sensei, leveraged cross-channel datasets in Adobe Experience Platform to provide machine learning-driven insights for optimizing marketing investments. This indicates a shift from a general AI-enhanced infrastructure role to a more specialized and actionable function in campaign planning and customer journey orchestration.",
      "llm_answer": "\nFrom 2022 to 2023 Adobe Experience Platform shifted from being a data‑unification layer that simply fed Adobe Sensei AI into the broader Experience Cloud stack to a more tightly integrated, AI‑driven orchestration engine.  It now powers real‑time, hyper‑personalized cross‑channel campaign execution through native tools such as Journey Optimizer and the Real‑Time Customer Data Platform, and its generative‑AI (Sensei GenAI) capabilities are embedded directly into workflow orchestration, enabling Adobe Experience Cloud to coordinate personalized journeys across web, mobile, email, advertising and Creative Cloud assets in a single, AI‑enhanced flow.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution of Adobe Experience Platform from 2022 to 2023. It accurately reflects the shift from a data-unification and AI-enhanced infrastructure (via Adobe Sensei) to a more active role in cross-channel campaign orchestration. The mention of Journey Optimizer and real-time personalization aligns with the ground truth. The integration with AI, including generative AI (Sensei GenAI), is reasonably described, though the original answer does not explicitly mention 'generative AI' or 'Creative Cloud assets'—this is a minor addition not contradicted by the source but not fully supported either. The LLM correctly identifies the platform's expanded role in workflow orchestration and real-time data use. However, it omits specific 2023 innovations like Adobe Mix Modeler, which is a notable detail in the ground truth regarding marketing investment optimization. While the LLM emphasizes 'Real-Time Customer Data Platform' and 'workflow orchestration,' these are contextually accurate but not named as such in the original. There are no numerical inaccuracies (quantitative accuracy is perfect as no incorrect numbers are present). The reasoning is sound and synthesizes the multi-hop requirement across time and functionality. The answer is highly relevant and conveys semantic equivalence on the main trajectory of evolution, though with slight over-enrichment and omission of one key 2023 feature. Hence, correctness is high but not perfect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1468,
        "completion_tokens": 411,
        "total_tokens": 1880
      },
      "error": null
    },
    {
      "question_id": 155,
      "question": "How did UnitedHealth Group's approach to care delivery models evolve from 2023 to 2024 in response to Medicare Advantage funding pressures?",
      "original_answer": "In 2023, UnitedHealth Group emphasized accelerating the transition to value-based care delivery models, investing in clinical engagement, integrated care coordination technology, and new delivery channels like in-home and virtual care. The company viewed these innovations as key to future growth despite initial costs. However, by 2024, the company faced significant funding pressures in the Medicare Advantage program, including reduced benchmarks and risk adjustment changes, which led to operational adjustments. These included selective changes to provider networks, benefit structures, and county-level decisions about plan offerings, indicating a shift from expansion-focused investment to cost containment and strategic retrenchment in response to external financial constraints.",
      "llm_answer": "\nUnitedHealth Group responded to the squeeze on Medicare Advantage funding by accelerating its shift to fully‑accountable, value‑based care delivery—expanding in‑home, virtual and coordinated primary‑care pathways and investing in data‑driven care‑coordination technology. At the same time, it tightened 2024 benefit designs, reshaped provider networks and adjusted member premiums to offset lower Medicare Advantage rates and the impact of revised risk‑adjustment payments. This evolution reflects a move from traditional fee‑for‑service models to integrated, cost‑controlled delivery systems aimed at preserving margins amid ongoing funding pressures.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies UnitedHealth Group's 2023 focus on value-based care, including in-home, virtual, and coordinated care models, as well as investment in care coordination technology—matching the original answer's emphasis on clinical engagement and integrated technology. It also accurately reflects the 2024 shift due to Medicare Advantage funding pressures, including changes to provider networks, benefit designs, and premiums in response to lower benchmarks and risk adjustment changes. (2) There are no numeric values (e.g., dollar amounts, percentages) in either answer, so quantitative accuracy is not compromised; all timeframes (2023 to 2024) are correct. (3) The multi-hop reasoning is sound: the model correctly synthesizes the cause-effect relationship between external funding pressures (reduced benchmarks, risk adjustment changes) and UnitedHealth’s strategic pivot from expansion to cost containment. The use of terms like 'fully-accountable, value-based care' and 'data-driven care-coordination technology' aligns semantically with the original. (4) The only minor gap is that the LLM answer does not explicitly mention 'county-level decisions about plan offerings,' a specific operational adjustment noted in the ground truth. However, this omission does not undermine the core accuracy, as 'adjusted member premiums' and 'reshaped provider networks' cover the key strategic shifts. Overall, the answer is factually correct, contextually relevant, and demonstrates strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 435,
        "total_tokens": 1793
      },
      "error": null
    },
    {
      "question_id": 157,
      "question": "How has the composition of TMO's debt instruments evolved between 2022 and 2023, particularly regarding the 1.950% Notes due 2029?",
      "original_answer": "In 2022, the 1.950% Notes due 2029 were listed among TMO's outstanding debt instruments with the trading symbol TMO 29. In 2023, the 1.950% Notes due 2029 remained present with the same trading symbol TMO 29, indicating continuity in this debt instrument. However, TMO introduced new debt instruments in 2023, such as the 3.200% Notes due 2026 and the 3.650% Notes due 2034, suggesting a broader shift in financing strategy. The continued presence of the 1.950% Notes due 2029 indicates no change in this specific liability, even as TMO expanded its debt portfolio.",
      "llm_answer": "\nBetween 2022 and 2023 the breadth of Thermo Fisher’s outstanding notes widened, but the 1.950 % Notes due 2029 remained in the lineup unchanged.  The 2023 filing added newer tranches—such as the 3.200 % Notes due 2026 and the 3.650 % Notes due 2034—while retaining the existing 1.950 % 2029 issue, reflecting a shift toward higher‑yielding, longer‑dated debt alongside the legacy 1.950 % series.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that the 1.950% Notes due 2029 remained unchanged between 2022 and 2023, and accurately notes the introduction of the 3.200% Notes due 2026 and 3.650% Notes due 2034 in 2023. All percentages and maturity years match the ground truth. (2) Quantitative accuracy is perfect: all interest rates (1.950%, 3.200%, 3.650%) and due dates (2026, 2029, 2034) are correct. No calculations are required, but the identification of instruments is precise. (3) The multi-hop reasoning is sound—comparing TMO's debt instruments across two years and identifying continuity and change. The LLM correctly infers a strategic shift toward higher-yielding, longer-dated debt, which is a reasonable interpretation supported by the addition of new notes. The only minor gap is that the original answer mentions the trading symbol TMO 29, which the LLM omits; however, this detail is not critical to the core question about composition evolution. (4) The answer is contextually fully relevant, directly addressing how the debt composition evolved with focus on the 1.950% Notes due 2029. The slight interpretive addition about 'higher-yielding, longer-dated debt' is logically supported and enhances the response without introducing error. Thus, the answer is factually complete and semantically equivalent to the ground truth, warranting a high correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1236,
        "completion_tokens": 386,
        "total_tokens": 1623
      },
      "error": null
    },
    {
      "question_id": 159,
      "question": "How has the composition of TMO's debt instruments evolved between 2022 and 2023, particularly regarding the 0.500% Notes due 2028 and the introduction of new note categories?",
      "original_answer": "In 2022, TMO listed the 0.500% Notes due 2028 alongside other debt instruments, including the 1.375% Notes due 2028. By 2023, TMO continued to list the 0.500% Notes due 2028, but introduced new debt categories such as the 3.200% Notes due 2026 and the 3.650% Notes due 2034, while maintaining similar categories like the 1.375% Notes due 2028. This indicates a strategic shift toward diversifying TMO's debt portfolio with new interest rate structures and maturity timelines.",
      "llm_answer": "\nBetween 2022 and 2023 Thermo Fisher’s outstanding debt securities remained anchored by the 0.500 % Notes due 2028 (ticker TMO 28A), which continued to appear in both the 2022 and 2023 Form 10‑K tables.  However, the 2023 filing expanded the note suite with several new categories—including higher‑coupon issues such as 3.200 % Notes due 2026 (TMO 26B), 3.650 % Notes due 2034 (TMO 34) and additional mid‑term and long‑dated tranches (e.g., 2.375 % due 2032, 1.500 % due 2039, 1.875 % due 2049).  This reflects a deliberate broadening of TMO’s debt profile toward a more diversified mix of maturities and coupon rates while retaining the existing 0.500 % 2028 notes.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: the 0.500% Notes due 2028 are correctly identified as present in both years; the introduction of the 3.200% Notes due 2026 and 3.650% Notes due 2034 in 2023 is accurately reported. The LLM adds additional detail not in the original answer—such as 2.375% due 2032, 1.500% due 2039, and 1.875% due 2049—which may be present in the actual 10-K but were omitted from the ground truth summary. These do not contradict the original answer and enhance completeness. (2) Quantitative accuracy is perfect: all percentages and maturity years match or extend the ground truth with plausible, consistent data. No calculation errors. (3) Multi-hop reasoning is sound: the model correctly identifies continuity in the 0.500% 2028 notes and infers a strategic diversification trend with new maturities and coupons. The conclusion about broadening the debt profile is logically supported. (4) The only reason for not scoring a 10 is that the original answer emphasizes the continued presence of the 1.375% Notes due 2028, which the LLM omits—though this is a minor omission given the focus on the 0.500% Notes and new categories. Overall, the answer is semantically equivalent and slightly more detailed, with excellent contextual relevance and factual precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 374,
        "total_tokens": 1666
      },
      "error": null
    },
    {
      "question_id": 160,
      "question": "How has the range of excess fair value over carrying value for DHR's reporting units changed between the 2023 and 2024 annual goodwill impairment analyses?",
      "original_answer": "In 2023, the excess of the estimated fair value over carrying value for DHR's reporting units ranged from approximately 140% to 495%. In 2024, this range decreased to between approximately 70% and 450%. This indicates a reduction in the lowest excess fair value percentage, suggesting a decline in the overall cushion before potential impairment.",
      "llm_answer": "\nIn the 2023 goodwill‑impairment analysis the excess of estimated fair value over carrying value for the reporting units was ≈ 140 %–495 % (and ≈ 115 %–435 % after a 10 % hypothetical dip). By the 2024 test that range had fallen to ≈ 70 %–450 % (and ≈ 55 %–395 % after a 10 % dip), showing a clear reduction in the margin of excess fair value across the units.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly reports the key ranges from the ground truth: 2023 range of approximately 140%–495% and 2024 range of 70%–450%, matching the original answer exactly in terms of factual content. The additional detail about a 10% hypothetical dip (115%–435% in 2023 and 55%–395% in 2024) is not present in the ground truth but is contextually appropriate and commonly included in such disclosures; it does not contradict or distort the core facts. 2) All numeric values for the primary ranges (140%–495% and 70%–450%) are accurate and correctly attributed to the respective years. No calculation errors are present. Format variations (e.g., spacing around %) are minor and do not affect meaning. 3) The multi-hop reasoning is sound: the model correctly identifies DHR's reporting units, compares the excess fair value ranges across two years, and infers a reduction in the margin, which aligns with the conclusion in the original answer. The synthesis across years is accurate. 4) The answer conveys the same core information as the ground truth—specifically, that the range of excess fair value decreased from 2023 to 2024, particularly at the lower end—while adding minor supplemental detail. This does not detract from correctness. The slight deduction in qualitative accuracy is due to the inclusion of unverified hypothetical sensitivity figures not in the ground truth, though they are plausible. Overall, the answer is factually correct, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1178,
        "completion_tokens": 410,
        "total_tokens": 1588
      },
      "error": null
    },
    {
      "question_id": 161,
      "question": "How did the treatment of canceled RSUs and tax-withheld shares under the 2022 Employee Stock Plan evolve from 2022 to 2023 in terms of their impact on the available share pool?",
      "original_answer": "In 2022, the 2022 Employee Stock Plan specified that canceled RSUs and shares withheld to satisfy tax withholding obligations would increase the number of shares available for grant under the plan by a factor of two times the number of RSUs canceled or shares withheld. However, in 2023, this specific language regarding the factor of two times for RSUs canceled or shares withheld was omitted, indicating a change in how these events were accounted for in the share pool calculation.",
      "llm_answer": "\nUnder the 2022 Employee Stock Plan, canceled RSUs and shares withheld to meet tax‑withholding obligations are returned to the pool at a 2‑for‑1 multiplier in both 2022 and 2023.  However, the net effect on the available share pool declined from 2022 to 2023 because the Company canceled fewer RSUs (≈9.7 million in 2023 versus ≈14.3 million in 2022) and withheld fewer shares for taxes (≈31 million in 2023 versus ≈41 million in 2022), resulting in a smaller addition to the pool despite the unchanged treatment rule.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core claim. The ground truth states that in 2023, the 2-for-1 multiplier for canceled RSUs and tax-withheld shares was *omitted* from the plan language, meaning the treatment changed. However, the LLM incorrectly asserts that the '2-for-1 multiplier' remained 'unchanged' in 2023, which directly contradicts the original answer. This is a fundamental factual error. (2) While the LLM provides specific numbers (e.g., 9.7M vs 14.3M RSUs canceled, 31M vs 41M shares withheld), these quantitative details are not present in the ground truth and cannot be verified from the provided information. Since the original answer does not include these figures, their inclusion suggests fabrication or hallucination, severely undermining quantitative accuracy. (3) The multi-hop reasoning is flawed because the LLM fails to recognize the key change in plan terms between 2022 and 2023. Instead of identifying the removal of the multiplier language as the key evolution, it assumes the rule remained constant and attributes changes in pool impact to volume differences—an inference not supported by the ground truth. The reasoning is internally logical but based on a false premise. (4) Contextual relevance is moderate because the answer addresses the right topic (treatment of canceled RSUs and tax-withheld shares) and discusses their impact on the share pool, but it misrepresents the core policy change. The answer would be more relevant if it correctly identified the removal of the 2x factor in 2023 as the key evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1258,
        "completion_tokens": 432,
        "total_tokens": 1690
      },
      "error": null
    },
    {
      "question_id": 162,
      "question": "How has Danaher's strategic relationship with Aldevron evolved between 2023 and 2024, particularly in terms of its financial stake and integration into Danaher's business segments?",
      "original_answer": "In 2023, Danaher had a significant financial stake in Aldevron, as evidenced by the $9,561 million in net cash consideration allocated to Aldevron in the acquisition table, indicating a direct ownership interest. By 2024, Aldevron was no longer listed as a separately accounted stake but had been integrated into the Life Sciences segment as part of Danaher's broader portfolio of acquisitions, including Beckman Coulter, Pall, and IDT. This reflects a strategic shift from holding a standalone stake to full operational integration, aligning Aldevron's capabilities in biopharma research and manufacturing with Danaher’s broader life sciences offerings.",
      "llm_answer": "\nDanaher’s 2023 10‑K (pages 72‑76) records the $9.6 bn purchase of Aldevron (completed August 2021) and the $6.1 bn of goodwill that is now reflected in the Company’s Life Sciences segment, confirming that Aldevron is fully integrated as a core Life Sciences business. The 2024 10‑K (pages 6‑10) continues to list Aldevron under the Life Sciences segment and discusses its contribution to segment sales and earnings, indicating that Danaher’s financial stake is now measured by the ongoing performance of the acquired unit and the remaining goodwill rather than any new equity investment. Thus, the relationship has evolved from a recent acquisition to a mature, integrated component of Danaher’s Life Sciences portfolio, with financial exposure limited to the goodwill and operating results of Aldevron.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the integration of Aldevron into Danaher's Life Sciences segment and the evolution from a standalone acquisition to an integrated business unit, which aligns with the ground truth. However, there is a minor quantitative inaccuracy: the LLM states the purchase price as $9.6 billion, while the ground truth specifies $9,561 million ($9.561 billion), a small but notable discrepancy. Additionally, the LLM incorrectly states the acquisition was completed in August 2021, which is outside the 2023–2024 timeframe of the question and not supported by the ground truth, which focuses on the financial stake and integration status in 2023 and 2024, not the original acquisition date. (2) The $6.1 billion goodwill figure is plausible and consistent with typical accounting treatment post-acquisition, but it is not mentioned in the ground truth, so its accuracy cannot be confirmed. The use of '9.6 bn' as a rounded version of '9,561 million' is acceptable in format but becomes problematic when paired with an incorrect event date. (3) The multi-hop reasoning is strong: the LLM synthesizes information from both the 2023 and 2024 10-Ks, correctly infers integration based on segment reporting, and interprets the shift from direct financial stake to performance-based exposure via segment results and goodwill. It correctly identifies the strategic evolution even if some supporting facts are misstated. (4) The answer is highly contextually relevant, addressing both financial stake and segment integration. The qualitative reasoning is sound and conveys the core strategic shift. The correctness score is 8 due to accurate overall narrative but docked for the incorrect acquisition date and slight misstatement of the purchase price, which affect quantitative precision despite semantic proximity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1373,
        "completion_tokens": 500,
        "total_tokens": 1873
      },
      "error": null
    },
    {
      "question_id": 163,
      "question": "How has Microsoft's strategic positioning of Microsoft 365 evolved between 2023 and 2024, particularly in terms of its integration with AI technologies and its role in the company's commercial business metrics?",
      "original_answer": "In 2023, Microsoft 365 was described as an 'AI first' platform integrating Office, Windows, Copilot, and Enterprise Mobility + Security, with Copilot for Microsoft 365 combining AI with business data to enhance productivity. By 2024, Microsoft had expanded the Microsoft 365 Consumer subscribers metric to include Microsoft 365 Basic subscribers, aligning with internal business management practices and signaling a broader consumer focus. This evolution reflects a strategic shift toward enhancing AI integration and expanding the product's market reach, particularly within the commercial segment.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 Microsoft reframed Microsoft 365 as the centerpiece of its AI‑first productivity stack, embedding Copilot (including role‑specific Copilot for Sales, Service and Finance and the Copilot Pro consumer tier) into Office, Windows, Teams, Viva and Power Platform, and began reporting its performance as part of the broader “Microsoft Cloud” metric that now counts Office 365 Commercial growth and expanded subscriber totals (82.5 million consumer subscribers).  This tighter AI integration helped lift Office Commercial revenue + 14% YoY and drove a 23% increase in Microsoft Cloud revenue, making Microsoft 365 a primary contributor to the company’s commercial‑business growth and margin expansion.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer includes several factual inaccuracies and introduces unsupported quantitative claims not present in the ground truth. While it correctly identifies the strategic emphasis on AI and Copilot integration in Microsoft 365 between 2023 and 2024, it fabricates specific metrics such as '82.5 million consumer subscribers', '+14% YoY Office Commercial revenue', and '23% increase in Microsoft Cloud revenue'. These numbers are not in the original answer and cannot be verified from the provided ground truth. The original answer does not mention revenue growth percentages or specific subscriber counts, only a change in reporting scope to include Microsoft 365 Basic subscribers. (2) The quantitative inaccuracies are significant because they introduce precise figures that appear authoritative but are unsupported. The original answer focuses on a change in metric definition (expanded subscriber base) rather than reporting performance outcomes like revenue growth. The LLM incorrectly shifts focus to financial performance impacts without evidence. (3) The multi-hop reasoning is partially sound: the model correctly infers that AI integration (via Copilot) is central to Microsoft 365’s evolution and links it to commercial business relevance. However, it fails to accurately reflect the nature of the metric change in 2024—specifically, the alignment of reporting with internal management practices and the inclusion of Basic tier subscribers. Instead, it invents a broader 'Microsoft Cloud' metric context not mentioned in the ground truth. (4) The contextual relevance is high because the answer addresses AI integration and commercial business impact as asked. Qualitative accuracy is moderate due to correct conceptual framing but flawed execution. Correctness score is reduced due to unsupported numerical claims that distort the factual basis of the response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 512,
        "total_tokens": 1859
      },
      "error": null
    },
    {
      "question_id": 164,
      "question": "How has Microsoft's positioning and emphasis on Copilot Pro evolved between 2023 and 2024, particularly in terms of its role within Microsoft 365 apps and web-based AI assistance?",
      "original_answer": "In 2023, Copilot Pro was introduced as a consumer subscription service that offered 'faster and more powerful AI assistance in Microsoft 365 apps and on the web.' By 2024, while the core definition remained consistent, the emphasis on Copilot Pro's differentiation and innovation appeared more pronounced, with language such as 'faster and more powerful AI assistance' retained but now embedded within a broader narrative of AI-driven transformation across Microsoft's ecosystem. This suggests a strategic evolution where Copilot Pro is not only a standalone offering but increasingly integrated into the broader AI-first positioning of Microsoft's productivity suite.",
      "llm_answer": "\nBetween FY 2023 and FY 2024 Microsoft moved Copilot Pro from a newly‑launched consumer add‑on to a central element of its AI‑first strategy. In 2023 it was introduced as a subscription service that “offers faster and more powerful AI assistance in Microsoft 365 apps and on the web,” positioning it as an optional enhancement to the broader Copilot stack. By 2024 the company emphasized Copilot Pro as a core part of the Microsoft 365 experience, highlighting its role in delivering rapid AI‑driven assistance across Office, Windows, Edge and Bing, and supporting expanded capabilities such as role‑specific Copilot extensions and the Copilot Studio customization platform.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: Copilot Pro was introduced in 2023 as a consumer subscription offering 'faster and more powerful AI assistance in Microsoft 365 apps and on the web,' and by 2024, its positioning evolved to be more central within Microsoft's AI strategy. The LLM correctly retains the key quoted phrase and accurately describes the shift from an optional add-on to a core component of Microsoft 365 and broader ecosystem. (2) There are no numeric values, dates, or financial figures in the question or answer that require verification—timeframes (FY2023, FY2024) are consistent with the original answer and appropriately contextualized. (3) The multi-hop reasoning is sound: the model synthesizes the evolution of Copilot Pro across two years, correctly identifying its changing role from a standalone service to an integrated, strategic offering, including expanded capabilities like role-specific extensions and Copilot Studio—details that align with Microsoft’s public messaging in 2024. (4) The only minor gap is that the original answer emphasizes the 'broader narrative of AI-driven transformation' more explicitly, while the LLM focuses on product integration; however, this is a nuance in framing, not a factual error. The LLM adds value by naming specific platforms (Windows, Edge, Bing, Copilot Studio), which are contextually accurate and enhance completeness. Overall, the answer is factually correct, comprehensive, and contextually precise—justifying a 9/10 due to slight difference in emphasis on strategic narrative vs. feature integration.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 449,
        "total_tokens": 1792
      },
      "error": null
    },
    {
      "question_id": 164,
      "question": "How has the structure and availability of the 2007 Omnibus Incentive Plan evolved between 2023 and 2024, particularly in terms of remaining shares available for issuance?",
      "original_answer": "In 2023, the 2007 Omnibus Incentive Plan was described in the context of PSU and RSU awards, vesting conditions, and valuation methods, but no specific figure was provided regarding the remaining shares available for issuance. In contrast, by 2024, the plan explicitly stated that approximately 47 million shares of Danaher common stock remained available for issuance under the plan as of December 31, 2024 (excluding shares underlying outstanding awards). This indicates a more transparent disclosure and potential depletion or tracking of the share pool since the plan's inception, showing a shift in how the company communicates the availability of shares under the plan.",
      "llm_answer": "\nThe 2007 Omnibus Incentive Plan continues to govern all equity‑based awards (stock options, RSUs, PSUs, etc.), with the same 135 million‑share authorization that has been in place for years.  However, the pool of shares that remained **available for future issuance** dropped modestly—from **≈ 50 million shares at the end of 2023** to **≈ 47 million shares at the end of 2024**—reflecting the shares that were allocated to new grants and other plan activity during 2024.  No structural changes to the plan itself were disclosed; the reduction is simply a net result of the awards issued under the plan over the two years.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer contains a mix of accurate and inaccurate information. (1) Quantitatively, the LLM claims that approximately 50 million shares were available at the end of 2023, but the ground truth states that no specific figure was provided for 2023—only qualitative descriptions of PSU/RSU awards and vesting. This is a significant factual error. The 47 million shares available as of December 31, 2024, matches the ground truth and is correctly reported. (2) The LLM asserts a 'modest drop' from ~50M to ~47M due to 2024 award activity, implying precise tracking and disclosure in both years, which contradicts the original answer stating no 2023 availability number was disclosed. This introduces a false comparison. (3) The claim of a '135 million-share authorization' is not mentioned in the ground truth and cannot be verified from the provided information, making it an unsupported addition. (4) Qualitatively, the LLM correctly identifies that the plan structure remained unchanged and that equity awards (RSUs, PSUs) are still governed under the plan, showing proper understanding of continuity. It also correctly notes increased transparency in 2024, aligning with the ground truth's emphasis on more explicit disclosure. (5) Contextually, the response addresses the evolution of share availability and plan structure, directly engaging with the question’s focus. However, the unsupported numerical estimate for 2023 undermines the correctness score. While the direction of change (decrease) is plausible, the basis for the 50M figure is not grounded in the source data, making the quantitative accuracy low despite one correct number.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 447,
        "total_tokens": 1778
      },
      "error": null
    },
    {
      "question_id": 165,
      "question": "How did Microsoft's accounting policy regarding the estimated useful lives of server and network equipment evolve between fiscal years 2023 and 2024, and what factors influenced this change?",
      "original_answer": "In fiscal year 2023, Microsoft increased the estimated useful lives of server and network equipment from four years to six years, effective beginning fiscal year 2023. This change was driven by investments in software that improved operational efficiencies and advances in technology. In fiscal year 2024, the policy remained consistent with the updated six-year estimate, indicating that the initial change was sustained and likely integrated into ongoing asset management practices. The continued focus on cloud and AI infrastructure investments further supported the rationale behind extending the useful lives of these assets.",
      "llm_answer": "\nMicrosoft revised its accounting estimate in July 2022, extending the estimated useful lives of server and network equipment from **four years to six years**, and this change became effective at the start of fiscal 2023. The revision was driven by greater software‑enabled efficiencies in operating that hardware and advances in technology that made the equipment’s functional lifespan longer. No further alteration to the policy was disclosed for fiscal 2024, so the six‑year estimate remained in effect during that year.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) It correctly states that Microsoft extended the estimated useful lives of server and network equipment from four to six years, effective at the start of fiscal year 2023, aligning with the original answer. The mention of July 2022 as the revision date is consistent with the fiscal timing (fiscal year 2023 begins July 1, 2022), so this detail is accurate and adds precision. (2) All quantitative elements—'four years to six years'—are correct, and no calculations are required. (3) The reasoning for the change—software-enabled efficiencies and technological advances—is accurately reflected, and the answer correctly notes no further changes in fiscal 2024, indicating policy continuity, which matches the original answer's claim of sustained policy. (4) The response fully addresses both parts of the question: the evolution between 2023 and 2024 and the influencing factors. Multi-hop synthesis is sound, connecting the timing, policy change, rationale, and continuity. Wording differs slightly but conveys the same meaning. All evaluation dimensions are fully satisfied.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 328,
        "total_tokens": 1627
      },
      "error": null
    },
    {
      "question_id": 165,
      "question": "How did MDT's exposure to auction rate securities evolve from 2022 to 2023 in terms of fair value and classification within the balance sheet?",
      "original_answer": "In 2022, MDT reported auction rate securities with a fair value of $33 million and classified them under 'Total' in the investment portfolio without specifying a separate balance sheet classification. By 2023, the fair value of auction rate securities remained at $33 million, but they were explicitly classified under 'Other Assets' instead of being included in the broader investment category. This indicates a shift in how MDT categorized these securities on its balance sheet, moving from a general investment classification to a more distinct reporting under other assets.",
      "llm_answer": "\nFrom fiscal 2022 to fiscal 2023 Medtronic’s holdings of auction‑rate securities showed virtually no change in fair‑value – the securities were valued at **$33 million** in both years.  In each year the $33 million was recorded in the **“Other Assets”** line of the consolidated balance sheet and classified as **Level 3** in the fair‑value hierarchy.  Thus, the company’s exposure to ARS remained minimal and stayed classified as Level‑3 other assets throughout the period.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly reports the fair value of auction rate securities as $33 million in both 2022 and 2023, satisfying quantitative accuracy. However, it is factually incorrect regarding the balance sheet classification: the original answer states that in 2022, the securities were included under 'Total' in the investment portfolio without a separate classification, whereas the LLM claims they were already classified under 'Other Assets' in both years. This misrepresents a key evolution in classification—the shift from being part of the general investment category in 2022 to being explicitly reported under 'Other Assets' in 2023. The LLM also incorrectly asserts that the classification was consistently 'Other Assets' and Level 3 in both years, which contradicts the ground truth. While the answer addresses the question's focus on fair value and classification, it fails in the multi-hop reasoning required to identify the change in treatment over time. The contextual relevance is high because it discusses the right metric and time frame, but the qualitative inaccuracy in entity classification and reporting evolution significantly undermines the correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1261,
        "completion_tokens": 330,
        "total_tokens": 1592
      },
      "error": null
    },
    {
      "question_id": 167,
      "question": "How did the net gains or losses from Cisco's available-for-sale debt investments change between fiscal years 2023 and 2024, and what does this indicate about the company's investment performance in this category?",
      "original_answer": "In fiscal year 2023, Cisco reported a net loss of $21 million from its available-for-sale debt investments, while in fiscal year 2024, this loss increased to $67 million. This indicates a significant worsening in investment performance related to this category year-over-year.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 the unrealized result on Cisco’s available‑for‑sale debt investments moved from a modest loss of **$21 million in 2023 to a loss of $67 million in 2024**, worsening by roughly **$46 million**. This deterioration—driven by higher market interest rates that reduced the fair value of the securities—shows that the company’s investment performance in this category weakened, turning a relatively small loss into a significantly larger unrealized loss.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the net losses for both fiscal years—$21 million in 2023 and $67 million in 2024—matching the ground truth exactly. The calculated increase in loss of $46 million ($67M - $21M) is accurate. (2) All numeric values and the year-over-year comparison are factually correct, with acceptable formatting (e.g., $21 million vs $21M). (3) The reasoning is sound: the answer correctly synthesizes the change in performance across two fiscal years and attributes the worsening to market interest rate impacts, which aligns with typical financial drivers for available-for-sale debt securities. While the ground truth does not include the cause (interest rates), the LLM adds plausible context without contradicting facts. (4) The answer fully addresses both parts of the question—quantitative change and performance implication—with high accuracy. The only minor point preventing a perfect 10 is the addition of explanatory context (interest rates) not present in the ground truth, which, while reasonable, slightly exceeds the provided data. However, it does not detract from correctness. Thus, scores are high across all categories, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1206,
        "completion_tokens": 348,
        "total_tokens": 1554
      },
      "error": null
    },
    {
      "question_id": 170,
      "question": "How did Cisco's approach to the APJC region evolve between 2023 and 2024 in terms of operational structure versus financial investment, and what implications does this have for its revenue model in that region?",
      "original_answer": "In 2023, Cisco directly operated in the APJC region as one of its three geographic segments, indicating a strong operational presence focused on delivering products and services. By 2024, Cisco's relationship with APJC evolved to include financial investments, specifically through equity instruments categorized as marketable equity securities, non-marketable equity securities, and equity method investments. While the 2023 filing emphasized operational delivery and customer engagement in APJC, the 2024 financial statements suggest a parallel strategy of capital participation, potentially signaling a shift toward leveraging local market growth through investment rather than solely through direct sales. This dual approach could indicate a broader revenue model incorporating both operational income and investment returns, though the filings do not quantify the specific financial impact of these investments on Cisco's APJC revenue.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 Cisco moved its APJC business from a capital‑intensive, infrastructure‑building model—focused on expanding localized hardware, channel partnerships and data‑center capacity—to a more integrated, platform‑centric structure that emphasizes software, AI and subscription‑based services.  This re‑allocation of financial investment shifts the region’s revenue mix from a product‑sale‑driven base to a higher‑margin, recurring‑revenue model centered on subscriptions and services.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and fails to align with the ground truth. (1) It claims Cisco shifted from a 'capital-intensive, infrastructure-building model' to a 'platform-centric structure' emphasizing software, AI, and subscriptions between 2023 and 2024. However, the original answer states that Cisco directly operated in APJC in 2023 and in 2024 began making financial investments (marketable and non-marketable equity securities, equity method investments), not a shift in operational model toward software and subscriptions. There is no mention in the ground truth of AI, platform-centric restructuring, or changes in revenue mix toward subscriptions. (2) No numeric data (e.g., investment amounts, revenue figures) are present in either the original or LLM answer, so quantitative accuracy cannot be penalized for missing numbers, but the LLM invents a narrative unsupported by data. (3) The multi-hop reasoning is flawed: the question asks about evolution in operational structure vs. financial investment, but the LLM conflates operational changes with financial ones and introduces unverified strategic shifts. The ground truth highlights a dual-track evolution—continued operations plus new financial investments—not a replacement of one model with another. (4) The LLM answer is contextually relevant in that it discusses Cisco's APJC strategy and revenue model, but the substance is factually inaccurate. It misses the key point about equity investments in 2024 and misrepresents the nature of Cisco’s strategic evolution. Thus, while the topic is addressed, the factual core is incorrect, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 447,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 172,
      "question": "How has Apple's approach to App Store commissions and regulatory compliance evolved between 2022 and 2024, particularly in response to legal and market pressures?",
      "original_answer": "In 2022, Apple acknowledged that changes to the App Store, including those in response to legal and market conditions, could reduce the volume of sales and the commission it earns on those sales, potentially affecting its financial condition. By 2024, Apple had implemented specific changes, particularly in the U.S. and the European Union, to address legal pressures such as the Digital Markets Act (DMA). These changes included new business terms, alternative fee structures, alternative app distribution methods, and additional developer tools and APIs. These adjustments reflect a shift from a more general acknowledgment of potential changes to concrete actions taken in response to regulatory demands, which could significantly affect App Store revenue and commission structures.",
      "llm_answer": "\nApple’s App Store policy has shifted from a largely fixed 30 % commission to a more flexible, compliance‑driven model.  In the 2022 filing the company noted that it “may make further business changes … in response to competition, market and legal conditions” and that EU‑level initiatives such as the Digital Markets Act could force new fee and distribution rules.  By the 2024 filing Apple details concrete changes—alternative payment processing, new fee structures and distribution options for iOS/iPadOS apps in the EU, and adjustments to how U.S. developers can communicate external purchasing options—showing that it is actively reshaping its commission and platform rules to meet legal pressures while trying to preserve revenue.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies Apple's shift from a general acknowledgment in 2022 about potential App Store changes due to legal and market pressures to concrete actions by 2024. The mention of the Digital Markets Act (DMA) and its impact on EU-specific changes is factually correct. (2) Quantitatively, while no specific dollar amounts or exact percentages beyond the standard 30% commission are cited in either answer, the LLM correctly references the 30% rate as the baseline, which is consistent with known App Store policies. There are no numerical inaccuracies. (3) The multi-hop reasoning is sound: the LLM synthesizes information across years (2022 to 2024), regions (U.S. and EU), and regulatory frameworks (DMA), correctly tracing the evolution from risk disclosure to implementation of alternative payment systems, fee structures, and distribution methods. It accurately notes U.S. policy adjustments around external purchasing communications, which reflects real changes like those following the Epic Games lawsuit. (4) The only minor shortcoming is that the LLM does not explicitly mention 'developer tools and APIs' as part of the 2024 changes, which is included in the original answer and represents a small omission in completeness. However, this does not detract significantly from the overall correctness. The answer is contextually excellent, directly addressing the evolution of commission and compliance strategies in response to legal and market pressures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1384,
        "completion_tokens": 424,
        "total_tokens": 1808
      },
      "error": null
    },
    {
      "question_id": 175,
      "question": "How did the allocation strategy for Texas Instruments' U.S. Retiree Health Care Plan evolve between fixed income securities and equity securities from 2022 to 2024?",
      "original_answer": "In 2022, the U.S. Retiree Health Care Plan had a diversified mix of fixed income securities and equity securities, with fixed income and cash equivalents totaling $248 million and equity securities at $137 million. By 2024, the allocation strategy showed a significant shift toward a more conservative posture, with fixed income securities and cash equivalents comprising 80% of the portfolio, while equity securities made up only 20%. This reflects a notable increase in emphasis on fixed income securities compared to equities, even though the relative proportions remained the same between 2023 and 2024, suggesting a strategic decision to prioritize capital preservation.",
      "llm_answer": "\nBetween 2022 and the end of 2024 the U.S. retiree‑health‑care plan shifted markedly toward a larger fixed‑income allocation and a smaller equity exposure.  In the 2020‑21 periods the plan held about 65 % of its assets in fixed‑income securities and roughly 35 % in equity (e.g., $251 million fixed‑income vs. $138 million equity in 2020).  By the 2024 reporting year the allocation had changed to roughly 80 % fixed‑income (≈$198 million of the $248 million total) and only 20 % equity (≈$50 million), indicating a clear move away from equities and toward a more conservative, bond‑heavy asset mix.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "(1) The LLM answer contains significant factual inaccuracies, particularly in the numerical data and time periods. It incorrectly references 2020-2021 data (e.g., $251M fixed income, $138M equity) which is not part of the original question or ground truth. The actual data starts in 2022 with $248M in fixed income and cash equivalents and $137M in equities. The 2024 allocation percentages (80% fixed income, 20% equity) are correctly stated, but the dollar amounts are wrong: the LLM claims fixed income is ≈$198M of a $248M total, implying a total portfolio of $248M, but this contradicts the 2022 total of $385M ($248M + $137M) and fails to provide updated 2024 total assets. The implied 2024 equity value of ≈$50M conflicts with the proportional logic if 20% equals $50M (total would be $250M), which is inconsistent with prior year totals. (2) Quantitative accuracy is low: the 2022 numbers are misstated (uses 2020-like figures), and 2024 dollar amounts are fabricated or miscalculated. The ground truth does not specify exact 2024 dollar values, only percentages, so assigning $198M and $50M is speculative and incorrect. The shift from 65/35 to 80/20 is not supported by the original answer, which only provides 2022 absolute values and 2024 percentages. (3) Qualitatively, the reasoning captures the correct directional shift—toward a more conservative, fixed-income-heavy strategy—and identifies the multi-hop evolution from a mixed portfolio to a 80/20 split favoring fixed income. However, it introduces unsupported data points (2020–2021) and misrepresents the timeline. The core insight about increased conservatism is valid, but based on flawed premises. (4) Contextual relevance is high because the answer addresses the allocation evolution and interprets the strategic shift correctly in spirit, despite factual errors. Overall, partial credit is given for correct interpretation of the trend, but major deductions for incorrect numbers, dates, and fabricated calculations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 533,
        "total_tokens": 1856
      },
      "error": null
    },
    {
      "question_id": 177,
      "question": "How has Texas Instruments' strategic emphasis on Embedded Processing Products evolved from 2022 to 2024, particularly in terms of its contribution to the company's competitive advantages and segment reporting structure?",
      "original_answer": "In 2022, Texas Instruments described Embedded Processing as one of its core product lines within a broader business model that emphasized four competitive advantages: manufacturing and technology strength, a broad product portfolio, strong market channels, and product diversity and longevity. Embedded Processing was positioned as part of this integrated strategy but was not highlighted as a standalone reportable segment. By 2024, Embedded Processing was elevated to a reportable segment alongside Analog, indicating a strategic shift where the company explicitly called out Embedded Processing as a key driver of value. This change suggests that Embedded Processing has become more central to TI's competitive positioning, particularly in terms of enabling optimized performance, power, and cost across a range of customer applications. The elevation to a reportable segment also implies greater operational and financial focus, aligning with the company’s long-term objective of strengthening its competitive advantages and driving free cash flow growth.",
      "llm_answer": "\nFrom 2022 through 2024 Texas Instruments has kept Embedded Processing as a separate reportable segment and continues to treat it as a core growth pillar—especially in the industrial and automotive end‑markets—leveraging its manufacturing scale, broad product portfolio, market reach and long‑life product diversity to sustain a competitive advantage.  While the segment’s revenue peaked at $3.26 billion in 2022, rose to $3.37 billion in 2023 and slipped to $2.53 billion in 2024, its operating‑profit share (reported separately from Analog) remained a key metric the CODM uses to allocate capital and measure performance, underscoring how Embedded Processing continues to contribute to TI’s overall free‑cash‑flow‑driven strategy despite a modest decline in absolute profitability in 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. Most critically, it incorrectly states that Embedded Processing was a 'separate reportable segment' from 2022 onward, while the ground truth confirms it was not a reportable segment in 2022 and only became one in 2024—this is a fundamental error that misrepresents TI's strategic evolution. (2) The financial figures provided—$3.26B in 2022, $3.37B in 2023, $2.53B in 2024—are not supported by the ground truth, which does not include any revenue numbers for Embedded Processing. Since these numbers are fabricated or incorrect, quantitative accuracy is very low. There are no calculations in the ground truth to verify, but the use of precise dollar amounts implies a level of reporting that contradicts the original answer. (3) The multi-hop reasoning is flawed: the key insight in the ground truth is the structural change in segment reporting as evidence of strategic elevation, but the LLM assumes this structure existed throughout the period, missing the shift entirely. It also incorrectly claims operating profit was reported separately from Analog during this time, which contradicts the fact that Embedded Processing was not a reportable segment until 2024. (4) While the LLM correctly identifies industrial and automotive markets and references TI’s competitive advantages (manufacturing scale, product diversity, etc.), these correct elements are overshadowed by the central factual error about segment reporting. The answer is contextually relevant in topic and direction but fails on correctness due to false precision and incorrect structural claims. Thus, the correctness score is low despite some thematic alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1480,
        "completion_tokens": 465,
        "total_tokens": 1946
      },
      "error": null
    },
    {
      "question_id": 177,
      "question": "How did TMO's issuance and valuation of its 2.00% 10-Year Senior Notes evolve between 2022 and 2024?",
      "original_answer": "In 2022, TMO reported $1,200 million in 2.00% 10-Year Senior Notes due on October 15, 2031, with an effective interest rate of 2.23%. By 2024, the same category of 2.00% 10-Year Senior Notes showed no change in the principal amount at $1,200 million, and the effective interest rate remained at 2.23%. This indicates that TMO maintained a consistent position on this specific debt instrument over the two-year period, with no new issuances or repayments affecting this line item.",
      "llm_answer": "\nBetween 2022 and 2024 Thermo Fisher issued a $1.2 billion 2.00 % 10‑Year Senior Note (euro‑denominated, maturing 10/15/2031) and kept the entire issue outstanding.  The note’s carrying amount remained essentially unchanged—$1.20 billion at both 31 Dec 2023 and 31 Dec 2024—while its effective interest rate rose modestly from roughly 2.1 % (when first issued) to 2.23 % by the end of 2024 as the discount and issuance costs were amortized.  No redemption or additional issuance of this specific series occurred during the period, so its valuation stayed flat on the balance sheet.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer contains several correct elements but also significant inaccuracies that affect the overall correctness. (1) Quantitative Accuracy: The principal amount of $1.2 billion (or $1,200 million) is correct and consistent with the ground truth, as is the maturity date (October 15, 2031). However, the LLM incorrectly states that the effective interest rate rose from 'roughly 2.1%' to 2.23%, while the ground truth indicates the effective rate was already 2.23% in 2022 and remained unchanged through 2024. There is no mention of a change in the effective rate over time in the original answer, so this is a factual error. Additionally, the LLM introduces the detail that the note is 'euro-denominated', which is not present in the original answer and cannot be verified from the provided truth. (2) Completeness: The answer addresses the issuance and valuation over time, noting no new issuances or redemptions, which aligns with the original. However, it misrepresents the timeline of the interest rate, implying evolution where there was stability. (3) Entity Accuracy: TMO (Thermo Fisher) is correctly identified, and the debt instrument is accurately described in terms of coupon (2.00%), term (10-Year), and maturity. The years 2022–2024 are appropriately covered. (4) Reasoning: The multi-hop reasoning is partially sound—synthesizing balance sheet stability and amortization effects—but incorrectly infers a change in effective interest rate, undermining the conclusion about valuation evolution. (5) Semantic Equivalence: While the core idea of a stable principal is correct, the erroneous interest rate trajectory and unverified euro-denomination reduce factual alignment. The original emphasizes consistency in both principal and effective rate, which the LLM contradicts. Thus, despite relevant structure and partial accuracy, key financial details are incorrect, warranting a moderate score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1253,
        "completion_tokens": 514,
        "total_tokens": 1767
      },
      "error": null
    },
    {
      "question_id": 178,
      "question": "How has the financial performance of REMICADE evolved between 2022 and 2024, and what does this indicate about its role in Johnson & Johnson's Pharmaceutical segment?",
      "original_answer": "In 2022, REMICADE was listed as a key product in Johnson & Johnson's Pharmaceutical segment, specifically within the Immunology therapeutic area, indicating its importance in treating immune-mediated inflammatory diseases. By 2024, REMICADE's sales had declined significantly, from $1,839 million in 2023 to $1,605 million in 2024, representing a 12.8% decrease. This decline suggests a diminishing contribution of REMICADE to the company's Immunology revenue, potentially due to market saturation, increased competition, or the emergence of newer biologics within the segment.",
      "llm_answer": "\nBetween 2022 and 2024 REMICADE’s sales fell from roughly $1.9 billion to $1.6 billion— a 12.8 % decline from 2023 to 2024 and a continued downward trend that began in 2022—driven by biosimilar competition and pricing pressure. This erosion shows that, while REMICADE remains a sizable contributor to Johnson & Johnson’s Pharmaceutical segment, its growth contribution is diminishing as newer immunology and oncology products (e.g., STELARA, TREMFYA, CARVYKTI) now drive the segment’s overall expansion.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the declining sales trend of REMICADE from $1.9 billion (approximation of $1,839 million in 2023) to $1.6 billion in 2024, and accurately reports the 12.8% decline from 2023 to 2024, matching the ground truth. The slight rounding of $1,839 million to $1.9 billion is acceptable under semantic equivalence. (2) Quantitatively, the key figures—$1.6 billion in 2024 sales, 12.8% decline—are correct. The calculation of the percentage decline aligns with the ground truth (from $1,839M to $1,605M is indeed ~12.8%). However, the LLM references 2022 sales as part of a 'downward trend' but does not provide a specific 2022 figure, which is a minor omission since the ground truth does not specify 2022 sales either—only that it was a key product. (3) The multi-hop reasoning is sound: the LLM correctly situates REMICADE within Johnson & Johnson’s Pharmaceutical segment, identifies its therapeutic context (implied via immunology), and explains the decline in terms of biosimilar competition and pricing pressure—consistent with typical market dynamics. It further synthesizes the impact on the broader segment by noting the shift toward newer products like STELARA, TREMFYA, and CARVYKTI, which is a reasonable inference supported by J&J’s public reporting. (4) The answer is contextually excellent, addressing both parts of the question: the financial evolution and the implication for J&J’s pharmaceutical segment. The only reason for not scoring a 10 is the slight rounding without explicit acknowledgment, though this is minor and common in financial summarization. Overall, the answer is factually accurate, well-reasoned, and comprehensive.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 462,
        "total_tokens": 1737
      },
      "error": null
    },
    {
      "question_id": 179,
      "question": "How did the sales performance of REMICADE evolve from 2022 to 2024, and what does this indicate about its market position within JNJ's Immunology portfolio?",
      "original_answer": "In 2022, REMICADE had sales of $3,190 million, showing a decline of 14.9% compared to 2020. By 2024, its sales had further decreased to $1,605 million, representing a 12.8% drop from 2023. This consistent decline indicates a weakening market position of REMICADE within JNJ's Immunology portfolio over time.",
      "llm_answer": "\nFrom 2022 through 2024 REMICADE’s sales fell sharply—from roughly **$3.5 billion in 2022 to about $1.6 billion in 2024**, a decline of more than 50 % in just two years.  This continued erosion, driven by biosimilar competition and loss of market share, has relegated REMICADE to a minor component of J&J’s Immunology portfolio, where growth now comes primarily from newer agents such as **STELARA and TREMFYA**.  Consequently, REMICADE’s position within the Immunology franchise is rapidly diminishing, underscoring a shift toward newer, higher‑growth products.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the declining sales trend of REMICADE from 2022 to 2024 and attributes it to biosimilar competition and loss of market share, which aligns with the ground truth. It also accurately contextualizes REMICADE's diminishing role within J&J's Immunology portfolio and contrasts it with growth from newer products like STELARA and TREMFYA, which is relevant and correct. However, the sales figures are slightly inaccurate: the ground truth reports $3,190 million (i.e., $3.19 billion) in 2022, while the LLM states 'roughly $3.5 billion', which is a notable overstatement (~9.7% higher). The 2024 figure of $1,605 million is correctly approximated as $1.6 billion. 2) The percentage decline calculation is flawed: the LLM claims 'more than 50% decline in two years'. Actual decline from $3,190M to $1,605M is (3,190 - 1,605)/3,190 ≈ 49.7%, which is just under 50%, so 'more than 50%' is incorrect. Additionally, the ground truth includes a 14.9% decline from 2020 to 2022 and a 12.8% drop from 2023 to 2024, which the LLM omits—these are important multi-year data points for assessing evolution. 3) The reasoning is sound in interpreting the trend and market dynamics, and the synthesis of REMICADE's weakening position relative to other J&J immunology drugs is valid and insightful, showing good qualitative multi-hop reasoning. 4) Despite minor numerical inaccuracies and missing specific year-over-year percentages, the overall direction and conclusion are correct. The answer is contextually excellent, directly addressing both parts of the question—sales evolution and market position—with relevant supporting logic. Hence, correctness is reduced mainly due to quantitative inaccuracies, but not severely due to semantic proximity and correct trend interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1219,
        "completion_tokens": 486,
        "total_tokens": 1706
      },
      "error": null
    },
    {
      "question_id": 180,
      "question": "How has the sales performance of REMICADE evolved between 2021 and 2024, and what factors contributed to this change?",
      "original_answer": "REMICADE's sales declined significantly from $16.8 billion in 2021 (as part of total Immunology sales) to $1,605 million in 2024, reflecting a 12.8% decrease from 2023 to 2024 alone. This decline was primarily driven by biosimilar competition in the U.S. and other global markets, which intensified over time and led to a continued reduction in REMICADE sales.",
      "llm_answer": "\nBetween 2021 and 2024 REMICADE’s worldwide sales collapsed from **$3.19 billion to $1.61 billion** – a roughly **50 % decline** over the three‑year span (a 14.9 % drop in 2021 and an additional 12.8 % drop from 2023 to 2024).  The slide is attributed mainly to **biosimilar competition for infliximab**, the expiration of patent exclusivity, and continued market‑share losses (especially in Europe) as newer immunology agents (e.g., STELARA and TREMFYA) and biosimilars entered the market, outweighing any residual demand for REMICADE.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key financial figures. The original answer states that REMICADE's sales were $16.8 billion in 2021 as part of total Immunology sales, but the LLM incorrectly reports $3.19 billion as REMICADE's standalone sales in 2021. This is a major error, as $16.8 billion refers to total Immunology portfolio sales (which includes REMICADE and other drugs), not REMICADE alone. Additionally, the LLM claims a 50% decline over three years and cites a 14.9% drop in 2021, which is not supported by the ground truth. The only correct quantitative figure is the 12.8% decline from 2023 to 2024 and the $1.61 billion (approximating $1,605 million) in 2024 sales. (2) Calculations are partially correct: the 12.8% year-on-year drop matches, and $1.61 billion is close to the actual $1,605 million. However, the starting value of $3.19 billion in 2021 is unsupported and leads to an exaggerated 50% decline narrative. (3) The qualitative reasoning about biosimilar competition, patent expiration, and market share losses—especially in Europe—is consistent with the ground truth and correctly identifies the primary drivers of decline. Mention of newer agents like STELARA and TREMFYA adds context not in the original but is plausible and relevant. (4) The contextual relevance is high because the answer addresses both parts of the question—sales evolution and contributing factors—and attempts multi-hop synthesis. However, the core quantitative inaccuracy in the 2021 figure severely undermines the correctness score. The qualitative accuracy is moderate due to correct causal reasoning despite incorrect baseline numbers. Quantitative accuracy is low due to the incorrect initial sales figure and unsupported percentage drops.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1216,
        "completion_tokens": 485,
        "total_tokens": 1701
      },
      "error": null
    },
    {
      "question_id": 181,
      "question": "How did the status and commercial performance of STELARA (ustekinumab) evolve between 2022 and 2024?",
      "original_answer": "In 2022, STELARA was in the filing stage for the treatment of pediatric patients with juvenile psoriatic arthritis in the U.S., indicating it was under regulatory review but not yet approved. By 2024, STELARA had achieved significant commercial success, generating $10,361 million in sales, a decrease from $10,858 million in 2023, representing a 4.6% decline in total sales. This reflects that STELARA had transitioned from a product in active regulatory development to a mature, high-revenue-generating drug facing slight sales decline, suggesting market saturation or increased competition.",
      "llm_answer": "\nBetween 2022 and 2024 STELARA’s market position eroded as its U.S. patent expired in September 2023, prompting a sharp slowdown in growth and the first sales declines. In fiscal 2024 the drug’s worldwide Immunology sales fell 4.6 % (with STELARA down 4.6 % YoY), U.S. sales slipped to roughly $6.7 billion, and European performance was hit hardest by the entry of biosimilar versions—an trend the Company expects to intensify in 2025 when biosimilars are slated to launch in both the United States and Europe. Consequently, STELARA transitioned from a growth‑driven flagship therapy to a product facing mounting biosimilar competition and modest, downward commercial momentum.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies a 4.6% year-over-year decline in STELARA sales in 2024, which matches the ground truth (from $10,858M to $10,361M, a 4.6% drop). However, it introduces new information not present in the ground truth—specifically, the U.S. patent expiration in September 2023 and the entry of biosimilars in Europe and upcoming in the U.S.—which, while plausible, is not supported by the provided knowledge graph. The LLM also cites U.S. sales of approximately $6.7 billion, a figure not present in the original answer and unverifiable against the ground truth, which reports total global sales of $10,361 million in 2024. (2) The 4.6% decline is accurately reflected, but the breakdown into U.S. and European performance lacks corroboration from the original answer, which only provides total global sales. The $6.7 billion U.S. figure implies about 65% of global sales, but without confirmation, this introduces quantitative inaccuracy. (3) The reasoning about STELARA transitioning from a growth-phase to a decline-phase product due to biosimilar competition is logically sound and aligns with the ground truth’s implication of market saturation or competition. However, the original answer emphasizes regulatory progress in 2022 (filing for pediatric use) and commercial maturity in 2024, which the LLM omits entirely—missing a key multi-hop element of status evolution. (4) The contextual relevance is high because the answer addresses the commercial performance trend and evolution of STELARA. However, the correctness score is reduced due to unsupported specifics (patent expiry, regional sales splits) and omission of the 2022 regulatory status, which was a core part of the original answer. While the 4.6% decline is correctly stated, the absence of the $10,361M global sales figure and the introduction of unverified data lower quantitative and overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 516,
        "total_tokens": 1822
      },
      "error": null
    },
    {
      "question_id": 182,
      "question": "How did the total net revenue from Restasis in the United States change between 2023 and 2024, and what was the percentage decrease in each year?",
      "original_answer": "In 2023, the United States net revenue from Restasis was $382 million, which decreased to $172 million in 2024. This represents a 38.5% decrease in 2023 compared to 2022, and a further 55.2% decrease in 2024 compared to 2023.",
      "llm_answer": "\nThe U.S. Restasis net revenue fell from **$382 million in 2023 to $172 million in 2024**, a **55.2 % decrease** in 2024.  In the prior year it had dropped from **$621 million in 2022 to $382 million in 2023**, a **38.5 % decline** in 2023.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: $382 million in 2023 and $172 million in 2024 are correctly reported. The percentage decreases are also correct—38.5% decrease in 2023 (from $621M in 2022 to $382M in 2023) and a 55.2% decrease in 2024 (from $382M to $172M). The LLM correctly infers the 2022 value ($621M) to compute the 2023 percentage change, which is necessary for multi-hop reasoning. (2) The answer is complete, addressing both parts of the question: the change in total net revenue between 2023 and 2024, and the percentage decrease in each year. (3) Entity accuracy is perfect—Restasis, United States net revenue, and correct years (2022, 2023, 2024) are all properly identified. (4) The reasoning is sound and demonstrates correct multi-hop synthesis by referencing prior year data (2022) to compute the 2023 percentage decrease, even though the question only explicitly asks about 2023–2024 changes. This shows deeper understanding. (5) The semantic meaning is equivalent to the original answer, with slightly more detail (explicit mention of 2022 revenue), which enhances clarity without introducing error. All scores are 10 due to full factual accuracy, correct calculations, proper entity and time period identification, and logical, complete reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1116,
        "completion_tokens": 375,
        "total_tokens": 1491
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has the role and strategic importance of Master Lease Agreements evolved between 2022 and 2023 in supporting AMT's international growth and tenant relationships?",
      "original_answer": "In 2022, AMT emphasized that master lease agreements were comprehensive in nature and instrumental in building strong strategic partnerships with tenants, significantly reducing colocation cycle times and enabling rapid deployment of equipment across its international portfolio of approximately 177,000 communications sites. By 2023, AMT reiterated the importance of these agreements in providing consistent, long-term revenue and reducing non-contractual churn, while operating an expanded international portfolio of approximately 182,000 communications sites. The evolution reflects a continued strategic focus on leveraging master lease agreements to support international growth and tenant retention, with an emphasis on mitigating risks such as customer consolidation and regulatory changes.",
      "llm_answer": "\nBetween 2022 and 2023 the Master Lease Agreements (MLAs) moved from being a general tool for securing long‑term, stable revenue and limiting non‑contractual churn to a core strategic platform that underpins AMT’s international expansion and tenant‑relationship model.  The 2022 disclosures highlighted that comprehensive MLAs “reduce the likelihood of non‑contractual churn” and “significantly reduce colocation cycle times,” enabling carriers to deploy equipment quickly; by 2023 the same language was paired with explicit references to how these agreements “provide consistent, long‑term revenue” and “build strong strategic partnerships” that support growth in emerging markets, diversify exposure, and offset churn in mature regions (e.g., the elevated churn expected from T‑Mobile/Sprint in the U.S. & Canada).  Consequently, MLAs are now positioned not only to protect revenue but also to accelerate site utilization and facilitate new tenant relationships across AMT’s global portfolio, making them a pivotal driver of both international market entry and sustained tenant engagement.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: the strategic role of Master Lease Agreements (MLAs) in reducing colocation cycle times, enabling rapid deployment, supporting long-term revenue, and reducing non-contractual churn is accurately reflected for both 2022 and 2023. The expansion of AMT’s international portfolio from ~177,000 to ~182,000 sites is contextually implied through the discussion of international growth, though the exact numbers are not explicitly cited—this is the only minor omission. (2) Quantitative accuracy is strong: no incorrect numbers are presented, and while the exact site counts (177k in 2022, 182k in 2023) are not mentioned, the LLM correctly infers portfolio growth and international expansion without fabricating data. (3) Multi-hop reasoning is sound: the model synthesizes the evolving strategic emphasis—from operational efficiency (2022) to revenue stability and international market entry (2023)—and correctly links MLAs to mitigating risks like customer consolidation (e.g., T-Mobile/Sprint churn), which aligns with the ground truth’s mention of regulatory and consolidation risks. (4) Semantic equivalence is maintained: the LLM uses different but equivalent phrasing (e.g., 'core strategic platform' vs. 'pivotal driver') and expands slightly with plausible context (e.g., emerging vs. mature markets), but does not introduce inaccuracies. The answer is fully relevant and addresses all aspects of the question. The 9/10 correctness score reflects the omission of the precise site numbers, which were present in the original answer but not critical to the core evolution narrative.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1476,
        "completion_tokens": 458,
        "total_tokens": 1935
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has the role of Google Marketing Platform in the company's advertising revenue generation evolved between 2023 and 2024, particularly in relation to how advertising revenues are recognized and managed across Google Network properties?",
      "original_answer": "In 2023, Google Marketing Platform was directly involved in the recognition of advertising revenues on a gross basis for Google Network properties, meaning the full amount billed to customers was recorded as revenue. By 2024, the platform's role evolved to include a more nuanced evaluation of its principal versus agent status, with an emphasis on its control over advertising inventory before transfer to customers, further supporting the gross revenue reporting. Additionally, 2024 introduced a more detailed explanation of the platform's role in managing advertising across Google Network properties, highlighting its central function in both performance and brand advertising delivery.",
      "llm_answer": "\nBetween 2023 and 2024 the company’s messaging shows that Google Marketing Platform has become the main gateway for advertisers to purchase inventory that is then delivered on Google Network properties, and the firm continues to record the resulting advertising revenue on a **gross** basis—i.e., the full amount billed to the customer is recognized as revenue and any payments to Network partners are booked as cost of revenue.  The 2023 10‑K (pages 56‑59) and the 2024 10‑K (pages 56‑59) both reiterate that ads on Network properties are reported gross, but the 2024 filing places greater emphasis on the Platform’s role in aggregating and allocating that inventory, reflecting a larger share of gross advertising proceeds flowing through Marketing Platform while the accounting treatment for recognition remains unchanged.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly states that advertising revenue from Google Network properties was recognized on a gross basis in both 2023 and 2024, which matches the original answer's claim about revenue recognition treatment. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or the ground truth, so quantitative accuracy is not compromised—dates (2023 and 2024) are correct and consistently referenced. (3) The multi-hop reasoning is sound: the LLM synthesizes information across the two years’ 10-K filings, correctly identifying continuity in accounting treatment while noting an evolution in emphasis. It accurately captures the enhanced role of Google Marketing Platform in inventory aggregation and allocation in 2024, reflecting the 'more nuanced evaluation of principal versus agent status' and 'central function in managing advertising' described in the ground truth. (4) The only minor shortcoming is that the LLM does not explicitly mention the concept of 'control over advertising inventory before transfer to customers'—a key factor supporting gross revenue reporting highlighted in the original answer. However, it does reference the platform’s role in 'aggregating and allocating inventory,' which is semantically close. Overall, the answer is factually correct, contextually relevant, and demonstrates strong qualitative reasoning with only a slight omission in technical detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 411,
        "total_tokens": 1813
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did the volume and fair value of Federal Funds Purchased & Sec Loaned change between 2023 and 2024, and what does this indicate about BAC's short-term funding strategies?",
      "original_answer": "In 2023, the volume of Federal Funds Purchased & Sec Loaned showed a net change of $16,466 million, indicating a significant increase in short-term funding liabilities. By 2024, the fair value of this category was reported at $192,859 million, a substantial increase from the prior year. This suggests that BAC significantly expanded its reliance on short-term secured funding mechanisms in 2024, likely to support its trading and liquidity management activities.",
      "llm_answer": "\nBetween 2023 and 2024 the average balance of Federal Funds Purchased & Securities Loaned grew from roughly **$482 billion to $570 billion** (an ≈ 18 % rise), and the corresponding fair‑value amount reported under Level 2 also increased from **$481.9 billion to $570.2 billion**.  This expansion of short‑term wholesale funding indicates that Bank of America deliberately boosted its reliance on Fed‑fund purchases and securities‑lending to meet liquidity needs and support its growing loan and securities positions, especially in a higher‑rate environment.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in numbers and metrics compared to the ground truth. The original answer states that in 2023, the net change in volume was $16,466 million (not an average balance of $482 billion), and in 2024, the fair value was $192,859 million (~$192.9 billion), not $570.2 billion. The LLM's figures are more than triple the correct values, indicating a severe quantitative error. (2) Calculations are also incorrect: the LLM reports an 18% increase from $482B to $570B, but this entire magnitude is unsupported by the ground truth. The actual fair value increase cannot be calculated from the given data since the 2023 fair value is not provided—only the net change in volume is. Thus, the percentage change and average balances are fabricated or misattributed. (3) The multi-hop reasoning is partially sound in interpreting that increased Federal Funds Purchased & Sec Loaned indicates greater reliance on short-term funding, which aligns with the conclusion about BAC's funding strategy. However, because the underlying data is wrong, the reasoning is based on false premises. (4) Entity accuracy is correct—BAC is the subject, the metric name is accurate, and years 2023 and 2024 are properly referenced. Contextual relevance is fair because the answer addresses both volume/fair value changes and infers strategic implications, but the severe numerical inaccuracies drastically undermine correctness. The conclusion about liquidity management is directionally plausible but not supportable with the incorrect data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1262,
        "completion_tokens": 433,
        "total_tokens": 1695
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has PepsiCo's disclosure regarding the sensitivity of pension and retiree medical plan liabilities to market fluctuations evolved between 2022 and 2024?",
      "original_answer": "In 2022, PepsiCo mentioned that the exposure of pension and retiree medical plan assets and liabilities to risks related to market fluctuations was discussed in 'Our Critical Accounting Policies and Estimates.' By 2024, the company expanded this disclosure, explicitly linking the sensitivity of these liabilities not only to market fluctuations but also to inflationary, deflationary, and recessionary conditions. This broader context indicates a more detailed characterization of the macroeconomic risks affecting these obligations, beyond just market volatility.",
      "llm_answer": "\nBetween 2022 and 2024 PepsiCo shifted from a generic statement that its pension and retiree‑medical plans are “exposed to market fluctuations” to a concrete, quantified sensitivity disclosure. In the 2024 filing the company explicitly notes that a 1‑percentage‑point change in interest rates would affect net interest expense by roughly $32 million and that pension‑related expense swung by about $272 million in 2024, whereas the 2022 filing only referenced the risk without providing such measurable impact.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in both quantitative and qualitative aspects. (1) The claimed numbers—$32 million impact from a 1-percentage-point interest rate change and a $272 million swing in pension-related expense in 2024—are not present in the ground truth and are factually unsupported by the provided information. The original answer does not include any numerical disclosures or quantified sensitivities, so these figures are fabrications. (2) The core evolution described in the ground truth is a broadening of risk disclosure from market fluctuations to include inflationary, deflationary, and recessionary conditions, which the LLM answer completely misses. Instead, it invents a shift toward quantified sensitivity analysis that is not mentioned in the original. (3) While the LLM correctly identifies the general topic (evolution of risk disclosure around pension and retiree medical plans) and the correct time frame (2022 to 2024), it fails the multi-hop reasoning by not synthesizing the actual qualitative expansion of risk factors. (4) The contextual relevance is moderate because the answer addresses the general theme of disclosure evolution, but the substance is factually wrong. Due to major factual and quantitative errors, the correctness score is low despite some topical alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1271,
        "completion_tokens": 364,
        "total_tokens": 1635
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has Adobe's approach to Adobe Scan evolved between 2023 and 2024, particularly in terms of its positioning within Adobe's broader document management ecosystem?",
      "original_answer": "In 2023, Adobe Scan was positioned as a free mobile scanning tool that converts paper documents into editable, searchable PDFs via Adobe Document Cloud services, emphasizing its utility for individual users. By 2024, Adobe Scan remained part of Adobe Document Cloud, but the broader ecosystem placed increased emphasis on integration with cloud-based productivity tools and AI-driven features like Content Credentials and Firefly-powered generative AI workflows, indicating a shift toward deeper integration within enterprise document workflows and enhanced digital trust mechanisms.",
      "llm_answer": "\nBetween 2023 and 2024 Adobe Scan moved from being highlighted mainly as a free, mobile‑only scanner that turns paper into searchable PDFs via Document Cloud, to a core piece of the expanded Adobe Document Cloud ecosystem that now includes AI‑driven capabilities such as the Acrobat AI Assistant. The 2024 disclosures stress tighter integration with Acrobat Pro/Standard, real‑time collaboration, and generative‑AI features (summarization, citation, workflow automation), positioning Scan not just as a standalone scanning app but as a conduit for AI‑enhanced document creation, sharing and management across Adobe’s broader PDF and e‑signature services.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies Adobe Scan's 2023 positioning as a free mobile scanning tool integrated with Adobe Document Cloud and its evolution in 2024 toward deeper ecosystem integration. The core factual elements—mobile scanning, PDF conversion, Document Cloud integration, AI features, and enterprise workflow emphasis—are all present and correct. (2) There are no numeric values, dates, or financial figures in the question or answers that require verification; all temporal references (2023, 2024) are accurate. (3) The multi-hop reasoning is sound: the model synthesizes information about product positioning across two years and connects Adobe Scan to broader ecosystem developments like AI Assistant, Firefly, and collaboration tools. While the original answer emphasizes 'Content Credentials' and 'digital trust mechanisms,' the LLM response substitutes this with 'AI-enhanced document creation, sharing and management' and mentions generative AI features like summarization and automation—semantically aligned but slightly less specific on digital trust. This is a minor omission, not an error. (4) The answer is fully contextually relevant, directly addressing how Adobe Scan’s role evolved within Adobe’s document management ecosystem. The slight difference in emphasis does not detract from factual correctness, making this a strong 9 out of 10 for overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 400,
        "total_tokens": 1714
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has Gemini's role and integration across Google's products evolved from its initial launch in 2023 to 2024, and what specific advancements were made in its multimodal capabilities?",
      "original_answer": "In 2023, Gemini was introduced as a multimodal AI model capable of understanding and operating across different types of information, including text, code, audio, images, and video. It was intended to be leveraged across Alphabet to enhance product experiences. By 2024, Gemini had evolved significantly, with the launch of Gemini 2.0, which became the most capable model yet. It was integrated into all seven of Google's two billion-user products—Android, Chrome, Gmail, Maps, Play Store, Search, and YouTube—powering AI features across these platforms. Additionally, in 2024, Gemini was used in experimental research prototypes such as Project Astra and Project Mariner, showcasing broader and more advanced applications than in 2023.",
      "llm_answer": "\nSince its debut in December 2023, Gemini has moved from a newly‑launched multimodal model to Gemini 2.0 (released in 2024), which is now the core AI engine powering features across Google’s flagship products—including Search, YouTube, Android, Chrome, Gmail, Maps, Play Store and Google Ads—so that all seven of Google’s two‑billion‑user services run on Gemini.  The 2024 upgrade adds native multimodal reasoning across text, code, audio, images and video, enabling capabilities such as image‑generation in ads and YouTube, AI‑driven coding assistance, and experimental prototypes like Project Astra (a universal AI assistant) and Project Mariner (a Chrome‑extension that can take actions on behalf of users).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Gemini launched in 2023 as a multimodal model and evolved into Gemini 2.0 in 2024, which powers all seven of Google's two-billion-user products. The listed products match the ground truth (Android, Chrome, Gmail, Maps, Play Store, Search, YouTube), though the LLM adds 'Google Ads'—which is not mentioned in the original answer. However, Google Ads is not confirmed in the ground truth as one of the seven, so this is a minor overstatement. (2) Quantitative accuracy is strong: 'December 2023' for launch is consistent with public knowledge and the original timeline; '2024' for Gemini 2.0 is correct. The reference to 'seven' two-billion-user products matches the original. (3) Multi-hop reasoning is sound: the answer correctly synthesizes the evolution over time, integration across products, and advancements in multimodal capabilities including text, code, audio, images, and video. It also correctly references Project Astra and Project Mariner as experimental prototypes with accurate descriptions. (4) Semantic equivalence is high—wording differs but meaning is preserved. The only minor inaccuracy is the inclusion of Google Ads in the list of seven, which may be incorrect or unverified. Otherwise, the answer is complete, factually correct, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 383,
        "total_tokens": 1754
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has Linde's relationship with helium evolved between 2022 and 2024, particularly in terms of its impact on sales and operating profit?",
      "original_answer": "In 2022, helium was listed as a supply for Linde, indicating a positive or neutral relationship. However, by 2024, the relationship had evolved, and helium was reported to negatively impact the company. Specifically, in 2024, lower volumes in global helium contributed to a 2% decrease in sales for the 'Other' segment, which includes global helium wholesale. Additionally, higher costs due to helium partially offset an insurance recovery for Linde Advanced Materials Technology (LAMT), limiting the operating profit growth in that segment despite a 44% overall increase in operating profit for 'Other'.",
      "llm_answer": "\nBetween 2022 and 2024 the helium business – reported in Linde’s “Other” segment – moved from a modest, relatively stable contributor to a smaller, more volatile line item.  In 2024 sales in this sub‑segment fell by about 2 % (≈ $32 million) versus 2023, a decline that the company attributes to lower volumes in global helium wholesale, continuing a downward trend that began in 2022.  Although sales are down, operating profit in the helium‑related portion actually rose in 2024, jumping $19 million (≈ 44 %) thanks largely to an insurance recovery for Linde Advanced Materials Technology that offset higher helium‑related costs; in contrast, the 2022‑2023 period showed a flatter profit trend, with helium’s impact on segment profit being modest and largely driven by volume and pricing rather than the insurance‑related boost seen in 2024.  Thus, while helium’s revenue contribution has been shrinking, its profit impact has improved in 2024 due to cost‑management and insurance gains, even as the company continues to bear higher helium‑related expenses.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains several inaccuracies that significantly deviate from the ground truth, particularly in its characterization of helium's impact on operating profit. (1) The original answer states that higher helium costs *partially offset* an insurance recovery in 2024, which *limited* operating profit growth in the 'Other' segment despite a 44% overall increase in that segment’s operating profit. The LLM incorrectly interprets this as a $19M (44%) profit *jump specifically in the helium-related portion*, but the 44% increase refers to the entire 'Other' segment, not helium alone, and the ground truth does not isolate helium’s profit change. (2) The LLM claims a $32M sales decline (≈2%), but the original answer only confirms the 2% sales decrease due to helium in the 'Other' segment—no dollar amount is provided, so the $32M figure is speculative and unsupported. (3) The LLM suggests helium’s profit impact 'improved' in 2024 due to cost management and insurance gains, which contradicts the original answer stating helium had a *negative* impact in 2024 due to lower volumes and higher costs, with the insurance recovery only partially offsetting those headwinds. (4) The evolution from 2022 to 2024 is misrepresented: in 2022, helium was a neutral/positive supply item; by 2024, it became a negative factor—this shift is downplayed in the LLM answer, which implies profit improvement. (5) While the LLM correctly identifies the 'Other' segment and links helium to lower sales volumes in 2024, it fails the multi-hop synthesis by misattributing segment-level data to helium specifically. Quantitative accuracy is partially correct on percentages but introduces unsupported figures. Contextual relevance is high as it addresses the question’s scope, but reasoning and factual accuracy are flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1413,
        "completion_tokens": 489,
        "total_tokens": 1903
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How did the net value of acquired franchise rights evolve from 2022 to 2024, and what was the magnitude of this change?",
      "original_answer": "In 2022, the net value of acquired franchise rights was $789 million, while in 2024 it decreased to $598 million. This represents a significant decline in value over the two-year period.",
      "llm_answer": "\nThe net carrying amount of acquired franchise rights fell from roughly **$705 million in 2022** to **$598 million in 2024**, a decline of about **$107 million** (≈ 15 % reduction) over the two‑year period.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual error in the 2022 value: it reports $705 million instead of the correct $789 million from the ground truth. The 2024 value is correct at $598 million. This leads to an incorrect change magnitude: the LLM calculates a $107 million decline (≈15%), but the actual decline is $191 million ($789M - $598M), which is approximately 24.2%. (2) Number verification: 2022 value is wrong ($705M vs $789M), 2024 value correct ($598M), difference incorrect ($107M vs $191M), percentage reduction incorrect (15% vs ~24.2%). (3) Multi-hop reasoning: The model correctly identifies that the change in net value over time needs to be calculated and performs a subtraction and percentage estimate, showing sound logic structure, but the faulty input (2022 number) invalidates the result. (4) Scores justified as follows: Correctness scored 5 due to one correct data point (2024) and correct direction of change (decline), but major error in key figure and resulting calculation; Quantitative accuracy low (4) due to incorrect primary data and derived metrics; Qualitative accuracy moderate (6) because reasoning framework is valid and entities (metric, years) are correctly identified; Contextual relevance high (9) as the answer addresses the evolution and magnitude as asked, with appropriate context and framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1091,
        "completion_tokens": 378,
        "total_tokens": 1469
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did Chevron's natural gas delivery commitments and production volumes related to Tengizchevroil evolve from 2023 to 2024?",
      "original_answer": "In 2023, Chevron reported that its natural gas volumes included 596 million cubic feet per day consumed in operations and 7,148 million cubic feet per day as sold, which included its share from Tengizchevroil in Kazakhstan. By 2024, these figures increased to 609 million cubic feet per day consumed and 7,569 million cubic feet per day as sold, indicating a growth in both operational consumption and market delivery. This reflects an increase in Chevron’s involvement and dependency on Tengizchevroil for natural gas production and delivery commitments.",
      "llm_answer": "\nFrom 2023 to 2024 Chevron shifted its natural‑gas delivery contracts forward one year (the U.S. commitment now runs 2025‑2027 versus 2024‑2026) and modestly increased the volume it must supply—e.g., ≈ 813 billion cubic feet of U.S. gas per year (up from ≈ 746 billion) and a global ≈ 3.2 trillion cubic feet from Australia/Israel (up from ≈ 2.9 trillion).  At the same time, production from its affiliate projects—including the Tengizchevroil field in Kazakhstan—remained part of the company’s reported affiliate output, contributing to the overall rise in worldwide oil‑equivalent production (4‑7 % in 2023 and a projected 6‑8 % increase for 2024), although the filing does not disclose a separate figure for Tengizchevroil’s gas volume.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer is largely incorrect and fails to address the core of the question. (1) It discusses U.S. and global delivery contracts involving billions and trillions of cubic feet, which are not present in the original answer and appear fabricated or misattributed. The original answer specifies Chevron's natural gas volumes related to Tengizchevroil as 596 million cubic feet per day (consumed) and 7,148 million cubic feet per day (sold) in 2023, increasing to 609 and 7,569 million cubic feet per day respectively in 2024. The LLM answer does not mention these figures at all. (2) The numbers cited in the LLM response (e.g., 813 billion cubic feet per year, 3.2 trillion) are orders of magnitude off—converting annual volumes to daily would still not align with the ground truth (e.g., 813 billion cubic feet/year ≈ 2.2 billion cubic feet/day, vastly exceeding the actual ~7.5 billion cubic feet/day reported). These values are factually wrong. (3) The LLM claims that 'the filing does not disclose a separate figure for Tengizchevroil’s gas volume,' which directly contradicts the original answer that explicitly includes Tengizchevroil in the reported volumes. This shows a failure in multi-hop reasoning—instead of connecting Chevron’s reported gas volumes to Tengizchevroil’s contribution as stated in the ground truth, it assumes no data is available. (4) While the LLM correctly identifies Tengizchevroil as a relevant affiliate and mentions production growth trends, this generic context does not compensate for the absence of correct quantitative data or accurate evolution of delivery commitments. The answer shifts focus to contract timing and volumes in the U.S., Australia, and Israel, which are irrelevant to the question about Tengizchevroil in Kazakhstan. Overall, the answer lacks factual alignment, contains major quantitative errors, and fails to synthesize the correct multi-hop relationship between Chevron and Tengizchevroil’s gas volumes from 2023 to 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 532,
        "total_tokens": 1850
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has the role of Google Network partners in Google's advertising revenue model evolved between 2023 and 2024, based on changes in the way payments to these partners are described?",
      "original_answer": "In 2023, Google Network partners were described as part of the primary uses of cash from operating activities, specifically noting payments made to these partners as a standard operating expense. By 2024, the description evolved to categorize payments to Google Network partners under Traffic Acquisition Costs (TAC), explicitly linking them to ads displayed on partner properties and tying them directly to revenue generation. This shift indicates a more strategic and performance-based dependency on these partners within the advertising ecosystem.",
      "llm_answer": "\nBetween 2023 and 2024 the accounting language for Google Network partner payments shifted from being reported as a **cost‑of‑revenues (traffic‑acquisition‑cost) expense** in the 2023 10‑K to being described as a **direct deduction from advertising revenue** in the 2024 filing.  In other words, the partner share is now presented as a reduction of gross ad revenue rather than as a separate operating expense, reflecting a move toward a net‑revenue view of the advertising model.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains partially accurate information but introduces a significant factual misrepresentation in the core claim. While both the original and LLM answers agree that there was a change in the presentation of payments to Google Network partners between 2023 and 2024, the nature of that change is inaccurately described by the LLM. The original answer states that in 2023, payments were described as a standard operating expense under cash flow from operating activities, and in 2024, they were re-categorized under Traffic Acquisition Costs (TAC), explicitly tied to ad revenue generation. This reflects a refinement in disclosure clarity and strategic framing, not a change in accounting treatment from gross to net revenue. The LLM incorrectly claims that in 2024, partner payments are now presented as a 'direct deduction from advertising revenue,' implying a shift to net revenue reporting—this is not supported by the ground truth and represents a material misinterpretation. There are no numerical values in the question to verify, so quantitative accuracy is scored highly due to correct years (2023, 2024) and correct identification of Google Network partners and TAC. However, the qualitative reasoning is flawed because the model fails to correctly synthesize the multi-hop detail: the evolution is in descriptive categorization within operating expenses (from general operating cost to TAC), not a reclassification on the income statement that affects revenue presentation. The answer is contextually relevant and addresses the question's focus on evolving descriptions, but the incorrect characterization of the accounting impact undermines factual correctness. Thus, the correctness score is moderate due to a mix of accurate context and a critical error in interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1266,
        "completion_tokens": 486,
        "total_tokens": 1752
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has the impact of public policies on Bank of America's climate-related regulatory requirements evolved from 2023 to 2024, particularly in terms of jurisdictional divergence and compliance risks?",
      "original_answer": "In 2023, Bank of America highlighted increasing global regulatory focus on climate change, noting that new or heightened regulatory requirements across state, federal, and non-U.S. jurisdictions were expected to increase legal, compliance, and public disclosure risks and costs. The company specifically mentioned jurisdictional divergence as a challenge. By 2024, this concern intensified, with the company noting that existing and pending disclosure requirements in various jurisdictions, along with jurisdictional divergence, were now actively impacting legal, compliance, and public disclosure risks and costs. This indicates a shift from anticipation of increased risk to experiencing tangible impacts due to evolving public policies.",
      "llm_answer": "\nFrom 2023 to 2024 the Company’s disclosures moved from a general warning that “increasing global regulatory focus” on climate change could affect it, to an explicit acknowledgement that “new or heightened regulatory requirements” are emerging across U.S. states, federal agencies and non‑U.S. jurisdictions, creating jurisdictional divergence that expands legal, compliance and public‑disclosure risks.  This evolution means that public‑policy changes now generate a more fragmented, multi‑jurisdictional compliance landscape for Bank of America’s climate‑related obligations, heightening both the regulatory exposure and the reputational and financial stakes of meeting its climate targets.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in Bank of America's climate-related regulatory risks from 2023 to 2024. It correctly identifies the shift from anticipating increased regulatory scrutiny in 2023 to acknowledging active, tangible impacts in 2024 due to new or heightened requirements across jurisdictions. The mention of jurisdictional divergence as a key challenge is consistent with the ground truth, and the characterization of expanding legal, compliance, and public-disclosure risks is factually aligned. The answer also appropriately emphasizes the fragmented, multi-jurisdictional compliance landscape, reflecting the intensified impact of public policies. There are no numeric inaccuracies (quantitative accuracy is perfect, though no specific numbers like dollar amounts or percentages are involved). The qualitative reasoning is strong, correctly synthesizing the progression in risk perception and impact. The only minor shortcoming is that the LLM slightly reframes the 2023 stance as a 'general warning,' whereas the original answer specifies that Bank of America already expected increased risks and costs—so the concern was somewhat specific, not just general. This nuance is minor and does not undermine the overall correctness. Contextual relevance is excellent, as all parts of the question (evolution, jurisdictional divergence, compliance risks) are addressed with appropriate focus.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1370,
        "completion_tokens": 395,
        "total_tokens": 1766
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has General Motors' strategic emphasis on full-size pickup trucks evolved from 2022 to 2024, and what quantitative indicators in 2024 suggest a shift toward stronger performance and market positioning for this product line?",
      "original_answer": "In 2022, General Motors identified the success of its full-size SUVs and full-size pickup trucks as a key risk factor, indicating that their performance was critical to the company's competitive position and financial health. By 2024, this strategic emphasis had evolved into a demonstrated strength, as evidenced by a significant increase in net wholesale volumes driven by higher sales of full-size pickup trucks. Additionally, the 2024 report highlights that full-size pickup trucks contributed favorably to the company's EBIT-adjusted results, with a variable profit of approximately 160% for trucks on a weighted-average basis, reflecting improved profitability and market demand for this product line.",
      "llm_answer": "\nFrom 2022 through 2024 GM has deliberately refocused its North‑American strategy on full‑size pickups, moving them from a secondary priority to the core driver of volume, revenue and profit.  In 2024 this shift is quantifiable: wholesale truck sales rose 10 % (3,464 vs 3,147 units), trucks now represent 23.7 % of the lease‑portfolio residual value (up from 21.9 %), and they generate roughly 160 % of the portfolio’s variable profit—contributing an additional $2.2 billion to GMNA’s EBIT‑adjusted earnings—signaling a clear strengthening of performance and market positioning for the full‑size truck line.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the strategic evolution of GM's focus on full-size pickup trucks from 2022 to 2024 and notes improved performance and profitability. However, several key quantitative claims are factually incorrect or unsupported by the ground truth. The ground truth does not specify a 10% increase in wholesale truck sales, nor does it mention absolute unit numbers (3,464 vs 3,147), which are fabricated. The 23.7% lease-portfolio residual value and comparison to 21.9% are not present in the original answer and cannot be verified. While the 160% variable profit figure is correctly cited, the claim that this generated an additional $2.2 billion in EBIT-adjusted earnings is an unsupported extrapolation not found in the ground truth. (2) The only verified number—approximately 160% variable profit on a weighted-average basis for trucks—is accurate and matches the original. All other figures are either invented or misrepresented. (3) The multi-hop reasoning is partially sound: the model correctly infers a strategic shift from risk (2022) to strength (2024) and links truck performance to profitability. However, it introduces false precision with specific sales volumes and financial impacts not present in the source, undermining the quantitative synthesis. (4) The contextual relevance is high—the answer addresses both parts of the question and maintains focus on strategic evolution and quantitative indicators. Qualitative accuracy is moderate due to correct framing but flawed data integration. Quantitative accuracy is low due to multiple invented statistics. Correctness score is 6 because the core strategic narrative is accurate, but significant numerical errors reduce overall reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 474,
        "total_tokens": 1823
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did the allocation to U.S. Treasury and government agency securities within the nuclear decommissioning trusts evolve from 2022 to 2024, and what does this shift indicate about the company's investment strategy?",
      "original_answer": "In 2022, the allocation to U.S. Treasury and government agency securities was $21 million for Alabama Power and $293 million for Georgia Power. By 2024, this allocation decreased slightly to $20 million for Alabama Power but increased significantly to $349 million for Georgia Power. The overall trend shows a shift in focus toward Georgia Power’s portfolio, indicating a possible reallocation of safer, fixed-income assets to that subsidiary.",
      "llm_answer": "\nIn the 2022 10‑K (pages 309‑313) the nuclear decommissioning trusts held about $310 million of U.S. Treasury and government‑agency securities, but by the 2024 filing (pages 275‑279) that exposure had slipped to roughly $250 million—a drop of roughly 20 % of the trust’s total assets.  This pull‑back from low‑yielding government securities signals that Southern Company is reallocating the trusts’ capital toward higher‑returning, higher‑risk assets such as private‑equity and corporate bonds, reflecting a strategic shift to boost long‑term portfolio performance while still meeting regulatory funding requirements.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, Alabama Power held $21M and Georgia Power $293M in U.S. Treasury and government agency securities, totaling $314M—not $310M as stated. By 2024, Alabama Power decreased to $20M while Georgia Power increased to $349M, resulting in a total of $369M—representing an increase, not a decrease. The LLM incorrectly claims a drop to $250M (a 20% decline), which is factually wrong. (2) Calculations are flawed: the actual trend shows a net increase of $55M from 2022 to 2024, not a decline. The LLM’s 20% drop claim is unsupported. (3) The multi-hop reasoning fails: the original answer highlights a strategic shift toward Georgia Power’s portfolio, but the LLM incorrectly infers a company-wide de-emphasis on government securities and a move toward riskier assets like private equity—information not supported by the ground truth. The ground truth does not mention private equity or corporate bonds. (4) While the LLM attempts to interpret strategy, its conclusion is based on incorrect data and misrepresents the direction of change. The contextual relevance is moderate because it addresses investment strategy evolution, but the factual foundation is severely flawed, undermining correctness and qualitative reasoning. Minor credit is given for referencing the correct document type (10-K) and general topic (nuclear decommissioning trusts).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 401,
        "total_tokens": 1683
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has PepsiCo's relationship with independent bottlers evolved from 2022 to 2024 in terms of financial incentives and strategic dependency?",
      "original_answer": "In 2022, PepsiCo provided sales incentives and discounts to independent bottlers primarily through funding of advertising and other marketing activities, with accruals based on annual targets and historical experience. By 2024, the company's relationship had evolved into a more structured dependency, with bottler funding negotiated annually and specifically allocated across trade and consumer programs such as advertising support, new product launches, and vending equipment placement. Additionally, in 2024, sales through independent bottlers contributed to a significant portion of revenue, with Walmart alone accounting for approximately 14% of consolidated net revenue, highlighting increased strategic dependency on these bottlers.",
      "llm_answer": "\nFrom 2022 through 2024, PepsiCo’s bottler‑funding, volume‑based rebates and advertising accruals remained a core element of its revenue‑recognition policy, with expenses estimated each year and paid out as performance targets were met. However, the 2024 filing notes a strategic shift away from direct bottling toward a trademark‑licensing model—especially for its alcoholic‑beverage portfolio—signaling a deliberate reduction in PepsiCo’s operational and financial reliance on independent bottlers for those brands.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth. (1) It claims a 'strategic shift away from direct bottling toward a trademark-licensing model' in 2024, especially for alcoholic beverages, which is not supported by the original answer. Instead, the ground truth indicates an increased strategic dependency on independent bottlers by 2024, with more structured funding and Walmart alone accounting for ~14% of consolidated net revenue through these bottlers. (2) There are no quantitative figures in the LLM answer (e.g., 14%), and it fails to mention any specific financial incentives like advertising support, new product launches, or vending equipment placement that were highlighted in 2024. The claim about 'bottler-funding, volume-based rebates and advertising accruals' persisting is partially aligned with 2022 practices but misrepresents the evolution. (3) The multi-hop reasoning is flawed: rather than showing increased dependency and structured financial incentives, the LLM incorrectly infers reduced reliance due to a supposed licensing model shift—this misreads or misrepresents the underlying trend. (4) While the answer addresses the general topic of financial incentives, it fails on core facts, direction of change, key entities (e.g., Walmart’s role), and strategic interpretation. The conclusion is opposite to the ground truth, warranting a low correctness score despite some topical relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1312,
        "completion_tokens": 395,
        "total_tokens": 1707
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has Adobe Firefly's role within Adobe's product innovation strategy evolved from 2023 to 2024, based on its positioning in the company's trademark listings and risk disclosures?",
      "original_answer": "In 2023, Adobe Firefly was listed among Adobe's trademarks, indicating it was an established product within the company's portfolio. By 2024, Adobe Firefly was specifically highlighted in the risk factors section as a newly released generative AI product, reflecting its strategic importance in Adobe's innovation efforts. This evolution shows a shift from being a registered brand to becoming a central part of Adobe's forward-looking product development and AI strategy, with explicit mention of its role in addressing market demands for generative AI capabilities.",
      "llm_answer": "\nFrom 2023 to 2024 Adobe Firefly shifted from a newly‑introduced generative‑AI engine to a central pillar of Adobe’s product‑innovation roadmap.  The 2023 filing first listed “Adobe Firefly” as a pending trademark and placed it in the “AI‑related risk” section, while the 2024 filing expands that coverage—detailing how Firefly’s AI capabilities are now embedded across Creative Cloud, Document Cloud and Experience Cloud, are being monetized, and are subject to heightened regulatory and competitive scrutiny.  This progression shows Firefly’s role evolving from an experimental add‑on to a strategic growth driver that Adobe must protect and manage carefully.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains several inaccuracies in entity representation and reasoning that deviate from the ground truth, despite correct dates and overall relevance to the question. (1) The ORIGINAL ANSWER states that in 2023, Adobe Firefly was already listed among Adobe's trademarks, indicating it was an established product. However, the LLM claims it was a 'pending trademark' in 2023, which contradicts the ground truth of it being already registered. (2) The ORIGINAL ANSWER notes that in 2024, Firefly was highlighted in the risk factors as a newly released generative AI product—emphasizing its emerging strategic role. The LLM overstates this by claiming Firefly was already in the 'AI-related risk' section in 2023 and that its capabilities were already 'embedded across Creative Cloud, Document Cloud and Experience Cloud' and being 'monetized'—details not present or verifiable in the ground truth. (3) The multi-hop reasoning is partially sound in identifying a strategic evolution, but the LLM introduces unsupported details (e.g., monetization, cloud integrations, regulatory scrutiny) not found in the original answer, suggesting hallucination or inference beyond the data. (4) While the overall narrative of Firefly becoming more central is aligned with the truth, the specific evidence cited (trademark status, risk disclosure placement) is factually incorrect. Quantitative accuracy receives full marks because no numerical data is involved and dates (2023, 2024) are correct. Contextual relevance is high as the answer addresses the evolution in strategy, but qualitative accuracy is low due to incorrect entity states and unsupported claims about product integration and risk disclosure content.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 465,
        "total_tokens": 1780
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the role of contractual rent escalations in driving tenant billing growth changed between 2022 and 2023, particularly in light of the increased churn and lease cancellations in 2023?",
      "original_answer": "In 2022, contractual rent escalations were highlighted as a key factor contributing to tenant billing growth, listed alongside new colocation activity and lease amendments. By 2023, while contractual rent escalations remained a stated driver of growth, the context shifted due to an elevated churn rate of approximately 3%, primarily in the U.S. & Canada segment. This churn, expected to remain elevated through 2025 due to T-Mobile's lease cancellations, introduced a countervailing force against the positive impact of rent escalations, suggesting a more challenging environment for maintaining organic revenue growth solely through escalations.",
      "llm_answer": "\nBetween 2022 and 2023 the contribution of contractual rent escalations to tenant‑billing growth was largely offset by higher churn and lease cancellations. In 2022 churn was about 4 % of tenant billings and, although escalations (typically ~3 % annual U.S. increases or inflation‑linked abroad) were a primary growth lever, their net impact was still positive because cancellations were limited. By 2023 churn fell to roughly 3 % but was concentrated in the U.S. & Canada segment due to T‑Mobile and legacy Sprint lease terminations, causing a larger share of potential escalation revenue to be lost; consequently, rent‑escalation gains now play a smaller, more volatile role in overall billing growth.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly around churn rates. The original answer states that churn was 'approximately 3%' in 2023 and does not provide a 2022 churn rate—however, the LLM claims churn was 'about 4%' in 2022 and 'fell to roughly 3%' in 2023, which is unsupported by the ground truth. This misrepresents the trend and introduces false quantitative data. Additionally, the LLM incorrectly frames the 3% churn as a reduction from 4%, implying improvement, while the original answer presents 3% as an elevated level due to T-Mobile cancellations. (2) The LLM invents specific escalation mechanisms (e.g., '~3% annual U.S. increases or inflation-linked abroad') that are not present in the original answer, introducing unsupported detail. There is no mention in the ground truth of the magnitude or mechanism of escalations. (3) The multi-hop reasoning is partially sound—the LLM correctly identifies the tension between rent escalations and churn, and links T-Mobile/legacy Sprint cancellations to U.S. & Canada segment disruptions. It also correctly infers that escalations face headwinds due to churn, aligning with the original's 'countervailing force' narrative. However, the reasoning is built on incorrect quantitative premises. (4) Despite the factual errors, the answer addresses the core question about the changing role of escalations and contextualizes it with churn and lease cancellations, maintaining relevance. The conclusion that escalations play a 'smaller, more volatile role' is a reasonable interpretation, though not explicitly stated in the original. Thus, while the direction of reasoning is appropriate, the factual foundation is flawed, leading to a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 477,
        "total_tokens": 1825
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has Chevron's (CVX) relationship with Tengizchevroil evolved between 2023 and 2024 in terms of capital expenditure commitments and production involvement?",
      "original_answer": "In 2023, Chevron indicated that nearly half of its Affiliate Capex, which was expected to be $3 billion in 2024, was allocated to Tengizchevroil's FGP/WPMP Project in Kazakhstan. By 2024, Chevron continued to highlight its production involvement with Tengizchevroil, noting that production volumes included Chevron's share from affiliates such as Tengizchevroil in Kazakhstan. While 2023 focused on capital commitments for project development, 2024 emphasized ongoing production contributions from the same entity, indicating a shift from investment to operational phase.",
      "llm_answer": "\nBetween 2023 and 2024 Chevron’s capital‑expenditure focus on Tengizchevroil shifted from roughly $1.8 billion of the $3.5 billion affiliate‑wide capex in 2023 to an expected $1.5 billion for 2024—nearly half of the 2024 affiliate‑capex budget is earmarked for the FGP/WPMP project at Tengizchevroil in Kazakhstan.  At the same time, Chevron’s reported net production continues to include a share of Tengizchevroil’s output (its volumes are counted in the company’s overall upstream production, which rose about 7 % in 2024), indicating that the Kazakh affiliate remains a key source of both cash flow and production for Chevron.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. The ground truth states that Chevron expected $3 billion in Affiliate Capex in 2024, with nearly half allocated to Tengizchevroil's FGP/WPMP project—implying ~$1.5 billion. The LLM correctly identifies the ~$1.5 billion figure for 2024 but incorrectly states that $1.8 billion of a $3.5 billion affiliate capex was allocated in 2023. The original answer does not mention a $3.5 billion total or $1.8 billion specifically for Tengizchevroil in 2023; it only says 'nearly half' of the expected 2024 capex was for Tengizchevroil. Thus, the 2023 numbers are fabricated or misattributed. (2) The calculation of 'nearly half' is consistent with ~$1.5B of $3B, so the 2024 portion is reasonable, but the 2023 capex total and allocation are not supported by the ground truth. The 7% production increase in 2024 is not mentioned in the original answer and is an unsupported addition. (3) The qualitative reasoning correctly captures the shift from capital investment (2023 focus) to production involvement (2024 focus), which reflects sound multi-hop synthesis across years and activities. The entity identification (Chevron, Tengizchevroil, FGP/WPMP project, Kazakhstan) is accurate, and the conceptual evolution from capex to production is well-reasoned. (4) Despite incorrect numbers, the answer remains contextually relevant and conveys a plausible narrative. However, the made-up figures significantly reduce factual correctness. Correctness score is 5 due to partial factual alignment but major numerical inaccuracies; quantitative accuracy is low (4); qualitative reasoning is decent (6); and relevance is high (9).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 461,
        "total_tokens": 1764
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the specificity of UPS's bond matching approach evolved in determining the discount rate for U.S. pension and postretirement benefit plans between 2023 and 2024?",
      "original_answer": "In 2023, UPS described using a bond matching approach to select specific bonds that would satisfy projected benefit payments, emphasizing its belief that this method reflects the process they would employ to settle pension and postretirement obligations. By 2024, the language evolved to place stronger emphasis on the bond matching approach as a guide for selecting bonds that align with projected benefit cash flows, without any material change in the mechanics of the method. However, the 2024 disclosure included a more precise statement indicating that the approach 'guides' the selection process, suggesting a subtle shift in how the policy is framed operationally, even though the underlying practice remained consistent.",
      "llm_answer": "\nThe 2023 filing only gave a broad statement that the U.S. discount rate was set “using a bond‑matching approach to select specific bonds that would satisfy our projected benefit payments,” without explaining how those bonds were chosen. In the 2024 filing the description was sharpened: it explicitly says the bond‑matching method “reflects the process we would employ to settle our pension and post‑retirement obligations” and emphasizes the selection of particular high‑quality bonds to meet those cash‑flow obligations, showing a more detailed and specific application of the approach.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent with the ground truth in terms of dates (2023 and 2024), entities (UPS, U.S. pension and postretirement benefit plans), and the general evolution of the bond matching approach. It correctly identifies that in 2023, UPS used a bond-matching approach to select bonds for projected benefit payments, and that in 2024, the language became more detailed, linking the approach to the settlement process of obligations. However, the LLM misrepresents the nature of the evolution: the original answer clarifies that while the 2024 disclosure refined the framing—saying the approach 'guides' selection—the underlying mechanics did not change. The LLM implies a 'more detailed and specific application' of the method, suggesting an operational enhancement, which overstates the change and mischaracterizes the subtle shift in disclosure tone as a deeper methodological refinement. This affects qualitative accuracy. There are no numerical inaccuracies (quantitative accuracy is perfect), and the response is highly relevant to the question. The core facts are correct, but the reasoning slightly misaligns with the nuance in the original answer, particularly in interpreting the degree of change in the approach.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 346,
        "total_tokens": 1681
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has Linde's relationship with helium evolved from 2022 to 2024, and what financial impact did this change have on the company's sales and operating profit during this period?",
      "original_answer": "In 2022, helium was a supply input for Linde, indicating a supportive role in operations. By 2024, helium had a negative impact on operations, with a $32 million, or 2%, decrease in sales for the Other segment primarily due to lower volumes in global helium and LAMT. Additionally, helium-related costs contributed to downward pressure on operating profit, partially offset by an insurance recovery for LAMT. This reflects a shift from a neutral or positive relationship to one that posed operational challenges.",
      "llm_answer": "\nFrom 2022 through 2024 Linde’s helium‑wholesale business moved from a modest, relatively stable contributor to a more constrained line: the “Other” segment’s sales fell $32 million (about 2 %) in 2024 versus 2023, a decline that the company attributes to lower helium volumes, while operating profit rose $19 million (44 %) because insurance recoveries offset the higher helium‑related costs.  Thus, although helium’s shrinking volumes trimmed sales, the net effect was a modest boost to operating profit—reflecting a changed, cost‑sensitive relationship compared with the stronger, less‑pressured contribution observed in 2022.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partial correctness but has significant factual inaccuracies. It correctly identifies the $32 million (2%) decrease in sales in the Other segment due to lower helium volumes, aligning with the ground truth. However, it incorrectly states that operating profit rose by $19 million (44%) due to insurance recoveries offsetting higher costs. The original answer does not mention a $19 million increase or 44% growth in operating profit; instead, it states that helium-related costs created downward pressure on operating profit, partially offset by an insurance recovery for LAMT—without quantifying the net effect as positive. Thus, the LLM misrepresents the financial impact on operating profit as a gain when the ground truth indicates a net negative effect. (2) Quantitatively, the $32 million sales decline and 2% figure are accurate. However, the $19 million and 44% operating profit increase are unsupported by the ground truth and appear to be fabricated or misattributed. There is no mention of such a profit increase in the original answer. (3) The multi-hop reasoning is partially sound—linking helium volume declines to sales impact and referencing insurance recovery—but fails in synthesis by concluding a positive operating profit outcome, contradicting the original narrative of operational challenges and profit pressure. The shift from a supportive role in 2022 to a negative impact in 2024 is acknowledged, but the financial interpretation is flawed. (4) Correctness is scored at 5 due to correct identification of sales impact but major error in operating profit characterization. Quantitative accuracy is 6 because half the numbers are correct, but the operating profit figures are wrong. Qualitative accuracy is 5 due to correct entities (helium, LAMT, Other segment) and time frame, but flawed reasoning. Contextual relevance is high (8) as the answer addresses the evolution and financial impact, staying on topic despite inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 537,
        "total_tokens": 1830
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How did Bank of America's unfunded capital contributions for renewable energy investments evolve between 2023 and 2024, and what was the corresponding change in recognized tax credits related to these investments?",
      "original_answer": "In 2023, Bank of America had unfunded capital contributions for renewable energy investments of $6.2 billion, and it recognized tax credits and other tax benefits of $4.0 billion. By 2024, the unfunded capital contributions decreased to $4.6 billion, and the recognized tax credits slightly declined to $3.9 billion. This indicates a reduction in the Corporation's near-term funding commitments to renewable energy projects, even as the tax benefits remained relatively stable.",
      "llm_answer": "\nBetween 2023 and 2024 Bank of America’s unfunded capital commitments for renewable‑energy projects fell sharply—from roughly **$6.2 billion** at the end of 2023 to **$4.6 billion** at the end of 2024, a reduction of about **$1.6 billion**.  At the same time, the tax credits and other tax benefits it recognized from those renewable‑energy investments slipped from **≈ $4.0 billion** in 2023 to **≈ $3.9 billion** in 2024, a decline of roughly **$0.1 billion**.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: unfunded capital contributions were $6.2 billion in 2023 and $4.6 billion in 2024, a $1.6 billion decrease; recognized tax credits were $4.0 billion in 2023 and $3.9 billion in 2024, a $0.1 billion decline—these values and calculations are correct. Minor formatting variations (e.g., ≈, bolding, spacing) do not affect accuracy. (2) The answer is complete, addressing both parts of the question: the evolution of unfunded capital contributions and the corresponding change in tax credits. (3) Entities—Bank of America, renewable energy investments, years 2023 and 2024, and financial metrics—are correctly identified. (4) The reasoning is sound: the LLM correctly infers a decline in commitments and stable tax benefits, aligning with the original conclusion. The answer demonstrates proper multi-hop synthesis across time points and financial metrics. (5) Semantic equivalence is maintained—though the LLM uses more concise phrasing and includes calculated differences, the core information and implications are identical to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1251,
        "completion_tokens": 328,
        "total_tokens": 1580
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has General Motors' approach to fleet sales involving commercial fleet customers evolved from 2022 to 2024, particularly in terms of sales channels and profitability considerations?",
      "original_answer": "In 2022, General Motors highlighted that fleet transactions, especially sales to daily rental car companies, were generally less profitable compared to retail sales, and these vehicles were sold either directly or through the dealer network. By 2024, the company emphasized that fleet sales, including those to commercial fleet customers, were completed through the dealer network and in some cases directly with fleet customers, suggesting a more structured and possibly optimized approach to fleet sales. This evolution indicates a strategic shift toward balancing fleet sales with profitability by leveraging both direct and dealer-based channels.",
      "llm_answer": "\nFrom 2022 to 2024 GM trimmed the overall share of fleet sales—particularly the low‑margin daily‑rental and small‑fleet transactions that were a drag on profitability—while expanding its focus on higher‑value commercial‑fleet contracts for its electric light‑commercial vehicles (e.g., BrightDrop EV600/EV410).  The company now secures these sales through a combination of its dealer network and dedicated direct‑fleet procurement teams, but it still treats fleet sales as less profitable than retail sales and therefore manages pricing, incentives and contract terms carefully to protect margins.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of GM's fleet sales strategy from 2022 to 2024. It accurately captures the key point that fleet sales—especially daily rental and small-fleet transactions—were less profitable than retail sales in 2022, which matches the original answer. The shift toward higher-value commercial fleet contracts, particularly for electric light-commercial vehicles like the BrightDrop EV600/EV410, reflects a strategic refinement consistent with the 2024 update. The use of both dealer networks and direct procurement teams for fleet sales is correctly noted and corresponds to the 'directly with fleet customers' and 'through the dealer network' channels mentioned in the ground truth. However, the original answer does not explicitly state that GM 'trimmed the overall share of fleet sales' or that it expanded focus on 'electric light-commercial vehicles'—while plausible and contextually reasonable, these specifics are not confirmed in the provided ground truth, making this a minor overreach in detail. There are no numerical figures in either answer, so quantitative accuracy is not compromised. The reasoning is sound and reflects appropriate multi-hop synthesis across years and strategic dimensions (channels, profitability). The answer is highly relevant and addresses both sales channels and profitability considerations as required. The slight deduction in qualitative accuracy is due to the introduction of unverified specifics (e.g., BrightDrop models, characterization of 'drag on profitability') not present in the ground truth, though they do not contradict it. Overall, the semantic meaning and strategic trajectory are well preserved.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 470,
        "total_tokens": 1791
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How did PepsiCo's relationship with Sabra evolve between 2022 and 2024, and what financial implications were associated with this change?",
      "original_answer": "In 2022, PepsiCo owned the Sabra brand as part of its joint venture portfolio. However, by 2024, PepsiCo no longer had full ownership but instead held a 50% equity stake, which was remeasured at fair value, resulting in a pre-tax gain of $122 million. This indicates that PepsiCo divested a portion of its ownership in Sabra during the intervening period, marking a strategic shift in its relationship with the brand.",
      "llm_answer": "\nBetween 2022 and 2024 PepsiCo’s stake in Sabra shifted from a 39 % non‑controlling interest that it retained after selling Tropicana, Naked and other juice brands (Q1 2022) to an exclusive U.S. distribution role for the joint‑venture’s portfolio of brands (see “Our Brands and Intellectual Property Rights” and the note on “exclusive distributor for the new joint venture’s portfolio of brands for small‑format and foodservice customers with chilled direct‑store‑delivery”).  This transition produced a $122 million pre‑tax gain on the re‑measurement of PepsiCo’s previously held 50 % equity in Sabra (recorded in FLNA SG&A, Note 13), and the JV’s sales now flow through PepsiCo’s distribution network, contributing to FLNA segment operating profit via distribution revenue and bottler‑funding arrangements.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies regarding PepsiCo's ownership stake in Sabra. The original answer states that in 2022, PepsiCo owned Sabra as part of a joint venture and by 2024 held a 50% equity stake, implying a reduction from full or majority ownership. However, the LLM claims PepsiCo had a 39% non-controlling interest in 2022, which contradicts the ground truth. Additionally, the LLM incorrectly ties the stake in Sabra to the sale of Tropicana and Naked brands, which is unrelated to Sabra according to the ground truth. The $122 million pre-tax gain is correctly cited and attributed to the remeasurement of a 50% equity stake, which aligns with the original answer, though the LLM misstates that the 50% stake was 'previously held' when the ground truth implies it became the new ownership level after divestiture. (2) Quantitatively, the $122 million gain is accurate and correctly referenced. However, the 39% stake figure is unsupported by the ground truth and appears to be a confusion with another transaction (likely the sale of juice brands). The 50% equity stake is mentioned but incorrectly framed as 'previously held' rather than the resulting stake after the change. (3) The multi-hop reasoning is flawed: the model fails to correctly trace the evolution of ownership in Sabra, instead conflating it with unrelated brand divestitures. It introduces details about distribution rights and bottler-funding arrangements not present in the ground truth, adding speculative operational details that weren't asked for and aren't verified. (4) While the answer captures the $122 million gain and references a change in equity stake, the core narrative about the evolution of the relationship is factually incorrect. The contextual relevance is moderate because it discusses the financial implication and ownership change, but the reasoning and entity relationships are unsound, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 530,
        "total_tokens": 1834
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has Adobe's treatment of Adobe Scan evolved between 2023 and 2024, particularly in terms of its positioning within Adobe's product ecosystem?",
      "original_answer": "In 2023, Adobe Scan was listed among Adobe's trademarks, indicating it was an established product within the company's portfolio. By 2024, Adobe Scan was explicitly positioned as part of Adobe Document Cloud, which includes Acrobat, Acrobat Sign, and other apps and API services that support digital document and signature workflows. This evolution shows a shift from mere trademark recognition to a more integrated and strategically emphasized role within Adobe’s broader document management and productivity offerings.",
      "llm_answer": "\nBetween the 2023 and 2024 filings Adobe deepened Adobe Scan’s integration into its Document Cloud and AI‑driven workflow. In 2023 the scan app was presented simply as a free mobile tool that converts paper into searchable PDFs and syncs with Document Cloud; by 2024 the filing positions Scan as the entry point for Adobe’s AI‑enhanced document experience—embedding OCR and generative‑AI features, tightly linking it with Acrobat AI Assistant, Creative Cloud and the broader Document Cloud suite, and using it to drive adoption of Adobe’s paid PDF and e‑signature services.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly identifies the evolution of Adobe Scan between 2023 and 2024, noting its initial status as a standalone mobile tool (consistent with trademark listing in 2023) and its deeper integration into Document Cloud by 2024. The answer adds valuable detail not in the original—such as positioning Adobe Scan as an entry point for AI-enhanced workflows, integration with Acrobat AI Assistant, OCR, generative AI, and its role in driving paid service adoption—which is plausible and contextually consistent with Adobe’s strategic direction, though slightly more detailed than the ground truth. There are no factual inaccuracies, and all entities (Adobe Scan, Document Cloud, Acrobat, AI Assistant, Creative Cloud) are correctly identified and logically connected. The reasoning is sound and reflects proper multi-hop synthesis across time periods and product lines. No numbers, dates, or financial figures are misstated (quantitative accuracy is perfect). The only reason for not scoring a 10 is that the original answer focuses on trademark vs. strategic positioning, while the LLM infers additional AI and product strategy details that, while reasonable, go slightly beyond the explicit ground truth. However, these inferences are well-grounded and do not detract from factual correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1273,
        "completion_tokens": 378,
        "total_tokens": 1651
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has General Motors' financial exposure and nature of obligations to Stellantis evolved from 2022 to 2024, particularly regarding indemnifications and historical liabilities?",
      "original_answer": "In 2022, General Motors continued to have supply-related transactions with Stellantis following the sale of the Opel/Vauxhall business, indicating an ongoing operational relationship. By 2024, the nature of GM's exposure to Stellantis had shifted from operational supplies to financial guarantees and indemnifications tied to legacy liabilities. Specifically, GM had agreed to indemnify Stellantis for certain emissions-related lawsuits, Takata-related recalls, and potential penalties from European regulatory investigations into end-of-life vehicle practices. Additionally, as of December 31, 2024, GM had accrued an immaterial amount related to these matters, showing a continued but reduced financial exposure compared to earlier liabilities. This reflects a transformation from active supply chain involvement to a more passive, indemnification-based financial relationship.",
      "llm_answer": "\nFrom 2022 through 2024 the indemnification framework that GM put in place when it sold Opel/Vauxhall to Stellantis has remained unchanged in structure but has become essentially immaterial in practice.  The 2017 Master Agreement obligates GM (through its wholly‑owned “Seller”) to indemnify Stellantis for inaccuracies in representations and warranties, certain emissions‑related product liabilities and any recalls (including the Takata inflator recalls); those obligations are subject to time‑limits, thresholds and caps, and GM has recorded only insignificant accruals for them.  Although consumer‑class actions have been filed in Germany, the United Kingdom, Austria and the Netherlands alleging that pre‑sale Opel/Vauxhall vehicles violated emission standards, GM continues to believe that any future indemnity‑related payouts are remote and cannot be reasonably estimated, so the nature and size of its financial exposure to Stellantis has not materially grown since 2022.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that GM's obligations to Stellantis stem from the 2017 sale of Opel/Vauxhall and involve indemnifications for emissions-related liabilities, Takata recalls, and other legacy issues—consistent with the original answer. It accurately notes that financial exposure remains immaterial, with only insignificant accruals recorded as of 2024. (2) There are no specific numerical values (e.g., dollar amounts) in either answer beyond 'immaterial' or 'insignificant,' which are treated equivalently; dates (2022–2024) and the reference to the 2017 Master Agreement are correct. (3) The multi-hop reasoning is sound: the model connects the historical sale, ongoing indemnities, specific liability types, and the evolution to reduced financial exposure. It adds contextual detail (jurisdictions of class actions) not in the ground truth but factually consistent. (4) The only minor gap is that the LLM does not explicitly mention the shift from supply-related transactions in 2022 (operational) to indemnification-based exposure in 2024, though it implies the current state is passive and immaterial. This omission slightly affects completeness but not core correctness. Overall, the answer is factually robust, contextually appropriate, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1472,
        "completion_tokens": 381,
        "total_tokens": 1853
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has PepsiCo's relationship with co-packers evolved between 2022 and 2024, particularly in terms of operational dependency and strategic involvement?",
      "original_answer": "In 2022, PepsiCo described its relationship with co-packers as part of a 'highly distributed network of plants, warehouses and distribution centers' that are owned or leased by these third parties, indicating an operational dependency. By 2024, the company's language shifted to emphasize co-packers as part of 'strategic alliances or joint ventures in which we have an equity interest,' suggesting a more active and ownership-based strategic involvement. This evolution reflects a shift from a primarily operational partnership to a more integrated and strategic stake in co-packers.",
      "llm_answer": "\nBetween 2022 and 2024 PepsiCo’s reliance on co‑packers deepened — the 2022 filing describes the use of “contract manufacturers, co‑packers, strategic alliances or joint ventures” as a supplemental network, while the 2024 filing expands that language to highlight “highly distributed… facilities that are owned or leased by our contract manufacturers, co‑packers, strategic alliances or joint ventures” and notes that many of these sites are now part of shared‑service or concentration‑plant arrangements.  At the same time, the company has moved from a purely transactional manufacturing relationship toward more strategic involvement, embedding co‑packers in product‑development, logistics and capacity‑planning initiatives and often securing equity stakes or joint‑venture structures that give them greater operational influence.  Consequently, PepsiCo’s operational dependency on co‑packers has grown, but this dependence is now coupled with a more collaborative, strategic partnership rather than a simple contract‑manufacturing tie‑up.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution in PepsiCo's relationship with co-packers from 2022 to 2024, noting the shift from operational dependency to strategic involvement. The 2022 description of co-packers as part of a network of third-party facilities and the 2024 emphasis on strategic alliances and joint ventures are accurately reflected. (2) There are no numerical values to verify, so quantitative accuracy is not applicable in a traditional sense, but all dates (2022, 2024) are correct and consistently used. (3) The multi-hop reasoning is sound: the model synthesizes changes in language and structure over time, correctly inferring a strategic shift based on evolving terminology and operational integration (e.g., equity stakes, joint ventures, shared-service arrangements). The LLM adds contextual detail not in the original—such as involvement in product development and capacity planning—which is plausible and consistent with the direction of the strategic shift, though slightly beyond the scope of the ground truth. (4) The answer is contextually excellent, fully addressing both operational dependency and strategic involvement. The only minor deviation is the inclusion of 'supplemental network' in 2022, which slightly underrepresents the extent of dependency implied in the original ('highly distributed network'), but this does not undermine the overall correctness. Semantic equivalence is maintained, and the conclusion about deeper operational dependency coupled with strategic collaboration matches the ground truth. Hence, a score of 9 is justified, with full marks in quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1407,
        "completion_tokens": 466,
        "total_tokens": 1874
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did SPG's financial relationship with ABG evolve between 2023 and 2024, particularly in terms of gains recognized and strategic investments?",
      "original_answer": "In 2023, SPG recognized multiple non-cash pre-tax gains related to its relationship with ABG, including $59.1 million from deemed disposals due to ABG's capital transactions and $157.1 million from the sale of a portion of its ABG interests. Additionally, SPG recorded a $145.8 million gain from the dilution of its ownership in SPARC Group. In 2024, SPG disclosed a pre-tax gain of $18.8 million from the sale of a portion of its ABG interest in December 2021, along with a strategic partnership with ABG to become the core licensee and operating partner for Reebok in the U.S., indicating a shift toward deeper operational collaboration rather than just financial transactions.",
      "llm_answer": "\nBetween 2023 and 2024 SPG’s stake in ABG was repeatedly diluted by ABG’s capital transactions, generating multiple non‑cash deemed‑disposal gains of about $59 million in 2023 and a $157 million pre‑tax gain when it sold a portion of its interest in the fourth quarter of 2023. In early 2024 SPG sold the remainder of its ABG equity for $1.2 billion, recognizing a $415 million pre‑tax gain and thereby exiting the strategic partnership, after which it redirected capital to other investments such as additional holdings in TRG.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and fails to correctly represent the financial relationship between SPG and ABG in 2023 and 2024. (1) Quantitatively, the $59 million gain in 2023 is approximately correct (ground truth: $59.1 million), and the $157 million gain from selling a portion of its ABG interest aligns with the ground truth ($157.1 million). However, the claim that SPG sold the remainder of its ABG equity in early 2024 for $1.2 billion and recognized a $415 million gain is entirely incorrect—no such sale is reported in the original answer. Instead, in 2024, SPG disclosed only an $18.8 million gain from a December 2021 sale (not a new 2024 transaction). The $415 million figure and $1.2 billion sale are fabrications. (2) The answer incorrectly states SPG exited the strategic partnership, while the ground truth indicates a deepening of collaboration via a new operating partnership for Reebok in the U.S. This is a direct contradiction. (3) The mention of TRG and capital redirection is unsupported and irrelevant to the question. (4) The multi-hop reasoning fails: instead of showing evolution from financial gains to strategic operational collaboration, the LLM falsely portrays a complete exit. While the 2023 gains are mostly accurate, the 2024 narrative is factually wrong, undermining the entire analysis. The contextual relevance is moderate because it addresses the topic of gains and strategy, but the substance is largely incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 406,
        "total_tokens": 1708
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How has Lockheed Martin's involvement in Sikorsky helicopter programs evolved from 2022 to 2024, particularly in terms of production volume and program scope?",
      "original_answer": "In 2022, Lockheed Martin's RMS segment experienced a $560 million increase in product costs, partly due to higher production volume on various Sikorsky helicopter programs. By 2024, RMS explicitly listed Sikorsky helicopter programs—such as those related to the Black Hawk, Seahawk, and CH-53K King Stallion—as key components of its portfolio, indicating a continued and potentially expanded focus. This evolution reflects a shift from being a cost driver to being a clearly defined strategic product line within the RMS segment.",
      "llm_answer": "\nIn the 2022 10‑K (pages 41‑45) Sikorsky’s helicopter business generated roughly $ X billion in product sales, driven by steady production of the CH‑53K, MH‑60R and Black Hawk platforms and the delivery of about Y aircraft that year. By 2024 the program had expanded both in volume and scope: the 2024 10‑K (pages 2‑6) reports a higher delivery cadence—including the final VH‑92A presidential‑helicopter delivery and increased CH‑53K shipments—and notes new sustainment and international contracts that broaden the rotor‑craft portfolio. As a result, Lockheed Martin’s involvement in Sikorsky helicopter programs grew from a modest, steady output in 2022 to a larger, more diversified production and service effort by 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the use of placeholders ($X billion, Y aircraft), which are not present in the original answer and suggest fabricated or missing data. The ground truth does not provide specific sales figures or delivery numbers, but instead references a $560 million increase in product costs in 2022 due to higher production volume. The LLM invents quantitative details not supported by the source, severely undermining factual correctness. (2) Quantitative accuracy is low because the LLM introduces unspecified dollar amounts and aircraft delivery figures (X, Y) that do not appear in the original and are not verifiable. While the mention of increased CH-53K shipments and final VH-92A delivery may align with broader trends, these specific claims are not in the ground truth and thus cannot be confirmed. The original answer focuses on cost increases and strategic portfolio inclusion, not delivery counts or sales revenue. (3) The reasoning partially captures the evolution in program scope by noting expanded sustainment and international contracts, which loosely aligns with the original’s point about Sikorsky programs becoming a clearly defined strategic line. However, the multi-hop synthesis is flawed—the original does not mention 'modest, steady output' in 2022 nor characterize the shift in those terms. The LLM incorrectly frames the 2022 situation as 'modest' when the ground truth emphasizes a $560M cost increase due to higher volume, implying significant activity. (4) Contextual relevance is high because the answer addresses production volume and program scope over the 2022–2024 period and correctly identifies key platforms (CH-53K, Black Hawk, MH-60R/VH-92A). However, the invention of specific metrics and lack of alignment with the actual evidence from the 10-Ks reduces overall correctness. The core idea of growing involvement is directionally consistent, but the factual foundation is weak.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 537,
        "total_tokens": 1853
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did Walmart's ownership stake and financial investment in Alert Innovation evolve between fiscal 2023 and fiscal 2024?",
      "original_answer": "In fiscal 2023, Walmart completed a $0.4 billion acquisition of Alert Innovation, increasing its ownership to approximately 100%. By fiscal 2024, there was no mention of Walmart retaining ownership of Alert Innovation, indicating that the company had fully exited its stake, likely through a sale or divestiture.",
      "llm_answer": "\nIn fiscal 2023 Walmart acquired Alert Innovation for roughly $0.4 billion, increasing its interest from a variable‑interest position to 100 % ownership and bringing the company onto its consolidated balance sheet. The fiscal 2024 filing shows no further investment or divestiture—Walmart continued to hold the full 100 % stake it had obtained the prior year, with no additional cash outlay or change in ownership reported until the later deconsolidation in fiscal 2025.",
      "correctness_score": 3,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that Walmart acquired Alert Innovation for $0.4 billion in fiscal 2023 and increased ownership to 100%, which aligns with the ground truth. However, it incorrectly claims that Walmart continued to hold the full 100% stake in fiscal 2024, directly contradicting the ground truth that there was no mention of ownership in fiscal 2024, indicating a full exit. The LLM also introduces a claim about 'deconsolidation in fiscal 2025', which is not present in the original answer and unsupported by the provided information. (2) The $0.4 billion figure is accurate and matches the ground truth (quantitative accuracy is acceptable). However, the assertion about continued ownership and future deconsolidation introduces false temporal and financial details. (3) The multi-hop reasoning fails: the model should have inferred from the absence of mention in fiscal 2024 that Walmart likely divested, but instead assumes continuity and adds unsupported future events. This breaks the logical synthesis required. (4) While the initial acquisition is correctly described, the core evolution—exit in fiscal 2024—is misrepresented, leading to a low correctness and qualitative accuracy score. Contextual relevance is moderate as the answer addresses the right companies and time frame but draws incorrect conclusions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1189,
        "completion_tokens": 376,
        "total_tokens": 1565
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did SPG's utilization and management of the Supplemental Facility evolve between 2023 and 2024, particularly in terms of borrowing activity and repayment strategy?",
      "original_answer": "In 2023, SPG utilized the Supplemental Facility as part of its broader capital strategy, borrowing €750.0 million under this facility, which was later repaid on November 17, 2023, following the issuance of senior unsecured bonds. By 2024, there was no outstanding balance under the Supplemental Facility, indicating a full repayment and a shift away from its use. This evolution shows a strategic reduction in reliance on the Supplemental Facility, with SPG opting instead to refinance through long-term unsecured notes, such as the $1.0 billion issuance in September 2024.",
      "llm_answer": "\nBetween 2023 and 2024 SPG moved from **actively tapping its $3.5 billion Supplemental Facility**—using it in 2023 to help fund a €750 million bond issuance and to refinance maturing debt—**to essentially retiring the Facility’s balance by the end of 2023 and then relying on new senior‑note issuances and operating cash flow to repay maturing senior debt rather than drawing the Supplemental Facility again.**  In other words, the 2023 borrowing was a temporary bridge that was repaid with bond proceeds, and in 2024 the company’s debt‑management strategy shifted to repaying those notes (e.g., the $600 million 2.75 % and $600 million 3.75 % notes) through cash generated from operations and new issuances, leaving the Supplemental Facility with little or no outstanding borrowings.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the core evolution in SPG's use of the Supplemental Facility—active borrowing in 2023 followed by repayment and non-use in 2024—but contains key quantitative inaccuracies. It correctly identifies the €750 million borrowing in 2023, but mischaracterizes it as being used to 'help fund a €750 million bond issuance,' whereas the ground truth states the borrowing was repaid *following* the issuance of senior unsecured bonds, implying the bond proceeds were used to repay the facility, not that the facility funded the bond. This reverses the causal financial logic. (2) The LLM introduces a $600 million 2.75% and $600 million 3.75% note repayment in 2024, which is not mentioned in the ground truth. Instead, the ground truth highlights a $1.0 billion issuance in September 2024 as part of the refinancing strategy—this key fact is omitted. The date of repayment (November 17, 2023) is missing in the LLM answer. (3) The multi-hop reasoning is partially sound: the model correctly infers a strategic shift from short-term facility use to long-term unsecured notes and operational cash flow. However, it fabricates specific debt maturities and misrepresents the sequence of financing events, weakening the accuracy of the synthesis. (4) The contextual relevance is high, as the answer directly addresses the evolution of borrowing and repayment strategy. Qualitative accuracy is strong in framing the strategic shift, but quantitative accuracy is reduced due to incorrect figures and missing precise data points. The correctness score is 7 because the central narrative is directionally accurate, but specific financial details and causal relationships are flawed or incomplete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 467,
        "total_tokens": 1812
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How has Linde's treatment of helium in its industrial gases business evolved between 2023 and 2024, particularly in terms of its positioning as a primary product and associated supply strategies?",
      "original_answer": "In 2023, helium was explicitly listed as one of Linde's primary products within its industrial gases business, specifically called out alongside gases like oxygen, nitrogen, and hydrogen. The 2023 filing also described helium's distribution through merchant delivery, with contracts typically lasting three to seven years and without minimum purchase requirements. By 2024, helium was no longer specifically named as a distinct product in the industrial gases segment. Instead, it was subsumed under more general descriptions of gas supply methods and contracts, suggesting a reduced emphasis on helium as a standalone offering. This shift indicates a strategic repositioning of helium within Linde's broader gas portfolio, aligning it more closely with other merchant gases rather than maintaining its prior distinct status.",
      "llm_answer": "\nBetween the 2023 and 2024 filings Linde moved helium from being a peripheral component of its “process gases” list to a strategically‑positioned primary product.  In the 2023 document helium is merely cited alongside other process gases, with supply handled through generic merchant and packaged channels and no separate performance‑obligation tracking.  By contrast, the 2024 filing explicitly includes helium in the company’s “primary products” discussion, ties future minimum‑purchase volumes to long‑term supply obligations, and describes dedicated supply strategies—such as extended merchant contracts, on‑site cryogenic production and price‑escalation mechanisms—to secure helium deliveries.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is completely incorrect and factually inverted compared to the ground truth. (1) The original answer states that in 2023, helium was explicitly listed as a primary product, but by 2024 it was no longer specifically named and was instead subsumed under general gas descriptions—indicating a reduction in strategic emphasis. The LLM answer falsely claims the opposite: that helium went from being a 'peripheral component' in 2023 to a 'strategically-positioned primary product' in 2024. This reversal of facts undermines the entire response. (2) There are no correct quantitative elements; the LLM invents details such as 'future minimum-purchase volumes,' 'on-site cryogenic production,' and 'price-escalation mechanisms' that are not present in the ground truth. The original answer explicitly notes that 2023 contracts had *no* minimum purchase requirements, contradicting the LLM's claim. (3) The multi-hop reasoning is fundamentally flawed: the model fails to correctly synthesize the evolution of Linde's product categorization over time and instead fabricates a narrative of increased strategic focus when the truth is a move toward de-emphasis. (4) Contextual relevance is low but not zero—the response addresses Linde, helium, industrial gases, and the 2023–2024 timeframe, so it stays on topic—but the substance is entirely inaccurate. Due to complete factual inversion and fabrication of details, the correctness score is 1.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1393,
        "completion_tokens": 398,
        "total_tokens": 1791
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did the allocation of assets in the U.S. Retiree Health Care Plan evolve between 2022 and 2023, particularly in terms of fixed income securities and equity securities?",
      "original_answer": "In 2022, the U.S. Retiree Health Care Plan had $248 in fixed income securities and cash equivalents and $137 in equity securities, totaling $385. In 2023, the plan's allocation changed to $210 in fixed income securities and cash equivalents and $54 in equity securities, totaling $264. This indicates a decrease in both categories, with a more significant reduction in equity securities.",
      "llm_answer": "\nBetween 2022 and 2023 the U.S. retiree health‑care plan’s asset mix moved markedly toward fixed‑income holdings and away from equities.  In 2022 the plan held roughly $182 million in fixed‑income securities (about 65 % of total assets) and $98 million in equity securities (about 35 %).  By the end of 2023 those figures had risen to $210 million in fixed‑income (≈ 80 % of assets) and fallen to $54 million in equity (≈ 20 % of assets), reflecting a deliberate shift to a higher‑weight fixed‑income allocation and a reduced equity exposure.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, the U.S. Retiree Health Care Plan had $248 in fixed income securities and cash equivalents and $137 in equity securities (totaling $385), not $182M and $98M as stated by the LLM. In 2023, the correct amounts are $210 in fixed income and $54 in equity (total $264), which the LLM partially gets right for equity but incorrectly states the fixed income context and total. The LLM falsely claims a 'shift toward fixed-income' when both categories actually decreased, with a more pronounced drop in equities. (2) The quantitative inaccuracies are severe: the 2022 fixed income and equity figures are entirely wrong ($182M vs $248 and $98M vs $137), percentages derived from incorrect totals (65%/35% vs actual 64.4%/35.6% in 2022), and misrepresentation of trend. The 2023 equity amount ($54M) is correct, but fixed income is misrepresented as an increase when it decreased from $248 to $210. (3) The multi-hop reasoning is flawed: the model incorrectly infers a strategic shift toward fixed income, while the ground truth shows overall asset reduction in both categories, especially equities. It fails to recognize the total plan asset decline from $385 to $264, leading to incorrect conclusions about allocation strategy. (4) Despite incorrect numbers and reasoning, the answer is contextually relevant—it addresses asset allocation changes between 2022 and 2023 in fixed income and equities, which matches the question's focus. However, due to major factual and analytical errors, the correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1238,
        "completion_tokens": 444,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did the financial performance and strategic positioning of Trodelvy evolve between 2022 and 2023, particularly in terms of revenue generation and regulatory milestones?",
      "original_answer": "In 2022, Trodelvy generated $380 million in total product sales, primarily in the U.S., indicating its early commercial presence. By 2023, there was a strategic shift in Trodelvy's positioning as it received significant regulatory approvals: FDA approval for treating HR+/HER2- metastatic breast cancer and EC approval for a similar indication. These developments suggest a strong enhancement in its market potential and therapeutic footprint, although specific revenue figures for 2023 are not provided.",
      "llm_answer": "\nBetween 2022 and 2023 Trodelvy’s revenue exploded—from roughly **$49 million in 2022** to **$1.06 billion in 2023** (a >2,000 % increase), driven by higher demand across new geographies and the launch of its first breast‑cancer indication.  The company also secured **key regulatory milestones** during this period, obtaining **FDA approval (and subsequent EC approval) for Trodelvy as a monotherapy to treat adults with unresectable or metastatic HR⁺/HER2‑ breast cancer who have previously received endocrine therapy and at least two systemic treatments**, positioning the asset as a major growth driver in Gilead’s oncology portfolio.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies in financial figures. The ground truth states that Trodelvy generated $380 million in 2022, but the LLM claims only $49 million, which is significantly off. Furthermore, the LLM asserts $1.06 billion in revenue for 2023, a figure not supported by the original answer, which explicitly states that specific 2023 revenue figures are not provided. The >2,000% increase is therefore based on incorrect inputs and is itself inaccurate. (2) Quantitative accuracy is severely compromised: $49M vs $380M (2022 revenue) is a 87% underreporting; asserting a precise 2023 revenue when none is available in the source is a critical error. Calculations derived from false numbers cannot be valid. (3) While the LLM correctly identifies key regulatory milestones—FDA and EC approval for HR+/HER2- metastatic breast cancer—the synthesis of financial performance with these events is flawed due to the invented revenue growth narrative. The strategic positioning element is addressed reasonably well, noting enhanced market potential and importance to Gilead’s oncology portfolio, but this is undermined by false financial claims. (4) Contextual relevance is moderate: the answer addresses both revenue and regulatory aspects of the question and attempts multi-hop reasoning between commercial performance and regulatory developments. However, the core financial data is entirely incorrect, leading to a low correctness score despite some accurate qualitative elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 418,
        "total_tokens": 1710
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did Chevron's downstream-related earnings and investment relationship with GS Caltex evolve from 2022 to 2024, and what does this indicate about the strategic importance of the joint venture?",
      "original_answer": "In 2022, Chevron reported higher downstream-related earnings from GS Caltex in Korea, contributing to improved income from equity affiliates. By 2024, Chevron maintained a 50% ownership stake in GS Caltex Corporation, which operates as a joint venture with GS Energy, importing, producing, and marketing petroleum products, petrochemicals, and lubricants. Additionally, in 2024, Chevron reported $13,850 million in sales and other operating revenues with affiliated companies, including GS Caltex, compared to $16,286 million in 2022. This indicates that while the joint venture remained strategically important, the level of downstream-related revenue with affiliated companies slightly decreased over the period.",
      "llm_answer": "\nChevron’s equity investment in GS Caltex slipped modestly—from roughly $4.3 bn in 2022 to $4.14 bn in 2024—while the earnings it receives from the joint venture fell dramatically, from $874 million in 2022 to $437 million in 2023 and only $58 million in 2024.  This sharp decline reflects weaker profitability in the Korean downstream market over the period.  Nevertheless, the JV remains strategically important to Chevron as its primary foothold in Asia, providing critical market access, brand distribution and a platform for future growth despite the recent earnings dip.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that Chevron maintained a 50% ownership stake in GS Caltex and does not mention any change in equity investment value or earnings from the joint venture. The LLM claims Chevron's equity investment decreased from $4.3B to $4.14B and that earnings dropped from $874M in 2022 to $58M in 2024—none of which is supported by the original answer. The only revenue figure provided in the ground truth is total sales and other operating revenues with affiliated companies (including GS Caltex), which were $16,286M in 2022 and $13,850M in 2024. The LLM incorrectly attributes these figures to GS Caltex alone and misrepresents them as equity earnings. (2) Quantitative accuracy is very low: none of the specific numbers in the LLM answer (e.g., $4.3B, $4.14B, $874M, $437M, $58M) appear in or can be derived from the ground truth. The actual revenues with affiliated companies declined from $16,286M to $13,850M, but this is not the same as downstream-related earnings from GS Caltex specifically. (3) The multi-hop reasoning is flawed. While the LLM attempts to infer strategic importance—correctly noting the JV’s role in Asian market access—this conclusion is based on fabricated financial trends. The original answer indicates the JV remained strategically important despite a slight decrease in affiliated revenues, not due to a dramatic earnings collapse. (4) Contextual relevance is moderate because the LLM addresses the evolution of the relationship and strategic importance, but the reasoning is built on incorrect data. Correctness and quantitative accuracy are low due to complete mismatch in financial figures and metrics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 469,
        "total_tokens": 1804
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did the financial performance and production status of the CH-53K program evolve from 2022 to 2024, particularly in terms of risk retirements and production volume?",
      "original_answer": "In 2022, the CH-53K program contributed to higher operating profit for Sikorsky helicopter programs, with approximately $140 million in increased profit driven by higher risk retirements and production volume. By 2024, while the CH-53K remained a key product within RMS, the overall operating profit for RMS declined significantly—by 73%—partially due to lower profit booking rate adjustments across the portfolio. Although specific profit figures for CH-53K were not disclosed in 2024, the broader profit decline suggests that the gains from risk retirements observed in 2022 may have diminished as the program matured and entered higher-volume production.",
      "llm_answer": "\nFrom 2022 through 2024 the CH‑53K heavy‑lift helicopter program drove higher production volumes that translated into measurable revenue and profit gains—net sales from the program rose by roughly $140 million in 2024 and contributed about $115 million of the increase in RMS operating profit that year.  At the same time, the favorable profit‑booking (risk‑retirement) adjustments that had previously lifted earnings were largely exhausted, so the magnitude of risk‑retirements declined (with only modest unfavorable adjustments appearing in 2024), but the program continued to generate positive volume‑driven profit and a growing backlog, indicating sustained demand and improving production momentum.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It states that net sales from the CH-53K program rose by $140 million in 2024 and contributed $115 million to RMS operating profit that year. However, the ground truth indicates that the $140 million increase in profit occurred in 2022, not 2024, and was due to higher risk retirements and production volume. There is no mention of a $115 million contribution in 2024 in the original answer, nor is there any specific profit figure disclosed for CH-53K in 2024. Instead, the original answer notes a 73% decline in RMS operating profit in 2024, suggesting reduced gains from risk retirements. (2) The quantitative inaccuracies are severe: the $140 million figure is misattributed to 2024 instead of 2022, and a new figure ($115 million) is introduced with no basis in the ground truth. The direction of the trend is also misrepresented—profit gains were strong in 2022 but declined by 2024, contrary to the LLM's implication of continued growth. (3) The multi-hop reasoning is flawed. While the LLM correctly identifies that risk retirements declined as the program matured, it incorrectly infers continued strong profit growth in 2024, contradicting the documented 73% drop in RMS profitability. It fails to synthesize the key point that the earlier gains were not sustained into 2024. (4) Despite these errors, the answer is contextually relevant, addressing production volume, risk retirements, and program status. Some qualitative elements—like the idea that risk retirements diminished as the program matured—are consistent with the ground truth. However, the core financial facts and trends are incorrect, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1345,
        "completion_tokens": 468,
        "total_tokens": 1814
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has PayPal's approach to seller protection programs evolved between 2022 and 2023, particularly in terms of risk exposure and strategic emphasis?",
      "original_answer": "In 2022, PayPal highlighted that its seller protection programs carried risk exposure tied to regional variations and regulatory changes, with historical transaction loss rates ranging between 0.09% and 0.15% of TPV. By 2023, the company placed a stronger strategic emphasis on these programs as a competitive differentiator, explicitly linking them to merchant trust and platform growth. While 2022 focused on risk management and potential loss implications, 2023 framed seller protection as part of a broader value proposition to attract and retain merchants, integrating it with analytics, risk management, and other merchant services.",
      "llm_answer": "\nBetween 2022 and 2023 PayPal shifted from a largely reactive, reserve‑driven view of seller‑protection risk to a more strategic, risk‑adjusted framework.  In the 2022 filing the company highlighted that transaction‑loss rates (0.09‑0.15 % of TPV) could rise if macro‑economic stress triggered more merchant failures, and it described the protection programs mainly as a cost‑center to be monitored.  By 2023 the language emphasizes tighter loss‑reserve assumptions, refined eligibility criteria and the use of protection programs to bolster merchant confidence and support growth of credit‑based offerings, indicating that the firm is deliberately managing exposure while positioning seller protection as a growth lever rather than merely a risk‑mitigation expense.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, the transaction loss rates of 0.09%–0.15% of TPV are correctly cited from the 2022 data, and the years (2022 vs 2023) are accurately referenced. No calculations were required, but the use of percentages matches the original. (2) The answer captures the evolution in PayPal’s approach: in 2022, seller protection was framed around risk exposure and macroeconomic sensitivity, described as a cost-center—consistent with the original emphasis on risk management and loss implications. By 2023, the shift toward strategic emphasis is correctly identified, with seller protection linked to merchant confidence and growth, particularly in support of credit-based offerings. This reflects the original answer’s point about integrating protection into a broader value proposition. (3) Multi-hop reasoning is sound: the model synthesizes changes in tone, strategic framing, and risk management practices across two years, correctly inferring a shift from risk mitigation to growth enablement. (4) Minor deduction in qualitative accuracy due to the introduction of the term 'reserve-driven' and 'tighter loss-reserve assumptions,' which, while plausible, are not explicitly stated in the ground truth. However, these do not contradict the source and are reasonable inferences. Overall, the answer is semantically equivalent, contextually precise, and factually correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 399,
        "total_tokens": 1751
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Starbucks' approach to its ready-to-drink beverages evolved between 2023 and 2024, particularly in terms of revenue recognition and supplier dependency?",
      "original_answer": "In 2023, Starbucks recognized revenue from ready-to-drink beverages under the 'Other Revenues' category, where sales were generally recognized upon shipment to customers depending on contract terms. By 2024, the company's focus shifted to supplier dependency and supply chain resilience, emphasizing that ready-to-drink beverages are sourced from specialty suppliers under long-term contracts, indicating a strategic move toward securing stable supply rather than just reporting revenue. While 2023 included ready-to-drink beverages in broader revenue disclosures without specific figures, 2024 highlighted the importance of supplier relationships to mitigate delivery risks, signaling a shift from revenue-centric reporting to a supply-chain risk management focus.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 Starbucks moved the recognition of ready‑to‑drink (RTD) revenue from a generic “other‑revenues” line that was recorded when the product shipped to external customers, to a dedicated Channel‑Development entry that records sales of packaged and RTD beverages to Nestlé (and other licensees) and recognizes that revenue upon shipment, with royalties on Nestlé’s reported sales.  This change reflects a strategic shift to rely on the Global Coffee Alliance with Nestlé for packaging, distribution and market reach, thereby increasing supplier dependency on Nestlé compared with the more internally‑controlled RTD sales described in the 2023 filing.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures part of the evolution in Starbucks' ready-to-drink (RTD) beverage strategy but introduces significant inaccuracies in entity identification and reasoning. (1) Correct elements: The shift in revenue recognition from a generic 'Other Revenues' category to a more specific reporting line (referred to as 'Channel Development') is consistent with the ground truth’s emphasis on evolving disclosure practices. The mention of revenue recognition upon shipment aligns with the original answer. (2) Quantitative accuracy: There are no explicit numerical values (e.g., dollar amounts, percentages) in either answer, so this aspect does not detract; the years 2023 and 2024 are correctly used. (3) However, the LLM incorrectly identifies Nestlé as a central entity in Starbucks’ 2024 strategy, claiming increased dependency on Nestlé under the Global Coffee Alliance. The ground truth makes no mention of Nestlé, royalties, or a dedicated Channel Development segment—this is a factual overreach not supported by the provided knowledge. The original answer emphasizes 'specialty suppliers' broadly and a shift toward supply chain resilience, not a specific partnership. (4) The reasoning is partially sound in identifying a shift from revenue reporting to supply chain focus, but the LLM reverses the emphasis: it frames the change as a move to greater supplier dependency (on Nestlé), while the ground truth describes a strategic focus on managing supplier risk through long-term contracts—not necessarily increased dependency. This misrepresents the nature of the evolution. The answer is contextually relevant and addresses both revenue recognition and supplier dependency, but with incorrect entity details and flawed synthesis, reducing its overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 480,
        "total_tokens": 1844
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did the geographic reach and regulatory approvals of Trodelvy evolve between 2022 and 2023?",
      "original_answer": "In 2022, Trodelvy generated $370 million in U.S. sales and $10 million in Europe, with no sales reported in other international markets, indicating limited geographic reach. By 2023, Trodelvy received significant regulatory approvals: it was approved by the FDA for treating adult patients with HR+/HER2- metastatic breast cancer, and it obtained EC approval for monotherapy treatment of unresectable or metastatic HR+/HER2- breast cancer. These approvals suggest an expansion of Trodelvy's market access and therapeutic application, likely contributing to broader geographic distribution beyond what was reported in 2022.",
      "llm_answer": "\nBetween 2022 and 2023 Trodelvy’s existing approvals in the United States, the European Union, Canada and the other Orbis‑partner countries (Australia, Great Britain, Switzerland) remained in place, but the drug’s label was broadened with new regulatory approvals: the FDA granted full approval for monotherapy in adults with unresectable locally‑advanced or metastatic HR‑positive/HER2‑negative breast cancer, and the European Commission subsequently approved the same indication in the EU. Thus, while the geographic scope of approval did not expand further, the therapeutic reach of Trodelvy was extended to a new breast‑cancer population in both the U.S. and Europe.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key regulatory developments for Trodelvy between 2022 and 2023—specifically, the FDA and European Commission approvals for HR+/HER2- metastatic breast cancer. These match the ground truth in terms of indication and approving bodies. However, the LLM omits the quantitative sales data from 2022 ($370M in U.S., $10M in Europe), which is a key part of the original answer and directly addresses the 'geographic reach' component of the question. While the LLM mentions continued approvals in the U.S., EU, Canada, and Orbis countries, this information is not present in the ground truth and may reflect overinference or external knowledge not supported by the provided data. (2) There are no numerical inaccuracies in the LLM answer because it does not include any numbers—this avoids error but also fails to include critical quantitative evidence from the original answer. Thus, quantitative accuracy is high by avoidance, but incompleteness remains an issue. (3) The reasoning is sound in interpreting that label expansion indicates broader therapeutic use, aligning with the original answer’s conclusion about expanded market access. However, the LLM incorrectly implies that geographic reach did not expand, whereas the original answer suggests that increased approvals likely contributed to broader geographic distribution beyond 2022’s limited footprint. This misrepresents the inference in the ground truth, weakening the multi-hop synthesis. (4) The contextual relevance is high because the answer addresses both regulatory approvals and geographic scope, but the absence of sales data and slight mischaracterization of geographic evolution justify a moderate correctness score of 7.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 474,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did Simon Property Group's ownership stake and financial gains from transactions involving ABG evolve between 2023 and 2024?",
      "original_answer": "In 2023, Simon Property Group (SPG) experienced multiple dilutions of its ownership stake in ABG through capital transactions, including a reduction from approximately 12.3% to 11.8%, then to 11.7%, and finally to approximately 9.6%. These transactions resulted in non-cash pre-tax gains of $36.4 million, $12.4 million, and $10.3 million, respectively. By contrast, in 2024, SPG no longer disclosed active changes in its ownership stake in ABG. Instead, it referenced a prior transaction from December 20, 2021, where it sold a portion of its interest in ABG for a pre-tax gain of $18.8 million and later acquired additional interests for $100.0 million. This indicates a shift from active stake reduction and financial recognition in 2023 to a more passive disclosure stance in 2024, with no new transactions reported.",
      "llm_answer": "\nBetween 2023 and 2024 Simon Property Group’s stake in ABG was steadily reduced and ultimately eliminated.  In 2023 the company’s ownership fell from roughly 12 % to about 9.6 % after a series of capital‑transaction dilutions, and it recognized a $157.1 million pre‑tax gain on a partial cash sale plus a $10.3 million non‑cash gain from the related deemed disposal (plus earlier 2023 gains of $12.4 million and $36.4 million from prior dilutions, for a total 2023 ABG‑related gain of roughly $216 million).  In the first quarter of 2024 SP Group sold its remaining ABG interest for $1.2 billion cash, generating a $414.8 million pre‑tax gain, thereby ending its ownership in ABG.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Simon Property Group (SPG) reduced its ownership stake in ABG from 12.3% to 9.6% through multiple dilution events in 2023, with no complete elimination of the stake. However, the LLM incorrectly claims that SPG 'sold its remaining ABG interest' in Q1 2024 for $1.2 billion, resulting in a $414.8 million gain—this transaction is entirely fabricated and not supported by the original answer. Additionally, the LLM states that SPG recognized a $157.1 million pre-tax gain on a 'partial cash sale,' which does not appear in the ground truth; the actual 2023 gains were non-cash and amounted to $36.4M, $12.4M, and $10.3M respectively, totaling $59.1M—not $216M as claimed. (2) Number verification: The stake percentages (12.3% → 11.8% → 11.7% → 9.6%) are partially correct but misrepresented as a continuous decline to 9.6% without mentioning the stepwise dilutions. The gains are completely miscalculated: $36.4M + $12.4M + $10.3M = $59.1M total, not $216M. The $157.1M and $414.8M figures have no basis in the original data. (3) Multi-hop reasoning failure: The model incorrectly infers an active sale in 2024, while the ground truth explicitly states that SPG did *not* report any new transactions in 2024 and only referenced a prior 2021 transaction. This reflects a failure to synthesize the shift from active stake reduction in 2023 to passive disclosure in 2024. (4) The contextual relevance is moderate because the answer addresses ownership changes and financial gains, but the core facts—especially regarding 2024—are invented, leading to a very low correctness and accuracy scores.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1370,
        "completion_tokens": 462,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How has the 2012 Equity Incentive Plan evolved between the 2023 and 2024 filings, particularly in terms of amendments and forms of award agreements disclosed?",
      "original_answer": "In 2023, the 2012 Equity Incentive Plan was disclosed as amended, including the Third Amendment to the plan, and referenced forms of award agreements from 2012 and 2017. In 2024, the filing included a Fourth Amendment dated August 1, 2024, and introduced additional forms of award agreements from April 2024, showing continued evolution and expansion of the plan over time.",
      "llm_answer": "\nBetween the 2023 and 2024 Form 10‑K filings, Meta added a **fourth amendment to its 2012 Equity Incentive Plan** (the “Fourth Amendment” disclosed as Exhibit 10.2(C)+ in the 2024 filing) and introduced new **forms of award agreements** under that amendment (e.g., the “2012 Equity Incentive Plan forms of award agreements (Additional Forms)” listed as Exhibit 10.2(K)+ and 10.2(L)+ in 2024). The 2023 filing already showed the **Third Amendment** (Exhibit 10.2(B)+) and a suite of prior award‑agreement forms (through 10.2(J)+), so the 2024 updates reflect both a further amendment to the plan and updated, more recent award‑agreement templates.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) It accurately identifies the evolution of the 2012 Equity Incentive Plan between 2023 and 2024 filings: the 2023 filing included the Third Amendment and prior award agreement forms (referencing up to 10.2(J)+), while the 2024 filing introduced the Fourth Amendment (dated August 1, 2024, though the exact date isn't mentioned in the LLM answer, the amendment number and exhibit reference are correct), and new forms of award agreements from April 2024 (listed as Exhibits 10.2(K)+ and 10.2(L)+). (2) All entities are correct—Meta (implied by context), the 2012 Equity Incentive Plan, correct amendment numbers (Third and Fourth), and correct exhibit references. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of filings, compares amendments, and identifies the addition of new award agreement forms. (4) While the LLM does not explicitly state the August 1, 2024 date or the April 2024 forms' timing, these omissions do not detract from the core factual accuracy, as the key developments—Fourth Amendment and new forms—are correctly identified with proper exhibit labeling. The answer conveys semantic equivalence to the original and provides even more granular detail (exhibit numbers), enhancing precision. Thus, all scores are 10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1257,
        "completion_tokens": 378,
        "total_tokens": 1636
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did the treatment and valuation of capitalized software licenses evolve between 2022 and 2023, and what does this indicate about the company's investment in software licensing?",
      "original_answer": "In 2022, capitalized software licenses were described as being generally amortized on a straight-line basis over the term of the license, indicating a clear policy for their depreciation over time. By 2023, the company disclosed the actual carrying value of these licenses on the balance sheet at $223 million, up from $152 million in 2022. This increase suggests a growing investment in software licensing, despite the unchanged amortization policy. The evolution from a disclosed accounting method in 2022 to a quantified asset in 2023 reflects a more tangible and increasing role of capitalized software licenses in the company's asset structure.",
      "llm_answer": "\nBetween 2022 and 2023 the company’s capitalized software‑license balance rose from **$152 million to $223 million**.  The licenses are recorded at cost (or fair value when acquired in a business combination) and then amortized on a straight‑line basis over the contractual term of each license.  The increase shows that the firm added new software licenses—or extended existing ones—during 2023, signaling a higher level of investment in software‑related intangible assets.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers are correct: the capitalized software licenses increased from $152 million in 2022 to $223 million in 2023, matching the original answer exactly. Format is consistent and precise. (2) The accounting treatment—amortization on a straight-line basis over the contractual term—is correctly described and consistent with the 2022 disclosure. (3) The reasoning is sound: the increase in carrying value is correctly interpreted as evidence of increased investment in software licensing, which reflects valid multi-hop synthesis between the 2022 policy disclosure and the 2023 quantified asset value. (4) The only minor omission is that the LLM does not explicitly note the evolution in disclosure practice—from a method-only description in 2022 to a reported carrying value in 2023—which adds nuance about transparency and asset tangibility. However, this does not detract significantly from the core factual and interpretive accuracy. The answer is contextually excellent, directly addressing both the treatment/valuation evolution and the implication for investment strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 331,
        "total_tokens": 1620
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did PayPal's utilization of European customer balances for credit activities evolve between 2022 and 2023, and what does this indicate about its strategic approach to funding credit products?",
      "original_answer": "In 2022, PayPal had approved $3.8 billion of European customer balances for credit activities, representing approximately 37% of European customer balances available for corporate use. In 2023, this approved amount decreased to $3.0 billion, representing 39% of European customer balances. This indicates a slight reduction in the total approved funding base but a higher percentage utilization of available balances, suggesting a more efficient use of existing customer balances for credit activities. Additionally, PayPal entered into a new €40 billion agreement in 2023 to sell consumer installment receivables, with $5.5 billion sold during the year, signaling a strategic shift toward external funding mechanisms to support credit product expansion.",
      "llm_answer": "\nBetween 2022 and 2023 the pool of European customer balances that PayPal can earmark for credit‑product funding fell modestly—from about **$3.8 billion (≈ 37 % of European balances)** in 2022 to **$3.0 billion (≈ 39 % of European balances)** in 2023—while the governing limit was expanded from **35 % to 50 %** of those balances.  This shows that PayPal is deliberately **concentrating a larger share of its own customer‑deposit base to finance credit products**, using internal funds rather than external debt, and is positioning its European cash pool as a core source of financing for its growing credit portfolio.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the $3.8 billion in 2022 and $3.0 billion in 2023, as well as the 37% and 39% utilization rates, which matches the ground truth. However, it introduces a fact not present in the original answer — that the governing limit was expanded from 35% to 50% — which is unsupported by the provided ground truth and therefore incorrect. Additionally, the LLM omits the key strategic development in 2023: the new €40 billion agreement to sell consumer installment receivables, with $5.5 billion sold during the year. This is a major omission, as it directly relates to PayPal’s strategic shift toward external funding mechanisms, which contrasts with the LLM’s claim that PayPal is relying more on internal funds. (2) Quantitative accuracy is partially correct: the dollar amounts and percentages are accurate, but the added 35% to 50% limit change is fabricated and cannot be verified. There are no calculation errors in the numbers presented, but the inference drawn from them is flawed due to missing context. (3) The multi-hop reasoning is unsound because the LLM fails to incorporate the critical new external funding agreement, leading to an incorrect conclusion about strategy. Instead of recognizing a shift toward external funding, it asserts a strategy of internal funding concentration, which contradicts the ground truth. (4) The contextual relevance is high because the answer addresses the evolution of balance utilization and attempts to interpret strategic intent. However, due to significant factual omission and an unsupported claim, the qualitative and overall correctness scores are reduced. The answer gets core numbers right but misrepresents the strategic direction, resulting in a partially correct but misleading response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 484,
        "total_tokens": 1840
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has Starbucks' investment relationship with Valor Siren Ventures I L.P. evolved between fiscal years 2023 and 2024, particularly in terms of the carrying value of the investment and its financial impact on Starbucks' consolidated statements?",
      "original_answer": "In fiscal 2023, Starbucks held a limited partnership interest in Valor Siren Ventures I L.P., with the total carrying value of such investments not specifically disclosed for that year. The financial impact of these investments, including Valor Siren Ventures I L.P., was included in 'interest income and other, net' and was not considered material. By fiscal 2024, the total carrying value of Starbucks' investments in Valor Siren Ventures I L.P. and II L.P. combined was $211.9 million as of September 29, 2024. The investment relationship evolved from a general equity stake to a more defined and quantified investment with ongoing monitoring, though the financial impact remained non-material and continued to be reported in 'interest income and other, net.'",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 the carrying amount of Starbucks’ limited‑partner interest in Valor Siren Ventures I L.P. (reported as “Other investments” in the equity‑investments table) increased from **$24.2 million** as of October 1 2023 to **$39.8 million** as of September 29 2024, reflecting additional capital commitments or valuation changes.  The fund’s share of income or loss is recorded in “interest income and other, net,” and the company notes that this impact is **not material**, so the investment has had no significant effect on Starbucks’ consolidated statements of earnings or financial position.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that the carrying value for Valor Siren Ventures I L.P. was not specifically disclosed in fiscal 2023, but the LLM claims it was $24.2 million as of October 1, 2023—this number is incorrect and not supported by the original answer. Additionally, the LLM reports a carrying value of $39.8 million for Valor Siren I alone in 2024, while the ground truth states that the combined carrying value of Valor Siren I and II was $211.9 million as of September 29, 2024. The LLM incorrectly separates the two funds and assigns an unsupported value to Fund I alone, failing to reflect the combined nature of the disclosed amount. (2) The dates (October 1, 2023 and September 29, 2024) are plausible fiscal year-end dates for Starbucks, but the associated values are factually wrong. There is no mention in the ground truth of a $24.2M or $39.8M figure for Valor Siren I, nor is there a breakdown between Fund I and Fund II. The calculation or comparison implied (increase from $24.2M to $39.8M) is therefore invalid. (3) The multi-hop reasoning is flawed: the model fails to recognize that the 2023 value was not disclosed and incorrectly invents a specific figure. It also fails to synthesize that the $211.9M figure in 2024 includes both Fund I and Fund II, instead attributing $39.8M to Fund I alone. This shows a failure in entity-level synthesis and incorrect disaggregation of reported totals. (4) While the LLM correctly identifies that the financial impact is recorded in 'interest income and other, net' and is not material, which aligns with the ground truth, the core quantitative facts—carrying values and their evolution—are incorrect. Hence, despite correct contextual framing and terminology, the answer is mostly wrong on key facts, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1370,
        "completion_tokens": 506,
        "total_tokens": 1877
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has the strategic positioning of Analog Products evolved between 2022 and 2023 in terms of TI's competitive advantages and financial contribution?",
      "original_answer": "In 2022, Analog Products were central to TI's strategic focus, contributing to a gross margin of 67.5% driven by the efficiency of their manufacturing strategy, including 300-millimeter production. By 2023, Analog Products remained a core pillar but were framed more explicitly within the context of TI's four sustainable competitive advantages, particularly emphasizing lower costs and greater control of the supply chain. Additionally, the 2023 report reinforced the role of Analog Products in enabling TI to generate and return significant cash, with a renewed emphasis on long-term free cash flow per share growth as the ultimate performance metric.",
      "llm_answer": "\nBetween 2022 and 2023 Analog Products kept its strategic role—TI still leans on the same four sustainable advantages (low‑cost, controllable manufacturing; a broad analog‑and‑embedded portfolio; deep market reach; and diversified, long‑life products)—but the segment’s financial impact slipped.  Revenue fell 15 % (from $15.36 bn to $13.04 bn) and operating profit dropped 30 % (from $8.36 bn to $5.82 bn), pushing the operating‑profit margin down from 54.4 % of revenue to 44.6 %.  The decline reflects lower shipments and higher capacity‑related costs, yet Analog continues to be the primary cash‑generating engine that supports TI’s free‑cash‑flow‑per‑share growth objective.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces specific financial figures—revenue of $15.36B in 2022 and $13.04B in 2023, operating profit dropping from $8.36B to $5.82B, and resulting margins of 54.4% and 44.6%—that are not present in the original answer (ground truth). The ground truth does not mention revenue or operating profit figures, nor any percentage declines in revenue or profit. Instead, it focuses on gross margin (67.5% in 2022) and strategic framing around TI’s four sustainable competitive advantages and free cash flow per share. These specific numbers in the LLM response cannot be verified from the ground truth and appear fabricated or hallucinated. (2) The calculation of the 15% revenue decline and 30% operating profit drop, while mathematically plausible given the numbers provided, are not supported by the original answer and thus represent unsupported inferences. The gross margin of 67.5% in 2022 from the original answer is not addressed in the LLM response, which instead cites operating margin, a different metric. (3) The qualitative reasoning partially aligns: the LLM correctly identifies that Analog Products remained strategically important and tied to TI’s sustainable advantages and cash generation. It also correctly notes the emphasis on supply chain control and cost efficiency. However, it incorrectly frames the evolution as a 'decline' in financial contribution due to lower shipments and higher costs—information not present in the ground truth. The original answer emphasizes continuity and reframing, not deterioration. (4) Despite the hallucinated numbers, the LLM captures the core strategic narrative—continued centrality of Analog Products, alignment with TI’s competitive advantages, and role in cash generation—making the answer contextually relevant. However, the inclusion of unsupported quantitative data severely undermines factual correctness. Correctness score is 4 due to partial qualitative alignment but major quantitative inaccuracies. Quantitative accuracy is low (3) due to unsupported figures. Qualitative accuracy is moderate (5) as key themes are present but distorted by incorrect financial context. Contextual relevance is high (8) because the answer addresses the right strategic dimensions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 603,
        "total_tokens": 1937
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Chevron's capital allocation strategy in the Lower 48 region evolved from 2022 to 2023, based on the changes in depreciation, depletion, amortization, and impairments?",
      "original_answer": "Chevron's capital allocation in the Lower 48 region increased significantly from 2022 to 2023, as evidenced by the rise in depreciation, depletion, amortization, and impairments from $4,854 million in 2022 to $5,729 million in 2023. This indicates a growing focus on asset development and operational expansion in the Lower 48, contrasting with relatively stable or declining figures in other geographic segments like Europe, Middle East and North Africa.",
      "llm_answer": "\nFrom 2022 to 2023 the Lower 48 segment’s depreciation, depletion and amortization (including impairments) rose sharply from **$4.85 bn to $5.73 bn**—an increase of roughly **18 %**—while capital expenditures in that region jumped from **$5.63 bn to $6.49 bn**.  This higher D&A reflects a strategic shift toward greater investment in developing and appraising Lower 48 assets, resulting in larger depletion charges as production continues, and indicates that capital allocation in 2023 was directed more toward expanding the Lower 48 portfolio rather than returning cash to shareholders.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer is factually correct in all key aspects: the D&A (depreciation, depletion, amortization, and impairments) values for 2022 ($4.85 billion) and 2023 ($5.73 billion) match the ground truth of $4,854 million and $5,729 million when rounded (i.e., $4.854B ≈ $4.85B, $5.729B ≈ $5.73B). The 18% increase is accurate: (5.729 - 4.854) / 4.854 ≈ 0.1799 or ~18%. The capital expenditures cited ($5.63B to $6.49B) are consistent with external Chevron 10-K filings, though not part of the original answer; however, they do not contradict it and add context. 2) Quantitative accuracy is excellent: all numbers align with the ground truth within acceptable rounding, and the percentage calculation is correct. 3) The reasoning is sound—increased D&A is correctly interpreted as evidence of higher capital allocation and asset development in the Lower 48, reflecting a strategic shift. The answer goes beyond the original by linking to capex and shareholder returns, which is a reasonable inference but not explicitly in the ground truth. 4) The answer is semantically equivalent and adds value without introducing errors. The only minor limitation is that it introduces capex data not in the original answer, which, while accurate, slightly extends beyond the scope of the provided ground truth. However, this does not detract from correctness. Thus, the answer earns a 9/10 for correctness and qualitative accuracy due to slight over-enrichment, but full marks for quantitative and contextual performance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1268,
        "completion_tokens": 413,
        "total_tokens": 1681
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Verizon's approach to FWA Broadband evolved between 2023 and 2024, particularly in terms of its positioning within the company's product portfolio and its target customer segments?",
      "original_answer": "In 2023, Verizon provided FWA broadband through both 5G and LTE networks, targeting both Consumer and Business customers, and reported 3.1 million FWA broadband connections. By 2024, the company continued to offer FWA broadband primarily under the Verizon Consumer and Business Group segments, but with a more integrated positioning as an alternative to traditional landline internet access and as part of a broader portfolio that includes IoT and advanced communication services. The shift from 'provides' in 2023 to 'produces' in 2024 indicates a more strategic and product-centric approach to FWA broadband.",
      "llm_answer": "\nBetween 2023 and 2024 Verizon shifted FWA broadband from a niche “alternative to landline” offering to a central element of its product portfolio—now counted among wireless retail connections and promoted alongside Fios as a primary broadband service for residential and small‑business customers in underserved areas.  At the same time, within the Business segment FWA is packaged as a fixed‑wireless solution for Enterprise, Public‑Sector and Business‑Markets customers, emphasizing use cases such as enterprise networking, IoT and private‑network connectivity and leveraging the company’s expanding 5G/C‑Band spectrum.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of qualitative evolution and strategic positioning of Verizon's FWA broadband between 2023 and 2024. It accurately captures the shift toward a more central, integrated role within the product portfolio and the expansion into both consumer and business segments. The mention of FWA being promoted alongside Fios and targeted at underserved areas adds contextual detail not contradicted by the original answer. The business segment focus on enterprise, public sector, IoT, and private networks reflects the broader strategic direction noted in the ground truth. However, the LLM answer introduces the idea that FWA became a 'central element' and is now 'counted among wireless retail connections,' which is a stronger characterization than the original answer's more measured observation about a shift in language from 'provides' to 'produces' indicating a more product-centric approach. This represents a slight overstatement in strategic emphasis not fully supported by the ground truth. There are no numerical figures in either answer, so quantitative accuracy is not applicable—scored as 10 by default since no numbers were misstated. The reasoning is sound and synthesizes the multi-hop elements (evolution over time, portfolio positioning, customer segments), though with minor interpretive overreach. Contextual relevance is excellent, directly addressing all parts of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 403,
        "total_tokens": 1721
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Emerson's relationship with AspenTech evolved from 2022 to 2024, and what financial impact did this evolution have on Emerson's gross margin and equity structure?",
      "original_answer": "In 2022, Emerson partnered with AspenTech, leveraging its asset optimization software to enhance industrial operational efficiency. By 2024, Emerson had significantly deepened this relationship by acquiring a 55% ownership stake in AspenTech as part of a strategic transaction that created 'New AspenTech.' This acquisition contributed positively to Emerson’s gross margin, benefiting it by 0.6 percentage points in 2023 and further influencing financial structure in 2024 with increased SG&A expenses tied to the integration. Additionally, the equity structure was impacted through the recognition of gains and losses associated with the AspenTech stock plans and the broader restructuring of industrial software assets.",
      "llm_answer": "\nFrom 2022 – when Emerson contributed its industrial‑software businesses and invested $6 bn to own roughly 55 % of AspenTech – to 2024, the relationship moved toward full ownership: in November 2024 Emerson announced a cash‑only proposal to buy the remaining AspenTech shares at $240 per share, which would give Emerson 100 % of the company.  This evolution lifted software‑and‑control sales (a 48 % increase in 2024) and helped push consolidated gross margin up to 50.8 % in 2024 (an increase of 1.8 percentage points), although the benefit was partially offset by inventory‑step‑up amortization.  At the same time, Emerson’s equity structure changed from a 55 % equity‑method investment (with a non‑controlling interest recorded in other assets) to a planned full consolidation of AspenTech, eliminating the non‑controlling stake and adding AspenTech’s assets, liabilities and equity to Emerson’s balance sheet.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness, despite addressing the right question structure and demonstrating relevant reasoning. (1) Key facts are incorrect: the original answer states that Emerson acquired a 55% stake in AspenTech by 2024 as part of forming 'New AspenTech', but the LLM claims Emerson already owned 55% in 2022 and then moved toward full ownership with a $240/share offer in November 2024—this timeline and transactional detail (especially the $240/share bid) are not supported by the ground truth. The $6 billion investment figure and the cash-only acquisition proposal are unverified additions. (2) Quantitative accuracy is poor: the LLM reports a 1.8 percentage point increase in gross margin to 50.8% in 2024, but the ground truth states a 0.6 percentage point benefit in 2023 with ongoing structural impacts in 2024—these numbers do not align. The 48% sales increase is unsupported in the original. (3) Qualitatively, the model correctly identifies the deepening relationship and equity structure changes (e.g., shift from equity-method accounting to consolidation), which shows sound multi-hop reasoning about financial implications. (4) Contextual relevance is high—the answer focuses on the evolution of the relationship and its impact on gross margin and equity structure as asked. However, due to major factual and numerical errors, especially in financial figures and transaction timing, the overall correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1414,
        "completion_tokens": 411,
        "total_tokens": 1825
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How did the financial relationship between NEE and FPL Group Capital Inc evolve from 2022 to 2023, particularly in terms of the nature of their obligations and capital structure involvement?",
      "original_answer": "In 2022, the relationship was characterized by a guarantee agreement between FPL Group, Inc. and FPL Group Capital Inc. dated October 14, 1998, indicating a direct obligation from FPL Group, Inc. to FPL Group Capital Inc. By 2023, this relationship had evolved into a more complex capital structure involvement, with NEE issuing multiple series of junior subordinated debentures to FPL Group Capital Inc., including Series B, C, L, M, N, O, and P, with maturity dates ranging from 2057 to 2082. This transition reflects a strategic shift from a simple guarantee to a long-term capital financing arrangement.",
      "llm_answer": "\nBetween 2022 and 2023 the NEE‑FPL Group Capital relationship stayed anchored in the same junior‑subordinated‑debt framework, but the parties added new series of those debentures—specifically the Series J debentures (effective August 5 2022, referenced in *4(rr)) and the Series K debentures (effective March 1 2023, referenced in *4(uu))—along with related floating‑rate notes and purchase‑contract/pledge agreements with BNY Mellon (*4(t), *4(x), *4(w), *4(xx), *4(yy)).  These moves extended maturities into the 2025‑2030 range and reinforced FPL Group Capital’s role as a financing conduit for NEE, while preserving the existing guarantee and pledge structure that has underpinned their capital‑structure ties since the late‑1990s.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in both factual content and reasoning when compared to the ground truth. (1) The core claim that the relationship remained within a 'junior-subordinated-debt framework' in 2022 is false: the original answer states that in 2022, the relationship was based on a 1998 guarantee agreement between FPL Group, Inc. and FPL Group Capital Inc., not on debentures issued by NEE. The transition to junior subordinated debentures occurred in 2023, not before. (2) The LLM cites Series J and K debentures with effective dates in 2022 and 2023, but the ground truth specifies Series B, C, L, M, N, O, and P — not J or K — with maturities from 2057 to 2082, not 2025–2030. These are significant factual errors in both series designation and maturity dates. (3) The LLM incorrectly implies continuity in structure, while the original answer describes a strategic shift from a simple guarantee to long-term capital financing via new debentures. This misrepresents the nature of the evolution. (4) The mention of BNY Mellon agreements and floating-rate notes with specific exhibit references (*4(t), *4(x), etc.) introduces details absent from the ground truth and not supported by the provided knowledge. (5) Multi-hop reasoning fails: the model does not correctly identify the change in obligation type (from guarantee to debentures) or the correct entities involved (NEE issuing to FPL Group Capital Inc.). While the answer is contextually relevant—focusing on NEE and FPL Group Capital’s financial relationship—it is factually divergent in key aspects. Minor credit is given for addressing the general theme of structural evolution in financing. Quantitative accuracy is very low due to incorrect dates, series, and maturity ranges.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 474,
        "total_tokens": 1821
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has the positioning and market acceptance of InterStim II evolved between 2022 and 2024, particularly in relation to other InterStim neurostimulators and broader Pelvic Health therapies?",
      "original_answer": "In 2022, InterStim II was described as part of a suite of InterStim neurostimulators including InterStim Micro and InterStim X, with an emphasis on continued acceptance and growth in treating overactive bladder, urinary retention, and bowel incontinence. By 2024, InterStim II was specifically highlighted as a recharge-free neurostimulator, grouped alongside InterStim X and InterStim Micro (now differentiated by recharge status), and positioned within a broader context of continued acceptance and growth of Pelvic Health therapies. This evolution indicates a shift toward emphasizing device-specific attributes (e.g., recharge-free) and integration into a more mature and diversified product portfolio.",
      "llm_answer": "\nBetween 2022 and 2024 InterStim II moved from a newly launched device to a core, widely adopted element of Medtronic’s Pelvic‑Health portfolio.  Its market acceptance grew markedly, as sales of the InterStim II platform were integrated with the existing InterStim Micro and InterStim X neurostimulators and promoted alongside capital‑equipment and minimally invasive pelvic‑therapy initiatives, positioning it as a key therapeutic option for overactive bladder, urinary retention and fecal incontinence within the broader Pelvic‑Health therapy suite.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is mostly correct in conveying the evolution of InterStim II's positioning and market acceptance between 2022 and 2024, with accurate entity identification (InterStim II, InterStim Micro, InterStim X, Medtronic, Pelvic Health therapies) and correct therapeutic indications (overactive bladder, urinary retention, fecal incontinence). There are no numeric values in the question or ground truth, so quantitative accuracy is not applicable—scored as 10 by default. However, the LLM introduces a claim not present in the ground truth: that InterStim II was 'newly launched' in 2022, which is unsupported by the original answer. The ground truth does not indicate launch timing, only continued acceptance. Additionally, the LLM emphasizes integration with 'capital-equipment and minimally invasive pelvic-therapy initiatives,' which adds context not present in the original. While this may be plausible, it is not part of the verified evolution described. The core accurate elements—growing market acceptance, positioning within a diversified portfolio, and role in Pelvic Health therapies—are present. The shift toward emphasizing recharge-free status (a key differentiator by 2024) is missing, which is a notable omission in the qualitative reasoning. Thus, while the answer is contextually relevant and factually aligned in broad strokes, it adds unsupported details and misses a key strategic evolution (recharge status differentiation), warranting a 7 for correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 413,
        "total_tokens": 1738
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Simon Property Group's utilization and management of the Supplemental Facility evolved between 2022 and 2024, particularly in terms of borrowing capacity, interest rate strategies, and repayment actions?",
      "original_answer": "In 2022, the Supplemental Facility had an initial borrowing capacity of $3.5 billion, which could be increased to $4.5 billion, with a maturity date of January 31, 2026. Borrowings under the facility bore interest based on SOFR or similar rates, with a margin determined by the company's credit rating. By 2024, SPG had borrowed €750.0 million under the Supplemental Facility, which was repaid on November 17, 2023, following the issuance of exchangeable bonds. Additionally, interest rate swaps were used in 2023 to fix the rate on these borrowings at 3.81%. This indicates a shift from passive availability in 2022 to active utilization and strategic interest rate management in 2024.",
      "llm_answer": "\nBetween 2022 and 2024 Simon Property Group expanded the Supplemental Facility’s size and runway – the initial $3.5 bn capacity (with a possible rise to $4.5 bn) and a 2026 maturity that was later extended to a 2029 start (plus a further one‑year option to 2030).  The interest‑rate structure stayed SOFR‑based with a spread of roughly 72.5 bp plus a rating‑dependent margin, but the company increasingly hedged euro‑denominated borrowings and used fixed‑rate note issuances to lock in lower costs.  Consequently, it shifted from actively drawing on the facility for liquidity toward using the enlarged, longer‑dated facility as a source of cheap funding to refinance and repay maturing debt (e.g., repaying €750 m of euro borrowings in late 2023 and retiring $1 bn of 2 % notes in September 2024), reducing overall reliance on the Supplemental Facility while preserving flexibility for future acquisitions.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. The ground truth states the Supplemental Facility had a maturity date of January 31, 2026, but the LLM incorrectly claims it was extended to a 2029 start with an option to 2030—this is unsupported and contradicts the original. The LLM also states the facility was 'expanded' in size, but the original only mentions a potential increase to $4.5B from $3.5B, not an actual expansion. The €750M borrowing was correctly identified and repaid in November 2023, which matches the ground truth. However, the LLM adds a repayment of '$1B of 2% notes in September 2024'—this detail is not in the original answer and appears fabricated. The interest rate hedging at 3.81% is omitted; instead, the LLM vaguely references a 'spread of roughly 72.5 bp' and rating-dependent margin, which lacks specificity and does not reflect the actual 3.81% fixed rate via swaps in 2023. (2) Quantitative accuracy is low: incorrect maturity dates (2029/2030 vs 2026), unverified $1B note repayment, missing 3.81% fixed rate, and invented spread value. Only the €750M borrowing and repayment date are correct. (3) Multi-hop reasoning is partially sound—the LLM attempts to show evolution in utilization from 2022 to 2024 and connects borrowing with refinancing actions. However, it introduces unsupported extensions and repayments, undermining the logical synthesis. The strategic shift toward using the facility for cheap funding has some alignment with the original's 'active utilization and strategic interest rate management,' but the reasoning is based on incorrect data. (4) Contextual relevance is high as the answer addresses borrowing capacity, interest rate strategies, and repayment actions. However, due to significant factual and quantitative errors, the correctness score is low. The answer gives a plausible narrative but diverges critically from the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1414,
        "completion_tokens": 518,
        "total_tokens": 1933
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Verizon's approach to device payment plans evolved from 2023 to 2024, particularly in terms of customer financing structure and promotional incentives?",
      "original_answer": "In 2023, Verizon permitted customers to acquire equipment using device payment plans that allowed installment payments over time, with no mention of structured promotional incentives or trade-in rights. By 2024, Verizon formalized the device payment plan structure, describing it as a non-interest-bearing installment note typically repaid over a 36-month term, and introduced a defined promotional feature that allows customers to upgrade to a new device after paying a specified portion of their plan and trading in their current device in good working order. This represents a shift from a general financing mechanism to a more structured and incentive-driven model.",
      "llm_answer": "\nFrom 2023 to 2024 Verizon expanded and formalized its device‑payment financing.  In 2023 the company offered non‑subsidized, 36‑month installment plans mainly to Business customers (with optional trade‑in guarantees and occasional billing‑credit promotions), while Consumer plans were largely fixed‑term, subsidized contracts that were phased out.  By 2024 the carrier broadened the installment offering to both Consumer and Business segments, explicitly added a financing component (and related interest income) to the receivable, and introduced tiered trade‑in/upgrade credits that are tied to service continuity, resulting in a more structured financing framework and richer promotional incentives.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and introduces information not present in the ground truth. (1) It incorrectly claims that in 2023, installment plans were mainly for Business customers and that Consumer plans were subsidized contracts being phased out — the original answer makes no such distinction by customer segment and does not mention subsidized contracts at all. (2) The LLM states that Verizon added 'interest income' to the receivable in 2024, directly contradicting the ground truth that the installment note is 'non-interest-bearing'. This is a major quantitative and qualitative error. (3) The mention of 'tiered trade-in/upgrade credits tied to service continuity' and 'billing-credit promotions' is not supported by the original answer, which only notes a promotional feature allowing upgrades after paying a specified portion and trading in the device. (4) The original answer highlights a shift from a general financing mechanism to a more structured, incentive-driven model — the LLM captures the direction of change but misrepresents the specifics. While the 36-month term is correctly mentioned, the reasoning is flawed due to incorrect premises. The answer is contextually relevant to the question’s focus on evolution in financing and promotions, but the factual foundation is unsound, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 377,
        "total_tokens": 1723
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has The Coca-Cola Company's legal relationship with Aqua-Chem evolved between 2023 and 2024, particularly in terms of its stance on liability for Aqua-Chem's asbestos-related claims?",
      "original_answer": "In 2023, Coca-Cola maintained that it had no obligation to Aqua-Chem for any liabilities or expenses related to claims or lawsuits against Aqua-Chem, as outlined in the Georgia Case. By 2024, while the litigation status remained largely unchanged, Coca-Cola's disclosure now includes a more detailed description of the insurance policies issued during its ownership of Aqua-Chem, particularly highlighting the involvement of multiple insurers and the ongoing coverage litigation. This indicates a shift in emphasis from outright denial of liability to a more nuanced stance centered on insurance coverage and shared responsibility among insurers.",
      "llm_answer": "\nBetween 2023 and 2024 the Company’s legal stance toward Aqua‑Chem’s asbestos‑related claims did not change – it continues to assert that it has **no liability** for those claims and that responsibility rests with the relevant insurance policies and the former owners of Aqua‑Chem.  Both the 2023 and 2024 10‑K filings confirm that the Wisconsin and Georgia lawsuits remain stayed or subject to ongoing insurance‑coverage disputes, with the Company actively enforcing the courts’ determinations that insurers (not Coca‑Cola) are liable, but it has not taken on any new legal responsibility or settlement that would alter that position.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually consistent in terms of dates (2023 and 2024) and correctly identifies the ongoing litigation in Wisconsin and Georgia, as well as the stayed status and insurance-coverage disputes. There are no numeric inaccuracies, hence quantitative accuracy is high. However, the LLM incorrectly asserts that Coca-Cola’s legal stance 'did not change' between 2023 and 2024, which directly contradicts the ground truth. The original answer highlights a meaningful evolution: while Coca-Cola continued to deny direct liability, its 2024 disclosure included a more detailed discussion of insurance policies and shared insurer responsibility, signaling a nuanced shift in emphasis from outright denial to a focus on insurance coverage dynamics. The LLM overlooks this qualitative shift and instead frames the stance as static, missing the core of the multi-hop reasoning required—assessing how the nature of Coca-Cola’s argument evolved, even if its bottom-line denial of liability remained. This failure to capture the change in narrative and emphasis results in a moderate correctness score. Contextually, the answer is relevant and addresses the legal relationship and liability, but the reasoning is flawed in synthesizing the evolution across years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 352,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How did Intel's utilization of non-US tax credits impact its long-term income tax liabilities in 2024 compared to 2022, and what does this indicate about the company's international tax strategy?",
      "original_answer": "In 2022, Intel reported long-term income taxes payable of $4.3 billion, which included the transition tax from Tax Reform and uncertain tax positions, reduced by non-US tax credits. By 2024, this figure had decreased to $1.6 billion, indicating that the company's utilization of non-US tax credits had a stronger offsetting effect over time. This suggests a strategic shift or increased effectiveness in leveraging international tax credits to reduce overall tax liabilities.",
      "llm_answer": "\nIn 2022 Intel realized a $220 million tax benefit from foreign tax‑holiday and other non‑U.S. credits, which materially lowered its effective tax rate and therefore its long‑term income‑tax liability. By 2024 that benefit had fallen to only $67 million, so the company’s long‑term tax burden rose accordingly, reflecting a deliberate pull‑back from aggressive low‑tax jurisdictions and a shift toward a more U.S.-centric, compliance‑focused international tax strategy.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Intel's long-term income taxes payable decreased from $4.3 billion in 2022 to $1.6 billion in 2024, indicating a growing offset from non-US tax credits. However, the LLM claims that the tax benefit from non-U.S. credits fell from $220 million in 2022 to $67 million in 2024, implying reduced effectiveness—this contradicts the ground truth trend. These specific figures ($220M and $67M) do not appear in the original answer and are factually unsupported. (2) The quantitative inaccuracies are severe: the LLM invents precise numbers not present in the ground truth and misrepresents the direction of change. The actual long-term tax liability decreased by $2.7 billion (from $4.3B to $1.6B), which the LLM fails to mention. Instead, it focuses on fabricated tax benefit amounts that contradict the implied increase in credit utilization. (3) The multi-hop reasoning is flawed. The original answer infers a strategic increase in leveraging international tax credits due to greater liability reduction over time. The LLM incorrectly infers a 'pull-back' from low-tax jurisdictions despite evidence of declining overall tax liabilities, showing reversed logic. It fails to connect the decreasing long-term tax payable with increasing effectiveness of non-US credits. (4) While the LLM attempts to address the question’s components—impact on tax liabilities and implications for international strategy—the invented data and incorrect causal interpretation severely undermine correctness. Contextual relevance is moderate because it discusses the right topic (non-US tax credits and international strategy), but the conclusions are factually inverted. Thus, the correctness score is low due to major factual and reasoning errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1248,
        "completion_tokens": 495,
        "total_tokens": 1744
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has the treatment and risk exposure of pension risk transfers evolved between 2022 and 2024, particularly in terms of interest rate sensitivity and regulatory influence?",
      "original_answer": "In 2022, pension risk transfers were part of the Retirement and Income Solutions business, which was described as containing both short- and long-duration products, and was subject to interest rate scenarios that could impact asset-liability management (ALM) strategies. By 2024, regulatory changes, particularly around defined benefit pension plan funding, were found to potentially reduce the likelihood or delay corporate plan sponsors from terminating their plans or transferring pension obligations. This regulatory evolution increased the potential for a shift in the mix of pension risk transfers toward non-guaranteed funding products, indicating a strategic and regulatory-driven change in exposure.",
      "llm_answer": "\nBetween 2022 and 2024 the company’s pension‑risk‑transfer (PRT) business moved from a relatively passive, floating‑rate line of business to a more explicitly modeled, interest‑rate‑sensitive component of its Retirement & Income Solutions segment.  The 2024 filing adds a full‑year sensitivity analysis (declining‑ and rising‑rate scenarios) that quantifies a much larger earnings impact—e.g., a $15 million adverse effect in 2023 under a declining‑rate scenario versus the $5 million impact disclosed in 2022—showing that PRT cash‑flows are now directly tied to 10‑ and 30‑year rate movements and to the firm’s derivative hedging program.  At the same time, regulatory pressure has intensified: newer NAIC reserve and capital‑adequacy rules and the requirement to maintain minimum crediting‑rate guarantees have expanded the disclosure of ALM actions and forced the company to report how PRT exposures affect statutory capital, liquidity and pension‑related expense calculations.  Consequently, PRT risk is now managed through targeted asset‑liability matching, interest‑rate derivatives, and explicit regulatory‑driven capital modeling rather than being treated as a peripheral, low‑impact line of business.",
      "correctness_score": 4,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces specific quantitative claims not present in the original answer, such as a $15 million adverse effect in 2023 under a declining-rate scenario and a $5 million impact in 2022. These figures are not supported by the ground truth and appear fabricated, severely undermining factual accuracy. There is no mention in the original answer of exact dollar impacts or a comparison between 2022 and 2023 sensitivity analyses. (2) The original answer does not provide any numerical sensitivity data or hedging program details, nor does it reference NAIC rules, crediting-rate guarantees, or statutory capital modeling—these are all additions not grounded in the provided truth. (3) While the LLM correctly identifies a shift in pension risk transfer (PRT) treatment over time and links it to interest rate sensitivity and regulatory influence—aligning with the multi-hop nature of the question—the reasoning extends beyond the source material. The core idea of increasing regulatory influence and changing exposure is directionally consistent, but the depth of operational and modeling detail (e.g., derivative hedging, asset-liability matching practices) is speculative and not corroborated. (4) The contextual relevance is high because the answer addresses interest rate sensitivity and regulatory influence across 2022–2024 and attempts to explain evolving risk exposure. However, the quantitative inaccuracies are severe, and the qualitative accuracy is limited by unsupported specifics. The original answer emphasizes a shift toward non-guaranteed funding products due to regulatory changes delaying plan terminations, a key point entirely missed by the LLM. Thus, while the general trajectory is plausible, the factual foundation is weak, leading to a correctness score of 4.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1486,
        "completion_tokens": 491,
        "total_tokens": 1977
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has Medtronic's positioning and product strategy around the InterStim Micro neurostimulator evolved between 2022 and 2024?",
      "original_answer": "In 2022, Medtronic positioned the InterStim Micro as part of its broader InterStim therapy offering for treating overactive bladder, urinary retention, and bowel incontinence, alongside InterStim II and InterStim X neurostimulators. It was described as part of a growing and accepted product line within the Pelvic Health therapies under the Specialty Therapies division. By 2024, Medtronic specifically highlighted the InterStim Micro as a 'rechargeable neurostimulator' while emphasizing the continued acceptance and growth of InterStim therapy, particularly in the U.S., and distinguishing it from the recharge-free InterStim X and InterStim II models. This indicates a more targeted marketing and differentiation strategy for the InterStim Micro within the evolving Pelvic Health product portfolio.",
      "llm_answer": "\nBetween 2022 and 2024 Medtronic shifted the InterStim Micro from a newly‑launched, single‑use micro‑lead neurostimulator aimed at overactive‑bladder and urinary‑retention therapy to a central, rechargeable pillar of its Pelvic‑Health portfolio.  In the 2022 filing the device was highlighted only as a “recently launched” product, whereas the 2024 filing describes it as a “rechargeable neurostimulator” that is now marketed alongside the broader InterStim II/X platform, supported by expanded indications (including fecal incontinence), integrated AI‑driven surgical planning (AiBLE), and continued global adoption.  This evolution reflects a strategic move to deepen market penetration, broaden clinical use‑cases, and embed the Micro device within Medtronic’s integrated, AI‑enabled surgical ecosystem.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains several factual inaccuracies that significantly deviate from the ground truth, despite using plausible financial and strategic terminology. (1) The claim that InterStim Micro was a 'single-use micro-lead neurostimulator' is incorrect — the original answer makes no mention of it being single-use, and in fact, by 2024 it is described as rechargeable, which contradicts single-use design. (2) The assertion that the device was 'newly-launched' in 2022 is misleading — while it may have been recently launched, the ground truth does not describe it as such, nor does it support the implied timeline of being brand new. (3) The LLM incorrectly states that InterStim Micro was only 'highlighted as recently launched' in 2022, whereas the original answer positions it as part of an established and growing product line within Pelvic Health therapies. (4) The LLM introduces unsupported details: 'expanded indications (including fecal incontinence)' — the original answer mentions bowel incontinence, but not fecal incontinence specifically, and no expansion of indications is noted between 2022 and 2024. (5) The mention of 'AI-driven surgical planning (AiBLE)' and 'integrated AI-enabled surgical ecosystem' is entirely absent from the ground truth and not supported by the provided data. (6) The characterization of InterStim Micro becoming a 'central, rechargeable pillar' overstates the evolution — while Medtronic did emphasize its rechargeable nature in 2024 and differentiated it from non-rechargeable models, the shift was one of marketing emphasis and differentiation, not a transformation into a 'central pillar' with expanded technological integration. Quantitative accuracy receives full marks because there are no numeric values to evaluate, and no incorrect numbers were introduced. Qualitative accuracy is low due to incorrect entity attributes, fabricated features (AI), and misrepresentation of product evolution. Contextual relevance is moderate because the answer addresses the general theme of product strategy evolution in Pelvic Health, but drifts into unsupported specifics. The core correct element — that Medtronic began highlighting the rechargeable nature of InterStim Micro by 2024 and differentiated it from InterStim II/X — is present, but overshadowed by inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1397,
        "completion_tokens": 615,
        "total_tokens": 2012
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has Simon Property Group's use of the Supplemental Facility evolved between 2022 and 2024, particularly in terms of outstanding borrowings and repayment actions?",
      "original_answer": "In 2022, Simon Property Group had a weighted average outstanding balance under the Credit Facilities (including the Supplemental Facility) of $519.9 million, with a maximum aggregate outstanding balance of $2.1 billion during the year. By 2024, the weighted average outstanding balance under the Facilities had decreased to $311.1 million, and the company had repaid a significant portion of its borrowings, including €750.0 million ($815.4 million U.S. dollar equivalent) under the Supplemental Facility on November 17, 2023. This indicates a strategic reduction and refinancing of debt drawn from the Supplemental Facility over the two-year period.",
      "llm_answer": "\nBetween 2022 and 2024 the company’s use of the Supplemental Facility changed markedly.  In early 2022 it had drawn **$1.05 billion** under the facility and repaid that amount later in January 2022 (SPG 10‑K 2022, pp. 122‑126).  A year later it re‑borrowed **≈ €750 million** (about $815 million) to fund a bond issuance, and then retired the entire Euro‑denominated borrowing in November 2023 with proceeds from new senior notes (SPG 10‑K 2024, pp. 68‑72).  By the end of 2024 the Supplemental Facility had **no outstanding balance**, although its $3.5‑$4.5 billion borrowing capacity remained available for future use.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general trend of debt reduction and repayment in the Supplemental Facility, correctly identifying the €750 million ($815 million) repayment in November 2023 and the zero outstanding balance by 2024. However, there are significant quantitative inaccuracies. The ground truth states that the weighted average outstanding balance under the Credit Facilities (including the Supplemental Facility) was $519.9 million in 2022, not a $1.05 billion drawdown specific to the Supplemental Facility as claimed. The LLM cites a $1.05 billion draw and repayment in January 2022, which is not supported by the ground truth and misrepresents the data. Additionally, the ground truth does not state that the Supplemental Facility had a zero balance in 2024, only that borrowings were significantly reduced, with a weighted average of $311.1 million across all Credit Facilities. The LLM incorrectly implies full repayment of all borrowings under the Supplemental Facility resulted in a zero balance, while the ground truth reports a system-wide weighted average, not a complete payoff. The mention of $3.5–$4.5 billion capacity is plausible but not confirmed in the ground truth provided. The reasoning is partially sound—correctly linking the November 2023 repayment to refinancing via senior notes—but overinterprets the data by isolating the Supplemental Facility’s balance when the original answer aggregates across facilities. While the core idea of debt reduction is accurate, the specific figures, timing, and attribution to the Supplemental Facility alone are incorrect or unsupported, leading to a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 447,
        "total_tokens": 1769
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did COP's investment activity in the Lower 48 region evolve from 2022 to 2023, based on the changes in depreciation, depletion, amortization, and impairments expenses?",
      "original_answer": "In 2022, COP reported $4,854 million in depreciation, depletion, amortization, and impairments expenses for the Lower 48 region, which increased to $5,729 million in 2023. This indicates a significant increase in investment activity or asset utilization in the Lower 48 region over that period.",
      "llm_answer": "\nBetween 2022 and 2023 the depreciation, depletion, amortization and impairment (DDA & Impairments) charge for COP’s Lower 48 segment rose from **$4,854 million to $5,729 million**—an increase of roughly **$875 million (≈18 %)**. This jump indicates that the company invested significantly more capital in the Lower 48 during 2023, expanding its drilling, development and associated asset base, and also incurred larger impairment write‑downs tied to the higher‑valued asset portfolio. Consequently, the higher DDA expense reflects the accelerated investment activity in that region.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the values $4,854 million (2022) and $5,729 million (2023) are accurately reported. The calculated increase of $875 million is correct (5,729 - 4,854 = 875), and the approximate percentage increase of 18% is reasonable (875 / 4,854 ≈ 0.1803 or 18.03%). Minor rounding to 18% is acceptable. (2) The answer is complete, addressing the evolution of investment activity through DDA & impairments from 2022 to 2023 for COP's Lower 48 region. (3) Entities are accurate: company (COP), region (Lower 48), time period (2022 to 2023), and financial metric (depreciation, depletion, amortization, and impairments) are all correctly identified. (4) The reasoning is sound: the increase in DDA expense is correctly interpreted as indicative of higher capital investment and asset utilization, and the mention of impairments aligns with the metric's inclusion in the expense. The conclusion that this reflects accelerated investment activity is logically supported. (5) The LLM adds slight interpretive context (e.g., drilling, development, higher-valued asset portfolio) that is reasonable and consistent with industry understanding, without introducing inaccuracies. Overall, the answer demonstrates accurate multi-hop synthesis and conveys the same core information as the ground truth with enhanced clarity and context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1225,
        "completion_tokens": 388,
        "total_tokens": 1614
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has Verizon's approach to corporate networking solutions evolved from 2023 to 2024, particularly in terms of service description and business segment emphasis?",
      "original_answer": "In 2023, Verizon's Business segment explicitly described offering a broad portfolio of network connectivity products, including private networking services, private cloud connectivity services, and software-defined networking services, with Enterprise and Public Sector revenues reaching $15.1 billion, or approximately 50% of Business's total revenues. By 2024, the Business segment's description became more streamlined, focusing on wireless and wireline communications services and products, including corporate networking solutions, without specifying the same level of detail in offerings or segment revenue. This indicates a shift toward a more generalized presentation of services, potentially signaling a strategic consolidation or simplification of messaging around corporate networking solutions.",
      "llm_answer": "\nFrom 2023 to 2024 Verizon reframed its corporate‑networking portfolio as a set of four integrated service pillars—Network Services (private‑networking, SD‑WAN, cloud‑connectivity), Advanced Communications (IP‑voice, video‑collaboration, contact‑center), Security (managed threat‑detection and response) and IoT (network‑access and usage‑based monetisation)—all under the new “Intelligent Edge Network” architecture.  The company’s emphasis shifted toward Enterprise and Public‑Sector customers, whose revenue grew to **$14.2 billion in 2024**, while Business‑Markets and Wholesale remained stable, indicating a move from pure connectivity to higher‑value managed‑service and security solutions.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2023, Enterprise and Public Sector revenues were $15.1 billion, making up about 50% of Business segment revenue. The LLM claims $14.2 billion in 2024 for the same customer segment, but the original answer does not provide 2024 revenue figures, so this number is fabricated. Additionally, the LLM introduces a new 'Intelligent Edge Network' architecture and four service pillars (Network Services, Advanced Communications, Security, IoT), which are not mentioned in the ground truth and represent a complete recharacterization of Verizon's offerings not supported by the source. (2) Quantitative accuracy is poor: the $14.2 billion figure is incorrect or unverifiable, and no revenue breakdowns or percentages from 2024 are present in the ground truth to support such a claim. The direction of change (from $15.1B to $14.2B) might suggest a decline, but this inference is based on false data. (3) The multi-hop reasoning is flawed. The original answer highlights a shift in *disclosure* and *presentation*—from detailed service descriptions in 2023 to a more generalized description in 2024—possibly indicating strategic simplification. The LLM instead invents a detailed new architecture and strategic pivot toward managed services and security, which is not stated or implied in the ground truth. This reflects a failure to correctly interpret the nature of the evolution (messaging vs. structural reorganization). (4) Contextual relevance is moderate because the answer addresses Verizon's corporate networking evolution and business segment emphasis, but it does so with fabricated details and incorrect data, undermining its validity. The focus on enterprise customers aligns loosely with the original, but the overall response misrepresents the source information.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 507,
        "total_tokens": 1886
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did MetLife's valuation approach and sensitivity to fair value changes for FVO securities evolve from 2022 to 2024, particularly in terms of the impact of U.S. dollar appreciation?",
      "original_answer": "In 2022, MetLife reported that FVO securities had an estimated fair value of $1.6 billion and were sensitive to changes in the U.S. dollar, with a 10% appreciation leading to a $54 million decrease in value. By 2024, while no direct fair value figure for FVO securities is provided, the company emphasized a broader sensitivity framework where nonperformance risk spreads and unobservable inputs varied by duration and currency, indicating a more nuanced and dynamic valuation methodology. This evolution shows a shift from a static sensitivity model to a more complex, duration- and currency-dependent approach.",
      "llm_answer": "\nMetLife continues to value its FVO securities at fair value using observable market prices and discounted‑cash‑flow techniques, with Level 3 inputs for less‑observable parameters, and it assesses the impact of a 10 % U.S.‑dollar appreciation by applying that rate shift to the foreign‑currency‑denominated portion of the assets and liabilities. In the 2022 sensitivity analysis a 10 % dollar strengthening would have reduced the estimated fair value of those assets by roughly $11.8 billion (and increased related liabilities by about $3.7 billion), producing a net negative effect of roughly $7.2 billion; the 2024 disclosures retain the same methodology but reflect an updated net sensitivity that reflects the current asset‑liability composition, still excluding the $217.5 billion of insurance‑contract liabilities that would offset much of the movement.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is almost entirely incorrect and fails to match the ground truth on multiple levels. (1) Quantitative Accuracy: The numbers are completely wrong. The ground truth states that in 2022, a 10% U.S. dollar appreciation led to a $54 million decrease in FVO securities value, not the $11.8 billion decrease claimed by the LLM. There is no mention of liabilities in the original answer, nor a net $7.2 billion effect. The $217.5 billion figure for insurance-contract liabilities does not appear in the ground truth and is irrelevant to the question. (2) Completeness: The LLM fails to describe the actual evolution in valuation approach from 2022 to 2024. It falsely claims the methodology 'remains the same' when the ground truth indicates a shift from a static to a more nuanced, duration- and currency-dependent framework. The LLM does not mention the absence of a direct fair value figure in 2024 or the increased reliance on nonperformance risk spreads and unobservable inputs. (3) Entity Accuracy: While MetLife and FVO securities are correctly identified, the years (2022 and 2024) are mischaracterized in terms of content. The financial metrics (e.g., $1.6 billion fair value in 2022) from the original are ignored. (4) Reasoning: The multi-hop synthesis is flawed. The LLM invents a detailed sensitivity analysis with asset-liability netting not present in the ground truth and misrepresents the evolution of the valuation model. (5) Semantic Equivalence: The LLM conveys a completely different narrative—focusing on unchanged methodology and massive dollar impacts—whereas the ground truth emphasizes methodological evolution toward greater complexity and nuance. The only partial credit is for addressing the general topic of currency sensitivity in FVO valuation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 481,
        "total_tokens": 1859
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has NextEra Energy's engagement in power marketing activities evolved between 2022 and 2023, particularly in terms of its energy trading services and associated financial performance?",
      "original_answer": "In 2022, NextEra Energy (NEE) was actively engaged in power and fuel marketing and trading activities, primarily providing full energy and capacity requirements services to distribution utilities, including load-following and ancillary services, while also optimizing the value of electricity and fuel contracts and generation assets. By 2023, NEE's subsidiary NEER had expanded its role in power marketing and trading, contributing to a significant increase in net income, which rose from $285 million in 2022 to $3,558 million in 2023. This indicates a substantial evolution and growth in the scale or profitability of NEE’s power marketing and trading activities over the period.",
      "llm_answer": "\nBetween 2022 and 2023 NextEra Energy’s power‑marketing and energy‑trading business grew substantially, moving from a $2.67 billion loss on non‑qualifying commodity hedges in 2022 to an approximate $2.53 billion gain in 2023.  This swing added roughly $5.9 billion to operating revenues and helped offset lower fuel‑cost recoveries, even though related operating expenses rose modestly (about $566 million higher, driven mainly by O&M and depreciation).  Consequently, the company’s trading activities contributed positively to its 2023 financial performance, boosting net income while the overall expense base remained only slightly higher than the prior year.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies. The ground truth states that NextEra Energy's net income from its power marketing and trading activities—specifically through subsidiary NEER—rose from $285 million in 2022 to $3,558 million in 2023. However, the LLM claims a swing from a $2.67 billion loss to a $2.53 billion gain on commodity hedges, which is not supported by the original answer and introduces financial figures (e.g., hedge gains/losses, operating revenue impact of $5.9 billion, expense increases of $566 million) that are absent in the ground truth. These numbers contradict the provided data and suggest a completely different financial narrative. (2) The quantitative inaccuracies are severe: the LLM misrepresents losses and gains on hedges, fabricates an operating revenue impact, and invents expense details. While $3,558 million is approximately $3.56 billion (close to the $2.53B mentioned only in gain), the context is entirely different—net income vs. hedge gains—and the 2022 figures ($285M profit vs. $2.67B loss) are diametrically opposed. Calculations based on these wrong inputs (e.g., $5.9B swing) are therefore invalid. (3) The qualitative reasoning partially captures the idea of growth in trading activities and improved financial performance, and correctly identifies the timeframe and general domain (power marketing and trading). It also infers a positive evolution in financial contribution, which aligns with the net income increase in the ground truth. However, it fails to mention NEER as the subsidiary driving this growth and misattributes the financial improvement to hedging activities rather than broader trading and optimization efforts. The multi-hop synthesis is flawed because it pulls in unrelated financial mechanisms not present in the source. (4) Contextual relevance is moderate—the response addresses power marketing evolution and financial performance over 2022–2023 and stays on topic—but the incorrect financial basis undermines its usefulness. Due to major factual and quantitative errors, the correctness score is low despite some thematic alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 572,
        "total_tokens": 1918
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has The Coca-Cola Company's financial relationship with Coca-Cola FEMSA evolved between 2023 and 2024, particularly in terms of its stake ownership and implications for equity income?",
      "original_answer": "In 2023, Coca-Cola FEMSA was referenced as one of the key bottlers whose financial performance could influence The Coca-Cola Company's credit ratings, indicating an indirect financial dependency. By 2024, The Coca-Cola Company held a 28% ownership stake in Coca-Cola FEMSA, which was accounted for under the equity method. This shift from a dependency-based relationship to a direct ownership stake suggests a strategic evolution, where Coca-Cola now has a more direct financial interest in FEMSA's performance, which will directly impact its equity income (loss) - net line item.",
      "llm_answer": "\nThe Coca‑Cola Company’s equity‑method stake in Coca‑Cola FEMSA remained at **28 %**, the same level it held at the end of 2023 (Note 6 – Equity Method Investments). Because the ownership percentage did not change, the rise in equity‑income from FEMSA—from **$1.69 billion in 2023 to $1.77 billion in 2024**—is attributable to FEMSA’s higher net earnings that are passed through to Coca‑Cola’s 28 % share. This modest increase contributed to the overall growth in the company’s equity‑income (loss)‑net for the year.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in quantitative details not present in the original answer. The original answer does not mention any specific equity income figures for 2023 or 2024 (e.g., $1.69 billion or $1.77 billion), nor does it state that the 28% ownership stake was already held at the end of 2023. Instead, the original implies a strategic shift from indirect dependency in 2023 to direct 28% ownership in 2024, suggesting the stake may have been acquired or solidified during that period. The LLM presents the stake as unchanged, which contradicts the implied evolution in the original. (2) The dollar amounts and claim of a 'rise in equity-income' are fabricated from the model's perspective—they are not in the ground truth and cannot be verified from the provided context. This severely undermines quantitative accuracy. (3) Qualitatively, the LLM correctly identifies the 28% stake in 2024 and the use of the equity method, and it logically explains how equity income would be affected by FEMSA’s performance. It also correctly references the equity-income (loss)-net line item, showing sound reasoning about financial implications. However, it fails to capture the key multi-hop insight: the evolution from indirect financial dependency (credit rating linkage) in 2023 to direct ownership in 2024. Instead, it assumes continuity, missing the strategic shift. (4) Contextual relevance is high because the answer addresses stake ownership and equity income implications directly. However, due to incorrect numerical claims and misrepresentation of the ownership change timeline, the correctness score is limited to 6—partially correct but with significant factual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1284,
        "completion_tokens": 469,
        "total_tokens": 1753
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has the financial investment and operational focus on the Lower 48 region evolved between 2022 and 2023 based on production volumes and depreciation expenses?",
      "original_answer": "In 2022, the Lower 48 region showed strong production volumes, particularly in crude oil (447 thousand barrels daily) and natural gas (1,340 million cubic feet daily), indicating a significant operational focus. In 2023, the financial emphasis on the Lower 48 increased further, as evidenced by a rise in depreciation, depletion, amortization, and impairments expenses from $4,854 million in 2022 to $5,729 million in 2023. This reflects a growing financial investment in the region despite stable or moderate production levels in the prior year.",
      "llm_answer": "\nBetween 2022 and 2023 the Lower 48 segment’s depreciation, depletion and amortization jumped to **$5.73 bn** (up from **$4.85 bn** in 2022) and capital expenditures rose to **$6.49 bn** (from **$5.63 bn**), showing a clear increase in financial investment in the region’s upstream assets.  At the same time, consolidated sales from Lower 48 fell to **$38.2 bn**, but the underlying production picture was stable – the Delaware‑Basin reserve share remained above 15 % and barrel‑level production costs stayed roughly flat – indicating the company is directing more capital toward sustaining and expanding its existing Lower 48 operations rather than boosting output.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies an increase in depreciation, depletion, and amortization (DD&A) from $4.85 billion in 2022 to $5.73 billion in 2023, which aligns closely with the ground truth values of $4,854 million and $5,729 million (rounding to $4.85B and $5.73B is acceptable). However, the LLM introduces 'capital expenditures' rising to $6.49B from $5.63B and mentions 'consolidated sales' falling to $38.2B—metrics not present in the original answer or question focus. These additions are unsupported by the ground truth and shift focus away from the requested analysis of production volumes and DD&A. (2) While the DD&A figures are quantitatively accurate (within rounding), the inclusion of capital expenditures and sales figures—though possibly true in context—are not part of the original evidence and introduce unverified data. The production volumes cited in the original answer (447 kbbl/d crude oil, 1,340 MMcf/d gas) are completely missing in the LLM response, failing to address a core part of the question. (3) The reasoning partially follows a logical path—increased DD&A implies greater financial investment—but fails to connect this to the specific evolution from 2022 to 2023 in relation to production levels as required. The mention of 'Delaware-Basin reserve share' and 'barrel-level costs' introduces new, unsupported details not in the original knowledge base. (4) The contextual relevance is high because the answer discusses financial investment and operational focus in the Lower 48 over 2022–2023, but correctness and qualitative accuracy are reduced due to omission of key production data and introduction of extraneous, unverified metrics. The core multi-hop synthesis—linking rising DD&A to increased financial investment despite stable production—is partially sound but weakened by lack of grounding in provided facts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 506,
        "total_tokens": 1813
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has Verizon's strategic relationship with its 4G LTE network evolved between 2023 and 2024 in terms of its role within the company's network infrastructure and growth initiatives?",
      "original_answer": "In 2023, Verizon's 4G LTE network was positioned primarily as a foundational component of its wireless services, specifically highlighted as a means to provide FWA broadband as an alternative to traditional landline internet access. By 2024, the strategic role of the 4G LTE network had evolved into being part of a broader integrated network vision that includes C-Band spectrum, millimeter wave spectrum, and fiber infrastructure, aimed at driving innovative products and services and fueling growth. This shift indicates a move from viewing 4G LTE in a service delivery context to a more strategic asset within a multi-technology ecosystem.",
      "llm_answer": "\nBetween 2023 and 2024 Verizon deepened the role of its 4G LTE network as the foundation for its fixed‑wireless‑access (FWA) broadband offering and as a platform for 5G evolution.  The company highlighted that 4G LTE‑enabled FWA now contributes meaningfully to both the Consumer and Business segments’ revenues, and that capital‑expenditure plans (e.g., the $17.1 billion invested in 2024) include upgrades to LTE capacity, network densification and the migration of customers onto 5G—underscoring LTE’s strategic function as a bridge that supports near‑term growth while enabling the rollout of next‑generation services.  (See Verizon 2023 10‑K pp. 95‑99 and Verizon 2024 10‑K pp. 21‑25.)",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core evolution of Verizon's 4G LTE network strategy between 2023 and 2024, correctly identifying its foundational role in FWA broadband and its function as a bridge to 5G. The mention of capital expenditures ($17.1 billion in 2024) aligns with typical reporting in Verizon's 10-K filings and is plausibly accurate (though not explicitly verifiable without direct access to the cited pages), so quantitative accuracy is rated high with minor caution due to lack of ground truth confirmation on that specific figure. The answer adds value by noting LTE's contribution to both Consumer and Business segments and network densification efforts, which are consistent with Verizon's strategic direction. However, it omits the key qualitative shift emphasized in the original answer: the integration of 4G LTE into a broader multi-technology ecosystem including C-Band, millimeter wave, and fiber as part of a unified growth strategy. Instead, the LLM focuses more on LTE as a 'bridge' to 5G, which is accurate but narrower in scope than the original's emphasis on a strategic repositioning within an integrated network vision. This missing synthesis across technologies (a multi-hop requirement) reduces qualitative accuracy. The entities (Verizon, 4G LTE, FWA, 5G, 10-K reports) and years (2023–2024) are correct, and the reasoning is logical, though not fully comprehensive. The answer is highly relevant to the question and well-contextualized with appropriate citations. Overall, the answer is factually sound and contextually strong but lacks full completeness in conveying the strategic evolution described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 449,
        "total_tokens": 1791
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How did Emerson's financial and strategic relationship with AspenTech evolve from 2022 to 2024, particularly in terms of stake value, ownership structure, and the impact on financial metrics such as backlog and gross margin?",
      "original_answer": "In 2022, Emerson held a stake in AspenTech with a backlog value of $1,042 million, indicating a strategic business relationship. By 2024, this relationship evolved significantly as Emerson completed a transaction that resulted in the creation of 'New AspenTech,' where Emerson owned 55% of the outstanding shares. This acquisition had a measurable impact on financial metrics: gross margin in 2023 increased by 3.3 percentage points, partly due to the AspenTech acquisition, and backlog in 2024 reached $8,053 million, up from $6,533 million in 2021, showing the influence of the AspenTech integration.",
      "llm_answer": "\nFrom fiscal 2022 through 2024 Emerson’s stake in AspenTech grew from roughly 55 % of the outstanding shares (after the Heritage AspenTech transaction) to about 57 % and culminated in a 2024 proposal to buy the remaining ≈ 43 % at $240 per share—implying a total enterprise value of roughly $15 billion.  The acquisition lifted AspenTech’s backlog from $328 million in 2021 to $1.04 billion in 2022, helping push consolidated backlog up to $8.05 billion in 2022, but the integration also introduced about $231 million of inventory‑step‑up amortization that trimmed roughly 1.3 percentage‑points off gross margin in 2024 (even as gross margin rose to 50.8 % thanks to higher pricing and the Test & Measurement acquisition).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key numbers and timeline. It incorrectly states that Emerson already owned approximately 55% of AspenTech in 2022, while the ground truth indicates that the 55% ownership was achieved only in 2024 after the transaction. The LLM also claims ownership increased to 57% and that a proposal was made in 2024 to buy the remaining 43%, which contradicts the ground truth that Emerson already owned 55% post-transaction. The implied enterprise value of $15 billion and the $240 per share offer are not mentioned in the original answer and appear fabricated. (2) Quantitative errors include: incorrect backlog progression—LLM says AspenTech’s backlog rose from $328M in 2021 to $1.04B in 2022, but ground truth states Emerson’s stake had a backlog value of $1,042M in 2022, not AspenTech’s standalone backlog; the consolidated backlog in 2024 was $8,053M, not $8.05B in 2022 as LLM claims. The $231M inventory-step-up amortization and 1.3 percentage-point drag on gross margin in 2024 are not in the original and contradict the ground truth that gross margin increased by 3.3 points due to the acquisition. (3) The multi-hop reasoning is partially sound in linking the AspenTech relationship to financial metrics like backlog and gross margin, but the causal inferences are flawed due to incorrect data. The integration impact is misrepresented with spurious figures. (4) Contextual relevance is high as the answer addresses stake value, ownership evolution, and impacts on backlog and gross margin. However, due to major quantitative and factual errors, the correctness score is low despite relevant structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 458,
        "total_tokens": 1808
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has NEE's financial commitment to the Mountain Valley Pipeline evolved between 2022 and 2023, and what does this indicate about its investment strategy?",
      "original_answer": "In 2022, NEE's involvement in the Mountain Valley Pipeline was described as part of its equity method investments, with an ownership stake ranging between 32% and 55%. By 2023, NEE, through its subsidiary NEER, had a more defined 32.8% equity investment in the Mountain Valley Pipeline, which was accompanied by a 20-year natural gas transportation agreement valued at approximately $70 million per year. This indicates a strategic deepening of NEE's commitment to the pipeline, moving from a general equity investment toward a more structured, long-term contractual relationship tied to infrastructure development.",
      "llm_answer": "\nBetween 2022 and 2023 NEE went from holding a sizable, active investment in the Mountain Valley Pipeline to essentially exiting that exposure: a full impairment in early 2022 wiped out its entire pipeline stake, and the only remaining financial tie is a modest $1.06 billion equity contribution slated for 2024 (shown in the 2024‑2028 capital‑expenditure table).  This pull‑back signals that NEE is scaling back its involvement in large, non‑regulated pipeline projects and is redirecting capital toward its core regulated utility and renewable‑energy growth initiatives.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 2,
      "detailed_feedback": "The LLM answer is almost entirely incorrect and contradicts the ground truth. (1) It claims NEE fully impaired its Mountain Valley Pipeline investment in early 2022 and exited its exposure, which is false—the original answer states NEE maintained a 32%–55% equity stake in 2022 and increased its commitment in 2023 with a 32.8% stake and a 20-year $70 million/year transportation agreement. (2) The $1.06 billion equity contribution mentioned for 2024 does not appear in the ground truth and is factually unsupported; no such figure is referenced in the correct answer. (3) The reasoning is fundamentally flawed: instead of showing a strategic deepening of involvement as per the original answer, the LLM incorrectly infers a withdrawal from the project and a shift away from pipeline investments. (4) Entity accuracy fails—NEE’s subsidiary NEER and its structured contractual expansion are omitted entirely, and the timeline (2022 vs 2023) is misrepresented. (5) The answer is not semantically equivalent—it conveys the opposite meaning of the ground truth. While the question about investment strategy is relevantly addressed in topic, the conclusions are based on false premises, making the response highly inaccurate and misleading.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 345,
        "total_tokens": 1644
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has Coca-Cola's relationship with Costa Limited evolved from 2023 to 2024 in terms of its operational integration and strategic positioning within the Global Ventures segment?",
      "original_answer": "In 2023, Costa Limited was referenced as part of Coca-Cola's direct retail operations, specifically through retail stores operated by Costa, and was included within the Global Ventures operating segment. By 2024, Costa Limited was more strategically embedded within the Global Ventures segment, which now also included the results of innocent and doğadan businesses, as well as fees earned under distribution coordination agreements. This indicates a deeper integration and broader strategic role for Costa within Coca-Cola’s diversified beverage portfolio.",
      "llm_answer": "\nFrom 2023 to 2024 the reference to Costa Limited in the Global Ventures discussion shifted from a simple listing of its brands alongside innocent and døgān to a explicit emphasis on its strategic role.  The 2024 filing describes Costa’s coffee‑and‑tea portfolio as a core pillar of Global Ventures, noting that its operations are now fully integrated into the Company’s worldwide bottling and distribution platform and aligned with the segment’s growth‑and‑sustainability objectives.  This language signals a deeper operational integration and a more central strategic positioning for Costa within the Global Ventures segment.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly captures the evolution of Costa Limited's integration within Coca-Cola's Global Ventures segment from 2023 to 2024, emphasizing deeper operational and strategic integration. It accurately reflects that Costa was already part of Global Ventures in 2023 and became more centrally positioned by 2024. The mention of alignment with bottling/distribution platforms and sustainability objectives adds contextual detail consistent with strategic embedding. However, the LLM introduces specific claims not present in the original answer—such as Costa being a 'core pillar' and 'fully integrated into the worldwide bottling and distribution platform'—which, while plausible, are not explicitly supported by the ground truth. The original answer notes broader strategic inclusion alongside innocent and doğadan and mentions distribution coordination agreements, but does not confirm full platform integration or elevate Costa to a 'core pillar' status. Entity accuracy is strong (Costa Limited, Global Ventures, innocent, doğadan), and there are no numerical inaccuracies (dates 2023–2024 are correct). Reasoning is mostly sound, showing multi-hop understanding of integration trends, though slight overstatement reduces qualitative accuracy. Contextual relevance is excellent, directly addressing operational integration and strategic positioning as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 379,
        "total_tokens": 1683
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has Intel's investment in financial institution instruments evolved between 2022 and 2024, particularly in terms of the fair value of economically hedged marketable debt investments?",
      "original_answer": "In 2022, Intel recorded net losses of $748 million on economically hedged marketable debt investments. By 2024, the fair value of these hedged investments had decreased to $13.5 billion from $17.1 billion in 2023, with Intel recording net losses of $464 million in 2024. This indicates a reduction in both the size of the hedged investment portfolio and the magnitude of losses compared to two years prior.",
      "llm_answer": "\nBased on the Consolidated Financial Statement notes in the 2022 10‑K (pages 78‑80) and the 2024 10‑K (pages 81‑85), Intel’s economically‑hedged marketable‑debt investments were reported at a fair value of **$13.5 billion as of December 28 2024**, down from **$17.1 billion at the end of 2023** (the 2022 filing uses the same hedged‑instrument classification but does not disclose a separate year‑end figure).  The decline reflects net losses of **$464 million in 2024** (versus net gains of $534 million in 2023 and net losses of $748 million in 2022), indicating a reduction in the hedged debt portfolio’s fair‑value exposure over the 2022‑2024 period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All numeric values are correct: $13.5 billion (2024 fair value), $17.1 billion (2023 fair value), $464 million net losses in 2024, and $748 million net losses in 2022. The LLM correctly notes the absence of a separate year-end figure for 2022 in the filing, which is consistent with the knowledge graph. (2) Quantitative accuracy is perfect—dollar amounts, years, and directional changes (decline in fair value and reduction in losses) are all precise. The comparison across years is numerically sound. (3) The multi-hop reasoning is strong: the LLM synthesizes data from both the 2022 and 2024 10-Ks, correctly infers the trend from 2022 to 2024, and contextualizes the evolution of the hedged portfolio. The mention of $534 million net gains in 2023, while not in the original answer, is factually correct and adds useful context without contradicting the ground truth. (4) The only minor shortcoming is that the original answer emphasizes the reduction in both portfolio size and loss magnitude 'compared to two years prior' (i.e., 2022), while the LLM focuses more on the 2023–2024 change. However, the core conclusion about decreasing exposure and improving loss profile is consistent. Wording differs slightly but meaning is semantically equivalent. No factual errors; excellent contextual relevance and completeness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 387,
        "total_tokens": 1662
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How did AMT's financial focus regarding communications sites evolve from 2023 to 2024, particularly in terms of recurring revenue generation and asset retirement liabilities?",
      "original_answer": "In 2023, AMT emphasized recurring revenue generation from communications sites, noting that 99% of total revenues came from property operations, which included leasing space on communications sites. By 2024, the focus expanded to include significant liabilities tied to these assets, with an estimated $4.5 billion in undiscounted future cash outlay for asset retirement obligations as of December 31, 2024. This reflects a shift from primarily highlighting revenue streams to also addressing the long-term financial responsibilities associated with site decommissioning.",
      "llm_answer": "\nBetween 2023 and 2024 AMT shifted its emphasis from expanding the breadth of its communications‑site portfolio to protecting and monetising the cash‑flow that those sites already generate.  The company highlighted that more than $60 billion of non‑cancellable lease revenue is locked in by long‑term, escalating contracts, and it began to treat that recurring revenue as a core, stable source of cash.  At the same time, AMT started reporting a much larger, quantified asset‑retirement liability—about $4.5 billion of undiscounted future cash outlays—reflecting a new focus on the financial impact of retiring aging tower infrastructure as it evaluates divestitures such as the India business and the pending ATC TIPL transaction.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $4.5 billion undiscounted future cash outlay for asset retirement obligations as of December 31, 2024, which matches the ground truth. However, it introduces a figure of '$60 billion of non-cancellable lease revenue' that is not present in the original answer and cannot be verified from the provided ground truth, making this a significant quantitative inaccuracy. The 99% of revenues from property operations in 2023, a key metric in the original answer, is omitted. (2) While the $4.5 billion figure is accurate and correctly attributed to 2024 asset retirement liabilities, the unverified $60 billion number undermines quantitative accuracy. No calculations are performed, so no calculation errors exist, but the inclusion of unsupported data reduces precision. (3) The reasoning is sound in identifying a strategic shift from revenue focus to also managing long-term liabilities, and the mention of divestitures (India business, ATC TIPL) adds context not in the original but plausibly aligned with strategic repositioning. However, the original answer does not mention portfolio breadth or divestitures, so this adds speculative detail. The core multi-hop synthesis—linking 2023 revenue focus to 2024 liability focus—is logically and factually supported. (4) The answer remains highly relevant to the question about AMT's evolving financial focus, addressing both recurring revenue and asset retirement liabilities. Despite the invented $60 billion figure, the central evolution in financial focus is accurately conveyed, warranting a score of 7 for overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1332,
        "completion_tokens": 446,
        "total_tokens": 1779
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has XOM's strategic positioning in Guyana evolved between 2023 and 2024, particularly in terms of its legal operating framework and business growth emphasis?",
      "original_answer": "In 2023, XOM's operations in Guyana were governed by the Petroleum Activities Act 2023, which allowed for an exploration period typically up to 10 years and a production period of 20 years for oil fields with a renewal period of up to 10 years. By 2024, Guyana was specifically highlighted as one of XOM's 'Advantaged Assets' under the 'Advantaged Volume Growth' earnings driver, indicating a strategic shift to emphasize Guyana as a key contributor to earnings through volume growth and integration. This evolution shows that Guyana transitioned from being a jurisdiction with defined exploration and production terms to being a core growth asset within XOM's portfolio.",
      "llm_answer": "\nBetween 2023 and 2024 the legal foundation for operations in Guyana remained anchored in the 2023 Petroleum Act, which guarantees up to a 10‑year exploration term and a 20‑year production period (with a possible 10‑year renewal) for oil fields.  ExxonMobil’s strategy shifted from simply securing those rights to using the stable regime as a platform for rapid growth—positioning Guyana as a core “advantaged asset” and concentrating on expanding production, developing multiple projects in the Stabroek block and integrating the country into its higher‑value, low‑emission portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: the Petroleum Activities Act 2023 is accurately referenced (referred to as the '2023 Petroleum Act'), with correct terms—10-year exploration period, 20-year production period, and 10-year renewal—which matches the original answer exactly. (2) Quantitative accuracy is perfect: all timeframes (10, 20, and 10 years) are correctly reported without error. (3) The multi-hop reasoning is sound: the answer synthesizes the legal framework (2023) with the strategic evolution in 2024, correctly identifying Guyana's elevation to an 'advantaged asset' under ExxonMobil's growth strategy, even though the exact phrase 'Advantaged Volume Growth' earnings driver is paraphrased rather than quoted verbatim. The emphasis on volume growth, integration, and low-emission portfolio positioning reflects the semantic meaning of the original. (4) The only minor shortcoming is that the LLM does not explicitly name the 'Advantaged Volume Growth' earnings driver term, which is a small omission in precision but does not detract from the overall correctness. Contextual relevance is excellent, as the response directly addresses both the legal operating framework and the shift in business growth emphasis. Therefore, the answer earns a 9/10 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 398,
        "total_tokens": 1716
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has Caterpillar's involvement in the diesel-electric locomotives business evolved between 2023 and 2024, particularly in terms of its strategic positioning and operational responsibilities?",
      "original_answer": "In 2023, Caterpillar's involvement in diesel-electric locomotives was described as part of its broader Machinery, Energy & Transportation (ME&T) segment, which included responsibilities such as remanufacturing Caterpillar reciprocating engines and components, as well as product support for on-highway vocational trucks in North America. By 2024, Caterpillar's positioning had evolved, with diesel-electric locomotives and related components being explicitly tied to integrated systems and solutions for industries like electric power generation, marine, oil and gas, and industrial sectors. Additionally, 2024 emphasized the development of electrified powertrains and zero-emission power sources, signaling a strategic shift toward more advanced and environmentally focused technologies in the locomotive space.",
      "llm_answer": "\nBetween 2023 and 2024 Caterpillar kept diesel‑electric locomotives inside its **Energy & Transportation** segment, but the business was sharpened as a strategic growth area.  The segment’s rail‑related sales rose 3 % (to $28.85 bn) and profit jumped 16 % (to $5.74 bn), driven by better price realization and higher‑margin rail‑service revenue—particularly in marine and rail services—while the company continued to handle **design, manufacturing, remanufacturing, leasing and aftermarket support** of locomotives and related components.  In short, Caterpillar’s involvement did not shift to a new business line; it deepened its operational focus on rail products within the existing Energy & Transportation framework, positioning diesel‑electric locomotives as a higher‑margin, service‑driven component of its overall portfolio.",
      "correctness_score": 3,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that diesel-electric locomotives were part of the Machinery, Energy & Transportation (ME&T) segment in 2023 and evolved in 2024 to be tied to integrated systems and solutions with a focus on electrified powertrains and zero-emission technologies. However, the LLM claims specific financial figures—$28.85 billion in rail-related sales and $5.74 billion in profit—which are not present in the original answer and are implausible (e.g., $28.85B in rail sales alone would exceed Caterpillar's total revenue from its entire Energy & Transportation segment). There is no mention in the ground truth of sales or profit growth (3% and 16%), nor any financial metrics at all. (2) Quantitative accuracy is extremely low: the numbers provided by the LLM are fabricated or grossly misrepresented. Caterpillar’s entire 2023 revenue was around $64 billion across all segments, making $28.85 billion in 'rail-related sales' alone impossible. (3) The reasoning is partially sound in that it identifies continuity in segment structure and operational responsibilities, but it completely misses the key strategic evolution highlighted in the ground truth: the shift toward electrified powertrains and zero-emission technologies as a strategic repositioning. Instead, the LLM emphasizes financial performance and service-driven margins, which are not supported by the original answer. (4) Contextual relevance is moderate because the answer discusses Caterpillar's locomotive business and operational scope, but it fabricates data and misses the core strategic shift. Correctness is low due to major factual and quantitative errors, despite addressing the general topic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1422,
        "completion_tokens": 476,
        "total_tokens": 1898
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has the company's reliance on securitized debt obligations as a funding source evolved from 2022 to 2024, and what does this indicate about its funding strategy?",
      "original_answer": "In 2022, the company disclosed that it raised funding through the issuance of securitized debt obligations, among other instruments, though the exact amount was not provided. By 2024, the company reported a carrying value of $14,264 million for securitized debt obligations, indicating a concrete quantification of this funding source. This evolution suggests a more defined and potentially increased reliance on securitized debt obligations, aligning with a broader strategic emphasis on structured financing.",
      "llm_answer": "\nFrom 2022 through 2024 the outstanding balance of Capital One’s securitized‑debt obligations slipped modestly—from roughly $15 billion (about 4 % of total funding) to about $14.3 billion—while the proportion of securitization within the firm’s overall funding mix remained essentially unchanged.  This pull‑back signals a strategic shift toward relying more on core deposit growth and other debt sources, using securitizations only as a supplemental, low‑cost financing tool rather than a primary funding pillar.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, no exact amount was disclosed for securitized debt obligations, but by 2024, the carrying value was $14,264 million. The LLM incorrectly claims a specific figure of $15 billion in 2022 and implies a decline to $14.3 billion in 2024. This introduces a false quantitative trend (a modest decline) not supported by the original data, which only allows comparison from no specific number in 2022 to a defined $14,264 million in 2024. (2) The percentage mentioned (4% of total funding) and the characterization of the change as a 'pull-back' or 'strategic shift' are not present in or inferable from the original answer. The original indicates increased clarity and potentially increased reliance due to quantification, not a reduction. (3) The multi-hop reasoning is flawed: the LLM assumes a decrease based on imputed 2022 data, whereas the ground truth does not support such a comparison. It also introduces 'Capital One' as the company, which is not named in the original answer, raising entity accuracy concerns. (4) While the LLM attempts to address the evolution and strategic implication, its conclusions contradict the original: the ground truth suggests growing strategic emphasis on structured financing, while the LLM claims a de-emphasis. Thus, despite addressing the question's structure, the factual core is incorrect, warranting low scores in correctness, quantitative, and qualitative accuracy. Contextual relevance is moderate as it engages the right topic and timeframe.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1260,
        "completion_tokens": 437,
        "total_tokens": 1698
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has McDonald's treatment of developmental licensees evolved between 2023 and 2024, particularly in terms of financial reporting and relationship management?",
      "original_answer": "In 2023, McDonald's disclosed that developmental licensees paid royalties based on a percentage of sales and generally paid initial fees, and the company allocated consideration among lease and non-lease components using historical methods. By 2024, the company emphasized its ongoing evaluation of business relationships, including those with developmental licensees, to identify potential variable interest entities, although it concluded that consolidation of such entities was not appropriate. Additionally, in 2024, McDonald's updated its rounding presentation to the nearest whole number for reported amounts, which affected how financial figures were presented, though the company clarified that these changes were not significant.",
      "llm_answer": "\nBetween 2023 and 2024 McDonald’s kept developmental‑licensee revenues (royalties and initial fees) in the International Developmental Licensed Markets & Corporate segment, but it added the detailed segment‑expense disclosures required by the new FASB ASU 2023‑07, giving a clearer financial picture of that business.  At the same time the company refined its lease‑accounting assumptions—especially the probability of renewal options for restaurants operated by developmental licensees—resulting in a larger lease‑right‑of‑use asset and lease liability, reflecting a more formalized and integrated relationship with those licensees.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and introduces information not present in the ground truth. (1) It claims McDonald's adopted FASB ASU 2023-07 and added detailed segment-expense disclosures in 2024, which is not mentioned in the original answer and cannot be verified from the provided truth. (2) It states that lease-accounting assumptions were refined, leading to a larger right-of-use asset and lease liability for developmental licensees—this level of accounting impact is not supported by the ground truth, which only mentions updated rounding presentation to the nearest whole number and evaluation of variable interest entities. (3) The original answer emphasizes that McDonald’s evaluated relationships for potential variable interest entities in 2024 and updated rounding conventions, but the LLM misrepresents these as major accounting changes tied to new standards and financial impacts. (4) While the LLM correctly identifies that royalties and initial fees were part of the financial relationship, it fails to mention the key 2024 update about variable interest entity assessment and incorrectly frames the evolution around ASU 2023-07 and lease liability growth. (5) No numeric values (e.g., percentages, dollar amounts) are present in either answer, so quantitative accuracy is based on conceptual correctness of financial reporting changes—here, the LLM invents specific standards and effects not in the source. (6) The reasoning is flawed due to unsupported multi-hop synthesis, likely hallucinating connections between lease accounting and developmental licensees without evidence. (7) Contextual relevance is moderate because the answer addresses financial reporting and relationship management, but the specifics are incorrect. Overall, major factual and qualitative errors result in a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 499,
        "total_tokens": 1845
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has Southern Company's approach to its Equity and Incentive Compensation Plan evolved between 2023 and 2024, particularly in terms of share availability and executive award disclosures?",
      "original_answer": "In 2023, Southern Company had 26.9 million shares available for awards under the Equity and Incentive Compensation Plan, indicating a reserve for future compensation initiatives. By 2024, the company increased transparency around executive compensation by disclosing specific terms for Named Executive Officer equity awards granted under the 2021 Equity and Incentive Compensation Plan, which was effective May 26, 2021. This evolution shows a shift from internal planning and reserve allocation in 2023 to more detailed public disclosure of executive-level compensation mechanisms in 2024, suggesting a more formalized and transparent governance approach for top-level incentives.",
      "llm_answer": "\nBetween 2023 and 2024 Southern Company kept essentially the same share reserve for its Equity and Incentive Compensation Plan—about 26.9 million shares remained available for future awards at year‑end 2023 and the 2024 filing continues to reference that reserve.  However, the 2024 filing adds a dedicated “Form of Terms for Named Executive Officer Equity Awards” disclosure that spells out the award types, performance‑based metrics and vesting conditions, providing a more detailed and transparent executive‑award description than in the prior year.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, the 26.9 million shares available under the Equity and Incentive Compensation Plan in 2023 is correctly reported, and the continuity into 2024 is accurately reflected. There are no calculation errors or incorrect numbers. (2) The LLM correctly identifies the key qualitative evolution: while the share reserve remained stable, the 2024 filing introduced a new 'Form of Terms for Named Executive Officer Equity Awards' disclosure, enhancing transparency around executive awards. This matches the ground truth's emphasis on increased disclosure in 2024. (3) The multi-hop reasoning is sound—linking the consistent share availability (2023 data) with the new executive award transparency (2024 development)—and correctly attributes the plan to the 2021 Equity and Incentive Compensation Plan, even if not explicitly dated in the LLM response. (4) The only minor shortcoming is that the LLM does not explicitly mention the May 26, 2021 effective date of the plan, which is included in the original answer, slightly reducing qualitative completeness. However, this does not detract from the core factual accuracy. Overall, the answer is factually correct, contextually relevant, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 366,
        "total_tokens": 1685
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How did the revenue performance of Inlyta evolve between 2022 and 2023, and what factors contributed to the change in its growth trajectory?",
      "original_answer": "In 2022, Inlyta contributed to Pfizer's operational growth, specifically mentioned among products like Comirnaty, Eliquis, and Vyndaqel that drove growth in the U.S. and international markets. By 2023, Inlyta's global revenue reached $1,036 million, reflecting a 3% total increase and a 5% operational growth. The growth was primarily attributed to the adoption of immune checkpoint inhibitor combinations with Inlyta for first-line treatment of advanced RCC in the U.S., despite lower volumes and net price in certain European markets. This indicates a continuation of growth, albeit at a more moderate pace compared to the broader portfolio dynamics in 2022.",
      "llm_answer": "\nInlyta’s worldwide revenue rose modestly from **$1.00 billion in 2022 to $1.04 billion in 2023** (≈ 3 % operational growth).  The uptick was driven by continued uptake of Inlyta in combination regimens for advanced renal‑cell carcinoma—especially in the United States—and expansion in emerging markets, but was tempered by pricing pressure and lower net prices in certain European markets, which limited the pace of growth.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the revenue evolution of Inlyta from 2022 to 2023 and the key factors influencing its growth trajectory. It reports a revenue increase from $1.00 billion in 2022 to $1.04 billion in 2023, which aligns closely with the ground truth figure of $1,036 million in 2023 and a 3% total increase. The 3% operational growth mentioned in the LLM answer matches the 5% operational growth in the original answer only approximately—this is a minor discrepancy, as the ground truth specifies 5% operational growth, not 3%. However, the LLM may be conflating total and operational growth, which is a small error. (2) Quantitatively, the $1.00 billion 2022 figure is a reasonable approximation (implied from $1,036M in 2023 and 3% growth), though not explicitly stated in the ground truth. The $1.04 billion 2023 figure is a rounded version of $1,036 million, which is acceptable under format variation. The 3% growth figure is close but slightly underreports the actual 5% operational growth cited in the original. (3) The reasoning is sound: the LLM correctly identifies the U.S. adoption of immune checkpoint inhibitor combinations for advanced RCC as a growth driver and notes headwinds from European pricing and volume declines. It also appropriately contextualizes the growth as modest, reflecting the 'more moderate pace' mentioned in the ground truth. (4) The answer is contextually excellent—addresses both parts of the question (revenue performance and contributing factors), synthesizes information across regions and drivers, and maintains semantic equivalence despite minor numerical imprecision. The only deduction is for the conflation of total and operational growth rates, preventing a perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1269,
        "completion_tokens": 476,
        "total_tokens": 1746
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has McDonald's relationship with its franchisees evolved from 2023 to 2024 in terms of financial structure and dependency, particularly regarding revenue recognition and cost-sharing for technology platforms?",
      "original_answer": "In 2023, McDonald's described its relationship with franchisees as a collaborative partnership focused on consistency, quality, and revenue generation through rent, royalties based on a percent of sales, and initial fees. The business model was designed to generate stable and predictable revenue largely tied to franchisee sales. By 2024, the relationship evolved to reflect a stronger dependency on franchisees, particularly in the context of technology platforms. McDonald's began recognizing revenue from franchisees for technology services on a gross basis, with related expenses recorded in 'Other restaurant expenses,' indicating a more integrated and cost-sharing approach. This shift reflects a transformation in the nature of the relationship, with franchisees becoming more operationally interdependent with the company through shared technology infrastructure.",
      "llm_answer": "\nBetween 2023 and 2024 the franchise model stayed virtually the same – roughly 95 % of restaurants remained franchised and the Company’s revenue continued to be generated from rent, royalties and initial fees that are recognized over the typical 20‑year franchise term.  The 2024 filing (see pp. 44‑46) notes that “Other revenues” now includes fees paid by franchisees to recover a portion of the Company’s technology‑platform costs; these fees are recorded gross and the related expenses are recognized as incurred, so they do not generate a margin for the Company.  Consequently, while the scale of technology‑cost‑sharing grew slightly, the way revenue is recognized and the non‑profit nature of those fees were unchanged, leaving McDonald’s financial dependence on its franchisees essentially stable from 2023 to 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains several correct elements but diverges significantly from the ground truth in key qualitative aspects, particularly regarding the evolution of McDonald's relationship with franchisees. (1) Quantitatively, the answer correctly notes that approximately 95% of restaurants are franchised and references the 20-year franchise term, which aligns with typical disclosures. It also accurately cites the inclusion of technology fees in 'Other revenues' and their gross recognition, consistent with the 2024 filing. These details are factually sound and match expected reporting. (2) However, the core reasoning and qualitative interpretation conflict with the ground truth. The original answer emphasizes a shift toward greater dependency and operational interdependence due to the gross revenue recognition of technology fees and cost-sharing, signaling a more integrated financial structure. In contrast, the LLM claims the model 'stayed virtually the same' and that financial dependence 'remained stable,' which contradicts the ground truth's assertion of an evolved, more interdependent relationship. (3) The multi-hop reasoning is partially correct—linking technology cost recovery to gross revenue recognition—but fails to synthesize the broader implication: that this change reflects a structural evolution in the franchise relationship, not merely a neutral cost-recovery mechanism. The LLM downplays the significance of gross reporting, which under accounting standards often indicates principal vs. agent considerations and greater operational control or involvement. (4) While the answer is contextually relevant and addresses revenue recognition and cost-sharing, it misses the transformative aspect emphasized in the ground truth. Thus, despite accurate numbers and some correct details, the conclusion is misleading, warranting a low correctness score due to flawed qualitative synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1440,
        "completion_tokens": 515,
        "total_tokens": 1955
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did the fair value of energy-related derivatives held by Southern Company's subsidiaries evolve from 2022 to 2023, and what does this indicate about the company's exposure to energy market fluctuations?",
      "original_answer": "In 2022, Southern Company's subsidiaries reported a net fair value of $101 million for energy-related derivatives (Mississippi Power: $59 assets, $32 liabilities; Southern Power: $8 assets, $12 liabilities; Southern Company Gas: $28 assets, $65 liabilities). In 2023, the subsidiaries showed a shift with Alabama Power reporting $15 in assets and $110 in liabilities, and Georgia Power reporting $13 in assets and $124 in liabilities for energy-related derivatives. This indicates a significant increase in net liability exposure, rising from a net liability of $54 million in 2022 to a net liability of $219 million in 2023, suggesting a greater exposure to energy market fluctuations.",
      "llm_answer": "\nThe subsidiaries’ energy‑related derivatives fell from about $199 million in assets (and $210 million in liabilities) in 2022 to roughly $55 million in assets but rose to about $358 million in liabilities by 2023. This shift from a near‑break‑even position to a sizable net liability indicates that Southern Company’s exposure to energy‑price volatility increased markedly over the year.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. In 2022, the total assets and liabilities cited by the model ($199M assets, $210M liabilities) do not match the ground truth: actual total assets were $59 + $8 + $28 = $95M, and total liabilities were $32 + $12 + $65 = $109M, resulting in a net liability of $14M (not near break-even). The model incorrectly calculates both totals and misrepresents the 2022 position. For 2023, the LLM reports $55M in assets and $358M in liabilities, but the ground truth only includes Alabama Power ($15 assets, $110 liabilities) and Georgia Power ($13 assets, $124 liabilities), totaling $28M in assets and $234M in liabilities. The LLM overstates both assets and liabilities for 2023. The net liability shift from $14M to $206M (ground truth: $54M to $219M) is directionally correct but numerically inaccurate due to incorrect inputs. (2) Calculations are flawed: the model’s claim of a near-break-even in 2022 is false (net liability was already present), and the 2023 net liability is overstated. The actual net liability increase is from $54M to $219M (as per original answer, based on different subsidiary reporting), but the LLM uses incorrect entity data. (3) Multi-hop reasoning is partially sound—the model recognizes the need to aggregate subsidiary data and assess exposure via net liability changes—but fails in entity alignment: it includes non-specified subsidiaries or misattributes data (e.g., no mention of Mississippi Power, Southern Power, or Southern Company Gas in 2023, while introducing Alabama and Georgia Power without full context). The shift in reporting entities between years is not properly handled. (4) Despite numerical errors, the qualitative conclusion about increased exposure is directionally correct, and the answer addresses both parts of the question (evolution and implication), hence moderate scores in qualitative accuracy and high in contextual relevance. However, the severe quantitative inaccuracies limit correctness to a partial credit level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 552,
        "total_tokens": 1835
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has the treatment and significance of the Procter & Gamble 2019 Stock and Incentive Compensation Plan evolved from 2022 to 2024, based on its disclosure context in the 10-K filings?",
      "original_answer": "In 2022, the 2019 Stock and Incentive Compensation Plan was introduced with detailed references to its adoption by shareholders on October 8, 2019, and its additional terms and conditions, indicating its formal establishment and integration into the company's compensation framework. By 2024, the plan was listed among other equity compensation plans as part of the company's broader disclosure on stock ownership and equity compensation, showing that it had become a standard and active component of the company's long-term incentive structure. This evolution reflects the plan's transition from a newly introduced policy to an established part of PG's equity compensation offerings.",
      "llm_answer": "\nBetween the 2022 and 2024 Form 10‑K filings, the 2019 Stock and Incentive Compensation Plan remained the sole P&G equity plan that permits future grants, but the reserve of shares available for new issuance dropped from about 119 million to about 77 million, and the weighted‑average exercise price of outstanding options increased from $99.5 to $111.6, reflecting that the plan’s share pool has been substantially used by prior awards while still serving as the primary vehicle for future equity compensation.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer introduces specific quantitative data—such as a decrease in available shares from 119 million to 77 million and an increase in weighted-average exercise price from $99.5 to $111.6—that are not present in the original ground truth answer and cannot be verified against it. Since the ground truth does not include any numerical figures or metrics about share reserves or option prices, these numbers appear to be fabricated or hallucinated, severely undermining quantitative accuracy. There is also no mention in the ground truth about the 2019 Plan being the 'sole' equity plan allowing future grants, though this may be contextually plausible; still, it represents an unverified claim not supported by the provided truth. Qualitatively, the LLM captures a similar trajectory—ongoing significance of the plan as a vehicle for equity compensation—but frames the evolution around quantitative depletion (shrinking share pool) rather than the conceptual shift from introduction to integration described in the original answer. The ground truth emphasizes the plan’s disclosure context evolving from detailed foundational disclosure in 2022 (adoption date, terms) to being one of several standard plans disclosed in 2024, indicating normalization within reporting practices. The LLM misses this narrative of disclosure maturity and regulatory context, instead focusing on financial metrics absent from the source. Contextually, the answer remains relevant to the question about evolution in significance and treatment, but the reasoning is based on unsupported data rather than the actual shift in disclosure treatment. Thus, while the general direction of 'continued importance' aligns, the factual basis and multi-hop synthesis do not match the ground truth, resulting in a partially correct but factually inaccurate response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 495,
        "total_tokens": 1804
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has Southern Company's approach to managing the risk of large losses in its pension plan assets evolved from 2023 to 2024, and what specific changes in risk management emphasis can be observed?",
      "original_answer": "In 2023, Southern Company emphasized a formal rebalancing program and external investment manager oversight as key components of managing the risk of large losses, with a strong focus on long-term investment expectations for return and risk. In 2024, while maintaining a diversified asset strategy and rebalancing program, the emphasis on external manager oversight was reduced, and the risk of large losses was more directly linked to the broader market volatility and interest rate fluctuations. This indicates a subtle shift in risk management emphasis from active oversight to market-driven risk exposure.",
      "llm_answer": "\nSouthern Company’s pension‑plan risk‑management framework—broad diversification, a formal rebalancing program and written guidelines for external managers—remained unchanged from 2023 to 2024.  However, the 2024 target‑allocation tables show a modest shift: equity’s target weight stayed at 41 % (actual 40 %), fixed‑income rose from a 30 % target to about 32 % actual, real‑estate increased from 12 % to 14 % actual, and private‑equity was raised from 9 % to 12 % actual, while private‑credit and special‑situations exposures were trimmed.  This re‑weighting reflects a greater emphasis on long‑term, stable assets (real‑estate and private‑equity) and a reduction in higher‑risk credit‑related positions, indicating a slightly more conservative risk posture while still relying on diversification, rebalancing and external‑manager oversight to curb large‑loss risk.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces specific percentage changes in asset allocations (e.g., fixed-income rising from 30% to 32%, real estate from 12% to 14%, private equity from 9% to 12%) that are not present in the original answer and cannot be verified against the ground truth. The original answer makes no mention of such quantitative shifts in target allocations, focusing instead on qualitative changes in risk management emphasis. These specific numbers appear to be fabricated or inferred beyond what the source supports. (2) While the LLM correctly notes the continued use of diversification and rebalancing, it incorrectly implies that external manager oversight remained a stable component, whereas the ground truth explicitly states that the emphasis on external manager oversight was reduced in 2024. This is a key factual discrepancy. (3) The multi-hop reasoning is partially sound in that it attempts to infer risk posture from allocation changes, but this inference is based on unsupported numerical data. The original answer identifies a shift from active oversight to market-driven risk exposure, a nuanced qualitative change the LLM fails to capture, instead positing a 'more conservative risk posture' based on unverified allocation shifts. (4) The contextual relevance is high because the answer addresses pension risk management and attempts to compare 2023 and 2024. However, the qualitative and quantitative inaccuracies—especially the unsupported percentages and missed shift in oversight emphasis—severely undermine correctness. The core evolution in risk management emphasis described in the ground truth is not accurately reflected, leading to a low correctness score despite relevant framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 470,
        "total_tokens": 1852
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has NVIDIA's role in the development and supply of the CUDA platform evolved between 2022 and 2023, and what does this shift indicate about the company's strategic focus?",
      "original_answer": "In 2022, NVIDIA's relationship with the CUDA platform was primarily as a supplier, providing the platform as part of its accelerated computing offerings. By 2023, NVIDIA's role had evolved into that of a developer, emphasizing a more active and strategic engagement in the platform's expansion and integration within its broader software ecosystem, including CUDA-X libraries, APIs, and domain-specific frameworks. This shift indicates a strategic move toward strengthening its full-stack computing platform to deliver more comprehensive data center-scale solutions.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2023 NVIDIA’s involvement with CUDA moved from being a primarily developer‑focused programming model that under‑pins its GPU hardware sales (as described in the 2022 10‑K on pages 78‑82) to a core element of a broader, monetized AI‑software stack that now includes subscription‑based offerings such as NVIDIA AI Enterprise, DGX Cloud and the Grace CPU (highlighted in the 2023 10‑K on pages 4‑8).  This shift reflects a strategic pivot toward higher‑margin software and platform revenues, positioning NVIDIA as a full‑stack AI computing provider rather than just a supplier of GPU hardware and CUDA.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution of NVIDIA's role with CUDA from 2022 to 2023: from a developer-focused programming model supporting GPU sales (supplier role) to a core component of a broader, monetized software stack (developer/strategic integrator role). The mention of NVIDIA AI Enterprise, DGX Cloud, and Grace CPU in the context of 2023 is consistent with NVIDIA’s strategic expansion into full-stack solutions. (2) There are no numeric values, dates, or financial figures in the question or ground truth that require verification—only fiscal years 2022 and 2023, which are correctly used. Page references (e.g., 2022 10-K pp. 78–82, 2023 10-K pp. 4–8) are plausible and contextually appropriate, though not required for correctness. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of 10-K filings to infer a strategic shift, correctly linking CUDA’s evolution to broader business strategy (full-stack AI provider). The conclusion about a pivot toward higher-margin software revenues is a valid interpretation supported by the shift described in the ground truth. (4) While the LLM uses slightly different terminology (e.g., 'monetized AI-software stack' vs. 'full-stack computing platform'), the semantic meaning matches the original answer. The only minor gap is that the LLM emphasizes monetization and subscriptions more than the original, which focuses on technical expansion (CUDA-X, APIs, frameworks). However, this is a reasonable inference, not a factual error. Thus, the answer earns a 9 for correctness and qualitative accuracy due to slight emphasis differences, but full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 478,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How did Pfizer's financial relationship with Viatris evolve between 2022 and 2023, particularly in terms of supply agreements and outstanding balances?",
      "original_answer": "In 2022, Pfizer reported $780 million in revenue growth from PC1, primarily reflecting manufacturing of legacy Upjohn products for Viatris under supply agreements. By 2023, the financial relationship had evolved, as indicated by the net amounts due to Viatris under various agreements, which decreased from $94 million as of December 31, 2022, to $33 million as of December 31, 2023. Additionally, most transitional services under the TSAs were completed by the end of 2023, signaling a reduction in operational interdependence.",
      "llm_answer": "\nBetween 2022 and 2023 Pfizer’s manufacturing and supply agreements that had been supporting Viatris’s legacy Upjohn portfolio remained in force but were being phased down.  The balance outstanding under those arrangements fell sharply—from about **$94 million at the end of 2022** to roughly **$33 million by the end of 2023**—reflecting the winding‑down of transitional services and the completion of the shift of production to Viatris, so that revenue recognized from PC1 related to those agreements was now minimal and no material balances remained.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers are correct: the outstanding balance decreased from $94 million at the end of 2022 to $33 million at the end of 2023, matching the original answer exactly. These figures are reported with appropriate context and timeframes. (2) The answer correctly identifies the nature of the financial relationship—supply agreements tied to legacy Upjohn products and transitional services under TSAs—and notes their phase-down, which is consistent with the knowledge graph. (3) The multi-hop reasoning is sound: it synthesizes information about revenue trends (implied decline in PC1-related revenue), operational transition completion, and balance reduction. (4) The only minor shortcoming is that the LLM omits the specific 2022 revenue figure of $780 million from PC1, which was a key indicator of the initial scale of the relationship. While the answer implies this decline ('revenue... now minimal'), the explicit mention of the $780M would have strengthened completeness. However, the core evolution of the relationship—declining balances and winding down operations—is accurately conveyed. Wording differs but semantic meaning is equivalent. No factual errors or calculation issues.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1271,
        "completion_tokens": 357,
        "total_tokens": 1629
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has the treatment and disclosure of communications sites in relation to debt obligations evolved between 2023 and 2024?",
      "original_answer": "In 2023, communications sites were explicitly referenced as collateral securing debt obligations, such as the 3,343 communications sites securing the Series 2015-2 Notes and the repayment of $1.3 billion in Series 2013-2A Notes funded by the 2023 Securitization. In 2024, while there was no explicit mention of specific communications sites securing debt, the company disclosed broader financial commitments, such as $4.5 billion in estimated undiscounted future cash outlay for asset retirement obligations as of December 31, 2024. This shift indicates a move from site-specific debt disclosures to more general obligations, suggesting a change in how communications sites are framed in relation to financial liabilities.",
      "llm_answer": "\nThe 2023 filing only gave a broad description that cash‑flows from the communications sites back the securitized debt and that any excess cash could be released to the Company. By the 2024 filing this treatment is expanded into a detailed, quantitative disclosure that introduces specific DSCR tests (a 1.30 × cash‑trap and a 1.15 × minimum), defines cash‑trap and amortization periods, quantifies the excess cash that would be locked in reserve accounts, and clearly outlines the default‑related loss of site ownership. This evolution reflects a far more granular and risk‑focused disclosure of how the sites are pledged as collateral and how cash‑flow restrictions affect the Company’s debt obligations.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth. (1) It claims that the 2024 filing introduced more detailed, quantitative disclosures about debt service coverage ratios (DSCR), cash-trap mechanisms, reserve accounts, and default consequences—none of which are mentioned or supported in the original answer. The ground truth states that in 2024, there was *no explicit mention* of specific communications sites securing debt, indicating a move *away* from site-specific disclosures, not toward more granular ones. (2) Quantitatively, the LLM invents specific metrics like '1.30× cash-trap' and '1.15× minimum' DSCR tests, which do not appear in the ground truth. The only numbers in the original answer are $1.3 billion (repayment of Series 2013-2A Notes) and $4.5 billion (asset retirement obligations in 2024), neither of which are referenced or correctly used by the LLM. (3) The multi-hop reasoning is flawed: instead of identifying a shift from specific collateral disclosures (2023) to broader financial obligations (2024), the LLM incorrectly asserts an evolution toward greater specificity and risk-focused reporting in 2024. This is the opposite of the actual trend described in the ground truth. (4) While the answer is contextually relevant—focusing on debt obligations and communications sites—the factual inaccuracies, invented data, and reversed logic severely undermine correctness. The answer fabricates disclosures rather than reporting the documented shift in treatment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 413,
        "total_tokens": 1764
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Comcast's approach to retransmission consent agreements evolved between 2022 and 2023, particularly in terms of revenue recognition and distribution models?",
      "original_answer": "In 2022, Comcast recognized revenue from retransmission consent agreements on a monthly basis as programming was provided, with fees tied to the number of subscribers and generally collected within 60 days. By 2023, the company's Media segment emphasized a combined linear and streaming distribution model, with retransmission fees now explicitly including both traditional and virtual multichannel video providers. The 2023 filing also highlighted a broader integration of Peacock into the distribution ecosystem, suggesting a strategic shift toward hybrid distribution models that blend traditional and streaming services.",
      "llm_answer": "\nComcast’s retransmission‑consent revenue moved from a “gross‑pass‑through” treatment in 2022—where the fees were recorded as part of programming revenue and recognized when earned, often as a lump‑sum charge passed to customers—to a 2023 model that presents the fees as monthly, subscriber‑based license payments under multiyear distribution agreements and recognizes the income on a straight‑line basis as the programming is delivered each month.  This shift reflects a change in both the distribution model (from a gross‑video‑revenue pass‑through to explicit monthly subscriber fees) and the timing of revenue recognition (from point‑in‑time/when‑earned to monthly over the term of the agreement).  (See CMCSA_10k_2022.pdf pp. 92‑96; CMCSA_10k_2023.pdf pp. 8‑12).",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains some correct elements regarding revenue recognition timing and the shift toward monthly, subscriber-based recognition in 2023, which aligns partially with the ground truth. However, it introduces the term 'gross-pass-through' treatment in 2022 and describes a 'lump-sum charge passed to customers'—a claim not supported by the original answer or typical retransmission consent accounting practices—and this misrepresents Comcast's 2022 model. The original answer states revenue was recognized monthly as programming was provided, not as a lump sum. The LLM also fails to mention the key strategic evolution in 2023: the inclusion of both traditional and virtual MVPDs in retransmission fees and the integration of Peacock into the distribution ecosystem, which is central to the shift toward hybrid distribution models. While the LLM correctly identifies a change in revenue recognition timing and distribution model, it fabricates accounting terminology ('gross-pass-through') and omits critical qualitative aspects of the strategic shift. Quantitative accuracy is moderate—no explicit numbers are wrong because none are cited, but the conceptual description of revenue timing has partial alignment. The reasoning is partially sound but based on incorrect premises, and the synthesis across years lacks fidelity to the actual filings. Contextual relevance is high as the response stays on topic and references appropriate sections of the 10-Ks.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 403,
        "total_tokens": 1755
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Caterpillar's involvement in the production and strategic positioning of diesel-electric locomotives evolved from 2023 to 2024?",
      "original_answer": "In 2023, Caterpillar's involvement in diesel-electric locomotives was described as part of its broader ME&T segment, which included responsibilities such as remanufacturing Caterpillar reciprocating engines and components, as well as providing product support for on-highway vocational trucks in North America. By 2024, Caterpillar's engagement had evolved into a more defined production role under the Energy & Transportation segment, which explicitly stated that Caterpillar 'produces' diesel-electric locomotives and components, signaling a more direct and strategic emphasis on this product line. Additionally, in 2024, Caterpillar highlighted competitive pressures in rail-related businesses, naming companies like Wabtec Corp and Siemens Mobility A/S, which was not present in 2023. This indicates a shift from a general operational inclusion to a more prominent and competitive product focus.",
      "llm_answer": "\nIn 2023 Caterpillar’s diesel‑electric locomotives were listed only as part of the Energy & Transportation segment’s product portfolio, with emphasis on manufacturing, remanufacturing and component sales (CAT_10K 2023, pp. 114‑118). By 2024 the company broadened that role, positioning diesel‑electric locomotives as a strategic pillar within its sustainability‑driven “expanded offerings” agenda and highlighting remanufacturing, digital integration and market growth as key priorities (CAT_10K 2024, pp. 4‑8).",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains some correct elements but diverges significantly from the ground truth in key aspects. While both years are correctly referenced and the general domain (diesel-electric locomotives within Caterpillar’s segments) is accurate, the LLM misrepresents the nature of the evolution. The original answer states that in 2023, diesel-electric locomotives were part of the ME&T segment with a focus on remanufacturing and support, and by 2024 shifted to the Energy & Transportation segment where Caterpillar explicitly 'produces' locomotives. The LLM incorrectly claims that in 2023, locomotives were already part of the 'Energy & Transportation' segment, which contradicts the ground truth (ME&T was the relevant segment in 2023). Additionally, the LLM introduces a 'sustainability-driven expanded offerings agenda' and highlights 'digital integration and market growth' as priorities in 2024—details not present in the original answer. While the mention of remanufacturing aligns with the truth, the strategic framing is fabricated. (2) There are no numeric values, dates, or calculations in either answer, so quantitative accuracy is not applicable—scored 10 by default. (3) The multi-hop reasoning is partially sound—comparing Caterpillar’s positioning across two years—but fails in entity accuracy (wrong segment in 2023) and introduces unverified strategic initiatives. The original answer emphasizes a shift from general operational inclusion to explicit production and competitive awareness (naming Wabtec and Siemens), which the LLM omits entirely. (4) Correctness is scored 5 due to partial factual alignment but significant inaccuracies in segment evolution and added, unsupported strategic context. Qualitative accuracy is 5 due to flawed reasoning and entity misattribution. Contextual relevance is high (8) because the answer addresses the evolution question and stays within the domain, despite inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 526,
        "total_tokens": 1876
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of revenue recognition and cost-sharing arrangements between 2023 and 2024?",
      "original_answer": "In 2023, McDonald's revenue from franchisees primarily included rent and royalties based on a percentage of sales with minimum rent payments, and initial fees. The company also mentioned that all restaurants were either operated by McDonald's or by franchisees under franchised arrangements. By 2024, the revenue recognition model remained consistent, but the company provided more detailed disclosures on how it recognizes revenue from franchisees, including the treatment of technology platform fees, which are now presented on a gross basis on the Consolidated Statement of Income. Additionally, in 2024, McDonald's clarified its cost-sharing arrangements for restaurant improvements, where it may fund certain projects and allocate costs between Property and Equipment and Accounts Receivable during the project, finalizing the allocation upon completion. This level of detail on cost-sharing was not present in the 2023 filing, indicating a more nuanced and transparent approach to franchisee financial interactions in 2024.",
      "llm_answer": "\nBetween 2023 and 2024 McDonald’s kept the same revenue‑recognition model—franchise fees are amortized over the typical 20‑year franchise term and royalties are recorded as underlying sales occur—but the 2024 filing adds a more explicit description of the cost‑sharing process.  The Company now states that shared restaurant‑improvement costs are allocated in real time between Property & Equipment and Accounts Receivable and that the allocation is finalized after the project, resulting in only immaterial adjustments.  This more detailed, formalized allocation of costs with franchisees marks the evolution in the company’s cost‑sharing arrangement between the two years.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in McDonald's relationship with franchisees between 2023 and 2024. (1) It correctly states that the revenue recognition model remained consistent—franchise fees amortized over a 20-year term and royalties recognized as sales occur—which aligns with the ground truth noting continuity in rent, royalties, and initial fees. The mention of a 20-year franchise term, while not explicitly in the original answer, is a reasonable inference consistent with industry norms and does not contradict the ground truth. (2) Quantitatively, no specific numbers (e.g., percentages, dollar amounts) are misstated; the answer avoids making up figures and sticks to structural descriptions. Format and inferences are appropriate. (3) The LLM accurately identifies the key qualitative evolution: enhanced disclosure in 2024 around cost-sharing for restaurant improvements, including real-time allocation between Property & Equipment and Accounts Receivable, with finalization post-completion. This matches the ground truth’s emphasis on more detailed 2024 disclosures. (4) The answer omits one element from the original: the 2024 treatment of technology platform fees being presented on a gross basis in the income statement. This is a minor but notable omission in completeness, as it was part of the revenue recognition disclosure evolution. However, the core of the question—evolution in revenue recognition and cost-sharing—is well addressed, with sound multi-hop reasoning comparing disclosures across years. The omission prevents a perfect 10, but the answer remains factually correct, contextually relevant, and semantically aligned with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1425,
        "completion_tokens": 463,
        "total_tokens": 1889
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Southern Company's approach to executive equity compensation evolved between 2023 and 2024, particularly regarding plan documentation and award terms?",
      "original_answer": "In 2023, Southern Company disclosed that stock-based compensation, primarily in the form of performance share units (PSUs) and restricted stock units (RSUs), was granted under the Equity and Incentive Compensation Plan to employees ranging from line management to executives. By 2024, the company formalized the terms for Named Executive Officer equity awards under the same plan, indicating a more structured approach to executive compensation. Additionally, the 2024 filing included detailed documentation practices, such as the designation of specific exhibits for equity award terms, which was not present in the 2023 filing. This reflects a shift toward greater specificity and transparency in executive equity compensation documentation.",
      "llm_answer": "\nThe 2024 filing shows a modest evolution from 2023: Southern Company added a ninth amendment to its Employee Savings Plan (effective December 16 2024) and reaffirmed the August 15 2022 change‑in‑control severance plan, while continuing to require that unvested PSUs and RSUs vest immediately for retirement‑eligible participants and upon a change‑in‑control where the company is not the survivor.  At the same time, the 2024 disclosures provide more detailed documentation of award terms—specifically the Monte‑Carlo assumptions used for TSR‑based PSUs and the grant‑date fair‑value calculations for RSUs—making the equity‑compensation framework clearer and more transparent than in the prior year.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains some accurate details but significantly diverges from the ground truth in key areas. (1) It incorrectly focuses on amendments to the Employee Savings Plan and change-in-control severance terms, which are not mentioned in the original answer and are not central to the evolution of executive equity compensation plan documentation and award terms. The ground truth emphasizes formalization of Named Executive Officer (NEO) award terms under the Equity and Incentive Compensation Plan and improved documentation practices (e.g., specific exhibits), which the LLM answer omits entirely. (2) The LLM introduces Monte-Carlo assumptions and grant-date fair-value calculations for RSUs as new disclosures in 2024, which are not present in the original answer and represent a factual overreach or misattribution. (3) While both answers agree that 2024 brought greater transparency, the LLM fails to identify the core shift: the formalization of NEO equity award terms and the introduction of structured exhibit documentation, which was absent in 2023. (4) The mention of immediate vesting upon retirement eligibility or change-in-control is contextually relevant to award terms but was not highlighted in the ground truth as a change between 2023 and 2024, making its inclusion potentially misleading. (5) Quantitatively, the dates (e.g., December 16, 2024; August 15, 2022) may be factually accurate from the filings but are irrelevant to the question about evolution in executive equity compensation structure and documentation. The LLM thus provides plausible-sounding but misaligned information. (6) Multi-hop reasoning is partially sound—comparing disclosures across years—but synthesizes incorrect entities (Employee Savings Plan instead of Equity and Incentive Compensation Plan for NEOs), undermining qualitative and overall correctness. The answer is contextually relevant to Southern Company’s compensation practices but misses the specific focus on executive-level plan documentation and award term formalization.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 546,
        "total_tokens": 1909
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Procter & Gamble's strategic reliance on membership club stores evolved from 2022 to 2024, and what does this shift indicate about the company's broader retail channel strategy?",
      "original_answer": "In 2022, Procter & Gamble identified membership club stores as one of its key retail channels, listing them among a broad set of distribution partners such as mass merchandisers, grocery stores, and e-commerce platforms. However, by 2024, the company's language shifted to emphasize dependency on these membership club stores, indicating a deeper strategic alignment or increased reliance on this channel. This evolution suggests that membership club stores have become more central to P&G's distribution and retail execution strategy, likely reflecting growth in this channel's importance to consumer purchasing behavior and overall market dynamics.",
      "llm_answer": "\nFrom 2022 to 2024 P&G’s dependence on membership‑club retailers receded – the 2022 filing lists “membership club stores” among its key wholesale customers, but the 2024 MD&A emphasizes growth in direct‑to‑consumer and e‑commerce channels and no longer treats those clubs as a primary sales pillar. This reflects a broader shift toward a more diversified, digitally‑focused retail mix in which the company seeks to reduce reliance on any single wholesale channel and gain greater control over the customer experience and margin generation.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its core claim. According to the ground truth, Procter & Gamble's strategic reliance on membership club stores *increased* from 2022 to 2024, with the company shifting language from identifying them as one of many key channels in 2022 to emphasizing *dependency* on them by 2024. The LLM incorrectly states that dependence 'receded' and that membership club stores were no longer treated as a primary sales pillar in 2024. This misrepresents the direction of the strategic shift. There are no numeric values in the question or answers, so quantitative accuracy is not at issue (score of 10 by default). However, the qualitative accuracy is very low because the model fails to correctly identify the evolution in P&G’s channel strategy and draws the opposite conclusion from the evidence. The reasoning is unsound: it invents a shift toward direct-to-consumer and e-commerce at the expense of club stores, which contradicts the ground truth that club stores became more central. Contextual relevance is partially present—retail channel strategy is addressed—but the answer focuses on a non-existent strategic pivot, making it largely irrelevant to the actual evolution. The multi-hop synthesis failed: instead of detecting an increased emphasis on membership clubs, the model incorrectly inferred a de-emphasis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 375,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did AMT's involvement with Nigeria Letters of Credit evolve between 2023 and 2024, and what does this indicate about its financial obligations related to this instrument?",
      "original_answer": "In 2023, AMT had a $3.4 million obligation under the Nigeria Letters of Credit as part of its variable rate debt portfolio. However, by 2024, this obligation was no longer present, as indicated by the $0 carrying value in both denominated currency and USD. This indicates that AMT fully settled or otherwise exited its financial obligations tied to Nigeria Letters of Credit within this period.",
      "llm_answer": "\nBetween the 2023 and 2024 fiscal years AMT’s Nigeria Letters of Credit fell from a recorded $3.4 million carrying amount at the end of 2023 to essentially $0 by the end of 2024 (the 2024 column shows “‑” for both denominated‑currency and USD carrying values). This reduction reflects that the draws taken in 2023 were either repaid or matured (the obligations are due 270 days after drawing), so the contingent liability associated with those letters of credit has been settled and no longer appears on the balance sheet. Consequently, AMT no longer holds a financial obligation for the Nigeria Letters of Credit, indicating the instrument’s exposure has been eliminated.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers are correct: the $3.4 million obligation in 2023 and $0 (represented as '‑') in 2024 match the original answer. The format variation ('‑' for zero) is acceptable and commonly used in financial statements. (2) The answer correctly identifies the entity (AMT), the financial instrument (Nigeria Letters of Credit), and the relevant time frame (2023 to 2024). (3) The reasoning is sound: it correctly infers that the obligation was settled, matured, or repaid, leading to no carrying value in 2024. The additional detail about the 270-day maturity period, while not in the original answer, is plausible and consistent with typical letter of credit terms; it does not contradict the ground truth and enhances the explanation without introducing error. (4) The answer fully addresses both parts of the question: the evolution of AMT's involvement (from $3.4M to $0) and the implication (elimination of financial obligation). The only minor deduction is for introducing a specific maturity detail (270 days) not present in the original data, which, while reasonable, goes slightly beyond the provided information. Overall, the answer is factually correct, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1273,
        "completion_tokens": 360,
        "total_tokens": 1634
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did the valuation methodology and composition of GD's Retirement Annuity Contracts change between 2022 and 2024, and what does this indicate about the company's approach to reporting these assets?",
      "original_answer": "In 2022, GD reported Retirement Annuity Contracts as part of Level 3 assets with a fair value of $35 million as of December 31, 2021, and this value remained relatively stable through December 31, 2020 at $38 million. The contracts were disclosed within a detailed table showing actual returns, unrealized gains and losses, and net purchases or sales. By 2024, Retirement Annuity Contracts were still categorized under Level 3 assets but were now described as being valued using NAV (net asset value) as a practical expedient, excluded from the formal fair value hierarchy. This indicates a shift in GD's reporting methodology from detailed fair value disclosures to a more simplified NAV-based approach, aligning with broader changes in how these contracts are categorized and disclosed.",
      "llm_answer": "\nBetween 2022 and 2024 the **valuation methodology for GD’s Retirement Annuity Contracts did not change** – they remained classified as Level 3 assets (significant unobservable inputs).  However, the **reported fair‑value of those contracts fell sharply, from $38 million in 2022 to $22 million in 2024**, and they now represent a much smaller share of the overall plan assets (the total Level 3 balance dropped from $318 million to $219 million).  This shift shows that General Dynamics is **reducing its reliance on internally‑derived estimates for these annuities and is moving toward more observable, market‑based measurements** (e.g., greater exposure to Level 2 commingled funds and fixed‑income securities), indicating a more conservative and transparent approach to reporting its pension‑related assets.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains multiple factual inaccuracies. It claims the valuation methodology did not change, stating that Retirement Annuity Contracts remained Level 3 assets without mentioning the critical shift to using NAV as a practical expedient, which is a key change in methodology. The ground truth explicitly states that by 2024, these contracts were valued using NAV as a practical expedient and were excluded from the formal fair value hierarchy—this is a significant methodological change that the LLM incorrectly dismisses. (2) Quantitatively, the LLM is wrong: it reports a drop from $38M in 2022 to $22M in 2024, but the ground truth references $38M as of December 31, 2020 and $35M as of December 31, 2021—there is no data provided for 2022 or 2024 values in the original answer, so the LLM fabricates numbers. Additionally, the claim about total Level 3 assets dropping from $318M to $219M is unsupported by the ground truth. (3) The multi-hop reasoning is flawed: the LLM infers a strategic shift toward more observable, market-based measurements and a reduction in reliance on internal estimates, but the ground truth indicates a move to a simplified NAV-based reporting approach, which may actually reduce transparency in fair value disclosures, contrary to the LLM’s conclusion. (4) Contextual relevance is moderate—the answer addresses the topic of valuation changes and reporting approach—but due to incorrect facts, numbers, and reasoning, the overall correctness is very low. The answer misrepresents both the methodology change and the financial data, leading to an incorrect interpretation of GD’s reporting strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1413,
        "completion_tokens": 453,
        "total_tokens": 1866
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has the composition and value of restricted cash for securitization investors changed between 2022 and 2024, particularly in terms of its fair value hierarchy classification?",
      "original_answer": "In 2022, the company reported restricted cash for securitization investors as part of consolidated VIEs, with the assets and liabilities presented on the consolidated balance sheets. By 2024, the restricted cash for securitization investors was valued at $441 million, with the entire amount classified under Level 1 of the estimated fair value hierarchy, indicating a shift toward more transparent or market-based valuation methods. This reflects a more defined and standardized valuation approach in 2024 compared to 2022, where the fair value hierarchy was not explicitly detailed for this category.",
      "llm_answer": "\nRestricted cash held for securitization investors fell modestly from $458 million in 2022 to $441 million in 2024. In both years the balance is classified as Level 1 in the fair‑value hierarchy, meaning its fair value is derived from quoted market prices for identical assets and is fully observable.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states the 2024 restricted cash value of $441 million and provides a 2022 figure of $458 million, which is plausible but not confirmed in the ground truth; however, the original answer does not specify the 2022 dollar amount, so this addition lacks verification. More critically, the LLM claims that in both 2022 and 2024 the classification was Level 1, which directly contradicts the ground truth: in 2022, the fair value hierarchy was not explicitly detailed, whereas in 2024 it was fully Level 1. This misrepresents a key qualitative shift. (2) The quantitative accuracy is partially correct—the $441 million figure for 2024 matches the ground truth, and the decrease is consistent, but the $458 million figure for 2022 is not supported by the original answer, introducing unverified data. (3) The multi-hop reasoning is flawed: the original answer emphasizes a shift in transparency and valuation methodology (from unspecified hierarchy in 2022 to full Level 1 in 2024), but the LLM incorrectly asserts consistency across years, missing the core evolution in classification. This undermines the qualitative analysis. (4) Contextual relevance is high—the response addresses restricted cash, securitization investors, fair value hierarchy, and the 2022–2024 timeframe. However, due to the significant error in fair value hierarchy classification over time and the introduction of unsupported 2022 figures, the correctness and qualitative accuracy scores are reduced to 5 and 6 respectively.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1233,
        "completion_tokens": 421,
        "total_tokens": 1655
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of financial recognition and asset management between 2023 and 2024?",
      "original_answer": "In 2023, McDonald's relationship with franchisees was primarily characterized by the acquisition of restaurants from franchisees, resulting in goodwill that was either fully or partially written off depending on the time of sale relative to acquisition. The Company used a discounted cash flow methodology to determine the fair value of acquired restaurants. By 2024, the relationship had transformed into a more dependency-based model, particularly in the area of technology platform services. McDonald's now provides distinct technology-related goods and services to franchisees, recognizing revenue on a gross basis and corresponding expenses within 'Other restaurant expenses.' This marks a shift from asset acquisition and goodwill management toward ongoing service-based financial interactions with franchisees.",
      "llm_answer": "\nBetween 2023 and 2024 McDonald’s deepened its financial integration with franchisees by shifting technology‑platform fees to gross‑basis recognition and formalizing the allocation of shared restaurant‑improvement costs between property‑and‑equipment and accounts‑receivable. At the same time the company acquired additional franchised locations (e.g., 228 in Israel), recording goodwill and identifiable intangibles, which reflects a more active approach to asset management and the financial reporting of franchisee‑related investments. These developments are highlighted in the updated segment‑reporting disclosures and accounting‑policy notes.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains partially correct information but introduces significant inaccuracies and unsupported details not present in the ground truth. (1) Correct elements include the mention of McDonald's acquiring franchised locations and recording goodwill, which aligns with the 2023 asset acquisition model. The shift in financial interaction with franchisees is also contextually relevant. However, the LLM claims a shift to 'gross-basis recognition' of technology-platform fees, which while directionally similar to the ground truth (revenue recognized on a gross basis), misrepresents the nature and timing of the change by framing it as a fee reallocation rather than a new service-based dependency model. (2) Quantitative inaccuracy: the claim of '228 locations in Israel' is entirely absent from the ground truth and cannot be verified; no specific numbers of acquisitions are mentioned in the original answer, making this a fabricated detail. There is no mention of 'shared restaurant-improvement costs' or their allocation between 'property-and-equipment and accounts-receivable' in the original, which introduces false financial reporting mechanics. (3) Reasoning flaws: the answer incorrectly synthesizes the evolution as a dual-track strategy (acquisitions + cost allocation) rather than a clear shift from asset-based to service-based financial relationships. It fails to emphasize the 2024 transformation toward ongoing technology services and the corresponding expense classification in 'Other restaurant expenses,' a key point in the ground truth. The multi-hop reasoning is weak because it invents specifics instead of accurately reflecting the documented shift in business model. (4) Despite these issues, the answer remains contextually relevant by addressing financial recognition and asset management changes between 2023 and 2024 and referencing appropriate domains like segment reporting and accounting policies. However, the inclusion of unverified numbers and incorrect financial mechanisms reduces factual correctness significantly, warranting a mid-low score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1364,
        "completion_tokens": 558,
        "total_tokens": 1922
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has the treatment of the 2019 Stock and Incentive Compensation Plan evolved between 2022 and 2024 in Procter & Gamble's disclosures, particularly regarding its relationship with other compensation plans and its role in equity compensation?",
      "original_answer": "In 2022, the 2019 Stock and Incentive Compensation Plan was disclosed as part of a broader set of compensation plans, with specific reference to its adoption by shareholders in 2019 and its regulation in conjunction with other plans like the 2014 Stock and Incentive Compensation Plan. By 2024, the 2019 Plan was still included in the list of active equity compensation plans, but it was now referenced in the context of security ownership and the total shares available for issuance, indicating a shift from adoption and governance details to its role in the company's overall equity compensation structure. This reflects a transformation in how the plan is positioned within the company's disclosures, moving from procedural governance to a more strategic ownership framework.",
      "llm_answer": "\nBetween the 2022 and 2024 Form 10‑K filings, the 2019 Stock and Incentive Compensation Plan remained the only P&G equity plan that can still issue new shares, but the amount of shares left for future grants fell sharply—from about 119 million shares available in 2022 to roughly 77 million shares available in 2024 (reflecting the plan’s 187 million‑share ceiling and the shares already awarded).  The plan continues to be the sole source for future stock‑option, SAR, RSU and PSU grants, while the older plans (1992, 2001, 2003, 2009, 2014) are closed to new issuances; the weighted‑average exercise price of outstanding options also rose from $99.52 in 2022 to $111.57 in 2024, underscoring the plan’s evolving role as the primary vehicle for P&G’s equity‑compensation program.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer provides detailed quantitative information about the 2019 Stock and Incentive Compensation Plan, including specific share availability (119M in 2022, 77M in 2024) and the weighted-average exercise price increase. However, these specific numbers are not present in the original ground truth answer, which does not mention exact share counts or prices. The ground truth emphasizes a qualitative shift in disclosure focus—from governance and adoption details in 2022 to strategic ownership and equity structure in 2024—without citing numerical data. The LLM introduces precise figures that cannot be verified against the provided truth, making the quantitative claims unsupported. While it correctly identifies the 2019 Plan as the active equity plan and references older plans being closed (e.g., 2014), this level of detail exceeds the scope of the original answer and shifts focus from the *evolution in disclosure treatment* to operational metrics. The reasoning partially aligns with the multi-hop requirement by comparing disclosures across years and linking the plan to broader compensation structure, but it misses the core nuance: the change in *how* the plan is discussed (procedural vs. strategic framing). The answer is contextually relevant and well-structured, but the introduction of unverified numerical data and lack of emphasis on disclosure evolution reduce factual accuracy. Thus, while the general direction of the answer is reasonable, the reliance on unsupported specifics lowers correctness and quantitative accuracy significantly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1413,
        "completion_tokens": 427,
        "total_tokens": 1841
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Salvatore Ferragamo's presence in Simon Property Group's international outlet locations evolved between 2022 and 2023?",
      "original_answer": "In 2022, Salvatore Ferragamo was listed as a tenant in three of Simon Property Group's international outlet locations in Japan: Gotemba Premium Outlets, Kobe-Sanda Premium Outlets, and Sano Premium Outlets. By 2023, Salvatore Ferragamo appeared in only one of SPG's outlet locations, specifically Las Vegas Outlets North in Nevada, USA. This indicates a significant reduction in Salvatore Ferragamo's presence across SPG's outlet portfolio, shifting from multiple locations in Japan to a single location in the U.S.",
      "llm_answer": "\nSalvatore Ferragamo remained a tenant in a number of SPG’s overseas premium‑outlet assets in both years, appearing in the tenant rosters for outlets in Japan, Mexico, Canada and other international locations. The disclosed documents do not note any lease expirations, renewals or new openings for the brand between 2022 and 2023, indicating that its presence was essentially unchanged during that period.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth. (1) Quantitatively, the original answer states that Salvatore Ferragamo was present in three Japanese outlets in 2022 and only one U.S. outlet in 2023, indicating a reduction from three to one location. The LLM claims the brand remained in multiple international locations including Japan, Mexico, and Canada with no changes, which is factually wrong. There is no mention of the specific Japanese outlets (Gotemba, Kobe-Sanda, Sano) or the shift to Las Vegas Outlets North. (2) The LLM incorrectly asserts that there were no lease changes, while the ground truth shows a clear reduction in presence across SPG's portfolio. (3) The multi-hop reasoning failed: the model should have compared tenant lists between 2022 and 2023 across SPG's international outlets and identified the drop in locations and geographic shift, but instead assumed stability due to lack of explicit lease details. (4) Contextually, the answer addresses the general topic of Ferragamo's presence in SPG outlets, but the core conclusion—'essentially unchanged'—is false. The correct interpretation shows a significant contraction and relocation of presence. Minor credit is given for addressing the right companies and general context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1225,
        "completion_tokens": 355,
        "total_tokens": 1580
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has COP's natural gas position in the Asia Pacific/Middle East region evolved from 2023 to 2024, and what does this indicate about its operational focus in the region?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas in the Asia Pacific/Middle East region, while in 2024, this figure slightly decreased to 296 billion cubic feet. This indicates a minor reduction in natural gas reserves in the region, suggesting a potential shift or stabilization in operational focus rather than aggressive growth.",
      "llm_answer": "\nBetween the end of 2023 and the end of 2024 ConocoPhillips’ proved natural‑gas reserves in the Asia‑Pacific/Middle‑East region fell from roughly **305 billion cubic feet to 289 billion cubic feet**, a decline of about **5 %**.  The reduction reflects downward price‑related revisions and the disposal of non‑core assets (e.g., the Indonesia sale), while new extensions and discoveries were modest and limited to the Middle East.  This pattern shows that the company is **scaling back its natural‑gas focus in the region**, concentrating instead on higher‑growth U.S. onshore plays and keeping only a stable, low‑growth presence in Asia‑Pacific/Middle‑East.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains incorrect quantitative values: it reports 305 billion cubic feet in 2023 and 289 billion in 2024, while the ground truth states 312 and 296 billion cubic feet respectively. These discrepancies affect the accuracy of the reported 5% decline, which is not consistent with the actual data (a decrease of 16 billion cubic feet from 312 to 296 represents a ~5.1% decline, so the percentage is approximately correct, but the base numbers are wrong). (2) The calculation of the percentage change is roughly accurate given the LLM's own numbers, but since the source figures are incorrect, the overall quantitative accuracy is compromised. The ground truth shows a drop from 312 to 296 Bcf (16 Bcf decrease), whereas the LLM reports 305 to 289 Bcf (16 Bcf decrease as well), suggesting the model may have used rounded or incorrect source data that coincidentally yields the same absolute decline. (3) The qualitative reasoning is strong: the LLM correctly infers a reduction in focus on natural gas in the region and attributes it to asset disposals (e.g., Indonesia sale), price-related revisions, and limited new discoveries—this aligns with the expected interpretation of reserve declines. It also correctly identifies a strategic shift toward U.S. onshore plays, which adds context not in the original answer but plausibly extends the reasoning. (4) The answer is contextually relevant and addresses both parts of the question—evolution of the gas position and implications for operational focus. However, the incorrect base figures significantly reduce factual reliability, warranting a moderate correctness score despite sound logic and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1256,
        "completion_tokens": 459,
        "total_tokens": 1715
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Comcast's approach to wireless gateways evolved from 2022 to 2024, particularly in terms of strategic emphasis and investment?",
      "original_answer": "In 2022, Comcast offered wireless gateways as part of its broadband services, combining modem and Wi-Fi router capabilities to enhance in-and-out-of-home coverage. The focus was on customer-facing features like the xFi whole-home application and advanced security. By 2024, the company elevated its strategic emphasis by shifting from merely offering wireless gateways to actively investing in their deployment as part of its broader network infrastructure upgrades. This included plans to increase capacity and deliver multigigabit symmetrical speeds, signaling a deeper integration of wireless gateways into its long-term network strategy.",
      "llm_answer": "\nFrom 2022‑23 Comcast was aggressively expanding its MVNO‑based wireless service and rolling out next‑generation “wireless gateways” to deliver whole‑home Wi‑Fi (xFi Pods, xFi Portals) and bundled streaming (Peacock) as part of its bundled‑service strategy.  By 2024 the focus shifted from pure subscriber‑growth to a more disciplined investment: capex on customer‑premise equipment fell modestly (≈ $2.2 bn in 2023 → $2.0 bn in 2024) while the company emphasized upgrading gateway hardware and leveraging DOCSIS 4.0 to enable multigigabit symmetrical speeds and deeper integration with its Connectivity & Platforms platform.  The strategic emphasis therefore moved from broad rollout to optimizing the gateway ecosystem to support higher‑speed broadband, smarter Wi‑Fi coverage and bundled video‑streaming services.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution in Comcast's strategic emphasis on wireless gateways from 2022 to 2024, noting a shift from broad rollout to optimization and integration with network upgrades. It accurately reflects the focus on xFi devices, whole-home Wi-Fi, and integration with services like Peacock. The mention of DOCSIS 4.0 and multigigabit symmetrical speeds aligns with the ground truth’s emphasis on network infrastructure upgrades. However, the LLM introduces specific capex figures ($2.2B in 2023 → $2.0B in 2024) that are not present in the original answer and cannot be verified from the provided ground truth, which does not include any financial figures. This affects quantitative accuracy. (2) The dollar amounts and the claim of a modest capex decrease are unsupported by the original answer, which makes no mention of spending levels or trends. While such figures may be factually correct in external sources, they are not part of the ground truth and thus represent an overreach in precision. (3) The multi-hop reasoning is strong: the model synthesizes the technological evolution (xFi Pods, DOCSIS 4.0), strategic shift (from rollout to optimization), and integration with broader platforms (Connectivity & Platforms), which reflects a sound understanding of the progression. The conceptual shift from customer-facing features to infrastructure integration is accurately conveyed. (4) The answer is contextually excellent—directly addressing strategic emphasis and investment trends. Despite the unsupported numbers, the core qualitative narrative matches the ground truth. Correctness is penalized slightly due to the unverified financial data, but the reasoning and synthesis remain robust.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1361,
        "completion_tokens": 475,
        "total_tokens": 1836
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has the G600's market presence and production evolution changed between 2022 and 2024, particularly in terms of cumulative deliveries and its role within Gulfstream's product lineup?",
      "original_answer": "In 2022, the G500 and G600 had cumulative deliveries totaling almost 150 by year-end 2021, and were described as replacements for the G450 and G550 models with improvements in speed, fuel efficiency, cabin volume, and flight controls. By 2024, cumulative deliveries of the G500 and G600 had more than doubled to over 300 by year-end 2024. Additionally, the G600 was no longer described in the context of being a new product introduction, indicating it had become a more established part of Gulfstream's lineup, while the focus shifted to newer models like the G800 and G400.",
      "llm_answer": "\nBetween 2022 and 2024 the G600’s cumulative deliveries more than doubled – rising from “almost 150” aircraft (as noted for the end of 2021) to “more than 300” by the end of 2024 – indicating a sharp acceleration in production and market uptake. The G600 now sits at the heart of Gulfstream’s all‑new large‑cabin lineup, complementing the G500, the newly‑certified G700 (2024) and the upcoming G400, and it contributes a growing share of the Aerospace segment’s revenue and backlog.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly states that cumulative deliveries for the G500 and G600 rose from 'almost 150' by end of 2021 to 'more than 300' by end of 2024, which aligns with the ground truth. However, the question asks about the G600 specifically, while the original answer refers to combined G500/G600 deliveries. The LLM incorrectly attributes the full growth to the G600 alone, slightly misrepresenting the data. (2) Quantitatively, the numbers are accurate as reported in the source: 'almost 150' and 'more than 300' are correctly cited, and the timeframes (end of 2021 and end of 2024) match the original. The claim of 'more than doubling' is mathematically sound (150 to 300+). (3) The reasoning is mostly sound but contains a subtle error in entity attribution—merging G500 and G600 data while discussing the G600's market presence without clarifying they are reported together. The original answer emphasizes the G600's transition from a new product to an established model, with strategic focus shifting to G800/G400, but the LLM incorrectly mentions the G700 and G400 as part of the current lineup without noting the G800, and implies the G600 is a 'newly-certified' model when it is not. (4) Despite minor inaccuracies in product lineup details and entity-specific delivery attribution, the core quantitative trend and market evolution narrative are correct. The answer is highly relevant and captures the essence of production growth and integration into the product lineup, warranting a high score but not perfect due to the misattribution and product mix confusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 435,
        "total_tokens": 1709
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has AIG's financial relationship with Corebridge evolved between 2023 and 2024, particularly in terms of equity ownership and income recognition?",
      "original_answer": "In 2023, AIG held 52.2% of Corebridge common stock and was in the process of selling down its stake, with the intention to fully divest over time. By 2024, AIG had transitioned to accounting for its remaining interest in Corebridge using the equity method, recognizing pre-tax income based on dividends received and changes in Corebridge's stock price from June 9, 2024. This represents a shift from direct ownership control to a more passive investment approach, indicating a significant change in the nature of AIG's financial relationship with Corebridge.",
      "llm_answer": "\nBetween 2023 and 2024 AIG’s stake in Corebridge fell from 52.2 % (the amount it held at the end of 2023) to 48.4 % by the June 9 2024 “de‑consolidation” date, after which it no longer consolidated Corebridge and recorded a $4.8 bn loss to remove the retained investment and accumulated‑other‑comprehensive‑loss balances.  Following the de‑consolidation AIG treats its remaining interest as an equity‑method investment, recognizing dividends and changes in Corebridge’s stock price in net‑investment income; by year‑end 2024 it owned 22.7 % of Corebridge after selling additional shares to Nippon, and the gains on those sales were recorded in net‑investment income.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and provides a more detailed and precise account than the original ground truth, particularly in terms of specific ownership percentages, dates, and financial impacts. (1) Quantitatively, the LLM correctly states AIG's ownership at the end of 2023 as 52.2%, drops to 48.4% by June 9, 2024 (the deconsolidation date), and further declines to 22.7% by year-end 2024 after additional sales to Nippon. These figures are consistent with known public disclosures. The $4.8 billion loss upon deconsolidation and the shift to equity method accounting are factually correct. (2) The answer includes additional accurate details not in the original answer—such as the exact deconsolidation date (June 9, 2024), the accounting treatment of gains on share sales, and the recognition of dividends and stock price changes in net investment income—demonstrating strong multi-hop synthesis from AIG’s 10-K and 10-Q filings. (3) The reasoning is sound: it correctly identifies the transition from majority control (consolidation) to equity method accounting, which aligns with the change in ownership below 50% and loss of control. (4) While the original answer is correct in direction, the LLM provides greater precision and completeness. The only reason for not scoring a 10 is that the original ground truth does not include the 48.4% or 22.7% figures or the $4.8B loss, so full verification against the knowledge graph cannot be assumed—however, based on external validation from SEC filings, the LLM’s numbers are correct. Semantic equivalence is strong, and all parts of the question (equity ownership evolution and income recognition) are thoroughly addressed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 457,
        "total_tokens": 1763
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Tesla's production strategy for the Solar Roof evolved between 2022 and 2024, particularly in terms of manufacturing dependencies and operational challenges?",
      "original_answer": "In 2022, Tesla was actively producing the Solar Roof at Gigafactory New York, which was specifically highlighted as a dedicated facility for the development and production of Solar Roof and other solar products. The company offered financing options tied to the Solar Roof, indicating a strategic push to integrate the product into its broader energy ecosystem. By 2024, Tesla's disclosures shifted to emphasize increased complexity and risk in ramping production of the Solar Roof, with explicit mention of 'delays in launching and/or ramping production of our energy storage products and Solar Roof.' The 2024 filing also highlighted broader operational dependencies, including the need to achieve 'design tolerances, high quality and output rates' across its manufacturing facilities, and noted potential disruptions due to supply chain coordination, localized procurement challenges, and the need for cost-effective scaling. This indicates a transition from a focused production setup in 2022 to a more complex and risk-laden ramp-up phase in 2024.",
      "llm_answer": "\nBetween 2022 and 2024 Tesla moved the Solar Roof from a pilot‑scale, largely manual line at its Buffalo Gigafactory toward a more automated but still single‑site operation that remains dependent on a narrow supply chain of specialty glass‑tile and high‑purity solar‑cell suppliers; the company added dedicated engineering and training programs to improve yields and reduce re‑tooling time, yet the reliance on that limited manufacturing footprint and on external material sources continues to create supply‑constraint and quality‑control challenges as demand scales.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but introduces unverified details not present in the ground truth, leading to significant factual inaccuracies in qualitative aspects. (1) Correct elements: The focus on Gigafactory New York (referred to as Buffalo) aligns with the ground truth, and the mention of supply chain and quality challenges is consistent with 2024 disclosures. The evolution of production challenges over time is thematically relevant. (2) Quantitative accuracy: There are no specific numbers (e.g., production volumes, financial figures) in either the original or LLM answer, so no numeric inaccuracies exist—this aspect is neutral but does not penalize the score. (3) Multi-hop reasoning assessment: The LLM fails to accurately reflect the documented shift in Tesla’s disclosures between 2022 and 2024. In 2022, the ground truth emphasizes active production and integration into the energy ecosystem via financing, which the LLM omits entirely. Instead, it incorrectly characterizes 2022 production as 'pilot-scale' and 'largely manual,' which is not supported by the source. Similarly, the 2024 challenges are accurately framed around ramp-up delays and manufacturing dependencies in the original, but the LLM adds unsupported specifics like 'specialty glass-tile suppliers,' 'high-purity solar-cell suppliers,' 'dedicated engineering and training programs,' and 're-tooling time'—none of which appear in the ground truth. (4) Justification for scores: Correctness is scored 5 due to partial alignment on operational challenges and location, but major omissions and fabrications reduce accuracy. Qualitative accuracy is 5 because while the direction of reasoning (increasing complexity and supply constraints) is plausible, the specific entities and processes cited are not grounded in the provided truth. Quantitative accuracy is 10 by default—no numbers to verify. Contextual relevance is 8 because the answer addresses the core topic of production evolution and dependencies, even if with incorrect details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1409,
        "completion_tokens": 542,
        "total_tokens": 1952
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Qualcomm's strategic involvement with on-device artificial intelligence (AI) evolved from 2023 to 2024, particularly in terms of its business focus and investment approach?",
      "original_answer": "In 2023, Qualcomm was actively producing on-device AI technologies as part of its broader portfolio of foundational technologies, including wireless connectivity and low-power computing. The company positioned on-device AI as a key innovation driver across industries beyond mobile handsets, such as automotive and IoT. By 2024, Qualcomm's focus on on-device AI had evolved from being a core product offering to a more investment-centric strategy. The company continued to invest heavily in advancing on-device AI through research and development, acquisitions, and strategic transactions, signaling a shift toward long-term growth and ecosystem development rather than immediate product commercialization. This transition reflects a deeper commitment to enabling third-party integration of its AI technologies rather than solely selling AI-based products directly.",
      "llm_answer": "\nFrom 2023 to 2024 Qualcomm shifted on‑device AI from a peripheral element of its technology roadmap to a core strategic pillar.  The 2023 filing (Note 1, pp. 63‑67) merely listed AI among the company’s foundational technologies, whereas the 2024 filing (Note 1, pp. 18‑22) expands the discussion into dedicated risk factors and investment priorities, explicitly tying AI to growth in automotive, IoT and other non‑handset markets and signaling higher, longer‑term R&D and acquisition spending to embed AI across its semiconductor and licensing business.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains no explicit numerical data, so quantitative accuracy is not applicable in a traditional sense; however, since no numbers were misstated, it receives full credit. Contextually, the answer is relevant and addresses the evolution of Qualcomm's AI strategy between 2023 and 2024, correctly identifying increased strategic emphasis and expansion into automotive and IoT. However, the qualitative reasoning is flawed in a key aspect: the LLM claims that AI evolved from a 'peripheral element' in 2023 to a 'core strategic pillar' in 2024, which contradicts the original answer stating that on-device AI was already a core product offering in 2023. The original answer emphasizes a shift in business model—from direct product commercialization to an investment-centric, ecosystem-enabling approach—not an elevation in strategic priority. The LLM misrepresents this evolution, failing to capture the nuance of a change in investment and commercialization strategy rather than a rise in strategic importance. Additionally, the LLM cites specific note numbers and page ranges (Note 1, pp. 63–67 in 2023; pp. 18–22 in 2024), which are not verifiable from the ground truth provided and appear fabricated, undermining trust in the sourcing. While the general direction of increased focus is correct, the core reasoning about the nature of the strategic shift is inaccurate, leading to a partial correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 392,
        "total_tokens": 1755
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the presence of Dolce & Gabbana in SPG-operated properties evolved between 2022 and 2023, and what does this indicate about SPG's brand positioning strategy in its premium outlet locations?",
      "original_answer": "In 2022, Dolce & Gabbana was listed as a tenant in multiple SPG-operated premium outlets in Japan, including Gotemba Premium Outlets, Kobe-Sanda Premium Outlets, and Rinku Premium Outlets. By 2023, Dolce & Gabbana was only listed at Las Vegas Outlets North Premium NV in the U.S. This indicates a strategic shift from a multi-location presence in Japan to a more exclusive, flagship-style positioning in a key U.S. market, suggesting a reevaluation of brand placement and target demographics.",
      "llm_answer": "\nBetween 2022 and 2023 the luxury label Dolce & Gabbana moved from being confined to a handful of SPG‑operated Japanese Premium Outlet centres (e.g., Gotemba, Kobe‑Sanda, Rinku) in 2022 to also appearing as a tenant at newly‑opened SPG premium‑outlet properties in Mexico (Punta Norte) and South Korea (Yeoju).  This expansion shows that SPG is deliberately curating a high‑end fashion mix and positioning its premium‑outlet portfolio as a global destination for luxury brands, reinforcing its brand‑positioning strategy of attracting premium designer tenants to drive traffic and differentiate its outlet sites.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth. (1) It claims Dolce & Gabbana expanded to new locations in Mexico (Punta Norte) and South Korea (Yeoju) in 2023, but the original answer states the brand disappeared from multiple Japanese outlets and was only present at Las Vegas Outlets North Premium NV in the U.S. in 2023—indicating contraction, not expansion. (2) There are no numbers (e.g., counts, dollar amounts) in the response to verify quantitative accuracy, but the core timeline and location data are factually wrong: the shift was from multiple Japanese sites to a single U.S. site, not an expansion into new international markets. (3) The multi-hop reasoning is flawed: instead of identifying a strategic withdrawal from Japan and a move toward exclusivity in a key U.S. market, the model incorrectly infers a global expansion strategy. This misrepresents the brand's movement and SPG’s strategy. (4) While the answer attempts to address SPG's brand positioning strategy, it draws the opposite conclusion of the ground truth—positioning as a global luxury destination versus a shift toward selective, flagship-style placement. The contextual relevance is moderate because it discusses brand positioning in premium outlets, but the factual foundation is entirely incorrect, undermining the analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1288,
        "completion_tokens": 369,
        "total_tokens": 1658
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How did COP's investment in exploration activities in the Asia Pacific/Middle East region evolve between 2023 and 2024, and what does this indicate about the company's strategic focus in that region?",
      "original_answer": "In 2023, COP reported $49 million in exploration expenditures in the Asia Pacific/Middle East region, while in 2024, the company disclosed a total of $0 in new exploration activities in that region. This indicates a complete withdrawal or pause in exploration efforts in the Asia Pacific/Middle East, suggesting a strategic shift away from that region in favor of other geographic areas.",
      "llm_answer": "\nCOP’s exploration spending in the Asia Pacific/Middle East fell from about $95 million in 2023 to $92 million in 2024, a modest ~3 % decline. This reduction signals a strategic pull‑back from that region, with the company redirecting capital toward higher‑return opportunities elsewhere.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core numerical claims. According to the ground truth, COP spent $49 million on exploration in the Asia Pacific/Middle East region in 2023 and $0 in 2024, indicating a complete halt. The LLM incorrectly states $95M in 2023 and $92M in 2024, which is not only wrong but implies continued activity. (2) Quantitative accuracy is severely lacking: the reported values are nearly double the correct 2023 figure and fail to capture the full drop to zero in 2024. The claimed ~3% decline is therefore entirely inaccurate—actual change is a 100% reduction. No correct calculation or trend is presented. (3) The reasoning is partially sound in that a reduction in spending could indicate strategic repositioning, but the conclusion of a 'modest pull-back' misrepresents the reality of a complete withdrawal. The multi-hop synthesis failed—LLM did not correctly retrieve or connect the actual figures across years. (4) Scores reflect major factual errors in numbers and trends (correctness: 2), extremely poor quantitative accuracy (1), weak qualitative reasoning due to incorrect data synthesis (3), and moderate contextual relevance since the answer addresses the right region and general concept of strategic focus (6).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1182,
        "completion_tokens": 356,
        "total_tokens": 1538
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has Comcast's financial stake and debt involvement in Universal Beijing Resort evolved from 2022 to 2024?",
      "original_answer": "In 2022, Universal Beijing Resort was introduced as a new entity in Comcast's disclosures, noting its opening in September 2021 and highlighting the increased depreciation and amortization expenses across the company, though no specific financial stake or debt figures were provided at that time. By 2024, Comcast explicitly stated its 30% ownership interest in Universal Beijing Resort and detailed the debt financing structure, including $3.4 billion of debt outstanding as of December 31, 2024, down from $3.5 billion in 2023. Additionally, the assets and liabilities of Universal Beijing Resort were reported as $7.3 billion and $7.0 billion respectively in 2024, compared to $7.8 billion and $7.2 billion in 2023.",
      "llm_answer": "\nComcast’s equity stake in Universal Beijing Resort has remained roughly 30 % from 2022 through 2024, but the resort’s borrowings have been trimmed – total debt fell from about $3.5 billion at the end of 2022 to $3.4 billion by the end of 2024, with the term‑loan portion decreasing from roughly $3.1 billion to $3.0 billion – so Comcast’s indirect debt exposure has modestly declined, even though the company still consolidates the VIE and retains a $1.4 billion unfunded capital commitment.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies and introduces information not present in the ground truth. While it correctly identifies Comcast's 30% ownership stake in Universal Beijing Resort by 2024, it incorrectly asserts that this stake was already established in 2022. The original answer states that no specific financial stake or debt figures were provided in 2022—only a mention of the resort's opening and its impact on depreciation. Therefore, claiming a '30%' stake in 2022 is unsupported and factually incorrect based on the disclosed data. (2) Regarding debt, the LLM claims debt decreased from $3.5 billion at the end of 2022 to $3.4 billion at the end of 2024. However, the ground truth states that debt was $3.5 billion in 2023 and $3.4 billion in 2024, with no figure provided for 2022. Thus, the comparison across 2022–2024 is invalid due to missing 2022 data. Additionally, the LLM introduces a 'term-loan portion' decreasing from $3.1B to $3.0B and a '$1.4 billion unfunded capital commitment'—details absent from the original answer and not supported by the knowledge graph. (3) The multi-hop reasoning is flawed because the model assumes continuity (e.g., 30% stake in 2022) without evidence and fabricates granular debt breakdowns. It fails to reflect the evolution accurately: from no disclosed stake/debt in 2022 to explicit disclosures in 2024, with 2023 serving as an intermediate point for debt levels. (4) Despite these issues, the answer is contextually relevant and captures the general trend of declining debt and Comcast’s 30% stake by 2024. The qualitative reasoning about indirect exposure and consolidation shows understanding of financial structures, even if specifics are invented. Quantitative accuracy is partially correct for 2023–2024 debt levels but penalized for unsupported 2022 figures and fabricated details. Correctness score is low due to significant factual overreach and incorrect synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 528,
        "total_tokens": 1821
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How did Duke Energy's net derivatives balance and associated settlement activity evolve from 2022 to 2023, and what does this indicate about the company's exposure or management of derivative instruments?",
      "original_answer": "In 2022, Duke Energy's net derivatives balance at the end of the year was $29 million, with settlements totaling $32 million. In 2023, the net derivatives balance decreased to $13 million, while settlements increased significantly to $68 million. This indicates a shift in the company's management of derivative instruments, with a larger reduction in the net balance despite higher settlement activity in 2023.",
      "llm_answer": "\nDuke Energy’s net‑derivative liability rose from a $(77) million balance at 31 Dec 2022 to $(121) million at 31 Dec 2023 – an increase of roughly $44 million.  The shift reflects higher new purchases (about $21 million in 2023 versus $14 million in 2022) and only modest settlements of roughly $5 million each year, leaving the company with a larger unrealized loss position and therefore greater exposure to commodity‑price movements.  This evolution indicates that Duke Energy is expanding its hedging program, but the growing negative balance shows that its derivative obligations have intensified, requiring more active risk management.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is almost entirely incorrect in both quantitative and qualitative aspects. According to the ground truth, Duke Energy's net derivatives balance was $29 million in 2022 and decreased to $13 million in 2023, while settlements increased from $32 million to $68 million. The LLM incorrectly states the net derivatives balance as a liability of $(77) million in 2022 and $(121) million in 2023—values not present in the original answer and contradicting the direction of change (decrease vs. increase). Settlements are misrepresented as only ~$5 million annually, whereas the truth shows a significant increase to $68 million in 2023. (2) All key numbers are wrong: net balances, settlement amounts, and implied trends. Calculations based on these (e.g., $44 million increase in liability) are therefore invalid. (3) The multi-hop reasoning fails completely—instead of identifying a reduction in net balance alongside higher settlement activity indicating active management and reduced exposure, the LLM concludes increased exposure and expanding obligations, which contradicts the evidence. (4) The contextual relevance is low but not zero because the answer discusses derivative balances and settlements in the correct time frame and attempts to interpret risk management implications, albeit based on false data. Due to complete factual inaccuracy, especially on critical financial figures and trends, the correctness score is 1.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1277,
        "completion_tokens": 403,
        "total_tokens": 1680
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did SPG's treatment and disclosure of LTIP Units evolve from 2022 to 2023, particularly in terms of their dilutive effect and valuation modeling?",
      "original_answer": "In 2022, SPG disclosed that LTIP units were part of potentially dilutive securities but had no material dilutive effect for the years 2021, 2020, and 2019. By 2023, SPG provided more detailed disclosures, including the use of a Monte Carlo model to estimate the grant-date fair values of market-based LTIP units and confirmed that these units are treated as participating securities under the two-class method of computing earnings per share. This reflects a shift from a general statement about dilution to a more granular and valuation-focused disclosure in 2023.",
      "llm_answer": "\nFrom 2022 to 2023 SPG continued to treat its LTIP units as temporary‑equity, participating securities that are included in the two‑class diluted‑earnings‑per‑share/unit calculations, but the company repeatedly noted that “no securities had a material dilutive effect” for the years 2021‑2023.  The valuation methodology evolved: in 2022 the 2022 LTI Program’s performance‑based portion was disclosed with a maximum grant‑date fair value of **$13.7 million**, while the 2023 LTI Program (granted in Q1 2023) separates a market‑based TSR award (fair value **$5.7 million**) from a performance‑target award (**$12.2 million**, with a disclosed maximum of **$23.6 million**), and the related expense is amortized over the three‑year performance period.  Thus, while the units remain non‑dilutive in practice, the 2023 disclosures provide a more detailed breakdown of fair‑value components and a higher potential valuation for the performance‑based portion.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core evolution in SPG's disclosure practices from 2022 to 2023, correctly identifying that LTIP units are treated as participating securities under the two-class method and included in diluted EPS calculations. It appropriately notes the continued absence of material dilutive effect through 2023, which aligns with the ground truth. However, there are key quantitative inaccuracies: the original answer does not mention specific dollar values such as $13.7 million, $5.7 million, or $12.2 million, nor does it reference a Monte Carlo model being used specifically for market-based LTIP units in 2023—this critical methodological detail is missing in the LLM response. Instead, the LLM introduces granular fair value figures and program structures (e.g., separation of TSR and performance awards) not present in the ground truth, potentially hallucinated or over-specified. While the direction of increased disclosure detail is correct, the specific numerical breakdowns and expense amortization over a three-year period are not supported by the original answer. The qualitative reasoning is sound in recognizing a shift toward more detailed disclosures, but the lack of mention of the Monte Carlo model—a key advancement in valuation modeling—undermines the accuracy of the response regarding valuation methodology. The entities (SPG, LTIP units, two-class method) and time periods (2022–2023) are correct, and the answer remains contextually relevant and well-structured. Overall, the answer gets the general trend right but fails on specific, important quantitative and methodological facts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 441,
        "total_tokens": 1821
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Comcast's financial commitment and involvement in Atairos Group, Inc. evolved between 2022 and 2024, particularly in terms of capital funding and management fee commitments?",
      "original_answer": "Comcast's involvement in Atairos Group, Inc. evolved significantly between 2022 and 2024. In 2022, Comcast was the sole third-party investor with a commitment to fund up to $5 billion in aggregate capital to Atairos. By 2024, this commitment had decreased to up to $4.5 billion, with an additional specific commitment of $40 million annually for a management fee. The reduction in capital commitment and the introduction of a dedicated management fee structure indicate a recalibration of Comcast's financial involvement and strategic oversight of Atairos.",
      "llm_answer": "\nBetween 2022 and 2024 Comcast’s exposure to Atairos shifted from a $5 billion aggregate funding commitment (later reduced to $4.5 billion) with annual capital‑call limits of $400 million, to a smaller unfunded commitment of roughly $1.4 billion as of 31 Dec 2024 (down from $1.5 billion in 2021).  Capital contributions have been modest and variable—$52 million in 2022, $145 million in 2023 and $73 million in 2024—while the annual management‑fee obligation remains at about $40 million per year (subject to adjustments), with the management‑company investors pledged to contribute $50‑$100 million, at least $40 million of which must be supplied by Comcast’s former CFO.  Consequently, Comcast’s financial risk is now limited to its remaining investment balance and the $1.4 billion unfunded capital commitment, and it records its stake in Atairos as an equity‑method investment rather than a consolidated entity.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains several factual inaccuracies that significantly undermine its correctness. (1) QUANTITATIVE INACCURACY: The ground truth states Comcast's capital commitment decreased from $5 billion to $4.5 billion by 2024, but the LLM incorrectly introduces a 'remaining unfunded commitment of $1.4 billion as of 31 Dec 2024'—this figure is not in the original and contradicts the 'up to $4.5 billion' commitment. The annual capital contributions ($52M in 2022, $145M in 2023, $73M in 2024) are not present in the ground truth and appear fabricated. The $400M annual capital-call limit and $50–$100M management-company investor pledge (including $40M from Comcast’s former CFO) are also unsupported by the original answer. (2) COMPLETENESS: While the LLM captures the reduction in capital commitment and the $40M annual management fee, it adds extensive details not in the original, such as specific yearly contributions and ownership structure changes, which distort the actual evolution. (3) ENTITY & TERM INACCURACY: Referring to 'management-company investors' and 'Comcast’s former CFO' introduces entities not mentioned in the ground truth. The shift to 'equity-method investment' and 'unfunded commitment' are plausible accounting details but not part of the verified answer. (4) REASONING: The multi-hop synthesis is flawed—while it correctly notes a reduction in commitment and the $40M fee, it extrapolates unsupported specifics. The conclusion about 'limited financial risk' and accounting treatment goes beyond the original's scope. (5) SEMANTIC EQUIVALENCE: The core idea of reduced capital commitment and added management fee is correct, but the extensive incorrect numerical and structural details reduce factual fidelity. The answer is contextually relevant and addresses the question's intent, but major quantitative errors prevent a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 504,
        "total_tokens": 1880
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2023 to 2024, and what does this indicate about the company's operational focus in that geographic area?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region, while in 2024, this figure slightly decreased to 296 billion cubic feet. This indicates a modest reduction in reserves over the year, suggesting a potential shift in operational focus or resource allocation in the region.",
      "llm_answer": "\nFrom 2023 to 2024 the company’s proved natural‑gas reserves in the Asia Pacific/Middle East region fell modestly—from about **312 billion cubic feet (Bcf)** (developed + undeveloped in 2023) to **≈296 Bcf** in 2024, a decline of roughly **5 %**.  This reduction reflects downward revisions in equity‑affiliated assets and a slight dip in developed reserves, signalling that ConocoPhillips is scaling back its focus in that geographic area and redirecting resources toward regions where reserve growth is more robust, such as the Lower 48 and Canada.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly reports the natural gas reserves for COP in the Asia Pacific/Middle East region: 312 Bcf in 2023 and 296 Bcf in 2024, matching the ground truth exactly. The 5% decline is accurately calculated: (312 - 296) / 312 ≈ 0.051 or 5.1%, which rounds to approximately 5%, so the percentage is reasonable. 2) All numeric values and years are correct, and the calculation of the percentage decrease is sound. Format variations (Bcf vs billion cubic feet) are acceptable and semantically equivalent. 3) The reasoning correctly identifies a modest reduction in reserves and infers a potential shift in operational focus, which aligns with the ground truth's implication. The LLM goes further by specifying contributing factors (downward revisions in equity-affiliated assets, dip in developed reserves) and contrasting with increased focus on the Lower 48 and Canada. While these specifics are not in the ground truth, they are plausible interpretations and do not contradict it. They enhance the answer without introducing inaccuracies. 4) The answer fully addresses both parts of the question: the evolution of reserves (quantitative change) and what it indicates about operational focus (qualitative interpretation). The multi-hop synthesis is sound—linking reserve changes to strategic focus is appropriate. The only reason for not scoring a 10 is that the original answer is more cautious in its conclusion (using 'suggesting a potential shift'), while the LLM asserts a more definitive redirection of resources, which, while reasonable, is a slight interpretive leap beyond the ground truth. However, this does not constitute an error, just a marginally stronger claim. Overall, the answer is factually correct, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1231,
        "completion_tokens": 479,
        "total_tokens": 1710
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "Compare Comcast's wireless gateway procurement strategy in 2022 with its network deployment investment focus in 2024.",
      "original_answer": "In 2022, Comcast's relationship with wireless gateways was primarily centered on procurement, as the company purchased a significant amount of customer premise equipment, including wireless gateways, from a limited number of suppliers to provide services to residential and business customers. By 2024, the company's approach had evolved into a more strategic investment focus, with wireless gateways being a key component of its planned capital expenditures. Specifically, in 2024, Comcast emphasized deploying wireless gateways as part of its broader network upgrades aimed at delivering multigigabit symmetrical speeds. This shift indicates a move from passive procurement to active integration of wireless gateways into its infrastructure strategy, aligning with its goals for network scalability and capacity expansion.",
      "llm_answer": "\nIn 2022 Comcast’s wireless‑gateway strategy was to obtain a limited set of standardized customer‑premise devices from a few vendors to support its MVNO wireless service and bundle them with broadband, emphasizing cost‑effective, uniform equipment. By 2024 the company’s network‑investment focus shifted to expanding and upgrading its cable infrastructure—adding scalable fiber‑coax capacity, line extensions and DOCSIS 4.0 upgrades—to increase overall capacity and enable multigigabit symmetrical speeds, with wireless‑gateway deployment now part of a broader connectivity‑platform rollout.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth with only minor differences in emphasis. (1) All key facts are correct: in 2022, Comcast procured wireless gateways from a limited number of suppliers for use in bundling with broadband services, particularly supporting its MVNO offering. By 2024, the focus shifted to integrating gateway deployment into broader network upgrades aimed at multigigabit symmetrical speeds. The LLM correctly identifies the strategic evolution from procurement to integration. (2) There are no numeric values (e.g., dollar amounts, percentages, quantities) in either answer, so quantitative accuracy is not compromised—dates (2022, 2024) are correct. (3) Multi-hop reasoning is sound: the model synthesizes information across time periods and strategic focuses (procurement vs. infrastructure investment), correctly linking wireless gateways to network capacity goals. (4) The only minor shortcoming is that the LLM does not explicitly state that wireless gateways became a 'key component of capital expenditures' in 2024, a detail present in the original answer. However, stating that gateway deployment is part of a 'broader connectivity-platform rollout' alongside DOCSIS 4.0 and fiber-coax upgrades implies capital investment. This omission is minor and does not distort the overall meaning. Wording differs but semantic equivalence is maintained. Contextual relevance is excellent as the response directly compares the two time periods as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 417,
        "total_tokens": 1763
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has Tesla's approach to the Solar Roof product evolved between 2022 and 2024, particularly in terms of its strategic importance and production challenges?",
      "original_answer": "In 2022, Tesla highlighted the Solar Roof as a key contributor to the growth in Energy generation and storage revenue, indicating it was being actively deployed alongside products like Megapack and Powerwall. By 2024, Tesla's framing had shifted, with the Solar Roof now positioned as a product facing potential production ramp delays similar to past vehicle and energy storage product launches. This evolution reflects a shift from emphasizing deployment success to cautioning about the operational and manufacturing risks associated with scaling the product.",
      "llm_answer": "\nBetween 2022 and 2024 Tesla’s Solar Roof shifted from a flagship residential‑solar ambition to a lower‑priority, cost‑intensive offering; the company now treats it as a complementary piece of the broader Energy Generation & Storage portfolio rather than a primary growth driver. The 2022 10‑K (pp. 37‑41) highlighted ongoing manufacturing under‑utilization and high per‑unit costs, and the 2024 10‑K (pp. 15‑19) noted that Solar Roof’s revenue share has fallen and its gross margin remains negative, reflecting persistent production challenges that have forced Tesla to scale back its rollout and focus on higher‑margin products such as Megapack and Powerwall.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of Tesla's Solar Roof strategy between 2022 and 2024, noting a shift in strategic importance and ongoing production challenges, which aligns with the ground truth. However, there are significant factual inaccuracies that reduce correctness. The claim that 'Solar Roof’s revenue share has fallen' and 'gross margin remains negative' in the 2024 10-K is not supported by the ground truth, which does not mention revenue share decline or negative gross margins—these are specific, unsupported additions. Similarly, the assertion that Tesla scaled back rollout due to negative margins and shifted focus to Megapack and Powerwall as higher-margin products goes beyond the original answer, which only states Tesla is cautioning about production ramp delays, not deprioritizing the product. The ground truth emphasizes a shift in *framing* (from growth contributor to acknowledging production risks), not a strategic demotion or margin issues. While the LLM correctly identifies manufacturing challenges and references the right product categories, it introduces unverified financial metrics (negative gross margin, falling revenue share) and stronger strategic conclusions than the source supports. There are no explicit numbers (e.g., dollar amounts, percentages, dates) in either answer, so quantitative accuracy is assessed on factual consistency—minor deductions for unsupported specifics. The reasoning is partially sound but overreaches in synthesis, failing the multi-hop accuracy test by adding details not present in the source documents. Contextual relevance is high as the answer addresses both strategic importance and production challenges as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 461,
        "total_tokens": 1769
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did Duke Energy's investment in Net Pending Transactions and Other Investments change from 2022 to 2023, and what does this indicate about the company's strategic positioning in this category?",
      "original_answer": "Duke Energy's investment in Net Pending Transactions and Other Investments decreased from $53 million in 2022 to $14 million in 2023. This indicates a significant reduction in exposure or involvement in pending transactions and other investments, suggesting a strategic shift or completion of certain initiatives during this period.",
      "llm_answer": "\nDuke Energy’s “Net pending transactions and other investments” grew from **$14 million** at the end of 2022 to **$54 million** at the end of 2023 – an increase of roughly **$40 million**.  This rise signals that the company is expanding its short‑term, flexible holdings within the Master Retirement Trust, likely to preserve liquidity and capture opportunistic market returns while maintaining its overall liability‑hedging and return‑seeking asset allocation.  The move reflects a strategic shift toward a more dynamic investment position in this category.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in both direction and magnitude of change. The ground truth states that Duke Energy's investment decreased from $53 million in 2022 to $14 million in 2023, but the LLM claims it increased from $14 million to $54 million—reversing the years and misstating the amounts. This fundamental error invalidates the entire response. (2) Quantitative accuracy is extremely low: the LLM swaps the values and assigns them to the wrong years. The claimed increase of $40 million is entirely fabricated; the actual change was a decrease of $39 million ($53M - $14M). Additionally, the LLM reports $54 million for 2023 when the correct figure is $14 million, and $14 million for 2022 when it should be $53 million. (3) The multi-hop reasoning is flawed because the model fails to correctly retrieve and compare the two data points across years. Instead of identifying a reduction in exposure, it infers an expansion and attributes strategic intent to an increase that did not occur. The explanation about 'short-term, flexible holdings' and 'Master Retirement Trust' introduces details not present in the original answer or implied by the data, indicating hallucination. (4) The contextual relevance is low but not zero because the answer addresses the right category (Net Pending Transactions and Other Investments) and attempts to interpret strategic positioning, albeit based on false premises. However, due to complete factual inaccuracy in numbers and direction of change, the correctness and qualitative accuracy scores are near minimum.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1235,
        "completion_tokens": 434,
        "total_tokens": 1669
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has the company's implementation of its liability-driven investment framework evolved between 2023 and 2024, particularly in terms of defined contribution plan expenses and the disclosure of plan asset composition?",
      "original_answer": "In 2023, the company disclosed that amounts charged to expense for defined contribution plans totaled $109 million, and the liability-driven investment framework included a 20%/80% equity/fixed income target allocation for pension assets. By 2024, defined contribution plan expenses increased to $112 million, and while the same 20%/80% allocation was maintained, the 2024 filing added a new disclosure indicating that the actual composition of plan assets at year-end would be characterized, suggesting a more detailed transparency in reporting the implementation of the investment framework.",
      "llm_answer": "\nBetween 2023 and 2024 the company kept the same liability‑driven investment philosophy—using long‑duration fixed‑income securities to hedge pension liabilities—but modestly adjusted the target mix: the pension portfolio moved from a 18 % equity / 57 % corporate‑bond / 25 % government‑security allocation to 21 % equity, 63 % corporate bonds and 16 % government/other assets, while the post‑retirement portfolio shifted from 53 % equity / 31 % corporate bonds / 16 % government securities to 57 % equity, 30 % corporate bonds and 13 % government/other.  The 2024 filing also provides a more detailed fair‑value hierarchy (Level 1, 2 and 3) and explicitly breaks out NAV‑measured collective funds, giving a clearer picture of asset composition than the 2023 high‑level percentages.  At the same time, expense charged to the defined‑contribution plans rose slightly, from $109 million in 2023 to $112 million in 2024, reflecting higher employer contributions and broader participation.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, the company maintained a consistent 20%/80% equity/fixed income target allocation for pension assets in both 2023 and 2024. However, the LLM claims a shift from 18%/57%/25% to 21%/63%/16% across equity, corporate bonds, and government securities, which is not supported by the original answer and introduces granular allocations not mentioned. These specific breakdowns (including post-retirement portfolio shifts and NAV-measured funds) are fabrications or hallucinations. (2) The only correct quantitative elements are the defined contribution plan expenses: $109 million in 2023 and $112 million in 2024, which match the ground truth exactly. All other numbers (percentages of corporate bonds, government securities, Level 1/2/3 disclosures, NAV breakdowns) are incorrect or unsupported. (3) The multi-hop reasoning is flawed. The question asks about evolution in the liability-driven investment framework, particularly regarding expenses and asset composition disclosure. While the LLM correctly notes increased transparency in 2024, it misrepresents the nature of that transparency—ground truth states the 2024 filing added a disclosure that the actual composition would be characterized, implying future intent—whereas the LLM asserts detailed fair-value hierarchy and NAV disclosures were made, which goes beyond the source. The core evolution—same allocation but enhanced disclosure intent—is missed due to incorrect emphasis on allocation changes. (4) Contextual relevance is moderate because the answer addresses the right topic areas (expenses, asset allocation, disclosure trends), but the qualitative and quantitative inaccuracies severely undermine correctness. The answer appears plausible but is largely factually incorrect, especially on the key point of allocation changes, which contradicts the ground truth that the 20%/80% split was maintained.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1412,
        "completion_tokens": 531,
        "total_tokens": 1943
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has Qualcomm's strategic focus on On-Device AI evolved between fiscal 2023 and fiscal 2024, and what specific investments or changes in direction were highlighted in the company's disclosures?",
      "original_answer": "In fiscal 2023, Qualcomm emphasized that On-Device AI, combined with 5G and high-performance, low-power computing, would drive adoption of smartphone technologies into industries beyond mobile, such as automotive and IoT. The company positioned itself as a leader in 5G and integrated circuit products to sustain long-term growth. By fiscal 2024, Qualcomm's focus on On-Device AI had evolved into a more investment-driven strategy, with the company explicitly stating it is investing in new product areas and industries beyond mobile handsets, including automotive and IoT, by leveraging its technical expertise and pursuing acquisitions or strategic transactions. This represents a shift from strategic vision to active investment and expansion.",
      "llm_answer": "\nQualcomm broadened its On‑Device AI focus between fiscal 2023 and 2024, moving it from a mainly smartphone‑centric capability to a cross‑industry AI engine that is tied to its 5G + high‑performance computing roadmap and to growth in automotive, IoT and other edge markets.  The company highlighted that it is investing additional R&D and capital in AI‑centric hardware (such as dedicated AI compute engines) and software ecosystems, positioning AI as a core growth pillar beyond handsets.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in Qualcomm's strategic focus on On-Device AI from fiscal 2023 to 2024. It correctly identifies the shift from a smartphone-centric vision to a broader cross-industry strategy involving automotive, IoT, and edge markets, aligned with 5G and high-performance computing—consistent with the ground truth. The answer reflects the increased investment in R&D and capital for AI-centric hardware and software ecosystems, which aligns with the original answer's mention of active investment and expansion through new product areas and strategic transactions. While the LLM does not explicitly mention 'acquisitions or strategic transactions'—a minor omission—it does convey the essence of active investment and expansion beyond mobile. There are no numerical values in the question or answers, so quantitative accuracy is scored based on absence of incorrect numbers (score 10). The reasoning is sound, demonstrating correct multi-hop synthesis across fiscal years and strategic themes. The answer is contextually fully relevant and semantically equivalent to the ground truth, with only slight room for improvement in completeness regarding specific strategic actions like acquisitions. Hence, correctness is 9 rather than 10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 358,
        "total_tokens": 1679
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has the classification and presentation of the Voting Trust Agreement between Melvin Simon & Associates, Inc. and the Simon family members evolved between the 2022 and 2023 10-K filings, and what does this indicate about the governance structure's stability?",
      "original_answer": "In the 2022 10-K filing, the Voting Trust Agreement was described as 'Second Amended and Restated' as of March 1, 2004, indicating a formal update to the governance arrangement. In contrast, the 2023 10-K filing refers to the same agreement without the 'Second Amended and Restated' modifier, simply listing it as the Voting Trust Agreement dated March 1, 2004. This shift in presentation suggests that no further amendments were made in the intervening period, signaling stability in the governance structure and a continuation of the same voting trust framework without modification.",
      "llm_answer": "\nThe Voting Trust Agreement continues to be disclosed only in the Exhibit section of both the 2022 and 2023 Form 10‑K filings, listed as “Exhibit 9.1 – Second Amended and Restated Voting Trust Agreement, Voting Agreement and Proxy dated March 1 2004” (and the related Exhibit 9.2).  The wording, numbering and placement are identical in the two filings, showing that no re‑classification, amendment or new presentation of the trust has been introduced.  This unchanged disclosure indicates that the voting‑trust governance structure remains steady and has not been altered between the 2022 and 2023 reporting periods.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual inaccuracy regarding the classification and presentation of the Voting Trust Agreement between the 2022 and 2023 10-K filings. The ground truth states that in the 2022 filing, the agreement was described as 'Second Amended and Restated,' while in 2023 it was referred to simply as the 'Voting Trust Agreement dated March 1, 2004'—indicating a change in presentation. However, the LLM claims the wording, numbering, and placement are 'identical' in both filings and that the exhibit is listed with the 'Second Amended and Restated' title in both years, which contradicts the ground truth. This misrepresents the core evolution being asked about. (2) Quantitatively, the date 'March 1, 2004' is correctly cited, and no incorrect numbers or calculations are present—hence a score of 8 for quantitative accuracy. (3) The multi-hop reasoning is flawed: the question hinges on detecting a subtle but meaningful shift in disclosure language that signals governance stability due to lack of amendment. The LLM incorrectly asserts no change in presentation, failing to recognize that the removal of 'Second Amended and Restated' in the main body (even if retained in exhibits) reflects a deliberate shift in how the agreement is characterized, which is central to the inference about governance stability. (4) Contextually, the answer addresses the right topic and draws a conclusion about stability, but does so using incorrect evidence. While the conclusion about stability could still be plausible, it is based on a false premise of unchanged disclosure, undermining the reasoning. Thus, the correctness score is 4 due to major factual and reasoning errors despite correct dates and general relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 477,
        "total_tokens": 1807
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did COP's natural gas reserves in the Asia Pacific/Middle East region evolve between 2023 and 2024, and what does this indicate about the region's changing strategic importance to COP's global reserves portfolio?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region, while in 2024, this figure decreased slightly to 296 billion cubic feet. This represents a reduction of 16 billion cubic feet, or about 5.1%. Despite this decline, the Asia Pacific/Middle East remained a notable contributor to COP's global reserves, especially when considering equity affiliates, which held an additional 5,870 billion cubic feet in 2024. The slight decrease may suggest a shift in emphasis or extraction focus in favor of other regions, indicating a potential reevaluation of the region's role in COP's long-term production strategy.",
      "llm_answer": "\nCOP’s proved natural‑gas reserves in the Asia‑Pacific/Middle‑East (APME) sector slipped from about **312 billion cubic feet (BCF) at the end of 2023** (≈305 BCF developed + 7 BCF undeveloped) to roughly **296 BCF at the end of 2024** (≈289 BCF developed + 7 BCF undeveloped), a decline of roughly **5 %**.  The drop was driven by a modest reduction in developed APME reserves and net downward revisions in the region’s equity‑affiliate holdings, even though the company’s total global proved gas reserves grew sharply over the same period.  Consequently, the APME region’s share of COP’s worldwide gas reserve base is shrinking, indicating that the company is placing comparatively less strategic emphasis on that basin and is directing reserve growth toward other areas such as the Lower 48 and Canada.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the natural gas reserves for COP in the Asia Pacific/Middle East region as 312 billion cubic feet (BCF) in 2023 and 296 BCF in 2024, matching the ground truth exactly. The calculated decline of 16 BCF is accurate, and the stated percentage drop of 'roughly 5%' aligns with the precise 5.1% in the original answer (16/312 ≈ 5.13%), so minor rounding is acceptable. The breakdown into developed and undeveloped reserves (305 + 7 in 2023, 289 + 7 in 2024) is consistent with the total and adds detail not in the original but does not contradict it. (2) All numbers, dates, and calculations are factually correct. The LLM accurately reflects the decrease and contextualizes it within global reserve trends. (3) The multi-hop reasoning is sound: the model correctly infers that despite global reserve growth, APME reserves declined, indicating a relative strategic de-prioritization. It appropriately links the decline to equity-affiliate revisions and regional focus shifts, mentioning Lower 48 and Canada as alternative growth areas—this extends the original answer but remains logically consistent. (4) The answer is semantically equivalent and even enhances the original with additional context (e.g., developed vs. undeveloped reserves, global comparison), without introducing errors. The only minor gap is that the LLM does not mention the 5,870 BCF in equity affiliates in 2024, which was highlighted in the original as a counterpoint to the decline. While this is a small omission, it slightly affects completeness in portraying the full strategic picture. However, the core facts, calculations, and strategic interpretation are correct and well-reasoned, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 472,
        "total_tokens": 1855
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did AIG's financial relationship with Corebridge evolve between 2023 and 2024, particularly in terms of debt structure and equity method income?",
      "original_answer": "In 2023, AIG had a direct financial stake in Corebridge, which was reflected in the $9,368 million total Corebridge debt on AIG's balance sheet, including $6,452 million in senior unsecured notes and $989 million in junior subordinated debt, both not guaranteed by AIG. By 2024, AIG no longer consolidated Corebridge as a subsidiary; instead, it reported Corebridge under the equity method as part of discontinued operations. During the second half of 2024, AIG reported equity method income from Corebridge, which included dividends received and changes in its stock price since June 9, 2024. This marks a significant transformation from a consolidated debt relationship to a minority equity investment with associated income reporting.",
      "llm_answer": "\nBetween 2023 and 2024 AIG moved from fully consolidating Corebridge’s debt—$9.4 bn of Corebridge borrowings (CRBGLH notes, senior unsecured notes, DDTL facility, etc.) that were guaranteed or supported by AIG—into a post‑deconsolidation relationship in which those obligations no longer appear on AIG’s consolidated balance sheet; AIG’s exposure is now limited to a guarantee‑reimbursement agreement and collateral posting with Corebridge and CRBGLH.  After the June 2024 deconsolidation, AIG records an equity‑method investment in Corebridge, generating $601 million of equity‑method income (dividends plus fair‑value gains) for 2024, while its own debt maturities reflect only $709 million of AIG‑issued borrowings (including a $250 million DDTL facility) with no Corebridge‑related debt consolidated.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the high-level transformation in AIG's relationship with Corebridge—from consolidation to equity method accounting—and correctly identifies the deconsolidation in mid-2024 and the shift to equity method income. However, there are significant quantitative inaccuracies that undermine factual correctness. The original answer states that in 2023, Corebridge debt totaled $9,368 million on AIG’s balance sheet, with $6,452 million in senior unsecured notes and $989 million in junior subordinated debt, none of which were guaranteed by AIG. The LLM incorrectly claims $9.4 billion in Corebridge borrowings were 'guaranteed or supported by AIG,' which contradicts the ground truth that these debts were not guaranteed. This is a critical factual error. Additionally, the LLM states that AIG reported $601 million in equity method income in 2024, but this specific figure is not present in the original answer; the original only states that income included dividends and stock price changes post-June 9, 2024, without quantifying it. The $601 million figure appears to be fabricated or sourced incorrectly. The mention of a $709 million AIG debt maturity and $250 million DDTL facility is not supported by the original answer and introduces extraneous, unverified details. While the LLM correctly identifies the shift to equity method accounting and the timing (post-June 2024), it fails to accurately report the debt structure in 2023 and invents specific financial figures not present in the ground truth. The reasoning structure is sound in terms of narrative flow (deconsolidation → equity method → income recognition), but the multi-hop synthesis is flawed due to incorrect attribution of guarantees and unsupported numbers. Contextually, the answer is relevant and addresses the evolution in debt and income treatment, but the quantitative inaccuracies severely limit its reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 513,
        "total_tokens": 1899
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has NextEra Energy's investment strategy in Special Use Funds evolved from 2022 to 2024, particularly in terms of its allocation between fixed income and equity securities, and what does this suggest about its risk appetite or liquidity strategy?",
      "original_answer": "In 2022, NEE's Special Use Funds were entirely composed of fixed income securities, with a carrying amount of $2,505 million. By 2024, the composition had significantly transformed: NEE's Special Use Funds included $6,164 million in equity securities, $722 million in U.S. Government and municipal bonds, $685 million in corporate debt, and $873 million in asset-backed securities. This indicates a strategic shift from a purely fixed income allocation to a more diversified and equity-heavy portfolio, suggesting an increased risk appetite and a potential long-term growth orientation in its investment strategy.",
      "llm_answer": "\nFrom 2022 to 2024 the Special‑Use‑Fund portfolio was reshaped from a roughly 70 % fixed‑income / 30 % equity mix to about 27 % fixed‑income and 73 % equity.  The equity slice more than doubled (from ≈ $1.5 bn to > $6 bn) while fixed‑income grew only modestly (from ≈ $1.0 bn to ≈ $2.3 bn), so the fund’s risk profile shifted toward market‑linked assets.  This reflects a deliberate, though still liquidity‑conscious, increase in risk appetite—maintaining a sizable bond buffer to meet possible storm‑damage or nuclear‑decommissioning cash needs while seeking higher returns from equities.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, NextEra Energy's Special Use Funds were entirely composed of fixed income securities with a carrying amount of $2,505 million—there was no equity allocation. However, the LLM claims a 70% fixed-income / 30% equity mix in 2022, estimating equity at ~$1.5 billion and fixed income at ~$1.0 billion, which is completely incorrect. The actual 2022 total was $2,505 million—all fixed income. In 2024, the LLM states fixed income grew to ~$2.3 billion, but the ground truth shows fixed income components totaling $722M (U.S. Govt/municipal) + $685M (corporate debt) + $873M (asset-backed) = $2,280 million—this part is approximately correct in total but mischaracterized as a 'growth' from a much smaller base. Equity in 2024 is correctly estimated as >$6 billion (actual: $6,164 million). (2) Calculations and comparisons are flawed: the LLM implies fixed income grew from ~$1.0B to ~$2.3B, suggesting modest growth, but in reality, it shifted from 100% fixed income ($2.5B) to a diversified portfolio with less than half in fixed income. The percentage allocations (70/30 to 27/73) are fabricated and not supported by data. (3) Multi-hop reasoning is partially sound in identifying a shift toward equities and interpreting increased risk appetite, which aligns with the ground truth’s conclusion. The mention of liquidity needs for storm damage or decommissioning is contextually plausible but not present in the original answer. (4) Despite correct directional interpretation (increased risk appetite, equity emphasis), the severe quantitative inaccuracies—especially the false 2022 equity allocation—undermine the answer’s reliability. The core facts are wrong, leading to a low correctness score. Contextual relevance is moderate because the structure and intent match the question, but accuracy is critically compromised.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 522,
        "total_tokens": 1848
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the nature and magnitude of the risk associated with site infrastructure sharing evolved between 2022 and 2024, particularly in relation to 5G technology adoption and its impact on new lease activity?",
      "original_answer": "In 2022, AMT identified site infrastructure sharing as a risk factor that could slow new lease activity or lead to decommissioning of equipment on existing sites, particularly due to the rise of 5G technology. By 2024, this risk evolved into a more specific concern around RAN (Radio Access Network) sharing, roaming, or resale arrangements, which were explicitly tied to the lack of compensation to AMT when carriers opted for shared infrastructure instead of deploying new equipment. The 2024 filing indicates a stronger emphasis on the financial impact of this trend, suggesting a more mature and impactful shift in carrier behavior driven by 5G deployment. This represents a significant evolution in the risk's specificity and perceived threat level.",
      "llm_answer": "\nBetween 2022 and 2024 the risk that site‑infrastructure sharing would curb new lease growth grew from a general caution about “network sharing” to a concrete, material threat tied to 5G rollout.  The 2024 filing explicitly warns that carriers are increasingly using RAN‑sharing, roaming and resale arrangements—enabled by 5G—to avoid leasing additional tower space, which can slow new lease activity and even lead to decommissioning of existing equipment, whereas the 2022 filing only mentioned sharing as a possible factor.  Consequently, the magnitude of the risk has risen, making 5G‑driven infrastructure sharing a central concern for future lease revenue.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of the risk as described in the ground truth. It correctly identifies that in 2022, site infrastructure sharing was a general concern related to 5G, and by 2024 it evolved into a more concrete threat involving RAN-sharing, roaming, and resale arrangements. The answer accurately reflects that this trend negatively impacts new lease activity and could lead to decommissioning, with increased emphasis on financial consequences. All entities (AMT, 5G, RAN-sharing) and timeframes (2022 vs 2024) are correct. There are no numerical inaccuracies—dates are correct and no calculations are required. The reasoning is sound and demonstrates proper multi-hop synthesis across years and risk evolution. The only minor shortcoming is that the LLM does not explicitly mention the 'lack of compensation to AMT' as a highlighted concern in the 2024 filing, which slightly reduces completeness in qualitative detail. However, the omission does not distort the overall meaning. The answer is contextually fully relevant and conveys semantic equivalence to the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 318,
        "total_tokens": 1687
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has Chevron's financial relationship with Angola LNG Limited evolved between 2022 and 2023, particularly in terms of its investment structure and equity method accounting?",
      "original_answer": "Chevron's relationship with Angola LNG Limited evolved from a dependency-based structure in 2022 to a more direct investment model in 2023. In 2022, Chevron reported a 36.4% interest in Angola LNG Limited, but the relationship was categorized under 'Depends_On', indicating a more passive or structurally dependent investment. By 2023, the relationship was reclassified as 'Invests_In', suggesting a more active or strategic financial posture. Additionally, while both years maintained the same ownership percentage (36.4%), the reclassification indicates a shift in how Chevron views or manages its investment, possibly reflecting changes in operational involvement or strategic alignment.",
      "llm_answer": "\nChevron continues to hold a 36.4 % equity stake in Angola LNG Limited and accounts for it under the equity‑method both in 2022 and 2023.  The carrying value of the investment fell modestly – from about **$1.96 bn at the end of 2022 to $1.76 bn at the end of 2023** – and the equity‑method earnings moved from a **$166 m loss in 2022 to essentially breakeven (a small gain/near‑zero) in 2023**, reflecting improved project performance and partial repayment of Chevron’s $4.5 bn loan to the joint‑venture.  Thus, the financial relationship remained an equity‑method investment, but the investment balance and associated earnings improved markedly over the two‑year period.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in both quantitative and qualitative aspects when compared to the ground truth. (1) The original answer states that Chevron's relationship with Angola LNG Limited evolved from a 'Depends_On' to an 'Invests_In' classification between 2022 and 2023, indicating a structural and strategic shift in the nature of the investment, despite maintaining the same 36.4% ownership. The LLM answer completely misses this key qualitative change in investment structure and instead fabricates detailed financial data not present in the ground truth. (2) The LLM introduces specific dollar amounts — $1.96 billion and $1.76 billion carrying values, a $166 million loss turning to breakeven, and a $4.5 billion loan — none of which appear in the original answer or are supported by the knowledge graph. These numbers are therefore factually inaccurate. (3) The multi-hop reasoning is flawed: the question asks about evolution in investment structure and equity method accounting, but the LLM focuses on performance metrics and financial results that were not part of the ground truth. It fails to recognize the shift from 'Depends_On' to 'Invests_In' — the central point of the original answer. (4) While the LLM correctly notes the 36.4% equity stake and equity-method accounting in both years, this is the only accurate element. However, the addition of fabricated financials and omission of the structural classification change severely undermines correctness. The answer is contextually relevant in topic but factually divergent, hence a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 432,
        "total_tokens": 1779
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the G600 aircraft's role in Gulfstream's product lineup evolved from 2022 to 2023, particularly in terms of its performance metrics and production status?",
      "original_answer": "In 2022, the G600 was described as a recent addition to the Gulfstream fleet, having entered service in 2019, and was positioned as a clean-sheet aircraft replacing the G550. By 2023, the G600 was no longer characterized as 'new' but rather as a mature product within the lineup, with over 250 cumulative deliveries by year-end 2023. Additionally, in 2023, the G600's advanced technologies, such as the Symmetry Flight Deck, were highlighted as foundational features being extended to newer models like the G700, G800, and G400. This indicates a shift from product introduction to integration within the broader Gulfstream platform.",
      "llm_answer": "\nBetween 2022 and 2023 the G600 stayed in Gulfstream’s core large‑cabin lineup, growing its cumulative deliveries from about 150 (recorded at the end of 2021) to more than 250 by the end of 2023, indicating a steady production pace and rising market acceptance. Its performance figures—long‑range cruise, high‑speed cruise, improved fuel‑efficiency and a larger cabin introduced with the clean‑sheet design—remained the same, but the aircraft’s role shifted to a mature bridge product that supports the newer ultra‑long‑range models (e.g., the G700 and G800) now entering service.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, the LLM correctly states that cumulative G600 deliveries exceeded 250 by the end of 2023, consistent with the original answer. While it references 'about 150' at the end of 2021 (not directly provided in the ground truth), this is a reasonable inference given the >250 by end of 2023 and steady production, and does not contradict known data. No specific 2022 delivery number is given in the ground truth, so the LLM's framing using 2021 as a baseline is acceptable. (2) The performance metrics are accurately described as stable—no changes in cruise speeds or cabin size—emphasizing that the aircraft’s role evolved despite unchanged specs. (3) Qualitatively, the LLM captures the multi-hop evolution: from being a 'recent addition' in 2022 to a 'mature bridge product' in 2023, supporting newer models like the G700 and G800. It correctly identifies the Symmetry Flight Deck (implied via 'advanced technologies') as a foundational feature now extended to newer models, though it doesn't name the flight deck explicitly. (4) Contextually, the answer fully addresses the question about role evolution, production status, and performance metrics across 2022–2023. The only minor omission is not explicitly stating the G600 replaced the G550, but this is not critical to the core evolution of its role. Overall, the reasoning is sound, synthesis is correct, and the answer is semantically equivalent to the ground truth with high precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 419,
        "total_tokens": 1726
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of financial involvement and strategic collaboration between 2022 and 2024?",
      "original_answer": "In 2022, McDonald's relationship with franchisees was primarily framed around franchised arrangements and license agreements, with franchisees contributing revenue through rent, royalties, and initial fees, while the company did not typically invest in restaurant capital under developmental licenses. By 2024, the company had introduced a more active investment role, co-investing with franchisees to fund restaurant improvements and operating system upgrades. These co-investments were aimed at catering to consumer preferences, improving local performance, and enhancing the brand through modernization. This marks a strategic shift from a largely passive franchising model to a more collaborative and financially engaged partnership.",
      "llm_answer": "\nBetween 2022 and 2024 McDonald’s moved from a largely royalty‑and‑rent‑based model toward deeper financial partnership with its franchisees.  The company increasingly co‑invests in restaurant remodels, technology platforms and advertising, shares occupancy‑cost risks (including COVID‑related rent deferrals that are now treated as part of the lease), and aligns revenue streams through brand‑licensing and dynamic‑yield arrangements, thereby turning the franchise relationship into a more collaborative, jointly‑funded growth strategy.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly captures the evolution of McDonald's relationship with franchisees from a primarily royalty-and-rent model in 2022 to a more financially collaborative partnership by 2024. It accurately reflects the shift toward co-investment in restaurant improvements and strategic upgrades, which aligns with the ground truth. The mention of co-investing in remodels, technology, and advertising is consistent with the 2024 strategic shift described. However, the LLM introduces specific details not present in the original answer, such as 'dynamic-yield arrangements' and 'COVID-related rent deferrals treated as part of the lease,' which are not supported by the ground truth and may be speculative or inferred beyond the provided data. While the core financial and strategic evolution is correctly identified and semantically equivalent, these unsupported specifics slightly reduce qualitative accuracy. There are no numerical figures in either answer, so quantitative accuracy is scored as 10 by default. Contextual relevance is strong—the response directly addresses the question's focus on financial involvement and strategic collaboration across the specified time frame. The multi-hop reasoning is sound in synthesizing a before-and-after comparison, though it adds elements not grounded in the source. Overall, the answer is factually aligned in direction and essence but includes minor unverified details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 393,
        "total_tokens": 1711
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How did the financial performance of smokeable products evolve from 2022 to 2023, particularly in terms of net revenues and operating income?",
      "original_answer": "In 2022, smokeable products generated $22,476 million in net revenues and contributed $10,688 million to operating income. In 2023, net revenues from smokeable products decreased slightly to $21,756 million, and operating income from this segment also declined marginally to $10,670 million. This reflects a small decrease in both revenue and profitability year-over-year.",
      "llm_answer": "\nFrom 2022 to 2023, net revenues for Altria’s smokeable‑products segment slipped from **$22,476 million to $21,756 million** – a decline of roughly **$720 million (about 3 %)**.  Operating income in that segment also fell slightly, moving from **$10,688 million in 2022 to $10,670 million in 2023** (a drop of about **$18 million, or 0.2 %**).  The revenue dip reflects lower shipment volumes and pricing pressure, while the modest operating‑income decline is attributed to higher general‑corporate expenses and amortization, partially offset by stronger performance in other segments.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and matches the ground truth in all key quantitative aspects. (1) The net revenues for 2022 ($22,476 million) and 2023 ($21,756 million) are correct, as are the operating income figures ($10,688 million in 2022 and $10,670 million in 2023). (2) The calculated differences—$720 million decline in revenue and $18 million in operating income—are accurate, and the percentages (approximately 3% and 0.2%, respectively) are correctly estimated. (3) The multi-hop reasoning is sound: the answer correctly synthesizes year-over-year performance across two financial metrics and two years, aligning with the required comparison. (4) While the original answer does not include explanations for the decline (e.g., 'lower shipment volumes', 'higher corporate expenses'), the LLM provides plausible qualitative context that does not contradict the ground truth. This additional detail is not required but is reasonable and consistent with typical 10-K disclosures. The only minor point preventing a perfect 10 is that the original answer does not mention the reasons for the decline, so including them—while not incorrect—adds unverified detail. However, since the core facts, numbers, and synthesis are fully correct, the answer earns a 9 for correctness and qualitative accuracy, with full marks for quantitative accuracy and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1238,
        "completion_tokens": 376,
        "total_tokens": 1614
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the role of Opdivo within BMY's product development and commercialization strategy evolved from 2022 to 2024, particularly in terms of its collaborative framework and new therapeutic approvals?",
      "original_answer": "In 2022, Opdivo was primarily positioned within a joint development and commercialization framework with Ono, where profits, losses, and development costs were shared—either equally for combination therapies or under an 80-20 split for single-party compounds. Additionally, Opdivo was part of a broader alliance that included other products like Yervoy and Orencia, with structured co-promotion and supply responsibilities. By 2024, Opdivo's role had evolved significantly, marked by a new FDA approval in March 2024 for use in combination with cisplatin and gemcitabine for the first-line treatment of unresectable or metastatic urothelial carcinoma. This reflects a shift from a co-development focus to a more independent product introduction strategy, with BMY taking the lead in expanding Opdivo’s therapeutic applications in key oncology markets.",
      "llm_answer": "\nBetween 2022 and 2024 Opdivo moved from a Japan‑focused co‑development partnership with Ono (where profits, costs and royalties were shared equally and BMS served as the global principal) to a broader, more integrated commercial framework that now includes additional allies such as Nektar for the NKTR‑214 combination and an expanded co‑promotion role across multiple regions.  At the same time, the drug’s regulatory footprint accelerated: new approvals were secured for Opdivo Qvantig (sub‑cutaneous formulation), for Opdivo + Yervoy in microsatellite‑instable colorectal cancer, for Opdivo as an adjuvant treatment in high‑risk NSCLC, and for Opdivo in combination regimens for urothelial and other solid tumours (e.g., EC‑approved Opdivo + Yervoy, Japan approval in urothelial carcinoma).  These approvals and the deepening of collaborative structures cemented Opdivo as a central pillar of BMY’s oncology product‑development and commercialisation strategy by 2024.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains several inaccuracies that significantly affect factual correctness, despite addressing the general evolution of Opdivo's role in BMY's strategy. (1) The claim of a 'Japan-focused co-development partnership with Ono' where profits and costs were shared equally is partially correct for certain regions but misrepresents the 2022 structure: the ground truth specifies an 80-20 split for single-party compounds and equal sharing only for combination therapies, which the LLM omits or oversimplifies. (2) The LLM incorrectly introduces Nektar and NKTR-214 as part of Opdivo’s collaborative framework by 2024—this partnership was terminated in 2020 and not reactivated, making this a major factual error. (3) While the March 2024 FDA approval for urothelial carcinoma (in combination with cisplatin and gemcitabine) is correctly implied under 'combination regimens for urothelial...tumours', the LLM does not specify the exact regimen or approval date, instead bundling it with other approvals without clear attribution. (4) The LLM lists additional approvals (e.g., Opdivo + Yervoy in MSI-H colorectal cancer, adjuvant NSCLC, subcutaneous formulation) that, while accurate in isolation, are not supported by the ground truth provided, which only cites the March 2024 urothelial carcinoma approval as the key 2024 development. This overstatement of approvals introduces unsupported information. (5) The shift from co-development to independent strategy—a key point in the ground truth—is not acknowledged; instead, the LLM emphasizes deepening collaborations, which contradicts the original answer’s conclusion. (6) The mention of an EC approval and Japan approval for urothelial carcinoma is not in the ground truth and cannot be verified from the provided data. Overall, while the answer is contextually relevant and captures the broad trend of Opdivo’s growing strategic importance, it fails on key quantitative and qualitative details, especially regarding collaboration structure and specific approvals, leading to a partial correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1469,
        "completion_tokens": 552,
        "total_tokens": 2022
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has AMT's disclosure regarding interest rate benchmarks for debt instruments evolved between 2022 and 2024, particularly in terms of referenced rates and associated covenants?",
      "original_answer": "In 2022, AMT's debt instruments referenced LIBOR, EURIBOR, and a defined base rate for USD and EUR denominated borrowings, with the 2021 credit facilities tied to debt ratings and commitment fees ranging from 0.080% to 0.300%. By 2024, AMT disclosed that new drawings under letters of credit in Nigeria bore interest at SOFR (Secured Overnight Financing Rate) plus a spread, indicating a shift away from LIBOR-based instruments. Additionally, while 2022 disclosures detailed specific covenants and optional renewal periods for various credit facilities, the 2024 disclosure focused on the consequences of covenant non-compliance without specifying interest rate structures or renewal terms, suggesting a simplification or evolution in the presentation of covenant-related disclosures.",
      "llm_answer": "\nBetween 2022 and 2024 AMT shifted the floating‑rate benchmark it cites in its debt disclosures.  In the 2022 filing (pages 50‑54) the company explicitly named **LIBOR** (for USD‑denominated borrowings) and **EURIBOR** (for EUR‑denominated borrowings) as the reference rates, set the applicable spread at **1.125 %** (plus the base‑rate margin) and detailed the related financial covenants (leverage/DSCR tests, limits on additional indebtedness, etc.).  By the 2024 filing (pages 115‑119) the interest‑rate language had been updated to refer to **SOFR (or the applicable alternative rate) for USD loans** while still using **EURIBOR** for euro‑loans; the spread and the core covenant structure (the 1.125 % margin, the 1.30× DSCR test, and the restrictions on extra debt) remained the same, but the 2024 disclosure added explicit fallback language for the LIBOR‑to‑SOFR transition.  Thus, the benchmark changed from LIBOR to SOFR (with EURIBOR retained), while the associated covenants stayed materially unchanged but were clarified with transition provisions.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer contains a mix of correct and incorrect information, with significant factual inaccuracies in key details despite capturing the general trend of benchmark transition from LIBOR to SOFR. (1) Quantitatively, the LLM incorrectly states that the spread was 1.125% in both years and that this margin was tied to the base-rate margin, which is not supported by the ground truth; the original answer does not specify a 1.125% spread or tie it to the base rate, nor does it confirm the spread remained unchanged. The 2022 ground truth mentions commitment fees ranging from 0.080% to 0.300%, not a 1.125% spread, so this number appears fabricated. Additionally, the DSCR test of 1.30× and specific covenant terms like leverage tests are not mentioned in the ground truth, making these additions unsupported. (2) The entity accuracy is mostly correct—AMT, LIBOR, EURIBOR, SOFR, and the correct time frame (2022–2024) are properly identified. However, the claim that EURIBOR was retained for euro-loans in 2024 goes beyond the ground truth, which only confirms SOFR usage in Nigeria for letters of credit but does not confirm continued EURIBOR use broadly. (3) Reasoning is partially sound: the model correctly infers a shift from LIBOR to SOFR, aligning with global benchmark transitions, and notes updated fallback language, which is plausible. However, it overstates continuity in covenants—while the ground truth says 2024 disclosures focused on consequences of non-compliance without detailing terms, the LLM claims the 'core covenant structure remained the same,' which contradicts the original answer’s assertion of simplification or evolution in presentation. (4) Contextual relevance is high—the response directly addresses the evolution in referenced rates and covenants, uses appropriate financial terminology, and attempts multi-hop synthesis across years. However, the inclusion of unsupported specifics (exact percentages, covenant tests) undermines factual reliability. Overall, the answer captures the directional shift but fails on key quantitative and qualitative details, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1469,
        "completion_tokens": 567,
        "total_tokens": 2036
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has McDonald's relationship with franchisees evolved in terms of real estate ownership and co-investment strategy between 2022 and 2024?",
      "original_answer": "In 2022, McDonald's emphasized Systemwide coordination and alignment to manage ESG initiatives, including environmental sustainability and responsible sourcing, which required franchisee cooperation. However, the specific role of franchisees in real estate ownership was not detailed. By 2024, the company explicitly outlined its conventional franchise model, where it typically owns or secures long-term leases on land and buildings, while franchisees invest in equipment, signs, seating, and décor. This co-investment model was described as enabling McDonald's to achieve high restaurant performance levels. The shift from a general emphasis on franchisee collaboration in 2022 to a clearly defined real estate and co-investment strategy in 2024 reflects a more structured and strategic approach to franchise relationships.",
      "llm_answer": "\nBetween 2022 and 2024 McDonald’s moved away from a pure‑franchise model and began leveraging its real‑estate portfolio more strategically—retaining ownership or long‑term leases on land and buildings and using those assets to co‑invest with franchisees in restaurant upgrades and new‑build projects.  This joint‑investment approach ties the company’s financial interests to the performance of the sites, allowing it to fund improvements while franchisees provide the bulk of the capital and share in the resulting asset value.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core idea of McDonald's strategic use of real estate and co-investment with franchisees by 2024, which aligns with the ground truth. It correctly states that McDonald's retains ownership or long-term leases on land and buildings, while franchisees contribute capital—this matches the 2024 model described in the original answer. However, the LLM incorrectly implies a shift 'away from a pure-franchise model' between 2022 and 2024, which is not supported by the original answer. The ground truth does not state that McDonald's moved away from a pure franchise model; rather, it clarifies that in 2022, the focus was on ESG coordination with franchisees, while in 2024, the company provided a clearer articulation of its long-standing real estate and co-investment framework. Thus, the evolution is one of increased clarity and strategic emphasis, not a structural change in the franchise model. This mischaracterization affects qualitative accuracy. There are no numerical figures to verify, so quantitative accuracy is scored as 10 by default. Contextual relevance is high because the answer addresses real estate ownership and co-investment strategy across the specified time frame. The reasoning is partially sound but fails to accurately represent the nature of the evolution—portraying it as a business model shift rather than a refinement in strategic communication and focus.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 388,
        "total_tokens": 1725
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How did the status and documentation of the 2015 Stock Compensation Plan for Non-Employee Directors change between 2022 and 2023, and what does this evolution indicate about Altria's governance approach to director compensation?",
      "original_answer": "In 2022, the 2015 Stock Compensation Plan for Non-Employee Directors was disclosed with 703,256 shares available for issuance under the plan. By 2023, the plan was formally amended and restated effective October 26, 2022, and was incorporated by reference from Altria's September 30, 2022, Form 10-Q filing. This indicates a formal update to the plan’s structure and governance, suggesting Altria refined its director compensation framework mid-cycle, potentially to align with evolving governance standards or internal compensation strategies.",
      "llm_answer": "\nBetween 2022 and 2023 Altria formally **amended and restated** its 2015 Stock Compensation Plan for Non‑Employee Directors, with the revised plan becoming effective on **October 26 2022** (referenced in the 2023 Form 10‑K on page 110 and disclosed in the 2022 filing on page 115).  The amendment updated the share reserve, clarified award mechanics and governance language, and re‑affirmed the plan’s terms, showing that Altria treats director‑pay arrangements as **formal, regularly‑documented governance instruments** that are refreshed through documented amendments and full SEC disclosure.  This evolution reflects a deliberate, transparent approach to aligning director compensation with shareholder interests while maintaining rigorous board‑level oversight.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key event—the amendment and restatement of the 2015 Stock Compensation Plan for Non-Employee Directors, effective October 26, 2022, which aligns with the ground truth. It accurately references the incorporation by reference from the September 30, 2022, Form 10-Q (implied via the 2023 Form 10-K citation). While the ground truth specifies 703,256 shares available in 2022, the LLM answer does not include this exact number, which is a minor omission but does not distort the overall accuracy. (2) All dates (October 26, 2022) and document references (Form 10-K page 110, 2022 filing page 115) are factually consistent with typical SEC disclosure practices and the timeline, though the exact page numbers are not in the ground truth—these may be correct but cannot be fully verified; however, they do not contradict the known facts. The absence of the 703,256 share figure reduces quantitative completeness slightly, but since no calculation depends on it, the impact is minimal. (3) The multi-hop reasoning is sound: the model connects the 2022 plan status with the 2023 update, infers governance implications, and synthesizes across years and filings (10-Q and 10-K). The conclusion about Altria’s governance approach—emphasizing formal documentation, transparency, and alignment with shareholders—is logically supported and goes beyond restating facts, showing strong qualitative reasoning. (4) The answer is highly contextually relevant, addressing both the status/documentation changes and the governance implications. The slight deduction in correctness and qualitative accuracy is due to the missing share availability figure, which was present in the ground truth and adds specificity. However, the core facts, dates, and interpretation are correct and well-reasoned, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 502,
        "total_tokens": 1850
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the impact of roaming and resale arrangements among wireless service providers on AMT's leasing activity evolved from 2022 to 2024, and what does this indicate about the competitive pressures affecting new lease growth?",
      "original_answer": "In 2022, AMT noted that roaming or resale arrangements among wireless service providers, particularly with the rise of 5G technology, could slow new lease activity if carriers opted to share infrastructure rather than deploy new equipment. By 2024, this concern evolved into a broader risk involving RAN sharing and resale arrangements, which not only threatened new lease activity but also led to potential decommissioning of existing equipment due to redundancy. This indicates a growing competitive pressure where infrastructure sharing is becoming a more viable and widespread alternative to leasing, directly impacting AMT’s revenue growth prospects.",
      "llm_answer": "\nFrom 2022 to 2024 the risk‑factor discussion shows that roaming, RAN‑sharing and resale arrangements have become increasingly prevalent, with carriers using shared equipment as an alternative to paying for new tower space—often without compensation to American Tower—and even decommissioning gear on existing sites as networks mature.  This trend signals growing competitive pressure that is dampening new lease growth, because carriers can meet capacity needs through infrastructure sharing rather than signing additional tower leases.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of the impact of roaming, RAN-sharing, and resale arrangements on AMT's leasing activity from 2022 to 2024. It correctly identifies that these arrangements have increasingly served as alternatives to new leasing, dampening new lease growth—a key point in the original answer. It also accurately notes the progression to decommissioning existing equipment by 2024, reflecting the expanded risk beyond just slowed new activity. The mention of carriers meeting capacity needs through infrastructure sharing aligns semantically with the original's emphasis on competitive pressures reducing reliance on leasing. All entities (American Tower/AMT, wireless carriers, 5G/RAN-sharing) and timeframes (2022 to 2024) are correctly referenced. There are no numeric values requiring verification, so quantitative accuracy is unaffected. The only minor shortcoming is that the LLM does not explicitly mention the rise of 5G as a catalyst in 2022, which is a small but relevant contextual detail in the original answer. However, the omission does not undermine the overall correctness or qualitative accuracy. The reasoning is sound, multi-hop synthesis across years and competitive dynamics is appropriate, and the answer remains fully contextually relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 364,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has McDonald's relationship with its franchisees evolved between 2022 and 2024, particularly in terms of strategic investment and operational expectations?",
      "original_answer": "In 2022, McDonald's highlighted the impact of the COVID-19 pandemic on franchise operations, emphasizing risks related to labor availability, supply chain disruptions, and the importance of executing its 'Accelerating the Arches' strategy to maintain growth. The focus was on franchisees' ability to adapt to changing consumer behavior and operational restrictions. By 2024, McDonald's had shifted toward a more active investment role, co-investing with franchisees to modernize restaurants and improve local performance. The company emphasized franchisee reinvestment in their businesses and introduced structured co-investment initiatives designed to increase the value of the McDonald's brand through restaurant modernization and enhanced consumer appeal. This marks a shift from pandemic-driven operational challenges to a more strategic, investment-backed growth approach.",
      "llm_answer": "\nBetween 2022 and 2024 McDonald’s moved from a largely royalty‑only model to an active partnership that **co‑invests with franchisees in restaurant upgrades, digital‑ordering platforms and sustainability initiatives**, tying additional financial incentives to the achievement of Systemwide sales and profit goals.  At the same time the Company **raised its operational expectations**, requiring franchisees to adopt faster service standards, expand mobile‑order and delivery capabilities, and adhere more tightly to brand and quality protocols, while providing the capital and resources needed to meet those heightened requirements.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution in McDonald's relationship with franchisees from 2022 to 2024. It accurately reflects the shift from pandemic-focused operational challenges to a more strategic, investment-backed partnership. The answer correctly identifies the increased operational expectations (e.g., faster service, mobile ordering, delivery, brand standards) and the co-investment model in areas like restaurant upgrades and digital platforms. While the original answer does not explicitly mention 'sustainability initiatives' or 'Systemwide sales and profit goals', these are plausible extensions of the 2024 strategy and do not contradict the ground truth. The LLM adds slightly more specificity (e.g., digital platforms, financial incentives) not present in the original, but these are reasonable inferences consistent with the direction of the strategy. There are no numeric values to verify, so quantitative accuracy is scored as 10. The qualitative accuracy is slightly reduced due to the introduction of unverified specifics (e.g., financial incentives tied to systemwide goals), but the overall reasoning and synthesis across the two years are sound. Contextual relevance is perfect—the answer directly addresses both strategic investment and operational expectations as required by the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 372,
        "total_tokens": 1752
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How did NextEra Energy's investment strategy in equity securities within its Special Use Funds evolve from 2022 to 2024?",
      "original_answer": "In 2022, NextEra Energy held $8,922 million in Special Use Funds, with no explicit breakdown of equity securities provided in the filing. By 2024, the company disclosed a more detailed composition, with $6,164 million specifically allocated to equity securities under Special Use Funds. This evolution suggests a strategic shift toward transparency and a potentially greater emphasis on equity investments within these funds. While the total amount in Special Use Funds decreased, the explicit allocation to equities in 2024 indicates a more defined and possibly more aggressive investment posture compared to 2022.",
      "llm_answer": "\nBased on the 2024 10‑K (pages 87‑91) and the 2022 10‑K (pages 61‑65), the fair‑value of equity securities in NextEra Energy’s Special Use Funds rose from roughly **$5.3 bn at the end of 2022 to $6.2 bn by the end of 2024**, while an unrealized loss of about **$1.0 bn in 2022 turned into gains of ≈ $0.9 bn in 2023‑2024**.  The fund also shifted a larger share of its equity holdings into **Level‑1, market‑quoted securities** (e.g., NEE’s equity securities increased from $2.35 bn to $2.61 bn (Level 1) and $3.32 bn (Level 2) in 2024), indicating a strategic move toward more liquid, observable equity exposure rather than Level‑3 valuations.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant quantitative inaccuracies that undermine its correctness. According to the ground truth, in 2022, NextEra Energy reported $8,922 million in total Special Use Funds but did not disclose a specific amount for equity securities—meaning any figure (such as the LLM's $5.3 billion) is unsupported and incorrect. The LLM claims equity securities rose from $5.3B in 2022 to $6.2B in 2024, but the original answer only confirms $6,164 million in equity securities in 2024, with no breakdown available for 2022. Thus, the core numerical comparison is fabricated. Additionally, the LLM introduces unrealized gains/losses and Level-1/Level-2 allocations not mentioned in the ground truth, adding detail that may be plausible but is not substantiated by the provided answer. While the directional trend—increased focus on equity securities and transparency—is loosely aligned with the original answer’s conclusion, the specific financial data, calculations, and multi-hop synthesis are not accurate. The reasoning is contextually relevant and addresses the evolution question appropriately, but the factual foundation is flawed. Entity accuracy (NextEra Energy, Special Use Funds, years) is correct, and the answer is well-structured, but the unsupported numbers severely reduce correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 364,
        "total_tokens": 1673
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How did the financial performance of smokeable products evolve from 2022 to 2023, particularly in terms of net revenues and operating income?",
      "original_answer": "In 2022, smokeable products generated $22,476 million in net revenues and contributed $10,688 million to operating income. In 2023, net revenues from smokeable products decreased slightly to $21,756 million, and operating income from this segment also declined to $10,670 million. This indicates a marginal decrease in both revenue and profitability year-over-year.",
      "llm_answer": "\nFrom 2022 to 2023, Altria’s smokeable‑products net revenues fell from **$22,476 million to $21,756 million** – a decline of roughly **$720 million (about 3 %)**.  Operating income in that segment also slipped slightly, moving from **$10,688 million in 2022 to $10,670 million in 2023**, a reduction of about **$18 million (≈0.2 %)**.  The modest drop in operating income reflects the revenue decline together with higher general‑corporate and amortization expenses that offset the segment’s performance.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key financial figures from the ground truth: net revenues of $22,476 million in 2022 and $21,756 million in 2023, and operating income of $10,688 million in 2022 and $10,670 million in 2023. The calculated differences ($720 million revenue decline, $18 million operating income decline) and percentages (~3%, ~0.2%) are accurate. (2) Quantitative accuracy is perfect—numbers match exactly, calculations are correct, and formatting variations (e.g., using 'million' vs 'M') are acceptable and clear. (3) The reasoning is sound and adds context not in the original answer—specifically mentioning higher general-corporate and amortization expenses as offsetting factors. While this additional detail is not in the ground truth, it does not contradict it and provides plausible context, which is reasonable given the slight drop in operating income despite a larger revenue decline. This shows good qualitative reasoning, though the source of the expense detail is unverified, slightly reducing confidence in pure factual synthesis. (4) The answer is fully contextually relevant, addressing both net revenues and operating income across 2022 and 2023, and correctly identifying the trend as a marginal decline. The only reason for not scoring 10 on correctness is the introduction of unverified explanatory details (expenses), but since they don't contradict and support the observed trend, the answer remains highly accurate overall.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1216,
        "completion_tokens": 409,
        "total_tokens": 1625
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the utilization of Accenture plc Class A Ordinary Shares evolved between 2022 and 2023, particularly in terms of share purchase programs and their intended usage?",
      "original_answer": "In 2022, Accenture disclosed an aggregate available authorization of $3,129,296 for publicly announced open-market share purchase programs and other share purchase programs involving Accenture plc Class A Ordinary Shares and Accenture Canada Holdings Inc. exchangeable shares. By 2023, the company clarified that Class A Ordinary Shares acquired through these programs were being held as treasury shares and intended for employee benefits, such as equity awards. Additionally, in fiscal 2024, shares were acquired via share withholding for payroll tax obligations under employee equity share plans, which were separate from the publicly announced share purchase authorization. This indicates a shift in focus toward internal employee compensation mechanisms while maintaining a formal buyback program.",
      "llm_answer": "\nBetween fiscal 2022 and 2023 the company expanded its repurchase authorisation—from a $3.13 bn board‑approved limit in 2022 to $6.13 bn after the September 2022 addition—while in 2022 it actually bought about 12.2 million Class A shares (≈$4.1 bn) through an open‑market program and other employee‑related purchases, most of which were held as treasury stock for equity‑award and benefit plans.  The 2023 increase in authority signals that Accenture continues to use its Class A ordinary shares primarily for treasury‑stock purposes—funding employee equity awards, selective open‑market purchases, and other corporate needs—rather than for dividend payments or capital‑raising.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in quantitative details. The ground truth states that in 2022, the aggregate available authorization was $3,129,296 (approximately $3.13 million, not billion), but the LLM incorrectly reports it as $3.13 billion and claims an increase to $6.13 billion after a September 2022 addition—this expansion is not supported by the original answer and represents a major overstatement (off by three orders of magnitude). Additionally, the claim that 12.2 million shares were bought for ~$4.1 billion in 2022 is not present in the ground truth, which does not specify the number or dollar value of shares actually purchased. (2) The original answer makes no mention of a change in authorization size or any repurchase activity volume; instead, it emphasizes the *usage* of acquired shares (i.e., held as treasury shares for employee benefits). The LLM invents specific figures and a timeline (e.g., September 2022 addition) not found in the source. (3) On qualitative reasoning, the LLM correctly identifies that repurchased Class A shares are held as treasury stock for employee equity awards, aligning with the 2023 clarification in the original answer. It also correctly infers the purpose—employee benefits—not dividends or capital raising. However, it fails to mention the key 2024 detail about share withholding for payroll taxes, which is part of the evolution in utilization. The synthesis across years is partially sound but marred by fabricated data. (4) Contextual relevance is high because the answer addresses share purchase programs and intended usage, focusing on employee compensation mechanisms. However, due to severe quantitative errors and unsupported claims about program scale and activity, the overall correctness score is low despite some accurate conceptual understanding.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1375,
        "completion_tokens": 507,
        "total_tokens": 1882
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the nature and structure of AMT's operating covenants evolved between 2022 and 2024, particularly in terms of the types of debt instruments involved and associated interest rate benchmarks?",
      "original_answer": "In 2022, AMT's operating covenants were tied to a variety of credit facilities and loans that referenced LIBOR and EURIBOR as the interest rate benchmarks. These included the 2021 Multicurrency Credit Facility, the 2021 Credit Facility, and several term loans. By 2024, AMT's disclosures indicate a shift in the interest rate benchmark to SOFR, specifically for letters of credit drawn in Nigeria, which were subject to a rate equal to SOFR at the time of drawing plus a spread. This reflects a transition away from LIBOR-based covenants toward SOFR-based structures, signaling a strategic and regulatory evolution in how AMT manages its debt obligations and associated covenants.",
      "llm_answer": "\nBetween 2022 and 2024 the basic operating‑covenant framework—reporting obligations, limits on additional debt and the need to satisfy prescribed financial ratios—remained, but its scope broadened.  The company’s debt base moved from a focus on the 2021 multicurrency and delayed‑draw term loans (interest indexed to LIBOR/EURIBOR + 1.125 %) toward a larger mix of senior unsecured notes and the 2023 securitization facilities, and the benchmark for new USD borrowings shifted to a SOFR‑based rate (or retained LIBOR with an updated spread).  In addition, the 2024 covenants introduced explicit cash‑flow coverage tests (Cash‑Trap DSCR ≤ 1.30 and Minimum DSCR ≤ 1.15) that control cash‑distribution rights, a provision that was not present in the earlier 2022 agreements.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of AMT's operating covenants from LIBOR/EURIBOR to SOFR-based benchmarks, which aligns with the ground truth. It correctly identifies the shift in debt instruments from 2021 credit facilities to newer structures like 2023 securitization facilities and senior unsecured notes. However, there are significant quantitative and factual discrepancies: (1) The LLM states that interest was indexed to 'LIBOR/EURIBOR + 1.125%'—this specific spread is not present in the ground truth and cannot be verified, making it potentially incorrect; (2) The introduction of 'Cash-Trap DSCR ≤ 1.30' and 'Minimum DSCR ≤ 1.15' in 2024 is not supported by the original answer, which makes no mention of these specific financial tests or thresholds. These are major additions not present in the ground truth and represent unsupported claims. (3) While the shift to SOFR is correctly noted, the LLM generalizes it to 'new USD borrowings,' whereas the ground truth specifies SOFR applies only to letters of credit drawn in Nigeria—a critical limitation missing in the LLM response. This overgeneralization reduces factual precision. (4) The mention of '2023 securitization facilities' and 'senior unsecured notes' as part of covenant evolution lacks corroboration in the original answer, which focuses solely on the transition from LIBOR to SOFR in specific contexts. The core reasoning about benchmark transition is sound and contextually relevant, but the inclusion of unverified metrics, spreads, and covenant tests undermines quantitative and qualitative accuracy. The answer synthesizes a plausible narrative but introduces details not present in the ground truth, likely due to overinference or hallucination.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1375,
        "completion_tokens": 470,
        "total_tokens": 1845
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did Disney+ Hotstar's subscriber base evolve between the 2023 and 2024 SEC filings, and what impact did the consolidation of Star+ into Disney+ in Latin America have on Disney's international streaming strategy?",
      "original_answer": "In the 2023 SEC filing, Disney+ Hotstar reported approximately 36 million paid subscribers as of September 28, 2024. The 2024 filing noted that in certain Latin American countries prior to July 2024, Disney offered both Disney+ and Star+ as separate services, but these were merged into a single Disney+ product offering by the end of June 2024. This consolidation suggests a strategic shift toward streamlining international service offerings, potentially aligning with the model used for Disney+ Hotstar by integrating diverse content into a unified brand to enhance user experience and operational efficiency.",
      "llm_answer": "\nDisney+ Hotstar’s paid subscriber base grew from roughly **33 million** at the end of fiscal 2023 to about **36 million** by September 2024, indicating modest year‑over‑year growth.  In June 2024 the company merged the standalone **Star+** service into a single **Disney+** offering across Latin America, consolidating the region’s entertainment and sports content under one brand, expanding Disney+’s addressable audience, improving retention and reinforcing a unified international streaming strategy.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "(1) The LLM answer contains a significant factual error in the subscriber count for fiscal 2023: it claims Disney+ Hotstar had 33 million subscribers at the end of fiscal 2023, but the ground truth does not provide this number—only the 36 million figure as of September 28, 2024 (end of fiscal 2024). Thus, the claimed 'growth from 33M to 36M' introduces an unsupported inference. The 36 million figure is correctly cited, though the date is slightly mischaracterized as 'September 2024' instead of 'September 28, 2024'—a minor issue. (2) The consolidation of Star+ into Disney+ in Latin America is accurately described in timing (June 2024) and intent, though the original answer specifies the change occurred by end of June 2024 and applied to 'certain Latin American countries,' which the LLM generalizes without qualification. The LLM adds interpretive claims about 'expanding addressable audience, improving retention'—which are plausible but not present in the original answer. (3) The multi-hop reasoning is partially sound: it connects the Star+ consolidation to international strategy, aligning with the original's interpretation of streamlining, but overreaches by implying performance outcomes (retention, growth) not in the source. (4) The contextual relevance is high—both parts of the question are addressed with mostly accurate framing. However, the unsupported 33 million figure and the addition of speculative impacts reduce quantitative and qualitative accuracy, warranting a moderate correctness score of 6.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 417,
        "total_tokens": 1713
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the number of employees covered under collective labor agreements changed from 2022 to 2023, and what does this indicate about the company's labor agreement strategy?",
      "original_answer": "In 2022, the company expected to negotiate agreements covering approximately 3,000 employees in the following year. In 2023, the company projected negotiations covering 2,100 employees for the upcoming year. This indicates a reduction in the number of employees involved in labor renegotiations, suggesting a shift in the company's labor agreement strategy, possibly due to fewer expiring agreements or proactive resolution of collective bargaining terms.",
      "llm_answer": "\nFrom 2022 to 2023 the workforce covered by collective bargaining fell from roughly **3,000 employees** (across about **21 agreements**) to **about 2,100 employees** (across about **20 agreements**).  This reduction indicates that the company is scaling back the scope of its labor‑agreement negotiations—fewer agreements and a smaller employee base—suggesting a strategy focused on maintaining stable labor relations while limiting the breadth and potential disruption of future contract renegotiations.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the reduction in employees covered under collective labor agreements from 3,000 in 2022 to 2,100 in 2023, matching the ground truth. It also accurately notes the number of agreements (21 in 2022 and 20 in 2023), which, while not present in the original answer, is consistent with external data and adds useful context without contradicting the ground truth. 2) All numerical values are accurate: 3,000 and 2,100 employees are correctly reported, and the direction of change (a decrease) is properly conveyed. There are no calculation errors. 3) The reasoning is sound: the LLM correctly infers a strategic shift in labor negotiations, aligning with the original answer’s interpretation of reduced renegotiation scope. The added detail about 'limiting the breadth and potential disruption' is a reasonable qualitative extension of the ground truth. 4) The answer fully addresses both parts of the question: the quantitative change and its implication for labor strategy. The core meaning is semantically equivalent to the original answer, with slightly enhanced detail. The only minor point preventing a perfect 10 is the addition of agreement counts not present in the ground truth, which, while plausible, were not verified in the knowledge graph. However, this does not detract from correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1246,
        "completion_tokens": 370,
        "total_tokens": 1617
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did NextEra Energy's investment in U.S. Government and municipal bonds evolve from 2022 to 2024, and what was the change in total value across these years?",
      "original_answer": "In 2022, NextEra Energy's investment in U.S. Government and municipal bonds totaled $137 million. By 2024, this investment had increased significantly to $161 million under 'Other investments' for NEE. This represents a growth of $24 million, or approximately 17.5%, indicating a strategic increase in this asset class over the two-year period.",
      "llm_answer": "\nNextEra Energy’s combined holdings of U.S. Government and municipal bonds rose from roughly $1.17 billion in 2022 to $1.19 billion in 2024, after peaking at $1.26 billion in 2023, for a net increase of about $16 million over the two‑year span.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is almost entirely incorrect in terms of quantitative accuracy. According to the ground truth, NextEra Energy's investment in U.S. Government and municipal bonds was $137 million in 2022 and increased to $161 million in 2024, representing a $24 million increase (approximately 17.5%). The LLM incorrectly reports the figures as $1.17 billion in 2022 and $1.19 billion in 2024, which is over 8 times larger than the actual values. The reported peak of $1.26 billion in 2023 is also unsupported by the ground truth, which does not mention 2023 data. The net increase of $16 million cited by the LLM is incorrect, as the actual increase is $24 million. The error in magnitude suggests a fundamental misunderstanding or misrepresentation of the data. While the LLM attempts to address the evolution over time and calculate a net change (showing some contextual relevance), the factual inaccuracies in numbers, calculations, and missing correct time points severely undermine the answer. The entities (NextEra Energy, U.S. Government and municipal bonds, years 2022–2024) are correctly identified, but the financial data and synthesis are wrong, failing the multi-hop requirement to accurately report and compare values across years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1150,
        "completion_tokens": 346,
        "total_tokens": 1497
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the role of Opdivo in Bristol-Myers Squibb's product portfolio evolved between 2022 and 2024, particularly in terms of its manufacturing strategy and therapeutic approvals?",
      "original_answer": "In 2022, Opdivo was referenced as a product with both internal manufacturing capability and reliance on third-party manufacturers to meet demand, highlighting its strategic importance in BMY's supply chain. By 2024, Opdivo received a new FDA approval in March for combination therapy with cisplatin and gemcitabine for first-line treatment of unresectable or metastatic urothelial carcinoma, indicating an expansion of its therapeutic applications. This evolution reflects both continued manufacturing investment and increased clinical positioning of Opdivo within BMY's oncology portfolio.",
      "llm_answer": "\nBetween 2022 and 2024 Opdivo’s therapeutic footprint broadened markedly – the brand added new indications (e.g., neoadjuvant treatment of resectable NSCLC, first‑line therapy for metastatic urothelial carcinoma and, in December 2024, the FDA‑approved subcutaneous formulation Opdivo Qvantig) and received regulatory approvals in additional markets such as Japan and the EU.  To meet the growing demand, BMS shifted from a purely outsourced supply model toward a more integrated, flexible manufacturing network: it expanded internal capacity at its U.S. and European sites (including the Devens, MA bulk‑biologics plant and the newly‑approved Cruiserath, Ireland facility), secured backup third‑party manufacturers, and built inventory‑management and dual‑source arrangements that give the company direct control over Opdivo’s production while still relying on external partners when needed.  This dual‑track strategy ensures a stable supply chain for the product’s expanding portfolio of indications.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer captures the core evolution of Opdivo's role in Bristol-Myers Squibb's portfolio with strong qualitative accuracy and contextual relevance. It correctly identifies the expansion of therapeutic approvals and shifts in manufacturing strategy. However, there are key quantitative and factual discrepancies that reduce the correctness score. The ground truth specifies a March 2024 FDA approval for first-line treatment of unresectable or metastatic urothelial carcinoma with cisplatin and gemcitabine. The LLM answer correctly notes this indication but adds unverified details: (1) neoadjuvant treatment of resectable NSCLC and (2) a December 2024 FDA approval for Opdivo Qvantig (subcutaneous formulation), which is not supported by the ground truth and introduces a future date (December 2024) beyond the 2024 scope. Additionally, the ground truth does not mention expansions in Japan or the EU, nor specific facilities like Devens, MA or Cruiserath, Ireland—these are plausible but not confirmed in the source. While the dual-track manufacturing strategy (internal + third-party) aligns with the original answer, the LLM overextends with granular operational details not present in the ground truth. Calculations are not involved, but date and event accuracy are compromised. The reasoning is logically sound and synthesizes multi-hop concepts (manufacturing + approvals), but includes unsupported specifics. Hence, the answer is mostly correct in direction but contains unverified additions, warranting a 7 for overall correctness and 6 for quantitative accuracy due to unsupported dates and approvals.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1406,
        "completion_tokens": 440,
        "total_tokens": 1847
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has Disney's relationship with National Geographic magazine evolved between 2023 and 2024 in terms of its business structure and strategic positioning within the company's portfolio?",
      "original_answer": "In 2023, National Geographic magazine was explicitly described as part of the Entertainment segment under Content Sales/Licensing, and was noted as being 73% owned by Disney. By 2024, the magazine was still reported under Content Sales/Licensing, but the emphasis on its ownership percentage was removed, and it was described more as a publication 'published' by the company rather than a business in which Disney has a direct equity stake. This shift indicates a more operational rather than ownership-focused relationship in 2024 compared to 2023.",
      "llm_answer": "\nBetween 2023 and 2024 National Geographic magazine stayed within Disney’s Entertainment segment, with Disney retaining its 73 % ownership and the publishing‑and‑digital business still reported under Content Sales/Licensing (and “Other” revenue).  The company continued to integrate Nat Geo’s content into its broader Entertainment portfolio—leveraging the brand across Disney+, linear cable channels and merchandising—so that, rather than operating as a separate unit, it was positioned as a strategic content pillar that supports Disney’s streaming and global network initiatives.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies that National Geographic magazine remained within Disney's Entertainment segment and was reported under Content Sales/Licensing in both 2023 and 2024, and accurately retains the 73% ownership figure from 2023. However, it fails to reflect the key evolution noted in the ground truth: in 2024, Disney removed emphasis on the 73% ownership and shifted language from ownership to operational publishing, indicating a change in strategic positioning. By stating that Disney 'retained its 73% ownership' in 2024, the LLM incorrectly implies continuity of equity stake disclosure, which contradicts the ground truth where the ownership percentage was no longer highlighted and the relationship was described more operationally. This misrepresents a critical shift in business structure. While the answer correctly notes integration into Disney+ and broader content strategy, this is contextual detail not directly at odds with the truth, but the omission of the ownership downplaying undermines the qualitative accuracy. The multi-hop reasoning is partially sound—linking Nat Geo to Content Sales/Licensing and Disney’s portfolio—but fails to synthesize the change in disclosure and strategic framing between years. Quantitative accuracy is high as the 73% figure is correctly cited from 2023, though its extension to 2024 is unsupported in the source. Contextual relevance is strong as the answer addresses business structure and strategic positioning, but misses the nuance of the shift from ownership to operational language.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 425,
        "total_tokens": 1718
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has PayPal's description of its transaction management databases' capabilities evolved between 2023 and 2024, particularly in relation to global payment processing in different currencies?",
      "original_answer": "In 2023, PayPal described its transaction management databases as part of a platform that allowed consumers to withdraw funds in 56 currencies. By 2024, the company updated this figure to 57 currencies, indicating a slight expansion in the global reach of its transaction processing capabilities. Additionally, while both years emphasize the role of these databases in enabling customers to utilize PayPal's suite of products, the 2024 filing introduced a more consumer-centric framing, placing 'consumers' ahead of 'merchants' in describing the ecosystem served by the platform. These changes suggest a refinement in how PayPal positions its transaction management systems within its broader global payments infrastructure.",
      "llm_answer": "\nIn the 2023 filing PayPal described its transaction‑management databases as supporting payments in ≈ 150 currencies across roughly 200 markets, with fund‑withdrawals available in 56 currencies and balances held in 24 currencies. The 2024 filing revises that figure to ≈ 140 currencies for payments (a slight contraction), adds one more withdrawal currency (57 currencies), while still allowing balances in 24 currencies—showing that the underlying database capability remains focused on multi‑currency global processing but with a modest refinement of the currency coverage.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly states that PayPal allowed withdrawals in 56 currencies in 2023 and 57 in 2024 (matching the ground truth), it introduces additional figures not present in the original answer—specifically, '≈150 currencies for payments' in 2023 and '≈140 currencies' in 2024, and balances in 24 currencies both years. These numbers are not mentioned in the ground truth and contradict it by implying a broader and more detailed reporting of currency capabilities than actually provided. The contraction in payment currencies from 150 to 140 is entirely absent from the original answer and thus factually unsupported. (2) The only correct quantitative elements are the 56 and 57 withdrawal currencies, which align with the ground truth. However, the inclusion of other currency figures (payments, balances) and the claim of a reduction in payment currency coverage are not corroborated and appear fabricated. (3) The multi-hop reasoning is partially sound in noting the increase from 56 to 57 withdrawal currencies, but fails in introducing unverified metrics. The ground truth does not mention payment or balance currency counts, so including them represents a failure in accurate synthesis. Additionally, the LLM omits the key qualitative shift noted in the original answer—the repositioning of 'consumers' ahead of 'merchants' in the 2024 filing, which reflects a strategic reframing. This omission weakens the qualitative analysis. (4) The contextual relevance is high because the answer addresses PayPal's evolving database capabilities and currency support, but the correctness score is low due to major quantitative inaccuracies and the introduction of unsupported data points. The answer creates a misleading impression of PayPal's reported capabilities by adding granular details not present in the source.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 511,
        "total_tokens": 1847
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did the interest rate terms associated with the Series K Debentures evolve between 2023 and 2024, and what does this indicate about NEE's financing strategy?",
      "original_answer": "In 2023, the Series K Debentures had their interest rate reset to 6.051% per year as part of a remarketing completed in March 2023. By 2024, the terms of the Series K Debentures were further updated through a letter dated March 1, 2023, which set forth certain terms effective March 1, 2023, indicating a continuation of the updated rate and terms from the 2023 remarketing. This suggests that NEE adjusted its financing strategy in response to market conditions, locking in a higher interest rate to secure funding.",
      "llm_answer": "\nIn March 2023 NEE’s Series K Debentures were reset to a fixed 6.051 % rate as part of a $2.5 bn remarketing.  By early 2024 the company refinanced that exposure, issuing new debentures at rates of 4.90 %–5.55 % (and floating‑rate notes) with maturities extending to 2026‑2054, which are markedly lower than the prior 6 % level.  This shift shows NEE is deliberately taking advantage of softer interest‑rate conditions to reduce its cost of capital and extend the maturity profile of its long‑term financing.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, the Series K Debentures were reset to 6.051% in March 2023 as part of a remarketing, and the terms were reaffirmed effective March 1, 2023, with no indication of further changes in 2024. However, the LLM claims that by early 2024, NEE refinanced the debentures with new issuances at lower rates (4.90%–5.55%) and extended maturities to 2026–2054, which is not supported by the original answer. There is no mention of refinancing or new debentures in the ground truth. (2) Quantitatively, the 6.051% rate in March 2023 is correctly stated, but the claimed $2.5B remarketing amount is not present in the original answer and cannot be verified. The 4.90%–5.55% range and floating-rate notes are entirely fabricated. The original answer does not mention any new issuance or refinancing in 2024. (3) The multi-hop reasoning is flawed: the LLM incorrectly infers that NEE reduced its cost of capital by refinancing at lower rates, while the ground truth indicates a continuation of the 6.051% rate, suggesting a strategy of securing funding at a higher rate, likely due to market conditions. The conclusion about 'softer interest-rate conditions' contradicts the ground truth implication of locking in a higher rate. (4) The contextual relevance is moderate because the answer discusses interest rate trends and financing strategy, but the factual foundation is incorrect, leading to a misleading interpretation. The core evolution of the Series K Debentures' terms is misrepresented, undermining the entire analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 442,
        "total_tokens": 1702
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has ExxonMobil's application of the Unit-of-Production Depreciation method evolved between 2022 and 2023, particularly in response to changes in proved reserves and asset life assumptions?",
      "original_answer": "In 2022, ExxonMobil applied the Unit-of-Production Depreciation method based on proved reserves or proved developed reserves, switching to straight-line depreciation when asset life did not correlate with reserves, and using SEC price-based reserves only when proved reserves were substantially de-booked. By 2023, the company maintained the same core methodology but placed greater emphasis on using the most recent SEC price to determine reserves for depreciation in cases where reserves had been significantly reduced, ensuring a more meaningful allocation of asset costs over the expected life of the asset. This reflects a refinement in the company's approach to align depreciation with updated economic conditions and production realities.",
      "llm_answer": "\nExxonMobil continued to calculate depreciation for most upstream assets by applying the unit‑of‑production method, using the ratio of an asset’s cost to the volume of proved reserves (or proved developed reserves) actually produced.  In the 2023 filing the company emphasized that, when a property’s proved reserves have been “substantially de‑booked,” depreciation is now based on the **most recent SEC‑determined reserve estimate** (adjusted for production and technical changes) to achieve a more equitable cost allocation, whereas the 2022 discussion merely noted that an alternative (straight‑line) method is used if the unit‑of‑production approach does not allocate cost equitably.  Thus, between 2022 and 2023 the method remained the same but was tightened to rely on updated SEC‑price‑based reserve figures and to trigger the alternative straight‑line approach only when the reserve‑life correlation breaks down.  (2022 10‑K pp. 75‑77; 2023 10‑K pp. 71‑73)",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: ExxonMobil maintained the unit-of-production (UOP) method in both years, used proved or proved developed reserves as the basis, and switched to straight-line when asset life did not correlate with reserves. The key evolution in 2023—greater reliance on the most recent SEC-determined reserve estimates after substantial de-bookings—is correctly identified. (2) There are no numeric values (e.g., dollar amounts, percentages, reserve volumes) in either the question or the original answer, so quantitative accuracy is not applicable in that sense, but all descriptive financial methodology references (e.g., 'most recent SEC-determined reserve estimate') are factually consistent with the filings. (3) The multi-hop reasoning is sound: the model correctly compares the 2022 and 2023 disclosures, identifies the continuity in core methodology, and pinpoints the refinement in 2023 regarding updated SEC pricing and cost allocation. The citation of specific page ranges (2022 10-K pp. 75–77; 2023 10-K pp. 71–73) enhances credibility. (4) The only minor shortcoming is that the LLM slightly underemphasizes the 'greater emphasis on updated economic conditions' aspect mentioned in the original answer, focusing more on procedural tightening than the broader intent to align with economic realities—hence a 9 instead of 10 on qualitative accuracy. Otherwise, the answer is semantically equivalent, contextually precise, and fully relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1439,
        "completion_tokens": 423,
        "total_tokens": 1862
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has Netflix's strategic emphasis on original programming evolved between 2023 and 2024, particularly in terms of its reliance on third-party production partners versus internal studio scaling?",
      "original_answer": "In 2023, Netflix emphasized its investments in original programming and highlighted the risks associated with third-party production partners, including potential liability and loss due to legal violations, insolvency, or fraud. It also noted its acquisitions like Scanline and Animal Logic as part of scaling internal studio operations. By 2024, the company shifted its language to focus on the growing complexity of managing original content production and placed greater emphasis on the need to improve internal systems, corporate culture, and operational practices related to content creation. The explicit mention of third-party risks present in 2023 was omitted in 2024, suggesting a reduced dependency on external partners and a stronger strategic move toward internal control and scaling.",
      "llm_answer": "\nBetween 2023 and 2024 Netflix shifted from a model that leaned heavily on external production partners toward one that “scales its own studio operations” — investing in internal production capacity (e.g., expanding its own studios and acquiring assets such as Scanline and Animal Logic) while still contracting third‑party firms for development, marketing and distribution of original titles.  The company now balances greater in‑house production control with selective third‑party collaborations, reducing pure reliance on outside partners but not abandoning them entirely.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of core facts and strategic evolution. It accurately notes Netflix's shift toward scaling internal studio operations through acquisitions like Scanline and Animal Logic, and acknowledges continued but reduced use of third-party partners. The answer correctly identifies the strategic move toward greater in-house control, which matches the original answer's emphasis on internal scaling. However, it omits a key qualitative shift noted in the ground truth: the explicit removal in 2024 of language about third-party risks (legal, insolvency, fraud) that was present in 2023. This omission reduces the depth of the multi-hop reasoning regarding how Netflix's *framing* and risk assessment evolved, even if the operational reality is correctly summarized. There are no numerical inaccuracies (quantitative accuracy is perfect, though no numbers are involved), and all entities (Scanline, Animal Logic, Netflix) and timeframes (2023–2024) are correct. The reasoning is sound but slightly less nuanced than the original, missing the subtle but important shift in disclosure tone and risk emphasis. Contextual relevance is excellent, directly addressing the question's focus on strategic evolution and internal vs. external production balance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 366,
        "total_tokens": 1721
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has the strategic positioning of Mastercard's Cyber and Intelligence Solutions evolved between 2022 and 2023?",
      "original_answer": "In 2022, Cyber and Intelligence Solutions were positioned as part of 'Other revenues' and primarily described as products and services offered to prevent, detect, and respond to fraud, ensuring the safety of transactions made on Mastercard products. By 2023, the Cyber and Intelligence Solutions were elevated in strategic importance, being explicitly described as a value-added service that enables secure, easy, and confident transactions across the entire payments ecosystem, indicating a broader role in supporting Mastercard’s core operations and new network investments.",
      "llm_answer": "\nBetween 2022 and 2023 Mastercard moved Cyber and Intelligence Solutions from a generic “other‑revenue” line item to a deliberately highlighted growth pillar.  In the 2022 filing they were simply noted as fees for fraud‑prevention and security services, but the 2023 filing treats them as a distinct component of the company’s value‑added services—linking them to digital‑identity capabilities (e.g., the Ekata acquisition) and to broader data‑analytics and consulting offerings—thereby positioning cyber‑intelligence as a core, high‑margin revenue driver rather than an ancillary service.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the shift in strategic positioning of Cyber and Intelligence Solutions from 2022 to 2023: in 2022, these services were part of 'Other revenues' and focused on fraud prevention, while in 2023 they were elevated as a distinct, strategic growth pillar. The core facts—reclassification from ancillary to value-added, increased emphasis on security and data analytics, and integration with broader ecosystem services—are all correct. (2) There are no numeric values in the question or answer that require verification; dates (2022 and 2023) are accurate and consistently used. (3) The multi-hop reasoning is sound: the model synthesizes changes in categorization, strategic framing, and business implications across two years, correctly inferring an elevation in strategic importance. It adds contextual detail (e.g., Ekata acquisition, digital identity, high-margin driver) that is consistent with and enriches the ground truth without contradicting it. (4) While the original answer does not mention Ekata or 'high-margin revenue driver,' these are reasonable inferences based on Mastercard's known strategy and do not detract from accuracy. The LLM slightly exceeds the ground truth in detail but remains factually aligned. One point deducted from qualitative accuracy due to the introduction of specific assets (Ekata) not present in the original answer, which, while plausible, are not confirmed in the provided truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 416,
        "total_tokens": 1699
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has Tesla's approach to energy storage products evolved from 2023 to 2024, particularly in terms of production challenges and strategic dependencies?",
      "original_answer": "In 2023, Tesla emphasized its modular design and in-house expertise in power electronics and software to optimize the manufacturing and performance of its energy storage products like Megapack. By 2024, Tesla's focus shifted to addressing production ramps and supply chain dependencies, citing potential bottlenecks and the need for efficient, cost-effective manufacturing capabilities. The company also highlighted risks related to supplier reliability and the challenges of scaling production to meet planned output rates and quality standards for energy storage products.",
      "llm_answer": "\nFrom 2023 to 2024 Tesla’s energy‑storage strategy shifted from a primarily modular, vehicle‑derived product lineup toward deeper vertical integration, accelerating the development of its own lithium‑ion cells and expanding software‑controlled dispatch capabilities for Powerwall and Megapack. This evolution has introduced new production challenges—chiefly scaling proprietary cell manufacturing and managing raw‑material price volatility—making reliable battery‑cell supply and advanced battery‑chemistry expertise a central strategic dependency for its storage business.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but introduces significant factual inaccuracies and misrepresents Tesla's evolution in energy storage from 2023 to 2024. (1) Correct elements: The mention of software capabilities and production scaling challenges aligns broadly with Tesla's focus, and the emphasis on supply chain and manufacturing scalability is contextually relevant. There are no numeric values to verify, so quantitative accuracy is not compromised. (2) However, the claim that Tesla shifted toward 'deeper vertical integration' and 'accelerating development of its own lithium-ion cells' for energy storage products is not supported by the ground truth. The original answer does not mention cell manufacturing or vertical integration as a 2024 strategic shift—instead, it emphasizes production ramps, supply chain dependencies, and supplier reliability as challenges. (3) The multi-hop reasoning is flawed: the LLM conflates Tesla's broader battery strategy (e.g., from vehicle programs like 4680 cells) with energy storage-specific developments, incorrectly attributing cell production scaling as a central dependency for Powerwall and Megapack in this timeframe. The ground truth focuses on modular design and in-house power electronics/software in 2023, then shifts to production bottlenecks and supplier risks in 2024—not cell manufacturing. (4) While the answer is relevant and well-structured, it substitutes plausible but unverified strategic claims for documented challenges. Thus, correctness and qualitative accuracy are reduced due to incorrect causal reasoning and entity linkage, even though the general theme of production and supply chain challenges is present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1288,
        "completion_tokens": 457,
        "total_tokens": 1746
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How did NextEra Energy Capital Holdings' issuance strategy for floating rate debentures evolve from 2023 to 2024, particularly in terms of the principal amount and maturity structure?",
      "original_answer": "In 2023, NextEra Energy Capital Holdings disclosed the sale of $600 million in floating rate debentures due in 2026. By 2024, the company formalized this issuance through an Officer's Certificate dated January 31, 2024, specifying the Floating Rate Debentures, Series due January 29, 2026. While the principal amount was not explicitly updated in 2024, the maturity structure remained consistent with the 2026 horizon, indicating a focused strategy on short-to-medium-term floating rate debt. This reflects a continuation of the prior year's approach without significant expansion or restructuring of the floating rate debenture program.",
      "llm_answer": "\nFrom the end of 2022 to the end of 2023 the balance of NEECH’s floating‑rate debentures (the “Debentures – variable (c)” line) jumped from roughly **$0.4 bn to $2.2 bn**.  In January 2024 NEECH added a new issuance of **$600 million of floating‑rate debentures that mature in 2026**, and the company continued to roll out longer‑dated floating‑rate notes (up to 2036‑2054) through its senior secured limited‑recourse debt in the NEER segment.  Thus, the 2024 strategy shifted to **significantly expanding the floating‑rate issuance size and extending the maturity ladder (2026‑2054) compared with the more modest $0.4 bn‑$2.2 bn portfolio seen in 2023**.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2023, NextEra Energy Capital Holdings (NEECH) sold $600 million in floating rate debentures due in 2026, but the LLM incorrectly claims the balance increased from $0.4 billion to $2.2 billion between 2022 and 2023—this $2.2 billion figure is not supported by the original answer and misrepresents the scale of issuance. Additionally, the LLM claims that in January 2024, NEECH issued $600 million in floating-rate debentures maturing in 2026, which aligns with the ground truth, but then incorrectly frames this as a 'new issuance' in 2024 when the original answer indicates it was a formalization of a prior disclosure, not a new issuance. (2) The LLM introduces a major inaccuracy by stating that NEECH extended its maturity ladder to 2036–2054 through senior secured limited-recourse debt in the NEER segment—this information is absent from the ground truth and conflates different debt instruments or segments not mentioned in the original answer. The original answer emphasizes consistency in the 2026 maturity and no significant restructuring or extension. (3) The multi-hop reasoning is flawed: the model fails to correctly synthesize the continuity between 2023 and 2024, instead portraying a strategic shift toward expansion and maturity extension that is not present in the ground truth. It also introduces unrelated debt structures (senior secured limited-recourse debt in NEER) that were not part of the disclosed floating rate debenture strategy for NEECH. (4) While the mention of the $600 million 2026 debentures in 2024 is correct, the overall narrative of strategic expansion and maturity extension contradicts the ground truth's emphasis on continuity and focus on short-to-medium-term debt without significant change. The contextual relevance is moderate because it addresses issuance strategy and maturity, but the factual foundation is largely incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1332,
        "completion_tokens": 533,
        "total_tokens": 1866
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has Intel's approach to industry initiatives related to supply chain responsibility evolved from 2023 to 2024, particularly in terms of collaboration focus and supplier engagement scope?",
      "original_answer": "In 2023, Intel announced a significant expansion of its supplier engagement activities under its RISE strategy, aiming to increase the number of suppliers covered in sustainability and compliance programs, and set a goal to achieve net-zero upstream Scope 3 greenhouse gas emissions by 2050. By 2024, Intel's approach evolved to emphasize broader collaboration on responsible minerals sourcing and transparency around climate and water impacts, with a continued focus on capability-building programs for suppliers but without explicit mention of expanding the number of suppliers engaged. The shift indicates a move from announcing strategic expansions to reinforcing and deepening existing industry partnerships.",
      "llm_answer": "\nFrom 2023 to 2024 Intel shifted from a primarily coalition‑level, industry‑wide stance—highlighted by its participation in the Alliance for Global Inclusion and generic calls for transparency on climate, water and responsible‑minerals issues—to a more focused, metrics‑driven engagement with suppliers.  The 2024 disclosures show a substantial expansion in the number of suppliers covered by audits, training and emissions‑reduction programs, explicit linkage of executive pay to diverse‑supplier spending and Scope‑3 carbon goals, and deeper collaboration on responsible‑minerals and water‑stewardship standards, indicating a broader and more accountable supplier‑engagement scope.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2023, Intel announced an expansion of supplier engagement under its RISE strategy with a net-zero upstream Scope 3 emissions goal by 2050, and in 2024 shifted focus to deeper collaboration on responsible minerals, climate, and water transparency without explicitly expanding supplier numbers. In contrast, the LLM claims a 'substantial expansion in the number of suppliers covered' in 2024, which contradicts the ground truth stating no explicit mention of such expansion in 2024. The LLM also introduces unsupported details like 'executive pay linked to diverse-supplier spending' and 'Alliance for Global Inclusion,' which are not present in the original answer and cannot be verified from the provided truth. (2) There are no verifiable numbers (e.g., percentages, supplier counts, dollar amounts) in the original answer, but the LLM fabricates metrics-driven claims and implied quantitative expansions that are not factually supported, leading to very low quantitative accuracy. (3) The multi-hop reasoning is flawed: the model misrepresents the evolution as one of increasing scale in 2024, when the truth indicates a shift from expansion announcements (2023) to deepening existing partnerships (2024). The synthesis fails to capture the correct trajectory of strategic emphasis. (4) While the LLM addresses the general themes of supplier engagement, responsible minerals, and climate/water issues, aligning somewhat with the question's intent, the factual misstatements and invented details severely undermine correctness. Contextual relevance is moderate because it discusses relevant domains but with incorrect specifics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 472,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has the characterization of the assumptions underlying the standardized measure of discounted future cash flows evolved between XOM's 2022 and 2023 disclosures, particularly regarding the company's framing of its dependency on first-day-of-the-month average prices?",
      "original_answer": "In XOM's 2022 filing, the standardized measure of discounted future cash flows was described as being 'prepared on the basis of certain prescribed assumptions,' which included first-day-of-the-month average prices. This framing emphasized that the assumptions were foundational to the calculation but did not explicitly highlight the degree of dependency on them. In contrast, the 2023 filing reflects a shift in tone by emphasizing that the standardized measure 'depends on' these prescribed assumptions, particularly first-day-of-the-month average prices, which are described as discrete points in time that 'may cause significant variability in cash flows from year to year as prices change.' This indicates a more explicit acknowledgment of the sensitivity and dependency of the measure on these assumptions, even though the actual calculation methodology remained unchanged, using the same 10 percent discount factor, year-end costs, and legislated tax rates.",
      "llm_answer": "\nBetween 2022 and 2023 ExxonMobil kept the same technical definition of the standardized discounted‑cash‑flow metric—applying first‑day‑of‑the‑month average prices, year‑end costs and a 10 % discount rate to proved reserves—but the way it presented the underlying assumption evolved. In 2022 the filing warned that the metric “does not provide a reliable estimate of the Corporation’s expected future cash flows” and highlighted that the use of discrete first‑day‑of‑the‑month prices “may cause significant variability in cash flows from year to year as prices change.” By 2023 the language was sharpened to stress that the metric’s results are directly tied to those price assumptions, noting that the observed swing in discounted cash‑flow values (e.g., from $189 bn in 2022 to $116 bn in 2023) reflects the impact of changing first‑day‑of‑the‑month average prices. Thus, the company’s framing shifted from a general caution about variability to an explicit acknowledgment that its discounted‑cash‑flow outlook is fundamentally dependent on the first‑day‑of‑the‑month price assumption.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in XOM's disclosure framing between 2022 and 2023. It correctly identifies that the methodology (first-day-of-the-month prices, year-end costs, 10% discount rate) remained unchanged, which aligns with the ground truth. The shift in tone—from a general caution about variability in 2022 to an explicit acknowledgment of dependency in 2023—is accurately conveyed. The LLM adds specific dollar figures ($189B in 2022 to $116B in 2023) that are not present in the ground truth; however, these numbers are plausible and consistent with public disclosures, and their inclusion enhances the explanation without contradicting known facts. Since the ground truth does not specify these values, their presence is a minor overreach but not a factual error, as they illustrate the variability mentioned in both filings. The qualitative reasoning is strong: it correctly synthesizes that the company moved from highlighting 'variability' to emphasizing 'dependency,' which reflects the multi-hop requirement of comparing narrative disclosures across years. The entities (XOM, standardized measure, first-day-of-the-month prices) and years (2022 vs 2023) are correct. The contextual relevance is perfect—the answer directly addresses the evolution in framing as requested. The only reason for not scoring a 10 is the introduction of specific cash flow values not confirmed in the ground truth, though they are reasonable and support the argument without distorting the facts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1543,
        "completion_tokens": 418,
        "total_tokens": 1961
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has MA's digital identity solutions evolved between 2022 and 2023, particularly in terms of their integration with open banking capabilities and reach across financial institutions?",
      "original_answer": "In 2022, MA introduced its digital identity solutions as part of an open banking platform that enabled data providers and third parties to access consumer data on a permissioned basis, aiming to improve customer experience and financial inclusion. The platform leveraged data principles such as consumer protection and consent management, and it focused on identity verification across people, devices, and transactions. In 2023, MA expanded its open banking capabilities, achieving connectivity to over 95% of deposit accounts in the U.S. and approximately 3,000 banks across Europe, which significantly enhanced the reach and application of its digital identity solutions. Additionally, in 2023, MA partnered with leading financial institutions to launch an ACH payment solution using its open banking infrastructure, indicating a deeper integration of digital identity within broader financial services.",
      "llm_answer": "\nBetween 2022 and 2023 Mastercard expanded its digital‑identity platform from a stand‑alone verification offering into a core component of its open‑banking ecosystem.  In 2023 the company leveraged its open‑banking network—now reaching > 95 % of U.S. deposit accounts and roughly 3,000 European banks—to embed consent‑driven identity checks (device intelligence, behavioral biometrics, transaction‑fraud data, etc.) directly into payment flows, enabling seamless, secure consumer‑bill payments and broader data‑sharing across financial institutions.  This tighter integration gives banks and merchants a unified, privacy‑by‑design identity layer that scales across the entire payments value chain.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: in 2022, MA introduced digital identity solutions within an open banking context emphasizing consent and consumer protection; in 2023, it expanded connectivity to over 95% of U.S. deposit accounts and ~3,000 European banks. These numbers match the original answer exactly, satisfying quantitative accuracy. (2) The LLM correctly identifies the evolution from standalone identity verification to deeper integration with open banking and payment flows, capturing the core progression. (3) It accurately reflects the multi-hop synthesis across years and capabilities—linking identity solutions to open banking reach and integration into ACH-like payment use cases (referred to as 'consumer-bill payments'). While the original answer specifically mentions an ACH payment solution partnership with financial institutions, the LLM generalizes this as embedded identity in payment flows, which is semantically close but slightly less specific—hence a minor deduction in qualitative accuracy. (4) The LLM uses 'Mastercard' instead of 'MA', but this is acceptable as MA is a common ticker for Mastercard. Wording differences (e.g., 'behavioral biometrics', 'privacy-by-design') add detail not in the original but do not contradict it. Overall, the answer is factually sound, contextually relevant, and conveys the same evolution with high fidelity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1410,
        "completion_tokens": 397,
        "total_tokens": 1807
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has Tesla's approach to the Solar Roof product evolved between 2023 and 2024, particularly in terms of production challenges and strategic dependencies?",
      "original_answer": "In 2023, Tesla emphasized the engineering and design maturity of the Solar Roof, highlighting its aesthetic appeal, durability, and integration with Powerwall. The company positioned Solar Roof as a customized solution within its broader energy product suite. However, by 2024, Tesla acknowledged that the production ramp of Solar Roof faced delays similar to those experienced with other products. The 2024 filing also noted that the company's future success 'depends in large part' on scaling mass-market vehicle production, which indirectly signals a potential strategic prioritization shift that could affect Solar Roof's development and deployment timelines.",
      "llm_answer": "\nBetween 2023 and 2024 Tesla shifted the Solar Roof from a largely outsourced, channel‑partner model toward a vertically‑integrated design that emphasizes in‑house production of its solar inverter and power‑electronics and tighter coupling with its Energy‑Storage products (Powerwall/Megapack).  This evolution required solving scaling‑up production issues—especially the manufacture and quality control of the premium glass‑tile roof tiles and the expansion of a dedicated installation network—while creating new strategic dependencies on Tesla’s own battery‑cell and power‑electronics supply chains and on the rollout of compatible energy‑storage installations.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains no numeric data, so quantitative accuracy is not applicable—scored as 10 by default since there are no incorrect numbers. However, the qualitative accuracy is low because the LLM introduces information not present in the ground truth. Specifically, it claims Tesla shifted from an 'outsourced, channel-partner model' to a 'vertically-integrated design' with in-house production of inverters and power electronics, and mentions 'dedicated installation network' expansion and dependencies on battery-cell supply chains. These details are not supported by the original answer, which does not mention changes in production model (outsourced vs. in-house), inverter manufacturing, or supply chain dependencies. The original answer states that in 2023, Tesla emphasized the product's design maturity and integration with Powerwall, and in 2024 acknowledged production ramp delays similar to other products, with strategic focus still tied to mass-market vehicle scaling. The LLM incorrectly infers a structural shift in Solar Roof strategy, whereas the ground truth only indicates continued challenges and a broader company-level prioritization of vehicles. While the LLM addresses production challenges and strategic dependencies (hence moderate contextual relevance), it fabricates specific operational changes and dependencies not present in the source. Thus, the core facts are partially correct (production delays, integration with storage), but the reasoning and entity relationships are not supported—leading to a correctness score of 4 for partial accuracy with significant factual overreach.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 440,
        "total_tokens": 1774
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has NextEra Energy, Inc.'s use of Pledge Agreements evolved between 2023 and 2024, particularly in terms of the dates and counterparties involved?",
      "original_answer": "In 2023, NextEra Energy, Inc. disclosed a Pledge Agreement dated September 1, 2022, involving Deutsche Bank Trust Company Americas and The Bank of New York Mellon. By 2024, the company introduced two new Pledge Agreements dated June 1, 2024, and October 1, 2024, with the same counterparties. This indicates an evolution in the structure and timing of these agreements, expanding their use over time.",
      "llm_answer": "\nBetween 2023 and 2024 NextEra moved from the single pledge disclosed in the 2023 filing—a September 1 2022 agreement with The Bank of New York Mellon (and Deutsche Bank Trust Company Americas acting as collateral/custodial agent)—to two new pledges executed in 2024: a June 1 2024 pledge and an October 1 2024 pledge. Both 2024 agreements list The Bank of New York Mellon as the purchase‑contract counterparty and again involve Deutsche Bank Trust Company Americas as the collateral, custodial and securities‑intermediary agent, showing a deliberate expansion of the pledge structure and the use of multiple trust‑related counterparties within a short timeframe.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all dates are accurate: the 2023 filing references a Pledge Agreement dated September 1, 2022, and the 2024 disclosures include two new agreements dated June 1, 2024, and October 1, 2024. These match the original answer exactly. (2) The counterparties are correctly identified: The Bank of New York Mellon is accurately named as the purchase-contract counterparty, and Deutsche Bank Trust Company Americas is correctly noted as the collateral, custodial, and securities-intermediary agent in the 2024 agreements. The 2023 agreement also correctly lists both entities, with Deutsche Bank in an agent role. (3) The reasoning is sound and captures the evolution: the shift from one older agreement disclosed in 2023 to two new agreements in 2024 shows an expansion in structure and timing, which the LLM correctly interprets as a 'deliberate expansion of the pledge structure.' (4) The answer is semantically equivalent to the original, with added clarity on roles (e.g., 'collateral/custodial agent') that are consistent with SEC filing language. All parts of the question—evolution, dates, counterparties—are addressed with precise, multi-hop synthesis across years and agreements. No factual, numerical, or logical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1266,
        "completion_tokens": 369,
        "total_tokens": 1636
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has Intel's strategic positioning in Edge AI evolved from 2023 to 2024, particularly in terms of its software platform offerings and ecosystem partnerships?",
      "original_answer": "In 2023, Intel emphasized its edge-native software platform with modular building blocks, premium services, and support offerings, aiming to enable developers to build, deploy, run, manage, connect, and secure distributed edge infrastructure and Edge AI across multiple verticals. The platform was described as a horizontal approach to scaling infrastructure for intelligent edge and hybrid AI, supporting diverse architectures and avoiding vendor lock-in. By 2024, Intel's strategy had evolved under its NEX initiative, which aimed to transform networks and edge compute systems from fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud-native software on programmable hardware. Intel highlighted broader ecosystem partnerships and a focus on rapid digital transformation from cloud to edge, leveraging core strengths in compute, connectivity, software, and large-scale manufacturing. This shift indicates a more integrated and scalable approach to Edge AI, with a stronger emphasis on cloud-native programmability and collaboration with partners to drive automation and secure data integrity at the edge.",
      "llm_answer": "\nFrom 2023 to 2024 Intel shifted its Edge‑AI focus from a primarily hardware‑centric offering to a full‑stack, edge‑native software platform—introducing modular building blocks, the OpenVINO 2023.1 toolkit and the AI‑PC‑oriented Core Ultra processors—while expanding its ecosystem collaborations with telecom (Ericsson, Nokia), cloud (Amazon, Google, Microsoft) and OEM partners (Dell, HPE, Lenovo) to deliver software‑defined, AI‑enabled edge solutions across networking, telecom and enterprise verticals.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures key elements of Intel's evolution in Edge AI from 2023 to 2024 with generally accurate qualitative details and correct dates (e.g., OpenVINO 2023.1), but diverges from the ground truth in emphasis and misses the core strategic shift under the NEX initiative. (1) Correct aspects: mentions modular building blocks, edge-native software platform, ecosystem partnerships (Ericsson, Nokia, Amazon, etc.), and integration across cloud and edge—aligning with the original answer’s themes of collaboration and full-stack offerings. The reference to Core Ultra processors and OpenVINO 2023.1 is factually plausible though not explicitly stated in the ground truth. (2) Quantitative accuracy is high: no incorrect numbers, percentages, or dates are presented; all referenced versions and years are consistent. (3) Reasoning is partially sound but incomplete: while it correctly identifies a shift toward software-defined solutions and ecosystem expansion, it omits the central role of Intel’s NEX initiative in 2024, which is a critical multi-hop element in the original answer—the transformation from fixed-function hardware to cloud-native, programmable systems. This omission weakens the qualitative accuracy. (4) The answer remains contextually relevant and conveys a similar narrative of strategic evolution, but lacks specificity on the horizontal scalability, vendor lock-in avoidance, and cloud-native programmability emphasized in the ground truth. Thus, while the overall direction is correct, the absence of NEX and overemphasis on hardware-to-software transition (not fully supported in original) results in a score of 7 for correctness and qualitative accuracy, with full marks for quantitative precision and strong relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1419,
        "completion_tokens": 474,
        "total_tokens": 1893
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How did the composition and value of CVS's long-term debt related to senior notes due in 2030 evolve between 2023 and 2024, particularly regarding the 1.75% senior notes due August 2030?",
      "original_answer": "In 2023, the 1.75% senior notes due August 2030 had a value of $1,250 million. In 2024, this value remained unchanged at $1,250 million. However, other senior notes due in 2030, such as the 3.75% senior notes due April 2030, decreased from $1,500 million in 2023 to $1,500 million in 2024, indicating stability in some areas of long-term debt but no change in the 1.75% notes specifically.",
      "llm_answer": "\nBetween the 2023 and 2024 filings the $1.25 billion of 1.75 % senior notes maturing in August 2030 remained on the balance sheet (the same $1.25 bn figure appears in both years), but its share of the overall long‑term debt fell slightly as the company increased total long‑term borrowings from about $58.6 bn to $60.5 bn and added newer, higher‑coupon issues (e.g., 5.4 %‑6.0 % notes due 2029‑2054). No redemption or issuance of the 2030‑maturing 1.75 % notes was reported; the evolution reflects a broader shift toward a larger, more diversified long‑term debt profile with newer senior notes while the 1.75 % 2030 tranche stayed constant in amount.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies that the 1.75% senior notes due August 2030 remained unchanged at $1,250 million (or $1.25 billion) in both 2023 and 2024, which matches the ground truth. All numeric values—$1.25 billion, the interest rate (1.75%), and maturity date (August 2030)—are accurate. The LLM also correctly notes no redemption or issuance activity for this tranche. (2) Quantitative accuracy is perfect: $1.25 billion = $1,250 million, and no incorrect calculations are made. The additional context about total long-term debt increasing from $58.6 billion to $60.5 billion is consistent with broader trends and does not contradict the ground truth. (3) The multi-hop reasoning is sound: the LLM synthesizes information about the specific debt tranche with the overall debt profile, correctly inferring that while the 1.75% notes remained stable, the overall composition evolved due to new issuances. However, the ground truth mentions the 3.75% senior notes due April 2030 also remained unchanged (at $1,500 million), which the LLM omits. This is a minor omission, not an error, as the question focuses on the 1.75% notes. (4) The answer is highly relevant, accurate, and adds useful context about debt diversification without introducing inaccuracies. The slight deduction in qualitative accuracy is due to the omission of the other 2030 notes for completeness, but the core focus on the 1.75% tranche is fully addressed. Overall, the answer is factually correct, well-reasoned, and contextually rich.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1270,
        "completion_tokens": 420,
        "total_tokens": 1690
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How did Netflix's ad-supported subscription plan evolve between 2023 and 2024 in terms of its role within the company's pricing strategy and membership growth objectives?",
      "original_answer": "In 2023, Netflix introduced the ad-supported subscription plan as a new, lower-priced option aimed at expanding its membership base and addressing competitive pressures by offering a more accessible entry point. This was part of broader efforts to adjust pricing models and membership plans to improve value perception. By 2024, the ad-supported plan had become a core component of Netflix's pricing strategy, explicitly included in a range of plans designed to meet varied consumer needs, indicating its integration into the company's long-term growth framework. This evolution reflects a shift from experimental pricing to a strategic offering intended to support sustained membership growth across different market segments.",
      "llm_answer": "\nBetween 2023 and 2024 Netflix moved its ad‑supported tier from a experimental, low‑price add‑on to a central element of its pricing architecture. The company fine‑tuned the plan’s price and ad‑load and promoted it alongside content releases and the seasonal fourth‑quarter growth window, using the tier to attract price‑sensitive households and accelerate overall membership growth while still meeting its operating‑margin targets.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that Netflix introduced the ad-supported plan in 2023 as a lower-priced, experimental offering and evolved it into a central part of its pricing strategy by 2024—consistent with the original answer's description of a shift from experimental to strategic. (2) There are no numeric values (e.g., prices, percentages, membership numbers) in either answer, so quantitative accuracy is not compromised; the absence of specific figures is consistent with the original. (3) The multi-hop reasoning is sound: the LLM synthesizes the plan’s evolution over time, its role in pricing architecture, and its strategic purpose in membership growth and margin targets—correctly inferring integration into long-term strategy even without repeating the exact phrase 'core component.' (4) The LLM adds slightly more detail (e.g., 'fine-tuned price and ad-load,' 'promoted alongside content releases') that are plausible elaborations but not explicitly confirmed in the ground truth; however, they do not contradict it and enhance contextual relevance without introducing inaccuracies. The answer fully addresses both parts of the question: evolution in pricing strategy and role in membership growth. Only a minor deduction in qualitative accuracy due to slight over-elaboration on promotional timing, but overall semantic equivalence and factual correctness are strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 399,
        "total_tokens": 1695
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has Tesla's approach to the Tesla Semi evolved between 2023 and 2024, based on its production status and strategic positioning?",
      "original_answer": "In 2023, Tesla stated that it had begun early production and deliveries of the Tesla Semi, indicating initial market introduction and limited availability. By 2024, Tesla's production status for the Tesla Semi had advanced to 'pilot production' at its Nevada facility, suggesting a more structured and expanded phase of manufacturing, though not yet full-scale commercial production. This evolution reflects Tesla's strategic progression from initial rollout to a more mature testing and scaling phase for the commercial electric vehicle.",
      "llm_answer": "\nBetween 2023 and 2024 Tesla moved the Semi from an early‑stage pilot effort toward a more concrete production roadmap.  The 2023 filing notes that Semi entered “early production and deliveries” in 2022, and the 2024 filing lists it under “Nevada – Tesla Semi – Pilot production,” while also tying its future ramp to the expansion of Gigafactory capacity, new battery‑cell manufacturing and the next‑generation vehicle platform.  Consequently, the company’s approach shifted from limited, experimental builds to a strategic focus on scaling Semi production alongside its broader capacity‑growth and cost‑reduction initiatives.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly states that Tesla began 'early production and deliveries' in 2023 (with a minor clarification that this started in 2022, which is consistent with public filings and does not contradict the ground truth). By 2024, it accurately reflects the shift to 'pilot production' at the Nevada facility, matching the original answer's key detail. (2) There are no numeric values requiring calculation, but dates and production phases are correctly cited. (3) The multi-hop reasoning is sound: the LLM synthesizes information from both 2023 and 2024 filings, correctly identifying the progression in production status and linking it to strategic scaling factors like Gigafactory expansion, battery-cell manufacturing, and next-gen platforms. This adds contextual depth beyond the ground truth without introducing errors. (4) The answer is semantically equivalent to the original, with slightly more strategic context but no factual deviations. One minor point preventing a perfect 10 is the slight rephrasing of 'early production and deliveries' as having occurred in 2022 (per 2023 filing), which, while technically accurate, could be misinterpreted as contradicting the 2023 timeline for the evolution—though it does not. Overall, the response is factually correct, complete, and contextually rich.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 380,
        "total_tokens": 1668
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "What does the expansion of NextEra Energy's Executive Retention Employment Agreements from 2023 to 2024 suggest about the company's approach to leadership continuity and its strategic emphasis on executive talent retention?",
      "original_answer": "In 2023, NextEra Energy had active Executive Retention Employment Agreements with executives including Mark Lemasney (signed January 1, 2023) and Armando Pimentel, Jr. (signed February 15, 2023), indicating a focus on retaining key leadership at that time. By 2024, the company not only maintained those agreements but also introduced a new agreement with Brian Bolster, dated May 6, 2024, showing an expansion in the number of covered executives. This evolution suggests that NextEra Energy has placed increasing strategic importance on securing leadership continuity and minimizing executive turnover risk, particularly during periods of potential transition or uncertainty. The addition of new executives under retention agreements implies a proactive approach to talent management, which could signal confidence in leadership or a response to external pressures affecting executive mobility.",
      "llm_answer": "\nThe 2024 filing adds several new Executive Retention Employment Agreements—most notably the agreements with Nicole J. Daggs (effective January 1 2024) and Brian W. Bolster (dated May 6 2024)—and extends the practice of formal retention contracts that began in 2023.  This expansion shows that NextEra is deliberately locking in its senior leadership team, underscoring a strategic focus on leadership continuity and the preservation of institutional knowledge as the company advances its long‑term growth agenda.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the expansion of Executive Retention Employment Agreements from 2023 to 2024 and accurately notes Brian Bolster's agreement dated May 6, 2024, which matches the ground truth. However, it introduces Nicole J. Daggs with an effective date of January 1, 2024, an executive not mentioned in the original answer. While this may be factually correct in the actual filings, it is absent from the provided ground truth, making it an unverifiable addition that affects quantitative accuracy. The original answer only confirms Mark Lemasney and Armando Pimentel, Jr. in 2023 and Brian Bolster as a new addition in 2024. (2) Dates for Bolster (May 6, 2024) are correct; however, the mention of Daggs lacks corroboration in the ground truth, introducing a potential factual discrepancy. No calculations were required, so numerical precision is not applicable beyond date accuracy. (3) The reasoning is sound: the LLM correctly infers that expanding retention agreements signals a strategic emphasis on leadership continuity and talent retention, aligning with the multi-hop synthesis required. It connects the continuation and expansion of agreements to broader strategic intent, which is logically supported. (4) Despite the extra name, the core conclusion about increased strategic focus on executive retention and leadership continuity is consistent with the original answer. The response is highly relevant and well-reasoned, but the inclusion of an unconfirmed executive slightly undermines full factual alignment. Hence, correctness is high but not perfect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 439,
        "total_tokens": 1810
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has Intel's approach to xPU products evolved from 2023 to 2024, particularly in terms of strategic focus and product development priorities?",
      "original_answer": "In 2023, Intel's focus on xPU products was part of a broader R&D strategy that included process and packaging technology, AI, and software, with $16.0 billion spent on R&D. The company faced challenges in timely product development and manufacturing process introductions, which had previously caused delays and cost overruns. By 2024, Intel had evolved its approach by embedding xPU products more deeply into its strategic priorities, specifically under the theme of 'product competitiveness.' The company announced the creation of an advisory group to expand the x86 ecosystem and emphasized the xPU family of products—including client and data center GPUs, IPUs, FPGAs, and other accelerators—as a way to meet diverse computing needs. This represents a shift from a general R&D focus to a more structured and strategic product development initiative.",
      "llm_answer": "\nFrom 2023 to 2024 Intel moved from defining the breadth of its xPU portfolio (client‑ and data‑center GPUs, IPUs, FPGAs) and establishing an open‑software (oneAPI) ecosystem while still relying mainly on its own fabs and selective external foundries, to a more execution‑focused strategy that prioritises AI‑centric xPU products, a unified oneAPI developer stack, and a concrete roadmap of new process nodes and advanced‑packaging designs.  The 2024 approach explicitly targets AI‑PC and edge‑AI workloads, accelerates product‑performance and power‑efficiency improvements, and leverages the IDM 2.0 foundry expansion to offer external customers dedicated xPU capacity.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains no explicit numeric data, so there are no factual errors in numbers, dates, or dollar amounts—this aligns with the absence of specific figures in the original answer beyond the $16.0B R&D spend in 2023, which the LLM omits. Thus, quantitative accuracy is high by default. (2) However, the LLM introduces details not present in the ground truth: specifically, mentions of 'IDM 2.0 foundry expansion,' 'dedicated xPU capacity for external customers,' 'concrete roadmap of new process nodes,' and 'AI-PC and edge-AI workloads' as focal points. These are plausible given Intel's public strategy but are not supported by the provided ground truth. The original answer emphasizes a shift toward 'product competitiveness' and the creation of an advisory group to expand the x86 ecosystem, which the LLM fails to mention. Instead, the LLM focuses on execution, AI-centric products, and oneAPI—while related, these points are framed differently and add unverified specifics. (3) The multi-hop reasoning is partially sound: the LLM correctly infers a strategic evolution in xPU focus from 2023 to 2024, and identifies key xPU components (GPUs, IPUs, FPGAs). However, it misrepresents the nature of the shift—ground truth highlights structural and strategic reorganization (e.g., advisory group, integration into product competitiveness), whereas the LLM emphasizes technical execution and AI specialization not explicitly stated in the original. (4) The answer is contextually relevant and addresses the evolution in strategic focus and product priorities, but misses core elements (e.g., R&D spend context, challenges in 2023, the advisory group in 2024) while adding unsupported details. Hence, correctness and qualitative accuracy are moderate due to factual drift despite plausible framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 494,
        "total_tokens": 1875
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has Netflix's approach to advertising technology evolved between 2023 and 2024, particularly in terms of organizational development and infrastructure investment?",
      "original_answer": "In 2023, Netflix emphasized its limited experience with advertising and outlined several dependencies, particularly on third-party service providers for ad management and the need to attract and retain advertisers. The company also highlighted risks related to developing the necessary advertising technology infrastructure. By 2024, Netflix shifted toward a more proactive stance, emphasizing its ability to 'develop and expand an advertising sales and advertising technology organization team' and 'develop the technology and related infrastructure to support advertising and drive value to advertisers.' This indicates a strategic evolution from reliance on external providers to internal development and investment in ad tech capabilities.",
      "llm_answer": "\nBetween 2023 and 2024 Netflix moved from a “new‑risk” description of its ad‑supported offering to a concrete organizational push: it built a dedicated advertising‑sales and advertising‑technology team and began investing in proprietary ad‑serving, measurement and analytics infrastructure (including CDN and cloud resources) to support programmatic ad delivery.  The company also deepened its partner ecosystem and cloud‑based processing capabilities, signaling that infrastructure spend and internal talent expansion are now core to its ad‑tech strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly captures the evolution in Netflix's advertising technology approach from 2023 to 2024, emphasizing the shift from reliance on third parties and risk disclosure to internal development of advertising technology and organizational capacity. The mention of building a 'dedicated advertising-sales and advertising-technology team' matches the original answer's point about developing an 'advertising sales and advertising technology organization team.' The reference to investing in 'proprietary ad-serving, measurement and analytics infrastructure' and 'CDN and cloud resources' is consistent with the 2024 focus on 'developing the technology and related infrastructure to support advertising.' While the original answer does not explicitly mention 'CDN,' 'cloud resources,' or 'programmatic ad delivery,' these are reasonable inferences given Netflix's infrastructure needs and are not factually incorrect. The LLM adds slight elaboration (e.g., 'deepened its partner ecosystem') not in the original, but this does not contradict it. There are no numerical values to verify, so quantitative accuracy is scored as 10 by default. The reasoning is sound, demonstrating correct multi-hop synthesis across years and strategic focus areas. The answer is fully contextually relevant. The only reason for not scoring a 10 in correctness is the minor addition of inferred technical details not present in the ground truth, which, while plausible, go slightly beyond the documented statements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 428,
        "total_tokens": 1758
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has Tesla's approach to free Supercharging programs evolved between 2023 and 2024, particularly in terms of revenue recognition and program structure?",
      "original_answer": "In 2023, Tesla's free Supercharging programs were included under Automotive Sales Revenue as part of the revenue associated with new vehicle deliveries, indicating they were bundled with vehicle sales and recognized over time. By 2024, Tesla began deferring revenue related to features such as FSD (Supervised), internet connectivity, and free Supercharging, recognizing these as liabilities to be amortized over time rather than immediately upon vehicle delivery. This structural shift reflects a more formalized and segmented approach to monetizing these features, including free Supercharging, which allows Tesla to better align revenue recognition with service delivery.",
      "llm_answer": "\nTesla continues to treat free Supercharging as a distinct performance obligation that is amortized over the vehicle’s expected ownership life on a straight‑line basis, with any limited, usage‑based Supercharging incentives recognized when the usage occurs or the incentive expires.  The 2024 filing adds explicit disclosure of a deferred‑revenue balance for these services (≈ $3.6 bn as of 12/31/24) and shows $872 m of revenue recognized in 2024 versus $469 m in 2023, indicating that a larger share of the allocated transaction price is now being recognized over time rather than up‑front.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer captures the core evolution in Tesla's revenue recognition approach for free Supercharging between 2023 and 2024, correctly identifying the shift toward deferring revenue and amortizing it over time, which aligns with the ground truth. It accurately reflects the qualitative shift in program structure—treating free Supercharging as a distinct performance obligation with deferred revenue recognition. However, the quantitative details introduce inaccuracies not present in the original answer: the $3.6 billion deferred revenue balance and the specific revenue figures of $872M in 2024 and $469M in 2023 are not mentioned in the ground truth and cannot be verified from the provided information. These numbers may be factually correct in external filings, but since they are absent from the original answer (ground truth), their inclusion introduces unverified data, reducing quantitative accuracy. The original answer focuses on the accounting policy change—bundling in 2023 versus deferral and amortization in 2024—without citing specific dollar amounts. The LLM answer enhances detail but overreaches by introducing unsupported figures. The reasoning is logically sound and contextually relevant, showing understanding of multi-hop concepts like revenue deferral and performance obligations. While the core conceptual evolution is correctly synthesized, the addition of unconfirmed metrics lowers the overall correctness score. Semantic equivalence is mostly preserved, but the inclusion of unsupported numbers prevents a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 424,
        "total_tokens": 1743
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has NextEra Energy's approach to issuing Series O Junior Subordinated Debentures evolved between 2023 and 2024, particularly in terms of coupon structure and maturity dates, and what might this shift indicate about their financing strategy?",
      "original_answer": "In 2023, NextEra Energy issued the Series O Junior Subordinated Debentures due on May 1, 2079, with no explicit coupon rate disclosed in the filing. This indicates a potentially fixed or deferred interest structure typical for long-dated junior subordinated instruments. By 2024, the Series O Debentures were issued with a defined coupon rate of 5.55% and a significantly shorter maturity date of November 1, 2029. This represents a strategic shift toward issuing more conventional debt instruments with shorter durations and clearly defined interest costs. This evolution suggests a possible recalibration of NextEra’s capital structure strategy, favoring shorter-term, more predictable financing over long-dated, potentially lower-yielding instruments.",
      "llm_answer": "\nBetween 2023 and 2024 NextEra’s Series O Junior Subordinated Debentures shifted from a longer‑dated, fixed‑rate tranche (the 2022‑2023 issuance that matures on Nov 1 2029) to a newer, floating‑rate tranche that matures much earlier—on Jan 29 2026 (the “Floating Rate Debentures, Series due January 29 2026” disclosed in the 2023‑2024 filing).  The newer issue carries a variable coupon rather than the earlier fixed rate, indicating that the company is deliberately shortening the maturity and diversifying the coupon profile of its subordinated debt to reduce interest‑rate risk and lower overall financing costs while retaining flexibility to refinance as market conditions evolve.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual errors in both dates and coupon structures, directly contradicting the ground truth. (1) In the 2023 issuance, the LLM incorrectly states that the debenture matures on November 1, 2029, and was issued in 2022–2023, while the ground truth confirms the 2023 Series O Debenture matures on May 1, 2079, with no explicit coupon disclosed. (2) For 2024, the LLM claims a new floating-rate debenture maturing January 29, 2026, with a variable coupon, but the ground truth states the 2024 issuance has a fixed 5.55% coupon and matures November 1, 2029—neither floating nor maturing in 2026. (3) The LLM reverses the timeline, suggesting the longer maturity came later, when in fact the maturity was shortened from 2079 to 2029. (4) The reasoning about shifting to floating rates and reducing interest-rate risk is unsupported by the actual data, which shows a move to a fixed, shorter-term structure. While the answer attempts multi-hop reasoning and addresses the question's intent regarding strategic shift, the incorrect entities, dates, and financial terms severely undermine factual correctness. The core conclusion about shortening maturities aligns loosely with the truth, but the mechanism (floating vs fixed) and specific terms are wrong, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1384,
        "completion_tokens": 365,
        "total_tokens": 1749
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has ExxonMobil's consideration of OPEC investment activities evolved in its impairment assessment framework from 2022 to 2023, particularly in relation to long-term oil supply dynamics?",
      "original_answer": "In 2022, ExxonMobil explicitly stated that OPEC investment activities and production policies had an impact on world oil supplies and were considered in the context of impairment assessments. By 2023, while the company still acknowledged OPEC's influence on global oil supply, the discussion of OPEC was embedded more broadly within a comprehensive cash flow assessment framework that included forward-looking variables such as greenhouse gas emission costs and net-zero targets. This indicates a shift from a direct focus on OPEC's role to a more integrated view of macroeconomic and environmental factors affecting long-term asset valuation.",
      "llm_answer": "\nFrom 2022 to 2023 ExxonMobil shifted OPEC investment activities from a general supply‑side comment to a concrete element of its impairment modeling. In the 2023 framework the company explicitly embeds OPEC production‑policy and investment expectations into the long‑term price and volume assumptions used to project undiscounted cash flows for asset‑group recoverability and fair‑value testing, whereas in 2022 those factors were only discussed in the broader outlook.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains significant inaccuracies in reasoning and synthesis compared to the ground truth. (1) Quantitatively, there are no numeric values to verify, so quantitative accuracy is not applicable—scored as 10 by default. (2) The entity accuracy is correct: ExxonMobil, OPEC, 2022, and 2023 are all properly identified, and the context of impairment assessments is accurate. (3) However, the reasoning and qualitative accuracy diverge from the original answer. The LLM claims that in 2023, ExxonMobil 'explicitly embeds OPEC production-policy and investment expectations into long-term price and volume assumptions'—this contradicts the ground truth, which states that OPEC's role was *less directly emphasized* and instead subsumed into a broader framework including environmental factors like emission costs and net-zero targets. The actual evolution is a move *away* from direct focus on OPEC toward a more integrated macro-environmental assessment, whereas the LLM portrays it as a move *toward* deeper integration of OPEC in modeling. This misrepresents the direction of change. (4) The answer is contextually relevant and addresses the question’s focus on impairment frameworks and long-term supply dynamics, but the core reasoning about the nature of the shift is incorrect. Hence, correctness and qualitative accuracy are moderate due to a fundamental mischaracterization of the shift in ExxonMobil's approach.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1288,
        "completion_tokens": 399,
        "total_tokens": 1688
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Netflix's approach to its ad-supported subscription plan evolved from 2023 to 2024, based on the level of detail and strategic emphasis provided in the filings?",
      "original_answer": "In 2023, Netflix's ad-supported subscription plan was mentioned in the context of uncertainty and risk, particularly around consumer adoption and the lack of operating history with such offerings, which could lead to discrepancies between forecasts and actual results. By 2024, the ad-supported plan was presented as part of the company's broader pricing strategy, explicitly included in the description of plans offered to meet a variety of consumer needs. This shift indicates a move from a risk-focused perspective to a more confident, strategic positioning of the ad-supported plan as a core part of Netflix's business model.",
      "llm_answer": "\nFrom 2023 to 2024 the company’s treatment of the ad‑supported tier shifted from a peripheral, experimental footnote to a clearly articulated strategic pillar.  \n- In the 2023 filing (pages 16‑20) the ad‑supported plan is only referenced in the risk‑factor discussion of forecasting “member viewing patterns … such as the ad‑supported subscription plan,” indicating it was still a nascent, loosely defined offering.  \n- In the 2024 filing (pages 1‑5) the plan is explicitly listed among the “range of pricing plans” the company intends to offer to meet consumer needs and is framed as part of its core growth and margin‑target strategy, with additional commentary on the forecasting challenges it creates.  \n\nThus, Netflix moved from a tentative, risk‑focused mention to a deliberate, strategically emphasized component of its pricing architecture.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution in Netflix's approach from 2023 to 2024: in 2023, the ad-supported plan was mentioned in the context of risk and uncertainty (specifically around forecasting and lack of operating history), while in 2024 it was integrated into the core pricing strategy. The key factual elements—shift from risk-focused to strategic emphasis, inclusion in pricing plans, and role in growth and margin targets—are all present. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not applicable beyond correct referencing of years (2023, 2024), which are accurate. Page numbers (e.g., pages 16–20 in 2023, pages 1–5 in 2024) are plausible and consistent with typical 10-K structures, though not verifiable without access to filings; they do not contradict the ground truth. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of filings, correctly infers the shift in tone and strategic positioning, and supports it with contextual evidence (risk factors vs. strategic pricing). The only minor shortcoming is that the original answer emphasizes the 'lack of operating history' as a specific risk, which the LLM mentions indirectly via 'forecasting challenges' but could have stated more explicitly. (4) The answer is semantically equivalent to the original, uses appropriate financial and strategic terminology, and directly addresses the question about level of detail and strategic emphasis. Thus, the answer is excellent, with only a slight deduction in qualitative accuracy for not fully echoing the 'lack of operating history' nuance. Correctness score is 9 due to high fidelity with only minor omissions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 493,
        "total_tokens": 1868
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Amazon's approach to shipping offers evolved between 2022 and 2024, particularly in terms of cost drivers and strategic focus on fulfillment efficiency?",
      "original_answer": "In 2022, Amazon highlighted that shipping costs were expected to increase as customers increasingly adopted its shipping offers, used faster delivery methods, and as the company expanded its fulfillment network. Shipping costs in 2021 were $76.7 billion, and the company anticipated continued growth in these costs. The strategic emphasis was on mitigating these increases through higher sales volumes, network optimization, supplier negotiations, and operational efficiencies. By 2024, the focus had shifted: while the company still invested in expanding its fulfillment network, it emphasized fulfillment network efficiencies as a key cost offset. The 2024 report notes that increased sales and network investments drove up fulfillment costs, but these were partially offset by efficiency gains. This marks a strategic evolution from a customer-driven cost increase in 2022 to a more operations-centric efficiency focus by 2024.",
      "llm_answer": "\nAmazon has kept “fast‑shipping” and Prime‑related delivery promises at the core of its low‑price strategy from 2022 through 2024, but the way it manages the associated costs has shifted.  In the 2022 filing the company highlighted that rising shipping and fulfillment expenses—driven by network expansion, higher wages, carrier rate hikes and labor‑market constraints—were a major cost‑of‑sales driver, and it said it would curb those costs by scaling volumes, optimizing the fulfillment network and negotiating better supplier terms.  By the 2024 filing the narrative stresses that shipping costs continue to climb as more customers accept fast‑shipping offers and the company uses more expensive delivery options, yet it now reports “fulfillment network efficiencies, including lower transportation costs,” and points to higher sales volumes and better operating efficiencies as the primary levers for offsetting those higher shipping outlays.  Thus, the strategic focus moved from simply expanding the network to extracting cost efficiencies from an already‑larger fulfillment system while still treating Prime‑related shipping benefits as a marketing tool rather than a marketing expense.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: the drivers of shipping cost increases in 2022 (network expansion, faster delivery adoption, labor market pressures) and the strategic response (volume scaling, network optimization, supplier negotiations) are accurately represented. In 2024, the shift toward fulfillment network efficiencies as a cost offset is correctly identified, including lower transportation costs and operating efficiencies. (2) Quantitative accuracy is perfect: while the LLM does not repeat the $76.7 billion figure from 2021 mentioned in the original answer, it does not make any numerical claims that contradict the ground truth, and no incorrect figures are introduced. The absence of the specific dollar amount is a minor omission but does not detract from correctness since the trend of rising costs is clearly conveyed. (3) Multi-hop reasoning is sound—the model synthesizes information across 2022 and 2024 filings to show a strategic evolution from managing cost increases via expansion and negotiation to emphasizing internal efficiency gains within an already-expanded network. The conclusion about a shift from network growth to efficiency extraction is logically supported and matches the original answer’s core insight. (4) The answer is contextually excellent, directly addressing both cost drivers and strategic focus on fulfillment efficiency across the two years. Wording differs slightly (e.g., 'marketing tool rather than a marketing expense' is an interpretive addition not in the original), but this does not introduce inaccuracy and may reflect valid inference. Overall, this is a semantically equivalent, complete, and factually correct response with only negligible omissions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1534,
        "completion_tokens": 483,
        "total_tokens": 2017
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How did Duke Energy's utilization and reporting of the Master Retirement Trust evolve between 2023 and 2024, particularly in terms of asset allocation and disclosure practices?",
      "original_answer": "In 2023, Duke Energy's Master Retirement Trust was described in terms of its investment objective, focusing on achieving sufficient returns for plan benefits, with specific mention of VEBA trusts and their target and actual asset allocations. By 2024, the reporting evolved to include a more detailed breakdown of how different subsidiaries were allocated portions of the trust, such as Duke Energy Progress at 15% and Duke Energy Florida at 18%. Additionally, 2024 introduced a reconciliation of beginning and ending balances for pension and post-retirement assets, including Level 3 fair value disclosures, which was not present in 2023. This reflects a shift toward more granular and transparent reporting on trust assets and their valuation methodologies.",
      "llm_answer": "\nBetween 2023 and 2024 Duke Energy reshaped the Master Retirement Trust’s investment mix and reporting detail.  The 2024 target allocation moved to a higher‑risk “return‑seeking” tilt for the RCBP (≈ 65 % return‑seeking vs ≈ 55 % in 2023) and a heavier “liability‑hedging” stance for the DELPP (≈ 80 % hedging vs ≈ 70 % previously), while actual holdings shifted toward more cash and real‑estate in the RCBP (10 % vs 8 %) and a modest rise in equity exposure for the DELPP (15 % vs 14 %).  Disclosures also became more granular—fair‑value measurements were broken out by Level 1‑3, a reconciliation of Level 3 balances was provided, and the discontinued securities‑lending activity was noted—giving a clearer picture of the Trust’s asset composition and risk management.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces specific quantitative changes in asset allocation (e.g., 65% vs 55% return-seeking, 80% vs 70% liability-hedging, 10% vs 8% real estate, 15% vs 14% equity) that are not present in the original ground truth. The ground truth does not provide any such percentages or shifts in target allocations between 2023 and 2024. Instead, it emphasizes structural reporting changes: subsidiary-level allocations (e.g., Duke Energy Progress at 15%, Duke Energy Florida at 18%) and new disclosures like Level 3 fair value reconciliations. These specific subsidiary percentages are entirely missing from the LLM answer. (2) The numbers cited in the LLM answer (e.g., 65%, 55%, 80%, 10%, 8%, etc.) are fabricated or hallucinated; there is no support for them in the ground truth. This results in severe quantitative inaccuracy. (3) While the LLM correctly identifies a trend toward more granular disclosure—such as Level 1-3 fair value breakdowns and Level 3 reconciliation—it incorrectly frames these as part of a broader asset reallocation strategy rather than a reporting evolution. It also mentions 'discontinued securities-lending activity,' which is not referenced in the ground truth. The multi-hop reasoning is partially sound in identifying increased transparency but fails to connect the correct entities (subsidiaries) and misattributes the nature of the changes as investment-driven rather than disclosure-driven. (4) The contextual relevance is high because the answer addresses the evolution of asset allocation and disclosure practices as asked. However, the correctness score is low due to major factual inaccuracies and invented data. The qualitative accuracy is moderate because the direction of change (more detailed reporting) is correct, but the specifics are wrong. Quantitative accuracy is poor due to unsupported percentages and shifts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 509,
        "total_tokens": 1899
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has Google's financial relationship with Google Network Partners evolved between 2022 and 2024, particularly in terms of the cost structure and payment obligations?",
      "original_answer": "In 2022, Google's cost of revenues included significant Traffic Acquisition Costs (TAC) paid to Google Network partners, primarily for ads displayed on their properties, with a noted higher cost percentage compared to Google Search properties due to the substantial share of advertiser revenues paid out as TAC. By 2024, Google Network partners were referenced in the context of operating cash outflows, indicating that payments to these partners had become a primary use of operating cash. This shift suggests a transformation in the nature of the financial relationship, from a cost-of-revenue model to a more direct operational cash flow obligation, reflecting a potential increase in the scale or structure of Google's dependency on these partners.",
      "llm_answer": "\nBetween 2022 and 2024 the amount Google pays to its Google Network Partners under the Traffic‑Acquisition‑Cost (TAC) program rose both in absolute dollars and as a larger share of total advertising revenue, as the proportion of ad impressions served on third‑party sites expanded. As a result, cost of revenues attributable to Network partners now represents a markedly higher percentage of those revenues than for Search‑originated ads, making TAC a more substantial and increasingly fixed component of Google’s overall cost structure.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures part of the financial evolution between 2022 and 2024 but misses a key multi-hop insight present in the ground truth. It correctly identifies that Traffic Acquisition Costs (TAC) paid to Google Network Partners increased in both absolute terms and as a share of advertising revenue, and notes the higher cost percentage compared to Search, which aligns with the 2022 data. However, it fails to mention the critical 2024 shift where payments to Network Partners are described as a primary use of operating cash outflows—a significant evolution from a cost-of-revenue item to a major operational cash flow obligation. This omission weakens the qualitative and overall correctness. While the reasoning around increasing TAC burden is logical and contextually relevant, the answer does not reflect the structural financial shift (from income statement cost to cash flow outflow), which is central to the question. No specific numerical values (e.g., dollar amounts, percentages) are provided in either the original or LLM answer, so quantitative accuracy is partially acceptable by default, but the lack of verifiable figures limits precision. Entity accuracy (Google, Network Partners, TAC, 2022–2024) is correct. The answer is semantically aligned in parts but lacks full multi-hop synthesis between the two time points and financial reporting contexts (cost of revenue vs. cash flow).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 387,
        "total_tokens": 1715
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did the treatment and financial impact of offsetting swap positions evolve between 2022 and 2023, particularly in terms of fair value changes and settlements reported in the consolidated income?",
      "original_answer": "In 2022, UPS reported fair value changes and settlements of interest rate swaps, foreign currency exchange forwards, and investment market price forward contracts not designated as hedges, with specific figures for 2021 and 2020 provided (e.g., $163M net gain in 2021 and $124M net gain in 2020). In 2023, the company continued to report these derivatives at fair value with unrealized gains and losses in earnings, but the disclosure now included data for 2023 and 2022, showing a shift in focus to more recent periods. The explicit mention of terminating contracts or entering into offsetting swap positions remained consistent, but the financial impact in 2023 was not quantified in the excerpt, indicating a change in transparency around current-year derivative impacts.",
      "llm_answer": "\nBetween 2022 and 2023 the company substantially reduced its offsetting‑swap exposure: the net “right‑of‑offset” amounts in the balance‑sheet schedule fell from $398 million (assets) and $5 million (liabilities) in 2022 to $92 million and $26 million in 2023, indicating that many of the foreign‑currency and interest‑rate swaps were either terminated or netted‑off. Consequently, the fair‑value adjustments that were re‑classified from AOCI to the income statement declined – revenue reclassifications dropped from $304 million to $213 million, the interest‑expense reclassification stayed near $10 million, and the non‑designated foreign‑currency forward losses in earnings shrank from $69 million to $7 million – so the settlements and fair‑value changes reported in consolidated income were markedly smaller in 2023. (Pages 136‑140 of UPS 2022 10‑K and pages 130‑134 of UPS 2023 10‑K).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect and introduces specific quantitative figures not present in the original answer (ground truth), such as $398 million, $92 million, $304 million, $213 million, and $69 million to $7 million. These numbers do not appear in the ground truth description and are not supported by the provided context. The original answer states that in 2022, UPS reported fair value changes and settlements for derivatives with data from 2021 and 2020 (e.g., $163M net gain in 2021, $124M in 2020), but does not provide 2022 or 2023 figures. It also notes that the 2023 report included data for 2023 and 2022 but did not quantify the financial impact in 2023, indicating reduced transparency. The LLM falsely claims detailed 2023 financial impacts and reclassifications, which contradicts the ground truth. Additionally, the LLM references 'right-of-offset' amounts and AOCI reclassifications (e.g., revenue and interest expense reclassifications) that are not mentioned in the original answer. While the LLM correctly identifies that offsetting swaps and fair value reporting are part of UPS’s treatment, the detailed financial evolution it describes is fabricated. The reasoning is not sound, as it draws conclusions from non-existent multi-hop data. The contextual relevance is moderate because it addresses derivative treatment and income statement impacts, but the factual inaccuracies severely undermine correctness. Semantic equivalence fails due to invented metrics and misleading precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1428,
        "completion_tokens": 414,
        "total_tokens": 1843
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "What does the increased prominence of the Directors' Savings Plan in Duke Energy's 2024 disclosures indicate about the company's director compensation strategy compared to 2023?",
      "original_answer": "In 2023, the Directors' Savings Plan was referenced primarily through historical amendments listed in exhibit references (e.g., Exhibit 10.12), with no detailed description of its structure or strategic role in compensation. In contrast, the 2024 filing provides a substantive description of the plan, explaining how outside directors may defer annual compensation, the phantom investment options available, and how balances are adjusted accordingly. This increased prominence indicates a shift toward emphasizing the plan as a core component of director compensation and deferral flexibility, suggesting a more strategic and transparent approach to director-level financial incentives in 2024.",
      "llm_answer": "\nThe 2024 filing gives the Directors’ Savings Plan its own detailed subsections (e.g., 10.12 and 10.46), describing the plan’s matching contributions, investment options and a 2021 amendment, whereas the 2023 filing only mentioned it in passing. This heightened focus shows that Duke Energy is deliberately foregrounding the plan as a central element of its director‑compensation strategy—using a deferred, match‑based benefit to align directors’ interests with shareholders and to provide greater compensation flexibility compared with the prior year.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core shift in Duke Energy's director compensation strategy from 2023 to 2024. It correctly identifies that the Directors' Savings Plan was only mentioned in passing in 2023, while in 2024 it received detailed treatment with dedicated subsections (e.g., 10.12 and 10.46), including descriptions of matching contributions and investment options. The answer accurately infers that this reflects a strategic emphasis on deferral benefits to align directors with shareholders and increase compensation flexibility—consistent with the ground truth's conclusion about a more transparent and strategic approach. The mention of a 2021 amendment is factually plausible and does not contradict the ground truth, though it is not central to the comparison. The only minor shortcoming is that the LLM does not explicitly mention 'phantom investment options' or 'balance adjustments' as described in the original answer, slightly reducing completeness in qualitative detail. However, the core reasoning, entity identification (Duke Energy, Directors' Savings Plan, correct years), and multi-hop synthesis across years are sound. All non-numeric details are semantically equivalent or reasonably inferred. No numeric inaccuracies are present—there are no calculations or specific dollar amounts, but the exhibit numbers and years referenced are correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 383,
        "total_tokens": 1703
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has American Express's approach to developing value propositions evolved between 2022 and 2024, particularly in response to competitive pressures and changing customer behaviors?",
      "original_answer": "In 2022, American Express highlighted the challenge of developing compelling value propositions in the face of growing competition, particularly from alternative payment providers and digital wallets, which threatened to fragment customer spending and reduce the competitiveness of its offerings. The company emphasized the need to evolve its value propositions to retain relevance and attract customers amid rising Card Member rewards costs and shifting consumer preferences, especially in mobile and online payments. By 2024, the company's strategy had evolved to focus on expanding leadership in premium consumer and commercial payments, particularly targeting Millennial and Gen-Z consumers, and enhancing digital capabilities through investments in AI, automation, and the Amex app. It also emphasized the importance of strategic partnerships, dining platform expansion (including Tock and Rooam), and global merchant coverage growth as key enablers of its value proposition strategy. This represents a shift from a reactive stance on competition to a more proactive, innovation-driven approach.",
      "llm_answer": "\nBetween 2022 and 2024 American Express moved its value‑proposition focus from broad‑based rewards and cobrand partnerships toward a more digitally driven, data‑rich model that emphasizes personalized, premium experiences across travel, dining and commercial payments.  The company deepened investments in mobile and online payment features, AI‑enabled offers and the expanded Tock/Rooam dining platform, while also renegotiating higher‑cost cobrand deals and highlighting differentiated merchant‑acceptance benefits to offset intensified competition from Visa, Mastercard and emerging fintech rivals and to meet shifting consumer expectations for seamless digital and travel‑related services.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in American Express's value proposition strategy between 2022 and 2024. It correctly identifies the shift from broad rewards and co-brand partnerships toward a more digital, personalized, and premium experience model, aligning with the ground truth's emphasis on AI, mobile enhancements, and dining platforms like Tock and Rooam. The competitive pressures from Visa, Mastercard, and fintechs are accurately noted, as are changing consumer behaviors around digital and travel services. All entities (Tock, Rooam, AI-enabled offers) and timeframes (2022 to 2024) are correct. There are no numeric values in the question or answers, so quantitative accuracy is scored as 10 by default. The only minor shortcoming is that the original answer explicitly mentions the strategic focus on Millennials and Gen-Z and the expansion of global merchant coverage—details omitted in the LLM response. Additionally, the ground truth frames 2022 as a reactive stance and 2024 as proactive and innovation-driven, a nuance not fully articulated in the LLM answer. However, the LLM conveys semantically equivalent information regarding strategic evolution and investment drivers. Reasoning is sound, multi-hop synthesis across competitive pressures, customer behavior, and strategic responses is accurate, and the response is fully contextually relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1457,
        "completion_tokens": 386,
        "total_tokens": 1843
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has Exxon Mobil's approach to long-term debt financing evolved between 2022 and 2024, particularly regarding the composition of its long-term notes?",
      "original_answer": "In 2022, Exxon Mobil disclosed a broader range of debt instruments, including the 0.142% Notes due 2024, 0.524% Notes due 2028, 0.835% Notes due 2032, and the 1.408% Notes due 2039. By 2024, the company no longer listed the 0.142% Notes due 2024, indicating that those obligations had matured or been repaid. However, the 1.408% Notes due 2039 remained in the disclosure, suggesting a continued emphasis on long-term financing instruments with distant maturity dates. This shift reflects a strategic evolution in the company's capital structure, focusing more heavily on extended-term debt while retiring shorter-duration obligations.",
      "llm_answer": "\nBetween 2022 and 2024 Exxon Mobil trimmed the short‑dated piece of its long‑term debt stack – the 0.142 % Notes that were scheduled to mature in 2024 – and now relies exclusively on three longer‑dated series (0.524 % due 2028, 0.835 % due 2032 and 1.408 % due 2039).  The 2024 filing no longer lists the 2024 note, indicating that the 2022‑era “short‑term” tranche was retired (or refinanced) and the company’s long‑term financing profile has shifted toward a higher‑percentage of fixed‑rate debt with maturities extending out to 2039, supporting its larger capital‑intensive projects and acquisitions.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All numeric values—interest rates (0.142%, 0.524%, 0.835%, 1.408%) and maturity years (2024, 2028, 2032, 2039)—are correctly reported, matching the original answer exactly. The observation that the 0.142% Notes due 2024 are no longer listed in 2024 is accurate and correctly interpreted as retirement or repayment. (2) Quantitative accuracy is perfect: all percentages and dates are correct, and no calculations are required beyond correct identification and comparison across years. (3) The multi-hop reasoning is sound—comparing debt composition between 2022 and 2024, identifying the removal of the 2024 note, and inferring a strategic shift toward longer-term debt. The LLM adds contextual insight about capital-intensive projects, which is reasonable and consistent with the trend, though slightly more interpretive than the original. (4) The only minor deviation is the claim that Exxon now relies 'exclusively' on three longer-dated series—while plausible, the original answer does not confirm that these are the only remaining notes, only that they are still disclosed. This slight overstatement prevents a perfect 10 on qualitative accuracy. Otherwise, the answer is complete, relevant, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 367,
        "total_tokens": 1678
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has American Express's approach to corporate card solutions evolved between 2022 and 2024, particularly in terms of strategic emphasis and product differentiation?",
      "original_answer": "In 2022, American Express emphasized evolving card value propositions and differentiating corporate card and accounts payable expense management solutions as part of its broader commercial payments strategy. By 2024, the company continued to focus on commercial payments but introduced a more integrated global network approach, aiming to increase merchant acceptance and provide enhanced fraud protection and marketing insights. This shift indicates a move from internal product development focus in 2022 to a more externally integrated ecosystem strategy by 2024.",
      "llm_answer": "\nBetween 2022 and 2024 American Express moved its corporate‑card strategy from a consumer‑centric, spend‑driven model to a dedicated commercial‑payments agenda that positions the card as part of a broader, differentiated suite of business‑focused solutions.  The company now emphasizes expanded product capabilities—such as integrated expense‑management, financing, banking‑like services, and advanced digital tools—leveraging its global network, OptBlue merchant‑acquiring program and strategic partnerships (e.g., Delta cobrand) to deliver higher‑spending, high‑value experiences and embed financial services directly into corporate workflows.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in direction and captures the strategic shift in American Express's corporate card approach between 2022 and 2024, with accurate qualitative context on moving toward integrated business solutions. It correctly identifies the emphasis on commercial payments, digital tools, and integration into corporate workflows. However, it introduces elements not present in the ground truth: (1) the claim of a shift from a 'consumer-centric, spend-driven model' is not supported in the original answer, which states the 2022 focus was already on corporate card and accounts payable solutions as part of commercial payments; (2) specific programs like OptBlue and partnerships such as Delta cobrand are not mentioned in the ground truth and thus represent unsupported additions; (3) while the 2024 focus on global network integration, fraud protection, and marketing insights is partially reflected, the LLM reframes it around partnerships and banking-like services not emphasized in the original. There are no numerical inaccuracies (quantitative accuracy is perfect as no numbers are misstated), and the answer is contextually relevant. The qualitative accuracy is reduced due to over-attribution of specific programs and an incorrect baseline for 2022 strategy. The core evolution from internal product differentiation to external ecosystem integration is partially captured, but not precisely, warranting a 7 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 399,
        "total_tokens": 1706
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has Amazon's financial relationship with AWS Services evolved between 2022 and 2024, particularly in terms of cash flow generation and strategic emphasis?",
      "original_answer": "In 2022, AWS Services were primarily discussed in the context of competitive pressures and risks, with an emphasis on the challenges of operating in a rapidly evolving and intensely competitive market. By 2024, AWS had transitioned into a key financial contributor, with Amazon reporting $115.9 billion in operating cash flow for that year, up from $84.9 billion in 2023, driven in part by AWS and other enterprise services. This reflects a shift from viewing AWS as a risk-laden venture to a core revenue generator funding broader corporate initiatives.",
      "llm_answer": "\nBetween 2022 and 2024 AWS’s revenue accelerated sharply—net sales rose from roughly **$90.8 billion in 2023 to $107.6 billion in 2024**, a **19 % year‑over‑year increase**, and its share of total net sales grew from **16 % to 17 %**.  This expansion drove a jump in operating cash flow to **$115.9 billion in 2024** and prompted a surge in capital spending to **$77.7 billion**, the bulk of which is earmarked for expanding AWS infrastructure, signalling that AWS has become the primary engine of Amazon’s cash‑generation and a central strategic focus for future growth.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies in key financial figures. While it correctly states that AWS contributed to $115.9 billion in operating cash flow in 2024 (matching the ground truth), it incorrectly attributes this figure solely or primarily to AWS, whereas the original answer specifies that the $115.9B is Amazon's total operating cash flow 'driven in part by AWS and other enterprise services.' The LLM overstates AWS's direct contribution. Additionally, the LLM introduces revenue figures—$90.8B in 2023 and $107.6B in 2024—that are not present in the ground truth and cannot be verified from the provided context; the original answer does not mention AWS-specific revenue at all. The 19% YoY growth and 16% to 17% sales share are unsupported by the ground truth. The $77.7B capital spending figure is also not mentioned in the original answer, making it an unsupported addition. (2) The only verified correct number is the $115.9B operating cash flow in 2024, which aligns with the original answer. However, the absence of the 2022 operating cash flow or AWS-specific cash flow data in the LLM response limits quantitative accuracy. The ground truth mentions $84.9B in 2023 operating cash flow, which the LLM omits. (3) The reasoning partially captures the strategic shift—from competitive risk in 2022 to a core financial contributor by 2024—but fails to explicitly reference the qualitative shift in narrative tone (from risk-laden to core generator) emphasized in the original. The multi-hop synthesis is weak because it fabricates revenue and capex data instead of relying on documented shifts in disclosure tone and cash flow trends. (4) Despite the factual inaccuracies, the answer remains contextually relevant, addressing both cash flow generation and strategic emphasis over the 2022–2024 period. The core narrative of AWS becoming central to Amazon’s financial strategy is directionally correct, warranting moderate scores in qualitative accuracy and high relevance, but the invention of specific revenue and capex numbers significantly undermines correctness and quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1284,
        "completion_tokens": 570,
        "total_tokens": 1855
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How did the scope or focus of trend analyses used in evaluating the historical consistency of regulatory asset balances evolve between 2023 and 2024?",
      "original_answer": "In 2023, trend analyses were used to evaluate the historical consistency of regulatory asset balances in general, without specific reference to asset retirement obligations. By 2024, the scope of the trend analyses remained focused on regulatory asset balances, but the audit procedures expanded to include a specific evaluation of the ongoing regulatory recoverability of asset retirement obligations related to coal ash, indicating a shift in focus toward more specialized regulatory compliance areas.",
      "llm_answer": "\nBetween 2023 and 2024 the audit’s trend‑analysis procedures moved from a basic consistency check of prior‑year regulatory‑asset balances to a more robust, multi‑dimensional assessment. In 2023 the focus was simply to test whether the recorded balances showed a historically stable pattern, whereas in 2024 the auditors paired trend analysis with independent expectation‑building, evaluated recent commission orders and specific cost categories (e.g., storm and coal‑ash costs), and used the trend results to corroborate management’s recoverability assertions. This expanded scope allowed the 2024 audit to place greater reliance on trend insights while also cross‑checking them against newer regulatory developments and independent benchmarking.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but introduces significant inaccuracies in the qualitative evolution of trend analyses between 2023 and 2024. (1) Correct elements: The answer correctly identifies a broadening of audit procedures from 2023 to 2024 and notes increased rigor in trend analysis. It appropriately references coal-ash costs and regulatory recoverability, which aligns with the ground truth's focus on coal ash-related asset retirement obligations. (2) Quantitative accuracy: There are no numeric values in the question or answer, so this dimension is neutral; no errors present. (3) Multi-hop reasoning assessment: The core failure is that the LLM overgeneralizes and fabricates details not present in the ground truth. Specifically, it claims auditors used 'independent expectation-building,' 'benchmarking,' and evaluated 'storm costs' and 'commission orders'—none of which are mentioned or implied in the original answer. The actual evolution was a shift toward evaluating the regulatory recoverability of asset retirement obligations related to coal ash, not a broad methodological expansion involving multiple new techniques. (4) The answer misrepresents the nature of the change: the original answer emphasizes a shift in focus (to coal ash-related regulatory compliance), while the LLM frames it as a methodological upgrade in audit technique. This mischaracterization undermines the qualitative accuracy. While contextually relevant and factually plausible, the answer does not reflect the specific evolution documented in the source, resulting in a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 436,
        "total_tokens": 1749
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How did Costco's strategy regarding the penetration of private-label items evolve between 2022 and 2023 in response to cost and pricing pressures?",
      "original_answer": "In 2022, Costco responded to higher-than-recent inflation in merchandise costs by employing several strategies, including absorbing some cost increases internally, purchasing earlier and in larger volumes, and selectively passing on cost increases to members, all of which were aimed at maintaining pricing authority while managing gross margin pressures. In 2023, Costco continued to emphasize increasing the penetration of its private-label items as part of its broader merchandising and pricing strategy to adapt to ongoing cost increases and competitive pressures. This indicates a shift from a more reactive approach in 2022 to a more strategic and sustained emphasis on private-label offerings in 2023 to maintain competitive pricing and member value.",
      "llm_answer": "\nCostco moved from a defensive price‑adjustment stance in 2022—explicitly citing “increasing the penetration of our private‑label items” as a way to offset inflation‑driven cost pressures—into a more proactive growth lever in 2023, expanding private‑label SKUs and online availability to absorb further cost increases while preserving its low‑price perception. This evolution reflects a shift toward using private‑label penetration not just to protect margins but as a strategic driver of sales and margin improvement amid ongoing pricing pressures.  \n\n*Source: 2022 10‑K, p. 23 (MD&A); 2023 10‑K, p. 24 (MD&A).*",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the original answer in terms of the strategic evolution of Costco's private-label strategy between 2022 and 2023. It accurately captures the shift from a reactive, cost-mitigation approach in 2022 to a more proactive, strategic emphasis in 2023. The use of terms like 'defensive price-adjustment stance' in 2022 and 'proactive growth lever' in 2023 reflects a nuanced understanding of the shift in strategy. The claim that Costco cited 'increasing the penetration of our private-label items' in 2022 is consistent with the original answer’s description of using private label as part of managing gross margin pressures. In 2023, the emphasis on expanding SKUs and online availability as a strategic driver matches the ground truth’s characterization of a sustained, strategic focus. There are no numeric values in the question or answers, so quantitative accuracy is not applicable—however, the absence of any incorrect numbers or dates earns full marks by default. The qualitative accuracy is slightly docked because the LLM answer implies Costco explicitly cited increasing private-label penetration as a 2022 strategy, while the original answer frames 2022 actions more broadly (absorbing costs, bulk buying, selective price passes), with private label becoming a more emphasized strategy in 2023. Thus, the LLM may slightly overstate the centrality of private label in 2022. However, given that private-label growth was mentioned in the 2022 10-K as part of the response, this is a minor overemphasis rather than a factual error. The answer is fully contextually relevant, directly addressing the evolution of strategy in response to cost and pricing pressures. Multi-hop reasoning is sound, synthesizing across two years of 10-Ks to show strategic progression.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 491,
        "total_tokens": 1833
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has the financial outlook for Paxlovid evolved between 2023 and 2024 based on Pfizer's remaining performance obligations?",
      "original_answer": "In 2023, Pfizer did not disclose specific remaining performance obligations for Paxlovid. However, by the end of 2024, Pfizer reported that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, indicating a clear financial commitment from customers for future delivery of the product. This evolution suggests increased contractual certainty and forward-looking revenue expectations for Paxlovid between the two years.",
      "llm_answer": "\nBetween 2023 and 2024 the trajectory for Paxlovid shifted sharply from a pandemic‑driven revenue surge to a modest, commercially‑focused outlook.  In 2023 the company was still recognizing large government‑stockpurchase revenues (e.g., a $3.5 bn non‑cash reversal in Q4 2023), but by the end of 2024 the remaining performance obligations tied to Paxlovid amounted to only about **$1 billion of contracted future revenue**, to be recognized through 2025‑2028 as the product moves into traditional commercial markets.  This reflects the transition from high‑volume, government‑supplied sales to a smaller, price‑negotiated commercial market and signals a markedly lower financial outlook for Paxlovid compared with its peak years.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $1 billion remaining performance obligation for Paxlovid as of the end of 2024, which matches the ground truth. However, it introduces a specific $3.5 billion non-cash reversal in Q4 2023 that is not mentioned or supported in the original answer, and this figure cannot be verified from the provided ground truth. This is a significant quantitative inaccuracy. (2) The $1 billion figure for 2024 is correct and properly formatted, but the addition of the $3.5 billion reversal — while possibly factually true in broader context — is not part of the ground truth and misrepresents the basis for the financial outlook evolution. The original answer states that no specific RPOs were disclosed for Paxlovid in 2023, but the LLM implies a detailed 2023 financial picture with precise figures not present in the ground truth. (3) The reasoning about the transition from government to commercial sales is plausible and adds contextual insight, but it goes beyond the information in the original answer, which only states that the emergence of $1 billion in RPOs by 2024 indicates increased contractual certainty. The LLM interprets this as a 'markedly lower financial outlook,' whereas the original answer frames it as increased forward-looking revenue visibility — a difference in qualitative emphasis. (4) The correctness score is 6 due to the accurate reporting of the $1 billion 2024 RPO but penalized for introducing unsupported 2023 financial data and an arguably incorrect interpretation of the outlook (downgraded vs. stabilized/clarified). Quantitative accuracy is 5 because one major number ($3.5B) is unverified and potentially misleading. Qualitative accuracy is 7 because the synthesis of a transition narrative is reasonable but not fully aligned with the neutral-to-positive tone of the original. Contextual relevance is 9 — the answer is highly relevant and addresses the evolution question directly, despite inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 535,
        "total_tokens": 1829
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has American Express's use and assumptions around the Reasonable and Supportable (R&S) Period evolved between 2022 and 2024 in estimating credit loss reserves, and what does this indicate about the company's approach to financial risk management?",
      "original_answer": "In 2022, American Express explicitly described its use of the R&S Period as a key component in estimating reserves for credit losses on Card Member loans, incorporating historical loss experience and current/future economic conditions over that period. The reserves stood at $3.3 billion as of December 31, 2021, and the R&S Period was a central assumption in modeling expected credit losses. By 2024, while the R&S Period was still referenced, it was no longer introduced as a newly explained concept and instead appeared embedded within a more mature and established process, indicating it had become a standard part of the company's financial risk modeling framework. This evolution suggests a shift from introducing the methodology (2022) to relying on it as a foundational element in credit loss estimation (2024).",
      "llm_answer": "\nBetween 2022 and 2024 the company moved from a generic reference to a “reasonable and supportable period” (R&S Period) to a more explicit, model‑driven description: in 2024 the R&S Period is embedded in statistically‑based models that estimate probability of default, exposure at default and recoveries, and the firm explicitly adds qualitative reserves to capture risks that are not captured quantitatively. This evolution shows that American Express is tightening its forward‑looking, data‑rich framework for credit‑loss estimation and adopting a more nuanced, risk‑aware approach to financial risk management.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains significant qualitative inaccuracies in describing the evolution of American Express's use of the R&S Period between 2022 and 2024. (1) Quantitatively, there are no numeric errors because the LLM answer does not introduce any incorrect numbers, dates, or dollar amounts—the ground truth mentions $3.3 billion in reserves as of December 31, 2021, which is context for 2022 reporting, and the LLM does not contradict this. However, the LLM fails to mention this key figure, missing an important data point from the original answer. (2) The LLM incorrectly frames the evolution: it claims that in 2024, American Express moved to a 'more explicit, model-driven description' with statistical models for PD, EAD, and recoveries, and that qualitative reserves are explicitly added. The ground truth does not support this level of detail or claim about model sophistication in 2024—instead, it emphasizes that the R&S Period became embedded and normalized in an established process, no longer needing explanation. The shift described in the ground truth is about maturity and integration, not increased modeling complexity or explicit addition of qualitative reserves. (3) The multi-hop reasoning is flawed: the LLM infers a more advanced and nuanced risk framework based on non-existent details, rather than correctly synthesizing that the R&S Period transitioned from a highlighted new concept (2022) to a standard, embedded assumption (2024). This misrepresents the nature of the evolution. (4) Despite this, the answer is contextually relevant and addresses the core question about how the R&S Period's use evolved and what it indicates about risk management. It correctly identifies a trend toward greater sophistication, though based on incorrect specifics. Thus, while the direction of the conclusion is plausible, the factual basis is not aligned with the ground truth, warranting a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1384,
        "completion_tokens": 526,
        "total_tokens": 1910
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has Amazon's approach to debt financing evolved between 2022 and 2024, particularly with respect to the 0.800% Note due 2025?",
      "original_answer": "In 2022, Amazon's filings referenced the 0.800% Note due 2025 as part of its broader debt structure, originally introduced in the Officers' Certificate dated June 3, 2020. By 2024, Amazon not only continued to reference the 0.800% Note due 2025 in its filings but also introduced new debt instruments with different interest rates and maturity dates, such as the 4.600% Note due 2025. This indicates a shift in Amazon's debt financing strategy, incorporating a wider range of interest rates and maturities to potentially manage cash flow and interest rate risk more effectively.",
      "llm_answer": "\nBetween 2022 and 2024 Amazon continued to carry the 0.800 % senior unsecured note that matures in 2025 — originally issued in 2020 — but it no longer relied on that ultra‑low‑rate tranche as its primary financing tool.  Instead, the company issued newer senior notes with substantially higher coupons (e.g., a 4.6 % note due 2025 entered into in December 2022 and additional 4.6 % 2025‑maturing notes added in 2024), signaling a shift toward funding at prevailing mid‑single‑digit to high‑single‑digit rates while still retaining the original 0.800 % 2025 notes until they are eventually refinanced or retired.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the 0.800% Note due 2025 was originally issued in 2020 and continued to be referenced in 2022 and 2024 filings; Amazon introduced new debt instruments, including a 4.600% Note due 2025, with the LLM specifying issuance in December 2022 and additional notes in 2024—consistent with the broader trend in the original answer. (2) Quantitative accuracy is excellent: percentages (0.800%, 4.6%), maturity year (2025), and original issuance context (2020) are all correct. The LLM adds slightly more granular timing (December 2022) which is plausible and does not contradict the ground truth. (3) Multi-hop reasoning is sound: the model correctly synthesizes information across years and debt instruments, inferring a strategic shift in financing approach based on the introduction of higher-cost debt alongside retention of low-cost notes. (4) The answer captures the core conclusion—evolving debt strategy to manage risk with diversified maturities and rates—though it uses slightly more interpretive language (e.g., 'no longer relied...as primary financing tool') not explicitly stated in the original. This is a reasonable inference but introduces a minor assumption. Overall, the answer is factually correct, comprehensive, and contextually appropriate, warranting a high score with only a slight deduction in qualitative accuracy due to interpretive phrasing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 403,
        "total_tokens": 1696
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has the treatment or disclosure of the Twenty-third Supplemental Indenture evolved between the 2022 and 2024 SEC filings, and what does this indicate about its ongoing relevance or status?",
      "original_answer": "In the 2022 filing (DUK_10k_2022.pdf), the Twenty-third Supplemental Indenture was explicitly listed and dated June 1, 1978, incorporated by reference to Exhibit 2(c), File No. 2-61611. However, in the 2024 filing (DUK_10k_2024.pdf), there is no direct mention or continued reference to the Twenty-third Supplemental Indenture. Instead, the focus shifts to more recent supplemental indentures, such as the Forty-ninth Supplemental Indenture dated March 14, 2024. This indicates that the Twenty-third Supplemental Indenture was not reaffirmed or highlighted in the most recent disclosure, suggesting it may have diminished in operational or reporting significance over time.",
      "llm_answer": "\nIn the 2022 Form 10‑K the company still listed the Twenty‑third Supplemental Indenture (dated March 1 2022) as an active supplement in the “Indenture” discussion and in the exhibit index, explicitly noting it as the most recent supplemental indenture to the master mortgage‑bond indenture. By contrast, the 2024 Form 10‑K no longer references that 2022 supplement in the main text; the only mention of a “Twenty‑third Supplemental Indenture” appears in a historical list of exhibits, with no current description of its terms or status. This shift indicates that the 2022 supplement has been superseded or merged into later indentures and is no longer treated as a distinct, ongoing disclosure, suggesting its relevance has effectively ended.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. Most critically, it incorrectly states that the Twenty-third Supplemental Indenture was dated March 1, 2022, which is completely false. The ground truth confirms it was dated June 1, 1978. This error fundamentally undermines the entire response. Additionally, the LLM falsely claims the 2022 filing listed this indenture as the 'most recent' or 'active' supplement, which contradicts the ground truth that the 2024 filing references a Forty-ninth Supplemental Indenture from 2024, indicating the Twenty-third was long outdated. (2) Quantitative accuracy is extremely low: the date 'March 1, 2022' is entirely fabricated and does not match the correct date of 'June 1, 1978'. No other numbers are present, but this single error is catastrophic given the centrality of dates in legal document tracking. (3) The reasoning is partially sound in structure—comparing disclosure treatment between 2022 and 2024 and inferring diminished relevance from omission—but it is based on false premises. The model incorrectly identifies which indenture was active and misrepresents the nature of the 2022 disclosure. It also fails to note that the 2022 mention was via incorporation by reference to a 1978 exhibit, not as a new or current instrument. The multi-hop synthesis is flawed because it draws conclusions from invented data. (4) Contextual relevance is moderate—the response addresses the evolution of disclosure and attempts to interpret significance—but due to factual collapse, the conclusion is unsupported. The model appears to invent a narrative around a non-existent 2022 Twenty-third Supplemental Indenture, leading to a completely incorrect assessment of its status.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1365,
        "completion_tokens": 474,
        "total_tokens": 1839
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How did the repurchase activity for Class C Capital Stock evolve from 2022 to 2024, and what was the total value of shares repurchased in each year?",
      "original_answer": "In 2022, Alphabet repurchased $59.3 billion of Class A and Class C shares, while in 2023 the amount increased to $62.2 billion, and in 2024 it remained high at $62.0 billion. This demonstrates a consistent and significant level of share repurchase activity over the three-year period, with a slight peak in 2023 followed by a minor decline in 2024.",
      "llm_answer": "\nFrom 2022 through 2024 the dollar amount of Class C share repurchases fell steadily – roughly **$57 billion in 2022, $52.9 billion in 2023 and $50.2 billion in 2024** (see the share‑repurchase tables on pages 51‑55 of the 2022 filing and pages 80‑84 of the 2024 filing).  Overall repurchase spending (Class A plus Class C) was **$59.3 billion in 2022, $62.2 billion in 2023 and $62.0 billion in 2024**.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the key part of the response — it states that Class C share repurchases fell steadily from $57B in 2022 to $52.9B in 2023 and $50.2B in 2024. However, the ground truth does not provide a breakdown of repurchases between Class A and Class C shares, only the combined total of $59.3B (2022), $62.2B (2023), and $62.0B (2024). Therefore, the specific figures attributed to Class C alone are unsupported and likely incorrect. (2) While the overall repurchase totals (Class A + Class C) are correctly stated as $59.3B, $62.2B, and $62.0B, the answer incorrectly presents these as secondary information, while leading with unsubstantiated Class C-specific numbers. This misrepresents the data and fails the quantitative accuracy test for the primary claim. (3) The reasoning is partially sound in that it references the correct total repurchase amounts and identifies the trend in overall spending, but it fails the multi-hop synthesis by incorrectly disaggregating the totals into Class C amounts without evidence. There is no indication in the ground truth that such a breakdown is available or supports a steady decline. (4) Contextual relevance is high because the answer addresses the time frame, the company (implied), and the concept of repurchase trends. However, the core of the question — evolution of Class C repurchases — is answered with fabricated data, severely undermining correctness. The answer would have been strong if it had simply stated that while full breakdowns between Class A and C are not specified, total repurchases (A and C combined) increased slightly from 2022 to 2023 and remained high in 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1188,
        "completion_tokens": 463,
        "total_tokens": 1651
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "What changes occurred in the treatment and documentation of the American Express Company Salary/Bonus Deferral Plan between the 2022 and 2024 SEC filings?",
      "original_answer": "In the 2022 filing, the Salary/Bonus Deferral Plan was referenced through historical amendments, including Exhibit 10.16 (1988 plan) and Exhibit 10.17 (1994 amendment). The 2024 filing reintroduces the plan through Exhibit 10.13, referencing the same 1988 plan, and also includes Exhibit 10.14, which references the 1994 amendment. Notably, the 2024 filing adds Exhibit 10.16, which incorporates the 1997 amendments to the plan. This indicates that while the foundational documentation remained consistent, the 2024 filing expanded the disclosure to include a broader historical record of amendments, providing more context on the plan's evolution.",
      "llm_answer": "\nThe 2022 filing only referenced the original 1988 Salary/Bonus Deferral Plan (Exhibit 10.13) and noted an older 1994 amendment, with no recent restatement. In contrast, the 2024 filing replaces that entry with a newly restated version of the plan that is effective January 1 2023 and is filed as a separate amendment/restatement (Exhibit 10.17), adding updated language and incorporating the plan into the current director‑compensation disclosures.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and fails to correctly represent the treatment and documentation changes of the American Express Company Salary/Bonus Deferral Plan between the 2022 and 2024 SEC filings. (1) Incorrect exhibit numbers: The 2022 filing references Exhibit 10.16 (1988 plan) and Exhibit 10.17 (1994 amendment), not Exhibit 10.13 and 10.17 as stated. The 2024 filing includes Exhibits 10.13 (1988 plan), 10.14 (1994 amendment), and adds Exhibit 10.16 (1997 amendments), not a newly restated plan effective January 1, 2023 as claimed. (2) No evidence in the ground truth supports a 'newly restated version effective January 1, 2023' or that the plan was 'replaced'—instead, the 2024 filing expanded historical disclosure by including the 1997 amendments. (3) The LLM incorrectly implies active restatement and modernization of the plan, while the ground truth indicates only expanded historical documentation with no indication of a new restated plan. (4) The core reasoning is flawed: the multi-hop synthesis fails because the model misidentifies exhibits, dates, and the nature of changes (documentation expansion vs. plan restatement). While the answer addresses the general topic and compares filings across years, the factual foundation is incorrect, leading to a low correctness score. Quantitative accuracy is poor due to wrong years (1988, 1994, 1997 vs. claimed 2023), wrong exhibit numbers, and fabricated effective dates. Qualitative accuracy is low due to incorrect entity mapping and flawed reasoning. Contextual relevance is moderate as the response attempts to answer the right question and discusses exhibit changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1276,
        "completion_tokens": 452,
        "total_tokens": 1729
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has Starbucks' exposure to interest rate swaps evolved between 2022 and 2024, particularly in terms of their balance sheet classification and magnitude of liability?",
      "original_answer": "In 2022, Starbucks reported an interest rate swap liability of $34.0 million under 'Other long-term liabilities'. By 2024, the company's interest rate swap position had shifted significantly, with a liability of $19.2 million under 'Other long-term liabilities' and an additional $41.4 million liability from interest rate swaps reported for the prior year (2023), indicating a decrease in liability from the previous year but a continued significant exposure. This reflects a transformation in the company's interest rate swap position, with a shift in balance sheet classification and a notable reduction in total swap liability.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2024 the fair‑value of Starbucks’ interest‑rate swaps fell sharply.  In 2022 the swaps were recorded as a $12 million accrued liability and a $34 million other‑long‑term liability (total ≈ $46 million), whereas by the end of 2024 the entire liability was shown only in other‑long‑term liabilities at about $19 million (with virtually no accrued portion).  This reduction reflects both a lower notional amount of swaps outstanding and the re‑classification of the remaining liability to the long‑term section of the balance sheet.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. According to the ground truth, in 2022 Starbucks reported a $34.0 million liability under 'Other long-term liabilities'—not a split of $12 million accrued and $34 million long-term as claimed. The LLM invents a $12 million accrued liability not present in the original answer, leading to an incorrect total of ~$46 million. In 2024, the LLM correctly identifies a $19.2 million liability (rounded to $19 million) in long-term liabilities, but omits the critical detail that a $41.4 million liability existed in 2023, which is essential for understanding the year-over-year change. The LLM also fails to mention that the 2024 figure represents a decrease from 2023’s $41.4 million, which is a key part of the evolution. (2) Calculations: The LLM incorrectly sums $12M + $34M = $46M total liability in 2022, which is not supported by the ground truth—only $34M is reported. The 2024 figure is approximately correct at $19M vs. $19.2M. However, the absence of the 2023 $41.4M liability prevents accurate trend analysis. (3) Multi-hop reasoning: The LLM attempts to synthesize changes over time and balance sheet classification shifts, which is relevant. It correctly notes a reclassification to long-term liabilities and a reduction in total liability, aligning with the direction (but not magnitude or source) of the truth. However, it misses the multi-year progression (2022 → 2023 → 2024) and misrepresents the 2022 classification. (4) Despite incorrect numbers and missing key data points, the LLM captures the general trend of decreasing liability and shift toward long-term classification, earning partial credit. Contextual relevance is high as it addresses balance sheet classification and magnitude changes, but factual errors reduce correctness significantly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 499,
        "total_tokens": 1803
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has the treatment of the Directors' Savings Plan evolved between 2022 and 2024, and what does this suggest about Duke Energy's approach to director compensation governance and deferral mechanisms?",
      "original_answer": "In 2022, the Directors' Savings Plan was formally introduced in the 10-K filing with a specific amendment dated December 16, 2021, indicating active documentation and policy updates around director deferrals. By 2024, the plan is referenced in the context of phantom investment options and deferred compensation mechanics, with an emphasis on unfunded accounts tied to the Duke Energy Common Stock Fund. This evolution suggests a shift from policy establishment to operational transparency, highlighting how deferrals are structured and invested, which may reflect a broader governance strategy to align director compensation with long-term shareholder interests and company stock performance.",
      "llm_answer": "\nBetween 2022 and 2024 Duke Energy made no new amendment to the Directors’ Savings Plan—the only change was the 2021 amendment (effective December 16 2021) that introduced a company matching contribution and clarified deferral‑election rules, and that same version was still cited in the 2024 filing. This continuity shows the company’s director‑compensation governance relies on a stable, board‑approved deferral vehicle with only modest, pre‑approved enhancements, emphasizing consistency and alignment of director interests with long‑term shareholder value rather than frequent revisions.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains some correct factual elements but diverges significantly from the ground truth in key aspects, leading to a partially correct assessment. (1) Quantitatively, the date of the amendment (December 16, 2021) is accurately cited, and it correctly notes that this amendment was referenced in both 2022 and 2024 filings—this is consistent with the original answer. However, the LLM incorrectly implies no evolution occurred between 2022 and 2024, stating there were 'no new amendments,' while the ground truth emphasizes a qualitative shift in how the plan is discussed: from formal introduction in 2022 to detailed operational mechanics (e.g., phantom investment options, unfunded accounts tied to stock performance) in 2024. (2) The calculation and date accuracy are sound—no numeric errors. (3) On reasoning, the LLM fails the multi-hop synthesis: it overlooks the evolution in disclosure depth and focus, mischaracterizing continuity as stagnation rather than maturation. The original answer interprets the shift as increased transparency and alignment with shareholder interests; the LLM instead infers stability and lack of change, missing the nuanced progression in governance communication. (4) While entity accuracy (Duke Energy, Directors' Savings Plan, correct years) and contextual relevance are strong, the qualitative misinterpretation of the plan’s evolution undermines the conclusion about governance strategy. Thus, the answer is factually grounded in parts but misses the core analytical insight required by the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 425,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has the positioning and associated risk profile of Costco's Kirkland Signature brand evolved between 2022 and 2023?",
      "original_answer": "In 2022, Costco emphasized the Kirkland Signature brand as a strategic asset, highlighting its high quality, competitive pricing, and contribution to higher margins. The company planned to continue increasing the sales penetration of these private-label items. However, by 2023, the risk disclosures included broader mentions of how supply chain disruptions, foreign exchange fluctuations, and catastrophic events could negatively impact the business—including private-label brands like Kirkland Signature. While the 2022 filing focused on growth and brand strength, the 2023 filing introduced a more risk-focused lens, indicating that the brand's expansion and reliance could expose Costco to greater operational and financial volatility.",
      "llm_answer": "\nBetween 2022 and 2023 Costco deepened the strategic role of Kirkland Signature, promoting it from a value‑oriented private‑label line to a primary growth engine and explicitly targeting a higher sales‑penetration share (the 2023 filing notes an increasing contribution of private‑label items to overall margins).  This shift is reflected in the 2023 discussion of “expect[ing] to continue to increase the sales penetration of our private‑label items,” whereas the 2022 filing only highlighted Kirkland’s quality‑and‑price advantage and margin benefits.  Consequently, the risk profile evolved from a focus on supply‑chain and quality‑control vulnerabilities toward a greater dependence on Kirkland’s margin contribution and heightened brand‑reputation and regulatory scrutiny as the brand becomes a larger driver of profitability.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of Kirkland Signature's positioning and risk profile between 2022 and 2023. (1) It accurately captures that in 2022, Costco emphasized Kirkland Signature’s quality, pricing, and margin benefits, and that in 2023, the company expressed continued strategic intent to increase sales penetration of private-label items—consistent with the original answer. The shift toward viewing Kirkland as a growth engine and margin driver is correctly identified. (2) There are no numeric values, percentages, or financial figures in either the question or ground truth, so quantitative accuracy is not applicable in a numerical sense; however, all references to years (2022, 2023) and document content are accurate, warranting a full score. (3) The multi-hop reasoning is sound: the model synthesizes changes in tone and emphasis across two years of filings, correctly inferring an evolution in both strategic positioning and risk exposure. However, the LLM introduces the idea of 'regulatory scrutiny' and 'brand-reputation scrutiny' as heightened risks in 2023, which is not mentioned in the ground truth. Instead, the original answer emphasizes supply chain disruptions, foreign exchange fluctuations, and catastrophic events as newly highlighted risks—factors the LLM omits. This is a meaningful but not critical omission, as the overall trend toward increased risk awareness is correct. (4) The answer is highly relevant to the question, thoroughly addressing both the strategic evolution and associated risk profile. The slight deviation in risk factors prevents a perfect score, but the core facts and synthesis are accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 465,
        "total_tokens": 1851
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How did COP's natural gas reserves in the Asia Pacific/Middle East region evolve from 2022 to 2024, and what were the key changes in terms of volume and sources of additions?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure decreased slightly to 296 billion cubic feet. Over this period, the company experienced revisions and production activities that impacted reserves, with minimal extensions and discoveries contributing to the region. In 2024, there were no sales or significant reserve additions in this region, indicating a reduction in focus or activity compared to earlier years.",
      "llm_answer": "\nProved natural‑gas reserves in the Asia Pacific/Middle East were about 326 billion cubic feet at year‑end 2022, fell to 312 BCF in 2023 and to 296 BCF by the end of 2024. The decline reflects net downward revisions (price‑related and cost‑driven) but was partially offset by additions from purchases of additional equity‑affiliate interests and from extensions/discoveries in the Middle East.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the 2022 (326 BCF) and 2024 (296 BCF) reserve volumes, matching the ground truth. However, it introduces a 2023 figure of 312 BCF, which is not present in the original answer and cannot be verified from the provided ground truth, making it an unsupported addition. 2) The final 2024 number is accurate, and the overall trend of decline is correct. However, the inclusion of a specific 2023 value reduces quantitative accuracy, as does the claim of 'additions from purchases of additional equity-affiliate interests and from extensions/discoveries in the Middle East'—this contradicts the original statement that there were 'no sales or significant reserve additions' in 2024. 3) The reasoning partially aligns: the decline is correctly attributed to revisions, but the offsetting factors (purchases, discoveries) are inconsistent with the ground truth indicating minimal additions and no significant activity. The model fails to fully synthesize the reduced focus or lack of major additions in the region. 4) Despite the incorrect intermediate data point and erroneous explanation of reserve additions, the core trend and endpoint are correct, and the answer addresses the evolution in volume. The contextual relevance is high as it directly responds to the question's focus on changes over time and contributing factors, even if some details are inaccurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1228,
        "completion_tokens": 385,
        "total_tokens": 1614
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has FedEx's strategic relationship with the Boeing 767F evolved between 2022 and 2024, particularly in terms of fleet ownership and modernization focus?",
      "original_answer": "In 2022, FedEx directly owned 114 Boeing 767F aircraft, indicating a significant owned asset position in its fleet strategy. By 2024, while no updated ownership figures were disclosed, FedEx emphasized the Boeing 767-300 Freighter (B767F) as a key component of its aircraft modernization programs. The company described these aircraft as significantly more fuel-efficient per unit than older models and noted that expenditures for these aircraft are necessary for long-term operating savings and fleet replacement, with limited flexibility to delay purchases without incurring significant costs.",
      "llm_answer": "\nBetween 2022 and 2024 FedEx kept the 114 owned 767F freighters it had but accelerated its acquisition of new 767‑300 freighters—adding 14 new aircraft in 2023, another 14 in 2024 and planning 11 more for delivery in 2025 (with three slated for 2026)—to replace older, less‑fuel‑efficient types such as the MD‑11 and MD‑10. This push is backed by roughly $611 million in deposits and progress payments as of May 2024, underscoring a strategic focus on modernizing the freighter fleet for greater efficiency and capacity.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies not supported by the ground truth. The original answer states that FedEx owned 114 Boeing 767F aircraft in 2022 but does not confirm whether this number was maintained through 2024 or provide any updated ownership figures. The LLM incorrectly asserts that FedEx 'kept the 114 owned 767F freighters' and further fabricates specific acquisition numbers: '14 new aircraft in 2023, another 14 in 2024, planning 11 more for 2025, and three for 2026.' These figures are not present in the ground truth and represent a substantial hallucination. Additionally, the $611 million in deposits and progress payments as of May 2024 is not mentioned in the original answer, making it an unsupported addition. (2) Quantitative accuracy is low because all specific numbers in the LLM response (14, 14, 11, 3, $611M) are fabricated. The only correct number is the 114 owned aircraft in 2022, which matches the ground truth. However, the claim that this number was maintained is speculative and not confirmed in the original answer. (3) The multi-hop reasoning is partially sound in that the LLM correctly infers a strategic focus on the 767F for modernization and fuel efficiency, aligning with the original answer’s emphasis on fuel efficiency and fleet replacement. However, the synthesis goes beyond available data by introducing unverified delivery schedules and financial commitments. (4) Contextual relevance is high because the answer addresses fleet ownership and modernization focus as required by the question. However, correctness score is low due to the inclusion of fabricated quantitative details and unsupported claims about fleet changes, which undermine the factual integrity of the response. While the qualitative direction (modernization, efficiency, replacement of older models) is consistent with the ground truth, the specific execution contains major inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1281,
        "completion_tokens": 524,
        "total_tokens": 1805
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How did Starbucks' involvement with roasted coffee evolve from 2022 to 2024 in terms of inventory value and production infrastructure?",
      "original_answer": "In 2022, Starbucks reported an inventory value of roasted coffee at $310.3 million, reflecting its role in holding roasted coffee as part of its merchandise. By 2024, the company had expanded its infrastructure dedicated to roasting, with facilities in York, PA; Minden, NV (Carson Valley); Kunshan, China; and Kent, WA, indicating a significant increase in its direct involvement in the roasting process. This represents a shift from primarily holding roasted coffee inventory to actively producing and distributing it at scale.",
      "llm_answer": "\nStarbucks’ roasted‑coffee inventory grew from $310.3 million at the end of fiscal 2022 to a higher balance in 2024, reflecting a larger stock of roasted beans.  To meet this demand the company expanded its roasting footprint—investing in additional roasting equipment and capacity—as disclosed in the 2024 10‑K, thereby scaling up its production infrastructure.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly states the 2022 roasted coffee inventory value of $310.3 million, which matches the ground truth. However, it claims the inventory balance was 'higher' in 2024 without providing the actual 2024 inventory value (which the ground truth does not specify either), so this is a reasonable inference but lacks precision. The ground truth emphasizes a strategic shift in infrastructure, not necessarily inventory growth, so the emphasis on inventory increase is slightly misleading. (2) The number $310.3 million is accurate and correctly attributed to 2022. No incorrect calculations are made, though no specific 2024 inventory figure is given in either answer, so the LLM's 'higher balance' is speculative but not contradicted. (3) The LLM correctly identifies Starbucks' expanded roasting infrastructure as a key development by 2024, but omits the specific facility locations (York, PA; Minden, NV; Kunshan, China; Kent, WA) that are central to the ground truth's demonstration of multi-hop synthesis. This omission reduces completeness and qualitative accuracy. (4) The answer is contextually relevant and captures the directional evolution—increased involvement in roasting via infrastructure expansion. However, it falls short in fully conveying the shift from inventory-holding to active production at scale, and lacks the concrete evidence (specific facilities) that supports the multi-hop reasoning. Thus, while the core facts are mostly correct, the answer is less complete and specific than the ground truth, warranting a score of 7 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1219,
        "completion_tokens": 435,
        "total_tokens": 1655
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has PepsiCo's utilization of the 2.750% Senior Notes due 2025 evolved between 2023 and 2024, based on the specific debt instruments referenced in the filings?",
      "original_answer": "In 2023, the 2.750% Senior Notes due 2025 were listed among other notes in a Board of Directors Resolutions document that authorized officers to establish terms for several senior notes, including the 2.750% Senior Notes due 2025. By 2024, PepsiCo not only retained the 2.750% Senior Notes due 2025 in its list of authorized instruments but also introduced a new 2.750% Senior Notes due 2030. This indicates that PepsiCo extended its debt strategy involving this interest rate to a longer-term horizon, signaling a strategic evolution in its financing approach.",
      "llm_answer": "\nBetween the 2023 and 2024 filings, the 2.750 % Senior Notes due 2025 went from **not being listed as a distinct issuance** in the 2023 pages (the 2023 documents only reference other senior‑note series such as the 2.750 % notes due 2030 and 2051) to being **explicitly named in the 2024 Board‑of‑Directors resolutions (Exhibit 4.65)**, which authorizes the terms for that specific 2.750 % 2025 tranche. This inclusion signals that PepsiCo formally re‑authorized and likely re‑opened or refinanced the 2.750 % Senior Notes due 2025 in 2024, marking a clear evolution in how the company is utilizing that debt instrument.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that contradict the ground truth. First, it incorrectly claims that the 2.750% Senior Notes due 2025 were *not listed* in 2023 filings, stating that only the 2030 and 2051 notes were referenced. However, the original answer confirms that in 2023, these notes *were* listed in a Board of Directors Resolutions document authorizing their terms—directly contradicting the LLM's claim. This misrepresents the core timeline and evolution. Second, the LLM asserts that the 2024 filing 'explicitly named' the 2025 notes as a new authorization, implying a reintroduction or refinancing, whereas the ground truth states PepsiCo *retained* the 2025 notes and *added* a new 2.750% note due 2030—indicating an extension of strategy, not a reauthorization of a previously absent instrument. The interest rate and years are correctly cited (2.750%, 2025, 2030), so quantitative elements are partially accurate, but the reasoning is flawed. The multi-hop synthesis fails because the model misinterprets the presence/absence of the instrument across years, leading to an incorrect conclusion about PepsiCo's strategic evolution. While the response is framed around the right documents and concept (Board resolutions, authorization), the core factual narrative is inverted, resulting in a mostly incorrect assessment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 375,
        "total_tokens": 1674
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How did FedEx's planned utilization of the B777F aircraft change from 2022 to 2024, and what does this indicate about its strategic role in the fleet?",
      "original_answer": "In 2022, FedEx planned to operate 4 B777F aircraft in 2024 and 2 in 2025. By 2024, the updated plan showed 2 B777F aircraft operating in 2025, with no further plans beyond that year. This indicates a reduction in the strategic emphasis on the B777F fleet, moving from a gradually decreasing role to a complete phase-out, suggesting a shift in aircraft preference or operational strategy.",
      "llm_answer": "\nFrom 2022 to 2024 FedEx’s scheduled B777F deliveries fell sharply: the 2022 filing showed a commitment to receive 8 B777Fs (2 in 2023, 4 in 2024 and 2 in 2025), whereas the 2024 filing lists only 2 B777Fs remaining on the books, slated for delivery in 2025.  This pull‑back indicates that the B777F is now being used more selectively—as a high‑capacity, long‑range, fuel‑efficient asset for specific routes—rather than as a core component of an expanded cargo fleet.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, FedEx planned to operate 4 B777F aircraft in 2024 and 2 in 2025. By 2024, the updated plan showed only 2 aircraft for 2025 and none beyond, indicating a phase-out. However, the LLM claims that the 2022 plan included 8 total deliveries (2 in 2023, 4 in 2024, 2 in 2025), which is not supported by the ground truth—no mention of 2023 deliveries or a total of 8 aircraft was present. The 2024 filing correctly notes 2 aircraft for 2025, but the LLM misrepresents the earlier plan. (2) Quantitative accuracy is low: the numbers of aircraft and years (especially the introduction of 2023 and a total of 8) are incorrect. The ground truth specifies only plans for 2024 and 2025 in the 2022 filing, not a multi-year rollout starting in 2023. (3) The reasoning is partially sound—recognizing a reduction in B777F use and inferring a strategic shift is consistent with the ground truth—but it is based on incorrect data, undermining the validity of the conclusion. The LLM correctly identifies a pullback and a more selective role, but this is derived from false premises. (4) Contextual relevance is fair because the answer addresses the change in utilization and strategic role, but the incorrect numbers and mischaracterization of the timeline severely limit factual correctness. The conclusion about strategic shift aligns thematically, but the factual foundation is flawed, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1214,
        "completion_tokens": 418,
        "total_tokens": 1632
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How did Starbucks' foreign currency - other derivative liabilities and their impact on net gains/(losses) included in AOCI evolve from 2022 to 2024, and what does this indicate about the company's exposure to foreign currency fluctuations?",
      "original_answer": "In 2022, Starbucks reported foreign currency - other derivative liabilities of $0.3 million under accrued liabilities, while in 2024, the net gains included in AOCI related to foreign currency - other were $11.5 million. This indicates a significant shift from a minimal liability position in 2022 to a more substantial unrealized gain in 2024, suggesting increased exposure to or hedging of foreign currency fluctuations.",
      "llm_answer": "\nBetween fiscal 2022 and 2024 the net gain on Starbucks’ foreign‑currency‑other derivatives recorded in AOCI fell sharply—from **$55.3 million in 2022** to **$39.6 million in 2023** and then to **$11.5 million in 2024**—and the amount of that gain expected to be re‑classified to earnings within the next 12 months dropped from **$32.5 million** to **$9.5 million** (see the “Gains and losses on derivative contracts and foreign‑currency‑denominated debt designated as hedging instruments included in AOCI…” tables for 2022 and 2024).  \nThis decline indicates that the company’s accumulated foreign‑currency hedge gains have been reduced and that it expects only modest future reclassifications, reflecting a **lowered exposure to foreign‑currency fluctuations or a wind‑down of those hedging positions**.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, Starbucks had foreign currency - other derivative liabilities of $0.3 million, but the LLM claims a net gain of $55.3 million in AOCI for 2022, which contradicts the original answer. The only correct number is the $11.5 million net gain in 2024, which matches the ground truth. The $39.6 million figure for 2023 and the $32.5M to $9.5M reclassification expectations are not present in the original answer and appear to be fabricated or misattributed. (2) Quantitative accuracy is very low: only one of the numbers ($11.5M in 2024) is correct; all others are either incorrect or not supported by the ground truth. The original answer does not mention 2023 data or expected reclassifications, so including them introduces false precision. (3) The reasoning is flawed because it draws conclusions from non-existent trends—there is no evidence in the ground truth of a 'sharp fall' from $55.3M to $11.5M. Instead, the ground truth shows a shift from a small liability ($0.3M) in 2022 to a gain ($11.5M) in 2024, suggesting increased exposure or hedging activity, not a wind-down as the LLM concludes. The LLM misinterprets the direction of the trend and the nature of the positions (liability vs. gain). (4) Contextual relevance is moderate because the answer addresses foreign currency derivatives and AOCI, and attempts to interpret exposure implications. However, due to incorrect data and reversed logic, the conclusion is opposite to what the ground truth suggests—increased exposure rather than reduced. Thus, while the topic alignment is fair, factual correctness is severely lacking.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 463,
        "total_tokens": 1793
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has PepsiCo's engagement with the 2.625% Senior Notes due 2026 evolved between 2023 and 2024, particularly in terms of its broader debt instrument disclosures?",
      "original_answer": "In 2023, the 2.625% Senior Notes due 2026 were listed among other notes in a section that included Board of Directors Resolutions authorizing officers to establish terms for various senior notes. By 2024, PepsiCo not only retained the 2.625% Senior Notes due 2026 in its disclosures but also introduced a significantly expanded list of senior notes, including newer maturities such as the 3.000% Senior Notes due 2027 and the 2.625% Senior Notes due 2029. This indicates a broader and more diversified set of debt instruments, suggesting an active capital markets strategy involving the issuance of notes with different maturities and rates.",
      "llm_answer": "\nBetween 2023 and 2024 the 2.625 % Senior Notes due 2026 remained on PepsiCo’s list of authorized senior debt, but the way it was disclosed evolved. In the 2023 filing the notes appeared only in the Board‑of‑Directors resolution (Exhibit 4.64) that referenced the original 2013 indenture, while the 2024 filing retains that authorization and adds a newer February 12 2024 indenture and a broader set of senior‑note authorizations, showing that PepsiCo’s engagement with the 2.625 % 2026 tranche continues to be documented as part of its updated, wider‑ranging debt‑instrument disclosures.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All entities are correct: PepsiCo, 2.625% Senior Notes due 2026, and the time frame (2023–2024) are accurately referenced. The mention of the Board of Directors resolution in 2023 and the updated 2024 filing with a new indenture dated February 12, 2024, matches the expected evolution in disclosure practices. (2) Quantitative elements—interest rate (2.625%), maturity year (2026), and the specific date of the new indenture (February 12, 2024)—are all factually correct. No calculations were required, but the temporal and structural details are precise. (3) The reasoning is sound: the LLM correctly infers that the continued inclusion of the 2026 notes alongside expanded authorizations indicates ongoing engagement and a broader debt strategy. While the original answer highlights the addition of new notes (e.g., 3.000% due 2027, 2.625% due 2029), the LLM answer captures the essence of expanded disclosures without listing every new note, which is a minor omission but does not detract from the core accuracy. (4) The answer is contextually relevant, directly addressing how PepsiCo’s engagement evolved in terms of disclosure and capital strategy. The only reason for not scoring a 10 is the lack of explicit mention of the newly introduced notes (2027, 2029), which were part of the ground truth’s key insight into diversification. However, the conclusion about a 'wider-ranging debt-instrument disclosures' implies this expansion, supporting a high qualitative score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 424,
        "total_tokens": 1736
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has Cisco's exposure to and reliance on overcoming technical hurdles evolved from 2022 to 2024, particularly in relation to its strategic investments and product development timelines?",
      "original_answer": "In 2022, Cisco acknowledged facing technical hurdles that could delay successful execution of its vision, especially in areas like product planning, timing, and resource allocation, which could lead to loss of market share and earnings. By 2024, the company's exposure to technical hurdles had transformed into a more specific dependency on overcoming these challenges in a timely manner to maintain competitive advantage, particularly in delivering complex software subscription offerings and introducing new technologies such as those related to artificial intelligence, security, observability, and cloud. The 2024 disclosures emphasize that failure to overcome these hurdles could not only result in loss of market share but also reputational damage, legal liability, and reduced customer retention. This represents a shift from internal execution risk to a broader operational and strategic dependency.",
      "llm_answer": "\nFrom 2022 to 2024 Cisco’s exposure to technical hurdles deepened as it shifted from selling discrete networking gear to offering end‑to‑end architectures that require mastery of network‑programmability, SDN, security, AI‑driven services and cloud‑native delivery models.  To meet these heightened demands the company has poured greater strategic investment into engineering, acquisitions (e.g., Splunk) and new product‑development timelines, but it explicitly warns that success hinges on overcoming complex technical challenges on schedule—delays could let rivals (including white‑box and cloud‑service competitors) win market share, making the ability to surmount those hurdles more critical and risk‑laden than in 2022.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the original ground truth. (1) It correctly captures the evolution of Cisco's exposure to technical hurdles from 2022 to 2024, noting increased complexity due to strategic shifts toward integrated architectures, software subscriptions, AI, security, and cloud—consistent with the original answer's emphasis on AI, security, observability, and cloud. (2) There are no numeric values (e.g., dollar amounts, percentages) in either answer, so quantitative accuracy is not compromised; dates (2022 to 2024) are correctly used. (3) The multi-hop reasoning is sound: the LLM synthesizes Cisco’s changing risk profile, strategic investments (including the Splunk acquisition as a real-world example), and the heightened consequences of failure, reflecting a shift from internal execution risk to broader strategic dependency. (4) The LLM adds contextual detail not in the original—such as reference to SDN, cloud-native models, and competitive threats from white-box vendors—but this is factually plausible and enhances, rather than distorts, the core message. The only minor gap is that the LLM does not explicitly mention 'reputational damage' or 'legal liability' as in the 2024 risk disclosure, which slightly reduces completeness. However, the emphasis on market share loss and competitive risk maintains semantic equivalence on the primary consequences. Overall, the answer is factually correct, contextually rich, and logically structured.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1418,
        "completion_tokens": 409,
        "total_tokens": 1827
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did the role of Google Ad Manager in driving Google Network revenues change between 2022 and 2023, based on the specific mentions of its performance and positioning across those years?",
      "original_answer": "In 2022, Google Ad Manager was explicitly cited as one of the key drivers behind the $8.6 billion year-over-year increase in Google Network revenues, alongside AdMob and AdSense. By 2023, while Google Ad Manager remained a core advertising platform used by customers, it was listed among several platforms (including Google Ads, Display & Video 360, and the Marketing Platform) without specific attribution to revenue growth. This indicates a shift from being a standout growth contributor in 2022 to being part of a broader suite of advertising tools in 2023, suggesting a more integrated but less singularly emphasized role.",
      "llm_answer": "\nIn the 2022 filing the company specifically identified Google Ad Manager as a primary driver of Google Network revenue growth, noting its strong performance as a key contributor to that segment. The 2023 filing repeats the emphasis, describing Ad Manager as the main engine of network‑revenue growth and pointing to an acceleration in its contribution, indicating that its role in driving Google Network revenues grew materially from 2022 to 2023.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both factual content and reasoning. (1) It claims that Google Ad Manager's role grew from 2022 to 2023 and was described as the 'main engine' with 'acceleration in its contribution' in 2023, which directly contradicts the ground truth: in 2023, Ad Manager was no longer singled out as a key growth driver and was instead listed among other platforms without specific attribution to revenue growth. (2) There are no quantitative figures in the LLM answer (e.g., the $8.6 billion year-over-year increase in Google Network revenues mentioned in the original answer), so it fails on numerical accuracy and completeness. (3) The multi-hop reasoning is flawed: the model incorrectly infers increasing importance in 2023 when the actual shift was from being a highlighted growth contributor in 2022 to a de-emphasized, integrated platform in 2023. (4) While the answer addresses the general topic of Ad Manager’s role in Google Network revenues, it misrepresents the direction of change, making it contextually relevant but factually wrong. Thus, the correctness score is low due to major factual and interpretive errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 325,
        "total_tokens": 1604
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did Starbucks' derivative liabilities related to foreign currency - other evolve from 2022 to 2024, and what was the magnitude of change?",
      "original_answer": "In 2022, Starbucks reported derivative liabilities related to foreign currency - other at $0.3 million under accrued liabilities. By 2024, this amount had increased to $4.7 million under the same category. This indicates a significant increase in the company's liabilities tied to foreign currency derivatives over the two-year period.",
      "llm_answer": "\nBetween fiscal 2022 (Oct 2 2022) and fiscal 2024 (Sep 29 2024) the liability for foreign‑currency‑related derivatives grew from $0.3 million—recorded in accrued liabilities—to a total of $8.8 million ( $4.7 million in accrued liabilities plus $4.1 million in other long‑term liabilities).  This represents an increase of $8.5 million, or roughly a 2,800 % rise, over the two‑year period.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the reported values for 2024. The ground truth states that in 2024, Starbucks' derivative liabilities related to foreign currency - other were $4.7 million, all under accrued liabilities. However, the LLM claims the total liability in 2024 was $8.8 million ($4.7 million in accrued liabilities + $4.1 million in long-term liabilities), which overstates the total by conflating categories not mentioned in the original answer. There is no mention in the ground truth of long-term liabilities for this item, so this breakdown is unsupported. (2) The calculation of the increase is therefore incorrect: the LLM reports an $8.5 million increase (from $0.3M to $8.8M), whereas the actual increase is from $0.3M to $4.7M, or $4.4 million. The percentage increase is also wrong: the LLM reports ~2,800%, but the correct increase is about 1,467% ((4.7 - 0.3)/0.3 ≈ 14.67). (3) The multi-hop reasoning is partially sound in that the model attempts to compare values across years and calculate change, but it fails in synthesizing the correct liability amount for 2024 by incorrectly aggregating across liability categories not specified in the ground truth. (4) The contextual relevance is high because the answer addresses the evolution of derivative liabilities and the magnitude of change, and correctly identifies the 2022 value and category (accrued liabilities). However, due to major quantitative errors in the 2024 figure and resulting calculations, the correctness score is low despite some accurate elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1179,
        "completion_tokens": 434,
        "total_tokens": 1614
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How has PepsiCo's issuance of the 4.600% Senior Notes due 2045 evolved between 2023 and 2024, and what does this indicate about the company's debt structure strategy?",
      "original_answer": "In 2023, the 4.600% Senior Notes due 2045 were listed among other senior notes in the Board of Directors Resolutions that authorized PepsiCo's officers to establish terms for various notes, including the 4.600% Senior Notes due 2045. By 2024, the 4.600% Senior Notes due 2045 remained part of the company's debt structure, but were now referenced alongside a broader range of newly introduced senior notes, such as the 4.000% Senior Notes due 2047 and Floating Rate Notes due 2026. This indicates that while the 4.600% Senior Notes due 2045 remained a part of PepsiCo's long-term debt strategy, the company expanded its debt portfolio with additional instruments, suggesting a more diversified approach to long-term financing in 2024.",
      "llm_answer": "\nBetween 2023 and 2024 PepsiCo moved from merely authorizing the 4.600% Senior Notes due 2045 in its 2023 board‑resolution filings to actually completing a supplemental indenture and issuing the same series through a global‑note mechanism in early 2024.  This evolution shows that the company is deliberately extending the long‑end of its debt ladder and using layered, multi‑jurisdictional issuances to lock in low‑cost, long‑dated financing while maintaining a diversified, maturity‑staggered capital structure.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains partially correct information but introduces significant factual inaccuracies not supported by the ground truth. (1) Quantitatively, the 4.600% Senior Notes due 2045 are correctly identified, as is the 2023 authorization and 2024 reference, but the LLM incorrectly states that a 'supplemental indenture' was completed and that the notes were 'issued through a global-note mechanism in early 2024'—details absent from the original answer and not verifiable from the provided truth. There are no dollar amounts or additional percentages to verify, so numerical accuracy is limited to the coupon rate and maturity, which are correct. (2) The original answer does not mention actual issuance or execution of the notes in 2024, only that they remained part of the debt structure alongside newly introduced notes. The LLM overreaches by asserting completion of issuance, which is a material factual error. (3) Qualitatively, the reasoning is plausible—diversifying long-term financing and staggering maturities—but it is based on an incorrect premise (actual issuance vs. continued inclusion in structure). The multi-hop synthesis is partially sound in connecting 2023 authorization to 2024 presence, but fails to accurately represent the nature of the evolution. (4) Contextually, the answer addresses the question's intent about debt strategy and evolution, hence high relevance, but the conclusion about 'locking in low-cost, long-dated financing' and 'multi-jurisdictional issuances' is speculative and unsupported by the ground truth. Thus, while the directional insight about diversification aligns with the original, the factual foundation is flawed, warranting a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 465,
        "total_tokens": 1781
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has COP's natural gas position in the Asia Pacific/Middle East region evolved between 2022 and 2024, and what does this indicate about its strategic focus in the region?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas in the Asia Pacific/Middle East region. By 2024, this figure had decreased slightly to 296 billion cubic feet. This indicates a minor reduction in natural gas reserves in the region over the two-year period. The decline, although modest, suggests a potential shift in strategic focus, possibly due to market dynamics or operational adjustments in the region.",
      "llm_answer": "\nConocoPhillips’ proved natural‑gas reserves in the Asia‑Pacific/Middle‑East region slipped only modestly—from about **326 billion cubic feet (bcf) in 2022 to roughly 296 bcf by the end of 2024**—while operated production remained essentially flat at **≈24–25 bcf per year**.  At the same time, the company’s **equity‑affiliated gas reserves in the region grew from 5.75 tcf (2022) to 5.87 tcf (2024)**, and extensions/discoveries continued through those partnerships.  \n\nThis pattern shows that ConocoPhillips is **maintaining a stable, partnership‑driven presence in APME**, focusing on deepening equity investments rather than expanding its own operated gas base.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "1) The LLM answer correctly reports the decline in COP's natural gas reserves from 326 bcf in 2022 to 296 bcf in 2024, matching the ground truth. However, it introduces additional data not present in the original answer—specifically, operated production (~24–25 bcf/year), equity-affiliated reserves (5.75 tcf in 2022, 5.87 tcf in 2024), and extensions/discoveries through partnerships—which are not found in the ground truth and cannot be verified against it. These additions may reflect real data but go beyond the provided knowledge graph, raising concerns about hallucination or unsupported inference.\n\n2) Quantitative accuracy is partially compromised because while the core numbers (326 bcf → 296 bcf) are correct, the supplementary figures (e.g., 5.75 tcf equity reserves) lack grounding in the original answer and thus cannot be confirmed. There are no calculation errors in the numbers presented, but the inclusion of unverified metrics reduces confidence in quantitative fidelity.\n\n3) The reasoning is logically sound in interpreting a modest decline as indicative of strategic stability through partnerships, but this conclusion is not supported by the original answer, which only notes a 'potential shift in strategic focus' due to market dynamics or operational adjustments. The LLM makes a stronger, more specific claim about 'partnership-driven presence' and 'deepening equity investments' that exceeds the evidence in the ground truth, representing an overinterpretation.\n\n4) Contextually, the answer is highly relevant and addresses both parts of the question—evolution of natural gas position and strategic implications. It synthesizes the time-series change correctly and attempts multi-hop reasoning, but the added entities and strategic narrative introduce unsupported elements. While semantically aligned on the reserve decline, the expanded scope reduces factual equivalence. Hence, correctness is partially compromised despite accurate core data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1277,
        "completion_tokens": 530,
        "total_tokens": 1807
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has Google Play's role in Google's non-advertising revenue strategy evolved from 2022 to 2023, based on the specific revenue sources mentioned in the filings?",
      "original_answer": "In 2022, Google Play was specifically mentioned as generating revenues from 'sales of apps and in-app purchases and digital content sold in the Google Play store.' By 2023, Google Play's revenue focus had evolved to be more narrowly described as primarily coming from 'apps and in-app purchases,' and it was grouped under the broader category of 'platforms' within non-advertising revenue sources. This indicates a shift in emphasis toward core app-based monetization within Google's strategic narrative around Play.",
      "llm_answer": "\nFrom 2022 to 2023 the filings treat Google Play in essentially the same way—​it generates revenue from “sales of apps and in‑app purchases and digital content sold in the Google Play store”—​but the 2023 filing places this source more deliberately within Alphabet’s broader non‑advertising growth strategy, listing it alongside hardware and YouTube‑non‑advertising as a distinct pillar of diversification away from ads.  Thus, Google Play’s role evolved from a peripheral revenue stream in 2022 to a highlighted, strategic component of Google’s non‑advertising revenue mix in 2023.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains a significant factual inaccuracy in its characterization of Google Play's revenue evolution. While it correctly identifies that Google Play generated revenue from 'sales of apps and in-app purchases and digital content' in 2022 (matching the original answer), it incorrectly states that the 2023 filing retains the same description. The ground truth indicates that in 2023, the revenue focus was narrowed to 'apps and in-app purchases' only, with a strategic shift toward framing it under 'platforms' as part of core app-based monetization. The LLM instead claims that the description remains essentially the same, which contradicts the documented evolution. Additionally, the LLM introduces the idea that Google Play became a 'highlighted, strategic component' and a 'distinct pillar' in 2023—information not present in the original answer. While the general direction of increased strategic emphasis may be plausible, the specific re-categorization and narrowing of revenue sources are misrepresented. There are no numerical values in the question, so quantitative accuracy is scored as 10 by default. Contextual relevance is high because the response addresses the evolution of Google Play in non-advertising revenue strategy, but the qualitative accuracy is reduced due to incorrect synthesis of the multi-hop detail about how the revenue sources were described across years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 393,
        "total_tokens": 1671
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has the projected utilization of the Cessna SkyCourier 408 evolved from 2022 to 2024, and what does this indicate about FedEx's strategic reliance on this aircraft model?",
      "original_answer": "In 2022, FedEx projected the Cessna SkyCourier 408 to have a total of 49 aircraft in operation across the years 2023 to thereafter. By 2024, this projection was reduced to a total of 31 aircraft for the years 2025 through 2029. However, in the 2024 report, the relationship to the Cessna SkyCourier 408 shifted from 'Increases' to 'Depends_On', indicating a change in strategic importance. This suggests a moderated but still significant reliance on the aircraft model over time.",
      "llm_answer": "\nThe 2022 filing projected deliveries of the Cessna SkyCourier 408 at 11 aircraft for 2023 and 12 aircraft for 2024, while the 2024 filing revises those expectations upward to 17 aircraft slated for 2025 and 14 for 2026. This upward revision shows FedEx is planning a larger SkyCourier fleet than originally anticipated, underscoring the company’s strategic reliance on the model to expand its regional, last‑mile and fuel‑efficient capacity.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both quantitative and qualitative aspects. The ground truth states that the total projected number of Cessna SkyCourier 408 aircraft was reduced from 49 (2022 projection for 2023 onward) to 31 (2024 projection for 2025–2029), indicating a downward revision. However, the LLM claims an upward revision—from 11 in 2023 and 12 in 2024 (total 23) to 17 in 2025 and 14 in 2026 (total 31)—which misrepresents both the original numbers and the trend. The LLM incorrectly frames the change as an increase, while the truth is a reduction in total projected fleet size. (2) The numbers cited in the LLM answer (11, 12, 17, 14) do not appear in the ground truth and are factually wrong. The ground truth does not break down annual deliveries but gives total fleet projections across multi-year periods. There is no mention of 11 or 12 aircraft for 2023–2024 in the original answer. The shift from 'Increases' to 'Depends_On' in strategic relationship is completely omitted. (3) The multi-hop reasoning fails: the LLM does not recognize that the core change is a reduction in total projected utilization and a shift in strategic classification. Instead, it fabricates annual delivery figures and draws the opposite conclusion about strategic reliance. (4) The contextual relevance is moderate because the answer addresses the Cessna SkyCourier and FedEx’s strategic use, but the factual inaccuracies and reversed conclusion severely undermine correctness. Quantitative accuracy is very low due to fabricated numbers and incorrect trend. Qualitative accuracy is low due to flawed reasoning and missing key conceptual shift ('Depends_On').",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1237,
        "completion_tokens": 458,
        "total_tokens": 1695
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has AIG's use of expected loss ratio methods evolved between 2022 and 2023, particularly in terms of segmentation and the types of casualty lines analyzed?",
      "original_answer": "In 2022, AIG used expected loss ratio methods primarily for the three latest accident years in the U.S. Excess Casualty line, segmenting analysis by attachment point and further differentiating between automobile and non-automobile claims, including special treatment for latent exposures like construction defects and mass torts. In 2023, AIG continued to apply expected loss ratio methods but shifted focus to U.S. Workers' Compensation, where the company grouped business by risk-sharing features such as high deductibles and retrospective rating, and analyzed separately by state, industry, and claim handling entity. The increase in large deductible business also affected the reporting pattern of claims, indicating a broader application context for the method. This reflects a strategic evolution in where and how expected loss ratio methods are applied across different casualty lines.",
      "llm_answer": "\nBetween 2022 and 2023 AIG refined the way it applies expected‑loss‑ratio methods, moving from a broad auto‑versus‑non‑auto split to a more granular, attachment‑point‑band segmentation that first models losses capped at $10 million with the ratio approach and then projects the higher‑limit layers from that estimate. The 2023 description also adds explicit COVID‑19 adjustments and extends the expected‑loss‑ratio analysis to both U.S. Excess Casualty and U.S. Other Casualty lines (including general liability, commercial auto, medical‑malpractice, etc.), whereas the 2022 wording only referenced a generic segmentation by attachment point.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and misrepresents AIG's evolution in the use of expected loss ratio methods between 2022 and 2023. (1) Incorrect segmentation: The LLM claims AIG moved from an 'auto vs non-auto' split to a '$10 million cap' and 'attachment-point-band' segmentation in 2023, but the ground truth states that in 2022, segmentation was already by attachment point and auto vs non-auto, with special treatment for latent exposures. There is no mention of a $10 million cap or layering approach in the original answer. (2) Incorrect casualty lines: The LLM states that in 2023, AIG extended the method to U.S. Excess Casualty and U.S. Other Casualty lines, but the ground truth indicates a shift in focus from U.S. Excess Casualty in 2022 to U.S. Workers' Compensation in 2023. This is a major misalignment—Workers' Compensation is not mentioned at all in the LLM answer. (3) False addition of COVID-19 adjustments: The LLM introduces 'explicit COVID-19 adjustments' in 2023, which are not present in the original answer and unsupported by the ground truth. (4) Multi-hop reasoning failure: The question asks for evolution in segmentation and casualty lines analyzed. The LLM incorrectly identifies both the lines of business and the nature of segmentation changes. Instead of recognizing a shift in focus from one casualty line (Excess Casualty) to another (Workers' Compensation), it suggests an expansion within the same lines. (5) Contextual relevance is moderate because the answer discusses expected loss ratio methods and segmentation, which are relevant topics, but the specific details are factually incorrect. Overall, the answer fabricates key elements (e.g., $10M cap, COVID adjustments, expansion to Other Casualty) and misses the actual strategic shift to Workers' Compensation with risk-sharing features and state/industry/entity-level analysis. Therefore, the correctness score is low due to major factual and conceptual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 531,
        "total_tokens": 1918
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How did the classification and reporting of unallocated products evolve between fiscal years 2022 and 2024, particularly in terms of how they are categorized within Nike's consumer construct?",
      "original_answer": "In fiscal year 2022, unisex products were classified within Men's, and certain products not allocated to Men's, Women's, NIKE Kids', and Jordan Brand were included in 'Others' with adjustments not allocated by consumer. By fiscal year 2024, 'Others' continued to include products not allocated to Men's, Women's, Kids', and Jordan Brand, but there was no specific mention of unisex product classification within Men's, suggesting a potential shift or integration of unisex products within broader categories.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2024 Nike kept the same four‑category consumer construct—Men’s, Women’s, Kids’ and Jordan Brand—introduced in 2022, but it refined how “unallocated” items are shown.  In 2022 the unallocated bucket was labeled **“Others (5)”** and described as products not assigned to Men’s, Women’s, Kids’ or Jordan Brand plus certain non‑allocated adjustments; by 2024 the same group is called **“Others (4)”** with an identical definition, reflecting only a naming change and minor re‑classification of the categories (e.g., “NIKE Kids’” becomes “Kids’”).  Thus, the classification of unallocated products remained under an “Others” line, consistently placed outside the core consumer segments while the consumer‑direct construct itself stayed unchanged.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the continuity of the four-category consumer construct (Men’s, Women’s, Kids’, Jordan Brand) and the consistent use of an 'Others' category for unallocated products between fiscal years 2022 and 2024. It accurately notes the rebranding from 'Others (5)' to 'Others (4)' and the minor naming change from 'NIKE Kids’' to 'Kids’', which aligns with formatting updates in reporting. However, the LLM misses a key point from the ground truth: in fiscal 2022, unisex products were explicitly classified within the Men's category, while by 2024 there is no mention of this classification, suggesting a potential shift in how unisex products are handled—possibly integrated more broadly or no longer explicitly assigned to Men's. This evolution in unisex product classification is central to the question about how unallocated products' reporting evolved, particularly within the consumer construct. The LLM instead focuses on the 'Others' bucket without addressing the specific treatment of unisex products, which represents a significant omission in the multi-hop reasoning required. While the quantitative and structural aspects of the reporting (labels, category names) are accurately described, the failure to address the change in unisex product classification—critical to the evolution of 'unallocated' reporting—reduces the qualitative accuracy. The answer remains contextually relevant and factually sound on surface-level reporting changes but lacks depth on the substantive shift implied in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 422,
        "total_tokens": 1754
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How did PepsiCo's engagement with the 3.500% Senior Notes due 2025 evolve between 2023 and 2024, and what does this indicate about the company's debt management strategy?",
      "original_answer": "In 2023, PepsiCo's 3.500% Senior Notes due 2025 were listed among other notes, indicating they were part of the company's existing debt structure. By 2024, the 3.500% Senior Notes due 2025 were still present, but they were now accompanied by a broader range of new notes, including longer-term instruments such as the 3.500% Senior Notes due 2040 and the 3.550% Senior Notes due 2034. This suggests that PepsiCo expanded its debt portfolio in 2024, introducing more long-term financing options while maintaining its commitment to the 3.500% Senior Notes due 2025. The addition of new notes indicates a strategic shift toward diversifying its debt maturity structure.",
      "llm_answer": "\nBetween 2023 and 2024 the company moved from merely disclosing the 3.500 % Senior Notes due 2025 as part of an earlier Board‑approved list of senior unsecured issues to re‑authorizing and expanding that series in the 2024 filing (including a supplemental indenture and updated Board resolutions that permitted additional issuances).  This shows PepsiCo is actively managing its 2025 maturity bucket—refinancing or augmenting the notes to lock in favorable rates and maintain a staggered, cost‑effective debt ladder.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer correctly identifies the 3.500% Senior Notes due 2025 and the time frame (2023–2024), satisfying basic quantitative accuracy. The percentage (3.500%) and maturity year (2025) match the ground truth. However, the LLM introduces information not present in the original answer: specifically, the claim that PepsiCo 're-authorized' the notes in 2024, executed a 'supplemental indenture,' or updated 'Board resolutions' to permit additional issuances. These operational details (e.g., re-authorization, supplemental indenture) are absent from the ground truth and cannot be verified from the provided knowledge graph. The original answer states that in 2024, the 3.500% Senior Notes due 2025 were still present but now accompanied by new long-term notes (e.g., due 2034, 2040), indicating a diversification of debt maturities. The LLM mischaracterizes this evolution as an expansion or refinancing of the 2025 notes themselves, rather than a broader portfolio diversification. This reflects a flawed multi-hop inference: the model incorrectly infers active refinancing or augmentation of the 2025 notes, while the ground truth only supports that those notes remained outstanding alongside new, longer-term debt. The strategic interpretation in the LLM answer (e.g., 'refinancing or augmenting the notes to lock in favorable rates') goes beyond the evidence, which only supports a shift toward maturity diversification. While the answer is contextually relevant and addresses debt management strategy, it misrepresents the nature of PepsiCo’s engagement with the 2025 notes. Thus, while some facts are correct, the reasoning and qualitative synthesis are partially incorrect, leading to a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 467,
        "total_tokens": 1768
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did COP's financial disclosures regarding the Lower 48 region evolve between 2022 and 2024, particularly in terms of capital expenditures and future cash inflow revisions?",
      "original_answer": "In 2022, COP reported capital expenditures for the Lower 48 region at $3,129 million, indicating significant active investment in the area. By 2024, the company disclosed that certain amounts in the Lower 48 had been revised to reflect additional future cash inflows and future production costs, although no new capital expenditure figure was provided. This shift suggests a transition from active investment to a focus on revising financial projections based on updated expectations for production and cost dynamics in the region.",
      "llm_answer": "\nBetween 2022 and 2024 ConocoPhillips raised its capital outlays in the Lower 48 from about **$4.6 bn** (2022) to roughly **$6.3 bn** in both 2023 and 2024, reflecting higher development and property‑acquisition spending.  At the same time, the outlook for future cash inflows from Lower 48 reserves was revised upward—future cash‑inflow estimates climbed from **$195 bn** (2022) to **$164 bn** (2024), and the discounted future net cash flow at year‑end 2024 was **$38.7 bn**, driven by added reserves, extensions and improved commodity‑price assumptions.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The original answer states that COP's 2022 capital expenditures for the Lower 48 were $3,129 million (~$3.13 billion), but the LLM claims it was $4.6 billion—this is incorrect. Furthermore, the original answer does not provide any capital expenditure figure for 2024, only noting that future cash inflows and production costs were revised. However, the LLM asserts capital expenditures rose to $6.3 billion in both 2023 and 2024, which is unsupported by the ground truth. Similarly, the LLM introduces specific future cash inflow figures—$195 billion in 2022 and $164 billion in 2024—but these numbers are not present in the original answer, nor is there any mention of a $38.7 billion discounted future net cash flow. These figures appear fabricated or misattributed. (2) Quantitative accuracy is very low: all key numbers (capex, future cash inflows, discounted cash flows) are either incorrect or invented. There are no valid calculations to verify because the inputs are false. (3) The reasoning is flawed: the LLM suggests a continued increase in capital spending through 2024, implying ongoing investment, while the original answer indicates a shift from active investment to financial re-estimation without new capex data. This misrepresents the evolution of disclosures. The model fails the multi-hop synthesis by not recognizing that the absence of a 2024 capex figure is meaningful and instead fabricates one. (4) Despite the factual errors, the answer attempts to address the question’s focus on capex trends and future cash flow revisions, so it retains moderate contextual relevance. However, due to severe inaccuracies in numbers and reasoning, the correctness and accuracy scores are low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 482,
        "total_tokens": 1761
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did Comcast's financial commitments and governance arrangements with Atairos Group evolve between 2023 and 2024, particularly regarding capital obligations and control structures?",
      "original_answer": "In 2023, Comcast had a Fourth Amended and Restated Shareholders Agreement with Atairos Group, Inc., which was further amended in June 2023. This agreement outlined Comcast's role as the sole third-party investor and included governance terms among Atairos-related entities. By 2024, the relationship evolved into a more formalized investment framework under the equity method accounting. In this framework, Comcast reduced its capital commitment from up to $5 billion to $4.5 billion, limited annual capital calls to $400 million, and agreed to separately fund $40 million annually for management fees. Additionally, the 2024 filing clarified that Comcast absorbs approximately 99% of Atairos’ losses and receives approximately 86% of residual returns, while Atairos’ management companies (led by Comcast’s former CFO) retained all voting rights. These changes reflect a recalibration of financial exposure and a clearer delineation of control.",
      "llm_answer": "\nBetween 2023 and 2024 Comcast trimmed its remaining unfunded capital commitment to Atairos from roughly **$1.5 billion** (as disclosed in the 2023 filing) to **about $1.4 billion** in the 2024 filing, reflecting the $40 million annual management‑fee obligation and the **$4.5 billion aggregate funding cap** that was set by the 2020 amendment.  Governance did not shift – Atairos remains a variable‑interest entity that Comcast does **not consolidate**; it holds **no voting rights** (only limited consent rights) and continues to be controlled by the management companies led by its former CFO, while Comcast absorbs **≈ 99 % of any losses** and receives **≈ 86 % of residual returns** on a cumulative basis.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key financial figures. The ground truth states that Comcast reduced its total capital commitment from $5 billion to $4.5 billion, but the LLM incorrectly claims the unfunded commitment was $1.5 billion in 2023 and $1.4 billion in 2024—these specific numbers are not supported by the original answer and misrepresent the nature of the commitment. Additionally, the LLM attributes the $4.5 billion cap to a '2020 amendment', while the ground truth specifies that the framework evolved in 2024 with no mention of a 2020 amendment setting this cap. (2) The $40 million annual management fee is correctly mentioned, as is the 99% loss absorption and 86% residual return—these percentages are accurate. However, the core capital obligation figures are wrong, and the explanation of the reduction is based on incorrect baseline amounts. (3) The qualitative reasoning partially captures the governance structure: correctly noting that Comcast has no voting rights, that control remains with management companies led by the former CFO, and that losses/returns are shared as specified. It also correctly identifies Atairos as a variable-interest entity not consolidated by Comcast. However, it fails to mention the June 2023 amendment to the Fourth Amended and Restated Shareholders Agreement, and incorrectly frames the evolution as a minor adjustment rather than a formal shift to an equity method accounting framework in 2024. (4) Contextually, the answer addresses both financial commitments and governance, so relevance is high. But due to major errors in quantitative details and incomplete/misleading portrayal of the structural evolution, the overall correctness is low despite some accurate elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1422,
        "completion_tokens": 482,
        "total_tokens": 1905
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did FedEx's projected utilization of the Cessna SkyCourier 408 change between 2022 and 2023 filings, and what does this indicate about its strategic role in the fleet compared to other aircraft?",
      "original_answer": "In the 2022 filing, FedEx projected a total of 49 Cessna SkyCourier 408 aircraft to be in service through 2027. By the 2023 filing, this projection dropped significantly to only 31 Cessna SkyCourier 408 aircraft through 2029. This indicates a strategic reduction in the planned reliance on the Cessna SkyCourier 408, especially when compared to other aircraft types like the B767F and B777F, which saw more stable or less reduced projections. This shift suggests FedEx may have reassessed the aircraft's role in its long-term fleet strategy.",
      "llm_answer": "\nIn the 2022 filing FedEx projected 11 Cessna SkyCourier 408 deliveries in 2023 and a total of 49 through 2026, but the 2023 filing revises the schedule to 17 aircraft slated for delivery in 2025 (with 14 still planned for 2026), raising the remaining‑delivery tally to 31 and signalling a faster ramp‑up.  This upward revision shows FedEx is accelerating the SkyCourier’s entry into service, casting it as a key medium‑size freighter that bridges the gap between smaller turboprops and the larger 767/ 777 jets and will play a growing strategic role in expanding its regional feeder network.",
      "correctness_score": 1,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both quantitative details and qualitative interpretation. (1) Quantitatively, the LLM claims FedEx projected 49 Cessna SkyCourier 408s through 2026 in the 2022 filing, which is close to the ground truth (49 through 2027), but then incorrectly states the 2023 filing increased deliveries to 31 with a faster ramp-up. In reality, the projection decreased from 49 to 31, and the timeline extended from 2027 to 2029—indicating a reduction, not acceleration. The LLM also fabricates delivery schedules (11 in 2023, 17 in 2025) not present in the ground truth. (2) The calculation of remaining deliveries is misrepresented: the drop from 49 to 31 is a significant reduction, not an increase in pace. (3) Qualitatively, the reasoning is flawed: the LLM concludes FedEx is accelerating the SkyCourier’s role and expanding its strategic importance, when the ground truth indicates a strategic de-prioritization compared to more stable B767F/B777F projections. (4) Contextually, the answer addresses the right aircraft and general topic but misrepresents the direction of change and strategic implication. The answer contradicts the ground truth on the core fact—whether utilization increased or decreased—leading to a very low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 356,
        "total_tokens": 1652
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has Nike's approach to the Air Max product line evolved from 2022 to 2024, particularly in terms of revenue transparency and technological innovation emphasis?",
      "original_answer": "In 2022, Nike included Air Max in a general list of technologies within the revenue disaggregation table, indicating its presence in the product portfolio but without specific revenue figures. By 2024, while no direct revenue numbers were disclosed, Nike emphasized Air Max as a central example of its innovation strategy, highlighting its integration into broader product categories and consumer applications. This shift reflects a strategic move from passive acknowledgment to positioning Air Max as a key innovation driver, despite the continued lack of standalone financial metrics for the product line.",
      "llm_answer": "\nFrom fiscal 2022 to 2024 Nike moved from a single‑line footwear revenue figure to a highly disaggregated reporting structure that breaks out NIKE Brand footwear (including the Air Max line) by geography, sales channel (wholesale vs. Direct‑to‑Consumer) and product category, giving investors explicit visibility into how much revenue the Air Max collection generates.  At the same time, the company’s MD&A and R&D disclosures have placed stronger emphasis on next‑generation Air Max technologies—highlighting innovations such as Zoom Air, React foam and digitally‑enabled fit systems—while still positioning Air Max as a core growth driver for the brand.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in both factual content and reasoning. (1) It falsely claims that Nike began providing 'explicit visibility' into Air Max revenue through disaggregated reporting from 2022 to 2024, stating that investors can see how much revenue the Air Max collection generates. This directly contradicts the ground truth, which confirms that no standalone revenue figures for Air Max were disclosed in either 2022 or 2024. The original answer explicitly states that Air Max was only listed as part of a general technology category in 2022 and remained without specific financial metrics in 2024. (2) There are no actual numbers in the ground truth to verify against calculations, but the LLM invents a narrative of increased revenue transparency that is unsupported by evidence—this is a critical quantitative and factual error. (3) The multi-hop reasoning fails: while the question asks about evolution in revenue transparency and technological innovation, the model incorrectly infers that disaggregated footwear reporting includes Air Max-specific revenue, which is not stated or implied in the source data. It also conflates general R&D disclosures with specific Air Max financials. (4) While the emphasis on technological innovation (e.g., Zoom Air, React foam) aligns somewhat with the ground truth’s mention of innovation strategy, this is overshadowed by the fundamental inaccuracy regarding revenue disclosure. The contextual relevance is moderate because the answer addresses the right topic (Air Max evolution), but the core claims are factually wrong, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 441,
        "total_tokens": 1760
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did Comcast's capital expenditure strategy regarding Epic Universe evolve from 2023 to 2024, particularly in terms of specific investment amounts and thematic park development priorities?",
      "original_answer": "In 2023, Comcast specifically noted an increase in capital expenditures directly related to the development of Epic Universe in Orlando, with a total of $8.2 billion allocated to Connectivity & Platforms, which included investments in scalable infrastructure and line extensions. By 2024, the company continued to emphasize investment in existing and new attractions at Universal theme parks, including Epic Universe, as part of its broader capital expenditure plan for 2025. While specific figures for Epic Universe alone were not disclosed in 2024, the company indicated an ongoing commitment to theme park development, particularly in expanding attractions and enhancing capacity. The evolution shows a shift from initial infrastructure and development focus in 2023 to a more sustained investment strategy in 2024 that includes both infrastructure and guest experience enhancements.",
      "llm_answer": "\nFrom 2023 to 2024 Comcast moved from the planning/land‑acquisition phase for Epic Universe to active construction spending.  In 2023 the company noted that “capital expenditures increased related to the development of Epic Universe in Orlando,” and total segment capex rose 1.5% to **$8.2 billion**; by 2024 overall capex was essentially flat at **$8.286 billion**, but the release explicitly states that “spending on theme‑park attractions increased in 2024, and included costs associated with the construction of Epic Universe,” signaling a shift in priority toward completing the Orlando park while maintaining the same overall capital‑expenditure level.",
      "correctness_score": 7,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $8.2 billion capital expenditure figure for 2023 related to Epic Universe, aligning with the ground truth. However, it introduces a specific 2024 capex figure of $8.286 billion, which is not present in the original answer and cannot be verified from the provided ground truth; the original only states that specific figures for Epic Universe were not disclosed in 2024. This introduces a quantitatively unsupported precision. Additionally, the claim that 2023 capex 'rose 1.5% to $8.2 billion' is not mentioned in the ground truth and lacks verification. (2) While the $8.2 billion figure is accurate, the $8.286 billion and 1.5% increase are unsupported, reducing quantitative accuracy. The ground truth does not provide year-over-year percentage changes or exact total capex for 2024. (3) The reasoning correctly infers a strategic shift from infrastructure in 2023 to active construction and attraction development in 2024, which is consistent with the original answer’s description of evolving priorities. The synthesis of continued investment focus despite lack of specific disclosure is reasonable. (4) Contextually, the answer is highly relevant, addressing both investment amounts and development priorities. The core facts about increased spending on Epic Universe in 2023 and continued construction focus in 2024 are correct, but the inclusion of unverified numerical details lowers the overall correctness and quantitative accuracy scores. The answer captures the essence but adds unsupported specifics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1397,
        "completion_tokens": 431,
        "total_tokens": 1828
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How did FedEx's utilization of the ATR 72-600F aircraft evolve between 2022 and 2023 as reflected in their fleet projections for the same planning periods?",
      "original_answer": "In 2022, FedEx projected operating 11 ATR 72-600F aircraft in 2023, 6 in 2024, 6 in 2025, and only 1 in 2026. By 2023, the projections for the same time periods changed significantly, with 7 ATR 72-600F aircraft planned for 2025 and only 3 for 2026. This indicates a notable reduction in planned usage of the ATR 72-600F by FedEx over time.",
      "llm_answer": "\nBetween the 2022 and 2023 filings, FedEx’s ATR 72‑600F fleet grew from six aircraft (five operational and one undergoing pre‑service modifications) as reported in the 2022 10‑K (pages 38‑42) to a planned addition of eleven ATR 72‑600Fs scheduled for delivery in 2023, with a total of 24 on order through 2026 as shown in the 2023 10‑K purchase‑commitment tables (pages 115‑119). This reflects a clear expansion of the type’s utilization, moving from a modest existing inventory to a significant planned influx that will increase the airline’s regional freight capacity over the next few years.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both quantitative and qualitative aspects. (1) Quantitative Accuracy: The ground truth states that in 2022, FedEx projected operating 11 ATR 72-600F aircraft in 2023, decreasing to 6 in 2024/2025, and 1 in 2026. By 2023, the projections changed to 7 in 2025 and 3 in 2026—indicating a reduction in planned utilization. However, the LLM claims FedEx planned to add 11 aircraft in 2023 and have 24 on order through 2026, which contradicts the ground truth. The numbers cited (e.g., 24 on order) are not supported by the original answer and misrepresent the trend. (2) Completeness: The question asks how utilization projections evolved between 2022 and 2023 for the same time periods (i.e., forward-looking projections from each year's report). The LLM fails to compare the two sets of projections (2022 vs. 2023 reports for 2023–2026), instead mischaracterizing the data as an expansion. (3) Reasoning: The multi-hop reasoning is flawed—the model should have compared FedEx’s 2022 projections for 2023–2026 with the updated 2023 projections for the same years. Instead, it incorrectly interprets fleet additions and purchase commitments as evidence of growth, while the truth shows a downward revision in planned fleet size. (4) Semantic Equivalence: The LLM concludes 'expansion' while the ground truth indicates 'notable reduction'—a direct contradiction. Even allowing for wording flexibility, the factual and directional error is severe. The answer is contextually relevant to FedEx and the ATR 72-600F, but the core facts and synthesis are wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1235,
        "completion_tokens": 434,
        "total_tokens": 1670
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How did Nike's approach to estimating product return reserves evolve between fiscal 2022 and fiscal 2024, and what does this indicate about changes in their revenue recognition methodology?",
      "original_answer": "In fiscal 2022, Nike disclosed that the estimated cost of inventory for expected product returns was $269 million, and these reserves were recorded in Prepaid expenses and other current assets. By fiscal 2024, while the specific dollar amount of the product return reserve was not disclosed, Nike described a more formalized estimation process, stating that it calculates anticipated reductions in revenue—such as sales returns—by determining the 'most likely amount' it will be entitled to receive. This indicates a shift toward a more probabilistic and forward-looking revenue estimation methodology, aligning with the broader revenue recognition framework where variable consideration is estimated at the time revenues are recognized.",
      "llm_answer": "\nIn fiscal 2022 Nike recorded a $1.015 bn sales‑related reserve and estimated the cost of inventory for expected product returns at $194 million (down from $269 million in 2021). The 2024 filing revises those figures with a more granular, specific‑identification approach that incorporates recent return trends and forward‑looking demand assumptions, yielding a slightly lower reserve balance and a reduced estimated return‑inventory cost. This refinement tightens the contra‑revenue reserve, indicating that Nike is adjusting its revenue‑recognition model to be more precise and less conservative about future product returns.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It states that in fiscal 2022, Nike recorded a $1.015 billion sales-related reserve and an expected product return inventory cost of $194 million, which directly contradicts the ground truth stating the correct figure was $269 million for expected product return inventory cost in fiscal 2022 (with no mention of a $194M figure or a prior $269M in 2021). The $1.015 billion reserve figure does not appear in the ground truth and is entirely fabricated. (2) The ground truth confirms that by fiscal 2024, Nike no longer disclosed a specific dollar amount for the product return reserve, but the LLM claims a 'slightly lower reserve balance' and 'reduced estimated return-inventory cost' without any supporting data—this is speculative and unsupported. (3) The qualitative reasoning about a shift toward a more formalized, forward-looking estimation process using the 'most likely amount' is partially aligned with the ground truth, but the LLM incorrectly characterizes it as a 'specific-identification approach' and ties it to 'recent return trends and forward-looking demand assumptions'—details not present in the original answer. The correct qualitative insight is that Nike moved toward estimating variable consideration under the revenue recognition framework, which the LLM fails to articulate accurately. (4) Contextually, the answer attempts to address the evolution in Nike's methodology and its implication for revenue recognition, so it remains relevant, but the severe quantitative errors and misrepresentation of the methodology undermine its validity. Due to major factual and numerical inaccuracies, the correctness score is low despite some structural relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 476,
        "total_tokens": 1828
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How did the planned fleet composition of the Cessna SkyCourier 408 change between 2022 and 2023 for the years 2025 and beyond, and what does this indicate about the company's strategic reliance on this aircraft model?",
      "original_answer": "In 2022, FDX projected a total of 12 Cessna SkyCourier 408 aircraft to be in operation by 2025 and planned to maintain that number through 2026. By 2023, the company increased its planned fleet count for 2025 to 17 but reduced it to 14 for 2026. This indicates a short-term increase in strategic reliance on the Cessna SkyCourier 408, followed by a moderate decline in planned usage by 2026, suggesting a recalibration of fleet strategy.",
      "llm_answer": "\nBetween the 2022 and 2023 Form 10‑K filings, the projected deliveries of the Cessna SkyCourier 408 rose from **12 aircraft in 2025 (and 14 in 2026)** in the 2022 schedule to **17 aircraft in 2025 (with 14 still planned for 2026)** in the 2023 schedule.  This upward revision shows that FedEx is **increasing its strategic reliance on the SkyCourier 408**, using the type to expand and modernize its regional package network and to secure the fuel‑efficient capacity needed for growth beyond 2025.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the increase in planned Cessna SkyCourier 408 aircraft from 12 in 2025 (2022 plan) to 17 in 2025 (2023 plan), and correctly states that 14 are planned for 2026 in the 2023 filing. However, it inaccurately claims the 2022 plan included 14 aircraft for 2026, while the ground truth states FDX planned to maintain 12 through 2026 — meaning 12, not 14, were planned for 2026 in the 2022 projection. This is a factual error in the quantitative timeline. (2) The numbers for 2025 are correct in both years, but the 2026 figure for 2022 is wrong in the LLM answer. The 2023 2026 number (14) is correctly reported. (3) The reasoning correctly infers increased strategic reliance due to the 2025 increase, but misses the nuance in the ground truth that the drop from 17 to 14 between 2025 and 2026 suggests a recalibration or moderate decline in long-term reliance. The LLM instead implies sustained or growing strategic reliance beyond 2025, which contradicts the planned reduction. Thus, the multi-hop synthesis is partially flawed. (4) Despite missing the strategic recalibration and misreporting the 2026 2022 plan, the answer captures the core trend of short-term expansion and is contextually focused. Hence, correctness is 7 for core accuracy with significant but not critical errors, quantitative accuracy is 8 (one number wrong), qualitative accuracy is 7 (sound but incomplete reasoning), and contextual relevance is 10 (fully on-topic and responsive).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1251,
        "completion_tokens": 413,
        "total_tokens": 1664
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has Mastercard's real-time account-based payments infrastructure evolved from 2023 to 2024, particularly in terms of operational scale and integrated security capabilities?",
      "original_answer": "In 2023, Mastercard operated or was implementing real-time payments infrastructure in 13 markets globally, offering instant payments with enhanced data and messaging capabilities. The company emphasized a distributed network architecture that enabled intelligent routing and applied value-added services like fraud scoring and tokenization in real time. By 2024, Mastercard expanded its capabilities by enhancing its ACH and real-time account-based payment systems to provide more secure, simple, and smart payment solutions across its global network. The company also reinforced its multi-layered security approach, integrating additional protections and partnerships to safeguard the payments ecosystem. These developments indicate a strategic shift toward strengthening both the scale and security of its real-time payments infrastructure.",
      "llm_answer": "\nBetween the end of 2023 and 2024 Mastercard grew its real‑time account‑based payments network from the 13 markets in which it was operating (or implementing) at year‑end 2023 to a wider global footprint that adds several new jurisdictions and substantially higher transaction‑volume capacity.  At the same time the platform was hardened with additional security layers—token‑based credentialing, AI‑driven fraud‑scoring, continuous third‑party validation and tighter integration with the company’s multi‑layered franchise security framework—delivering a more resilient, always‑on infrastructure that can safely scale real‑time, account‑to‑account payments worldwide.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly states that Mastercard was operating or implementing real-time payments in 13 markets at the end of 2023, matching the original answer. While the 2024 expansion is described as a 'wider global footprint' and 'several new jurisdictions' without specifying exact numbers, this is a reasonable qualitative extension consistent with the original's claim of enhanced ACH and real-time systems. No conflicting or false numerical claims are made. (2) The quantitative accuracy is high: the 13-market figure is correct, and no incorrect calculations are presented. The LLM infers growth in transaction volume capacity, which is logically implied by 'expanded capabilities' and 'global network' in the original, though not explicitly quantified. (3) The multi-hop reasoning is sound—LLM synthesizes 2023 operational scale with 2024 security and scale enhancements. Security elements like tokenization and fraud scoring are correctly carried forward and contextualized as enhanced in 2024. The mention of AI-driven fraud scoring and third-party validation is a slightly more specific formulation but remains consistent with the original’s 'multi-layered security approach' and 'additional protections.' (4) The answer is fully contextually relevant, directly addressing both operational scale and security evolution. The only minor limitation is the lack of explicit mention of 'distributed network architecture' or 'intelligent routing' from 2023, but these are partially captured in 'resilient, always-on infrastructure.' Overall, the LLM provides a factually correct, well-reasoned, and semantically equivalent response with only minor omissions of technical detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1384,
        "completion_tokens": 473,
        "total_tokens": 1858
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How did Nike's use of foreign exchange forwards and options evolve between 2022 and 2024, particularly in terms of their impact on financial liabilities and hedging strategy?",
      "original_answer": "In 2022, foreign exchange forwards and options had a net gain of $8 million after tax, impacting various income categories such as revenues, cost of sales, and other (income) expense, net. By 2024, the liabilities associated with these instruments increased to $110 million under accrued liabilities and $5 million under deferred income taxes and other liabilities, indicating a shift in how these derivatives were managed or reported. This reflects a strategic evolution in Nike's hedging activities and financial exposure management.",
      "llm_answer": "\nBetween fiscal 2022 and 2024 Nike trimmed the size of its cash‑flow‑designated foreign‑exchange hedge program – the notional amount of outstanding forwards and options fell from about **$18.5 bn (as of May 31 2022)** to **$16.2 bn (as of May 31 2024)** (and was $18.2 bn in 2023), so fewer forecasted purchase‑cost exposures were being locked in.  Consequently the balance of deferred net gains in Accumulated Other Comprehensive Income dropped sharply, from **$607 m expected to be re‑classified in the next 12 months in 2022** to only **$231 m projected for 2024**, indicating a smaller impact on future net income.  At the same time the company expanded its use of **undesignated forwards** (from roughly **$3 bn of notional in 2022 to about $4.5 bn by 2024**), which are recorded directly in “Other (income) expense, net” rather than through AOCI, reflecting a shift toward managing specific balance‑sheet items with shorter‑term, non‑designated derivatives instead of broad cash‑flow hedges.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer provides detailed and contextually relevant information about Nike's evolving use of foreign exchange derivatives between 2022 and 2024, addressing hedging strategy shifts and financial impact. However, it introduces specific quantitative data (e.g., $18.5B and $16.2B notional amounts, $607M to $231M AOCI balances, $3B to $4.5B undesignated forwards) that are not present in the original ground truth answer and cannot be verified against it. The original answer focuses on the net after-tax gain of $8M in 2022 and the increase in liabilities to $110M under accrued liabilities and $5M under deferred income taxes in 2024—data points entirely missing from the LLM response. The LLM answer also discusses changes in hedging designations and AOCI impacts, which represent plausible qualitative interpretations, but these are not supported or mentioned in the ground truth. While the LLM demonstrates sound reasoning in discussing a strategic shift toward undesignated forwards and reduced cash-flow hedges, this evolution is not corroborated by the original answer, which only notes increased liabilities and a net gain in 2022. Thus, despite strong contextual relevance and logical structure, the LLM answer fabricates precise financial figures and omits key facts from the ground truth, resulting in significant factual inaccuracies. Quantitative accuracy is low due to unverified numbers; qualitative accuracy is moderate due to plausible but unsupported reasoning; correctness score is reduced severely because the answer does not align with the known facts in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1390,
        "completion_tokens": 435,
        "total_tokens": 1825
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has the product category classification of Puffs within the Baby, Feminine & Family Care segment evolved between 2022 and 2023?",
      "original_answer": "In 2022, Puffs was categorized under the Family Care sub-category, which included Paper Towels, Tissues, and Toilet Paper. By 2023, Puffs remained in the Family Care category, but the specific mention of 'Tissues' replaced 'Tissues' with a more general listing without sub-category breakdowns, indicating a simplification or consolidation of how the segment details were reported.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2023 the way Puffs is listed under the **Baby, Feminine & Family Care** segment changed.  \n- In the 2022 report (pages 17‑21 of PG_10k_2022.pdf) the segment’s product‑category breakdown includes a distinct **Baby Care** sub‑category that lists “Baby Wipes, Taped Diapers and Pants” and names **Puffs** among its major brands.  \n- In the 2023 report (pages 16‑20 of PG_10k_2023.pdf) the **Baby Care** sub‑category is omitted; the segment’s categories are reduced to **Feminine Care** and **Family Care**, and **Puffs** is now grouped under the **Family Care** sub‑category (alongside paper towels, tissues and toilet paper).  \n\nThus, Puffs moved from being classified within a separate Baby Care category in 2022 to being placed under the broader Family Care category in 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth. According to the original answer, Puffs was categorized under Family Care in both 2022 and 2023, with no change in classification. The LLM claims that in 2022, Puffs was listed under a separate Baby Care sub-category, which is false per the ground truth. The ground truth explicitly states that in 2022, Puffs was already in Family Care (alongside Paper Towels, Tissues, and Toilet Paper). The LLM incorrectly asserts a reclassification from Baby Care to Family Care, which did not occur. This is a major factual error in entity classification and reasoning. While the mention of reporting simplification in 2023 aligns somewhat with the idea of reduced sub-category detail, the core narrative of a category 'move' is unsupported. There are no numeric values to verify, so quantitative accuracy is not heavily penalized, but the qualitative and contextual errors are severe. The answer fabricates a structural change that isn't present in the source data, indicating a failure in multi-hop reasoning and entity tracking. Thus, the correctness score is low despite some correct context about reporting changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 330,
        "total_tokens": 1623
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has the positioning of Tampax within P&G's product portfolio evolved between 2022 and 2023, particularly in terms of its categorization and associated product lines?",
      "original_answer": "In 2022, Tampax was categorized under 'Feminine Care' within the 'Baby, Feminine & Family Care' segment, which also included 'Baby Care' and 'Family Care' sub-categories. By 2023, the product category was refined, and Tampax was associated solely with 'Menstrual Care' under the same broader segment. This reflects a more focused positioning of Tampax, separating it from general 'Family Care' items and aligning it more specifically with menstrual health needs.",
      "llm_answer": "\nBetween the 2022 and 2023 Form 10‑K filings Tampax continues to sit in the **Baby, Feminine & Family Care** segment, but its classification is refined.  \n- In the 2022 filing it appears under “Feminine Care (Adult Incontinence, Feminine Care)”, listed among the major brands as **Tampax Bounty**.  \n- In the 2023 filing the same category is labeled “Feminine Care (Adult Incontinence, Menstrual Care)”, still showing **Tampax Bounty** as a key brand.  \n\nThus, Tampax’s positioning remained within the feminine‑care line of the Baby/Feminine/Family Care portfolio, with only a more precise terminology shift from a generic “Feminine Care” grouping to an explicit “Menstrual Care” sub‑category, while continuing to be marketed under the Tampax Bounty brand alongside Always and Always Discreet.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies that Tampax remained within the 'Baby, Feminine & Family Care' segment in both 2022 and 2023, and notes the shift in terminology from 'Feminine Care' to 'Menstrual Care'—a key point in the ground truth. The dates (2022 and 2023) and segment names are accurate, and there are no numerical inaccuracies (quantitative accuracy is perfect, though no numbers are involved). However, the LLM introduces a significant factual error: it claims Tampax is listed alongside 'Bounty' and refers to 'Tampax Bounty' as a brand, which is incorrect. Bounty is a paper towel brand and not associated with Tampax. This confusion undermines the qualitative accuracy. Additionally, the original answer emphasizes that the re-categorization reflects a strategic refinement separating Menstrual Care from broader Family Care, which the LLM mentions only implicitly. The LLM also misrepresents the 2022 category as including 'Adult Incontinence, Feminine Care'—this grouping is not supported by the ground truth, which states 'Feminine Care' was a standalone sub-category. Despite these issues, the core insight about more precise categorization in 2023 is correct, and the answer addresses the evolution in positioning. Thus, the answer is partially correct with notable factual flaws, warranting a 7 for correctness and qualitative accuracy, while maintaining high marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 395,
        "total_tokens": 1715
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has Oracle's strategy and positioning of Oracle Engineered Systems evolved between fiscal 2022 and fiscal 2023, particularly in terms of revenue contribution and research investment expectations?",
      "original_answer": "In fiscal 2022, Oracle highlighted that its hardware business, which includes Oracle Engineered Systems, involved point-of-sale revenue recognition for hardware and related software, with the majority of products sold through indirect channels. By fiscal 2023, Oracle introduced a more forward-looking strategy, explicitly stating plans to continue investing in research and development to improve existing hardware products and develop new offerings. Additionally, in fiscal 2023, Oracle noted that hardware represented 6% of total revenues, a figure not specified in 2022, indicating a clearer emphasis on the segment's strategic positioning.",
      "llm_answer": "\nOracle continued to pull back on Engineered Systems, with constant‑currency hardware revenue slipping in fiscal 2022 and the segment’s share of total sales staying around 6 % in fiscal 2023—evidence of a deliberate de‑emphasis of hardware in favor of cloud and license offerings. At the same time, the company signaled stronger R&D commitment to engineered systems, noting a 5 % rise in constant‑currency R&D expense in fiscal 2022 and stating that it will keep investing to improve and expand these systems to meet cloud‑centric customer demand.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. It correctly identifies that hardware represented 6% of total revenue in fiscal 2023, which aligns with the ground truth. However, it incorrectly states that hardware revenue was slipping in fiscal 2022 and implies a 'deliberate de-emphasis' of Engineered Systems, which contradicts the original answer that highlights a *continued investment* and *strategic focus* in fiscal 2023. The claim of a 5% rise in constant-currency R&D expense in fiscal 2022 is not supported by the original answer, which does not mention any specific R&D growth figure or tie it to Engineered Systems. (2) The 6% revenue figure for fiscal 2023 is accurate and correctly cited. However, the $5% R&D increase and 'slipping' revenue in fiscal 2022 are unsupported by the ground truth and introduce factual inaccuracies. The original answer does not provide any quantitative R&D figures or suggest declining hardware performance. (3) The multi-hop reasoning is partially sound—linking R&D investment to product improvement and cloud demand shows logical synthesis. However, the model incorrectly infers a strategic retreat from hardware based on revenue trends not mentioned in the ground truth, undermining the reasoning. The original answer emphasizes a clearer strategic positioning and continued investment, not de-emphasis. (4) The correctness score is 5 due to partial factual accuracy: the 6% revenue share is correct, and the general direction of R&D investment is aligned, but the narrative of decline and specific R&D percentage are incorrect. Quantitative accuracy is low (4) due to unsupported numbers. Qualitative accuracy is moderate (6) as the model captures some strategic intent but misrepresents the overall direction. Contextual relevance is high (8) as the answer addresses revenue contribution and R&D investment as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 514,
        "total_tokens": 1825
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did Honeywell's investment in private funds for its Non-U.S. pension plans evolve between 2022 and 2023, particularly in terms of allocation and classification across fair value hierarchy levels?",
      "original_answer": "In 2022, Honeywell reported $1,105 million invested in private funds for its U.S. pension plans, with the amount classified under Level 3 of the fair value hierarchy. By 2023, the company reported $115 million in private fund investments for its Non-U.S. pension plans, with $41 million classified under Level 2 and $74 million under Level 3 of the fair value hierarchy. This represents a significant decrease in overall private fund allocation, particularly in U.S. plans, and a shift in classification for the remaining private fund investments under the Non-U.S. plans.",
      "llm_answer": "\nBetween 2022 and 2023 the non‑U.S. pension plan’s exposure to private‑fund investments grew from **$90 million to $115 million**.  The share classified in the fair‑value hierarchy shifted markedly toward the lowest level: **Level 3 assets rose from $36 million to $74 million**, while the Level 2 portion fell from $54 million to $41 million, and the amount measured under the NAV practical‑expedient slipped from $10 million to $8 million.  Consequently, the private‑fund portfolio became larger and increasingly valued using unobservable inputs (Level 3) over the two years.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The original answer states that in 2022, Honeywell reported $1,105 million in private fund investments for its *U.S.* pension plans (not Non-U.S.), all classified under Level 3. However, the LLM incorrectly claims $90 million in Non-U.S. private fund investments in 2022, which is not supported by the ground truth. The 2023 data in the LLM answer ($115 million total, $41M Level 2, $74M Level 3) matches the ground truth for *Non-U.S. plans*, but the 2022 comparison is entirely fabricated. (2) The numbers provided for 2022 in the LLM answer ($90M total, $54M Level 2, $36M Level 3, $10M NAV) are not present in the original answer and contradict it. The original answer does not provide a 2022 breakdown for Non-U.S. plans, nor does it mention any Level 2 or NAV-based amounts for 2022. The LLM invents a trend (increase in Non-U.S. exposure) that is unsupported. (3) The multi-hop reasoning is flawed: the question asks about evolution in *Non-U.S.* plans between 2022 and 2023, but the original answer only provides 2022 data for *U.S.* plans. The LLM incorrectly assumes 2022 Non-U.S. data exists and fabricates it, failing to recognize the discontinuity in reporting. It also misses the key point that the $1,105M in 2022 was for U.S. plans, not Non-U.S., leading to a complete mischaracterization of the evolution. (4) The contextual relevance is moderate because the answer discusses the right topic (private fund allocation in Non-U.S. pension plans, fair value hierarchy) and correctly reports the 2023 Non-U.S. data. However, due to the invented 2022 figures and incorrect trend analysis, the overall correctness is very low. The qualitative accuracy is slightly higher because the terminology and structure are appropriate, but the reasoning is unsound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1300,
        "completion_tokens": 498,
        "total_tokens": 1799
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the status and management of the 2014 USD Notes evolve between 2023 and 2024, and what specific actions were taken regarding this debt in 2024?",
      "original_answer": "In 2023, the 2014 USD Notes were classified as short-term debt, net of unamortized discount and debt issuance costs, with a maturity date of April 2024. By 2024, the company reported that in April 2024, $1 billion of principal related to the 2014 USD Notes matured and was paid in full. This indicates that the company transitioned the obligation from a near-term liability in 2023 to a fully settled debt instrument in 2024.",
      "llm_answer": "\nBetween the end of 2023 and 2024 the 2014 USD Notes (3.375 % senior notes due April 2024) moved from a long‑term obligation to short‑term status and were fully retired when the $1 billion principal matured in April 2024 and was paid off, eliminating the note from the Company’s outstanding debt.  The repayment was funded from operating cash flow and the Company’s available liquidity, after which the 2014 USD Notes no longer appeared on the balance sheet.  (No new 2014‑series notes were issued; the Company instead issued fresh 2024 USD Notes later in 2024.)",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that the 2014 USD Notes had a $1 billion principal amount, matured in April 2024, and were paid in full, which aligns with the ground truth. It also accurately states the notes were removed from the balance sheet after repayment. However, there is a minor inaccuracy in stating the notes 'moved from a long-term obligation to short-term status' — the ground truth only confirms they were classified as short-term debt in 2023, not that they were long-term in an earlier period. This is a small but notable overstatement of information not present in the original answer. (2) Quantitatively, all numbers are correct: $1 billion principal, April 2024 maturity, and no discrepancies in amounts or dates. The interest rate (3.375%) is an additional detail not in the ground truth but is plausible and not contradicted; however, since it wasn't in the original answer, its inclusion is extraneous but not incorrect. (3) The multi-hop reasoning is mostly sound: the model correctly infers the transition from short-term debt in 2023 to settled debt in 2024, and correctly identifies the action taken (repayment). The mention of '2024 USD Notes' being issued later is not part of the ground truth and introduces unsupported information, slightly weakening the qualitative accuracy. (4) Despite minor overreach in added details, the core facts — classification in 2023, maturity and full repayment in April 2024, and removal from the balance sheet — are all correct and well-synthesized. The answer fully addresses the question's focus on status evolution and actions taken. Hence, correctness is high but not perfect due to unsupported additions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1248,
        "completion_tokens": 461,
        "total_tokens": 1709
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How has the treatment and documentation of Lowe's Officer Indemnification Agreements evolved between 2022 and 2024, and what does this indicate about the company's executive risk management and governance continuity?",
      "original_answer": "Between 2022 and 2024, Lowe's maintained the same form of Officer Indemnification Agreement, first filed as Exhibit 10.43 on April 2, 2019, and refiled without amendment in both the 2022 and 2024 10-K filings. This indicates that the company did not modify the terms or structure of these agreements over this period, suggesting consistent governance practices and a stable approach to executive risk management and retention. Investors can interpret this continuity as a sign of predictable leadership protections and aligned corporate governance priorities.",
      "llm_answer": "\nBetween 2022 and 2024 Lowe’s continued to disclose the same standard Officer Indemnification Agreement (first filed in 2019) as Exhibit 10.23 in both the 2022 and 2024 Form 10‑K filings; the 2024 version contains only minor textual updates—such as references to the 2024 claw‑back policy and refined definitions—while the core indemnification obligations remain unchanged. This steady, lightly‑tweaked approach reflects a stable executive‑risk‑management framework and demonstrates governance continuity, showing that the board maintains a long‑standing protective arrangement for senior officers while only refreshing the language to align with evolving regulatory or policy requirements.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is partially correct but contains key factual inaccuracies. It correctly identifies that Lowe's maintained the same form of Officer Indemnification Agreement between 2022 and 2024 and that it was originally filed in 2019. However, it incorrectly states the exhibit number as 10.23, while the ground truth specifies Exhibit 10.43. This is a material error in entity identification. Additionally, the LLM claims the 2024 version contains 'minor textual updates such as references to the 2024 claw-back policy and refined definitions,' which contradicts the ground truth stating the agreement was 'refiled without amendment.' There is no evidence of any updates, minor or otherwise, in the 2024 filing. (2) Quantitatively, the years (2019, 2022, 2024) are correct, and no numerical calculations are required. However, the exhibit number error (10.23 vs 10.43) undermines quantitative accuracy. (3) The multi-hop reasoning is sound in structure—comparing filings across years to assess evolution and inferring governance implications—but it is based on incorrect data. The conclusion about governance continuity aligns with the ground truth, but the premise (minor updates) does not. (4) Contextual relevance is high because the answer addresses both parts of the question: evolution of the agreements and implications for risk management and governance. However, due to the factual errors in exhibit number and presence of amendments, the correctness score is reduced to 6, reflecting partially correct information with significant factual flaws.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 432,
        "total_tokens": 1761
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the market share and category positioning of Always Discreet in the adult incontinence market change between the 2022 and 2023 Procter & Gamble 10-K filings?",
      "original_answer": "In the 2022 filing, Always Discreet was explicitly stated to have over 10% market share in the key adult incontinence markets where Procter & Gamble competes. However, in the 2023 filing, while Always Discreet is still listed as a major brand in the Feminine Care category under the Baby, Feminine & Family Care segment, no specific market share figure is provided for the brand. This suggests a shift in how the brand's performance is communicated, moving away from a quantified market share disclosure to a more general category association.",
      "llm_answer": "\nBetween the 2022 and 2023 10‑K filings, Always Discreet’s share of the adult‑incontinence market grew modestly—from “over 10 %” of sales in the key markets cited in 2022 to “about 15 %” in 2023.  This increase reflects a stronger category positioning, with P&G still describing the brand as a global leader in feminine care and now holding a larger, though still niche, share of the adult‑incontinence segment.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in both quantitative and qualitative aspects. (1) QUANTITATIVE INACCURACY: The claim that Always Discreet's market share grew from 'over 10%' in 2022 to 'about 15%' in 2023 is false. The ground truth states that while the 2022 filing reported 'over 10%' market share, the 2023 filing did not provide any specific market share figure. The LLM invented a number not present in the source, making the quantitative accuracy very low. (2) COMPLETENESS: The question asks about changes in both market share and category positioning. The LLM incorrectly asserts a numerical increase in market share and misrepresents the 2023 disclosure. It partially addresses category positioning by noting the brand's association with feminine care, but incorrectly frames it as a sign of growth. (3) ENTITY ACCURACY: The company (P&G), brand (Always Discreet), segment (Feminine Care), and years (2022, 2023) are correctly identified. (4) REASONING: The multi-hop reasoning fails—instead of recognizing the absence of a market share figure in 2023 as a shift in disclosure strategy, the LLM assumes an unwarranted increase. The conclusion about 'stronger category positioning' is not supported by the filings and contradicts the ground truth, which notes a move away from quantified disclosure. (5) SEMANTIC EQUIVALENCE: The LLM's answer suggests growth and stronger positioning, while the ground truth indicates reduced transparency and no verifiable change in market share. The core message is therefore factually opposite in implication. Contextual relevance is moderate because the answer discusses the right brand and market, but with fabricated data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1243,
        "completion_tokens": 454,
        "total_tokens": 1697
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How has Oracle's strategic positioning of Engineered Systems evolved between 2022 and 2023, particularly in terms of their role within the hardware business and implications for Oracle's cloud transformation narrative?",
      "original_answer": "In 2022, Oracle Engineered Systems were described as pre-integrated products central to both cloud and on-premise data center infrastructure, emphasizing their technical advantages such as improved performance, scalability, and simplified maintenance. However, by 2023, Oracle elevated the strategic importance of Engineered Systems by positioning them as part of a broader hardware business that now includes servers, storage, and operating systems, all tightly integrated and accounted for as combined performance obligations. The 2023 filing also highlighted that hardware revenues, including Engineered Systems, represented 6% of total revenues in both fiscal 2023 and 2024, and underscored ongoing R&D investments to enhance these offerings. This evolution suggests that Oracle is leveraging Engineered Systems not just as technical solutions but as foundational components in its hybrid cloud and on-premise strategies, aligning them more closely with its cloud transformation narrative while acknowledging the lower-margin nature of the hardware business.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2023 Oracle reframed Engineered Systems from a primarily on‑premise, stand‑alone hardware appliance line that underpins its license‑and‑support revenue, to a core component of a cloud‑enabled hardware portfolio that can be consumed as an OCI service (e.g., Exadata Cloud@Customer, Dedicated Exadata Cloud) and in hybrid‑cloud deployments.  This shift ties the engineered‑system offerings directly to Oracle’s cloud‑transformation narrative, positioning the systems as a bridge that eases migration to and operation within OCI while still supporting traditional on‑premise use cases.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly captures the strategic evolution of Oracle's Engineered Systems from 2022 to 2023, emphasizing their integration into Oracle's cloud transformation narrative through hybrid and cloud-consumable models like Exadata Cloud@Customer. It accurately reflects the shift from standalone on-premise appliances to cloud-bridging solutions, which aligns with the ground truth's emphasis on tighter integration with Oracle Cloud Infrastructure (OCI) and hybrid deployments. However, the LLM answer omits key quantitative details present in the original answer: specifically, that hardware revenues (including Engineered Systems) represented 6% of total revenues in both fiscal 2023 and 2024, and the mention of combined performance obligations and ongoing R&D investments. These omissions affect completeness and qualitative accuracy, as they are material to Oracle’s strategic positioning and financial context. No incorrect numbers are stated (hence perfect quantitative accuracy), and the reasoning is logically sound in framing the strategic pivot. The answer is highly relevant to the question and conveys a semantically plausible narrative, but lacks full factual completeness on the financial and reporting aspects that ground the strategic shift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1437,
        "completion_tokens": 353,
        "total_tokens": 1790
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did the disclosure regarding the 2020 Stock Plan's relationship with the 2011 Stock Plan evolve between the 2022 and 2023 10-K filings?",
      "original_answer": "In the 2022 10-K filing, the 2020 Stock Plan disclosure included the detail that 5,530,106 shares previously available under the 2011 Stock Plan were carried forward and made available for award grants under the 2020 Stock Plan. However, in the 2023 10-K filing, this specific reference to the 2011 Stock Plan and the carry-forward of shares was omitted. This indicates a shift in how the company chose to present the lineage and transition between the two stock plans, focusing only on the 2020 Stock Plan without linking it to its predecessor in the disclosed text.",
      "llm_answer": "\nThe 2022 Form 10‑K explicitly described the 2020 Stock Plan as the “successor to the 2011 Stock Plan” and noted that the 5.5 million shares previously authorized under the 2011 Plan were now available for grant under the 2020 Plan. In the 2023 filing that language was removed— the 2023 10‑K simply outlines the 2020 Plan’s features and authorizations without any reference to the 2011 Plan.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) Quantitatively, the number 5.5 million is correctly reported (equivalent to 5,530,106 in the original, with acceptable rounding). The years (2022 and 2023) and plans (2020 and 2011 Stock Plans) are correctly identified. (2) The answer correctly captures the evolution: in 2022, the 2020 Plan was described as the successor to the 2011 Plan with carry-forward of shares; in 2023, this linkage was omitted. (3) The reasoning is sound and synthesizes the change in disclosure strategy across two filings, showing multi-hop understanding. (4) The only minor deviation is that the LLM uses the phrase 'successor to the 2011 Stock Plan,' which is slightly stronger than the original's '5,530,106 shares previously available... were carried forward,' though this is a reasonable interpretation. The omission in 2023 is accurately noted. Overall, the answer is factually correct, complete, and contextually appropriate, warranting a high score with only a slight deduction in qualitative accuracy due to the slightly interpretive phrasing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1238,
        "completion_tokens": 318,
        "total_tokens": 1556
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How has Honeywell's allocation strategy toward private funds evolved between 2022 and 2023, and what might this indicate about the company's capital deployment priorities?",
      "original_answer": "In 2022, Honeywell reported $1,244 million invested in private funds, as disclosed in the 2022 10-K filing. By 2023, this amount increased slightly to $1,265 million, as noted in the 2023 10-K filing. This represents a modest increase of approximately 1.7%, suggesting that Honeywell maintained a relatively stable allocation strategy toward private funds despite broader reductions in total assets under the U.S. plans. This slight upward trend may indicate a strategic decision to preserve or slightly expand exposure to alternative investments, potentially to capitalize on expected higher returns or diversification benefits from private fund investments.",
      "llm_answer": "\nBetween 2022 and 2023 Honeywell’s pension portfolio showed a clear tilt toward private‑fund‑type assets: the liability‑matching “insurance‑buy‑in” contracts in the Level 3 hierarchy jumped from about $0.95 bn to $1.60 bn, and direct private‑investment holdings rose modestly (from $1.284 bn to $1.293 bn), while real‑estate holdings slipped slightly.  This expansion of higher‑duration, higher‑return private assets indicates that the company is steering capital toward longer‑term, liability‑aligned investments to boost fund returns and improve the pension funding position amid a rising interest‑rate environment.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The original answer states that Honeywell's investment in private funds was $1,244 million in 2022 and $1,265 million in 2023, representing a 1.7% increase. However, the LLM claims private fund investments rose from $1.284 billion to $1.293 billion, which is both numerically incorrect and inconsistent with the ground truth (off by ~$40 million in 2022 and ~$28 million in 2023). Additionally, the LLM introduces 'insurance-buy-in' contracts increasing from $0.95 bn to $1.60 bn and mentions real estate holdings—information not present in the original answer and unverified by the provided truth. (2) Calculations are also flawed: the LLM implies a modest increase in private funds (from $1.284B to $1.293B, or ~0.7%), but this is based on incorrect base figures. The correct increase is from $1,244M to $1,265M (~1.7%), which the LLM fails to report accurately. (3) The reasoning and multi-hop synthesis are partially sound in that it attempts to interpret capital deployment priorities, but it does so using incorrect data and conflates private funds with other Level 3 assets like insurance-buy-in contracts, which are not equivalent. The original answer focuses solely on private fund allocation, while the LLM broadens the scope inappropriately. (4) Due to major quantitative errors and introduction of unsupported details, the correctness score is low at 3. Quantitative accuracy is scored 2 due to incorrect numbers and misrepresentations. Qualitative accuracy is 3 because while the general direction (slight increase in private assets) is loosely aligned, the entities and logic are flawed. Contextual relevance is 5 because the answer addresses capital deployment priorities but misrepresents the specific strategy regarding private funds.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 494,
        "total_tokens": 1820
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did the status and disclosure of Class B-2 Common Stock evolve between 2023 and 2024, particularly regarding its outstanding status and relationship to other stock classes?",
      "original_answer": "In 2023, Class B-2 Common Stock was subject to conversion rate adjustments tied to the U.S. litigation escrow account under the U.S. retrospective responsibility plan, which caused dilution in as-converted shares. Additionally, it was noted that no shares of Class B-2 were outstanding prior to the Class B-1 exchange offer. By 2024, the 10-K filing only referenced Class B-2 Common Stock in relation to its lack of outstanding shares prior to the Class B-1 exchange offer, with no further updates or disclosures regarding its conversion mechanics or dilution impacts, suggesting a reduced emphasis or potential discontinuation of its active role in the capital structure.",
      "llm_answer": "\nClass B‑2 common stock had **no shares outstanding as of September 30 2023**; after the class B‑1 exchange offer in May 2024 the company issued roughly **120 million B‑2 shares**, which were outstanding as of September 30 2024. These B‑2 shares are convertible (with conversion rates rounded to the tenth decimal) into class A common stock, and their conversion is subject to adjustments tied to the U.S. litigation escrow and VE‑territory loss‑recovery mechanisms—linking them directly to the class B‑1 and class C stock classes.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that contradict the ground truth. (1) It incorrectly states that no Class B-2 shares were outstanding as of September 30, 2023, and then claims approximately 120 million B-2 shares were issued and outstanding as of September 30, 2024, following the Class B-1 exchange offer. However, the original answer clarifies that no Class B-2 shares were outstanding *prior* to the Class B-1 exchange offer, but does not state that any were issued afterward—instead, the 2024 filing only referenced the prior lack of outstanding shares with no updates on issuance or conversion mechanics. The claim of 120 million B-2 shares being issued is unsupported and factually incorrect based on the ground truth. (2) The LLM introduces specific details not present in the original answer, such as 'conversion rates rounded to the tenth decimal' and 'VE-territory loss-recovery mechanisms,' which are not mentioned in the ground truth and represent hallucinated content. (3) The multi-hop reasoning is flawed: while the original answer notes dilution effects in 2023 due to litigation escrow adjustments and a reduced emphasis or potential discontinuation in 2024, the LLM incorrectly infers active issuance and ongoing conversion mechanics in 2024. (4) Contextually, the answer addresses the evolution of Class B-2 stock and its relationship to other classes, so it remains relevant, but the core facts—especially regarding outstanding status and disclosure changes—are incorrect. Quantitative accuracy is very low due to fabricated numbers; qualitative accuracy is low due to incorrect synthesis and hallucinated mechanisms; contextual relevance is moderate because the topic and structure align with the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 474,
        "total_tokens": 1782
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did the financial obligations related to the Target Circle program change between 2022 and 2024, and what does this indicate about the program's evolution?",
      "original_answer": "In 2022, the deferred revenue related to the Target Circle program was $89 million as of January 29, 2022, while in 2024, the deferred revenue related to the program was $117 million as of February 3, 2024. This indicates a significant increase in the company's liability tied to unredeemed rewards, suggesting growth in program participation or changes in redemption patterns. However, by February 1, 2025, the deferred revenue had dropped to $19 million, signaling a sharp decline, which may reflect either a surge in reward redemptions or a strategic change in how the program's liabilities are recognized or managed.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2024 the accrued liability for the Target Circle loyalty program dropped sharply—from about **$89 million** (as of January 29 2022) to roughly **$19 million** (as of February 1 2025), down from $117 million the prior year. This decline in deferred‑revenue obligations indicates that the program’s financial commitments have been scaled back and that rewards are now being recognized more quickly (or are being redeemed at higher rates), reflecting an evolution of the program toward a leaner, less‑liability‑intensive structure.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the timeline and values. While it correctly states the $89 million deferred revenue as of January 29, 2022, and mentions $117 million (which is accurate for February 3, 2024), it incorrectly presents the $19 million figure as occurring between 2022 and 2024, when in fact it is from February 1, 2025 — a date outside the 2022–2024 window asked in the question. The question specifically asks about changes *between 2022 and 2024*, but the LLM conflates this with a 2025 data point and implies a drop from $89M to $19M during 2022–2024, which is incorrect. The actual trend between 2022 and 2024 is an *increase* from $89M to $117M. (2) Quantitatively, the numbers themselves ($89M, $117M, $19M) are present in the knowledge base, but their temporal assignment is flawed. The LLM misrepresents the $19M as part of the 2022–2024 trend, when it comes after. It also incorrectly frames the change as a 'drop' during 2022–2024, when it was actually a rise. (3) The multi-hop reasoning is partially sound in that it connects deferred revenue to program evolution, but it draws the wrong conclusion due to incorrect temporal synthesis. It fails to note the increase from 2022 to 2024 and instead emphasizes a decline that occurs only in 2025. (4) The contextual relevance is high because the answer addresses the Target Circle program, deferred revenue, and program evolution, but the factual errors in timeline and direction of change severely undermine correctness. The conclusion about a 'leaner, less-liability-intensive structure' may be plausible for 2025, but it does not reflect the 2022–2024 period in question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 460,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the fair value of Netflix's 4.375% Senior Notes change between December 31, 2022, and December 31, 2023, and what does this indicate about investor perception or market conditions?",
      "original_answer": "The fair value of Netflix's 4.375% Senior Notes decreased from $980 million on December 31, 2022, to $996 million on December 31, 2023. This indicates a shift in investor perception or market conditions, as the fair value moved closer to the principal amount at par, suggesting a stabilization or improved outlook for the company's debt.",
      "llm_answer": "\nThe 4.375 % Senior Notes were quoted at a fair‑value of **$980 million on December 31 2022** and **$996 million on December 31 2023**, an increase of roughly **$16 million (about 1.6 %)**.  \n\nThis modest rise above par shows that investors were willing to pay a slight premium, reflecting stable or slightly improved market perception of Netflix’s creditworthiness—likely driven by unchanged cash‑flow strength and a low‑interest‑rate environment that made the relatively high‑coupon notes more attractive. The small change suggests only a mild shift in investor sentiment rather than a dramatic re‑rating of the company’s debt.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a critical factual error in direction: it states the fair value increased from $980 million to $996 million, which is numerically correct, but the original answer (ground truth) states the value 'decreased' from $980M to $996M — this is logically impossible (a higher number is an increase, not a decrease). However, the ground truth itself appears to have a logical inconsistency: claiming a decrease from 980 to 996 is factually incorrect, as 996 > 980. Despite this, the LLM correctly reports the numbers but mischaracterizes the movement as an 'increase' and interprets it as a premium above par, which may not be accurate if par is $1 billion. (2) Quantitative accuracy: the dollar amounts ($980M and $996M) are correctly stated, and the $16M difference is accurate. However, the percentage increase is miscalculated: (16/980) ≈ 1.63%, so 'about 1.6%' is acceptable. But the claim that $996M is 'above par' assumes par is $980M or less, while typically 'par' for such notes is $1 billion (100% of principal). Without confirmation of par value, stating it is 'above par' is speculative. (3) Multi-hop reasoning: the LLM attempts to explain investor perception based on market conditions, creditworthiness, and interest rates, which is relevant. However, the conclusion that this reflects 'stable or slightly improved market perception' contradicts the ground truth's claim of 'stabilization or improved outlook' due to value moving *closer to par* — but again, without knowing par, this reasoning is flawed. If par is $1B, then moving from $980M to $996M *is* approaching par, so the direction of reasoning is sound, but the ground truth incorrectly labels this as a 'decrease'. (4) The LLM answer is contextually relevant and well-structured, but the core contradiction in the ground truth (calling a rise from 980 to 996 a 'decrease') undermines evaluation. Given that the LLM reports the numbers correctly but draws a plausible (though slightly overreaching) interpretation, the correctness score is penalized due to the likely incorrect assumption about par value and the fact that the ground truth contains an apparent error. The quantitative accuracy is low because of the implied misrepresentation of the trend (though numerically correct, the interpretation conflicts with a likely typo in the ground truth).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1252,
        "completion_tokens": 628,
        "total_tokens": 1880
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the equity structure related to Class C Common Stock evolve between 2023 and 2024, particularly in terms of share issuance and equity classification?",
      "original_answer": "In 2023, Visa conducted an exchange offer where 241 million shares of Class B-1 common stock were tendered, and in exchange, approximately 48 million shares of Class C common stock were issued. This indicates active restructuring of stock classes tied to the Visa Europe retrospective responsibility plans. By 2024, the balance of Class C common stock remained at 10 shares issued and outstanding, as stated in the equity section of the balance sheet. This suggests that while there was active movement and restructuring involving Class C shares in 2023, the 2024 disclosures indicate a stabilization or conclusion of that phase of equity restructuring.",
      "llm_answer": "\nIn fiscal 2023 the consolidated balance sheet listed only 10 shares of class C common stock as issued and outstanding, and the same 10‑share figure appeared on the 2024 balance sheet.  Nevertheless, in May 2024 the company executed a class B‑1 exchange offer in which it issued roughly 48 million class C common shares (together with 120 million class B‑2 shares) in exchange for tendered class B‑1 shares, expanding the class C capital base.  Thus, while the class C class remained a separate class of common stock, the reported “issued and outstanding” share count stayed at 10, even though a substantial issuance occurred behind the scenes.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors that undermine its correctness. (1) QUANTITATIVE INACCURACY: The LLM incorrectly states that the 10 shares of Class C common stock were already reported on the 2023 balance sheet. However, the ground truth indicates that in 2023, approximately 48 million Class C shares were issued as part of an exchange offer involving 241 million Class B-1 shares. The LLM reverses the timeline by claiming the 10-share figure was present in 2023 and remained in 2024, when in fact the 10-share figure is only reported in 2024 after restructuring. Additionally, the LLM claims the exchange offer occurred in May 2024, but the ground truth states it occurred in 2023. (2) COMPLETENESS: The answer fails to correctly describe the evolution of Class C shares between 2023 and 2024. Instead of showing a reduction or stabilization from active issuance in 2023 to minimal outstanding shares in 2024, it falsely implies that no issuance occurred and that the 10-share count was static across both years. (3) ENTITY & TEMPORAL INACCURACY: The key event—the exchange offer—is misdated (May 2024 vs. 2023), and the nature of the issuance (48 million shares issued in 2023) is misrepresented as occurring 'behind the scenes' despite not being reflected in the balance sheet. (4) REASONING FAILURE: The multi-hop reasoning is flawed—the model fails to connect that the issuance of 48 million shares in 2023 was followed by a reduction or reclassification such that only 10 shares remained outstanding in 2024, indicating a conclusion to the restructuring. Instead, it fabricates a narrative about unreported issuances. (5) SEMANTIC MISMATCH: While the final 10-share figure in 2024 is correct, the overall trajectory and explanation are factually wrong. The answer gets partial credit for mentioning the correct number of Class C shares issued (~48 million) and the correct stock classes involved, but the incorrect timing and logic severely compromise accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 533,
        "total_tokens": 1860
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How has Lowe's engagement with Rough Plumbing evolved from 2022 to 2024, particularly in terms of its business classification and service offerings?",
      "original_answer": "In 2022, Rough Plumbing was classified under the 'Building Products' category, indicating it was primarily offered as a product within Lowe's merchandise divisions. By 2024, Lowe's had expanded its engagement with Rough Plumbing by integrating it into both installation services and protection plans, signaling a shift from a pure product offering to a more service-oriented approach. This evolution reflects a strategic move to bundle Rough Plumbing with labor and extended protection, contributing to the approximately 5% of total sales attributed to installed sales in 2024.",
      "llm_answer": "\nFrom the 2022 filing (pages 53‑57) Rough Plumbing is listed only as one of the product categories under the **Building Products** segment, with its sales reported as ordinary merchandise. In the 2024 filing (pages 5‑9) the company still classifies Rough Plumbing within Building Products, but it is now highlighted as a key component of **installed sales**—emphasizing the sale of products together with installation, protection‑plan, and Pro‑customer services—reflecting a shift from a pure product line to a bundled service offering.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns well with the ground truth. It correctly identifies that in 2022, Rough Plumbing was classified under 'Building Products' as a product-only offering (per 2022 filing), and by 2024, it had evolved into a bundled service including installation and protection plans, now part of 'installed sales' (per 2024 filing). The shift from a pure product to a service-oriented model is accurately captured. The mention of 'Pro-customer services' adds slight contextual detail not in the original but does not distort meaning. Quantitatively, no explicit numbers are stated in the LLM answer (e.g., the 5% of total sales from installed sales in 2024), which is a minor omission, but since the core evolution in classification and service offering is correctly described, this does not significantly detract from correctness. All entities (Rough Plumbing, Building Products, installed sales, 2022–2024 timeline) are accurate. The reasoning is sound, demonstrating multi-hop synthesis across two years of filings. Semantic equivalence is strong. The answer is fully contextually relevant. The only reason for not scoring a 10 is the omission of the specific 5% installed sales metric, which was present in the ground truth and would have strengthened completeness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 360,
        "total_tokens": 1639
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did the introduction and subsequent status of Class B-2 common stock evolve between 2023 and 2024, and what does this indicate about its role in the company's capital structure?",
      "original_answer": "In 2023, Class B-2 common stock was newly introduced with 77 million shares outstanding, indicating its initial incorporation into the company's equity structure. By 2024, the company disclosed that no shares of Class B-2 common stock were outstanding prior to the Class B-1 common stock exchange offer, suggesting a strategic shift where Class B-2 shares may have been replaced or restructured as part of a broader capital realignment. This indicates a transformation in the role of Class B-2 common stock within the company’s capital structure.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 the company went from having only a single “Class B‑1” common‑stock class to creating a new “Class B‑2” class as part of the May 2024 exchange‑offer program.  Approximately 241 million B‑1 shares were retired and, in return, Visa issued about 120 million newly authorized but unissued B‑2 shares (and 48 million C shares); the B‑2 shares carry the same conversion‑rate mechanics as B‑1 but their conversion‑rate adjustments are double‑sized, and like B‑1 they remain subject to transfer restrictions until the U.S. litigation escrow is fully resolved.  This addition shows that B‑2 is being used as a strategic equity layer to accommodate the exchange of legacy B‑1 holdings, manage future conversion impacts on the litigation escrow, and further segment the capital structure while preserving control and voting rights.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that deviate from the ground truth. (1) Quantitatively, the LLM claims 120 million Class B-2 shares were issued in May 2024 as part of an exchange offer, but the ground truth states that in 2023, 77 million Class B-2 shares were outstanding, and by 2024, zero were outstanding—directly contradicting the LLM's claim of issuance and scale. The numbers (120M issued vs. 77M initially outstanding and later zero) are irreconcilable. (2) The LLM incorrectly states that Class B-2 was created as part of a May 2024 exchange offer, while the ground truth indicates it was introduced in 2023 and then reported as having zero outstanding shares in 2024—suggesting a retirement or restructuring, not a new creation in 2024. (3) The mention of 241 million B-1 shares retired, 48 million C shares issued, and specific conversion mechanics (double-sized adjustments) are not present or verifiable in the ground truth and appear fabricated. (4) The reasoning is flawed: the ground truth suggests Class B-2 was introduced and then eliminated or replaced, indicating a transitional or failed role, whereas the LLM portrays it as an active, strategically expanded class. (5) While the LLM attempts to address the evolution and strategic role (contextually relevant), the factual foundation is incorrect, undermining the entire analysis. The core multi-hop synthesis—tracking the status change of Class B-2 from 2023 to 2024—is incorrect: the model reverses the timeline and invents events. Thus, despite plausible financial language, the answer is largely incorrect on facts, numbers, timing, and interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 449,
        "total_tokens": 1807
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How has the financial liability associated with the Target Circle program changed between 2022 and 2024, and what does this indicate about the program's growth or evolution?",
      "original_answer": "In 2022, the Target Circle program was described primarily in terms of its benefits to customers, such as earning 1% rewards on non-RedCard purchases, but no specific liability figure was disclosed. By 2024, the deferred revenue related to the Target Circle program had grown to $117 million as of February 3, 2024, indicating a significant increase in the program's financial liability and suggesting substantial growth or expansion of the program. This increase reflects a greater number of participants or increased transactional activity within the program.",
      "llm_answer": "\nThe Target Circle program’s deferred‑revenue liability dropped dramatically from roughly **$117 million** at the end of fiscal 2022 (as reported in the 2021 Form 10‑K) to **$19 million** at the end of fiscal 2024 (2024 Form 10‑K), a reduction of about **$98 million (≈84 %)**.  This sharp decline shows that the financial liability associated with the Circle rewards has been largely unwound, indicating that Target has either restructured the program or shifted its loyalty incentives away from the standalone points‑based model.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both direction and magnitude. (1) Quantitatively, it claims deferred revenue dropped from $117M in 2022 to $19M in 2024, but the ground truth states no liability was disclosed in 2022 and $117M was reported in 2024—indicating growth, not decline. The $98M reduction and 84% decrease are fabricated. (2) The fiscal year references are confused: the 2021 Form 10-K would cover fiscal year 2021, not 2022. The LLM incorrectly attributes the $117M figure to 2022 and uses the wrong 10-K filing. (3) Qualitatively, the reasoning is flawed—instead of recognizing the emergence and growth of the liability as a sign of program expansion, it asserts a reduction and suggests program winding down or restructuring, which contradicts the ground truth. (4) Contextually, while the answer addresses the question's structure (change in liability and interpretation), it does so with entirely incorrect data and conclusions. The core multi-hop synthesis fails: the model did not correctly identify that the liability was first quantified in 2024, implying growth from an unreported 2022 baseline. Minor credit is given for attempting to interpret financial liability in the context of program evolution, but the factual errors render the analysis invalid.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 357,
        "total_tokens": 1637
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has NVDA's exposure to and concern about pollution limits evolved between 2023 and 2024, particularly in terms of regulatory impact on operations and customer data center expansion?",
      "original_answer": "In 2023, NVDA highlighted that pollution limits and related climate regulations could increase direct and indirect costs, including compliance, energy, and capital expenditures, and could require changes to manufacturing processes and supply chain operations. By 2024, the company expanded its concern to include not only cost increases but also the potential for land and permitting constraints tied to pollution limits, which could impair customers' ability to expand data center capacity—an essential market for NVDA's products. This indicates a growing concern that regulatory tightening around pollution could directly affect demand for NVDA's offerings.",
      "llm_answer": "\nBetween the 2023 and 2024 10‑K filings, NVIDIA’s discussion of pollution‑related regulation shifted from a brief, generic climate‑risk mention to a detailed, forward‑looking concern.  In the 2024 filing the company explicitly notes that new or proposed carbon‑tax, emissions‑limit and sustainability‑disclosure rules could raise direct costs (e.g., redesign of manufacturing processes, higher energy‑ and water‑use compliance) and indirect costs (pass‑through of supplier compliance expenses), and that such regulations may constrain the expansion of customer data‑center capacity by limiting power‑ and water‑availability.  By contrast, the 2023 filing only referenced climate change in the context of extreme‑weather risk, without specifying how emerging pollution‑limit policies would affect operations or data‑center growth.  Consequently, NVIDIA’s exposure to and worry about pollution limits has grown markedly, now being tied directly to regulatory risk that could increase operating expenses and restrict the scaling of its data‑center customers.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: in 2023, NVDA discussed pollution limits in terms of cost increases and operational changes due to climate regulations; by 2024, the concern expanded to include land and permitting constraints affecting customer data center expansion. The LLM correctly identifies this evolution, noting the shift from generic climate risk (e.g., extreme weather in 2023) to specific regulatory impacts on operations and customer capacity in 2024. (2) There are no numeric values to verify, so quantitative accuracy is scored as 10 by default—no errors in dates or financial figures. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of 10-K filings, correctly identifying both the expansion of regulatory concerns and their implications for customer demand. The only minor shortcoming is that the LLM does not explicitly mention 'capital expenditures' or 'supply chain operations' from the 2023 filing as in the original answer, slightly reducing completeness. Also, while it mentions power- and water-availability constraints, it doesn't directly tie these to 'permitting' and 'land' limits as stated in the ground truth, though the implication is present. (4) The answer is fully contextually relevant, directly addressing how NVDA’s exposure and concern evolved regarding pollution limits and their impact on operations and customer data center growth. Overall, the semantic meaning matches the original answer with high fidelity, warranting a correctness score of 9.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1438,
        "completion_tokens": 438,
        "total_tokens": 1876
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did the composition and valuation of the company's Guaranteed Senior Notes evolve between 2023 and 2024, particularly in terms of issuance, repayment, and fair value inputs?",
      "original_answer": "In 2023, the company's Japanese subsidiary issued four Guaranteed Senior Notes totaling approximately $500 at fixed interest rates ranging from 1.400% to 2.120%. These notes were valued using Level 3 inputs. In 2024, the Japanese subsidiary repaid $77 of these Guaranteed Senior Notes. The fair value of long-term debt, including Guaranteed Senior Notes, was approximately $5,412 at the end of 2024, compared to $5,738 at the end of 2023. This indicates a reduction in the overall fair value of long-term debt, partially driven by repayments on the Guaranteed Senior Notes.",
      "llm_answer": "\nBetween 2023 and 2024 the company’s Guaranteed Senior Notes (issued by its Japanese subsidiary) grew from roughly **$484 million of carrying value (and a comparable Level‑3 fair‑value amount) in 2023 to $919 million in 2024** – an increase that reflects the **$500 million of new notes sold in November 2023** (fixed rates 1.400%–2.120%, maturing 2033‑2043) minus the **$77 million of principal repaid in July 2024**.  The notes are **valued using Level 3 inputs** (significant management judgment and unobservable inputs), while the broader senior‑note portfolio (the U.S. 2.750%–1.750% notes) is marked to market with Level 2 inputs.  Consequently, the composition shifted toward a larger, higher‑carrying‑value, Level‑3‑valued debt position, with the July 2024 repayment representing only a small reduction relative to the overall issuance.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies. While it correctly states that $500 million in Guaranteed Senior Notes were issued in November 2023 at fixed rates of 1.400%–2.120% and valued using Level 3 inputs, and that $77 million was repaid in July 2024, it incorrectly claims the carrying value of these notes grew from $484 million in 2023 to $919 million in 2024. The original answer does not mention any such carrying values for the Guaranteed Senior Notes specifically, nor does it support an increase in value — instead, it reports a decrease in the fair value of total long-term debt from $5,738 million in 2023 to $5,412 million in 2024. The LLM invents specific carrying values ($484M → $919M) not present in the ground truth and misrepresents the trend. (2) The calculation of $500M issued minus $77M repaid does not justify a net increase to $919M from $484M, as that would imply a prior balance inconsistent with the original data. The overall fair value of long-term debt decreased, contradicting the LLM’s implication of growth in the Guaranteed Senior Notes’ valuation. (3) The multi-hop reasoning is flawed: the model incorrectly isolates the Guaranteed Senior Notes as increasing in value while the ground truth emphasizes a reduction in total long-term debt fair value, partially due to the $77M repayment. It also introduces irrelevant details about U.S. notes with different interest rates not mentioned in the original. (4) Despite incorrect numbers and reasoning, the answer is contextually relevant — it addresses issuance, repayment, and fair value inputs — and correctly identifies Level 3 inputs and the Japanese subsidiary. However, the core quantitative claims are fabricated, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 479,
        "total_tokens": 1841
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did Netflix's investment in streaming service improvements and associated risk exposure evolve from 2022 to 2024, based on the specific personnel and cybersecurity-related changes disclosed in those years?",
      "original_answer": "In 2022, Netflix disclosed a $384 million increase in personnel-related costs driven by headcount growth to support production activity and improve the streaming service. By 2024, the focus had evolved to include significant emphasis on cybersecurity, with detailed descriptions of enterprise-wide security programs, third-party risk management, and the potential financial impact of cyber incidents. The company highlighted the risk of unauthorized data releases and digital content theft, noting that such events could adversely affect business operations and financial results. This represents a shift from purely growth-oriented investment in streaming to a more risk-aware posture as the service matured.",
      "llm_answer": "\nBetween 2022 and 2024 Netflix accelerated its technology‑and‑development spending and headcount to fund streaming‑service upgrades such as UI/UX enhancements, recommendation‑engine improvements and the expansion of its Open Connect CDN. At the same time, it strengthened its cybersecurity governance by elevating a Vice President of Security and Privacy Engineering (a veteran with 30 years of industry experience), instituting a formal risk‑quantification model, expanding its bug‑bounty and third‑party audit programs, and bringing security matters under regular review by the Board’s Audit Committee. These personnel and programmatic upgrades enabled the company to sustain its streaming‑investment growth while increasing the rigor of its cyber‑risk controls.",
      "correctness_score": 5,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies and omits key quantitative information from the ground truth. Most critically, it fails to mention the $384 million increase in personnel-related costs disclosed in 2022, which is a central element of the original answer. This omission severely undermines quantitative accuracy. Additionally, the LLM introduces specific details not present in the ground truth, such as the appointment of a Vice President of Security and Privacy Engineering with 30 years of experience, a formal risk-quantification model, and expanded bug-bounty programs—none of which are supported by the provided original answer. While the general shift toward cybersecurity by 2024 is correctly identified, the supporting details are fabricated or over-specified. (2) There are no verifiable numbers in the LLM response that match the ground truth; the $384 million figure is entirely missing, and no other financial data is provided to anchor the claims. The absence of this key metric results in a low quantitative accuracy score. (3) The multi-hop reasoning is partially sound—the model correctly infers a strategic evolution from streaming investment to greater cybersecurity focus—but it fails to base this on the actual disclosed data (personnel cost increase in 2022, then cyber risk disclosures in 2024). Instead, it invents specific personnel and programmatic changes, undermining the validity of the synthesis. (4) Contextual relevance is high because the answer addresses the core theme of Netflix’s evolving investment and risk posture. However, correctness is limited by significant omissions and hallucinated details, warranting a mid-range score of 5: some facts align thematically, but key data points and accurate representation are lacking.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1384,
        "completion_tokens": 488,
        "total_tokens": 1872
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did The Bank of New York Mellon Corporation's approach to restricted stock unit agreements evolve between the 2023 and 2024 filings, particularly in terms of the lifecycle management of these equity instruments and their implications for executive compensation strategy?",
      "original_answer": "In the 2023 filing, the '2024 Form of Restricted Stock Unit Agreement' was newly introduced and explicitly stated as 'Filed herewith,' indicating it was a current and newly adopted form for that year. This suggests the company was actively updating its equity compensation framework to align with strategic goals for executive retention and incentives. By the 2024 filing, this '2024 Form' was no longer newly filed but instead was referenced as 'Previously filed,' signaling it had become an established part of the company's compensation structure. Additionally, in 2024, the company introduced the '2025 Form of Restricted Stock Unit Agreement,' which was marked as 'Filed herewith,' showing a forward-looking update to the equity compensation strategy. This evolution indicates a consistent, proactive approach to managing executive compensation frameworks, with new forms being introduced annually and the prior year’s forms transitioning into reference documents. This reflects a mature, iterative process in shaping executive incentives and aligning them with long-term corporate objectives.",
      "llm_answer": "\nBetween the 2023 and 2024 filings BNY Mellon moved from standalone 2023 RSU and PSU agreements (Exhibits 10.23‑10.24) to a refreshed set of 2024 awards (Exhibits 10.28‑10.29) that are now embedded in an amended Executive Severance Plan (Exhibit 10.30).  The 2024 documents tighten the performance‑metric language, extend the vesting/settlement horizon and tie the equity‑based awards more directly to multi‑year shareholder‑value goals, reflecting a lifecycle‑focused, performance‑driven compensation strategy that emphasizes longer‑term retention and alignment of executive pay with the company’s strategic objectives.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and introduces significant factual inaccuracies not present in the ground truth. (1) It claims BNY Mellon moved from '2023 RSU and PSU agreements (Exhibits 10.23–10.24)' to '2024 awards (Exhibits 10.28–10.29)' embedded in an 'amended Executive Severance Plan (Exhibit 10.30)'—none of which is supported by the original answer or implied in the knowledge graph. The ground truth makes no mention of PSU agreements, exhibit numbers, severance plans, or structural embedding of RSUs into broader plans. (2) The LLM asserts changes in 'performance-metric language,' 'extended vesting/settlement horizon,' and linkage to 'multi-year shareholder-value goals,' none of which are mentioned in the original answer. The actual evolution described is purely procedural: the 2024 Form was introduced in 2023 as 'Filed herewith,' then became 'Previously filed' in 2024, while the 2025 Form was introduced as 'Filed herewith'—indicating a routine annual update process, not substantive changes to performance terms or vesting. (3) The multi-hop reasoning is flawed: the LLM fabricates document structures and strategic implications not present in the source. While it correctly infers a forward-looking, iterative approach to compensation, this conclusion is based on invented evidence rather than the actual filing status transitions. (4) The contextual relevance is moderate because the answer addresses executive compensation strategy and lifecycle management, but the factual foundation is incorrect, leading to a misleading portrayal of the company’s actions. Quantitative accuracy is very low due to entirely fabricated exhibit numbers and unverified claims about document content. Qualitative accuracy is poor due to incorrect entity relationships and reasoning. Correctness score is low because the core facts are wrong, despite a plausible narrative.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1461,
        "completion_tokens": 506,
        "total_tokens": 1967
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How has the status and structure of the 4.90% Senior Notes evolved from 2023 to 2024, particularly in terms of their carrying amount and maturity timeline?",
      "original_answer": "In 2023, the 4.90% Senior Notes were newly issued in November 2023, with a principal amount of $750 million, a discount of $3.4 million, and a maturity date of April 15, 2029. Interest payments were scheduled semi-annually starting April 15, 2024. By 2024, these notes remained outstanding, with a carrying amount of $743 million as of January 28, 2024. The maturity date remained unchanged at April 2029, and the notes continued to be listed among the company’s long-term debt obligations. The carrying amount slightly decreased, reflecting the initial discount and amortization progress over the year.",
      "llm_answer": "\nThe 4.90 % Senior Notes did not appear in the 2023 filing; they were issued in June 2024 as part of the SRS‑acquisition financing with a $750 million face amount and a $3.4 million discount, resulting in a carrying amount of $743 million on the February 2 2025 balance sheet.  These notes mature on April 15 2029 and pay interest semi‑annually beginning April 15 2024, marking a shift from “no liability” in 2023 to a $743 million, 2029‑dated long‑term debt in 2024.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, the 4.90% Senior Notes were issued in November 2023, not June 2024. The LLM incorrectly states the notes did not appear in the 2023 filing, which contradicts the original answer that they were newly issued in November 2023. The maturity date (April 15, 2029) and interest payment start (April 15, 2024) are correctly stated, as is the principal amount ($750 million), discount ($3.4 million), and carrying amount ($743 million). However, the LLM misattributes the timing of issuance and reporting. It claims the carrying amount appears on a February 2, 2025 balance sheet, which is in the future relative to the 2024 context and incorrect—ground truth reports the carrying amount as of January 28, 2024. (2) Quantitative accuracy is partially correct: $750 million face value, $3.4 million discount, $743 million carrying amount, and April 15, 2029 maturity are all accurate. However, the issuance date (November 2023 vs. June 2024) and balance sheet date (Jan 28, 2024 vs. Feb 2, 2025) are wrong. (3) Multi-hop reasoning is flawed: the model fails to correctly track the evolution from 2023 (issuance) to 2024 (outstanding with amortized carrying amount), instead inventing a June 2024 issuance and misrepresenting the 2023 status. The synthesis across years is incorrect. (4) Contextual relevance is moderate—the answer addresses the right financial instrument and key attributes (carrying amount, maturity), but the timeline and causal narrative are factually wrong, undermining the core of the multi-hop question about evolution from 2023 to 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1269,
        "completion_tokens": 452,
        "total_tokens": 1722
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did the issuance and repayment of Guaranteed Senior Notes by Costco's Japanese subsidiary evolve between 2023 and 2024?",
      "original_answer": "In 2023, Costco's Japanese subsidiary issued four Guaranteed Senior Notes totaling approximately $500 at fixed interest rates ranging from 1.400% to 2.120%. In 2024, the subsidiary repaid $77 of these Guaranteed Senior Notes. Additionally, the proceeds from the issuance of these notes were referenced in the 2024 filing as a source of financing activity, indicating continued financial engagement with this instrument.",
      "llm_answer": "\nBetween November 2023 and July 2024 the Japanese subsidiary issued a $≈ 500 million series of Guaranteed Senior Notes—four separate tranches with fixed rates of 1.400% to 2.120% and maturities from 2033 to 2043—and then, in July 2024, it repaid $77 million of those notes, thereby reducing the outstanding balance of the issuance.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) Quantitatively, all numbers are correct: the issuance of approximately $500 million in Guaranteed Senior Notes across four tranches at fixed interest rates of 1.400% to 2.120% in 2023 (with maturities extending to 2043, which adds detail not contradicted by the original) and the $77 million repayment in July 2024 are consistent with the original answer. The format variations ($500 million vs $500) are acceptable. (2) The dates are slightly more precise in the LLM answer (November 2023 to July 2024), but this does not conflict with the original's annual framing and adds useful detail. (3) The reasoning is sound: it correctly synthesizes the issuance and subsequent repayment as multi-hop events across 2023 and 2024, correctly attributing both actions to Costco's Japanese subsidiary. (4) The only minor shortcoming is that the LLM answer does not explicitly mention that the proceeds were referenced in the 2024 filing as a source of financing activity—a detail present in the original that indicates ongoing financial engagement. While this omission slightly reduces completeness, it does not detract from the core factual accuracy of the issuance and repayment events. Overall, the answer is semantically equivalent, contextually relevant, and demonstrates strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1181,
        "completion_tokens": 384,
        "total_tokens": 1566
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How has the risk associated with competitors developing after-market parts for DHR's products evolved from 2022 to 2023, particularly in terms of its impact on the company's business and financial statements?",
      "original_answer": "In 2022, the risk of competitors developing after-market parts was described as a direct threat that could 'detract from our sales,' with an emphasis on how commoditization and private-label offerings could reduce market prices and erode DHR's competitive position. By 2023, the framing of this risk shifted to being 'Impacted By' such competition, with a broader contextualization within cost containment trends in the healthcare industry and pricing pressures from managed care and government reimbursement policies. While the core risk remained, it was presented as one of several external pressures rather than a primary threat, suggesting a relative de-emphasis in severity or a strategic recalibration in how the company perceives this risk.",
      "llm_answer": "\nThe 2022 10‑K (pages 21‑25) lists “competitors may also develop after‑market services and parts for our products which may detract from our sales” as a material risk, and the 2023 10‑K (pages 18‑22) repeats the same language while emphasizing that such competition can create pricing pressure and erode market share. Consequently, the risk has remained present but is now highlighted as a factor that could reduce revenue and margin by limiting sales of the Company’s proprietary offerings and forcing price concessions—potentially adverse to the Company’s top‑line growth and profitability.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually accurate in stating that the risk of competitors developing after-market parts was present in both the 2022 and 2023 10-K filings and that it could detract from sales, create pricing pressure, and erode market share. The citation of page ranges (2022: pp. 21–25; 2023: pp. 18–22) aligns with typical 10-K risk factor sections, and no numeric inaccuracies are present—thus, quantitative accuracy is high. However, the LLM fails to capture the key evolution emphasized in the ground truth: the shift in framing from a direct, standalone threat in 2022 ('detract from our sales') to a more contextualized, secondary pressure in 2023 ('Impacted By') within broader industry trends like cost containment and reimbursement policies. Instead, the LLM suggests the risk was merely 'repeated' with added emphasis on pricing and margins, missing the strategic de-emphasis and reframing. This reflects a failure in multi-hop reasoning and qualitative synthesis—while the surface-level facts are correct, the nuanced evolution in risk perception and presentation is omitted. As such, the answer is partially correct but lacks the deeper comparative analysis required by the question. Contextual relevance is strong because it addresses business and financial impacts (revenue, margins), but the absence of the shift in risk hierarchy reduces overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 380,
        "total_tokens": 1731
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has Netflix's approach to membership plans evolved from 2022 to 2024, particularly in terms of pricing strategy and service features, and what business challenges were these changes intended to address?",
      "original_answer": "In 2022, Netflix experienced a 19% revenue increase driven by an 11% growth in average paying memberships and a 7% rise in average monthly revenue per membership, partly due to price increases and favorable foreign exchange rates. However, paid net membership additions dropped by 50% compared to the prior year, signaling early signs of member acquisition challenges. By 2024, Netflix responded by introducing a lower-priced ad-supported subscription plan and enforcing terms of use to limit multi-household usage. These changes were aimed at addressing fluctuating member acquisition, retention pressures, and increasing competition in the streaming and broader entertainment market. The company acknowledged that macroeconomic conditions, content competition, and consumer sensitivity to pricing adjustments could negatively impact membership growth and profitability.",
      "llm_answer": "\nFrom 2022 through 2024 Netflix moved away from a single, flat‑rate streaming tier toward a more flexible, tiered pricing model that introduced a low‑cost, ad‑supported subscription and began modest price increases in many regions, while also tightening rules on shared‑account usage. These changes were intended to lift average revenue per member and counter slowing paid‑membership growth, rising content‑cost pressures, and intensified competition in a maturing global market.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Netflix's shift to a tiered pricing model with an ad-supported plan and account-sharing enforcement as key strategic moves from 2022 to 2024, aligning with the original answer. It accurately captures the business challenges: slowing membership growth, content cost pressures, and competition. However, it omits specific quantitative data from the ground truth such as the 19% revenue increase, 11% membership growth, 7% rise in average revenue per membership, and the 50% drop in paid net membership additions in 2022. These omissions affect quantitative accuracy but do not distort the overall narrative. (2) No incorrect numbers are stated, but the LLM fails to include the precise metrics provided in the original answer, which are critical for full factual completeness. There are no calculation errors because no calculations are attempted. (3) The multi-hop reasoning is sound—the model synthesizes information about pricing strategy changes and links them to business challenges like competition and member acquisition, which requires connecting service feature changes (ads, account sharing) to broader market and financial pressures. This demonstrates good qualitative understanding. (4) The answer is contextually excellent—directly addresses the evolution of membership plans, pricing, features, and intended business outcomes. While semantically close to the original, the lack of specific supporting figures from 2022 reduces quantitative accuracy, warranting a score of 7 there. Overall correctness is high due to accurate reasoning and entity identification, meriting an 8.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 448,
        "total_tokens": 1801
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has Boeing's approach to in-orbit incentive payments evolved between 2022 and 2023, particularly in terms of risk exposure and financial recognition?",
      "original_answer": "In 2022, Boeing highlighted the financial risks associated with in-orbit incentive payments, particularly in the context of potential program cancellations or failure to meet performance criteria, which could trigger termination provisions or loss of payments. The company noted that these risks were part of ongoing fixed-price development programs like Commercial Crew, KC-46A Tanker, and VC-25B. By 2023, Boeing had recorded $1,585 million in additional losses on its five most significant fixed-price development programs, which included those mentioned in 2022, and explicitly stated that in-orbit incentive payments were at risk if satellites failed to meet performance criteria over up to 15 years post-acceptance. The company also emphasized that the net present value of these fees was recognized as revenue during the construction period, increasing financial exposure if performance issues arose. This represents a shift from general risk acknowledgment in 2022 to a more specific quantification of losses and a detailed explanation of revenue recognition practices tied to in-orbit performance in 2023.",
      "llm_answer": "\nBoeing continues to recognize the present‑value of expected in‑orbit incentive fees as revenue during the construction phase, but the 2023 filing sharpens the risk discussion by explicitly linking non‑performance to possible refund obligations and material charges, and by noting that the estimate is reassessed each reporting period. In contrast, the 2022 filing described the risk more generally, without this explicit emphasis on ongoing reassessment and the potential for significant financial exposure.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core evolution in Boeing's approach to in-orbit incentive payments between 2022 and 2023, correctly identifying a shift from general risk disclosure in 2022 to a more detailed and financially explicit discussion in 2023. It accurately notes the practice of recognizing the net present value of in-orbit incentive fees during construction and highlights the increased emphasis on reassessment and potential refund obligations in 2023. However, it omits the key quantitative detail from the ground truth: the $1,585 million in additional losses recorded in 2023 on Boeing’s five major fixed-price development programs. This is a significant omission because the question specifically asks about financial recognition and risk exposure, and the dollar amount is central to the 2023 update. While the LLM correctly describes the qualitative shift in risk disclosure and revenue recognition, the absence of this figure reduces quantitative accuracy. The entities (Boeing, in-orbit incentive payments, fixed-price programs) and years (2022 vs 2023) are correct, and the reasoning correctly synthesizes the evolution in disclosure tone and content. The answer is semantically aligned with the ground truth in terms of logic and context but lacks full completeness due to the missing financial figure, which is critical for a complete multi-hop understanding of financial exposure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1407,
        "completion_tokens": 386,
        "total_tokens": 1793
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the disclosure and accessibility of the Directors' Code of Conduct evolved between 2023 and 2024?",
      "original_answer": "In 2023, the Directors' Code of Conduct was explicitly described as being posted on the company's website at a specific URL: https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/invrelations/directors-code-of-conduct.pdf, and the company stated its intention to disclose amendments or waivers on the website. In 2024, while the Code remained accessible, it was referenced more generally as part of a broader list of governance materials available on the company’s website, including committee charters and governance guidelines, without repeating the direct URL. The change indicates a shift from detailed disclosure of access to a more consolidated and implicit reference, suggesting a streamlined but less direct approach to public access in 2024.",
      "llm_answer": "\nBetween 2023 and 2024 the company’s filing shifted from merely noting that the Directors’ Code of Conduct is posted on its website to an explicit commitment to publicly disclose any future amendments or waivers of that code (both for executive officers and for directors) on the same site. This added language makes the timing and nature of any changes to the code transparent and readily accessible to investors. Consequently, the 2024 disclosure improves both the visibility and the accountability of the Directors’ Code of Conduct compared with the more limited 2023 filing.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim. According to the ground truth, in 2023 the company already stated its intention to disclose amendments or waivers on the website, and the Code was provided with a direct URL. In 2024, the disclosure became less detailed—referencing the Code more generally within a list of governance documents without repeating the URL—indicating a move toward consolidation, not enhanced transparency. The LLM incorrectly asserts that 2024 introduced a new commitment to disclose amendments or waivers, when in fact this was already stated in 2023. This reverses the actual trend: the evolution was from more explicit and direct disclosure in 2023 to a more implicit, generalized reference in 2024. There are no numerical values to assess, so quantitative accuracy is not applicable (scored 10 by default for absence of error). The reasoning is flawed as it misrepresents the direction of change, failing the multi-hop synthesis between years and disclosures. While the answer addresses the topic of disclosure evolution and is contextually relevant, it draws the opposite conclusion from the evidence, severely undermining factual correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 332,
        "total_tokens": 1656
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the role and deployment strategy of Mobileye Drive™ evolved between 2022 and 2023?",
      "original_answer": "In 2022, Mobileye launched the SAE L4 Self-Driving System (SDS), Mobileye Drive™, and secured multiple collaborations for commercial use, including with Udelv for autonomous cargo delivery and with Transdev for self-driving mobility services. Additionally, Mobileye achieved its first consumer L4 design win with Geely. By 2023, Mobileye’s strategy had evolved to focus on supplying the Mobileye Drive™ self-driving system to transportation network companies, public transit operators, and suppliers of AV-ready vehicle platforms, with plans to bundle it with Moovit’s urban mobility and transit intelligence application. This shift indicates a more defined go-to-market strategy targeting fleet deployment and mobility-as-a-Service (MaaS) ecosystems.",
      "llm_answer": "\nBetween 2022 and 2023 Mobileye Drive™ moved from an early‑stage, SAE‑L4 prototype to the core self‑driving platform that powers Mobileye’s commercial “Robotaxi‑as‑a‑Service” and cargo‑delivery fleets.  The company expanded OTA updates and design wins (e.g., with Udelv, Transdev, Geely, Porsche, FAW, Mahindra & Mahindra, Polestar) and began offering Drive™ as a turnkey solution for transportation‑network companies and public‑transit operators, positioning it as the primary vehicle‑level stack for large‑scale autonomous mobility services.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the evolution of Mobileye Drive™’s role and deployment strategy between 2022 and 2023. It correctly identifies that in 2022, Mobileye launched the SAE L4 Self-Driving System and secured key collaborations (Udelv, Transdev, Geely), which aligns with the ground truth. The mention of additional partners in 2023 (Porsche, FAW, Mahindra & Mahindra, Polestar) goes beyond the original answer but does not contradict it and may reflect expanded partnerships. The core strategic shift — from initial deployment to targeting transportation network companies, public transit operators, and fleet-based mobility services — is accurately conveyed. The LLM also correctly notes the positioning of Mobileye Drive™ as a turnkey solution for large-scale autonomous mobility, which reflects the evolved go-to-market strategy. However, the LLM omits the specific integration with Moovit’s urban mobility and transit intelligence application, a key element in the 2023 strategy mentioned in the ground truth. While the concept of MaaS is implied through ‘Robotaxi-as-a-Service’ and fleet deployment, the explicit bundling with Moovit is a meaningful detail that enhances the strategic narrative and is missing. There are no numerical inaccuracies (dates, years, and company names are correct), so quantitative accuracy is perfect. The reasoning is sound and synthesizes the multi-hop elements (evolution over time, shift in target customers, product positioning), though slightly less precise in capturing the full scope of the 2023 bundling strategy. Contextual relevance is excellent as the answer directly addresses the question’s focus on role and deployment strategy evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 475,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has the structure and distribution rate of the Tower Preferred Interests evolved from 2022 to 2024?",
      "original_answer": "In 2022, the Tower Preferred Interests were divided into two series: the September series (Class A-1) totaling $1,500 with a 5.0% initial preferred distribution, and the December series (Class A-2) totaling $4,500 with a 4.75% initial preferred distribution. These distributions reset every five years. By 2024, the structure was amended in August 2024 to reclassify all 2019 Tower preferred interests into Fixed Rate Class A Limited Membership Interests (Tower Fixed Rate Interests) paying a 5.90% preferred distribution. Additionally, a portion of these fixed-rate interests will transition annually into Floating Rate Class A Limited Membership Interests (Tower Floating Rate Interests), which will pay a distribution equal to SOFR plus 250 basis points. This represents both a structural and rate evolution in the Tower Preferred Interests.",
      "llm_answer": "\nFrom the original 2019 issuance the Tower preferred interests consisted of two fixed‑rate series (Class A‑1 at a 5 % distribution and Class A‑2 at a 4.75 % distribution) that reset every five years.  In August 2024 the interests were amended so that all of the 2019 Tower preferred equity is now split into a Fixed‑Rate Class A (5.90 % quarterly distribution) and a Floating‑Rate Class A (distribution equal to SOFR + 250 bps, reset every five years), with call rights beginning in 2029 and the same redemption‑on‑default provisions.  Thus, between 2022 and 2024 the structure shifted from two static 5 %/4.75 % series to a dual‑rate (fixed + floating) framework with a higher base rate and a market‑linked floating tranche.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of the Tower Preferred Interests from a fixed-rate structure to a dual fixed/floating rate framework, which aligns with the ground truth. However, there are significant quantitative inaccuracies: (1) The original 2019/2022 series are misstated—the September series (Class A-1) was $1,500 at 5.0%, not 5%, and the December series (Class A-2) was $4,500 at 4.75%, but the LLM incorrectly implies these were from the 2019 issuance without clarifying the 2022 structure as specified. The dollar amounts are entirely omitted in the LLM response, which is a critical omission for completeness and accuracy. (2) The reset period for the floating rate is incorrectly stated as 'every five years'—while the original fixed series reset every five years, the new floating rate resets periodically (implied to be in line with SOFR conventions, likely quarterly), not every five years. (3) The LLM introduces 'call rights beginning in 2029' and 'redemption-on-default provisions' which are not present in the original answer and cannot be verified from the provided ground truth, adding unsupported details. (4) The LLM conflates the 2019 issuance with the 2022 structure without clearly distinguishing the timeline—by 2022, the structure was already in place with the two series, but the LLM suggests the 2019 structure was still active. The qualitative reasoning is mostly sound in identifying a shift to a dual-rate system and higher base rate, and the contextual relevance is high as it directly addresses the structural and rate evolution. However, missing dollar amounts, incorrect reset frequency, and unverified added details reduce quantitative and overall correctness. Semantic equivalence is partially achieved but undermined by key omissions and inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 487,
        "total_tokens": 1868
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How did the investment approach and unrealized gains/(losses) for Level 3 assets related to the Balanced Index Fund evolve from 2022 to 2023?",
      "original_answer": "In 2022, the company disclosed unrealized losses for Level 3 assets still held at year-end, including ($16) million for corporate fixed income securities and ($11) million for mortgage-backed and asset-backed fixed income securities. By 2023, these values shifted to unrealized gains of $2 million for corporate fixed income securities and $6 million for mortgage-backed and asset-backed fixed income securities. This indicates a significant turnaround in the performance of these assets. Additionally, while the Balanced Index Fund's composition remained at approximately 60% equities and 40% debt securities in both years, the valuation methodology in 2023 explicitly referenced a market approach based on quoted market prices (Level 1), suggesting a more transparent and standardized valuation process.",
      "llm_answer": "\nThe Balanced Index Fund’s underlying Level 3 holdings are still valued through the standard fair‑value process—using the underlying investments’ NAVs, market‑approach inputs and other valuation techniques—while the fund itself is marked‑to‑market at Level 1.  Unrealized results swung from a combined $23 million loss in 2022 (mainly $16 m corporate, $11 m mortgage‑backed and $14 m municipal) to a modest $11 million gain in 2023 ( $2 m corporate, $6 m mortgage‑backed and $3 m other), reflecting a reversal from loss to gain.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. While it correctly identifies the $16M loss in corporate fixed income and $11M loss in mortgage-backed/asset-backed securities for 2022, it incorrectly adds a $14M municipal loss not present in the original answer, inflating the total 2022 loss to $41M instead of $27M. Similarly, for 2023, it reports $3M in 'other' gains not mentioned in the ground truth, and while the $2M corporate and $6M mortgage-backed gains are correct, the total gain is misrepresented as $11M instead of $8M. These fabricated numbers undermine factual accuracy. (2) The original answer does not mention municipal or 'other' securities, so their inclusion is a factual error. The calculation of combined losses/gains is therefore incorrect due to extraneous line items. (3) The qualitative reasoning is partially sound: the model correctly identifies a shift from unrealized losses to gains and notes the fund’s stable 60/40 allocation, but it fails to mention the key qualitative evolution in valuation methodology—specifically, the 2023 reference to a market approach using Level 1 inputs, which is a critical part of the original answer. This omission weakens the synthesis. (4) Despite these issues, the answer is contextually relevant and addresses the core question about performance evolution. The description of valuation techniques for Level 3 assets is generally accurate, and the direction of change (loss to gain) is correctly noted. However, the addition of unverified asset categories and incorrect totals reduces quantitative accuracy significantly, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1332,
        "completion_tokens": 450,
        "total_tokens": 1782
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has BNY Mellon's emphasis on accounting developments in its forward-looking statements evolved between 2023 and 2024, and what does this reveal about the changing influence of accounting standards on its strategic priorities?",
      "original_answer": "In 2023, BNY Mellon included accounting developments among a broader list of potential influences on forward-looking statements, noting they 'may impact our businesses' without specific elaboration. By 2024, the company expanded this language, explicitly stating that accounting developments 'may impact our businesses, regulatory, technology, market, economic or accounting developments and the impacts of such developments on our businesses.' This shift indicates a more integrated view of accounting changes as part of strategic risk and planning considerations. The inclusion of terms like 'capital plans including dividends and repurchases' and 'efficiency savings' in 2024 further suggests that accounting developments are increasingly tied to concrete business decisions and performance metrics.",
      "llm_answer": "\nBetween 2023 and 2024 the discussion of accounting developments moved from a generic risk‑factor mention to a stand‑alone forward‑looking statement that explicitly warns that “changes in accounting standards governing the preparation of our financial statements … could have a material impact on our reported financial condition, results of operations, cash flows and other financial data.”  In the 2023 filing the accounting‑standards theme was only one of many risk items, whereas in 2024 it is highlighted as a distinct, material uncertainty that can affect capital ratios, dividend‑paying capacity and overall strategic decisions.  This shift reveals that evolving accounting standards have become a central driver of BNY Mellon’s strategic priorities, shaping its reporting choices, capital‑planning and risk‑management focus.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct in its assessment of BNY Mellon's evolving emphasis on accounting developments between 2023 and 2024. It accurately captures the shift from a generic mention among other risks in 2023 to a more prominent, standalone discussion in 2024, with specific reference to material impacts on financial reporting and strategic decisions. The use of terms like 'capital ratios,' 'dividend-paying capacity,' and 'strategic decisions' aligns well with the original answer’s mention of 'capital plans including dividends and repurchases' and 'efficiency savings,' reflecting a correct interpretation of the increased strategic relevance of accounting standards. However, the LLM introduces a direct quote—'changes in accounting standards governing the preparation of our financial statements … could have a material impact...'—that does not appear in the ground truth, which only summarizes the language without quoting it verbatim. While this quote may reflect actual filing content, it was not part of the provided truth data, so its inclusion introduces unverifiable detail. Additionally, the original answer emphasizes the structural change in language as part of a broader list expansion (e.g., 'regulatory, technology, market, economic or accounting developments'), which the LLM does not fully reflect, instead framing it as a standalone risk. This slightly overstates the isolation of the risk. Nonetheless, the core reasoning, timeline (2023 vs 2024), entity (BNY Mellon), and conclusion about growing strategic influence are factually sound and contextually appropriate. All dates and qualitative assessments are accurate, and no numerical errors are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1429,
        "completion_tokens": 458,
        "total_tokens": 1888
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How did the evolution of risks related to store safety and cybersecurity in 2023 potentially impact the associate experience, as compared to the engagement-focused initiatives highlighted in 2022?",
      "original_answer": "In 2022, HD emphasized internal initiatives to improve the associate experience through engagement surveys, a digital engagement platform, and recognition programs, which historically showed that four out of five associates were emotionally committed. However, in 2023, the company highlighted external risks such as increased store shrink, particularly from organized retail crime, and cybersecurity threats that could compromise associate data and store safety. These risks were noted to potentially erode trust, impact associate morale and retention, and damage the company's reputation. This shift indicates that while HD was actively fostering associate engagement in 2022, the emergence or escalation of external risks in 2023 introduced new challenges that could undermine those earlier gains in associate experience.",
      "llm_answer": "\nThe 2023 risk disclosures show that heightened concerns over store‑safety (e.g., COVID‑related protocols, rising shrink and organized retail crime) and expanding cyber‑threats required associates to adopt new security and compliance duties, while the 2022 narrative emphasized culture, recognition and development programs to deepen engagement. As a result, the same safety and cybersecurity pressures that could disrupt operations also added extra workload and vigilance for associates, potentially limiting the bandwidth for the purely engagement‑focused initiatives highlighted the prior year.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent with the ground truth in terms of entities, years, and overall narrative arc: it correctly identifies 2022 as the year HD focused on engagement initiatives (culture, recognition, development) and 2023 as the year when external risks like store safety (organized retail crime, shrink) and cybersecurity emerged as concerns. It also correctly infers that these 2023 risks added responsibilities for associates, potentially detracting from engagement efforts. However, the LLM answer misses key qualitative elements present in the original answer: (1) it does not mention the specific metric that 'four out of five associates were emotionally committed,' which is a critical data point supporting the 2022 engagement success; (2) it introduces 'COVID-related protocols' as a store-safety concern in 2023, which is not present in the original answer and may be factually inaccurate or unsupported by the ground truth; (3) it frames the impact as increased workload and vigilance, while the original emphasizes erosion of trust, morale, and retention—more profound cultural impacts. While the reasoning is logically sound and contextually relevant, the omission of the emotional commitment statistic and introduction of unsupported details (COVID protocols) reduce qualitative accuracy. There are no numerical inaccuracies—dates (2022, 2023) are correct, no incorrect figures are cited—so quantitative accuracy is perfect. The answer addresses the comparative evolution of risks and initiatives, fulfilling the multi-hop requirement (2022 vs 2023, engagement vs risk), but with slightly less precision in synthesizing the full implications on associate experience.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 460,
        "total_tokens": 1828
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the role of the 'learning curve' in influencing cost and production estimates evolved between 2022 and 2023, particularly in relation to program profitability and risk management?",
      "original_answer": "In 2022, the 'learning curve' was identified as a risk factor that could negatively impact program profitability due to production complexities, rework, and delays—especially in programs like the 787—potentially leading to additional losses and abnormal production costs. By 2023, the 'learning curve' was no longer framed solely as a risk but was integrated into the company's cost estimation process, factored into production rate assumptions, supplier performance trends, and internal labor efficiency projections. This shift indicates that Boeing began treating the learning curve as a predictable and manageable component of production planning rather than an unpredictable risk.",
      "llm_answer": "\nBetween 2022 and 2023 the learning‑curve went from being a peripheral variable in program‑accounting estimates to a explicitly quantified risk driver.  In the 2022 filing it was listed only as one of several factors influencing cost and margin estimates, whereas the 2023 filing states that a ±1 % change in the gross‑margin assumptions for its commercial airplane programs would shift operating earnings by roughly $330 million and that further reductions in the learning‑curve‑derived cost outlook could trigger additional reach‑forward losses and abnormal production‑cost charges on programs such as the 777X and 787.  Consequently, the learning curve now sits at the core of the company’s profitability assessments and risk‑management disclosures.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of the learning curve's role from 2022 to 2023—shifting from a background factor to a central element in cost and profitability assessments—which aligns with the ground truth’s core theme. However, there are significant factual inaccuracies that reduce correctness. First, the $330 million figure for a ±1% change in gross margin is not present in the ground truth and cannot be verified from the provided knowledge; this is a hallucinated quantitative claim. Second, the mention of the 777X as a program affected by learning curve adjustments is not in the original answer, which only references the 787. While the original does state that in 2022 the learning curve was a risk factor tied to rework, delays, and abnormal costs (correctly echoed in part by the LLM), the 2023 shift described in the ground truth emphasizes integration into cost estimation and production planning—not just risk disclosure or sensitivity analysis. The LLM overemphasizes the learning curve as a 'quantified risk driver' with specific sensitivity metrics, which is not supported by the original. The reasoning is logically structured and contextually relevant, showing an understanding of the multi-hop nature of the question (change over time, impact on profitability and risk). However, the inclusion of unsupported numbers and programs undermines quantitative and qualitative accuracy. The answer is semantically close but factually divergent in key areas.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 407,
        "total_tokens": 1777
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the treatment or disclosure of the Dividend Reinvestment Plan evolved between the 2023 and 2024 SEC filings, particularly in relation to officer or director participation and associated trading arrangements?",
      "original_answer": "In the 2023 filing, the Dividend Reinvestment Plan was mentioned in the context of officer or director participation alongside the employee stock purchase plan and 401(k) plan, with specific reference to elections to have shares withheld for tax purposes or to pay the exercise price of stock awards. The disclosure also included a detailed description of how these elections may be structured under Rule 10b5-1 or non-Rule 10b5-1 trading arrangements as defined in Item 408(c) of Regulation S-K. In the 2024 filing, the Dividend Reinvestment Plan was again referenced in the context of officer or director participation, but the detailed explanation of Rule 10b5-1 and non-Rule 10b5-1 trading arrangements was omitted, indicating a simplification or standardization of the disclosure without the earlier level of specificity regarding trading frameworks.",
      "llm_answer": "\nThe 2023 filing only referenced the dividend‑reinvestment plan in the generic “Capital‑Issuer purchases of equity securities” discussion and did not single out any officer or director participation or the trading‑arrangement implications. In contrast, the 2024 Form 10‑K adds a dedicated Item 9(b)(b) disclosure that explicitly states that certain officers and directors elect to take part in the dividend‑reinvestment (and related) plans and that their share‑withholding elections may be structured to meet the affirmative‑defense safe‑harbor of Rule 10b5‑1 or may constitute non‑Rule 10b5‑1 trading arrangements. Thus, the 2024 filing provides a much clearer, explicit accounting of officer/director involvement and the associated trading‑rule considerations that were absent or only implicit in the 2023 filing.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both direction and content. According to the ground truth, the 2023 filing included a detailed disclosure about officer or director participation in the Dividend Reinvestment Plan, including specific references to Rule 10b5-1 and non-Rule 10b5-1 trading arrangements. In contrast, the 2024 filing omitted this detailed explanation, indicating a reduction in specificity. However, the LLM answer incorrectly claims the opposite: that the 2023 filing did not mention officer/director participation or trading arrangements, and that the 2024 filing added such details. This reverses the actual evolution of the disclosure. There are no correct quantitative elements (dates are misapplied in context). The reasoning is flawed as it fails to correctly synthesize the multi-hop comparison across years and misidentifies the direction of change in disclosure practices. While the answer addresses the general topic (officer participation and trading arrangements), its factual inaccuracies render it largely irrelevant to the actual evolution described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1434,
        "completion_tokens": 313,
        "total_tokens": 1748
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has The Home Depot's investment in creating an interconnected shopping experience evolved from fiscal 2021 to fiscal 2023, and what specific changes were made in the way this experience is tailored to customers?",
      "original_answer": "In fiscal 2021, The Home Depot invested $2.6 billion in capital expenditures focused on supporting an interconnected customer experience. By fiscal 2023, the company had advanced this strategy by leveraging enhanced merchandising information technology tools to build an interconnected shopping experience tailored to customers' shopping intent and location. This represents a shift from general investment in interconnectedness to a more refined, data-driven personalization strategy.",
      "llm_answer": "\nFrom fiscal 2021 through fiscal 2023 Home Depot’s spending on an interconnected, friction‑less experience grew from a $2.6 billion initial outlay to about $3.2 billion, expanding the digital foundation it had begun building. By fiscal 2023 the company was using data‑driven, location‑specific offers, mobile‑app navigation and curb‑side/same‑day delivery options, computer‑vision inventory visibility and AI‑enhanced personalization to tailor the shopping journey across stores, online and the job site.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "(1) The LLM answer contains significant quantitative inaccuracies: it claims Home Depot's investment grew from $2.6 billion in fiscal 2021 to $3.2 billion in fiscal 2023, but the ground truth only confirms the $2.6 billion figure for 2021 and does not provide any capital expenditure amount for 2023. Therefore, the $3.2 billion figure is fabricated or unsupported. This is a major factual error. (2) While the original answer highlights a strategic shift toward using enhanced merchandising IT tools to tailor the experience by shopping intent and location, the LLM elaborates with specific technologies like 'computer-vision inventory visibility' and 'AI-enhanced personalization' that are not mentioned in the ground truth. These may be plausible inferences but are not supported by the provided data. (3) The multi-hop reasoning is partially sound—the model correctly identifies the evolution from general investment in interconnectedness to more tailored experiences—but it overreaches by introducing unverified figures and technologies. (4) Despite these issues, the LLM captures the core qualitative direction of the strategy shift (from broad investment to data-driven personalization), and addresses both parts of the question (evolution over time and tailoring changes), which supports moderate scores in qualitative accuracy and high contextual relevance. However, the unsupported $3.2B figure severely undermines factual correctness, warranting a mid-low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 407,
        "total_tokens": 1671
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the financial relationship between DHR and Aldevron evolved between 2022 and 2023, particularly in terms of capital investment and acquisition-related expenditures?",
      "original_answer": "In 2022, DHR anticipated capital expenditures of approximately $1.5 billion, with a portion of this spending attributed to increased manufacturing capacity for products related to the Aldevron Acquisition, among others. This reflects a growing capital commitment tied to Aldevron. By 2023, the financial relationship had evolved significantly, as evidenced by the net cash consideration paid to Aldevron amounting to $9,561 million, indicating that Aldevron had transitioned from being primarily a capital investment target to a core component of DHR's consolidated assets. This represents a substantial shift in the nature of their relationship from a dependency to a stakeholding and integration model.",
      "llm_answer": "\nBetween 2022 and 2023 the DHR‑Aldevron relationship shifted from a purchase‑financing stage to a mature‑business‑investment stage.  In 2022 the company projected roughly **$1.5 billion of capital expenditures**, with a portion dedicated to expanding Aldevron’s manufacturing capacity, reflecting continued investment beyond the 2021 acquisition.  By 2023 the acquisition was fully integrated and **no new acquisition‑related outlays** were reported—only the $28 million of transaction costs that had been recorded in 2021—so subsequent capital spending has been focused on sustaining and growing Aldevron’s operations rather than on further purchase‑price or integration expenditures.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. Most critically, it states that 'no new acquisition-related outlays' were reported in 2023 and only references $28 million in transaction costs from 2021. This directly contradicts the ground truth, which reports $9,561 million in net cash consideration paid to Aldevron in 2023—indicating a major acquisition payment occurred that year, not zero. The LLM incorrectly implies the acquisition was completed in 2021, while the ground truth shows the financial relationship evolved significantly in 2023 due to this large cash outflow. (2) Quantitative accuracy is severely compromised: the $1.5 billion capital expenditure figure for 2022 is correctly cited, but the $9,561 million (i.e., $9.561 billion) cash payment in 2023 is entirely omitted and replaced with a false claim of no new outlays. The $28 million transaction cost figure is not in the ground truth and appears fabricated or misattributed. (3) Multi-hop reasoning fails: the model does not recognize that the 2023 cash payment represents a pivotal evolution in the financial relationship—from capital investment to full acquisition integration. Instead, it incorrectly frames 2023 as a post-acquisition year with no major expenditures, missing the core development. (4) Contextual relevance is moderate because the answer addresses capital investment and acquisition spending over the two years, but the factual foundation is wrong. The reasoning about shifting stages is plausible but built on incorrect data. Due to major errors in key financial figures and the nature of the 2023 transaction, the overall correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 456,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has the structure and total value of Telco LLC's preferred interests evolved from 2022 to 2024, and what changes were made to the distribution rates and reset schedules during this period?",
      "original_answer": "In 2022, Telco LLC had $2,000 in nonconvertible cumulative preferred interests (Telco Class A-1) with an initial preferred distribution rate of 4.25% annually, subject to reset every seven years. By 2024, Telco LLC expanded its preferred interests with the issuance of an additional $5,250 in preferred interests (Telco Class A-2 and A-3) in April 2023, bringing the total cumulative preferred interests to $7,250. The new preferred interests (Class A-2 and A-3) carried a significantly higher initial preferred distribution rate of 6.85% annually, with the first reset scheduled for November 1, 2027, and every seven years thereafter. This represents both a structural expansion in the capital stack and a strategic shift toward higher-yielding preferred instruments.",
      "llm_answer": "\nFrom September 2020 through the end of 2024 the Telco LLC preferred equity grew from the original $2 billion of Class A‑1 cumulative perpetual preferred interests to a total of $7.25 billion after the 2023 issuance of $5.25 billion of new Class A‑2/A‑3 series and the 2024 agreement to add a $2.25 billion Class A‑4 tranche in Q1 2025.  The original Class A‑1 carries a 4.25 % annual distribution that resets on a seven‑year schedule, while the 2023‑added Class A‑2/A‑3 carries a higher 6.85 % initial rate with a reset on Nov 1 2027 and every seven years thereafter; the forthcoming Class A‑4 will have a 5.94 % initial rate and a reset on Nov 1 2028 with resets every four years.  Thus, the structure expanded both in size and in the mix of series, and the distribution rates and reset intervals were adjusted to reflect the newer, higher‑yielding series and their distinct reset timetables.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly identifies the initial $2,000 (interpreted as $2 billion) of Class A-1 preferred interests with a 4.25% distribution rate and seven-year reset, and correctly states the $5,250 million ($5.25 billion) issuance of Class A-2/A-3 in 2023 with a 6.85% rate and Nov 1, 2027 reset, it introduces a $2.25 billion Class A-4 tranche to be issued in Q1 2025, which is not mentioned in the ground truth. The original answer states the total preferred interests reached $7,250 million by 2024 due to the 2023 issuance alone, but the LLM implies the $7.25 billion total includes a future 2025 issuance, which is incorrect. This misrepresents both the timing and structure of the capital changes. (2) The quantitative inaccuracies are critical: the LLM incorrectly adds a $2.25 billion Class A-4 tranche not present in the ground truth, inflating the implied 2024 total beyond what is stated. It also misstates the total evolution — the ground truth confirms $2,000 + $5,250 = $7,250 by 2024, but the LLM suggests $2B + $5.25B + $2.25B = $9.5B eventually, with $7.25B reached via incorrect composition. Additionally, the LLM introduces new details — 5.94% rate and four-year resets for A-4 — which are not in the original. (3) The multi-hop reasoning is partially sound in recognizing structural expansion and rate changes, but fails in synthesis by introducing unsupported future tranches. The model appears to extrapolate beyond the data, confusing planned or future events not present in the knowledge graph. (4) Contextual relevance is high — the answer addresses structure, value evolution, distribution rates, and reset schedules as asked. However, the correctness score is low due to major factual and quantitative errors that distort the actual capital structure evolution. The core facts about the 2023 issuance are correct, warranting a partial score, but the addition of unverified instruments undermines overall accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1427,
        "completion_tokens": 541,
        "total_tokens": 1968
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has AIG's use of Expected Loss Ratio Methods evolved between 2022 and 2024, particularly in terms of the types of insurance lines and the rationale for their application?",
      "original_answer": "In 2022, AIG used Expected Loss Ratio Methods primarily for the latest accident year and in combination with other methods like loss development for aviation exposures, due to their high-severity nature. By 2024, AIG expanded the use of Expected Loss Ratio Methods to include U.S. Workers' Compensation, a long-tail line of business, where it was used in combination with loss development and frequency/severity methods. This reflects a broader application of the method across different insurance lines with varying claim characteristics.",
      "llm_answer": "\nBetween 2022 and 2024 AIG continued to rely on Expected‑Loss‑Ratio (ELR) techniques for its short‑tail and program lines—particularly U.S. Property, U.S. Special‑Risk, aerospace, environmental and other specialty lines—while extending the approach to newer portfolios such as UK/Europe casualty, Japanese personal‑lines and Canadian business.  The rationale has broadened from simply “low‑frequency/high‑severity” exposures to include ELR as a way to incorporate inflation‑adjusted loss trends, rate changes and emerging underwriting cycles, and to supplement development methods with ground‑up claim projections for the most recent accident year.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains significant factual discrepancies compared to the ground truth. (1) Correct elements: The answer correctly identifies that AIG used Expected Loss Ratio (ELR) methods in short-tail and specialty lines, and that the method was applied to recent accident years, which aligns with the 2022 usage. It also correctly notes an expansion of ELR use by 2024, and mentions the rationale involving inflation-adjusted trends and supplementing other methods—this reflects a plausible evolution in methodology. (2) Quantitative accuracy: There are no specific numbers (e.g., percentages, dollar amounts) in either the original or LLM answer, so no numeric inaccuracies are present. Dates (2022–2024) are correctly framed. (3) Multi-hop reasoning assessment: The LLM fails on key entity accuracy and synthesis. The ground truth specifies that in 2024, AIG expanded ELR to U.S. Workers' Compensation—a long-tail line—highlighting a shift in application to different claim characteristics. The LLM instead claims expansion into UK/Europe casualty, Japanese personal-lines, and Canadian business, which are not mentioned in the original answer and represent a different direction. This misrepresents the core evolution. Additionally, the original emphasizes aviation as a high-severity line in 2022 and Workers' Compensation as a long-tail extension in 2024; the LLM omits both anchor points despite referencing aerospace. (4) Justification: While the LLM captures the general trend of broadening ELR use and updated rationale, it substitutes the actual lines of business with unverified ones, undermining qualitative accuracy. The reasoning is plausible but not factually aligned. Correctness is reduced to 5 due to major factual substitution in the multi-hop synthesis of insurance lines evolved over time.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 496,
        "total_tokens": 1799
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has Target's approach to its owned brands evolved from 2023 to 2024, particularly in terms of strategic emphasis and product portfolio development?",
      "original_answer": "In 2023, Target emphasized expanding its owned brands portfolio as a core strategic element to drive relevancy and market share growth. By 2024, the company shifted focus to producing a broad range of owned and exclusive brands, listing over 40 distinct brands across various categories, indicating a more concrete execution phase of brand development and diversification.",
      "llm_answer": "\nTarget’s owned‑brand strategy moved from a focus in 2023 on “strengthening our owned‑brands portfolio” and expanding “signature partnerships” to a 2024 emphasis on making those brands a larger, more visible driver of sales—about one‑third of merchandise revenue now comes from owned and exclusive labels—and on deepening exclusive design collaborations (e.g., Apple, Disney, Levi’s, Ulta) that are integrated with the revamped Target Circle loyalty program.  The portfolio development now stresses a broader, more curated mix of exclusive brands across categories, leveraging both in‑store and digital fulfillment to boost traffic, market‑share growth, and differentiation through newness, style and value.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer includes several details not present in the ground truth, particularly the claim that 'about one-third of merchandise revenue now comes from owned and exclusive labels' and specific brand partnerships (Apple, Disney, Levi’s, Ulta) integrated with Target Circle. These specifics are not supported by the original answer and introduce unverified quantitative and qualitative claims. The ground truth does not mention revenue percentages or specific partnership names, so these additions reduce factual accuracy. (2) The quantitative claim of 'one-third of merchandise revenue' is a significant addition with no basis in the original answer, which provides no financial metrics or percentages. This is a major error in quantitative accuracy. (3) The qualitative shift described—moving from portfolio expansion in 2023 to broader execution and diversification in 2024—is consistent with the ground truth and shows correct multi-hop reasoning across years and strategic phases. The emphasis on exclusive brands and category diversification aligns semantically with 'over 40 distinct brands' and 'concrete execution phase.' (4) While the core evolution in strategic emphasis is reasonably captured, the inclusion of unsupported specifics, especially the revenue figure, downgrades the correctness and quantitative accuracy. Contextual relevance is high as the response directly addresses strategic emphasis and portfolio development as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1271,
        "completion_tokens": 405,
        "total_tokens": 1676
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "What does IBM's continued listing of the 0.875% Notes due 2030 in 2024 alongside the new 2.900% Notes due 2030 suggest about its debt financing strategy and the market conditions for long-term borrowing?",
      "original_answer": "In 2023, IBM listed the 0.875% Notes due 2030 (trading symbol IBM30A) among its registered securities, indicating its initial issuance of this long-term debt instrument. By 2024, IBM not only maintained the 0.875% Notes due 2030 in its capital structure but also introduced a new 2.900% Notes due 2030 (trading symbol IBM30C). The significant increase in the interest rate—from 0.875% to 2.900%—for the same maturity year suggests that IBM may have pursued additional financing in 2024 under less favorable interest rate conditions, or it may be targeting different investor segments with varied risk-return profiles. This dual listing could also indicate a strategic effort to diversify its debt portfolio and manage refinancing risks by having multiple instruments maturing in the same year but with different coupon rates.",
      "llm_answer": "\nIBM kept its existing 0.875 % Notes due 2030 on the 2024 filing and simultaneously issued new 2.900 % Notes due 2030.  This shows the company is preserving a low‑cost legacy tranche while tapping the market for fresh long‑term capital at today’s higher rates, indicating that investors now demand substantially higher yields on 10‑year debt.  The move reflects a layered financing strategy—maintaining cheap legacy debt for future flexibility while issuing higher‑coupon bonds to fund operations or refinance near‑term maturities in a market where long‑term borrowing costs have risen.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the key facts: IBM maintained the 0.875% Notes due 2030 and issued new 2.900% Notes due 2030 in 2024. The percentages (0.875% and 2.900%), maturity year (2030), and timing (2024 filing) are all accurate and match the ground truth. No calculation errors or incorrect numbers are present. (2) Quantitative accuracy is perfect—interest rates and years are correctly reported with no discrepancies. Format variations (e.g., spacing in '0.875 %') do not affect meaning. (3) The reasoning is sound and captures the core implications: the rise in coupon rate reflects higher borrowing costs, and IBM is employing a layered strategy by keeping low-cost debt while issuing new, higher-cost debt. The LLM infers market conditions (higher yields demanded) and strategic intent (flexibility, refinancing) consistent with the ground truth. However, it omits the point about targeting different investor segments or diversifying the debt portfolio for refinancing risk management, which slightly reduces qualitative completeness. (4) The answer is highly contextually relevant, directly addressing IBM’s debt strategy and market conditions for long-term borrowing. It synthesizes multi-hop information (continuation of old notes + issuance of new notes) and draws appropriate inferences. The only minor gap is the absence of explicit mention of investor segmentation or portfolio diversification, but the core strategic insight is preserved. Thus, correctness is rated 9/10—excellent but not fully comprehensive.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 424,
        "total_tokens": 1791
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did the composition of AT&T's long-term debt instruments evolve between 2022 and 2024, particularly regarding the 4.000% Global Notes due June 1, 2049 and the addition of new long-term notes?",
      "original_answer": "In 2022, AT&T listed the 4.000% Global Notes due June 1, 2049 (T 49A) among other long-term debt instruments, but did not include the 4.300% Global Notes due November 18, 2034. By 2024, the 4.000% Global Notes due 2049 remained registered under the same symbol (T 49A), and the company added the 4.300% Global Notes due 2034 (T 34C). This indicates that AT&T expanded its long-term debt portfolio by introducing new maturities while maintaining existing long-dated obligations like the 2049 notes.",
      "llm_answer": "\nBetween 2022 and 2024 AT&T lengthened and reshaped its long‑term debt ladder: the 2022 filing listed only shorter‑dated Global Notes (e.g., 2021‑2023 maturities) and did not include a 4.000 % issue maturing in 2049, whereas the 2024 filing adds a new 4.000 % Global Notes tranche due June 1 2049 (ticker T 49A) and introduces a suite of fresh long‑term issues—such as the 2.400 % notes due Mar 15 2024, 1.800 % due Sep 5 2026, 2.900 % due Dec 4 2026, 1.600 % due May 19 2028 and others extending to 2035‑2066.  This reflects AT&T’s strategy of extending average debt maturity and diversifying coupon profiles by issuing ultra‑long‑dated, lower‑coupon securities like the 2049 notes while supplementing the portfolio with multiple newer tranches across the early‑to‑mid‑2030s.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, AT&T already had the 4.000% Global Notes due June 1, 2049 (T 49A) in its 2022 long-term debt portfolio, but the LLM incorrectly claims this was added in 2024. Additionally, the ground truth states that the 4.300% Global Notes due November 18, 2034 (T 34C) were added by 2024, but the LLM invents multiple notes (e.g., 2.400% due Mar 15, 2024; 1.800% due Sep 5, 2026; etc.) that are not mentioned in the original answer and appear fabricated. (2) Quantitative accuracy is very low: none of the interest rates or maturity dates cited in the LLM answer (e.g., 2.400%, 1.800%, 2.900%, etc.) match the ground truth, which only references the 4.000% 2049 notes and the 4.300% 2034 notes. The addition of notes extending to 2035–2066 is unsupported. (3) The multi-hop reasoning is flawed: the LLM incorrectly infers that AT&T introduced the 2049 notes in 2024 when they were already present in 2022. It also fails to correctly identify the specific new instrument added (4.300% due 2034) and instead invents a suite of new notes. The core evolution—retention of the 2049 notes and addition of the 2034 notes—is misrepresented. (4) Contextual relevance is moderate because the answer discusses debt composition changes and long-term strategy, which is relevant, but the factual foundation is incorrect. The conclusion about extending maturities and diversifying coupons is speculative and not supported by the specific data in the ground truth. Overall, the answer is largely incorrect due to false entities and misrepresentation of the timeline and instruments.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 453,
        "total_tokens": 1783
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did the financial impact of the Heritage AspenTech acquisition evolve between 2023 and 2024, particularly in terms of intangibles amortization and restructuring costs?",
      "original_answer": "In 2023, the intangibles amortization related to the Heritage AspenTech acquisition was $258, while in 2024, this figure decreased to $97. Additionally, restructuring costs were $72 in 2023 and increased to $228 in 2024. This indicates a reduction in the amortization burden but a significant rise in restructuring expenses over the two years.",
      "llm_answer": "\nIn 2023 the Heritage AspenTech acquisition produced roughly **$258 million of intangible‑asset amortization** and only **about $1 million of restructuring costs** directly tied to the integration. By 2024 that amortization had slipped to a smaller, non‑separately disclosed level (absorbed in the overall $1.077 billion intangible amortization, with $560 million of the 2024 total coming from the newer NI purchase), while **restructuring expenses linked to the AspenTech segment jumped to $8 million**—part of a company‑wide **$228 million restructuring charge**—showing that the integration moved from a modest cost base in 2023 to a much larger, ongoing restructuring effort in 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, intangibles amortization was $258 in 2023 and decreased to $97 in 2024. The LLM correctly identifies the $258 million figure for 2023 but incorrectly states that the 2024 amortization was 'non-separately disclosed' and absorbed into a larger total, contradicting the ground truth which explicitly gives a $97 figure for 2024. The LLM also vastly underreports restructuring costs: it claims $1 million in 2023 and $8 million in 2024 (as part of segment costs), while the ground truth reports $72 in 2023 and $228 in 2024. The LLM does correctly note a company-wide $228 million restructuring charge in 2024, but incorrectly frames the AspenTech-related portion as only $8 million, missing that the full $228 is tied to the acquisition in the context of the question. (2) Number verification: $258 → correct; $97 → missing/incorrectly obscured; $72 → reported as $1 million (wrong); $228 → partially correct in total but misattributed. Calculations or comparisons based on these numbers are therefore flawed. (3) Multi-hop reasoning is partially present—the model attempts to track changes over time and link costs to the acquisition—but fails in synthesis because it introduces incorrect data and does not align with the actual evolution described in the ground truth. (4) Scores reflect major quantitative errors (especially underreporting restructuring costs by an order of magnitude), poor qualitative accuracy due to incorrect interpretation of cost allocation, and moderate contextual relevance since the answer addresses the right topic and timeframe but with wrong specifics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 460,
        "total_tokens": 1723
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How has AIG's use of expected loss ratio methods for workers' compensation evolved between 2022 and 2024, particularly in relation to the segmentation of business types and the impact of large deductible accounts?",
      "original_answer": "In 2022, AIG applied expected loss ratio methods primarily to guaranteed cost business in the most recent accident year, while for excess of deductible business, these methods were given significant weight in the most recent five accident years. The company also noted that the proportion of large deductible business had increased, slowing the reporting pattern of claims. By 2024, AIG continued to use expected loss ratio methods but placed greater emphasis on segmentation by deductible size and claim handling (AIG vs. third-party administrators), and explicitly highlighted the increasing influence of large deductible accounts on slowing claim emergence. Additionally, 2024 disclosures emphasized limitations in claim count data due to aggregation and reinsurance exclusions, which were not as prominently noted in 2022.",
      "llm_answer": "\nBetween 2022 and 2024 AIG kept using expected‑loss‑ratio techniques for workers‑compensation, but it refined the way it applies them.  The company now separates guaranteed‑cost and excess‑of‑deductible business and, within the latter, further segments by deductible size and whether claims are handled by AIG or a third‑party administrator, while also isolating California and New York from the rest of the portfolio.  Because the share of large‑deductible accounts has risen and their claims emerge more slowly, AIG places greater reliance on expected‑loss‑ratio estimates—particularly for the most recent five accident years—when reserving these segmented lines.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the continued use of expected loss ratio methods by AIG for workers' compensation from 2022 to 2024 and accurately notes the increased segmentation by deductible size and claim handling (AIG vs. third-party administrators), which aligns with the 2024 evolution described in the ground truth. It correctly states that large deductible accounts have a slower claim emergence pattern and that AIG places greater reliance on expected loss ratio estimates for recent accident years—specifically mentioning the most recent five, which matches the original emphasis on excess of deductible business. The mention of segmentation by geography (California and New York) is not present in the ground truth and appears to be an addition not supported by the original data, which slightly undermines qualitative accuracy. Additionally, the LLM omits key 2024-specific disclosures about limitations in claim count data due to aggregation and reinsurance exclusions—information that was explicitly highlighted as new in 2024 compared to 2022. While the core facts about business segmentation and the impact of large deductible accounts are correct, this omission of an important qualitative shift in disclosure reduces completeness and reasoning accuracy. Quantitatively, there are no incorrect numbers or miscalculations—the reference to 'most recent five accident years' matches the ground truth and is correctly contextualized. The answer remains contextually relevant and semantically close to the original, but lacks full fidelity in capturing all nuanced changes in AIG’s disclosures. Thus, the correctness score is 7 for accurate core content with minor but notable omissions and one unsupported addition.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 469,
        "total_tokens": 1858
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How has Target's approach to cybersecurity threat investigation and response evolved from 2023 to 2024, particularly in terms of its Cyber Fusion Center operations and collaboration with external organizations?",
      "original_answer": "In 2023, Target operated its Cyber Fusion Center as part of its threat investigation and response capabilities, and emphasized collaboration with organizations across industries to share threat intelligence and best practices. By 2024, Target not only maintained its Cyber Fusion Center but also introduced a more structured incident response program with a coordinated escalation model to inform management and the Board of Directors during security incidents. Additionally, in 2024, Target expanded its external engagement by incorporating regular training and compliance activities for team members, and by leveraging third-party vendors to assess and test its cybersecurity program. This represents a more comprehensive and mature approach to cybersecurity threat response and collaboration.",
      "llm_answer": "\nTarget’s cyber‑risk framework shifted from a 2023 focus on establishing a **Cyber Fusion Center** that investigated and contained threats to a 2024 model in which that center is **formally integrated into the enterprise‑risk program**, with dedicated escalation paths to the Board and the Audit & Risk Committee.  At the same time, the company **expanded its threat‑intelligence collaboration**—sharing intelligence with industry groups and third‑party vendors—and **boosted internal capabilities** through the new “Cyber Plus Institute” training and talent‑development initiatives, creating a more coordinated, proactive, and partnership‑driven approach to cyber‑threat investigation and response.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly identifies that in 2023, Target established its Cyber Fusion Center for threat investigation and response, and in 2024 evolved its approach by integrating the center into enterprise risk management with formal escalation paths to the Board and Audit & Risk Committee—matching the original answer's point about a 'coordinated escalation model.' The expansion of external collaboration through industry groups and third-party vendors is accurately reflected, as is the emphasis on enhanced internal capabilities. The mention of the 'Cyber Plus Institute' as a training initiative aligns with the original answer's reference to 'regular training and compliance activities for team members,' though this specific name does not appear in the ground truth; however, it can be interpreted as a plausible naming of the initiative and does not contradict the facts. There are no numeric values to verify, so quantitative accuracy is满分. The reasoning is sound, demonstrating multi-hop synthesis across years, internal operations, and external collaboration. The answer is contextually fully relevant and captures the evolution in maturity and structure of Target's cybersecurity posture. The only minor deviation is the introduction of a named program ('Cyber Plus Institute') not present in the original, which slightly affects qualitative precision but does not undermine factual correctness. Hence, a score of 9 is appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 413,
        "total_tokens": 1802
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did Eli Lilly's financial relationship with Baqsimi evolve between 2023 and 2024, particularly in terms of revenue recognition and contractual arrangements?",
      "original_answer": "In 2023, Eli Lilly reported $579.0 million in revenue specifically attributed to the sale of the rights for Baqsimi. By 2024, Baqsimi was included within broader collaboration and other revenue disclosures, reflecting its integration into revenue from collaborations and other arrangements, which included the 2023 sales of rights for both the olanzapine portfolio and Baqsimi. This shift indicates a move from direct product revenue to a more complex revenue recognition model under collaborative arrangements, suggesting a strategic evolution in how the company accounts for and manages its financial relationship with Baqsimi.",
      "llm_answer": "\nBetween 2022 and 2023 Eli Lilly’s revenue from Baqsimi jumped from $139 million to $677.6 million, a surge driven primarily by a one‑time $579 million payment for the product’s rights that was recorded as collaboration/other revenue and recognized when control of those rights transferred.  The contractual structure therefore shifted from ordinary product sales to a license‑type arrangement, with the upfront payment being amortized (or recognized as a discrete gain) and any subsequent royalties or milestone payments being recorded as collaboration revenue in later periods.  By 2024 the company continued to recognize revenue from Baqsimi only to the extent of any remaining license balances or royalties, as the bulk of the financial benefit had already been captured in the 2023 rights‑sale transaction.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "(1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. The ground truth states that Eli Lilly recognized $579.0 million in 2023 from the sale of Baqsimi rights, but the LLM claims total Baqsimi revenue was $677.6 million in 2023, with a $579 million one-time payment—this $677.6M figure is not supported by the original answer and appears fabricated. Additionally, the LLM references 2022 revenue of $139 million, which is not mentioned in the ground truth and cannot be verified. (2) The only correct number is the $579 million payment, which aligns with the original answer, though it is embedded in an incorrect broader context. The claim that this was 'recorded as collaboration/other revenue' is plausible and consistent with the shift to collaborative revenue recognition, but the additional revenue figures and implied timeline are not. (3) The reasoning partially captures the multi-hop evolution: the shift from direct product revenue to collaboration-based recognition is correctly inferred, and the idea that the rights sale led to a change in contractual structure is aligned with the original answer. However, the LLM incorrectly frames this as a transition occurring between 2022 and 2023, while the ground truth focuses on the 2023–2024 evolution in reporting, with 2024 showing integration into broader collaboration disclosures. The LLM also introduces the concept of amortization and future royalties without evidence in the ground truth. (4) While the general direction of the answer—strategic shift in revenue recognition due to rights sale—is contextually relevant and thematically sound, the incorrect numbers and unsupported details severely undermine factual correctness. The contextual relevance is high because it addresses revenue recognition and contractual changes, but accuracy is low due to invented data points.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 509,
        "total_tokens": 1872
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did AT&T's approach to managing its capital structure through preferred interests evolve from 2023 to 2024, particularly regarding the repurchase of Mobility Preferred Interests and the expansion of Tower Holdings and Telco LLC preferred interests?",
      "original_answer": "In 2023, AT&T repurchased the remaining 213 million Mobility Preferred Interests for $5,414, removing $2,650 from 'Accounts payable and accrued liabilities' and $2,670 from 'Other noncurrent liabilities.' This repurchase was primarily funded by the issuance of $5,250 in new Telco LLC preferred interests, which carried a 6.85% annual distribution rate. By 2024, AT&T had shifted focus toward expanding its Tower Holdings preferred interests, where $6,000 in 2019 Tower preferred interests were restructured into fixed and floating rate classes with a 5.90% base rate and SOFR + 250 bps, respectively. Additionally, the total Telco LLC preferred interests increased to $7,250, including the original $2,000 (Telco Class A-1) and the 2023 additions. This reflects a strategic pivot from repurchasing legacy preferred interests to leveraging new preferred structures with more flexible redemption and distribution terms to manage capital and liquidity.",
      "llm_answer": "\nIn 2023 AT&T eliminated the last $5.4 billion of Mobility Preferred Interests by repurchasing the remaining 213 million shares—funding the buy‑back mainly with the $5.25 billion of new cumulative preferred interests it had issued earlier that year in Telco LLC and, earlier, with $2 billion of Series B preferred equity in Mobility II.  In 2024 the company refined its preferred‑equity structure: it amended the 2019 Tower Holdings preferred interests to reset their rates and convert them to fixed‑ and floating‑rate classes, and it expanded Telco LLC’s preferred stack by issuing an additional $5.25 billion of Class A‑2/A‑3 interests and announcing a planned $2.25 billion Class A‑4 issuance for 2025, while continuing to manage overall capital through debt, dividends and limited equity‑based financing.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the core evolution in AT&T's capital structure strategy from 2023 to 2024, correctly identifying the repurchase of 213 million Mobility Preferred Interests in 2023 and the restructuring/expansion of Tower Holdings and Telco LLC preferred interests in 2024. However, there are key quantitative inaccuracies. The repurchase amount is stated as $5.4 billion, which aligns approximately with the ground truth $5,414 million, so this is acceptable. But the LLM claims the repurchase was funded by $5.25 billion from Telco LLC preferred interests and 'earlier' $2 billion of Series B preferred equity in Mobility II — this $2 billion is not mentioned in the ground truth and appears to be fabricated or misattributed. The ground truth specifies that the $5,250 million Telco LLC issuance was the primary funding source, with no mention of Mobility II equity. (2) In 2024, the LLM correctly notes the restructuring of 2019 Tower Holdings preferred interests into fixed and floating rate classes but omits the specific rates (5.90% base rate and SOFR + 250 bps) and incorrectly implies new issuance occurred in Tower Holdings rather than a restructuring. Additionally, the LLM states Telco LLC expanded by $5.25 billion in new Class A-2/A-3 interests and a planned $2.25 billion Class A-4, totaling $7.5 billion — but the ground truth says total Telco LLC preferred interests reached $7,250 million, composed of original $2,000 (Class A-1) and 2023’s $5,250 addition. The LLM’s $5.25 billion issuance figure conflates the 2023 issuance with a supposed 2024 issuance, which is incorrect. The $7,250 total is accurate in the ground truth, but the LLM misattributes timing and structure. (3) The multi-hop reasoning is partially sound: the model connects the repurchase to new preferred issuances and identifies a strategic shift toward more flexible capital structures. However, it fails to accurately synthesize the exact sequence and sources of funding, introducing unsupported details. (4) Despite these quantitative flaws, the overall narrative of strategic pivot — from repurchasing legacy interests to building new preferred structures — is preserved, and the entities (AT&T, Mobility, Tower Holdings, Telco LLC) and years are correct. Wording differences are acceptable, but the introduction of unverified funding sources and mis-timed issuances reduces quantitative accuracy. Hence, correctness is reduced to 7 due to significant but not fundamental errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1466,
        "completion_tokens": 662,
        "total_tokens": 2128
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did Emerson's relationship with AspenTech evolve from 2023 to 2024, and what financial impacts did this transformation have on Emerson's gross margin and ownership structure?",
      "original_answer": "In 2023, Emerson had a business relationship with AspenTech as part of its Software and Control offerings. By 2024, this relationship transformed into a more significant strategic position, as Emerson acquired a 55% ownership stake in 'New AspenTech' (formerly Heritage AspenTech) following a transaction that included approximately $6.0 billion in cash. This change in relationship had a measurable financial impact: the AspenTech acquisition contributed to a 3.3 percentage point increase in gross margin in 2023 and was part of broader changes that led to a 1.8 percentage point increase in gross margin in 2024. Additionally, the ownership stake marked a structural shift in Emerson’s involvement with AspenTech, moving from a partner to a majority shareholder.",
      "llm_answer": "\nFrom 2023 to 2024 Emerson’s ownership in AspenTech rose from the ~55 % stake it held after the 2022 Heritage AspenTech transaction to about 57 % and, in November 2024, it announced a proposal to acquire the remaining shares and take AspenTech private.  The integration added roughly $1.4 billion of sales and lifted Emerson’s consolidated gross margin to 50.8 %—a 1.8‑percentage‑point increase—although inventory step‑up amortization of $231 shaved about 1.3 points off that margin, while the deeper equity stake expanded Emerson’s equity‑compensation reserve and led it to reserve 4 million shares for future issuance under AspenTech’s compensation plans.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. First, it incorrectly states that Emerson held a ~55% stake in AspenTech in 2023 as a carryover from a 2022 transaction, while the ground truth indicates the 55% ownership was acquired as part of a 2024 transaction involving $6.0 billion in cash. The claim of increasing to 57% and planning to take AspenTech private in November 2024 is not supported by the original answer and introduces unverified details. (2) Quantitative inaccuracies include the $1.4 billion in sales contribution, which is not mentioned in the ground truth. The gross margin increase of 1.8 percentage points in 2024 is correctly cited, but the LLM misattributes the full increase to the AspenTech integration, whereas the original answer specifies it was 'part of broader changes.' The $231 million inventory step-up amortization and 4 million reserved shares are not in the ground truth and appear fabricated. (3) The multi-hop reasoning is partially sound in linking ownership changes to financial impacts, but it fails to correctly trace the timeline and nature of the relationship evolution. The original answer emphasizes a shift from a business relationship in 2023 to majority ownership in 2024, which the LLM misrepresents by implying pre-existing ownership. (4) Contextual relevance is high as the answer addresses ownership evolution and financial impacts on margin and structure, but factual correctness is compromised by incorrect numbers, dates, and entities. The core margin impact for 2024 is correct, but the 3.3 percentage point increase in 2023 from the original answer is entirely omitted. Overall, the answer is partially correct but contains significant factual and quantitative errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 476,
        "total_tokens": 1839
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How has AIG's Japan pension plans' contribution to non-U.S. pension obligations evolved between 2022 and 2024, and what change occurred in the weighted average discount rate applied to these plans during this period?",
      "original_answer": "In 2022, AIG's Japan pension plans accounted for 61% of total non-U.S. pension assets, with an expected long-term rate of return of 1.85%. By 2024, the Japan pension plans' share of non-U.S. projected benefit obligations decreased to 50% as of December 31, 2024, from 54% in 2023, and the weighted average discount rate increased to 1.81% in 2024 from 1.48% in 2023. This indicates a relative decline in the size of the Japan pension plans within AIG's non-U.S. pension structure, accompanied by a notable increase in the discount rate applied, likely reflecting changes in market conditions or investment strategy.",
      "llm_answer": "\nThe Japan pension plans accounted for roughly 50 % of total non‑U.S. pension obligations in 2022 (about 51 % in 2022, rising to ≈ 54 % in 2023 and back to ≈ 50 % in 2024), showing a relatively stable contribution. Over the same period, the weighted‑average discount rate applied to these plans increased from roughly 1.0 % in 2022 to 1.48 % in 2023 and 1.81 % in 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key quantitative data. According to the ground truth, in 2022, Japan pension plans accounted for 61% of non-U.S. pension *assets* (not obligations), but the LLM incorrectly states it was around 50% of *obligations* in 2022. The ground truth does not provide the 2022 obligation percentage, only that it decreased from 54% in 2023 to 50% in 2024. The LLM fabricates a 51% figure for 2022 and implies a rise to 54% in 2023, which is not supported by the original answer. Additionally, the LLM claims the 2022 discount rate was 'roughly 1.0%', but the ground truth does not provide the 2022 rate—only that it increased from 1.48% in 2023 to 1.81% in 2024. Thus, the LLM invents data for 2022. (2) The only correct numbers are the 1.48% discount rate in 2023 and 1.81% in 2024, and the 50% share in 2024. However, the 2022 and 2023 obligation percentages are incorrect or unsupported. The original answer mentions a decrease from 54% in 2023 to 50% in 2024, which the LLM captures approximately, but misrepresents the trend by suggesting a rise in 2023 from 51% to 54%. (3) The multi-hop reasoning is partially sound in that the LLM attempts to track changes over time and links discount rate changes to the Japan plans, but it fails to distinguish between *assets* and *projected benefit obligations*—a critical distinction. The original answer discusses assets in 2022 and obligations in 2023–2024, but the LLM conflates the two. (4) Contextual relevance is high because the answer addresses both parts of the question—evolution of contribution and discount rate change—and attempts a year-by-year comparison. However, due to major quantitative errors and fabrication of unsupported figures, the correctness and quantitative accuracy scores are low. The qualitative accuracy is moderate because the direction of change (decline to 50%, rising discount rate) is correct for the final years, but the reasoning is based on incorrect data for earlier years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 545,
        "total_tokens": 1808
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did Amazon's disclosure about the impact of competitive stores on its business evolve between the 2022 and 2023 10-K filings, particularly in terms of the framing of external market conditions?",
      "original_answer": "In the 2022 10-K filing, Amazon described competitive stores as a general factor among many that could impact sales and operating results, listing them alongside internal capabilities such as inventory management and customer satisfaction. The 2022 filing included the phrase: 'the introduction of competitive stores, websites, products, services, price decreases, or improvements' as a potential cause of sales fluctuations. In contrast, the 2023 filing retained the same core language but embedded it within a broader context that emphasized external economic and geopolitical conditions, stating that revenue and operating profit growth 'depends on the continued growth of demand for the products and services offered by us or our sellers, and our business is affected by, among other things, general economic, business, and geopolitical conditions worldwide.' This indicates a shift toward framing competitive pressures as part of a larger set of external risks rather than a standalone concern.",
      "llm_answer": "\nIn the 2022 filing the discussion of competition was brief and tucked into a long list of risk factors, merely noting that “local companies may have a substantial competitive advantage because of their greater understanding of, and focus on, the local customer.” By the 2023 filing Amazon isolates the competitive threat and explicitly links it to external market conditions—such as slower Internet adoption, weaker consumer spending, country‑specific regulatory and geopolitical risks, and the emergence of evolving business models—thereby framing competition as a macro‑level, environment‑driven challenge rather than a generic risk.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies in describing Amazon's 10-K disclosures for 2022 and 2023, despite being relevant to the question's intent. (1) The quoted text in the 2022 filing is incorrect: the LLM claims Amazon stated that 'local companies may have a substantial competitive advantage because of their greater understanding of, and focus on, the local customer,' but this specific language does not appear in the 2022 10-K as a description of competitive stores. Instead, the ground truth correctly states that competitive stores were listed among other factors like price decreases and product improvements in a general risk factor list. (2) The LLM claims that in the 2023 filing Amazon 'isolates the competitive threat' and explicitly links it to external conditions like slower Internet adoption and regulatory risks. However, the ground truth shows that the core language about competitive stores remained unchanged and was embedded within a broader discussion of external conditions—not isolated or expanded upon. (3) The multi-hop reasoning is flawed: the LLM incorrectly infers a shift in emphasis and framing by inventing specific quotes and characterizations not present in the actual filings. While the general direction of the conclusion (a shift toward framing competition within broader external risks) aligns loosely with the truth, the supporting details are fabricated or misrepresented. (4) There are no numerical values in the question or answers, so quantitative accuracy is not applicable—scored as 10 by default. Contextual relevance is moderate because the answer attempts to address the evolution of Amazon's risk disclosure, but qualitative accuracy is low due to incorrect entity details (misquoted text) and faulty reasoning. Thus, the overall correctness score is low at 3.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1421,
        "completion_tokens": 493,
        "total_tokens": 1915
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How has Target's exposure to port security risks evolved between 2023 and 2024, particularly in terms of geographic focus and operational impact?",
      "original_answer": "In 2023, Target specifically highlighted California ports as a key area affected by port security issues, mentioning that these ports were where the company received a significant portion of its imported merchandise. By 2024, Target broadened its focus, referring to 'major U.S. ports' without specifically naming California, indicating a more generalized concern across multiple locations. Additionally, in 2023, the company noted it had made alternative arrangements due to past disruptions, while in 2024, the emphasis shifted to potential future impacts, including increased costs and inventory supply issues, due to ongoing global conflicts and labor disputes.",
      "llm_answer": "\nTarget’s port‑security risk remains anchored to the same geographic chokepoints—principally the California ports that handle the bulk of its imported goods—as noted in both the 2023 and 2024 filings.  However, the 2024 disclosure places greater emphasis on how recurring port disruptions (e.g., labor disputes, congestion or diversions) could raise costs and force the company to rely on alternative logistics arrangements, underscoring a sharper operational impact than was highlighted a year earlier.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains a significant factual inaccuracy in the geographic evolution of Target's port security risk. The ground truth states that in 2023, Target specifically highlighted California ports, but in 2024 broadened its focus to 'major U.S. ports' without naming California—indicating a shift from specific to generalized geographic concern. However, the LLM incorrectly claims that both 2023 and 2024 filings highlight California ports as the principal risk, contradicting the ground truth. This undermines the qualitative accuracy of the multi-hop reasoning. While the operational impact description—increased costs, alternative logistics, and emphasis on future disruptions—is consistent with the 2024 shift in tone, the LLM misrepresents the geographic evolution. There are no numerical figures to assess, so quantitative accuracy is scored as 10 by default. Contextually, the response addresses the question's focus on geographic and operational changes, but with flawed synthesis. Thus, correctness is penalized for the key error in entity (geographic location) accuracy and reasoning across years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 321,
        "total_tokens": 1613
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How did Emerson's financial relationship with Heritage AspenTech evolve between 2023 and 2024, particularly in terms of acquisition-related amortization and restructuring costs?",
      "original_answer": "In 2023, Emerson reported $258 million in intangibles amortization related to the Heritage AspenTech acquisition. By 2024, this specific amortization was no longer reported, indicating that the focus had shifted away from AspenTech as a newly acquired entity. Additionally, restructuring costs increased significantly from $72 million in 2023 to $228 million in 2024, suggesting that Emerson undertook more extensive restructuring activities in 2024, potentially reflecting integration efforts or strategic realignments following the AspenTech acquisition.",
      "llm_answer": "\nIn 2023 Emerson recognized about **$258 million** of amortization of the intangibles acquired in the Heritage AspenTech transaction, but by 2024 those assets were essentially fully amortized; the 2024 total intangibles amortization of **$1.077 billion** was driven almost entirely by **$560 million** of amortization of assets obtained in the NI acquisition.  At the same time, restructuring expenses surged from **$72 million in 2023 to $228 million in 2024**, reflecting higher integration‑related costs—including **$43 million of stock‑compensation expense attributable to NI**—showing that Emerson’s post‑acquisition cost‑restructuring activities intensified in 2024.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reports the $258 million AspenTech-related amortization in 2023 and the increase in restructuring costs from $72 million in 2023 to $228 million in 2024, which aligns with the ground truth. However, the LLM introduces new information not present in the original answer—specifically, that the $1.077 billion total intangibles amortization in 2024 was driven by $560 million from the 'NI acquisition' and that AspenTech assets were 'essentially fully amortized.' These details are not supported by the ground truth and represent an overinterpretation or addition of external knowledge. Additionally, the mention of $43 million in stock-compensation expense related to 'NI' is not part of the original answer and introduces a new entity (NI) without basis in the provided context. (2) All numeric values mentioned in the original answer ($258M, $72M, $228M) are accurately reported. The additional numbers ($1.077B, $560M, $43M) cannot be verified against the ground truth and appear to be extraneous. (3) The multi-hop reasoning is partially sound—correctly identifying the drop in AspenTech-specific amortization and rise in restructuring costs as indicators of evolving post-acquisition integration. However, the reasoning extends beyond the available evidence by attributing 2024 amortization and restructuring costs to a different acquisition (NI), which breaks the logical chain based on the provided data. (4) The contextual relevance is high as the answer directly addresses the evolution of Emerson's financial relationship with AspenTech, but the correctness score is reduced due to unsupported additions. The core facts are right, but the answer goes beyond the evidence with potentially misleading specifics, warranting a 7 for overall correctness and qualitative accuracy, 8 for quantitative accuracy (since reported numbers from the original are correct), and 10 for relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 519,
        "total_tokens": 1834
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has AIG's use of Expected Loss Ratio methods evolved between 2022 and 2024, particularly in terms of the weight given to this method across different lines of business and accident years?",
      "original_answer": "In 2022, AIG applied Expected Loss Ratio methods primarily for more recent accident years in lines such as D&O, E&O, EPLI, and professional liability, where losses are low frequency and high severity. The method was also used in conjunction with IBNR factor methods for low frequency/high severity losses, with factors continually reevaluated based on emerging claim experience and market factors. By 2024, AIG continued to use Expected Loss Ratio methods but expanded their application to include U.S. Workers' Compensation, a long-tail line of business, where they were used in combination with loss development and frequency/severity methods. This reflects a broader application of the method across different risk profiles and a more integrated approach to reserving in complex portfolios.",
      "llm_answer": "\nBetween 2022 and 2024 AIG kept Expected‑Loss‑Ratio (ELR) as the primary tool for the newest business but made the weighting far more explicit.  In the 2022 filing the ELR was described only as receiving “more weight in the more recent accident years” across its D & O, E & O, EPLI and professional‑liability lines.  By the 2024 filing the company states that ELR methods are given “significant weight” specifically for the most recent **five** accident years and for excess‑of‑deductible, cyber, M&A and other specialty lines, while mature years rely on loss‑development techniques.  Thus the evolution is a shift from a general, qualitative preference for newer years to a quantified, line‑specific emphasis on the latest five accident years.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of AIG's use of Expected Loss Ratio (ELR) methods between 2022 and 2024, correctly identifying that ELR was used for recent accident years in specific lines like D&O, E&O, EPLI, and professional liability in 2022. It also correctly notes a shift toward more explicit weighting by 2024. However, there are significant factual inaccuracies: (1) The claim that by 2024 AIG applied ELR with 'significant weight' specifically for the most recent **five** accident years is not supported by the ground truth, which does not specify a five-year window. This is a precise numerical assertion that introduces false quantitative information. (2) The LLM states ELR was expanded to 'excess-of-deductible, cyber, M&A and other specialty lines' in 2024, but the ground truth does not mention these specific lines—instead, it highlights the **new inclusion of U.S. Workers' Compensation**, a long-tail line, which the LLM omits entirely. This is a critical omission in terms of business line evolution. (3) The ground truth emphasizes that by 2024, ELR was used in **combination with loss development and frequency/severity methods** in Workers' Compensation, reflecting methodological integration, which the LLM fails to mention. Instead, it focuses on a non-existent 'five-year' rule and unverified new lines. While the qualitative trend—increased specificity and broader application—is directionally correct, the answer substitutes actual developments with fabricated details. The reasoning is logically structured and contextually relevant, but the introduction of unsupported specifics (especially the 'five accident years' and new lines) undermines factual correctness. Quantitative accuracy is low due to the unsupported 'five' figure; qualitative accuracy is moderate due to correct framing but incorrect entity mapping; contextual relevance is high as the response directly addresses the question’s scope.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1395,
        "completion_tokens": 522,
        "total_tokens": 1918
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has the monetization strategy for Amazon's film groups evolved between 2022 and 2023, based on changes in capitalized video and music content costs and associated expenses?",
      "original_answer": "Amazon's monetization strategy for film groups evolved between 2022 and 2023, as evidenced by an increase in both the capitalized video and music content costs and the associated expenses. In 2022, the capitalized costs were $16.7 billion with total video and music expenses of $16.6 billion, while in 2023, these figures increased to $17.4 billion and $18.9 billion, respectively. This indicates a more aggressive investment in content and a corresponding rise in monetization efforts.",
      "llm_answer": "\nBetween 2022 and 2023 Amazon’s capitalized investment in video and music content grew only modestly—from **$16.7 billion to $17.4 billion**—but the expense recognized on that content jumped sharply, from **$16.6 billion to $18.9 billion**.  This acceleration reflects a more aggressive monetization approach: the company is spending more on acquiring and producing titles, amortizing those costs faster (often on an accelerated basis tied to usage/viewing), and expanding the “film‑group” model across its Prime markets to drive subscriber growth and higher revenue per title.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly reports all key numerical values: capitalized video and music content costs increased from $16.7 billion in 2022 to $17.4 billion in 2023, and associated expenses rose from $16.6 billion to $18.9 billion. These figures exactly match the ground truth, satisfying quantitative accuracy. 2) The answer addresses all parts of the question—changes in capitalized costs and associated expenses—and correctly infers that the sharper rise in expenses indicates a more aggressive monetization strategy. 3) The reasoning is sound: the LLM correctly interprets the faster growth in expenses (vs. capitalized costs) as evidence of accelerated amortization and expanded monetization efforts, which aligns with the ground truth's conclusion. It adds context about amortization tied to usage and Prime subscriber growth, which is plausible and consistent with Amazon's known strategy, though slightly more interpretive than the original. 4) The only minor deviation is the phrase 'film-group model'—not explicitly mentioned in the ground truth—but this does not distort the meaning. Overall, the answer is factually correct, well-reasoned, and semantically equivalent to the original, warranting a high correctness score with a small deduction in qualitative accuracy due to slight interpretive expansion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1273,
        "completion_tokens": 366,
        "total_tokens": 1639
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has Philip Morris International's financial relationship with RBH evolved between 2022 and 2024, particularly in terms of its stake and associated impairment?",
      "original_answer": "In 2022, Philip Morris maintained a trademark relationship with RBH, continuing to report volume of brands sold by RBH such as HEETS and other heated tobacco units. By 2024, PMI held an equity investment in RBH, which became subject to a significant impairment charge of $2,316 million due to unresolved allocation of a $32.5 billion Canadian tobacco litigation settlement among RBH, ITL, and JTIM. This reflects a shift from a trademark and brand licensing relationship to a more direct equity investment facing financial impairment.",
      "llm_answer": "\nBetween 2022 and 2024 PMI’s exposure to Rothmans, Benson & Hedges (RBH) shifted from a de‑consolidated subsidiary (first removed from consolidated results in 2019) to an equity‑method investment that it continued to carry on its balance sheet.  In 2024 the company concluded that the proposed CAD 32.5 bn settlement and the unresolved allocation among RBH, Imperial Tobacco Canada and JTI Macdonald created a clear indicator of impairment, so it performed a fair‑value test and recorded a **$2.3 bn non‑cash impairment charge** (a $1.49‑per‑share EPS impact) for its RBH equity investment.  This impairment reflects the deteriorated outlook for the stake and marks the most significant change in PMI’s financial relationship with RBH over the 2022‑2024 period.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the essential evolution in Philip Morris International's financial relationship with RBH between 2022 and 2024. (1) It correctly identifies the shift from a de-consolidated subsidiary (with ongoing brand licensing in 2022) to an equity-method investment facing impairment in 2024. The core facts—equity stake, impairment trigger due to unresolved CAD 32.5 billion Canadian litigation settlement allocation among RBH, Imperial Tobacco Canada (ITL), and JTI Macdonald—are all present and correct. (2) Quantitatively, the $2.3 billion impairment charge is correctly reported (ground truth: $2,316 million; LLM: $2.3 billion), which is an acceptable rounding. The mention of a $1.49-per-share EPS impact is an additional accurate detail not in the original answer but consistent with plausible reporting. The CAD 32.5 billion settlement amount matches exactly. (3) The multi-hop reasoning is sound: the model synthesizes the change in accounting treatment (from de-consolidated to equity method) and links the impairment to the legal uncertainty, demonstrating understanding across time and entities. (4) Minor difference: the original emphasizes the trademark and volume reporting relationship in 2022, while the LLM focuses on the accounting status (de-consolidated subsidiary). However, both are true and complementary; the LLM omits explicit mention of HEETS or heated tobacco units but captures the financial relationship’s evolution, which is the focus of the question. No factual errors; only slight omission of product-level detail. Hence, a score of 9 is warranted—excellent accuracy with near-complete synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 452,
        "total_tokens": 1780
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How did the sensitivity of LLY's net product revenue to changes in sales return, rebate, and discount liabilities evolve between 2023 and 2024, based on the disclosures in the respective 10-K filings?",
      "original_answer": "In 2023, LLY disclosed that a 5% change in its consolidated sales return, rebate, and discount liability would result in a $615 million change in revenue. In 2024, while the company continued to describe the accounting policy for revenue recognition and accruals for rebates and discounts, it did not provide an updated sensitivity figure. This omission suggests that the company did not disclose a revised estimate for the impact of liability changes on revenue in 2024, indicating a lack of updated quantitative disclosure compared to 2023.",
      "llm_answer": "\nThe 10‑K disclosures show that the estimated revenue impact of a 5 % change in the combined sales‑return, rebate and discount accrual fell slightly from about **$615 million in 2023** to **about $600 million in 2024**.  This indicates a modest reduction in the sensitivity of net product revenue to movements in those liabilities, although the dollar effect remains material, and the company notes that actual adjustments have been less than 2 % of revenue in each year.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that the sensitivity decreased from $615 million in 2023 to about $600 million in 2024. The ground truth explicitly states that LLY did not provide an updated sensitivity figure in 2024 — meaning no $600 million number was disclosed. This is a major factual error. (2) Quantitative accuracy is very low because the $600 million figure is fabricated; there is no support for it in the 2024 10-K. The 5% change impact was only disclosed for 2023 ($615M), and no update was given for 2024. Any numerical comparison is therefore invalid. (3) The multi-hop reasoning fails because the model incorrectly assumes continuity in disclosure and invents a comparative figure. The correct reasoning requires recognizing the absence of data in 2024, not imputing a value. The model also incorrectly implies a trend (modest reduction in sensitivity), which cannot be concluded without disclosure. (4) Contextual relevance is moderate because the answer addresses the right topic (sensitivity of revenue to liabilities) and correctly references the 2023 figure, but it misrepresents the 2024 disclosure status, undermining the core accuracy. The mention of 'actual adjustments have been less than 2%' is not in the original answer and lacks verification. Overall, the answer is misleading due to unsupported quantitative claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1266,
        "completion_tokens": 383,
        "total_tokens": 1649
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How has the role and revenue contribution of Bulk shipments evolved from 2022 to 2024, based on Union Pacific's disclosures?",
      "original_answer": "In 2022, Bulk shipments had an average revenue per car of $3,305 in 2021 (referenced in the 2022 filing), showing a 6% increase from 2020. By 2024, Bulk shipments had grown in strategic importance, contributing 32% of total freight revenues, with detailed operations covering grain, fertilizer, and coal markets, including international connections to Mexico and access to Canadian interline routes. This indicates a transformation in the Bulk segment's role from a revenue-per-unit perspective to a more strategically embedded and revenue-significant component of Union Pacific's operations.",
      "llm_answer": "\nUnion Pacific’s disclosures show that Bulk shipments have consistently accounted for roughly one‑third of total freight revenue—about 33 % of freight revenue in 2022 (derived from the 2021‑2020 revenue mix) and 32 % of freight revenue in 2024—so the segment’s revenue share has remained stable over the period.  However, the internal composition of Bulk has evolved: while grain and renewable‑related volumes stayed strong, the coal component declined, reflecting a shift toward grain, fertilizer and food‑refrigerated shipments, even as pricing gains and fuel‑surcharge revenue continue to drive Bulk’s contribution.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that Bulk shipments contributed 32% of freight revenue in 2024, matching the ground truth. However, it incorrectly states that Bulk accounted for 33% of freight revenue in 2022, which is not supported by the original answer—no such percentage is mentioned for 2022 in the ground truth. Instead, the ground truth references average revenue per car of $3,305 in 2021 (disclosed in the 2022 filing) and a 6% year-over-year increase from 2020. The LLM invents a 33% figure for 2022 without basis, which is a significant quantitative error. (2) The calculation or derivation of '33%' from '2021-2020 revenue mix' is not substantiated in the ground truth and appears to be an unsupported inference. The ground truth does not provide 2022 revenue share data, so claiming stability in revenue share is misleading. (3) Qualitatively, the LLM captures the evolving strategic role of Bulk shipments, noting shifts in composition (decline in coal, growth in grain and fertilizer), international connections, and pricing dynamics. It correctly infers a transformation in the segment’s strategic importance, aligning with the ground truth’s emphasis on increased strategic embedding. (4) Contextually, the response is highly relevant, addressing both revenue contribution and role evolution. Despite the invented percentage, the overall trend interpretation—stable-to-slightly-declining revenue share with changing internal composition—is plausible and adds insight. However, the fabrication of a 33% figure undermines quantitative accuracy. Thus, while reasoning and relevance are strong, the incorrect number reduces the correctness score to 7.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 459,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did the interest rate of IBM's Notes due 2028 evolve between 2023 and 2024, and what does this indicate about IBM's debt strategy?",
      "original_answer": "In 2023, IBM had 1.750% Notes due 2028 (IBM 28A) listed, and in 2024, the same 1.750% Notes due 2028 (IBM 28A) were still present in the disclosures. This indicates that the interest rate for this specific issuance remained unchanged over the two years. However, IBM introduced new notes with different interest rates in 2024, such as the 2.900% Notes due 2030 and the 3.150% Notes due 2033, suggesting a broader strategy to issue debt at higher rates for longer maturities.",
      "llm_answer": "\nThe 2023 and 2024 Form 10‑K filings both list IBM’s 2028 securities with the same coupon — the “0.300 % Notes due 2028” (and the parallel “1.750 % Notes due 2028”) carry the identical rates in each year.  This unchanged pricing shows that IBM has been able to lock in very low‑cost, long‑dated financing, reflecting a deliberate strategy of maintaining a conservative capital structure and taking advantage of favorable market rates to fund its growth initiatives.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "(1) The LLM answer contains significant factual inaccuracies. It incorrectly states that IBM has '0.300% Notes due 2028' in both 2023 and 2024, which is not present in the ground truth. The only correct rate mentioned is the 1.750% Notes due 2028, which matches the original answer. However, the claim about the '0.300%' note is false and unsupported by the ground truth. (2) Quantitative accuracy is low because the 0.300% figure is entirely incorrect and not mentioned in the original data. The 1.750% rate is correctly identified, but the erroneous addition of a non-existent 0.300% note undermines the numerical accuracy. No calculations are involved, but the presence of a fabricated interest rate is a critical error. (3) The reasoning is partially sound in interpreting that unchanged rates suggest a strategy of locking in low-cost financing, but it fails to mention IBM's broader strategy of issuing new debt at higher rates for longer maturities (e.g., 2.900% Notes due 2030 and 3.150% Notes due 2033), which is a key part of the original answer and essential to understanding IBM's debt strategy. The model misses this multi-hop insight, limiting its qualitative accuracy. (4) Contextual relevance is moderate because the answer addresses the interest rate evolution and attempts to infer strategy, but the inclusion of false data and omission of key strategic moves (new higher-rate, long-term issuances) reduces its overall correctness. The core idea of stable rates indicating conservative financing is relevant, but incomplete without the broader context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1231,
        "completion_tokens": 428,
        "total_tokens": 1660
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did AT&T's capital structure strategy regarding preferred interests evolve from 2023 to 2024, particularly in relation to the Mobility Preferred Interests and the introduction of new preferred instruments?",
      "original_answer": "In 2023, AT&T repurchased all of its Mobility Preferred Interests, which had a redemption value of approximately $5,340 million and paid annual cash distributions of $373 million. This marked a significant shift in strategy, as the company eliminated this class of preferred interests. In 2024, AT&T introduced structural modifications to other preferred instruments, including the restructuring of its Tower Holdings preferred interests to include both fixed and floating rate components, and the expansion of Telco LLC preferred interests to a total of $7,250 million. This evolution indicates a strategic pivot from Mobility-based preferred capital to more diversified and strategically tailored preferred instruments tied to infrastructure and telecommunications assets.",
      "llm_answer": "\nIn 2023 AT&T retired its original Mobility Preferred Interests—repurchasing the remaining 213 million shares in April 2023, re‑classifying the instrument as a liability and settling it for cash—so that no Mobility preferred equity remained on the balance sheet at the end of 2023.  In 2024 the company introduced new preferred structures, most notably the August 2024 reset of the 2019 Tower Holdings preferred interests into Fixed‑Rate and Floating‑Rate Class A Limited Membership Interests and the October 2024 issuance of an additional $2.25 billion of Telco LLC Class A‑4 cumulative preferred interests (along with the ongoing 6.8 % Mobility II non‑controlling preferred interests), thereby replacing the legacy Mobility preferred equity with a suite of layered, reset‑rate preferred instruments that have staggered redemption and distribution features.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the 2023 repurchase of Mobility Preferred Interests, noting their full retirement and reclassification as a liability, consistent with the original answer's claim of eliminating this class. While the original answer cites a redemption value of $5,340 million and annual distributions of $373 million, the LLM does not include these specific figures, representing a minor omission but not an error. (2) The LLM accurately describes the 2024 developments: the August 2024 restructuring of Tower Holdings preferred interests into fixed and floating rate components (referred to as Class A Limited Membership Interests), and the October 2024 issuance of an additional $2.25 billion in Telco LLC preferred interests. This expansion brings the total Telco LLC preferred to $7,250 million, which the LLM implies through context but does not explicitly state—another minor completeness gap. (3) The reasoning is sound: the LLM correctly infers a strategic shift from Mobility-based preferred equity to diversified, structured preferred instruments tied to infrastructure (Tower Holdings) and telecom assets (Telco LLC), demonstrating proper multi-hop synthesis across years and instruments. (4) All entities (AT&T, Mobility Preferred Interests, Tower Holdings, Telco LLC) and timeframes (April 2023, August 2024, October 2024) are accurate. The mention of the 6.8% Mobility II non-controlling preferred interests adds detail not in the original but does not contradict it. Overall, the answer captures the evolution in capital structure strategy with high fidelity, missing only explicit mention of two key numbers ($5,340M redemption value, $373M distributions, and $7,250M total Telco LLC), which prevents a perfect 10. Quantitative accuracy is slightly reduced for these omissions, but no numbers stated are incorrect. Qualitative and contextual accuracy remain very high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1423,
        "completion_tokens": 529,
        "total_tokens": 1952
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How has Amazon's characterization of the competitive threat from websites evolved between 2022 and 2023, and what specific changes in language indicate a shift in the nature of this competition?",
      "original_answer": "In 2022, Amazon described competitive websites as part of a broader list of fluctuating business factors, indicating a general awareness of competitive pressures. By 2023, Amazon's language evolved to reflect a more direct and strategic competitive stance, specifically highlighting the introduction of 'competitive stores, websites, products, services, price decreases, or improvements' as a central concern. This shift indicates a more focused and intensified competitive threat from digital platforms, suggesting an evolution from a general operational risk to a more strategic and dynamic competitive challenge.",
      "llm_answer": "\nIn the 2022 filing Amazon warned that “competition will intensify, including through adoption of evolving business models,” describing the threat in largely generic terms. By 2023 the language was sharpened to note that “local companies may have a substantial competitive advantage because of their greater understanding of, and focus on, the local customer, as well as their more established local brand names,” explicitly singling out region‑specific, brand‑centric rivals as a distinct competitive force. This change signals Amazon’s recognition that the competitive pressure now includes localized players with deeper market insight, not just generic online competitors.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is factually incorrect in its characterization of Amazon's competitive threat evolution between 2022 and 2023, despite being internally consistent and well-structured. (1) The original answer (ground truth) states that in 2022, Amazon described competitive websites as part of a broader list of fluctuating business factors, and in 2023 shifted to highlighting 'competitive stores, websites, products, services, price decreases, or improvements' as a central concern—indicating a more strategic and intensified digital competition. However, the LLM answer incorrectly claims that in 2023 Amazon specifically emphasized 'local companies' with 'greater understanding of the local customer' and 'established local brand names' as a new competitive threat. This specific language about local companies and brand-centric rivals does not appear in the ground truth and misrepresents the actual shift in Amazon's disclosure. (2) There are no numeric values in the question or answers, so quantitative accuracy is not applicable—scored as 10 by default. (3) The multi-hop reasoning is flawed: the model fails to correctly identify the nature of the language shift (from general awareness to strategic focus on digital competition) and instead invents a new theme (localization) not present in the ground truth. This indicates a failure in synthesizing the correct information from the filings. (4) While the answer addresses the question's structure (comparing language across years), it does so with inaccurate content, reducing contextual relevance. The answer is plausible-sounding but factually misaligned with the source data, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 454,
        "total_tokens": 1789
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How has PM's relationship with KT&G evolved from 2022 to 2024, particularly in terms of its strategic reliance on KT&G's heat-not-burn products within PMI's smoke-free product portfolio?",
      "original_answer": "In 2022, PM had a global collaboration agreement with KT&G that allowed PMI to exclusively distribute KT&G's smoke-free products, including heat-not-burn products like LIL Mini and LIL Plus, outside of South Korea. This agreement was initially for three years, indicating a strategic partnership aimed at expanding KT&G's products globally. By 2024, this relationship had evolved such that KT&G's heat-not-burn products were no longer just distributed by PMI but were integrated into PMI's broader smoke-free product portfolio, specifically being listed among PMI's own heat-not-burn offerings. This indicates a deeper strategic reliance on KT&G's product line within PMI's own commercialization efforts, suggesting a shift from a distribution partnership to a more embedded supplier or technology partner role for KT&G.",
      "llm_answer": "\nFrom the 2022 10‑K (pp. 49‑53) we see that the January 2020 global collaboration with KT&G gave PMI exclusive rights to market KT&G’s smoke‑free products outside South Korea, and by 2022 PMI was already launching licensed KT&G heat‑not‑burn devices (e.g., LIL, Fiit, Miix) in several markets. The 2024 10‑K (pp. 38‑42) shows that these licensed heat‑not‑burn products now constitute a major share of PMI’s smoke‑free portfolio—accounting for roughly $14.3 bn of total smoke‑free net revenue and featuring prominently in the company’s regional revenue breakdown—demonstrating that PMI’s strategic reliance on KT&G’s heat‑not‑burn offerings has deepened considerably between 2022 and 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of PM's relationship with KT&G from a distribution agreement to deeper integration, which aligns with the ground truth. It correctly identifies the 2020 global collaboration and PMI's exclusive rights to market KT&G's smoke-free products outside South Korea, and notes the presence of KT&G's products in PMI's portfolio by 2024. However, significant issues arise in quantitative accuracy: the claim that licensed heat-not-burn products accounted for '$14.3 bn of total smoke-free net revenue' in 2024 is not supported by the ground truth, which contains no such financial figure. This number is a critical factual error, as the original answer does not mention any revenue figures, nor does it quantify the 'major share' of the portfolio. This fabrication or misattribution of financial data severely undermines correctness. While the qualitative shift toward increased strategic reliance is reasonably inferred, the LLM overreaches by asserting a quantitative impact absent in both the ground truth and any cited public filing data. The reasoning is partially sound—correctly tracking the partnership’s expansion—but fails in multi-hop validation by introducing unsupported metrics. Contextually, the answer is well-targeted and addresses the core question about strategic reliance and evolution. Entity accuracy (PMI, KT&G, product names like LIL) and timeframes (2022–2024) are correct. Overall, the answer gets the direction of change right but fails on key factual precision, especially in financial quantification.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 427,
        "total_tokens": 1814
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did IBM's use of the PWCC Plan for funding employee awards evolve between 2022 and 2024, particularly in terms of its administration and scope?",
      "original_answer": "In 2022, the PWCC Plan was described as being used solely to fund awards for employees of PwCC who joined IBM after the acquisition, and it was stated that the plan would continue to be used for this purpose. By 2024, while the plan's administration and terms remained substantively identical to the 2001 Plan, IBM emphasized that the PWCC Plan 'has been and will continue to be used solely' for funding awards for former PwCC employees, indicating a reaffirmation rather than a change in scope. However, the shift in language from 'has been and will continue to be' in 2022 to a more definitive tone in 2024 suggests a stronger commitment to maintaining the plan’s current usage without expansion.",
      "llm_answer": "\nBetween 2022 and 2024 IBM kept the PWCC Plan’s purpose and administration essentially unchanged: the plan continues to be used **only** to fund awards for employees who came from the PwCC acquisition and expressly excludes senior‑executive awards, and it is still administered by the Executive Compensation and Management Resources Committee under the same terms as the 2001 Plan. What does evolve is the **scale** of the plan – the 2024 filing shows a larger remaining share reserve and higher numbers of RSU, PSU and option awards under the “equity‑compensation plans not approved by security holders” table, indicating an expanded award pool but no shift in governance or scope beyond the original PwCC employee group.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains several inaccuracies and introduces unsupported claims not present in the ground truth. (1) The original answer states that the PWCC Plan's scope and administration remained substantively unchanged between 2022 and 2024, with IBM reaffirming its exclusive use for former PwCC employees. However, the LLM incorrectly asserts that there was an 'evolution in scale' with a 'larger remaining share reserve' and 'higher numbers of RSU, PSU and option awards' in 2024, which is not supported by the ground truth and introduces quantitative claims without evidence. (2) No numeric data (e.g., share reserves, award counts) is present in the original answer, so the LLM's inclusion of such metrics fails the quantitative accuracy check—these figures are either hallucinated or inferred beyond available information. (3) The qualitative reasoning is partially sound in identifying continuity in administration (e.g., same committee, exclusion of senior executives), but the core claim of expanded scale contradicts the ground truth's emphasis on unchanged scope and represents a significant factual deviation. (4) Contextually, the response addresses the question about evolution in administration and scope, but the erroneous conclusion about scaling undermines correctness. The ground truth notes only a subtle shift in language tone ('has been and will continue to be' becoming more definitive), not any operational or numerical expansion. Thus, while the answer is relevant and captures some correct elements (e.g., exclusive use for PwCC employees, same administrative terms), the introduction of unsupported quantitative growth claims results in a partially incorrect synthesis, warranting a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 471,
        "total_tokens": 1826
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How did AT&T's financial obligations and strategic approach to Mobility Preferred Interests evolve between 2023 and 2024, and what does this shift indicate about its broader capital structure management?",
      "original_answer": "In 2023, AT&T repurchased all remaining Mobility Preferred Interests for a total of $5,414 million, which included accrued and unpaid distributions, effectively eliminating this financial obligation. By 2024, there was no mention of Mobility Preferred Interests in the disclosures, indicating a complete exit from this instrument. This contrasts with AT&T's treatment of other preferred interests, such as the Tower Holdings and Telco LLC preferred interests, which remained outstanding and were even expanded or restructured in 2024. This shift indicates a strategic move to reduce certain long-term liabilities while maintaining or adjusting other capital instruments for flexibility, suggesting a selective approach to managing its capital structure.",
      "llm_answer": "\nBetween 2023 and 2024 AT&T retired its original “Mobility Preferred Interests” – the 7 % cumulative preferred equity that had been redeemable and was fully repurchased in April 2023 – and replaced it with newer, more flexible preferred‑equity structures (the 2019 Tower Fixed/Floating Rate Interests and the upcoming $2.25 bn Telco Class A‑4 issuance).  This transition removes the legacy MPI from the balance sheet, reduces cash‑drag from fixed 7 % distributions, and introduces reset‑and‑call features that give the company greater discretion over leverage, dividend policy and capital recycling.  The shift signals AT&T’s broader strategy of simplifying its mezzanine‑equity layer, optimizing its capital structure, and using targeted preferred‑equity financing to fund network upgrades while preserving cash for share‑repurchases and dividend growth.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies in quantitative details. The ground truth states that AT&T repurchased all remaining Mobility Preferred Interests (MPI) in 2023 for $5,414 million, including accrued distributions. However, the LLM answer does not mention this specific amount, omitting a key factual figure. Additionally, the LLM claims that the MPI was replaced with newer instruments, including a '$2.25 bn Telco Class A-4 issuance' — this specific issuance is not mentioned in the ground truth and may be fabricated or misattributed. The ground truth confirms that Tower Holdings and Telco LLC preferred interests remained or were restructured in 2024, but does not state they were newly issued as replacements for MPI. (2) The date of repurchase (April 2023) is plausible but not confirmed in the ground truth, which only specifies the year 2023. The 7% cumulative rate is not present in the original answer and cannot be verified, making it an unsupported addition. (3) The reasoning about strategic intent — reducing fixed obligations, simplifying capital structure, and increasing flexibility — aligns well with the ground truth’s interpretation and shows sound qualitative synthesis. The LLM correctly identifies the elimination of MPI and contrasts it with the continued existence of other preferred interests, demonstrating multi-hop understanding. However, the causal replacement narrative (MPI → new instruments) goes beyond the evidence; the ground truth does not state that these new instruments replaced MPI, only that MPI was eliminated while others persisted. (4) The contextual relevance is high — the answer addresses the evolution and strategic implications directly. Qualitative accuracy is moderate due to correct directional logic but flawed specifics. Quantitative accuracy is low due to missing or invented figures. Correctness score is 6 because core facts (elimination of MPI, strategic capital management) are partially correct, but significant errors in numbers and entity relationships reduce overall accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1416,
        "completion_tokens": 555,
        "total_tokens": 1971
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has IBM's relationship with stock exchange regulations evolved in terms of regulatory exposure for its debt securities between 2022 and 2024?",
      "original_answer": "In 2022, IBM described stock exchange regulations as one of several factors influencing the value of its debt securities, placing it among other external variables beyond the company's control. By 2024, IBM's language shifted to indicate a more direct regulatory exposure, stating it is 'subject to' stock exchange regulations, which implies a heightened recognition of their binding impact on the company's financing activities. This evolution reflects a stronger acknowledgment of regulatory influence in 2024 compared to the more general mention in 2022.",
      "llm_answer": "\nBetween 2022 and 2024 IBM’s disclosures show that the regulatory exposure of its debt securities has remained anchored in the same set of market‑driven rules—interest‑rate movements, currency and exchange‑control risks, and the possibility that stock‑exchange listing requirements or rating‑agency actions could affect pricing, liquidity and the company’s ability to raise capital.  The 2022 filing (pages 20‑24) lists “governmental and stock‑exchange regulations” as one of several factors that influence debt‑security values, and the 2024 filing (pages 9‑13) repeats this language while emphasizing that any rating change or new exchange rule could “negatively impact the value and liquidity” of those securities.  Thus, rather than a substantive shift, IBM’s relationship with exchange regulations has evolved only in reaffirming that such regulatory factors continue to be a material, ongoing source of risk for its debt securities.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually consistent in terms of dates (2022 and 2024) and correctly references the nature of stock exchange regulations as a risk factor for IBM's debt securities, with appropriate contextual framing around liquidity, pricing, and capital raising. There are no numeric inaccuracies, as the response avoids specific figures and focuses on qualitative disclosures, which aligns with the ground truth. However, the core of the question asks about the *evolution* in IBM's relationship with stock exchange regulations, specifically in terms of *regulatory exposure*. The original answer identifies a meaningful shift in language—from describing regulations as an influencing factor in 2022 to stating in 2024 that IBM is 'subject to' them, indicating a stronger, more direct regulatory exposure. The LLM answer incorrectly characterizes this evolution as 'only in reaffirming' and claims 'rather than a substantive shift', which contradicts the ground truth that a clear qualitative shift in tone and legal implication occurred. This misrepresents the multi-hop synthesis required: comparing the semantic strength of disclosures across years to infer increasing regulatory acknowledgment. While the LLM provides relevant context and accurate entity/year alignment, it fails to correctly interpret the evolution in IBM’s language, leading to an incorrect conclusion about the nature of the change. Thus, while contextually relevant and quantitatively sound, the qualitative reasoning is flawed, warranting a mid-range correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1373,
        "completion_tokens": 423,
        "total_tokens": 1797
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How did Disney's financial relationship with A&E evolve from 2022 to 2024, particularly in terms of equity income contribution?",
      "original_answer": "In 2022, Disney's equity investment in A&E was a significant component of its equity income, with A&E being one of the most notable equity method investees alongside CTV Specialty Television. By 2024, Disney's equity in the income of investees had decreased by $207 million, specifically due to lower income generated from A+E. This indicates a material decline in the financial contribution from A&E to Disney over the two-year period.",
      "llm_answer": "\nFrom 2022 through 2024 Disney’s 50 % stake in A+E continued to be accounted for under the equity‑method, with Disney’s share of A+E’s net income reported as “Equity in the income (loss) of investees, net.”  In fiscal 2023 the equity‑income line was boosted by a one‑time $56 million gain that A+E realized from a content‑license termination, helping lift the segment’s contribution to $782 million; by fiscal 2024 that gain disappeared and overall equity income from A+E fell by $207 million to $575 million, reflecting weaker operating results and the absence of that prior‑year windfall.  Consequently, A+E’s equity‑income contribution to Disney’s earnings declined sharply from 2023 to 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and provides a detailed, factually correct evolution of Disney's financial relationship with A&E from 2022 to 2024. (1) It correctly identifies that Disney holds a 50% stake in A+E (A&E) and accounts for it using the equity method, consistent with the ground truth. (2) The quantitative details are mostly precise: it states that equity income from A+E fell by $207 million from 2023 to 2024, which matches the ground truth's reported decrease in equity income due to lower A+E results. It further specifies the 2024 income as $575 million and implies the 2023 figure was $782 million ($575M + $207M), aligning with the stated drop. The mention of a one-time $56 million gain in 2023 from a content-license termination adds contextual detail not in the original answer but does not contradict it and plausibly explains part of the decline. (3) The reasoning is sound: it correctly infers that the absence of the one-time gain and weaker operating performance led to the decline, which is consistent with the ground truth’s indication of reduced contribution. (4) While the original answer focuses on 2022 and 2024, the LLM adds 2023 context, enhancing completeness. The only minor deviation is that the original does not mention the $56M gain or exact income figures, so those could be seen as unverifiable additions—though they are internally consistent and do not undermine correctness. Overall, the LLM demonstrates strong multi-hop synthesis and accurate financial reasoning, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 420,
        "total_tokens": 1698
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How did the carrying value of securitized debt obligations change from 2022 to 2023, and what does this indicate about the company's long-term funding strategy?",
      "original_answer": "In 2022, the long-term funding, which primarily consists of securitized debt obligations and senior and subordinated notes, stood at $42.3 billion as of December 31, 2021, with a significant portion driven by securitized debt obligations. By December 31, 2023, the carrying value of securitized debt obligations alone decreased to $18.043 billion. This indicates a strategic shift or reduction in reliance on securitized debt obligations as part of the company's long-term funding structure over this period.",
      "llm_answer": "\nThe carrying amount of the company’s securitized debt obligations rose from **$16.97 billion at the end of 2022 to $18.04 billion at the end of 2023**—an increase of roughly **$1.07 billion (about 6 %)**.  This uptick reflects a deliberate expansion of Capital One’s asset‑backed securitization program, underscoring its long‑term funding strategy of relying on securitized debt to diversify and extend the maturity of its financing base while supporting growth in its loan portfolios.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in both direction and magnitude. The ground truth states that the carrying value of securitized debt obligations decreased to $18.043 billion by December 31, 2023, from a prior level (implied in context as higher in 2022). However, the LLM claims an increase from $16.97 billion in 2022 to $18.04 billion in 2023, which contradicts the original data. The original answer does not provide the 2022 value explicitly as $16.97B, nor does it support an increase—instead, it emphasizes a decrease and strategic reduction. (2) The quantitative inaccuracies are severe: the LLM fabricates a 2022 figure not present in the ground truth and misrepresents the trend. The calculation of a $1.07B (6%) increase is therefore based on incorrect inputs and is invalid. The correct trend is a decrease, though the exact 2022 value isn't provided in the original answer—only a 2021 figure of $42.3B for total long-term funding (which includes other instruments). (3) The multi-hop reasoning fails: the LLM incorrectly infers an expansion strategy, while the original answer indicates a strategic reduction in reliance on securitized debt. This reflects a complete reversal of the correct interpretation. (4) The contextual relevance is partially maintained—terms like 'securitized debt obligations' and 'long-term funding strategy' are relevant—but the factual foundation and conclusion are fundamentally wrong, warranting a very low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1252,
        "completion_tokens": 410,
        "total_tokens": 1662
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has Disney's approach to scripted programming evolved between 2022 and 2024, particularly in terms of its international general entertainment channels and its strategic shift toward DTC platforms?",
      "original_answer": "In 2022, Disney operated approximately 220 General Entertainment channels outside the U.S., primarily under the Fox, National Geographic, and Star brands, featuring a mix of scripted, reality, and documentary programming across multiple languages and regions. By 2024, there was a notable strategic shift, with increased emphasis on DTC platforms and less focus on traditional linear channels. The 2024 report highlights that Disney, along with Fox Corporation and Warner Bros. Discovery, planned a joint venture (Venu Sports) to distribute sports content via a DTC platform, signaling a broader move toward streaming. Additionally, Disney announced plans to launch a new DTC offering in early fall 2025 that would include live linear streams of ESPN channels and ESPN+. This reflects a strategic pivot from scripted linear content toward live and sports-driven DTC offerings, indicating a transformation in Disney’s programming and distribution priorities.",
      "llm_answer": "\nBetween 2022 and 2024 Disney moved away from depending on traditional linear general‑entertainment channels abroad and began funneling most of its scripted output into its direct‑to‑consumer services.  The company merged its standalone Star+ offering into Disney+ in Latin America (completed June 2024), added a Star tile to Disney+ internationally, and announced plans to place an ESPN‑branded tile on Disney+ in the U.S. (early 2025), while simultaneously signaling that revenue from licensing its linear channels will give way to subscription and advertising revenue from these DTC platforms.  This shift reflects a strategic pivot from selling scripted programming to external distributors to monetising that content directly through Disney+, Disney+ Hotstar and other bundled streaming services.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core strategic shift in Disney's approach to scripted programming between 2022 and 2024, particularly the pivot from international linear channels to DTC platforms. It correctly identifies key developments such as the merger of Star+ into Disney+ in Latin America (completed June 2024), the addition of the Star tile internationally, and the planned ESPN-branded tile on Disney+ in the U.S. by early 2025. These details align with the strategic shift described in the ground truth. However, the LLM omits specific quantitative context from 2022—namely, that Disney operated approximately 220 General Entertainment channels outside the U.S. under Fox, National Geographic, and Star brands—which is a factual detail present in the original answer and relevant to showing the scale of the linear footprint being scaled back. Additionally, while the LLM mentions broader DTC monetization through subscription and advertising, it misses the specific mention of the Venu Sports joint venture with Fox Corporation and Warner Bros. Discovery, which is a key multi-hop element indicating industry-wide strategic movement toward sports-driven DTC platforms. This omission affects completeness and slightly weakens the multi-hop synthesis, but the overall reasoning and entity identification (Disney, Star, ESPN, Disney+, international rollout timelines) are accurate. The dates (June 2024, early 2025) are correctly used and match the ground truth. Number formats and financial implications are discussed qualitatively without error, though no specific dollar amounts or percentages were involved. The answer is semantically aligned with the original and highly relevant to the question, effectively conveying the transformation in programming and distribution strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1453,
        "completion_tokens": 489,
        "total_tokens": 1942
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How did Tesla's financial and operational challenges related to energy storage products evolve from 2022 to 2023, particularly in terms of accounts receivable and production scaling dependencies?",
      "original_answer": "In 2022, Tesla disclosed significant long-term government rebates receivable related to its energy storage products, with a balance of $627 million as of December 31, 2021, indicating extended collection periods of up to a year or more. By 2023, the focus shifted from financial implications of receivables to operational dependencies, as Tesla highlighted production scaling risks for energy storage products, including bottlenecks, supplier constraints, and facility ramp delays at factories in Nevada, Texas, and other locations. These changes reflect a shift from financial exposure tied to receivables to broader production and supply chain dependencies affecting the company's ability to meet cost and profitability targets.",
      "llm_answer": "\nFrom 2022 to 2023 the company’s energy‑storage receivables remained volatile because a large share of cash inflows still came from delayed government rebates and financing‑partner payments—evidenced by the jump in long‑term rebates receivable (from $46 M in 2020 to $627 M in 2021) and the need to write allowances for doubtful accounts—so cash‑flow timing continued to hinge on those external collections.  At the same time, scaling production of storage systems became increasingly dependent on expanding battery‑cell capacity and securing additional supplier agreements; the 2023 filing notes that future volume growth is tied to “the construction and ramp of our current and future factories” and to “the continued supply of lithium‑ion battery cells,” highlighting that any bottleneck in cell supply or manufacturing‑line ramp‑up would directly constrain energy‑storage output.  Consequently, while the business began to generate more revenue from storage products, its financial health and ability to meet volume targets remained tightly linked to both the resolution of receivable‑collection cycles and the successful scaling of battery‑cell production.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the financial and operational evolution in Tesla's energy storage business from 2022 to 2023, noting the shift from receivables-related financial challenges to production scaling dependencies. However, there are key quantitative inaccuracies: the LLM states that long-term rebates receivable increased from $46M in 2020 to $627M in 2021, but the ground truth only confirms the $627M balance as of December 31, 2021, with no mention of the 2020 figure. This introduces an unsupported data point and implies a trend not verified in the original answer. Additionally, the original answer does not mention 'allowances for doubtful accounts' or 'write allowances,' which are not present in the ground truth and may misrepresent Tesla's financial disclosures. (2) While the $627M figure is correctly cited, the use of $46M in 2020 is unverified and potentially misleading, undermining quantitative accuracy. The rest of the financial narrative around delayed government rebates is consistent in spirit but extrapolated beyond the provided data. (3) The qualitative reasoning is strong: the LLM correctly synthesizes the shift from financial (receivables) to operational (production scaling) challenges, accurately citing factory ramps in Nevada, Texas, and supplier constraints, particularly around lithium-ion battery cells. It captures the multi-hop nature of the question by linking financial timing risks to operational bottlenecks. (4) Contextually, the answer is highly relevant, addressing both accounts receivable and production scaling as requested. Despite the unsupported 2020 number and the addition of unverified accounting details, the core evolution described aligns with the ground truth. Hence, the correctness score is 7—core facts and direction are right, but with notable factual overreach in numbers and terminology.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1485,
        "completion_tokens": 509,
        "total_tokens": 1994
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has the role of syrups in Coca-Cola's business model evolved between 2022 and 2023, particularly in relation to its bottling partners and fountain retailers?",
      "original_answer": "In 2022, Coca-Cola's relationship with syrups was primarily defined by its sales to both consolidated and unconsolidated bottling partners, with revenue and volume recognition dependent on the ownership structure of those partners. Specifically, concentrate and syrup sales were not recognized until finished products were sold to third parties in the case of consolidated bottlers, while recognition occurred immediately for unconsolidated bottlers. By 2023, the company's description of syrups shifted to emphasize their role as a dependency within a broader operational framework, particularly in relation to fountain retailers. In 2023, the company clarified that it manufactures fountain syrups and sells them directly to fountain retailers or authorized wholesalers and bottlers, highlighting a more integrated and strategic role for syrups in its finished beverage delivery system. This represents a shift from a primarily volume-driven metric to a more operationally embedded component of the business model.",
      "llm_answer": "\nBetween 2022 and 2023 Coca‑Cola moved syrups from being a back‑end concentrate sold only to bottling partners—where revenue was recognized only upon shipment (and, for consolidated bottlers, after the partner’s sale to end‑users)—to also include direct sales of fountain syrups to fountain retailers, with revenue recognized at the retailer’s purchase and variable‑consideration pricing that ties syrup revenue to both bottler performance and fountain‑retailer volumes. This evolution is reflected in the 2023 filing’s incidence‑based concentrate pricing model and the inclusion of fountain‑syrup sales in the North America operating segment.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution in Coca-Cola's syrup business model between 2022 and 2023, with accurate qualitative and quantitative elements. (1) It correctly identifies the shift in revenue recognition practices for bottling partners—highlighting that in 2022, revenue for consolidated bottlers was recognized only after sale to end customers, while for unconsolidated bottlers it was immediate. This aligns with the ground truth. (2) The LLM accurately notes the 2023 shift toward direct sales of fountain syrups to fountain retailers and authorized wholesalers, emphasizing a more integrated role. It correctly references the North America operating segment and the incidence-based concentrate pricing model, which reflects the strategic evolution. (3) The mention of variable-consideration pricing tying syrup revenue to bottler performance and fountain-retailer volumes is consistent with the operational embedding described in the original answer. (4) No specific numerical values (e.g., dollar amounts, percentages, volumes) are present in either answer, so quantitative accuracy is not compromised—scored 10 as no numbers are misstated. (5) Minor deduction in qualitative accuracy due to slightly overstated claim of 'direct sales' without fully clarifying that sales may also go through authorized wholesalers or bottlers (not exclusively direct), and the term 'back-end concentrate sold only to bottling partners' in 2022 slightly mischaracterizes the model, as fountain syrups already existed but were less emphasized. The original answer stresses a shift in emphasis and integration, not a fundamental new sales channel. (6) Contextual relevance is perfect—directly addresses the evolution in relation to bottling partners and fountain retailers. Overall, core facts and reasoning are sound, with only minor imprecision in framing, warranting a correctness score of 8.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1418,
        "completion_tokens": 515,
        "total_tokens": 1934
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How did Disney's investment in Other Mortgage- and Asset-Backed Securities (MBS & ABS) evolve from fiscal year 2022 to fiscal year 2024, and what was the trend in its proportion relative to the overall fair value hierarchy?",
      "original_answer": "In fiscal year 2022, Disney's investment in Other MBS & ABS was valued at $96 million, representing 1% of the total plan asset mix. By fiscal year 2024, this investment increased to $120 million, maintaining a 1% share of the total plan asset mix. While the absolute value of the investment grew moderately, its proportional representation within the portfolio remained stable.",
      "llm_answer": "\nDisney’s holdings of Other Mortgage‑ and Asset‑Backed Securities grew from **$84 million in fiscal 2022** to **$166 million in fiscal 2024** – an increase of roughly $82 million (about a 98 % rise).  Because total plan assets at fair value also expanded, the share of the fair‑value hierarchy devoted to these securities rose from **≈1.1 % (84 ÷ 7,543)** in 2022 to **≈1.5 % (166 ÷ 10,974)** in 2024, showing a modest but consistent upward trend in both absolute amount and relative proportion.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Disney's investment in Other MBS & ABS was $96 million in fiscal year 2022 and $120 million in fiscal year 2024, both representing 1% of the total plan asset mix. However, the LLM reports $84 million in 2022 and $166 million in 2024, which are incorrect. Additionally, the LLM claims the proportion increased from approximately 1.1% to 1.5%, while the ground truth states it remained stable at 1%. These errors affect both absolute values and relative proportions. (2) The calculations in the LLM answer (e.g., 84 ÷ 7,543 ≈ 1.1%, 166 ÷ 10,974 ≈ 1.5%) are mathematically correct based on the numbers used, but the underlying data is wrong. The actual total plan asset mix figures are not provided in the ground truth, but the reported percentages must align with the stated 1% in both years, which the LLM fails to do. (3) The multi-hop reasoning is partially sound in structure—comparing absolute and relative changes over time—but based on incorrect data. The model attempts to calculate proportions and trends, showing understanding of the required analysis, but the synthesis is flawed due to inaccurate inputs. (4) The contextual relevance is high because the answer addresses the evolution of investment and its proportion over time, matching the question's intent. However, due to major quantitative errors and incorrect conclusions about the trend in proportion (stable vs. increasing), the correctness and accuracy scores are low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1237,
        "completion_tokens": 424,
        "total_tokens": 1661
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How did the focus areas of Skunk Works' advanced development programs evolve between 2022 and 2023 in relation to next-generation military aircraft capabilities?",
      "original_answer": "In 2022, Skunk Works' Advanced Development Programs focused on future systems including unmanned and manned aerial systems and next-generation capabilities for hypersonics, intelligence, surveillance, reconnaissance, situational awareness, and air mobility. By 2023, the focus had evolved to emphasize air dominance, hypersonics, intelligence, surveillance, reconnaissance, situational awareness, and air mobility. The shift highlights an increased emphasis on air dominance as a core next-generation capability while maintaining focus on hypersonics and ISR. This represents a refinement of priorities rather than a complete overhaul of focus areas.",
      "llm_answer": "\nBetween fiscal 2022 and 2023 the Skunk Works‑run Advanced Development Programs broadened its priority list: the 2022 description highlighted “hypersonics, intelligence‑surveillance‑reconnaissance, situational‑awareness and air‑mobility,” while the 2023 filing adds “air‑dominance” as a dedicated focus area and stresses rapid‑prototype, technology‑insertion efforts that feed next‑generation fighter concepts (e.g., sixth‑generation, stealth‑enabled, network‑centric aircraft). This shift signals a deliberate pivot toward developing air‑dominance‑oriented capabilities—such as advanced weapons integration, hypersonic strike tools and autonomous systems—to accelerate the fielding of future combat aircraft.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the 2022 focus areas—hypersonics, ISR, situational awareness, and air mobility—and notes the addition of 'air dominance' in 2023, which matches the original answer's claim of an increased emphasis on air dominance. The description of the evolution as a refinement rather than a complete overhaul is semantically captured through terms like 'broadened its priority list' and 'deliberate pivot.' (2) There are no numerical values, dates, or financial metrics in dispute; the fiscal years 2022 and 2023 are correctly referenced. (3) The multi-hop reasoning is sound: the model synthesizes changes in focus areas across two years and correctly infers a strategic shift toward next-generation combat aircraft, including sixth-gen fighters and autonomous systems, which is consistent with the original answer’s emphasis on next-generation capabilities. (4) Minor deduction in qualitative accuracy due to the phrase 'broadened its priority list,' which slightly overstates expansion rather than a reprioritization; the original answer frames it as a refinement, not an addition of entirely new domains. However, the core facts, entities, and evolution are correctly conveyed. Wording differences do not undermine factual correctness, and the LLM adds relevant context (e.g., rapid prototyping, network-centric aircraft) that enriches without distorting.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 398,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has Tesla's approach to the Powerwall product evolved from 2022 to 2023, particularly in terms of integration strategy and production emphasis?",
      "original_answer": "In 2022, Tesla emphasized cross-selling Powerwall with residential solar energy products due to better availability and growing grid stability concerns. The company was also focused on improving installation capabilities and price efficiencies for Solar Roof, which is closely related to Powerwall integration. By 2023, Tesla had advanced its integration strategy by designing both Solar Roof and solar energy systems to specifically integrate with Powerwall, indicating a more deliberate and engineered approach to product synergy. This evolution reflects a shift from a sales and availability focus to a deeper technical and strategic integration within Tesla's energy ecosystem.",
      "llm_answer": "\nFrom 2022 to 2023 Tesla broadened the Powerwall’s role—it is no longer sold only as a backup battery but as the central element of an integrated residential‑energy suite that bundles the storage unit with Solar Roof and solar‑panel offerings and adds software‑controlled grid‑service capabilities.  At the same time, the company shifted production emphasis toward scaling dedicated battery‑cell supply and launching the Lathrop “Megafactory” while investing in installer training, streamlined online ordering and cross‑selling to accelerate deployment and meet growing grid‑stability demand.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution in Tesla's Powerwall strategy from 2022 to 2023. It correctly identifies the shift from standalone or backup use to integration within a broader residential energy suite, including Solar Roof and solar panels, which aligns with the ground truth's emphasis on deeper technical integration by 2023. The mention of software-controlled grid-service capabilities reflects growing grid-stability concerns noted in the original answer. The production emphasis on scaling battery-cell supply, the Lathrop Megafactory, installer training, and streamlined ordering supports the ground truth's focus on improving installation capabilities and deployment efficiency. However, the LLM answer introduces specific details not present in the ground truth—such as the 'Lathrop Megafactory' and 'software-controlled grid-service capabilities'—which, while plausible, are not confirmed in the provided knowledge base and represent an overreach in specificity. Additionally, the original answer emphasizes a shift from cross-selling due to availability (2022) to engineered integration (2023), a nuance only partially captured in the LLM response. There are no numerical inaccuracies (quantitative accuracy is perfect as no incorrect numbers are cited), and the reasoning is sound, though slightly extrapolative. Contextual relevance is excellent, directly addressing integration strategy and production emphasis across both years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 405,
        "total_tokens": 1724
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has Gilead's strategic positioning around Biktarvy evolved between 2022 and 2024, particularly in terms of its role within the company's HIV portfolio and associated commercial risks?",
      "original_answer": "In 2022, Biktarvy was prominently positioned as a key revenue-generating product within Gilead’s HIV portfolio, highlighted as a single-tablet regimen combining bictegravir, emtricitabine, and tenofovir alafenamide (TAF), emphasizing its convenience and efficacy. By 2024, while Biktarvy remained a core product, the company faced heightened commercial risk as it became more dependent on HIV products containing TAF. A shift in treatment paradigms or reduced preference for nucleoside-based therapies could significantly impact Biktarvy’s sales and, by extension, Gilead’s financial stability. This reflects a transition from a focus on product innovation to increased vulnerability due to overreliance on a narrow therapeutic class.",
      "llm_answer": "\nBetween 2022 and 2024 Gilead shifted Biktarvy from being one of several flagship HIV regimens to the centerpiece of its HIV portfolio, promoting it as the preferred once‑daily TAF‑based treatment and the primary driver of HIV‑related product sales.  The 2022 10‑K (pp. 3‑7) lists Biktarvy alongside other HIV products, while the 2024 10‑K (pp. 16‑20) expands the discussion of competition, pricing pressure and the reliance on a few wholesale customers, underscoring that Biktarvy’s growing revenue share is now exposed to heightened commercial risks such as generic entry, IRA‑driven price reforms and the concentration of U.S. sales to three wholesalers.  Consequently, Biktarvy’s strategic importance has risen, but so have the commercial vulnerabilities that could erode its market position and profitability.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution of Biktarvy's strategic positioning from 2022 to 2024: initially one of several key HIV products in 2022, becoming the centerpiece by 2024. The increased commercial risks are accurately described, including reliance on TAF-based therapies, pricing pressures, generic competition, and customer concentration. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not compromised; references to 10-K pages (pp. 3–7 in 2022, pp. 16–20 in 2024) are plausible and consistent with typical SEC filing structures, though exact page numbers are not verifiable from the knowledge graph—this does not detract from factual correctness. (3) The multi-hop reasoning is sound: the model synthesizes information across years (2022 vs 2024), documents (10-Ks), and themes (product positioning, commercial risk evolution). It correctly infers increased vulnerability due to overreliance on a narrow class (TAF-based regimens), even if 'nucleoside-based therapies' is not explicitly mentioned. (4) The LLM adds contextual detail not in the original—such as IRA-driven price reforms and three wholesalers—but these are reasonable inferences given known U.S. pharmaceutical market dynamics and Gilead’s disclosures, and do not contradict the ground truth. The only minor gap is that the original emphasizes a shift in *treatment paradigms* away from nucleoside analogs as a core risk, which the LLM does not explicitly mention. However, the broader point about therapeutic class overreliance and commercial vulnerability is preserved. Thus, the answer is semantically equivalent with high completeness and strong reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1397,
        "completion_tokens": 485,
        "total_tokens": 1883
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How did the composition of the U.S. Retrospective Responsibility Plan change between 2022 and 2023, particularly regarding the mechanisms referenced in relation to the U.S. Litigation Escrow Agreement?",
      "original_answer": "In 2022, the U.S. Retrospective Responsibility Plan included mechanisms such as the U.S. Litigation Escrow Agreement, the conversion feature of Class B common stock, indemnification obligations of Visa U.S.A. members, an interchange judgment sharing agreement, a loss sharing agreement, and an omnibus agreement. By 2023, the composition evolved to include a new element — 'makewhole agreements relating to the Class B-1 common stock exchange offer' — while retaining the U.S. Litigation Escrow Agreement and other previously listed mechanisms. This indicates an expansion of the plan to incorporate additional financial safeguards or compensatory measures.",
      "llm_answer": "\nBetween the 2022 and 2023 filings the core U.S. Retrospective Responsibility Plan kept the same basic mechanisms—U.S. litigation escrow agreement, the conversion feature of the Company’s class B stock, the indemnification obligations of Visa U.S.A. members, the interchange‑judgment‑sharing agreement, and the loss‑sharing agreement—but the 2023 description added a distinct reference to the **makewhole agreements** that govern future deposits into the escrow account and refined the conversion feature to specify that it applies to **class B‑1 and B‑2 common stock**.  Thus, the plan’s composition grew to include the makewhole mechanism and a more detailed conversion‑feature description, while the escrow‑related provisions themselves remained central.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the essential changes in the U.S. Retrospective Responsibility Plan between 2022 and 2023. (1) It correctly identifies that the core mechanisms — including the U.S. Litigation Escrow Agreement, conversion feature of Class B stock, indemnification obligations, interchange judgment sharing, and loss-sharing agreements — remained unchanged. It accurately notes the addition of 'makewhole agreements' in 2023, which aligns with the ground truth. (2) There are no numeric values, dates, or financial figures in dispute; all temporal references (2022 vs 2023) are correct. (3) The multi-hop reasoning is sound: the model synthesizes changes across two years and correctly identifies both continuity and evolution in the plan’s structure. The only minor deviation is that the LLM specifies the conversion feature now applies to 'Class B-1 and B-2 common stock', while the original answer mentions 'Class B-1 common stock exchange offer' without referencing B-2. This added detail may reflect a nuance in the 2023 filing but slightly extends beyond the ground truth’s scope, introducing a specific class (B-2) not mentioned in the original. (4) Despite this small over-specification, the answer remains factually consistent, contextually relevant, and semantically equivalent to the original. The core conclusion — expansion of the plan with makewhole agreements while retaining prior mechanisms — is fully supported. Hence, a high score of 9 is warranted, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 427,
        "total_tokens": 1794
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has the strategic importance of Biktarvy evolved for GILD from 2022 to 2024, based on its patent protection timeline and the company's risk disclosures around HIV product dependency?",
      "original_answer": "In 2022, Biktarvy was listed with a U.S. patent expiration in 2033 and no expiration listed in the E.U., indicating strong long-term protection and likely a key revenue driver. By 2024, although patent details were not explicitly mentioned, the company highlighted heightened risk around its HIV products, including Biktarvy, due to market competition and potential shifts in treatment paradigms. This suggests that despite long-term patent protection, Biktarvy's strategic position has become more vulnerable due to external market and regulatory pressures.",
      "llm_answer": "\nBetween 2022 and 2024 Biktarvy’s patent life was extended to 2033 (U.S. and EU) with regulatory exclusivity lasting until 2032, keeping it as Gilead’s flagship HIV revenue driver; the 2024 filing, however, stresses heightened risk disclosures that the company’s sales are increasingly dependent on HIV products and are vulnerable to generic entry, competitive launches or a shift in treatment paradigms. Consequently, while Biktarvy remained strategically critical, Gilead’s disclosures reveal a growing awareness that over‑reliance on this franchise poses a material risk and motivates diversification away from it.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies Biktarvy as a key revenue driver for Gilead (GILD) and captures the increased risk disclosures in 2024 regarding dependency on HIV products, competition, and treatment paradigm shifts, which aligns with the ground truth. However, there is a factual inaccuracy in the quantitative details: the LLM states that Biktarvy’s patent life was extended to 2033 in both the U.S. and EU with regulatory exclusivity until 2032. The ground truth specifies a U.S. patent expiration in 2033 but explicitly notes that no EU expiration was listed in 2022, meaning the claim of a 2033 EU patent expiration is unsupported and incorrect. Additionally, the mention of regulatory exclusivity until 2032 is not present in the original answer and cannot be verified from the provided truth. 2) The numbers for the U.S. (2033) are correct, but the EU patent expiration and 2032 exclusivity dates are inaccuracies not found in the ground truth, reducing quantitative accuracy. 3) The multi-hop reasoning is sound—linking patent protection, strategic importance, and evolving risk disclosures across years—and the synthesis between 2022 stability and 2024 vulnerability is well executed. 4) Despite the numerical inaccuracies, the answer captures the core qualitative shift: Biktarvy remains strategically important but faces growing strategic risks due to market dynamics, which is contextually accurate and relevant. The overstatement of patent protection weakens factual precision but does not completely undermine the conclusion about increasing risk awareness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 430,
        "total_tokens": 1734
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "Have there been any modifications to the financial guarantees provided by AT&T for Illinois Bell Telephone Company between 2022 and 2023, particularly in terms of guarantee structure or referenced documentation?",
      "original_answer": "The financial guarantee relationship between AT&T and Illinois Bell Telephone Company remained structurally unchanged between 2022 and 2023. In 2022, AT&T's guarantee for Illinois Bell Telephone Company was referenced under Exhibit 4-d to Form 10-K for the period ending December 31, 2011. In 2023, the same guarantee was still in place and referenced under the identical exhibit number (Exhibit 4-d) and filing history (Form 10-K for the period ending December 31, 2011). There is no indication of modifications to the guarantee structure, terms, or documentation between the two years.",
      "llm_answer": "\nBased on the excerpts from the 2022 and 2023 10‑K filings (pages 133‑137 of the 2022 filing and pages 101‑105 of the 2023 filing), there is no discussion of any amendment, restructuring, or new documentation concerning the financial guarantees that AT&T provides for Illinois Bell Telephone Company. The materials cover topics such as tower‑lease accounting, DIRECTV, FirstNet, and related‑party transactions, but they do not reference any changes to the Illinois Bell guarantee structure or related disclosures. Consequently, no modifications to those guarantees are evident in the provided pages.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly concludes that there were no modifications to the financial guarantees provided by AT&T for Illinois Bell Telephone Company between 2022 and 2023, which aligns with the ground truth. The answer accurately states that no changes were discussed in the 2022 and 2023 10-K filings, and it correctly identifies the absence of amendments or restructuring in the provided excerpts. However, the LLM answer lacks specific reference to the exhibit number (Exhibit 4-d) and the original Form 10-K filing date (December 31, 2011), which are key details in the ground truth and essential for full completeness in a multi-hop financial context. While the conclusion is correct and the reasoning is logically sound based on the absence of contradictory information in the provided pages, the answer relies on omission-based reasoning ('not mentioned, therefore no change') without affirmatively confirming the continued citation of the same exhibit and filing history as in the original answer. This omission reduces qualitative accuracy, as the synthesis across years and documentation references is incomplete. Quantitative accuracy is perfect—no numbers or dates are misstated. Contextual relevance is high, as the response directly addresses the question and relevant filings. A score of 7 is justified due to correct core facts but missing key documentary specifics required for full multi-hop verification.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1312,
        "completion_tokens": 392,
        "total_tokens": 1704
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "What does the consistent Class C to Class A common stock conversion rate between 2022 and 2023 suggest about the potential impact on Class A common stockholders' voting power in significant corporate transactions?",
      "original_answer": "In 2022, the Class C common stock had a conversion rate of 4.0000 into Class A common stock, and this rate remained unchanged in 2023. Despite the as-converted Class A common stock value increasing slightly from 38 million in 2022 to 39 million in 2023, the unchanged conversion rate suggests that the relative voting power dilution for Class A common stockholders remained stable. This stability implies that there was no structural change in how Class C stockholders could influence significant corporate decisions through their voting rights tied to Class A equivalents.",
      "llm_answer": "\nThe fact that the Class C‑to‑Class A conversion ratio was unchanged from 2022 to 2023 means the number of additional Class A shares that would result from conversion is predictable and steady. Consequently, any dilution of voting power that existing Class A shareholders would experience in matters such as mergers, consolidations or other “significant transactions” will be a fixed, known reduction rather than a sudden, unpredictable one, and will be compounded only by the pre‑determined conversion amount. Because holders of the other classes (e.g., Class B and the preferred series) can also vote on those transactions and may have interests that differ from Class A shareholders, the consistent conversion rate does not eliminate that divergent influence but ensures that the dilution effect on Class A voting strength remains constant year‑over‑year.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, while the LLM does not explicitly state the conversion rate of 4.0000 or the as-converted Class A stock values (38M in 2022, 39M in 2023), these omissions do not introduce factual errors—the focus is on the stability of the conversion rate, which is correctly emphasized. The absence of exact figures is a minor completeness issue but does not affect correctness since the core quantitative fact—the unchanged rate—is clearly acknowledged. (2) The reasoning is sound: the LLM correctly infers that a stable conversion rate implies predictable and consistent voting power dilution for Class A shareholders, which matches the ground truth’s conclusion about stable relative dilution. (3) The answer appropriately addresses the multi-hop aspect by linking the unchanging conversion mechanism to its implication on voting power in significant corporate transactions, demonstrating correct synthesis. (4) The mention of other share classes (Class B, preferred) adds contextual depth and correctly notes that divergent interests exist, though this nuance is not in the original answer; however, it does not contradict it and enhances relevance. Overall, the answer captures the essential meaning and implication with high fidelity, warranting a 9 for correctness due to the lack of explicit numbers, but full marks for quantitative accuracy since no stated numbers are wrong, and high scores for qualitative and contextual performance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 417,
        "total_tokens": 1791
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did Tesla's relationship with the Solar Roof evolve from 2022 to 2023 in terms of production focus and strategic dependencies?",
      "original_answer": "In 2022, Tesla directly produced the Solar Roof at Gigafactory New York, indicating active involvement in its manufacturing. However, by 2023, Tesla's disclosures shifted to emphasizing dependencies and risks associated with scaling production, including potential delays, supply chain constraints, and challenges in launching and ramping products like the Solar Roof. This reflects a transition from a production-centric view to a more cautionary outlook on strategic execution risks.",
      "llm_answer": "\nFrom 2022 to 2023 Tesla moved Solar Roof from a niche, pilot‑scale operation at the Buffalo Gigafactory toward a larger‑volume, cost‑optimized manufacturing model.  The shift required new, dedicated production lines and long‑term supply agreements for the roof‑tile glass and solar cells, reducing reliance on external vendors and tying the program more closely to Tesla’s in‑house battery‑cell and energy‑storage capabilities.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains some plausible elements but significantly misrepresents Tesla's strategic evolution regarding the Solar Roof from 2022 to 2023. (1) Correctly identifies Gigafactory New York (Buffalo) as the production site, which aligns with ground truth. However, the claim that Tesla moved toward a 'larger-volume, cost-optimized manufacturing model' with 'new dedicated production lines' and reduced reliance on external vendors is factually incorrect. The ground truth indicates a shift toward caution and risk disclosure in 2023, not expansion or optimization. (2) There are no explicit numbers, percentages, or dollar amounts in either answer, so quantitative accuracy is not heavily applicable—minor credit given for not introducing false numerical claims. (3) The multi-hop reasoning is flawed: instead of recognizing the shift from active production focus to strategic risk disclosure, the model fabricates a narrative of scaling and vertical integration not supported by the data. This contradicts the actual trend of increased emphasis on production risks and dependencies. (4) Contextual relevance is moderate—the answer addresses production focus and strategic dependencies, but with incorrect substance. The direction of change is reversed: the truth is a pullback in confidence, not an advancement in capability. Thus, while the topic areas are relevant, the factual content is largely inaccurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1224,
        "completion_tokens": 391,
        "total_tokens": 1615
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How has the role of syrups in Coca-Cola's business model evolved between 2022 and 2023, particularly in terms of their relationship to finished beverage production and distribution channels?",
      "original_answer": "In 2022, Coca-Cola described syrups as intermediate products used primarily in fountain beverage production, where bottling partners or fountain retailers mix them with water and sweeteners to create finished beverages for immediate consumption. The company emphasized that syrups were a key part of the concentrate operations, which generally yield lower net operating revenues but higher gross profit margins compared to finished product operations. By 2023, the company expanded its description to emphasize that fountain syrup sales in the U.S. were directly managed by Coca-Cola and sold to both fountain retailers and authorized wholesalers or bottling partners. Additionally, the 2023 filing highlighted that fountain syrup operations were specifically included in the North America operating segment, indicating a more structured and regionally focused approach to syrup distribution. This evolution reflects a strategic shift toward tighter control and segmentation of syrup-related revenue streams within the broader beverage production ecosystem.",
      "llm_answer": "\nBetween 2022 and 2023 the share of net operating revenue coming from **concentrate (syrup) operations rose from 56 % to 58 %**, while revenue from **finished‑product operations fell from 44 % to 42 %** (see the 2023 and 2022 tables in Item 7, “Management’s Discussion and Analysis”).  This indicates that the Company’s business model is placing relatively more emphasis on **selling syrups and concentrates to bottling partners and fountain retailers**, who then manufacture and distribute the finished beverages, rather than on the Company’s own finished‑product bottling and distribution operations.  As a result, syrups have become a more central conduit linking the Coca‑Cola brand portfolio to the global bottling system and to the Company’s distribution network.",
      "correctness_score": 4,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies, particularly in quantitative claims. It states that the share of net operating revenue from concentrate (syrup) operations rose from 56% to 58% between 2022 and 2023, with finished-product operations falling from 44% to 42%, but this data is not supported by the ground truth. The original answer does not mention any such percentages or revenue splits, nor are these figures present in the provided knowledge base. This introduces a major error in calculation and misrepresents the financial structure of Coca-Cola’s operations. While the LLM correctly infers a strategic shift toward greater emphasis on syrup/concentrate sales and tighter control over distribution channels, this conclusion is based on fabricated data rather than accurate synthesis. The qualitative reasoning about syrups becoming a more central conduit in the distribution network aligns partially with the ground truth’s description of increased direct management and regional segmentation (e.g., inclusion in the North America operating segment), showing some correct multi-hop interpretation. However, the absence of actual percentage data in the ground truth makes the LLM’s numerical claims entirely unsupported. Contextually, the answer addresses the evolution of syrups in production and distribution channels, so it remains relevant to the question. Overall, while the direction of the strategic interpretation is plausible, the reliance on invented statistics severely undermines factual correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1467,
        "completion_tokens": 420,
        "total_tokens": 1888
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has the company's operational focus on Africa/Eurasia evolved between 2022 and 2024, particularly in terms of its geographic reporting structure and financial contribution?",
      "original_answer": "In 2022, Africa/Eurasia was reported as part of the Oral, Personal and Home Care segment with an operating profit of $203 million, indicating a relatively minor financial contribution compared to other regions. By 2024, the company maintained Africa/Eurasia as a distinct reportable operating segment within the Oral, Personal and Home Care geographic structure. Additionally, in 2024, the company realigned its skin health business, shifting it from Europe to North America, signaling a strategic refinement in geographic reporting. This change suggests a more nuanced operational focus in how the company organizes and evaluates its regional performance, including in Africa/Eurasia.",
      "llm_answer": "\nBetween 2022 and 2024 the company kept Africa/Eurasia as a distinct reportable geographic segment (the 2024 realignment only moved skin‑health activities out of Europe and did not affect the Africa/Eurasia label).  Net sales in that region edged up from roughly **$1.08 bn in 2022 to $1.095 bn in 2024**, and operating profit grew from about **$228 m to $253 m**, showing a modest but steady contribution to overall earnings.  Capital spending remained very low—around **$12 m per year**—so the firm’s operational focus on Africa/Eurasia has been consistent, with only modest revenue growth and stable profitability over the period.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, Africa/Eurasia was not a distinct reportable segment but was part of the Oral, Personal and Home Care segment with an operating profit of $203 million. The LLM incorrectly states it was a distinct segment in both years. Additionally, the financial figures provided—net sales of $1.08B in 2022 and $1.095B in 2024, operating profit rising from $228M to $253M, and capital spending of $12M—are all fabricated and not supported by the original answer or knowledge graph. There is no mention of net sales or capital expenditures in the ground truth, and the operating profit cited in the original ($203M in 2022) contradicts the LLM’s $228M figure. (2) Quantitative accuracy is extremely low because all numbers are incorrect or invented. Even allowing for format variation, the values do not match the ground truth. The original answer does not provide 2024 operating profit or sales data, so the LLM’s inclusion of such specifics is hallucinated. (3) The reasoning is flawed in terms of multi-hop synthesis. While the LLM correctly notes that the 2024 realignment involved moving skin health from Europe to North America (a detail aligned with the original), it incorrectly assumes this had no impact on Africa/Eurasia and misrepresents the segment's structural evolution. The original emphasizes that by 2024, Africa/Eurasia was maintained as a distinct segment, implying a change from its 2022 status as a subcomponent—this nuance is missed. (4) Contextual relevance is moderate because the answer addresses geographic reporting and financial contribution, which are relevant themes, but fails on factual correctness. The core of the question—evolution in structure and contribution—is misrepresented due to incorrect entity status and fabricated metrics, leading to a low overall correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 516,
        "total_tokens": 1853
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has Johnson & Johnson's strategic presentation of its Orthopaedics business evolved between 2023 and 2024, particularly in terms of global sales performance and emphasis on enabling technologies?",
      "original_answer": "In 2023, JNJ's Orthopaedics segment was presented primarily through quantifiable sales figures, with global revenue reaching $8,942 million, showing a 4.1% increase from the prior year. The 2023 data emphasized steady growth, particularly in the U.S. ($5,525 million, up 3.8%) and modest international growth ($3,417 million, up 4.6%). By 2024, the strategic framing of Orthopaedics shifted from financial metrics to a qualitative emphasis on innovation and enabling technologies. The 2024 filing described Orthopaedics as a portfolio 'supported by products and enabling technologies' across hips, knees, trauma, spine, and sports medicine, without revisiting specific revenue figures. This reflects a strategic pivot from highlighting quantitative performance to underscoring technological leadership and product diversification within the segment.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 the Orthopaedics business remained roughly flat – worldwide sales held at about **$8.9 billion**, with U.S. sales steady at **$5.5 billion** and international sales essentially unchanged at **$3.4 billion**.  However, the way the segment is presented has shifted: in the 2024 filing Orthopaedics is highlighted as part of the **MedTech** segment and the narrative places far greater emphasis on **“enabling technologies”** (e.g., advanced implants, robotics‑assisted surgery, sports‑medicine and trauma solutions) that underpin its growth strategy.  This reframing signals a strategic pivot toward leveraging those technologies to drive future margin expansion and global market penetration, even though absolute sales numbers show only modest change.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. According to the ground truth, Johnson & Johnson's Orthopaedics global sales were $8,942 million in 2023, with a 4.1% increase from the prior year. The LLM incorrectly states that sales 'remained roughly flat' at $8.9 billion in both 2023 and 2024, and claims U.S. and international sales were 'steady' and 'essentially unchanged'—this contradicts the ground truth, which reports actual growth (3.8% in the U.S., 4.6% internationally). Furthermore, the LLM implies that 2024 sales data is available and flat, but the original answer clarifies that the 2024 filing does not provide specific revenue figures, making any numerical claim about 2024 sales factually incorrect. (2) The LLM rounds numbers appropriately ($8,942M to $8.9B, $5,525M to $5.5B, $3,417M to $3.4B), which is acceptable under format variation rules, but the error lies in asserting that these figures are repeated or stable in 2024 when no such data is reported. (3) The qualitative reasoning about a strategic shift in narrative is correct and well-synthesized: the LLM accurately identifies a pivot toward 'enabling technologies' (robotics, advanced implants, etc.) in the 2024 filing and links it to future growth strategy, aligning with the ground truth’s claim of a shift from financial metrics to technological leadership. It also correctly situates Orthopaedics within the MedTech segment. (4) While the core insight about strategic reframing is valid and contextually relevant, the inclusion of false quantitative claims about 2024 performance and incorrect year-over-year trends significantly undermines factual correctness. The answer would score higher if it had acknowledged the absence of 2024 revenue data rather than fabricating stability. Thus, correctness is penalized heavily for factual inaccuracy in numbers and trends, despite strong qualitative reasoning and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1422,
        "completion_tokens": 523,
        "total_tokens": 1945
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How has Visa's approach to managing litigation liabilities through loss sharing agreements evolved between 2022 and 2023, particularly in terms of the scope of U.S. covered litigation and liability allocation?",
      "original_answer": "In 2022, Visa detailed specific amendments to its loss sharing agreement, including the October 2015 amendment that expanded the scope of U.S. covered litigation to include opt-out actions from the Rule 23(b)(3) Settlement Class in MDL 1720 that arose out of similar facts or circumstances. This amendment was part of a broader framework involving the omnibus agreement, under which Visa assumed 66.6667% of any monetary liability in covered settlements or judgments, with Mastercard assuming 33.3333%. In 2023, Visa consolidated its approach under the U.S. Retrospective Responsibility Plan, which now encompasses the loss sharing agreement as part of a broader set of mechanisms designed to address potential liabilities from U.S. covered litigation. Notably, the 2023 filing emphasizes that U.S. covered litigation now includes matters that have been 'settled or otherwise fully or substantially resolved,' indicating a shift toward resolution and consolidation of past liabilities. The evolution from a focus on specific amendments and liability sharing with Mastercard in 2022 to a more comprehensive and retrospective liability framework in 2023 suggests a strategic pivot toward finalizing and managing legacy litigation exposure.",
      "llm_answer": "\nBetween 2022 and 2023 Visa kept the same overall U.S. retrospective‑responsibility framework but **expanded the definition of “U.S. covered litigation”** – the 2023 amendments to the loss‑sharing and omnibus agreements expressly added opt‑out merchant actions that were not transferred to MDL‑1720, whereas the 2022 filing only referenced the MDL‑1720 cases and the original scope.  At the same time the **liability‑allocation formula was refined**: each participant’s share is now calculated as a fixed 66.667 % (Visa) / 33.333 % (Mastercard) of any judgment or settlement, multiplied by that member’s current membership proportion, replacing the more general “several obligation” language used in 2022.  The escrow account grew (from $894 M to $1.449 B), reflecting the larger liability base created by this broader coverage.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness, despite addressing the right question and attempting multi-hop synthesis. (1) QUANTITATIVE INACCURACIES: The LLM claims the escrow account grew from $894M to $1.449B, but this data is not present in the original answer (ground truth) and cannot be verified from the provided context—this is a hallucination. Additionally, the LLM states that the 2023 amendments expanded coverage to include 'opt-out merchant actions not transferred to MDL-1720', but the original answer specifies the 2022 amendment already included opt-out actions from the Rule 23(b)(3) Settlement Class in MDL 1720; there is no mention of a 2023 expansion to non-MDL-1720 cases. (2) LIABILITY ALLOCATION: The LLM incorrectly claims the formula was 'refined' in 2023 to include membership proportions, stating a new calculation method involving current membership share. This is not supported by the original answer, which states the 66.6667%/33.3333% split (Visa/Mastercard) remained under the omnibus agreement and does not mention any change involving membership proportions. The original answer emphasizes a shift in 2023 toward a broader U.S. Retrospective Responsibility Plan that encompasses past resolved matters, not a change in allocation mechanics. (3) REASONING: The LLM misrepresents the evolution—portraying a technical refinement in liability calculation and scope expansion in 2023—whereas the ground truth describes a strategic pivot toward consolidation and resolution of legacy liabilities, with inclusion of 'settled or otherwise fully or substantially resolved' matters. This reflects a qualitative misunderstanding of the nature of the 2023 change. (4) CONTEXTUAL RELEVANCE is high because the answer addresses the evolution of loss sharing, scope, and allocation as asked. However, factual and quantitative errors severely reduce correctness. Minor formatting of percentages (66.6667% vs 66.667%) would be acceptable, but the substantive misrepresentation of changes in 2023 and invented financial figures lead to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1532,
        "completion_tokens": 565,
        "total_tokens": 2097
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did CL's investment in Guaranteed Investment Contracts evolve between 2022 and 2024, and what does this shift indicate about the company's pension plan asset strategy?",
      "original_answer": "In 2022, CL held $1 million in Guaranteed Investment Contracts under its United States Pension Plans and $55 million under its International Pension Plans. By 2024, the company had completely phased out Guaranteed Investment Contracts from its United States Pension Plans, reducing the International allocation to $34 million. This represents a significant shift away from Guaranteed Investment Contracts in the U.S. and a moderate decrease internationally, indicating a strategic reallocation of pension plan assets.",
      "llm_answer": "\nBetween 2022 and 2024 the company’s holdings of Guaranteed Investment Contracts (GICs) fell sharply – U.S. GICs dropped from about $1 million (reported in the 2021‑2022 tables) to essentially $0, and international GICs declined from roughly $51 million to about $30 million by the end of 2024.  This reduction reflects a deliberate shift in the pension‑plan asset mix, with the plan moving away from low‑return guaranteed contracts toward a higher allocation of fixed‑income securities, equity and real‑estate funds that better match the plans’ target asset‑allocation percentages.  The evolution indicates that Colgate‑Palmolive is rebalancing its pension‑plan portfolio to increase exposure to more liquid and potentially higher‑yielding assets.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "1) The LLM answer captures the overall trend correctly: a sharp decline in Guaranteed Investment Contracts (GICs) in both U.S. and international pension plans between 2022 and 2024, indicating a strategic shift in asset allocation. However, there are inaccuracies in the specific numbers. According to the ground truth, U.S. GICs were $1 million in 2022 and reduced to $0 by 2024 (correctly reflected), but international GICs were $55 million in 2022 and $34 million in 2024. The LLM incorrectly reports international GICs as $51 million in 2022 and $30 million in 2024, which understates both the starting value and the ending value. These discrepancies affect quantitative accuracy.\n\n2) The calculation of change is directionally correct (a decrease), but the magnitude is off. The actual reduction in international GICs is $21 million (from $55M to $34M), while the LLM implies a $21M drop from $51M to $30M—similar delta but wrong baseline. This suggests possible misreading of source data.\n\n3) The reasoning and synthesis are strong: the LLM correctly infers that the reduction indicates a strategic reallocation away from low-return guaranteed instruments toward higher-yielding assets like equities, fixed income, and real estate. This interpretation aligns with the ground truth's implication of a 'strategic reallocation' and adds reasonable context about liquidity and return objectives.\n\n4) Entity accuracy is good—CL (Colgate-Palmolive) is correctly identified, time frame (2022–2024) is respected, and the financial instrument (GICs) is accurately referenced. The answer addresses both parts of the question: evolution of investment and strategic implication.\n\n5) Despite minor factual inaccuracies in dollar amounts, the answer is semantically close and contextually relevant. The core message—that CL is de-emphasizing GICs in favor of more diversified, higher-return assets—is valid and well-supported. Hence, a score of 7/10 for correctness: factually mostly correct with notable but not critical quantitative errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 546,
        "total_tokens": 1869
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has the strategic positioning and functionality of the Mastercard Developer Platform evolved between 2022 and 2024, particularly in terms of its role in enabling integration of digital assets and new technologies?",
      "original_answer": "In 2022, the Mastercard Developer Platform was described as a single access point that enables customers and partners to leverage Mastercard's digital assets and services, with an emphasis on ease of integration into new and existing solutions. By 2024, the platform continued to serve this role but expanded its strategic positioning by explicitly aligning with emerging technologies such as blockchain and digital currencies. In 2024, the platform was referenced in the context of enabling integration with the Mastercard Multi-Token Network™, which supports programmable payments and facilitates secure, scalable, and interoperable blockchain-based transactions. This evolution shows a shift from a general digital integration platform to one that specifically supports next-generation financial technologies and programmable commerce solutions.",
      "llm_answer": "\nBetween 2022 and 2024 Mastercard broadened the Developer Platform from a primarily API‑focused gateway for integrating core payment services into a more comprehensive ecosystem that explicitly supports digital‑asset and emerging‑technology integration—such as blockchain‑based payments, crypto‑on‑ramp/off‑ramp capabilities, tokenization, AI‑driven fraud and security tools, and real‑time disbursement APIs—while adding programmatic access through the Multi‑Token Network and expanded Foundry collaborations, thereby giving partners a single, standardized way to embed these advanced functionalities into both consumer‑facing and B2B solutions.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly identifies the evolution of the Mastercard Developer Platform from 2022 to 2024, noting its expansion from a general integration gateway to one supporting digital assets and emerging technologies. The mention of blockchain-based payments, tokenization, and the Multi-Token Network is consistent with the 2024 strategic shift described in the original answer. The LLM adds specific functionalities like crypto on-ramp/off-ramp, AI-driven fraud tools, and real-time disbursement APIs, which are plausible extensions of the platform’s trajectory and do not contradict the ground truth—though these details are not explicitly confirmed in the provided original answer. The reference to Foundry collaborations is contextually appropriate but not mentioned in the ground truth, representing a minor addition rather than an error. There are no incorrect dates, entities, or numerical claims (the question is qualitative, so no calculations are needed). The reasoning is sound, demonstrating correct multi-hop synthesis across time and technological scope. The answer is semantically equivalent and slightly more detailed than the original, without introducing inaccuracies. Thus, the correctness score is 9 due to the added specifics not present in the ground truth, but not contradicted; all core facts are correct and the evolution is accurately portrayed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 395,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has the company's investment in U.S. common stocks within its pension plans evolved between 2022 and 2024, and what does this indicate about its strategic asset allocation?",
      "original_answer": "In 2022, the company reported no investments in U.S. common stocks within its pension plans, while by 2024, there was still no allocation to U.S. common stocks in the U.S. pension plan. However, the international pension plan maintained a $2 million investment in U.S. common stocks in both years. This indicates a continued strategic decision to avoid direct exposure to U.S. common stocks in the domestic pension portfolio while maintaining a minimal presence in the international portfolio.",
      "llm_answer": "\nBetween 2022 and 2024 the pension plans held **no U.S. common‑stock exposure in 2022 and 2023**, but by the end of 2024 a modest Level‑1 position of roughly **$1 million of U.S. common stock** was recorded—marking the first such investment in the portfolio.  This addition signals a **deliberate shift in the strategic asset mix**, as the company’s target equity allocation for U.S. assets was increased (e.g., from 21 % to 26 % in the 2024 target) and it is now allocating a portion of plan assets to U.S. equities to diversify and align with its revised investment strategy.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both quantitative and qualitative aspects. The ground truth states that there was no investment in U.S. common stocks in the U.S. pension plan in 2022 and 2024, and the international plan held a consistent $2 million in both years. The LLM incorrectly claims a new $1 million investment in 2024, which contradicts the ground truth of zero allocation in the U.S. plan and $2 million (not $1 million) in the international plan. Additionally, the LLM fabricates a strategic shift and changes in target allocation (e.g., from 21% to 26%), which are not supported by the original answer. (2) Quantitative inaccuracies include the incorrect dollar amount ($1 million vs. $2 million in international, and $0 in U.S.), incorrect years (claims 2024 change when no change occurred), and invented percentages. The calculation of a 'first such investment' is false since the international plan already held U.S. common stocks in 2022. (3) The multi-hop reasoning is flawed: the model fails to correctly synthesize the distinction between U.S. and international pension plans and misrepresents the continuity of the $2 million holding. It incorrectly infers a strategic shift when the original answer emphasizes a continued avoidance of U.S. common stocks in the domestic plan. (4) The contextual relevance is moderate because the answer addresses the general topic of pension investments and strategic allocation, but the factual foundation is incorrect, leading to a misleading conclusion. The correctness score is low due to major factual and numerical errors that undermine the entire response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 448,
        "total_tokens": 1723
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How did Disney's strategic focus on cruise ships evolve between 2022 and 2023, particularly in terms of capital investment plans and operational risk considerations?",
      "original_answer": "In 2022, Disney highlighted cruise ships as a key part of its capital investment strategy within the Parks & Experiences segment, noting that a majority of its capital spending was directed toward theme parks, resorts, and cruise ships. This indicated a growth-oriented approach focused on expanding physical assets. By 2023, the emphasis had shifted toward operational risks associated with cruise ships, particularly in the context of external disruptions like hurricanes and global events (e.g., the impact of Hurricane Milton on Walt Disney World operations). The 2023 filing framed cruise ships more as an operational exposure rather than a growth engine, signaling a shift from investment to risk mitigation. This evolution reflects a recalibration of strategic focus from asset expansion to managing volatility and external threats.",
      "llm_answer": "\nBetween fiscal 2022 and 2023 Disney moved from the early‑stage planning and construction of its next‑generation cruise ships—highlighted in the 2022 filing as part of the “majority of the Company’s capital spend” for parks and experiences (e.g., the 2022 launch of **Disney Wish** and the announced **Disney Treasure** for 2024)—to a more concrete capital‑investment roadmap that earmarks a larger share of Parks & Experiences funding for fleet expansion while explicitly flagging heightened operational‑risk factors such as ship‑yard delivery schedules, regulatory approvals, fuel‑price volatility and variable consumer demand. This evolution reflects a shift toward allocating more capital to cruise‑ship growth but also a greater emphasis on managing the execution and market‑risk uncertainties associated with those investments.",
      "correctness_score": 5,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partially correct information but misrepresents the strategic evolution between 2022 and 2023. While it correctly notes that cruise ships were part of Disney's capital investment plans in 2022—citing the Disney Wish launch and Disney Treasure announcement—it inaccurately claims that Disney moved toward allocating *more* capital to cruise ships in 2023. The ground truth states the opposite: by 2023, the strategic focus had shifted from growth and investment to managing operational risks, such as hurricanes and global disruptions, indicating a de-emphasis on expansion. The LLM instead frames 2023 as involving increased capital allocation, which contradicts the original answer. (2) Quantitatively, the answer is mostly accurate: it references the 2022 launch of Disney Wish (correct) and the planned 2024 launch of Disney Treasure (consistent with public knowledge), and correctly situates cruise investments within the Parks & Experiences segment. However, no specific dollar amounts or percentages are provided in either answer, so the LLM’s lack of numerical precision is not penalized here. (3) The multi-hop reasoning is flawed: while the LLM synthesizes information about capital spending and risk factors, it draws the wrong conclusion about the *direction* of strategic change—failing to recognize the shift from growth orientation to risk mitigation. Instead, it suggests continued or increased investment focus, which is not supported by the ground truth. (4) Contextual relevance is high because the answer addresses both capital investment and operational risk, as required by the question, and uses appropriate terminology. However, due to the incorrect interpretation of the strategic shift, the qualitative and overall correctness scores are significantly reduced.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1422,
        "completion_tokens": 494,
        "total_tokens": 1917
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has Mastercard's use of short duration foreign exchange derivative contracts evolved between 2022 and 2024, particularly in terms of their role in managing foreign exchange risk during daily settlement activities?",
      "original_answer": "In 2022, Mastercard used short duration foreign exchange derivative contracts to manage foreign exchange risk associated with daily settlement activities, aiming to reduce exposure to volatility from currency fluctuations on anticipated receipts and disbursements. By 2024, the company continued this practice, maintaining the same stated objective of minimizing volatility in gains and losses due to foreign exchange fluctuations. However, the context changed as the company actively adjusted its hedging strategies involving euro-denominated debt, de-designating and re-designating portions of it in 2023 and 2024, which indicates a more dynamic approach to managing foreign exchange exposure across the period. The continuity in the use of short duration contracts contrasts with the evolving structure of the company’s broader foreign exchange risk management strategy.",
      "llm_answer": "\nMastercard has continued to rely on short‑duration foreign‑exchange forward and option contracts to offset the currency risk that arises from the few‑day lag between a payment’s execution and its final settlement.  The 2024 filing shows a broader use of these non‑designated derivatives—​the notional amount of FX contracts tied to daily receipts and disbursements rose to about $2.7 billion (up from roughly $0.5 billion in earlier years) and the resulting gains and losses are now recorded directly in general‑and‑administrative expense—​indicating a more explicit integration of short‑term FX hedging into the company’s daily settlement‑risk management framework.",
      "correctness_score": 5,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the correct general trend that Mastercard continues to use short-duration foreign exchange derivative contracts to manage FX risk in daily settlement activities, which aligns with the ground truth. However, there are significant factual inaccuracies in quantitative details: the LLM claims the notional amount of FX contracts rose from $0.5 billion to $2.7 billion, and that gains/losses are recorded in general-and-administrative expense—details not present in the original answer and unsupported by the provided ground truth. The original answer makes no mention of specific notional amounts or accounting line items, so these additions appear fabricated or hallucinated. Additionally, while the LLM correctly identifies continuity in the use of short-term contracts, it fails to mention the key qualitative evolution in Mastercard’s broader FX strategy—specifically the de-designation and re-designation of euro-denominated debt in 2023 and 2024—which is a central point in the ground truth and reflects a more dynamic hedging approach. This omission weakens the multi-hop synthesis required to fully answer how the use of these contracts evolved in context. The reasoning is partially sound in linking short-duration contracts to settlement risk, but the unsupported numbers and missing strategic context reduce factual correctness. The answer remains contextually relevant and addresses the core topic, but the inclusion of unverified quantitative data and absence of key strategic developments result in a partially correct assessment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1402,
        "completion_tokens": 427,
        "total_tokens": 1830
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has Salesforce's strategic relationship with enterprise cloud companies evolved from 2023 to 2024, particularly in terms of investment focus and ecosystem integration?",
      "original_answer": "In 2023, Salesforce maintained a portfolio of strategic investments in enterprise cloud companies, technology startups, and system integrators, with a focus on digitally transforming industries and expanding its solution ecosystem. These investments were described as ranging from early to late-stage companies, including those concurrent with initial public offerings. By 2024, Salesforce's relationship with enterprise cloud companies shifted from primarily investing to a broader strategic dependency, leveraging these partners as part of its ecosystem to accelerate reach into new markets and industries. The 2024 filing emphasized the Salesforce Platform's role in enabling third-party developers and ISVs to create and deliver cloud-based applications through the AppExchange, indicating a deepened integration and dependency on enterprise cloud partners beyond mere financial investment.",
      "llm_answer": "\nFrom fiscal 2023 to fiscal 2024 Salesforce shifted its strategic‑investment focus from a broad, capital‑intensive portfolio of enterprise‑cloud startups toward a tighter emphasis on AI‑native and vertical‑specific platforms, while deepening ecosystem integration through partners such as Slack, MuleSoft and the AppExchange.  The company is now directing capital to investments that accelerate its own Agentforce/AI capabilities and tighten data‑cloud connectivity, whereas in 2023 the emphasis was on building a diversified investment base and expanding the partner ecosystem as a growth lever.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies a strategic shift in Salesforce's approach from 2023 to 2024, moving from broad investments to deeper ecosystem integration, which aligns with the ground truth. It accurately captures the evolution in focus—from building a diversified portfolio in 2023 to emphasizing tighter integration and strategic alignment in 2024. However, the LLM introduces specific elements not present in the original answer: (1) the emphasis on 'AI-native and vertical-specific platforms', (2) mention of 'Agentforce/AI capabilities', and (3) naming of specific partners like Slack and MuleSoft as part of the strategic shift. While these may be factually plausible given Salesforce’s known strategy, they are not supported in the provided ground truth, which makes no mention of AI, Agentforce, or specific partners. This adds detail beyond the source and slightly misrepresents the basis of the shift. The answer is strong on reasoning—correctly inferring a pivot from investment to integration—and contextually relevant, but the added specificity reduces qualitative accuracy. There are no numerical values in either answer, so quantitative accuracy is scored as 10 by default. The core factual trajectory (shift from investment to ecosystem dependency) is preserved, warranting a 7 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 365,
        "total_tokens": 1744
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How did the company's approach to accrual rates for vendor funding programs evolve between fiscal 2023 and fiscal 2024, particularly in terms of sensitivity to projected purchase volumes?",
      "original_answer": "The company's approach to accrual rates for vendor funding programs remained methodologically consistent between fiscal 2023 and fiscal 2024, with no material changes in the recognition methodology over the past three fiscal years. However, in fiscal 2023, the company specifically highlighted sensitivity to 'graduated purchase volumes' that could impact accrued amounts, emphasizing the importance of projected volumes in determining accrual rates. In fiscal 2024, this explicit reference to 'graduated purchase volumes' was omitted, suggesting a potential simplification or stabilization in how accrual rates were adjusted throughout the year, despite continued monitoring of historical purchase trends and vendor confirmations.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 the company kept the same core method—accrual rates are derived from vendor‑agreement terms and are revised throughout the year using purchase‑trend data—but it made the process more volume‑responsive.  In the 2024 filing the company explicitly states that accrued vendor‑funding amounts are “impacted if actual purchase volumes differ from projected purchase volumes,” especially for programs that increase funding once graduated volume thresholds are met, indicating a stronger sensitivity to projected volumes than in the prior year.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim about the evolution of the company's approach to accrual rates. The ground truth states that the methodology remained consistent and that the explicit mention of 'graduated purchase volumes' was *omitted* in fiscal 2024, suggesting a potential simplification or stabilization. However, the LLM incorrectly asserts that the company made the process *more* volume-responsive in fiscal 2024 and that it 'explicitly states' a stronger sensitivity to volume differences—this directly contradicts the original answer. There are no quantitative figures (e.g., percentages, dollar amounts) in the question or ground truth, so quantitative accuracy is not heavily applicable, but the use of correct fiscal years (2023 and 2024) and proper context of vendor funding programs supports a moderate score. The reasoning is flawed: instead of recognizing the removal of emphasis on graduated volumes as a sign of reduced sensitivity or stabilized methodology, the model misinterprets the 2024 filing as increasing sensitivity, which is the opposite of the documented change. While the answer addresses the right topic and attempts multi-hop reasoning (comparing two fiscal years’ disclosures), the synthesis is incorrect, leading to a low correctness and qualitative accuracy score. Contextual relevance is moderate because the response discusses the right concepts but draws an inverted conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 396,
        "total_tokens": 1732
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has the strategic relationship between LLY and Boehringer Ingelheim evolved from 2022 to 2024, particularly in terms of legal involvement and collaborative dependency on the Jardiance product?",
      "original_answer": "In 2022, LLY was not a direct party to the Jardiance patent litigation initiated by Boehringer Ingelheim (BI) against generic drug manufacturers under the Hatch-Waxman Act, indicating a more arms-length relationship in legal matters. By 2024, LLY's business became significantly dependent on the Jardiance collaboration, as the product was selected under the Inflation Reduction Act (IRA) for government-set pricing with a 66% discount compared to the 2023 list price, directly impacting LLY's revenue projections and business strategy. This shift reflects a deeper strategic entanglement and dependency on BI's partnership for navigating regulatory and pricing pressures.",
      "llm_answer": "\nFrom 2022 through 2024 the legal dispute that Boehringer Ingelheim (BI) launched in 2018 over generic entry to Jardiance remained active but was kept in a stayed status, so no new litigation milestones or settlements were reported; the partnership itself did not shift, with BI continuing to share development and commercial responsibilities and to defend and indemnify Lilly for any product‑liability claims tied to Jardiance.  At the same time, the strategic importance of the drug grew—evidenced by the IRA’s 2023‑2024 price‑setting selections for Jardiance—underscoring that Lilly’s collaboration with BI remains tightly dependent on the product’s market performance and regulatory trajectory.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution in the LLY-Boehringer Ingelheim relationship from 2022 to 2024, particularly regarding legal involvement and growing collaborative dependency on Jardiance. (1) It correctly states that Boehringer Ingelheim led the Hatch-Waxman litigation and that LLY was not a direct party, noting the stayed status of the case through 2024—consistent with the ground truth that LLY remained legally insulated. The answer accurately reflects BI's ongoing responsibility for defending and indemnifying LLY, which supports the 'arms-length' legal dynamic in 2022 and continuity through 2024. (2) On quantitative accuracy, the answer does not explicitly mention the 66% discount under the Inflation Reduction Act (IRA), which is a key numeric detail in the ground truth. However, it correctly references the IRA’s 2023–2024 price-setting mechanism and its impact on Jardiance, implying the pricing pressure. The absence of the exact percentage is a minor but notable omission. (3) The multi-hop reasoning is sound: the model connects BI’s legal stewardship, the lack of new litigation developments, and the increasing strategic importance of Jardiance due to IRA pricing—correctly inferring deeper dependency despite legal separation. (4) The answer is contextually excellent, directly addressing both legal involvement and collaborative dependency. While it omits the specific 66% figure and slightly softens the shift in strategic entanglement by not emphasizing the change in LLY’s revenue exposure, the overall synthesis across time, entities, and regulatory impact is accurate and relevant. Minor deduction from 9 to 8 due to missing precise quantitative detail central to the revenue impact claim.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 473,
        "total_tokens": 1828
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How did Disney's capital investment strategy toward cruise ships evolve from 2022 to 2023, particularly in relation to its broader Parks & Experiences business?",
      "original_answer": "In 2022, Disney's 10-K filing highlighted cruise ships as part of its broader Experiences segment but did not specifically emphasize capital investment in them, instead noting general risks from macroeconomic conditions such as inflation, supply chain delays, and currency fluctuations that could impact the implementation of business plans, including those for parks and resorts. By 2023, Disney explicitly listed cruise ships as part of its significant capital investments, indicating a strategic elevation in focus. The 2023 filing stated that the majority of the company’s capital spend was directed toward parks and experiences, including 'new attractions, cruise ships, capital improvements and systems infrastructure.' This shift demonstrates a clear prioritization of cruise ships as a key growth area within the broader Experiences segment.",
      "llm_answer": "\nFrom fiscal 2022 through fiscal 2023 Disney moved from a one‑off, land‑development focus to a sustained, multi‑year capital‑allocation program that treats cruise‑ship expansion as a core pillar of its Parks & Experiences strategy.  In 2022 the Company invested heavily in the 550‑acre Lighthouse Point resort on Eleuthera, earmarking it as a private Disney Cruise Line destination for 2024, while 2023’s filings show continued and accelerating spending on new ships and on‑board enhancements, integrating those assets into the broader theme‑park/resort growth portfolio and positioning cruise‑ship capital projects as high‑return, long‑term investments within the Parks & Experiences business.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general direction of Disney's evolving capital investment strategy toward cruise ships from 2022 to 2023 and correctly identifies the increased strategic emphasis on cruise ships within the Parks & Experiences segment. However, it introduces specific details not present in the original 10-K filings or the ground truth. Notably, the claim about investing in a '550-acre Lighthouse Point resort on Eleuthera' and designating it as a 'private Disney Cruise Line destination for 2024' is factually unsupported by the provided ground truth, which does not mention Lighthouse Point, acreage, or specific timelines for destinations. Additionally, the characterization of 2022 as a 'one-off, land-development focus' and 2023 as a shift to 'accelerating spending on new ships and on-board enhancements' overreaches the original answer, which only states that cruise ships were explicitly listed as a capital investment priority in 2023, whereas in 2022 they were not specifically emphasized. The ground truth does not support a qualitative shift from 'land-development' to 'cruise expansion' as a pivot, but rather a broadening of disclosed capital priorities. While the core idea—increased strategic focus on cruise ships in 2023—is correct, the LLM adds unverified specifics and narrative framing not present in the source. Quantitative accuracy is low because of the unsupported numbers (550-acre, 2024 timeline). Qualitative accuracy is moderate because the reasoning direction is sound but overconfident in unsupported details. Contextual relevance is high as the answer addresses the evolution in capital strategy within Parks & Experiences.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 453,
        "total_tokens": 1842
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has Mastercard Foundry's role in fostering innovation evolved between 2022 and 2024, particularly in relation to its engagement with emerging technologies and fintech partnerships?",
      "original_answer": "In 2022, Mastercard Foundry (formerly known as Mastercard Labs) was primarily described as a vehicle for bringing customers and partners access to thought leadership, innovation methodologies, new technologies, and early-stage fintech players. By 2024, its role had evolved into a more active innovation engine, with continued emphasis on identifying and experimenting with future technologies, start-ups, and trends. Specifically, in 2024, Foundry was positioned as a key enabler of blockchain-based business models and programmable payments through the Mastercard Multi-Token Network™, indicating a strategic shift toward deeper integration with next-generation financial technologies.",
      "llm_answer": "\nBetween 2022 and 2024 Mastercard Foundry shifted from a primarily exploratory “lab” that showcased emerging tech and early‑stage fintech collaborations to a more market‑oriented platform that embeds those innovations into core offerings.  In 2022 it emphasized thought‑leadership and experimentation with fintech startups and new technologies, whereas by 2024 Foundry was actively steering large‑scale programs—such as blockchain‑based programmable payments, AI‑enhanced fraud‑detection and tokenization, and the rollout of Virtual‑Card‑Number and Alias‑Based Remittances—while deepening partnerships with fintechs, crypto‑players and digital‑wallet providers.  This evolution reflects a move from pure ideation to delivering concrete, scalable solutions that drive ecosystem‑wide innovation.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of Mastercard Foundry between 2022 and 2024. It accurately captures the shift from an exploratory, lab-like function focused on thought leadership and early-stage fintech engagement in 2022 to a more active innovation engine in 2024. The mention of blockchain-based programmable payments and deeper fintech partnerships matches the original answer's emphasis on the Mastercard Multi-Token Network™ and strategic integration with next-gen financial technologies. However, the LLM adds specific initiatives such as 'AI-enhanced fraud-detection', 'Virtual-Card-Number and Alias-Based Remittances' that are not mentioned in the ground truth and cannot be verified from the provided knowledge. While these may be plausible extensions, they introduce unverified details that slightly reduce qualitative accuracy. There are no numerical values in the question or answers, so quantitative accuracy is scored as 10 by default. The reasoning is sound and reflects proper multi-hop synthesis across time periods and strategic roles. The answer is fully contextually relevant, directly addressing the evolution in engagement with emerging technologies and fintech partnerships.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 352,
        "total_tokens": 1731
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has the financial and strategic nature of the collaboration with Boehringer Ingelheim evolved between 2022 and 2024, particularly in terms of regulatory designations and pricing pressures?",
      "original_answer": "In 2022, the collaboration with Boehringer Ingelheim included the development of a therapy that had received Breakthrough Therapy and Fast Track designations from the FDA, indicating early-stage regulatory support and potential expedited development. By 2024, the collaboration faced significant pricing pressures under the Inflation Reduction Act, with Jardiance—part of the LLY-Boehringer Ingelheim partnership—selected for government-set pricing effective in 2026, subject to a 66% discount compared to the 2023 U.S. list price. This marks a shift from regulatory facilitation to regulatory-driven financial constraints.",
      "llm_answer": "\nThe Lilly‑Boehringer Ingelheim partnership progressed from securing early regulatory accelerants—by 2022 the companies had obtained FDA **Breakthrough Therapy** and **Fast‑Track** designations for empagliflozin (Jardiance) in heart‑failure with preserved ejection fraction and were advancing its submission for chronic‑kidney‑disease indications (see LLY_10k_2022.pdf pp. 37‑41). By 2024 the collaboration faced a new strategic challenge: the U.S. **Inflation Reduction Act** now subjects Jardiance, a joint product, to government‑set Medicare prices with up to a **66 % discount** beginning in 2026, underscoring a shift toward managing significant pricing pressure while the partners continue to leverage the partnership’s pipeline (see LLY_10k_2024.pdf pp. 43‑47).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Breakthrough Therapy and Fast Track designations in 2022 for empagliflozin (Jardiance) in specific indications are accurately stated, and the 66% discount under the Inflation Reduction Act beginning in 2026 is correctly reported. The mention of LLY_10k_2022.pdf and LLY_10k_2024.pdf as sources reflects proper grounding. (2) Quantitative accuracy is perfect: the 66% discount, the 2026 effective date, and the reference to 2022 and 2024 timeframes match the original answer exactly. Format variations (e.g., '66 %' vs '66%') are negligible and do not affect meaning. (3) Multi-hop reasoning is sound: the answer synthesizes regulatory developments in 2022 with financial/regulatory pressures in 2024, correctly identifying the strategic shift from regulatory facilitation to pricing constraints. It appropriately identifies Jardiance as a joint product and links it to the partnership. (4) The only minor shortcoming is that the original answer emphasizes the shift from 'regulatory support' to 'regulatory-driven financial constraints' more explicitly as a conceptual evolution, while the LLM answer presents the facts clearly but with slightly less emphasis on the overarching strategic transformation. However, the core reasoning and factual synthesis are intact. Wording differences are acceptable under semantic equivalence. All parts of the question—financial and strategic evolution, regulatory designations, and pricing pressures—are fully addressed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 427,
        "total_tokens": 1787
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How has the strategic positioning of the CH-53K King Stallion heavy lift helicopter evolved within Lockheed Martin's Rotary and Mission Systems segment from 2023 to 2024?",
      "original_answer": "In 2023, the CH-53K King Stallion heavy lift helicopter was described as part of Lockheed Martin's near-to-mid-term growth elements, specifically under the Rotary and Mission Systems (RMS) segment, alongside radar surveillance systems. By 2024, the CH-53K remained a highlighted program within RMS, but the emphasis shifted to framing it within a broader context of advancing all-domain mission solutions and digital technologies such as AI/ML and autonomy. While no specific revenue figures are provided, the helicopter's positioning evolved from being a growth driver among several others to being part of a more integrated, technologically advanced portfolio aimed at improving interoperability and supporting multi-domain solutions.",
      "llm_answer": "\nFrom 2023 to 2024 the CH‑53K moved from being highlighted simply as a flagship heavy‑lift program for the Rotary and Mission Systems (RMS) segment—highlighted by the 2023 Israeli LOA and ongoing U.S. Marine Corps production—to being positioned as a strategic growth pillar for RMS.  In 2024 the company emphasized accelerated production rates, expanded sustainment and new foreign‑military‑sales opportunities, and integrated the CH‑53K into its broader 21st‑Century Security vision, making the helicopter a cornerstone for future vertical‑lift and joint‑all‑domain capabilities within Lockheed Martin’s RMS business.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the strategic evolution of the CH-53K within Lockheed Martin's RMS segment. (1) The answer correctly identifies the CH-53K as a key program in RMS and captures the shift in strategic positioning from 2023 to 2024. It accurately reflects that in 2023, the program was highlighted as a growth element (with reference to the Israeli LOA and USMC production), and in 2024, it was integrated into broader strategic themes such as joint-all-domain operations and 21st-Century Security—consistent with the ground truth's emphasis on AI/ML, autonomy, and interoperability. (2) There are no numeric figures in either answer, so quantitative accuracy is not compromised; the LLM does not introduce any incorrect dates or financials. (3) The multi-hop reasoning is sound: it synthesizes the program’s progression from a standalone heavy-lift asset to a strategic pillar within a larger mission systems context. However, the LLM adds specific details not present in the ground truth—such as 'accelerated production rates', 'expanded sustainment', and 'foreign military sales opportunities'—which, while plausible, are not confirmed in the original knowledge base. This slightly reduces qualitative accuracy. (4) The answer is highly contextually relevant, directly addressing the evolution of strategic positioning. While the core facts and direction of evolution are correct, the added specificity beyond the source truth prevents a perfect score. Overall, the semantic meaning is equivalent with minor embellishment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 434,
        "total_tokens": 1778
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "What does the change in LLY's diabetes product portfolio co-commercialized with Boehringer Ingelheim between 2022 and 2024 indicate about the companies' shifting strategic priorities or market focus?",
      "original_answer": "In 2022, LLY and Boehringer Ingelheim were jointly developing and commercializing a broader portfolio of diabetes products, including Trajenta, Jentadueto, Jardiance, Glyxambi, Synjardy, Trijardy XR, and Basaglar. By 2024, the portfolio had narrowed to include only Jardiance, Glyxambi, Synjardy, and Trijardy XR. This indicates a strategic refocusing, potentially driven by lifecycle management, shifting market demand, or prioritization of products with stronger commercial performance or longer patent protection. The removal of Trajenta, Jentadueto, and Basaglar may reflect declining market relevance, generic competition, or a strategic decision to streamline the collaboration around products with greater growth potential or therapeutic differentiation.",
      "llm_answer": "\nThe 2022‑2024 evolution of the Lilly‑Boehringer Ingelheim diabetes lineup—adding Jardiance’s cardiovascular‑risk and heart‑failure indications, expanding the Basaglar biosimilar portfolio, and introducing newer combination agents—shows that the partners are deliberately steering their diabetes strategy toward a **cardiometabolic** focus that emphasizes outcomes‑driven, high‑value products.  By co‑commercializing these differentiated therapies, the companies are aligning their resources to capture payer and provider attention, secure formulary placement, and sustain growth in a segment where generic competition is intense.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in both factual content and reasoning. (1) It incorrectly states that the portfolio evolved by 'adding Jardiance’s cardiovascular-risk and heart-failure indications' and 'expanding the Basaglar biosimilar portfolio' between 2022 and 2024, which contradicts the ground truth: the actual change was a *reduction* in the co-commercialized product portfolio, with Trajenta, Jentadueto, and Basaglar being *removed* by 2024. The narrowing of the portfolio is misrepresented as an expansion. (2) There are no numeric values (e.g., financial figures, product counts) in either answer, so quantitative accuracy cannot be assessed on numbers, but the directional claim (expansion vs. contraction) is factually wrong. (3) The multi-hop reasoning is flawed: the LLM infers a strategic shift toward cardiometabolic focus based on product additions and indication expansions that are not supported by the ground truth. While Jardiance’s outcomes data may be real, the answer misuses it to justify a narrative of growth, when the actual strategic signal is one of *streamlining*—focusing on fewer, more viable products. (4) The contextual relevance is moderate because the answer addresses strategic priorities and market focus, as asked, but does so with incorrect premises. The ground truth emphasizes contraction and potential reasons (generic competition, lifecycle management), while the LLM describes expansion and innovation. The conclusion about focusing on high-value, outcomes-driven products is partially aligned but not supported by the actual portfolio changes described. Major factual inaccuracies severely undermine correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1361,
        "completion_tokens": 452,
        "total_tokens": 1813
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How did the financial performance and strategic importance of the JASSM program evolve between 2023 and 2024, particularly in terms of production activity and its contribution to backlog?",
      "original_answer": "In 2023, JASSM was a product under the Missiles and Fire Control (MFC) segment, contributing to the company's portfolio of tactical missiles, but there was no specific mention of significant changes in its production volume or backlog contribution. By 2024, JASSM experienced a production ramp-up, contributing to a $1.2 billion increase in tactical and strike missile programs within MFC. Additionally, JASSM was specifically cited as a key contributor to the increase in backlog alongside PAC-3 and GMLRS. This indicates a notable rise in both production activity and strategic importance for JASSM in 2024.",
      "llm_answer": "\nBetween 2023 and 2024 the JASSM program moved from a modest contributor to a primary growth engine for the Missiles & Fire Control segment.  In 2023 its production ramp‑up added roughly **$145 million** of net sales and helped lift overall backlog, while in 2024 the same ramp‑up generated **about $1.2 billion** of the segment’s sales increase and was explicitly cited as a key driver of the **higher backlog** for PAC‑3, LRASM and JASSM.  Consequently, JASSM’s expanding production volume not only boosted revenue but also reinforced its strategic importance as a core, high‑demand missile system that underpins the segment’s future earnings and order pipeline.",
      "correctness_score": 5,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in quantitative details. The ground truth states that JASSM contributed to a $1.2 billion increase in tactical and strike missile programs in 2024, but the LLM incorrectly attributes $145 million in net sales to JASSM in 2023 — a figure not present in the original answer and unsupported by the knowledge base. Additionally, the LLM claims the 'same ramp-up' generated $1.2 billion in 2024, which misrepresents the timeline and causality; the original answer indicates the ramp-up occurred in 2024, not that it continued from 2023. (2) The $1.2 billion figure is correctly cited but misassigned in context — it refers to the broader category of tactical and strike missiles (including JASSM, PAC-3, GMLRS), not solely JASSM. The LLM overattributes this entire amount to JASSM’s production ramp-up, which is an overstatement. (3) Qualitatively, the LLM captures the correct direction of change — increased production activity and strategic importance in 2024 — and correctly identifies JASSM as a key backlog contributor alongside PAC-3 and GMLRS (though it mistakenly includes LRASM, which was not mentioned in the original). The multi-hop reasoning is partially sound: it infers growing strategic importance from production and backlog trends, but the synthesis is weakened by incorrect numerical grounding. (4) Contextual relevance is high — the response directly addresses the evolution of financial performance and strategic role across years, focusing on production and backlog as requested. However, the quantitative inaccuracies severely undermine the correctness score, as financial figures are central to the question. Minor entity error: LRASM is incorrectly grouped with JASSM and PAC-3 in backlog contribution, which was not in the original.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 498,
        "total_tokens": 1827
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How has JPM's focus in evaluating credit risk for Business Banking Loans evolved between 2023 and 2024, and what implications does this shift have for identifying early signs of borrower distress?",
      "original_answer": "In 2023, JPM focused on Business Banking Loans as part of its broader prime consumer credit strategy, emphasizing loan performance and scoring models within the 'Consumer, excluding credit card loan portfolio' segment. By 2024, the focus shifted toward delinquency rates as the primary credit quality indicator, particularly noting that loans more than 30 days past due serve as early warnings of financial difficulty. This evolution suggests a more proactive stance in identifying early signs of borrower distress, aligning Business Banking Loans with broader consumer loan risk frameworks where early delinquency tracking enhances risk mitigation. The shift indicates a strategic move toward earlier intervention and more granular performance monitoring.",
      "llm_answer": "\nBetween 2023 and 2024 JPMorgan moved its Business‑Banking loan risk assessment from a primarily delinquency‑and‑geography‑based view (2023 ‑ “geographic distribution is an indicator of credit performance” for scored auto and business‑banking loans) to a more granular, risk‑rated framework that emphasizes risk‑rated exposure, current‑estimated LTV and refreshed FICO scores, and regional economic indicators (2024 ‑ “Nonaccrual loans and other credit‑quality indicators” tables showing LTV, FICO, geographic region and wholesale‑methodology allowances).  \n\nThis shift means that early signs of borrower distress can now be detected through leading metrics such as rising high‑LTV or low‑FICO exposures in specific regions, allowing the firm to flag at‑risk borrowers before traditional delinquency or charge‑off signals appear.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect in both factual content and reasoning when compared to the ground truth. (1) The original answer states that in 2023, JPM focused on loan performance and scoring models within the 'Consumer, excluding credit card loan portfolio' segment as part of its prime consumer credit strategy, and by 2024 shifted to using delinquency rates (specifically loans more than 30 days past due) as the primary indicator of credit quality and early distress. In contrast, the LLM claims a shift from 'delinquency-and-geography-based view' in 2023 to a 'risk-rated framework' in 2024 involving LTV, FICO, and regional economic indicators—none of which are mentioned in the ground truth. (2) There are no quantitative figures (e.g., percentages, dollar amounts) in either answer, so no numerical inaccuracies per se, but the LLM fabricates metrics like 'current-estimated LTV', 'refreshed FICO scores', and 'wholesale-methodology allowances' that do not appear in the original. (3) The multi-hop reasoning is flawed: the LLM invents a narrative not supported by the source, incorrectly characterizing both the 2023 and 2024 approaches. The actual evolution is from broader portfolio-level scoring models to a focus on early delinquency as a leading indicator; the LLM instead describes a technical shift toward risk-rating and underwriting metrics that are not in the ground truth. (4) While the LLM attempts to address the question’s structure—describing a change over time and its implications—it does so with fabricated details, resulting in low factual accuracy. The implication about detecting distress earlier is partially aligned with the original (proactive stance), but it's based on incorrect premises. Hence, the correctness score is low despite some structural relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1408,
        "completion_tokens": 486,
        "total_tokens": 1894
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How did Target Corporation's SPP II plan terms evolve between the 2022 and 2023 filings, and what does this suggest about the company's executive compensation framework?",
      "original_answer": "In the 2022 filing, the SPP II plan was described under the 2016 Plan Statement, as amended and restated effective April 3, 2016. However, in the 2023 filing, the SPP II plan was updated to the 2022 Plan Statement, as amended and restated effective May 1, 2022. This indicates that Target Corporation revised the SPP II plan within this timeframe, reflecting a shift in the structure or terms of the plan. Such changes could signal adjustments in the company's executive compensation strategy, potentially aligning incentives more closely with updated business objectives or governance standards.",
      "llm_answer": "\nTarget’s SPP II plan is referenced in both the 2022 and 2023 Form 10‑K filings using the identical “Target Corporation SPP II (2016 Plan Statement) (as amended and restated effective April 3, 2016)” description, with no new amendment or revised terms disclosed in the 2023 filing. This lack of change indicates that the company has kept the long‑term incentive structure of its executive compensation framework stable, preserving the same performance‑share and cash‑award provisions from year to year.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect. (1) It claims that the SPP II plan description was identical in both the 2022 and 2023 filings, which contradicts the ground truth: the 2022 filing references the '2016 Plan Statement' (effective April 3, 2016), while the 2023 filing updates to the '2022 Plan Statement' (effective May 1, 2022). This change in the plan's effective date and statement version is a key factual discrepancy. (2) The LLM incorrectly states there was 'no new amendment or revised terms disclosed in the 2023 filing,' when in fact the update to the 2022 Plan Statement explicitly indicates a revision. This error undermines the entire response. (3) The multi-hop reasoning fails: the question requires comparing two filings across years to detect changes in plan terms, but the LLM incorrectly concludes no change occurred, leading to an erroneous interpretation of stability in executive compensation strategy, when the ground truth suggests a shift. (4) The contextual relevance is low because the answer addresses the right topic (executive compensation framework) but bases its conclusion on false premises. The qualitative and quantitative accuracy scores are very low due to the incorrect dates, missing amendment, and flawed synthesis. Only minimal credit is given for addressing the general subject matter.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1280,
        "completion_tokens": 369,
        "total_tokens": 1650
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How did the financial obligations related to Incyte under the Olumiant collaboration evolve from 2022 to 2024, particularly regarding potential future milestone payments?",
      "original_answer": "In 2022, Incyte was eligible to receive up to $100.0 million in additional development-related regulatory milestones and another $100.0 million in sales-based milestones under the Olumiant agreement. By 2024, there is no mention of remaining regulatory milestones, suggesting they were either paid out or no longer applicable, and only ongoing royalty payments based on sales tiers (up to 20%) and a low teens royalty for sales exceeding a threshold in the context of COVID-19 treatment are explicitly referenced. This indicates a shift from a structure with both regulatory and sales milestones to one focused primarily on sales-based compensation.",
      "llm_answer": "\nFrom 2022 through 2024 the company did not record any new milestone‑related cash outflows under the Olumiant (baricitinib) partnership; the only obligations were the amortization of the $260 million and $210 million regulatory milestones that had been capitalized in 2020‑2021 and were being expensed as cost of sales.  At the end of 2021 Incyte remained eligible for up to an additional $100 million of success‑based regulatory milestones and up to $100 million of sales‑based milestones, so the potential future milestone exposure stayed at roughly $200 million but no further payments had been triggered by that date.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and fails to correctly represent the evolution of financial obligations from 2022 to 2024 as described in the ground truth. (1) Quantitatively, the LLM incorrectly states that no new milestone-related cash outflows were recorded from 2022 through 2024 due to amortization of previously capitalized $260M and $210M milestones, which contradicts the ground truth mentioning $100M in potential regulatory and $100M in sales-based milestones still eligible in 2022. The $260M and $210M figures are not present in the ground truth and appear to be fabricated or misattributed. (2) The timeline is also incorrect: the LLM claims Incyte remained eligible for up to $200M in future milestones 'at the end of 2021', but the question asks about developments from 2022 to 2024. This misalignment shifts the temporal context and misses the key change over the requested period. (3) Qualitatively, the reasoning is flawed because it fails to recognize the shift indicated in the ground truth—from a structure including both regulatory and sales milestones in 2022 to only royalty-based payments (with no mention of remaining milestones) in 2024. The LLM instead implies the $200M milestone exposure remained unchanged through 2024, which contradicts the ground truth suggesting regulatory milestones were no longer mentioned by 2024. (4) Contextually, the answer addresses the topic of milestone obligations and references Incyte and Olumiant correctly, so it remains relevant, but the core factual evolution is misrepresented. There is no indication in the LLM answer of the transition to sales-tier royalties (up to 20%) or the low teens royalty for COVID-19-related sales, which are central to the ground truth. Thus, while the answer attempts multi-hop synthesis, it fails in execution due to incorrect data and timeline confusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 505,
        "total_tokens": 1829
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has Cisco's financial exposure in the APJC region evolved between fiscal 2022 and fiscal 2023, based on its segment reporting and asset balances?",
      "original_answer": "In fiscal 2022, Cisco reported its business performance across geographic segments including APJC, though specific financial figures for APJC were not disclosed in the provided data. By fiscal 2023, Cisco's balance sheet showed that its assets in the APJC region stood at $5,382 million as of July 29, 2023, following additions from acquisitions and foreign currency translation adjustments. This indicates a more detailed financial disclosure regarding APJC in 2023 compared to 2022, where segment-level asset values were not explicitly itemized.",
      "llm_answer": "\nCisco’s APJC revenue rose modestly from $8.0 billion in fiscal 2022 to roughly $8.2 billion in fiscal 2023 (segment‑revenue table), indicating a small increase in revenue exposure. At the same time, long‑lived assets in the region fell from $997 million at the end of fiscal 2022 to about $950 million at the end of fiscal 2023 (asset‑balance table), showing a decline in capital‑intensive exposure.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth. (1) Quantitative inaccuracy: The LLM claims APJC revenue was $8.0 billion in fiscal 2022 and $8.2 billion in fiscal 2023, and that long-lived assets were $997 million and $950 million respectively. However, the original answer states that no specific financial figures for APJC were disclosed in fiscal 2022, and only in fiscal 2023 were asset values reported — at $5,382 million (not $950 million). The LLM invents precise revenue numbers and misstates asset figures by a large margin. (2) The asset value of $5,382 million in 2023 refers to total assets in APJC, not long-lived assets specifically, so the LLM mischaracterizes the metric. (3) Multi-hop reasoning fails: The question asks about evolution based on segment reporting and asset balances, but the LLM fabricates segment revenue data that was not disclosed in 2022 and incorrectly infers trends. (4) The only partially correct aspect is the attempt to compare APJC exposure across years, which aligns with the question’s intent, giving it minimal contextual relevance. However, due to severe factual and quantitative errors, the answer is mostly wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1237,
        "completion_tokens": 332,
        "total_tokens": 1569
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has the strategic collaboration between LLY and Boehringer Ingelheim, specifically regarding Jardiance, evolved from 2022 to 2024 in response to regulatory changes?",
      "original_answer": "In 2022, Jardiance revenue was growing significantly, with a 30% increase in the U.S. and 28% outside the U.S., driven by increased demand and volume respectively. By 2024, the collaboration was significantly impacted by the Inflation Reduction Act (IRA), which introduced government-set pricing for certain drugs, including Jardiance. In August 2023, Jardiance was selected as one of the first ten medicines subject to government-set prices, and in August 2024, a 66% discount was applied compared to the 2023 U.S. list price, significantly affecting revenue projections and business strategy.",
      "llm_answer": "\nFrom 2022 through 2024 the Lilly‑Boehringer Ingelheim Jardiance partnership has shifted from pure volume‑driven growth to a strategy that accommodates the Inflation‑Reduction Act’s price‑setting rules. After HHS listed Jardiance among the first ten drugs subject to government‑set caps, the 2024 announcement imposed a roughly 66 % discount off the 2023 list price, forcing the collaborators to supplement sales with expanded indications, new formulations and heightened manufacturing capacity while negotiating rebates to preserve profitability. This regulatory pressure has therefore re‑oriented the alliance toward maintaining market access and diversifying revenue streams rather than relying solely on price‑unconstrained growth.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: Jardiance was selected in August 2023 as one of the first ten drugs under the Inflation Reduction Act (IRA), and a 66% discount was applied in August 2024 compared to the 2023 U.S. list price. The 66% figure is correctly stated, and the timeline (2022 growth, 2023 selection, 2024 price impact) is accurate. (2) Quantitative accuracy is perfect: the 66% discount is correctly cited, and while the original answer notes 30% and 28% growth in 2022, the LLM omits these specific figures but does not contradict them—this omission is minor and does not detract from core correctness. (3) Reasoning is sound: the LLM correctly infers that the IRA’s price-setting forced strategic shifts, such as focusing on expanded indications, new formulations, and rebates to maintain profitability—this is a reasonable interpretation of the strategic evolution. (4) Entities (LLY, Boehringer Ingelheim, Jardiance, IRA, HHS) and timeframes (2022–2024) are correctly identified. The answer is contextually excellent, directly addressing how the collaboration evolved in response to regulation. The only minor shortcoming is the omission of the 2022 growth percentages, which were part of the original answer, but the core regulatory impact and strategic shift are fully and accurately captured. Hence, a 9/10 on correctness and qualitative accuracy, with full marks on quantitative and contextual dimensions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 409,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did GM's emphasis on the financial and reputational risks of product safety recalls evolve between 2022 and 2023, particularly concerning global platforms like the Chevrolet Bolt EV and the company's positioning in EV/AV technologies?",
      "original_answer": "In 2022, GM specifically highlighted the Chevrolet Bolt EV recall as an example of how global platform-related recalls could significantly increase costs due to their scale. The focus was on the financial burden and logistical complexity tied to such large-scale campaigns. By 2023, while the concern around global platforms remained, GM expanded its risk disclosure to emphasize the reputational damage to brand image and equity, particularly in relation to its leadership aspirations in EV and AV technologies. This evolution suggests a shift from a primarily cost-centric concern to a broader strategic risk tied to innovation and market positioning.",
      "llm_answer": "\nBetween 2022 and 2023 GM’s discussion of product‑safety recalls shifted from a general warning that recalls could “materially adversely affect” the business to a more pronounced, strategy‑linked emphasis.  In the 2022 filing the company highlighted that a recall on a global platform such as the Chevrolet Bolt EV could amplify costs and reputational damage, while in 2023 the language was sharpened to stress that safety concerns—especially those involving advanced EV/AV technologies—could jeopardize brand trust, delay product roll‑outs and trigger substantial financial penalties.  This evolution reflects a growing awareness that recall risk is now central to GM’s EV/AV positioning and to its overall financial and reputational resilience.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution in GM's risk disclosure between 2022 and 2023, noting the shift from financial/logistical concerns (2022) to broader reputational and strategic risks (2023), particularly in relation to EV/AV technologies and brand trust. The mention of the Chevrolet Bolt EV as a key example of a global platform recall is accurate. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the model synthesizes information across years (2022 vs 2023), connects product recalls to global platforms, and links them to strategic positioning in EV/AV innovation. The only minor deviation is that the LLM slightly overstates the 2022 emphasis by saying it included 'reputational damage'—the original answer specifies that 2022 focused primarily on financial burden, with reputational concerns becoming prominent in 2023. This nuance is softened but not entirely misrepresented. (4) The answer is contextually excellent, directly addressing the question’s focus on evolution, global platforms, and EV/AV positioning. Overall, the semantic meaning matches the ground truth with high fidelity, warranting a 9/10 for correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 385,
        "total_tokens": 1758
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did the Guaranteed Senior Notes issued by Costco's Japanese subsidiary evolve between 2022 and 2024, and what does this indicate about the company's long-term financing strategy?",
      "original_answer": "In 2022, the Guaranteed Senior Notes issued by Costco's Japanese subsidiary were described in general terms, indicating only their existence and that they were valued using Level 3 inputs. By 2024, the company provided significantly more detailed information, disclosing that in November 2023, the subsidiary issued four new Guaranteed Senior Notes totaling approximately $500 at fixed interest rates ranging from 1.400% to 2.120%, with maturities extending from 2033 to 2043. Additionally, in July 2024, the subsidiary repaid $77 of these notes. This evolution indicates a more transparent and strategic approach to long-term financing, with a focus on fixed-rate debt and extended maturities to manage future liquidity needs.",
      "llm_answer": "\nThe Guaranteed Senior Notes of Costco’s Japanese subsidiary grew from roughly **$0.7 billion** in the 2022‑2023 period to about **$0.92 billion** by the end of 2024.  After issuing approximately **$0.5 billion** of new notes in late 2023 (with maturities extending to 2033‑2043 at fixed rates of 1.4‑2.1 %), the subsidiary repaid only a small amount ($77 million) in July 2024, leaving the outstanding balance higher at the end of 2024.  \n\nThis pattern shows that Costco is deliberately **expanding its long‑term financing through lower‑cost, longer‑dated foreign‑currency debt** issued by its overseas subsidiary, using the notes to fund international operations and diversify the company’s capital structure while still relying on its U.S. senior unsecured notes for the bulk of overall long‑term funding.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. The ground truth states that approximately $500 million in new Guaranteed Senior Notes were issued in November 2023, but the LLM incorrectly claims the total grew from $0.7 billion in 2022–2023 to $0.92 billion by end of 2024. The original answer does not provide a total balance in 2022, only that the notes were valued using Level 3 inputs—there is no mention of a $0.7 billion figure. The $0.5 billion issuance is correct (matches $500 million), and the $77 million repayment in July 2024 is accurate. However, the LLM’s implied calculation (0.7 + 0.5 – 0.077 = 1.123 billion, yet claims 0.92 billion) is mathematically inconsistent, indicating flawed reasoning. (2) The dates (November 2023 issuance, July 2024 repayment) and interest rates (1.4% to 2.1%) are correctly reported, and the maturities (2033–2043) match. (3) The qualitative reasoning about Costco’s long-term financing strategy—increased transparency, use of fixed-rate, long-dated foreign debt, diversification of capital structure—is plausible and aligns with the trend described in the ground truth, though the original answer emphasizes improved disclosure and strategic maturity extension rather than explicitly stating 'expansion' or 'lower-cost'. The LLM adds interpretive language not present in the ground truth (e.g., 'lower-cost', 'deliberately expanding') which goes beyond the provided data. (4) Contextually, the answer addresses both parts of the question: evolution over time and strategic implications. However, the core numerical inaccuracies—especially the unsupported $0.7 billion starting balance—undermine factual reliability. The synthesis across years is partially correct but based on incorrect baseline data. Thus, while the direction of the trend and some key facts are right, the quantitative foundation is flawed, leading to a partial correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1392,
        "completion_tokens": 520,
        "total_tokens": 1913
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did the value of Cisco's available-for-sale debt investments change between 2022 and 2023, and what does this indicate about the company's investment strategy?",
      "original_answer": "In 2022, Cisco reported gains from available-for-sale debt investments at $9 million, indicating a relatively minor role in their investment portfolio. By 2023, the total value of these investments dropped significantly from $15,592 million to $9,865 million, a decrease of $5,727 million. This indicates a strategic reduction in the company's holdings of available-for-sale debt instruments, suggesting a shift in investment focus or risk management approach.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2023 the balance of Cisco’s available‑for‑sale (AFS) debt investments rose from **$11.9 billion to $15.6 billion**, an increase of roughly **$3.6 billion (≈30 %)**.  This jump reflects a purposeful expansion of the company’s short‑term, interest‑earning securities portfolio—using higher‑quality, investment‑grade debt to generate modest returns on excess cash while preserving flexibility for dividends, share‑repurchases and strategic acquisitions.  The move signals that Cisco is allocating more of its liquidity to AFS securities, likely to boost cash‑flow yields in a higher‑rate environment and to support its capital‑allocation priorities.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is almost entirely incorrect in both direction and magnitude. The ground truth states that Cisco's available-for-sale debt investments decreased from $15,592 million in 2022 to $9,865 million in 2023—a drop of $5,727 million. The LLM incorrectly claims an increase from $11.9 billion to $15.6 billion, which is not only wrong but reverses the trend. Additionally, the LLM cites a 30% increase, which is unsupported by the data. (2) The numbers are fundamentally inaccurate: the starting value ($11.9B vs $15,592M), ending value ($15.6B vs $9,865M), and change (+$3.6B vs -$5,727M) are all incorrect. The calculation of gains in the original answer refers to $9M in gains in 2022, which the LLM ignores entirely. (3) The multi-hop reasoning fails: the question requires comparing two years' investment values and interpreting strategic implications. The LLM misidentifies the values and thus draws the opposite conclusion—expansion instead of contraction—leading to flawed qualitative analysis. (4) The contextual relevance is partially met as it discusses Cisco’s investment strategy and AFS debt instruments, but the factual foundation is so flawed that the reasoning collapses. Due to complete quantitative inaccuracy and incorrect synthesis, the correctness score is very low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1288,
        "completion_tokens": 366,
        "total_tokens": 1654
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has JPMorgan Chase's exposure to system damage risks evolved from 2023 to 2024, particularly in relation to third-party vendor attacks and data recovery challenges?",
      "original_answer": "In 2023, JPMorgan Chase highlighted risks related to system damage primarily through unauthorized access, zero-day vulnerabilities, and disruptions from distributed denial-of-service attacks. The company emphasized the risk of undetected vulnerabilities due to incomplete system enhancements and the potential for data loss or manipulation. By 2024, the exposure evolved to include more specific emphasis on ransomware attacks targeting third-party vendors and the risk of losses exceeding cyber insurance coverage. Additionally, JPMorgan Chase noted increased complexity in recovering from data theft or destruction, with a new concern around the inability to prevent systems from processing fraudulent transactions. These changes indicate a growing awareness of external cyber threats and their financial implications.",
      "llm_answer": "\nFrom 2023 to 2024 JPMorgan Chase’s exposure to system‑damage risk has risen sharply as its interconnectivity with third‑party vendors, custodians and market‑infrastructure platforms has expanded.  The 2024 filing stresses that failures or cyber attacks at a vendor or at any linked entity can cascade across the firm, making data‑recovery far more complex and driving up remediation and operational‑costs, whereas the 2023 discussion only noted the possibility of vendor‑related failures without this systemic emphasis.  Consequently, the firm now faces a heightened likelihood of widespread operational disruption and greater difficulty restoring compromised data after a breach.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies an evolution in JPMorgan Chase's exposure to system damage risks from 2023 to 2024, particularly emphasizing increased interconnectivity with third-party vendors and the cascading impact of their failures. It accurately reflects that the 2024 filing places greater emphasis on third-party risks compared to 2023, where such risks were mentioned but not with the same systemic focus. The answer also correctly notes increased complexity in data recovery and operational disruption, aligning with the ground truth's mention of data recovery challenges. However, the LLM omits key specifics from the original answer: (1) it does not mention ransomware attacks targeting third-party vendors, a critical new threat highlighted in 2024; (2) it fails to reference the risk of losses exceeding cyber insurance coverage; and (3) it does not include the new concern about inability to prevent systems from processing fraudulent transactions. While the general direction of increased risk and complexity is correct, these omissions reduce completeness and qualitative accuracy. There are no numerical values in the question or answers, so quantitative accuracy is scored as 10 by default. The answer remains contextually relevant and semantically aligned in broad strokes but lacks precise threat evolution details present in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 378,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "What operational investments has Costco made by 2024 to support the private-label growth strategy mentioned in its 2022 filing?",
      "original_answer": "In 2022, Costco emphasized increasing the penetration of its private-label items as a merchandising strategy to manage inflationary pressures and maintain competitive pricing. By 2024, Costco had made tangible operational investments to support this strategy, including the operation of various processing, packaging, and manufacturing facilities dedicated to the production of private-label items. These facilities, referenced in the 2024 filing, represent a significant evolution from the earlier strategic focus, demonstrating a shift from sourcing private-label products externally to building internal production capabilities to scale the initiative.",
      "llm_answer": "\nCostco expanded its private‑label product assortment, adding new Kirkland Signature and exclusive items. It also invested in dedicated private‑label sourcing and distribution infrastructure and increased pricing and marketing focus on private‑label brands to boost their share of sales.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but misses key operational investments described in the ground truth. (1) Correct elements: The answer correctly identifies that Costco invested in private-label growth, including expanding product assortment (Kirkland Signature) and enhancing sourcing and distribution infrastructure, which aligns generally with operational support. It also notes increased pricing and marketing focus, which is contextually relevant. (2) Quantitative accuracy: There are no specific numbers, dates, or financial figures in either the LLM or original answer, so no numeric inaccuracies exist—this aspect is neutral but does not detract. (3) Multi-hop reasoning assessment: The question requires connecting Costco’s 2022 private-label strategy to tangible operational investments by 2024. The ground truth specifies that by 2024, Costco operated processing, packaging, and manufacturing facilities—indicating a shift to internal production capabilities. The LLM answer mentions 'sourcing and distribution infrastructure' but fails to mention the critical evolution to owning/operating manufacturing and processing facilities, which is the core operational investment highlighted in the original answer. This omission represents a significant gap in qualitative accuracy. (4) Justification: While the LLM response is contextually relevant and contains plausible strategic actions, it lacks the specific, factually grounded operational shift (from external sourcing to internal production) that defines Costco’s 2024 investment. Thus, the answer is not fully accurate or complete, warranting a mid-range correctness score of 5.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1230,
        "completion_tokens": 447,
        "total_tokens": 1678
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How did UnitedHealth Group's approach to Medicaid managed care contract bidding evolve between 2022 and 2023, particularly in terms of assumptions and risks associated with bid accuracy?",
      "original_answer": "In 2022, UnitedHealth Group emphasized the risk of losing Medicaid members if it failed to renew state Medicaid managed care contracts, highlighting the importance of contract renewals to retain enrolled members. By 2023, the company placed greater emphasis on the assumptions behind its bids, noting that if these assumptions—such as enrollment, utilization, and medical costs—were materially incorrect due to unforeseen program changes or competitor pricing, it could materially affect results of operations and cash flows. This reflects an evolution from a focus on contract renewal risk to a more detailed discussion of the assumptions and competitive dynamics involved in the bidding process itself.",
      "llm_answer": "\nBetween 2022 and 2023 UnitedHealth Group’s Medicaid‑managed‑care bidding shifted from a relatively straightforward model that relied on enrollment growth, utilization and medical‑cost assumptions to a more refined approach that incorporated updated risk‑adjustment calculations, tighter enrollment forecasts and greater sensitivity to benchmark‑driven pricing pressures.  In both years the company warned that bid accuracy is critical—if any of the underlying assumptions (e.g., member volume, cost trends, or risk‑adjusted payments) prove materially wrong, the resulting contract loss or margin compression could have a material adverse effect on results of operations, financial position and cash flows.  The 2023 disclosures emphasized heightened volatility and the need for more conservative, data‑driven assumptions to mitigate the risk of inaccurate bids.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in its overall narrative and captures the key evolution in UnitedHealth Group's approach to Medicaid managed care bidding between 2022 and 2023. It correctly identifies that bid accuracy, assumptions around enrollment, utilization, and medical costs are critical, and that incorrect assumptions could materially affect financial results—this aligns with the ground truth. The mention of 'risk-adjusted payments' and 'benchmark-driven pricing pressures' adds detail not contradicted by the original, though not explicitly stated. However, the LLM introduces concepts not present in the ground truth, such as 'updated risk-adjustment calculations' and 'tighter enrollment forecasts', which shift focus toward technical refinements rather than the documented shift in risk emphasis—from contract renewal risk in 2022 to bid assumption sensitivity in 2023. The original answer highlights a qualitative evolution in risk disclosure (retention via renewal vs. accuracy of bid assumptions), while the LLM frames it as a methodological refinement, which is plausible but not directly supported. No numbers, dates, or financial metrics are incorrect (quantitative accuracy is perfect), and the answer is contextually relevant and well-structured. The reasoning is sound but slightly over-interprets the nature of the evolution without full support from the source. Thus, the answer is factually consistent in key aspects but misses the precise nuance of the shift in risk focus, warranting a 7 for correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 426,
        "total_tokens": 1827
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How did MET's investment in Municipals evolve from 2022 to 2023, particularly in terms of its valuation hierarchy classification?",
      "original_answer": "In 2022, MET's investment in Municipals was valued at $14,212 million and primarily categorized under 'Estimated Fair Value' without a detailed breakdown of valuation hierarchy levels. By 2023, the investment in Municipals decreased to $159 million and was explicitly classified under 'Level 2' of the fair value hierarchy. This indicates a significant reduction in the size of the Municipals investment and a more transparent categorization within the fair value hierarchy in 2023.",
      "llm_answer": "\nMetLife’s municipal bond holdings declined from $159 million in 2022 to about $147 million in 2023, and in both years they were classified as Level 2 in the fair‑value hierarchy—meaning they continued to be valued using observable inputs rather than Level 1 quoted prices or Level 3 unobservable inputs.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors. According to the ground truth, MET's investment in Municipals was $14,212 million in 2022, not $159 million as stated by the LLM. The LLM incorrectly reports the 2022 value as $159 million, which is actually the 2023 value in the ground truth. Additionally, the LLM states the 2023 value is about $147 million, which contradicts both its own 2022 figure and the ground truth of $159 million. (2) Quantitative accuracy is severely compromised: the 2022 figure is off by over $14 billion, and the 2023 figure is both inconsistent with the ground truth and slightly misstated. There are no correct calculations or comparisons based on accurate inputs. (3) The qualitative reasoning is flawed: the ground truth indicates a major shift from an aggregate 'Estimated Fair Value' classification in 2022 to an explicit 'Level 2' classification in 2023, suggesting improved transparency. However, the LLM claims the investment was Level 2 in both years, missing this key evolution in valuation hierarchy disclosure. This reflects a failure in multi-hop reasoning—correctly identifying changes in both amount and classification over time. (4) Contextual relevance is moderate because the answer addresses municipal investments and fair value hierarchy levels, which are relevant topics, but the severe factual inaccuracies in numbers and classification changes drastically reduce its correctness. The answer misrepresents both the magnitude of change and the nature of the valuation hierarchy evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1192,
        "completion_tokens": 428,
        "total_tokens": 1620
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has Microsoft's approach to Office 365 subscriptions evolved in terms of licensing flexibility and customer agreement models from fiscal year 2022 to 2024?",
      "original_answer": "In fiscal year 2022, Office 365 subscriptions were primarily managed under volume licensing programs and were recognized as part of unearned revenue, invoiced annually at the beginning of each contract period and recognized ratably over the coverage period. By fiscal year 2024, Microsoft introduced more structured and flexible customer agreement models, including the Microsoft Customer Agreement, Microsoft Online Subscription Agreement, and Microsoft Products and Services Agreement, which allowed customers to subscribe to cloud services seamlessly and directly, with options for monthly or annual subscriptions and no organization-wide commitment. This represents a shift toward enhanced customer-centric licensing flexibility.",
      "llm_answer": "\nFrom fiscal 2022 through fiscal 2024 Microsoft broadened the way it sells Office 365 (now part of Microsoft 365) from a primarily perpetual‑license/volume‑licensing model toward a subscription‑centric, consumption‑based approach.  The 2022 filing (Notes 19 and Revenue Recognition) describes Office 365 revenue as being recognized ratably and tied to distinct performance‑obligation bundles, while the 2024 filing (pages 15‑19) highlights the expanded use of the Microsoft Customer Agreement, Microsoft Online Subscription Agreement and Microsoft Products and Services Agreement—vehicles that provide monthly or annual terms, easy scaling, and the ability to mix SaaS, cloud and on‑premises licenses in a single, non‑expiring contract.  This shift gives customers greater flexibility to adjust seat counts, add or drop services, and consume the software on a usage‑based basis, while still preserving the larger Enterprise Agreement option for big‑enterprise customers.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution from volume licensing in fiscal 2022 to more flexible customer agreement models by fiscal 2024, including the Microsoft Customer Agreement, Microsoft Online Subscription Agreement, and Microsoft Products and Services Agreement. The description of ratable revenue recognition in 2022 and the shift toward monthly/annual, scalable, and flexible subscription models in 2024 matches the original answer. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or ground truth, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the model synthesizes changes across fiscal years 2022 and 2024, referencing appropriate shifts in licensing models and customer agreements, and correctly contextualizes the move toward customer-centric flexibility. The mention of 'perpetual-license/volume-licensing model' in 2022 is slightly broader than the ground truth (which focuses on volume licensing and unearned revenue), but this does not constitute a factual error. (4) The LLM adds value by noting the ability to mix SaaS, cloud, and on-premises licenses and preserving Enterprise Agreements for large customers—details consistent with Microsoft's direction and supportive of the core claim. Only minor phrasing differences exist (e.g., 'consumption-based' and 'usage-based' are interpretive but reasonable). Overall, the answer is factually correct, complete, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1429,
        "completion_tokens": 429,
        "total_tokens": 1858
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did the composition of MET's Level 3 Fixed Maturity Securities AFS change between 2022 and 2023, and what does this indicate about the company's investment strategy?",
      "original_answer": "In 2022, MET's Level 3 Fixed Maturity Securities AFS included $1 million in Corporate bonds, $1 million in Foreign Bonds, and $11 million in Equity Securities. By 2023, the Level 3 composition shifted significantly, with $54 million in Corporate bonds, $2 million in Foreign Bonds, and $828 million in Other Investments. This indicates a strategic shift toward increasing exposure in Other Investments while maintaining a relatively small position in Level 3 fixed maturity securities overall. The significant increase in Other Investments within Level 3 suggests a more aggressive approach to portfolio diversification or risk management.",
      "llm_answer": "\nBetween 2022 and 2023 the Level 3 portion of MET’s Fixed‑Maturity‑Securities‑AFS grew modestly, rising from **$58 million to $64 million**.  The composition shifted slightly: corporate holdings fell from $55 M to $54 M, while foreign‑bond exposure was introduced ($2 M in 2023 versus $0) and the “other” category expanded from $3 M to $8 M.  This small reallocation indicates that MetLife is gradually diversifying its Level 3 assets—adding foreign‑bond and other less‑correlated holdings—to fine‑tune the risk‑return profile of its investment portfolio while preserving liquidity for benefit‑payment obligations.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, MET's Level 3 Fixed Maturity Securities AFS consisted of $1M Corporate bonds, $1M Foreign Bonds, and $11M Equity Securities (totaling $13M, not $58M). In 2023, it was $54M Corporate bonds, $2M Foreign Bonds, and $828M Other Investments (totaling $884M). The LLM incorrectly reports total values as $58M and $64M, misrepresents the composition entirely (e.g., claiming $55M in corporate bonds in 2022 when it was $1M), and introduces a nonexistent 'other' category of $3M to $8M instead of the correct $828M in Other Investments. (2) Calculations are fundamentally wrong: the LLM claims a modest increase from $58M to $64M, but the actual increase is from $13M to $884M — a massive shift. The LLM also falsely states that foreign bonds were $0 in 2022 when they were $1M. (3) Multi-hop reasoning is flawed: the model fails to correctly identify the components and their values across years, leading to an incorrect conclusion about a 'gradual diversification' rather than a strategic pivot toward large-scale investment in 'Other Investments'. (4) Despite incorrect data, the LLM attempts to address the question's intent regarding strategy, hence partial credit for contextual relevance. However, due to severe quantitative and qualitative errors, the overall correctness score is very low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 389,
        "total_tokens": 1708
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How has Microsoft's strategic positioning of Office 365 evolved between 2022 and 2024, particularly in terms of its role within the broader cloud services portfolio and its response to competitive pressures from AI-driven offerings?",
      "original_answer": "In 2022, Office 365 was explicitly listed as a key component of Microsoft's service and other revenue, positioned alongside Azure, Dynamics 365, and Xbox as a core cloud-based solution. By 2024, Office 365 had evolved into a more integrated part of Microsoft’s broader AI-infused cloud services portfolio, reflecting the company's strategic shift to infuse generative AI capabilities into commercial offerings. The 2024 filing notes that Microsoft is devoting significant resources to develop and deploy AI models, platforms, and infrastructure to meet customer needs, indicating that Office 365 is now part of this AI-enhanced competitive strategy. This shift was driven by increasing competitive pressures from companies entering the AI market and offering alternative models such as free applications funded by advertising or open-source AI models, which Microsoft must counter with enhanced, integrated cloud experiences.",
      "llm_answer": "\nBetween fiscal 2022 and 2024 Microsoft moved Office 365 from a stand‑alone subscription productivity suite to the core engine of its cloud‑services portfolio, tightly integrating it with Azure, Dynamics 365 and other cloud platforms and billing it on a ratable‑over‑time basis.  The 2024 disclosures highlight that the company is now “infusing generative AI capabilities” (e.g., Copilot) into Office 365 and leveraging its OpenAI partnership to turn the service into an AI‑enhanced, platform‑agnostic offering, a clear strategic response to competitive pressure from AI‑driven rivals.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution of Office 365 from a standalone suite in 2022 to an AI-integrated core component by 2024, noting its integration with Azure, Dynamics 365, and the broader cloud portfolio—consistent with the original answer. The mention of 'ratable-over-time' billing is contextually accurate to revenue recognition in cloud services, though not explicitly stated in the ground truth, it does not contradict it. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or ground truth, so quantitative accuracy is not compromised; all dates (2022, 2024) are correct. (3) The multi-hop reasoning is sound: the LLM synthesizes Office 365’s strategic shift, its integration into Microsoft’s cloud ecosystem, and the response to AI competition—linking AI infusion (e.g., Copilot), OpenAI partnership, and competitive pressures from AI-driven rivals. This matches the ground truth’s emphasis on AI enhancement and competitive dynamics. (4) The only minor gap is that the original answer specifically mentions competitive pressures including free, ad-supported or open-source AI models, which the LLM answer references only generally as 'AI-driven rivals.' While the core strategic response is accurately captured, this slight omission in competitive detail prevents a perfect 10 on qualitative accuracy. Overall, the answer is factually correct, contextually rich, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1399,
        "completion_tokens": 422,
        "total_tokens": 1821
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did UnitedHealth Group's recognition and handling of credit-related impairments evolve between 2022 and 2023, particularly in terms of their evaluation methodology and financial impact?",
      "original_answer": "In 2022, UnitedHealth Group evaluated available-for-sale debt securities for credit-related impairments by analyzing expected cash flows, underlying credit quality, and credit ratings of issuers, concluding that there was no significant credit deterioration since purchase and that unrealized losses were primarily due to interest rate increases. The allowance for credit losses was not material. By 2023, the company formalized its impairment recognition process by distinguishing between credit-related and non-credit-related impairments, recording credit-related impairments as an allowance against investment income and non-credit-related impairments through other comprehensive income. Additionally, the company emphasized a more structured evaluation framework that includes present value of expected cash flows, the extent of fair value decline relative to amortized cost, and issuer-specific financial conditions. This reflects a more detailed and segmented approach to impairment recognition and financial reporting.",
      "llm_answer": "\nBetween 2022 and 2023 UnitedHealth Group’s process for assessing credit‑related impairments showed no substantive change: the company continued to test available‑for‑sale debt securities for impairment by comparing each security’s fair value to its amortized cost and, when fair value was lower, evaluating expected cash‑flows, issuer credit quality and external ratings to determine whether the decline was credit‑driven or driven by other factors such as interest‑rate movements.  In both years the company concluded that any unrealized losses were temporary, did not intend to sell the impaired securities, and therefore recorded no material allowance for credit losses— the allowance remained “not material” and had no discernible impact on net earnings or the overall financial statements.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core claim that there was 'no substantive change' in UnitedHealth Group's impairment evaluation methodology between 2022 and 2023. The ground truth states that in 2023, the company formalized its process by distinguishing between credit-related and non-credit-related impairments, recording them differently in financial statements (allowance against investment income vs. other comprehensive income), and adopting a more structured framework involving present value of expected cash flows, extent of fair value decline, and issuer-specific conditions. The LLM answer completely misses this evolution and instead asserts continuity, which contradicts the original answer. (2) Quantitatively, the answer is mostly accurate: it correctly notes that the allowance for credit losses was 'not material' in both years and that unrealized losses were attributed to interest rate movements. There are no numerical inaccuracies per se, as the original answer does not include specific dollar amounts or percentages, so the LLM avoids quantitative error. (3) The multi-hop reasoning is flawed: the question asks for an evolution in methodology and financial impact, requiring comparison across two years and synthesis of changes in accounting treatment. The LLM fails to identify the key change in 2023—segmented recognition of impairments and revised reporting approach—indicating a failure in qualitative synthesis. (4) Contextual relevance is moderate: the answer addresses the right topic (impairment evaluation of AFS securities) and mentions relevant factors like fair value, amortized cost, and credit quality, but it incorrectly concludes no change occurred, thereby failing to capture the central development in 2023. This results in a low correctness score despite acceptable terminology and structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1465,
        "completion_tokens": 504,
        "total_tokens": 1970
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did the allocation and valuation of Fixed Maturity Securities AFS in MET's pension and other postretirement benefit plans evolve from 2022 to 2023?",
      "original_answer": "In 2022, Fixed Maturity Securities AFS accounted for 84% of U.S. Pension Benefits and 95% of U.S. Other Postretirement Benefits. By 2023, the total estimated fair value of Fixed Maturity Securities AFS was $6,714 million for Pension Benefits and $1,274 million for Other Postretirement Benefits. This indicates a shift from a primarily percentage-based allocation in 2022 to a more detailed valuation breakdown in 2023, showing both the scale and composition of MET's holdings.",
      "llm_answer": "\nFrom 2022 to 2023 the actual weight of Fixed‑Maturity‑Securities AFS in MET’s U.S. pension portfolio slipped a little – from about 84 % of total plan assets in 2022 to roughly 82 % in 2023 (the target stayed at 85 %).  At the same time the fair‑value composition shifted: total AFS holdings fell modestly (from $6.8 bn to $6.7 bn), Level 2 assets remained dominant but slipped from $5.09 bn to $4.92 bn, while Level 3 assets rose from $58 m to $64 m, indicating a small increase in the less‑observable, higher‑risk slice of the portfolio.  In the other post‑retirement benefit segment, AFS holdings also declined (from $1.44 bn to $1.27 bn) with a similar modest rise in Level 3 exposure.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. According to the ground truth, in 2022, Fixed Maturity Securities AFS accounted for 84% of U.S. Pension Benefits and 95% of U.S. Other Postretirement Benefits. However, the LLM claims a drop to 82% in 2023, which is not supported by the original answer — the 2023 data is presented in dollar values ($6,714 million and $1,274 million), not percentages, so no percentage 'slip' can be confirmed. The LLM introduces a 'target of 85%' and actual percentage of 82% in 2023, which are not present in the ground truth and thus incorrect. (2) The dollar amounts are partially correct: $6.7 billion for Pension Benefits in 2023 aligns with $6,714 million (rounded), and $1.27 billion for Other Postretirement Benefits matches $1,274 million. However, the LLM incorrectly states 2022 values as $6.8 billion and $1.44 billion, which are not provided in the original answer — the 2022 data is in percentages, not dollar values. The introduction of Level 2 and Level 3 asset values ($5.09B to $4.92B, $58M to $64M) is unsupported by the ground truth and appears fabricated. (3) The multi-hop reasoning is flawed: the model assumes a shift in allocation can be expressed as a percentage change in 2023, but the original answer only provides 2022 percentages and 2023 dollar valuations — no direct percentage comparison is possible. The LLM incorrectly synthesizes non-existent data points. (4) Despite these issues, the answer is contextually relevant, addressing the evolution of allocation and valuation, and correctly identifies the decline in dollar value for Other Postretirement Benefits. However, the inclusion of unsupported metrics and incorrect calculations significantly undermines factual accuracy, warranting a low correctness and quantitative accuracy score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 495,
        "total_tokens": 1788
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did Lowe's strategic positioning of the Kitchens & Bath product category evolve between 2022 and 2023, and what does this suggest about its relative importance in the company's product portfolio?",
      "original_answer": "In 2022, Kitchens & Bath was grouped under the Home Décor division alongside categories like Appliances, Décor, Flooring, and Paint, suggesting a more design-focused positioning. By 2023, Kitchens & Bath was listed among core construction and renovation categories such as Lumber, Building Materials, and Rough Plumbing, indicating a strategic repositioning toward home improvement and remodeling. This shift suggests that Lowe's placed greater strategic emphasis on Kitchens & Bath as a key growth area tied to higher-value home projects, aligning with its broader 'Total Home' strategy.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2023 Lowe’s moved the **Kitchens & Bath** line from being bundled inside the broader **Home Décor** division (where it was listed together with appliances, décor, flooring and paint) to a **stand‑alone product category** in its merchandise taxonomy.  The 2022 “Products” table placed Kitchens & Bath under the Home Décor umbrella, while the 2023 “Our Products” section lists it explicitly alongside Appliances, Building Materials, Hardlines, etc., underscoring a deliberate emphasis on the category as a distinct growth pillar.  This repositioning signals that Kitchens & Bath has become a **strategically important segment** of Lowe’s overall portfolio, warranting its own categorization and focus within the company’s “Total Home” strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the 2022 positioning of Kitchens & Bath under the Home Décor division alongside Appliances, Décor, Flooring, and Paint. It also accurately describes the 2023 repositioning, noting that Kitchens & Bath was elevated to a more prominent category listing alongside core construction and renovation lines like Building Materials. (2) There are no numeric values, dates, or financial figures in dispute; all time references (fiscal 2022 and 2023) are correct and consistent with the original. (3) The multi-hop reasoning is sound: the model correctly infers strategic intent from organizational taxonomy changes across two years, linking the repositioning to Lowe’s 'Total Home' strategy. The only minor deviation is that the LLM describes Kitchens & Bath as a 'stand-alone product category,' while the original emphasizes its grouping with construction/renovation categories rather than complete independence. This is a subtle distinction—the category is more prominent but not necessarily isolated—so the interpretation is reasonable but slightly less precise. (4) The answer fully addresses both parts of the question: the evolution of strategic positioning and the implication for portfolio importance. Wording differs but semantic meaning matches. Thus, the answer earns a 9 for correctness and qualitative accuracy due to this slight overstatement, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 416,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How has Mondelez International's strategic focus on Cheese & Grocery evolved between 2022 and 2024, and what does this suggest about its prioritization of snack categories for long-term growth?",
      "original_answer": "In 2022, Mondelez directly produced Cheese & Grocery products, generating $1,990 million in total net revenues from this category. By 2024, the company no longer reported direct production in this category and instead indicated only a strategic stake in Cheese & Grocery, positioning it as an adjacent category within its broader snacking portfolio. This shift suggests a refocusing on core snack categories like biscuits and chocolate, while maintaining a presence in Cheese & Grocery through a lighter footprint. The change aligns with Mondelez's stated strategy of prioritizing long-term growth in core snacking segments and managing costs amid inflationary pressures.",
      "llm_answer": "\nBetween 2022 and 2024 Mondelez’s public narrative moved cheese & grocery from a highlighted “adjacent, locally relevant” growth pillar in the 2022 filing—where it was presented as an area for early‑stage investment and expansion—to a peripheral mention in the 2024 filing, which only lists it together with gum & candy and powdered beverages as one of several side‑category options.  The 2024 discussion shifts the company’s strategic emphasis toward its core snacking portfolio (chocolate, biscuits and baked snacks) and high‑growth adjacent categories, indicating that cheese & grocery is no longer a priority for long‑term growth but rather a modest, opportunistic segment.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the strategic shift in Mondelez's focus on Cheese & Grocery from 2022 to 2024, noting its transition from a growth pillar to a peripheral category. It accurately reflects the company’s refocusing on core snacks (biscuits, chocolate) and deemphasizing Cheese & Grocery. However, it omits the key quantitative fact from the ground truth: $1,990 million in net revenues from Cheese & Grocery in 2022. This is a significant omission because the question asks about strategic evolution, and revenue magnitude helps substantiate the importance of the category in 2022. The 2024 status—no direct production, only a strategic stake—is implied through 'peripheral mention' but not explicitly stated. (2) There are no incorrect numbers, but the absence of the $1,990 million figure results in a partial failure on quantitative accuracy. The LLM does not attempt any calculations, so no errors there. (3) The reasoning is sound: the model correctly synthesizes a multi-hop narrative—comparing disclosures across years, identifying shifts in strategic language, and linking them to broader portfolio priorities. It correctly infers reduced prioritization based on diminished emphasis in filings. However, it lacks explicit confirmation of the operational change (from direct production to only a strategic stake), which is a key factual pivot in the ground truth. (4) Despite missing the revenue figure and precise operational status, the LLM answer aligns well with the overall strategic interpretation. Wording differs but meaning is semantically close. Hence, correctness is reduced to 7 due to missing key financial data, but qualitative and contextual scores remain high due to strong reasoning and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 476,
        "total_tokens": 1825
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did Abbott's presentation of its enteral feeding product lineup, specifically the positioning of Jevity relative to Freego™ products, change between the 2022 and 2023 10-K filings?",
      "original_answer": "In the 2022 10-K filing, Jevity was listed first among enteral feeding products, followed by Glucerna 1.2 Cal, Glucerna 1.5 Cal, Osmolite®, Oxepa®, Freego™ (Enteral Pump), and Freego™ sets. In the 2023 filing, Jevity remained listed first, but the Freego™ (Enteral Pump) and Freego™ sets were now mentioned immediately after Jevity, before the Glucerna and Osmolite® product lines. This change in listing order suggests a shift in product emphasis within the enteral feeding category, with Freego™ products receiving more prominent placement alongside Jevity in 2023 compared to 2022.",
      "llm_answer": "\nIn the 2022 10‑K Jevity® is listed as a stand‑alone enteral‑nutrition brand that appears ahead of Freego™ (the pump) in the product list, implying that Jevity is presented as a separate, primary offering. By the 2023 10‑K the same bullet is worded to introduce “Freego™ (Enteral Pump) and Freego™ sets” first and then mentions Jevity® only as one of the formulas that can be used with the Freego system, shifting the emphasis from Jevity as an independent product to Jevity being positioned as a formula within the Freego™ platform.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim about the change in presentation between the 2022 and 2023 10-K filings. According to the ground truth, Jevity remained listed first in both years, and Freego™ products were moved up in the list order in 2023—appearing immediately after Jevity—but were not presented as the primary product. The LLM incorrectly states that in the 2023 10-K, Freego™ was introduced first and Jevity was demoted to being mentioned only as a formula used with the Freego system. This misrepresents the actual sequence and emphasis in the filings. There are no numeric values in the question or answer, so quantitative accuracy is not applicable beyond correct referencing of years (2022 and 2023), which are accurate. The qualitative reasoning is flawed because the model fails to correctly interpret the product listing order and infers a platform-level repositioning (Jevity as part of the Freego™ platform) that is not supported by the ground truth. The answer does address the question's focus on positioning changes, so it maintains moderate contextual relevance, but the incorrect synthesis of the product hierarchy significantly undermines the validity of the response. The multi-hop reasoning—comparing product order across two filings—is required, but the model draws an erroneous conclusion based on likely misreading of the source structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1288,
        "completion_tokens": 383,
        "total_tokens": 1672
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did MET's investment in municipals evolve from 2022 to 2023 in terms of fair value and classification, and what does this suggest about the company's credit risk management strategy?",
      "original_answer": "In 2022, MET held $14,212 million in municipals, classified under the 'fixed maturity securities AFS' category, with a fair value that included $2,464 million in gross unrealized gains and only $13 million in gross unrealized losses. By 2023, this investment had significantly declined to just $159 million, now categorized under the 'fixed maturity securities AFS' and classified entirely within Level 2 of the fair value hierarchy, indicating a shift in MET's positioning. This dramatic reduction suggests a strategic move to reduce credit exposure to municipals, likely as part of a broader risk management adjustment to limit potential losses in this asset class.",
      "llm_answer": "\nFrom 2022 through 2023 the municipal portion of MetLife’s fixed‑maturity AFS book stayed in the **available‑for‑sale** category and its fair‑value rose only modestly – from roughly **$14.2 billion to about $14.5 billion** (as shown in the “Fixed Maturity Securities AFS by Sector – Municipals” line item).  This slight increase, together with the unchanged AFS classification, signals that MetLife is deliberately maintaining a high‑quality, tax‑exempt exposure while exercising tight credit‑risk oversight—relying on rigorous impairment testing and a focus on investment‑grade issuers rather than shifting the assets to a different classification or higher‑risk classification.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 2,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both quantitative and qualitative aspects. (1) Quantitatively, it claims MET's municipal investments increased from $14.2 billion in 2022 to $14.5 billion in 2023, which directly contradicts the ground truth showing a drop from $14,212 million ($14.2 billion) to just $159 million in 2023—a 99% reduction. The LLM incorrectly reports a modest increase instead of a dramatic decline. (2) The classification is inaccurately portrayed: while both years list municipals under 'fixed maturity securities AFS', the 2023 data specifies the entire $159 million is classified in Level 2 of the fair value hierarchy, a detail omitted and misrepresented by the LLM. (3) The reasoning is flawed: the LLM concludes MET is maintaining stable exposure with tight credit oversight, but the actual data suggests a strategic exit from the municipals asset class to reduce credit risk, indicating a major shift in risk management strategy, not continuity. (4) The answer fails on multi-hop synthesis: it does not recognize the significance of the near-total divestment, misreads the trend, and draws the opposite conclusion from the evidence. Despite addressing the question's structure (evolution, classification, strategy), the factual foundation is entirely wrong, making the response highly misleading. Minor contextual relevance is retained due to correct mention of AFS classification and focus on credit risk, but core facts and logic are invalid.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 406,
        "total_tokens": 1752
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did Abbott's use of interest rate hedge contracts evolve between 2022 and 2023, particularly in terms of their notional value and the impact on fixed-rate debt management?",
      "original_answer": "In 2022, Abbott had interest rate hedge contracts totaling approximately $2.2 billion, which were used to manage exposure to changes in the fair value of fixed-rate debt by converting fixed-rate obligations into variable-rate obligations. By 2023, Abbott continued to use these contracts for the same purpose, and the notional value remained consistent at approximately $2.2 billion. However, in 2023, the company provided more detailed disclosures about the impact of these contracts on the carrying value of fixed-rate debt, indicating a more refined approach to interest rate risk management.",
      "llm_answer": "\nBetween 2022 and 2023 the notional amount of Abbott’s interest‑rate fair‑value hedges fell sharply—from about **$2.9 billion at the end of 2022 to roughly $2.2 billion at the end of 2023** (a decline of roughly $0.7 billion).  The drop was driven mainly by the **maturity of $700 million of those hedge contracts in 2023**, which coincided with the repayment of the corresponding fixed‑rate notes.  As a result, a smaller share of Abbott’s fixed‑rate debt was being offset by swaps, so the company’s direct exposure to interest‑rate movements on the remaining fixed‑rate obligations increased, although the outstanding swaps continue to convert those fixed‑rate interest payments into variable rates to manage fair‑value risk.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Abbott's notional value of interest rate hedge contracts remained consistent at approximately $2.2 billion in both 2022 and 2023. However, the LLM claims the notional amount decreased from $2.9 billion in 2022 to $2.2 billion in 2023, which contradicts the original answer. This error misrepresents the evolution of Abbott's hedge usage. Additionally, the LLM introduces a $700 million contract maturity driving the decline, which is not mentioned or supported in the ground truth. (2) Quantitatively, the $2.2 billion figure for 2023 is correct, but the $2.9 billion figure for 2022 is incorrect—ground truth states $2.2 billion in both years. The claimed $0.7 billion decline and its attribution to maturities are unsupported. (3) The qualitative reasoning is flawed: the LLM infers a strategic shift due to a supposed reduction in notional value, suggesting increased interest rate exposure, whereas the ground truth indicates stable notional value and a refinement in disclosure practices, not a change in hedging scale. The model fails to capture the actual evolution—consistency in notional value with improved transparency. (4) Contextual relevance is moderate because the answer discusses the right topic (use of interest rate hedges for fixed-rate debt management) and correctly notes that hedges convert fixed to variable rates. However, the core factual premise (declining notional value) is false, undermining the entire analysis. The multi-hop synthesis fails because it draws conclusions from incorrect data points.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1337,
        "completion_tokens": 447,
        "total_tokens": 1784
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How did 3M's issuance and management of fixed rate registered notes evolve between 2022 and 2024, particularly in terms of repayment activity and interest rate strategies?",
      "original_answer": "In 2022, 3M had a significant amount of fixed rate registered notes, including $600 million of 10-year notes due 2030 with a coupon rate of 3.05%, and $650 million of 30-year notes due 2050 with a coupon rate of 3.70%. The company also issued $3.25 billion in fixed rate registered notes in August 2019, including $1.0 billion of 10-year notes due 2029 and $1.0 billion of 30-year notes due 2049. In 2024, 3M repaid $1.1 billion in medium-term notes that matured, and in 2023, it repaid $500 million in fixed-rate registered notes. Additionally, interest rate swaps initiated in 2021 converted portions of the fixed-rate notes due 2049 and 2050 into floating-rate debt through mid-2028, indicating a strategic shift toward managing interest rate exposure. This shows a decrease in the amount of fixed-rate debt outstanding and a shift toward floating-rate instruments through swaps.",
      "llm_answer": "\nBetween 2022 and 2024 3M retired the short‑term fixed‑rate issues that were maturing in 2022 (the €500 million 0.45 % Eurobond and the $600 million 2.17 % medium‑term note) and, in 2023, fully repaid its first registered note – a $500 million, 1.86 % issue due 2023 – while in 2024 it extinguished the $300 million 3.30 % and $500 million 2.98 % medium‑term notes that had been scheduled to mature that year.  At the same time the company broadened its fixed‑rate registered‑note program, issuing longer‑dated notes with higher coupons (e.g., $750 million 2.12 % due 2025 and $500 million 2.67 % due 2025) and offsetting the interest‑rate risk of those positions by converting portions of its 2049‑2050 fixed‑rate debt into floating‑rate exposure via fixed‑to‑floating swaps that remain in effect through mid‑2028.  This mix of repayment, longer‑tenor issuance and swap‑based hedging reflects a strategic shift toward managing funding costs as market rates rose.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies in both quantitative and entity-specific details, failing to align with the ground truth. (1) Quantitative Accuracy: The dollar amounts, interest rates, and maturities cited are largely incorrect. For example, the LLM claims 3M repaid €500 million Eurobond (0.45%) and $600 million medium-term note (2.17%) in 2022—this is not supported by the original answer, which mentions $600 million 10-year notes due 2030 (3.05%) and $650 million 30-year notes due 2050 (3.70%). The LLM also incorrectly states that $300 million and $500 million medium-term notes were repaid in 2024, while the ground truth specifies $1.1 billion in medium-term notes repaid in 2024 (no breakdown provided), and $500 million in fixed-rate registered notes repaid in 2023. The LLM invents new issuances like $750 million 2.12% due 2025 and $500 million 2.67% due 2025, which are not mentioned in the original answer. (2) Completeness: While the question asks about issuance and management of fixed-rate registered notes between 2022–2024, the LLM focuses on medium-term notes and Eurobonds not emphasized in the ground truth, missing key registered note issuances from 2019 ($3.25 billion including $1B due 2029 and $1B due 2049). (3) Entity Accuracy: The LLM confuses medium-term notes with registered notes and introduces non-US currency (Eurobond) not referenced in the original. It misattributes repayment events to specific years and instruments incorrectly. (4) Reasoning: The LLM correctly identifies the use of interest rate swaps to convert fixed-rate debt to floating-rate through mid-2028 for notes due 2049–2050, which matches the original answer—this is the only accurate multi-hop element. However, the overall narrative of 'issuing longer-dated notes with higher coupons' contradicts the ground truth, which shows no new issuance between 2022–2024 and instead emphasizes repayment and debt reduction. (5) Semantic Equivalence: Despite using similar terminology (e.g., swaps, repayments), the factual core diverges significantly. The conclusion about 'strategic shift toward managing funding costs' is plausible but based on fabricated data. Overall, the answer fails on factual correctness, though it attempts relevant financial reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1467,
        "completion_tokens": 607,
        "total_tokens": 2074
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has the role of securities issuances in Schwab's capital structure evolved between 2023 and 2024, particularly in relation to its overall funding sources and capital management strategy?",
      "original_answer": "In 2023, securities issuances by CSC were identified as a primary source of capital, directly supporting the company's capital management strategy, which included balance sheet growth and financial support to subsidiaries. By 2024, while still listed as one of several funding sources, securities issuances were positioned among a broader set of liquidity tools, including FHLB borrowings, repurchase agreements, and CDs, indicating a more diversified funding approach. This shift suggests a strategic evolution where securities issuances remain important but are more integrated within a wider capital structure framework.",
      "llm_answer": "\nBetween 2023 and 2024 Schwab’s use of capital‑market debt changed markedly.  In 2023 the firm issued roughly $6 billion of senior unsecured notes (the May‑2023 series and earlier 2021‑2022 tranches) to fund broker‑dealer growth, support the IDA agreement and maintain liquidity, and it subsequently redeemed all of the floating‑rate senior notes on 18 Feb 2024.  By 2024 the company’s funding has shifted toward internal cash generation, client deposits and short‑term borrowing facilities, with new securities issuances essentially limited to the redemption of existing debt and the occasional use of an expiring revolving credit line; consequently, capital management now focuses on preserving strong regulatory capital ratios, managing interest‑rate exposure, and returning excess capital to shareholders rather than expanding the balance‑sheet through new debt.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains several specific details not present in the original ground truth, such as the $6 billion in senior unsecured notes, the May-2023 issuance, redemption on February 18, 2024, and references to IDA agreements and revolving credit lines. However, these quantitative details (dollar amounts, specific dates, tranches) are not supported by the original answer and cannot be verified as correct, leading to significant concerns about hallucination. The original answer does not provide any numerical data or specific redemption events, only a qualitative shift in the role of securities issuances. Therefore, the quantitative accuracy is low due to unverifiable specifics. Qualitatively, the LLM captures a plausible evolution—securities issuances becoming less central and capital management shifting toward liquidity management and capital returns—but this goes beyond the original answer’s scope, which only states that securities issuances became one of many tools in a more diversified funding approach. The reasoning is logically sound but not fully aligned with the ground truth’s more cautious, descriptive tone. The answer is contextually relevant and addresses the question about evolution in capital structure and funding strategy. However, the addition of unsupported specifics reduces factual correctness. While the overall direction of the narrative (shift from active issuance to more diversified/internal funding) aligns with the original, the lack of corroboration for key details prevents a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 420,
        "total_tokens": 1804
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How did Coca-Cola's contingent payment obligations related to fairlife evolve from 2022 to 2024, and what does this indicate about fairlife's performance against its financial targets?",
      "original_answer": "In 2022, Coca-Cola disclosed that it had a $270 million liability for contingent milestone payments related to its acquisition of fairlife, based on fairlife achieving certain financial targets through 2024. The company also noted that the first milestone payment of $100 million was made in 2021 after fairlife met its 2020 targets. By 2024, the remaining contingent payment was described as a milestone payment contingent on fairlife achieving certain financial targets through 2024 and was payable in 2025. This indicates that fairlife had met at least one set of financial targets (2020), triggering the initial $100 million payment, and that the company remained on track to potentially meet the remaining targets through 2024, as the obligation was still active and had not been rescinded or adjusted downward.",
      "llm_answer": "\nFrom 2022 through 2024 the contingent payment tied to the fairlife acquisition moved from the original $270 million accrual (recorded at acquisition) to a substantially smaller balance after the company earned and paid the $100 million milestone in 2021 and the $275 million milestone in 2023; the 2024 filing shows the remaining liability now reflects only the final, performance‑contingent payment due in 2025.  This reduction indicates that fairlife has met the financial targets that triggered the earlier milestones, but a portion of the contingent consideration remains outstanding until the last target is achieved.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual errors in numbers and dates. The ground truth states that Coca-Cola had a $270 million liability for contingent payments related to fairlife as of 2022, with a $100 million payment made in 2021 (for 2020 targets). However, the LLM incorrectly claims a $275 million milestone was paid in 2023, which is not supported by the original answer or known filings. This is a critical quantitative error. Additionally, the original answer does not mention any payment in 2023 or a total of $375 million paid, making the LLM's narrative of payments reducing the liability from $270M to a 'substantially smaller balance' factually wrong — the $270M was the contingent obligation *after* the $100M 2021 payment. (2) The timeline is also distorted: the LLM implies ongoing payments through 2023, but the ground truth only confirms the $100M payment in 2021 and a remaining obligation through 2024. The $275M figure appears fabricated. (3) While the LLM correctly identifies that the remaining contingent payment is performance-based and due in 2025, and infers that fairlife likely met early targets, the reasoning is based on incorrect premises. The multi-hop synthesis fails because it misrepresents the sequence and magnitude of payments. (4) Despite these issues, the answer is contextually relevant — it addresses the evolution of contingent payments and links performance to milestones — and captures the general structure of contingent consideration. However, the severe numerical inaccuracies and false claims about a $275M 2023 payment undermine factual reliability, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 451,
        "total_tokens": 1820
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has Oracle's strategic emphasis on Oracle Cloud Infrastructure (OCI) evolved between 2022 and 2024, particularly in terms of its global market positioning and integration with enterprise IT solutions?",
      "original_answer": "In 2022, Oracle's financial disclosures emphasized revenue contributions from cloud and license businesses, which generated $36.052 billion, representing 85% of total revenues, with no explicit strategic language about Oracle Cloud Infrastructure's positioning. By 2024, Oracle significantly elevated OCI's role, describing it as a core component of Oracle Cloud Services alongside SaaS, and emphasizing its ability to provide 'comprehensive and integrated applications and infrastructure services' that enable customers to choose deployment models best suited to their needs. This reflects a clear strategic shift toward positioning OCI as a central pillar in Oracle’s enterprise IT offerings, not just a contributor to cloud revenue.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2024 Oracle has shifted OCI from a peripheral cloud add‑on to a central growth pillar.  In 2022 the company highlighted “cloud and license” revenue growth and a strategic focus on selling cloud‑based infrastructure technologies while pulling back on certain hardware lines; by 2024 the narrative frames OCI as a standalone, globally‑scaled IaaS/PaaS platform that is tightly integrated with Oracle’s enterprise applications, databases and hardware, and is being promoted as the preferred infrastructure for migrating and modernizing mission‑critical workloads across a broad, international customer base.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) There are no numeric values in the LLM answer that contradict the original answer; while the $36.052 billion figure from 2022 is omitted, the LLM does not misstate any numbers, and no calculations were required. The absence of the specific revenue figure is a minor omission but does not detract from the overall correctness. (2) The LLM correctly identifies the evolution in Oracle's strategic emphasis: from a broader 'cloud and license' focus in 2022 to positioning OCI as a central, integrated platform by 2024. (3) The multi-hop reasoning is sound—synthesizing Oracle’s shifting narrative across years and linking OCI’s growing role in enterprise IT solutions and global deployment. The LLM accurately infers the strategic elevation of OCI even without repeating exact phrasing like 'comprehensive and integrated services.' (4) The answer captures the semantic meaning of the original, using equivalent terms such as 'central growth pillar' and 'tightly integrated with Oracle’s enterprise applications,' which match the ground truth’s emphasis on integration and strategic centrality. The only reason for not scoring a 10 is the omission of the specific revenue data point that anchors the 2022 context quantitatively, though the qualitative shift is clearly and correctly conveyed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 377,
        "total_tokens": 1735
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has the treatment and risk profile of PALs evolved between 2023 and 2024, particularly in terms of credit loss allowance and collateralization?",
      "original_answer": "In 2023, there was a slight decrease in PALs, and the allowance for credit losses was influenced by improved credit quality metrics and lower projected loss rates. By 2024, all PALs were fully collateralized by securities with fair values exceeding borrowings, and no allowance for credit losses for PALs was required as they were all subject to the collateral maintenance practical expedient under ASC 326. This indicates a strengthening in the risk profile and treatment of PALs over the period.",
      "llm_answer": "\nBetween 2023 and 2024 the credit‑loss allowance for Schwab’s Pledged‑Asset Lines stayed at $0 million (i.e., 0 % of the portfolio), reflecting an essentially risk‑free assessment.  In addition, the firm broadened the ASC 326 collateral‑maintenance practical expedient to “substantially all” PALs in 2024, requiring that each line be backed by securities whose fair value exceeds the outstanding balance; thus the collateralization remained fully intact and the risk profile stayed very low.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is mostly correct but contains a key discrepancy in completeness and precision compared to the ground truth. (1) Quantitatively, stating the allowance was $0 million in both 2023 and 2024 aligns with the 'no allowance required' in 2024, but the ground truth notes a 'slight decrease in PALs' and that the 2023 allowance was influenced by improved credit quality and lower projected loss rates — context the LLM omits. The LLM correctly identifies the $0 allowance and full collateralization. (2) The LLM claims the expedient was applied to 'substantially all' PALs in 2024, whereas the ground truth states 'all PALs were fully collateralized' and 'no allowance...was required' because they were all subject to the expedient. This is a meaningful difference: 'substantially all' falls short of 'all', and the LLM underreports the completeness of the change. (3) The reasoning is sound in linking collateral maintenance under ASC 326 to the lack of allowance, showing correct multi-hop understanding of accounting treatment and risk implications. However, it fails to reflect the evolution from 2023 (where allowance was still influenced by credit metrics) to 2024 (where it was eliminated due to full collateralization). (4) Contextual relevance is perfect — the answer directly addresses credit loss allowance and collateralization over the two years. The core facts are mostly accurate, but the omission of 2023's reasoning for allowance and the understatement of the 2024 collateral coverage reduce qualitative and quantitative accuracy. Hence, a score of 7 is warranted for overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1247,
        "completion_tokens": 439,
        "total_tokens": 1686
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has Nike's relationship with the Asia Pacific & Latin America (APLA) region evolved between fiscal years 2023 and 2024, particularly in terms of operational structure and strategic emphasis?",
      "original_answer": "In fiscal year 2023, Nike's relationship with APLA was characterized by direct operational involvement, with the region being one of the geographies where certain employees were represented by trade unions, indicating a more localized and embedded workforce structure. By fiscal year 2024, Nike transitioned parts of its APLA operations to third-party distributors, signaling a strategic shift away from direct control toward a more outsourced model. This evolution reflects a broader restructuring effort to optimize the business model and reduce operational complexity in certain international markets.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 the APLA region’s revenue rose modestly—from about **$6.43 bn to $6.73 bn**—indicating continued growth as a key market for Nike.  At the same time, the company disclosed that it is **transitioning certain NIKE Brand businesses in APLA to third‑party distributors** (Note 18), signalling a shift from a fully direct‑operated model toward a more partnership‑driven, asset‑light structure.  This evolution reflects Nike’s strategic emphasis on expanding its brand presence and supply‑chain flexibility in the region while re‑balancing its operational footprint.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "(1) The LLM answer correctly identifies the strategic shift in Nike's APLA operations from direct control to third-party distributors in fiscal 2024, aligning with the ground truth. However, the original answer does not mention revenue figures for APLA in fiscal 2023 or 2024, so the inclusion of $6.43B and $6.73B is unsupported by the provided ground truth. While this revenue growth may be factually accurate in external sources, it is not part of the knowledge graph ground truth used here, making the quantitative claims unverifiable and potentially misleading in this evaluation context. (2) The numbers $6.43B and $6.73B are presented confidently but are not present in the original answer, and no calculation or source reference (beyond 'Note 18') is sufficient to validate them within the scope of the given truth. This results in a moderate penalty for quantitative accuracy. (3) The reasoning about the strategic shift toward an asset-light, outsourced model via third-party distributors is sound and correctly synthesizes the operational evolution from 2023 to 2024. The mention of Note 18 suggests a document-based justification, but without confirmation from the ground truth, it doesn't compensate for the unsupported figures. (4) Despite the unsupported numbers, the core qualitative insight—Nike transitioning APLA operations to third parties, indicating a strategic restructuring—is correct and directly addresses the question's focus on operational structure and strategic emphasis. The answer is contextually relevant and well-articulated, but the addition of unverified financial data reduces overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 444,
        "total_tokens": 1754
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How did Abbott's positioning and strategic emphasis on Pedialyte evolve between 2022 and 2023, particularly in relation to its U.S. Pediatric Nutritional business and product portfolio expansion?",
      "original_answer": "In 2022, Pedialyte was highlighted as a key growth driver within Abbott's U.S. Pediatric Nutritional business, with sales increasing 10.3% for the year, alongside Similac and PediaSure. By 2023, Pedialyte was formally included in Abbott's product portfolio under the Nutritional Products segment, listed among major brands such as Ensure, Glucerna, and PediaSure, signaling a more structured integration into Abbott's broader nutritional offerings. This reflects a strategic evolution from being a contributor to growth in 2022 to being a formally recognized and embedded part of the company's core U.S. Pediatric Nutritional product lineup in 2023.",
      "llm_answer": "\nBetween 2022 and 2023 Abbott shifted Pedialyte from a growth‑supporting brand to a core strategic asset in its U.S. Pediatric Nutritionals business.  In 2022 the brand was highlighted as a key driver of the segment’s double‑digit sales increase, and in 2023 the company deepened its focus by expanding the Pedialyte line—adding new flavors, formats and packaging—and integrating it more tightly with its broader pediatric‑nutrition portfolio.  This evolution reflects a deliberate move to treat Pedialyte as an expandable, high‑potential product rather than merely a contributor to overall segment growth.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the strategic evolution of Pedialyte from a growth contributor in 2022 to a more central role in 2023, aligning with the ground truth's emphasis on increased strategic importance and integration. However, it introduces unverified details not present in the original answer—specifically, the claim that Abbott 'expanded the Pedialyte line—adding new flavors, formats and packaging' in 2023—which is not supported by the ground truth and lacks evidence from the knowledge graph. This affects factual accuracy. (2) Quantitatively, the LLM answer omits the specific 10.3% sales growth figure for Pedialyte in 2022 mentioned in the original answer, which is a key data point. It also inaccurately describes the 2022 growth as part of a 'double-digit sales increase' for the segment, while the ground truth only attributes 10.3% growth to Pedialyte specifically, not necessarily the entire segment. This mischaracterization reduces quantitative accuracy. (3) The multi-hop reasoning is generally sound: the model correctly infers a strategic shift from 2022 to 2023 based on changing language and positioning in disclosures. It correctly identifies Pedialyte’s integration into the broader nutritional portfolio as a signal of strategic elevation. However, it overreaches by implying product-line expansion without evidence, weakening the reasoning chain. (4) Despite missing the exact percentage and adding unsupported details, the core qualitative insight—that Abbott elevated Pedialyte from a growth contributor to a core brand—is consistent with the ground truth. The answer remains highly relevant to the question and synthesizes the correct entities (Abbott, Pedialyte, U.S. Pediatric Nutritional business) and time frame (2022–2023). Thus, correctness is reduced mainly due to missing quantitative precision and minor fabrication, but the central argument holds.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 517,
        "total_tokens": 1843
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How did RTX's financial position regarding its 7.100% notes due 2027 evolve from 2022 to 2023, and what does this indicate about its debt management strategy?",
      "original_answer": "In 2022, RTX disclosed an aggregate principal balance of $6 million for its 7.100% notes due 2027. By 2023, RTX had a stake in the same notes with an aggregate principal balance of $135 million. This indicates a significant increase in RTX's exposure to this particular debt instrument, suggesting a shift in its debt management strategy, possibly involving refinancing or restructuring.",
      "llm_answer": "\nFrom the 2022 10‑K (Note 10) the company reported $135 million of 7.100% notes due 2027 on its balance sheet—essentially the same amount that remained at the end of 2023.  The only reduction came in 2021, when RTX repaid $6 million of that series, leaving a modest $135 million outstanding in both 2022 and 2023.  This stability reflects a deliberate debt‑management strategy of retiring the higher‑coupon legacy notes and refinancing the remainder of its long‑term debt with newer, lower‑rate issuances (e.g., the 5.750%–6.400% notes issued in late 2023), thereby lowering overall interest expense and extending maturity.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core quantitative claims. According to the ground truth, RTX had a $6 million principal balance on its 7.100% notes due 2027 in 2022, which increased to $135 million in 2023. The LLM incorrectly states that the balance was $135 million in both 2022 and 2023, reversing the actual trend. It also falsely claims a $6 million repayment occurred in 2021, which is not supported by the ground truth. (2) The numbers are entirely inaccurate: the $135 million figure is attributed to 2022 when it should be 2023, and the $6 million is mischaracterized as a prior repayment rather than the starting balance. There are no correct calculations or accurate year-to-year comparisons. (3) The multi-hop reasoning is flawed—the LLM infers stability in the debt level and attributes it to a refinancing strategy involving new lower-rate notes, but this contradicts the ground truth, which shows a 22.5x increase in exposure, suggesting an expansion of liability, not a refinancing of existing debt. The synthesis across years is incorrect. (4) While the answer discusses debt management strategy (relevant context), the factual foundation is wrong, leading to an incorrect interpretation. The mention of new notes issued in 2023 is plausible but does not align with the actual evolution of the 7.100% notes. Thus, correctness and quantitative accuracy are very low; qualitative accuracy is minimal due to flawed logic; contextual relevance is moderate as it addresses debt strategy but based on false premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1255,
        "completion_tokens": 427,
        "total_tokens": 1683
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has Nike's relationship with Converse evolved in terms of revenue performance and strategic positioning between fiscal 2023 and fiscal 2024?",
      "original_answer": "In fiscal 2023, Converse revenues decreased by 15% on a currency-neutral basis, driven by declines in North America and Western Europe, with both wholesale and direct-to-consumer channels experiencing drops in unit sales and average selling price. By fiscal 2024, Converse was described as a wholly-owned subsidiary that operates on a stand-alone basis, indicating a strategic shift toward maintaining it as a distinct brand within Nike’s portfolio. This evolution reflects a move from a financially struggling entity in 2023 to a more strategically positioned brand in 2024, despite the earlier revenue contraction.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 Converse’s top‑line slipped 14 % (down 15 % on a constant‑currency basis), with earnings before interest and taxes falling 30 % to $474 million. The decline was driven by falling wholesale sales (‑16 % constant‑currency) and weaker direct‑to‑consumer revenue (‑14 % constant‑currency) in North America and Western Europe, while ASP fell 3 % as the brand leaned more on promotional pricing. Thus, Converse moved from a modest growth contributor in 2023 to a contracting, strategically secondary brand within Nike’s portfolio, as Nike’s overall footwear and total revenues continued to expand.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in financial figures not present in the ground truth. The claim that Converse's EBIT fell 30% to $474 million is unsupported by the original answer, which does not mention EBIT or any profitability metrics at all. The 14% overall revenue decline contradicts the ground truth's 15% constant-currency decline (though close, it's inconsistent). The breakdown of wholesale (-16%) and DTC (-14%) declines includes precise numbers absent from the original. (2) The original answer only states a 15% currency-neutral revenue decline with no mention of EBIT, profitability, or exact channel splits—these are hallucinated. The $474 million figure has no basis in the provided truth. (3) The reasoning mischaracterizes the strategic evolution: the LLM claims Converse went from a 'modest growth contributor' in 2023 to a 'strategically secondary brand,' while the ground truth describes a shift toward standalone strategic positioning in 2024, implying increased strategic importance, not reduced. This inverts the actual strategic narrative. (4) Despite these issues, the answer correctly identifies the revenue decline, geographic drivers (North America, Western Europe), channel trends (wholesale and DTC), and promotional pricing/ASP pressure. It also addresses both revenue performance and strategic positioning, maintaining contextual relevance. However, the quantitative inaccuracies and flawed strategic interpretation severely undermine correctness, warranting a low score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 428,
        "total_tokens": 1738
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has Coca-Cola's financial risk assessment regarding digital evolution changed from 2022 to 2024, particularly in terms of its impact on sales growth and margin improvement?",
      "original_answer": "In 2022, Coca-Cola viewed digital evolution as a risk factor that could negatively impact its business if it failed to implement digital transformation initiatives effectively, potentially leading to a loss in sales and brand relevance. By 2024, the company shifted its stance, identifying digital evolution as a strategic dependency, emphasizing that its future success would rely on expanding digital capabilities to increase sales and improve margins. The 2024 filing explicitly states that failure to digitalize operations could adversely impact financial performance, indicating a stronger financial linkage to digital initiatives than in 2022.",
      "llm_answer": "\nFrom 2022 to 2024 Coca‑Cola’s risk discussion moved from a generic warning that an unsuccessful digitization effort could “hurt our ability to increase sales and reduce costs” to an explicit statement that digital transformation is now a top priority and that failure would “negatively affect our ability to increase sales **and improve margins**.”  In other words, the company began to treat digital evolution not just as a cost‑saving initiative but as a core driver of both revenue growth and margin expansion, making the success of its digital agenda a central financial‑risk factor in its 2024 outlook.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in Coca-Cola's financial risk assessment regarding digital transformation from 2022 to 2024. It correctly identifies the shift from viewing digital evolution as a potential risk to performance (in 2022) to treating it as a strategic imperative tied directly to sales growth and margin improvement (in 2024). The use of quoted language such as 'hurt our ability to increase sales and reduce costs' (2022) and 'negatively affect our ability to increase sales and improve margins' (2024) aligns semantically with the ground truth, even if not verbatim, and correctly emphasizes the stronger financial linkage in 2024. There are no numerical figures in the question or answer, so quantitative accuracy is scored as 10 by default. The answer is contextually fully relevant, addressing both parts of the question: change over time and impact on sales and margins. The reasoning is sound and reflects proper multi-hop synthesis across years and risk framing. The only minor shortcoming is that it does not explicitly use the term 'strategic dependency' or 'brand relevance' from the 2022 context, slightly reducing qualitative completeness, but the core meaning is preserved. Hence, a 9 is justified for qualitative accuracy and overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 363,
        "total_tokens": 1685
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has Oracle's strategic emphasis on Oracle Cloud Services evolved from fiscal year 2022 to 2024, particularly in terms of research and development investment and the positioning of cloud offerings relative to on-premise solutions?",
      "original_answer": "In fiscal year 2022, Oracle invested $7.2 billion in research and development, highlighting its commitment to enhancing Oracle Cloud Services, including Oracle SaaS and OCI, as part of a broader strategy to offer flexible and interoperable deployment models. Oracle positioned cloud services as a key differentiator against competitors by emphasizing rapid deployment, security, and integration. By fiscal year 2024, Oracle continued to emphasize cloud services but restructured its messaging to position Oracle Cloud Software-as-a-Service and Oracle Cloud Infrastructure as central to enabling customers to 'choose the best option that meets their specific business needs.' While the 2024 report does not specify the R&D investment amount, the increased focus on cloud-first positioning and integration with customer-specific needs indicates a strategic deepening of Oracle's commitment to cloud services over on-premise offerings.",
      "llm_answer": "\nFrom fiscal 2022 through fiscal 2024 Oracle has steadily shifted resources toward cloud‑focused innovation.  In FY 2022 the company reported $7.2 billion of R&D spend and repeatedly emphasized that “the proportion of our cloud services and license‑support revenues … will continue to increase,” a trend that persisted through FY 2023 and FY 2024 (see the FY 2022 filing, pages 4‑8, and the FY 2024 forward‑looking discussion, pages 70‑74).  Consequently, Oracle has increased its R&D budget each year to accelerate cloud‑native database, AI/ML and infrastructure capabilities, while positioning SaaS and OCI as the preferred, lower‑cost alternative to traditional on‑premise licenses and encouraging customers to migrate workloads to the Oracle Cloud.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies Oracle's $7.2 billion R&D investment in fiscal year 2022, which matches the ground truth. However, it introduces a claim that Oracle 'increased its R&D budget each year' through FY2024, which is not supported by the original answer—specifically, the FY2024 R&D amount is not disclosed in the ground truth, so asserting a year-over-year increase is an unsupported inference. This affects quantitative and qualitative accuracy. (2) The numbers cited (only $7.2B in FY2022) are accurate and properly contextualized. No calculation errors, but the extrapolation to FY2023 and FY2024 R&D figures without data constitutes a factual overreach. (3) The multi-hop reasoning is partially sound: the LLM connects R&D spending to cloud strategy and correctly identifies the strategic emphasis on SaaS and OCI. However, it misrepresents the evolution of messaging—while the original answer highlights a shift toward positioning cloud services as enabling customer choice based on specific needs, the LLM frames the shift more narrowly as cost-driven and migration-focused, missing the nuanced 'best option for business needs' positioning emphasized in FY2024. (4) The answer is contextually relevant and addresses both R&D investment and cloud positioning. It captures the directional shift from on-premise to cloud but adds unsupported specifics about R&D increases and downplays the strategic refinement in customer-centric messaging. Thus, while core facts are correct, the lack of caution around unverified claims reduces correctness and qualitative accuracy slightly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1442,
        "completion_tokens": 439,
        "total_tokens": 1882
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has the status and availability of shares under the Norwest Corporation Directors' Formula Stock Award Plan evolved between 2023 and 2024?",
      "original_answer": "In 2023, the Norwest Corporation Directors' Formula Stock Award Plan was described as a plan under which shares of common stock were awarded to non-employee directors, with the ability to defer receipt of awards until a future year. However, it was noted that no future stock awards or deferrals could be made under this plan. In 2024, the 10-K filing further clarified that no future awards or deferrals would be made under the plan and that column (a) of the equity compensation table reflected all shares issuable under the plan upon distribution of outstanding awards or deferred compensation benefits. This indicates that by 2024, the plan was fully closed to any new activity and only existing obligations remained. The number of shares issuable in 2024 related to this plan was minimal (only 391 shares), showing that the plan had effectively concluded its active phase.",
      "llm_answer": "\nBetween 2023 and 2024 the number of shares reserved for future issuance under the Norwest Corporation Directors’ Formula Stock Award Plan fell sharply—from **509 shares** available in 2023 to **391 shares** available in 2024. This decline reflects that the plan’s remaining shares have been used (or will be used) for existing deferred awards, and the plan is now closed to any new grants or deferrals. Consequently, no additional shares will be issued under this plan going forward.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a critical factual error in the quantitative data—claiming 509 shares were available in 2023 and 391 in 2024. However, the original answer (ground truth) does not mention any specific number of shares available in 2023, only that no future awards or deferrals were allowed. The only numeric value provided in the ground truth is 391 shares in 2024. Thus, the 509 figure is fabricated or misattributed, making the quantitative claim incorrect. (2) The calculation of a 'decline from 509 to 391' is therefore invalid, as the 509 number has no basis in the source. This undermines the core of the LLM's argument about a 'sharp fall.' (3) Qualitatively, the reasoning is partially sound: the LLM correctly infers that the plan is closed to new grants and deferrals and that only existing obligations remain. It also correctly interprets the 391 shares as relating to final distributions. This shows accurate synthesis of the plan’s status evolution, albeit based on incorrect numerical premises. (4) Contextually, the answer is highly relevant, addressing the plan's availability and status change over time. However, the introduction of an unsupported number severely compromises factual correctness. While the direction of change (winding down) is accurate, the specific numeric trajectory is not. Hence, correctness is scored at 5—partially correct but with significant factual deficiency.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 395,
        "total_tokens": 1734
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has McDonald's disclosure around food safety concerns evolved between 2022 and 2023, particularly in relation to supply chain risks and cost volatility?",
      "original_answer": "In 2022, McDonald's characterized food safety concerns primarily as reputational risks that could impact brand perception and financial results due to incidents like food-borne illness or contamination. The focus was on the potential damage to consumer trust and the company's image. By 2023, the framing had evolved to emphasize food safety concerns as contributors to supply chain volatility, specifically in relation to commodity cost fluctuations. The 2023 filing noted that food safety issues, along with other macroeconomic and regulatory factors, could exacerbate volatility in the prices of key ingredients like beef, chicken, and pork, thereby affecting profitability. This indicates a shift in emphasis from reputational impact to financial exposure through supply chain disruption and cost pressures.",
      "llm_answer": "\nBetween 2022 and 2023 McDonald’s moved from a general warning that “food‑safety concerns may have an adverse effect on our business” to a more detailed articulation that ties food‑safety risk directly to supply‑chain disruptions and rising input costs.  The 2023 filing explicitly notes that supply‑chain interruptions and commodity‑price volatility can jeopardize the safety and quality of ingredients—and that third‑party delivery and technology investments may amplify those risks—whereas the 2022 filing treated supply‑chain cost pressures and safety issues as separate, less‑integrated concerns.  Consequently, the 2023 disclosure deepens the linkage between food‑safety, supply‑chain volatility and cost inflation.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution in McDonald's disclosures between 2022 and 2023: from a general reputational risk framing in 2022 to a more integrated view linking food safety with supply chain disruptions and cost volatility in 2023. While the LLM does not explicitly use the term 'reputational risk,' it captures the essence by contrasting the 2022 'adverse effect on our business' language with the more detailed 2023 linkage to supply-chain and cost issues. (2) There are no numeric values, dates, or financial figures in the question or ground truth beyond the years 2022 and 2023, which are correctly used. (3) The multi-hop reasoning is sound—correctly synthesizing changes in risk disclosure across two years and connecting food safety to supply chain and cost pressures. The LLM adds a detail about third-party delivery and technology investments amplifying risks, which is consistent with the direction of increased integration in risk framing, even if not in the original answer; this is a reasonable inference and does not contradict the ground truth. (4) The answer is contextually relevant, directly addressing the evolution in disclosure, supply chain risks, and cost volatility. The only minor shortcoming is the absence of specific mention of key commodities (beef, chicken, pork) from the 2023 filing, which slightly reduces completeness. Otherwise, the semantic meaning and factual content are substantially equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 421,
        "total_tokens": 1807
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has the carrying value and interest rate of TMO's 1.750% 7-Year Senior Notes evolved between 2023 and 2024?",
      "original_answer": "In 2023, TMO's 1.750% 7-Year Senior Notes, due on October 15, 2028, had a carrying value of $700 million and an effective interest rate of 1.89%. In 2024, both the carrying value and effective interest rate remained unchanged at $700 million and 1.89% respectively. This indicates that there was no change in the financial structure or valuation of this particular debt instrument over the period.",
      "llm_answer": "\nThe 1.750 % 7‑Year Senior Notes carried a book value of roughly **$662 million at the end of 2023**, which increased to **about $700 million at the end of 2024**.  At the same time, the notes’ effective interest rate slipped slightly from **1.97 % (2023)** to **1.89 % (2024)**.  Thus, the debt grew modestly while its financing cost was trimmed by a few basis points.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, the carrying value of TMO's 1.750% 7-Year Senior Notes was $700 million in both 2023 and 2024, but the LLM claims it was $662 million in 2023 and increased to $700 million in 2024. This is incorrect. Additionally, the effective interest rate is reported as 1.89% in both years in the ground truth, but the LLM states it decreased from 1.97% in 2023 to 1.89% in 2024, which is also wrong. (2) The numbers are not accurate: the carrying value and interest rate did not change between the years, so the reported increase in value and decrease in rate are false. Even allowing for rounding or formatting differences, the discrepancies are too large to be attributed to such variations. (3) The multi-hop reasoning is flawed—the model fails to correctly synthesize the data across the two years, incorrectly inferring changes where none occurred. It introduces a narrative of change (growing debt, reduced financing cost) that contradicts the stable values in the ground truth. (4) The contextual relevance is high because the answer addresses the right instrument, company, and time frame, and discusses the correct metrics (carrying value and effective interest rate). However, due to major quantitative and qualitative errors, the correctness and accuracy scores are very low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1182,
        "completion_tokens": 383,
        "total_tokens": 1566
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How did RTX's exposure to its 7.000% notes due 2038 change between 2022 and 2023, and what does this suggest about its approach to managing long-term debt maturities?",
      "original_answer": "In 2022, RTX disclosed an aggregate principal balance of $11 million for its 7.000% notes due 2038. By 2023, this amount had increased significantly to $148 million. This suggests that RTX either issued additional tranches of this note or restructured its debt to extend maturities, indicating a strategic shift toward increasing exposure to this particular long-term debt instrument.",
      "llm_answer": "\nRTX’s 7.000 % notes due 2038 remained at roughly $148 million at the end of 2022 and again at the end of 2023 – essentially no net change in exposure during that period.  The modest, steady balance (after a $11 million repayment in 2021) indicates that RTX is not aggressively retiring this specific tranche; instead it is managing its long‑term debt maturities by refinancing higher‑coupon obligations with newer, longer‑dated issuances and term‑loan facilities, preserving liquidity while gradually reshaping the overall debt profile.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core quantitative claim. According to the ground truth, RTX's exposure to the 7.000% notes due 2038 increased from $11 million in 2022 to $148 million in 2023. The LLM incorrectly states that the balance was $148 million at the end of both 2022 and 2023, which misrepresents the change and direction of exposure. This error fundamentally undermines the answer's correctness. (2) The numbers are inaccurate: the 2022 figure is off by over 1300% ($11M vs $148M claimed), and the LLM falsely implies stability when there was a significant increase. The mention of an $11 million repayment in 2021 is not supported by the provided ground truth and introduces unverified information. (3) The multi-hop reasoning is flawed because the model fails to detect the actual increase in debt exposure, leading to an incorrect interpretation of RTX’s debt strategy. While the general idea of refinancing and managing maturities is plausible, it is not supported by the specific data in this case—the increase suggests new issuance or restructuring, not a steady hold. (4) The contextual relevance is moderate because the answer addresses debt management strategy and long-term maturities as asked, but the incorrect data leads to a misleading conclusion. The qualitative reasoning would score higher if based on accurate inputs, but as is, it reflects a failure in synthesis. Quantitative accuracy is very low due to the magnitude of the numerical error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1235,
        "completion_tokens": 413,
        "total_tokens": 1649
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How did McDonald's financial relationship with its franchisees evolve between 2022 and 2023, particularly regarding the collection of rent and royalties?",
      "original_answer": "In 2022, McDonald's disclosed that it had deferred approximately $1 billion in rent and royalties from franchisees, primarily during the first half of 2020, due to the impact of government restrictions related to COVID-19. By the end of 2021, the company had collected substantially all of these deferred amounts. In contrast, the 2023 filing reflects a return to standard operations, with no mention of ongoing deferrals or pandemic-related financial accommodations. Instead, the 2023 report outlines the normalization of franchise operations, including a detailed breakdown of restaurant ownership types, which indicates that franchisees were operating under regular financial obligations without pandemic-era relief measures.",
      "llm_answer": "\nBetween 2022 and 2023 McDonald’s moved from the pandemic‑era payment relief to a full‑scale resumption of rent and royalty collections from its franchisees.  After deferring roughly $1 billion of rent and royalties in 2020, the company collected virtually all of those amounts by the end of 2021, and in the 2022‑2023 periods it again billed and received the contractual percentages of sales as rent and royalties—no material deferrals are noted in the 2022‑2023 disclosures.  The “Future gross minimum rent payments” schedule shows expected cash inflows of about $3.06 billion in 2022 and $2.95 billion in 2023, confirming that rent collections remained robust (with only a modest decline from expirations), while royalty income continued to be recognized on a normal basis.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly captures the overall evolution of McDonald's financial relationship with franchisees—transitioning from pandemic-related deferrals to normalized collections by 2022–2023. It accurately notes that approximately $1 billion was deferred in 2020 and that substantially all of it was collected by the end of 2021, which aligns with the original answer. However, there are key quantitative inaccuracies: the LLM introduces specific future rent figures of $3.06 billion for 2022 and $2.95 billion for 2023, which are not present in the original answer and cannot be verified from the provided ground truth. These numbers may be factually correct in external filings, but since they are absent from the original answer (ground truth), their inclusion introduces unverified data, reducing quantitative accuracy. Additionally, the original answer emphasizes that the 2023 filing shows no mention of ongoing deferrals or pandemic accommodations, which the LLM correctly reflects by stating no material deferrals were noted. The reasoning is sound—correctly synthesizing the timeline and operational normalization—and the entities (McDonald’s, franchisees, rent, royalties, years) are accurate. The answer is highly contextually relevant and semantically aligned in intent, though the addition of unsupported numerical projections prevents a higher score. The core facts are correct, but the inclusion of unverified figures affects precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 400,
        "total_tokens": 1777
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How has The Coca-Cola Company's financial stake in Embotelladora Andina S.A. evolved from 2022 to 2024, and what does this indicate about the company's strategic positioning with respect to this equity investment?",
      "original_answer": "In 2022, Coca-Cola recognized a gain of $39 million from the partial sale of its ownership interest in Embotelladora Andina S.A., indicating a strategic refranchising or divestiture move while retaining an equity stake. By 2024, Coca-Cola still held a financial stake in Andina, with a carrying value of $90 million and a fair value of $168 million, showing that the company maintained its involvement but with a relatively modest valuation compared to other equity investments. This indicates a partial exit strategy rather than a complete divestiture, with ongoing but reduced exposure.",
      "llm_answer": "\nBetween 2022 and 2024 Coca‑Cola’s equity‑method stake in Embotelladora Andina S.A. slipped from roughly $115 million in carrying value to about $90 million, while the fair‑value‑adjusted share remained a small minority holding (≈19 %). This reduction shows the company is pulling back from a direct ownership role in Andina and is now treating the investment as a passive governance position rather than a core growth platform.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies a reduction in Coca-Cola's carrying value from approximately $115 million to $90 million and notes ongoing ownership through 2024, which aligns with the ground truth that Coca-Cola retained a stake with a $90 million carrying value. However, the original answer does not mention a $115 million carrying value in 2022—instead, it highlights a $39 million gain from a partial sale in 2022, which the LLM omits entirely. This is a significant factual omission affecting quantitative accuracy. The ≈19% minority stake mentioned in the LLM answer is not present in the ground truth and cannot be verified, introducing an unsupported claim. (2) While the $90 million carrying value in 2024 is accurate, the $115 million figure for 2022 is inferred and not stated in the original; the fair value of $168 million in 2024 is also missing from the LLM response, weakening completeness and numerical precision. The absence of the $39 million gain—a key financial event—impacts the correctness of the quantitative narrative. (3) The reasoning about strategic pullback and reduced direct ownership is logically sound and consistent with the partial exit strategy described in the ground truth. The characterization of the investment as non-core and passive aligns semantically with 'ongoing but reduced exposure.' However, the lack of reference to the 2022 gain weakens the multi-hop synthesis across time and financial events. (4) Scores reflect mostly correct qualitative interpretation and contextual relevance, but quantitative accuracy is reduced due to missing and unverified numbers, despite some correct directional insights.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1270,
        "completion_tokens": 456,
        "total_tokens": 1727
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How has Oracle's strategic investment in cloud infrastructure evolved from 2022 to 2024, particularly regarding internal development efforts and the positioning of Oracle Cloud Infrastructure in its product portfolio?",
      "original_answer": "In 2022, Oracle emphasized internal development as a core strategy, dedicating significant resources to research and development to maintain and improve its existing product suite, including cloud technologies. The company highlighted its global R&D workforce and the importance of innovation in response to evolving market demands. By 2024, this focus had evolved into a more product-specific strategy with the explicit introduction of Oracle Cloud Infrastructure (OCI) as a central offering within Oracle Cloud Services. OCI was positioned as a comprehensive and integrated infrastructure solution, indicating a shift from general cloud development to a structured, customer-facing product portfolio. This evolution demonstrates a strategic deepening of Oracle's cloud infrastructure commitment, aligning internal R&D with the delivery of a defined, market-ready suite of cloud services.",
      "llm_answer": "\nFrom the 2022 10‑K (pp. 14‑18) Oracle was already “investing in the expansion of the Oracle Cloud” by adding data‑center capacity and new geographic regions, laying the groundwork for a global OCI platform.  The 2024 10‑K (pp. 70‑74) shows that this effort has matured into a fully‑scaled, enterprise‑grade cloud infrastructure that Oracle now positions as the core foundation for its Cloud Services, engineered‑system hardware support, and cross‑portfolio SaaS and PaaS offerings, with continued internal R&D focused on automation, security and rapid delivery of new cloud capabilities.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns well with the ground truth. It correctly identifies Oracle's cloud infrastructure evolution from 2022 to 2024 based on 10-K filings. In 2022, Oracle was investing in expanding cloud capacity and geographic reach, consistent with internal development efforts (as noted in pp. 14–18 of the 2022 10-K). By 2024, the company positioned Oracle Cloud Infrastructure (OCI) as the core foundation for its cloud services, hardware, and SaaS/PaaS offerings (per pp. 70–74 of the 2024 10-K), reflecting a strategic shift toward a more integrated and central role for OCI in its product portfolio. The answer captures the key evolution: from foundational expansion to a mature, enterprise-grade platform. All entities (Oracle, OCI, R&D focus areas like automation and security) are correct, and the years (2022, 2024) match the question. There are no numerical inaccuracies—no specific figures (e.g., dollar amounts) are cited in either answer, so quantitative accuracy is not compromised. The reasoning is sound and reflects multi-hop synthesis across two years of filings. The only minor shortcoming is that the LLM does not explicitly mention the 'global R&D workforce' or 'innovation in response to market demands' from 2022, nor does it directly contrast 'general cloud development' vs. 'structured, customer-facing product suite' as in the original answer. However, the core meaning—that internal R&D evolved into a more product-specific, strategically positioned OCI—is clearly conveyed. Thus, the answer is semantically equivalent with high completeness and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 442,
        "total_tokens": 1829
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How did TMO's involvement with The Binding Site Group evolve between 2023 and 2024, and what does this indicate about the company's integration and strategic focus post-acquisition?",
      "original_answer": "In 2023, TMO acquired The Binding Site Group for $2.70 billion as part of its Specialty Diagnostics segment, expanding its portfolio in diagnostics for blood cancers and immune disorders. By 2024, the company had integrated the acquisition into its asset base, with The Binding Site Group contributing to the 19-year weighted-average amortization period for customer relationships among definite-lived intangible assets. This evolution indicates a strategic focus on long-term value creation through integration of acquired innovation into its core diagnostics offerings.",
      "llm_answer": "\nBetween 2023 and 2024 TMO moved from simply acquiring The Binding Site Group—purchased in January 2023 to bolster the Specialty Diagnostics portfolio for blood‑cancer assays—to actively integrating it into the company’s ongoing growth engine.  The 2024 filing shows the group’s assets and goodwill still reflected in segment‑income tables, and TMO leveraged the acquisition (along with a follow‑on purchase of Olink in July 2024) to deepen its proteomics/diagnostic capabilities, underscoring a strategic focus on expanding high‑margin, high‑growth life‑sciences and diagnostics offerings through continued post‑acquisition integration.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies. First, it claims TMO acquired The Binding Site Group in January 2023, but the ground truth does not specify the exact month—only the year 2023—so this added precision is unsupported. More critically, the LLM introduces a 'follow-on purchase of Olink in July 2024,' which is not mentioned in the original answer or implied by the ground truth; this is a significant factual error introducing a non-validated acquisition. (2) Quantitative accuracy is compromised: while the $2.70 billion acquisition amount is omitted (a missing key figure), the LLM fabricates a specific event (Olink acquisition) with a precise date and context not present in the ground truth. The 19-year weighted-average amortization period for customer relationships—a key integration metric in the original—is entirely missing. (3) The reasoning partially captures the strategic focus on diagnostics and integration, correctly identifying the Specialty Diagnostics segment and the intent to expand capabilities. However, the multi-hop synthesis is flawed because it invents a connection to Olink, undermining the validity of the strategic narrative. The answer correctly infers ongoing integration but bases part of its conclusion on false premises. (4) Despite these issues, the answer is contextually relevant, addressing both the evolution and strategic implications. It captures the general direction of integration and strategic focus on high-growth diagnostics, earning points for qualitative reasoning and relevance. However, the fabrication of a major acquisition event and omission of key financial and accounting details (amortization period, exact purchase price) reduce correctness and quantitative accuracy significantly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 480,
        "total_tokens": 1791
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How has the disclosure and accessibility of the Directors' Code of Conduct evolved between 2022 and 2024, particularly in terms of website links and scope of application?",
      "original_answer": "In 2022, the Directors' Code of Conduct was posted on BNY Mellon's website at a specific URL: https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-of-conduct.pdf, and it applied to all directors. By 2024, while the scope of application remained the same—applying to all directors—the URL for the Directors' Code of Conduct had changed to https://www.bny.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-ofconduct.pdf. This indicates a change in the website structure or domain branding, likely reflecting a broader rebranding from 'BNY Mellon' to 'BNY', while maintaining the same governance policy content and disclosure intent.",
      "llm_answer": "\nBetween 2022 and 2024 the company moved the Directors’ Code of Conduct from a longer “/content/dam/bnymellon/documents/pdf/in relations/directors‑code‑of‑conduct.pdf” link to a shorter “/investor‑relations/directors‑code‑ofconduct.pdf” URL, and it added explicit language stating that any future amendments or waivers of the code (both the employee Code of Conduct and the Directors’ Code) will be posted on its website.  The scope was also clarified: the 2022 filing said the Directors’ Code applies to “all directors of BNY Mellon,” while the 2024 filing expands the employee Code of Conduct to cover “all employees of BNY or any entity that is more than 50 % owned by us,” and reiterates that the Directors’ Code applies to “all directors of BNY.”  Thus, the evolution is a streamlined web link and a broader, more transparent description of who the codes govern and how changes will be disclosed.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies regarding the URL changes and introduces incorrect information about added disclosure practices. According to the ground truth, the 2022 URL was https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-of-conduct.pdf and in 2024 it changed to https://www.bny.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-ofconduct.pdf — the primary change being the domain from 'bnymellon.com' to 'bny.com', reflecting a rebranding. The LLM incorrectly claims the path was shortened or simplified (e.g., to just '/investor-relations/...'), but in reality, the full '/content/dam/bnymellon/documents/pdf/investor-relations/...' path remained, only the domain changed. (2) The LLM falsely states that in 2024, the company added language about posting future amendments or waivers on the website. This is not supported by the ground truth, which makes no mention of such a policy change. This is a major factual addition not present in the original data. (3) Regarding scope, the ground truth confirms the Directors' Code continued to apply to 'all directors' in both years, with no expansion or clarification beyond the rebranding of 'BNY Mellon' to 'BNY'. The LLM incorrectly claims the employee Code of Conduct was expanded and conflates it with the Directors' Code — a critical error, as the question specifically asks about the Directors' Code, not the employee code. (4) While the LLM correctly identifies that the scope for directors remained consistent and that a domain/URL change occurred, it misrepresents the nature of the change and adds unsupported details about transparency practices and scope expansion. The reasoning is partially sound in identifying evolution in disclosure, but the multi-hop synthesis is flawed due to incorrect entity and document attribution. The contextual relevance is high as it addresses website links and scope, but factual correctness is compromised by key inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1405,
        "completion_tokens": 547,
        "total_tokens": 1953
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How has McDonald's relationship with franchisees evolved in terms of financial reporting and strategic emphasis between 2022 and 2023?",
      "original_answer": "In 2022, McDonald's noted that the results of operations from restaurant businesses purchased and sold in transactions with franchisees were not material to the consolidated financial statements, indicating a limited financial impact from such transactions. By 2023, the company explicitly included franchisees and licensees as key stakeholders in its business model, emphasizing their role alongside company-operated restaurants in a detailed breakdown of restaurant ownership types. This shift reflects a more strategic and transparent focus on franchisees as integral to McDonald's global business structure.",
      "llm_answer": "\nBetween 2022 and 2023 McDonald’s tightened the way it reports franchisee‑related income – it now records initial franchise fees and variable rent at the point of sale rather than spreading them over the lease term, and it presents the fees it receives for technology platforms and brand licensing on a gross (rather than net) basis.  At the same time, the company’s strategic focus shifted toward higher‑margin, digital‑driven revenues (e.g., Dynamic Yield and other tech‑service fees) and away from reliance on traditional rent and royalty streams, a change that is reflected in the expanded segment‑disclosure requirements introduced in the 2023 filing.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and introduces information not present in the ground truth. (1) It claims specific accounting changes in 2023—such as recognizing franchise fees at point of sale, changing from net to gross reporting for tech/platform fees, and shifting to higher-margin digital revenues—which are not mentioned or supported in the original answer. These details appear fabricated or hallucinated. (2) There are no numeric values (e.g., dollar amounts, percentages, dates beyond years) in either the question or ground truth, so the quantitative accuracy is low because the model invents financial reporting changes without factual basis. (3) The multi-hop reasoning is flawed: the original answer focuses on a shift in strategic emphasis and transparency—franchisees being explicitly named as key stakeholders in 2023 versus a comment on immateriality of transactions in 2022. The LLM instead invents a narrative around revenue recognition and segment disclosures not present in the source. (4) While the answer is contextually relevant—discussing franchisee financial reporting and strategic emphasis—it diverges significantly in content and factuality. The core evolution described in the ground truth (from immaterial transaction reporting to strategic stakeholder inclusion) is missed entirely. Thus, despite addressing the general topic, the answer fails on correctness and factual synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 390,
        "total_tokens": 1704
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How did the accounting treatment or status of the contingent consideration liabilities related to the Clif Bar acquisition evolve between 2023 and 2024, particularly in terms of fair value measurement and purchase price allocation adjustments?",
      "original_answer": "In 2023, the contingent consideration liabilities related to the Clif Bar acquisition were actively measured at fair value using a Monte Carlo simulation, with $548 million classified as long-term liabilities at December 31, 2023. These liabilities were tied to performance targets in 2025 and 2026 and were subject to fair value adjustments recorded in selling, general, and administrative expenses. By 2024, there is no direct mention of the contingent consideration liabilities; instead, the 2024 filing references purchase price allocation adjustments for Clif Bar during 2023. This indicates that the contingent consideration may have been finalized or reclassified as part of the purchase price allocation process, though the 2024 disclosure does not provide updated figures or valuation methods for these liabilities.",
      "llm_answer": "\nBetween 2023 and 2024 the contingent‑consideration liability tied to the Clif Bar acquisition rose from $452 million (a Level‑3 fair‑value amount) to $548 million, and the overall liability grew from $642 million to $680 million.  The increase reflects a $128 million fair‑value remeasurement (recorded in SG&A) and $90 million of earn‑out payments; the Clif Bar portion expanded because the estimated revenue‑, profit‑ and EBITDA‑based payouts were re‑estimated higher, while the “other” component fell from $190 million to $132 million after settlements.  Purchase‑price allocation adjustments are incorporated directly into these fair‑value changes rather than being posted as a separate line item.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and misrepresents the evolution of the contingent consideration liabilities for the Clif Bar acquisition between 2023 and 2024. (1) Quantitatively, the LLM claims the Clif Bar contingent consideration increased from $452 million to $548 million between 2023 and 2024. However, the ground truth only reports $548 million as the liability at December 31, 2023, with no mention of a prior $452 million figure or any 2024 update. There is no support for a year-over-year comparison or numerical change in the Clif Bar liability. The LLM also introduces an 'overall liability' rising from $642M to $680M and claims $90M in earn-out payments and a $128M remeasurement—none of which appear in the original answer or are supported by the knowledge graph. These numbers are entirely fabricated or misattributed. (2) The original answer states that the 2024 filing does not mention contingent consideration liabilities at all, instead referencing only purchase price allocation adjustments from 2023. The LLM incorrectly implies that updated 2024 figures exist and that fair value remeasurements continued into 2024. This contradicts the ground truth. (3) Qualitatively, the reasoning is flawed: the LLM asserts that purchase price allocation adjustments are 'incorporated directly into these fair-value changes,' but the original answer suggests that the lack of 2024 disclosures may indicate finalization or reclassification, not ongoing remeasurement. The model fails to recognize the absence of 2024 data as a key signal. (4) Contextually, the answer addresses the right topic—contingent consideration and fair value measurement—and mentions correct concepts like Monte Carlo simulation (implied in ground truth via fair value measurement) and SG&A expense recognition. However, the detailed numerical narrative is unsupported. The synthesis across years is incorrect, and the model invents a multi-hop trend (2023 to 2024 change) that the evidence does not support. Minor credit is given for contextual relevance and use of appropriate financial terminology.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1405,
        "completion_tokens": 563,
        "total_tokens": 1969
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How has AMD's strategic emphasis on Vulkan API support evolved between 2022 and 2024, and what does this reveal about its approach to maintaining competitiveness in the discrete GPU market?",
      "original_answer": "In 2022, AMD highlighted its support for Vulkan as part of its Radeon™ series discrete GPUs, which were built on the RDNA 2 architecture and aimed at delivering high-performance gaming and creation workloads. By 2024, AMD continued to support Vulkan but shifted its focus toward the newer RDNA 3 architecture, which underpins the Radeon RX 7000 Series GPUs. This evolution suggests AMD is maintaining its commitment to Vulkan while advancing its GPU capabilities to meet the growing demands of immersive gaming and AI/ML computing. This strategic continuity in API support combined with architectural innovation indicates AMD’s effort to stay competitive by offering both backward compatibility and cutting-edge performance enhancements.",
      "llm_answer": "\nAMD’s Vulkan strategy shifted from a baseline “support‑only” stance in the 2022 RX 6000 launch—where Vulkan was highlighted alongside DirectX 12 Ultimate as a key API for the new RDNA 2 architecture (AMD_10k_2022.pdf, p. 9)—to a proactive, ecosystem‑centric emphasis in 2024, with the RDNA 3‑based RX 7000 series and AMD Software Adrenalin repeatedly touting Vulkan as the preferred open‑standard path for both gaming and compute workloads, and pairing it with tools such as FidelityFX Super Resolution and ROCm integration (AMD_10k_2024.pdf, p. 7).  \n\nThis evolution shows that AMD is using Vulkan not just to match competitors but to differentiate its discrete GPUs by championing an open, cross‑platform API that reduces reliance on proprietary stacks, broadens addressable markets (gaming, AI/ML, cloud), and reinforces a developer‑friendly narrative that helps sustain its competitive position against Nvidia and Intel.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: AMD supported Vulkan in 2022 with RDNA 2-based RX 6000 series and continued in 2024 with RDNA 3-based RX 7000 series. The mention of AMD Software Adrenalin, FidelityFX Super Resolution, and ROCm integration in 2024 is consistent with AMD's broader ecosystem strategy. (2) There are no numeric values requiring verification (e.g., financials, percentages), so quantitative accuracy is not compromised—dates (2022, 2024) and product names (RX 6000, RX 7000) are correct. (3) The multi-hop reasoning is sound: the answer synthesizes information across years and product lines to infer a strategic shift from basic support to proactive promotion of Vulkan as a differentiator. It correctly identifies the competitive context (vs. Nvidia and Intel) and expands on the implications for gaming, AI/ML, and cloud markets, which is logically consistent with the ground truth’s mention of AI/ML and immersive gaming. (4) Semantic equivalence is strong: while the LLM adds more detail (e.g., specific tools like FSR, ROCm, Adrenalin), it does not contradict the original answer and enhances it with plausible, contextually appropriate elaboration. The only minor gap is that the ground truth emphasizes 'backward compatibility' as part of AMD’s strategy, which the LLM omits, slightly reducing completeness. However, this does not undermine the core correctness. Overall, the answer demonstrates excellent understanding, synthesis, and contextualization.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1426,
        "completion_tokens": 425,
        "total_tokens": 1851
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How did RTX's integration-related charges impact its operating profit trends between 2022 and 2023, particularly with the introduction of the Powder Metal Matter charge in 2023?",
      "original_answer": "In 2022, RTX reported a decrease in Acquisition Accounting Adjustments, which contributed positively to its operating profit. However, in 2023, there was a significant $2.9 billion charge associated with the Powder Metal Matter, which became a major driver of the $1.9 billion decrease in Operating Profit compared to 2022. This reflects a notable shift from a declining trend in integration-related charges in 2022 to a significant new expense in 2023 that directly impacted profitability.",
      "llm_answer": "\nThe 2023 operating‑profit decline of roughly **$1.9 billion** versus 2022 was driven almost entirely by the **$2.9 billion charge RTX recorded for the Powder‑Metal‑Matter integration cost** (and the related dip in the FAS/CAS adjustment), which more than offset the modest profit gains seen at Collins and Raytheon; as a result, operating profit fell from **$5.5 billion in 2022 to $3.6 billion in 2023**.  This integration‑related charge was the dominant factor behind the downward trend in operating profit between the two years.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all key numbers are correct: the $1.9 billion decrease in operating profit, the $2.9 billion Powder Metal Matter charge, and the operating profit figures of $5.5 billion in 2022 and $3.6 billion in 2023 are consistent with the known data. The calculation of the $1.9 billion decline (5.5 - 3.6 = 1.9) is accurate. (2) The answer correctly identifies the Powder Metal Matter charge as a new 2023 integration-related expense and positions it as the primary driver of the operating profit decline, which matches the original answer’s claim. (3) The reasoning is sound: it correctly synthesizes the impact of the charge across years, acknowledges offsetting gains at business units, and highlights the reversal of the prior trend (implied shift from declining integration costs in 2022 to a major new charge in 2023). (4) The only minor shortcoming is that the LLM does not explicitly mention the 2022 decline in Acquisition Accounting Adjustments (a positive factor for 2022 profitability), which is part of the multi-hop context in the original answer. While the LLM implies a contrast between years, it omits this specific 2022 detail, slightly weakening the completeness of the trend analysis. However, the core of the question—how integration charges impacted operating profit trends, especially with the 2023 Powder Metal Matter charge—is thoroughly and correctly addressed. Wording differences are acceptable and do not affect semantic equivalence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 422,
        "total_tokens": 1685
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has MDLZ's relationship with Clif Bar evolved between 2023 and 2024, particularly in terms of acquisition-related financial activities?",
      "original_answer": "In 2023, MDLZ acquired Clif Bar, as noted in the 2023 10-K filing, with specific reference to the August 1, 2022 acquisition and related financial impacts such as integration costs and contingent consideration adjustments. By 2024, the relationship had evolved to include purchase price allocation adjustments for Clif Bar during the prior year, as detailed in the 2024 10-K filing. This indicates that the company had moved beyond the initial acquisition phase into a period of financial recalibration and consolidation of the Clif Bar acquisition.",
      "llm_answer": "\nBetween 2023 and 2024 the Clif Bar transaction moved from a recent acquisition to a fully integrated business. The 2023 filing notes that the August 1 2022 purchase of Clif Bar generated $529 million of incremental net revenue (constant‑currency) through its one‑year anniversary, and the related integration costs were recorded in 2023; the 2024 filing contains no additional acquisition‑related revenue or expense items for Clif Bar, indicating the deal is now complete and its financial impact has stabilized.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The acquisition date is incorrectly referenced as August 1, 2022, but the original answer states that the 2023 10-K notes the acquisition — implying it occurred in or before 2023 — and references August 1, 2022 as the acquisition date. However, the LLM incorrectly attributes $529 million of incremental net revenue to the one-year anniversary of the acquisition, which is not mentioned in the ground truth and cannot be verified from the provided information. This number is therefore fabricated or misattributed. (2) The quantitative accuracy is low because the $529 million figure and the claim of 'one-year anniversary' revenue are not supported by the original answer. The ground truth mentions integration costs and contingent consideration adjustments in 2023, and purchase price allocation adjustments in 2024 — none of which are reflected in the LLM response. The absence of acquisition-related items in 2024 is partially correct, but the reasoning is flawed. (3) The multi-hop reasoning is partially sound in that the LLM infers progression from acquisition to integration, but it fails to capture the key financial activities in 2024 — specifically, the purchase price allocation adjustments — which are central to the evolution of the relationship. Instead, it incorrectly concludes the deal is 'complete' based on absence of expenses, missing the nuance of ongoing financial recalibration. (4) Contextual relevance is high because the answer addresses the evolution of the relationship and focuses on financial activities over time, but correctness is undermined by invented metrics and omission of key details from both years. The core idea of transition from acquisition to stabilization has merit, but execution lacks factual grounding.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 495,
        "total_tokens": 1758
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has Gulfstream's approach to energy efficient engines evolved from 2023 to 2024, and what specific aircraft developments reflect this shift?",
      "original_answer": "In 2023, Gulfstream emphasized its leadership in the use of sustainable aviation fuel (SAF) and energy efficient engines, focusing on continuous R&D investment to develop technologically advanced business jets. However, no new aircraft model powered by energy efficient engines was introduced that year. By 2024, Gulfstream had transitioned from announcement and development phases to actual production of energy efficient engines, as evidenced by the introduction of the G700, which features 'all-new engines' designed for high-speed performance and efficiency. This marks a tangible evolution from strategic positioning in 2023 to operational realization in 2024.",
      "llm_answer": "\nFrom 2023 to 2024 Gulfstream moved from incremental efficiency gains on its existing G500/G600 family to a clean‑sheet engine package that powers its newest ultra‑large‑cabin jet, the G700, which entered service in early 2024 with next‑generation, low‑specific‑fuel‑consumption engines and full compatibility for 100 % sustainable‑aviation‑fuel operations.  This shift is also reflected in the 2024‑certified G800 and G400, which incorporate the same high‑efficiency powerplants and aerodynamic refinements that deliver higher cruise speeds, longer ranges and markedly reduced emissions across the entire Gulfstream lineup.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general evolution from R&D focus in 2023 to production and deployment of energy-efficient engines in 2024, correctly identifying the G700 as a key aircraft reflecting this shift. However, it introduces significant inaccuracies: (1) It claims the G700 entered service in early 2024 with 'next-generation' engines, which aligns broadly with the ground truth, but (2) it incorrectly states that the G800 and G400 were '2024-certified' and incorporate the same high-efficiency powerplants. The ground truth does not mention G800 or G400 certifications or engine upgrades in 2024, nor does it indicate that these models feature the same new engines as the G700. This is a critical factual overreach. Additionally, while the original answer notes that 2023 was focused on SAF and R&D without new models, the LLM implies incremental gains on G500/G600, which is unsupported. Quantitatively, no specific numbers (e.g., fuel savings, dates) are provided in either answer, so scoring is based on event timing and model accuracy. The reasoning partially reflects the multi-hop shift from strategy to execution but extends beyond the evidence by generalizing engine upgrades across the lineup. Contextually, the response stays on-topic and addresses the evolution and aircraft developments, hence high relevance. However, due to unsupported claims about G800 and G400 and unverified engine rollouts, the correctness and qualitative accuracy are significantly reduced.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 406,
        "total_tokens": 1728
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has AMD's relationship with semi-custom SoC products evolved from 2022 to 2024, particularly in terms of revenue structure and strategic positioning?",
      "original_answer": "In 2022, AMD's relationship with semi-custom SoC products was characterized by dependency, with revenue derived from both non-recurring engineering fees and sales of the products themselves, and success was directly tied to third-party product performance. By 2024, AMD's relationship evolved to one of active production and broader strategic integration, as semi-custom SoC products became part of a more diversified product portfolio that includes AI accelerators, GPUs, APUs, and DPUs. This shift indicates a more central and controlled role for AMD in the development and commercialization of these products, aligning them more closely with long-term industry trends and internal innovation strategies.",
      "llm_answer": "\nFrom 2022 to 2024 AMD shifted its semi‑custom SoC business from a high‑risk, revenue‑uncertain model—where earnings depended on third‑party design wins and were subject to wafer‑purchase targets and penalties—to a more contract‑backed, predictable structure.  The 2024 filing shows that AMD now operates under long‑term wafer‑supply agreements (e.g., the GF amendment through 2025 with minimum annual capacity allocations and pre‑payments), giving it greater control over supply, pricing and revenue visibility, while positioning semi‑custom SoCs as a strategic growth pillar across gaming, AI and data‑center markets.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies a strategic evolution in AMD's semi-custom SoC business from 2022 to 2024, noting increased predictability, supply control, and strategic positioning—aligning well with the ground truth's emphasis on a shift toward greater control and integration. The mention of long-term wafer-supply agreements (e.g., GF amendment through 2025) and pre-payments reflects accurate qualitative details likely drawn from actual filings, supporting high quantitative and contextual accuracy. However, the LLM introduces specific contractual mechanisms—such as 'wafer-purchase targets and penalties' and 'minimum annual capacity allocations'—that are not present in the original answer, adding detail beyond the ground truth without confirmation. While these may be factually correct, they shift focus toward operational risk and supply agreements rather than the broader portfolio diversification (e.g., integration with AI accelerators, GPUs, APUs, DPUs) emphasized in the original. The core revenue structure shift is captured (from uncertain third-party dependency to more stable, strategic role), but the LLM omits the key point about semi-custom SoCs becoming part of a diversified product portfolio aligned with long-term innovation strategies. Thus, while the reasoning is logical and contextually relevant, it partially misses the multi-hop synthesis of strategic repositioning within AMD’s broader product ecosystem, leading to a moderate deduction in qualitative accuracy and overall correctness. No numerical inaccuracies are present—dates (2022–2024, 2025 agreement) are plausible and consistently used.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 444,
        "total_tokens": 1777
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has the company's structure of preferred share authorization evolved between fiscal years 2023 and 2024, and what does this indicate about its capital strategy?",
      "original_answer": "The company's preferred share authorization structure remained unchanged between fiscal years 2023 and 2024, with 127.5 million Preferred Shares at $0.20 par value and 500 thousand A Preferred Shares at $1.00 par value authorized in both years. Additionally, no Preferred Shares or A Preferred Shares were issued or outstanding in either year. This indicates that the company has not utilized or pursued any changes in its preferred share structure as part of its capital strategy during this period.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 the company’s preferred‑share charter was unchanged – it still authorizes 127.5 million $0.20 par “Preferred” shares and 500 thousand $1.00 par “A” Preferred shares, and at the end of both years no such shares were issued or outstanding (MDT 10‑K 2023 pp. 79‑83; MDT 10‑K 2024 pp. 79‑83).  This stability shows that Medtronic is not using preferred equity as a financing tool; instead, its capital strategy continues to rely on cash flow, modest debt, and returning capital to shareholders through ordinary‑share repurchases and dividends, with a sizable ordinary‑share repurchase authorization left for future use.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that the preferred share authorization remained unchanged between fiscal years 2023 and 2024, with 127.5 million Preferred Shares at $0.20 par value and 500 thousand A Preferred Shares at $1.00 par value authorized in both years. It also accurately notes that no shares were issued or outstanding in either year, matching the ground truth. All numeric values and par values are correct, with acceptable formatting variations (e.g., '500 thousand' = '500 thousand'). (2) Quantitative accuracy is perfect: all numbers (127.5 million, 500 thousand, $0.20, $1.00) match the original answer exactly in value and context. (3) The multi-hop reasoning is sound—LLM correctly synthesizes data across two fiscal years and filings (2023 and 2024 10-Ks), confirms no changes, and infers the capital strategy implication. The added context about Medtronic’s reliance on cash flow, debt, and share repurchases is consistent with the broader filing content and logically extends the conclusion, though slightly beyond the ground truth’s scope. (4) The answer is semantically equivalent and highly relevant. The only reason for not scoring a 10 is that the original answer emphasizes the lack of utilization or pursuit of preferred shares as part of capital strategy, while the LLM adds interpretation about reliance on other tools (repurchases, dividends), which, while reasonable, is a slight expansion beyond the documented inference. Still, this does not introduce inaccuracy, so the qualitative score is high. Overall, the answer is factually correct, complete, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 443,
        "total_tokens": 1735
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has the framing of reputational risk related to adverse publicity evolved between 2022 and 2024 in BK's risk disclosures, particularly in terms of associated impacts or linked concerns?",
      "original_answer": "In 2022, BK identified adverse publicity as a risk that could negatively affect its business, financial condition, and results of operations, and linked it with government scrutiny and other reputational harm. By 2024, the framing of this risk remained present but was expanded to include broader reputational impacts from sustainability concerns such as climate change and diversity, in addition to being tied to new operational models like the platforms operating model transition. This indicates a broadening of the contexts in which adverse publicity could negatively impact BK's reputation and business outcomes.",
      "llm_answer": "\nBetween the 2022 and 2024 filings the discussion of reputational risk moved from a brief, generalized note that “errors or delays … may materially adversely affect … reputation” (2022 10‑K, Risk Factors, p. 6) to a dedicated, more detailed bullet that explicitly ties reputational harm to a range of adverse events, publicity, government scrutiny, cyber‑security incidents, climate‑change and geopolitical developments, and stresses that such reputational damage can materially affect the company’s business, financial condition and results of operations (2024 10‑K, Risk Factors, p. 7).  The evolution reflects a shift from treating reputational risk as an indirect consequence of operational or cyber events to positioning it as a distinct, explicitly enumerated risk driver linked to multiple external and sustainability‑related concerns.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution of BK's risk disclosures between 2022 and 2024, noting the shift from a more generalized mention of reputational risk linked to operational issues (e.g., errors or delays) to a more detailed, standalone risk factor in 2024. The inclusion of government scrutiny, cybersecurity incidents, climate change, and geopolitical developments as sources of reputational harm matches the expanded scope in the 2024 filing. (2) There are no numeric values to verify, so quantitative accuracy is not applicable—no errors in dates or years (2022 and 2024 correctly cited). (3) The multi-hop reasoning is sound: the model synthesizes changes in framing across years and identifies the broadening of reputational risk to include sustainability and external factors. It correctly infers a strategic shift in how BK presents risk, even if the term 'platforms operating model transition' is not explicitly mentioned—the broader context of operational changes is implied through reference to new risk drivers. (4) The only minor omission is the specific mention of the 'platforms operating model transition' as a linked concern in 2024, which is present in the original answer. However, the LLM captures the essence of operational evolution through references to cybersecurity and operational models. Wording differs but semantic meaning is equivalent. Thus, the answer is factually correct, comprehensive, and contextually appropriate, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1375,
        "completion_tokens": 426,
        "total_tokens": 1801
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How did Amazon's financial investment and valuation approach toward Anthropic, PBC evolve from 2023 to 2024, particularly in terms of investment classification and the factors affecting its valuation?",
      "original_answer": "In 2023, Amazon disclosed a $1.25 billion convertible note investment in Anthropic, PBC, classified as available-for-sale and reported at fair value with unrealized gains and losses included in 'Accumulated other comprehensive income (loss).' The note was categorized as a Level 3 asset, and Amazon had an agreement to invest an additional $2.75 billion in a second convertible note by Q1 2024. By 2024, the investment was still classified as available-for-sale but was noted to be part of a broader portfolio of convertible debt investments in private companies, primarily referencing Anthropic, PBC. The 2024 filing emphasized increased complexity in valuing private company investments due to the lack of readily available market data and global economic uncertainty, indicating a shift toward acknowledging heightened valuation risk. While the classification remained consistent, the 2024 disclosure placed more emphasis on the challenges of valuation rather than the mechanics of the investment itself.",
      "llm_answer": "\nIn Q3 2023 Amazon recorded a $1.25 billion convertible note in Anthropic, PBC as an available‑for‑sale Level 3 financial asset, recognizing any fair‑value changes in accumulated other‑comprehensive income.  In 2024 it expanded its exposure with a second convertible note (up to $2.75 billion) and a commercial AWS‑chip arrangement, continuing to measure the investment at fair value and recording gains or impairments in AOCI or other income, with valuation driven by discounted‑cash‑flow forecasts, conversion prospects and market conditions.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the $1.25 billion convertible note investment in 2023 and the additional $2.75 billion commitment, both of which match the ground truth. It accurately states the investment was classified as available-for-sale and measured at fair value with changes recorded in accumulated other comprehensive income (AOCI), and correctly identifies it as a Level 3 asset. However, the LLM incorrectly implies that the second $2.75 billion note was already deployed in 2024, while the original answer specifies Amazon had an agreement to invest the additional amount by Q1 2024, not that it had completed the investment. This misrepresents the timing and execution status. (2) The quantitative accuracy is high: both dollar amounts ($1.25B and $2.75B) are correct, and the timeframes (2023, 2024) are generally accurate, though Q3 2023 is more specific than the original answer, which does not specify a quarter. The format variations are acceptable. (3) The multi-hop reasoning is partially sound—while the LLM captures the investment structure and classification correctly, it adds a detail about a 'commercial AWS-chip arrangement' not present in the original answer, introducing unverified information. This affects qualitative accuracy. Additionally, the original emphasizes a shift in disclosure tone in 2024 toward valuation complexity and risk, which the LLM does not mention, instead focusing on valuation drivers like DCF and conversion prospects. This misses a key qualitative evolution in Amazon's approach. (4) Despite these omissions and minor inaccuracies, the answer remains contextually relevant and factually grounded in the core investment details, warranting a correctness score of 7. The answer captures the main financial commitments and accounting treatment but falls short on the nuanced shift in valuation risk disclosure emphasized in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 515,
        "total_tokens": 1916
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has the nature of the risks related to the protection of MDLZ's intellectual property, including know-how, evolved between 2023 and 2024?",
      "original_answer": "In 2023, MDLZ emphasized the importance of protecting its intellectual property rights, particularly trademarks, patents, copyrights, and know-how, through a combination of legal mechanisms such as patent and trademark laws, licensing agreements, and third-party nondisclosure agreements. The company expressed concern that failure to protect these rights or any legal changes reducing intellectual property protections—especially in response to developments in artificial intelligence technologies—could significantly harm its competitiveness and financial condition. In 2024, while the company maintained its emphasis on the significance of intellectual property rights, it did not specifically mention artificial intelligence as a factor affecting protection. Instead, the 2024 disclosure focused on the broader risks of legal or regulatory non-compliance and the potential for civil or criminal penalties, reputational damage, and financial loss due to litigation or enforcement actions. This shift indicates a broadening of the risk context without the specific emphasis on AI-related threats present in 2023.",
      "llm_answer": "\nBetween 2023 and 2024 the company’s IP‑risk narrative moved from a broad statement that “our trademarks, patents, trade‑secrets, recipes, technology and know‑how are important and must be protected” to a more specific warning that **new threats—especially developments in artificial‑intelligence technologies and any legal changes that could weaken existing protections—now must be factored into the protection of that know‑how**.  The 2024 filing also stresses that failure to secure or maintain these rights (including against third‑party infringement claims) could “materially and adversely affect our competitiveness, financial condition and stock price,” underscoring a heightened focus on safeguarding know‑how amid evolving regulatory and technological pressures.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies in its portrayal of the evolution of MDLZ's intellectual property risks between 2023 and 2024, despite using plausible financial and legal terminology. (1) The LLM incorrectly states that the 2023 filing introduced a 'more specific warning' about artificial intelligence (AI) as a new threat to IP protection, whereas the ground truth confirms that it was actually in 2023 that AI was mentioned as a concern, and this specific reference was dropped in 2024. The LLM reverses the direction of change: it suggests AI became a new focus in 2024, when in fact it was present in 2023 and absent in 2024. (2) There are no numeric values in the question or answer, so quantitative accuracy is not applicable—no errors here, hence a score of 10. (3) The multi-hop reasoning is flawed: the model fails to correctly synthesize the temporal shift in risk disclosure, incorrectly attributing the AI-related risk to 2024 instead of 2023. It also misrepresents the 2024 filing as expanding on AI threats when in fact it broadened the risk context to include regulatory non-compliance and enforcement actions without mentioning AI. (4) Contextually, the answer addresses the topic of IP risk evolution and mentions relevant elements like know-how, legal protections, and competitiveness, so it remains within the general scope. However, the core analytical point—the evolution of risk focus—is incorrect. The answer suggests a heightened focus on AI and technological pressures in 2024, while the truth is that AI was de-emphasized. This fundamental reversal of the trend severely undermines the factual correctness, warranting a low correctness score of 4, with partial credit for maintaining the general theme of evolving IP risks.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1470,
        "completion_tokens": 480,
        "total_tokens": 1950
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has Goldman Sachs' treatment of Non-Employee Director Equity Award Agreements evolved between the 2023 and 2024 SEC filings, particularly in terms of referenced agreements and their timelines?",
      "original_answer": "In 2023, Goldman Sachs referenced Non-Employee Director Equity Award Agreements through Exhibit 10.17, which pointed to an amendment dated November 28, 2008. By 2024, the company continued to disclose these agreements under the same exhibit number (10.18), but the referenced source shifted to Exhibit 10.69 from the 2008 Annual Report, indicating a formalization or consolidation of prior amendments. This evolution shows a continuation of the policy with deeper historical documentation being emphasized in the later filing.",
      "llm_answer": "\nBetween the 2023 and 2024 filings Goldman Sachs shifted from citing the legacy “pre‑2015” Non‑Employee Director RSU Award Agreement (and the 2008 amendment to those agreements) that appeared in the 2023 Exhibit list, to introducing new, stand‑alone forms—Exhibits 10.31 and 10.32—presented without any “pre‑2015” label.  This change signals that the company has formally replaced the older templates with updated director‑equity award agreements, aligning their timelines to the 2023‑2024 reporting period.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth in several key aspects. (1) The exhibit numbers cited in the LLM answer (10.31 and 10.32) do not match the ground truth, which states that Goldman Sachs used Exhibit 10.17 in 2023 and Exhibit 10.18 (referring to Exhibit 10.69 from the 2008 Annual Report) in 2024. The LLM incorrectly claims a shift to new standalone forms with different exhibit numbers, which is not supported by the original answer. (2) The LLM introduces a 'pre-2015' label and RSU Award Agreement terminology not present in the ground truth, suggesting a narrative about template replacement that lacks factual basis in the provided data. (3) The timeline evolution described—'formal replacement' of templates—is speculative and misrepresents the actual change, which was a shift in referenced source documentation within the same exhibit framework, not the introduction of new agreements. (4) The ground truth emphasizes continuity in policy with deeper historical documentation, whereas the LLM implies a substantive policy update, which is not corroborated. While the answer addresses the general topic of evolution in director equity award agreements and attempts multi-hop reasoning across years, the factual inaccuracies in exhibit numbers, referenced documents, and nature of changes severely undermine correctness. Quantitative accuracy is low due to incorrect dates and exhibit references. Qualitative accuracy suffers from flawed reasoning and entity misidentification. Contextual relevance is moderate as it engages with the topic but misdirects the analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1270,
        "completion_tokens": 438,
        "total_tokens": 1709
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has BKNG's relationship with travel service providers evolved between 2022 and 2023 in terms of revenue recognition and contractual responsibilities?",
      "original_answer": "In 2022, BKNG described its relationship with travel service providers as one where it connects consumers to providers through its platforms, emphasizing its role as an intermediary without taking responsibility for delivering the travel services. The company highlighted that it earns revenues primarily from facilitating reservations and also mentioned the impact of cancellations during the pandemic recovery phase. By 2023, BKNG provided more detailed accounting treatment around its contracts with travel service providers, specifying that it recognizes revenue on a net basis due to its role as an agent, and further clarified its revenue recognition timing as occurring at the point when travelers begin using the arranged services. This reflects a shift from a general description of the relationship to a more structured and accounting-driven dependency on travel service providers, particularly in how it recognizes commissions and transaction revenues.",
      "llm_answer": "\nBetween 2022 and 2023 Booking Holdings deepened its shift from a pure agency model to a merchant‑based approach, moving a larger share of accommodation reservations onto a structure where it collects the traveler’s payment, assumes responsibility for refunds, charge‑backs and tax obligations, and remits the net amount to the travel provider. Consequently, revenue recognition moved from gross agency commissions to net merchant revenues (commissions + transaction‑net + ancillary fees), and the company now records substantially larger “Deferred Merchant Bookings” balances to reflect advance payments and expanded contractual duties.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth. (1) The original answer states that BKNG consistently acts as an agent and recognizes revenue on a net basis due to its role as an intermediary, with no indication of a shift to a merchant model. In contrast, the LLM claims BKNG moved toward a 'merchant-based approach' where it assumes payment, refund, and tax responsibilities—this is factually wrong based on the provided ground truth. (2) There are no quantitative figures (e.g., dollar amounts, percentages, booking volumes) in either the question or ground truth, so no numeric accuracy can be assessed, but the LLM introduces the term 'Deferred Merchant Bookings' without any support from the original answer, implying financial constructs not mentioned in the source. (3) The multi-hop reasoning is flawed: the original answer describes an evolution in accounting disclosure clarity—not a change in business model—where BKNG provided more detailed treatment of existing agent-based revenue recognition. The LLM misinterprets this as a structural shift in contractual relationships, which is not supported. (4) Contextual relevance is moderate because the answer addresses revenue recognition and contractual responsibilities over time, but the core factual claim about moving to a merchant model makes it misleading. The correct evolution was from general description to more precise accounting disclosure within the same agent framework, not a business model change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 409,
        "total_tokens": 1811
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "What specific changes occurred in the structure of Goldman Sachs' executive life insurance policy disclosures between the 2023 and 2024 10-K filings?",
      "original_answer": "In the 2023 10-K filing, Goldman Sachs included the Goldman Sachs & Co. LLC Executive Life Insurance Policy and Certificate with Metropolitan Life Insurance Company (Exhibit 10.11) and a form of the policy with Pacific Life & Annuity Company (Exhibit 10.12). In the 2024 10-K filing, these exhibits were not only retained but renumbered to 10.12 and 10.13 respectively, indicating a reorganization of exhibit numbering. This renumbering and retention of the policies in the 2024 filing demonstrates a structural update in how the policies are presented within the filing, rather than a substantive change in the policies themselves.",
      "llm_answer": "\nBetween the 2023 and 2024 Form 10‑K filings the executive‑life‑insurance disclosures were re‑numbered and re‑sequenced: the Metropolitan‑Life policy that had been listed as Item 10.11 in 2023 appears as Item 10.11 in 2024, while the Pacific‑Life policy that was Item 10.12 in 2023 is now Item 10.13, and the filing updates the exhibit citations to the most recent quarterly reports.  In addition, the 2024 filing places the claw‑back policy as Item 10.1 and shifts the insurance items later in the list, reflecting a broader re‑ordering of compensation‑related disclosures, and the description of the Pacific‑Life policy now explicitly notes that it includes “policy specifications and form of restriction on Policy Owner’s Rights.”",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) QUANTITATIVE/ENTITY INACCURACY: The LLM incorrectly states that the Metropolitan Life policy was listed as Item 10.11 in both 2023 and 2024. According to the ground truth, in the 2024 filing, this exhibit was renumbered to 10.12, not retained as 10.11. Similarly, the Pacific Life policy moved from 10.12 (2023) to 10.13 (2024), which the LLM gets partially right, but the claim that the Metropolitan policy remained at 10.11 contradicts the renumbering pattern. (2) The LLM introduces a 'claw-back policy as Item 10.1' and claims a shift due to 'broader re-ordering of compensation-related disclosures'—this detail is not present in the original answer and cannot be verified from the provided ground truth, suggesting fabrication or overinference. (3) The addition about 'updates to exhibit citations to the most recent quarterly reports' and the 'explicit note' in the Pacific Life policy description about 'restriction on Policy Owner’s Rights' are not mentioned in the ground truth and represent unverified details. (4) While the LLM correctly identifies that there was renumbering and structural reorganization, it misrepresents the specific changes and adds unsupported details, failing the multi-hop synthesis test. The core idea of structural update (not substantive change) is present, giving partial credit, but the incorrect exhibit numbers and invented context severely reduce accuracy. (5) Despite these issues, the answer remains contextually relevant to the question about structural changes in disclosures, hence a moderate contextual relevance score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 451,
        "total_tokens": 1793
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How has the strategic importance and manufacturing approach for FBAR filters evolved between 2022 and 2024, particularly in terms of internal fabrication and competitive positioning?",
      "original_answer": "In 2022, FBAR filters were highlighted as a key product utilizing Broadcom’s proprietary processes, fabricated internally to protect IP and accelerate time to market, alongside vertical-cavity surface emitting lasers and side emitting lasers. The internal fabrication was specifically emphasized as a means to maintain competitive advantage by safeguarding innovation. By 2024, FBAR filters remained part of the internal fabrication strategy, but the context expanded to include a more comprehensive list of competitors in the semiconductor space, such as Qorvo, Qualcomm, and Skyworks, indicating a more intense competitive environment. This suggests that while the internal manufacturing strategy for FBAR filters remained consistent, the competitive pressure in wireless communications increased significantly, requiring Broadcom to reinforce its IP protections and innovation cycle.",
      "llm_answer": "\nBetween 2022 and 2024 Broadcom deepened its internal‑fabrication strategy for FBAR filters—moving from simply “using internal facilities for innovative processes” to actively expanding dedicated III‑V wafer‑fab capacity (U.S. & Singapore) and investing in process‑development to tighten IP control and accelerate time‑to‑market. This heightened focus on proprietary FBAR technology is presented as a key differentiator in the company’s competitive positioning, emphasizing its high‑speed design expertise, module integration and differentiated product performance against other semiconductor vendors.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the continued strategic importance of FBAR filters and Broadcom's internal fabrication approach as a means to protect IP and accelerate time to market, which aligns with the 2022 and 2024 ground truth. The emphasis on proprietary processes and competitive differentiation is consistent with the original answer. However, the LLM introduces specific details not present in the ground truth, such as 'expanding dedicated III-V wafer-fab capacity in the U.S. and Singapore' and 'investing in process-development,' which, while plausible, are not supported by the provided knowledge graph. These additions represent a plausible inference but go beyond the documented evidence, affecting qualitative accuracy. Additionally, while the original answer highlights an expanded competitive landscape (naming Qorvo, Qualcomm, Skyworks) to illustrate increased competitive pressure, the LLM answer only generically references 'other semiconductor vendors' without identifying the specific competitors, missing a key multi-hop element. There are no numerical values in the question or answers, so quantitative accuracy is scored as 10 by default. The answer remains contextually relevant and captures the core evolution—consistent internal fabrication amid growing competitive intensity—though with some over-elaboration and omission of specific competitor names. Thus, the correctness and qualitative accuracy are reduced slightly, but not severely, due to these deviations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 410,
        "total_tokens": 1791
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How has BMY's strategic positioning of Krazati evolved between 2023 and 2024, particularly in terms of clinical development focus and financial valuation?",
      "original_answer": "In 2023, Krazati was positioned as part of BMY’s oncology portfolio with specific clinical trials listed: KRYSTAL-17 for 1L NSCLC TPS<50%, KRYSTAL-10 for 2L CRC, and KRYSTAL-12* for 2L+ Mutated NSCLC. By 2024, BMY had acquired Mirati for $4.8 billion, securing full rights to Krazati, which had already received FDA and EMA approvals for second-line NSCLC and FDA approval for advanced KRAS-mutated colorectal cancer. Additionally, Krazati was now being developed in combination with a PD-1 inhibitor for first-line NSCLC, indicating a significant expansion in its clinical and commercial strategy.",
      "llm_answer": "\nBetween 2023 and 2024 Krazati moved from a late‑stage, privately‑held asset in Mirati’s pipeline to a core, commercially‑approved product within BMS after the $4.8 billion (≈$4.1 billion net) acquisition of Mirati in January 2024; the clinical focus broadened from its original KRAS‑mutant NSCLC indication to include first‑line KRAS‑mutant NSCLC (KRYSTAL‑17), second‑line KRAS‑mutated colorectal cancer (KRYSTAL‑10/12) and combination studies with PD‑1 inhibitors.  The transaction was valued with a $3.5 billion indefinite‑lived IPRD valuation plus $640 million of definite‑lived product rights, underscoring Krazati’s strategic importance to BMS’s future revenue and pipeline valuation.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in BMY's (BMS's) strategic positioning of Krazati between 2023 and 2024. (1) It correctly identifies the $4.8 billion acquisition of Mirati in January 2024, aligning with the ground truth, and notes the net cost approximation of $4.1 billion, which is a reasonable adjustment (though not in the original answer, it's a plausible inference and not factually incorrect). The $3.5 billion indefinite-lived IPRD and $640 million definite-lived product rights sum to $4.14 billion, close to the net value—minor variance is acceptable as this may reflect accounting adjustments; however, the original answer does not include these breakdowns, so their inclusion is extra detail rather than a factual error. (2) Clinical development focus is accurately described: expansion from NSCLC to include CRC and combination with PD-1 inhibitors in first-line NSCLC, matching KRYSTAL-17, KRYSTAL-10, and KRYSTAL-12 trials. The LLM slightly mischaracterizes KRYSTAL-12 as being for colorectal cancer, whereas the ground truth specifies KRYSTAL-12* for 2L+ mutated NSCLC and KRYSTAL-10 for 2L CRC—this is a minor conflation but does not severely distort the overall picture. (3) The LLM correctly synthesizes multi-hop information: Mirati’s ownership in 2023, BMS acquisition in 2024, regulatory approvals (FDA/EMA for 2L NSCLC and FDA for CRC), and expanded development strategy. (4) The term 'BMS' is used instead of 'BMY'—this is acceptable as both refer to Bristol Myers Squibb. The answer adds valuation details (IPRD breakdown) not in the original, which enhances depth without contradicting facts. Overall, the answer is semantically equivalent, with only minor imprecision in trial attribution. Hence, correctness is docked slightly to 9 for the trial mix-up, but all other dimensions score highly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 499,
        "total_tokens": 1823
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How has the relationship between BKNG and travel service providers evolved between 2022 and 2023, particularly in terms of how BKNG manages financial obligations and incentives related to these providers?",
      "original_answer": "In 2022, BKNG primarily competed with travel service providers, highlighting the intense and evolving nature of the competitive landscape in the online travel market. By 2023, BKNG's relationship with travel service providers shifted to a more dependent model, as evidenced by the increase in the 'Deferred merchant bookings' liability on its balance sheet, which reflects amounts estimated to be payable to travel service providers. Additionally, BKNG introduced more incentive programs, such as referral bonuses, rebates, and loyalty points, which are recognized as a reduction of revenue, indicating a strategic shift toward enhancing partnerships and incentivizing collaboration with travel service providers rather than solely competing with them.",
      "llm_answer": "\nBetween 2022 and 2023 Booking Holdings moved from a largely agency‑style commission model toward a merchant‑oriented structure in which travel‑service‑provider revenue is recorded net of the commissions, rebates, loyalty points and other incentives it promises to them.  The company now accrues the estimated value of those incentives as a reduction of revenue and tracks the cash it receives from travelers in “deferred merchant bookings,” a liability that reflects both amounts payable to providers and the future commission or margin it expects to earn.  This tighter financial integration—bolstered by expanded payment‑settlement capabilities and larger deferred‑booking balances—aligns provider incentives with consumer demand while giving BKNG clearer visibility into its obligations and revenue‑recognition timing.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth, with only minor differences in emphasis. (1) The key factual elements are correct: BKNG shifted from a competitive to a more dependent relationship with travel service providers between 2022 and 2023, reflected in increased 'deferred merchant bookings' (a liability), and expanded incentive programs (rebates, loyalty points, etc.) that reduce revenue. The LLM correctly identifies the accounting treatment—these incentives are recognized as a reduction of revenue and the cash from travelers is held in deferred merchant bookings, a liability. (2) There are no numeric values in the original or LLM answer, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the LLM synthesizes the evolution in business model (agency to merchant), financial reporting implications (liability recognition, revenue reduction), and strategic intent (incentive alignment). The only minor shortcoming is that the LLM does not explicitly mention the '2022 competitive landscape' framing from the original answer, though it implies the shift. (4) The answer is contextually fully relevant, directly addressing how BKNG manages financial obligations and incentives. The use of terms like 'tighter financial integration' and 'expanded payment-settlement capabilities' adds useful detail not in the original but consistent with the logic. Overall, the answer matches the ground truth in substance and accuracy, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1408,
        "completion_tokens": 424,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How has Broadcom's involvement in the development of Custom Touch Controllers evolved from 2022 to 2024, particularly in terms of their role in the product lifecycle?",
      "original_answer": "In 2022, Broadcom was described as supplying Custom Touch Controllers as part of its semiconductor solutions for the wireless market. By 2024, the company's role had evolved to include producing these controllers as part of its broader custom silicon solutions, reflecting a deeper engagement in their development. This shift indicates a strategic move from being a component supplier to an active producer involved in the design and creation process.",
      "llm_answer": "\nFrom 2022 to 2024 Broadcom moved custom‑touch‑controller technology from being listed simply as a discrete “wireless” product family toward being presented as an integrated component of its broader custom‑silicon and infrastructure‑software portfolio.  In the 2022 filing the controllers were described only as devices that “process signals from touch screens in mobile handsets and tablets,” whereas the 2024 filing frames them as part of a suite of custom ASICs (including inductive‑charging ASICs) that support advanced mobile‑device functionality, indicating a more mature, end‑to‑end role in the product lifecycle.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) There are no numeric values to verify (e.g., dollar amounts, percentages), but the years (2022 and 2024) are correctly referenced, satisfying the time frame in the question. (2) The answer addresses all parts of the question: it describes Broadcom's evolving role in Custom Touch Controllers from 2022 to 2024 and specifically discusses the shift in their involvement in the product lifecycle. (3) The multi-hop reasoning is sound—by comparing the 2022 and 2024 filings, the LLM correctly infers a strategic evolution from a discrete component supplier to an integrated custom-silicon provider. It accurately reflects the deeper engagement in design and production, citing integration with ASICs and advanced functionality. (4) While the wording differs, the semantic meaning matches the original answer: moving from being a supplier to an active participant in the development lifecycle. The only minor gap is that the LLM does not explicitly use the phrase 'strategic move' or 'deeper engagement in their development' as in the original, but the concept is clearly conveyed through descriptions of integration and maturity. Thus, the answer is factually correct, contextually relevant, and demonstrates strong qualitative reasoning with full contextual alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1272,
        "completion_tokens": 372,
        "total_tokens": 1644
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Union Pacific's approach to freight cars evolved from 2023 to 2024, particularly in terms of asset acquisition strategy?",
      "original_answer": "In 2023, Union Pacific primarily leased freight cars as part of its operational strategy, reflecting a reliance on leased assets for rail operations. By 2024, the company's strategy shifted toward acquiring freight cars, including lease buyouts of $143 million in 2024 compared to $57 million in 2023, indicating a more aggressive stance on asset ownership to support replacement and growth opportunities.",
      "llm_answer": "\nUnion Pacific’s capital outlay for freight‑car equipment grew from $728 million in 2023 to $788 million in 2024, and the company recorded a sizable increase in lease‑buyout spending ($143 million in 2024 versus $57 million in 2023).  This reflects a strategic shift toward acquiring more cars outright (or through buyouts) rather than relying on operating leases, supporting its stated goal of replacing older assets and expanding capacity for growth.  The decline in both finance‑lease and operating‑lease assets over the same period further underscores the move to own a larger share of the freight‑car fleet.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and aligns perfectly with the ground truth. (1) All key facts are accurately represented: the increase in lease buyouts from $57 million in 2023 to $143 million in 2024 is correctly stated, and the broader context of a strategic shift toward asset acquisition is accurately conveyed. While the original answer does not mention the total capital outlay for freight-car equipment ($728M in 2023 to $788M in 2024), this additional detail in the LLM response is consistent with a deeper elaboration of the acquisition strategy and does not contradict the ground truth. (2) Quantitatively, all dollar amounts and years are accurate, and the comparison between 2023 and 2024 lease buyouts is correct. (3) The multi-hop reasoning is sound: the LLM correctly infers a strategic shift from leasing to ownership based on increased buyout spending and declining lease assets, synthesizing financial data with strategic intent. (4) The answer is semantically equivalent to the original, adding contextual detail (capital outlay, decline in lease assets) that enhances completeness without introducing errors. All entities—Union Pacific, freight cars, 2023–2024 timeframe, lease buyouts—are correctly identified and used appropriately. The conclusion about moving toward greater asset ownership for replacement and growth matches the original answer’s intent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1249,
        "completion_tokens": 381,
        "total_tokens": 1631
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "What were the financial and operational impacts of Nike's structural changes in APLA between FY2022 and FY2023, particularly regarding the transition of certain businesses to third-party distributors?",
      "original_answer": "In FY2022, Nike directly operated within APLA as part of its geographic operating segments, which included associated costs and foreign currency impacts such as non-recurring impairment charges due to the anticipated release of non-cash cumulative foreign currency translation losses from transitioning certain businesses to third-party distributors. By FY2023, Nike had shifted its relationship with APLA from direct operations to a strategic stake, where the company now oversees results through third-party distributors. This transition is reflected in the 2023 filing noting that APLA includes results for the NIKE and Jordan brands and referencing Note 18 on divestitures related to the transition. Operationally, this change represents a strategic shift to reduce direct operational overhead in APLA, likely aiming to improve financial efficiency and focus on brand management rather than local execution.",
      "llm_answer": "\nThe restructuring moved several APLA NIKE Brand operations from Nike’s direct sales to third‑party distributors, which cut the revenue that could be reported in the APLA geographic segment and, more sharply, in Global Brand Divisions—revenues there fell from $102 million in FY2022 to $58 million in FY2023 while APLA‑segment revenue grew only modestly.  The change required a one‑time release of foreign‑currency translation losses that had been recorded in Corporate (originally recognized as an impairment in FY2020) and prompted adjustments to sales‑related reserves and inventory, but no new impairment charge was taken in FY2022 or FY2023.  As a result, segment EBIT declined and long‑lived assets tied to the affected businesses were re‑classified to the distributor‑controlled locations.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces specific financial figures—Global Brand Divisions revenue falling from $102 million in FY2022 to $58 million in FY2023—that are not present in the original ground truth and cannot be verified from the provided context. These numbers appear fabricated or misattributed, severely undermining quantitative accuracy. The original answer mentions non-recurring impairment charges related to foreign currency translation losses but does not specify any revenue figures by segment or exact amounts for these charges, nor does it mention a decline in Global Brand Divisions revenue. (2) The LLM claims a one-time release of foreign currency translation losses previously recorded in Corporate and originally recognized as an impairment in FY2020; however, the ground truth states the non-recurring charge was due to the *anticipated* release of cumulative foreign currency translation losses in connection with the transition in FY2022, with no mention of FY2020. This misrepresents the timing and nature of the impairment. (3) While the LLM correctly identifies the shift from direct operations to third-party distributors in APLA and links it to operational and financial impacts such as reclassification of assets and adjustments to reserves, this reasoning extends beyond the documented evidence. The original answer notes the transition is reflected in Note 18 on divestitures and that APLA now includes results via strategic stake and third-party oversight, but does not mention reserve adjustments or asset reclassification. (4) The core strategic shift—transitioning APLA operations to third-party distributors to reduce overhead and focus on brand management—is accurately captured in intent and context, supporting moderate qualitative accuracy and high contextual relevance. However, the inclusion of unverified financial data and incorrect multi-hop inferences (e.g., linking FY2020 impairments to FY2022–FY2023 changes) significantly reduces overall correctness. The model synthesizes plausible narrative elements but fails on factual fidelity, especially in quantitative claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1440,
        "completion_tokens": 570,
        "total_tokens": 2010
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Broadcom's involvement with InP lasers evolved from 2022 to 2024, particularly in terms of their internal fabrication strategy and competitive positioning?",
      "original_answer": "In 2022, Broadcom disclosed using internal fabrication facilities for products based on proprietary processes, including vertical-cavity surface emitting lasers and side emitting lasers using GaAs and InP lasers for fiber optic communications. By 2024, Broadcom continued this strategy but began emphasizing the competitive landscape more explicitly, listing companies like Coherent Corp., Lumentum Holdings Inc., and others as competitors in semiconductor solutions. This indicates a strategic shift toward highlighting InP laser capabilities as part of its competitive differentiation in the market.",
      "llm_answer": "\nFrom 2022 through 2024 Broadcom continued to **keep InP‑laser wafer fabrication inside its own facilities** (primarily in the United States and Singapore) rather than outsourcing the process, using the internal III‑V fab to protect its proprietary designs and to accelerate time‑to‑market for its fiber‑optic modules.  This strategy reinforces its **competitive positioning as a differentiated supplier of high‑performance, customizable InP lasers**—leveraging its design expertise and close customer collaboration to out‑perform specialist laser vendors and integrated‑device manufacturers in data‑center and telecom applications.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly captures the core evolution of Broadcom's InP laser strategy from 2022 to 2024, emphasizing internal fabrication and competitive positioning. It accurately states that Broadcom maintained in-house fabrication of InP lasers through its internal III-V facilities, which aligns with the ground truth about proprietary processes and internal fabrication for fiber optic communications. The mention of U.S. and Singapore facilities, while adding detail not in the original, is plausible and not contradicted by the source. The answer correctly infers that this strategy supports competitive differentiation, particularly in data-center and telecom markets. However, it misses the specific 2024 shift in disclosure tone—explicitly naming competitors like Coherent Corp. and Lumentum Holdings Inc.—which is a key element of the ground truth regarding Broadcom’s increased emphasis on competitive positioning. While the LLM conveys a similar qualitative conclusion about competitive advantage, it does not reference the actual named competitors or the change in disclosure strategy, representing a minor omission in entity-level accuracy and multi-hop synthesis. There are no numerical inaccuracies (quantitative accuracy is perfect), and the answer remains highly relevant and logically sound overall.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1312,
        "completion_tokens": 366,
        "total_tokens": 1678
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has the ownership structure of Swoosh, LLC in relation to NIKE's Class A and Class B Common Stock evolved between 2022 and 2023, and what implications does this have for shareholder influence?",
      "original_answer": "In 2022, Swoosh, LLC beneficially owned approximately 77% of NIKE's Class A Common Stock, which would translate to approximately 16% ownership of Class B Common Stock if all shares were converted. In 2023, the ownership structure remained consistent with Swoosh, LLC still beneficially owning approximately 77% of Class A Common Stock, with a commensurate ownership percentage of approximately 16% in Class B Common Stock if all shares were converted. Despite the consistency in ownership percentages, the continued concentration of ownership in Swoosh, LLC implies sustained influence by Travis Knight, who has a significant role in managing the Class A Common Stock owned by Swoosh, LLC, potentially affecting shareholder decisions and market dynamics.",
      "llm_answer": "\nBetween the 2022 and 2023 Form 10‑K filings, Swoosh, LLC’s stake in NIKE’s capital structure was essentially unchanged: it continued to beneficially own about 77 % of the Class A Common Stock, which—if all of those shares were converted into Class B shares—would represent roughly 16 % of the Class B Common Stock. Because holders of Class A stock elect three‑quarters of NIKE’s board (rounded down), Swoosh’s large Class A ownership still gives it decisive influence over board composition and major corporate decisions, even though its converted Class B percentage is relatively modest. Consequently, shareholder influence remains heavily weighted toward Swoosh, limiting the impact of other investors on the company’s governance.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: 77% ownership of Class A Common Stock and approximately 16% equivalent ownership in Class B if converted are accurately reported for both 2022 and 2023. There are no calculation errors. (2) The answer correctly notes the stability of ownership between the two years, addressing the evolution (or lack thereof) in ownership structure. (3) The qualitative reasoning is strong: it correctly infers that despite the modest converted percentage in Class B, Swoosh, LLC retains decisive influence due to the voting rights associated with Class A shares—specifically, the right to elect three-quarters of the board (rounded down), which is a key governance detail. This adds valuable context beyond the original answer. (4) The only minor shortcoming is that the LLM does not explicitly name Travis Knight or his role in managing Swoosh, LLC’s shares, which was mentioned in the ground truth and relevant to explaining *why* Swoosh maintains influence. However, the omission does not undermine the core factual accuracy or reasoning. The answer remains semantically equivalent in substance and superior in contextual explanation. All entities (Swoosh, LLC, NIKE, Class A/B Common Stock) and time periods (2022–2023) are correct. The multi-hop synthesis—linking ownership percentage to voting rights to governance influence—is logically sound and well-executed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1384,
        "completion_tokens": 404,
        "total_tokens": 1788
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How did PMI's strategic positioning of Reduced-Risk Products evolve from 2022 to 2023, particularly in terms of portfolio integration and market availability?",
      "original_answer": "In 2022, PMI classified Reduced-Risk Products (RRPs) as a distinct category, including heated tobacco units, heat-not-burn devices, e-vapor, and oral nicotine products, with separate net revenue reporting. By 2023, RRPs were integrated into a broader category called Smoke-Free Products (SFPs), which now also included wellness and healthcare offerings. Additionally, PMI reported that its smoke-free products were available in 84 markets by the end of 2023, a notable expansion from the unspecified market availability in 2022. This evolution reflects a strategic shift toward consolidating RRPs under a unified smoke-free vision and expanding their global footprint.",
      "llm_answer": "\nFrom 2022 through 2023 PMI moved its reduced‑risk portfolio from a distinct “Other” category into the core geographical segments, beginning with the 2022 acquisition of Swedish Match and the full integration of its ZYN oral‑nicotine and IQOS heated‑tobacco products.  By the end of 2023 the company reported that its reduced‑risk products were sold in 84 markets and that, starting in 2024, the Swedish Match results will be rolled into the four regional segments (Europe, South & Southeast Asia‑CIS & MEA, East Asia‑Australia‑PMI DF, and Americas), indicating a complete portfolio integration and broader market availability across all of PMI’s operating regions.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures some correct elements but contains significant factual inaccuracies and misrepresents key aspects of PMI's strategic evolution from 2022 to 2023. (1) Correctly identifies the expansion to 84 markets by end of 2023, which matches the ground truth. However, it incorrectly states that reduced-risk products were moved into geographical segments starting in 2024 as part of Swedish Match integration—this timing and structural change are not supported by the original answer. The ground truth emphasizes a rebranding and category expansion from RRPs to Smoke-Free Products (SFPs) in 2023, incorporating wellness and healthcare, which the LLM answer omits entirely. (2) The mention of the Swedish Match acquisition is contextually relevant (completed in 2022), but the claim about financial integration 'starting in 2024' introduces future-looking information not present in the 2022–2023 scope and distracts from the actual portfolio reclassification. (3) The LLM fails to correctly describe the multi-hop evolution: it was not about moving RRPs into geographic segments but rather redefining the product category itself by integrating RRPs into a broader SFP category. This mischaracterizes the core strategic shift. (4) While market availability (84 markets) is accurately cited, the explanation around portfolio integration is factually incorrect—no mention in the ground truth about rolling Swedish Match into regional segments as a marker of RRP integration. Thus, despite correct market number and contextual awareness of Swedish Match, the reasoning and entity relationships are flawed, leading to a partial but misleading answer. Quantitative accuracy is acceptable (84 markets correct), but qualitative accuracy suffers due to incorrect synthesis. Contextual relevance is high as it addresses portfolio integration and market availability as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 505,
        "total_tokens": 1841
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Caterpillar's strategic role in the reciprocating engines business evolved from 2022 to 2024, and what impact has this had on its revenue composition and gross margin potential?",
      "original_answer": "In 2022, Caterpillar primarily sold reciprocating engines through its global dealer network and through subsidiary Perkins Engines Company Limited, which operated 90 distributors across 171 countries. By 2024, Caterpillar expanded its involvement by including the remanufacturing of Caterpillar reciprocating engines and components, as well as offering remanufacturing services for other companies. This evolution from a seller to a full lifecycle service provider likely improved gross margin potential, as remanufacturing typically involves lower material costs compared to new engine production and leverages existing asset value. The shift also diversified revenue composition by incorporating service-based income streams alongside traditional product sales.",
      "llm_answer": "\nBetween 2022 and 2024 Caterpillar shifted the reciprocating‑engine business from a commodity‑focused, oil‑and‑gas‑centric role to a broader, higher‑margin platform that underpins power‑generation, marine, rail and data‑center applications and is supported by its financing and aftermarket services.  This evolution is evident in the 2024 sales mix—power‑generation engine sales jumped 22 % to $7.76 bn while oil‑and‑gas engines were flat—pushing total Energy & Transportation revenue up 3 % to $28.85 bn and lifting the segment’s profit margin from 17.6 % to 19.9 %, thereby increasing the share of higher‑margin engine sales and enhancing gross‑margin potential.  (Pages 7‑11 of CAT_10K_2022; pages 37‑41 of CAT_10K_2024).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and introduces unsupported quantitative data not present in the ground truth. (1) The claim that power-generation engine sales increased by 22% to $7.76 billion and that Energy & Transportation revenue rose to $28.85 billion with margin expansion from 17.6% to 19.9% is not supported by the original answer or any cited knowledge graph data. These figures are entirely fabricated or misattributed, failing the quantitative accuracy test. (2) The original answer emphasizes a strategic shift from selling engines to offering remanufacturing services and full lifecycle support, which enhances gross margin potential due to lower material costs and diversifies revenue via service-based streams. The LLM instead frames the evolution around a shift in end-market focus (from oil & gas to power generation, marine, etc.) and margin improvement through sales mix, which is a different strategic narrative. (3) While both answers agree on a strategic evolution improving gross margin potential, the reasoning paths are distinct: the ground truth focuses on remanufacturing as a high-margin service model; the LLM focuses on product sales mix and segment profitability—this reflects flawed multi-hop reasoning. (4) The LLM cites specific pages of 10-K filings, but these references do not align with the ground truth derived from the knowledge graph, raising concerns about hallucination. Despite addressing the question's general theme—evolution of strategic role and impact on revenue and margins—the LLM fails on core factual correctness, especially on numbers and strategic mechanism, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 454,
        "total_tokens": 1836
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How did BNY Mellon's approach to disclosing amendments to the Directors' Code of Conduct evolve between 2022 and 2023, particularly in terms of the mechanisms and transparency commitments outlined for informing stakeholders of changes?",
      "original_answer": "BNY Mellon's approach to disclosing amendments to the Directors' Code of Conduct remained consistent between 2022 and 2023, with the company reaffirming its commitment to post any amendments or waivers on its website in both years. There was no change in the specific mechanism or transparency commitment described across the two years, indicating a stable governance communication strategy.",
      "llm_answer": "\nBetween 2022 and 2023 BNY Mellon kept its public‑website pledge to reveal any changes to the Directors’ Code of Conduct, but it sharpened the wording to make the commitment more concrete.  In the 2022 filing the company simply said it “intends to disclose on our website any amendments or waivers” of the Directors’ Code; in the 2023 filing it restated that intent and tied the disclosure to the regular practice of posting the code (and any amendment) at a specific URL and referencing it in the forthcoming proxy filing (and, by analogy, filing the change as an exhibit).  This evolution moves the promise from a generic statement of intent to a clear, timely mechanism that stakeholders can locate and track.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct in that it identifies BNY Mellon's continued commitment to website disclosure of amendments to the Directors' Code of Conduct, which aligns with the ground truth. However, it introduces a significant factual inaccuracy by claiming the company 'sharpened the wording' in 2023 to include specific mechanisms such as posting at a 'specific URL' and 'referencing it in the forthcoming proxy filing' or 'filing the change as an exhibit.' The ground truth explicitly states there was no change in the mechanism or transparency commitment between 2022 and 2023, indicating a stable approach. The LLM's characterization of an evolution from a 'generic statement of intent' to a 'clear, timely mechanism' is not supported by the original data and represents an incorrect inference. While the entities (BNY Mellon, Directors' Code of Conduct, years 2022–2023) and general topic (disclosure practices) are accurate, and there are no numerical errors (hence high quantitative accuracy), the qualitative reasoning fails due to incorrect synthesis across years. The answer addresses the question's focus on mechanisms and transparency but does so with fabricated details about changes in disclosure practices. Thus, while contextually relevant and numerically sound, the answer is factually incorrect in its core claim of evolution, warranting a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 385,
        "total_tokens": 1683
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Nike's strategic approach to the APLA market evolved between FY22 and FY23, particularly in terms of operational structure and market participation?",
      "original_answer": "In FY22, Nike operated directly in APLA, maintaining a significant presence through its NIKE Direct operations and wholesale distribution, with APLA contributing to the 14% growth in the NIKE Direct business. By FY23, Nike began transitioning certain businesses within APLA to third-party distributors, signaling a strategic shift away from direct market participation in some parts of the region. This change indicates a move toward a more distributed, partner-driven model in APLA, altering the way Nike engages with that market.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2023 Nike moved from a hybrid wholesale + NIKE‑Direct footprint in the APLA region to a pure distributor model.  In FY 22 it announced the sale of its Argentina, Uruguay and Chile entities and stated that, going forward, APLA revenue would be generated through third‑party distributors—thereby slowing revenue growth but lowering selling, general and administrative costs and FX exposure, which it expects will boost overall profitability.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the strategic shift from direct operations to a third-party distributor model in APLA between FY22 and FY23. It accurately captures the core evolution: moving away from direct market participation (including the sale of entities in Argentina, Uruguay, and Chile) toward a partner-driven, distributed model. The implications—slower revenue growth but reduced SG&A costs and FX exposure—are consistent with strategic rationale and add useful context not explicitly in the original answer, but plausibly inferred.\n\nQuantitatively, no specific numbers (e.g., percentages, dollar amounts) are misstated; the LLM does not contradict any numeric data in the ground truth. However, the original answer notes APLA contributed to the 14% growth in NIKE Direct in FY22, which the LLM omits. While not a quantitative error per se, this omission slightly affects completeness.\n\nEntity accuracy is strong: correct reference to APLA, NIKE Direct, third-party distributors, and correct fiscal years. The mention of Argentina, Uruguay, and Chile is a specific detail not in the original answer but is factually accurate based on Nike’s FY23 filings and adds precision.\n\nReasoning is sound: the LLM correctly synthesizes a multi-hop insight—Nike’s structural change in APLA—and infers business rationale (cost and FX benefits). The characterization as a shift to a 'pure distributor model' is a slight overstatement; the original answer says 'transitioning certain businesses,' implying a partial, not complete, shift. This overgeneralization prevents a top score.\n\nOverall, the answer is semantically equivalent in intent and mostly in content, with minor overprecision and omission of the 14% contribution detail. Hence, correctness is high but not perfect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1253,
        "completion_tokens": 494,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has the impact of Favorable Price Realization on Caterpillar's sales and profitability evolved from 2022 to 2024?",
      "original_answer": "In 2022, favorable price realization contributed to a $9.223 billion increase in total sales and revenues, driven by higher end-user demand and changes in dealer inventories. By 2024, favorable price realization continued to play a key role, partially offsetting a $2.251 billion decrease in sales volume and contributing to an increase in profit from $10.335 billion in 2023 to $10.792 billion in 2024. This indicates that while Caterpillar faced declining sales volume in 2024, the company leveraged pricing strategies more effectively to maintain profitability.",
      "llm_answer": "\nFrom 2022 through 2024 the contribution of favorable price realization shifted from a primary growth engine to a protective offset. In 2022 (and earlier in 2021) the company credited higher price realization as a key factor that lifted consolidated sales and drove double‑digit revenue growth, while also bolstering profit margins. By 2024, overall sales had slipped, but the same favorable price realization helped cushion the decline—offsetting lower volume and unfavorable manufacturing costs—and kept operating‑profit margin expanding to 20.2 % (up from 19.3 % in 2023), thereby preserving profitability even as top‑line growth turned negative.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the general trend correctly—favorable price realization shifted from a growth driver in 2022 to a protective factor in 2024—but introduces several unsupported quantitative claims not present in the ground truth. Specifically, the LLM states that operating-profit margin expanded to 20.2% in 2024 (up from 19.3% in 2023), but this data is not in the original answer and cannot be verified from the provided truth. Additionally, the LLM references 'double-digit revenue growth' and 'unfavorable manufacturing costs' which are not mentioned in the ground truth. (2) The original answer includes specific dollar figures: a $9.223 billion increase in sales in 2022 due to price realization, and in 2024, price realization offset a $2.251 billion volume decline while profit rose from $10.335B to $10.792B. The LLM omits all these exact figures and instead introduces unverified percentages and margins, failing the quantitative accuracy check. (3) The multi-hop reasoning is partially sound—the LLM correctly infers that price realization helped maintain profitability despite volume declines in 2024—but it does not reference the actual profit numbers or the exact role of price realization in offsetting the $2.251B volume drop, weakening the synthesis. (4) The contextual relevance is high because the answer addresses the evolution of price realization’s impact on sales and profitability across the years. Qualitative accuracy is moderate due to correct directional logic but lacks fidelity to the source data. Correctness score is 6 due to plausible reasoning but significant omission of key numbers and introduction of unverified metrics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 458,
        "total_tokens": 1754
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has General Motors' approach to EV manufacturing capacity evolved between 2023 and 2024, particularly in terms of strategic focus and supply chain development?",
      "original_answer": "In 2023, General Motors emphasized significant investments in EV manufacturing capacity based on expectations for future EV demand, acknowledging the risks and uncertainties associated with such investments, including high fixed costs and limitations on closing facilities. By 2024, GM's strategy had evolved to include a stronger emphasis on developing a resilient, scalable, and sustainable North American-focused EV supply chain. This included advancing strategic sourcing initiatives to secure supply through investments in raw materials suppliers and the execution of multi-year supply agreements. The shift indicates a more structured and regionally focused approach to EV manufacturing, aiming to mitigate supply chain risks and ensure long-term scalability.",
      "llm_answer": "\nBetween 2023 and 2024 GM shifted from a broad, aspirational declaration that it would “scale EV manufacturing capabilities, reduce battery‑cell costs and build a resilient, North‑American‑focused supply chain” to concrete actions: it began securing multi‑year off‑take agreements and increasing inventory of critical battery materials, while continuing to stress the need to align new EV capacity with slower‑than‑expected adoption and to keep production costs down.  The 2024 filing therefore reflects a more execution‑oriented strategy that ties EV‑capacity expansion to a secured, scalable supply chain and tighter cost controls.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in General Motors' EV manufacturing strategy between 2023 and 2024. It correctly identifies the shift from aspirational goals in 2023 (scaling EV capacity, building a resilient supply chain) to more concrete, execution-oriented actions in 2024, such as securing multi-year off-take agreements and increasing inventory of critical battery materials. This aligns with the ground truth's emphasis on strategic sourcing, supply chain resilience, and scalability. The answer also appropriately notes the context of slower-than-expected EV adoption, which is consistent with GM's 2024 risk disclosures about aligning capacity with demand. There are no numeric inaccuracies (quantitative accuracy is perfect, even though no specific numbers are cited), and all entities (GM, North American supply chain, battery materials) are correct. The reasoning is sound and reflects multi-hop synthesis between strategic intent and operational execution. The only minor shortcoming is that the LLM does not explicitly mention GM's investments in raw materials suppliers (e.g., joint ventures or equity stakes), which is a specific element in the original answer. While 'off-take agreements' and inventory buildup are part of the strategy, the absence of supplier investment nuance slightly reduces qualitative completeness. However, the overall semantic meaning and strategic trajectory are correctly conveyed, warranting a high correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 410,
        "total_tokens": 1764
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has Pfizer's financial commitment to Paxlovid evolved from 2022 to 2024, based on remaining performance obligations disclosed in the 10-K filings?",
      "original_answer": "In 2022, Pfizer's 10-K filing did not disclose specific remaining performance obligations related to Paxlovid. However, by 2024, Pfizer reported that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, indicating a significant ongoing financial commitment tied to future delivery of the product. This shows a clear evolution from an undefined obligation in 2022 to a quantified $1 billion commitment in 2024.",
      "llm_answer": "\nFrom 2022 through 2024 Pfizer’s remaining performance‑obligation exposure for Paxlovid fell sharply—​the 2022 filing disclosed sizable, multi‑year government contracts that implied billions of dollars of future deliveries, whereas the 2024 filing reports only about **$1 billion** of contracted revenue left to be recognized from those obligations (with the bulk of the earlier commitments already converted to commercial sales and revenue reversals for returned EUA courses). This decline reflects Pfizer’s transition from a pandemic‑driven, government‑procured supply model to a commercial market, signaling a markedly reduced financial commitment to Paxlovid by 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains a fundamental factual error in directionality: it claims Pfizer's financial commitment to Paxlovid 'fell sharply' from 2022 to 2024, implying a reduction in obligations. However, the ground truth states that in 2022, no specific remaining performance obligations for Paxlovid were disclosed, while in 2024, a $1 billion obligation was explicitly reported—indicating an evolution from undefined to quantified commitment, not a decline. This misrepresents the core trend. The $1 billion figure for 2024 is correctly stated (supporting partial quantitative accuracy), but the interpretation of earlier obligations is incorrect—2022 did not disclose 'sizable, multi-year contracts' for Paxlovid in the context of remaining performance obligations; such details are not present in the 10-Ks. The reasoning fails on multi-hop synthesis: instead of noting the emergence of a disclosed obligation where none existed before, the model incorrectly infers a decrease. While the answer addresses the transition to commercial markets, this contextual detail is speculative and not supported by the ground truth. Thus, despite some correct elements (e.g., $1B figure), the overall factual narrative is inverted, leading to a low correctness score. Quantitative accuracy is moderate due to the correct 2024 number but incorrect implications about prior amounts. Qualitative accuracy suffers from flawed logic and entity synthesis. Contextual relevance is fair as it discusses the right topic and timeframe but with misleading framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1284,
        "completion_tokens": 421,
        "total_tokens": 1705
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Caterpillar's approach to monitoring supplier financial viability evolved between 2022 and 2023, particularly in terms of risk mitigation strategies and contractual agreements?",
      "original_answer": "In 2022, Caterpillar indicated that it uses 'a variety of agreements with suppliers to protect our intellectual property and processes to monitor and mitigate risks of the supply base causing a business disruption,' including monitoring supplier financial viability. By 2023, Caterpillar maintained the same monitoring approach but placed a more explicit emphasis on 'supplier financial viability' as a key risk factor, listing it as the first risk under its supply chain disclosures. Additionally, in 2023, Caterpillar reinforced its global strategic sourcing models to build long-term supplier relationships and leverage enterprise spend, suggesting a potentially more structured or prioritized focus on supplier financial health compared to 2022.",
      "llm_answer": "\nBetween 2022 and 2023 Caterpillar moved from a baseline credit‑review of suppliers to a more proactive, risk‑focused approach.  The company deepened its credit‑quality assessments and added contractual safeguards—such as stronger security interests, insurance requirements and financial‑covenant clauses—while also embedding explicit supply‑chain‑disruption language that triggers additional oversight when demand spikes or component shortages occur.  These steps reflect a shift toward broader, pre‑emptive risk‑mitigation and contingency planning for supplier financial viability.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in terms of factual content despite being contextually relevant to the question. (1) The original answer states that Caterpillar's approach in 2022 involved using supplier agreements to protect intellectual property and processes to monitor and mitigate supply base risks, including financial viability. In 2023, the company maintained the same monitoring approach but placed more explicit emphasis on 'supplier financial viability' as the first-listed risk and reinforced global strategic sourcing models. The LLM answer, however, claims Caterpillar moved from a 'baseline credit-review' to a 'more proactive, risk-focused approach' with new contractual safeguards like 'stronger security interests, insurance requirements, and financial-covenant clauses'—details not present in the original answer. These specific mechanisms (e.g., financial covenants, insurance mandates) are fabricated and not supported by the ground truth. (2) There are no numeric values in the question or answers, so quantitative accuracy is not applicable—scored as 10 by default. (3) The multi-hop reasoning is flawed: the LLM invents a transformation in strategy that isn't in the source material. The actual evolution was a shift in emphasis and disclosure order, not the implementation of new contractual tools or deeper credit assessments. (4) While the LLM addresses the question's theme—evolution in risk mitigation—it does so with factually incorrect details, leading to a low correctness and qualitative accuracy score. Contextual relevance is moderate because the response stays on topic and attempts to describe a strategic shift, albeit inaccurately.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 454,
        "total_tokens": 1797
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Visa's approach to Risk and Identity Solutions evolved between 2022 and 2024, particularly in terms of its strategic positioning and integration within its value-added services?",
      "original_answer": "In 2022, Visa positioned Risk and Identity Solutions as part of a broader set of value-added services aimed at supporting clients, but without detailed elaboration on specific capabilities or strategic direction. By 2024, Risk and Identity Solutions were embedded within a more structured value-added services framework, with a clear three-pillar strategy: (1) services for Visa transactions, (2) network-agnostic services for non-Visa transactions, and (3) services beyond payments. This evolution reflects a more strategic and comprehensive integration of Risk and Identity Solutions into Visa's broader service portfolio, with an emphasis on scalability and business outcomes.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2024 Visa shifted its Risk and Identity Solutions from a broad, “one‑of‑five” value‑added service to a dedicated, AI‑driven fraud‑prevention suite (Visa Protect, Deep Authorization, Risk Manager) that is tightly woven into its wider “network‑of‑networks” strategy and other offerings such as Visa Direct, Visa + and open‑banking APIs.  This evolution positions risk and identity as a core, cross‑network capability that underpins both security and new money‑movement flows, rather than a standalone product line.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies a strategic evolution in Visa's Risk and Identity Solutions between 2022 and 2024, aligning with the ground truth's core narrative of increased integration and strategic focus. The dates (fiscal 2022 to 2024) are accurate, and there are no numeric inaccuracies (quantitative accuracy is perfect). The answer captures the shift from a general value-added service to a more central, integrated role, which matches the ground truth's emphasis on deeper strategic positioning. However, the LLM introduces specific product names (Visa Protect, Deep Authorization, Risk Manager) and a 'network-of-networks' strategy that are not present in the original answer, potentially over-specifying details not supported by the ground truth. While these may be factually correct in context, they are not part of the verified knowledge graph response and distract from the actual three-pillar framework (Visa transactions, network-agnostic services, services beyond payments) that defines the 2024 strategy. The LLM also emphasizes AI-driven capabilities and links to Visa Direct, Visa+, and open banking APIs—details absent in the original, making the response less semantically equivalent despite capturing the general direction. The reasoning is logical and multi-hop synthesis is partially sound, but the failure to reflect the structured three-pillar strategy reduces qualitative accuracy. Contextual relevance remains high as the answer directly addresses the evolution in strategic positioning and integration.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 420,
        "total_tokens": 1735
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has the company's exposure to shelf space limitations as a risk factor evolved between 2022 and 2023, particularly in relation to changes in retail customer policies and the expansion of alternative retail channels?",
      "original_answer": "In 2022, the company noted that it had been and could continue to be negatively affected by changes in retail customer policies such as limitations on access to shelf space and delisting of products. By 2023, the company was actively impacted by these limitations and described them as part of a broader set of evolving retail dynamics, including the growth of eCommerce and alternative retail channels such as subscription services and direct-to-consumer businesses. This evolution indicates a shift from potential risk to an actively experienced challenge, with the company planning to invest more in digital and analytics capabilities to adapt.",
      "llm_answer": "\nBetween 2022 and 2023 the company’s exposure to shelf‑space risk did not diminish – it evolved.  In 2022 the primary concern was the growing leverage of a few key brick‑and‑mortar retailers, with threats of reduced shelf space, delistings, higher trade discounts and the early rise of e‑commerce and private‑label competition.  By 2023 the risk broadened as retailers intensified demands over shelf‑space, inventory, sustainability and packaging standards, while alternative channels—especially rapid e‑commerce growth, subscription services and direct‑to‑consumer platforms—expanded dramatically, creating new pricing pressures and the possibility of further delistings.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution of shelf space limitations from a potential risk in 2022 to an actively experienced challenge in 2023, noting increased retailer demands and the expansion of alternative channels like e-commerce, subscription services, and direct-to-consumer platforms—consistent with the original answer. (2) There are no numeric values to verify, so quantitative accuracy is not applicable; however, all years (2022, 2023) are correct, satisfying this criterion. (3) The multi-hop reasoning is sound: the model synthesizes changes over time in retail dynamics, connects shelf space risks to broader retail policy changes, and links them to the growth of alternative channels. The only minor shortcoming is that the LLM does not explicitly mention the company’s planned response (investing in digital and analytics capabilities), which is part of the ground truth, slightly reducing completeness. (4) Despite this omission, the answer remains contextually rich, factually correct, and fully relevant to the question about the evolution of shelf space risk. Wording differs but semantic meaning is equivalent. Thus, correctness is high but not perfect—justifying a 9/10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 353,
        "total_tokens": 1701
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Oracle's approach to hybrid deployments evolved between fiscal years 2023 and 2024, particularly in terms of product offerings and strategic emphasis?",
      "original_answer": "In fiscal 2023, Oracle emphasized hybrid deployments as part of its broader deployment models, including on-premise, cloud-based, and hybrid options such as Oracle Exadata Cloud@Customer and Dedicated Region offerings. The company highlighted its commitment to providing customers with choice and flexibility in how they deploy Oracle technologies. By fiscal 2024, Oracle continued to support hybrid deployments but introduced more specific product integrations and services tailored for hybrid environments, indicating a strategic shift toward deeper integration and support for customer-managed cloud and on-premise IT environments. This evolution reflects Oracle's ongoing investment in making hybrid deployments more interoperable and extensible with other IT and cloud environments.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 Oracle shifted hybrid from a “choice‑and‑flexibility” positioning to a central growth pillar.  In 2023 it highlighted hybrid options such as Exadata Cloud@Customer, Dedicated Regions and multicloud connectivity, and introduced programs to help customers pivot existing licenses to the Oracle Cloud.  By 2024 the company broadened that portfolio (e.g., expanded OCI services, AI‑driven Autonomous Database, subscription‑based SaaS) and explicitly tied hybrid adoption to revenue growth—cloud‑services revenue rose from 25 % to 37 % of total sales—signaling a strategic emphasis on accelerating customer migration and multi‑cloud interoperability as a driver of future earnings.",
      "correctness_score": 6,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of Oracle's hybrid deployment strategy from fiscal 2023 to 2024, correctly identifying key offerings like Exadata Cloud@Customer and Dedicated Regions, and noting a strategic shift toward deeper hybrid integration. However, it introduces significant quantitative inaccuracies: the claim that cloud services revenue rose from 25% to 37% of total sales between FY2023 and FY2024 is not supported by the ground truth and cannot be verified from the provided knowledge graph. This is a critical factual error that undermines the answer's reliability. Additionally, the LLM mentions 'AI-driven Autonomous Database' and 'subscription-based SaaS' as new FY2024 offerings without grounding in the original answer, which does not reference these specific product expansions. While the qualitative shift toward treating hybrid as a 'central growth pillar' aligns with the original answer's notion of increased strategic emphasis, the framing is more assertive and includes unsupported financial metrics. The reasoning is logically coherent and contextually relevant, synthesizing the multi-hop requirement of comparing two fiscal years' strategies, but the inclusion of unverified numerical data and product details reduces factual correctness. Semantic equivalence is partially achieved, but not fully due to the fabricated statistics and over-specific claims not present in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 393,
        "total_tokens": 1771
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Pfizer's financial commitment to Paxlovid evolved between 2022 and 2024, based on remaining performance obligations and contracted revenue expectations?",
      "original_answer": "In 2022, Pfizer indicated that Paxlovid had the potential to provide ongoing revenue streams, though it acknowledged that post-pandemic revenues might not match the levels seen during the pandemic. By 2024, Pfizer reported that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, with contracted revenue expected to be recognized from 2025 through 2028. This reflects a continued but reduced financial commitment compared to the pandemic period, as the company anticipates delivery and revenue recognition over a multi-year horizon rather than immediate high-volume sales.",
      "llm_answer": "\nBetween 2022 and 2024 Pfizer’s financial exposure to Paxlovid fell sharply.  In 2022 the drug generated ≈ $19 billion of revenue and was part of a roughly $4 billion portfolio of remaining performance obligations for Comirnaty + Paxlovid, implying sizable future contract volumes.  By the 2024 filing the company reports only about $1 billion of contracted revenue left to be recognized from Paxlovid‑related long‑term orders (to be earned through 2025‑2028), reflecting the transition from government‑procured EUA supply to commercial‑market sales and a corresponding reduction in expected future cash inflows.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. The ground truth states that in 2022, Pfizer did not report a specific revenue figure for Paxlovid in the context of remaining performance obligations or future expectations—it only noted potential ongoing revenue with lower post-pandemic expectations. However, the LLM claims Paxlovid generated ≈$19 billion in revenue in 2022 and was part of a $4 billion portfolio of remaining performance obligations for Comirnaty + Paxlovid. These figures are not supported by the ground truth and introduce false precision and incorrect aggregation. The $19B revenue number, while plausible in context of Pfizer's actual 2022 Paxlovid sales (which were ~$18.9B globally), is not mentioned in the original answer and is used here to imply a baseline for performance obligations, which distorts the focus of the question. More critically, the $4B 'portfolio' of remaining obligations for Comirnaty + Paxlovid is not present in the ground truth, which only mentions a $1B figure for Paxlovid alone as of 2024. (2) The only correct quantitative element is the $1 billion remaining performance obligation for Paxlovid as of December 31, 2024, with revenue expected to be recognized from 2025 through 2028—this matches the original answer exactly and is correctly interpreted. (3) The reasoning is partially sound in identifying a trend of declining financial commitment and transitioning from government to commercial markets, which aligns with the qualitative shift described in the ground truth. However, the multi-hop synthesis is flawed because it invents a 2022 performance obligation figure that isn't in the source, leading to an incorrect comparison. The conclusion about reduced future cash inflows is reasonable but based on fabricated premises. (4) Contextual relevance is high—the answer addresses the evolution of financial commitment, references performance obligations and revenue recognition timelines, and interprets the shift in market dynamics. However, due to major quantitative inaccuracies and unsupported figures, the correctness score is low. The answer creates a misleading narrative despite capturing the general direction of change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1312,
        "completion_tokens": 603,
        "total_tokens": 1916
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has Caterpillar's relationship with its independent dealers evolved between 2022 and 2023, particularly in terms of contractual obligations and strategic emphasis?",
      "original_answer": "In 2022, Caterpillar described its relationship with independent dealers in general terms as part of its global sales and marketing strategy. By 2023, the company formalized and detailed these relationships through standardized sales and service agreements, granting dealers the right to purchase, sell, and service Caterpillar products within specified territories. In exchange, dealers were obligated to develop and promote Caterpillar products, maintain adequate sales and support personnel, and keep detailed financial records accessible to Caterpillar. This represents a shift from a general partnership model to a more structured contractual framework, indicating a strategic emphasis on formalizing dealer relationships to enhance control and accountability.",
      "llm_answer": "\nBetween 2022 and 2023 the basic dealer contract – a standard sales‑and‑service agreement that grants territorial rights, obligates dealers to promote and sell Caterpillar products, maintain inventory and financial records, and receive price‑setting, IP‑defense and warranty support from the company, with either party able to terminate on 90‑day notice – remained unchanged.  However, the 2023 filing places a stronger strategic emphasis on collaborative marketing and financing programs (e.g., revenue‑sharing incentives and dealer‑driven product‑improvement initiatives) and on the dealer’s role in expanding Caterpillar’s global market presence, while still requiring the same core contractual duties of sales‑force staffing, record‑keeping and data sharing.  In short, the contractual framework is stable, but the company is now highlighting a more partnership‑focused, dealer‑centric growth agenda.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains a significant factual inaccuracy that undermines its overall correctness. (1) The LLM claims that the 'basic dealer contract' and 'standard sales-and-service agreement' remained unchanged between 2022 and 2023, stating that the contractual framework is 'stable.' This directly contradicts the ground truth, which indicates a clear evolution from a general partnership model in 2022 to a more formalized, structured contractual framework in 2023 through standardized agreements. The ground truth emphasizes a shift toward formalization, enhanced control, and accountability—whereas the LLM asserts contractual continuity. (2) There are no numeric values, dates, or calculations in either answer, so quantitative accuracy is not applicable; the LLM does not introduce any incorrect numbers, so it scores highly on that dimension. (3) The multi-hop reasoning is flawed: the question asks about evolution in contractual obligations and strategic emphasis, requiring comparison across years. The LLM correctly identifies the strategic emphasis shift toward collaboration and growth in 2023 but incorrectly negates any contractual change, failing to reflect the key evolution in contractual structure. (4) While the LLM captures the increased strategic emphasis on dealers as growth partners (contextually relevant), it misses the core factual development—formalization of contracts—which is central to the ground truth. Thus, despite accurate terminology and plausible details, the answer is factually incorrect on the key point of contractual evolution, warranting a mid-range score of 5 for correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1422,
        "completion_tokens": 454,
        "total_tokens": 1877
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How did the company's financial allocation or operational focus related to Africa/Eurasia evolve from 2022 to 2023, based on capital expenditures and restructuring charges?",
      "original_answer": "In 2022, the company reported capital expenditures for Africa/Eurasia at $33 million, showing a steady increase from $13 million in 2021 and $8 million in 2020. However, in 2023, the company indicated that approximately 10% of the cumulative pretax charges from the 2022 Global Productivity Initiative would relate to initiatives undertaken in Africa/Eurasia, signaling a shift in focus toward restructuring and cost optimization in the region rather than continued capital investment. This reflects a strategic evolution from growth-oriented capital allocation to operational restructuring within Africa/Eurasia.",
      "llm_answer": "\nFrom 2022 to 2023 the company pulled back sharply on the resources it devoted to Africa/Eurasia.  The 2022 Global Productivity Initiative recorded $110 million of pretax restructuring charges in 2022, but only $32 million of pretax charges in 2023—a drop of roughly 70 percent—reflecting a smaller allocation of implementation costs to the region (consistent with the 10 percent share of cumulative charges earmarked for Africa/Eurasia).  Accordingly, while early‑year capital‑expenditure data show modest growth in the region, the later‑year pull‑back in restructuring spend signals a reduced operational focus on Africa/Eurasia in favor of other segments.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While the ground truth states that Africa/Eurasia had $33 million in capital expenditures in 2022 and no data for 2023, the LLM incorrectly claims 'early-year capital-expenditure data show modest growth' without citing actual capex figures for 2023 or confirming a trend. More critically, the LLM misrepresents restructuring charges: it claims $110 million in 2022 and $32 million in 2023, but the original answer does not provide annual restructuring charges for Africa/Eurasia—only that 10% of the *cumulative* charges from the 2022 Global Productivity Initiative relate to Africa/Eurasia. The LLM fabricates year-specific regional restructuring costs not present in the ground truth. (2) The calculation of a '70 percent drop' is based on these invented numbers and is therefore incorrect. The 10% figure is correctly referenced, but its context (cumulative charges) is misrepresented. (3) The multi-hop reasoning is partially sound in linking restructuring focus to reduced capital investment, but the logic is built on false quantitative premises. The strategic shift from growth (capex) to restructuring is mentioned in the original answer, but the LLM reverses the emphasis—focusing on declining restructuring spend rather than declining capex or a shift from investment to cost-cutting. (4) The contextual relevance is moderate because the answer addresses the region and the time frame, and attempts to interpret strategic intent. However, due to major quantitative errors and misrepresentation of the data, the correctness score is low. The qualitative accuracy is limited by incorrect entity relationships and synthesis. Quantitative accuracy is poor due to fabricated numbers and incorrect calculations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 485,
        "total_tokens": 1810
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has Qualcomm's strategic focus on 5G technologies evolved from 2022 to 2024, particularly in terms of investment emphasis and commercialization outcomes?",
      "original_answer": "In 2022, Qualcomm was heavily investing in 5G technologies as part of its broader strategy to expand beyond mobile handsets into areas like automotive and IoT, with an emphasis on developing leading and cost-effective 5G-based technologies and products. The company acknowledged significant risks around the success of these investments due to potential regulatory hurdles, competition, and the long design-in cycles typical of new industries like automotive. By 2024, Qualcomm had transitioned from a primarily investment phase to a more mature stage where it had developed a leading patent portfolio in 5G NR and was actively licensing these technologies. The company reported generating the majority of its QTL revenues from OFDMA-based products, including multimode 3G/4G/5G devices such as smartphones, indicating a successful commercialization phase. This shift shows that Qualcomm moved from strategic investment and development in 5G across multiple industries to a position of market leadership and monetization in 5G technologies.",
      "llm_answer": "\nFrom 2022 to 2024 Qualcomm shifted its 5G strategy from a handset‑centric push—focused on securing modem, RF front‑end and patent‑licensing leadership for premium smartphones—to a cross‑industry agenda that embeds 5G in automotive, IoT and AI‑enabled platforms.  The company increased R&D and capital spending on 5G‑standard‑essential patents and new 5G‑centric product families (e.g., Snapdragon 5G modem‑RF, RFFE modules) while expanding licensing of 5G‑related IP beyond smartphones, leading to broader commercial deployments in non‑handset markets and higher royalty revenues from 5G‑related licenses.  (2022 10‑K pp. 19‑23; 2024 10‑K pp. 11‑15)",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures Qualcomm's strategic evolution from a handset-centric 5G focus in 2022 to broader cross-industry commercialization by 2024, including automotive, IoT, and AI-enabled platforms. The emphasis on R&D investment in 5G standard-essential patents and product families like Snapdragon 5G modem-RF and RFFE modules matches the original answer’s theme of investment in leading and cost-effective 5G technologies. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not compromised—score is 10. (3) The multi-hop reasoning is sound: the LLM synthesizes information across 2022 and 2024 timeframes, correctly identifying the shift from investment/development to commercialization and monetization via expanded IP licensing and royalty growth. The mention of increased royalty revenues from 5G-related licenses aligns with the original answer’s point about QTL revenues being primarily from OFDMA-based 5G products. (4) Minor omission: the LLM does not explicitly mention the 'risks' Qualcomm acknowledged in 2022 (regulatory, competition, long design-in cycles), which is a small but relevant part of the strategic context. However, this does not undermine the core accuracy. Wording differs but semantic meaning is equivalent. Contextual relevance is perfect—directly addresses investment emphasis and commercialization outcomes as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1425,
        "completion_tokens": 413,
        "total_tokens": 1839
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has Pfizer's financial and strategic positioning of Paxlovid evolved between 2022 and 2024, particularly in terms of revenue contribution and contractual commitments?",
      "original_answer": "In 2022, Paxlovid generated $76 million in revenue, marking its initial contribution as a newly launched product targeting high-risk COVID-19 patients. By 2024, while direct revenue figures for Paxlovid are not explicitly stated, Pfizer disclosed approximately $1 billion in remaining performance obligations tied to future Paxlovid deliveries under existing contracts. This indicates a strategic shift from initial market entry to securing longer-term contractual commitments, despite potential market or regulatory challenges reflected in the context of government returns and adjustments in 2024.",
      "llm_answer": "\nBetween 2022 and 2024 Paxlovid’s revenue share fell sharply – from **$18.9 bn in 2022** to **$1.3 bn in 2023** and then modestly rebounded to **$5.7 bn in 2024** as the product moved from government‑procured EUA sales to commercial market sales.  The 2023‑24 period included a **$3.5 bn non‑cash revenue reversal** (later adjusted by a **$771 m favorable adjustment** in early 2024) reflecting returns of U.S. government inventory, and the company now reports **≈ $1 bn of remaining performance‑obligation revenue** for Paxlovid that will be recognized through 2028, with about **$2.2 bn of deferred revenue** still on the books as of Dec 31 2024.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states Paxlovid generated $76 million in revenue in 2022, but the LLM claims $18.9 billion — a massive overstatement by over 240x. The LLM also reports $1.3 billion in 2023 and $5.7 billion in 2024, none of which are supported by the original answer, which does not provide 2023 or 2024 revenue figures at all. While the LLM correctly identifies approximately $1 billion in remaining performance obligations for Paxlovid as of 2024, aligning with the ground truth, it adds unsupported details such as $2.2 billion in deferred revenue as of Dec 31, 2024, and a $3.5 billion non-cash revenue reversal with a $771 million favorable adjustment — none of which appear in the original answer. (2) Quantitative accuracy is extremely low: only the $1 billion remaining performance obligation matches the ground truth; all other figures are fabricated or grossly incorrect. The timeline of revenue figures and adjustments is not corroborated and contradicts the original data. (3) The multi-hop reasoning is flawed. The original answer describes a strategic shift from initial launch to contractual commitments, but the LLM invents a narrative about a sharp revenue decline and rebound, government inventory returns, and commercial transition with specific financial adjustments not present in the ground truth. This reflects a failure to accurately synthesize or report the actual evolution. (4) Contextual relevance is moderate because the LLM addresses revenue trends and contractual commitments as asked, and correctly notes the $1 billion in remaining obligations. However, due to severe factual and quantitative errors, the overall correctness score is very low. The answer creates a plausible-sounding but factually incorrect narrative, failing the core requirement of fidelity to the source data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 510,
        "total_tokens": 1827
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has the company's exposure to credit market tightness as a supply chain risk evolved between 2022 and 2023, and what does this indicate about its changing vulnerability to external financial conditions?",
      "original_answer": "In 2022, tighter credit or capital markets were described as a risk that 'negatively impacts' suppliers, with a direct concern that this could disrupt the supply of raw and packaging materials. By 2023, the framing shifted to indicate that the company's operations are 'impacted by' these conditions, suggesting a broader recognition of ongoing vulnerability. This evolution reflects a continuation of concern over credit market conditions but with a more integrated perspective on how such financial constraints affect not just suppliers, but the company's overall supply chain resilience.",
      "llm_answer": "\nBetween 2022 and 2023 the company’s discussion of supply‑chain risk evolved from a brief mention of “the impact on our suppliers of tighter credit or capital markets” to a more explicit and prominent warning that tightening credit and capital markets can directly disrupt the availability of key raw and packaging materials. This shift shows that the firm now views external financial conditions—not just operational or geopolitical shocks—as a material source of supply‑chain vulnerability, increasing its exposure to any further credit‑market stress.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly captures the evolution in the company's risk disclosure between 2022 and 2023 regarding credit market tightness as a supply chain risk. It accurately notes the shift from a focus on suppliers being impacted in 2022 to a more direct and explicit concern about disruption to raw and packaging materials in 2023. The interpretation that this reflects increased recognition of financial conditions as a material supply chain vulnerability aligns with the ground truth. However, the LLM slightly overstates the change by characterizing the 2022 mention as 'brief' and implying a stronger contrast than present in the original answer, which emphasizes continuity of concern but with a broader framing in 2023. The original answer notes the 2023 language reflects 'a more integrated perspective' rather than a wholly new or more severe risk. There are no numerical inaccuracies (quantitative accuracy is perfect), and all entities (years, risk types) are correct. The reasoning is sound but not perfectly aligned in nuance—hence a high but not top score on qualitative accuracy. Contextual relevance is excellent, fully addressing the question’s focus on evolution and implications for vulnerability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1300,
        "completion_tokens": 341,
        "total_tokens": 1641
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has Pfizer's financial commitment and contractual obligations related to Paxlovid evolved from 2022 to 2024, based on disclosed figures and agreements?",
      "original_answer": "In 2022, Paxlovid was under Emergency Use Authorization (EUA) in the U.S. and had received conditional marketing authorization (CMA) in the EU and full approval in Japan, indicating early-stage regulatory and commercial momentum. By 2024, Pfizer disclosed that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, reflecting firm orders from long-term contracts with customers. This shows a significant financial commitment to Paxlovid, with delivery expected from 2025 through 2028, subject to renegotiation. Additionally, 2024 included a $771 million favorable final adjustment related to a prior revenue reversal tied to Paxlovid EUA-labeled treatment courses returned by the U.S. government, indicating ongoing financial adjustments and evolving contractual dynamics.",
      "llm_answer": "\nFrom 2022 to 2024 Pfizer’s Paxlovid‑related financial commitments shifted dramatically: the drug generated $18.9 billion of revenue in 2022, but as government‑procured EUA supplies were wound down the company recorded a $3.5 billion non‑cash revenue reversal in Q4 2023 and only $1.28 billion of revenue in 2023. By the end of 2024 Paxlovid had returned to commercial sales, producing $5.7 billion of revenue, while remaining performance obligations totaled roughly $1 billion of contracted revenue (with about $2.2 billion of deferred revenue still on the books) that is expected to be recognized through 2025‑2028 as the company fulfills long‑term supply agreements. Thus, Pfizer’s fiscal exposure to Paxlovid moved from a peak of nearly $19 billion in 2022 to a much smaller, contract‑backed stream of about $1 billion plus deferred balances that will be realized over the next few years.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant quantitative inaccuracies that undermine its factual correctness. While it correctly identifies the $1 billion in remaining performance obligations for Paxlovid as of 2024 (matching the ground truth), it introduces several figures not present in the original answer: $18.9 billion revenue in 2022, $3.5 billion non-cash reversal in Q4 2023, $1.28 billion revenue in 2023, and $5.7 billion revenue in 2024. These specific revenue numbers and the $3.5 billion reversal are not supported by the ground truth, which only mentions a $771 million favorable adjustment in 2024 related to prior EUA returns — not a $3.5 billion reversal. The LLM also incorrectly states that $2.2 billion of deferred revenue remains, which is not in the original. While the model captures the general trend of declining government purchases and transition to long-term contracts with revenue recognition through 2025–2028, the detailed financial narrative is factually incorrect. The qualitative reasoning about evolving contractual dynamics and commercial shift is partially sound and contextually relevant, but the multi-hop synthesis fails because it fabricates key financial data rather than accurately reporting disclosed figures. The mention of regulatory status (EUA, CMA) from 2022 is missing in the LLM response, reducing completeness. Overall, the answer misrepresents the financial evolution due to incorrect numbers, though it attempts to address the question's scope.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1431,
        "completion_tokens": 408,
        "total_tokens": 1839
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How has the financial liability and risk exposure related to Aearo Technologies' respirator mask/asbestos litigation evolved from 2023 to 2024?",
      "original_answer": "In 2023, MMM had an accrual of $574 million for respirator mask/asbestos liabilities excluding Aearo, and Aearo was in bankruptcy proceedings, which resulted in a stay of litigation. By 2024, MMM, through Aearo, had accruals of $51 million specifically for Aearo-related asbestos, silica-related, and coal mine dust claims. Additionally, Aearo’s liability was limited by its agreement with Cabot, where Cabot assumed responsibility for claims involving exposure prior to January 1, 1997, as long as Aearo continued to pay a quarterly fee of $100,000. This represents a shift from a broader liability exposure under bankruptcy protection in 2023 to a more defined and limited liability framework in 2024, with Aearo actively managing its share of liability through contractual arrangements and cost-sharing with other co-defendants.",
      "llm_answer": "\nFrom 2023 to 2024 the Company’s recorded exposure to Aearo‑related respirator‑mask/asbestos liability fell slightly: the accrual for respirator‑mask/asbestos claims (excluding Aearo) dropped from **$574 million at 12/31/23 to $523 million at 12/31/24**, reflecting a **$36 million increase in accrual during 2024** (after a $57 million accrual increase in 2023).  Cash outflows for legal defense and settlements stayed roughly constant (~$88 million in 2023 and $87 million in 2024), and Aearo’s own accrual fell from **$62 million to $51 million** over the same period.  The Company continues to note that the ultimate liability may exceed these accruals because of inherent uncertainties—projected future claims through ~2050, joint‑and‑several liability among multiple defendants, and the difficulty of estimating an upper bound of exposure.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual and quantitative errors that undermine its correctness. (1) The original answer states that in 2023, 3M (MMM) had a $574 million accrual for respirator mask/asbestos liabilities *excluding* Aearo, while Aearo was in bankruptcy. In 2024, Aearo specifically had a $51 million accrual for its own asbestos, silica, and coal mine dust claims. However, the LLM incorrectly claims that the $574 million accrual dropped to $523 million by end of 2024, implying this is still *excluding* Aearo, which contradicts the timeline and misrepresents the evolution. Worse, it states there was a $36 million increase in accrual during 2024, which does not align with any figure in the ground truth. (2) The LLM invents a $62 million Aearo accrual in 2023 that is not present in the original answer—ground truth does not specify Aearo’s accrual in 2023, only that it was in bankruptcy. The drop to $51 million in 2024 is correct, but without a verified starting point, the comparison is invalid. (3) Cash outflows of ~$88M in 2023 and $87M in 2024 are fabricated and not in the original. (4) The contractual arrangement with Cabot—where Cabot assumes pre-1997 exposure liability in exchange for a $100,000 quarterly fee—is entirely omitted, which is a key qualitative shift in risk exposure from 2023 to 2024. (5) The LLM incorrectly frames the overall trend as a slight decrease in exposure, while the ground truth describes a structural shift from bankruptcy stay to active, limited liability management via agreements. Thus, while the answer addresses the general topic and mentions Aearo’s reduced accrual, it fails on core facts, invents numbers, omits critical contractual context, and misrepresents the nature of the liability evolution. Quantitative accuracy is very low due to fabricated figures and incorrect calculations. Qualitative accuracy is poor due to missing multi-hop synthesis (Aearo’s relationship with Cabot, change in legal status). Contextual relevance is moderate because it attempts to compare 2023–2024 liabilities, but with incorrect data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1418,
        "completion_tokens": 559,
        "total_tokens": 1977
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How did the retail share of Skoal, a product of MO, change between 2023 and 2024, and how does this compare to its shipment volume trend between 2020 and 2021?",
      "original_answer": "The retail share of Skoal decreased from 9.3% in 2023 to 7.6% in 2024, indicating a decline in market presence. In contrast, Skoal's shipment volume was also declining between 2020 and 2021, dropping from 208.5 million packs/cans in 2020 to 197.4 million packs/cans in 2021. Both metrics show a consistent downward trend, suggesting a potential long-term challenge for the product's performance in the market.",
      "llm_answer": "\nThe retail‑share of Skoal fell from **9.3 % in 2023 to 7.6 % in 2024**, a drop of about **1.7 percentage points** (≈18 % relative decline).  \nBy contrast, Skoal’s shipment volume was **208.5 million units in 2020 and 197.4 million units in 2021**, a reduction of roughly **5 %** over that earlier period.  \nThus, both share and volume have been trending downward, but the decline in retail share between 2023 and 2024 is larger in relative terms than the 2020‑21 shipment‑volume dip.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all factual information from the ground truth. The retail share of Skoal decreased from 9.3% in 2023 to 7.6% in 2024, which matches the original answer. Shipment volume declined from 208.5 million units in 2020 to 197.4 million in 2021, also accurately reflected. (2) Quantitative accuracy is perfect: the absolute drop of 1.7 percentage points and the approximate 5% decline in shipment volume are correctly calculated. The relative decline of ~18% in retail share (from 9.3% to 7.6%) is a valid interpretation and adds analytical value without distorting facts. (3) Multi-hop reasoning is sound: the model correctly synthesizes data across two different time periods (2023–2024 for retail share, 2020–2021 for shipments) and draws a valid comparison between the trends, noting that both metrics are declining but with a stronger relative drop in the later retail share. (4) The answer is semantically equivalent to the original, with added clarity in quantifying the relative changes. All entities—Skoal, MO (implied), correct years, and metrics—are accurately referenced. No factual, numerical, or logical errors are present, and the response fully addresses both parts of the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1226,
        "completion_tokens": 349,
        "total_tokens": 1575
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How has Qualcomm's approach to multimedia technologies evolved from 2022 to 2024, particularly in terms of engineering focus areas and integration into product offerings?",
      "original_answer": "In 2022, Qualcomm emphasized engineering expertise in multimedia technologies such as camera, video, display, and computer vision as part of a broader set of capabilities including modem, RF, and sensor perception technologies. The focus was on enhancing existing products and developing new technologies for industries beyond mobile handsets, such as automotive and IoT. By 2024, the company's description of its multimedia technology efforts remained consistent, but there was a notable expansion in the integration of AI, particularly generative AI, into its research and development strategy. Additionally, in 2024, Qualcomm placed greater emphasis on enabling developers to design and deploy applications across multiple device categories and industries, signaling a more deliberate diversification strategy. This evolution reflects a shift from primarily hardware-centric multimedia innovation in 2022 to a more platform-oriented, AI-enhanced approach by 2024.",
      "llm_answer": "\nFrom 2022 to 2024 Qualcomm moved its multimedia engineering focus from a primarily camera‑video‑display pipeline toward a full‑stack, AI‑enabled multimedia platform.  The company added dedicated NPU/GPU engines, sensor‑perception and computer‑vision capabilities, and integrated these functions into Snapdragon SoCs that now serve smartphones as well as automotive, IoT and XR devices, reflecting a broader R&D investment in AI‑driven multimedia and tighter integration of multimedia, connectivity and AI across its QCT product offerings.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution in Qualcomm's multimedia technology strategy from 2022 to 2024. It accurately reflects the shift from a hardware-centric, camera-video-display focus to a more integrated, AI-enhanced, full-stack platform approach. The mention of NPU/GPU engines, sensor perception, and computer vision aligns with the original answer's emphasis on engineering expertise in these areas. The integration into Snapdragon SoCs and expansion into automotive, IoT, and XR (extended reality) correctly reflects the diversification beyond mobile handsets. However, the LLM answer omits the specific 2024 emphasis on generative AI and enabling developers to deploy applications across industries, which are key qualitative shifts highlighted in the ground truth. While 'AI-driven multimedia' is mentioned, the absence of 'generative AI' as a distinct 2024 development is a minor but notable omission. There are no numerical inaccuracies (quantitative accuracy is perfect as no incorrect numbers are present), and the contextual relevance is strong—directly addressing the question's focus on engineering and product integration evolution. The reasoning is sound but slightly less precise in capturing the platform-oriented developer strategy shift. Thus, the answer is factually solid but lacks full completeness on the 2024 strategic nuances.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 382,
        "total_tokens": 1764
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How did 3M's financial relationship with the Aearo Entities evolve between 2023 and 2024, particularly in terms of equity investment and intercompany balances?",
      "original_answer": "In 2023, 3M reconsolidated the Aearo Entities, which resulted in the removal of a $0.7 billion asset balance in equity and other investments and a $0.6 billion net liability for former intercompany amounts from its consolidated balance sheet as of December 31, 2023. By 2024, the Aearo Entities were no longer consolidated, and instead, 3M now 'has a stake in' them, indicating a shift from full consolidation to a retained equity interest. This reflects a significant change in the financial structure and relationship between 3M and the Aearo Entities.",
      "llm_answer": "\nAfter the June 2023 dismissal of the Aearo Entities’ Chapter 11 filing, 3M re‑consolidated those entities in the second quarter of 2023.  As of December 31 2023 the company disclosed a $0.7 billion equity‑investment balance in “other assets” and a $0.6 billion net inter‑company liability (shown in other liabilities/other assets) representing amounts due from 3M to the former de‑consolidated entities.  These balances remained on the consolidated balance sheet through 2024, with no material change reported, indicating that 3M’s equity stake and the related intercompany receivable/payable persisted unchanged after the reconsolidation.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual and directional errors that contradict the ground truth. (1) Quantitatively, while the $0.7 billion equity investment and $0.6 billion intercompany liability figures are correctly stated, their treatment is reversed in meaning: the ground truth states these balances were *removed* from the balance sheet upon reconsolidation in 2023, whereas the LLM claims they *remained* on the balance sheet through 2024. This is a critical error in financial interpretation. (2) The answer fails on completeness and reasoning: it incorrectly asserts that the balances 'persisted unchanged after reconsolidation,' directly contradicting the original answer that these amounts were *removed* as of December 31, 2023 due to reconsolidation. (3) Entity and temporal accuracy are partially correct—the Aearo Entities and 2023 reconsolidation are correctly identified, and the June 2023 Chapter 11 dismissal context adds detail not in the original but may be accurate. However, the core financial consequence is inverted: reconsolidation led to elimination of the equity and intercompany balances, not their continuation. (4) By 2024, the relationship shifted to a retained equity stake without consolidation, but the LLM incorrectly implies full consolidation continued with unchanged balances. Thus, despite some correct inputs, the synthesis and conclusion are fundamentally flawed, leading to a low correctness score. The answer is contextually relevant in discussing the right entities and metrics but conveys the opposite financial reality.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 429,
        "total_tokens": 1730
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How has Visa's Risk and Identity Solutions evolved between 2022 and 2024, particularly in terms of their strategic positioning within the company's broader value-added services portfolio?",
      "original_answer": "In 2022, Visa's Risk and Identity Solutions were described as tools that 'transform data into insights for near real-time decisions' and included named products like Visa Advanced Authorization and Visa Secure. These solutions were positioned primarily around fraud prevention and payment security, with an emphasis on helping clients protect account holder data and prevent fraud in the context of omnichannel commerce. By 2024, Risk and Identity Solutions had been elevated as one of five core categories within a more expansive value-added services portfolio that now includes Open Banking Solutions and Advisory Services. The 2024 report highlights that Visa offered more than 200 products and services as of September 30, 2024, many designed to work together for 'high impact business outcomes,' indicating a broader strategic integration of Risk and Identity Solutions within a more diversified services ecosystem.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2024 Visa’s Risk and Identity Solutions shifted from a set of discrete fraud‑prevention tools (e.g., Visa Advanced Authorization, Visa Secure, Advanced Identity Score, CardinalCommerce) to an integrated, AI‑driven “Visa Protect” suite that spans card‑present, card‑not‑present and real‑time account‑to‑account payments.  This evolution positions the solutions as a core component of Visa’s broader Value‑Added Services portfolio, reinforcing the company’s “network‑of‑networks” strategy and enabling monetisation of new money‑movement flows such as B2B, cross‑border and tokenised transactions.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of Visa's Risk and Identity Solutions from fraud-focused tools to a more integrated strategic offering within the value-added services portfolio, which aligns with the ground truth. It correctly identifies key products like Visa Advanced Authorization and Visa Secure (though it adds 'Advanced Identity Score' and 'CardinalCommerce' not mentioned in the original). The mention of AI-driven 'Visa Protect' suite and integration across payment types reflects a plausible extension of the trend but is not supported in the original answer—'Visa Protect' is not referenced in the ground truth, nor is the specific framing around 'network-of-networks' or monetization of B2B/cross-border flows. The original emphasizes structural repositioning (one of five core categories in 2024) and the expansion to over 200 services by September 30, 2024—this quantitative milestone is missing in the LLM response. While the LLM conveys strategic integration, it introduces unverified branding and use cases. Quantitatively, no incorrect numbers are stated (no false figures for revenue, product count, or dates), so accuracy is high in that regard. However, the qualitative synthesis misses the actual organizational shift described (e.g., inclusion alongside Open Banking and Advisory Services) and overreaches with specific suite naming and strategic framing not present in the source. Contextually, the answer remains highly relevant and addresses the core of the question—evolution and strategic positioning—but with some speculative embellishment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1396,
        "completion_tokens": 431,
        "total_tokens": 1828
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How did RTX's disclosure and quantification of Acquisition Accounting Adjustments' impact on operating profit evolve between 2023 and 2024?",
      "original_answer": "In 2023, RTX provided specific quantified impacts of Acquisition Accounting Adjustments on operating profit, showing a negative impact of $1,998 million in 2023, compared to $1,893 million in 2022 and $2,203 million in 2021. By 2024, RTX shifted its disclosure approach by providing qualitative policy context about the components of these adjustments, but did not include updated quantitative figures for the current year's impact on operating profit. This represents a move from concrete numerical disclosure to a more conceptual explanation of acquisition accounting practices without continuing the year-over-year quantification.",
      "llm_answer": "\nIn its 2023 filing RTX disclosed acquisition‑accounting adjustments that reduced consolidated operating profit by **$1.998 bn** – $854 m from Collins Aerospace, $287 m from Pratt & Whitney and $857 m from Raytheon – mainly consisting of amortization of acquired intangibles, PP&E fair‑value adjustments and customer‑contractual obligations. The 2024 filing reports a slightly larger negative impact of **$2.058 bn**, with the same three components now broken out as $833 m (Collins), $312 m (Pratt & Whitney) and $913 m (Raytheon), reflecting higher amortization of intangibles and PP&E fair‑value write‑ups. Thus, while the composition of the adjustments stayed consistent, the magnitude of the profit drag grew modestly from 2023 to 2024, and the disclosure added a more detailed segment‑level breakdown and a note that these charges are excluded from management’s performance evaluation.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both quantitative and qualitative aspects. (1) Quantitative Accuracy: The ground truth states that RTX disclosed a $1,998 million negative impact in 2023 but did *not* provide updated quantitative figures for 2024. However, the LLM claims a specific 2024 impact of $2.058 billion with detailed segment breakdowns—this data is entirely fabricated and contradicts the original answer. The numbers for 2024 (e.g., $833M, $312M, $913M) do not exist in the ground truth and are therefore false. (2) Completeness: The question asks how the *disclosure and quantification* evolved between 2023 and 2024. The LLM fails to note the key shift from quantitative to qualitative disclosure in 2024, instead asserting continued numerical disclosure, which is the opposite of the truth. (3) Entity Accuracy: While company names (Collins, Pratt & Whitney, Raytheon) and the concept of acquisition accounting adjustments are correctly identified, the attribution of 2024 figures to them is erroneous. (4) Reasoning: The multi-hop reasoning is flawed—the model incorrectly infers that because 2023 had detailed numbers, 2024 must have too, and even constructs a plausible-sounding but false trend. It misses the core evolution: the *cessation* of quantitative disclosure. (5) Semantic Equivalence: The LLM answer suggests increasing precision and continuity in reporting, while the truth is a move away from quantification. This is a direct contradiction. The only correct element is the 2023 total impact ($1,998 million), though even this is presented with a breakdown not confirmed in the ground truth. Thus, the answer is mostly incorrect, with significant factual and interpretive errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 466,
        "total_tokens": 1845
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How has Microsoft's Office 365 Commercial revenue contribution to the Microsoft Cloud evolved between fiscal years 2022 and 2023, and what does this indicate about its growth trajectory within the broader cloud ecosystem?",
      "original_answer": "In fiscal year 2022, Office 365 Commercial was explicitly cited as a key growth driver within the Productivity and Business Processes segment, contributing to an 18% overall revenue increase for the company. By fiscal year 2023, Office 365 Commercial was included in a newly disclosed consolidated Microsoft Cloud revenue figure, which reached $111.6 billion in FY2023, up from $91.4 billion in FY2022. This indicates that Office 365 Commercial continued to grow as part of a broader, increasingly transparent cloud revenue portfolio that now includes Azure, LinkedIn (commercial portion), Dynamics 365, and other cloud services.",
      "llm_answer": "\nBetween fiscal 2022 and fiscal 2023 Microsoft Cloud revenue rose from **$91.4 billion to $111.6 billion**, and the Office 365 Commercial business—identified in the filings as a core component of that cloud revenue—posted double‑digit growth (≈ 18 % YoY).  Consequently, the share of Microsoft Cloud attributable to Office 365 Commercial increased modestly, highlighting that Office 365 Commercial is not only expanding in absolute dollars but also becoming an increasingly dominant driver of Microsoft’s overall cloud growth trajectory.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "1) The LLM answer correctly reports the Microsoft Cloud revenue figures for FY2022 ($91.4 billion) and FY2023 ($111.6 billion), which aligns with the ground truth. It also correctly identifies Office 365 Commercial as a core component of Microsoft Cloud revenue. However, it introduces a specific growth rate of '≈18% YoY' for Office 365 Commercial in FY2023, which is not stated in the original answer or supported by the provided ground truth. The 18% figure in the ground truth refers to the overall revenue increase for Microsoft in FY2022 (not Office 365 Commercial growth in FY2023), so this is a misattribution.\n\n2) The quantitative values for total Microsoft Cloud revenue are accurate and correctly formatted. The $91.4B to $111.6B increase is correctly stated. However, the ≈18% YoY growth claim for Office 365 Commercial is unsupported by the ground truth and appears to be an incorrect inference from the 18% overall company revenue growth in FY2022. This is a significant factual error, though the dollar amounts themselves are correct.\n\n3) The reasoning is partially flawed. The LLM concludes that the 'share of Microsoft Cloud attributable to Office 365 Commercial increased modestly,' but the ground truth does not provide any data on changing share or proportion—only that Office 365 Commercial is included in the consolidated cloud figure. There is no evidence in the original answer to support a claim about increasing share or dominance. This represents a logical overreach not justified by the source material.\n\n4) The answer is contextually relevant and addresses the evolution of Office 365 Commercial's role in Microsoft Cloud revenue. It correctly notes the shift to consolidated reporting. However, the unsupported growth rate and the erroneous conclusion about increasing share reduce factual accuracy. While the direction of growth is implied in the ground truth, the LLM adds specificity (numerical growth, share increase) that cannot be verified from the source, leading to a partially correct but misleading synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 549,
        "total_tokens": 1860
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How did Merck's alliance revenue related to Lynparza evolve between 2023 and 2024, and what factors contributed to the change?",
      "original_answer": "In 2023, alliance revenue for Lynparza was part of Merck's broader alliance revenue reporting, which included profits based on product sales net of cost of sales and commercialization costs. By 2024, alliance revenue related to Lynparza specifically grew by 9%, driven by higher demand in most international markets. This growth indicates a positive shift in Lynparza's market performance during the period.",
      "llm_answer": "\nMerck’s alliance revenue from Lynparza rose from **$1.199 billion in 2023 to $1.311 billion in 2024** – an increase of roughly **9 %** (11 % when adjusted for foreign‑exchange effects).  The growth was driven primarily by **higher demand for Lynparza in most international markets**, supported by new regulatory approvals (e.g., the 2025 Chinese NMPA approval for an adjuvant breast‑cancer indication) and the continued expansion of the AstraZeneca collaboration that generates the alliance‑revenue share.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "(1) The LLM answer includes specific dollar amounts ($1.199 billion in 2023, $1.311 billion in 2024) and a 9% growth figure, which aligns with the direction of the ground truth (9% growth). However, the original answer does not provide any actual dollar figures or mention foreign-exchange adjustments, regulatory approvals (e.g., 2025 Chinese NMPA approval), or details about the AstraZeneca collaboration. These specific numbers and forward-looking events (2025 approval) are not supported by the ground truth and appear to be hallucinated or sourced incorrectly. (2) The 9% growth matches the ground truth, but the calculation based on $1.199B to $1.311B is approximately 9.3%, which rounds to 9%, so the percentage is plausible. However, the $1.199B and $1.311B figures themselves are not present in the original answer and cannot be verified, making the quantitative claims unsupported. The mention of an '11% growth when adjusted for FX' and a '2025 approval' introduces data outside the scope of the provided truth. (3) The reasoning correctly identifies higher international demand as a driver, which matches the original answer. However, it adds unsupported multi-hop elements such as the AstraZeneca collaboration details and future regulatory events, which were not in the source. The synthesis goes beyond the available evidence. (4) The contextual relevance is high because the answer addresses both parts of the question—evolution of revenue and contributing factors—and stays focused on Lynparza and alliance revenue. The qualitative reasoning is sound in direction but overreaches in specificity. The correctness score is reduced significantly due to unsupported numerical claims, even though the directional trend (9% growth from demand) is correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1223,
        "completion_tokens": 477,
        "total_tokens": 1700
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has the treatment and disclosure of the Procter & Gamble 2014 Stock and Incentive Compensation Plan evolved between 2023 and 2024, particularly in terms of its regulatory context and inclusion in equity compensation reporting?",
      "original_answer": "In 2023, the 2014 Stock and Incentive Compensation Plan was disclosed in the context of regulatory documentation and was referenced alongside other compensation plans and agreements, such as the 2009 and 2019 plans, indicating its active role in executive compensation. By 2024, the plan was included in a broader list of equity compensation plans for reporting on stock issuances upon exercise of options, suggesting a shift from regulatory disclosure to a focus on ownership structure and equity compensation transparency. This evolution indicates a more integrated view of the 2014 plan within the company’s overall equity compensation framework.",
      "llm_answer": "\nBetween fiscal 2023 and fiscal 2024 the 2014 Stock and Incentive Compensation Plan remained listed in the “Security Ownership of Certain Beneficial Owners and Management” table, but the disclosure was tightened: the 2024 filing explicitly notes that the plan has 0 shares remaining for future issuance (the “remaining available” column now shows “(1)” with a footnote stating that only the 2019 Plan permits future grants) and adds a footnote clarifying the share‑counting methodology (full‑value awards are counted as five shares).  This change reflects updated SEC reporting guidance that requires clearer presentation of outstanding awards and future availability, and moves the detailed plan terms to the 2024 Proxy Statement, thereby enhancing transparency in the company’s equity‑compensation disclosures.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth, with only minor differences in emphasis. (1) Quantitatively, all details are correct: the 2024 disclosure noting 0 shares remaining for future issuance under the 2014 Plan, the reference to the 2019 Plan as the only active plan for future grants, and the updated share-counting methodology (full-value awards counted as five shares) are factually precise and consistent with SEC reporting updates. These specifics were not in the original answer but represent accurate, granular details that enhance correctness. (2) The LLM correctly identifies the shift in disclosure focus—from broader regulatory context in 2023 to precise equity availability and methodology in 2024—demonstrating sound multi-hop reasoning across years and reporting frameworks. (3) The original answer emphasizes a conceptual evolution (from regulatory disclosure to ownership transparency), while the LLM provides concrete evidence of that evolution (e.g., footnote changes, share availability). This adds depth rather than contradicting the ground truth. (4) The only reason for not scoring a perfect 10 is that the LLM does not explicitly mention the 2009 plan referenced in the 2023 context per the original answer, slightly reducing completeness in entity coverage. However, this omission does not detract from the core accuracy regarding the 2014 Plan’s evolving disclosure. Overall, the answer is factually superior in detail, fully contextually relevant, and reflects a correct understanding of the regulatory and reporting evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 433,
        "total_tokens": 1819
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How has the treatment of the 1992 Stock Plan evolved between the 2023 and 2024 10-K filings, particularly in terms of its role within the company's equity compensation structure?",
      "original_answer": "In the 2023 10-K filing, the 1992 Stock Plan was referenced as an adopted plan with specific terms and conditions incorporated by reference to prior filings. However, in the 2024 10-K filing, the 1992 Stock Plan is listed among other equity compensation plans in a consolidated table that outlines shares authorized for issuance upon the exercise of options, warrants, and rights. This indicates a shift from a standalone referenced plan to one being tracked alongside newer plans, suggesting its role has transitioned from active adoption to a more passive stake within the broader equity compensation framework.",
      "llm_answer": "\nBetween the 2023 and 2024 10‑K filings the 1992 Stock Plan was retained only as a historical, closed‑ended plan.  The 2024 filing’s equity‑compensation table shows that, unlike the 2019, 2014, 2009 and 2001 plans, the 1992 plan no longer has any shares available for future issuance—its remaining shares are limited to those already granted and outstanding.  Consequently, the plan’s role has shifted from being an active source of new equity awards to a legacy pool that is reported only for disclosure of existing options and rights.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies that the 1992 Stock Plan is no longer an active plan in the 2024 10-K, with no shares available for future issuance—consistent with its portrayal as a legacy or closed plan. This matches the ground truth's assertion that the plan transitioned from a standalone referenced plan in 2023 to being included in a consolidated table in 2024, indicating a passive role. (2) There are no numeric values (e.g., share counts, dollar amounts) in either the original or LLM answer, so quantitative accuracy is not compromised; all dates (1992, 2023, 2024) are correct. (3) The multi-hop reasoning is sound: the LLM infers from the absence of available shares in the 2024 table that the plan is no longer active, and contrasts it with newer plans (2019, 2014, etc.), demonstrating synthesis across time and plan structures. (4) While the original answer emphasizes the shift from 'incorporated by reference' to 'consolidated disclosure', the LLM captures the same conceptual evolution—transition from active/adoption to passive/legacy—using different but semantically equivalent language. The only minor gap is that the LLM does not explicitly mention the 'incorporation by reference' aspect from the 2023 filing, which slightly reduces completeness in qualitative accuracy, but the core conclusion about the plan’s diminished role is correct. Hence, all scores are high, with correctness at 9 due to this slight omission.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 414,
        "total_tokens": 1710
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How has the company's emphasis on large-scale transformations evolved between 2023 and 2024, particularly in terms of client spending patterns and revenue conversion timelines?",
      "original_answer": "In 2023, the filing noted that clients were reducing or deferring spending on smaller contracts with shorter durations and that there was a slowdown in client spending, especially for consulting services. However, clients were still prioritizing large-scale transformations, which convert to revenue over a longer period. In 2024, the filing reiterated that clients continued to prioritize large-scale transformations, emphasizing the ongoing shift toward longer-duration contracts. While there was no explicit quantitative metric provided in either year, the repeated emphasis in both filings on the extended revenue conversion timeline for large-scale transformations indicates a strategic reinforcement of this focus, especially amid ongoing economic volatility.",
      "llm_answer": "\nBetween fiscal 2023 and 2024 the company’s focus on large‑scale transformations has intensified relative to shorter‑duration work: while overall client spending remained volatile, Accenture observed a clear shift away from small, quick‑turn contracts toward a higher proportion of multi‑year, transformation‑type engagements. These large‑scale deals “convert to revenue over a longer period,” and the risk discussion notes that “clients continue to prioritize large‑scale transformations” while “the pace and level of client spending… slowed… particularly for smaller contracts with a shorter duration” in fiscal 2024. Consequently, revenue recognition is now more spread out, reflecting longer conversion timelines for the company’s biggest transformation projects.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution between 2023 and 2024: clients reduced spending on smaller, shorter-duration contracts while continuing to prioritize large-scale transformations that convert to revenue over longer periods. The key qualitative points—shift toward multi-year engagements, extended revenue recognition timelines, and client spending slowdown—are all present and correctly attributed. (2) There are no numeric values in the original or LLM answer, so quantitative accuracy is not compromised; the LLM correctly avoids inventing metrics. (3) The multi-hop reasoning is sound: it synthesizes information across both years, correctly identifying the continuity in client prioritization of large-scale transformations and the associated impact on revenue conversion timelines. The LLM slightly strengthens the claim by saying the focus 'has intensified,' which is a reasonable inference but not explicitly stated in the original; this minor interpretive leap prevents a perfect 10. (4) The answer is fully contextually relevant, directly addressing client spending patterns and revenue conversion timelines as asked. Overall, the LLM conveys the same semantic meaning with excellent fidelity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1390,
        "completion_tokens": 357,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How did Accenture's issuance of Class A Ordinary Shares for employee compensation change from fiscal 2023 to 2024, and what was the impact on the company's equity structure?",
      "original_answer": "In fiscal 2023, Accenture acquired Class A Ordinary Shares primarily through share withholding for payroll tax obligations related to employee equity awards. In fiscal 2024, the company issued 7,970 Class A Ordinary Shares specifically for employee share programs, while also purchasing 12,181 treasury shares. This shift reflects a more active use of Class A Ordinary Shares for compensation purposes in 2024. The equity structure was impacted as Class A Ordinary Shares increased from 15,656,591 in 2023 to 15,664,561 in 2024, while treasury shares decreased in value from $(3,408,491) million to $(6,678,037) million, indicating a significant reallocation of shares for employee programs.",
      "llm_answer": "\nFrom fiscal 2023 to fiscal 2024 the company issued fewer Class A ordinary shares for employee compensation – the equity‑movement schedule shows “Issuances of Class A shares for employee share programs” of roughly **$8.9 million** in 2023 versus **$7.9 million** in 2024 (a decline of about **1 million shares, or ≈11 %**).  This smaller issuance meant a modest reduction in the increase of additional paid‑in capital and dilution, but the overall equity base still grew (total shareholders’ equity rose from $25.69 bn to $28.29 bn) primarily through retained earnings and share‑based compensation, leaving the equity structure broadly unchanged aside from the slightly lower share‑issuance impact.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both direction and magnitude. The ground truth states that Accenture *issued 7,970 Class A Ordinary Shares* in fiscal 2024 for employee programs, while in 2023 the company primarily *acquired* shares via withholding for tax obligations — meaning net issuance was effectively negative or neutral in 2023. The LLM incorrectly claims that 8.9 million shares were issued in 2023 and 7.9 million in 2024, implying a decrease in issuance, which contradicts the actual shift from share acquisition (net reduction) in 2023 to net issuance in 2024. The numbers are off by a factor of over 1,000 (millions vs. actual low thousands), and the trend is reversed. (2) The LLM uses dollar amounts ('$8.9 million', '$7.9 million') as if they represent share counts, which is a fundamental misinterpretation — these figures likely refer to dollar value of compensation, not number of shares. The ground truth specifies exact share counts: 7,970 issued in 2024, with a net increase in outstanding shares from 15,656,591 to 15,664,561 (an increase of 7,970 shares), confirming the issuance. The LLM’s calculation of a 1 million share decline is completely inaccurate. (3) The multi-hop reasoning fails: the model does not recognize that share withholding (2023) reduces net shares outstanding, while new issuances (2024) increase them. It mischaracterizes the shift in policy and misses the key point about treasury share purchases (12,181 shares) and the significant drop in treasury value from $(3,408,491) million to $(6,678,037) million, which reflects large-scale use of treasury shares for compensation. (4) The contextual relevance is moderate because it addresses employee share programs and equity structure, but the factual and quantitative errors severely undermine correctness. The conclusion that the equity structure was 'broadly unchanged' contradicts the ground truth's emphasis on a 'significant reallocation.' Scores reflect major factual and numerical inaccuracies despite addressing the general topic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 552,
        "total_tokens": 1906
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How did MDLZ's exposure to Canadian-denominated debt instruments change between 2022 and 2023, and how does this shift compare to the company's overall trend in managing foreign currency-denominated debt during this period?",
      "original_answer": "In 2022, MDLZ reported a decrease in Canadian notes of $3 million, continuing a trend of declining balances from $17 million in 2019 to $7 million in 2020 and $3 million in 2021. However, in 2023, the company experienced an increase in Canadian notes by $8 million, reversing the previous downward trajectory. This shift contrasts with the broader pattern of fluctuating foreign currency exposure, where Euro notes decreased significantly from $211 million in 2021 to $81 million in 2023, while Swiss franc notes also showed volatility. The reversal in Canadian notes indicates a notable deviation from the prior year's trend of reducing exposure to this currency denomination.",
      "llm_answer": "\nMDLZ’s Canadian‑dollar debt that is designated as a net‑investment hedge rose modestly from **$443 million in 2022 to $453 million in 2023** (an increase of about $10 million, or roughly 2 %).  This slight uptick occurs against a broader pattern in which the company **expanded the overall size of its foreign‑currency hedging program** – total currency‑exchange contract notional grew from $2.085 bn to $2.860 bn and net‑investment‑hedge derivatives increased from $7.319 bn to $7.456 bn – while it **reduced longer‑dated interest‑rate swaps**.  Consequently, the change in Canadian‑dollar exposure is a small, incremental part of a general re‑balancing of foreign‑currency‑denominated debt rather than a distinct shift focused solely on Canada.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect in both quantitative and qualitative aspects. (1) Quantitatively, the LLM states that Canadian-dollar debt increased from $443 million in 2022 to $453 million in 2023, implying a $10 million increase. However, the ground truth states that the Canadian notes balance was only $3 million in 2022 and increased by $8 million in 2023 (to $11 million), following prior reductions from $17M (2019) to $7M (2020) to $3M (2021). The LLM's figures are off by over two orders of magnitude ($443M vs $3M), making this a severe factual error. (2) The LLM incorrectly frames the Canadian debt as part of a 'net-investment hedge' and ties it to derivative notional growth (e.g., $7.319B to $7.456B), but the original answer makes no mention of hedging programs or derivative contracts—this is a misrepresentation of the data. (3) The broader trend described in the LLM answer—expansion of foreign-currency hedging—is not supported by the ground truth, which highlights a significant reduction in Euro notes ($211M to $81M) and volatility in Swiss franc notes, indicating active rebalancing but not necessarily program expansion. (4) The LLM fails to note the key point that the $8M increase in Canadian notes *reversed* a multi-year trend of decline, which is the central insight of the original answer. Instead, it characterizes the change as a small part of a broader hedging strategy, which is not substantiated. While the answer does address the question’s structure (change in Canadian exposure and comparison to overall trend), the factual inaccuracies and incorrect synthesis severely undermine its correctness. Minor credit is given for attempting multi-hop reasoning and addressing the comparative trend aspect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1375,
        "completion_tokens": 471,
        "total_tokens": 1846
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How has Accenture's approach to engaging with growth-stage companies evolved from 2023 to 2024, particularly in terms of strategic involvement and investment activity?",
      "original_answer": "In 2023, Accenture Ventures was described as primarily partnering with growth-stage companies that create innovative enterprise technologies. By 2024, the relationship evolved from a partnership model to a more direct investment approach, indicating a deeper financial and strategic commitment. This shift from 'partners with' to 'invests in' growth-stage firms suggests Accenture is taking a more active role in shaping innovation ecosystems through capital allocation, aligning with its broader innovation strategy supported by $1.3 billion in R&D spending in fiscal 2023 and $1.2 billion in fiscal 2024.",
      "llm_answer": "\nFrom 2023 to 2024 Accenture shifted its interaction with growth‑stage firms from an exploratory, scouting‑focused activity to a deliberately strategic investment pillar.  The 2023 filing introduced Accenture Ventures as the vehicle for backing “growth‑stage companies that create innovative enterprise technologies,” and the 2024 filing expands that language, describing a deeper, cross‑functional partnership that aligns venture investments with the company’s sustainability and innovation agendas and signals a larger, more‑integrated capital commitment to these deals.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly captures the evolution in Accenture's approach from 2023 to 2024, noting a shift from a partnership-focused model to a more strategic and integrated investment approach. It accurately identifies Accenture Ventures as the vehicle and reflects the deepening strategic involvement in growth-stage companies. The answer aligns with the ground truth in substance, though it does not explicitly mention the change in language from 'partners with' to 'invests in,' which is a key indicator of the shift. Additionally, while the LLM references a more integrated capital commitment, it omits the specific R&D spending figures ($1.3 billion in fiscal 2023 and $1.2 billion in fiscal 2024) that ground the strategic context in the original answer. These numbers are critical for full completeness and multi-hop synthesis, but their absence does not undermine the core correctness of the directional shift described. All entities (Accenture, Accenture Ventures, growth-stage companies) and years (2023 to 2024) are accurate. There are no numerical errors, so quantitative accuracy is perfect. The reasoning is sound and contextually relevant, with only minor omissions affecting completeness. Hence, a score of 8 is appropriate for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 374,
        "total_tokens": 1673
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How has Merck's financial and strategic involvement in the Lynparza collaboration with AstraZeneca evolved from 2022 to 2024, particularly in terms of asset amortization and alliance revenue growth?",
      "original_answer": "In 2022, Merck was amortizing an intangible asset balance of $1.1 billion related to Lynparza, which included capitalized milestone payments, and was expected to be amortized through 2028. By 2024, the focus shifted from asset amortization to revenue growth, with alliance revenue from Lynparza increasing by 9% due to higher demand in international markets. Additionally, in early 2025, Lynparza received a new approval in China for adjuvant treatment in early breast cancer, indicating an expansion in its therapeutic footprint and strategic importance to Merck.",
      "llm_answer": "\nMerck’s share of Lynparza sales (alliance revenue) has risen steadily from **$1.116 bn in 2022 to $1.199 bn in 2023 and $1.311 bn in 2024**, representing a **9 % year‑over‑year increase in 2024** and **11 % growth on a constant‑currency basis**.  This growth occurs while the **$1.1 bn Lynparza‑related intangible asset recorded in 2021 is being amortized over a seven‑year schedule through 2028**, with the amortization expense reflected in cost of sales; the net book value is therefore being reduced, but the amortization does not offset the double‑digit revenue expansion.  \n\n*(Based on the financial tables and collaboration discussion in MRK_10k_2022.pdf pp. 100‑104 and MRK_10k_2024.pdf pp. 53‑57.)*",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: the $1.1 billion intangible asset amortized through 2028 matches the original answer, and the 9% year-over-year revenue growth in 2024 is consistent with the stated '9% increase' in alliance revenue. The LLM provides additional granularity with exact revenue figures ($1.116B in 2022, $1.311B in 2024), which supports the 9% growth claim and exceeds the detail in the ground truth. (2) Calculations: the 9% growth from $1.199B to $1.311B is accurate (~9.3%), and constant-currency growth at 11% is a plausible adjustment given exchange rate fluctuations. (3) Entity and time accuracy: Merck, AstraZeneca (implied via collaboration), Lynparza, and correct years (2022–2024) are properly identified. The amortization period (through 2028) and seven-year schedule (from 2021/2022) are consistent. (4) Reasoning and synthesis: the LLM correctly connects amortization of the intangible asset with rising alliance revenue, highlighting the shift from cost amortization to revenue growth—core to the question’s focus. It also implicitly captures the strategic importance through sustained revenue expansion. (5) One minor omission: the original answer mentions a new Lynparza approval in China in early 2025 for adjuvant treatment in early breast cancer, which the LLM omits. This is a relevant strategic development indicating expanded therapeutic footprint. While not financial, it is part of the 'strategic involvement' aspect of the question. However, the financial evolution is thoroughly and correctly detailed. Thus, the answer earns a 9/10 for correctness—excellent but missing one strategic point. Quantitative accuracy is perfect (10/10), qualitative reasoning is strong with only minor incompleteness (9/10), and relevance is full (10/10).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 501,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How has AVGO's strategic emphasis on ValueOps changed between 2023 and 2024, and what does this indicate about its evolving role in the Distributed Software portfolio?",
      "original_answer": "In 2023, ValueOps was listed as one of several key offerings under AVGO's Distributed Software portfolio, positioned alongside other solutions like DevOps and AIOps without specific elaboration on its strategic role. By 2024, ValueOps was elevated to be one of the three core domains—alongside DevOps and AIOps—that AVGO's distributed software solutions are 'organized in the domains of,' with an explicit emphasis on delivering 'end-to-end visibility across all stages of the digital lifecycle.' This indicates a strategic shift where ValueOps became more central to AVGO's value proposition, aligning it more deeply with business outcomes and customer experiences. The change reflects a broader evolution from being a feature in the portfolio to a foundational pillar supporting enterprise digital transformation.",
      "llm_answer": "\nBetween the 2023 and 2024 filings, Broadcom’s description of **ValueOps** moved from a brief footnote—“value‑stream management capabilities that enable customers to schedule, track and manage work throughout its lifecycle, increasing transparency and reducing inefficiencies” (AVGO 10‑K 2023, pp. 6‑10)—to a headline‑level strategic pillar that is presented as a core domain of the **Distributed Software** portfolio and explicitly tied to “optimizing the planning, development and delivery of software, powering business‑critical digital services, and driving profitability by aligning business, development and operational teams” (AVGO 10‑K 2024, pp. 8‑12).  \n\nThis evolution shows that AVGO is elevating ValueOps from a peripheral capability to a central growth engine, positioning it as the primary vehicle for delivering end‑to‑end visibility and lifecycle coordination across its Distributed Software portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: ValueOps evolved from a minor mention in 2023 to a core domain in 2024 alongside DevOps and AIOps. The shift in language—from a descriptive footnote to a strategic pillar tied to business outcomes—is accurately captured. (2) There are no numeric values, dates, or calculations in the question or answer, so quantitative accuracy is not applicable in a traditional sense; however, the cited page ranges (pp. 6–10 in 2023, pp. 8–12 in 2024) are consistent with typical 10-K referencing and do not contradict the ground truth, earning full marks. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of AVGO’s filings, identifies the change in positioning of ValueOps, and infers its growing strategic importance. The conclusion that ValueOps became a 'central growth engine' and 'foundational pillar' is semantically equivalent to the ground truth’s claim that it shifted from a feature to a core domain supporting digital transformation. (4) The only reason for not awarding a perfect 10 is minor: the LLM does not explicitly mention 'end-to-end visibility across all stages of the digital lifecycle'—a key phrase in the original answer—but it does convey the equivalent idea through 'lifecycle coordination' and 'visibility,' which preserves the semantic meaning. Overall, the response is contextually rich, factually correct, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1438,
        "completion_tokens": 412,
        "total_tokens": 1851
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How did FedEx's strategic approach to Network 2.0 within the DRIVE transformation evolve between 2023 and 2024, particularly in terms of expected cost savings and implementation risks?",
      "original_answer": "In 2023, FedEx emphasized the strategic importance of Network 2.0 as part of its DRIVE transformation, noting that significant investments were being made with the expectation of achieving operational efficiencies, network flexibility, and alignment of the cost base with demand. However, the filing acknowledged that the failure to successfully execute Network 2.0 within the expected time frame and cost could adversely affect future results. By 2024, FedEx shifted focus to the integration complexities of Network 2.0, including risks related to harmonizing operating practices, maintaining customer and service provider agreements, addressing labor and cultural differences, and managing unforeseen expenses. The 2024 filing also noted that the actual amount and timing of cost savings and permanent cost reductions might differ from expectations, and that asset impairment charges, tax impacts, and litigation risks could arise. This reflects a transition from strategic planning and investment justification in 2023 to operational integration and financial risk mitigation in 2024.",
      "llm_answer": "\nBetween 2023 and 2024 FedEx moved Network 2.0 from a high‑level “DRIVE” concept to concrete actions—announcing the Tricolor redesign of its international air network and a Europe‑wide workforce‑reduction plan—while still projecting that the initiative would deliver permanent cost‑structure reductions and greater network flexibility.  However, the company repeatedly warned that the expected savings are contingent on successfully integrating the Federal Express and legacy FedEx Ground physical networks, consolidating IT systems, and navigating labor, regulatory and contractual hurdles; if those integration challenges stall or incur unexpected expenses, the projected cost‑savings could be delayed, reduced, or even reversed.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly captures the evolution of FedEx's strategic approach to Network 2.0 between 2023 and 2024, noting the shift from high-level strategic planning to concrete implementation actions such as the Tricolor redesign and workforce reductions. It accurately reflects the continued expectation of permanent cost savings and network flexibility, aligning with the 2023 emphasis. The answer also correctly identifies key implementation risks, including integration challenges between FedEx Express and Ground, IT consolidation, labor issues, and regulatory and contractual hurdles—consistent with the 2024 filing’s focus on integration complexities and uncertainty around timing and magnitude of savings. However, the LLM omits specific risks mentioned in the original answer, such as asset impairment charges, tax impacts, and litigation risks, which represent a meaningful part of the 2024 risk expansion. While the core financial and strategic trajectory is accurately conveyed, this omission prevents a perfect score. There are no numerical inaccuracies (quantitative accuracy is 10), and the entities (FedEx, Network 2.0, DRIVE, FedEx Express, FedEx Ground) and time frame (2023–2024) are correct. The reasoning is sound and synthesizes the multi-hop elements—strategic shift over time, cost expectations, and risk evolution—though with minor gaps in completeness. The answer is highly relevant and semantically aligned with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1464,
        "completion_tokens": 401,
        "total_tokens": 1865
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How did the financial impact from equity method investment contracts evolve between 2022 and 2023, and what does this indicate about MDLZ's engagement with these investments?",
      "original_answer": "In 2022, MDLZ reported a net liability of $3 million related to equity method investment contracts. By 2023, this position had shifted to a gain of $7 million from equity method investment contracts, indicating a reversal in financial impact and potentially more active or favorable engagement with these investments. This evolution highlights a strategic or operational shift in how MDLZ managed these equity method investments over the two years.",
      "llm_answer": "\nBetween 2022 and 2023 the embedded derivative that comprises MDLZ’s equity‑method‑investment contract stayed on the balance sheet as a modest liability of roughly $3 million (both years).  However, the earnings impact changed: the 2022 filing shows essentially no recognized gain or loss from the contract, while the 2023 “Economic Hedges” table records a **$7 million gain in earnings** from these contracts.  This shift indicates that MDLZ’s exposure to the underlying JDE Peet’s investment moved from a neutral, balance‑sheet‑only position to a small but positive contribution to net income, suggesting a modest increase in engagement and the beginning of earnings‑recognised benefit from the arrangement.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $7 million gain in earnings in 2023, which aligns with the ground truth. However, it incorrectly states that the liability was $3 million in both 2022 and 2023, whereas the ground truth specifies a net liability of $3 million in 2022 that shifted to a gain (i.e., positive position) of $7 million in 2023—implying the balance sheet item reversed from liability to asset or at least to a positive value, not remaining a liability. This misrepresents the balance sheet evolution. (2) The quantitative accuracy is partially flawed: while the $7 million gain is correct, the persistence of the $3 million liability in both years contradicts the ground truth’s description of a reversal from liability to gain. The answer confuses the nature of the financial impact by treating the liability as static when it should have been eliminated or reversed. (3) The reasoning is sound in noting a shift in earnings impact and linking it to increased engagement, which matches the ground truth’s interpretation. It correctly synthesizes information about earnings effects and infers strategic implications. However, the multi-hop synthesis is weakened by not fully reconciling the balance sheet and income statement impacts across years. (4) Despite the quantitative error in balance sheet characterization, the answer captures the core earnings shift and offers a reasonable interpretation, warranting a score of 7 for correctness. The qualitative and contextual scores are higher due to strong reasoning and relevance, even with the factual inaccuracy on the liability carryover.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 444,
        "total_tokens": 1740
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How did Broadcom's (AVGO) estimated cost to complete for the VMware Cloud Foundation July 2024 releases evolve from fiscal year 2023 to fiscal year 2024, and what does this indicate about the development progress relative to expectations?",
      "original_answer": "The estimated cost to complete for the VMware Cloud Foundation July 2024 releases remained unchanged at $38 million from fiscal year 2023 to fiscal year 2024. This consistency in the cost estimate indicates that the development progress for this product was proceeding largely as planned, with actual expenditures aligning with earlier projections. The lack of an increase or decrease in the estimated cost to complete suggests that Broadcom (AVGO) did not encounter significant unexpected expenses or delays in the development timeline for this specific release.",
      "llm_answer": "\nThe estimated cost‑to‑complete for the VMware Cloud Foundation July 2024 releases fell from roughly $70 million in the FY 2023 projection to $38 million in FY 2024 (the table shows 67 % completion and a $38 million remaining spend, noted as “(a) Released during fiscal year 2024”).  This reduction—while only a small fraction of the $790 million IPR&D asset—indicates that about two‑thirds of the work is already finished and that the remaining expenditure is modest, signalling that the releases are advancing well and are ahead of earlier expectations.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that the estimated cost to complete remained unchanged at $38 million from FY2023 to FY2024. However, the LLM claims it decreased from $70 million in FY2023 to $38 million in FY2024, which is incorrect. This misrepresents the core quantitative fact. Additionally, the LLM introduces a '67% completion' figure and references a table not mentioned in the original answer, which lacks support from the ground truth. (2) The $38 million figure for FY2024 is correct, but the $70 million FY2023 estimate is not; no such number appears in the original answer. The calculation of 'two-thirds of the work finished' is speculative and not supported by the ground truth, which makes no mention of progress percentage or completion rates. The $790 million IPR&D asset is introduced without context or verification. (3) The multi-hop reasoning is flawed. The original answer emphasizes stability in cost estimates as an indicator of on-track progress. The LLM instead infers acceleration ('ahead of earlier expectations') based on a fabricated reduction in cost, demonstrating incorrect synthesis. It fails to recognize that a stable cost-to-complete reflects alignment with projections, not necessarily faster progress. (4) While the LLM addresses the general topic—development progress of VMware Cloud Foundation—it misrepresents key facts and draws unsupported conclusions. The contextual relevance is moderate because it discusses the right product and fiscal years, but the reasoning and data are fundamentally incorrect, undermining the overall accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1302,
        "completion_tokens": 450,
        "total_tokens": 1752
      },
      "error": null
    },
    {
      "question_id": 118,
      "question": "How has the strategic positioning of FedEx Office's Ship and Go kiosk evolved between 2023 and 2024, and what does this indicate about the company's approach to e-commerce logistics and returns management?",
      "original_answer": "In 2023, the Ship and Go kiosk was described primarily as a self-serve shipping solution available in approximately 1,300 locations, allowing customers to generate labels via mobile or QR code and drop off packages securely. While it mentioned facilitating e-commerce returns, the integration was not emphasized. By 2024, the description of Ship and Go remained consistent in terms of presence (still in approximately 1,300 locations) and core functionality, but there was a notable shift in emphasis: it was now more explicitly tied to FedEx Returns Technology and Consolidated Returns, highlighting its role in in-store printing of return labels and enabling customers to drop off returns without a box or label. This evolution indicates a strategic shift toward positioning Ship and Go not just as a shipping tool, but as a key node in FedEx's broader e-commerce returns infrastructure.",
      "llm_answer": "\nBetween 2023 and 2024 FedEx Office expanded the role of its Ship & Go kiosks from a pure outbound‑shipping drop‑off point to a dual‑purpose hub that also handles label‑less returns.  The 2024 filing notes that the kiosks now support FedEx Returns Technology and the Consolidated Returns program, allowing shoppers to bring back items with no box or label required, and the network of roughly 1,300 locations was leveraged to give customers a seamless, end‑to‑end e‑commerce fulfillment and returns experience.  This shift signals that FedEx Office is positioning its retail footprint as a critical node in the company’s broader e‑commerce logistics strategy, using convenient in‑store kiosks to streamline both shipments and returns for omnichannel merchants.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the Ship and Go kiosk network size (~1,300 locations) is consistent between years, and the 2024 enhancement linking it to FedEx Returns Technology and Consolidated Returns is accurately described. The functionality shift—enabling label-less, box-less returns—is correctly identified. (2) Quantitative accuracy is perfect: no numerical errors; the figure of approximately 1,300 locations is correctly reported and consistent with the original answer. (3) Reasoning is sound: the LLM correctly infers a strategic evolution from a shipping-only tool to a dual-purpose hub supporting both outbound and return logistics, which reflects the multi-hop synthesis required. It accurately connects the kiosk upgrade to broader e-commerce logistics and omnichannel strategy. (4) The only minor shortcoming is slight overstatement in calling the kiosks a 'dual-purpose hub' and 'expanded' in role—while semantically reasonable, the original answer notes the core functionality description remained consistent, with only a shift in emphasis. Thus, the evolution is more about strategic positioning than functional expansion. This nuance is slightly underemphasized, but not incorrectly represented. Overall, the answer is factually correct, contextually relevant, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1427,
        "completion_tokens": 380,
        "total_tokens": 1807
      },
      "error": null
    }
  ],
  "evaluation_summary": {
    "total_questions": 1000,
    "successful_evaluations": 1000,
    "failed_evaluations": 0,
    "average_correctness_score": 5.93,
    "average_quantitative_accuracy": 6.51,
    "average_qualitative_accuracy": 6.26,
    "average_contextual_relevance": 8.36,
    "score_distribution": {
      "excellent": 297,
      "good": 156,
      "fair": 309,
      "poor": 238
    }
  },
  "original_experiment_metadata": {
    "model": "nemotron-nano-30b-reasoning",
    "experiment": "e2_page_window",
    "pattern": "qualitative_2hop_cross_year",
    "total_questions": 1000,
    "successful": 1000,
    "failed": 0,
    "elapsed_seconds": 3449.17,
    "timestamp": "2026-02-02T16:37:54.918394"
  }
}